<SEC-DOCUMENT>0001178913-25-001205.txt : 20250404
<SEC-HEADER>0001178913-25-001205.hdr.sgml : 20250404
<ACCEPTANCE-DATETIME>20250404171733
ACCESSION NUMBER:		0001178913-25-001205
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		100
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250404
DATE AS OF CHANGE:		20250404

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Chemomab Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001534248
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				813676773
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38807
		FILM NUMBER:		25815796

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002
		BUSINESS PHONE:		972-77-331-0156

	MAIL ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Anchiano Therapeutics Ltd.
		DATE OF NAME CHANGE:	20180906

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioCancell Ltd.
		DATE OF NAME CHANGE:	20111104
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>zk2532902.htm
<DESCRIPTION>20-F
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--INTEGIX by Ez-XBRL-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:cmmb="http://www.anchiano.com/20241231" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2024" xmlns:cyd-af="http://xbrl.sec.gov/cyd-af/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/><title>Chemomab Therapeutics Ltd. - 1534248 - 2025</title></head><body style="font-size:10pt;font-family:Times New Roman, Times, serif;"><div style="font-size: 10pt;"><div style="font-size: 10pt;"><div style="font-size: 10pt;"><div style="font-size: 10pt;"><div style="font-size: 10pt;">
        <div style="display:none">
        <ix:header><ix:hidden><ix:footnote id="FN20250326215635448" xml:lang="en-US">This excludes capital losses of approximately $14,224 thousands for which the company will create a full valuation allowance.</ix:footnote>
<ix:footnote id="FN20250325144245313" xml:lang="en-US">Less than 1 thousand</ix:footnote>
<ix:footnote id="FN20240325165534634" xml:lang="en-US">Number of shares has been retroactively adjusted to reflect the share reverse split effected on March 16, 2021 (refer to Note 1)</ix:footnote>
<ix:footnote id="FN20250325190120111" xml:lang="en-US">1 American Depositary Share (ADS) represents 20 Ordinary Shares.</ix:footnote>
<ix:footnote id="FN20250326103158154" xml:lang="en-US">The weighted average share price is based on the Company's Ordinary Share closing price on the stock exchange as at the grant date</ix:footnote>
<ix:footnote id="FN20250326103217779" xml:lang="en-US">Expected life for the periods presented was determined according to the simplified method since, at the date of grant, the Company did not have enough history to make an estimate. This method effectively assumes that exercise occurs over the period from vesting until expiration, and therefore the expected term is the midpoint between the service period and the contractual term of the award. The simplified method is applicable to service conditions.</ix:footnote>
<ix:footnote id="FN20230201025249960" xml:lang="en-US">Expected volatility is based on historical volatility over the most recent period commensurate with the expected term of the option. As the Company has a short trading history for its ordinary shares, when the Company's trading period is shorter than the expected term, the expected volatility is derived from the average historical share volatilities of several unrelated public companies within the Company&#8217;s industry that the Company considers to be comparable to its own business over a period equivalent to the option&#8217;s expected term.</ix:footnote>
<ix:footnote id="FN20230201025314607" xml:lang="en-US">The risk-free rate for the expected term of the options is based on the Black-Scholes option-pricing model on the yields of U.S. Treasury securities with maturities appropriate for the expected term of employee share option awards.</ix:footnote>
<ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="C_20240101to20241231" id="FFact_0000000000489">0001534248</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="C_20240101to20241231" id="FFact_0000000000490">FY</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="C_20240101to20241231" id="FFact_0000000000491">false</ix:nonNumeric></ix:hidden>
<ix:references>
        <link:schemaRef xlink:type="simple" xlink:href="cmmb-20241231.xsd"/>
        </ix:references><ix:resources><xbrli:context id="C_20240101to20241231_srtStatementGeographicalAxis_countryIL"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_srtStatementGeographicalAxis_countryUS_usgaapIncomeTaxAuthorityAxis_usgaapDomesticCountryMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_srtStatementGeographicalAxis_countryIL"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_srtStatementGeographicalAxis_countryIL"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_srtStatementGeographicalAxis_countryIL"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_srtCurrencyAxis_currencyUSD"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_srtCurrencyAxis_currencyUSD"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_srtCurrencyAxis_currencyILS"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_srtCurrencyAxis_currencyILS"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_srtCurrencyAxis_currencyXXX"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:XXX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_srtCurrencyAxis_currencyXXX"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:XXX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cmmb:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_srtRangeAxis_srtMinimumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_srtRangeAxis_srtMaximumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_srtRangeAxis_srtMinimumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_srtRangeAxis_srtMaximumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200510"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-05-10</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200501to20200510"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-05-01</xbrli:startDate>
        <xbrli:endDate>2020-05-10</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211001to20211024"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-10-24</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231212"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-12</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cmmb:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapSoftwareDevelopmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapSoftwareDevelopmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_usgaapCapitalAdditionsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:CapitalAdditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_cmmbCapitalAdditionsOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">cmmb:CapitalAdditionsOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241229"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-29</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapStatementClassOfStockAxis_cmmbAmericanDepositarySharesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmmb:AmericanDepositarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapStatementClassOfStockAxis_cmmbOrdinarySharesNoParValuePerShareMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmmb:OrdinarySharesNoParValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_srtRangeAxis_srtMinimumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_srtRangeAxis_srtMaximumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmmb:TwoThousandsFifteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmmb:TwoThousandsSeventeenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220901to20220919_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:RepurchaseArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-09-01</xbrli:startDate>
        <xbrli:endDate>2022-09-19</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220930_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:RepurchaseArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221101to20221116_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:RepurchaseArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-11-01</xbrli:startDate>
        <xbrli:endDate>2022-11-16</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220401to20220425_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:AtmAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-25</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:AtmAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:AtmAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-04-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210301to20210322_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-03-01</xbrli:startDate>
        <xbrli:endDate>2021-03-22</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210301to20210315_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-03-01</xbrli:startDate>
        <xbrli:endDate>2021-03-15</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:AtmAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231101to20231117"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-11-01</xbrli:startDate>
        <xbrli:endDate>2023-11-17</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231001to20231031"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231001to20231031_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRothCapitalPartnersLlcMember_usgaapSubsidiarySaleOfStockAxis_cmmbMarketOfferingAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cmmb:RothCapitalPartnersLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:MarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRothCapitalPartnersLlcMember_usgaapSubsidiarySaleOfStockAxis_cmmbMarketOfferingAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cmmb:RothCapitalPartnersLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:MarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240701to20240725_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-07-25</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240701to20240730_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-07-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember_usgaapStatementClassOfStockAxis_cmmbRestrictedOrdinarySharesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmmb:TwoThousandsFifteenPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmmb:RestrictedOrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:unit id="ILS_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:ILS</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_Per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<ix:relationship fromRefs="FFact_0000000000422" toRefs="FN20250326215635448"/><ix:relationship fromRefs="FFact_0000000000423" toRefs="FN20250326215635448"/><ix:relationship fromRefs="Fxbrl_20240325113127688" toRefs="FN20250326215635448"/><ix:relationship fromRefs="Fxbrl_20250325144319085" toRefs="FN20250325144245313"/><ix:relationship fromRefs="FFact_0000000000106" toRefs="FN20240325165534634"/><ix:relationship fromRefs="Fxbrl_20230214141238310" toRefs="FN20250325190120111"/><ix:relationship fromRefs="FFact_0000000000107" toRefs="FN20240325165534634"/><ix:relationship fromRefs="Fxbrl_20230131213329528" toRefs="FN20250325190120111"/><ix:relationship fromRefs="Fxbrl_20240325100018415" toRefs="FN20240325165534634"/><ix:relationship fromRefs="Fxbrl_s_20240325100018414" toRefs="FN20250325190120111"/><ix:relationship fromRefs="Fxbrl_20230131221528825" toRefs="FN20250325190120111"/><ix:relationship fromRefs="Fxbrl_20230131221535249" toRefs="FN20250325190120111"/><ix:relationship fromRefs="Fxbrl_20230207232832534" toRefs="FN20250325190120111"/><ix:relationship fromRefs="Fxbrl_20230207233006128" toRefs="FN20250325190120111"/><ix:relationship fromRefs="Fxbrl_20230207233039147" toRefs="FN20250325190120111"/><ix:relationship fromRefs="Fxbrl_20230207233201211" toRefs="FN20250325190120111"/><ix:relationship fromRefs="Fxbrl_20230207233430996" toRefs="FN20250325190120111"/><ix:relationship fromRefs="Fxbrl_20230207234506438" toRefs="FN20250325190120111"/><ix:relationship fromRefs="Fxbrl_20230207234515566" toRefs="FN20250325190120111"/><ix:relationship fromRefs="Fxbrl_20240325100655099_xbrl_20230207233201211" toRefs="FN20250325190120111"/><ix:relationship fromRefs="Fxbrl_20240325100745487_xbrl_20230207233430996" toRefs="FN20250325190120111"/><ix:relationship fromRefs="Fxbrl_20240325100756924_xbrl_20230207234515566" toRefs="FN20250325190120111"/><ix:relationship fromRefs="FFact_0000000000373" toRefs="FN20250326103158154"/><ix:relationship fromRefs="FFact_0000000000377" toRefs="FN20250326103217779"/><ix:relationship fromRefs="FFact_0000000000378" toRefs="FN20250326103217779"/><ix:relationship fromRefs="FFact_0000000000379" toRefs="FN20230201025249960"/><ix:relationship fromRefs="FFact_0000000000380" toRefs="FN20230201025249960"/><ix:relationship fromRefs="FFact_0000000000381" toRefs="FN20230201025314607"/><ix:relationship fromRefs="FFact_0000000000382" toRefs="FN20230201025314607"/></ix:resources></ix:header></div><div>
  <div>
    <div>
      <div>
        <div>
          <div>
            <div style="line-height:1.25">
              <hr style="border:none;border-bottom:1px solid black;border-top:4px solid black;height:10px;color:#ffffff;background-color:#ffffff;text-align:center;margin-left:auto;margin-right:auto;text-align:center"/>
            </div>
            <div style="line-height:1.25">
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:12pt;font-weight:bold"><span style="font-size:12pt"><span style="font-family:Times New Roman,Times,serif"><span>UNITED STATES</span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:12pt;font-weight:bold"><span style="font-size:12pt"><span style="font-family:Times New Roman,Times,serif"><span>SECURITIES AND EXCHANGE COMMISSION</span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Washington, D.C. 20549</span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:14pt;font-weight:bold"><span style="font-size:14pt"><span style="font-family:Times New Roman,Times,serif"><span>FORM <ix:nonNumeric id="Fxbrl_20230213103251859" name="dei:DocumentType" contextRef="C_20240101to20241231">20-F</ix:nonNumeric></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(Mark One)</span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:Arial;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="Fxbrl_20240325124822695" name="dei:DocumentRegistrationStatement" contextRef="C_20240101to20241231" format="ixt:fixed-false">&#9744;</ix:nonNumeric>&#8195;REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934</span></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>OR</span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="line-height:1.25;font-family:Arial;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="Fxbrl_20240325124850731" name="dei:DocumentAnnualReport" contextRef="C_20240101to20241231" format="ixt:fixed-true">&#9746;</ix:nonNumeric>&#8195;ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934&#8201;&#8201;</span></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>For the fiscal year ended <ix:nonNumeric id="Fxbrl_20240325125020590" name="dei:DocumentPeriodEndDate" contextRef="C_20240101to20241231" format="ixt:date-monthname-day-year-en"><ix:nonNumeric id="Fxbrl_20240325125039815" name="dei:CurrentFiscalYearEndDate" contextRef="C_20240101to20241231" format="ixt:date-monthname-day-en">December 31</ix:nonNumeric>, <ix:nonNumeric id="Fxbrl_20240325125103526" name="dei:DocumentFiscalYearFocus" contextRef="C_20240101to20241231">2024</ix:nonNumeric></ix:nonNumeric></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>OR</span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:Arial;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="Fxbrl_20240325125127518" name="dei:DocumentTransitionReport" contextRef="C_20240101to20241231" format="ixt:fixed-false">&#9744;</ix:nonNumeric>&#8195;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>For the transition period from &#8195;&#8195;&#8195;&#8195; to</span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>OR</span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:Arial;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="Fxbrl_20240325125149159" name="dei:DocumentShellCompanyReport" contextRef="C_20240101to20241231" format="ixt:fixed-false">&#9744;</ix:nonNumeric>&#8195;SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Date of event requiring this shell company report</span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Commission File Number <ix:nonNumeric id="Fxbrl_20240325125212477" name="dei:EntityFileNumber" contextRef="C_20240101to20241231">001-40490</ix:nonNumeric></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><img src="image0.jpg" alt="image0.jpg" style="width:156px;height:87px"/></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:16pt;font-weight:bold"><span style="font-size:16pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="Fxbrl_20230213104107012" name="dei:EntityRegistrantName" contextRef="C_20240101to20241231">Chemomab Therapeutics Ltd.</ix:nonNumeric></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(Exact name of Registrant as specified in its charter)</span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Not Applicable</span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(Translation of Registrant&#8217;s name into English)</span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>State of <ix:nonNumeric id="Fxbrl_20240325171717506" name="dei:EntityIncorporationStateCountryCode" contextRef="C_20240101to20241231" format="ixt-sec:edgarprovcountryen">Israel</ix:nonNumeric></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(Jurisdiction of incorporation or organization)</span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="Fxbrl_20240325130645061" name="dei:EntityAddressAddressLine1" contextRef="C_20240101to20241231">Kiryat Atidim, Building 7</ix:nonNumeric>, <ix:nonNumeric id="Fxbrl_20240325130702398" name="dei:EntityAddressCityOrTown" contextRef="C_20240101to20241231">Tel Aviv</ix:nonNumeric>&#160;<ix:nonNumeric id="Fxbrl_20240327173314698" name="dei:EntityAddressPostalZipCode" contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"><ix:nonNumeric id="Fxbrl_20240325125444047" name="dei:EntityAddressPostalZipCode" contextRef="C_20240101to20241231">6158002</ix:nonNumeric></ix:nonNumeric>, <ix:nonNumeric id="Fxbrl_20240325125500854" name="dei:EntityAddressCountry" contextRef="C_20240101to20241231" format="ixt-sec:countrynameen">Israel</ix:nonNumeric></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>+972 77-331-0156</span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(Address of principal executive offices)</span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="Fxbrl_20240325125533965" name="dei:ContactPersonnelName" contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">Sigal Fattal</ix:nonNumeric></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Chief Financial Officer</span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="Fxbrl_20240325130613231" name="dei:EntityAddressAddressLine1" contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">Kiryat Atidim Building 7</ix:nonNumeric></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="Fxbrl_20240325130913214" name="dei:EntityAddressCityOrTown" contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">Tel Aviv</ix:nonNumeric>, <ix:nonNumeric id="Fxbrl_20240325130944047" name="dei:EntityAddressCountry" contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember" format="ixt-sec:countrynameen">Israel</ix:nonNumeric></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Telephone: (<ix:nonNumeric id="Fxbrl_20240325130506462" name="dei:CityAreaCode" contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">855</ix:nonNumeric>) <ix:nonNumeric id="Fxbrl_20240325130536510" name="dei:LocalPhoneNumber" contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">492-5563</ix:nonNumeric></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</span></span></span></div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Securities registered or to be registered, pursuant to Section 12(b) of the Act</span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:Arial;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:55.71%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Title of each class</span></span></span></div>
                    </td>
                    <td style="width:0.72%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
                      <div style="line-height:1.25">&#160;</div>
                    </td>
                    <td style="width:14.68%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Trading Symbol(s)</span></span></span></div>
                    </td>
                    <td style="width:0.72%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
                      <div style="line-height:1.25">&#160;</div>
                    </td>
                    <td style="width:28.17%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Name of each exchange on which registered</span></span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width:55.71%;vertical-align:top;font-family:'Times New Roman',Times,serif">
                      <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="Fxbrl_20230213103433506" name="dei:Security12bTitle" contextRef="C_20240101to20241231_usgaapStatementClassOfStockAxis_cmmbAmericanDepositarySharesMember">American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share</ix:nonNumeric></span></span></span></div>
                    </td>
                    <td style="width:0.72%;vertical-align:top;font-family:'Times New Roman',Times,serif">
                      <div style="line-height:1.25">&#160;</div>
                    </td>
                    <td style="width:14.68%;vertical-align:top;font-family:'Times New Roman',Times,serif">
                      <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="Fxbrl_20230213103437662" name="dei:TradingSymbol" contextRef="C_20240101to20241231_usgaapStatementClassOfStockAxis_cmmbAmericanDepositarySharesMember">CMMB</ix:nonNumeric></span></span></span></div>
                    </td>
                    <td style="width:0.72%;vertical-align:top;font-family:'Times New Roman',Times,serif">
                      <div style="line-height:1.25">&#160;</div>
                    </td>
                    <td style="width:28.17%;vertical-align:top;font-family:'Times New Roman',Times,serif">
                      <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="Fxbrl_20230213103445669" name="dei:SecurityExchangeName" contextRef="C_20240101to20241231_usgaapStatementClassOfStockAxis_cmmbAmericanDepositarySharesMember" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Capital Market</span></span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width:55.71%;vertical-align:top;font-family:'Times New Roman',Times,serif">
                      <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="Fxbrl_20230213103508728" name="dei:Security12bTitle" contextRef="C_20240101to20241231_usgaapStatementClassOfStockAxis_cmmbOrdinarySharesNoParValuePerShareMember">Ordinary shares, no par-value</ix:nonNumeric>*</span></span></span></div>
                    </td>
                    <td style="width:0.72%;vertical-align:top;font-family:'Times New Roman',Times,serif">
                      <div style="line-height:1.25">&#160;</div>
                    </td>
                    <td style="width:14.68%;vertical-align:top;font-family:'Times New Roman',Times,serif">
                      <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="Fxbrl_20230213103458685" name="dei:TradingSymbol" contextRef="C_20240101to20241231_usgaapStatementClassOfStockAxis_cmmbOrdinarySharesNoParValuePerShareMember">NA</ix:nonNumeric></span></span></span></div>
                    </td>
                    <td style="width:0.72%;vertical-align:top;font-family:'Times New Roman',Times,serif">
                      <div style="line-height:1.25">&#160;</div>
                    </td>
                    <td style="width:28.17%;vertical-align:top;font-family:'Times New Roman',Times,serif">
                      <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="Fxbrl_20230213103452851" name="dei:SecurityExchangeName" contextRef="C_20240101to20241231_usgaapStatementClassOfStockAxis_cmmbOrdinarySharesNoParValuePerShareMember" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Capital Market</span></span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>*Not for trading; only in connection with the registration of American Depository Shares.</span></span></span></div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Securities registered or to be registered pursuant to Section 12(g) of the Act: <span style="font-weight:bold">None</span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: <span style="font-weight:bold">None</span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Indicate the number of outstanding shares of each of the issuer&#8217;s classes of capital stock or common stock as of the close of the period covered by the annual report. As of December 31, 2024, the registrant had outstanding <ix:nonFraction id="Fxbrl_20240325131407326" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_20241231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">377,132,220</ix:nonFraction> ordinary shares, no par value.</span></span></span></div>
              <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
                <div style="page-break-after:always">
                  <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
                </div>
              </div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Yes &#9744; &#160; &#160; &#160; <ix:nonNumeric id="Fxbrl_20240325131448134" name="dei:EntityWellKnownSeasonedIssuer" contextRef="C_20240101to20241231">No</ix:nonNumeric>&#160;<span style="font-weight:bold">&#9746;</span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.</span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Yes &#9744; &#160; &#160; &#160; <ix:nonNumeric id="Fxbrl_20240325131518183" name="dei:EntityVoluntaryFilers" contextRef="C_20240101to20241231">No</ix:nonNumeric>&#160;<span style="font-weight:bold">&#9746;</span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Note-Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.</span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="Fxbrl_20240325131547950" name="dei:EntityCurrentReportingStatus" contextRef="C_20240101to20241231">Yes</ix:nonNumeric>&#160;<span style="font-weight:bold">&#9746;</span> &#160; &#160; &#160; No &#9744;</span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="Fxbrl_20240325131614371" name="dei:EntityInteractiveDataCurrent" contextRef="C_20240101to20241231">Yes</ix:nonNumeric>&#160;<span style="font-weight:bold">&#9746;</span> &#160; &#160; &#160; No &#9744;</span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:Arial;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:25.66%;vertical-align:top">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#9744; Large accelerated filer</span></span></span></span></div>
                    </td>
                    <td style="width:19.5%;vertical-align:top">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#9744; Accelerated filer</span></span></span></span></div>
                    </td>
                    <td style="width:24.4%;vertical-align:top">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#9746; <ix:nonNumeric id="Fxbrl_20240325131641177" name="dei:EntityFilerCategory" contextRef="C_20240101to20241231" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></span></span></span></span></div>
                    </td>
                    <td style="width:30.44%;vertical-align:top">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="Fxbrl_20240325172008738" name="dei:EntityEmergingGrowthCompany" contextRef="C_20240101to20241231" format="ixt:fixed-false">&#9744;</ix:nonNumeric> Emerging growth company</span></span></span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#8201;provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.<ix:nonNumeric id="Fxbrl_20240327182011473" name="dei:IcfrAuditorAttestationFlag" contextRef="C_20240101to20241231" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span></span></span></div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.&#160;<ix:nonNumeric id="Fxbrl_20240325173248259" name="dei:DocumentFinStmtErrorCorrectionFlag" contextRef="C_20240101to20241231" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span></span></span></div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:Arial;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:11.82%;vertical-align:top">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#9746; <ix:nonNumeric id="Fxbrl_20240325172525187" name="dei:DocumentAccountingStandard" contextRef="C_20240101to20241231">U.S. GAAP</ix:nonNumeric></span></span></span></span></div>
                    </td>
                    <td style="width:80.4%;vertical-align:top">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#9744; International Financial Reporting Standards as issued by the International Accounting Standards Board</span></span></span></span></div>
                    </td>
                    <td style="width:7.78%;vertical-align:top">
                      <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">&#9744; Other</span></span></span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>If &#8220;Other&#8221; has been checked in response to the previous question indicate by check mark which financial statement item the registrant has elected to follow.</span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Item 17 &#9744; &#160; &#160; &#160; Item 18 &#9744;</span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Yes &#9744; &#160; &#160; &#160; No <span style="font-weight:bold"><ix:nonNumeric id="Fxbrl_20240325132317597" name="dei:EntityShellCompany" contextRef="C_20240101to20241231" format="ixt:fixed-false">&#9746;</ix:nonNumeric></span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.</span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Yes &#9744; &#160; &#160; &#160; No <span style="font-weight:bold"><ix:nonNumeric id="Fxbrl_20240327183652256" name="dei:DocumentFinStmtErrorCorrectionFlag" contextRef="C_20240101to20241231" format="ixt:fixed-false">&#9746;</ix:nonNumeric></span></span></span></span></div>
              <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
                <div style="page-break-after:always">
                  <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
                </div>
              </div>
            </div>
            <div style="line-height:1.25">&#160;</div>
          </div>
        </div>
      </div>
    </div>
  </div>

      <div>
        <!-- Field: Include-Text; File: PF\body.htm; Date: 2025%2D04%2D05T00:11:34; Size: 0x00146010; Options: XMLPreprocess -->
<p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman"> </span></p>

<div>

<div> <br/> </div>

<table cellspacing="0" cellpadding="0" id="z79d8c4efb6784e2fbc31fa2dc6ad54c7" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td colspan="2" style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#CAUTIONARYSTATEMENTREGARD">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
        STATEMENTS</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">2<br/> </td> </tr>
  <tr>
    <td colspan="2" style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td colspan="2" style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#PRESENTATIONOFFINANCIALIN">PRESENTATION OF FINANCIAL AND OTHER INFORMATION</a></div>
        </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">5<br/> </td> </tr>
  <tr>
    <td colspan="2" style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td colspan="2" style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#PARTI">PART I</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">6<br/> </td> </tr>
  <tr>
    <td colspan="2" style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td colspan="2" style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#Item1">ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</a></div>
        </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">6<br/> </td> </tr>
  <tr>
    <td colspan="2" style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td colspan="2" style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#Item2">ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">6<br/> </td> </tr>
  <tr>
    <td colspan="2" style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td colspan="2" style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#Item3">ITEM 3. KEY INFORMATION</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">6<br/> </td> </tr>
  <tr>
    <td colspan="2" style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">A.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">[Reserved.]</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">6<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">B.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Capitalization and Indebtedness</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">6<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">C.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Reasons for the Offer and Use of Proceeds</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">6<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">D.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Risk Factors</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">6<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td colspan="2" style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#Item4">ITEM 4. INFORMATION ON THE COMPANY</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">34<br/> </td> </tr>
  <tr>
    <td colspan="2" style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">A.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">History and Development of the Company</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">34<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">B.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Business Overview</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">35<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">C.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Organizational Structure</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">D.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Property, Plants and Equipment</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td colspan="2" style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#Item4A">ITEM 4A. UNRESOLVED STAFF COMMENTS</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">83<br/> </td> </tr>
  <tr>
    <td colspan="2" style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td colspan="2" style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#Item5">ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">83<br/> </td> </tr>
  <tr>
    <td colspan="2" style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">A.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Operating Results</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">84<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">B.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Liquidity and Capital Resources</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">91<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">C.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Research and Development, Patents and Licenses, Etc.</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">91<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">D.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Trend Information</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">91<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">E.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Critical Accounting Estimates</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">91<br/> </td> </tr>
  </table>

<div><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div><br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td colspan="2" style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#Item6">ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">92<br/> </td> </tr>
  <tr>
    <td colspan="2" style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">A.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Directors and Senior Management</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">92<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">B.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Compensation</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">94<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">C.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Board Practices</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">99<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">D.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Employees</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">109<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">E.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Share Ownership</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">109</td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">F.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Disclosure of a Registrant&#8217;s Action to Recover Erroneously Awarded Compensation</div>
        </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">109</td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td colspan="2" style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#Item7">ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</a></div>
        </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">109</td> </tr>
  <tr>
    <td colspan="2" style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">A.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Major Shareholders</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">109</td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">B.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Related Party Transactions</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">112<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">C.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Interests of Experts and Counsel</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">112<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td colspan="2" style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#Item8">ITEM 8. FINANCIAL INFORMATION</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">112<br/> </td> </tr>
  <tr>
    <td colspan="2" style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">A.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Consolidated Statements and Other Financial Information</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">112<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">B.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Significant Changes</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">113<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td colspan="2" style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#Item9">ITEM 9. THE OFFER AND LISTING</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">113<br/> </td> </tr>
  <tr>
    <td colspan="2" style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">A.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Offer and Listing Details</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">113<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">B.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Plan of Distribution</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">113<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">C.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Markets</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">113<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">D.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Selling Shareholders</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">113<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">E.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Dilution</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">113<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">F.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Expenses of the Issue</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">113<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td colspan="2" style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#Item10">ITEM 10. ADDITIONAL INFORMATION</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">114<br/> </td> </tr>
  <tr>
    <td colspan="2" style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">A.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Share Capital</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">114<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">B.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Memorandum and Articles of Association</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">114<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">C.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Material Contracts</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">114<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">D.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Exchange Controls</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">115<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">E.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Taxation</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">115<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">F.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Dividends and Paying Agents</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">124<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">G.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Statement by Experts</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">124<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">H.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Documents on Display</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">124<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">I.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Subsidiary Information</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">125<br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 6.01%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">J.</div> </td>
    <td style="width: 89%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Annual Report to Security Holders</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">125<br/> </td> </tr>
  </table>

<div> <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div> <br/> </div>

<table cellspacing="0" cellpadding="0" id="zc60093ea7afe4b7a85656356b6b15999" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#Item11">ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></div>
        </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">125<br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#Item12">ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</a></div>
        </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">126<br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#PARTII">PART II</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">133<br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#Item13">ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</a></div>
        </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">133<br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#Item14">ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS
        AND USE OF PROCEEDS</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">134<br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#Item15">ITEM 15. CONTROLS AND PROCEDURES</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">134<br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#Item16">ITEM 16. [RESERVED]</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">135<br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#Item16A">ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">135<br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#Item16B">ITEM 16B. CODE OF ETHICS</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">135<br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#Item16C">ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">135<br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#Item16D">ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</a></div>
        </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">136<br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#Item16E">ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED
        PURCHASERS</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">136<br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#Item16F">ITEM 16F. CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</a></div>
        </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">136<br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#Item16G">ITEM 16G. CORPORATE GOVERNANCE</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">136<br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#Item16H">ITEM 16H. MINE SAFETY DISCLOSURE</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">137<br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#Item16I">ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT
        INSPECTIONS</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">137<br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#Item16J">ITEM 16J. INSIDER TRADING POLICY</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">138<br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#Item16K">ITEM 16K. CYBERSECURITY</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">138<br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#PARTIII">PART III</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">139<br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#Item17">ITEM 17. FINANCIAL STATEMENTS</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">139<br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#Item18">ITEM 18. FINANCIAL STATEMENTS</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">139<br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#Item19">ITEM 19. EXHIBITS</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">139<br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold"><a href="#SIGNATURES">SIGNATURES</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">141<br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">INDEX</div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman; text-align: center">F-1<br/> </td> </tr>
  </table>

<div> <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman; font-weight: bold">INTRODUCTION</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman">&#160;&#160;&#160;&#160; In this
Annual Report on Form 20-F (the &#8220;Annual Report&#8221;), unless context otherwise requires:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z25be5018b6d641fcbe3fe6c2cbc1dca1" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">references to &#8220;Chemomab Therapeutics Ltd.&#8221;, &#8220;Chemomab,&#8221; the
        &#8220;Company,&#8221; &#8220;us,&#8221; &#8220;we&#8221; and &#8220;our&#8221; refer to Chemomab Therapeutics Ltd., an Israeli company
        and its consolidated subsidiaries; however, with respect to the presentation of financial results for historical periods that preceded
        the Merger (as defined below), these terms refer to the financial results of the Company&#8217;s wholly owned subsidiary, Chemomab Ltd.,
        which was the accounting acquirer in the Merger;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6378354e595145618861979b99949511" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">references to &#8220;ordinary shares,&#8221; &#8220;our shares&#8221; and similar
        expressions refer to the Company&#8217;s ordinary shares, no nominal (par) value;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1a0c01248fea404980b55902f2a33b87" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">references to &#8220;ADS&#8221; refer to the American Depositary Shares listed on
        the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;CMMB,&#8221; each representing twenty (20) ordinary shares;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z67211844d0c14f05b538a128a9354a9c" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">references to &#8220;dollars,&#8221; &#8220;U.S. dollars&#8221; and &#8220;$&#8221;
        are to United States Dollars;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5d3639e335bd4c2a8e56f2be213184c8" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">references to &#8220;NIS&#8221; are to New Israeli Shekels;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8e23f3e3e8d84b45b87dbf749e15e5c8" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">references to the &#8220;Companies Law&#8221; are to Israel&#8217;s Companies Law,
        5759-1999, as amended;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z83259753e830410fb29e771004c6a677" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">references to the &#8220;SEC&#8221; are to the U.S. Securities and Exchange Commission;
        and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za56dc926993e4bdea11ace2d7a05f371" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">references to the &#8220;Merger&#8221; refer to the merger involving Anchiano Therapeutics
        Ltd., or Anchiano, and Chemomab Ltd., whereby a wholly owned subsidiary of Anchiano merged with and into Chemomab Ltd., with Chemomab
        Ltd. surviving as a wholly owned subsidiary of Anchiano. Upon consummation of the Merger on March 16, 2021, Anchiano changed its name
        to &#8220;Chemomab Therapeutics Ltd.&#8221; and the business conducted by Chemomab Ltd. became primarily the business conducted by the
        Company.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;This Annual Report contains
estimates, projections and other information concerning our industry and our business, as well as data regarding market research, estimates
and forecasts prepared by our management. Information that is based on estimates, forecasts, projections, market research or similar methodologies
is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances that are
assumed in this information. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of
factors, including those discussed under the headings &#8220;Special Note Regarding Forward-Looking Statements&#8221; and Item 3.D. &#8220;Risk
Factors&#8221; in this Annual Report.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>
<!--PROfilePageNumberReset%Num%2%%%-->

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman; font-weight: bold"><span id="CAUTIONARYSTATEMENTREGARD"><!--Anchor--></span>CAUTIONARY
STATEMENT REGARDING FORWARD-LOOKING STATEMENTS AND A </div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman; font-weight: bold">SUMMARY OF RISK FACTORS</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;This Annual Report contains
forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. We intend such forward-looking
statements to be covered by the safe harbor provisions for forward-looking statements as contained in Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). All statements
contained in this Annual Report other than statements of historical fact, including, without limitation, statements regarding our future
operating results and financial position, including our revenue and operating expenses profitability; our business strategies and plans;
our expectations regarding the development of our industry and the competitive environment in which we operate; our expectations regarding
partnerships and collaborations; our objectives for future operations; our ability to raise additional capital to fund our operations;
and the sufficiency of our cash, cash equivalents and short-term investments, are forward-looking statements. The words &#8220;may,&#8221;
&#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221;
&#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;seek,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221;
&#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;contemplate,&#8221; &#8220;possible,&#8221; &#8220;forecasts,&#8221;
&#8220;aims&#8221; or the negative of these terms and similar expressions are intended to identify forward-looking statements, though
not all forward-looking statements use these words or expressions. These forward-looking statements are contained principally in the sections
titled Item 3.D. &#8220;Key Information-Risk Factors,&#8221; Item 4. &#8220;Information on the Company,&#8221; and Item 5. &#8220;Operating
and Financial Review and Prospects.&#8221; These statements are neither promises nor guarantees, but involve known and unknown risks,
uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from
any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to,
the following:</div>

<div style="line-height: 1.25; font-family: Times New Roman"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z3b249ad9582a46e7a5bdb451e146b92b" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.27%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">we have incurred significant losses since inception and anticipate that we will continue
        to incur increasing levels of operating losses over the next several years and for the foreseeable future. We are unable to predict the
        extent of any future losses or when we will become profitable, if at all. Even if we become profitable, we may not be able to sustain
        or increase our profitability on a quarterly or annual basis;&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">we have a limited operating history and funding, which may make it difficult to evaluate
        our prospects and likelihood of success;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">our business is highly dependent on the success of our lead product candidate, nebokitug,
        and any other product candidates that we advance into clinical studies. All of our programs will require significant additional clinical
        development;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">our central objective is to design and develop targeted treatments for inflammation
        and fibrosis with an initial focus on the antagonism of CCL24 signaling, which is known to regulate fibrotic and inflammatory processes.
        While several studies are currently underway, our approach in the area of fibrotic diseases is novel and unproven and may not result in
        marketable products;&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the successful completion of clinical studies is a prerequisite to submitting a marketing
        application to the FDA and similar marketing applications to comparable foreign regulatory authorities, for each product candidate and,
        consequently, the ultimate approval and commercial marketing of any product candidates. We may experience negative or inconclusive results,
        which may result in us deciding, or regulators requiring us, to conduct additional clinical studies or trials or abandon some or all of
        our product development programs, which could have a material adverse effect on our business;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">we may encounter difficulties enrolling patients in our clinical studies, including
        any public health emergencies and related clinical development activities could be delayed or otherwise adversely affected;</div> </td>
        </tr>
  <tr>
    <td rowspan="1" style="width: 3.27%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 96.73%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">our ongoing and future clinical studies may reveal significant adverse events or immunogenicity-related
        responses and may result in a safety profile that could delay or prevent regulatory approval or market acceptance of our product candidate;&#160;</div>
        </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the regulatory approval processes of the FDA and comparable foreign authorities are
        lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for nebokitug or any
        other product candidates, our business will be substantially harmed;&#160;</div> </td> </tr>
  </table> <br/>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">2</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div> <br/>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">if we do not achieve our projected development and commercialization goals in the
        timeframes we announce and expect, the commercialization of our product candidates may be delayed and our business will be harmed;&#160;</div>
        </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">we face substantial competition, which may result in others discovering, developing
        or commercializing products before or more successfully than us;&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">we have been granted Orphan Drug Designation for nebokitug in connection with three
        indications and may seek Orphan Drug Designation for other indications or product candidates, and we may be unable to maintain the benefits
        associated with Orphan Drug Designation, including the potential for market exclusivity, and may not receive Orphan Drug Designation for
        other indications or for our other product candidates;&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">we expect to experience significant growth in the number of our employees over time
        and the scope of our operations, particularly in the areas of product candidate development, regulatory affairs and sales and marketing.
        We will therefore need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our
        operations;&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">if we are unable to protect our patents or other proprietary rights, or if we infringe
        the patents or other proprietary rights of others, our competitiveness and business prospects may be materially damaged. In addition,
        changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect
        our product candidates;&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">risks related to our operations in Israel could materially adversely impact our business,
        financial condition and results of operations;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">our principal executive offices are located in Israel and US and certain of our product
        candidates may be manufactured at third-party facilities located in Europe. In addition, our business strategy includes potentially expanding
        internationally if any of our product candidates receives regulatory approval. A variety of risks associated with operating internationally
        could materially adversely affect our business;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">holders of ADSs are not treated as holders of our Ordinary Shares;&#160;</div> </td>
        </tr>
  </table> <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">3</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" id="z88f588aa0d2d489da77ee13ef58eab56" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">holders of ADSs may not have the same voting rights as the holders of our Ordinary
        Shares and may not receive voting materials in time to be able to exercise their right to vote;&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">holders of ADSs may be subject to limitations on the transfer of their ADSs and the
        withdrawal of the underlying Ordinary Shares;&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">we are entitled to amend the deposit agreement and to change the rights of ADS holders
        under the terms of such agreement, or to terminate the deposit agreement, without the prior consent of the ADS holders;&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">ADSs holders may not be entitled to a jury trial with respect to claims arising under
        the deposit agreement, which could result in less favorable outcomes to the plaintiff(s) in any such action;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">obtaining and maintaining our patent protection depends on compliance with various
        procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection
        could be reduced or eliminated for non-compliance with these requirements;&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the regulatory approval processes of the FDA and comparable foreign authorities are
        lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for nebokitug or any
        other product candidates, our business will be substantially harmed;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">obtaining and maintaining regulatory approval of our product candidates in one jurisdiction
        does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions;</div> </td>
        </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">even if we obtain regulatory approval for nebokitug or any product candidate, we will
        still face extensive and ongoing regulatory requirements and obligations and any product candidates, if approved, may face future development
        and regulatory difficulties;&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">disruptions at the FDA and other government agencies caused by funding shortages or
        global health concerns could hinder our ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new
        or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our
        business;&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">if we do not achieve our projected development and commercialization goals in the
        timeframes we announce and expect, the commercialization of our product candidates may be delayed and our business will be harmed;</div>
        </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">we face substantial competition, which may result in others discovering, developing
        or commercializing products before or more successfully than us;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">even if nebokitug or any other product candidate we develop receives marketing approval,
        it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for
        commercial success;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">we rely completely on third-party suppliers to manufacture our clinical drug supplies
        for our product candidates, and we intend to rely on third parties to produce preclinical, clinical, and commercial supplies of any future
        product candidates;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">if we are unable to establish sales, marketing and distribution capabilities either
        on our own or in collaboration with third parties, we may not be successful in commercializing nebokitug, if approved;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">a variety of risks associated with operating internationally could materially adversely
        affect our business;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">conditions in Israel, including the ongoing hostilities&#160; by Hamas and other terrorist
        organizations from the Gaza Strip and Israel&#8217;s war against them, may affect our operations;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">because a certain portion of our expenses are incurred in currencies other than the
        U.S. Dollar, our results of operations may be harmed by currency fluctuations and inflation;</div> </td> </tr>
  </table>

<div> <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">4</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" id="za39258909a83495ab9ba76191f7508c2" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">we received Israeli government grants for certain of their research and development
        activities as detailed below. The terms of those grants require us to satisfy specified conditions in order to transfer outside of Israel
        the manufacture of products based on know-how funded by the Israel Innovation Authority or to transfer outside of Israel the know-how
        itself. If we fail to comply with the requirements of Israeli law in this regard, we may be required to pay penalties, and it may impair
        our ability to sell our technology outside of Israel;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">we will need to raise additional capital to fund our operations, which may be unavailable
        to us on acceptable terms or at all, or may cause dilution or place significant restrictions on our ability to operate our business;</div>
        </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the trading price of the ADSs has been highly volatile, and is expected to continue
        to be volatile;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">we have not paid dividends in the past and do not expect to pay dividends in the future,
        and, as a result, any return on investment may be limited to the value of the ADSs; and</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">if we fail to continue to meet all applicable Nasdaq requirements, Nasdaq may delist
        the ADSs, which could have an adverse impact on the liquidity and market price of the ADSs.</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;You should not rely on forward-looking
statements as predictions of future events. We have based the forward-looking statements contained in this Annual Report primarily on
our current expectations and projections about future events and trends that we believe may affect our business, financial condition and
operating results. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and other
factors described in the section titled &#8220;Risk factors&#8221; and elsewhere in this Annual Report. Moreover, we operate in a very
competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict
all risks and uncertainties that could have an impact on the forward-looking statements contained in this Annual Report. The results,
events and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results, events or circumstances
could differ materially from those described in the forward-looking statements.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;The forward-looking statements
made in this Annual Report relate only to events as of the date on which the statements are made. We undertake no obligation to update
any forward-looking statements made in this Annual Report to reflect events or circumstances after the date of this Annual Report or to
reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions
or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements.
Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or
investments.<br/> &#160;</div>

<div style="text-align: center; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman; font-weight: bold"><span id="PRESENTATIONOFFINANCIALIN"><!--Anchor--></span>PRESENTATION
OF FINANCIAL INFORMATION</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;Our consolidated financial
statements have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. We present
our consolidated financial statements in U.S. dollars.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;Our fiscal year ends on December
31 of each year.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;Certain monetary amounts,
percentages and other figures included elsewhere in this Annual Report have been subject to rounding adjustments. Accordingly, figures
shown as totals in certain tables or charts may not be the arithmetic aggregation of the figures that precede them, and figures expressed
as percentages in the text may not total 100% or, as applicable, when aggregated may not be the arithmetic aggregation of the percentages
that precede them.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">5</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman; font-weight: bold"><span id="PARTI"><!--Anchor--></span>PART
I</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman; font-weight: bold">Item 1<span id="Item1"><!--Anchor--></span>. Identity
of Directors, Senior Management and Advisers</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1529650bbf8b45c887e50a1a5c531721" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">Not applicable.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman; font-weight: bold">Item 2<span id="Item2"><!--Anchor--></span>. Offer Statistics
and Expected Timetable</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze2b5970b38114033aab7a6d2f43bb3fb" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">Not applicable.</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br/>
</div>

<div style="line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold">Item 3<span id="Item3"><!--Anchor--></span>.
Key Information</span>&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z58aa7139cd3b460eb11fff80f84ea86e" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: middle">
        <div style="line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold">A.</span>&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold">[Reserved.]</span>&#160;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf2fd34d3f8994955a6e3f50bd76072c0" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">B.</div> </td>
    <td style="width: 97.5%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold">Capitalization and Indebtedness</span>&#160;</div>
        <div style="line-height: 1.25; font-family: Times New Roman"><span style="line-height: 1.25">&#160;</span></div>
        <div style="line-height: 1.25; font-family: Times New Roman">Not applicable.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2ff25b63199a465086be95a5aae21303" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">C.</div> </td>
    <td style="width: 97.5%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold">Reasons for the Offer and Use of Proceeds</span>&#160;</div>
        <div style="line-height: 1.25; font-family: Times New Roman"><span style="line-height: 1.25">&#160;</span></div>
        <div style="line-height: 1.25; font-family: Times New Roman">Not applicable.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold">D.</span>&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold">Risk Factors</span>&#160;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; font-style: italic">You should carefully
consider the risks and uncertainties described below and the other information contained in this Annual Report before making an investment
decision. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business
operations. Our business, financial condition, results of operations, or strategic objectives could be materially and adversely affected
by any of these risks and uncertainties. The trading price and value of our ordinary shares could decline due to any of these risks and
uncertainties, and you may lose all or part of your investment. This Annual Report also contains forward- looking statements that involve
risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result
of certain factors, including the risks and uncertainties faced by us described below and elsewhere in this Annual Report.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Risks Relating to Our Business and
Industry</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Our limited operating
history and funding may make it difficult to evaluate our prospects and likelihood of success.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We are a clinical-stage biopharmaceutical
company with a limited operating history. We were&#160; incorporated in 2011, have no products approved for commercial sale and have not
generated any revenue. Our operations to date have been limited to organizing and staffing the company, business planning, raising capital,
establishing our intellectual property portfolio and conducting research and development of our product candidates, technology related
to CCL24 and novel therapies for the treatment of inflammation and fibrosis. Our approach to the discovery and development of product
candidates is unproven, and we do not know whether we will be able to develop any products of commercial value. In addition, our lead
product candidate, nebokitug (CM-101), is in relatively early clinical development for the treatment of primary sclerosing cholangitis
(PSC) (as defined below) and systemic sclerosis (SSc) (as defined below). The clinical programs will require substantial additional development
and clinical research, both in time and resources, before we are in a position to apply for or receive regulatory approvals and begin
generating revenue in connection with the sale of such product candidates. We have not yet demonstrated the ability to successfully complete
a large-scale, pivotal clinical trial, obtain marketing approval, manufacture a commercial scale product, or arrange for a third party
to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, predictions
about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully
developing and commercializing pharmaceutical products. &#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">6</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold; font-style: italic">Our business is highly
dependent on the success of our lead product candidate, nebokitug, and any other product candidates that we advance into clinical studies.
All of our programs will require significant additional clinical development.</span>&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We currently have no products that
are approved for commercial sale and may never be able to develop marketable products. We are relatively early in our development efforts
and have only one product candidate, nebokitug, in clinical development. Because nebokitug is our lead product candidate, if&#160; nebokitug
encounters safety or efficacy problems, development delays, regulatory issues or other problems, our development plans and business would
be significantly harmed. We have completed a Phase 1a single ascending dose (SAD) safety study in healthy volunteers, a Phase 1b multiple
ascending dose (MAD) study of nebokitug in metabolic-associated fatty liver disease, or MAFLD, a Phase 2a safety, Pk and liver fibrosis
biomarker study in metabolic dysfunction-associated steatohepatitis, or MASH patients, an open-label exploratory study in severe lung
injury in hospitalized COVID-19 patients and a Phase 2 trial in PSC patients.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We expect that a substantial portion
of our efforts and expenditures over the next few years will be devoted to nebokitug, which will require additional clinical development,
management of clinical and manufacturing activities, regulatory approval in multiple jurisdictions, obtaining manufacturing supply, building
of a commercial organization, substantial investment and significant marketing efforts before we can generate any revenues from any commercial
sales. We cannot be certain that we will be able to successfully complete any of these activities. In addition, if one or more of our
product candidates are approved, we may need to ensure access to sufficient commercial manufacturing capacity and conduct significant
marketing efforts in connection with any commercial launch. These efforts will require substantial investment, and we may not have the
financial resources to continue the development of our product candidates. &#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold; font-style: italic">We
will need to raise substantial additional funds through public or private equity or debt transactions and/or complete one or more strategic
transactions or partnerships, to complete development of nebokitug or any other product candidates. If we are unable to raise such financing
or complete such a transaction, we may not be able to fund the clinical trials of our product candidates and potentially commercialize
those product candidates.</span>&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">As a result of the expected development
timeline to potentially obtain FDA approval for nebokitug, the substantial additional costs associated with the development of our product
candidates, including the costs associated with clinical trials related thereto, and the substantial cost of commercializing nebokitug,
we will need to raise substantial additional funding through public or private equity or debt transactions or a strategic combination
or partnership. If we are delayed in obtaining funding or are unable to complete a strategic transaction, we may have to delay or discontinue
development activities on nebokitug and our other product candidates. Even if we are able to fund continued development of nebokitug&#160;
or any of our other product candidates is approved, we expect that we will need to raise substantial additional funding through public
or private equity or debt securities or complete a strategic transaction or partnership to successfully commercialize nebokitug or any
other product candidate.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We believe our cash and cash equivalents
and bank deposits as of December 31, 2024, will be sufficient to fund our operations through the first quarter&#160; of 2026. Sales of
our ADSs dilute the ownership interest of our shareholders and may cause the price per ADS to decrease. Changing circumstances may cause
us to consume capital significantly faster or slower than we currently anticipate. We have based these estimates on assumptions that may
prove to be wrong, and we could exhaust our available financial resources sooner than currently anticipated.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our liquidity, and ability to raise additional capital
or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zeb3f893ce16d46c693fe105fd9978a08" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the costs and timing for potential additional clinical trials in order to gain possible
        regulatory approval for nebokitug and our other product candidates;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the market price of our ADSs and the availability and cost of additional equity capital
        from existing and potential new investors;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">our ability to retain the listing of our ADSs on the Nasdaq Capital Market;</div>
        </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">general economic and industry conditions affecting the availability and cost of capital,
        including as a result of deteriorating market conditions due to investor concerns regarding inflation, the imposition of tariffs and other
        measures affecting trade and the economy in the U.S. and continued hostilities between Israel and Hamas, and Russia and Ukraine;</div>
        </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">our ability to control costs associated with our operations;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the costs of filing, prosecuting, defending and enforcing any patent claims and other
        intellectual property rights; and</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the terms and conditions of our existing collaborative and licensing agreements.</div>
        </td> </tr>
  </table>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">7</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The sale of additional equity or
convertible debt securities would likely result in substantial dilution to our shareholders. If we raise additional funds through the
incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of our capital stock and
could contain covenants that would restrict our operations. We also cannot predict what consideration might be available, if any, to us
or our shareholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available
to us, or not be available on acceptable terms, we may be unable to realize value from our assets and discharge our liabilities in the
normal course of business which may, among other alternatives, cause us to further delay, substantially reduce or discontinue operational
activities to conserve our cash resources. &#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold; font-style: italic">Our
approach in the area of fibrotic diseases is novel and unproven and may not result in marketable products. </span>&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our central objective is to design
and develop targeted treatments for inflammation and fibrosis with an initial focus on the neutralization of CCL24 signaling, which is
shown to regulate fibrotic and inflammatory processes. While several studies are currently underway, this mechanism has not yet been proven
to successfully treat inflammation and fibrosis in patients. Targeting CCL24 to treat inflammation and fibrosis is a novel approach in
a rapidly developing field, and there can be no assurance that we can avoid unforeseen problems or delays in the development of our product
candidates, that such problems or delays will not result in unanticipated costs, or that any such development problems can or will be
solved. We have completed clinical studies of our lead product candidate, nebokitug, in relatively early trials in healthy volunteers,
MAFLD, MASH, PSC and COVID-19 lung injury patients. Therefore, we may ultimately discover that our approach does not possess properties
required for therapeutic effectiveness. As a result, we may elect to abandon the program or never succeed in developing a marketable product,
which would have a significant effect on the success and profitability of our business. &#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Clinical development
involves a lengthy, complex and expensive process, with an uncertain outcome.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold; font-style: italic">&#160;</span>&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">Before obtaining the requisite
regulatory approvals from the FDA or other comparable foreign regulatory authorities for the sale of any of our product candidates, we
must support our application with clinical studies that prove that such product candidate is safe and effective in humans. Clinical testing
is expensive and can take many years to complete, and its outcome is inherently uncertain. In particular, the general approach for FDA
approval of a new drug requires positive data from two well-controlled Phase 3 clinical studies of the relevant drug in the relevant patient
population. Failure can occur at any time during the clinical study process. We may experience delays in initiating and completing any
clinical studies that we are conducting or intend to conduct, including as a result of public health emergencies, and we do not know whether
our ongoing or planned clinical studies will begin or progress on schedule, need to be redesigned, enroll patients on time or be completed
on schedule, or at all.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">8</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">Phase 3 clinical studies typically
involve hundreds of patients, have significant costs and take years to complete. A product candidate can fail at any stage of testing,
even after observing promising signals of activity in earlier preclinical studies or clinical trials. The results of preclinical studies
and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical studies. In addition,
initial or interim success in clinical studies may not be indicative of results obtained when such studies are completed. There is typically
an extremely high rate of attrition from the failure of product candidates proceeding through clinical studies. Product candidates in
later stages of clinical studies may fail to show the desired safety and efficacy profile despite having progressed through preclinical
studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced
clinical studies due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier studies. Most product
candidates that commence clinical studies are never approved as products and there can be no assurance that any of our future clinical
studies will ultimately be successful or support further clinical development of nebokitug. Product candidates that appear promising in
the early phases of development may fail to reach the market for several reasons, including:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z30b2cdcab0564fafb1598731eed0748d" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the FDA or comparable foreign regulatory authorities disagreeing as to the design
        or implementation of our clinical studies;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">obtaining regulatory authorizations to commence a trial or consensus with regulatory
        authorities on trial&#8217;s design;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">reaching an agreement on acceptable terms with prospective clinical research organizations,
        or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different
        CROs and trial sites;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">obtaining IRB approval at each site, or Independent Ethics Committee, or IEC, approval
        at sites outside the United States;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">imposition of a clinical hold by regulatory authorities, including as a result of
        unforeseen safety issues or side effects or failure of trial sites to adhere to regulatory requirements or follow trial protocols;</div>
        </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">clinical studies may show the product candidates to be less effective than expected
        (e.g., a clinical study could fail to meet its primary endpoint(s)) or to have unacceptable side effects or toxicities;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">failure to establish clinical endpoints that applicable regulatory authorities would
        consider clinically meaningful;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the occurrence of serious adverse events in trials of the same class of agents conducted
        by other companies;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">adding a sufficient number of clinical study sites;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">manufacturing sufficient quantities of product candidate with sufficient quality for
        use in clinical studies;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">having patients complete a trial or return for post-treatment follow-up;</div> </td>
        </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">recruiting suitable patients to participate in a trial in a timely manner and in sufficient
        numbers;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">a facility manufacturing our product candidates or any of their components being ordered
        by the FDA or comparable foreign regulatory authorities to temporarily or permanently shut down due to violations of current good manufacturing
        practice, or cGMP, regulations or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing
        process;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">third-party clinical investigators losing the licenses or permits necessary to perform
        our clinical studies, not performing our clinical studies on our anticipated schedule or consistent with the clinical study protocol,
        GCP, or other regulatory requirements;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">third-party contractors not performing data collection or analysis in a timely or
        accurate manner;</div> </td> </tr>
  </table>

<div>

<div> <br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">manufacturing costs, formulation issues, pricing or reimbursement issues, or other
        factors that make a product candidate uneconomical; or</div> </td> </tr>
  </table>

<div><br/> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">9</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div> <br/>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the proprietary rights of others and their competing products and technologies that
        may prevent our product candidates from being commercialized.</div> </td> </tr>
  </table>

<div> <br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;In addition, differences
in trial design between early-stage clinical studies and later-stage clinical studies make it difficult to extrapolate the results of
earlier clinical studies to later clinical studies. Moreover, clinical data are often susceptible to varying interpretations and analyses,
and many companies that have believed their product candidates performed satisfactorily in clinical studies have nonetheless failed to
obtain marketing approval of their products.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;In addition, the standards
used by the FDA and comparable foreign regulatory authorities when regulating us require judgment and can change, which makes it difficult
to predict with certainty how they will be applied. For more information, see &#8220;<span style="font-style: italic">Risk Factors &#8211;
Risks Related to Our Regulatory Approvals</span>.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;Successful completion of
clinical studies is a prerequisite to submitting a marketing application to the FDA and similar marketing applications to comparable foreign
regulatory authorities, for each product candidate and, consequently, the ultimate approval and commercial marketing of any product candidates.
We may experience negative or inconclusive results, which may result in us deciding, or us being required by regulators, to conduct additional
clinical studies or trials or abandon some or all of our product development programs, which could have a material adverse effect on our
business. &#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">We may incur
additional costs or experience delays in completing the development and commercialization of nebokitug or any other product candidates.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We may experience delays in initiating
or completing clinical studies. We also may experience numerous unforeseen events during, or as a result of, any future clinical studies
that could delay or prevent our ability to receive marketing approval or commercialize nebokitug or any other product candidates, including:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z94b9350e44d54395886ae82b826e3b57" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">regulators, IRBs, or IECs may not authorize us or our investigators to commence a
        clinical study or conduct a clinical study at a prospective trial site;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the FDA or other comparable regulatory authorities may disagree with our clinical
        study design, including with respect to dosing levels administered in our planned clinical studies, which may delay or prevent us from
        initiating our clinical studies with our originally intended trial design;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective
        trial sites and prospective CROs, which can be subject to extensive negotiation and may vary significantly among different CROs and trial
        sites;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the number of subjects required for clinical studies of any product candidates may
        be larger than we anticipate or subjects may drop out of these clinical studies or fail to return for post-treatment follow-up at a higher
        rate than we anticipate;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">our third-party contractors may fail to comply with regulatory requirements or meet
        our contractual obligations to us in a timely manner, or at all, or may deviate from the clinical study protocol or drop out of the trial,
        which may require that we add new clinical study sites or investigators;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">due to the impact of emerging public health threats, we may experience delays and
        interruptions to clinical studies, we may experience delays or interruptions to our manufacturing supply chain, or we could suffer delays
        in reaching, or we may fail to reach, agreement on acceptable terms with third-party service providers on whom we rely;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">additional delays and interruptions to our clinical studies could extend the duration
        of the trials and increase the overall costs to finish the trials as our fixed costs are not substantially reduced during delays;</div>
        </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">we may elect to, or regulators, IRBs, Data Safety Monitoring Boards or ethics committees may require that
        us or its investigators suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory
        requirements or a finding that the participants are being exposed to unacceptable health risks;</div> </td> </tr>
  </table> <br/>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">10</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">we may not have the financial resources available to begin and complete the planned trials, or the cost
        of clinical studies of any product candidates may be greater than we anticipate; and</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the supply or quality of our product candidates or other materials necessary to conduct
        clinical studies of our product candidates may be insufficient or inadequate to initiate or complete a given clinical study.</div> </td>
        </tr>
  </table>

<div> <br/> </div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our product development costs will
increase if we experience additional delays in clinical testing or in obtaining marketing approvals. We do not know whether any of our
clinical studies will begin as planned, will need to be restructured or will be completed on schedule, or at all. If we do not achieve
our product development goals in the time frames we announce and expects, the approval and commercialization of our product candidates
may be delayed or prevented entirely. Significant clinical study delays also could shorten any periods during which we may have the exclusive
right to commercialize our product candidates and may allow our competitors to bring products to market before we do, potentially impairing
our ability to successfully commercialize our product candidates and harming our business and results of operations. Any delays in our
clinical development programs may harm our business, financial condition and results of operations significantly.<br/> &#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Our ongoing and
future clinical studies may reveal significant adverse events or immunogenicity related responses and may result in a safety profile that
could delay or prevent regulatory approval or market acceptance of our product candidate.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We completed our Phase 1a and Phase
1b and Phase 2 clinical studies of our product candidate, nebokitug, in healthy volunteers, MAFLD, MASH, PSC and COVID-19 lung injury
patients, and, with the exception of a number of reported minor adverse events (including mild headaches, changes in blood pressure and
mild-moderate increases in liver enzymes,) and one serious adverse event (a transient ischemic attack or seizure judged to be unrelated
to administration of nebokitug, nebokitug&#160; was observed to be generally well-tolerated across all doses in about 120 trial participants.
Some potential therapeutics developed in the biopharmaceutical industry that initially showed therapeutic promise in early-stage trials
have later been found to cause side effects that prevented their further development and ultimately commercialization. Even if side effects
do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance
of the approved product due to its tolerability versus other therapies.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Protein biopharmaceuticals, including
monoclonal antibodies, or mAbs, may be immunogenic and promote immune responses against themselves. In particular, anti-drug antibodies,
or ADAs, may be produced by patients following infusion of mAbs and may disturb the pharmacokinetics of mAbs, neutralize their therapeutic
activities or induce allergic or autoimmune symptoms. Clinical immunogenicity can range from mild, transient antibody responses with no
apparent clinical manifestations to loss of therapeutic efficacy and even life-threatening reactions. Several approved therapeutic antibodies
have been found to induce neutralizing antibodies, as illustrated by the approved anti-TNFa antibodies infliximab and adalimumab as well
as the approved anti-IL-17 mAb ixekizumab. Our product candidate, nebokitug, is a humanized antibody that, similar to other humanized
approved mAbs, was shown to include several non-germline sequences that may serve as a source for immunogenicity in therapeutic antibodies.
Clinical studies to date have not identified any anti-drug antibodies, or ADAs. Additional larger clinical studies will be needed to address
the risk of immunogenicity and, if discovered, our business will be materially and adversely affected.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">11</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Additionally, if unacceptable side
effects, including materialized risks of immunogenicity, do arise in the development of our product candidates, we, the FDA or the IRBs
at the institutions in which our studies are conducted, or the Data Safety Monitoring Board, if constituted for our clinical studies,
could recommend a suspension or termination of our clinical studies, or the FDA or comparable foreign regulatory authorities could order
us to cease further development of or deny approval of a product candidate for any or all targeted indications. In addition, drug-related
side effects could affect patient recruitment or the ability of enrolled patients to complete a trial or result in potential product liability
claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have
to train medical personnel using our product candidates to understand the side effect profiles for our clinical studies and upon any commercialization
of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates
could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Additionally, if one or more of our
product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number
of potentially significant negative consequences could result, including:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5be2e7f3ff2b42cca66141ea7b14d93a" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">regulatory authorities may withdraw approvals of such product;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">regulatory authorities may require additional warnings on the label, such as a &#8220;black
        box&#8221; warning or contraindication;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">additional restrictions may be imposed on the marketing of the particular product
        or the manufacturing processes for the product or any component thereof;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS,
        or create a medication guide outlining the risks of such side effects for distribution to patients;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">we could be sued and held liable for harm caused to patients;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the product may become less competitive; and</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">our reputation may suffer.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Any of these events could prevent
us from achieving or maintaining market acceptance of a product candidate, if approved, and could significantly harm our business, results
of operations and prospects.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold; font-style: italic">Interim,
topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become
available or as additional analyses are conducted and are subject to audit and verification procedures that could result in material changes
in the final data.</span>&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">From time to time, we may publicly
disclose preliminary, interim or topline data from our clinical trials. The preliminary data is based on a preliminary analysis of then
available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the
data related to the particular study or trial. For example, we may report responses in certain patients that are unconfirmed at the time
and which do not ultimately result in confirmed responses to treatment after follow-up evaluations. We also make assumptions, estimations,
calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully
evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions
or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject
to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously
published. As a result, topline data should be viewed with caution until the final data are available. In addition, we may report interim
analyses of only certain endpoints rather than all endpoints. Interim data from clinical trials that we may complete are subject to the
risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available.
Adverse changes between interim data and final data could significantly harm our business and prospects. Further, additional disclosure
of interim data by us or by our competitors in the future could result in volatility in the price of our common stock.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">12</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In addition, the information we choose
to publicly disclose regarding a particular clinical trial is typically selected from a more extensive amount of available information.
You or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure,
and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views,
activities or otherwise regarding a particular product candidate or our business. If the preliminary or topline data that we report differ
from late, final or actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability
to obtain approval for any product candidates that we may develop in the future may be harmed, which could harm our business, financial
condition, results of operations and prospects.<br/> &#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold; font-style: italic">Changes
in methods of product candidate manufacturing or formulation may result in additional costs or delay. </span>&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">As product candidates progress through
preclinical studies and clinical trials to regulatory approval and commercialization, it is common that various aspects of the development
program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize yield and manufacturing batch
size, minimize costs and achieve consistent quality and results. Any material manufacturing changes made to any product candidate that
we may develop could perform differently and affect the results of planned clinical trials or other clinical trials conducted with the
altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of
one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commercialize
any product candidates that we may develop in the future, if approved, and generate revenue.<br/> &#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold; font-style: italic">If
we encounter difficulties enrolling patients in our clinical studies, our clinical development activities could be delayed or otherwise
adversely affected.</span><br/> &#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We may experience difficulties in
patient enrollment in our clinical studies for a variety of reasons. The timely completion of clinical studies in accordance with our
protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion.
The enrollment of patients depends on many factors, including:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z0792762353f44bfd8e114ff1b383a4b4" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">the patient eligibility and exclusion criteria defined in the protocol;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the need to receive study drug via an IV infusion;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the size of the patient population required for analysis of the trial&#8217;s primary
        endpoints and the process for identifying patients;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the willingness or availability of patients to participate in our trials;</div> </td>
        </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the proximity of patients to trial sites;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the design of the trial;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">our ability to recruit clinical study investigators with the appropriate competencies
        and experience;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and
        risks of the product candidate being studied with respect to other available therapies, including any new products that may be approved
        for the indications we are investigating;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the availability of competing commercially available therapies and other competing
        product candidates&#8217; clinical studies;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">our ability to obtain and maintain patient informed consents; and</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the risk that patients enrolled in clinical studies will drop out of the trials before
        completion.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Further, timely enrollment in clinical
studies is reliant on clinical study sites which may be adversely affected by global health matters, including, among other things, pandemics
or armed conflicts.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">13</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">

<div style="line-height: 1.25"><span style="font-weight: bold; font-style: italic">The market opportunities for nebokitug, if approved,
may be smaller than we anticipate.&#160; </span><br/> </div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We expect to initially seek approval
of nebokitug for the treatment of PSC and SSc. Our projections of the number of PSC and SSc patients is based on our beliefs and estimates.
These estimates have been derived from a variety of sources, including scientific literature, patient foundations and publicly available
databases, and may prove to be incorrect. Further, new sources may reveal a change in the estimated number of patients, and the number
of patients may turn out to be lower than we expected. The potential addressable patient population for our current programs or future
product candidates may be limited. The ultimate market opportunity for our product candidates will depend on, among other things, the
final labeling for such product candidates as agreed with the FDA or comparable foreign regulatory authorities, acceptance by the medical
community and patient access, potential competition and drug pricing and reimbursement. Even if we obtain significant market share for
any product candidate, if approved, if the potential target populations are small, we may never achieve profitability without obtaining
marketing approval for additional indications.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold; font-style: italic">Due
to our limited resources and access to capital, we must make decisions on the allocation of resources to certain programs and product
candidates; these decisions may prove to be wrong and may adversely affect our business.</span>&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We have limited financial and human
resources and intend to initially focus on research programs and product candidates for a limited set of indications. As a result, we
may forgo or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial
potential or a greater likelihood of success.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">There can be no assurance that we
will ever be able to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product
candidates through internal research programs, which could materially adversely affect our future growth and prospects. We may focus our
efforts and resources on potential product candidates or other potential programs that ultimately prove to be unsuccessful.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold; font-style: italic">If product liability
lawsuits are brought against us, we may incur substantial financial or other liabilities and may be required to limit commercialization
of our product candidates.</span><br/> &#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We face an inherent risk of product
liability as a result of testing nebokitug, and will face an even greater risk if we commercialize any products. For example, we may be
sued if any of our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical studies,
manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design,
a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted
under state consumer protection acts. If we cannot successfully defend itself against product liability claims, we may incur substantial
liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial
and management resources. Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential
product liability claims could prevent or inhibit the commercialization of products we develop. We will need to obtain additional insurance
for clinical studies as we continue clinical development of nebokitug&#160; and as additional product candidates enter clinical studies.
However, we may be unable to obtain, or may obtain on unfavorable terms, clinical study insurance in amounts adequate to cover any liabilities
from any of our clinical studies. Our insurance policies may also have various exclusions, and we may be subject to a product liability
claim for which we have no coverage. We may have to pay any amount awarded by a court or negotiated in a settlement that exceeds our coverage
limitations or that are not covered by insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even
if our agreements with any future corporate collaborators entitles us to indemnification against losses, such indemnification may not
be available or adequate should any claim arise.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">14</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-align: left; line-height: 1.25"><br/> </div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold; font-style: italic">We
have been granted Orphan Drug Designation for nebokitug&#160; in connection with three indications and may seek Orphan Drug Designation
for other indications or product candidates, and we may be unable to maintain the benefits associated with Orphan Drug Designation, including
the potential for market exclusivity, and may not receive Orphan Drug Designation for other indications or for our other product candidates.</span>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"></div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; text-indent: 36pt">Regulatory authorities in some jurisdictions,
including the United States and Europe, may designate drugs intended for relatively small patient populations as orphan drugs. Under the
Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is
generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than
200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales
in the United States. In the United States, Orphan Drug Designation has entitled a party to financial incentives such as opportunities
for grant funding toward clinical study costs, tax advantages and user-fee waivers. In addition, if a product that has Orphan Drug Designation
subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug
exclusivity, which means that the FDA may not approve any other applications, including a full NDA to market the same product for the
same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan
drug exclusivity or where the manufacturer is unable to assure sufficient product quantity. However, Orphan Drug Designation neither shortens
the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.
In 2022, the Eleventh Circuit&#8217;s decision in Catalyst Pharmaceuticals, Inc. v. FDA challenges FDA&#8217;s long-standing interpretation
and provides that the orphan drug exclusivity should be applied to block FDA approval of the same drug for the &#8220;same disease or
condition&#8221; instead of the approved indication during the exclusivity period. If the Catalyst decision is applied beyond the facts
of that case, FDA may revoke approvals or the grant of subsequent orphan exclusivity periods for the same drugs approved for different
indications within the same orphan-designated disease or condition. Catalyst has created some uncertainty with respect to the scope of
the orphan drug exclusivity and may increase legal challenges in the field. FDA may work with the Congress to amend the orphan drug provisions
in the law to provide more clarity to stakeholders. The extent of the impact of the Catalyst decision on the industry and on FDA&#8217;s
regulation and policies with respect to orphan exclusivity as well as the impact of any future legislation on orphan drug approval and
exclusivity is unclear.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In Catalyst Pharms., Inc. v. Becerra,
14 F.4th 1299 (11th Cir. 2021), the court disagreed with the FDA&#8217;s longstanding position that the orphan drug exclusivity only applies
to the approved use or indication within an eligible disease. This decision created uncertainty in the application of the orphan drug
exclusivity. On January 24, 2023, the FDA published a notice in the Federal Register to clarify that while the agency complies with the
court&#8217;s order in Catalyst, FDA intends to continue to apply its longstanding interpretation of the regulations to matters outside
of the scope of the Catalyst order &#8211; that is, the agency will continue tying the scope of orphan-drug exclusivity to the uses or
indications for which a drug is approved, which permits other sponsors to obtain approval of a drug for new uses or indications within
the same orphan designated disease or condition that have not yet been approved. It is unclear how future litigation, legislation, agency
decisions, and administrative actions will impact the scope of the orphan drug exclusivity.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The FDA and EMA granted Orphan Drug
Designation to nebokitug in its primary indications of PSC, SSc and idiopathic pulmonary fibrosis, or IPF. We may seek Orphan Drug Designations
for nebokitug in other indications or for other product candidates. There can be no assurance that we will be able to obtain such designations.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Even if we obtain Orphan Drug Designation
for any product candidate in specific indications, we may not be the first to obtain marketing approval of such product candidate for
the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. In addition, exclusive marketing
rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may
be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure
sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Further, even if we obtain orphan
drug exclusivity in the United States for a product, that exclusivity may not effectively protect the product from competition because
different drugs with different active moieties can be approved for the same condition. Even after an orphan product is approved, the FDA
can subsequently approve the same drug with the same active moiety for the same condition if the FDA concludes that the later drug is
safer, more effective or makes a major contribution to patient care.<br/> &#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">15</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold; font-style: italic">We
will need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.
</span>&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;As of December 31, 2024,
we had 16 employees /&#160; consultants. In the future, we expect to experience significant growth in the number of our employees and
the scope of our operations, particularly in the areas of product candidate development, regulatory affairs and sales and marketing. We
may have difficulty identifying, hiring and integrating new personnel. Future growth would impose significant additional responsibilities
on our management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors.
Also, our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial
amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may
result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced
productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources
from other projects, such as the development of product candidates. If our management is unable to effectively manage our growth, our
expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement
our business strategy. Our future financial performance and our ability to commercialize our product candidates and compete effectively
will depend, in part, on our ability to effectively manage any future growth.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;Many of the biopharmaceutical
companies that we compete against for qualified personnel and consultants have greater financial and other resources, different risk profiles
and a longer history in the industry than we do. If we are unable to continue to attract and retain high-quality personnel and consultants,
the rate and success at which we can discover and develop product candidates and operate our business will be limited.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold; font-style: italic">We
have incurred significant operating losses since our inception and anticipate we will incur continued losses for the foreseeable future.</span>&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We have funded our operations to date through
proceeds from sales of our equity and grants from the Israel Innovation Authority, or the IIA, which as of December 31, 2024, resulted
in gross proceeds of approximately $1.2 million. As of December 31, 2024, our cash, cash equivalents and deposits were approximately $14.3
million. We have incurred net losses in each year since our inception, and we have an accumulated deficit of $102.6 million as of December
31, 2024. We expect our existing cash, cash equivalents and bank deposits will allow us to fund our operating expenses and capital expenditure
requirements through the end of first quarter of 2026.These indicators raising substantial doubt about our ability to continue as a going
concern. The Company will be required to raise additional funds to support its operations and continue as a going concern. While we believe
that the Company can raise additional funds, there can be no assurance that these efforts will be successful or sufficient.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;Substantially all of our
operating losses have resulted from general and administrative costs associated with our operations, and costs associated with our research
and development programs, including for our preclinical and clinical product candidates. We expect to incur increasing levels of operating
losses over the next several years and for the foreseeable future. Our prior losses, combined with expected future losses, have had and
will continue to have an adverse effect on our shareholders&#8217; deficit and working capital. In any particular quarter or quarters,
our operating results could be below the expectations of securities analysts or investors, which could cause the price of our ADSs to
decline.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;We expect our research and
development expenses to significantly increase in connection with our clinical studies of our product candidates. In addition, if we obtain
marketing approval for our product candidates, we will incur significant sales and marketing, legal, and outsourced-manufacturing expenses.
As a public company, we expect to continue to incur significant and increasing operating losses for the foreseeable future. Because of
the numerous risks and uncertainties associated with developing pharmaceutical products, we are also unable to predict the extent of any
future losses or when we will become profitable, if at all. Even if we do become profitable, we may not be able to sustain or increase
our profitability on a quarterly or annual basis.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">16</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold; font-style: italic">We
may be subject to cyber-attacks or other disruptions to or breaches of our information technology, systems or networks that could irreparably
damage our reputation and our business, expose us to liability and materially and adversely affect our results of operations.</span>&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;In conducting our business,
we routinely collect, store and otherwise process proprietary, confidential or sensitive data, including personal information and proprietary
technology and information about our business and patients, suppliers and business partners, including proprietary technology. The secure
maintenance, transmission and other processing of this data and information is critical to our operations and business strategy. Our employees
occasionally work remotely, based on a hybrid work model, which creates a heightened risk of cyber-attacks or other disruptions to or
breaches of our information technology, systems or networks.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;We may be subject to cyber-attacks
or other disruptions to or breaches of our information technology, systems or networks caused by computer viruses, software bugs, server
malfunctions, software or hardware failure, illegal hacking, criminal fraud or impersonation, ransomware attacks, denial-of-service attacks,
malware, social engineering or phishing attacks, acts of vandalism or terrorism, unauthorized access, theft or employee malfeasance or
error.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;Cyber-attacks are increasing
in number and sophistication, are well-financed, in some cases supported by state actors, and are designed to not only attack, but also
to evade detection. Since the techniques used to obtain unauthorized access to information technology, systems, and networks, or to otherwise
sabotage them, change frequently, have become increasingly complex and sophisticated, including through the use of artificial intelligence,
and are often not recognized until launched against a target, we and third parties associated with us may be unable to anticipate these
techniques or to implement adequate preventative measures. Cyber-attacks can originate from a wide variety of sources, including organized
crime, hackers, activists, terrorists, nation-states, nation-state supported actors and others, any of which may see their effectiveness
enhanced by the use of artificial intelligence.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;In addition, certain global
geopolitical events can increase our cybersecurity risk. For example, due to the ongoing Russia-Ukraine conflict, there have been publicized
threats to increase cyber-attack activity against the critical infrastructure of any nation or organization that retaliates against Russia
for its invasion of Ukraine. There have also been similar publicized threats in connection with the geopolitical tension with the Iranian
regime and more specifically in connection with the terror attacks by Hamas on Israel, since October 7,&#160;2023. These threats include
threats to harm Western countries&#8217; infrastructure and assets. The costs to us to reduce the risk of or alleviate cybersecurity breaches
and vulnerabilities could be significant.</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 33.5pt; line-height: 1.25">&#160;Any type of security breach, attack or misuse of data, whether actual or perceived,
and whether experienced by us or an associated third party, could harm our reputation or deter existing or prospective patients from enrolling
or continuing in clinical trials, increase our operating expenses in order to contain and remediate the&#160;incident, expose us to unbudgeted
or uninsured liability, disrupt our operations, divert management focus away from other priorities, increase our risk of regulatory scrutiny,
result in litigation from patients, employees or other third parties, lead to the imposition of penalties, reporting obligations and fines
under state, federal and foreign laws or by payment networks or adversely affect our continued payment network registration and financial
institution sponsorship. Moreover, any such compromise of our information security could result in the loss, misappropriation, corruption
or unauthorized publication of our confidential business or proprietary information or personal or sensitive information, or that of other
parties with which we do business, an interruption or other failure of our information technology, systems, networks or operations, the
unauthorized transfer of cash or other of our assets, the unauthorized release of patient or employee data or a violation of laws, regulations,
industry standards or other legal or contractual obligations related to privacy, data protection and information security. Computer programmers
and hackers also may be able to develop and deploy viruses, worms and other malicious software programs that attack our products, or that
otherwise exploit any security vulnerabilities, and any such attack, if successful, could expose us to liability to patient claims. In
addition, our ability to monitor our third-party service providers&#8217; data security is limited. Some of our third-party service providers
may store or have access to our data and may not have effective controls, processes, or practices to protect our information from loss,
unauthorized disclosure, unauthorized use or misappropriation or other cyber-attacks or other disruptions to or breaches of information
security. A vulnerability in our third-party service providers&#8217; software or information technology, systems or networks, a failure
of our third-party service providers&#8217; safeguards, policies or procedures, or a cyber-attack or other disruption to or breach of
information security affecting any of these third parties could irreparably damage our reputation and business. The costs related to significant
cyber-attacks or other disruptions to or breaches of our information technology, systems or networks could be material and cause us to
incur significant expenses. If the information technology, systems or networks of third parties associated with us become subject to cyber-attacks
or other disruptions or security breaches, we may have insufficient recourse against such third parties and we may have to expend significant
resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this nature from
occurring. Any of the foregoing could irreparably damage our reputation and business, which could have a material adverse effect on our
results of operations.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">17</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman"><br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;We cannot ensure that any
limitation of liability provisions in our agreements with patients, service providers, business partners and other third parties with
which we do business would be enforceable or adequate or would otherwise protect us from any liabilities or damages with respect to any
particular claim in connection with a cyber-attack or other disruption to or breach of information security. Additionally, we cannot be
certain that our insurance coverage will be adequate for cybersecurity liabilities actually incurred, that insurance will continue to
be available to us on economically reasonable terms, or at all, or that our insurer will not deny coverage as to any future claim.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman; font-weight: bold">Risks Related to Our Intellectual Property Rights</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold; font-style: italic">If
we are unable to protect our patents or other proprietary rights, or if we infringe the patents or other proprietary rights of others,
our competitiveness and business prospects may be materially damaged.</span>&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;Patent and other proprietary
rights are essential to our business. Our success depends to a significant degree on our ability to obtain and enforce patents and licenses
to patent rights, both in the United States and in other countries. We cannot guarantee that pending patent applications will result in
issued patents, that patents issued or licensed will not be challenged or circumvented by competitors, that the patents and other intellectual
property rights of us and our business partners will not be found to be invalid or that the intellectual property rights of others will
not prevent us from selling our products or from executing on our strategies.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;The patent position of a
biopharmaceutical company is often uncertain and involves complex legal and factual questions. Significant litigation concerning patents
and products is pervasive in our industry. Patent claims include challenges to the coverage and validity of our patents on products or
processes as well as allegations that our products infringe patents held by competitors or other third parties. A loss in any of these
types of cases could result in a loss of patent protection or the ability to market products, which could lead to a significant loss of
sales, or otherwise materially affect future results of operations. We also rely on trademarks, copyrights, trade secrets and know-how
to develop, maintain and strengthen our competitive positions. Third parties may know, discover or independently develop equivalent proprietary
information or techniques, or they may gain access to our trade secrets or disclose such trade secrets to the public.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;Although our employees, consultants,
parties to collaboration agreements and other business partners are generally subject to confidentiality or similar agreements to protect
our confidential and proprietary information, these agreements may be breached, and we may not have adequate remedies for any breach.
In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our employees,
consultants, parties to collaboration agreements and other business partners use intellectual property owned by others in their work for
the company, disputes may arise as to the rights in related or resulting know-how and inventions.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;Furthermore, our intellectual
property, other proprietary technology and other sensitive company data is potentially vulnerable to loss, damage or misappropriation
from system malfunction, computer viruses, unauthorized access to data or misappropriation or misuse thereof by those with permitted access
and other events. While we have invested to protect our intellectual property and other data, and continue to work diligently in this
area, there can be no assurance that our precautionary measures will prevent breakdowns, breaches, cyber incidents or other events. Such
events could have a material adverse effect on our reputation, business, financial condition or results of operations. Misappropriation
or other loss of our intellectual property from any of the foregoing could have a material adverse effect on our competitive position
and may cause us to incur substantial litigation costs.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">18</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman">&#160;<br/> <span style="font-weight: bold; font-style: italic">We
may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent,
which might adversely affect our ability to develop, manufacture and market our product candidates.</span>&#160;</div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">From time to time, we may identify
patents or applications in the same general area as our products and product candidates. We may determine these third-party patents are
irrelevant to our business based on various factors, including our interpretation of the scope of the patent claims and our interpretation
of when the patent expires. If the patents are asserted against us, however, a court may disagree with our determinations. Further, while
we may determine that the scope of claims that will issue from a patent application does not present a risk, it is difficult to accurately
predict the scope of claims that will issue from a patent application, our determination may be incorrect, and the issuing patent may
be asserted against us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims.
If we fail in any such dispute, in addition to being forced to pay monetary damages, we may be temporarily or permanently prohibited from
commercializing our product candidates or be required to obtain a license under such patent, which may not be available on reasonable
terms or at all. We might, if possible, also be forced to redesign our product candidates so that it no longer infringes, misappropriates
or otherwise violates the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could
require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. Any of
the foregoing could have a material adverse effect on our business, financial condition, results of operations, and prospects.<br/> &#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold; font-style: italic">Changes
in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product
candidates.</span><br/> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">As is the case with other biopharmaceutical
and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing
patents in the biopharmaceutical and pharmaceutical industries involves both technological and legal complexity. Therefore, obtaining
and enforcing biopharmaceutical and pharmaceutical patents is costly, time-consuming and inherently uncertain. In addition, the Leahy-Smith
America Invents Act, or the AIA, which was passed in September 2011, resulted in significant changes to the United States patent system.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">An important change introduced by
the AIA is that, as of March 16, 2013, the United States transitioned from a &#8220;first-to-invent&#8221; to a &#8220;first-to-file&#8221;
system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming
the same invention. Under a &#8220;first-to-file&#8221; system, assuming the other requirements for patentability are met, the first inventor
to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the
invention earlier. A third party that files a patent application in the USPTO after that date but before we could therefore be awarded
a patent covering an invention of ours even if we made the invention before it was made by the third party. This will require us to be
cognizant of the time from invention to filing of a patent application and be diligent in filing patent applications, but circumstances
could prevent us from promptly filing patent applications on our inventions.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Among some of the other changes introduced
by the AIA are changes that limit where a patentee may file a patent infringement suit and providing opportunities for third parties to
challenge any issued patent with the USPTO. This applies to all of our United States patents, even those issued before March 16, 2013.
Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary
to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold
a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Accordingly, a third party may attempt
to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party
as a defendant in a district court action. It is not clear what, if any, impact the AIA will have on the operation of our business. However,
the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors&#8217; patent
applications and the enforcement or defense of our or our licensors&#8217; issued patents.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We may become involved in opposition,
interference, derivation, inter partes review, post-grant review, reexamination or other proceedings challenging our or our licensors&#8217;
patent rights, and the outcome of any proceedings are highly uncertain. An adverse determination in any such proceeding could reduce the
scope of, or invalidate, our owned or in-licensed patent rights, in whole or in part, allow third parties to commercialize our technology
or products and compete directly with us, without payment to it, or result in our inability to manufacture or commercialize products without
infringing third-party patent rights.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">19</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Additionally, the United States Supreme
Court has ruled on several patent cases in recent years either narrowing the scope of patent protection available in certain circumstances
or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain
patents in the future, this combination of events has created uncertainty with respect to the validity, enforceability and value of patents,
once obtained. Depending on decisions by Congress, the federal courts and the USPTO, as well as similar bodies in other jurisdictions,
the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to
enforce our existing patents and patents that we might obtain in the future. Similarly, the complexity and uncertainty of European patent
laws have also increased in recent years. In addition, the European patent system is relatively stringent in the type of amendments that
are allowed during prosecution. Complying with these laws and regulations could limit our ability to obtain new patents in the future
that may be important for our business, and these laws and regulations patents could continue to change in unpredictable ways that could
have a material adverse effect on our existing patent rights and our ability to protect and enforce our intellectual property in the future.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold; font-style: italic">Obtaining
and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><br/>
&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">The USPTO and European and other
patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent
application process. In addition, periodic maintenance, renewal and annuity fees on any issued patent are due to be paid to the USPTO
and European and other patent agencies over the lifetime of a patent. While an inadvertent failure to make payment of such fees or to
comply with such provisions can in many cases be cured by additional payment of a late fee or by other means in accordance with the applicable
rules, there are situations in which such noncompliance will result in the abandonment or lapse of the patent or patent application, and
the partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or
lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees
and failure to properly legalize and submit formal documents within prescribed time limits. If we or our licensors fails to maintain the
patents and patent applications covering our product candidates or if we or our licensors otherwise allow our patents or patent applications
to be abandoned or lapse, our competitors might be able to enter the market, which would hurt our&#160; competitive position and could
impair our ability to successfully commercialize our product candidates in any indication for which they are approved, which could have
a material adverse effect on our business, financial condition, results of operations, and prospects.</div>

<div style="line-height: 1.25; font-family: Times New Roman; font-weight: bold">&#160;<br/> Risks Related to Our Regulatory Approvals
&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">The regulatory
approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are
ultimately unable to obtain regulatory approval for nebokitug or any other product candidates, our business will be substantially harmed.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The time required to obtain approval
by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical studies
and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies,
regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s
clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application.
Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that
our data is insufficient for approval and require additional preclinical, clinical or other data. Even if we eventually complete clinical
testing and receives approval of any regulatory filing for our product candidates, the FDA and other comparable foreign regulatory authorities
may approve our product candidates for a more limited indication or a narrower patient population than we originally requested. We have
not obtained regulatory approval for any product candidate and it is possible that we will never obtain regulatory approval for nebokitug
or any other product candidate. We are not permitted to market any of our product candidates in the United States until we receive regulatory
approval of an NDA from the FDA.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">20</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Prior to obtaining approval to commercialize
a product candidate in the United States or abroad, we must demonstrate with substantial evidence from well-controlled clinical studies,
and to the satisfaction of the FDA or foreign regulatory agencies, that such product candidate is safe and effective for its intended
use. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe the preclinical or
clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory
authorities.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zab1e6b24ee794b07850c6b03e0c20982" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the FDA or any foreign regulatory bodies can delay, limit or deny approval of our
        product candidates or require us to conduct additional preclinical or clinical testing or abandon a program for many reasons, including:</div>
        </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the FDA or comparable foreign regulatory authorities may disagree with the design
        or implementation of our clinical studies;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign
        regulatory authorities that a product candidate is safe and effective for its proposed indication;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">serious and unexpected drug-related side effects experienced by participants in our
        clinical studies or by individuals using drugs similar to our product candidates, or other products containing the active ingredient in
        our product candidates;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">negative or ambiguous results from our clinical studies or results that may not meet
        the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the population studied in the clinical study may not be sufficiently broad or representative
        to assure efficacy and safety in the full population for which we seek approval;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">we may be unable to demonstrate that a product candidate&#8217;s clinical and other
        benefits outweigh its safety risks;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the FDA or comparable foreign regulatory authorities may disagree with our interpretation
        of data from preclinical studies or clinical trials;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the data collected from clinical studies of our product candidates may not be acceptable
        or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere,
        and we may be required to conduct additional clinical studies;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the FDA&#8217;s or the applicable foreign regulatory agency&#8217;s disagreement regarding
        the formulation, labeling and/or the specifications of our product candidates;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the FDA or comparable foreign regulatory authorities may fail to approve or find deficiencies
        with the manufacturing processes or facilities of third-party manufacturers with which our contracts for clinical and commercial supplies;
        and</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">the approval policies or regulations of the FDA or comparable
        foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;Moreover, preclinical and
clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates
performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or comparable foreign regulatory
authority approval. We cannot guarantee that the FDA or foreign regulatory authorities will interpret trial results as we do, and more
trials could be required before we are able to submit applications seeking approval of our product candidates. To the extent that the
results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may
be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval
of our product candidates. Furthermore, the approval policies or regulations of the FDA or comparable foreign regulatory authorities may
significantly change in a manner rendering our clinical data insufficient for approval, which may lead to the FDA or comparable foreign
regulatory authorities delaying, limiting or denying approval of our product candidates.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">21</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;Of the large number of drugs
in development, only a small percentage successfully complete the regulatory approval processes and are commercialized. This lengthy approval
process, as well as the unpredictability of future clinical trial results, may result in us failing to obtain regulatory approval to market
nebokitug or any other product candidate, which would significantly harm our business, results of operations and prospects.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;In addition, the FDA or the
applicable foreign regulatory agency also may approve a product candidate for a more limited indication or patient population than we
originally requested, and the FDA or applicable foreign regulatory agency may approve a product candidate with a REMS or a label that
does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Regulatory
authorities may also grant approval contingent on the performance of costly post-marketing clinical trials. Any of the foregoing scenarios
could materially harm the commercial prospects for our product candidates.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold; font-style: italic">Obtaining
and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining
regulatory approval of our product candidates in other jurisdictions.</span>&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;In order to market any product
outside of the United States, we must establish and comply with the numerous and varying safety, efficacy, and other regulatory requirements
of other countries. Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that
we will be able to obtain or maintain regulatory approval in any other jurisdiction, but a failure or delay in obtaining regulatory approval
in one jurisdiction may have a negative effect on the regulatory approval process in others. Our product candidates may not receive marketing
approval even if they achieve their primary endpoints in future Phase 3 clinical studies or registrational trials. The FDA or comparable
foreign regulatory authorities may disagree with our trial designs and our interpretation of data from preclinical studies or clinical
trials. In addition, any of these regulatory authorities may change requirements for the approval of a product candidate even after reviewing
and providing comments or advice on a protocol for a pivotal Phase 3 or registrational clinical study. In addition, any of these regulatory
authorities may also approve a product candidate for fewer or more limited indications than our request or may grant approval contingent
on the performance of costly post-marketing clinical trials. The FDA or comparable foreign regulatory authorities may not approve the
labeling claims that we believe would be necessary or desirable for the successful commercialization of our product candidates, if approved.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;Furthermore, even if the
FDA or other comparable foreign regulatory authority grants marketing approval of a product candidate, comparable regulatory authorities
in foreign jurisdictions must also approve the manufacturing, marketing, and promotion of the product candidate in those countries. Approval
procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United
States, including additional preclinical studies or clinical trials as clinical studies conducted in one jurisdiction may not be accepted
by regulatory authorities in other jurisdictions. The marketing approval processes in other countries may implicate all of the risks detailed
above regarding FDA approval in the United States, as well as other risks. In many jurisdictions outside the United States, a product
candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we
intend to charge for our products is also subject to approval.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;Obtaining foreign regulatory
approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties, and costs for us and could
delay or prevent the introduction of our products in certain countries. Failure to obtain marketing approval in other countries or any
delay or other setback in obtaining such approval would impair our ability to market our product candidates in such foreign markets. Any
such impairment would reduce the size of our potential market, which could have a material adverse impact on our business, results of
operations, and prospects.&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">22</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold; font-style: italic">Even
if we obtain regulatory approval for nebokitug or any product candidate, we will still face extensive and ongoing regulatory requirements
and obligations and any product candidate, if approved, may face future development and regulatory difficulties.</span>&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Any product candidate for which we
obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse
event reporting, storage, recordkeeping, export, import, advertising and promotional activities for such product, among other things,
will be subject to extensive and ongoing requirements of and review by the FDA and other regulatory authorities. These requirements include
submissions of safety and other post-marketing information and reports, establishment registration and drug listing requirements, continued
compliance with cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records
and documents, requirements regarding the distribution of samples to physicians and recordkeeping and GCP requirements for any clinical
studies that we conduct post-approval.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Even if marketing approval of a product
candidate is granted, the approval may be subject to limitations on the indicated uses for which the product candidate may be marketed
or to the conditions of approval, including a requirement to implement a REMS. If any of our product candidates receives marketing approval,
the accompanying label may limit the approved indicated use of the product candidate, which could limit sales of the product candidate.
The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy
of a product. Violations of the Federal Food, Drug, and Cosmetic Act, or FDCA, relating to the promotion of prescription drugs may lead
to FDA enforcement actions and investigations alleging violations of federal and state healthcare fraud and abuse laws, as well as state
consumer protection laws.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In addition, later discovery of previously
unknown adverse events or other problems with our products, manufacturers or manufacturing processes or failure to comply with regulatory
requirements, may yield various results, including:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z50fd5d9e6dd842e9b520d7fe052bbc78" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">restrictions on manufacturing such products;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">restrictions on the labeling or marketing of products;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">restrictions on product manufacturing, distribution or use;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">requirements to conduct post-marketing studies or clinical trials;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">warning letters or untitled letters;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">withdrawal of the products from the market;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">refusal to approve pending applications or supplements to approved applications that we submit;</div> </td>
        </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">recall of products;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">fines, restitution or disgorgement of profits or revenues;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">suspension or withdrawal of marketing approvals;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">refusal to permit the import or export of our products;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">product seizure; or</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">injunctions or the imposition of civil or criminal penalties.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;Further, the FDA&#8217;s
policies may change, and additional government regulations may be enacted that could impose extensive and ongoing regulatory requirements
and obligations on any product candidate for which we obtain marketing approval. If we are&#160; slow or unable to adapt to changes in
existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may
lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or
sustain profitability.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">23</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold; font-style: italic">Disruptions
at the FDA and other government agencies caused by funding shortages or global health concerns could hinder our ability to hire, retain
or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized
in a timely manner or at all, which could negatively impact our business.</span>&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;The ability of the FDA to
review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire
and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the
agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and
development activities is subject to the political process, which is inherently fluid and unpredictable.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Disruptions at the FDA and other
agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would harm
our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the United States government
has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical
activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process
our regulatory submissions, which could harm our business.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">During the COVID-19 pandemic, the
FDA imposed preventive measures, including postponements of non-United States manufacturing and product inspections. If global health
concerns re-occur, similar restrictions could be implemented that might prevent the FDA or other regulatory authorities from conducting
their regular inspections, reviews, or other regulatory activities. This could significantly impact the ability of the FDA or other regulatory
authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Current and future
legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our drug candidates and affect
the prices we may obtain.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The healthcare industry in the United
States is subject to extensive regulation by a number of governmental entities at the federal, state and local level. The healthcare regulatory
landscape is also subject to frequent change. In addition to the FDA&#8217;s restrictions on marketing of pharmaceutical products, the
U.S. healthcare laws and regulations that may apply to pharmaceutical companies include, without limitation: the federal fraud and abuse
laws, including the federal anti-kickback and false claims laws; federal health data privacy and security laws; and federal transparency
laws related to payments and/or other transfers of value made to physicians and other healthcare professionals and teaching hospitals.
Many states have similar laws and regulations that may differ from each other and federal law in significant ways, thus complicating compliance
efforts. These laws may impose administrative and compliance burdens on the sales, marketing and other activities of pharmaceutical manufacturers
with approved products for market in the United States.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Because of the breadth of these laws
and the narrowness of available statutory exceptions and regulatory safe harbors, it is possible that some of our business activities,
could be subject to legal challenge and enforcement actions. Violations of any of the federal and state laws described above or any other
governmental regulations, may result in significant civil, criminal, and administrative penalties, including, without limitation, damages,
fines, imprisonment, exclusion from participation in government healthcare programs, additional reporting obligations and oversight pursuant
to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or
restructuring of operations.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Additionally, in the United States
and some foreign jurisdictions there have been, and continue to be, several legislative, executive and regulatory changes and proposed
reforms of the healthcare system in an effort to contain costs, improve quality, and expand access to care, particularly in light of the
recent U.S. Presidential and Congressional elections. These reform initiatives may, among other things, result in modifications to the
aforementioned laws and/or the implementation of new laws affecting the healthcare industry. The adoption of any future cost containment
or other health reform initiative may result in additional downward pressure on the price for any approved product.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">24</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Risks Related to Commercialization
of Our Product Candidates</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold; font-style: italic">If
we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, the commercialization
of our product candidates may be delayed and our business will be harmed.</span>&#160;</div>

<div style="text-align: justify; text-indent: 34pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; text-indent: 34pt; line-height: 1.25; font-family: Times New Roman">&#160;For planning purposes, we sometimes
estimate the timing of the accomplishment of various scientific, clinical, regulatory and other product development objectives. These
milestones may include our expectations regarding the commencement or completion of scientific studies and clinical trials, the regulatory
submissions or commercialization objectives. From time to time, we may publicly announce the expected timing of some of these milestones,
such as the completion of an ongoing clinical study, the initiation of other clinical studies, receipt of regulatory approval or the commercial
launch of a product. The achievement of many of these milestones may be outside of our control. All of these milestones are based on a
variety of assumptions which may cause the timing of achievement of the milestones to vary considerably from our estimates, including:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z68b31eaa8faf4cc296ddebf73f1b377e" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">our available capital resources or capital constraints we experience;</div> </td>
        </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the rate of progress, costs and results of our clinical studies and research and development
        activities, including the extent of scheduling conflicts with participating clinicians and collaborators;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">our ability to identify and enroll patients who meet clinical study eligibility criteria;</div>
        </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">our receipt of authorizations by the FDA and comparable foreign regulatory authorities,
        and the timing thereof;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">other actions, decisions or rules issued by regulators;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">our ability to access sufficient, reliable and affordable supplies of materials used
        in the manufacture of our product candidates;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">our ability to manufacture and supply clinical study materials to our clinical sites
        on a timely basis;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the efforts of our collaborators with respect to the commercialization of our products,
        if any; and</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the securing of, costs related to, and timing issues associated with, commercial product
        manufacturing as well as sales and marketing activities.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 34pt; line-height: 1.25; font-family: Times New Roman">&#160;If we fail to achieve announced
milestones in the timeframes we expect, the commercialization of any of our product candidates may be delayed, and our business, results
of operations, financial condition and prospects may be adversely affected.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold; font-style: italic">We
face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully
than us.</span>&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The development and commercialization
of new drug products is highly competitive. We may face competition with respect to any product candidates that we seek to develop or
commercialize in the future from major biopharmaceutical companies, specialty biopharmaceutical companies, and biotechnology companies
worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research organizations
that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and
commercialization.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">There are a number of large biopharmaceutical
and biotechnology companies that are currently pursuing the development of products for the treatment of inflammation and fibrosis. Companies
that we are&#160; aware of that are targeting the treatment of inflammation and fibrosis include large companies with significant financial
resources as well as a substantial number of small-mid size biotechnology companies. However, we do not know of any other companies currently
in clinical development with an anti CCL24 mAb. For additional information regarding our competition, see &#8220;Business Overview - Competition.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Many of our current or potential
competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in research and
development, manufacturing, preclinical testing, conducting clinical studies, obtaining regulatory approvals, and marketing approved products
than we do.&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">25</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Even if nebokitug
or any other product candidate we develop receives marketing approval, it may fail to achieve market acceptance by physicians, patients,
third-party payors or others in the medical community necessary for commercial success.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If nebokitug or any other product
candidate we develop receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients,
third-party payors and others in the medical community. If it does not achieve an adequate level of acceptance, we may not generate significant
product revenues or become profitable. The degree of market acceptance of our product candidates, if approved, will depend on a number
of factors, including but not limited to:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8094e636c74d42e0ab102f80c5564af8" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the efficacy and potential advantages compared to alternative treatments;</div> </td>
        </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">effectiveness of sales and marketing efforts;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the cost of treatment with respect to alternative treatments, including any similar
        generic treatments;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">our ability to offer our products for sale at competitive prices;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the convenience and ease of administration compared to alternative treatments;</div>
        </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the willingness of the target patient population to try new therapies and of physicians
        to prescribe these therapies;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the strength of marketing and distribution support;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the timing of market introduction of competitive products;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the availability of third-party coverage and adequate reimbursement;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">product labeling or product insert requirements of the FDA, EMA or other regulatory
        authorities, including any limitations on warnings contained in a product&#8217;s approved labeling;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the prevalence and severity of any side effects; and</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">any restrictions on the use of our product together with other medications.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Because we expect sales of our product
candidates, if approved, to generate substantially all of our revenues for the foreseeable future, the failure of our product candidates
to find market acceptance would harm its business and could require us to seek additional financing.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">We rely completely
on third-party suppliers to manufacture our clinical drug supplies for our product candidates, and we intend to rely on third parties
to produce preclinical, clinical, and commercial supplies of any future product candidates.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;We do not currently have,
nor do we plan to acquire, the infrastructure or capability to internally manufacture our clinical drug supply of our product candidates,
or any future product candidates, for use in the conduct of our preclinical studies and clinical trials.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;We lack the internal resources
and the capabilities to manufacture any product candidates on a clinical or commercial scale. The facilities used by our contract manufacturers
to manufacture the active pharmaceutical ingredient and final drug product must complete a pre-approval inspection by the FDA and other
comparable foreign regulatory agencies to assess compliance with applicable requirements, including cGMPs, after we submit our NDA or
relevant foreign regulatory market application to the applicable regulatory agency.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">26</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">We are responsible for setting
the product specifications and approving master batch records, but do not oversee the manufacturing process itself, and are completely
dependent on our contract manufacturers to comply with cGMPs for manufacture of both active drug substances and finished drug products.
If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements
of the FDA or applicable foreign regulatory agencies, they will not be able to pass a pre-approval inspection or secure and/or maintain
regulatory approval for their manufacturing facilities. In addition, we have no direct control over our contract manufacturers&#8217;
ability to maintain adequate quality control, quality assurance, and qualified personnel. Furthermore, all of our contract manufacturers
are engaged with other companies to supply and/or manufacture materials or products for such companies, which exposes our manufacturers
to regulatory risks for the production of such materials and products. As a result, failure to satisfy the regulatory requirements for
the production of those materials and products may affect the regulatory clearance of our contract manufacturers&#8217; facilities generally.
If the FDA or an applicable foreign regulatory agency determines now or in the future that these facilities for the manufacture of our
product candidates are noncompliant, we may need to find alternative manufacturing facilities, which would adversely impact our ability
to develop, obtain regulatory approval for or market our product candidates. Our reliance on contract manufacturers also exposes us to
the possibility that they, or third parties with access to their facilities, will have access to and may compromise our trade secrets
or other proprietary information.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold; font-style: italic">If
we are unable to establish sales, marketing and distribution capabilities either on our own or in collaboration with third parties, we
may not be successful in commercializing nebokitug, if approved. </span>&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We do not have any infrastructure
for the sales, marketing or distribution of nebokitug , and the cost of establishing and maintaining such an organization may exceed the
cost-effectiveness of doing so. In order to market and successfully commercialize nebokitug or any other product candidate we develop,
if approved, we must build our sales, distribution, marketing, managerial and other non-technical capabilities or make arrangements with
third parties to perform these services. We expect to build a focused sales, distribution and marketing infrastructure to market nebokitug,
if approved. There are significant expenses and risks involved with establishing our own sales, marketing and distribution capabilities,
including our ability to hire, retain and appropriately incentivize qualified individuals, generate sufficient sales leads, provide adequate
training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay
in the development of our internal sales, marketing and distribution capabilities could delay any product launch, which would adversely
impact the commercialization of that product. Additionally, if the commercial launch of nebokitug for which we recruit a sales force and
establishes marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these
commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing
personnel.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Factors that may inhibit our efforts
to commercialize our product candidates on our own include:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zaf7f042fdcb64f929bd14038a7e3ed78" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;</div>
        </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">the inability of sales personnel to obtain access to physicians or attain adequate numbers of physicians
        to prescribe our products; and</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We do not anticipate having the resources
in the foreseeable future to allocate to the sales and marketing of our product candidates, if approved, in certain markets overseas.
Therefore, our future success will depend, in part, on our ability to enter into and maintain collaborative relationships for such capabilities,
the collaborator&#8217;s strategic interest in a product and such collaborator&#8217;s ability to successfully market and sell the product.
We intend to pursue collaborative arrangements regarding the sale and marketing of nebokitug, if approved, for certain markets overseas;
however, we cannot guarantee that we will be able to establish or maintain such collaborative arrangements, or if able to do so, that
we will have effective sales forces. To the extent that we depend on third parties for marketing and distribution, any revenues we receive
will depend upon the efforts of such third parties, and there can be no assurance that such efforts will be successful.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">27</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If we are unable to build our own
sales force or negotiate a collaborative relationship for the commercialization of nebokitug, we may be forced to delay the potential
commercialization of nebokitug or reduce the scope of our sales or marketing activities for nebokitug. If we need to increase our expenditures
to fund commercialization activities for nebokitug, we will need to obtain additional capital, which may not be available to us on acceptable
terms, or at all. We may also have to enter into collaborative arrangements for nebokitug at an earlier stage than otherwise would be
ideal and we may be required to relinquish rights to&#160; nebokitug or otherwise agree to terms unfavorable to us. Any of these occurrences
may have an adverse effect on our business, operating results and prospects.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If we are unable to establish adequate
sales, marketing and distribution capabilities, either on our own or in collaboration with third parties, we will not be successful in
commercializing our product candidates and may never become profitable. We will be competing with many companies that currently have extensive
and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales
functions, we may be unable to compete successfully against these more established companies.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Even if we receive
marketing approvals our current or any future product candidates, we may not be able to successfully commercialize our product candidates
due to unfavorable pricing regulations or third-party coverage and reimbursement policies, which could make it difficult for us to sell
our product candidates profitably.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">There may be significant delays in
obtaining such coverage and reimbursement for newly approved products, and coverage may be more limited than the purposes for which the
product is approved by the FDA or comparable non-U.S. regulatory agencies. Moreover, eligibility for coverage and reimbursement does not
imply that a product will be paid for in all cases or at a rate that covers costs, including research, development, intellectual property,
manufacture, sale and distribution expenses. Interim reimbursement levels for new products, if applicable, may also not be sufficient
to cover costs and may not be made permanent. Obtaining coverage and reimbursement approval for a product from a government or other third-party
payor is a time consuming and costly process that could require us to provide supporting scientific, clinical and cost effectiveness data
to the payor. Reimbursement rates may vary according to the use of the product and the clinical setting in which it is used, may be based
on reimbursement levels already set for lower cost products and may be incorporated into existing payments for other services. Net prices
for products may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors, by any future
laws limiting drug prices and by any future relaxation of laws that presently restrict imports of product from countries where they may
be sold at lower prices than in the United States.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">There is significant uncertainty
related to the insurance coverage and reimbursement of newly approved products. Third-party payors in the United States often rely upon
Medicare coverage policy and payment limitations in setting reimbursement policies, but also have their own methods and approval process
apart from Medicare coverage and reimbursement determinations. Pricing and reimbursement outside of the United States vary widely and
are constantly evolving, with requirements and limitations becoming increasingly strict.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our inability to promptly obtain
coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could
have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall
financial condition.<br/> &#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold; font-style: italic">A
variety of risks associated with operating internationally could materially adversely affect our business.</span>&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our research and development facilities
and certain of our executives are located in Israel and certain of our product candidates may be manufactured at third-party facilities
located in Europe. In addition, our business strategy includes potentially expanding internationally if any of our product candidates
receives regulatory approval. Doing business internationally involves a number of risks, including but not limited to:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z13dcac30a3e04c1b892d5ab983d0eff6" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">multiple, conflicting and changing laws and regulations, such as privacy regulations,
        tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses;</div>
        </td> </tr>
  </table>

<div><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">28</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>
<!--PROfilePageNumberReset%Num%29%%%-->

<div><br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">failure by us to obtain and maintain regulatory approvals for the use of our products
        in various countries;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">additional potentially relevant third-party patent rights;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">complexities and difficulties in obtaining protection and enforcing our intellectual
        property;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">difficulties in staffing and managing foreign operations;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">complexities associated with managing multiple payor reimbursement regimes, government
        payors or patient self-pay systems;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">limits in our ability to penetrate international markets;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">financial risks, such as longer payment cycles, difficulty collecting accounts receivable,
        the impact of local and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate
        fluctuations;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">natural disasters, political and economic instability, including wars, terrorism and
        political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">certain expenses including, among others, expenses for travel, translation and insurance;
        and</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">regulatory and compliance risks that relate to maintaining accurate information and
        control over sales and activities that may fall within the purview of the United States Foreign Corrupt Practices Act, its books and records
        provisions, or its anti-bribery provisions.</div> </td> </tr>
  </table>

<div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Any of these factors could significantly
harm our international expansion and operations and, consequently, our results of operations. <br/> </div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Risks Related to Our Incorporation
and Location in Israel</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Conditions in Israel, including the
attack by Hamas and other terrorist organizations from the Gaza Strip and elsewhere in the region, and the threat of a wider regional
conflict and Israel&#8217;s actions to counter these threats, may affect our operations.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our headquarters, ten of our employees,
including our Chief Executive Officer and Chief Financial Officer, and two members of our board of directors (not including our Chief
Executive Officer) are located in Israel and therefore our business and operations are at risk of being directly affected by economic,
political, geopolitical and military conditions in Israel.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Since the establishment of the State
of Israel in 1948, a number of armed conflicts have occurred between Israel and its neighboring countries and terrorist organizations
active in the region. These conflicts have involved missile strikes, hostile infiltrations and terrorism against civilian targets in various
parts of Israel, which have negatively affected business conditions in Israel.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Following the October 7<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">th</sup>
attacks by Hamas terrorists in Israel's southern border, Israel declared war against Hamas and since then, Israel has been involved in
military conflicts with Hamas, Hezbollah, a terrorist organization based in Lebanon, and Iran, both directly and through proxies like
the Houthi movement in Yemen and armed groups in Iraq and other terrorist organizations. Additionally, following the fall of the Assad
regime in Syria, Israel has conducted limited military operations targeting the Syrian army, Iranian military assets and infrastructure
linked to Hezbollah and other Iran-supported groups. Although certain ceasefire agreements have been reached with Hamas and Lebanon (with
respect to Hezbollah), and some Iranian proxies have declared a halt to their attacks, there is no assurance that these agreements will
be upheld, military activity and hostilities continue to exist at varying levels of intensity, and the situation remains volatile, with
the potential for escalation into a broader regional conflict involving additional terrorist organizations and possibly other countries.
Also, the fall of the Assad regime in Syria may create geopolitical instability in the region.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">29</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The continuation of the war has also
led to a deterioration of certain indicators of Israel&#8217;s economic standing, for instance, a downgrade in Israel&#8217;s credit rating
by rating agencies (such as by Moody&#8217;s, S&amp;P Global, and Fitch).</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In connection with the war, several
hundred thousand Israeli military reservists were called up to service. All of our Israeli personnel (including employees, consultants
and directors) are exempt from military reserve duty, including our Chief Executive Officer and Chief Financial Officer.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Nebokitug clinical trial supplies
are manufactured by our supplier in Denmark and are not required to be manufactured in Israel under the regulations of the Israel Innovation
Authority of the Israeli Ministry of Economy and Industry.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our commercial insurance does not
cover losses that may occur as a result of events associated with war and terrorism. Although the Israeli government currently covers
the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot assure that such government coverage
will be maintained or that it will sufficiently cover our potential damages. Any losses or damages incurred by us could have a material
adverse effect on our business.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The global perception of Israel and
Israeli companies, influenced by actions by international judicial bodies, may lead to increased sanctions and other negative measures
against Israel, as well as Israeli companies and academic institutions. There is also a growing movement among countries, activists, and
organizations to boycott Israeli goods, services and academic research or restrict business with Israel, which could affect business operations.
If these efforts become widespread, along with any future rulings from international tribunals against Israel, they could significantly
and negatively impact business operations.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Prior to the October 2023 war, the
Israeli government pursued changes to Israel&#8217;s judicial system and has recently renewed its efforts to effect such changes. In response
to the foregoing developments, certain individuals, organizations, and institutions, both within and outside of Israel, voiced concerns
that such proposed changes, if adopted, may negatively impact the business environment in Israel. Such proposed changes may also lead
to political instability or civil unrest. If such changes to Israel&#8217;s judicial system are pursued by the government and approved
by the parliament, this may have an adverse effect on our business, results of operations, and ability to raise additional funds, if deemed
necessary by our management and board of directors.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold; font-style: italic">Because
a certain portion of our expenses are incurred in currencies other than the U.S. Dollar, our results of operations may be harmed by currency
fluctuations and inflation.</span>&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our reporting and functional currency
is the United States Dollar, but some portion of our clinical studies and operations expenses are in NIS. As a result, we are exposed
to some currency fluctuation risks. Fluctuation in the exchange rates of foreign currency has an influence on the cost of goods sold and
our financing revenues and expenses. We may, in the future, decide to enter into currency hedging transactions to decrease the risk of
financial exposure from fluctuations in the exchange rate of the currencies mentioned above with respect to the U.S. Dollar. These measures,
however, may not adequately protect us from adverse effects.<br/> &#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">30</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold; font-style: italic">We
received Israeli government grants for certain of our research and development activities as detailed below. The terms of those grants
require us to satisfy specified conditions in order to transfer outside of Israel the manufacture of products based on know-how funded
by the Israel Innovation Authority or to transfer outside of Israel the know-how itself. If we fail to comply with the requirements of
Israeli law in this regard, we may be required to pay penalties, and it may impair our ability to sell our technology outside of Israel.</span>&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Some of our research and development
efforts were financed through grants that were received from the Israel Innovation Authority of the Israeli Ministry of Economy and Industry,
or the IIA (formerly known as the Office of the Chief Scientist). When know-how is developed using IIA grants, the Encouragement of Research,
Development and Technological Innovation in Industry Law 5744-1984, or the Innovation Law, and the regulations thereunder, restrict our
ability to transfer outside of Israel either the manufacture of products based on IIA-funded know-how or the know-how itself. Such restrictions
continue to apply even after financial obligations to the IIA are paid in full. The consideration available to our shareholders in a future
transaction involving the transfer outside of Israel of know-how developed with IIA funding (such as a merger or similar transaction)
may be reduced by any amounts that we are required to pay to the IIA.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Risks Related to our ADSs</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">We will need
to raise additional capital to fund our operations, which may be unavailable to us on acceptable terms or at all, or may cause dilution
or place significant restrictions on our ability to operate our business.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman">&#160;&#160;&#160;&#160; If our
available cash resources are insufficient to satisfy our liquidity requirements, we will be required to raise additional capital through
issuances of equity or convertible debt securities, or seek debt financing or other form of third-party funding.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman">&#160;&#160;&#160;&#160; If we
are unable to obtain adequate financing or financing on terms satisfactory to us when needed, our ability to continue to pursue our business
objectives and to respond to business opportunities, challenges, or unforeseen circumstances could be significantly limited, and could
have a material adverse effect on our business, financial condition, results of operations and prospects.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman">&#160;&#160;&#160;&#160; The various
ways we could raise additional capital carry potential risks. If we raise funds by issuing equity securities, dilution to our shareholders
would result. If we raise funds by issuing debt securities, those debt securities would have rights, preferences and privileges senior
to those of holders of our ADSs. The terms of debt securities issued or borrowings pursuant to a credit agreement could impose significant
restrictions on our operations. If we raise funds through collaborations or licensing arrangements, we might be required to relinquish
significant rights to our product candidates or grant licenses on terms that are not favorable to us.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">The trading price
of the ADSs has been highly volatile and is expected to continue to be volatile.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The trading price of the ADSs has
been highly volatile, particularly over the last year. For example, on September 3, 2024, the closing price of the ADSs was $2.46 and
on January 22, 2024, the closing price of the ADSs was $0.51. This volatility may affect the price at which you are able to sell ADSs.
Our ADS price is likely to continue to be volatile and subject to significant price and volume fluctuations in response to market and
economic factors that are beyond our control. In addition, while the stock market in general has experienced high volatility, biotechnology
companies in particular have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to operating
performance. Broad market and industry factors may negatively affect the market price of the ADSs, regardless of our actual operating
performance.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">We have not paid
dividends in the past and do not expect to pay dividends in the future, and, as a result, any return on investment may be limited to the
value of the ADSs.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We have never paid dividends and
do not anticipate paying dividends in the foreseeable future. The payment of dividends will depend on our earnings, capital requirements,
financial condition, prospects and other factors our board of directors may deem relevant. If we do not pay dividends, the ADSs may be
less valuable because a return on your investment will only occur if our ADS price appreciates and you sell your ADS thereafter. In addition,
the Companies Law imposes restrictions on our ability to declare and pay dividends.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">As a foreign
private issuer whose ADSs are listed on the Nasdaq, we intend to follow certain home country corporate governance practices instead of
certain Nasdaq requirements.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">As a foreign private issuer whose
ADSs are listed on the Nasdaq, we are permitted to follow certain home country corporate governance practices instead of certain requirements
of the rules of the Nasdaq. &#160;For more information regarding our corporate governance practices and foreign private issuer status,
see Item 16G. &#8220;Corporate Governance.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Accordingly, our shareholders and,
indirectly, our ADS holders may not be afforded the same protection as provided under the Nasdaq corporate governance rules. Following
our home country governance practices as opposed to the requirements that would otherwise apply to a U.S. company listed on the Nasdaq
may provide less protection than is accorded to investors of domestic issuers.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">31</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">As a foreign
private issuer, we are not subject to U.S. proxy rules and are exempt from certain reports under the Exchange Act.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">As of June 30, 2023, we became a
foreign private issuer and are not now subject to the requirements that are imposed upon U.S. domestic issuers by the SEC. As a foreign
private issuer, we are exempt from the rules and regulations under the Exchange Act related to the furnishing and content of proxy statements,
and our officers, directors, and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained
in Section 16 of the Exchange Act. Furthermore, although under regulations promulgated under the Companies Law, as an Israeli public company
listed on the Nasdaq, we are required to disclose the compensation of our five most highly compensated officers on an individual basis,
this disclosure is not as extensive as that required of U.S. domestic reporting companies. In addition, we are not required under the
Exchange Act to file annual, quarterly and current reports and financial statements with the SEC, as frequently or as promptly as U.S.
domestic reporting companies whose securities are registered under the Exchange Act. These exemptions and leniencies reduce the frequency
and scope of information and protections available to you in comparison to those applicable to a U.S. domestic reporting companies.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">If we cease to
qualify as a foreign private issuer, we would be required to comply fully with the reporting requirements of the Exchange Act applicable
to U.S. domestic issuers, and we would incur significant legal, accounting and other expenses that we do not incur as a foreign private
issuer.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We would lose our foreign private
issuer status if a majority of our shares are owned by U.S. residents and a majority of our directors or executive officers are U.S. citizens
or residents or we fail to meet additional requirements necessary to avoid loss of foreign private issuer status. We cannot assure you
that at June 30, 2025, the next determination date of our foreign private issuer status, we will qualify as a foreign private issuer.
If we cease to qualify as a foreign private issuer at this determination date, we will be required to begin reporting as a domestic issuer
on January 1, 2026. The regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic issuer may be significantly
higher. If we are not a foreign private issuer, we will be required to file periodic reports and registration statements on U.S. domestic
issuer forms with the SEC, which are more detailed and extensive than the forms available to a foreign private issuer.&#160; In addition,
we would lose our ability to rely upon exemptions from certain Nasdaq corporate governance requirements that are available to foreign
private issuers.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Holders of ADSs
are not treated as holders of our ordinary shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Holders of ADSs are not treated as
holders of our ordinary shares, unless they withdraw the ordinary shares underlying their ADSs in accordance with the deposit agreement
and applicable laws and regulations. The depositary is the holder of the ordinary shares underlying the ADSs. Holders of ADSs therefore
do not have any rights as holders of our ordinary shares, other than the rights that they have pursuant to the deposit agreement.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">You may not have
the same voting rights as the holders of our ordinary shares and may not receive voting materials in time to be able to exercise your
right to vote.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Except as described in the deposit
agreement, holders of the ADSs will not be able to exercise voting rights attaching to the ordinary shares represented by the ADSs. If
we request the depositary to solicit your voting instructions (and we are not required to do so), the depositary will notify you of a
shareholders&#8217; meeting and send or make voting materials available to you. Those materials will describe the matters to be voted
on and explain how ADS holders may instruct the depositary how to vote. We cannot guarantee that ADS holders will receive the voting materials
in time to ensure that they can instruct the depositary to vote the ordinary shares underlying their ADSs. For instructions to be valid,
they must reach the depositary by a date set by the depositary. The depositary will try, as far as practical, subject to the laws of Israel
and the provisions of our articles of association or similar documents, to vote or to have its agents vote the ordinary shares or other
deposited securities as instructed by ADS holders. If we do not request the depositary to solicit your voting instructions, you can still
send voting instructions, and, in that case, the depositary may try to vote as you instruct, but it is not required to do so.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">32</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Otherwise, ADS holders will not be
able to exercise their right to vote, unless they withdraw the ordinary shares underlying the ADSs they hold. However, ADS holders may
not know about the meeting far enough in advance to withdraw those ordinary shares. In any event, the depositary will not exercise any
discretion in voting deposited securities and it will only vote or attempt to vote as instructed. In addition, the depositary and its
agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. This means
that you may not be able to exercise your right to vote and there may be nothing you can do if your ordinary shares are not voted as you
requested.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Holders of ADSs
may be subject to limitations on the transfer of their ADSs and the withdrawal of the underlying ordinary shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">ADSs are transferable on the books
of the depositary. However, the depositary may refuse to deliver ADSs or register transfers of ADSs when the transfer books of the depositary
or our transfer books are closed or at any time if the depositary or we think it advisable to do so. These limitations on transfer may
have a material adverse effect on the value of the ADSs.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">We are entitled
to amend the deposit agreement and to change the rights of ADS holders under the terms of such agreement, or to terminate the deposit
agreement, without the prior consent of the ADS holders.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We are entitled to amend the deposit
agreement and to change the rights of the ADS holders under the terms of such agreement without the prior consent of the ADS holders.
We and the depositary may agree to amend the deposit agreement in any way we decide is necessary or advantageous to us or to the depositary.
Amendments may reflect, among other things, operational changes in the ADS program, legal developments affecting ADSs or changes in the
terms of our business relationship with the depositary. If an amendment adds or increases fees or charges, except for taxes and other
governmental charges or expenses of the depositary for registration fees, facsimile costs, delivery charges or similar items, or prejudices
a substantial right of ADS holders, it will not become effective for outstanding ADSs until 30 days after the depositary notifies ADS
holders of the amendment. At the time an amendment becomes effective, you are considered, by continuing to hold the ADSs, to agree to
the amendment and to be bound by the ADSs and the deposit agreement as amended. If we make an amendment to the deposit agreement that
is disadvantageous to ADS holders or terminate the deposit agreement, the ADS holders may choose to sell their ADSs or surrender their
ADSs and become direct holders of the underlying ordinary shares, but they will have no right to any compensation whatsoever.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">ADS holders may
not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable outcomes
to the plaintiff(s) in any such action.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The deposit agreement governing the
ADSs representing our ordinary shares provides that, to the fullest extent permitted by law, holders and beneficial owners of ADSs irrevocably
waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to the ADSs or the
deposit agreement.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If this jury trial waiver provision
is not permitted by applicable law, an action could proceed under the terms of the deposit agreement with a jury trial. If we or the depositary
opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable based on the facts and circumstances
of that case in accordance with the applicable state and federal law. We believe that a contractual pre-dispute jury trial waiver provision
is generally enforceable, including under the laws of the State of New York, which governs the deposit agreement. In determining whether
to enforce a contractual pre-dispute jury trial waiver provision, courts will generally consider whether a party knowingly, intelligently
and voluntarily waived the right to a jury trial. We believe that this is the case with respect to the deposit agreement and the ADSs.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">33</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If any holders or beneficial owners
of ADSs bring a claim against us or the depositary in connection with matters arising under the deposit agreement or the ADSs, including
claims under federal securities laws, such holder or beneficial owner may not be entitled to a jury trial with respect to such claims,
which may have the effect of limiting and discouraging lawsuits against us or the depositary. If a lawsuit is brought against us or the
depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would be conducted
according to different civil procedures and may result in different outcomes than a trial by jury would have had, including results that
could be less favorable to the plaintiff(s) in any such action, depending on, among other things, the nature of the claims, the judge
or justice hearing such claims, and the venue of the hearing.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">No condition, stipulation or provision
of the deposit agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of compliance
with any substantive provision of the U.S. federal securities laws and the rules and regulations promulgated thereunder.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold; font-style: italic">If
we are unable to satisfy the requirements of Sections&#160;404(a) and 404(b) of the Sarbanes-Oxley Act of 2002 or if our internal control
over financial reporting is not effective, investors may lose confidence in the accuracy and the completeness of our financial reports,</span>&#160;<span style="font-weight: bold; font-style: italic">and
the trading price of our ADSs may be negatively affected.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Pursuant to Section&#160;404 of the
Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;), we are required to furnish a report by management on the effectiveness
of our internal control over financial reporting.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If we identify material weaknesses
in our internal control over financial reporting, if we are unable to comply with the requirements of Section&#160;404in a timely manner
or to assert that our internal control over financial reporting is effective, or if our independent registered public accounting firm
is unable to express an opinion or issues an adverse opinion in its attestation as to the effectiveness of our internal control over financial
reporting required by Section 404, investors may lose confidence in the accuracy and completeness of our financial reports and the trading
price of our ordinary shares could be negatively affected. We could also become subject to investigations by Nasdaq, the SEC or other
regulatory authorities, which could require additional financial and management resources.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">

<div style="line-height: 1.25; font-style: italic; font-weight: bold">We have not yet determined whether we were classified as a PFIC
for our 2024 taxable year, and the determination of our status as a PFIC for our 2025 taxable year is made at the end of the 2025 taxable
year,&#160; accordingly,&#160; no assurances can be provided in this regard.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We would be classified as a passive foreign investment company,
or PFIC, for any taxable year if, after the application of certain look-through rules, either: (i) 75% or more of our gross income for
such year is &#8220;passive income&#8221; (as defined in the relevant provisions of the Internal Revenue Code of 1986, as amended, or
the Code), or (ii) 50% or more of the value of our assets (generally determined on the basis of a quarterly average) during such year
is attributable to assets that produce or are held for the production of passive income. Passive income generally includes, among other
things, rents, dividends, interest, royalties, gains from the disposition of passive assets, and gains from commodities and securities
transactions. For the purposes of this test, we will be treated as owning a proportionate share of the assets and earning a proportionate
share of the income of any other corporation of which we own, directly or indirectly, at least 25% (by value) of the stock. We have not
yet determined whether we were a PFIC for our 2024 taxable year, and the determination of our status as a PFIC for our 2025 taxable year
is made at the end of the 2025 taxable year,&#160; accordingly, no assurances can be made in this regard. If we were treated as a PFIC,
a U.S. holder of the ordinary shares may be subject to adverse U.S. federal income tax consequences, such as taxation at the highest marginal
ordinary income tax rates on capital gains and on certain actual or deemed distributions, interest charges on certain taxes treated as
deferred, and additional reporting requirements. U.S. Holders should consult their own tax advisors and should read the discussion below
under &#8220;Item 10. Additional Information - E. Taxation - Material U.S. Federal Income Tax Considerations for U.S. Holders.&#8221;</div>
</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="line-height: 1.25; font-family: Times New Roman; font-weight: bold">Item 4<span id="Item4"><!--Anchor--></span>. Information
on the Company</div>

<div style="line-height: 1.25; font-family: Times New Roman"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z8e4ae1043e3a45cb976382fb5b964018" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">A.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">History and Development of the Company</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;We were incorporated on November
30, 2011, under the laws of the State of Israel. In March 2021, in connection with the Merger, we changed our name from Anchiano Therapeutics
Ltd. to Chemomab Therapeutics Ltd. Our principal executive offices are located at Kiryat Atidim, Building 7, Tel Aviv, Israel 6158002,
and our phone number is +972-77-331-0156. Our website is: www.chemomab.com.&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">34</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We use our website as a means of
disclosing material non-public information. Such disclosures will be included on our website in the &#8220;Investor Relations&#8221; sections.
Accordingly, investors should monitor such sections of our website, in addition to following our press releases, SEC filings and public
conference calls and webcasts. Information contained on, or that can be accessed through, our website does not constitute a part of this
Annual Report and is not incorporated by reference herein. We have included our website address in this Annual Report solely for informational
purposes. Our SEC filings are available to you on the SEC&#8217;s website at http://www.sec.gov. This site contains reports and other
information regarding issuers that file electronically with the SEC. The information on that website is not part of this Annual Report
and is not incorporated by reference herein.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our agent for service of process
in the United States is Chemomab Therapeutics, Inc. which maintains its principal offices at One Kendall Square, Building 1400E, Suite
14-105, Cambridge, MA 02139. Its telephone number is (857) 259-4622.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">For a description of our principal
capital expenditures and divestitures, see Item 5. &#8220;Operating and Financial Review and Prospects-Liquidity and Capital Resources&#8221;
and Note 2 to our audited consolidated financial statements included elsewhere in this Annual Report.</div>

<div style="line-height: 1.25; font-family: Times New Roman"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z3a9b55d994614712b58722e1c4b1f983" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">B.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Business Overview</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Overview</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We are a clinical-stage biotechnology
company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet needs.
Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, we have developed nebokitug,
a monoclonal antibody designed to bind and block CCL24 activity. Nebokitug&#160; has demonstrated the potential to treat multiple severe
and life-threatening fibrotic and inflammatory diseases.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We have pioneered the therapeutic
targeting of CCL24, a chemokine also known as eotaxin-2, which promotes various types of cellular processes that regulate inflammatory
and fibrotic activities through the CCR3 receptor. CCL24 is expressed in various types of cells, including immune cells, endothelial cells
and epithelial cells. We have developed a novel CCL24 inhibiting product candidate with dual anti-fibrotic and anti-inflammatory activity
that modulates the complex interplay of these inflammatory and fibrotic mechanisms, which drive abnormal states of fibrosis and fibrotic
diseases. This innovative approach is currently being developed for difficult-to-treat rare diseases, also known as orphan indications
or diseases, such as primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc) for which patients have no established disease-modifying
or standard-of-care treatment options. We estimate that there are approximately 77,000 patients suffering from PSC in the United States,
European Union and Japan, representing a more than $1 billion market opportunity, and approximately 170,000 patients suffering from SSc
in those same markets, representing a more than $1.5 billion market opportunity.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Nebokitug, our lead clinical product
candidate, is a first-in-class humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory
and fibrotic pathways. We have demonstrated that nebokitug interferes with the underlying biology of inflammation and fibrosis through
a novel and differentiated mechanism of action. We have recently completed a Phase 2 clinical study in PSC, a rare obstructive and cholestatic
liver disease. Positive topline results from the double-blinded portion of this trial were reported in July, 2024 and results from the
open label part were reported in March 2025. The company had an End-of-Phase 2 meeting with the FDA in December, 2024. At this meeting,
the FDA and Chemomab agreed on the design for a single Phase 3 pivotal PSC trial that could result in full regulatory approval of nebokitug
for patients with PSC.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">35</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The randomized, placebo-controlled
Phase 2 study design included two doses of nebokitug (10 or 20mg/kg) vs placebo, administered once every three weeks for 15 weeks, as
well as an open label extension in which all nebokitug eligible patients could receive nebokitug for an additional 33 weeks. In the Phase
2 study, nebokitug achieved its primary endpoint of safety and tolerability and demonstrated anti-fibrotic, anti-inflammatory and anti-cholestatic
effects across a broad range of disease-related secondary efficacy endpoints, including statistically significant improvements in liver
stiffness, a key PSC disease marker, after just 15-weeks of treatment. Moreover, nebokitug showed a reduction in total bilirubin, an important
marker of cholestasis and liver health, as well as reductions in pruritus, a cholestatic indicator of great relevance to patients. Nebokitug
is the first investigational drug being developed for PSC to exhibit broad, clinically relevant effects on all three components of the
disease, establishing clinical proof-of-concept and providing further evidence of its multifactorial mechanism of action and disease-modifying
potential.&#160;The open label extension portion of the trial was reported recently and showed the nebokitug continued to demonstrate
good tolerability safety and anti-fibrotic, anti-inflammatory and anti-cholestatic activity of nebokitug up to 48 weeks of treatment.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; text-indent: 36pt">Chemomab and the FDA aligned on a
clinical events-driven Phase 3 trial design, The trial is planned to be a randomized placebo-controlled clinical event-driven study. Patients
in the active treatment arm will receive 20 mg/kg of nebokitug administered intravenously every three weeks. The primary endpoint is the
time-to-first clinical event. The endpoint is a composite encompassing multiple, equally-weighted adverse clinical events associated with
PSC disease progression, which may include acute cholangitis, biliary strictures requiring intervention, portal hypertension, hepatic
decompensation, elevated MELD score (a measure associated with the need for liver transplant), liver transplantation, cholangiocarcinoma
and death. Enrolled patients remain in the trial until they experience an event, and the trial continues until the requisite number of
events has been collected. It is estimated that in the absence of intervention, participants would require on average about two years
to achieve a clinically meaningful event. Clinical events will be assessed in a blinded fashion by an independent clinical endpoint adjudication
committee. Approximately 350 PSC patients will be enrolled in the trial, and the study population will be enriched for patients with moderate
to advanced disease. Chemomab expects to leverage the strong relationships with global clinical investigators it developed during its
successful Phase 2 SPRING study to facilitate enrollment in the nebokitug pivotal trial.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The nebokitug SSc clinical program is Phase
2-ready and we have an open IND in the United States for a Phase 2 clinical trial. However, Chemomab has suspended initiation of this
study while we focus our resources on the Phase 2 PSC Program.&#160; We believe that nebokitug could have disease-modifying potential
in this poorly treated condition.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">While our primary focus is on these
two rare indications, early in 2024 we reported results from a completed Phase 2a clinical study in patients with liver fibrosis due to
metabolic dysfunction-associated steatohepatitis (MASH).&#160; This trial provided safety and pharmacokinetic (&#8220;PK&#8221;) data
and information useful for assessing our current subcutaneous formulation of nebokitug. Additionally, the trial measured a number of biomarkers
that may be relevant to the activity of nebokitug in other fibro-inflammatory conditions. The results showed that the trial met its primary
endpoint of safety and tolerability, and that nebokitug demonstrated consistent data trends and positive activity across secondary endpoints
that included a range of liver fibrosis biomarkers and physiologic assessments. A secondary analysis, that further confirmed and extended
these initial results was reported at the 2023 EASL Congress in June 2023.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Fibrosis is the abnormal and excessive
accumulation of collagen and extracellular matrix, the non-cellular component in all tissues and organs, which provides structural and
biochemical support to surrounding cells. When present in excessive amounts, collagen and extracellular matrix lead to scarring and thickening
of connective tissues, affecting tissue properties and potentially leading to organ dysfunction and failure. Fibrosis can occur in many
different tissues, including lung, liver, kidney, muscle, skin, and the gastrointestinal tract, resulting in a wide array of progressive
fibrotic conditions. Fibrosis and inflammation are intrinsically linked. While a healthy inflammatory response is necessary for efficient
tissue repair; after disease or injury, an excessive, uncontrolled inflammatory response can lead to tissue fibrosis that in turn can
further stimulate inflammatory processes in a fibro-inflammatory vicious cycle.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Recent Developments</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;

<div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman, Times, serif">&#8226;</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
&#160;&#160; <span style="font-family: Times New Roman, Times, serif">On March 27, 2025,&#160; Chemomab reported positive clinical data
from the open label (OLE) part of the PSC SPRING study. Treatment with nebokitug for up to 48 weeks was well-tolerated and the data reinforced
and expanded the positive results seen in the 15-week double-blinded portion of the Phase 2 SPRING trial. Treatment in PSC patients with
moderate/advanced disease for up to 48 weeks resulted in continued substantial improvements across key biomarkers of liver injury/inflammation
and fibrosis, including ELF score, fibrosis-related ELF score components and PRO-C. OLE patients treated with nebokitug showed stabilization
of liver stiffness and a significantly lower number of clinical events compared to historical controls.</span></div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; text-indent: 36pt">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif">On February 19, 2025, Chemomab reported that the International
Nonproprietary Names (INN) program of the World Health Organization had assigned the INN designation nebokitug to the company&#8217;s
lead product candidate CM-101.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">36</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25"><span style="font-family: Times New Roman, Times, serif">&#8226;</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<span style="font-family: Times New Roman, Times, serif">On February 19, 2025, Chemomab announced the successful completion of its End-of-Phase
2 Meeting with the U.S. Food and Drug Administration (FDA) and alignment with the FDA on the design of a Phase 3 registration study for
nebokitug for the treatment of PSC. We believe the design provides clarity on a streamlined path to full regulatory approval based on
a single pivotal trial that does not require liver biopsies or confirmatory studies. The primary endpoint measures time-to-first clinical
event and encompasses multiple clinical events associated with disease progression. Key publications have shown that the reductions in
PSC biomarkers seen in the nebokitug Phase 2 SPRING trial are associated with reductions in clinical events, which we believe increases
confidence in the relevance of this approach for the nebokitug Phase 3 trial.</span></div> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On
November 19, 2024, Chemomab reported that data from its Phase 2 SPRING trial in patients with PSC was presented at the American Association
for the Study of Liver Disease (AASLD) The Liver Meeting&#174; 2024. In an oral, late-breaking presentation, Professor Christopher Bowlus,
MD, a SPRING trial investigator and&#160; Professor and Chief of the Division of Gastroenterology and Hepatology at the University of
California Davis School of Medicine, discussed data from the double-blinded, placebo-controlled portion of the Phase 2 trial.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On
July 30, 2024, Chemomab announced the closing of a private placement that resulted in gross proceeds of approximately $10 million to the
company. Existing investors such as OrbiMed and new investors including HBM Partners and Sphera Biotech Master Fund participated in the
financing. The financing extended the Chemomab&#8217;s runway through early 2026.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On
July 25, 2024, Chemomab reported positive topline results from the nebokitug Phase 2 SPRING trial in patients with PSC. Nebokitug met
the primary study endpoint, demonstrating that it is well tolerated and nebokitug-treated patients with moderate/advanced disease showed
improvements on a wide range of disease-related secondary endpoints, including liver stiffness, liver fibrosis biomarkers, such as the
Enhanced Liver Fibrosis (ELF) score and PRO-C3 levels; total bilirubin and liver function tests; pruritus (itch) and markers of inflammation.
Dose-dependent responses were observed for multiple disease-related biomarkers. A consistent pattern of greater improvement on the secondary
endpoints was observed in the study arm receiving the 20mg/kg dose of nebokitug. This dose has been selected for the active treatment
arm of the Phase 3 trial.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On
June 18, 2024, Chemomab announced new scientific publications had been published in the peer-reviewed journals International Journal of
Molecular Science and Drug Safety that reinforced the clinical potential of nebokitug in PSC.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On
June 6, 2024, Chemomab presented new scientific and clinical data at EASL 2024 and at a Gordon Research Conference supporting the clinical
potential of nebokitug as a novel treatment for PSC. The findings helped elucidate nebokitug&#8217;s mode of action in liver fibrosis
and could help in characterizing its anti-fibrotic drug effects.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On
April 18, 2024, Chemomab announced the publication of a new study in the journal Arthritis Care and Research that confirms the key role
of CCL24 in systemic sclerosis. The longitudinal study of more than 200 SSc patients showed that elevated levels of serum CCL24&#160;
are associated with increased mortality and disease severity across the fibrotic and vascular manifestations of the disease.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On
April 10, 2024, Chemomab hosted an expert PSC webinar featuring Christopher Bowlus, MD, of UC Davis Health; Ricky Safer, founder and CEO
of PSC Partners Seeking a Cure and Massimo Pinzani, MD, PhD, of the UCL Institute for Liver and Digestive Health and UPMC ISMETT.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In
March, 2024, Chemomab reported that the European Patent Office had granted a new patent for nebokitug, covering the use of nebokitug and
sequence-related anti-CCL24 antibodies for the treatment of liver diseases, such as PSC. In February, new patents were granted in Brazil
and Israel.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In
January, 2024, Chemomab reported publication of new proteomics research in the peer-reviewed journal Cells. The proteomic analyses of
human samples highlighted the unique role of CCL24 in activating key PSC-related disease mechanisms and further confirmed the potential
of nebokitug as a promising treatment for PSC.</span></div>

<div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman"> <br/> </span></div>

<div style="text-align: justify; line-height: 1.25">

<div style="line-height: 1.25"><span style="font-family: Times New Roman">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In
January, 2024, Chemomab announced early completion of patient enrollment in the nebokitug Phase 2 PSC SPRING trial and moved up the expected
topline data readout to midyear 2024.</span></div> <span style="font-family: Times New Roman"> </span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">37</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Private Placement</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">Securities Purchase Agreement</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25">On July 25, 2024, the Company entered into a Securities Purchase Agreement (the &#8220;Securities
Purchase Agreement&#8221;) with certain investors (the &#8220;Purchasers&#8221;), pursuant to which the Company agreed to sell to the
Purchasers: (i) 4,148,867 ADSs, at a purchase price of $1.235 per ADS; and (ii), in lieu of ADSs, Pre-Funded Warrants to purchase up to
3,948,300 ADSs at a purchase price of $ 1.2349 per warrant. The Pre-Funded Warrants&#160; have an exercise price of $0.0001 per ADS, are
immediately exercisable and remain exercisable until exercised in full.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The July 2024 Private Placement closed
on July 30, 2024, and the Company received gross proceeds from the July 2024 Private Placement of approximately $10.0 million before deducting
any offering expenses payable by the Company.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The Company is using the net proceeds from
the July 2024 Private Placement, together with the Company&#8217;s existing cash and cash equivalents, to fund its development programs
for nebokitug and for general corporate purposes and working capital.&#160; <br/> </div> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">Registration Rights Agreement</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In connection with the July 2024
Private Placement, the Company also entered into a registration rights agreement, dated July 25, 2024 (the &#8220;Registration Rights
Agreement&#8221;) with the Purchasers requiring the Company to file a registration statement with respect to the resale of the securities.
The Company filed a registration statement with the SEC on August 23, 2024, which was declared effective on September 6, 2024. The Company
granted the Purchasers customary indemnification rights in connection with the Registration Rights Agreement, and the Purchasers granted
the Company customary indemnification rights in connection with the Registration Rights Agreement.<br/> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Pipeline</div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><img src="image00019.jpg" alt=""/></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">38</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our lead product candidate,&#160;nebokitug,
is a first-in-class humanized monoclonal antibody targeting CCL24 that is being assessed in two orphan indications: PSC and SSc. CCL24
has been extensively studied in airway inflammation and, more recently, we have demonstrated in preclinical studies and early clinical
studies that it plays an important role in additional indications, including inflammation and fibrosis of the liver, skin and lung. While
CCL24 is found in low levels in blood and tissue samples from healthy volunteers, elevated levels of both CCL24 and its receptor CCR3
have been found in patients with PSC, SSc and MASH. CCL24 levels have also been correlated to different stages of disease. Based on extensive
preclinical, nonclinical and early clinical studies, we expect that neutralizing CCL24 will result in anti-fibrotic and anti-inflammatory
effects in patients. Nebokitug has been granted orphan drug designation by both the FDA and the EMA in its primary indications of PSC
and SSc. In addition, nebokitug was granted a Fast Track designation in PSC from the FDA. These designations provide multiple benefits
for these indications, including the potential for accelerated clinical and regulatory pathways as well as exclusive marketing and development
rights for a period of time.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">PSC is a rare, chronic cholestatic
liver disease characterized by progressive inflammation, fibrosis, and destruction of the intrahepatic and extrahepatic bile ducts. The
cause of the disease is not known, although a high proportion of PSC patients also have inflammatory bowel disease. Fibrosis and inflammatory
responses induce a progressive spread of the fibrotic condition. Cholestasis is a symptom of liver injury and is characterized as the
interruption of bile flow from hepatocytes to the intestine, which leads to bile acid accumulation in the liver, resulting in oxidative
stress, inflammation, apoptosis and fibrosis. PSC affects approximately 30,000-45,000 patients in the United States. It leads to end-stage
liver disease and cancer, which causes about half of PSC deaths. About half of patients require liver transplantation, but PSC then re-occurs
in about 20% of transplant recipients, Median transplant-free survival is estimated at 10-20 years.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">No treatment aside from a liver transplant
has been associated with change of the disease course or significant long-term improvement in the clinical outcome. PSC is a clear serious
unmet medical need with no FDA approved therapeutics and for which the current standard of care is inadequate.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">SSc is a rare connective tissue disease
characterized by excessive fibrosis and extracellular matrix accumulation in the skin, lung and other visceral organs. The disease initiates
with an early inflammatory phase involving the immune cell network, as well as endothelial cells. As the disease progresses, the inflammation
increases and fibroblasts and myofibroblasts generate tissue fibrosis, while endothelial cells promote vascular injury, which can lead
to skin fibrosis, interstitial lung disease, myocardial insufficiency, vascular obliteration, distal ulcerations and gangrene. SSC affects
approximately 75,000-100,000 patients in the United States. SSc has the highest mortality rate among the systemic rheumatic diseases and
has high unmet need, as current treatments manage only disease manifestations and there is no disease modifying drug available.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We are primarily focused on the orphan
indications PSC and SSc but believe that nebokitug may have additional applications in other fibrotic-inflammatory disease areas such
as idiopathic pulmonary fibrosis, or IPF and MASH. Nebokitug has shown promising anti-fibrotic and anti-inflammatory effects in preclinical
studies of liver fibrosis and PSC, with significant reductions in fibrotic genes, liver enzymes, bile acid and cholangiocyte proliferation,
all reflecting a potential improvement in disease status. In preclinical studies of SSc, nebokitug reduced inflammatory and fibrotic injury
resulting in reductions in dermal thickness, collagen concentration in the skin and the lung, and immune cell infiltration in the lung.<br/>
&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We have completed two Phase 1a single
ascending dose studies with intravenous, or IV, and subcutaneous, or SC, administrations of nebokitug in healthy volunteers. The drug
was shown to be well-tolerated, with a PK profile supporting dosing once every 2-4 weeks. We also completed a Phase 1b multiple administration
ascending dose study in 16 MAFLD patients, expanding the safety, tolerability, and pharmacodynamics database with patients with early
liver disease. Early evidence of anti-fibrotic activity was also seen in this study.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In 2023 we reported topline and secondary
results from our Phase 2a randomized, double-blind, placebo-controlled study in patients with liver fibrosis associated with MASH. The
trial met its primary endpoint of safety and tolerability, and nebokitug demonstrated promising activity in secondary endpoints that included
pharmacokinetic and target engagement profiles of the SC formulation, as well as a range of liver fibrosis biomarkers and physiologic
assessments measured at baseline and at week 20.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">39</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The trial enrolled 23 MASH patients
with stage F1c, F2 and F3 disease who were randomized to receive either nebokitug or placebo. Patients received eight doses of 5 mg/kg
of study drug administered by SC injection once every two weeks, for a treatment period of 16 weeks. Key findings of the nebokitug&#160;
Phase 2a trial included the following.</div>

<div style="line-height: 1.25; font-family: Times New Roman"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zf47e8ee962754a36820a0928ce13ac45" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.27%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 96.73%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">Nebokitug appeared to be well tolerated when administered
        subcutaneously. Most reported adverse events observed were mild, with one unrelated serious adverse event reported. No significant injection
        site reactions were reported and no anti-drug antibodies, or ADAs, were detected.&#160;Nebokitug administered subcutaneously demonstrated
        favorable pharmacokinetics and target engagement profiles as expected, which were similar to what we have previously reported.&#160;A
        higher proportion of patients in the nebokitug-treated group showed improvement than in the placebo group in a number of liver fibrosis-related
        biomarkers, including ProC-3, ProC-4, ProC-18, TIMP-1, ELF and Liver stiffness.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Data from this trial provided important
insights in support of the nebokitug development program, including the favorable safety and tolerability of nebokitug in patients with
serious liver disease, confirmation of early signs of biomarker activity that are relevant for a number of fibro-inflammatory disorders,
and additional tolerability and pharmacokinetic data needed to assess next steps in the development of our current subcutaneous formulation.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Earlier, we also reported positive
clinical data from an investigator-initiated clinical study assessing nebokitug activity and safety in hospitalized patients with severe
lung injury derived from COVID-19. The objective of the study was to evaluate the drug&#8217;s safety and activity in hospitalized COVID-19
patients with severe pneumonia, including its impact on biomarkers related to lung inflammation that are also relevant in systemic sclerosis.
The open label, single arm trial enrolled 16 hospitalized adult COVID-19 patients with severe respiratory involvement. All patients were
receiving standard of care therapy. All were treated with a single 10mg/kg intravenous dose of nebokitug on the first day of the study
and followed for 30 days. Administration of nebokitug to this acutely ill patient population appeared to be well tolerated. Nebokitug
exposures and target engagement profiles were similar to what our researchers have seen in previous clinical studies of nebokitug. Importantly,
rapid reductions in serum biomarkers of lung inflammation, fibrogenesis and neutrophil activity were observed post-treatment with nebokitug.
Overall, this study confirmed and extended the safety and tolerability profile of nebokitug and demonstrated clinically relevant changes
in biomarkers associated with lung inflammation and fibrogenesis, further supporting nebokitug&#8217;s anti-inflammatory and anti-fibrotic
effects.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The Phase 2 SPRING study enrolled
76 patients with PSC who were treated with nebokitug or placebo for 15 weeks. The double-blinded&#160; trial design included 2 dose cohorts
of nebokitug (10 or 20 mg/kg) vs placebo who received treatment for 15 weeks, as well as an open-label (OLE) extension of 33 weeks to
evaluate the safety, tolerability and durability of effect over longer treatment durations. The open label part of the study included
50 patients who elected to continue, out of 54 patients who were eligible to enter into the open label phase.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In July, 2024 we reported the results
of the Phase 2 SPRING trial, a randomized, double-blind, placebo-controlled study of nebokitug in PSC patients. Nebokitug met the primary
study endpoint, demonstrating that it is well tolerated and nebokitug-treated patients with moderate/advanced disease showed improvements
on a wide range of disease-related secondary endpoints, including liver stiffness, liver fibrosis biomarkers, such as the Enhanced Liver
Fibrosis (ELF) score and PRO-C3 levels; total bilirubin and liver function tests; pruritus (itch) and markers of inflammation. Dose-dependent
responses were observed for multiple disease-related biomarkers. A consistent pattern of greater improvement on the secondary endpoints
was observed in the study arm receiving the 20mg/kg dose of nebokitug. This dose has been selected for the active treatment arm of the
Phase 3 trial design.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In March 2025, we reported the results
of the open label part of the study. The OLE study confirmed that in PSC patients receiving 10 mg/kg or 20 mg/kg of nebokitug administered
once every three weeks for 48 weeks, the drug was safe and well-tolerated and resulted in positive effects, including continued improvements
in key liver biomarkers such as the ELF score, the fibrosis-related components of ELF and the fibrosis biomarker PRO-C3. Liver stiffness
scores (transient elastography), as measured by FibroScan&#174; were substantially lower in the nebokitug-treated patients with moderate/advanced
disease compared to matching historical controls. Cholestasis-related markers stabilized over 48 weeks of treatment and total serum bile
acids were reduced.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">40</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We may also explore nebokitug in other indications, where
the dual activity of nebokitug acting on both inflammation and fibrosis could provide new avenues for treating inflammatory and fibrotic
conditions.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Chemomab was founded in 2011, based
on a novel discovery originating from the Sourasky Medical Center in Tel-Aviv, Israel, where Professor Jacob George first identified CCL24
as a key regulator of unstable plaque formation in atherosclerotic patients. In our early years, we focused on research directed at clarifying
the role and effectiveness of CCL24 blockade. In 2015, we selected our proprietary lead product candidate, nebokitug, and started product
development directed towards human testing.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We have assembled an executive team with highly relevant
experience in inflammation and fibrosis, and biologics drug discovery and clinical development. Adi Mor, Ph.D., our Chief Executive Officer,
Chief Scientific Officer and Co-founder, has 16 years of experience in immunology and has led the nebokitug program from discovery stage
into Phase 2 clinical studies. Matthew Frankel, M.D., our Chief Medical Officer, brings deep experience in clinical development. Dr. Frankel,
who is based in the U.S., has more than 25 years of experience in the discovery and clinical development of novel therapeutics and has
held senior executive roles at both global pharmaceutical and biotechnology companies. Jack Lawler, our Senior Vice President of Global
Development Operations, is highly experienced in managing clinical trials across a wide range of indications and geographies.<br/> &#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Company strategy</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We aim to become a world-leading
company for the treatment of diseases involving inflammation and fibrosis, developing novel therapies across a wide range of indications.
To achieve this, we are focused on the following key strategies:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z74f987c0cb514a15aeff863e31bdec18" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Advance our lead product, nebokitug, for the
        treatment of PSC and potentially SSc, through clinical development to approval</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The clinical development plan of
lead product candidate nebokitug was optimized to maximize the clinical information obtained, generating additional important data to
support future advancement to registration trials, and decreasing the overall risk of the nebokitug clinical development program in the
lead indication of PSC and potentially SSc, as well as potentially in additional indications where the scientific rationale is strong.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<table cellspacing="0" cellpadding="0" id="z4116f46f211a40048c00531f2b02649f" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Selectively evaluate partnership opportunities</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We continuously explore partnership
opportunities to advance nebokitug development in PSC and SSc, and possibly additional indications, identifying companies with drugs (either
approved or in development) that could possibly be combined with nebokitug, extending the development of nebokitug to new indications
beyond PSC and SSc, and seeking additional significant commercial or drug development capabilities that may accelerate nebokitug&#8217;s
time to market.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb60397e6e54942bc8f42740442a8fa48" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Explore opportunities for nebokitug in additional
        inflammatory/fibrotic indications</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We continue to evaluate the potential
benefit of nebokitug outside of our current lead indications of PSC and SSc, in order to maximize the product&#8217;s potential. nebokitug
has shown anti-fibrotic activity in animal models and human tissue studies of IPF and MASH. We will continue to assess ways to leverage
the dual anti-inflammatory and anti-fibrotic activity of nebokitug in new disease areas and to form additional collaborations with global
medical researchers and drug developers.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z41ca16824a39485cb9b1de2309a824af" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Strengthen our intellectual property portfolio</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We believe that we have developed a strong intellectual
property portfolio and will continue to seek, maintain, and defend our patent rights, whether developed internally or licensed to protect
and enhance the proprietary technology, inventions, and improvements that are commercially important to the development of our business
proprietary position in the field of inflammation and fibrosis.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">41</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Fibrosis and inflammation</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Tissue damage activates a repair
process that includes acute inflammation followed by either successful complete repair or tissue replacement by fibrosis. However, persistent
and repeated damage can result in continuous activation of the repair process leading to chronic inflammation, progressive tissue fibrosis
and sclerosis.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Fibrosis is an accumulation of non-functional
tissue and can occur in many different tissues, including lung, liver, kidney, muscle, skin and the gastrointestinal tract, resulting
in a number of chronic fibrotic conditions. Liver fibrosis is the process of excessive accumulation of extracellular matrix proteins,
predominantly collagen, which occurs as the result of liver injury. In cases of acute temporary damage, these changes are transient and
liver fibrosis may resolve. In chronic cases, however, the liver damage persists and chronic inflammation and accumulation of the extracellular
matrix eventually lead to cirrhosis. The various fibrotic manifestations in conditions like SSc are still not well understood. Disease
progression is characterized by an early inflammatory onset followed by tissue fibrosis, vascular injury and organ damage. Fibrosis, and
specifically lung fibrosis, is the main cause of disease progression and mortality in SSc, although manifestation of the disease in other
organs can cause patients considerable distress and adversely impact their health and their quality of life.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Fibrosis and inflammation are intrinsically
linked; a healthy inflammatory response is necessary for efficient wound healing; however, a prolonged response can contribute to the
pathogenesis of fibrosis. The inflammatory response during chronic liver injury is a dynamic process with intrahepatic accumulation of
diverse immune cells. Recruitment and infiltration of these cells to the liver and their localization is mainly determined by chemokines
and cytokines that are produced by hepatocytes, immune cells, biliary epithelial cells, and endothelial cells. Notably, activated liver
fibroblasts, the hepatic stellate cells, or HSCs, secrete various chemokines, thereby contributing to the ongoing immune response during
fibrotic liver diseases. Similarly, for SSc, the early inflammatory phase leading to fibrosis in multiple organs of the body includes
activation of the immune cell network of lymphocytes, eosinophils, and monocytes, as well as endothelial and endothelial progenitor cells.
In the advanced SSc phase, fibroblasts and myofibroblasts take the lead to generate tissue fibrosis.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Chemokine involvement
in inflammation and fibrosis</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Chemokines are a group of small signaling
proteins thought to be involved in the etiology, or causation, of multiple inflammatory diseases. They are not only implicated in immune
cell recruitment during inflammation, but also contribute to immune surveillance, direct cells to target organs in homeostasis, and exert
pleiotropic, or diverse, effects on non-immune cells, for instance, directly influencing the functionality of fibrogenic cells. Chemokines
and their corresponding chemokine receptors are key players in orchestrating the sequential influx of immune cells into damaged or diseased
organs, driving inflammatory responses to specific triggers.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; text-indent: 36pt">In the liver, chemokines have a key
role in the development of inflammation and wound healing responses, which can lead to either resolution of liver injury or promote, if
ongoing, maladaptive responses with chronic inflammation, fibrosis, and development of clinically manifest liver disease. Although the
pathophysiology underlying PSC has not yet been fully clarified, animal models of PSC have contributed to dissecting the molecular basis
of this disease and highlighting the role of cytokines and chemokines as important pathogenetic mediators of liver inflammation and fibrosis.
Recently published studies demonstrated that in most of the processes suggested for the onset and development of PSC, chemokines and chemokine
receptors play a key role. Hematopoietic stem cells&#160;(HSCs) may be the main producers of cytokines and play an initial role in the
progression of liver fibrosis by attracting different types of immune cells, resulting in further production of cytokines and liver injury
in a vicious disease cycle. Extensive proliferation, trans-differentiation and activation of HSCs result in ongoing chronic tissue remodeling
and severe fibrosis. In addition, chemokines are also involved in promoting polarization of the recruited immune cells. Therefore, chemokines
may participate in PSC by promoting migration of inflammatory and fibrotic cells, by activating inflammatory and fibrotic cells locally,
or by inducing cytokines that promote collagen and matrix deposition.<br/> &#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">42</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Likewise, in SSc pathogenesis, chemokines
foster migration and activation of inflammatory and fibrotic cells, inducing the secretion of cytokines that promote collagen and matrix
deposition in affected organs. Indeed, patients with SSc exhibit increased systemic levels of proinflammatory chemokines and some of these
have also been shown to correlate with limited or diffuse cutaneous disease phenotype and/or to organ-specific pathology such as lung
disease or skin vascular inflammation.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">The role of CCL24</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">CCL24 is a chemokine that promotes
various types of cellular processes that regulate inflammatory and fibrotic activities through the CCR3 receptor. This chemokine is known
to be expressed by activated T-cells, monocytes, epithelial cells and endothelial cells, as well as by activated fibroblasts. CCL24 induces
chemotaxis and activation of CCR3-expressing cells, including immune cells and fibroblasts.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We have been the driving force in
establishing the role of CCL24 in the pathogenesis of PSC and SSc, however, others have highlighted its contribution to other indications.
For example, published work has shown that both CCL24 and CCR3 are involved in lung and skin inflammation and fibrosis. CCR3 is robustly
expressed on eosinophils and recent data has suggested that eosinophilic inflammation may be involved in the pathogenesis and progression
of SSc. For example, in SSc patients, eosinophil counts, but not total leukocytes, were significantly higher than in patients with other
connective autoimmune diseases. Eosinophil counts correlated positively with both interstitial lung disease severity and the modified
Rodnan skin thickness score, or mRSS.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Notably, CCR3 was shown to be expressed
on oral and dermal fibroblasts where it modulates wound healing and tissue remodeling processes. A recent academic study also demonstrated
overexpression of CCR3 on monocyte populations isolated from SSc patients. CCL24 was shown to be involved in proinflammatory reactions,
specifically contributing to the type 2 immune reaction involving Th2 lymphocytes and M2 macrophages that were shown to be present in
skin lesions of SSc patients. Accordingly, CCL24 was found to play a dominant role in inducing profibrotic effects and to be overexpressed
in fibrotic lungs and bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosis, a disease sharing similar lung dysfunction
features with SSc. Furthermore, CCL24 was shown to promote collagen production in human lung fibroblasts and to be constitutively expressed
by dermal fibroblasts.</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman"><img src="image00020.jpg" alt=""/></div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">CCL24 is a critical mediator promoting
inflammation and fibrosis</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">43</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Challenges to
drug development in fibrosis and inflammation</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Successful treatment of fibrotic
disorders has in large part remained elusive, primarily due to incomplete understanding of the complexity and multi-mechanism contributions
to disease progression. This has complicated preclinical investigations for new products and new targets, with animal models having limited
resemblance to human disease. Additionally, preclinical animal data is often of short treatment duration and does not capture the effects
of treating chronic fibrotic indications. This is particularly applicable to complex, orphan indications like PSC and&#160; SSc, where
there is still no approved standard of care or proven target mechanism.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Notwithstanding challenges in the
field of fibrosis and inflammation, there is significant and growing industry interest given the associated unmet medical need and the
continuing opportunity to identify better therapeutic targets. For example, in 2024 Gilead acquired Cymabay for its PPAR agonist in Primary
biliary cirrhosis.&#160; In 2019 Novartis completed two transactions related to the treatment of MASH, a liver metabolic fibrotic disease.
It acquired IFM Tre for NLRP3 antagonists for a $310 million upfront payment and total potential consideration of $1.5 billion and licensed
an integrin inhibitor from Pliant Therapeutics for an $80 million upfront payment. Additionally, Gilead Sciences licensed two preclinical
programs, one in MASH for a $15 million upfront payment (total potential consideration of $785 million) and the other for TGF-&#946; inhibitors
in fibrosis for an $80 million upfront payment and total potential consideration of $1.4 billion. In 2020, Roche acquired Promedior for
a $390 million upfront payment and total potential consideration of $1 billion in milestones for its Phase 2 product in pulmonary fibrosis,
and Bayer partnered with Recursion Pharmaceuticals to develop and commercialize preclinical-stage small molecule treatments for fibrotic
conditions for a $30 million upfront payment and total potential consideration of $1 billion.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Targeting chemokines
as a treatment for fibrotic indications</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We believe that our approach, selectively
targeting fibrotic conditions by attenuating both inflammation and fibrosis, may be an optimal approach for both effectiveness and reduction
of toxicity. As central regulators of initiation and progression of fibrotic disorders, chemokines are an ideal target to impact both
inflammation and fibrosis. Some chemokines are also disease-specific, allowing for potential selectivity.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Chemokine receptors, or CCRs, have
been more extensively studied as drug targets in fibrotic conditions compared to chemokine ligands, however, the therapeutic effects of
CCR inhibitors have generally fallen short in the clinic. Pharmaceutical companies have previously explored the CCL24 ligand receptor,
CCR3, and its other ligands CCL7 and CCL11, with small or large molecule inhibitors. These programs were directed at inhibiting eosinophilic
trafficking in respiratory and allergic inflammation, however, despite promising preclinical data, most programs were discontinued largely
due to poor safety profiles and limited efficacy of the antagonist used. To our knowledge, only Alkahest has an active program that explores
CCR3 inhibition, which is under license from Boehringer Ingelheim and is being developed as a treatment for wet AMD. In contrast, we believe
CCL24 presents a more promising opportunity. Unlike other CCR3 ligands, CCL24 binds only to the CCR3 receptor and is also organ/disease-specific,
which together could provide enhanced selectivity and tolerability. For example, in PSC, CCL24 is elevated in the liver and cholangiocytes
(bile duct epithelia) and immune cells that play a key role in the progression of the disease.&#160; Likewise, elevation of CCL24 has
been shown in fibrotic lungs and bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosis, a disease sharing similar
lung dysfunction features with SSc and which recently was correlated, by us, with disease severity and lung involvement in a cohort of
SSc patients from the United Kingdom. Furthermore, CCL24 is constitutively expressed by skin and dermal fibroblasts. The use of an antibody
in targeting this chemokine is a novel approach to targeting fibrosis.<br/> &#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">44</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Our expertise and approach to drug
discovery</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We are a clinical stage biotechnology
company focused on the discovery and development of novel drugs to address fibrotic indications with unmet medical needs. CCL24 is a key
target promoting fibrosis as it regulates the two main processes that drive fibrosis: fibroblast activation and immune cell migration
and activation. Using our expertise in monoclonal antibody, or mAb, development and deep knowledge of chemokine biology, we are developing
nebokitug, a proprietary, first-in-class, fully humanized mAb that through research and studies to date, has been shown to neutralize
CCL24 and by so doing inhibits its disease-related functions in both inflammation and fibrosis. This represents an innovative approach
to anti-fibrotic drug discovery and is a key differentiator for us. The ability of nebokitug to directly attenuate fibroblast activation
and concurrently attenuate recruitment of immune cells is novel and could address a wide range of hard-to-treat fibrotic diseases.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our ongoing collaborations are complementary
to both preclinical and clinical aspects of research and development. We have created an extensive panel of in vitro, ex vivo and in vivo
assays which we have used to further the understanding of fibrotic processes together with the role of CCL24 in various diseases and the
effects of its neutralization by nebokitug. These assays have allowed us to sequentially explore target validation and proof of mechanism
in disease relevant human and animal samples that we believe help de-risk the translation of nebokitug into the clinic.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; font-style: italic">Target expression
and engagement</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We regularly collaborate with leading
academic centers around the world to investigate the role of CCL24 and nebokitug in various indications. For example, we work with The
Royal Free Hospital, or RFH, in London, and Birmingham University in Birmingham, United Kingdom to access liver biopsy and serum samples
from patients with PSC. Using immunohistochemistry and florescence microscopy to stain CCL24 and CCR3, it explores the expression patterns
of these targets in disease relevant human samples and compares them to healthy volunteers. Similarly, we have tested biopsies of SSc
patients through a collaboration with the University of Florence in Italy and serum samples of SSc patients through a collaboration with
Leeds University in the UK.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; font-style: italic">Proof of mechanism</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We explore fibroblast activation
and immune cell recruitment in response to nebokitug treatment through inhouse ex vivo and in vitro assays. We have executed multiple
validated genetic and treatment-based disease models in fibrotic and inflammatory indications in which we have investigated nebokitug&#8217;s
effects. Additionally, as part of a collaboration with Nordic Biosciences, Copenhagen, Denmark, we have gained access to proprietary tools
and expertise to explore the effects of nebokitug on key fibrogenesis and fibrolysis biomarkers. Nordic Biosciences is a world-leading
extracellular matrix specialist and continues to contribute additional analyses to our clinical samples.</div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;<br/> <br/> &#160;<br/> <img src="image00021.jpg" alt=""/><br/>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; font-weight: bold">We have created
a broad array of biological assays to explore CCL24 and nebokitug</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We may explore next-generation biologic
products, and, based on our wide database of patient samples and extensive knowledge and experience in fibrosis, may identify targets
that could complement CCL24 inhibition. Next-generation assets could therefore be dual targeting and would be screened through the panel
of assays available to us that evaluate target expression in fibrotic tissues as well as the anti-fibrotic activity of potential candidates.
Similar to nebokitug, this process would establish proof-of-biological-mechanism in both animal models and human tissue prior to commencing
product development and initiating clinical studies.<br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">45</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25; font-family: Times New Roman"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Our pipeline</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Nebokitug
in PSC and SSc</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our lead product, nebokitug, is a
first-in-class humanized monoclonal antibody targeting CCL24 that is being developed initially for the treatment of PSC and SSc, with
potential future opportunities in other fibrotic-inflammatory indications. We have completed two Phase 1a studies of nebokitug in healthy
volunteers as well as a Phase 1b safety, tolerability and proof-of-mechanism study in MAFLD patients and a Phase 2a liver fibrosis biomarker
study in MASH patients with liver fibrosis, which was reported in 2023. Topline results showed favorable safety and tolerability profiles
for nebokitug in patients with serious liver disease, confirmed early signs of biomarker activity that are also relevant for a number
of fibro-inflammatory disorders, and reinforced tolerability and pharmacokinetic data relevant to the development of our current subcutaneous
formulation.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In the Phase 2 SPRING trial in PSC,
nebokitug met the primary study endpoint, demonstrating that it is well tolerated and nebokitug-treated patients with moderate/advanced
disease showed improvements on a wide range of disease-related secondary endpoints, including liver stiffness, liver fibrosis biomarkers,
such as the Enhanced Liver Fibrosis (ELF) score and PRO-C3 levels; total bilirubin and liver function tests; pruritus (itch) and markers
of inflammation. Dose-dependent responses were observed for multiple disease-related biomarkers. A consistent pattern of greater improvement
on the secondary endpoints was observed in the study arm receiving the 20mg/kg dose of nebokitug, An Open Label Extension portion of this
study was recently reported in which nebokitug showed continued safety and activity over 48 weeks, most notably in the 20mg/kg dose arm
and in patients with moderate to advanced disease.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">A global Phase 2 study in SSc that
will assess the safety and activity of nebokitug in this patient population has an open U.S. IND and is Phase 2-ready.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Primary
Sclerosing Cholangitis</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">PSC is a progressive, rare, and chronic
cholestatic liver disorder that is characterized by thickening, inflammation, and fibrosis of the intra- and extra-hepatic bile ducts.
This generally leads to cholestasis, liver damage, cirrhosis, and eventually liver failure. The exact cause of PSC remains mostly unknown;
however, immune system dysregulation, genes, viruses, and bacteria may be involved. PSC is commonly associated with inflammatory bowel
disease, or IBD. Approximately three in every four individuals with PSC also have ulcerative colitis. Most individuals affected with PSC
are adults with an average age of 40 years at diagnosis; however, it may also occur in children. Disease progression, symptoms, and severity
may vary greatly between individuals. Patients in the initial stages of PSC are generally asymptomatic or have only mild symptoms.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Abdominal discomfort, fatigue, and
pruritus, or itching, are common initial symptoms of PSC that can be severe and debilitating. The initial step in diagnosing PSC is to
evaluate liver enzyme levels through blood tests. Physicians will then confirm a diagnosis with cholangiography ultrasound and, in rare
cases, a liver biopsy. As the disease progresses, bile flow from the liver is obstructed and is subsequently absorbed into the bloodstream
leading to the yellowing of the mucous membranes, whites of the eyes, and skin. Furthermore, individuals may also experience abdominal
pain, malaise, light-colored stools, nausea, dark urine, weight loss, and/or hepatomegaly or splenomegaly. PSC patients have a 40-fold
increased risk of liver cancer and a 400-fold increased risk of cholangiocarcinoma, and the disease may lead to other conditions including
osteoporosis, bacterial cholangitis, portal hypertension, bleeding, as well as vitamin deficiencies.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">46</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">There are currently no specific medical
therapies that can alter or cure the course of the disease; instead, available treatments are directed towards slowing the progression
of PSC and treating symptoms. In certain individuals, endoscopic surgery may be performed to enlarge the narrowed bile ducts and to remove
blockages. Complications due to vitamin deficiencies can be prevented with the help of vitamin supplements, while infections and inflammation
can be controlled by using antibiotics. Cholestyramine and UCDA can be effective in managing itching and can be used with or without antihistamines.
Patients with advanced symptoms such as end-stage liver disease, recurrent bacterial cholangitis and intractable pruritus, will often
undergo liver transplantation, however, in 20-25% of cases, PSC will recur even after liver transplantation. The median survival is 10-12
years without intervention.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Systemic
Sclerosis</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">SSc is an autoimmune inflammatory
condition that results in widespread fibrosis and vascular abnormalities affecting the skin, lungs, gastrointestinal tract, heart and
kidneys. Other key features of SSc include thickening and hardening of the skin, autoantibody production and abnormal nail fold capillaries.
The underlying mechanisms that cause SSc are complex and for the most part unknown but most likely involve a combination of factors including
the immune system, genetics, and environmental triggers. Various pathways are involved in the pathogenesis of SSc including cytokines
that injure blood vessels, growth factors that stimulate collagen, integrin signaling, morphogen pathways, and co-stimulatory pathways.
SSc is generally diagnosed between the age of 30 and 50 years and is more prevalent in women.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Given that SSc can affect many different
parts of the body there are a multitude of different symptoms of the disease. The most widely observed symptoms include fatigue, arthralgia,
and myalgia. However, the earliest sign is often the Raynaud phenomenon in which the body&#8217;s normal response to cold or emotional
stress is exaggerated, resulting in abnormal spasms in arterioles. Cutaneous features include sclerosis of the skin, particularly the
face and hands. Gastrointestinal symptoms of the upper tract include acid reflux and of the lower tract include bloating, nausea and incontinence.
Cardiopulmonary presentations include interstitial lung disease, pulmonary arterial hypertension and cardiac scleroderma. Renal and ocular
symptoms can also present and 20% of SSc patients have an overlapping diagnosis with other connective tissue diseases and can develop
arthritis, lupus or myositis. SSc is subdivided into two main types related to the distribution of skin involvement: diffuse cutaneous
(two-thirds of cases) and limited cutaneous. Diffuse SSc, or dcSSc, is rapidly progressive with more significant organ involvement.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">There is no cure for SSc. Established
treatments can help with symptoms and may modify the disease outcome only if given early in the disease course. Prescribed medications,
used off-label, primarily focus on suppressing inflammation with NSAIDs and dilating abnormal or constricted blood vessels with losartan,
sildenafil, iloprost and SSRIs, or selective serotonin reuptake inhibitors, as well as treatments to manage individual organ involvement.
The only three drugs that are approved for the treatment of SSc symptoms are bosentan by Actelion Pharmaceuticals, approved in Europe
for the prevention of digital ulcer development, nintedanib by Boehringer Ingelheim, and tocilizumab by Roche, approved in the United
States, Europe and Japan for the treatment of SSc associated interstitial lung disease. The clinical course of SSc is determined by the
extent of vascular and fibrosis complications and has the highest mortality rate among the systemic rheumatic diseases. Forty percent
of patients die within 10 years of disease onset, with pulmonary involvement being the leading cause of death.<br/> </div> <br/>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">47</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div><br/> </div>

<div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Nebokitug may have disease-modifying
potential</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The dual anti-fibrotic and anti-inflammatory activity of nebokitug
enables the targeting of a wide range of pathogenic mechanisms and may afford patients a new treatment that may have a more impactful
effect on disease progression.</div> </div>

<div><br/> </div>

<div><br/> </div> <img src="image00022.jpg" alt=""/></div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Targeting CCL24
offers a dual activity approach</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In order to understand CCL24&#8217;s
role in disease pathophysiology, we have collected data on CCL24 levels from patients with multiple fibrotic-inflammatory indications,
including those with PSC, SSc and MASH. PSC patients&#8217; liver biopsies and SSc skin samples were stained for CCL24 and its receptor,
CCR3. Blood samples taken from PSC and SSc patients were used to further evaluate the role of the CCL24-CCR3 axis exploring levels of
circulating CCL24 and CCR3. To explore the influence of CCL24 on disease status, CCL24 serum levels were correlated with fibrotic biomarkers
and disease severity markers.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">48</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; font-style: italic">CCL24 levels
in liver biopsies from PSC patients</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">PSC pathology generally initiates
with bile duct damage leading to cholestasis, bile duct inflammation and fibrosis and finally to substantial liver damage. We assessed
the accumulation and cellular localization of CCL24 in livers of PSC patients focusing on CCL24 levels in the periductal damaged zone
that is most relevant to disease pathology. CCL24 was mainly found in inflammatory cells in the liver of PSC patients. Due to the robust
liver inflammatory insult in PSC, reflected by massive accumulation of resident and recruited immune cells in the periductal space, CCL24
positive staining was extensive. Specific and robust CCL24 staining was also shown in cholangiocytes, the epithelial cells of the bile
ducts. Activated myofibroblasts that surround the bile ducts, whether they originate from hepatic stellate cells or portal fibroblasts,
are the main drivers of the excess extracellular matrix accumulation in this area, comprising the unique &#8220;onion ring&#8221; shape
seen in PSC liver sections. The collective expression pattern shows high CCL24 levels in areas that are most affected in PSC and highlights
its central role in PSC related liver pathology.</div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;<br/> <br/> &#160;<img src="image00023.jpg" alt=""/></div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Elevated CCL24
staining in liver biopsies from PSC patients</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; font-style: italic">CCR24 levels
association with PSC related pathways</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">To further elucidate the involvement
of CCL24 in PSC and its association with disease-related pathways, sera from healthy controls (n=30) and from patients with PSC (n=45)
were analyzed using the Olink proximity extension assay (PEA) of 3072 proteins. Serum proteomics data were analyzed according to three
comparisons: (1) healthy controls vs. patients with PSC, (2) fibrosis severity in patients, defined by ELF score (9.8 cutoff), and (3)
serum levels of CCL24 in patients.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Differentially expressed proteins
(DEPs) from each of the three comparisons were interpreted using Ingenuity Pathway Analysis (IPA), to identify dysregulated canonical
biological pathways, upstream regulators, and toxicity-functions. The enriched canonical pathways, upstream regulators and toxicity-functions
overlapped between the three comparisons (disease, fibrosis and CCL24), suggesting that there are biological mechanisms related to PSC
and its progression also related to CCL24 expression levels. Overlapping canonical pathways included HSC activation pathway, immune cell
trafficking pathways (granulocyte and agranulocyte adhesion and diapedesis) and inflammation pathways (Th1 and Th2 activation, Th1 activation
and pathogen induced cytokine storm).&#160; In patients with PSC, those that had high levels of CCL24 also showed significantly higher
average expression of these pathways.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">49</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman"><img src="image5.jpg" alt="" style="width: 545px; height: 706px"/></div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">PSC-related mechanisms are upregulated
in patients with high CCL24 levels. (A) Analysis over-view: sera from patients with PSC and HC were analyzed by the Olink Explore 3072
proteomic platform, and differentially expressed proteins (DEPs) were compared by disease, fibrosis or CCL24. (B) Score plots of principal
component analysis of proteome profiles in HC and Patients with PSC with low or high ELF scores. (C) Correlation of CCL24 to representative
proteins associated with inflammation/chemotaxis (CCL7 or CXCL10), in HC (n = 30) or patients with PSC with ALP &gt; 1.5 ULN (n = 34).
(D-I) Ingenuity Pathway Analysis of canonical pathways, upstream regulators and liver-related toxicity functions. Venn diagrams show top
30 significant canonical pathways (D), top 20 significant upstream regulators (F), and significant liver-related toxicities (H). The average
ex-pression of protein lists of specific canonical pathways (E), upstream regulators (G) and liver-related toxicities (I) is presented
for HC and patients with low and high CCL24 serum levels. Boxes rep-resent interquartile ranges with medians (n = 20-30). *, p &lt; 0.05;
**, p &lt; 0.01; ****, P &lt; 0.0001.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">50</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; font-style: italic"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; font-style: italic">CCR3 levels in
circulating PBMCs in PSC patients</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Chronic liver inflammation is driven
in most hepatic injuries by several different immune cell populations originating from either resident hepatic immune cells or recruited
cells from the circulation to the damaged site. In collaboration with the Kaplan Medical Center, Israel, we explored systemic changes
of CCR3, given that this could impact cell recruitment to the PSC damaged liver. Peripheral blood mononuclear cells (PBMCs) from ten PSC
patients and healthy controls were stained for expression of CCR3 and demonstrated that levels were significantly higher in PSC patient
samples compared to healthy donors.<br/> &#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; font-style: italic">CCL24 and CCR3
levels in skin biopsies from SSc patients</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We analyzed skin samples from diffuse
SSc patients and healthy volunteers and the SSc samples showed elevations in CCL24 and CCR3. Specifically, higher accumulation of CCL24
on immune cells skin infiltration was shown in the SSc samples and CCR3 was evident in skin fibroblasts, immune cells and endothelial
cells. These elevations led to a CCL24-mediated robust activation of CCR3 expressing cells, which enhances the recruitment of immune cells
and fibroblasts to the diseased organ.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: center; text-indent: 0.4pt; line-height: 1.25; font-family: Times New Roman"><img src="image00024.jpg" alt=""/><br/>
&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; font-weight: bold">SSc patients showed
elevated levels of CCL24 in skin tissue</div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><img src="image00027.jpg" alt=""/></div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; font-weight: bold">SSc patients showed
elevated levels of CCR3 in skin tissue</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 27pt; line-height: 1.25; font-family: Times New Roman">&#160;&#160; <span style="font-style: italic">CCL24 levels
in serum samples from SSc patients and correlation with fibrotic biomarkers</span><br/> &#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our researchers analyzed SSc serum
samples that showed that CCL24 levels were significantly increased in SSc patients compared with healthy individuals. Notably, in diffuse
SSc patients, CCL24 levels were fourfold higher than in healthy control patients.&#160; Additionally, the levels of CCL24 were correlated
with a biomarker of SSc severity, anti-topoisomerase, an autoantibody seen in diffuse SSc patients.</div>

<div style="line-height: 1.25; font-family: Times New Roman"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">51</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><img src="image00028.jpg" alt=""/></div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; font-style: italic">CCL24 levels in serum samples from
SSc patients and association with disease manifestations and mortality</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The relationship between serum CCL24
levels and disease characteristics in a comprehensive real-life cohort of patients with SSc (n=213)&#160;was further studied. The study
highlights the association between higher CCL24 levels with critical clinical variables linked to the most severe forms of SSc. Specifically,
these variables include male gender, anti-Scl70 positivity, severity of skin fibrosis, presence of ILD, presence of digital ulcers and
lung microvascular impairment as measured by DLco. In a longitudinal setting, high serum CCL24 was predictive of lung deterioration. Accordingly,
a higher baseline CCL24 level was associated with SSc-related mortality.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman"><img src="image00029.jpg" alt=""/></div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Comparison of baseline serum CCL24
levels based on the occurrence of rapid ILD progression (A) and the relationship between baseline serum CCL24 levels and the relative
change in FVC over the following 12 months (B).</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">52</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman"><img src="image00030.jpg" alt=""/><br/> &#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Cumulative incidence curves comparing
SSc-related and other-cause mortality in SSc patients with High and Low baseline CCL24 Status</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; font-style: italic">Preclinical Efficacy
of nebokitug in models of PSC</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Preclinical experiments in models
of PSC</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6c9365b94430448d9a447d902a959f37" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Human hepatic stellate cells demonstrated reduced transition to myofibroblasts following
        incubation of nebokitug with CCL24.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Human hepatic stellate cells showed reduced motility towards CCL24 following treatment
        with nebokitug.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Nebokitug demonstrated in vivo activity on liver fibrosis and cholangiocyte proliferation
        induced by bile duct ligation in the Sprague Dawley rat model.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Nebokitug (D8-a murine surrogate of nebokitug) inhibits the progression of liver fibrosis
        and bile duct damage in a chronic cholangitis cholestasis model using the hepatobiliary toxin ANIT.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Nebokitug (D8) reduces bile duct epithelial cell (cholangiocyte) proliferation, collagen
        deposition, macrophage infiltration, liver enzymes, bile acid and circulating inflammatory monocytes in an experimental cholangitis model
        in MDR2 knockout mice.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Nebokitug reduces liver enzymes, fibrosis, collagen, and fibrotic gene expression
        in a TAA-induced liver fibrosis model in rats.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Nebokitug (D8) prevented fibrosis and inflammation in a TAA-induced liver fibrosis
        model in mice.</div> </td> </tr>
  </table>

<div> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Results from the multi-drug resistant
2, or MDR2, knock out mouse model that reflects sclerosing cholangitis and the thioacetamide (TAA) rat model reflecting liver fibrosis
are described below.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">53</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 27pt; line-height: 1.25; font-style: italic">&#160;&#160; Nebokitug demonstrates anti-cholestatic, anti-inflammatory,
and anti-fibrotic activity in MDR2 knock out mouse model in vivo</div>

<div style="text-indent: 27pt; line-height: 1.25; font-style: italic"> <br/> </div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Mice with targeted disruption of
the MDR2 transporter gene develop chronic and progressive hepatic sclerosing cholangitis that closely resembles PSC and therefore this
model has been extensively used to study the pathogenesis and progression of PSC. Using MDR2 knockout mice (six weeks of age), we tested
the ability of nebokitug (D8) to attenuate PSC related symptoms. Mice (n=15/group) received either vehicle control, or nebokitug 10 mg/kg
SC twice weekly during weeks 6-12 following established disease and were sacrificed at the end of week 12. In this study mice were tested
for changes in alkaline phosphatase, or ALP, bile acid levels, collagen deposition (histology, Sirius red), macrophage presence in the
liver and cholangiocyte proliferation. We observed a significant decrease in all three core pathologies that play a role in PSC: inflammation,
fibrosis and cholangiocyte proliferation after nebokitug (D8) treatment compared to non-active treatment. Reduction in the serum markers
that represent the cholestatic state, ALP and bile acid, was also observed.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;<br/> </div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman"><img src="image00031.jpg" alt=""/></div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold">
<br/> </span></div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold">Nebokitug
reduces liver fibrosis, inflammation and bile duct epithelial proliferation in MDR2 knockout model</span><br/> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; font-style: italic">Nebokitug demonstrates
in vivo activity in a thioacetamide induced liver fibrosis model in rats using a therapeutic model</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">To assess the potential efficacy
of nebokitug on liver fibrosis, we used the TAA-induced liver fibrosis model. Liver fibrosis was induced by intraperitoneal administration
of TAA at a dose of 250 mg/kg twice weekly for eight weeks. Rats (n=10/group) received either vehicle control or nebokitug 2.5 mg/kg IV
twice weekly during weeks four to eight following established fibrosis and were sacrificed at week eight. After eight weeks of TAA treatment,
all vehicle-treated animals had developed liver fibrosis, as confirmed by Sirius-red-stained liver histology.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">54</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><img src="image00032.jpg" alt=""/></div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; font-weight: bold">nebokitug reduces
fibrosis in rat livers</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Plasma ALP, ALT, and AST levels decreased
in the nebokitug study arm. Liver collagen content and fibrotic areas were significantly reduced in the nebokitug-treated group compared
to non-active treatment. nebokitug was also shown to reduce fibrotic markers in the TAA treated rats.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">&#160;Efficacy of nebokitug in models
of SSc</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">&#160;<br/> Preclinical experiments
in models of SSc</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zecb31449fb9f457aa9ad7ee7bd6023c8" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Nebokitug reduces SSc serum-induced dermal fibroblast activation and transition to
        myofibroblasts and interferes with endothelial cell activation.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Nebokitug treatment attenuated skin fibrotic remodeling in the bleomycin (BLM)-induced
        dermal fibrosis mouse model.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Nebokitug attenuated lung fibrosis and inflammation in the bleomycin (BLM)-induced
        pulmonary fibrosis mouse model.</div> </td> </tr>
  </table>

<div> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Results from the bleomycin (BLM)-induced
dermal and lung fibrosis mouse models are discussed below in more detail.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; font-style: italic">Nebokitug treatment
attenuates skin fibrotic remodeling in the bleomycin (BLM)-induced dermal fibrosis mouse model</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The activity of nebokitug (D8) in SSc was tested in the
dermal bleomycin model. Treatment started after the onset of fibrotic signs, eight days following the first BLM injection. Histological
assessment of skin lesions stained with H&amp;E and Masson&#8217;s trichrome revealed significant elevation of dermal thickness and collagen
deposition following 21 days of BLM administration. This elevation was significantly reduced when mice were treated with 2.5 mg/kg nebokitug
with significant reductions in both skin thickness and collagen deposition compared with the mouse group treated with BLM alone.<br/>
<br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">55</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><img src="image00033.jpg" alt=""/></div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Nebokitug treatment
attenuates skin fibrotic remodeling in the bleomycin-induced dermal fibrosis mouse model</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Another feature that characterizes
the BLM model and is representative of human SSc is the development of bronchoalveolar inflammation. To evaluate the effect of nebokitug
on lung inflammation, we collected bronchoalveolar lavage, or, BAL, fluid, and assessed the number of white blood cells, or WBC, and mononuclear
cells. Treatment with BLM for 21 days significantly increased WBC and mononuclear cells in BAL fluid and the number of WBC and mononuclear
cells was decreased significantly following nebokitug treatment compared with the group that was administered only BLM. This data supports
the anti-inflammatory effect of nebokitug in SSc.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; font-style: italic">Nebokitug inhibits
lung fibrosis in the BLM-induced pulmonary fibrosis mouse model</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We also tested nebokitug in the experimental
lung SSc model where mice were given a single intratracheal administration of BLM followed by either nebokitug, non-active treatments
(PBS or control immunoglobulin G (IgG)) or the approved anti-fibrosis drugs, pirfenidone and nintedanib. nebokitug had a significant anti-fibrotic
and anti-inflammatory effect in the experimental BLM-induced lung fibrosis model as compared with non-active treatment-treated animals.
BLM animals treated with non-active treatments showed massive immune cell infiltration, extensive fibrosis and severe tissue injury. nebokitug-treated
mice exhibited significantly reduced levels of lung fibrosis similar to levels in healthy animals and showed superior effects compared
to the approved fibrosis drugs pirfenidone and nintedanib.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">56</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; font-weight: bold"><img src="image00034.jpg" alt=""/><br/>
&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Nebokitug attenuates
lung fibrosis and collagen deposition in the bleomycin (BLM)-induced pulmonary fibrosis mouse model</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Preclinical safety
and toxicology of nebokitug</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Preclinical safety evaluation of
nebokitug included tissue cross reactivity, assessment of the effect of nebokitug on pro-inflammatory cytokine secretion ex-vivo, and
in vivo GLP toxicology studies in mice and non-human primates. No safety concerns were observed in these preclinical assessments.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Immunogenicity may be triggered following
administration of humanized monoclonal antibodies, an effect that is frequently seen with approved mAbs. To date, no meaningful ADA effects
were identified in three completed clinical studies, which supports a preliminary conclusion that nebokitug may have low immunogenic potential.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">As summarized below, there were no safety concerns related
to nebokitug in any of the other preclinical safety experiments.<br/> &#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">57</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Summary of key preclinical safety experiments</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd1b159f57a004f76aa61c15b60f8cb79" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 50%; vertical-align: bottom; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Preclinical findings</div> </td>
    <td style="width: 2%; vertical-align: bottom; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 48%; vertical-align: bottom; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Observation</div> </td> </tr>
  <tr>
    <td style="width: 50%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-style: italic">Ex vivo</div> </td>
    <td style="width: 2%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8203;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 48%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><br/> &#160;</div> </td> </tr>
  <tr>
    <td style="width: 50%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">Antibody dependent cell-cytotoxic (ADCC) and complement
        dependent cell-cytotoxic (CDC) activity was tested in PBMCs from healthy volunteers.</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 2%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8203;</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 48%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">Nebokitug did not have Fc-related effector functions
        such as ADCC and CDC.</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 50%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">Cytokine release was assessed in human whole blood from
        healthy volunteers.</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 2%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8203;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 48%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">Nebokitug did not induce pro-inflammatory cytokine secretion.</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 50%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">Tissue cross reactivity was evaluated from healthy human
        tissues.</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 2%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8203;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 48%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">Nebokitug does not bind non-specifically to healthy
        tissues, and therefore is expected to only bind to its target, circulating CCL24.</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 50%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">In vivo</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 2%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8203;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 48%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8203;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 50%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">GLP repeated dose 4-week toxicity study of nebokitug
        (IV) in mice.</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 2%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8203;</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 48%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">1. No obvious treatment related adverse reactions.<br/> &#160;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">2. No gross or microscopic pathological findings.<br/> &#160;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">3. No cases of treatment related mortality were observed.<br/> &#160;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">4. No significant elevation was seen in IL1&#946;, IL2, IL4, IL5, IL10, GM-CSF,
        IFN and TNF&#945;.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">58</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" id="zbf7b5df5c7074ffa8d6cbac178bc5c17" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 50%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">GLP repeated dose (up to 50 mg/kg) 6-month toxicity
        study of nebokitug (SC) in Cynomolgus Monkey.</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 2%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8203;</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 48%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">1. No obvious treatment related adverse reactions.</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">2. No clinical signs or injection site reactions.</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">3. No cases of treatment related mortality were observed.</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">4. Blood and urine tests were found to be within normal ranges for monkeys.<br/>
        &#160;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">5. No treatment-related organ weight changes and no treatment-related necropsy
        findings.<br/> &#160;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">6. No treatment-related histopathology findings.<br/> &#160;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">7. Three samples from treated animals were confirmed ADA positive but there
        was no obvious correlation between positive ADA results and nebokitug serum concentrations or systemic exposure.</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Preclinical proof
of mechanism studies for nebokitug</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We conducted a series of in vitro
and in vivo studies to demonstrate the proposed mechanism of action and provide proof-of-concept for administering nebokitug in the clinic
for target indications.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;<span style="font-style: italic">Affinity, selectivity,
and binding kinetics</span></div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We evaluated the kinetic binding
parameters of nebokitug to human CCL24, as well as the specificity of nebokitug binding to other chemokines using commercial binding assays.
nebokitug demonstrated a strong and stable, high affinity binding to CCL24.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">Nebokitug reduced CCL24 dependent
CCR3 activation</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In an <span style="font-style: italic">in
vitro</span> assay, nebokitug was shown to robustly attenuate the ability of CCL24 to induce activation of the CCR3 receptor following
pre-incubation of CCL24 with nebokitug.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">59</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Clinical Development
of nebokitug</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">Completed clinical studies</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The nebokitug Phase 1 program included
two Phase 1a single administration, or SAD, studies, using IV and SC administration with doses ranging from 0.75-10 mg/kg, in healthy
volunteers and a Phase 1b multiple administration (MAD) study (5 administrations) in MAFLD patients with normal liver function, testing
2.5 mg/kg IV and 5 mg/kg SC. In the Phase 1 studies 42 subjects have received at least one nebokitug dose, the majority by IV infusion
(12/42 subjects received SC).</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">Safety</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The first Phase 1a study, which was
a single-center, randomized double-blind, placebo-controlled, single-dose, dose-escalation study, included four escalating dose groups
of eight subjects each. In each dose group subjects were randomized in a 3:1 ratio to receive a single IV infusion of either nebokitug
(n=6) or placebo (n=2). A total of 24 subjects were enrolled into the study and randomized to the treatment groups (0.75 mg/ kg, 2.5 mg/kg,
5.0 mg/kg, 10 mg/kg) and eight subjects received a placebo. All 32 subjects completed the study as planned. Single, IV doses of nebokitug
were well tolerated up to the highest dose level (10 mg/ kg) in healthy subjects. No severe or serious adverse events, or AEs, occurred
during the study and all nebokitug related AEs were mild, with one moderate AE reported in the placebo group (myalgia).</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The second Phase 1a study was also
a single-center, randomized double-blind, placebo-controlled, single-dose study, but evaluated only one dose group. Subjects were randomized
in a 3:1 ratio to receive a single SC injection of either nebokitug 5 mg/kg (n=6) or matching placebo (n=2). A total of eight subjects
were enrolled into the study and randomized; all eight subjects completed the study as planned. Single SC administration of 5 mg/kg of
nebokitug was well tolerated with no severe or serious AEs occurring during the study. A total of 6 AEs were reported in two subjects
treated with nebokitug; only one AE was classified as related to nebokitug (change in diastolic blood pressure) and that AE was classified
as mild in intensity.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">60</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In both Phase 1a studies, all AEs
reported were resolved; no subjects discontinued the study prematurely due to AEs, and no concomitant medications were required for treatment
of any drug-related AEs. No clinically significant changes in laboratory tests (hematology, chemistry or urinalysis), vital signs, ECG,
physical examination or infusion site examination were observed. In the first Phase 1a study with nebokitug delivered by IV administration,
the effect on cytokine secretion was tested pre-treatment and one hour, eight hours and 24 hours post drug administration. Serum levels
of a panel of cytokines including IL-6, IFN&#947;, GM-CSF, TNF-&#945;, IL-2, IL-4, IL-8 and IL-10 showed no significant change at all
tested nebokitug doses and timepoints. These findings suggest that single nebokitug administration does not cause immune activation nor
cytokine secretion. Additionally, none of the subjects in either of the Phase 1a studies tested positive for anti-drug antibodies (ADA).</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The multiple administration randomized,
placebo-controlled, Phase 1b study in MAFLD patients with normal liver function tests evaluated two dose levels. The first dose level
of 2.5 mg/kg nebokitug was administered as an IV infusion and the second dose level of 5 mg/kg was administered as an SC injection. Both
dose levels involved five drug administrations over 12 weeks (Q3W), providing 15 weeks of treatment coverage. At both dose levels, subjects
were randomized in a 3:1 ratio to receive either nebokitug (n=6 per cohort) (2.5 mg/kg IV or 5 mg/kg SC) or matching placebo (n=2 per
cohort). Five repeated IV and SC nebokitug administrations were well tolerated and there were no deaths, or severe or serious drug related
AEs reported throughout the study. Only mild to moderate AEs were reported in the nebokitug treatment groups of which only two AEs were
classified as possibly related to nebokitug. No injection site reactions or clinically significant trends in laboratory tests (hematology,
chemistry, or urinalysis), vital signs, ECG or physical examination were observed. One patient experienced a non-drug-related SAE. This
patient was a 61-year-old female that was subsequently diagnosed with a non-treatment related meningioma. The tumor was treated surgically,
and the patient was discontinued from the study.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">Pharmacokinetics with single-dose
administration</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">PK analysis was conducted for the
Phase 1 studies and the quantification of nebokitug in plasma samples was performed using a validated ELISA-based assay by Eurofins (UK).
Following IV infusion in healthy volunteers, nebokitug exhibited a biphasic serum concentration vs. time curve (rapid distribution phase
and slow elimination phase) which is typical for monoclonal antibodies. Target-mediated drug disposition (TMDD), or presence of ADAs,
was not evident in the analyzed concentration vs. time curves of nebokitug, which exhibited linear terminal slope without apparent TMDD
kinetics or other concentration-dependent changes of the elimination kinetics. Comparison of the PK data of 5 mg/kg nebokitug using IV
administration against SC administration indicates consistent distribution and elimination behavior of nebokitug.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">At either IV or SC administration,
the values of the PK parameters obtained in the non-compartmental and compartmental analysis of nebokitug concentration vs. time data
appear to be typical for monoclonal antibodies that undergo FcRn-mediated recycling. The terminal half-life of nebokitug was long for
both SC and IV formulations, which supports administration of nebokitug at a frequency of once every 2-4 weeks.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">Pharmacokinetics with multiple-dose
administration</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">PK analysis of the data from the
Phase 1b study was conducted to evaluate nebokitug following multiple IV infusion of 2.5 mg/kg or 5 mg/kg SC injections of nebokitug in
MAFLD patients. Following repeated IV infusions (2.5 mg/kg Q3W) and SC injection (5 mg/kg Q3W), nebokitug exhibited a long terminal half-life,
similar to the terminal half-life seen in the single dose studies. nebokitug accumulated over time, resulting in significant systemic
exposure over time and potentially reaching a steady state.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Overall, nebokitug reached steady
state conditions more slowly following SC injection, as compared to IV infusion. The inter-patient variability in nebokitug serum concentrations
was higher for SC dosing injection, as compared to IV. The trough nebokitug serum concentrations after repeated 5 mg/kg SC injections
were proportionally higher than those after 2.5 mg/kg IV infusions, considering the difference in administration modes. Comparison of
the PK data of nebokitug in the Phase 1b to the Phase 1a studies indicates a consistency in PK behavior of nebokitug.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">61</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">Pharmacodynamics and target engagement
of nebokitug</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Serum was taken from patients in
all three Phase 1 studies at different times and the levels of both CCL24 and nebokitug were measured. Total CCL24 levels represent nebokitug&#8217;s
engagement to its target. Total CCL24 levels were increased following administration of the drug, which indicates that nebokitug is effective
in target engagement, as the higher levels of CCL24 correlated significantly with greater doses of nebokitug, and such levels decreased
gradually from the peak of nebokitug administration. These findings demonstrate that nebokitug effectively binds to CCL24 in the circulation,
which reflects a strong drug-target interaction.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In the Phase 1b study, nebokitug
treatment of 2.5mg/kg IV attained the highest levels of total CCL24 by the third administration, maintaining these levels until the end
of treatment. Nebokitug 5mg/kg administered by SC injection reached the highest levels of CCL24 by the fourth treatment and maintained
these levels until the end of treatment. The matching placebo did not have any effect on CCL24 levels.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">As exemplified in the in-vitro studies,
binding of CCL24 by nebokitug attenuates the binding of CCL24 to its cognate CCR3 receptor, thereby reducing its downstream activation.
Altogether, CCL24 levels following treatment with nebokitug provide strong evidence for target engagement and pharmacodynamic response
of nebokitug in healthy volunteers and patients.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">Phase 1b exploratory endpoints</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Fibrotic biomarkers were analyzed
as part of the Phase 1b study in NAFLD patients with normal liver function. Circulating fibrotic biomarkers were tested in serum pre-
and post-treatment. The analysis included data from patients that presented with more active disease, reflected by baseline elastography
(FibroScan) score &gt;4 kPa. Tissue inhibitor of metalloproteinases-1 (TIMP-1) and tissue inhibitor of metalloproteinases-2 (TIMP-2),
considered well established fibrotic biomarkers, were evaluated, and showed that nebokitug treatment led to reductions of both markers
by week 15. The growth factor PDGF-AA, known as a pro-fibrotic secreted factor, was also reduced in nebokitug treated patients. Conversely,
in the placebo group TIMP-1, TIMP-2 and PDGF-AA all increased.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Evaluation of the fibrogenesis and
fibrolysis/inflammatory biomarkers, Pro-C3, Pro-C4 and C3M measured in serum, conducted by Nordic Bioscience, Copenhagen, Denmark, were
also used as sensitive indicators of the liver&#8217;s fibrotic state. In accordance with reduced liver stiffness, Pro-C3, Pro-C4 and
C3M were all reduced in the nebokitug treated groups. No reductions were identified in the placebo control group.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Changes in liver stiffness, a measurement
of liver fibrosis, were also evaluated using FibroScan measurements taken at screening and end of treatment (EoT) following 15 weeks of
treatment coverage. 80% of nebokitug treated patients had significant decreases in FibroScan measurements, unlike placebo patients where
there was no significant change from baseline.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic">Results of investigator-initiated clinical study of nebokitug
in patients with COVID-19-derived lung damage</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">On November 9, 2022, encouraging
clinical data from an investigator-initiated clinical study assessing nebokitug activity and safety in hospitalized patients with severe
lung injury derived from COVID-19 infection was presented at the 2022 Union Conference, an international conference on lung health. A
key rationale for the study is that some of the mechanisms underlying lung inflammation resulting from COVID-19 infection are similar
to those seen in systemic sclerosis and other chronic diseases involving lung inflammation and fibrosis.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The objective was to evaluate the
safety and activity of nebokitug in hospitalized COVID-19 patients with severe pneumonia, including its impact on biomarkers related to
lung inflammation that are also relevant in SSc.<span style="font-weight: bold">&#160;</span>The open label, single arm trial enrolled
16 hospitalized adult COVID-19 patients with severe respiratory involvement. All patients were receiving standard of care therapy. All
were treated with a single 10mg/kg intravenous dose of nebokitug on the first day of the study and followed for 30 days.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Administration of nebokitug to this
acutely ill patient population appeared well tolerated. nebokitug exposures and target engagement profiles were similar to what our researchers
have seen in previous clinical studies of nebokitug.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">62</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Importantly, rapid reductions in
serum biomarkers of lung inflammation, fibrogenesis and neutrophil activity were observed post-treatment with nebokitug.<span style="font-weight: bold">&#160;</span>Overall,
this study confirmed and extended the safety and tolerability profile of nebokitug and demonstrated clinically relevant changes in biomarkers
associated with lung inflammation and fibrogenesis, further supporting nebokitug&#8217;s anti-inflammatory and anti-fibrotic effects.<span style="font-weight: bold">&#160;</span></div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Moreover, we believe that these results
add to the data suggesting that nebokitug has the potential to attenuate lung inflammation and fibrosis, further strengthening the rationale
for treating SSc patients with this drug. These new clinical data also contribute to a growing body of evidence demonstrating nebokitug&#8217;s
anti-fibrotic and anti-inflammatory effects in varied organs including the lung, liver and skin.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Primary endpoints for the study were
safety and tolerability. Secondary endpoints included the evaluation of the pharmacokinetic and target engagement profile of the SC formulation
as well as changes in relevant biomarkers that may provide further mechanistic understanding of nebokitug effects on liver fibrosis. This
trial was primarily designed to assess a subcutaneous formulation of nebokitug and to evaluate the drug&#8217;s impact on liver fibrosis
biomarkers relevant to both MASH and fibro-inflammatory conditions that represent the focus for Chemomab, such as PSC and SSc.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The randomized, placebo-controlled
trial enrolled 23 MASH patients with stage F1c, F2 and F3 disease who were randomized to receive either nebokitug or placebo. Patients
received eight doses of 5 mg/kg of study drug administered by subcutaneous injection once every two weeks, for a treatment period of 16
weeks. Key findings of the nebokitug Phase 2a trial included the following.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z36ca55df7dbf4d2fb0bf7a1a71e18f52" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Nebokitug appeared to be well tolerated when administered subcutaneously. Most reported
        adverse events observed were mild, with one unrelated serious adverse event reported. No significant injection site reactions were reported
        and no anti-drug antibodies were detected.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Nebokitug administered subcutaneously demonstrated favorable pharmacokinetics and
        target engagement profiles as expected and were similar to what we have previously reported.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Nebokitug-treated patients showed greater improvements than the placebo group in a
        number of liver fibrosis-related biomarkers, including ProC-3, ProC-4, ProC-18, TIMP-1 and ELF.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">A majority of nebokitug-treated patients showed improvements in more than one liver
        fibrosis-related biomarker&#8212;almost 60% of nebokitug patients responded in at least three biomarkers at week 20, compared to no patients
        in the placebo group.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">A higher proportion of patients in the nebokitug-treated group showed improvement
        in a physiologic measure of liver stiffness as compared to placebo (reduction of at least one grade of fibrosis score as assessed by the
        non-invasive elastography method known as FibroScan&#174;).</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Nebokitug-treated patients with higher CCL24 levels at baseline showed greater reductions
        in fibrosis-related biomarkers than patients with lower levels. Multiple fibrosis-related biomarkers showed more pronounced reductions
        in nebokitug-treated patients who had higher CCL24 levels at baseline than in patients with lower CCL24 levels at baseline, adding to
        the growing body of evidence validating the role of CCL24 in the pathophysiology of fibrotic liver disease.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">After completion of the study, the unblinded data showed that patients in the nebokitug-treated
        group had higher baseline levels of fibrosis compared to placebo patients. The impact of this difference on the results, if any, is unknown.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">Secondary analysis results of Phase
2a study in patients with liver fibrosis derived from MASH</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In June 2023, at the 2023 EASL Congress,<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;</sup>Chemomab
researchers reported topline results from secondary analyses of the Phase 2a liver fibrosis trial assessing nebokitug, in patients with
MASH. The results were included in a late-breaking poster presentation.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">63</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Overall, the data showed improvements
across an additional set of inflammatory and fibrotic biomarkers that are consistent with the positive clinical results Chemomab released
in January of 2023. Additionally, in MASH patients at greater risk of disease progression, nebokitug treatment resulted in a greater biomarker
response than in MASH patients with lower risk disease or in placebo-treated patients.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The new analyses&#160;assessed additional
biomarkers and also used the FibroScan-AST (FAST) score to categorize study patients based on progressive disease risk, thereby enabling
the evaluation of nebokitug activity in the main target population of patients with more active disease.&#160;FAST is a validated score
composed of non-invasive FibroScan<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#174;</sup>&#160;and AST
measurements that is used to identify patients with a high risk of MASH progression.&#160;The results showed that:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6c3550174cdd4ad1b50ae52baece9e03" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">FAST scores were improved in a higher proportion of nebokitug-treated patients than
        in placebo patients.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Nebokitug-treated patients with higher FAST scores demonstrated greater improvements
        in key&#160;fibro-inflammatory biomarkers, such as Pro-C3, than patients with lower FAST scores or placebo patients.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Nebokitug-treated patients with higher FAST scores showed improvements in several&#160;fibro-inflammatory
        biomarkers generally comparable&#160;to those achieved in several recent successful MASH clinical trials.</div> </td> </tr>
  </table>

<div> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Additionally, in these secondary
analyses, nebokitug-treated patients showed improvements in an additional set of biomarkers associated with active fibrosis and inflammation:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za8c994385d7441138493a57f4276fbb2" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">FIB-4, an index for determining MASH status that includes age, platelet count,&#160;AST
        and ALT levels, was improved in nebokitug-treated patients vs. placebo patients.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">AST/ALT ratio, a liver enzyme ratio, was improved in nebokitug-treated patients vs.
        placebo patients.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Neutrophil-to-Lymphocyte Ratio (NLR), an indicator of inflammation, was improved in
        nebokitug-treated patients vs. placebo patients, and NLR was further improved in groups with higher FAST scores.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">PRO-C3, which captures active fibrogenesis and correlates with fibrotic disease severity,
        was improved in nebokitug-treated patients vs. placebo patients and was further improved in groups with higher FAST scores. As an overall
        indicator of fibrogenesis and fibrotic disease, PRO-C3 is also considered a potential "bridge" to PSC and other anti-fibrotic indications.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We believe the that the data analyses
from this trial provide important insights in support of the nebokitug development program, including the favorable safety and tolerability
of nebokitug in patients with serious liver disease, confirmation of early signs of biomarker activity that are relevant for a number
of fibro-inflammatory disorders, and support of the tolerability and pharmacokinetic data needed to assess next steps in the development
of our current subcutaneous formulation.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-style: italic">SPRING Trial: Phase
2 Clinical study in PSC</span>&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The Phase 2 SPRING trial in PSC was
a randomized, double-blind, placebo-controlled, study designed to evaluate the safety and efficacy of nebokitug in adult subjects with
PSC. Participants must have a serum alkaline phosphatase, or ALP, level of at least 1.5 times the upper limit of normal (x 1.5 ULN). Subjects
with concomitant inflammatory bowel disease (IBD) are eligible for recruitment if their disease is stable and there is an absence of high-grade
dysplasia in colonic biopsies within 18 months of randomization. Subjects were randomized to receive 10 mg/kg or 20mg/kg of nebokitug
IV, or placebo, in a 2:1 ratio. Patients received a dose of investigational product once every three weeks for a total of five administrations
resulting in a total coverage of 15 weeks during the double-blind portion of the study. The study design also includes a 33-week long
open-label extension period during which all participants receive either 10 mg/kg or 20 mg/kg of nebokitug via IV administration every
three weeks.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">64</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The primary endpoint for the study
is safety and tolerability. Secondary endpoints include evaluations of changes from baseline in the fibrotic marker enhanced liver function,
or ELF, score at week 15 as well as evaluation of change in liver stiffness using elastography. ELF score is a biochemical test panel
made up of serum markers that are indicators of the extracellular matrix. Additional secondary endpoints included evaluations of changes
from baseline in liver enzymes and additional fibrotic markers, including ALP, AST, ALT, total bilirubin, Pro-C3, as well as PK, PD and
ADA parameters. Measurements of cholestasis related activity like pruritus were also evaluated.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman; font-weight: bold">Nebokitug SPRING Trial &#8211; Overview of Key Results</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Nebokitug met the primary study endpoint,
demonstrating it is well tolerated over the 15-week treatment period. Nebokitug -treated patients with moderate/advanced disease showed
improvements on a wide range of disease-related secondary endpoints, including assessments of changes from baseline relative to placebo
at Week 15 in liver stiffness; in liver fibrosis biomarkers, including the Enhanced Liver Fibrosis (ELF) score and PRO-C3 levels; in total
bilirubin and liver function tests; in pruritus (itch) and in markers of inflammation.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Dose-dependent responses were observed
for multiple disease-related biomarkers. A consistent pattern of greater improvement on the secondary endpoints was seen in the study
arm receiving 20 mg/kg of nebokitug and in the prespecified subgroup of PSC patients with moderate/advanced disease. Since PSC is a slowly
progressive disease, longer duration of treatment with nebokitug may also result in greater improvement in patient populations with lower
disease burden, with the goal of slowing or preventing disease progression.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Primary Endpoint</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Nebokitug demonstrated it was well-tolerated
over the 15-week treatment period. It also exhibited favorable and dose-dependent pharmacokinetic profiles. Adverse events, which most
commonly included fatigue, headache, and pruritus, were generally mild/moderate and distributed similarly between the placebo and nebokitug
-treated dosing arms.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Key Secondary Endpoints</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold">Liver Stiffness Measures
Improved&#160;in&#160;</span>Nebokitug<span style="font-weight: bold"> -Treated&#160;PSC Patients</span></div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; text-indent: 36pt">Notably, both doses of nebokitug
improved liver stiffness relative to placebo at Week 15, with a statistically significant improvement achieved in patients with moderate/advanced
disease This is the first time that an investigational drug for the treatment of PSC has demonstrated significant improvements in liver
stiffness in a relatively short study.</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman"> <img src="image00035.jpg" alt=""/></div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold">ELF Score Improved in&#160;</span>Nebokitug<span style="font-weight: bold">
-Treated&#160;PSC Patients</span></div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Patients treated with the 20 mg/kg
dose of nebokitug with moderate/advanced disease had reduced ELF scores relative to placebo at all time points in the trial. In addition,
in all patients treated with the 20 mg/kg dose of nebokitug, ELF changes&#160; from baseline remained consistently below 0.19, a recognized
threshold for predicting long-term PSC-related clinical events.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">65</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold">PRO-C3 Improved in </span>Nebokitug<span style="font-weight: bold">
-Treated in PSC Patients</span></div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Reductions in PRO-C3 levels at Week
15 relative to placebo were observed&#160;in patients receiving both&#160;the 10 mg/kg&#160;and 20 mg/kg doses of nebokitug. PRO-C3, a
serum biomarker of type III collagen synthesis, has been shown to be elevated in patients with PSC and has been identified as an independent
predictor of transplant-free survival in PSC.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold">Total Bilirubin Improved
in&#160;</span>Nebokitug<span style="font-weight: bold"> -Treated&#160;PSC Patients</span></div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Bilirubin is a key biomarker that
is an indicator of bile duct health. Nebokitug -treated patients showed a dose-dependent improvement in total bilirubin relative to placebo
at Week 15 that further supports the anti-cholestatic activity of nebokitug</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold">5-D Itch Scale Total
Pruritus Scores Improved in&#160;</span>Nebokitug<span style="font-weight: bold"> -Treated&#160;PSC Patients</span></div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Pruritus total scores on the 5-D
Itch Scale relative to placebo improved in nebokitug -treated patients, who demonstrated decreased pruritus scores compared to placebo
starting as soon as six weeks after their first dose. Nebokitug -treated patients&#160;experienced decreased pruritus&#160;scores across
all timepoints compared to placebo and the decrease reached statistical significance in patients receiving the 10 mg/kg dose at Week 15.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold">Liver Function Tests
Improved in </span>Nebokitug<span style="font-weight: bold"> -Treated PSC Patients</span></div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">All liver function tests improved
in nebokitug -treated patients relative to placebo at Week 15. Levels of alkaline phosphatase (ALP), alanine aminotransferase (ALT) aspartate
aminotransferase (AST) and gamma-glutamyl transferase (GGT) decreased in nebokitug -treated patients receiving the 20 mg/kg dose.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold">Anti-inflammatory Activity
Demonstrated in </span>Nebokitug<span style="font-weight: bold"> -Treated PSC Patients</span></div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Levels of the inflammatory cytokines
IL-6 and TGF&#946;1, which are known to play an important role in inflammation and fibrosis, were reduced in nebokitug -treated&#160;patients
relative to placebo at Week 15. The reduction reached statistical significance in moderate/advanced disease patients receiving the 20
mg/kg dose.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">SPRING Trial Open Label Extension
(OLE)</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">More than 90% of SPRING trial patients
eligible to participate in the OLE (50 out of 54 eligibles) chose to continue. OLE participants who had been in the treatment arms of
the 15-week double-blinded portion of the SPRING trial received another 33 weeks of treatment with nebokitug, for at total of up to 48
weeks of treatment, and former placebo patients crossed over to receive 33-weeks of treatment with nebokitug.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The OLE study confirmed that in PSC
patients receiving 10 mg/kg or 20 mg/kg of nebokitug administered once every three weeks for 48 weeks, the drug was safe and well-tolerated
and resulted in positive effects, including continued improvements in key liver biomarkers such as the ELF score, the fibrosis-related
components of ELF and the fibrosis biomarker PRO-C3. Liver stiffness scores (transient elastography), as measured by FibroScan<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#174;</sup>
were substantially lower in the nebokitug-treated patients with moderate/advanced disease compared to matching historical controls. Cholestasis-related
markers stabilized over 48 weeks of treatment and total serum bile acids were reduced. OLE patients with moderate/advanced disease treated
with nebokitug for 48 weeks showed a significantly lower number of clinical events (4.8%) compared to matching historical controls (25.8%).
Results from the patients receiving placebo in the double-blinded period who rolled over to receive 33 weeks of treatment with nebokitug
during the OLE were consistent with the results in patients treated with nebokitug in the double-blinded study, including stabilization
of ELF scores and improvements in liver stiffness compared to baseline.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">66</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><img src="image00036.jpg" alt=""/></div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The company views the broad and consistent
stabilization and improvement in disease-related biomarkers for up to 48 weeks of nebokitug treatment in the OLE results, including reductions
in the risk of disease progression as shown by the ELF score, as directly translatable and potentially derisking to the planned nebokitug
PSC Phase 3 study. Additionally, the new data&#160; showed a lower rate of clinical events in patients treated with nebokitug for up to
48 weeks compared to historical controls, further increasing confidence in the Phase 3 trial design, where the primary endpoint is reduction
in time to first clinical event. The findings represent an important milestone in Chemomab&#8217;s continued clinical progress and reinforce
the rationale for the planned Phase 3 trial that provides a pathway to potential full regulatory approval for nebokitug in PSC.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">67</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; font-style: italic">Phase 2 in SSc</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Chemomab has a Phase 2 ready study
in SSc that may enable proof-of-concept and further elucidation of different nebokitug mechanisms of action in treating SSc skin, lung
and vascular damage. The U.S. FDA cleared our IND application to commence the Phase 2 SSc trial</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;<span style="font-weight: bold">Competition</span></div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The development and commercialization
of new drug products is highly competitive across major pharmaceutical companies, specialty pharmaceutical companies and biotechnology
companies worldwide. We face competition with respect to our current product and expect to face competition with respect to any product
candidates that we may develop or commercialize in the future. Specifically, there are a number of companies developing treatments for
fibrotic/inflammatory diseases, including multiple major pharmaceutical and biotechnology companies with substantially greater resources
than us. We are a small biotech company with limited resources compared to the major pharmaceutical companies, however, we believe that
the unique nebokitug platform together with our knowledge and experience in inflammatory-fibrotic research provides us with competitive
advantages.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Therapeutic options for PSC and SSc
are limited and despite significant biopharmaceutical industry investment, the FDA has not approved any disease modifying therapies for
the treatment of PSC or SSc. Liver transplant is currently the only treatment shown to improve clinical outcomes for PSC patients while
SSc patients are being treated with drugs that were approved for different manifestations of the disease like interstitial lung disease
(nintedanib, Boehringer Ingelheim and tocilizumab, Hoffmann-La Roche).</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We are assessing nebokitug, a first-in-class
monoclonal antibody that interferes directly with both inflammation and fibrosis, into clinical development for the treatment of PSC and
SSc. There are a number of large biopharmaceutical and biotechnology companies that are currently pursuing the development of products
for the treatment of fibrotic indications like PSC and SSc, such as, Mitsubishi Tanabe Pharma, Horizon Therapeutics, Pliant Therapeutics,&#160;and
others. However, we know of no other companies currently in clinical development with a monoclonal antibody that targets CCL24.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">68</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Although the approach is novel with
respect to targeting both inflammation and fibrosis, we will need to compete with products further advanced in the pipeline towards market
approval. Investigational products, include:</div>

<div style="line-height: 1.25; font-family: Times New Roman"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z0fe3bba62b734ed7bcf3c08546c5e8ea" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-style: italic">PSC</div> </td> </tr>
  </table>

<div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">There are currently no FDA-approved
therapies for the treatment of PSC. Companies currently developing product candidates in Phase 3 clinical studies include Dr. Falk Pharma,
targeting cholestasis and liver metabolism (Dr. Falk; norUrso), rather than anti-fibrotic and anti-inflammatory manifestations of PSC.
Other companies with clinical candidates in earlier stages of development include Mirum Pharmaceuticals and NGM Bio. As shown in the table
below, most competitors are targeting the metabolic or symptomatic aspects of PSC. Only the Chemomab and NGM Bio compounds have disease
modifying potential, and we believe that our unique dual anti-fibrotic and anti-inflammatory activity gives nebokitug a potential advantage.</div>

<div><br/> </div> </div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman"><img src="image00037.jpg" alt=""/></div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<table cellspacing="0" cellpadding="0" id="za5f1b94ad9f74fd3b85fb4fe35c11634" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-style: italic">SSc</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">There are currently two FDA approved
products for the treatment of clinical manifestations of SSc--nintedanib, marketed by Boehringer Ingelheim GmbH and tocilizumab, marketed
by Hoffmann-La Roche for the treatment of interstitial lung disease. Companies currently developing product candidates in SSc in early
clinical stage include Amgen, Merck, GSK, Boehringer Ingelheim , AstraZeneca, and others. Additionally a number of pharmaceutical and
biotechnology companies are in the early stages of assessing new approaches that might be applicable to the treatment of SSc, such as
CAR-T cell therapies.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The availability of reimbursement
from government and other third-party payors will affect the pricing and competitiveness of nebokitug and any future products. More advanced
competitors also may obtain regulatory approval for their products more rapidly than us, which could result in competitors establishing
a strong market position.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Intellectual Property</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Overview</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We strive to protect and enhance
the proprietary technology, inventions, and improvements that are commercially important to the development of our business, including
seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties. We also rely on trade
secrets relating to our proprietary technology platform and know-how, continuing technological innovation and in-licensing opportunities
to develop, strengthen, and maintain our proprietary position in the field of inflammation and fibrosis that may present areas of opportunity
for the development of our business. We may also rely on regulatory protection afforded through data exclusivity, market exclusivity,
and patent term extensions, where available.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our commercial success may depend
in part on our ability to: obtain and maintain patent and other proprietary protection for commercially important technology, inventions
and know-how related to our business; defend and enforce our patents; preserve the confidentiality of our trade secrets; and operate without
infringing the valid enforceable patents and proprietary rights of third parties. Our ability to prevent third parties from making, using,
selling, offering to sell, or importing our products may depend on the extent to which we have rights under valid and enforceable licenses,
patents, or trade secrets that cover these activities. In certain cases, enforcement of these rights may depend on third party licensors.
With respect to both licensed and company-owned intellectual property rights, we cannot be sure that patents will be granted with respect
to any of our pending patent applications or with respect to any patent applications that may be filed by us in the future, nor can we
be sure that any of our existing patents or any patents that may be granted to us in the future will be commercially useful in protecting
our commercial products and methods of manufacturing the same.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">As of the date of this Annual Report
on Form 20-F, we owned or licensed seven pending or issued US patents and patent applications as well as patents and patent applications
in other jurisdictions. The first patent family has been issued in each of the United States, Europe (validated in France, Germany and
the United Kingdom) and Israel to the Tel Aviv Souraski Medical Center, whose rights have been licensed to Chemomab on an exclusive basis.
A composition of matter patent was issued in United States and certain corresponding foreign jurisdictions. To date, three additional
patent families were filed concerning the use of anti CCL24 antibodies in specific indications, dosing regimens, and routes of administration.
We will seek United States and foreign patent protection for a variety of additional technologies, including: research compounds and methods,
candidate compounds and antibodies for modulating the activity of CCL24, methods for treating diseases of interest, and methods for treating
our products. We will seek additional protection, in part, through confidentiality and proprietary information agreements.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">69</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="line-height: 1.25; font-style: italic; font-weight: bold; text-indent: -9pt; margin-left: 9pt">Company Owned Intellectual
Property</div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We own multiple families of patent
applications that pertain to anti-CCL24 monoclonal antibody compositions capable of blocking CCL24 activity and methods for treating or
preventing diseases associated with inflammation and fibrosis. Certain applications in these families relate to our nebokitug antibody,
backup variants, various unit dosages, dosing regimens, and other routes of administration. Patents that are or will be issued from these
submissions will expire between the years 2035 to 2041, subject to possible patent term adjustments and/or extensions.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In addition to the above, we have
established expertise and development capabilities focused in the areas of preclinical research and development, manufacturing and manufacturing
process development, quality control, quality assurance, regulatory affairs, and clinical study design and implementation. We believe
that our focus and expertise will help us develop products based on our proprietary intellectual property.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Licensed IP</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">As mentioned above, we have obtained
an exclusive license from the Tel Aviv Souraski Medical Center for one patent, which is expected to expire in 2029. This patent was issued
in each of the United States, Europe and Israel, and pertains to anti CCL24 inhibitors (specifically, anti CCL24 antibodies) and methods
of using such inhibitors for treating inflammatory, autoimmune and cardiovascular diseases.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Trade Secret
Protection</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We may rely, in some circumstances,
on trade secrets to protect our technology. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality
agreements with our employees, consultants, scientific advisors, and contractors. We also seek to preserve the integrity and confidentiality
of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information
technology systems.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Material Agreements</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">Tel-Aviv Souraski Medical Center
(TASMC) License Agreement</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In December 2011, we entered into
a license agreement, or the TASMC Agreement, with the Medical Research, Infrastructure, Health Services Fund of the Tel Aviv Souraski
Medical Center., or TASMC, for the research, development and commercialization of the CCL24 platform and CCR3 blockade platform (nebokitug),
which license includes patent rights covering the foregoing platforms and related know how and products. Under the terms of the TASMC
Agreement, we are responsible for the research, development, manufacturing and commercialization of nebokitug. This license was granted
on an exclusive basis and we were also granted rights to sublicense the instant license to third parties pursuant to certain terms described
therein.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In accordance with the TASMC Agreement,
we paid TASMC a non-refundable and non-creditable payment in four milestone installments, related to TASMC&#8217;s past patent maintenance
and prosecution costs.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">Certain additional terms of the TASMC Agreement include:</div>

<div style="line-height: 1.25; font-family: Times New Roman"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zbe37edc1a77a49d8a345d8301be1f0f0" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">We will be required to pay TASMC non-refundable and non-creditable milestone payments
        of up to (i) $300,000 upon the submission of an NDA, BLA or equivalent for each of the licensed products to the FDA and to equivalent
        European and Asian foreign regulatory agencies, and (ii) $600,000 upon the grant by the FDA or equivalent European and/or Asian regulatory
        agencies of their marketing approval for each licensed product;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">In the event of an &#8220;exit,&#8221; as such term is defined therein, we must pay
        TASMC an exit fee of 1% of the transaction consideration (which shall be capped at $3 million);</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">In the event we sublicense a licensed product, we must pay TASMC a sublicense fee
        of 10% of all attributed income, in addition to a low-single digit percentage tiered royalty payment of our earned royalties.</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">70</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Unless terminated earlier, the TASMC
Agreement will expire upon the later of the expiration of the last-to-expire valid patent claim and any extension granted prior thereto.
The termination of the TASMC Agreement will not preclude TASMC from receiving sublicense payments or royalties. In addition to the foregoing,
the TASMC Agreement includes customary termination provisions.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">CMC Collaboration Agreement</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In June 2015, we entered into a collaboration
agreement, or the CMC Agreement, with CMC ICOS Biologics, Inc. (acquired by AGC Biologics in 2018), or CMC, which, under the terms thereof,
granted the us certain licenses to use proprietary rights, materials and know-how of CMC for purposes of research and development of nebokitug
as well as commercialization thereof. Pursuant to the terms of the CMC Agreement, we received (i) a worldwide, non-exclusive, non-transferable,
non-sublicensable license for research purposes, or the Research License, and (ii) an option, or the Option License, to a worldwide, non-exclusive,
non-transferable, sublicensable license for commercialization purposes, subject to a fee schedule in addition to that described below.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In accordance with the terms of the
CMC Agreement, we agreed to pay in exchange for the foregoing license payments to CMC upon the achievement of certain pre-determined clinical
and regulatory events, an amount stipulated in the CMC Agreement, aggregating a six-digit number. Additionally, for any product that is
commercialized pursuant to the CMC Agreement, we are required to pay CMC a royalty payment based on annual aggregate worldwide net sales
thresholds for such products. In the event CMC exclusively manufactures our products, CMC agrees to waive the foregoing royalty.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Unless terminated earlier pursuant
to the customary termination provisions set forth in the CMC Agreement, the Research License will expire upon the conclusion of the term
as defined therein, and the Option License will expire upon the later of (a) the tenth anniversary following our obtainment of regulatory
approval, or (b) the last to expire of the patent rights and country-by-country basis.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Manufacturing</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our product candidate, nebokitug,
is a monoclonal antibody amenable to standard formulation technologies. We have developed the biological process and manufactured kilogram
quantities through processes similar to the manufacturing processes that will be required to provide drug product for the Phase 2 clinical
studies. The manufacturing process of the drug substance used for such product candidates is robust, well established and requires the
use of readily available starting materials. The biological route is amenable to large-scale production and does not require unconventional
equipment or handling during the manufacturing process. We have obtained an adequate supply chain of the drug substance for nebokitug
from our contract manufacturing organization, or CMO, to satisfy both our clinical and preclinical requirements for this year. We rely
on a sole supplier for the manufacture of nebokitug. Our manufacturer has the capabilities to support late stage clinical studies as well
as product launch and marketing.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We do not own or operate facilities
for clinical drug manufacturing, storage, distribution or quality testing. Currently, all of our clinical manufacturing is outsourced
to third-party manufacturers. As our development programs expand and we build new process efficiencies, we expect to continually evaluate
this strategy with the objective of satisfying demand for our clinical studies and, if approved, the manufacture, sale and distribution
of commercial products.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Commercialization</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We intend to develop and, if approved
by the FDA, to commercialize our product candidates alone or in collaboration with others. We may work in combination with one or more
large pharmaceutical partners for certain indications, where specialist capabilities are needed. We intend to enter into distribution
or licensing arrangements for global or regional commercialization rights. We will, however, continuously review our partnering strategy
in the light of new clinical data and market understanding.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">71</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="line-height: 1.25; font-weight: bold; text-indent: -9pt; margin-left: 9pt">Regulatory Matters</div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The Food and Drug Administration,
or FDA, and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome
requirements upon companies involved in the clinical development, manufacture, marketing and distribution of drugs, such as those that
we are developing. These agencies and other federal, state and local entities regulate, among other things, the research and development,
testing, manufacture, quality control, safety, effectiveness, labelling, storage, record keeping, approval, advertising and promotion,
distribution, post-approval monitoring and reporting, sampling and export and import of our product candidates.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">United States
government regulation of drug products</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Drugs in the United States are subject
to rigorous regulation under the Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The FDA also regulates biological
products under the FDCA and the Public Health Service Act, or PHSA. The process of obtaining regulatory approvals and the subsequent compliance
with applicable federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial
resources. Failure to comply with the applicable United States requirements at any time during the product development process, approval
process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal
to approve a pending New Drug Application, or NDA, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters,
product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government
contracts, restitution, disgorgement or civil or criminal penalties.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The process required by the FDA before
a drug or biologic may be marketed in the United States generally involves the following:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb26cea3771664358859c5bf15dba522e" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">completion of preclinical laboratory tests, animal studies and formulation studies
        in compliance with the FDA&#8217;s Good Laboratory Practice, or GLP, regulations;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">submission to the FDA of an Investigational New Drug application, or IND, which must
        become effective before human clinical studies may begin;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">approval by an Institutional Review Board, or IRB, at each clinical site before each
        study may be initiated;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">performance of adequate and well-controlled human clinical studies in accordance with
        Good Clinical Practice, or GCP requirements to establish the safety and efficacy of the proposed drug product for each indication;</div>
        </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">completion of all manufacturing requirements to ensure robust manufacturing process,
        and product quality and safety as per Good Manufacturing Practice, or cGMP guidelines;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">completion of non-clinical reproductive studies, as applicable, prior to late stage
        clinical studies and NDA or Biologics License Application, or BLA, submission;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">development of an appropriate pediatric plan for clinical testing or exclusion, pre-
        or post-approval, as applicable;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">submission to the FDA of an NDA or BLA;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">satisfactory completion of an FDA advisory committee review, if applicable;&#160;</div>
        </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">satisfactory completion of an FDA inspection of the manufacturing facility or facilities
        at which the product is produced to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are
        adequate to preserve the drug&#8217;s identity, strength, quality and purity;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">satisfactory completion of FDA audits of clinical study sites to assure compliance
        with GCPs and the integrity of the clinical data;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">payment of user fees and securing FDA approval of the NDA;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">FDA review and approval of an NDA or BLA; and</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">compliance with any post-approval requirements, including the potential requirement
        to implement a Risk Evaluation and Mitigation Strategies, or REMS, and the potential requirement to conduct post-approval studies.</div>
        </td> </tr>
  </table>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">72</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Preclinical studies</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Preclinical studies include laboratory
evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor
must submit the results of the preclinical tests, together with manufacturing information, analytical data and any available clinical
data or literature, among other things, to the FDA as part of an IND. Some preclinical testing may continue even after the IND is submitted.
An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions
related to one or more proposed clinical studies and places the clinical study on a clinical hold. In such a case, the IND sponsor and
the FDA must resolve any outstanding concerns before the clinical study can begin. As a result, submission of an IND may not result in
the FDA allowing clinical studies to initiate.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Clinical studies</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Clinical studies involve the administration
of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements,
which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical
study. Clinical studies are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be
used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical study and any subsequent protocol
amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical study
must review and approve the plan for any clinical study before it initiates at that institution. Information about certain clinical studies
must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on their www.clinicaltrials.gov
website.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Human clinical studies are typically
conducted in three sequential phases, which may overlap or be combined. A fourth, or post-approval, phase may include additional clinical
studies. These phases generally include the following:</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" id="z25a2f8abd0c0495e857128c63b4b4745" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold">Phase 1:</span> The
        drug or biologic is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety,
        dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness.
        For some products for severe or life-threatening diseases, especially if the product may be too toxic to administer to healthy humans,
        the initial clinical trials may be conducted in individuals having a specific disease for which use the tested product is indicated.</div>
        </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold">Phase 2:</span> The
        drug or biologic is administered is administered to a limited patient population to identify possible adverse effects and safety risks,
        to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</div>
        </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold">Phase 3:</span> The
        drug or biologic is administered to an expanded patient population, generally at geographically dispersed clinical study sites, in well-controlled
        clinical studies to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the
        overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product.</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold">Phase 4:</span> Phase
        4 clinical trials are studies required of, or agreed to by, a sponsor that are conducted after the FDA has approved a product for marketing.
        These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication and to document
        a clinical benefit in the case of drugs approved under accelerated approval regulations. If the FDA approves a product while a company
        has ongoing clinical trials that were not necessary for approval, a company may be able to use the data from these clinical trials to
        meet all or part of any Phase 4 clinical trial requirement. Failure to promptly conduct Phase 4 clinical trials where necessary could
        result in withdrawal of approval for products approved under accelerated approval regulations.</div> </td> </tr>
  </table>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">73</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Progress reports detailing the results
of the clinical studies must be submitted at least annually to the FDA and more frequently if serious adverse events occur. Phase 1, Phase
2 and Phase 3 studies may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may
suspend or terminate a clinical study at any time on various grounds, including a finding that the research subjects are being exposed
to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical study at its institution if the clinical
study is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious
harm to patients.<br/> &#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Marketing approval</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Assuming successful completion of
the required clinical testing, the results of the preclinical and clinical studies, together with detailed information relating to the
product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA
or BLA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA or BLA is subject
to a substantial application user fee. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the
FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard NDA, for a new molecular entity to review and act on
the submission. This review typically takes twelve months from the date the NDA or BLA is submitted to FDA because the FDA has approximately
two months to make a &#8220;filing&#8221; decision.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In addition, under the Pediatric
Research Equity Act of 2003, or PREA, as amended and reauthorized, certain NDAs/BLAs or supplements thereof must contain data that are
adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and
to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its
own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of
the product for use in adults, or full or partial waivers from the pediatric data requirements. An Agreed Initial Pediatric Study Plan
requesting a waiver from the requirement to conduct clinical studies may be submitted to the FDA.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The FDA also may require submission
of a REMS plan to ensure that the benefits of the drug outweigh its risks. The REMS plan could include medication guides, physician communication
plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries, or other risk
minimization tools.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The FDA conducts a preliminary review
of all NDAs/BLAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently
complete to permit substantive review. The FDA may request additional information rather than accept an NDA/BLA for filing. In this event,
the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the
FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews
an NDA/BLA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured,
processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality and purity.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The FDA may refer an application
for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific
experts, which reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions.
The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Before approving an NDA, the FDA
typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it
determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent
production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical
study sites to assure compliance with GCP requirements.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">74</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">After evaluating the NDA/BLA and
all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities
and clinical study sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter
generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA/BLA and may require
additional clinical or preclinical testing in order for the FDA to reconsider the application. Even with submission of this additional
information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those
conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes
commercial marketing of the drug with specific prescribing information for specific indications.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman; text-indent: 36pt">Even if the FDA approves a product, it may limit the approved
indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require
that post-approval studies, including Phase 4 clinical studies, be conducted to further assess a drug&#8217;s safety after approval, require
testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and
use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability
of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance
programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional
labeling claims, are subject to further testing requirements and FDA review and approval.<br/> &#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">FDA Expedited
Development and Review Programs</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The FDA has various programs, including
fast track designation, priority review, accelerated<span style="font-style: italic">&#160;</span>approval, and breakthrough therapy designation,
which are intended to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment
of serious or life-threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these
programs is to provide important new drugs to patients earlier than under standard FDA review procedures.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The FDA has a fast track designation
program that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. Specifically,
new drugs are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and
demonstrate the potential to address unmet medical needs for the disease or condition. With regard to a fast track product, the FDA may
consider for review sections of the NDA/BLA on a rolling basis before the complete application is submitted, if the sponsor provides a
schedule for the submission of the sections of the NDA/BLA, the FDA agrees to accept sections of the NDA/BLA and determines that the schedule
is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA/BLA. In November 2023, the
Company announced that the FDA had awarded Fast Track status to nebokitug for the treatment of PSC in adult patients.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Any product submitted to the FDA
for approval, including a product with a fast track designation, may also be eligible for other types of FDA programs intended to expedite
development and review, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential
to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment,
diagnosis, or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation
of an application for a new drug designated for priority review in an effort to facilitate the review.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In addition, a product may be eligible
for accelerated approval. Drug products intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated
approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit,
or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict
an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of
the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require a sponsor of a drug
receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity
or mortality, or other clinical endpoint and to submit promotional materials for preapproval and pre-use review, which could adversely
impact the timing of the commercial launch of the product. In addition, the drug may be subject to accelerated withdrawal procedures.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">75</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The Food and Drug Administration
Safety and Innovation Act established a category of drugs referred to as &#8220;breakthrough therapies&#8221; that may be eligible to
receive breakthrough therapy designation. A sponsor may seek FDA designation of a product candidate as a &#8220;breakthrough therapy&#8221;
if the product is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or
condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies
on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation
includes all of the fast track program features, as well as more intensive FDA interaction and guidance. The breakthrough therapy designation
is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria
are met. If a product is designated as breakthrough therapy, the FDA will work to expedite the development and review of such drug.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Fast track designation, priority
review, accelerated approval, and breakthrough therapy designation do not change the standards for approval but may expedite the development
or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer
meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Orphan drug designation
and exclusivity</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Under the Orphan Drug Act, the FDA
may designate a drug product as an &#8220;orphan drug&#8221; if it is intended to treat a rare disease or condition (generally meaning
that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation that
the cost of developing and making a drug product available in the United States for treatment of the disease or condition will be recovered
from sales of the product). A company must request orphan product designation before submitting an NDA. If the request is granted, the
FDA will disclose the identity of the therapeutic agent and its potential use. Orphan product designation does not convey any advantage
in or shorten the duration of the regulatory review and approval process. As of the current date, we have obtained orphan drug designation
for three indications, PSC, SSc and IPF.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If a product with orphan status receives
the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare
disease or condition for which it was designated, the product generally will be receiving orphan product exclusivity. Orphan product exclusivity
means that the FDA may not approve any other applications for the same product for the same indication for seven years, except in certain
limited circumstances. If a drug or drug product designated as an orphan product ultimately receives marketing approval for an indication
broader than what was designated in its orphan product application, it may not be entitled to exclusivity. Orphan exclusivity will not
bar approval of another product under certain circumstances, including if a subsequent product with the same active ingredient for the
same indication is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a
major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. Further, the FDA
may approve more than one product for the same orphan indication or disease as long as the products contain different active ingredients.
Moreover, competitors may receive approval of different products for the indication for which the orphan product has exclusivity or obtain
approval for the same product but for a different indication for which the orphan product has exclusivity.<br/> &#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In <span style="font-style: italic">Catalyst
Pharms., Inc. v. Becerra</span>, 14 F.4th 1299 (11th Cir. 2021), the court disagreed with the FDA&#8217;s longstanding position that the
orphan drug exclusivity only applies to the approved use or indication within an eligible disease. This decision created uncertainty in
the application of the orphan drug exclusivity. On January 24, 2023, the FDA published a notice in the Federal Register to clarify that
while the agency complies with the court&#8217;s order in <span style="font-style: italic">Catalyst</span>, FDA intends to continue to
apply its longstanding interpretation of the regulations to matters outside of the scope of the <span style="font-style: italic">Catalyst</span>
order &#8211; that is, the agency will continue tying the scope of orphan-drug exclusivity to the uses or indications for which a drug
is approved, which permits other sponsors to obtain approval of a drug for new uses or indications within the same orphan designated disease
or condition that have not yet been approved. It is unclear how future litigation, legislation, agency decisions, and administrative actions
will impact the scope of the orphan drug exclusivity.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">76</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">United States
marketing exclusivity</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Market exclusivity provisions under
the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year period of non-patent marketing
exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical
entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible
for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an Abbreviated New Drug Application,
or ANDA, or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal
right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification
of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement
to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant
are deemed by the FDA to be essential to the approval of the application, for example, new indications, dosages or strengths of an existing
drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not prohibit
the FDA from approving ANDAs for the original non-modified version of the drug. Five-year and three-year exclusivity will not delay the
submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference
to all of the preclinical studies and adequate and well-controlled clinical studies necessary to demonstrate safety and effectiveness.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Abbreviated Licensure Pathway of Biological
Products as Biosimilars or Interchangeable Biosimilars</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; text-indent: 36pt">The Patient Protection and Affordable
Care Act (Affordable Care Act or ACA), signed into law in 2010, includes the Biologics Price Competition and Innovation Act of 2009 (BPCIA),
which created an abbreviated approval pathway for biological products shown to be highly similar to an FDA-licensed reference biological
product. The BPCIA attempts to minimize duplicative testing, and thereby lower development costs and increase patient access to affordable
treatments.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman; text-indent: 36pt; text-align: justify">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; text-indent: 36pt">Biosimilarity means that the biological
product is highly similar to the reference product notwithstanding minor differences in clinically inactive components, and that there
are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity and potency
of the product. In addition, the law provides for a designation of &#8220;interchangeability&#8221; between the reference and biosimilar
products, whereby the biosimilar may be substituted for the reference product without the intervention of the healthcare provider who
prescribed the reference product.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman; text-align: justify">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">A biosimilar product sponsor may
not submit an application for four years from the date of first licensure of the reference product. A reference product may also be entitled
to exclusivity under other statutory provisions. For example, a reference product designated for a rare disease or condition (an orphan
drug) may be entitled to seven years of exclusivity, in which case no product that is biosimilar to the reference product may be approved
until either the end of the twelve-year period provided under the biosimilarity statute or the end of the seven-year orphan drug exclusivity
period, whichever occurs later. In certain circumstances, a regulatory exclusivity period can extend beyond the life of a patent, and
thus block biosimilarity applications from being approved on or after the patent expiration date.</div>

<div style="line-height: 1.25; font-family: Times New Roman; text-align: justify">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Pediatric exclusivity is another
type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing regulatory
exclusivity periods. This six-month exclusivity may be granted based on the voluntary completion of a pediatric study in accordance with
an FDA-issued &#8220;Written Request&#8221; for such a study.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Post-approval
requirements</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Drugs and biologics manufactured
or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things,
requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting
of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other
labeling claims are subject to prior FDA review and approval. There are continuing, annual user fee requirements for any marketed products
and the establishments where such products are manufactured, as well as new application fees for supplemental applications with clinical
data.<br/> &#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">77</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The FDA may impose a number of post-approval
requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical
studies, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In addition, drug and biologic manufacturers
and other entities involved in the manufacture and distribution of approved drugs and biologics are required to register their establishments
with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance
with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being
implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and
documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers
must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Once an approval of a drug or biologic
is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems
occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of
unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in
mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess
new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among
other things:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zdb91d494ddd646cfaa2e2a5c73be241c" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Restrictions on the marketing or manufacturing of the product, complete withdrawal
        of the product from the market or product recalls;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z286cbd2f1ebd45808d4de73c56f963d9" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Fines, warning letters or holds on post-approval clinical studies;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za7570ad7a7d44b5680e44c27448f1903" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Refusal of the FDA to approve pending NDAs or BLAs or supplements to approved NDAs
        or BLAs, or suspension or revocation of product approvals;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zea57bf32abe545c2a371b5dab528c57b" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Product seizure or detention, or refusal to permit the import or export of products;
        and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze7a8f42881a44eb59e29912b85314375" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Injunctions or the imposition of civil or criminal penalties.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The FDA strictly regulates marketing,
labeling, advertising and promotion of products that are placed on the market. Drugs and biologics may be promoted by a manufacturer and
any third parties acting on behalf of a manufacturer only for the approved indications and in a manner consistent with the approved label
for the product. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and
a company that is found to have improperly promoted off-label uses may be subject to significant liability.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Other U.S. healthcare
laws</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Healthcare providers, physicians,
and third party payors play a primary role in the recommendation and prescription of drug products for which we obtain marketing approval.
Arrangements with third party payors, healthcare providers and physicians, in connection with the clinical research, sales, marketing
and promotion of products, once approved, and related activities, may expose a pharmaceutical manufacturer to broadly applicable fraud
and abuse and other healthcare laws and regulations. In the United States, these laws include, without limitation, state and federal anti-kickback,
physician self-referral prohibitions, false claims, physician transparency, and patient data privacy and security laws and regulations,
including but not limited to those described below:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z56988f9d4e044f0c9d72257570e2ce09" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">The federal Anti-Kickback Statute, or AKS, which makes it illegal for any person,
        including a prescription drug manufacturer (or a party acting on its behalf) to knowingly and willfully solicit, receive, offer or pay
        any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, that is
        intended to induce or reward, referrals including the purchase recommendation, order or prescription of a particular drug for which payment
        may be made under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual
        knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert
        that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent
        claim for purposes of the federal False Claims Act, or FCA;</div> </td> </tr>
  </table>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">78</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>
<!--PROfilePageNumberReset%Num%80%%%-->

<table cellspacing="0" cellpadding="0" id="z7b464ef23e3141828559379bd8190d74" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">The federal civil and criminal false claims laws, including the FCA, which can be
        enforced through &#8220;qui tam&#8221; or &#8220;whistleblower&#8221; actions, and civil monetary penalty laws, which impose criminal
        and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims
        for payment or approval from Medicare, Medicaid, or other federal health care programs that are false or fraudulent; knowingly making
        or causing a false statement material to a false or fraudulent claim or an obligation to pay or transmit money or property to the federal
        government; or knowingly concealing or knowingly and improperly avoiding or decreasing such an obligation. Similar to the AKS, a person
        or entity does not need to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation;</div>
        </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA,
        which created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme
        to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the
        money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public
        or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially
        false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;</div>
        </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health
        Act of 2009, or HITECH, and their respective implementing regulations, which impose requirements on certain covered healthcare providers,
        health plans, and healthcare clearinghouses as well as their respective business associates and their subcontractors that perform services
        for them that involve the creation, use, receipt, maintenance or disclosure of individually identifiable health information, relating
        to the privacy, security and transmission of individually identifiable health information;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">The federal Physician Payments Sunshine Act, created under Patient Protection and
        Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the ACA, and its implementing
        regulations, which require manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare,
        Medicaid or the Children&#8217;s Health Insurance Program to report annually to the Centers for Medicare and Medicaid Services, or CMS,
        under the Open Payments Program, information related to payments or other transfers of value made to physicians (defined to include doctors,
        dentists, optometrists, podiatrists and chiropractors), certain non-physician healthcare professionals (such as physician assistants and
        nurse practitioners, among others),&#160; and teaching hospitals, as well as ownership and investment interests held by physicians and
        their immediate family members; and</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Analogous state and foreign laws and regulations, such as state and foreign anti-kickback,
        physician self-referral prohibitions, false claims, consumer protection and unfair competition laws which may apply to pharmaceutical
        business practices, including but not limited to, research, distribution, sales and marketing arrangements as well as submitting claims
        involving healthcare items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical
        companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated
        by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources;
        state laws that require drug manufacturers to file reports with states regarding pricing and marketing information, such as the tracking
        and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities; state
        and local laws requiring the registration of pharmaceutical sales representatives; and state and foreign laws governing the privacy and
        security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the
        same effect, thus complicating compliance efforts.</div> </td> </tr>
  </table>

<div> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Because of the breadth of these laws
and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of a pharmaceutical manufacturer&#8217;s
business activities could be subject to challenge under one or more of such laws. Efforts to ensure that business arrangements comply
with applicable healthcare laws involve substantial costs. It is possible that governmental and enforcement authorities will conclude
that a pharmaceutical manufacturer&#8217;s business practices do not comply with current or future statutes, regulations or case law interpreting
applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against a pharmaceutical manufacturer,
and it is not successful in defending itself or asserting its rights, those actions could have a significant impact on its business, including
the imposition of significant civil, criminal and administrative penalties, damages, disgorgement, imprisonment, monetary fines, possible
exclusion from participation in Medicare, Medicaid and other federal healthcare programs, reporting obligations and oversight if we become
subject to integrity and oversight agreements to resolve allegations of non-compliance, contractual damages, reputational harm, diminished
profits and future earnings, and curtailment of operations, any of which could adversely affect a pharmaceutical manufacturer&#8217;s
ability to operate its business and the results of operations. In addition, commercialization of any drug product outside the United States
will also likely be subject to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Prescription drug advertising is
subject to federal, state and foreign regulations. In the United States, the FDA regulates prescription drug promotion, including direct-to-consumer
advertising. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use. Any distribution
of prescription drug products and pharmaceutical samples must comply with the United States Prescription Drug Marketing Act, or PDMA,
a part of the FDCA. In addition, Title II of the Federal Drug Quality and Security Act of 2013, known as the Drug Supply Chain Security
Act, or DSCSA, has imposed new &#8220;track and trace&#8221; requirements on the distribution of prescription drug products by manufacturers,
distributors, and other entities in the drug supply chain. The DSCSA requires product identifiers (i.e., serialization) on prescription
drug products in order to eventually establish an electronic interoperable prescription product system to identify and trace certain prescription
drugs distributed in the United States and preempts existing state drug pedigree laws and regulations on this topic. The DSCSA also establishes
new requirements for the licensing of wholesale distributors and third-party logistic providers. The FDA is in the process of finalizing
regulations addressing national standards for the licensure of wholesale distributors and third-party logistics providers.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In the United States, numerous federal
and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and
state consumer protection laws, govern the collection, use, disclosure, and protection of health-related and other personal information.
For example, in June&#160;2018, the State of California enacted the California Consumer Privacy Act of 2018, or the CCPA, which came into
effect on January&#160;1, 2020 and provides new data privacy rights for consumers and new operational requirements for companies, which
may increase our compliance costs and potential liability. The CCPA gives California residents expanded rights to access and delete their
personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information
is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected
to increase data breach litigation. While there is currently an exception for protected health information that is subject to HIPAA and
clinical study regulations, as currently written, the CCPA may impact certain of our business activities. The CCPA could mark the beginning
of a trend toward more stringent state privacy legislation in the United States, which could increase our potential liability and adversely
affect our business.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">79</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In the event we decide to conduct
clinical studies or continue to enroll subjects in our ongoing or future clinical studies, we may be subject to additional privacy restrictions.
The collection, use, storage, disclosure, transfer, or other processing of personal data regarding individuals in the European Economic
Area, or EEA, including personal health data, is subject to the EU General Data Protection Regulation, or GDPR, which became effective
on May&#160;25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including
requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates,
providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality
of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR
also imposes strict rules&#160;on the transfer of personal data to countries outside the EEA, including the United States, and permits
data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20&#160;million
or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations
to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations
of the GDPR. In addition, the GDPR includes restrictions on cross-border data transfers. The GDPR may increase our responsibility and
liability with respect to personal data that we process where such processing is subject to the GDPR, and we may be required to put in
place additional mechanisms to ensure compliance with the GDPR, including as implemented by individual countries. Compliance with the
GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices,
and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection
with our European activities. Further, the United Kingdom&#8217;s decision to leave the EU, often referred to as Brexit, has created uncertainty
with regard to data protection regulation in the United Kingdom and transfers of personal data to the UK and from the UK to both the EEA
and countries outside the UK/EEA. For the time being, transfers of personal data from the EU to the UK are covered by an adequacy decision
of the EU Commission, and the UK has recently implemented its own regime for safeguarding transfers from the UK to countries outside the
UK/EEA which sit alongside the new EU safeguards which were brought in during 2021.&#160; However, both the adequacy decision and the
UK regime remain vulnerable to withdrawal or legal challenge.&#160; Further both the new UK and EU personal data transfer regimes remain
relatively untested and therefore impose risk that a transfer of personal data and/or its subsequent processing would be held unlawful
and give rise to liabilities from administrative fines and/or damages claims from data subjects.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Current and future
healthcare reform legislation</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In both the United States and certain
foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system. In particular, in 2010
the ACA was enacted, which, among other things, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug
Rebate Program, extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed
care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, and provided incentives
to programs that increase the federal government&#8217;s comparative effectiveness research.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In addition, other legislative changes
have been proposed and adopted in the United States since the ACA was enacted. In August&#160;2011, the Budget Control Act of 2011, among
other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending
a targeted deficit reduction of at least $1.2 trillion for the&#160;years 2013 through 2021, was unable to reach required goals, thereby
triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare
payments to providers of 2% per fiscal year, which went into effect in 2013, and, due to subsequent legislative amendments, will remain
in effect through 2032. The American Taxpayer Relief Act of 2012 further reduced Medicare payments to several providers, including hospitals
and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers
from three to five&#160;years. The Bipartisan Budget Act of 2018, also amended the ACA, effective January&#160;1, 2019, by increasing
the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part&#160;D and closing the coverage
gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole&#8221;.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">80</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Additionally, there has been heightened
governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics.
In August 2022, Congress passed the Inflation Reduction Act of 2022, which includes prescription drug provisions that have significant
implications for the pharmaceutical industry and Medicare beneficiaries, including allowing the federal government to negotiate a maximum
fair price for certain high-priced single source Medicare drugs that have been on the market for at least 7 years and biologics that have
been on the market for at least 11 years, and, imposing penalties and excise tax for manufacturers that fail to comply with the drug price
negotiation requirements; requiring inflation rebates for all Medicare Part B and Part D drugs, with limited exceptions, if their drug
prices increase faster than inflation; and redesigning Medicare Part D to reduce out-of-pocket prescription drug costs for beneficiaries,
among other changes. The impact of these legislative, executive, and administrative actions and any future healthcare measures and agency
rules implemented by the second Trump administration on us and the pharmaceutical industry as a whole is unclear. The implementation of
cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize
any of the product candidates for which we receive approval. At the state level, legislatures have increasingly passed legislation and
implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts,
restrictions on certain product access and marketing cost disclosure and transparency measures and, in some cases, designed to encourage
importation from other countries and bulk purchasing.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Legislative and regulatory proposals,
executive orders, and enactment of laws, at the foreign, federal and state levels, directed at containing or lowering the cost of healthcare,
will continue into the future.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Rest of World
Regulation</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">For other countries outside of the
European Union and the United States, such as countries in Eastern Europe, Latin America or Asia, the requirements governing product development,
the conduct of clinical studies, manufacturing, distribution, marketing approval, product licensing, pricing and reimbursement vary from
country to country. Additionally, clinical studies must be conducted in accordance with GCP requirements and the applicable regulatory
requirements and the ethical principles that have their origin in the Declaration of Helsinki.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If we fail to comply with applicable
foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product
recalls, seizure of products, operating restrictions and criminal prosecution.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Additionally, to the extent that
any of our product candidates, once approved, are sold in a foreign country, we may be subject to applicable post-marketing requirements,
including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments
or other transfers of value to healthcare professionals.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Coverage and
reimbursement</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Successful commercialization of new
drug products depends in part on the extent to which reimbursement for those drug products will be available from government health administration
authorities, private health insurers, and other organizations. Government authorities and third-party payors, such as private health insurers
and health maintenance organizations, decide which drug products they will pay for and establish reimbursement levels. The availability
and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford a drug product. Sales
of drug products depend substantially, both domestically and abroad, on the extent to which the costs of drugs products are paid for by
health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health
administration authorities, private health coverage insurers and other third-party payors.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">A primary trend in the United States
healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by
limiting coverage and the amount of reimbursement for particular drug products. In many countries, the prices of drug products are subject
to varying price control mechanisms as part of national health systems. In general, the prices of drug products under such systems are
substantially lower than in the United States. Other countries allow companies to fix their own prices for drug products but monitor and
control company profits. Accordingly, in markets outside the United States, the reimbursement for drug products may be reduced compared
with the United States.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In the United States, the principal
decisions about reimbursement for new drug products are typically made by CMS, an agency within the U.S. Department of Health and Human
Services. CMS decides whether and to what extent a new drug product will be covered and reimbursed under Medicare, and private payors
tend to follow CMS to a substantial degree. However, no uniform policy of coverage and reimbursement for drug products exists among third-party
payors and coverage and reimbursement levels for drug products can differ significantly from payor to payor.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">81</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The Medicare Prescription Drug,&#160;Improvement,
and Modernization Act of 2003, or the MMA, established the Medicare Part&#160;D program to provide a voluntary prescription drug benefit
to Medicare beneficiaries. Under Part&#160;D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities
that provide coverage of outpatient prescription drugs. While all Medicare drug plans must give at least a standard level of coverage
set by Medicare, Part&#160;D prescription drug plan sponsors are not required to pay for all covered Part&#160;D drugs, and each Part&#160;D
prescription drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However,
Part&#160;D prescription drug formularies must include drugs within each therapeutic category and class of covered Part&#160;D drugs,
though not necessarily all the drugs in each category or class. Any formulary used by a Part&#160;D prescription drug plan must be developed
and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand
for drugs for which we obtain marketing approval. Any negotiated prices for any of our products covered by a Part&#160;D prescription
drug plan will likely be lower than the prices it might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare
beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction
in payment that results from the MMA may result in a similar reduction in payments from non-governmental payors.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">For a drug product to receive federal
reimbursement under the Medicaid or Medicare Part&#160;B programs or to be sold directly to United States government agencies, the manufacturer
must extend discounts to entities eligible to participate in the 340B drug pricing program. The required 340B discount on a given product
is calculated based on the average manufacturer price, or AMP, and Medicaid rebate amounts reported by the manufacturer. As of 2010, the
ACA expanded the types of entities eligible to receive discounted 340B pricing, although under the current state of the law these newly
eligible entities (with the exception of children&#8217;s hospitals) will not be eligible to receive discounted 340B pricing on orphan
drugs. As 340B drug pricing is determined based on AMP and Medicaid rebate data, the revisions to the Medicaid rebate formula and AMP
definition described above could cause the required 340B discount to increase. If third-party payors do not consider our drugs to be cost-effective
compared to other available therapies, they may not cover our drugs after approval as a benefit under their plans or, if they do, the
level of payment may not be sufficient to allow us to sell our drugs on a profitable basis.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">These laws, and state and federal
healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding
and otherwise affect the prices we may obtain for any product candidates for which we may obtain regulatory approval or the frequency
with which any such product candidate is prescribed or used.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Outside of the United States, the
pricing of pharmaceutical products and medical devices is subject to governmental control in many countries. For example, in the European
Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only
after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost effectiveness
of a particular therapy to currently available therapies or so-called health technology assessments, in order to obtain reimbursement
or pricing approval. Other countries may allow companies to fix their own prices for products, but monitor and control product volumes
and issue guidance to physicians to limit prescriptions. Efforts to control prices and utilization of pharmaceutical products and medical
devices will likely continue as countries attempt to manage healthcare expenditures.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Employees and Human Capital Resources</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">As of December 31, 2024, we had 16
employees / consultants, including 6 with Ph.D. or M.D. degrees and including 11 who are engaged in research and development activities.
We are dependent on our management and scientific personnel, and it is crucial that we continue to attract and retain valuable employees.
To facilitate attraction and retention, we strive to make ourselves an inclusive and safe workplace, with opportunities for our employees
to grow and develop in their careers, supported by strong compensation and benefits programs. None of our employees are represented by
labor unions or covered by collective bargaining agreements.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">82</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Corporate Information and History</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We were incorporated on November
30, 2011, under the laws of the State of Israel. In March 2021, in connection with the Merger, we changed our name from Anchiano Therapeutics
Ltd. to Chemomab Therapeutics Ltd. Our principal executive offices are located at Kiryat Atidim, Building 7, Tel Aviv, Israel 6158002,
and our phone number is +972-77-331-0156. Our website is:&#160;<span style="font-style: italic">www.chemomab.com.</span>&#160;The information
contained on, or that can be accessed through, our website is not incorporated by reference into this Annual Report.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Available Information</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our investor relations website is<span style="font-style: italic">
https://investors.chemomab.com/</span>. We promptly make available on our investor relations website, free of charge, the reports that
we file or furnish with the SEC, corporate governance information (including our Code of Business Conduct and Ethics) and all press releases.
The SEC maintains a website at www.sec.gov that contains reports, proxy and information statements and other information regarding Chemomab
and other issuers that file electronically with the SEC.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Item 4A<span id="Item4A"><!--Anchor--></span>.
Unresolved Staff Comments</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;None.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman; font-weight: bold">Item 5<span id="Item5"><!--Anchor--></span>. Operating
and Financial Review and Prospects</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman; font-style: italic">&#160;You should
read the following discussion together with the consolidated financial statements and related notes included elsewhere in this Annual
Report. The statements contained in this discussion regarding industry outlook, our expectations regarding our future performance, planned
investments in our expansion into additional geographies, research and development, sales and marketing and general and administrative
functions as well as other non-historical statements contained in this discussion are forward-looking statements. These forward-looking
statements are subject to numerous risks and uncertainties, including, but not limited to, the risks and uncertainties described in Item
3.D. entitled &#8220;Risk factors&#8221; and &#8220;Special note regarding forward-looking statements&#8221; included elsewhere in this
Annual Report. Our actual results may differ materially from those contained in or implied by any forward-looking statements.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman; font-weight: bold">Overview</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 35.25pt; line-height: 1.25; font-family: Times New Roman">We are a clinical-stage biotechnology
company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet needs.
Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, we have developed nebokitug,
a monoclonal antibody designed to bind and block CCL24 activity. nebokitug has demonstrated the potential to treat multiple severe and
life-threatening fibrotic and inflammatory diseases.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 35.25pt; line-height: 1.25; font-family: Times New Roman">We have pioneered the therapeutic
targeting of CCL24, a chemokine also known as eotaxin-2, which promotes various types of cellular processes that regulate inflammatory
and fibrotic activities through the CCR3 receptor. CCL24 is expressed in various types of cells, including immune cells, endothelial cells
and epithelial cells. We have developed a novel CCL24 inhibiting product candidate with dual anti-fibrotic and anti-inflammatory activity
that modulates the complex interplay of these inflammatory and fibrotic mechanisms, which drive abnormal states of fibrosis and fibrotic
diseases. This innovative approach is currently being developed for difficult-to-treat rare diseases, also known as orphan indications
or diseases, such as primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc) for which patients have no established disease-modifying
or standard-of-care treatment options. We estimate that there are approximately 77 thousand patients suffering from PSC in the United
States., European Union and Japan, representing a more than $1 billion market opportunity, and approximately 170,000 patients suffering
from SSc in those same markets, representing a more than $1.5 billion market opportunity.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 35.25pt; line-height: 1.25; font-family: Times New Roman">Nebokitug, our lead clinical product
candidate, is a first-in-class humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory
and fibrotic pathways. We have demonstrated that nebokitug interferes with the underlying biology of inflammation and fibrosis through
a novel and differentiated mechanism of action.&#160; We are currently concluding a Phase 2 clinical study of nebokitug in PSC, a rare
obstructive and cholestatic liver disease, with sites in the United States, Europe and Israel. Positive topline results from the double-blinded
and open label portions of this trial were reported in July, 2024 and March 2025, respectively.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">83</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 35.25pt; line-height: 1.25; font-family: Times New Roman">The randomized, placebo-controlled
study design included two doses of nebokitug (10 or 20mg/kg) vs placebo, administered once every three weeks for 15 weeks, as well as
an open label extension in which all eligible patients could receive nebokitug for an additional 33 weeks. In the Phase 2 study, nebokitug
achieved its primary endpoint of safety and tolerability and demonstrated anti-fibrotic, anti-inflammatory and anti-cholestatic effects
across a broad range of disease-related secondary efficacy endpoints, including statistically significant improvements in liver stiffness,
a key PSC disease marker, after just 15-weeks of treatment. Moreover, nebokitug is among the first investigational drugs to show a reduction
in total bilirubin, an important marker of cholestasis and liver health, as well as reductions in pruritus, a cholestatic indicator of
great relevance to patients. Nebokitug is the first investigational drug being developed for PSC to exhibit broad, clinically relevant
effects on all three components of the disease, establishing clinical proof-of-concept and providing further evidence of its multifactorial
mechanism of action and disease-modifying potential.&#160;Data from the open label extension portion of the trial was recently reported
showing continued safety and anti-fibrotic, anti-inflammatory and anti-cholestatic activity of nebokitug over 48 weeks of treatment .
The company had an End of Phase 2 meeting with the FDA in December, 2024 to discuss the Phase 2 SPRING trial results and the path forward
to Phase 3 and potential regulatory approval for PSC. Chemomab and the FDA aligned on the design of a single, clinical-events-driven Phase
3 trial.&#160; If successful in finalizing a strategic partnership or a major financing, Chemomab could initiate this pivotal trial in
PSC before the end of 2025.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 35.25pt; line-height: 1.25; font-family: Times New Roman">The nebokitug SSc clinical program
is Phase 2-ready and we have an open IND in the United States for a Phase 2 clinical trial. However, Chemomab has suspended initiation
of this study while we focus our resources on the nebokitug PSC program.&#160; We believe that nebokitug could have disease-modifying
potential in this poorly treated condition. While our primary focus is on these two rare indications, we previously reported results from
a completed Phase 2a clinical study in patients with liver fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH).&#160;
This trial provided safety and pharmacokinetic (&#8220;PK&#8221;) data and information useful for assessing our current subcutaneous formulation
of nebokitug. Additionally, the trial measured a number of biomarkers that may be relevant to the activity of nebokitug in other fibro-inflammatory
conditions. The results showed that the trial met its primary endpoint of safety and tolerability, and that nebokitug demonstrated consistent
data trends and positive activity across secondary endpoints that included a range of liver fibrosis biomarkers and physiologic assessments.
A secondary analysis, that further confirmed and extended these initial results was reported at the 2023 EASL Congress in June 2023.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 35.25pt; line-height: 1.25; font-family: Times New Roman">Fibrosis is the abnormal and excessive
accumulation of collagen and extracellular matrix, the non-cellular component in all tissues and organs, which provides structural and
biochemical support to surrounding cells. When present in excessive amounts, collagen and extracellular matrix lead to scarring and thickening
of connective tissues, affecting tissue properties and potentially leading to organ dysfunction and failure. Fibrosis can occur in many
different tissues, including lung, liver, kidney, muscle, skin, and the gastrointestinal tract, resulting in a wide array of progressive
fibrotic conditions. Fibrosis and inflammation are intrinsically linked. While a healthy inflammatory response is necessary for efficient
tissue repair; after disease or injury, an excessive, uncontrolled inflammatory response can lead to tissue fibrosis that in turn can
further stimulate inflammatory processes in a fibro-inflammatory vicious cycle.</div>

<div style="text-align: justify; text-indent: 35.25pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">A. Components
of Operating Results</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Revenues</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">To date, we have not generated any
revenue from product sales and do not expect to generate any revenue from product sales in the near future. If development efforts for
our product candidates are successful and result in our receipt of necessary regulatory approvals, or if our development efforts otherwise
lead to any commercialized products or additional license agreements with third parties, then we may generate revenue in the future from
product sales.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">84</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div> <br/>

<div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Research and
Development Expenses, net</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Research and development expenses
consist primarily of costs incurred in connection with the development of our product candidates. These expenses include:</div> </div>
<br/> </div>

<table cellspacing="0" cellpadding="0" id="zc7141f7363444ef4a6ed05b9cdead129" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">expenses incurred under agreements with clinical research organizations and contract
        manufacturing organizations, as well as investigative sites and consultants that conduct our clinical trials, preclinical studies and
        other scientific development services;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf33f5e07b4c848cb97f45d5cbf3e822f" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">manufacturing scale-up expenses and the cost of acquiring and manufacturing preclinical
        and clinical trial materials;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z00b95119b706424aa0ebc42e026c7bc6" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">employee-related expenses, including salaries, related benefits, travel and share-based
        compensation expenses for employees engaged in research and development functions, as well as external costs, such as fees paid to outside
        consultants engaged in such activities;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze441f1fec1a648148ebb9d6564f9a0bc" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">license maintenance fees and milestone fees incurred in connection with various license
        agreements;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze69ba7fc65eb4998aa20b3e50a3d16f3" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">costs related to compliance with regulatory requirements; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb00263eff8b14d2aa3bdd05997b39902" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">depreciation and other expenses.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We recognize external development
costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We do not allocate employee costs
or facility expenses, including depreciation or other indirect costs, to specific programs because these resources are deployed across
multiple programs and, as such, the related costs are not separately classified. We use internal resources primarily to oversee our research,
as well as for managing our preclinical development, process development, manufacturing and clinical development activities. Our employees
work across multiple programs; therefore, we do not track the related expenses by program.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Research and development activities
are fundamental to our business. Product candidates in later stages of clinical development generally have higher development costs than
those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a
result, we expect that our research and development expenses will increase substantially over the next several years as we continue to
advance the development of our product candidates. We also expect to incur additional expenses related to milestone and royalty payments
payable to third parties with whom we have entered into license agreements.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">General and Administrative Expenses</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">General and administrative expenses
consist primarily of salaries and related benefits, share-based compensation expenses for personnel in executive and administrative functions,
insurance and professional fees for legal, consulting, accounting and audit services.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We anticipate that our general and
administrative expenses will increase in the future due to increased headcount and professional fees to support our continued research
activities and development of our product candidates. We also anticipate that we will continue to incur accounting, audit, legal, regulatory,
compliance, director and officer insurance costs, as well as investor and public relations expenses associated with being a public company.
Additionally, once we believe that regulatory approval of a product candidate appears likely, we will begin to incur a material increase
in payroll and related expenses as a result of preparation for commercial operations, particularly in respect of sales and marketing.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Financing Expenses,
Net</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Financing expenses, net consist primarily
of income or expenses related to revaluation of foreign currencies and interest income on our bank deposits.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Results of Operations</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The following table summarizes our
results of operations for the years ended December 31, 2024, 2023 and 2022:</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">85</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<table cellspacing="0" cellpadding="0" class="cfttable" id="z9c4c01d3d6814f2192da5ffc265a21f4" style="font: 10pt Arial; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman; padding-bottom: 2px">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom; font-family: Times New Roman">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Year ended December 31,</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman; padding-bottom: 2px">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom; font-family: Times New Roman">
        <div style="text-align: center; line-height: 1.25; font-weight: bold"> 2024</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom; font-family: Times New Roman">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">2023</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom; font-family: Times New Roman">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">2022</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman; padding-bottom: 2px">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman"><span style="font-style: italic">(in thousands</span>)</div>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Operating Expenses:</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman; width: 64%">
        <div style="text-align: justify; line-height: 1.25">Research and development</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">11,327</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">18,381</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">16,977</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman; width: 64%; padding-bottom: 2px">
        <div style="text-align: justify; line-height: 1.25">General and administrative</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">3,412</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">7,078</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">11,556</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman; width: 64%">
        <div style="text-align: justify; line-height: 1.25">Total operating expenses</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">14,739</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">25,459</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">28,533</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman; width: 64%">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman; width: 64%">
        <div style="text-align: justify; line-height: 1.25">Financing income, net</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(794</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(1,238</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(353</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman; width: 64%">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Loss before taxes</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">13,945</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">24,221</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">28,180</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman; width: 64%; padding-bottom: 2px">
        <div style="text-align: justify; line-height: 1.25">Taxes benefit</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; border-bottom: rgb(0, 0, 0) 2px solid; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; border-bottom: rgb(0, 0, 0) 2px solid; font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; border-bottom: rgb(0, 0, 0) 2px solid; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; border-bottom: rgb(0, 0, 0) 2px solid; font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(534</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%; padding-bottom: 2px">
        <div style="line-height: 1.25">)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman; width: 64%">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman; width: 64%">
        <div style="text-align: justify; line-height: 1.25">Net loss</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">13,945</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">24,221</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">27,646</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our results of operations have varied
in the past and can be expected to vary in the future due to numerous factors. We believe that period-to-period comparisons of our operating
results are not necessarily meaningful and should not be relied upon as indications of future performance.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Year ended December
31, 2024, Compared to the Year Ended December 31, 2023</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">Research and development expenses</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Research and development expenses
decreased by approximately $7.1 million, or 38%, to approximately $11.3 million for the year ended December 31, 2024, compared to approximately
$18.4 million for the year ended December 31, 2023. The decrease resulted due to production for clinical trial done in 2023 and decrease
in clinical related expenses due to completion of phase 2 clinical study in Q3 2024.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">General and administrative expenses</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">General and administrative expenses
decreased by approximately $3.7 million, or 52%, to approximately $3.4 million for the year ended December 31, 2024, compared to approximately
$7.1 million for the year ended December 31, 2023. The decrease was primarily due to a decrease in headcount,&#160;professional fees,&#160;insurance
expenses and share-based compensation.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">Financing&#160; income, net</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Financing income, net, decreased
by approximately $444 thousand, or 36%, to net income of $794 thousand for the year ended December 31, 2024, compared to a net income
of $1,238 thousand for the year ended December 31, 2023. The decrease was primarily due to a reduction in the amount of deposits and cash
and cash equivalents between the periods. Financing income, net for the year ended December 31, 2024, was primarily related to interest
income on deposits offset by foreign currency exchange rate differences.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Year ended December
31, 2023, Compared to the Year Ended December 31, 2022</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">Research and development expenses</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Research and development expenses
increased by approximately $1.4 million, or 8.3%, to approximately $18.4 million for the year ended December 31, 2023, compared to approximately
$17.0 million for the year ended December 31, 2022. The increase resulted primarily from an increase in from a continued&#160;investment
in the clinical programs of the Company.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">86</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">General and administrative expenses</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">General and administrative expenses
decreased by approximately $4.5 million, or 38.8%, to approximately $7.1 million for the year ended December 31, 2023, compared to approximately
$11.6 million for the year ended December 31, 2022. This decrease was primarily due to decrease in headcount and professional fees and
insurance expenses and share-based compensation.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">Financing income, net</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Financing income, net, increased by approximately
$885 thousand, or 251%, to net income of $1,238 thousand for the year ended December 31, 2023, compared to a net income of $353 thousand
for the year ended December 31, 2022. Financing income , net for the year ended December 31, 2023, was primarily related interest income
on deposits offset by foreign currency exchange rate differences.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">Taxes on Income</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The tax benefit in 2022 is related
to a tax return of Chemomab Therapeutics Inc., a wholly owned subsidiary of ours, derived by carryback of net operating losses</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;<span style="font-weight: bold; font-style: italic">Cash Flows</span></div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The following table summarizes our
cash flows for the years ended December 31, 2024, 2023 and 2022:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" class="cfttable" id="z3caae05472c445beb2250962cdbbaf1b" style="font: 10pt Arial; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman; padding-bottom: 2px">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="14" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom; font-family: Times New Roman">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Year ended December 31,</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom; font-family: Times New Roman">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Increase/(decrease)</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman; padding-bottom: 2px">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom; font-family: Times New Roman">
        <div style="text-align: center; line-height: 1.25; font-weight: bold"> 2024</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom; font-family: Times New Roman">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">2023</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom; font-family: Times New Roman">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">2022</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom; font-family: Times New Roman">
        <div style="text-align: center; line-height: 1.25; font-weight: bold"> %</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman; padding-bottom: 2px">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="14" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom; font-family: Times New Roman">
        <div style="text-align: center; line-height: 1.25; font-style: italic">(in thousands)</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman; width: 40%">
        <div style="text-align: justify; line-height: 1.25">Net cash used in operating activities</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(15,386</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(23,611</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(20,370</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">8,225</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">35</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">%</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman; width: 40%">
        <div style="text-align: justify; line-height: 1.25">Net cash provided by&#160; investing activities</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">2,297</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">15,879</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">19,533</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(13,582</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(86</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">)%</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman; width: 40%">
        <div style="text-align: justify; line-height: 1.25">Net cash provided by (used in) financing activities</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">9,868</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">3,504</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(808</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">6,364</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">182</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman; vertical-align: bottom; width: 1%">%</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman; width: 40%">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Net decrease in cash, cash equivalents and restricted cash</div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(3,221</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(4,228</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(1,645</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">1,007</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">24</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Year ended December
31, 2024, Compared to the Year Ended December 31, 2023</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">Operating activities</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Net cash used in operating activities
for the year ended December 31, 2024, was approximately $15 million and included net loss of $13.9 million, and by net cash used by changes
in operating assets and liabilities of approximately $2.1 million offset by non-cash charges of $0.7 million, which mainly included share-based
compensation expenses.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Net cash used in operating activities
for the year ended December 31, 2023, was approximately $23.6 million and included net loss of $24.2 million, partially offset by net
cash used by changes in operating assets and liabilities of approximately $0.9 million and non-cash charges of $1.6 million, which mainly
included share-based compensation expenses.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">87</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="line-height: 1.25; font-style: italic; text-indent: -9pt; margin-left: 9pt">Investing activities</div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Net cash provided by investing activities
for the year ended December 31, 2024, was approximately $2.3 million, due to decrease in short term deposits.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Net cash provided in investing activities
for the year ended December 31, 2023, was $15.9 million, due to decrease in short term deposits.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">Financing activities</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Net cash provided by financing activities
for the year ended December 31, 2024, was approximately $9.9 million due to proceeds from issuance of shares net of issuance costs.</div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Net cash provided by financing activities
for the year ended December 31, 2023, was $3.5 million, consisting of $2.9 million of proceeds from issuance of shares net of issuance
costs , $0.6&#160; of proceeds from the sale of treasury shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Year ended December
31, 2023, Compared to the Year Ended December 31, 2022</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">Operating activities</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Net cash used in operating activities
for the year ended December 31, 2023, was approximately $23.6 million and included net loss of $24.2 million, partially offset by net
cash used by changes in operating assets and liabilities of approximately $0.9 million and non-cash charges of $1.6 million, which mainly
included share-based compensation expenses.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;<br/>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Net cash used in operating activities for the year ended
December 31, 2022 was approximately $20.4 million and included net loss of $27.6 million, partially offset by net cash used by changes
in operating assets and liabilities of approximately $4.0 million and non-cash charges of $3.3 million, which mainly included share-based
compensation expenses.</div> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">Investing activities</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Net cash provided by investing activities
for the year ended December 31, 2023, was $15.9 million, which was primarily related to funds received from bank deposits.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Net cash provided by investing activities
for the year ended December 31, 2022, was approximately $19.5 million, which was primarily related to investment in short-term deposits
offset by purchasing of fixed assets.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;<span style="font-style: italic">Financing activities</span></div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Net cash provided by financing activities
for the year ended December 31, 2023, was approximately $3.5 million, consisting of $2.9 million of proceeds from the sale of ADSs, $0.6&#160;
of proceeds from the sale of treasury shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Net cash used in financing activities for
the year ended December 31, 2022, was approximately $0.8 million, consisting of $0.3 million of proceeds from the sale of ADSs, $0.14
million of proceeds from the exercise of stock options offset by the repurchase of shares in the amount of $1.2 million.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Funding Requirements</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We expect our expenses to increase
substantially as we advance the clinical trials of our product candidate. In addition, we expect to continue to incur additional costs
associated with operating as a public company.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">88</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We believe that our existing cash, cash
equivalents and bank deposits will enable us to fund our operating expenses and capital expenditure requirements through March 31, 2026.
This means that there is a substantial doubt about our ability to continue as a going concern, and that we will be required to raise additional
funds to support our operations and continue as a going concern. While we believe that we can raise additional funds, there can be no
assurance that these efforts will be successful or sufficient. We have based these estimates on assumptions that may prove to be wrong,
and we could expend our capital resources sooner than we expect. If we receive regulatory approval for any of our product candidates,
we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Until such time, if ever, that we
generate product revenue sufficient to achieve profitability, we expect to finance our cash needs through the sales of our securities
and through other outside funding sources. Debt financing and preferred equity financing, if available, may involve agreements that include
covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures
or declaring dividends. If we raise additional funds through government and other third-party funding, collaboration agreements, strategic
alliances, licensing arrangements or marketing and distribution arrangements, then we may have to relinquish valuable rights to our technologies,
future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are
unable to raise additional funds through equity or debt financings when needed, then we may be required to delay, limit, reduce or terminate
our product development or future commercialization efforts or grant rights to develop and market products or product candidates that
we would otherwise prefer to develop and market.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">B. Liquidity
and Capital Resources</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In connection with the Merger, on
March 15, 2021, we entered into Securities Purchase Agreements with certain investors, pursuant to which we agreed to sell approximately
$45.5 million of the ADSs in a private placement transaction (the Private Placement). The Private Placement closed on March 22, 2021,
at which time we sold 2,619,270 ADSs together with warrants to purchase up to 261,929 ADSs at an exercise price of $17.35 per ADS. The
warrants expire five years from the date of issuance, and, if exercised in full, will provide proceeds of approximately $4.5 million.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">On April 30, 2021, we entered into
the Sales Agreement with Cantor Fitzgerald &amp; Co. (Cantor). Pursuant to the Sales Agreement, we may offer and sell, from time to time,
ADSs having an aggregate offering price of up to $75 million through Cantor (the &#8220;Cantor ATM Facility&#8221;). Sales of ADSs, if
any, under the Sales Agreement will be issued and sold pursuant to our Registration Statement on Form S-3 which was declared effective
on May 17, 2021, and will be made in sales deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated
under the Securities Act. &#160;Pursuant to the Sales Agreement, Cantor has agreed to act as sales agent on a best efforts basis and use
commercially reasonable efforts to sell on our behalf all of the ADSs we requested to be sold in accordance with the Sales Agreement,
consistent with Cantor&#8217;s normal trading and sales practices, on mutually agreed terms.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">On April 25, 2022, we filed a prospectus
supplement with the SEC for the issuance and sale of up to $18,125,000 of ADSs in connection with the reactivation of the Cantor ATM Facility
and pursuant to General Instruction I.B.6 of Form S-3, which, subject to certain exceptions, limits the amount of securities we are able
to offer and sell under such registration statement during any twelve month period to one-third of our unaffiliated public float.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In October 2023, we entered into
an At the Market Offering Agreement (the &#8220;Roth ATM Agreement&#8221;) with Roth Capital Partners, LLC, (&#8220;Roth&#8221;). Pursuant
to the Roth ATM Agreement, we may offer and sell, from time to time, our ADSs having an aggregate offering price of up to $2,863,664 through
Roth or the Roth ATM Agreement (the &#8220;Roth ATM Facility&#8221;). Accordingly, in October 2023, we filed a prospectus supplement with
the SEC for the issuance and sale of up to $2,863,664 of our ADSs in connection with the reactivation of the Roth ATM Facility.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">On November 15, 2024, we filed a
prospectus supplement with the SEC for the issuance and sale of up to $8,626,564 of ADSs in connection with the Roth ATM .Facility and
pursuant to General Instruction I.B.6 of Form S-3, which, subject to certain exceptions, limits the amount of securities we are able to
offer and sell under such registration statement during any twelve month period to one-third of our unaffiliated public float.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">89</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">On July 25, 2024, we entered into
a Securities Purchase Agreement with the Purchasers as identified therein, pursuant to which we sold to the Purchasers: (i) 4,148,867
ADSs, at a purchase price of $1.235 per ADS; and (ii), in lieu of ADSs, Pre-Funded Warrants to purchase up to 3,948,300 ADSs at a purchase
price of $ 1.2349 per warrant (the July 2024 Private Placement). The Pre-Funded Warrants will have an exercise price of $0.0001 per ADS,
be immediately exercisable and remain exercisable until exercised in full. The July 2024 Private Placement closed on July 30, 2024, and
we received gross proceeds from the July 2024 Private Placement of approximately $10.0 million before deducting any offering expenses.
On August 23, 2024, we filed a Registration Statement on Form F-3 with the SEC for the issuance and sale of the 8,097,167 of ADSs sold
to the Purchasers in the July 2024 Private Placement.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">During the year ended December 31,
2022,&#160;we&#160;sold 130,505 ADSs at an average price of USD 2.11 per ADS, through the Cantor ATM Facility, resulting in gross proceeds
of $275,000.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; text-indent: 36pt">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif">During the year ended December 31, 2023, we sold 1,800,000ADSs
at an average price of USD 0.96 per ADS, through the Roth ATM Facility, resulting in gross proceeds of USD1.73 million and 772,900 ADSs
at an average price of&#160; USD 1.83 per ADS, through the Cantor ATM Facility, resulting in gross proceeds of approximately USD1.4 million</div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">During the year ended December 31,
2023, we sold 582,023 ADSs which were held in treasury for consideration of approximately $580 thousand.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">During the year ended December 31,
2024, we sold 503,009 ADSs at an average price of USD 1.65 per ADS, through the Roth ATM Facility, resulting in gross proceeds of approximately
$0.8 million shown in the accompanying consolidated financial statements, we have incurred losses and cash flow deficits from operations
since inception, resulting in an accumulated deficit as of December 31, 2024, of $102.6 million. We have financed operations to date primarily
through public and private placements of equity securities. We anticipate that we will continue to incur net losses for the foreseeable
future. We believe that our existing cash, cash equivalents and bank deposits will be sufficient to fund our projected cash needs through
March 31, 2026. To meet future capital needs we would need to raise additional capital through equity or debt financing or other strategic
transactions. However, any such financing may not be available to us on favorable terms or at all. Our failure to obtain sufficient funds
on commercially acceptable terms when needed would have a material adverse effect on our business, results of operations and financial
condition.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Current Outlook</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We estimate that our current liquidity
resources will allow us to execute our business plans through March 31, 2026.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Developing drugs, conducting preclinical
and clinical trials, obtaining commercial manufacturing capabilities and commercializing products is expensive, and we will need to raise
substantial additional funds to achieve our strategic objectives. We will require significant additional financing in the future to fund
our operations, including if and when we progress into clinical trials of our product candidates, obtain regulatory approval for one or
more of our product candidates, obtain commercial manufacturing capabilities and commercialize one or more of our product candidates.
Our future capital requirements will depend on many factors, including, but not limited to:</div>

<div style="line-height: 1.25; font-family: Times New Roman"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z7c433a0002234cdc9359c2c6f5313851" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the progress and costs of our preclinical and clinical trials and other research and
        development activities;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z83784605b8334ce1ae23b6e8ae047c13" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the scope, prioritization and number of our preclinical and clinical trials and other
        research and development programs;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc2d85895c0074e99940cb61185bf5ca0" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the amount of revenues and contributions we receive under future licensing, collaboration,
        development and commercialization arrangements with respect to our product candidates;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd6fa2b853c4942d29430322c3f35f68b" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the costs of development and expansion of our operational infrastructure;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze1f8b27ea0b5492c8ea81fd350efcf2e" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the costs and timing of obtaining regulatory approval for one or more of our product
        candidates;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">90</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">our ability, or that of our collaborators, to achieve development milestones, marketing
        approval and other events or developments under potential future licensing agreements;</div> </td> </tr>
  </table>

<div>&#160;</div> </div>

<table cellspacing="0" cellpadding="0" id="z4bd7248c6ab24074ae5bc31f02102401" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the costs of filing, prosecuting, enforcing and defending patent claims and other
        intellectual property rights;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z84166415399547d7ad8abf90d6071212" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the costs and timing of securing manufacturing arrangements for clinical or commercial
        production;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9f1d18c2cf7c48f1982759d01c0483f1" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the costs of contracting with third parties to provide sales and marketing capabilities
        for us or establishing such capabilities ourselves;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z652d4926bc174724a82ea7321bad807d" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the costs of acquiring or undertaking development and commercialization efforts for
        any future products, product candidates or technology;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc21ae2d8ad354d489750d9d027ba82d1" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the magnitude of our general and administrative expenses; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z11ccc834bc5546ebb581a5d88486a157" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">any additional costs that we may incur under future in- and out-licensing arrangements
        relating to one or more of our product candidates.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Until we can generate significant
recurring revenues, we expect to satisfy our future cash needs through capital raising or by out-licensing and/or co-developing applications
of one or more of our product candidates. We cannot be certain that additional funding will be available to us on acceptable terms, if
at all. If funds are not available, we may be required to delay, reduce the scope of or eliminate research or development plans for, or
commercialization efforts with respect to, one or more of our product candidates and make the necessary change to our operations to reduce
the level of our expenditures in line with available resources.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We are a development-stage company
and it is not possible for us to predict with any degree of accuracy the outcome of our research and development efforts. As such, it
is not possible for us to predict with any degree of accuracy any significant trends, uncertainties, demands, commitments or events that
are reasonably likely to have a material effect on our net loss, liquidity or capital resources, or that would cause financial information
to not necessarily be indicative of future operating results or financial condition. However, to the extent possible, certain trends,
uncertainties, demands, commitments and events are described in this item.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold; font-style: italic">C.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman; font-style: italic">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Research and Development, Patents and Licenses</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">For information concerning our research
and development policies and a description of the amount spent during each of the last three fiscal years on company-sponsored research
and development activities, see &#8220;Item 5. Operating and Financial Review and Prospects&#8212;Results of Operations.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold; font-style: italic">D.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman; font-style: italic">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Trend Information</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Other than as disclosed elsewhere
in this Annual Report, we are not aware of any trends, uncertainties, demands, commitments or events for the period from January 1, 2024
to December 31, 2024 that are reasonably likely to have a material adverse effect on our revenue, profitability, liquidity or capital
resources, or that caused the disclosed financial information to be not necessarily indicative of future operating results or financial
condition.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold; font-style: italic">E.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman; font-style: italic">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Critical Accounting Estimates</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our financial statements are prepared
in accordance with generally accepted accounting principles in the United States (GAAP). The preparation of our financial statements and
related disclosures in accordance with GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities,
revenue, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates
on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the
results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent
from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates
under different assumptions or conditions.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25">Our significant accounting policies are described in more detail in Note 2 to our consolidated
financial statements</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">91</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Item 6<span id="Item6"><!--Anchor--></span>.
Directors, Senior Management and Employees</div>

<div style="line-height: 1.25; font-family: Times New Roman"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z9a97654c8e514da0a1d978ff2987d339" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">A.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Directors and Senior Management</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;The following table sets
forth the name and position of each of our executive officers and directors as of March 31, 2025:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z231ecae2cd4e4e1a9516aa82090b180d" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 30.04%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Name</div> </td>
    <td style="width: 0.64%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 4.32%; vertical-align: bottom; font-family: Times New Roman">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Age</div> </td>
    <td style="white-space: nowrap; width: 0.64%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 64.36%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Position</div> </td> </tr>
  <tr>
    <td style="width: 30.04%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-style: italic">Executive Officers:</div> </td>
    <td style="width: 0.64%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 4.32%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td style="white-space: nowrap; width: 0.64%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 64.36%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#160;&#160;</div> </td> </tr>
  <tr>
    <td style="width: 30.04%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Adi Mor</div> </td>
    <td style="width: 0.64%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 4.32%; vertical-align: bottom; font-family: Times New Roman">
        <div style="text-align: center; line-height: 1.25">43</div> </td>
    <td style="white-space: nowrap; width: 0.64%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 64.36%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Director, Chief Executive Officer and Chief Scientific Officer</div> </td> </tr>
  <tr>
    <td style="width: 30.04%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Sigal Fattal&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td>
    <td style="width: 0.64%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 4.32%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: center; line-height: 1.25">54</div> </td>
    <td style="white-space: nowrap; width: 0.64%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 64.36%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Chief Financial Officer</div> </td> </tr>
  <tr>
    <td style="width: 30.04%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Matthew Frankel</div> </td>
    <td style="width: 0.64%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 4.32%; vertical-align: bottom; font-family: Times New Roman">
        <div style="text-align: center; line-height: 1.25">56</div> </td>
    <td style="white-space: nowrap; width: 0.64%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 64.36%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Chief Medical Officer</div> </td> </tr>
  <tr>
    <td style="width: 30.04%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-style: italic">Non-Employee Directors:</div> </td>
    <td style="width: 0.64%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 4.32%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 0.64%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 64.36%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 30.04%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">Nissim Darvish&#8224;(2)(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td>
    <td style="width: 0.64%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 4.32%; vertical-align: bottom; font-family: Times New Roman">
        <div style="text-align: center; line-height: 1.25">59</div> </td>
    <td style="white-space: nowrap; width: 0.64%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 64.36%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Chairman of the Board</div> </td> </tr>
  <tr>
    <td style="width: 30.04%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Alan Moses&#8224;(1)</div> </td>
    <td style="width: 0.64%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 4.32%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: center; line-height: 1.25">76</div> </td>
    <td style="white-space: nowrap; width: 0.64%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 64.36%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Director</div> </td> </tr>
  <tr>
    <td style="width: 30.04%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Claude Nicaise&#8224;(1)</div> </td>
    <td style="width: 0.64%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 4.32%; vertical-align: bottom; font-family: Times New Roman">
        <div style="text-align: center; line-height: 1.25">71</div> </td>
    <td style="white-space: nowrap; width: 0.64%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 64.36%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Director</div> </td> </tr>
  <tr>
    <td style="width: 30.04%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Neil Cohen&#8224;(2)(3)</div> </td>
    <td style="width: 0.64%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 4.32%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: center; line-height: 1.25">60</div> </td>
    <td style="white-space: nowrap; width: 0.64%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 64.36%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Director</div> </td> </tr>
  <tr>
    <td style="width: 30.04%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Jill Quigley&#8224;(1)</div> </td>
    <td style="width: 0.64%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 4.32%; vertical-align: bottom; font-family: Times New Roman">
        <div style="text-align: center; line-height: 1.25">49</div> </td>
    <td style="white-space: nowrap; width: 0.64%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 64.36%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Director</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;<br/> &#8224; Independent Director</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb9f3139e8c6043eeb28e6d0ea01a3fd7" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">(1)</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Member of Audit Committee</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">(2)</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Member of Compensation Committee</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">(3)</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Member of Corporate Governance and Nominating Committee</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Executive Officers</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><span style="font-style: italic">Dr.
Adi Mor </span>is the co-founder of Chemomab Ltd., the wholly-owned subsidiary of the Company, and served as Chemomab Ltd.&#8217;s Chief
Executive Officer, Chief Scientific Officer and a member of Chemomab Ltd.&#8217;s board of directors from its formation in 2011 until
the Chemomab Ltd.&#8211;- Anchiano Therapeutics Ltd. merger that was consummated on March 16, 2021 (the &#8220;Merger&#8221;). Dr. Mor
previously served as Chief Executive Officer of the Company through October 25, 2021. Dr. Mor has in-depth knowledge in immunology focusing
on rare diseases and broad experience in designing, developing and patenting a novel class of monoclonal antibodies to treat inflammatory
and fibrotic diseases. Dr. Mor received her Ph.D. in immunology from Tel Aviv University in the Department of Neurobiochemistry in Israel
and is the lead author of numerous scientific journal publications regarding immunology and inflammatory disorders.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><span style="font-style: italic">Sigal
Fattal</span> previously served as Chemomab Ltd.&#8217;s interim Chief Financial Officer from October 2020 until the Merger and continued
in that capacity for the Company following the Merger until November 8, 2021, following which she became the Company&#8217;s VP of Finance.
Prior to joining Chemomab Ltd., from March 2017 to December 2019, Ms. Fattal served as Chief Financial Officer at BiomX (NYSE American:
PHGE), a clinical stage microbiome product discovery company. Prior to joining BiomX, Ms. Fattal served as Chief Financial Officer at
Evogene (Nasdaq and TASE: EVGN), a computational biology company, from 2013 to 2016. Prior to that time, Ms. Fattal served in multiple
financial and operational executive roles in various companies. Ms. Fattal also currently serves as co-founder of Simbiz, which was founded
in September 2020 and which offers one-stop-shop corporate services to startup companies. Ms. Fattal is a certified CPA (Isr.), and holds
a BA in Accounting and Economics, and an MBA, both from Tel Aviv University.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">92</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><span style="font-style: italic">Dr.
Matthew B. Frankel</span> has 20 years of experience in the pharmaceutical industry, encompassing clinical development and medical affairs.
From 2018 until November 2022, Dr. Frankel served as Vice President, Clinical Development and Medical Affairs, Specialty Pharma at Boehringer-Ingelheim
Pharmaceuticals, Inc. Prior to that, he served as the Vice President &amp; Head, Immunology and Dermatology Medical Unit at Novartis Pharmaceuticals
Corporation from 2016 to 2018. From 2012 to 2016, Dr. Frankel served as the Executive Medical Director of Sandoz and from 2010 through
2012 held the role of Global Medical Director, Clinical Development at Reata Pharmaceuticals (RETA). From 2003 through 2010, he held various
senior roles across different companies in the research field. Dr. Frankel received his undergraduate degree from Vassar College, his
MD from the University of California, Los Angeles School of Medicine, and his MBA from the J. L. Kellogg Graduate School of Management.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Directors</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 30.7pt; line-height: 1.25; font-family: Times New Roman"><span style="font-style: italic">Nissim
Darvish</span>, M.D., Ph.D. has served on our Board since March 16, 2021 and as chairman of the Board since June 2023. Dr. Darvish is
a General Partner at Eliraz Ventures, a venture capital fund. Dr. Darvish currently serves as a director of several private companies.
Prior to his current position, Dr. Darvish served as a Venture Partner at OrbiMed Israel and as a member of the boards of directors of
9 Meters Biopharma Inc. and Medigus Ltd. Previously, Dr. Darvish was employed at Pitango Venture Capital, where he was a General Partner
managing life sciences investments. He was also the founder and CEO of Impulse Dynamics, where he oversaw a $250 million realization event.
Dr. Darvish obtained his M.D. and Ph.D. in Biophysics and Physiology from the Technion in Israel, and subsequently conducted his post-doctoral
research at NIH. He has published over 100 patents and authored over 20 publications.</div>

<div style="text-align: justify; text-indent: 30.7pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; text-indent: 30.7pt; line-height: 1.25; font-family: Times New Roman"><span style="font-style: italic">Alan
Moses, MD, FACP</span> has served on our Board since March 16, 2021. Dr. Moses is board certified by the ABIM with subspecialty certification
in Endocrinology and Metabolism and is a Fellow of the American College of Physicians.&#160; Dr. Moses serves as a Director for BiomX/APT
Inc.&#160; He also serves as Chair of the Board of Trustees of The diaTribe Foundation, a nonprofit located in San Francisco and as a
member of the Board of Trustees of the Joslin Diabetes Center. Prior to that time, from 2008 to 2018, Dr. Moses served as the Global Chief
Medical Officer of Novo Nordisk A/S (CPH: NOVO-B), a company he joined in 2004. Dr. Moses served as a Professor of Medicine at Harvard
Medical School from 2002 to 2006, and in collaboration with MIT, he co-founded and co-directed the Clinical Investigator Training Program,
which focused on training physician-scientists in translational research. Dr. Moses previously served as the Senior Vice President and
Chief Medical Officer of the Joslin Diabetes Center from 1998 to 2004. Dr. Moses holds a BS from Duke University, North Carolina and an
MD from Washington University School of Medicine, Missouri. He received additional postgraduate training at the National Institutes of
Health and completed his endocrinology Fellowship at Tufts-New England Medical Center.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><span style="font-style: italic">Claude
Nicaise, MD</span>&#160;has served on our Board since March 16, 2021. Dr. Nicaise is a physician with extensive U.S. and international
experience in clinical drug development, strategic management, worldwide regulatory strategy, pharmaceuticals, biotechnology, including
clinical cancer research, infectious diseases and neuroscience. Dr. Nicaise is the owner and founder of Clinical Regulatory Services,
which provides consulting services to the life science and biotechnology industry in support of all aspects of clinical and regulatory
development. Since 2015, Dr. Nicaise has served on the board of directors and as the Chairman of the Compensation Committee of Sarepta
Therapeutics, Inc. (NASDAQ: SRPT). Dr Nicaise has also served on the board of directors of Mynoryx Therapeutics since 2017. Prior to that
time, from 2008 to 2014, Dr. Nicaise served as the Senior Vice President of Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), and between 1984
and 2008, he held numerous senior management roles at Bristol Myers Squibb (NYSE: BMY). Dr. Nicaise holds an MD and a degree in Internal
Medicine, Clinical Oncology, from Brussels University, Belgium.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">93</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><span style="font-style: italic">Neil
Cohen</span>&#160;has served as a member of our Board since April 2020 and served as our interim Chief Executive Officer from October
2020 until the consummation of the Merger. Mr. Cohen has served as the Chairman and Chief Executive Officer of Castel Partners Ltd. since
January 2012. In 1994, he co-founded Israel Seed Partners, a leading venture capital firm, and managed the firm until 2019. Mr. Cohen
has invested in and served on the boards of directors of many private technology companies, including a large number which were acquired
or completed successful initial public offerings, including Compugen (Nasdaq: CGEN), Shopping.com (Nasdaq: SHOP, acquired by EBAY), Broadlight
(acquired by Broadcom, Nasdaq: AVGO) and Cyota (acquired by RSA). He is a venture partner at SKY, an Israeli middle-market private equity
firm, Hetz Ventures Management Ltd., an early-stage Israeli venture capital fund, and Shavit Capital. Mr. Cohen was previously the Business
Editor of The Jerusalem Post and began his career in the private equity group at N M Rothschild &amp; Sons Limited in London. Mr. Cohen
received a B.A. and M.A. in Oriental Studies, with first class honors, from Oxford University.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><span style="font-style: italic">Jill
M. Quigley</span> has served as a member of our Board since June 2022. Since September 2023 Ms. Quigley serves as CEO of a stealth biotech
company. Since December 2020, Ms. Quigley has served as a member of the board of directors of Terns Pharmaceuticals, Inc. (Nasdaq: TERN),
including her role as chairperson of its audit committee. From November 2018 until December 2021, Ms. Quigley served as Chief Operating
Officer of Passage BIO, Inc. (Nasdaq: PASG). Previously, she served as the Interim Chief Executive Officer and General Counsel of Nutrinia,
Inc., from January 2016 to November 2018. From July 2012 to January 2016, Ms. Quigley served in various roles at Shire plc, most recently
as Senior Legal Counsel. Ms. Quigley received her undergraduate degree in Communications, Legal Institutions, Economics &amp; Governance
(CLEG) from American University and J.D. from Rutgers School of Law.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;&#160;&#160;&#160;&#160; <br/> </div>

<table cellspacing="0" cellpadding="0" id="z6cdc2aae8f0c4c21a982dfc7db0a9682" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">B<span id="B"><!--Anchor--></span>.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Compensation</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 27pt; line-height: 1.25; font-family: Times New Roman"><span style="font-style: italic">&#160;&#160;
Directors.</span> Under the Companies Law, the compensation of our directors requires the approval of our compensation committee, the
subsequent approval of the board of directors and, unless exempted under regulations promulgated under the Companies Law, the approval
of the shareholders at a general meeting. If the compensation of our directors is inconsistent with our stated compensation policy, then,
those provisions that must be included in the compensation policy according to the Companies Law must have been considered by the compensation
committee and board of directors, and shareholder approval by a simple majority will also be required, provided that:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2360b5f6a8ae48c38e4922c168b3f016" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">at least a majority of the shares held by all shareholders who are not controlling
        shareholders and do not have a personal interest in such matter, present and voting at such meeting, are voted in favor of the compensation
        package, excluding abstentions; or</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the total number of shares of non-controlling shareholders and shareholders who do
        not have a personal interest in such matter voting against the compensation package does not exceed two percent (2%) of the aggregate
        voting rights in the Company.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 27pt; line-height: 1.25; font-family: Times New Roman"><span style="font-style: italic">&#160;&#160;&#160;
Executive Officers other than the Chief Executive Officer</span>. The Companies Law requires the approval of the compensation of a public
company&#8217;s executive officers (other than the chief executive officer) in the following order: (1) the compensation committee, (2)
the company&#8217;s board of directors, and (3) if such compensation arrangement is inconsistent with the company&#8217;s stated compensation
policy, the company&#8217;s shareholders (by a special majority vote as discussed above with respect to the approval of director compensation).
However, if the shareholders of the company do not approve a compensation arrangement with such executive officer that is inconsistent
with the company&#8217;s stated compensation policy, the compensation committee and board of directors may override the shareholders&#8217;
decision if each of the compensation committee and the board of directors provide detailed reasons for their decision.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">An amendment to an existing arrangement
with an office holder (who is not a director) requires only the approval of the compensation committee, if the compensation committee
determines that the amendment is not material in comparison to the existing arrangement. However, under the Companies Law, an amendment
to an existing arrangement with an office holder (who is not a director) who is subordinate to the chief executive officer will not require
the approval of the compensation committee, if (1) the amendment is approved by the chief executive officer, (2) the company&#8217;s compensation
policy provides that a non-material amendment to the terms of service of an office holder (other than the chief executive officer) may
be approved by the chief executive officer and (3) the engagement terms are consistent with the company&#8217;s compensation policy.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">94</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><span style="font-style: italic">Chief
Executive Officer</span>. Under the Companies Law, the compensation of a public company&#8217;s chief executive officer is required to
be approved by: (1) the company&#8217;s compensation committee; (2) the company&#8217;s board of directors, and (3) the company&#8217;s
shareholders (by a special majority vote as discussed above with respect to the approval of director compensation). However, if the shareholders
of the company do not approve the compensation arrangement with the chief executive officer, the compensation committee and board of directors
may override the shareholders&#8217; decision if each of the compensation committee and the board of directors provide detailed reasons
for their decision. The approval of each of the compensation committee and the board of directors should be in accordance with the company&#8217;s
stated compensation policy; however, in special circumstances, they may approve compensation terms of a chief executive officer that are
inconsistent with such policy provided that they have considered those provisions that must be included in the compensation policy according
to the Companies Law and that shareholder approval is obtained (by a special majority vote as discussed above with respect to the approval
of director compensation). In addition, the compensation committee may waive the shareholder approval requirement with regards to the
approval of the engagement terms of a candidate for the chief executive officer position, if they determine that the compensation arrangement
is consistent with the company&#8217;s compensation policy and that the chief executive officer candidate did not have a prior business
relationship with the company or a controlling shareholder of the company and that subjecting the approval of the engagement to a shareholder
vote would impede the company&#8217;s ability to employ the chief executive officer candidate.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Compensation of Directors and Executive
Officers</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;The aggregate compensation paid
by us and our subsidiaries to our directors and executive officers, including share-based compensation expenses recorded in our financial
statements, for the year ended December 31, 2024, was approximately $2.5 million (including $0.4 million in share-based compensation).
This amount includes deferred or contingent compensation accrued for such year (and excludes deferred or contingent amounts accrued for
during the year ended December 31, 2023 and paid during the year ended December 31, 2024). This amount includes&#160; amounts set aside
or accrued to provide pension, severance, retirement or similar benefits or expenses, but does not include business travel, relocation,
professional and business association dues and expenses reimbursed to our directors and executive officers.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;During the year ended December 31,
2024, our directors and officers were granted options to purchase an aggregate of 1,645,020&#160; ordinary shares (equal to 82,251 ADSs),&#160;
at a weighted average exercise price of $0.037 per share (equal to approximately $0.7 per ADS). In addition, 4,363,580 restricted ordinary
shares (equal to 218,179 restricted ADSs) were granted to executive officers of the Company.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;The following is a summary of the
salary expenses, bonus and social benefit costs of our three executive officers in 2024, or the &#8220;Covered Executives&#8221;. All
amounts reported reflect the cost to us as recognized in our financial statements for the year ended December 31, 2024.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc8e514826b0d4a4aa555f5e53bdafdc1" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Adi Mor, <span style="font-style: italic">Chief Executive Officer, Chief Scientific
        Officer and Director</span>. Compensation expenses recorded in 2024 were $0.7 million in salary expenses.</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">Sigal Fattal, <span style="font-style: italic">Chief Financial Officer</span>. Compensation expenses recorded
        in 2024 were $0.5 million in salary expenses.</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">Matthew Frankel, <span style="font-style: italic">Chief Medical Officer</span>. Compensation expenses recorded
        in 2024 were $0.7 million in salary expenses and $77 thousand in social benefits.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;The salary expenses summarized
above include the gross salary paid to the Covered Executives, severance and bonus.&#160;The benefit costs include the social benefits
paid by us on behalf of the Covered Executives, contributions made by us to an insurance policy, pension fund or 401(K) fund.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;We also recorded equity-based
compensation expenses in our financial statements for the year ended December 31, 2024, of $0.6 million.</div>

<div style="text-align: justify; text-indent: 9pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman">&#160;All equity-based compensation
grants to our Covered Executives were made in accordance with the parameters of our compensation policy and were approved by our compensation
committee and board of directors. Assumptions and key variables used in the calculation of such amounts are described in Note 8 to our
audited consolidated financial statements included in Item 18 of this Annual Report.<br/> &#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">95</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 27pt; line-height: 1.25; font-family: Times New Roman">&#160;&#160;&#160; Additionally,
we annually pay to each of our non-employee directors a cash retainer of $40,000 (or $65,000 for the Chairperson) with an additional annual
payment for service on board committees as follows: $15,500 for the chairperson of the audit committee and $7,625 for the other committee
members. $11,000 for the chairperson of the compensation committee and $5,500 for the other committee members. $9,000 for the chairperson
of the corporate governance and nominating committee or any other board committee and $4,500 for the other committee members.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;In addition, upon election,
non-employee directors (other than the Chairperson), will be granted equity awards equal to 0.1% of our share capital on a fully diluted
basis, under our incentive plan, which will vest on a monthly basis over a period of three years. In addition, each non-employee director
will be granted equity awards under our incentive plan (provided the director is still in office) equal to 0.06% of our share capital
on a fully diluted basis, which will vest on the first anniversary of the date on which such options were granted, subject to such director&#8217;s
continued service through such date.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The non-employee Chairperson, on
election, will be granted an equity award equal to 0.2% of our share capital on a fully diluted basis, under our incentive plan, which
will vest on a monthly basis over a period of three years. In addition, the non-employee Chairperson will be granted equity awards under
our incentive plan (provided the Chairperson is still in office) equal to 0.1% of our share capital on a fully diluted basis, which will
vest on the first anniversary of the date on which such options were granted, subject to such Chairperson continued service through such
date.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman; font-weight: bold">Equity Incentive Plans</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We maintain (i) the 2011 Share Option Plan
(the &#8220;2011 Plan&#8221;), (ii) the 2017 Plan and (iii) the 2015 Plan, which was assumed by our company from the Subsidiary upon the
effectiveness of the Merger. At that time, outstanding options under the 2015 Plan became exercisable for such number of ADSs of our company
(formerly known as Anchiano Therapeutics Ltd.) as was determined based on the exchange ratio in the Merger Agreement, with a reciprocal
adjustment to exercise price. As of December 31, 2024, a total of 1,422,153 ADSs were reserved for issuance under the 2015 Plan, of which
172,276&#160; ADSs had been issued pursuant to previous exercises options, and 456,745 ADSs&#160;were issuable under outstanding options.
Of such outstanding options, options to purchase 333,869 ADSs had vested and were exercisable as of that date, with a weighted average
exercise price of $$6.17 per ADS.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">As of December 31, 2024, a total
of 1,153,069 of ADSs were reserved for issuance under the 2017 Plan, of which&#160;1,145,770 ADSs&#160;were issuable under outstanding
options. Of such outstanding options, options to purchase 573,013 ADSs had vested and were exercisable as of that date, with a weighted
average exercise price of $2.63 per ADS. No ADSs had been issued pursuant to previous exercises options.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">2011 Plan</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">On December 19, 2011, our board of
directors adopted the 2011 Plan to allocate options to purchase our ordinary shares to our directors, officers, employees and consultants,
and those of our affiliated companies (as such term is defined under the 2011 Plan), or the Grantees. The 2011 Plan is administered by
our board of directors or a committee that was designated by our board of directors for such purpose (the &#8220;Administrator&#8221;).</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">96</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Under the 2011 Plan, we may grant
options to purchase ordinary shares (&#8220;Options&#8221;), under four tracks: (i) Approved 102 capital gains Options through a trustee,
which was approved by the Israeli Tax Authority in accordance with Section 102(a) of the Israeli Income Tax Ordinance (&#8220;ITO&#8221;),
and granted under the tax track set forth in Section 102(b)(2) of the ITO, or the Approved 102 Capital Gains Options. The holding period
under this tax track is 24 months from the date of allocation of Options to the trustee or such period as may be determined in any amendment
of Section 102 of the ITO, or any applicable tax ruling or guidelines; (ii) Approved 102 Earned Income Options through a trustee, granted
under the tax track set forth is Section 102(b)(1) of the ITO, or the Approved 102 Earned Income Options. The holding period under this
tax track is 12 months from the date of allocation of Options to the trustee or such period as may be determined in any amendment of Section
102 of the ITO; (iii) Unapproved 102 Options (the Options will not be allocated through a trustee and will not be subject to a holding
period), or the Unapproved 102 Options; and (iv) 3(i) Options (the Options will not be subject to a holding period). These Options shall
be subject to taxation pursuant to Section 3(i) of the ITO, or Section 3(i).</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Options pursuant to the first three
tax tracks (under Section 102 of the ITO) can be granted to our employees and directors and the grant of Options under Section 3(i) can
be granted to our consultants and controlling shareholders (a controlling shareholder is defined under the Section 102 of the ITO is a
person who holds, directly or indirectly, alone or together with a &#8220;relative,&#8221; (i) the right to at least 10% of the company&#8217;s
issued capital or 10% of the voting power; (ii) the right to hold at least 10% of the company&#8217;s issued capital or 10% of the voting
power, or the right to purchase such rights; (iii) the right to receive at least 10% of the company&#8217;s profits; or (iv) the right
to appoint a company&#8217;s director). Grantees who are not Israeli residents may be granted options that are subject to the applicable
tax laws in their respective jurisdictions.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We determine, in our sole discretion,
under which of the first three tax tracks above the Options are granted and we notify the Grantee in a grant letter, as to the elected
tax track. As mentioned above, consultants and controlling shareholders can only be granted Section 3(i) Options.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The number of ordinary shares authorized
to be issued under the 2011 Plan will be proportionately adjusted for any increase or decrease in the number of ordinary shares issued
as a result of a distribution of bonus shares, change in our capitalization (split, combination, reclassification of the shares or other
capital change), or issuance of rights to purchase ordinary shares or payment of a dividend. We will not allocate fractions of ordinary
shares and the number of ordinary shares shall be rounded up to the closest number of ordinary shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Unless otherwise determined by the
Administrator, the exercise price of an Option granted under the 2011 Plan will be the average of the market price of our ordinary shares
during the 22 business days prior to the date on which our board of directors authorized the grant of Options; provided, however, that
such exercise price cannot be lower than the market price at the close of the trading day at which it was granted by our board of directors.
The exercise price will be specified in the grant letter every Grantee received from us in which the Grantee notifies of the decision
to grant him/her Options under the 2011 Plan.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Unless otherwise determined by the
Administrator, the Options granted under the 2011 Plan will become vested and may be exercised in 16 equal portions of 6.25% of the total
number of Options, at the end of each quarter following the day the Options were granted. Unless otherwise determined by our board of
directors, the Options may be exercised for ten years following the date of grant, unless terminated earlier, and as long as the Grantee
is employed by us (or by an affiliated company), or provides service to us (or an affiliated company).</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The Administrator may, in its absolute
discretion, accelerate the time at which Options granted under the 2011 Plan or any portion of which will vest.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Unless otherwise determined by the
Administrator, in the event that the Grantee&#8217;s employment was terminated, not for Cause (as defined in the 2011 Plan), the Grantee
may exercise that portion of the Options that had vested as of the date of such termination until the end of the specified term in the
grant letter or the 2011 Plan. The portion of the Options that had not vested at such date, will be forfeited and can be re-granted according
to the terms of the 2011 Plan.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">2015 Plan</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In November 2015, the Subsidiary&#8217;s
board of directors adopted, and its shareholders subsequently approved, the 2015 Plan. The 2015 Plan provides for the grant of options,
restricted shares, restricted share units and other share-based awards to the Subsidiary&#8217;s (following the Merger, the Company&#8217;s)
and its subsidiaries&#8217; and affiliates&#8217; directors, employees, officers, consultants, advisors, and any other person whose services
are considered valuable to us or our affiliates. Any such grants are intended to incentivize the foregoing persons to continue as service
providers, to increase their efforts on our behalf or on behalf of our subsidiaries or affiliates, and to promote the success of our business.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">97</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The 2015 Plan is administered by
our board of directors or by a committee designated by the board of directors, which determines, subject to Israeli law, the grantees
of awards and the terms of the grant, including, exercise prices, vesting schedules, acceleration of vesting and the other matters necessary
in the administration of the 2015 Plan. The 2015 Plan enables us to issue awards under various tax regimes, including, without limitation,
pursuant to Section 102 of the Israeli Income Tax Ordinance, or the Ordinance, and under Section 3(i) of the Ordinance and Section 422
of the United States Internal Revenue Code of 1986, as amended, or the Code.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The 2015 Plan provides that options
granted to our employees, directors and officers who are not controlling shareholders and who are considered Israeli residents are intended
to qualify for special tax treatment under the &#8220;capital gain track&#8221; provisions of Section 102(b) of the Ordinance. Our Israeli
non-employee service providers and controlling shareholders may only be granted options under Section 3(i) of the Ordinance, which does
not provide for similar tax benefits.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Options granted under the 2015 Plan
to U.S. residents may qualify as &#8220;incentive stock options&#8221; within the meaning of Section 422 of the Code, or may be non-qualified.
The exercise price for &#8220;incentive stock options&#8221; must not be less than the fair market value on the date on which an option
is granted, or 110% of the fair market value if the option holder holds more than 10% of our share capital.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Options and other awards granted
under the 2015 Plan generally vest over four years commencing on the date of grant, such that 25% vests on the first anniversary of the
date of grant and an additional 6.25% vests at the end of each subsequent calendar quarter over the course of the next three years, provided
that the participant remains continuously employed or engaged by us.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Options, other than certain incentive
share options, that are not exercised within ten years from the grant date expire, unless otherwise determined by our board of directors
or our designated committee, as applicable. Share options that qualify as &#8220;incentive stock options&#8221; and are granted to a person
holding more than 10% of our voting power will expire within five years from the date of the grant. In the event of the death of a grantee
while employed by or performing service for us or our subsidiary or within three months after the date of the employee&#8217;s termination,
or the termination of a grantee&#8217;s employment or services for reasons of disability, the grantee, or in the case of death, his or
her legal successor, may exercise options or other awards that have vested prior to termination within a period of one year from the date
of disability or death. If we terminate a grantee&#8217;s employment or service for cause, all of the grantee&#8217;s vested and unvested
options or other awards will expire on the date of termination. If a grantee&#8217;s employment or service is terminated for any other
reason, the grantee may generally exercise his or her vested options or other award within three months of the date of termination. Any
expired or unvested options return to the pool and become available for reissuance. From time to time, we may consider issuing options
with slightly different terms or accelerating, extending or otherwise modifying options in accordance with applicable law and regulation
and the terms of the 2015 Plan.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In the event of a merger or consolidation,
or a sale of all, or substantially all, of our shares or assets or other transaction having a similar effect on us, then without the consent
of the option holder, our board of directors or our designated committee, as applicable, may, but is not required, to (i) cause any outstanding
award to be assumed or an equivalent award to be substituted by such successor corporation, or (ii) in case the successor corporation
does not assume or substitute the award (a) provide the grantee with the option to exercise the award as to all or part of the shares
or (b) cancel the options and pay in cash an amount determined by the board of directors or the committee as fair in the circumstances.
Notwithstanding the foregoing, our board of directors or our designated committee may upon such event amend, modify or terminate the terms
of any award, including conferring the right to purchase any other security or asset that the board of directors or the committee shall
deem, in good faith, appropriate.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The 2015 plan was assumed by our
company from the Subsidiary upon the effectiveness of the Merger.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">2017 Plan</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">On February 22, 2017, our board of
directors adopted the 2017 Plan to allocate a variety of share-based awards to our directors, officers, employees, consultants, advisors
and service providers, and those of our affiliates (companies that control us, are controlled by us or are under common control with us)
(the &#8220;Participants&#8221;). The 2017 Plan is currently administered by our board of directors and may be administered by a committee
designated by our board of directors for such purpose.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">98</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Under the 2017 Plan, we may grant
options to purchase ordinary shares or ADSs, restricted shares or ADSs, restricted share units and other awards based on our ordinary
shares, all of which are referred to as Awards. We may grant Awards under the same four tracks as described above with respect to the
2011 Plan, subject to the same conditions as apply for the 2011 Plan. In addition, we may grant incentive stock options and nonqualified
stock options to Participants who are residents of the United States, and we may grant awards to Participants who are residents of other
countries that comply with the laws of those jurisdictions.<br/> &#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The number of ordinary shares authorized
to be issued under the 2017 Plan will be proportionately adjusted for any increase or decrease in the number of ordinary shares issued
as a result of a distribution of bonus shares, change in our capitalization (split, combination, reclassification of the shares or other
capital change), issuance of rights to purchase ordinary shares or payment of a dividend. We will not allocate fractions of ordinary shares
and the number of ordinary shares shall be rounded down to the closest number of ordinary shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze0e15d041b854949b1764924f97c7c38" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">C.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Board Practices</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Corporate Governance Practices</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">As an Israeli company, we are subject
to various corporate governance requirements under the Companies Law. However, pursuant to regulations promulgated under the Companies
Law, companies with securities traded on certain U.S. stock exchanges, including Nasdaq, may, subject to certain conditions, &#8220;opt
out&#8221; from the Companies Law requirements to appoint external directors and related Companies Law rules concerning the composition
of the audit committee and compensation committee of the board of directors (other than the gender diversification rule under the Companies
Law, which requires the appointment of a director from the other gender if at the time a director is appointed all members of the board
of directors are of the same gender). In accordance with these regulations, we elected to &#8220;opt out&#8221; from those requirements
of the Companies Law. Under these regulations, the exemptions from such Companies Law requirements will continue to be available to us
so long as: (i) we do not have a &#8220;controlling shareholder&#8221; (as such term is defined under the Companies Law), (ii) our ADSs
are traded on a U.S. stock exchange, Nasdaq, and (iii) we comply with the director independence requirements and the audit committee and
compensation committee composition requirements under U.S. laws (including applicable rules of Nasdaq) applicable to U.S. domestic issuers.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We are a &#8220;foreign private issuer&#8221;
(as such term is defined in Rule 3b-4 under the Exchange Act). As a foreign private issuer, we are permitted to comply with Israeli corporate
governance practices instead of the corporate governance rules of Nasdaq, provided that we disclose which requirements we are not following
and the equivalent Israeli requirement. We rely on this &#8220;foreign private issuer exemption&#8221; with respect to the following:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z754a174e34e242578b0c362a1611cfcc" style="font: 10pt Arial; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman"><br/> </td>
    <td style="width: 36pt; vertical-align: top; font-family: Times New Roman">(i)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div style="font-family: Times New Roman"><span style="font-style: italic">Quorum for Shareholder Meetings</span>. Whereas under the corporate
        governance rules of Nasdaq, a quorum requires the presence, in person or by proxy, of holders of at least 33 1/3% of the total issued
        and outstanding voting power of our shares at each general meeting of shareholders, pursuant to the Articles, and as permitted under the
        Companies Law, the quorum required for a general meeting of shareholders will consist of at least two shareholders present in person or
        by proxy in accordance with the Companies Law who hold or represent at least 33 1/3% of the total outstanding voting power of our shares,
        except if (i) any such general meeting of shareholders was initiated by and convened pursuant to a resolution adopted by the board of
        directors and (ii) at the time of such general meeting, we qualify as a &#8220;foreign private issuer,&#8221; then in such case, the requisite
        quorum will consist of two or more shareholders present in person or by proxy who hold or represent at least 25% of the total outstanding
        voting power of our shares (and if the meeting is adjourned for a lack of quorum, the quorum for such adjourned meeting will be, subject
        to certain exceptions, any number of shareholders).</div> </td> </tr>
  </table>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">99</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="ze445ad782df4440287595b71ee6f9eee" style="font: 10pt Arial; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman"><br/> </td>
    <td style="width: 36pt; vertical-align: top; font-family: Times New Roman">(ii)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div style="font-family: Times New Roman"><span style="font-style: italic">Shareholder approval</span>. We do not intend to follow Nasdaq
        Stock Market rules which require shareholder approval in order to enter into any transaction, other than a public offering, involving
        the sale, issuance or potential issuance by the Company of ordinary shares (or securities convertible into or exercisable for ordinary
        shares) equal to 20% or more of the outstanding share capital of the Company or 20% or more of the voting power outstanding before the
        issuance for less than the greater of book or market value of the ordinary shares. We will follow Israeli law with respect to any requirement
        to obtain shareholder approval in connection with any private placements of equity securities.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z877ece08660a476c852b8864d1c69cdd" style="font: 10pt Arial; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman"><br/> </td>
    <td style="width: 36pt; vertical-align: top; font-family: Times New Roman">(iii)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div style="font-family: Times New Roman"><span style="font-style: italic">Adoption or Amendment of Equity-Based Compensation Plan</span>s.
        We have elected to follow Israeli corporate governance practice instead of the Nasdaq Listing Rule 5635(c), which requires listed issuers
        to obtain shareholder approval for the establishment or material amendment of certain equity-based compensation plans and arrangements.
        Under Israeli law and practice, in general, the approval of the board of directors is required for the establishment or amendment of equity-based
        compensation plans and arrangements.</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Board of Directors</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 34.5pt; line-height: 1.25; font-family: Times New Roman">&#160;Under the Israeli Companies
Law, 5759-1999 (the &#8220;Companies Law&#8221;), our board of directors is responsible for setting our general policies and supervising
the performance of management. Our board of directors may exercise all powers and may take all actions that are not specifically granted
by the Companies Law or our articles of association to our shareholders or to management. Our executive officers are responsible for our
day-to-day management and have individual responsibilities established by our board of directors.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 34.5pt; line-height: 1.25; font-family: Times New Roman">&#160;Under the Companies Law,
the chief executive officer of a public company, or a relative of the chief executive officer, may not serve as the chairperson of the
board of directors of such public company, and the chairperson of the board of directors of a public company, or a relative of the chairperson,
may not be vested with authorities of the chief executive officer of such public company without obtaining shareholder approval pursuant
to special majority requirements set forth in the Companies Law.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 34.5pt; line-height: 1.25; font-family: Times New Roman">&#160;Our board of directors is
currently composed of six (6) members. Our board of directors consists of three classes of directors (as illustrated below), each serving
staggered three-year terms. Upon expiration of the term of a class of directors, directors in that class will be elected for a three-year
term at the Annual General Meeting of shareholders in the year in which that term expires. Each director&#8217;s term continues until
the election and qualification of his or her successor, or his or her earlier death, resignation or removal. Any increase or decrease
in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of&#160;one-third&#160;of
the directors. The division of our board of directors into three classes with staggered three-year terms may delay or prevent a change
of management or a change of control of our company.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z689e4215b1894affaf9b7e60a5ba42a9" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8226;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">Class I consists of Nissim Darvish and Jill Quigley, each with a term expiring at the 2025 annual meeting
        of shareholders.</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8226;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">Class II consists of Neil Cohen and Claude Nicaise, each with a term expiring at the 2026 annual meeting
        of shareholders.</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Class III consists of Adi Mor and Alan Moses, each with a term expiring at the 2027
        annual meeting of shareholders.&#160;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our directors are appointed by a
simple majority vote of holders of our ordinary shares, participating and voting at an annual general meeting of our shareholders, provided
that (i) in the event of a contested election, the method of calculation of the votes and the manner in which the resolutions will be
presented to our shareholders at the general meeting will be determined by our board of directors in its discretion, and (ii) in the event
that our board of directors does not or is unable to make a determination on such matter, then the directors will be elected by a plurality
of the voting power represented at the general meeting in person or by proxy and voting on the election of directors.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">100</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Each director will hold office until
the annual general meeting of our shareholders for the year in which such director&#8217;s term expires, unless the tenure of such director
expires earlier pursuant to the Companies Law or unless such director is removed from office as described below.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Under our Articles of Association,
the approval of the holders of at least 65% of the total voting power of our shareholders is generally required to remove any of our directors
from office or any amendment to this provision shall require the approval of at least 65% of the total voting power of our shareholders
to remove any of our directors from office. In addition, vacancies on our board of directors may only be filled by a vote of a simple
majority of the directors then in office. A director so appointed will hold office until the next annual general meeting of our shareholders
for the election of the class of directors in respect of which the vacancy was created, or in the case of a vacancy due to the number
of directors being less than the minimum number of directors stated in our Articles of Association, the new director filling the vacancy
will serve until the next annual general meeting of our shareholders for the election of the class of directors to which such director
was assigned by our board of directors.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Chairperson of
the Board</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our Articles of Association provide
that the Chairperson of our board of directors is appointed by the members of our board of directors from among them. Under the Companies
Law, the chief executive officer of a public company, or a relative of the chief executive officer, may not serve as the chairperson of
the board of directors of such public company, and the chairperson of the board of directors of a public company, or a relative of the
chairperson, may not be vested with authorities of the chief executive officer of such public company without shareholder approval consisting
of a majority vote of the shares present and voting at a shareholders meeting, and in addition, either:</div>

<div style="line-height: 1.25; font-family: Times New Roman"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zd20ba8987fcf411a82555231214b1a7e" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">at least a majority of the shares of non-controlling shareholders and shareholders
        that do not have a personal interest in the approval voted at the meeting are voted in favor (disregarding abstentions); or</div> </td>
        </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the total number of shares of non-controlling shareholders and shareholders who do
        not have a personal interest in such appointment that re voted against such appointment does not exceed two percent (2%) of the aggregate
        voting rights in the company.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The shareholders&#8217; approval
can be effective for a period of up to five years following an initial public offering, and subsequently, for additional periods of up
to three years.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In addition, a person who is subordinated,
directly or indirectly, to the chief executive officer may not serve as the chairperson of the board of directors; the chairperson of
the board of directors may not be vested with authorities that are granted to persons who are subordinated to the chief executive officer;
and the chairperson of the board of directors may not serve in any other position in the company or in a controlled subsidiary, but may
serve as a director or chairperson of a controlled subsidiary.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">External Directors</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Under the Companies Law, companies
incorporated under the laws of the State of Israel that are &#8220;public companies,&#8221; including companies with shares listed on
Nasdaq, are required to appoint at least two external directors. Pursuant to regulations promulgated under the Companies Law, companies
with shares traded on certain U.S. stock exchanges, including Nasdaq, which do not have a &#8220;controlling shareholder,&#8221; may,
subject to certain conditions, &#8220;opt out&#8221; from the Companies Law requirements to appoint external directors and related Companies
Law rules concerning the composition of the audit committee and compensation committee of the board of directors. In accordance with these
regulations, we have elected to &#8220;opt out&#8221; from the Companies Law requirement to appoint external directors and related Companies
Law rules concerning the composition of the audit committee and compensation committee of our board of directors.<br/> &#160;&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">101</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Committees of our Board of Directors</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Audit Committee</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Under the Companies Law, the Exchange
Act and Nasdaq rules, we are required to establish an audit committee, and we have a separately-designated standing audit committee established
in accordance with section 3(a)(58)(A) of the Exchange Act.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The responsibilities of an audit
committee under the Companies Law include identifying and addressing flaws in the business management of the company, reviewing and approving
related party transactions, establishing whistleblower procedures, overseeing the company&#8217;s internal audit system and the performance
of its internal auditor, and assessing the scope of the work and recommending the fees of the company&#8217;s independent accounting firm.
In addition, the audit committee is required to determine whether certain related party actions and transactions are &#8220;material&#8221;
or &#8220;extraordinary&#8221; for the purpose of the requisite approval procedures under the Companies Law and to establish procedures
for considering proposed transactions with a controlling shareholder.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In accordance with U.S. law and Nasdaq
requirements, our audit committee is also responsible for the appointment, compensation and oversight of the work of our independent auditors
and for assisting our board of directors in monitoring our financial statements, the effectiveness of our internal controls and our compliance
with legal and regulatory requirements.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Under the Companies Law and related
regulations, the audit committee must consist of at least three directors who meet certain independence criteria. Under the Nasdaq rules,
we are required to maintain an audit committee consisting of at least three independent directors, all of whom are financially literate
and one of whom has accounting or related financial management expertise. Each of the members of the audit committee is required to be
&#8220;independent&#8221; as such term is defined in Rule 10A-3(b)(1) under the Exchange Act.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The members of the audit committee are Jill
Quigley, Alan Moses and Claude Nicaise. Claude Nicaise is the chairperson of the audit committee and is a financial expert under the rules
of the SEC. Our board of directors has concluded that each member of the audit committee is independent under the rules and regulations
of Nasdaq and the SEC.<br/> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Compensation
Committee</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Under both the Companies Law and
Nasdaq rules, we are required to establish a compensation committee.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The responsibilities of a compensation
committee under the Companies Law include recommending to the board of directors, for ultimate shareholder approval by a special majority,
a policy governing the compensation of directors and officers based on specified criteria, reviewing modifications to and implementing
such compensation policy from time to time, and approving the actual compensation terms of directors and officers prior to approval by
the board of directors.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In accordance with U.S. law and Nasdaq
requirements, our compensation committee is also responsible for the appointment, compensation and oversight of the work of any compensation
consultant, independent legal counsel and other advisors retained by the compensation committee.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The Companies Law and related regulations
require the appointment of a compensation committee that complies with the requirements of Nasdaq. Under Nasdaq rules, we are required
to maintain a compensation committee consisting of at least two independent directors; each of the members of the compensation committee
is required to be independent under Nasdaq rules relating to compensation committee members, which are different from the general test
for independence of board and committee members. The members of the compensation committee are Nissim Darvish and Neil Cohen. Nissim Darvish
is the chairperson of the compensation committee. Our board of directors has determined that each member of the compensation committee
is independent within the meaning of the independent director guidelines of Nasdaq and under Rule 10C-1 under the Exchange Act.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">102</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">Compensation Policy under the Companies
Law</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In general, under the Companies Law,
a public company must have a compensation policy approved by the board of directors after receiving and considering the recommendations
of the compensation committee. In addition, our compensation policy must be approved at least once every three years, first, by our board
of directors, upon the recommendation of our compensation committee, and second, by a simple majority of the ordinary shares present,
in person or by proxy, and voting (excluding abstentions) at a general meeting of shareholders, provided that either:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" id="zdbac50db23a44a22a61c95c4dc2c8a84" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">such majority includes at least a majority of the shares held by shareholders who
        are not controlling shareholders and shareholders who do not have a personal interest in such compensation policy; or</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the total number of shares of non-controlling shareholders and shareholders who do
        not have a personal interest in the compensation policy and who vote against the policy does not exceed two percent (2%) of the aggregate
        voting rights in the Company.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Under special circumstances, the
board of directors may approve the compensation policy despite the objection of the shareholders on the condition that the compensation
committee and then the board of directors decide, on the basis of detailed grounds and after discussing again the compensation policy,
that approval of the compensation policy, despite the objection of shareholders, is for the benefit of the company.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If a company that initially offers
its securities to the public, like us, adopts a compensation policy in advance of its initial public offering, and describes it in its
prospectus for such offering, then such compensation policy shall be deemed a validly adopted policy in accordance with the Companies
Law requirements described above. Furthermore, if the compensation policy is established in accordance with the aforementioned relief,
then it will remain in effect for a term of five years from the date such company becomes a public company.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The compensation policy must be based
on certain considerations, include certain provisions and reference certain matters as set forth in the Companies Law. The compensation
policy must serve as the basis for decisions concerning the financial terms of employment or engagement of office holders, including exculpation,
insurance, indemnification or any monetary payment or obligation of payment in respect of employment or engagement. The compensation policy
must be determined and later reevaluated according to certain factors, including: the advancement of the company&#8217;s objectives, business
plan and long-term strategy; the creation of appropriate incentives for office holders, while considering, among other things, the company&#8217;s
risk management policy; the size and the nature of the company&#8217;s operations; and with respect to variable compensation, the contribution
of the office holder towards the achievement of the company&#8217;s long-term goals and the maximization of its profits, all with a long-term
objective and according to the position of the office holder. The compensation policy must furthermore consider the following additional
factors:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5df06e610f3e4d4babf7068247baa267" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the education, skills, experience, expertise and accomplishments of the relevant office
        holder;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the office holder&#8217;s position and responsibilities;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">prior compensation agreements with the office holder;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8226;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the ratio between the cost of the terms of employment of an office holder and the
        cost of the employment of other employees of the company, including employees employed through contractors who provide services to the
        company, in particular the ratio between such cost to the average and median salary of such employees of the company, as well as the impact
        of disparities between them on the work relationships in the company;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">if the terms of employment include variable components - the possibility of reducing
        variable components at the discretion of the board of directors and the possibility of setting a limit on the value of non-cash variable
        equity-based components; and</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8226;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">if the terms of employment include severance compensation - the term of employment
        or office of the office holder, the terms of the office holder&#8217;s compensation during such period, the company&#8217;s performance
        during such period, the office holder&#8217;s individual contribution to the achievement of the company goals and the maximization of
        its profits and the circumstances under which he or she is leaving the company.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">103</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160; <br/>

<div style="text-indent: 36pt; line-height: 1.25">The compensation policy must also include, among other things:</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z27c6a0688a0b4f0582b8d97f0b12255d" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: middle; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">with regards to variable components:</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8226;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">with the exception of office holders who report to the chief executive officer, a
        means of determining the variable components on the basis of long-term performance and measurable criteria; provided that the company
        may determine that an immaterial part of the variable components of the compensation package of an office holder shall be awarded based
        on non-measurable criteria, or if such amount is not higher than three months&#8217; salary per annum, taking into account such office
        holder&#8217;s contribution to the company;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the ratio between variable and fixed components, as well as the limit of the values
        of variable components at the time of their payment, or in the case of equity-based compensation, at the time of grant;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8226;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">a condition under which the office holder will return to the company, according to
        conditions to be set forth in the compensation policy, any amounts paid as part of the office holder&#8217;s terms of employment, if such
        amounts were paid based on information later to be discovered to be wrong, and such information was restated in the company&#8217;s financial
        statements;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the minimum holding or vesting period of variable equity-based components to be set
        in the terms of office or employment, as applicable, while taking into consideration long-term incentives; and</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">a limit to retirement grants.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our compensation policy is designed
to promote retention and motivation of directors and executive officers, incentivize superior individual excellence, align the interests
of our directors and executive officers with our long-term performance and provide a risk management tool. To that end, a portion of our
executive officer compensation package is targeted to reflect our short and long-term goals, as well as the executive officer&#8217;s
individual performance. On the other hand, our compensation policy includes measures designed to reduce the executive officer&#8217;s
incentives to take excessive risks that may harm us in the long-term, such as limits on the value of cash bonuses and equity-based compensation,
limitations on the ratio between the variable and the total compensation of an executive officer and minimum vesting periods and performance
based vesting for equity-based compensation.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our compensation policy also addresses
our executive officers&#8217; individual characteristics (such as their respective position, education, scope of responsibilities and
contribution to the attainment of our goals) as the basis for compensation variation among our executive officers and considers the internal
ratios between compensation of our executive officers and directors and other employees. Pursuant to our compensation policy, the compensation
that may be granted to an executive officer may include: base salary, annual bonuses and other cash bonuses (such as a signing bonus and
special bonuses with respect to any special achievements, such as outstanding personal achievement, outstanding personal effort or outstanding
company performance), equity-based compensation, benefits and retirement and termination of service arrangements. All cash bonuses are
limited to a maximum amount linked to the executive officer&#8217;s base salary.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">An annual cash bonus may be awarded
to executive officers upon the attainment of pre-set periodic objectives and individual targets. The annual cash bonus that may be granted
to our executive officers other than our Chief Executive Officer will be based on performance objectives and a discretionary evaluation
of the executive officer&#8217;s overall performance by our Chief Executive Officer and subject to minimum thresholds. The annual cash
bonus that may be granted to executive officers other than our Chief Executive Officer may alternatively be based entirely on a discretionary
evaluation. Furthermore, our Chief Executive Officer will be entitled to approve performance objectives for executive officers who report
to her.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The measurable performance objectives
of our Chief Executive Officer will be determined annually by our compensation committee and board of directors. A non-material portion
of the Chief Executive Officer&#8217;s annual cash bonus, as provided in our compensation policy, may be based on a discretionary evaluation
of the Chief Executive Officer&#8217;s overall performance by the compensation committee and the board of directors.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">104</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The equity-based compensation under
our compensation policy for our executive officers (including members of our board of directors) is designed in a manner consistent with
the underlying objectives in determining the base salary and the annual cash bonus, with its main objectives being to enhance the alignment
between the executive officers&#8217; interests with our long-term interests and those of our shareholders and to strengthen the retention
and the motivation of executive officers in the long term. Our compensation policy provides for executive officer compensation in the
form of share options or other equity-based awards, such as restricted shares and restricted share units, in accordance with our equity
incentive plan then in place. The equity-based compensation shall be granted from time to time and be individually determined and awarded
according to the performance, educational background, prior business experience, qualifications, role and the personal responsibilities
of the executive officer.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In addition, our compensation policy
contains compensation recovery provisions which allow us under certain conditions to recover bonuses paid in excess, enable our Chief
Executive Officer to approve an immaterial change in the terms of employment of an executive officer who reports directly to her (provided
that the changes of the terms of employment are in accordance with our compensation policy) and allow us to exculpate, indemnify and insure
our executive officers and directors to the maximum extent permitted by Israeli law subject to certain limitations set forth therein.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our compensation policy also provides
for compensation to the members of our board of directors either (i) in accordance with the amounts provided in the Companies Regulations
(Rules Regarding the Compensation and Expenses of an External Director) of 2000, as amended by the Companies Regulations (Relief for Public
Companies Traded in Stock Exchange Outside of Israel) of 2000, as such regulations may be amended from time to time, or (ii) in accordance
with the amounts determined in our compensation policy.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our compensation policy was approved
by our board of directors and shareholders and became effective on July 19, 2021.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">Corporate Governance and Nominating
Committee</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We have established a Corporate Governance
and Nominating Committee, responsible for making recommendations to the board of directors regarding candidates for directorships and
the size and composition of the board. In addition, the committee is responsible for overseeing our corporate governance guidelines and
reporting and making recommendations to the board concerning corporate governance matters. Under the Companies Law, nominations for director
may also, under certain circumstances, be made by shareholders in accordance with the conditions prescribed by applicable law and our
articles of association. The members of the Corporate Governance and Nominating Committee are Neil Cohen and Nissim Darvish. Neil Cohen
is the chairperson of the Corporate Governance and Nominating Committee. Our board of directors has determined that each member of the
Corporate Governance and Nominating Committee is independent within the meaning of the independent director guidelines of Nasdaq.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Internal Auditor</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Under the Companies Law, the board
of directors is required to appoint an internal auditor recommended by the audit committee. The role of the internal auditor is to examine,
among other things, whether the company&#8217;s actions comply with applicable law and proper business procedures. The internal auditor
may not be an interested party, a director or an officer of the company, or a relative of any of the foregoing, nor may the internal auditor
be our independent accountant or a representative thereof. Yisrael Gewirtz of Grant Thornton Israel currently serves as our internal auditor.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">105</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Approval of Related Party Transactions
under Israeli Law</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Fiduciary duties
of directors and Executive Officers</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">An office holder&#8217;s fiduciary
duties consist of a duty of care and a duty of loyalty. The duty of care requires an office holder to act with the level of care with
which a reasonable office holder in the same position would have acted under the same circumstances. The duty of care includes, among
other things, a duty to use reasonable means, in light of the circumstances, to obtain:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" id="z43c4a42c68c64957b2a90fb19e69b7fd" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">information on the business advisability of a given action brought for his, her or
        its approval or performed by virtue of his, her or its position; and</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">all other important information pertaining to such action.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The duty of loyalty requires that
an office holder act in good faith and in the best interests of the company, and includes, among other things, the duty to:</div>

<div style="line-height: 1.25; font-family: Times New Roman"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z100d73894fe54310b4ffc0f4db993e7e" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">refrain from any act involving a conflict of interest between the performance of his,
        her or its duties in the company and his, her or its other duties or personal affairs;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">refrain from any activity that is competitive with the business of the company;</div>
        </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">refrain from exploiting any business opportunity of the company for the purpose of
        gaining a personal advantage for himself, herself or itself or others; and</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">disclose to the company any information or documents relating to the company&#8217;s
        affairs which the office holder received as a result of his, her or its position as an office holder.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Under the Companies Law, a company
may approve an act specified above which would otherwise constitute a breach of the office holder&#8217;s duty of loyalty, provided that
the office holder acted in good faith, neither the act nor its approval harms the company, and the office holder discloses his, her or
its personal interest a sufficient time before the approval of such act. Any such approval is subject to the terms of the Companies Law
setting forth, among other things, the appropriate bodies of the company required to provide such approval and the methods of obtaining
such approval.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Disclosure of
Personal Interests of an Office Holder and Approval of Certain Transactions</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The Companies Law requires that an
office holder promptly disclose to the board of directors any personal interest that such office holder may have and all related material
information known to such office holder concerning any existing or proposed transaction with the company. A personal interest includes
an interest of any person in an act or transaction of a company, including a personal interest of one&#8217;s relative or of a corporate
body in which such person or a relative of such person is a 5% or greater shareholder, director or general manager or in which such person
has the right to appoint at least one director or the general manager, but excluding a personal interest stemming solely from one&#8217;s
ownership of shares in the company. A personal interest includes the personal interest of a person for whom the office holder holds a
voting proxy or the personal interest of the office holder with respect to the officer holder&#8217;s vote on behalf of a person for whom
he or she holds a proxy even if such shareholder has no personal interest in the matter.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If it is determined that an office
holder has a personal interest in a non-extraordinary transaction, meaning any transaction that is in the ordinary course of business,
on market terms or that is not likely to have a material impact on the company&#8217;s profitability, assets or liabilities, approval
by the board of directors is required for the transaction unless the company&#8217;s articles of association provide for a different method
of approval. Any such transaction that is adverse to the company&#8217;s interests may not be approved by the board of directors.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Approval first by the company&#8217;s
audit committee and subsequently by the board of directors is required for an extraordinary transaction (meaning any transaction that
is not in the ordinary course of business, not on market terms or that is likely to have a material impact on the company&#8217;s profitability,
assets or liabilities) in which an office holder has a personal interest.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">A director and any other office holder
who has a personal interest in a transaction which is considered at a meeting of the board of directors or the audit committee may generally
(unless it is with respect to a transaction which is not an extraordinary transaction) not be present at such a meeting or vote on that
matter unless a majority of the directors or members of the audit committee, as applicable, have a personal interest in the matter. If
a majority of the members of the audit committee or the board of directors have a personal interest in the matter, then all of the directors
may participate in deliberations of the audit committee or board of directors, as applicable, with respect to such transaction and vote
on the approval thereof and, in such case, shareholder approval is also required.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">106</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Certain disclosure and approval requirements
apply under Israeli law to certain transactions with controlling shareholders, certain transactions in which a controlling shareholder
has a personal interest and certain arrangements regarding the terms of service or employment of a controlling shareholder. For these
purposes, a controlling shareholder is any shareholder that has the ability to direct the company&#8217;s actions, including any shareholder
holding 25% or more of the voting rights if no other shareholder owns more than 50% of the voting rights in the company. Two or more shareholders
with a personal interest in the approval of the same transaction are deemed to be one shareholder.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">For a description of the approvals
required under Israeli law for compensation arrangements of officers and directors, see &#8220;-Compensation of Directors and Executive
Officers.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Shareholder Duties</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Pursuant to the Companies Law, a
shareholder has a duty to act in good faith and in a customary manner toward the company and other shareholders and to refrain from abusing
his or her power with respect to the company, including, among other things, in voting at a general meeting and at shareholder class meetings
with respect to the following matters:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3686ece9e9f04d2e94a84cf565bb4321" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">an amendment to the company&#8217;s articles of association;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">an increase of the company&#8217;s authorized share capital;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">a merger; or</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">interested party transactions that require shareholder approval.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In addition, a shareholder has a
general duty to refrain from discriminating against other shareholders.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Certain shareholders also have a
duty of fairness toward the company. These shareholders include any controlling shareholder, any shareholder who knows that it has the
power to determine the outcome of a shareholder vote and any shareholder who has the power to appoint or to prevent the appointment of
an office holder of the company or exercise any other rights available to it under the company&#8217;s articles of association with respect
to the company. The Companies Law does not define the substance of this duty of fairness, except to state that the remedies generally
available upon a breach of contract will also apply in the event of a breach of the duty of fairness.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Exculpation,
Insurance and Indemnification of Office Holders</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Under the Companies Law, a company
may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate an office holder
in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of duty of care
but only if a provision authorizing such exculpation is included in its articles of association. Our Articles of Association include such
a provision. An Israeli company may not exculpate a director from liability arising out of a prohibited dividend or distribution to shareholders.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">An Israeli company may indemnify
an office holder in respect of the following liabilities and expenses incurred for acts performed as an office holder, either in advance
of an event or following an event, provided a provision authorizing such indemnification is contained in its articles of association:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1e90d06f217d46ae924fe27fb5147aba" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8226;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">a financial liability imposed on him or her in favor of another person pursuant to
        a judgment, including a settlement or arbitrator&#8217;s award approved by a court. However, if an undertaking to indemnify an office
        holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion
        of the board of directors, can be foreseen based on the company&#8217;s activities when the undertaking to indemnify is given, and to
        an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall
        detail the above mentioned events and amount or criteria;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8226;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">reasonable litigation expenses, including legal fees, incurred by the office holder
        (1) as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation
        or proceeding, <span style="font-style: italic">provided</span> that (i) no indictment was filed against such office holder as a result
        of such investigation or proceeding; and (ii) no financial liability, such as a criminal penalty, was imposed upon him or her as a substitute
        for the criminal proceeding as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed
        with respect to an offense that does not require proof of criminal intent; and (2) in connection with a monetary sanction;</div> </td>
        </tr>
  </table>

<div><br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8226;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">reasonable litigation expenses, including legal fees, incurred by the office holder
        or imposed by a court in proceedings instituted against him or her by the company, on its behalf or by a third-party or in connection
        with criminal proceedings in which the office holder was acquitted or as a result of a conviction for an offense that does not require
        proof of criminal intent; and</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8226;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">expenses, including reasonable litigation expenses and legal fees, incurred by an
        office holder in relation to an administrative proceeding instituted against such office holder, or certain compensation payments made
        to an injured party imposed on an office holder by an administrative proceeding, pursuant to certain provisions of the Israeli Securities
        Law.</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">107</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">An Israeli company may insure an
office holder against the following liabilities incurred for acts performed as an office holder if and to the extent provided in the company&#8217;s
articles of association:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za35c8f4061904f7dbbc4b67c40721b8f" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">a breach of the duty of loyalty to the company, to the extent that the office holder
        acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">a breach of the duty of care to the company or to a third-party, including a breach
        arising out of the negligent conduct of the office holder;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">a financial liability imposed on the office holder in favor of a third-party;</div>
        </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">a financial liability imposed on the office holder in favor of a third-party harmed
        by a breach in an administrative proceeding; and</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">expenses, including reasonable litigation expenses and legal fees, incurred by the
        office holder as a result of an administrative proceeding instituted against him or her, pursuant to certain provisions of the Israeli
        Securities Law.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">An Israeli company may not indemnify
or insure an office holder against any of the following:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160; <br/> </div>

<table cellspacing="0" cellpadding="0" id="z818c6c71ac0945479b9d25db681500a1" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">a breach of the duty of loyalty, except to the extent that the office holder acted
        in good faith and had a reasonable basis to believe that the act would not prejudice the company;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">a breach of the duty of care committed intentionally or recklessly, excluding a breach
        arising out of the negligent conduct of the office holder;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">an act or omission committed with intent to derive illegal personal benefit; or</div>
        </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">a fine, monetary sanction or forfeit levied against the office holder.</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Under the Companies Law, exculpation,
indemnification and insurance of office holders must be approved by the compensation committee and the board of directors (and, with respect
to directors and the chief executive officer, by the shareholders). However, under regulations promulgated under the Companies Law, the
insurance of office holders does not require shareholder approval and may be approved by only the compensation committee if the engagement
terms are determined in accordance with the company&#8217;s compensation policy, which was approved by the shareholders by the same special
majority required to approve a compensation policy, provided that the insurance policy is on market terms and the insurance policy is
not likely to materially impact the company&#8217;s profitability, assets or obligations.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">108</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our Articles of Association allow
us to exculpate, indemnify and insure our office holders for any liability imposed on them as a consequence of an act (including any omission)
which was performed by virtue of being an office holder. Our office holders are currently covered by a directors and officers&#8217; liability
insurance policy.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We have entered into indemnification
agreements with each of our directors and executive officers exculpating them in advance, to the fullest extent permitted by law, from
liability to us for damages caused to us as a result of a breach of duty of care, and undertaking to indemnify them to the fullest extent
permitted by law. This indemnification is limited to events determined as foreseeable by the board of directors based on our activities,
and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In the opinion of the SEC, indemnification
of directors and office holders for liabilities arising under the Securities Act, however, is against public policy and therefore unenforceable.</div>

<div style="line-height: 1.25; font-family: Times New Roman"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z66ba1eece9af4ce7a009461e879537d0" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="font-weight: bold">D.</span></div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Employees</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">As of December 31, 2024, we had 16 employees/consultants,
including 6 with Ph.D. or M.D. degrees and including 10 who are engaged in research and development activities. We are dependent on our
management and scientific personnel, and it is crucial that we continue to attract and retain valuable employees. To facilitate attraction
and retention, we strive to make ourselves an inclusive and safe workplace, with opportunities for our employees to grow and develop in
their careers, supported by strong compensation and benefits programs. None of our employees are represented by labor unions or covered
by collective bargaining agreements.<br/> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zf2e27549c58042d4bbf44daa8f89ffae" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">E.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Share Ownership</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">For information regarding the share
ownership of directors and officers, see Item 7.A. &#8220;Major Shareholders and Related Party Transactions-Major Shareholders.&#8221;
For information as to our equity incentive plans, see Item 6.B. &#8220;Director, Senior Management and Employees-Compensation- Equity
incentive plans.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zdec8b445233d4b77b861e7cfe16ce90f" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">F.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Disclosure of a Registrant&#8217;s Action to Recover Erroneously
        Awarded Compensation</div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold"> <br/> </div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: normal">Not applicable.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Item 7<span id="Item7"><!--Anchor--></span>.
Major Shareholders and Related Party Transactions</div>

<div style="line-height: 1.25; font-family: Times New Roman"><br/> </div>

<table cellspacing="0" cellpadding="0" border="0" id="zfe6108d844784bdc9d9a78fc11703817" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">A.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Major Shareholders</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The beneficial ownership of ordinary
shares is determined in accordance with the SEC rules and generally includes any ordinary shares over which a person exercises sole or
shared voting or investment power. For purposes of the table below, we deem shares subject to options or warrants that are currently exercisable
or exercisable within 60 days of December 31, 2024, to be outstanding and to be beneficially owned by the person holding the options or
warrants for the purposes of computing the percentage ownership of that person but we do not treat them as outstanding for the purpose
of computing the percentage ownership of any other person. The percentage of shares beneficially owned is based on 377,132,220 ordinary
shares outstanding as of December 31, 2024.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">All of our shareholders, including
the shareholders listed below, have the same voting rights attached to their ordinary shares.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">109</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">A description of any material relationship
that our principal shareholders have had with us or any of our affiliates within the past three years is included under &#8220;Certain
relationships and related party transactions.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="line-height: 1.25; font-family: Times New Roman">

<table cellspacing="0" cellpadding="0" class="cfttable" id="z209122c24b7349719f8fe8b803f2a626" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="line-height: 1.25; font-weight: bold">NAME OF BENEFICIAL OWNER</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Total</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Beneficial</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Ownership (ADSs)</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Percentage of</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">ADSs Beneficially</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Owned</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-style: italic">5% and Greater Shareholders</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%">
        <div style="line-height: 1.25">OrbiMed Israel (1)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">1,860,906</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">9.99</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Sphera Funds Management Ltd. (2)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">1,214,575</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">6.4</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">%<br/>
        </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%">
        <div style="line-height: 1.25">Apeiron Group (3)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">1,175,246</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">6.2</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Erik Otto (4)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">1,155,000</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">6.1</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">%<br/>
        </td> </tr>
  <tr>
    <td style="vertical-align: top; width: 76%">
        <div style="line-height: 1.25">Rivendell Investments 2017-9 (5)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; width: 9%; text-align: right">
        <div style="line-height: 1.25">1,131,563</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; width: 9%; text-align: right">
        <div style="line-height: 1.25">6.0</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-style: italic">Directors and Executive Officers</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25">Adi Mor (6)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%"><br/> </td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%"><br/> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">874,739</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><br/> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%"><br/> </td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%"><br/> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">4.6</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Sigal Fattal (7)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">93,264</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">*</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25">Matthew Frankel (8)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">96,392</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">*</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Neil Cohen (9)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">167,467</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">*</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25">Nissim Darvish (10)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">48,312</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">*</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Alan Moses (11)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">25,561</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">*</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25">Claude Nicaise (12)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">25,561</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">*</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Jill Quigley (13)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">18,981</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">*</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%">
        <div style="line-height: 1.25; font-weight: bold">All current executive officers and directors as a group (8 persons)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">1,350,277</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">6.9</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="line-height: 1.25; font-family: Times New Roman">* Less than one percent (1%)</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">

<table cellspacing="0" cellpadding="0" id="z30955f4c356f420c83517b241a025cbd" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">(1)</div>
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Pursuant to a Schedule 13D/A filed with the SEC by OrbiMed Israel BioFund GP Limited
        Partnership (&#8220;OrbiMed BioFund&#8221;) and OrbiMed Israel GP Ltd. (&#8220;OrbiMed GP&#8221;, and together with OrbiMed BioFund, &#8220;OrbiMed
        Israel&#8221;) on September 16, 2024, such amount consists of (i) 1,741,274 ADSs, (ii) 28,817 ADSs issuable upon the exercise of warrants
        to purchase ADSs and (iii) 90,816 ADSs issuable upon the exercise of pre-funded warrants to purchase ADSs. The foregoing pre-funded warrants
        are subject to an exercise limitation that prohibits the holder from exercising the pre-funded warrants to the extent that after giving
        effect to the issuance of ADSs after such exercise, the holder (together with the holder&#8217;s affiliates) would beneficially own in
        excess of 9.99% of the ADSs outstanding. OrbiMed GP, a company that acts as general partner of certain limited partnerships, is the general
        partner of OrbiMed BioFund, which is the general partner of OrbiMed Israel Partners Limited Partnership, which is the entity that holds
        the foregoing securities. The address of OrbiMed Israel is 5 Hahoshlim St., Herzliya Pituach, Israel. Telephone: +972 73 2822600.</div>
        </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">&#160;</td>
    <td style="width: 97.5%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="line-height: 1.25">&#160;(2)</div> </td>
    <td style="width: 97.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Pursuant to a Schedule 13G filed with the
        SEC on August 20, 2024 by Sphera Funds Management Ltd., Sphera Global Healthcare GP Ltd. and Sphera Global Healthcare Management LP, the
        foregoing beneficially own 1,214,575 ADSs, which are held directly by Sphera Biotech Master Fund, which has delegated its investment management
        authority to Sphera Global Healthcare Management LP.&#160;Sphera Global Healthcare Management LP is managed, controlled, and operated
        by its general partner, Sphera Global Healthcare GP Ltd., the shares of which are owned 90% by Sphera Funds Management Ltd.</div> </td>
        </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">&#160;</td>
    <td style="width: 97.5%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">(3)</div>
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">The Apeiron Group consists of (i) Apeiron SICAV Ltd. - Presight Capital Fund One,
        of which owns 438,993 ADSs, (ii) Apeiron Presight Capital Fund II, LP, of which owns 693,028 ADSs and 28,817 ADSs issuable upon the exercise
        of warrants and (iii) Apeiron Investment Group Ltd., of which owns 14,408 ADSs issuable upon the exercise of warrants. Each of Fabian
        Hansen and Christian Angermayer may be deemed to share voting and investment power with respect to the ADSs held by the Apeiron Group.</div>
        </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">&#160;</td>
    <td style="width: 97.5%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">(4)</div> </td>
    <td style="width: 97.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Pursuant to a Schedule 13G filed with the SEC by Erik Otto on November 30, 2024, Mr.
        Otto is the beneficial owner of 1,155,000 ADSs.</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">110</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">

<div> <br/> </div>

<table cellspacing="0" cellpadding="0" id="z57b030aa575945de95c536b9ac66c863" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">(5)</div>
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Represents 1,108,509 ADSs held by Rivendell
        Investments 2017-9 LLC, or Rivendell, as reported by Rivendell on Schedule 13G filed with the SEC on March 26, 2021, and 23,054 ADSs,
        issuable upon the exercise of warrants. Rivendell is the shareholder of record. Peter Thiel is the beneficial owner of Rivendell and has
        sole voting and investment power over the securities held by Rivendell. The address of Rivendell is 1209 Orange Street, Wilmington, Delaware
        19801.</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">&#160;</td>
    <td style="width: 97.5%; vertical-align: top; text-align: justify">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">(6)</div> </td>
    <td style="width: 97.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Consists of (i) 317,075 ADSs owned directly by Dr. Mor, (ii) 200,236 ADSs owned by
        Dr. George, (Dr. Mor&#8217;s spouse), (iii) 323,703 ADSs issued to Dr. Mor, issuable upon the exercise of options within 60 days of the
        date hereof, and (iv) 33,725 options to purchase 33,725 ADSs issued to Dr. George, (Dr. Mor&#8217;s spouse) issuable upon the exercise
        thereof within 60 days of the date hereof.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">(7)</div> </td>
    <td style="width: 97.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Includes 2,555ADSs, and 90,709 ADSs issuable upon the exercise of options within 60
        days of the date hereof.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">(8)</div> </td>
    <td style="width: 97.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Represents 96,392ADSs issuable upon the exercise of options within 60 days of the
        date hereof.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">(9)</div> </td>
    <td style="width: 97.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Includes 141,218 ADSs, and 26,249 ADSs issuable upon the exercise of options within
        60 days of the date hereof.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">(10)</div> </td>
    <td style="width: 97.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Includes 1,200 ADSs, and 47,112 ADSs issuable
        upon the exercise of options within 60 days of the date hereof.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">(11)</div> </td>
    <td style="width: 97.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Represents 25,561 ADSs issuable upon the exercise of options within 60 days of the
        date hereof.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">(12)</div> </td>
    <td style="width: 97.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Represents 25,561 ADSs issuable upon the exercise of options within 60 days of the
        date hereof.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2.5%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 97.5%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">(13)</div> </td>
    <td style="width: 97.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Represents 18,981 ADSs issuable upon the exercise of options within 60 days of the
        date hereof.</div> </td> </tr>
  </table> &#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Significant Changes in Ownership</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">To our knowledge, other than as disclosed
in the table above, our other filings with the SEC and this Annual Report, there has been no significant change in the percentage ownership
held by any major shareholder during the past three years.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Voting Rights</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Neither our major shareholders nor
our directors and executive officers will have different or special voting rights with respect to their ordinary shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Registered Holders</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">As of the date of this Annual Report,
there are seven shareholders of record of our ordinary shares, of whom five are in the United States. The number of record holders is
not representative of the number of beneficial holders of our ordinary shares, as most of the shares we have issued, including those represented
by ADSs are currently recorded in the name of our ADS registrar, The Bank of New York Mellon.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Change in Control Arrangements</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We are not aware of any arrangement
that may at a subsequent date, result in a change of control of the Company.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">111</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" id="z25903afbfb7e4b39a663bb4daf02d91d" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">B.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Related Party Transactions</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Other Transactions</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Agreements with Directors and Officers</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><span style="font-style: italic">Employment
and Consulting Agreements.</span> We have entered into written employment agreements with each of our executive officers. See Item 6.
&#8220;Management-Employment and Consulting Agreements with Executive Officers.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><span style="font-style: italic">Awards.</span>
Since our inception, we have granted options to purchase our ordinary shares to our executive officers and certain of our directors. Such
option agreements may contain acceleration provisions upon certain merger, acquisition or change of control transactions and other circumstances.
We describe our option plans under &#8220;Equity Incentive Plans.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><span style="font-style: italic">Exculpation,
Indemnification and Insurance.</span> Our Articles of Association permit us to exculpate, indemnify and insure certain of our office holders
to the fullest extent permitted by the Companies Law. We have entered into agreements with certain office holders, exculpating them from
a breach of their duty of care to us to the fullest extent permitted by law and undertaking to indemnify them to the fullest extent permitted
by law, subject to certain exceptions, including with respect to liabilities resulting from the IPO to the extent that such liabilities
are not covered by insurance. See Item 6. &#8220;Directors, Senior Management and Employees-Exculpation, Insurance and Indemnification
of Directors and Officers.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><span style="font-style: italic">The
Repurchase Agreement.</span> As previously reported in&#160;our Registration Statement on Form S-4 (File No. 333-252070), filed with SEC
on January 13, 2021 and declared effective by the SEC on February 10, 2021, Chemomab Ltd. filed an application with the Israel Tax Authority
for a tax ruling (the &#8220;Tax Ruling&#8221;) in connection with the Merger, pursuant to which certain of Chemomab Ltd.&#8217;s shareholders
were entitled to defer an immediate Israeli tax liability resulting from the exchange of shares that otherwise would have been deemed
a sale. The deferral of the aforementioned tax liability is set to lapse on March 16, 2023, which is the two-year anniversary of the closing
date of the Merger. Dr. Adi Mor, co-founder of Chemomab Ltd. and both our Chief Scientific Officer and a Class III director, and Professor
Kobi George, co-founder of Chemomab Ltd. (together with Dr. Adi Mor, the &#8220;Co-Founders&#8221;), will be required to pay a substantial
tax liability to the Israeli Tax Authority upon the expiration date of the deferral period. In order to pay this tax liability, the Co-Founders
had to sell part of their holdings in the Company.&#160;In light of the foregoing, we elected to enter into a share purchase agreement
(the &#8220;Repurchase Arrangement&#8221;) with the Co-Founders whereby we agreed, subject to the requisite court approval required under
Section 303(a) of the Companies Law, which we received on November 14, 2022, to repurchase up to 582,023 of our ADSs owned by the Co-Founders,
for consideration not to exceed an aggregate amount of $2,500,000, depending on the market price of the ADSs at the time of any repurchase.
Accordingly, on November 16, 2022, we repurchased the entire amount of 582,023 ADSs from the Co-Founders at a price of $2.0848 and for
total consideration of approximately $1,218,000.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Related Party Transaction Policy</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our board of directors has adopted
a written related party transaction policy that sets forth the policies and procedures for the review and approval or ratification of
related person transactions. This policy covers interested party transactions under the Companies Law, interested party transactions as
defined in Part I, Item 7.B of Form 20-F and transactions between the Company and an interested party, which are material to the Company
or the interested party, and any such transactions between the Company and an interested party that are unusual in their nature or conditions,
involving goods, services, or tangible or intangible assets.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" id="z91ab82f1b40a4191a5a6c0bfd73c2a44" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">C.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Interests of Experts and Counsel</div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold"> <br/> </div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: normal">Not applicable.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">112</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">

<div style="line-height: 1.25"><span id="Item8"><!--Anchor--></span><span style="font-weight: bold; font-style: normal">Item 8. Financial
Information</span><span style="font-style: normal">&#160;</span></div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">A.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Consolidated Statements and Other Financial Information</div> </td>
        </tr>
  </table>

<div>&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Consolidated
Financial Statements</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">See Item 18. &#8220;Financial Statements.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Legal and Arbitration
Proceedings</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">From time to time, we may be involved
in various claims and legal proceedings arising from the normal course of our business activities and operations. Other than as noted
below, we are not presently a party to any litigation the outcome of which, we believe, if determined adversely to us, would individually
or taken together have a material adverse effect on our business, operating results, cash flows or financial condition. Defending such
proceedings is costly and can impose a significant burden on management and employees. The outcomes of any such claims or proceedings,
regardless of the merits, is inherently uncertain and can have an adverse impact on us because of defense and settlement costs, diversion
of management resources and other factors.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Dividend Policy</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We do not anticipate paying any dividends
in the foreseeable future. We currently intend to retain future earnings, if any, to finance operations and expand our business. Our board
of directors has sole discretion whether to pay dividends. If our board of directors decides to pay dividends, the form, frequency and
amount will depend upon our future operations and earnings, capital requirements and surplus, general financial condition, contractual
restrictions, restrictions under our Credit Facility and other factors that our directors may deem relevant. The Companies Law imposes
restrictions on our ability to declare and pay dividends.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Payment of dividends may be subject
to Israeli withholding taxes. See Item 10.E. &#8220;Taxation-Israeli Tax Considerations&#8221; for additional information.</div>

<div style="line-height: 1.25; font-family: Times New Roman"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z5632be359e5f4432aeea720b7c0c42ab" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">B.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Significant Changes</div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold"> <br/> </div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: normal">None.</div> </div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Item 9<span id="Item9"><!--Anchor--></span>.
The Offer and Listing</div>

<div style="line-height: 1.25; font-family: Times New Roman"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zb2d06fa47dec431cb8893adf25bdbcd9" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">A.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Offer and Listing Details</div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold"> <br/> </div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: normal">Our ADSs are listed on Nasdaq under the symbol &#8220;CMMB&#8221;.</div> </div> </td>
        </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z9530cf0d7d694d118e5ddf6b491244c8" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">B.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Plan of Distribution</div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold"> <br/> </div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: normal">Not applicable.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za7961630b5624fd38e29b1f095294725" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">C.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Markets</div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold"> <br/> </div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: normal">Our ADSs are listed on Nasdaq under the symbol &#8220;CMMB&#8221;.</div> </div> </td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za813270ff1e742f8bf61bc1c8f44620d" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">D.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Selling Shareholders</div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold"> <br/> </div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: normal">Not applicable.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4826fc6990fd4f30868f78850b26bb84" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">E.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Dilution</div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold"> <br/> </div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: normal">Not applicable.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z891ab3e8d4964322800c9fe83c4cfadc" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">F.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Expenses of the Issue</div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold"> <br/> </div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: normal">Not applicable.</div> </div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">113</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Item 10<span id="Item10"><!--Anchor--></span>.
Additional Information</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold"> <br/> </div>

<table cellspacing="0" cellpadding="0" id="z9fa4d0d6d93a464b8b0ebaebf0d14953" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">A.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Share Capital</div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold"> <br/> </div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: normal">Not applicable.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z42cf339a3d524564956dadd4e7180814" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">B.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Memorandum and Articles of Association</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">

<div style="text-align: justify; line-height: 1.25; font-weight: bold">

<div style="line-height: 1.25; font-weight: normal; text-indent: 36pt">A copy of our Articles of Association is attached as Exhibit 1.1
to this Annual Report. Other than as set forth below, the information called for by this Item is set forth in Exhibit 2.1 to this Annual
Report and is incorporated by reference into this Annual Report.</div> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<table cellspacing="0" cellpadding="0" id="za607d2bbbb854210af5d072a166d4d2b" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">C.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Material Contracts</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Except as disclosed below or otherwise
disclosed in this Annual Report (including the Exhibits), we are not currently, nor have we been for the two years immediately preceding
the date of this Annual Report, party to any material contract, other than contracts entered into in the ordinary course of business.</div>

<div style="line-height: 1.25; font-family: Times New Roman"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zbdf95006a53f4b069b24cf5c2c4d1e5d" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8226;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Form of Deposit Agreement between Chemomab Therapeutics Ltd. (f/k/a Anchiano Therapeutics
        Ltd.), the Bank of New York Mellon as Depositary, and owners and holders from time to time of ADSs issued by the Company, dated February
        14, 2019 (incorporated by reference to Exhibit 4.1 to the Registrants registration statement on Form S-1 filed with the SEC on January
        13, 2023). &#160;</div>
        <div style="text-align: justify; line-height: 1.25"> <br/> </div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8226;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">Form of Indemnification Agreement (incorporated by reference
        to Exhibit 10.7 of the Company&#8217;s Amendment No. 1 to its Registration Statement on Form S-4 filed with the Securities and Exchange
        Commission on February 10, 2021). See Item 6, "Directors, Senior Management and Employees" for more information about this document.</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8226;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">Compensation Policy for Officers and Directors (incorporated
        by reference to Exhibit 10.2 of the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with
        the SEC on March 30, 2022). See Item 6, "Directors, Senior Management and Employees" for more information about this document.</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8226;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">2011 Incentive Plan for Employees, Officers and Consultants
        (previously filed as Exhibit 10.6 of our Registration Statement on Form F-1 (File No. 333-229155) as filed with the SEC on January 7,
        2019 and incorporated by reference herein). See Item 6, "Directors, Senior Management and Employees" for more information about this document.</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8226;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">2017 Equity-Based Incentive Plan (previously filed as
        Exhibit 10.8 of our Registration Statement on Form F-1 (File No. 333-229155) as filed with the SEC on January 7, 2019 and incorporated
        by reference herein). See Item 6, "Directors, Senior Management and Employees" for more information about this document.</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#8226;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">Chemomab Ltd. 2015 Share Incentive Plan (incorporated
        by reference to Exhibit 10.4 to the Registrant&#8217;s registration statement on Form S-4 (SEC file number 333- 252070), filed with the
        SEC on January 13, 2021) See Item 6, "Directors, Senior Management and Employees" for more information about this document.</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">Tel-Aviv Souraski Medical Center (TASMC) License Agreement
        between Chemomab Ltd. and the Medical Research, Infrastructure, Health Services Fund of the Tel Aviv Souraski Medical Center., dated December
        1, 2011, as amended on May 9, 2013 (incorporated by reference to Exhibit 10.8 of the Company&#8217;s Amendment No. 1 to its Registration
        Statement on Form S-4 filed with the Securities and Exchange Commission on February 10, 2021).</div>
        <div style="line-height: 1.25; font-family: Times New Roman"><span style="line-height: 1.25">&#160;</span></div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">CMC Collaboration Agreement between Chemomab Ltd. and
        CMC ICOS Biologics, Inc., dated June 7, 2015 (incorporated by reference to Exhibit 10.9 of the Company&#8217;s Amendment No. 1 to its
        Registration Statement on Form S-4 filed with the Securities and Exchange Commission on February 10, 2021).</div>
        <div style="line-height: 1.25; font-family: Times New Roman"><span style="line-height: 1.25">&#160;</span></div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Securities Purchase Agreement by and between Chemomab Ltd. and the Purchasers listed
        therein, dated July 25, 2024 (as filed with the SEC on July 25, 2024 as Exhibit 99.1 to our Report of Foreign Private Issuer on Form 6-K
        and incorporated by reference herein).</div> </td> </tr>
  </table>

<div> <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">114</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z6645ec2929914182a270f3538416da7e" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">D.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Exchange Controls</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">There are currently no Israeli currency
control restrictions on remittances of dividends on our ordinary shares, proceeds from the sale of the ordinary shares or interest or
other payments to non-residents of Israel, except for shareholders who are subjects of countries that are, have been, or will be, in a
state of war with Israel.</div>

<div style="line-height: 1.25; font-family: Times New Roman"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z783aa4dfc6844d5f95c1ec056f01d290" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">E.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Taxation</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Israeli Tax Considerations</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">General corporate tax structure
in Israel</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Israeli companies are generally subject
to corporate tax. The standard corporate tax rate in 2024 was 23%. However, the effective tax rate payable by a company that derives income
from a &#8220;Preferred Enterprise&#8221;, a &#8220;Special Preferred Enterprise&#8221;, a &#8220;Preferred Technological Enterprise&#8221;,
or a &#8220;Special Preferred Technological Enterprise&#8221; (as discussed below) may be considerably less. Capital gains derived by
an Israeli company are generally subject to the prevailing corporate tax rate.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">Law for the Encouragement of Capital
Investments, 5719-1959</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The Law for the Encouragement of
Capital Investments, 5719-1959, generally referred to as the Investment Law, provides certain incentives for capital investments in production
facilities (or other eligible assets).</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The Investment Law was significantly
amended effective as of April 1, 2005 (the &#8220;2005 Amendment&#8221;), as of January 1, 2011 (the &#8220;2011 Amendment&#8221;) and
as of January 1, 2017 (the &#8220;2017 Amendment&#8221;). Pursuant to the 2005 Amendment, tax benefits granted in accordance with the
provisions of the Investment Law prior to its revision by the 2005 Amendment remain in force but any benefits granted subsequently are
subject to the provisions of the amended Investment Law. Similarly, the 2011 Amendment introduced new benefits to replace those granted
in accordance with the provisions of the Investment Law in effect prior to the 2011 Amendment. However, companies entitled to benefits
under the Investment Law as in effect prior to January 1, 2011, were entitled to choose to continue to enjoy such benefits, provided that
certain conditions are met, or elect instead, irrevocably, to forego such benefits and have the benefits of the 2011 Amendment apply.
The 2017 Amendment introduced new benefits for Preferred Technological Enterprises, alongside the existing tax benefits.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">Tax benefits under the 2011 Amendment</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The 2011 Amendment introduced new
benefits for income generated by a &#8220;Preferred Company&#8221; through its &#8220;Preferred Enterprise&#8221; (as such terms are defined
in the Investment Law) as of January 1, 2011. The definition of a Preferred Company includes a company incorporated in Israel that is
not fully owned by a governmental entity, and that has, among other things, Preferred Enterprise status and is controlled and managed
from Israel.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Pursuant to the 2011 Amendment, a
Preferred Company was entitled to a reduced corporate tax rate of 15% with respect to its income derived from its Preferred Enterprise
in 2011 and 2012, unless the Preferred Enterprise is located in a certain development zone, in which case the rate was 10%. Under the
2011 Amendment, together with amendments to the Investment Law from 2014 and 2017, such corporate tax rate was reduced from 15% and 10%,
respectively, to 12.5% and 7%, respectively, in 2013, 16% and 9% respectively, in 2014, 2015 and 2016, and 16% and 7.5%, respectively,
in 2017 and thereafter. Income derived by a Preferred Company from a &#8220;Special Preferred Enterprise&#8221; (as such term is defined
in the Investment Law) would be entitled, during a benefits period of 10 years, to further reduced tax rates of 8%, or 5% if the Special
Preferred Enterprise is located in a certain development zone. Since January 1, 2017, the definition for &#8220;Special Preferred Enterprise&#8221;
includes less stringent conditions.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">115</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Dividends distributed from preferred
income which is attributed to a &#8220;Preferred Enterprise&#8221; or to a &#8220;Special Preferred Enterprise&#8221; should generally
be subject to withholding tax at source at the following rates: (i) Israeli resident corporations - 0%, (although, if such dividends are
subsequently distributed to individuals or a non-Israeli company the below rates detailed in sub sections (ii) and (iii) shall apply),
(ii) Israeli resident individuals - 20% and (iii) non-Israeli residents (individuals and corporations)- subject to the receipt in advance
of a valid certificate from the Israel Tax Authority (&#8220;ITA&#8221;) allowing for a reduced tax rate, 20% or such lower rate as may
be provided under the provisions of any applicable double tax treaty.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The 2011 Amendment also provided
transitional provisions to address companies already enjoying existing tax benefits under the Investment Law. These transitional provisions
provide, among other things, that unless an irrevocable request is made to apply the provisions of the Investment Law as amended in 2011
with respect to income to be derived as of January 1, 2011, a &#8220;Benefited Enterprise&#8221; (as such term is defined under the Investment
Law) can elect to continue to benefit from the benefits provided to it before the 2011 Amendment came into effect, provided that certain
conditions are met.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We currently do not intend to implement
the 2011 Amendment.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">Tax benefits under the 2017 Amendment</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The 2017 Amendment was enacted as
part of the Economic Efficiency Law that was published on December 29, 2016, and is effective as of January 1, 2017. The 2017 Amendment
provided new tax benefits for two types of &#8220;Preferred Technological Enterprises,&#8221; as described below, and is in addition to
the other existing tax beneficial programs under the Investment Law.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The 2017 Amendment provides that
a technology company satisfying certain conditions should qualify as a Preferred Technological Enterprise (&#8220;PTE&#8221;) and thereby
enjoy a reduced corporate tax rate of 12% on income that qualifies as &#8220;Preferred Technological Income,&#8221; as defined in the
Investment Law. The tax rate is further reduced to 7.5% for a PTE located in development zone &#8220;A&#8221;. In addition, a PTE will
enjoy a reduced corporate tax rate of 12% on capital gain derived from the sale of certain &#8220;Benefited Intangible Assets&#8221; (as
defined in the Investment Law) to a related foreign company if the Benefited Intangible Assets were acquired from a foreign company on
or after January 1, 2017 for at least NIS 200 million, and the sale received prior approval from the National Authority for Technological
Innovation (previously known as the Israeli Office of the Chief Scientist), to which we refer as IIA.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The 2017 Amendment further provides
that a technology company satisfying certain conditions (group turnover of at least NIS 10 billion) should qualify as a &#8220;Special
Preferred Technological Enterprise&#8221; and will thereby enjoy a reduced corporate tax rate of 6% on &#8220;Preferred Technological
Income&#8221; regardless of the company&#8217;s geographic location within Israel. In addition, a Special Preferred Technological Enterprise
should enjoy a reduced corporate tax rate of 6% on capital gain derived from the sale of certain &#8220;Benefited Intangible Assets&#8221;
to a related foreign company if the Benefited Intangible Assets were either developed by the Special Preferred Technological Enterprise
or acquired from a foreign company on or after January 1, 2017, and the sale received prior approval from IIA. A Special Preferred Technological
Enterprise that acquires Benefited Intangible Assets from a foreign company for more than NIS 500 million should be eligible for these
benefits for at least ten years, subject to certain approvals as specified in the Investment Law.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Dividends distributed to Israeli
shareholders by a PTE or a Special Preferred Technological Enterprise, paid out of Preferred Technological Income, should generally subject
to withholding tax at source at the rate of 20% (in the case of non-Israeli shareholders subject to the receipt in advance of a valid
certificate from the ITA allowing for a reduced tax rate, 20%, or such a lower rate as may be provided in an applicable tax treaty). However,
if such dividends are paid to an Israeli company, no tax is generally required to be withheld (although, if such dividends are subsequently
distributed to individuals or a non-Israeli company, the aforesaid should apply). If such dividends are distributed to a foreign company
that holds solely or together with other foreign companies 90% or more in the Israeli company and other conditions are met, the withholding
tax rate should be 4% (or such lower rate as may be provided in an applicable tax treaty, in either case, subject to the receipt in advance
of a valid certificate from the ITA allowing for such reduced tax rate).</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Currently we have not exhausted the
benefits we believe we may qualify for as a PTE and continue to examine the degree to which we may qualify as a PTE, the amount of Preferred
Technological Income that we may have and other benefits that we may receive from the 2017 Amendment in the future.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">116</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">Tax benefits and grants for research
and development</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Israeli tax law allows, under certain
conditions, a tax deduction for expenditures, including capital expenditures, in scientific research in the fields of industry, agriculture,
transportation or energy, for the year in which they are incurred. Expenditures are deemed related to scientific research and development
projects, if:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z94ccda0b356740a49ffc06dd841fc833" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">The expenditures are approved by the relevant Israeli government ministry, determined
        by the field of research;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">The research and development must be for the promotion of the company; and</div> </td>
        </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">The research and development is carried out by or on behalf of the company seeking
        such tax deduction.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The amount of such deductible expenses is reduced by the
sum of any funds received through government grants for the finance of such scientific research and development projects. No deduction
under these research and development deduction rules is allowed if such deduction is related to an expense invested in an asset depreciable
under the general depreciation rules of the Ordinance. Expenditures that are unqualified under the conditions above are deductible in
equal amounts over three years.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">From time to time we may apply to
the Israel Innovation Authority for approval to allow a tax deduction for all or most of research and development expenses during the
year incurred. There can be no assurance that such application will be accepted.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Taxation of our
shareholders</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><span style="font-style: italic">Capital
gains taxes applicable to non-Israeli resident shareholders</span>. Capital gain tax is imposed on the disposition of capital assets by
an Israeli resident for tax purposes, and on the disposition of such assets by a non-Israeli resident for tax purposes if those assets
are (i) located in Israel; (ii) are shares or a right to a share in an Israeli resident corporation, or (iii) represent, directly or indirectly,
rights to assets the majority of which are located in Israel, unless a specific exemption is available or unless a tax treaty between
Israel and the shareholder&#8217;s country of residence provides otherwise. The Ordinance distinguishes between &#8220;Real Capital Gain&#8221;
and the &#8220;Inflationary Surplus.&#8221; Real Capital Gain is the excess of the total capital gain over Inflationary Surplus.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Inflationary Surplus is a portion
of the total capital gain which is equivalent to the increase in the relevant asset&#8217;s cost base that is attributable to the increase
in the Israeli consumer price index or, in certain circumstances, a foreign currency exchange rate, between the date of purchase and the
date of disposition. Inflationary Surplus attributed to the period after December 31, 1993, is not currently subject to tax in Israel.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Real Capital Gain accrued by individuals
from the sale of our shares should generally be taxed at the rate of 25%. However, if the individual shareholder is a &#8220;substantial
shareholder&#8221; (as defined below) at the time of sale or at any time during the preceding 12-month period, such capital gain should
be taxed at the rate of 30%. Furthermore, where an individual claimed real interest expenses and linkage differentials on securities,
the capital gain on the sale of the securities should be taxed at a rate of 30%. Real Capital Gain derived by corporations should generally
be subject to the corporate tax rate (23% in 2024).</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Individual and corporate shareholders
dealing in securities in Israel are taxed at the tax rates applicable to business income (a corporate tax rate for a corporation and a
marginal tax rate of up to 47% for an individual in 2024, excluding surtax as discussed below) unless contrary provisions in a relevant
tax treaty apply.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">117</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">A non-Israeli resident who derives
capital gains from the sale of shares in an Israeli resident company that were purchased upon or after the company was listed for trading
on a stock exchange outside of Israel, should be exempt from Israeli capital gains tax so long as the capital gain derived from the sale
of shares was not attributed to a permanent establishment that the non-Israeli resident maintains in Israel. However, non-Israeli entities
(including corporations) should not be entitled to the foregoing exemption if Israeli residents: (i) have a controlling interest of more
than 25% in such non-Israeli entity or (ii) are the beneficiaries of, or are entitled to, 25% or more of the revenues or profits of such
non-Israeli corporation, whether directly or indirectly. In addition, such exemption is not applicable to a person whose gains from selling
or otherwise disposing of the shares are deemed to be business income.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Additionally, a sale of securities
by a non-Israeli resident may be exempt from Israeli capital gains tax under the provisions of an applicable tax treaty, subject to the
eligibility of such person to the treaty benefits. For example, under the Convention Between the Government of the United States of America
and the Government of the State of Israel with respect to Taxes on Income, as amended (the &#8220;U.S. Israel Tax Treaty&#8221;), the
sale, exchange or other disposition of shares by a shareholder who is a United States resident (for purposes of the U.S. Israel Tax Treaty)
holding the shares as a capital asset and is entitled to claim the benefits afforded to such a resident by the U.S. Israel Tax Treaty
(a &#8220;Treaty U.S. Resident&#8221;) is generally exempt from Israeli capital gains tax unless: (i) the capital gain arising from such
sale, exchange or disposition is attributed to real estate located in Israel; (ii) the capital gain arising from such sale, exchange or
disposition is attributed to royalties; (iii) the capital gain arising from the such sale, exchange or disposition is attributed to a
permanent establishment in Israel, under certain terms; (iv) such Treaty U.S. Resident holds, directly or indirectly, shares representing
10% or more of the voting capital during any part of the 12 month period preceding the disposition, subject to certain conditions; or
(v) such Treaty U.S. Resident, being an individual, was present in Israel for 183 days or more during the relevant taxable year. In such
case, the sale, exchange or disposition of our shares would be subject to Israeli tax, to the extent applicable; however, under the U.S.
Israel Tax Treaty, a Treaty U.S. resident would be permitted to claim a credit for such taxes against the U.S. federal income tax imposed
with respect to such sale, exchange or disposition, subject to the limitations under U.S. law applicable to foreign tax credits. The U.S.
Israel Tax Treaty does not relate to tax credits against U.S. state or local taxes.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Shareholders may be required to demonstrate
that they are exempt from tax on their capital gains in order to avoid withholding at source at the time of sale, by presenting a valid
withholding exemption certificate issued by the ITA prior to the applicable payment. In addition, in transactions involving a sale of
all of the shares of an Israeli resident company, in the form of a merger or otherwise, the ITA may require from shareholders who are
not liable for Israeli tax to sign declarations in forms specified by this authority or obtain a specific exemption from the ITA to confirm
their status as a non-Israeli resident for tax purposes, and, in the absence of such declarations or exemptions, may require the purchaser
of the shares to withhold taxes.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">118</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><span style="font-style: italic">Taxation
of non-Israeli shareholders on receipt of dividends</span>. Non-Israeli residents (either individuals or corporations) are generally subject
to Israeli income tax on the receipt of dividends paid on our ordinary shares at the rate of 25%, which tax will be withheld at source,
unless relief is provided in a treaty between Israel and the shareholder&#8217;s country of residence (subject to the receipt in advance
of a valid certificate from the ITA allowing for a reduced tax rate). With respect to a person who is a &#8220;substantial shareholder&#8221;
at the time of receiving the dividend or on any time during the preceding twelve months, the applicable tax rate is 30%. A &#8220;substantial
shareholder&#8221; is generally a person who alone or together with such person&#8217;s relative or another person who collaborates with
such person on a permanent basis, holds, directly or indirectly, 10% or more of any of the &#8220;means of control&#8221; of the corporation.
&#8220;Means of control&#8221; generally include the right to vote, receive profits, nominate a director or an executive officer, receive
assets upon liquidation, or order someone who holds any of the aforesaid rights how to act, regardless of the source of such right. Such
dividends are generally subject to Israeli withholding tax at a rate of 25% so long as the shares are registered with a nominee company
(whether the recipient is a substantial shareholder or not), or 20% if the dividend is distributed from income attributed to a Preferred
Enterprise or PTE, subject to the receipt in advance of a valid certificate from the ITA allowing for a reduced tax rate, 20% or such
lower rate as may be provided in an applicable tax treaty. For example, under the U.S. Israel Tax Treaty, and subject to the eligibility
to the benefits under this treaty, the maximum rate of tax withheld at source in Israel on dividends paid to a holder of our ordinary
shares who is a Treaty U.S. Resident is 25%. However, generally, the maximum rate of withholding tax on dividends, not generated by a
Preferred Enterprise, that are paid to a United States corporation holding 10% or more of the outstanding voting capital throughout the
tax year in which the dividend is distributed as well as during the previous tax year, is 12.5%, provided that not more than 25% of the
gross income for such preceding year consists of certain types of dividends and interest. Notwithstanding the foregoing, dividends distributed
from income attributed to a Preferred Enterprise are not entitled to such reduction under the tax treaty but are subject to a withholding
tax rate of 15% for a shareholder that is a U.S. corporation, provided that the conditions related to 10% or more holding and to our gross
income for the previous year (as set forth in the previous sentence) are met. If the dividend is attributable partly to income derived
from a Preferred Enterprise, and partly to other sources of income, the withholding rate will be a blended rate reflecting the relative
portions of the two types of income. We cannot assure you that we will designate the profits that we may distribute in a way that will
reduce shareholders&#8217; tax liability. The aforementioned rates under the U.S. Israel Tax Treaty would not apply if the dividend income
is derived through a permanent establishment of the Treaty U.S. Resident in Israel. U.S. residents who are subject to Israeli withholding
tax on a dividend may be entitled to a credit or deduction for United States federal income tax purposes in the amount of the taxes withheld,
subject to detailed rules contained in U.S. tax legislation.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">A non-Israeli resident who receives
dividends from which full tax was withheld is generally exempt from the obligation to file tax returns in Israel with respect to such
income, provided that (i) such income was not generated from business conducted in Israel by the taxpayer, (ii) the taxpayer has no other
taxable sources of income in Israel with respect to which a tax return is required to be filed, and (iii) the taxpayer is not obligated
to pay surtax (as further explained below).</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><span style="font-style: italic">Surtax.</span>
Subject to the provisions of an applicable tax treaty, individuals who are subject to tax in Israel (whether any such individual is an
Israeli resident or non-Israeli resident) are also subject to an additional tax at a rate of 3% on annual taxable income (including, but
not limited to, dividends, interest and capital gain) exceeding NIS 721,560 for 2024, which amount is generally linked to the annual change
in the Israeli consumer price index (with the exception that based on Israeli new legislation such amount, and certain other statutory
amounts will not be linked to the Israeli consumer price index for the years 2025-2027). According to new legislation, in effect as of
January 1, 2025, an additional 2% surtax is imposed on Capital-Sourced Income (defined as income from any source other than employment
income, business income or income from &#8220;personal effort&#8221;), to the extent that the Individual&#8217;s Capital Sourced Income
exceeds the specified threshold of NIS 721,560 (and regardless of the employment/business income amount of such individual). This new
surtax applies, among other things, to income from capital gains, dividends, interest, rental income, or the sale of real property.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><span style="font-style: italic">Estate
and Gift Tax.</span> Israeli law presently does not impose estate or gift taxes.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Material U.S. Federal Income Tax
Considerations for U.S. Holders</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The following is a description of
certain material United States federal income tax considerations of the ownership and disposition of our ordinary shares. This description
addresses only the United States federal income tax consequences to U.S. Holders (as defined below) that hold our ordinary shares as capital
assets within the meaning of Section 1221 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), and that have the
U.S. dollar as their functional currency. This discussion is based upon the Code, applicable U.S. Treasury regulations, administrative
pronouncements and judicial decisions, in each case as in effect on the date hereof, all of which are subject to change (possibly with
retroactive effect). No ruling will be requested from the Internal Revenue Service (the &#8220;IRS&#8221;) regarding the tax consequences
of the ownership or disposition of the ordinary shares, and there can be no assurance that the IRS will agree with the discussion set
out below. This summary does not address any U.S. tax consequences other than U.S. federal income tax consequences (e.g., the estate and
gift tax or the Medicare tax on net investment income) and does not address any state, local or non-U.S. tax consequences.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">119</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>
<!--PROfilePageNumberReset%Num%121%%%-->

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">This description does not address
tax considerations applicable to holders that may be subject to special tax rules, including, without limitation:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z19eb002740a04f37a3073ffd9a5f9091" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">banks, financial institutions or insurance companies;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">real estate investment trusts or regulated investment companies;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">dealers or brokers;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">traders that elect to mark to market;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">tax-exempt entities or organizations;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8220;individual retirement accounts&#8221; and other tax-deferred accounts;</div>
        </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">certain former citizens or long-term residents of the United States;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">persons that are resident or ordinarily resident in or have a permanent establishment
        in a jurisdiction outside the United States;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">persons that acquired our ordinary shares pursuant to the exercise of any employee
        share option or otherwise as compensation for the performance of services;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">persons holding our ordinary shares as part of a &#8220;hedging,&#8221; &#8220;integrated&#8221;
        or &#8220;conversion&#8221; transaction or as a position in a &#8220;straddle&#8221; for United States federal income tax purposes;</div>
        </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">persons subject to special tax accounting as a result of any item of gross income
        with respect to the ordinary shares being taken into account in an applicable financial statement;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">partnerships or other pass-through entities and persons holding the ordinary shares
        through partnerships or other pass-through entities; or</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">holders that own directly, indirectly or through attribution 10% or more of the total
        voting power or value of all of our outstanding shares.</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">For purposes of this description,
a &#8220;U.S. Holder&#8221; is a beneficial owner of our ordinary shares that, for United States federal income tax purposes, is:</div>

<div style="line-height: 1.25; font-family: Times New Roman"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z06e7333c28a044468fb8e4b49d4c8cae" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">an individual who is a citizen or resident of the United States;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">a corporation (or other entity treated as a corporation for United States federal
        income tax purposes) created or organized in or under the laws of the United States or any state thereof, including the District of Columbia;</div>
        </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">an estate the income of which is subject to United States federal income taxation
        regardless of its source; or</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">a trust if such trust has validly elected to be treated as a United States person
        for United States federal income tax purposes or if (1) a court within the United States is able to exercise primary supervision over
        its administration and (2) one or more United States persons have the authority to control all of the substantial decisions of such trust.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If an entity or arrangement treated
as a partnership for United States federal income tax purposes holds our ordinary shares, the tax treatment of a partner in such partnership
will generally depend on the status of the partner and the activities of the partnership. Such a partner or partnership should consult
its tax advisor as to the particular United States federal income tax consequences of owning and disposing of our ordinary shares in its
particular circumstance.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; font-weight: bold">You should consult
your tax advisor with respect to the United States federal, state, local and non-U.S. consequences of owning and disposing of our ordinary
shares.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">120</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Distributions</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Subject to the discussion under &#8220;-Passive
Foreign Investment Company Considerations&#8221; below, the gross amount of any distribution made to you with respect to our ordinary
shares, before reduction for any Israeli taxes withheld therefrom, generally will be includible in your income as dividend income on the
date on which the dividends are actually or constructively received, to the extent such distribution is paid out of our current or accumulated
earnings and profits as determined under United States federal income tax principles. To the extent that the amount of any distribution
by us exceeds our current and accumulated earnings and profits as determined under United States federal income tax principles, it will
be treated first as a tax-free return of your adjusted tax basis in our ordinary shares and thereafter as capital gain. However, we do
not expect to maintain calculations of our earnings and profits under United States federal income tax principles and, therefore, you
should expect that the entire amount of any distribution generally will be taxable as dividend income to you. Non-corporate U.S. Holders
may qualify for the lower rates of taxation with respect to dividends on ordinary shares applicable to long-term capital gains (i.e.,
gains from the sale of capital assets held for more than one year), provided<span style="font-style: italic">&#160;</span>that we are
not a PFIC (as discussed below under &#8220;-Passive Foreign Investment Company Considerations&#8221;) with respect to you in our taxable
year in which the dividend was paid or in the prior taxable year and certain other conditions are met, including certain holding period
requirements and the absence of certain risk reduction transactions. However, such dividends will not be eligible for the dividends received
deduction generally allowed to corporate U.S. Holders. You should consult your tax advisor regarding the availability of the lower rate
for dividends paid with respect to our shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The amount of any distribution paid
in foreign currency will be equal to the U.S. dollar value of such currency, translated at the spot rate of exchange on the date such
distribution is received, regardless of whether the payment is in fact converted into U.S. dollars at that time.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Dividends paid to you with respect
to our ordinary shares generally will be treated as foreign source income, which may be relevant in calculating your foreign tax credit
limitation. Subject to certain conditions and limitations, Israeli tax withheld on dividends may be credited against your United States
federal income tax liability or, at your election, be deducted from your U.S. federal taxable income. Dividends that we distribute generally
should constitute &#8220;passive category income&#8221; for purposes of the foreign tax credit. However, if we are a &#8220;United States-owned
foreign corporation,&#8221; solely for foreign tax credit purposes, a portion of the dividends allocable to our U.S. source earnings and
profits may be recharacterized as U.S. source. A &#8220;United States-owned foreign corporation&#8221; is any foreign corporation in which
United States persons own, directly or indirectly, 50% or more (by vote or by value) of the stock. In general, United States-owned foreign
corporations with less than 10% of earnings and profits attributable to sources within the United States are excepted from these rules.
In the event we are treated as a &#8220;United States-owned foreign corporation,&#8221; if 10% or more of our earnings and profits are
attributable to sources within the United States, a portion of the dividends paid on our ordinary shares allocable to our U.S. source
earnings and profits will be treated as U.S. source, and, as such, a U.S. Holder may not offset any foreign tax withheld as a credit against
U.S. federal income tax imposed on that portion of dividends. A foreign tax credit for foreign taxes imposed on distributions may be denied
if you do not satisfy certain minimum holding period requirements. The rules relating to the determination of the foreign tax credit are
complex, and you should consult your tax advisor regarding the availability of a U.S. foreign tax credit in your particular circumstances
and the possibility of claiming a deduction (in lieu of the U.S. foreign tax credit) for any foreign taxes paid or withheld.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Sale, Exchange
or Other Disposition of Ordinary Shares</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Subject to the discussion under &#8220;-Passive
Foreign Investment Company Considerations&#8221; below, you generally will recognize gain or loss on the sale, exchange or other disposition
of our ordinary shares equal to the difference between the amount realized on such sale, exchange or other disposition and your adjusted
tax basis in our ordinary shares, and such gain or loss will be capital gain or loss. If you are a non-corporate U.S. Holder, capital
gain from the sale, exchange or other disposition of ordinary shares is generally eligible for a preferential rate of taxation applicable
to capital gains, if your holding period for such ordinary shares exceeds one year (i.e., such gain is long-term capital gain). The deductibility
of capital losses for United States federal income tax purposes is subject to limitations under the Code. Any such gain or loss that a
U.S. Holder recognizes generally will be treated as U.S. source income or loss for foreign tax credit limitation purposes.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25">If the consideration received upon the sale or other disposition of our ordinary shares
is paid in foreign currency, the amount realized will be the U.S. dollar value of the payment received, translated at the spot rate of
exchange on the date of the sale or other disposition. If the ordinary shares are treated as traded on an established securities market
and you are either a cash basis taxpayer or an accrual basis taxpayer who has made a special election (which must be applied consistently
from year to year and cannot be changed without the consent of the IRS), the U.S. dollar value of the amount realized in foreign currency
will be determined by translating the amount received at the spot rate of exchange on the settlement date of the sale. If our ordinary
shares are not treated as traded on an established securities market, or you are an accrual basis taxpayer that does not elect to determine
the amount realized using the spot rate of exchange on the settlement date, you will recognize foreign currency gain or loss to the extent
of any difference between the U.S. dollar amount realized on the date of sale or disposition (as determined above) and the U.S. dollar
value of the currency received translated at the spot rate of exchange on the settlement date, and such gain or loss generally will constitute
U.S. source ordinary income or loss.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">121</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The adjusted tax basis in an ordinary
share generally will be equal to the cost of such ordinary share. If you used foreign currency to purchase the ordinary shares, the cost
of the ordinary shares will be the U.S. dollar value of the foreign currency purchase price on the date of purchase, translated at the
spot rate of exchange on that date. If our ordinary shares are treated as traded on an established securities market and you are either
a cash basis taxpayer or an accrual basis taxpayer who has made the special election described above, the U.S. dollar value of the cost
of such ordinary shares will be determined by translating the amount paid at the spot rate of exchange on the settlement date of the purchase.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Passive Foreign
Investment Company Considerations</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If a non-U.S. company is classified
as a PFIC in any taxable year, a U.S. Holder of such PFIC&#8217;s shares will be subject to special rules generally intended to reduce
or eliminate any benefits from the deferral of U.S. federal income tax that such U.S. Holder could derive from investing in a non-U.S.
company that does not distribute all of its earnings on a current basis.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In general, a non-U.S. corporation
will be classified as a PFIC for any taxable year if at least (i) 75% of its gross income is classified as &#8220;passive income&#8221;
or (ii) 50% of its gross assets (determined on the basis of a quarterly average) produce or are held for the production of passive income
(the &#8220;asset test&#8221;). Passive income for this purpose generally includes dividends, interest, royalties, rents, gains from commodities
and securities transactions and the excess of gains over losses from the disposition of assets which produce passive income. For these
purposes, cash and other assets readily convertible into cash are considered passive assets, and the company&#8217;s goodwill and other
unbooked intangibles are generally taken into account. In making this determination, the non-U.S. corporation is treated as earning its
proportionate share of any income and owning its proportionate share of any assets of any corporation in which it directly or indirectly
holds 25% or more (by value) of the stock.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We have not yet determined
whether we were a PFIC for the&#160; taxable year ended December 31, 2024, and the determination of our status as a PFIC for our 2025
taxable year is made at the end of the year, accordingly,&#160; no assurances can be made in this regard. Our status as a PFIC requires
a factual determination that depends on, among other things, our income, assets and operations in each year. Fluctuations in the market
price of our ordinary shares may cause our classification as a PFIC for the current or future taxable years to change because the value
of our assets for purposes of the asset test, including the value of our goodwill and unbooked intangibles, may be determined by reference
to the market price of our shares from time to time (which may be volatile). Among other matters, if our market capitalization subsequently
declines, it may make our classification as a PFIC more likely for the current or future taxable years. The composition of our income
and assets may also be affected by how, and how quickly, we use our liquid assets. Therefore, there can be no assurance that we will not
be treated as a PFIC for our current taxable year or any future taxable year.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Under the PFIC rules, if we were
considered a PFIC at any time that you hold our ordinary shares, we would continue to be treated as a PFIC with respect to your investment
in all succeeding years during which you own our ordinary shares (regardless of whether we continue to meet the tests described above)
unless (i) we have ceased to be a PFIC and (ii) you have made a &#8220;deemed sale&#8221; election under the PFIC rules. If such election
is made, you will be deemed to have sold your ordinary shares at their fair market value on the last day of the last taxable year in which
we were a PFIC, and any gain from the deemed sale would be subject to the rules described in the following paragraph. After the deemed
sale election, so long as we do not become a PFIC in a subsequent taxable year, the ordinary shares with respect to which such election
was made will not be treated as shares in a PFIC. You should consult your tax advisor as to the possibility and consequences of making
a deemed sale election if we are (or were to become) and then cease to be a PFIC, and such election becomes available.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">122</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If we are considered a PFIC at any
time that you hold ordinary shares, unless you make one of the elections described below, any gain recognized by you on a sale or other
disposition of the ordinary shares, as well as the amount of any &#8220;excess distribution&#8221; (defined below) received by you, would
be allocated ratably over your holding period for the ordinary shares. The amounts allocated to the taxable year of the sale or other
disposition (or the taxable year of receipt, in the case of an excess distribution) and to any year before we became a PFIC would be taxed
as ordinary income. The amount allocated to each other taxable year would be subject to tax at the highest rate in effect for individuals
or corporations, as appropriate, for that taxable year, and an interest charge would be imposed. For purposes of these rules, an excess
distribution is the amount by which any distribution received by you on your ordinary shares in a taxable year exceeds 125% of the average
of the annual distributions on the ordinary shares during the preceding three taxable years or your holding period, whichever is shorter.
Distributions below the 125% threshold are treated as dividends taxable in the year of receipt and are not subject to the highest tax
rates or the interest charge described above.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If we are treated as a PFIC with
respect to you for any taxable year, you will be deemed to own shares in any entities in which we directly or indirectly own equity that
are also PFICs, and you may be subject to the tax consequences described above with respect to the shares of such lower-tier PFIC you
would be deemed to own.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">Mark-to-market elections</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If we are a PFIC for any taxable
year during which you hold ordinary shares, then in lieu of being subject to the tax and interest charge rules discussed above, you may
make an election to include gain on the ordinary shares as ordinary income under a mark-to-market method, provided that such ordinary
shares are &#8220;marketable.&#8221; The ordinary shares will be marketable if they are &#8220;regularly traded&#8221; on a qualified
exchange or other market, as defined in applicable U.S. Treasury regulations, such as the Nasdaq Global Select Market. For these purposes,
the ordinary shares will be considered regularly traded during any calendar year during which they are traded, other than in <span style="font-style: italic">de
minimis </span>quantities, on at least 15 days during each calendar quarter. Any trades that have as their principal purpose meeting this
requirement will be disregarded. However, because a mark-to-market election cannot be made for any lower-tier PFICs that we may own, you
will generally continue to be subject to the PFIC rules discussed above with respect to your indirect interest in any investments we hold
that are treated as an equity interest in a PFIC for United States federal income tax purposes. As a result, it is possible that any mark-to-market
election will be of limited benefit. If you make an effective mark-to-market election, in each year that we are a PFIC, you will include
in ordinary income the excess of the fair market value of your ordinary shares at the end of the year over your adjusted tax basis in
the ordinary shares. You will be entitled to deduct as an ordinary loss in each such year the excess of your adjusted tax basis in the
ordinary shares over their fair market value at the end of the year, but only to the extent of the net amount previously included in income
as a result of the mark-to-market election. If you make an effective mark-to-market election, in each year that we are a PFIC, any gain
that you recognize upon the sale or other disposition of your ordinary shares will be treated as ordinary income and any loss will be
treated as ordinary loss, but only to the extent of the net amount of previously included income as a result of the mark-to-market election.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Your adjusted tax basis in the ordinary
shares will be increased by the amount of any income inclusion and decreased by the amount of any deductions under the mark-to-market
rules discussed above. If you make an effective mark-to-market election, it will be effective for the taxable year for which the election
is made and all subsequent taxable years unless the ordinary shares are no longer regularly traded on a qualified exchange or the IRS
consents to the revocation of the election. You should consult your tax advisor about the availability of the mark-to-market election,
and whether making the election would be advisable in your particular circumstances.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">Qualified electing fund elections</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In certain circumstances, a U.S.
equity holder in a PFIC may avoid the adverse tax and interest-charge regime described above by making a &#8220;qualified electing fund&#8221;
or QEF election to include in income its share of the corporation&#8217;s income on a current basis. However, you may make a qualified
electing fund election with respect to the ordinary shares only if we agree to furnish you annually with a PFIC annual information statement
as specified in the applicable U.S. Treasury regulations. There is no assurance that we will be able to timely provide the information
necessary for you to make a qualified electing fund election if we are classified as a PFIC.&#160; U.S. Holders should consult with their
U.S. tax advisors concerning the availability of a QEF election, if we are classified as a PFIC for any taxable year.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">123</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">Tax reporting</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If you own ordinary shares during
any year in which we are a PFIC and you recognize gain on a disposition of such ordinary shares or receive distributions with respect
to such ordinary shares, you generally will be required to file an IRS Form 8621 with respect to us, generally with your federal income
tax return for that year. If we are a PFIC for a given taxable year, then you should consult your tax advisor concerning your annual filing
requirements.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; font-weight: bold">You should consult
your tax advisor regarding whether we are a PFIC as well as the potential U.S. federal income tax consequences of holding and disposing
of our ordinary shares if we are or become classified as a PFIC, including the possibility of making a mark-to-market or QEF election
in your particular circumstances.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Backup Withholding
Tax and Information Reporting Requirements</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Dividend payments on and proceeds
paid from the sale or other taxable disposition of the ordinary shares may be subject to information reporting to the IRS. In addition,
a U.S. Holder may be subject to backup withholding on cash payments received in connection with dividend payments and proceeds from the
sale or other taxable disposition of ordinary shares made within the United States or through certain U.S. related financial intermediaries.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Backup withholding will not apply,
however, to a U.S. Holder who furnishes a correct taxpayer identification number, provides other required certification and otherwise
complies with the applicable requirements of the backup withholding rules or who is otherwise exempt from backup withholding (and, when
required, demonstrates such exemption). Backup withholding is not an additional tax. Rather, any amount withheld under the backup withholding
rules will be creditable or refundable against the U.S. Holder&#8217;s U.S. federal income tax liability, provided the required information
is timely furnished to the IRS.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Foreign Asset
Reporting</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Certain U.S. Holders are required
to report their holdings of certain foreign financial assets, including equity of foreign entities, if the aggregate value of all of these
assets exceeds certain threshold amounts by filing an IRS Form 8938 with their federal income tax return. Our ordinary shares are expected
to constitute foreign financial assets subject to these requirements unless the ordinary shares are held in an account at certain financial
institutions. U.S. Holders are urged to consult their tax advisors regarding their information reporting obligations, if any, with respect
to their ownership and disposition of our ordinary shares and the significant penalties for non-compliance.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; font-weight: bold">The above description
is not intended to constitute a complete analysis of all tax consequences relating to the ownership and disposition of our ordinary shares.
You should consult your tax advisor concerning the tax consequences of your particular situation.</div>

<div style="line-height: 1.25; font-family: Times New Roman"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z1561951523c84c44b0a19653ef37be17" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">F.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Dividends and Paying Agents</div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold"> <br/> </div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: normal">
        <div style="line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: normal">
        <div style="line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: normal">Not applicable.</div> </div> </div> </div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z892b0f1a31eb423691a355b60d431294" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">G.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Statement by Experts</div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold"> <br/> </div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: normal">
        <div style="line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: normal">
        <div style="line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: normal">Not applicable.</div> </div> </div> </div> </div> </div> </div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zdc91df4dbe8d48d397079522430803c4" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">H.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Documents on Display</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We are subject to the informational
requirements of the Exchange Act. Accordingly, we are required to file reports and other information with the SEC, including annual reports
on Form 20-F and reports on Form 6-K. The SEC maintains an internet website that contains reports and other information about issuers,
like us, that file electronically with the SEC. The address of that website is www.sec.gov.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">124</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We maintain a corporate website at
<span style="font-style: italic">http://www.chemomab.com</span>. Information contained on, or that can be accessed through our website
does not constitute a part of this Annual Report on Form 20-F. We also make available on our website&#8217;s investor relations page at
<span style="font-style: italic">http://investors.chemomab.com</span>, free of charge, our Annual Report and the text of our reports on
Form 6-K and 8-K, including any amendments to these reports, as well as certain other SEC filings, as soon as reasonably practicable after
they are electronically filed with or furnished to the SEC. The information contained on our website is not incorporated by reference
in this Annual Report.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">As a foreign private issuer, we are
exempt under the Exchange Act from, among other things, the rules prescribing the furnishing and content of proxy statements, and our
officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section
16 of the Exchange Act. In addition, we are not required under the Exchange Act to file periodic reports and financial statements with
the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. However, we will file with
the SEC, within four months after the end of each subsequent fiscal year, or such applicable time as required by the SEC, an annual report
on Form 20-F containing financial statements audited by an independent registered public accounting firm. We also intend to furnish certain
other material information to the SEC under cover of Form 6-K.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We will send our transfer agent a
copy of all notices of shareholders&#8217; meetings and other reports, communications and information that are made generally available
to shareholders. The transfer agent has agreed to mail to all shareholders a notice containing the information (or a summary of the information)
contained in any notice of a meeting of our shareholders received by the transfer agent and will make available to all shareholders such
notices and all such other reports and communications received by the transfer agent.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7de619e37e40414cb22c46acd2510e01" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">I.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Subsidiary Information</div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold"> <br/> </div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: normal">
        <div style="line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: normal">
        <div style="line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: normal">Not applicable.</div> </div> </div> </div> </div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc8519b9cd4a84f3499eb82a50924b567" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">J.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Annual Report to Security Holders</div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold"> <br/> </div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: normal">
        <div style="line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: normal">
        <div style="line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: normal">Not applicable.</div> </div> </div> </div> </div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Item 11<span id="Item11"><!--Anchor--></span>.
Quantitative and Qualitative Disclosures about Market Risk</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We are exposed to market risk from
changes in exchange rates, interest rates and inflation. All of these market risks arise in the ordinary course of business, as we do
not engage in speculative trading activities. The following analysis provides additional information regarding these risks.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Interest rate
risk</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our investments are subject to market
risk due to changes in interest rates, which may affect our interest income and fair market value of our investments. To minimize this
risk, we maintain our portfolio in a variety of high-grade securities, including U.S. treasury bonds and government agencies. The primary
objectives of our investment activities are to support liquidity, preserve principal and to maximize income without significantly increasing
risk.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">As of December 31, 2024, we had $14.3
million of cash and cash equivalent, bank deposits and marketable securities. Interest-earning instruments carry a degree of interest
rate risk. However, our historical interest income has not fluctuated significantly. A hypothetical 10% change in interest rates would
not have had a material impact on our financial results for the years ended December 31, 2023 and 2024. We do not enter into investments
for trading or speculative purposes and have not used any derivative financial instruments to manage our interest rate risk exposure.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">125</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Foreign Currency
Exchange Risk</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Our functional currency is the U.S. Dollar.
We are exposed to foreign exchange rate risk. We are located in Israel, where part of our general and administrative expenses costs is
incurred in New Israeli Shekels. During each of the years ended December 31, 2024, and 2023, we recognized foreign currency transaction
gain of $9 thousand and $14 thousand, respectively, respectively. These foreign currency transaction gains&#160; were recorded in financial
expenses. We believe that a 10% change in the exchange rate between the U.S. Dollar and New Israeli Shekel would not have a material impact
on our financial position or results of operations.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">As we continue to grow our business,
our results of operations and cash flows will be subject to fluctuations due to changes in foreign currency exchange rates, which could
adversely impact our results of operations. To date, we have not entered into any foreign currency hedging contracts to mitigate our exposure
to foreign currency exchange risk.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Item 12<span id="Item12"><!--Anchor--></span>.
Description of Securities Other than Equity Securities</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za6a00c630e3a4ae79b7cb5c36cdbd55d" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">A.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Debt Securities</div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold"> <br/> </div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: normal">
        <div style="line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: normal">
        <div style="line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: normal">Not applicable.</div> </div> </div> </div> </div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zffce3644ae1e49518395f975e19d8e0d" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">B.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Warrants and Rights</div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold"> <br/> </div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: normal">
        <div style="line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: normal">
        <div style="line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: normal">Not applicable.</div> </div> </div> </div> </div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb1a693590b074a97a1a47be246e697d9" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">C.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Other Securities</div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold"> <br/> </div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: normal">
        <div style="line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: normal">
        <div style="line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25; font-weight: normal">Not applicable.</div> </div> </div> </div> </div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z19bba454b4b54fffbdb633be2de000f5" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">D.</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">American Depositary Shares</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The Bank of New York Mellon, as depositary,
registers and delivers our ADSs. Each ADS will represent ordinary shares (or a right to receive twenty (20) ordinary shares). Each ADS
will also represent any other securities, cash or other property which may be held by the depositary. The depositary&#8217;s office at
which our ADSs will be administered and its principal executive office are located at 240 Greenwich Street, New York, New&#160;York&#160;10286.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">You may hold ADSs either (A)&#160;directly
(i)&#160;by having an ADR, which is a certificate evidencing a specific number of ADSs, registered in your name or (ii)&#160;by having
uncertificated ADSs registered in your name or (B)&#160;indirectly by holding a security entitlement in ADSs through your broker or other
financial institution that is a direct or indirect participant in DTC. If you hold ADSs directly, you are a registered ADS holder, also
referred to as an ADS holder. This description assumes you are an ADS holder. If you hold our ADSs indirectly, you must rely on the procedures
of your broker or other financial institution to assert the rights of ADS holders described in this section. You should consult with your
broker or financial institution to find out what those procedures are.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Registered holders of uncertificated
ADSs will receive statements from the depositary confirming their holdings.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">As an ADS holder, we will not treat
you as one of our shareholders and you will not have shareholder rights. Israeli law governs shareholder rights. The depositary will be
the holder of the ordinary shares underlying your ADSs. As a registered holder of ADSs, you will have ADS holder rights. A deposit agreement
among us, the depositary, ADS holders and all other persons indirectly or beneficially holding ADSs sets out ADS holder rights as well
as the rights and obligations of the depositary. New York law governs the deposit agreement and our ADSs.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The following is a summary of the
material provisions of the deposit agreement. For more complete information, you should read the entire deposit agreement and the form
of ADR. For directions on how to obtain copies of those documents see &#8220;<span style="font-style: italic">Where You Can Find More
Information</span>.&#8221;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">126</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Dividends and Other Distributions</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">How will you receive dividends and
other distributions on the shares?</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The depositary has agreed to pay
or distribute to ADS holders the cash dividends or other distributions it or the custodian receives on ordinary shares or other deposited
securities, upon payment or deduction of its fees and expenses. You will receive these distributions in proportion to the number of ordinary
shares your ADSs represent.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold">Cash.</span>&#160;&#160;&#160;The
depositary will convert any cash dividend or other cash distribution we pay on the ordinary shares into U.S. dollars, if it can do so
on a reasonable basis and can transfer the U.S. dollars to the United States. If that is not possible or if any government approval is
needed and cannot be obtained, the deposit agreement allows the depositary to distribute the foreign currency only to those ADS holders
to whom it is possible to do so. It will hold the foreign currency it cannot convert for the account of our ADS holders who have not been
paid. It will not invest the foreign currency and it will not be liable for any interest.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Before making a distribution, any
withholding taxes or other governmental charges that must be paid will be deducted. See &#8220;Taxation and Government Programs.&#8221;
It will distribute only whole U.S. dollars and cents and will round fractional cents to the nearest whole cent. If the exchange rates
fluctuate during a time when the depositary cannot convert the foreign currency, you may lose some or all of the value of the distribution.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold">Shares.</span>&#160;&#160;&#160;The
depositary may distribute additional ADSs representing any ordinary shares we distribute as a dividend or free distribution. The depositary
will only distribute whole ADSs. It will sell ordinary shares which would require it to deliver a fraction of an ADS (or ADSs representing
those ordinary shares) and distribute the net proceeds in the same way as it does with cash. If the depositary does not distribute additional
ADSs, the outstanding ADSs will also represent the new shares. The depositary may sell a portion of the distributed ordinary shares (or
ADSs representing those ordinary shares) sufficient to pay its fees and expenses in connection with that distribution.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold">Rights
to purchase additional shares.</span>&#160;&#160;&#160;If we offer holders of our securities any rights to subscribe for additional ordinary
shares or any other rights, the depositary may (i)&#160;exercise those rights on behalf of ADS holders, (ii)&#160;distribute those rights
to ADS holders or (iii)&#160;sell those rights and distribute the net proceeds to ADS holders, in each case after deduction or upon payment
of its fees and expenses. To the extent the depositary does not do any of those things, it will allow the rights to lapse.&#160;<span style="font-style: italic">In
that case, you will receive no value for them.</span>&#160;The depositary will exercise or distribute rights only if we ask it to and
provide satisfactory assurances to the depositary that it is legal to do so. If the depositary will exercise rights, it will purchase
the securities to which the rights relate and distribute those securities or, in the case of ordinary shares, new ADSs representing the
new ordinary shares, to subscribing ADS holders, but only if ADS holders have paid the exercise price to the depositary. U.S. securities
laws may restrict the ability of the depositary to distribute rights or ADSs or other securities issued on exercise of rights to all or
certain ADS holders, and the securities distributed may be subject to restrictions on transfer.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold">Other
Distributions.</span>&#160;&#160;&#160;The depositary will send to ADS holders anything else we distribute on deposited securities by
any means it thinks is legal, fair and practical. If it cannot make the distribution in that way, the depositary will have a choice. It
may decide to sell what we distributed and distribute the net proceeds, in the same way as it does with cash. Or, it may decide to hold
what we distributed, in which case ADSs will also represent the newly distributed property. However, the depositary is not required to
distribute any securities (other than ADSs) to ADS holders unless it receives satisfactory evidence from us that it is legal to make that
distribution. The depositary may sell a portion of the distributed securities or property sufficient to pay its fees and expenses in connection
with that distribution. U.S. securities laws may restrict the ability of the depositary to distribute securities to all or certain ADS
holders, and the securities distributed may be subject to restrictions on transfer.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The depositary is not responsible
if it decides that it is unlawful or impractical to make a distribution available to any ADS holders. We have no obligation to register
ADSs, ordinary shares, rights or other securities under the Securities Act. We also have no obligation to take any other action to permit
the distribution of ADSs, shares, rights or anything else to ADS holders. This means that you may not receive the distributions we make
on our ordinary shares or any value for them if it is illegal or impractical for us to make them available to you.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">127</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Deposit, Withdrawal and Cancellation</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">How are ADSs issued?</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The depositary will deliver ADSs
if you or your broker deposits ordinary shares or evidence of rights to receive ordinary shares with the custodian. Upon payment of its
fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the depositary will register the appropriate
number of ADSs in the names you request and will deliver our ADSs to or upon the order of the person or persons that made the deposit.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">How can ADS holders withdraw the
deposited securities?</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">You may surrender your ADSs for the
purpose of withdrawal at the depositary&#8217;s office. Upon payment of its fees and expenses and of any taxes or charges, such as stamp
taxes or stock transfer taxes or fees, the depositary will deliver the ordinary shares and any other deposited securities underlying our
ADSs to the ADS holder or a person the ADS holder designates at the office of the custodian. Or, at your request, risk and expense, the
depositary will deliver the deposited securities at its office, if feasible. However, the depositary is not required to accept surrender
of ADSs to the extent it would require delivery of a fraction of a deposited share or other securities. The depositary may charge you
a fee and its expenses for instructing the custodian regarding delivery of deposited securities.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">How do ADS holders interchange between
certificated ADSs and uncertificated ADSs?</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">You may surrender your ADR to the
depositary for the purpose of exchanging your ADR for uncertificated ADSs. The depositary will cancel that ADR and will send to the ADS
holder a statement confirming that the ADS holder is the registered holder of uncertificated ADSs. Alternatively, upon receipt by the
depositary of a proper instruction from a registered holder of uncertificated ADSs requesting the exchange of uncertificated ADSs for
certificated ADSs, the depositary will execute and deliver to the ADS holder an ADR evidencing those ADSs.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Voting Rights</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">How do you vote?</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">ADS holders may instruct the depositary
how to vote the number of deposited ordinary shares their ADSs represent. If we request the depositary to solicit your voting instructions
(and we are not required to do so), the depositary will notify you of a shareholders&#8217; meeting and send or make voting materials
available to you. Those materials will describe the matters to be voted on and explain how ADS holders may instruct the depositary how
to vote. For instructions to be valid, they must reach the depositary by a date set by the depositary. The depositary will try, as far
as practical, subject to the laws of Israel and the provisions of our articles of association or similar documents, to vote or to have
its agents vote the ordinary shares or other deposited securities as instructed by ADS holders. If we do not request the depositary to
solicit your voting instructions, you can still send voting instructions, and, in that case, the depositary may try to vote as you instruct,
but it is not required to do so.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"><span style="font-style: italic">Except
by instructing the depositary as described above, you won&#8217;t be able to exercise voting rights unless you surrender your ADSs and
withdraw the ordinary shares. However, you may not know about the meeting enough in advance to withdraw the ordinary shares.</span>&#160;In
any event, the depositary will not exercise any discretion in voting deposited securities and it will only vote or attempt to vote as
instructed.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We cannot assure you that you will
receive the voting materials in time to ensure that you can instruct the depositary to vote your shares. In addition, the depositary and
its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. This
means that you may not be able to exercise your right to vote and there may be nothing you can do if your ordinary shares are not voted
as you requested.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In order to give you a reasonable
opportunity to instruct the Depositary as to the exercise of voting rights relating to Deposited Securities, if we request the Depositary
to act, we agree to give the Depositary notice of any such meeting and details concerning the matters to be voted upon at least 45&#160;days
in advance of the meeting date.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">128</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman; font-weight: bold">Fees and Expenses</div>

<div style="line-height: 1.25; font-family: Times New Roman; font-weight: bold"> <br/> </div>

<table cellspacing="0" cellpadding="0" id="zdd5e440405854aec92092761f7156c18" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 49%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Persons depositing or withdrawing ordinary shares or<br/> ADS holders must pay</div>
        </td>
    <td style="width: 1%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">&#8203;</div> </td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 50%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">For</div> </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)</div> </td>
    <td style="width: 1%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8203;</div> </td>
    <td style="width: 50%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">Issuance of ADSs, including issuances resulting from a distribution of ordinary shares or rights or other
        property Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates</div> </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 50%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">$.05 (or less) per ADS</div> </td>
    <td style="width: 1%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8203;</div> </td>
    <td style="width: 50%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">Any cash distribution to ADS holders</div> </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 50%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">A fee equivalent to the fee that would be payable if securities distributed to you had been ordinary shares
        and the ordinary shares had been deposited for issuance of ADSs</div> </td>
    <td style="width: 1%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8203;</div> </td>
    <td style="width: 50%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">Distribution of securities distributed to holders of deposited securities (including rights) that are distributed
        by the depositary to ADS holders</div> </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 50%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">$.05 (or less) per ADS per calendar year</div> </td>
    <td style="width: 1%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8203;</div> </td>
    <td style="width: 50%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">Depositary services</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb07f9d674ee9472189657aa4b110d2dd" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 49%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">Persons depositing or withdrawing ordinary shares or<br/> ADS holders must pay</div>
        </td>
    <td style="width: 1%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">&#8203;</div> </td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 50%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25; font-weight: bold">For</div> </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">Registration or transfer fees</div> </td>
    <td style="width: 1%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8203;</div> </td>
    <td style="width: 50%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">Transfer and registration of ordinary shares on our share register to or from the name of the depositary
        or its agent when you deposit or withdraw ordinary shares</div> </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 50%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">Expenses of the depositary</div> </td>
    <td style="width: 1%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8203;</div> </td>
    <td style="width: 50%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">Cable, telex and facsimile transmissions (when expressly provided in the
        deposit agreement)</div>
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>
        <div style="line-height: 1.25; font-family: Times New Roman">Converting foreign currency to U.S. dollars</div> </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 50%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">Taxes and other governmental charges the depositary or the custodian have to pay on any ADSs or ordinary
        shares underlying ADSs, such as stock transfer taxes, stamp duty or withholding taxes</div> </td>
    <td style="width: 1%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8203;</div> </td>
    <td style="white-space: nowrap; width: 50%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">As necessary</div> </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 50%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">Any charges incurred by the depositary or its agents for servicing the deposited securities</div> </td>
    <td style="width: 1%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">&#8203;</div> </td>
    <td style="white-space: nowrap; width: 50%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25">As necessary</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The depositary collects its fees
for delivery and surrender of ADSs directly from investors depositing ordinary shares or surrendering ADSs for the purpose of withdrawal
or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from
the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for
depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts
of participants acting for them. The depositary may collect any of its fees by deduction from any cash distribution payable (or by selling
a portion of securities or other property distributable) to ADS holders that are obligated to pay those fees. The depositary may generally
refuse to provide fee-attracting services until its fees for those services are paid.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">From time to time, the depositary
may make payments to us to reimburse us for costs and expenses generally arising out of establishment and maintenance of our ADS program,
waive fees and expenses for services provided to us by the depositary or share revenue from the fees collected from ADS holders. In performing
its duties under the deposit agreement, the depositary may use brokers, dealers, foreign currency or other service providers that are
owned by or affiliated with the depositary and that may earn or share fees, spreads or commissions.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">129</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The depositary may convert foreign
currency itself or through any of its affiliates and, in those cases, acts as principal for its own account and not as an agent, fiduciary
or broker on behalf of any other person and earns revenue, including, without limitation, fees and spreads that it will retain for its
own account. The revenue is based on, among other things, the difference between the exchange rate assigned to the currency conversion
made under the deposit agreement and the rate that the depositary or its affiliate receives when buying or selling foreign currency for
its own account. The depositary makes no representation that the exchange rate used or obtained in any currency conversion under the deposit
agreement will be the most favorable rate that could be obtained at the time or that the method by which that rate will be determined
will be most favorable to ADS holders, subject to its obligations under the deposit agreement. The methodology used to determine exchange
rates used in currency conversions is available upon request.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Payment of Taxes</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">You will be responsible for any taxes
or other governmental charges payable on your ADSs or on the deposited securities represented by any of your ADSs. The depositary may
refuse to register any transfer of your ADSs or allow you to withdraw the deposited securities represented by your ADSs until such taxes
or other charges are paid. It may apply payments owed to you or sell deposited securities represented by your ADSs to pay any taxes owed
and you will remain liable for any deficiency. If the depositary sells deposited securities, it will, if appropriate, reduce the number
of ADSs to reflect the sale and pay to ADS holders any proceeds, or send to ADS holders any property, remaining after it has paid the
taxes.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Tender and Exchange Offers; Redemption,
Replacement or Cancellation of Deposited Securities</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The depositary will not tender deposited
securities in any voluntary tender or exchange offer unless instructed to do by an ADS holder surrendering ADSs and subject to any conditions
or procedures the depositary may establish.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If deposited securities are redeemed
for cash in a transaction that is mandatory for the depositary as a holder of deposited securities, the depositary will call for surrender
of a corresponding number of ADSs and distribute the net redemption money to the holders of called ADSs upon surrender of those ADSs.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If there is any change in the deposited
securities such as a subdivision, combination or other reclassification, or any merger, consolidation, recapitalization or reorganization
affecting the issuer of deposited securities in which the depositary receives new securities in exchange for or in lieu of the old deposited
securities, the depositary will hold those replacement securities as deposited securities under the deposit agreement. However, if the
depositary decides it would not be lawful and practical to hold the replacement securities because those securities could not be distributed
to ADS holders or for any other reason, the depositary may instead sell the replacement securities and distribute the net proceeds upon
surrender of our ADSs.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If there is a replacement of the
deposited securities and the depositary will continue to hold the replacement securities, the depositary may distribute new ADSs representing
the new deposited securities or ask you to surrender your outstanding ADRs in exchange for new ADRs identifying the new deposited securities.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If there are no deposited securities
underlying ADSs, including if the deposited securities are cancelled, or if the deposited securities underlying ADSs have become apparently
worthless, the depositary may call for surrender or of those ADSs or cancel those ADSs upon notice to the ADS holders.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">130</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Amendment and Termination</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">How may the deposit agreement be
amended?</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We may agree with the depositary
to amend the deposit agreement and the ADRs without your consent for any reason. If an amendment adds or increases fees or charges, except
for taxes and other governmental charges or expenses of the depositary for registration fees, facsimile costs, delivery charges or similar
items, or prejudices a substantial right of ADS holders, it will not become effective for outstanding ADSs until 30&#160;days after the
depositary notifies ADS holders of the amendment. At the time an amendment becomes effective, you are considered, by continuing to hold
your ADSs, to agree to the amendment and to be bound by the ADRs and the deposit agreement as amended.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">How may the deposit agreement be
terminated?</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The depositary will initiate termination
of the deposit agreement if we instruct it to do so. The depositary may initiate termination of the deposit agreement if:</div>

<div style="line-height: 1.25; font-family: Times New Roman"><br/> </div>

<table cellspacing="0" cellpadding="0" border="0" id="zed7ac280b63f45f7870df106f2c48a43" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">90&#160;days have passed since the depositary told us it wants to resign but a successor
        depositary has not been appointed and accepted its appointment;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z438e805da18448989a0f4e6ad0a60540" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">we delist our ADSs from an exchange on which they were listed and do not list our
        ADSs on another exchange within a reasonable time;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb87cbad0fa364f5983ea79ea4a6a2f28" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">we appear to be insolvent or enter insolvency proceedings;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z308c9e8bd84c464d8e17baf854ec8655" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">all or substantially all the value of the deposited securities has been distributed
        either in cash or in the form of securities;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z0cc9dd0e08214084b554e0ceefc184ad" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">there are no deposited securities underlying our ADSs or the underlying deposited
        securities have become apparently worthless; or</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3cefeca9f3cc4a6aa0ad1f045baa729d" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">there has been a replacement of deposited securities.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If the deposit agreement is terminated,
the depositary will notify ADS holders at least 90&#160;days before the termination date. At any time after the termination date, the
depositary may sell the deposited securities. After that, the depositary will hold the money it received on the sale, as well as any other
cash it is holding under the deposit agreement, unsegregated and without liability for interest, for the pro&#160;rata benefit of the
ADS holders that have not surrendered their ADSs. Normally, the depositary will sell as soon as practicable after the termination date.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">After the termination date and before
the depositary sells, ADS holders can still surrender their ADSs and receive delivery of deposited securities, except that the depositary
may refuse to accept a surrender for the purpose of withdrawing deposited securities or reverse previously accepted surrenders of that
kind if it would interfere with the selling process. The depositary may refuse to accept a surrender for the purpose of withdrawing sale
proceeds until all the deposited securities have been sold. The depositary will continue to collect distributions on deposited securities,
but, after the termination date, the depositary is not required to register any transfer of ADSs or distribute any dividends or other
distributions on deposited securities to the ADSs holder (until they surrender their ADSs) or give any notices or perform any other duties
under the deposit agreement except as described in this paragraph.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Limitations on Obligations and Liability</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">Limits on our obligations and the
obligations of the depositary; Limits on liability to holders of ADSs</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The deposit agreement expressly limits
our obligations and the obligations of the depositary. It also limits our liability and the liability of the depositary. We and the depositary:</div>

<div style="line-height: 1.25; font-family: Times New Roman"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z219298c6447246abb8e848527e2b75ac" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">are only obligated to take the actions specifically set forth in the deposit agreement
        without negligence or bad faith and the depositary will not be a fiduciary or have any fiduciary duty to holders of ADSs;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">131</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" id="z9333d33cd8f8472bba3a02019f7ecabb" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">are not liable if we are or it is prevented or delayed by law or circumstances beyond
        our or its control from performing our or its obligations under the deposit agreement;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zad6c1fe7cf39496ca577218debc4b5e3" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">are not liable if we exercise or it exercises discretion permitted under the deposit
        agreement;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zbac59854fe26433c87002d93720d44ee" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">are not liable for the inability of any holder of ADSs to benefit from any distribution
        on deposited securities that is not made available to holders of ADSs under the terms of the deposit agreement, or for any special, consequential
        or punitive damages for any breach of the terms of the deposit agreement;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z18e6201ab73549e2ab19af3a22ea87ac" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">have no obligation to become involved in a lawsuit or other proceeding related to
        our ADSs or the deposit agreement on your behalf or on behalf of any other person;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z608768dd97e847bdba2f744556066022" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">are not liable for the acts or omissions of any securities depository, clearing agency
        or settlement system;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z24fdf9a6b41f4612ade75e730e942d2c" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">may rely upon any documents we believe or it believes in good faith to be genuine
        and to have been signed or presented by the proper person; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb871c4d7988e4e88a34698c0ce93475d" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">the depositary has no duty to make any determinations or provide any information as
        to our status, or any liability for any tax consequences that may be incurred by ADS holders as a result of owning or holding ADSs or
        liable for the inability or failure of an ADS holder to obtain the benefit of a foreign tax credit reduced rate of withholdings or refund
        of amounts withheld in respect of tax or any other tax benefit.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In the deposit agreement, we and
the depositary agree to indemnify each other under certain circumstances.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Requirements for Depositary Actions</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Before the depositary will deliver
or register a transfer of ADSs, make a distribution on ADSs, or permit withdrawal of shares, the depositary may require:</div>

<div style="line-height: 1.25; font-family: Times New Roman"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z408b66fb453d495cb3d2a59ecb28a5a0" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">payment of stock transfer or other taxes or other governmental charges and transfer
        or registration fees charged by third parties for the transfer of any ordinary shares or other deposited securities;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z0e2e049734ff45b59f7c747218c89b60" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">satisfactory proof of the identity and genuineness of any signature or other information
        it deems necessary; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4265dfb7a2194555a4d8ee8a52e589e6" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">compliance with regulations it may establish, from time to time, consistent with the
        deposit agreement, including presentation of transfer documents.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The depositary may refuse to deliver
ADSs or register transfers of ADSs when the transfer books of the depositary or our transfer books are closed or at any time if the depositary
or we think it advisable to do so.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">132</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Your Right to Receive the Ordinary
Shares Underlying your ADSs</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">ADS holders have the right to cancel
their ADSs and withdraw the underlying ordinary shares at any time except:</div>

<div style="line-height: 1.25; font-family: Times New Roman"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z91904045f23a4a2daa3653bf1a69a375" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">when temporary delays arise because: (i)&#160;the depositary has closed its transfer
        books or we have closed our transfer books; (ii)&#160;the transfer of ordinary shares is blocked to permit voting at a shareholders&#8217;
        meeting; or (iii)&#160;we are paying a dividend on our shares;</div> </td> </tr>
  </table>

<div> <br/> </div>

<table cellspacing="0" cellpadding="0" id="z2bea2fce318342598d98a80b63f3d1d9" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">when you owe money to pay fees, taxes and similar charges; or</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5f7e3571945b476c84523f72b31bd385" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">when it is necessary to prohibit withdrawals in order to comply with any laws or governmental
        regulations that apply to ADSs or to the withdrawal of ordinary shares or other deposited securities.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">This right of withdrawal may not be limited by any other
provision of the deposit agreement.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Direct Registration System</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In the deposit agreement, all parties
to the deposit agreement acknowledge that the Direct Registration System, or DRS, and Profile Modification System, or Profile, will apply
to our ADSs. DRS is a system administered by DTC that facilitates interchange between registered holding of uncertificated ADSs and holding
of security entitlements in ADSs through DTC and a DTC participant. Profile is a feature of DRS that allows a DTC participant, claiming
to act on behalf of a registered holder of uncertificated ADSs, to direct the depositary to register a transfer of those ADSs to DTC or
its nominee and to deliver those ADSs to the DTC account of that DTC participant without receipt by the depositary of prior authorization
from the ADS holder to register that transfer.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In connection with and in accordance
with the arrangements and procedures relating to DRS/Profile, the parties to the deposit agreement understand that the depositary will
not determine whether the DTC participant that is claiming to be acting on behalf of an ADS holder in requesting registration of transfer
and delivery as described in the paragraph above has the actual authority to act on behalf of the ADS holder (notwithstanding any requirements
under the Uniform Commercial Code). In the deposit agreement, the parties agree that the depositary&#8217;s reliance on and compliance
with instructions received by the depositary through the DRS/Profile system and in accordance with the deposit agreement will not constitute
negligence or bad faith on the part of the depositary.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Shareholder Communications; Inspection
of Register of Holders of ADSs</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The depositary will make available
for your inspection at its office all communications that it receives from us as a holder of deposited securities that we make generally
available to holders of deposited securities. The depositary will send you copies of those communications or otherwise make those communications
available to you if we ask it to. You have a right to inspect the register of holders of ADSs, but not for the purpose of contacting those
holders about a matter unrelated to our business or our ADSs.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Jury Trial Waiver</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The deposit agreement provides that,
to the extent permitted by law, ADS holders waive the right to a jury trial of any claim they may have against us or the depositary arising
out of or relating to our shares, our ADSs or the deposit agreement, including any claim under the U.S. federal securities laws. If we
or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable in the
facts and circumstances of that case in accordance with applicable case law.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">PART II<span id="PARTII"><!--Anchor--></span></div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Item 13<span id="Item13"><!--Anchor--></span>.
Defaults, Dividend Arrearages and Delinquencies</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">None.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">133</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Item 14<span id="Item14"><!--Anchor--></span>.
Material Modifications to the Rights of Security Holders and Use of Proceeds</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">None.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Item 15<span id="Item15"><!--Anchor--></span>.
Controls and Procedures</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Disclosure Controls
and Procedures</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We have evaluated, with the participation
of our chief executive officer and chief financial officer, the effectiveness of our disclosure controls and procedures (as that term
is defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2024. There are inherent limitations to the effectiveness
of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the
controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving
their control objectives. Based upon our evaluation, our chief executive officer and chief financial officer concluded that our disclosure
controls and procedures were effective as of December 31, 2024 to provide reasonable assurance that information required to be disclosed
by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods
specified in the applicable rules and forms, and that it is accumulated and communicated to our management, including our chief executive
officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Management&#8217;s
Annual Report on Internal Control over Financial Reporting</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our management is responsible for
establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting is defined
in Rules&#160;13a-15(f)&#160;and 15d-15(f)&#160;promulgated under the Exchange Act as a process designed by, or under the supervision
of, our principal executive and principal financial officers and effected by our board of directors, management and other personnel to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with GAAP and includes those policies and procedures that:</div>

<div style="line-height: 1.25; font-family: Times New Roman">

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">
        <div style="line-height: 1.25">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions
        and dispositions of our assets;</div> </div> </td> </tr>
  </table>

<div>&#160;

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">
        <div style="text-align: left; line-height: 1.25">provide reasonable assurance that transactions are recorded as necessary to permit preparation
        of financial statements in accordance with GAAP, and that our receipts and expenditures are being made only in accordance with authorizations
        of our management; and</div> </div> </td> </tr>
  </table>

<div>&#160;

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 2.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 97.5%; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">
        <div style="text-align: left; line-height: 1.25">provide reasonable assurance regarding prevention or timely detection of unauthorized
        acquisition, use or disposition of our assets that could have a material effect on the financial statements.</div> </div> </td> </tr>
  </table>

<div>&#160;</div> </div> </div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Because of its inherent limitations,
internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future
periods are subject to the risks that controls may become inadequate because of changes in conditions or that the degree of compliance
with the policies or procedures may deteriorate.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our management, including our Chief
Executive Officer and Chief Financial Officer, assessed the effectiveness of our internal control over financial reporting at December&#160;31,
2024. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission
(COSO) in Internal Control&#8212;Integrated Framework (2013). Based on that assessment under those criteria, management determined that,
as of December&#160;31, 2024, our internal control over financial reporting was effective.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">134</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Attestation Report
of the Registered Public Accounting Firm</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our independent registered public
accounting firm, Somekh Chaikin, a member firm of KPMG International, has audited the consolidated financial statements included in this
annual report on Form 20-F, This Annual Report on Form 20-F does not include an attestation report of our registered public accounting
firm regarding internal control over financial reporting. Management&#8217;s report was not subject to attestation by the Company&#8217;s
registered public accounting firm pursuant to the exemption provided to issuers that are not &#8220;large accelerated filers&#8221; or
&#8220;accelerated filers&#8221; under the Dodd-Frank Wall Street Reform and Consumer Protection Act.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Changes in Internal
Control over Financial Reporting</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">There were no changes in our internal
control over financial reporting (as such term is defined in Rules&#160;13a-15(f) and 15d-15(f) under the Exchange Act) that occurred
during the period covered by this annual report that have materially affected, or that are reasonably likely to materially affect, our
internal control over financial reporting.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Item 16<span id="Item16"><!--Anchor--></span>.
[Reserved]</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Item 16A<span id="Item16A"><!--Anchor--></span>.
Audit Committee Financial Expert</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The members of the audit committee
are Jill Quigley, Alan Moses and Claude Nicaise. Claude Nicaise is the chairperson of the audit committee and is a financial expert under
the rules of the SEC. Our board of directors has concluded that the composition of the audit committee meets the requirements for independence
under the rules and regulations of Nasdaq and the SEC.<br/> &#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Item 16B<span id="Item16B"><!--Anchor--></span>.
Code of Ethics</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We have adopted a Code of Business
Conduct and Ethics that includes provisions ranging from restrictions on gifts to conflicts of interest. All of our employees and directors
are bound by this Code of Business Conduct and Ethics. Violations of our Code of Business Conduct and Ethics may be reported to the audit
committee. The Code of Business Conduct and Ethics includes provisions applicable to all of our employees, including senior financial
officers and members of our board of directors and is posted on our website. We intend to post amendments to or waivers from any such
Code of Business Conduct and Ethics.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We granted no waivers under our Code
of Ethics and Conduct in 2024.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Item 16C<span id="Item16C"><!--Anchor--></span>.
Principal Accountant Fees and Services</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Somekh Chaikin, a member firm of
KPMG International, located in Tel Aviv, Israel, PCAOB ID 1057, has served as our independent registered public accounting firm for the
years 2024, 2023 and 2022. The following table sets forth fees billed to us by our independent registered public accounting firm during
the fiscal years ended December 31, 2024, 2023 and 2022 for (i) services rendered for the audit of our annual financial statements and
the review of our quarterly financial statements; (ii) services by our independent registered public accounting firm that are reasonably
related to the performance of the audit or review of our financial statements and that are not reported as audit fees; (iii) services
rendered during the period in connection with tax compliance, tax advice and tax planning; and (iv) all other fees for services rendered.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z15a68b350b8844af8648ccd21fdac825" style="font: 10pt Arial; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 63.93%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 0.93%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="10" style="border-bottom: rgb(0, 0, 0) 2px solid; width: 34.2%; vertical-align: bottom; font-family: Times New Roman">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Year ended December 31,</div> </td>
    <td style="white-space: nowrap; width: 0.94%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 63.93%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 0.93%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; width: 10.15%; vertical-align: bottom; font-family: Times New Roman">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">2024</div> </td>
    <td style="white-space: nowrap; width: 0.94%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 0.94%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; width: 10.15%; vertical-align: bottom; font-family: Times New Roman">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">2023</div> </td>
    <td style="white-space: nowrap; width: 0.94%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 0.94%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; width: 10.15%; vertical-align: bottom; font-family: Times New Roman">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">2022</div> </td>
    <td style="white-space: nowrap; width: 0.94%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 63.93%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 0.93%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="10" style="border-bottom: rgb(0, 0, 0) 2px solid; width: 34.2%; vertical-align: bottom; font-family: Times New Roman">
        <div style="text-align: center; line-height: 1.25">(in thousands)</div> </td>
    <td style="white-space: nowrap; width: 0.94%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 63.93%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Audit Fees</div> </td>
    <td style="width: 0.93%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1.2%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">$</div> </td>
    <td style="width: 8.95%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: right; line-height: 1.25">180</div> </td>
    <td style="white-space: nowrap; width: 0.94%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 0.94%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1.2%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">$</div> </td>
    <td style="width: 8.95%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: right; line-height: 1.25">233</div> </td>
    <td style="white-space: nowrap; width: 0.94%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 0.94%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1.2%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">$</div> </td>
    <td style="width: 8.95%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: right; line-height: 1.25">223</div> </td>
    <td style="white-space: nowrap; width: 0.94%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 63.93%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 0.93%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1.2%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 8.95%; vertical-align: bottom; font-family: Times New Roman">
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 0.94%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 0.94%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1.2%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 8.95%; vertical-align: bottom; font-family: Times New Roman">
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 0.94%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 0.94%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1.2%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 8.95%; vertical-align: bottom; font-family: Times New Roman">
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 0.94%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 63.93%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Audit-Related Fees</div> </td>
    <td style="width: 0.93%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td style="width: 1.2%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td style="width: 8.95%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: right; line-height: 1.25">-</div> </td>
    <td style="white-space: nowrap; width: 0.94%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td style="width: 0.94%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td style="width: 1.2%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td style="width: 8.95%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: right; line-height: 1.25">-</div> </td>
    <td style="white-space: nowrap; width: 0.94%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td style="width: 0.94%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td style="width: 1.2%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td style="width: 8.95%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: right; line-height: 1.25">-</div> </td>
    <td style="white-space: nowrap; width: 0.94%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="width: 63.93%; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td style="width: 0.93%; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td style="width: 1.2%; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td style="width: 8.95%; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td style="white-space: nowrap; width: 0.94%; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td style="width: 0.94%; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td style="width: 1.2%; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td style="width: 8.95%; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td style="white-space: nowrap; width: 0.94%; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td style="width: 0.94%; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td style="width: 1.2%; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td style="width: 8.95%; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td style="white-space: nowrap; width: 0.94%; vertical-align: bottom; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 63.93%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Tax Fees</div> </td>
    <td style="width: 0.93%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1.2%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 8.95%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: right; line-height: 1.25">5</div> </td>
    <td style="white-space: nowrap; width: 0.94%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 0.94%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1.2%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 8.95%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: right; line-height: 1.25">4</div> </td>
    <td style="white-space: nowrap; width: 0.94%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 0.94%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1.2%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 8.95%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: right; line-height: 1.25">30</div> </td>
    <td style="white-space: nowrap; width: 0.94%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 63.93%; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td style="width: 0.93%; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td style="width: 1.2%; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td style="width: 8.95%; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td style="white-space: nowrap; width: 0.94%; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td style="width: 0.94%; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td style="width: 1.2%; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td style="width: 8.95%; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td style="white-space: nowrap; width: 0.94%; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td style="width: 0.94%; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td style="width: 1.2%; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td style="width: 8.95%; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td style="white-space: nowrap; width: 0.94%; vertical-align: bottom; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 63.93%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">All Other Fees</div> </td>
    <td style="width: 0.93%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td style="width: 1.2%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td style="width: 8.95%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td style="white-space: nowrap; width: 0.94%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">-</div> </td>
    <td style="width: 0.94%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td style="width: 1.2%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td style="width: 8.95%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: right; line-height: 1.25">-</div> </td>
    <td style="white-space: nowrap; width: 0.94%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td style="width: 0.94%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td style="width: 1.2%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td style="width: 8.95%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: right; line-height: 1.25">-</div> </td>
    <td style="white-space: nowrap; width: 0.94%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="width: 63.93%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 0.93%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1.2%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 8.95%; vertical-align: bottom; font-family: Times New Roman">
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 0.94%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 0.94%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1.2%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 8.95%; vertical-align: bottom; font-family: Times New Roman">
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 0.94%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 0.94%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1.2%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 8.95%; vertical-align: bottom; font-family: Times New Roman">
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 0.94%; vertical-align: bottom; font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 63.93%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25">Total</div> </td>
    <td style="width: 0.93%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 1.2%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">$</div> </td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 8.95%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: right; line-height: 1.25">185</div> </td>
    <td style="white-space: nowrap; width: 0.94%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 0.94%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 1.2%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">$</div> </td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 8.95%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: right; line-height: 1.25">237</div> </td>
    <td style="white-space: nowrap; width: 0.94%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 0.94%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 1.2%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">$</div> </td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 8.95%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="text-align: right; line-height: 1.25">253</div> </td>
    <td style="white-space: nowrap; width: 0.94%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">135</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>
<!--PROfilePageNumberReset%Num%139%%%-->

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Audit Fees</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Audit fees for the years ended December
31, 2024, 2023 and 2022 consisted of fees for professional services provided in connection with the audit of our annual consolidated financial
statements and audit services that are normally provided by an independent registered public accounting firm in connection with statutory
and regulatory filings or engagements for those years. &#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Tax Fees</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Tax fees for the years ended December
31, 2024, and 2023 refer to professional services rendered by our auditors, which include ongoing tax advisory, tax compliance and tax
consulting associated with transfer pricing.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Pre-Approval Policies and Procedures</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our audit committee has the sole
authority to approve the scope of the audit and any audit-related services, as well as all audit fees and terms. The audit committee must
pre-approve any audit and non-audit services provided by our independent registered public accounting firm. The audit committee will not
approve the engagement of the independent registered public accounting firm to perform any services that the independent registered public
accounting firm would be prohibited from providing under applicable laws, rules and regulations, including those of self-regulating organizations.
The audit committee will approve permitted non-audit services by our independent registered public accounting firm only if it determines
that using a different firm to perform such services will be less efficient or cost-effective. The audit committee reviews and pre-approves
the statutory audit fees that can be provided by the independent registered public accounting firm on an annual basis.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Item 16D<span id="Item16D"><!--Anchor--></span>.
Exemptions from the Listing Standards for Audit Committees</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Item 16E<span id="Item16E"><!--Anchor--></span>.
Purchases of Equity Securities by the Issuer and Affiliated Purchasers</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">None.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Item 16F<span id="Item16F"><!--Anchor--></span>.
Change in Registrant&#8217;s Certifying Accountant</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">None.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Item 16G<span id="Item16G"><!--Anchor--></span>.
Corporate Governance</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">As an Israeli company, we are subject
to various corporate governance requirements under the Companies Law, relating to matters such as external directors, the audit committee,
the compensation committee and an internal auditor.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We are a &#8220;foreign private issuer&#8221;,
as such term is defined in Rule 405 under the Securities Act. As a foreign private issuer we will be permitted to comply with Israeli
corporate governance practices instead of the certain listing rules of Nasdaq, provided that we disclose which requirements we are not
following and the equivalent Israeli requirements.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageFooter"></div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">136</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-family: Times New Roman"> </span><br/>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We rely on this &#8220;foreign private issuer exemption&#8221;
with respect to the following:</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-family: Times New Roman">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Quorum
for Shareholder Meetings. Whereas under the corporate governance rules of Nasdaq, a quorum requires the presence, in person or by proxy,
of holders of at least 33 1/3% of the total issued and outstanding voting power of our shares at each general meeting of shareholders,
pursuant to the Articles, and as permitted under the Companies Law, the quorum required for a general meeting of shareholders will consist
of at least two shareholders present in person or by proxy in accordance with the Companies Law who hold or represent at least 33 1/3%
of the total outstanding voting power of our shares, except if (i) any such general meeting of shareholders was initiated by and convened
pursuant to a resolution adopted by the board of directors and (ii) at the time of such general meeting, we qualify as a &#8220;foreign
private issuer,&#8221; then in such case, the requisite quorum will consist of two or more shareholders present in person or by proxy
who hold or represent at least 25% of the total outstanding voting power of our shares (and if the meeting is adjourned for a lack of
quorum, the quorum for such adjourned meeting will be, subject to certain exceptions, any number of shareholders).</span></div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-family: Times New Roman">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Shareholder approval. We do not intend to follow Nasdaq Stock Market rules which require shareholder approval in order to enter into any
transaction, other than a public offering, involving the sale, issuance or potential issuance by the Company of ordinary shares (or securities
convertible into or exercisable for ordinary shares) equal to 20% or more of the outstanding share capital of the Company or 20% or more
of the voting power outstanding before the issuance for less than the greater of book or market value of the ordinary shares. We will
follow Israeli law with respect to any requirement to obtain shareholder approval in connection with any private placements of equity
securities.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-family: Times New Roman">(iii)&#160;&#160;&#160;&#160;&#160;&#160;
Adoption or Amendment of Equity-Based Compensation Plans. We have elected to follow Israeli corporate governance practice instead of the
Nasdaq Listing Rule 5635(c), which requires listed issuers to obtain shareholder approval for the establishment or material amendment
of certain equity-based compensation plans and arrangements. Under Israeli law and practice, in general, the approval of the board of
directors is required for the establishment or amendment of equity-based compensation plans and arrangements.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We otherwise comply with and intend
to continue to comply with the rules generally applicable to U.S. domestic companies listed on the Nasdaq Capital Market. We may in the
future, however, decide to use other foreign private issuer exemptions with respect to some or all of the Listing Rules of the Nasdaq
Stock Market. Following our home country governance practices may provide less protection than is accorded to investors under the Listing
Rules of the Nasdaq Stock Market applicable to domestic issuers.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Item 16H<span id="Item16H"><!--Anchor--></span>.
Mine Safety Disclosure</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Item 16I<span id="Item16I"><!--Anchor--></span>.
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">137</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div> </div>

<p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman"> </span></p>
<!-- Field: /Include-Text -->
<div style="line-height:1.25">
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman';font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="Item16J"><span>Item 16J. Insider Trading Policies</span></span></span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman'"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="Fxbrl_20250402151124810" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" contextRef="C_20240101to20241231" format="ixt:fixed-true">We have adopted an insider trading policy</ix:nonNumeric> governing the purchase, sale, and other dispositions of our securities by directors, senior management, and employees that is reasonably designed to promote compliance with applicable insider trading laws, rules and regulations, and any listing standards applicable to us. A copy of our insider trading policy is attached as Exhibit 11.1 to this Annual Report.</span></span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman';font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="Item16K"><span>Item 16K.&#160; Cybersecurity Risk Management Policies and Procedures</span></span></span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>
          <ix:nonNumeric id="Fxbrl_20250402151200330" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" contextRef="C_20240101to20241231" escape="true">
            <div style="font-size:10pt;font-family:Times New Roman">
              <div>
                <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman';font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Risk management and strategy</span></span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>
                <div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman'">
                  <ix:nonNumeric id="Fxbrl_20250402151451097" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" contextRef="C_20240101to20241231" escape="true"><span style="font-size:10pt;font-family:Times New Roman"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>We maintain a cyber risk management program designed to <ix:nonNumeric id="Fxbrl_20250402151419652" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" contextRef="C_20240101to20241231" format="ixt:fixed-true">identify, assess, manage, mitigate, and respond to material risks from cybersecurity threats</ix:nonNumeric>&#160;to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic, or competitive in nature, and our clinical trial and related data (&#8220;Information Systems and Data&#8221;).</span></span></span></span></ix:nonNumeric>
                </div>
                <div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>
                <div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman'"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The underlying processes and controls of our cyber risk management program incorporate various practices and standards for cybersecurity and information technology. <ix:nonNumeric id="Fxbrl_20250402151639776" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" contextRef="C_20240101to20241231" format="ixt:fixed-true">We conduct an annual assessment performed by a <ix:nonNumeric id="Fxbrl_20250402151527434" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" contextRef="C_20240101to20241231" format="ixt:fixed-true">third-party service provider</ix:nonNumeric> of our cyber risk management program. The annual risk assessment identifies, quantifies, and categorizes material cyber risks to our Company. In addition,&#160;we, in conjunction with the third-party cyber risk assessment vendor, develop a risk mitigation plan designed to address such risks, and where necessary, remediate potential vulnerabilities identified through the annual assessment process.</ix:nonNumeric></span></span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>
                <div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman'"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>In addition, we maintain various policies to help identify, address, and mitigate risks from cybersecurity threats, including, for example in areas such as information security, access on/offboarding, and access and account management. We monitor threat intelligence as well as other information obtained from governmental, public, or private sources, including external consultants engaged by us. We also partner with IT and cybersecurity providers, such as cybersecurity consultants. We leverage these third-party providers and solutions to support our cybersecurity risk management strategy and processes, which include, for example, maintenance of an IT assets inventory, periodic vulnerability scanning, identity access management controls, endpoint protection, endpoint detection and response, remote monitoring management on certain devices, encryption of certain data, critical data backups, infrastructure maintenance, incident detection and response, cybersecurity strategy, and cyber risk advisory, assessment and remediation.&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;</span></span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>
                <div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman'"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Our assessment and management of material risks from cybersecurity threats are integrated into the Company&#8217;s overall risk management processes. For example, (1) cybersecurity risk is addressed as a component of the Company&#8217;s enterprise risk management program and identified in the Company&#8217;s risk register; (2) the security department/security management works with management to prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business; or (3) our senior management evaluates material risks from cybersecurity threats against our overall business objectives and reports to the audit committee of the board of directors, which evaluates our overall enterprise risk.</span></span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>
                <div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman'"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>We have implemented third-party risk management processes to manage material risks from cybersecurity threats associated with reliance on vendors, critical service providers, and other third parties we engage, such as software-as-a-service providers, data hosting companies, and contract research organizations. These processes include, for example, conducting risk assessment for certain vendors, reviewing vendor security assessments and questionnaires, and conducting annual reviews of vendor audits and reports.&#160;Depending on the nature of the services provided, the sensitivity of the Information Systems and Data at issue, and the identity of the provider, our third-party risk management process may involve different levels of assessment designed to help identify cybersecurity risks associated with a provider.</span></span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>
                <div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman'">
                  <ix:nonNumeric id="Fxbrl_20250402151855635" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" contextRef="C_20240101to20241231" escape="true"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="Fxbrl_20250402151839085" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" contextRef="C_20240101to20241231" format="ixt:fixed-true">For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 3.</ix:nonNumeric> Section D Risk Factors in this Annual Report on Form 20-F, including &#8220;Cyber-attacks, security breaches or other disruptions to our information technology systems, or those of third parties upon which we rely, or our data could irreparably damage our reputation and our business, expose us to liability and materially and adversely affect our results of operations.&#8221;</span></span></span></ix:nonNumeric>
                </div>
              </div>
            </div>
          </ix:nonNumeric>
          <div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>
          <ix:nonNumeric id="Fxbrl_20250402155112636" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" contextRef="C_20240101to20241231" escape="true">
            <div style="font-size:10pt;font-family:Times New Roman">
              <div>
                <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman';font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Governance</span></span></span></div>
                <div>
                  <div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>
                  <ix:nonNumeric id="Fxbrl_20250402155410834" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" contextRef="C_20240101to20241231" escape="true">
                    <div style="font-size:10pt;font-family:Times New Roman">
                      <div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman'"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The audit committee of the board of directors oversees our cybersecurity risk exposures and the steps taken by management to monitor and mitigate cybersecurity risks. The cybersecurity stakeholders, including member(s) of management assigned with cybersecurity oversight responsibility and/or third-party consultants providing cyber risk services brief the audit committee of the board of directors on cyber vulnerabilities identified through the risk management process, the effectiveness of our cyber risk management program, and the emerging threat landscape and new cyber risks on at least an annual basis. In addition, cybersecurity risks are reviewed by our board of directors at least annually, as part of our corporate risk oversight processes.&#160;</span></span></span></div>
                    </div>
                  </ix:nonNumeric>
                  <p style="margin:0pt;text-align:center">&#160;</p>
                </div>
                <div><ix:exclude>
                  <p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">138</span></p>
                  <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
                    <div style="break-after:page;margin-top:0pt;margin-bottom:0pt">
                      <hr style="border-width:0px;clear:both;margin:0pt 0px;width:100%;height:2px;color:rgb(0, 0, 0);background-color:rgb(0, 0, 0);margin-bottom:10pt"/>
                    </div>
                  </div>
                </ix:exclude></div>&#160;<div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:Times New Roman;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="Fxbrl_20250402155336668" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" contextRef="C_20240101to20241231" escape="true"><span style="font-size:10pt;font-family:Times New Roman">Our <ix:nonNumeric id="Fxbrl_20250402155628902" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" contextRef="C_20240101to20241231" format="ixt:fixed-true">Chief Information Security Officer (&#8220;CISO&#8221;)</ix:nonNumeric> is responsible for oversight and administration of our cyber risk management program, and for informing senior management and other relevant stakeholders regarding the prevention, detection, mitigation, and remediation of cybersecurity incidents.</span></ix:nonNumeric>&#160;<ix:nonNumeric id="Fxbrl_20250402160221706" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" contextRef="C_20240101to20241231" escape="true"><span style="font-size:10pt;font-family:Times New Roman">Our CISO is a Certified Information Systems Security Professional and has prior experience selecting, deploying, and overseeing cybersecurity technologies, initiatives, and processes directly or via selection of strategic third-party partners.</span></ix:nonNumeric></span></span></span></div>
                <div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:Times New Roman;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                <div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:Times New Roman;margin-top:0pt;margin-bottom:0pt">
                  <ix:nonNumeric id="Fxbrl_20250402160109615" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" contextRef="C_20240101to20241231" escape="true"><span style="font-size:10pt;font-family:Times New Roman"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">We have developed an incident response plan&#160;that is designed to escalate certain cybersecurity incidents to members of management, including the CISO, depending on the circumstances. Such members of management work with the Company&#8217;s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified. In addition, the Company&#8217;s incident response plan includes reporting to the <ix:nonNumeric id="Fxbrl_20250402160027285" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" contextRef="C_20240101to20241231" format="ixt:fixed-true">audit committee of the board of directors</ix:nonNumeric> for certain cybersecurity incidents.</span></span></span></span></ix:nonNumeric>
                </div>
              </div>
            </div>
          </ix:nonNumeric>
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman'">&#160;</div>
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman';font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="PARTIII"><span>PART III</span></span></span></span></div>
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman'">&#160;</div>
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman';font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="Item17"><span>Item 17. Financial Statements</span></span></span></span></div>
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman'">&#160;</div>
          <div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman'"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>We have elected to provide financial statements pursuant to Item 18.</span></span></span></div>
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman'">&#160;</div>
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman';font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="Item18"><span>Item 18. Financial Statements</span></span></span></span></div>
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman'">&#160;</div>
          <div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman'"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The audited consolidated financial statements as required under Item 18 are attached hereto starting on page F-1 of this Annual Report. The audit report of Somekh Chaikin, a member firm of KPMG International, an independent registered public accounting firm, is included herein preceding the audited consolidated financial statements.</span></span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman';font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="Item19"><span>Item 19. Exhibits</span></span></span></span></div>
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman'">&#160;</div>
          <div>
            <table border="0" cellpadding="0" cellspacing="0" style="font-family:Arial;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:8%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exhibit&#160;No.</span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Description</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="line-height:1.25">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_1-1.htm">1.1</a></span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_1-1.htm">Amended and Restated Articles of Association</a></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="line-height:1.25">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891324001124/exhibit_2-1.htm">2.1</a></span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891324001124/exhibit_2-1.htm"><span>Description of Securities (incorporated by reference to Exhibit 2.1 to the Registrant&#8217;s annual report on Form 20-F filed with the SEC on March 28, 2024)</span></a></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="line-height:1.25">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_4-1.htm">2.2</a></span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_4-1.htm">Form of Deposit Agreement between Chemomab Therapeutics Ltd. (f/k/a Anchiano Therapeutics Ltd.), the Bank of New York Mellon as Depositary, and owners and holders from time to time of ADSs issued by the Company, dated February 14, 2019 (incorporated by reference to Exhibit 4.1 to the Registrants registration statement on Form S-1 filed with the SEC on January 13, 2023)</a></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="line-height:1.25">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921019580/tm211883-4_s4a.htm#tANF">4.1</a></span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921019580/tm211883-4_s4a.htm#tANF">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.7 of the Company&#8217;s Amendment No. 1 to its Registration Statement on Form S-4 filed with the Securities and Exchange Commission on February 10, 2021)</a></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="line-height:1.25">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891322001304/exhibit_10-2.htm">4.2+</a></span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891322001304/exhibit_10-2.htm">Compensation Policy for Officers and Directors (incorporated by reference to Exhibit 10.2 of the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on March 30, 2022)</a></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="line-height:1.25">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000114420419000925/tv507924_ex10-6.htm">4.3</a></span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000114420419000925/tv507924_ex10-6.htm">2011 Incentive Plan for Employees, Officers and Consultants (previously filed as Exhibit&#160;10.6 of our Registration Statement on Form&#160;F-1 (File No.&#160;333-229155) as filed with the SEC on January&#160;7, 2019 and incorporated by reference herein).</a></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="line-height:1.25">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000114420419000925/tv507924_ex10-8.htm">+4.4+</a></span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000114420419000925/tv507924_ex10-8.htm">2017 Equity-Based Incentive Plan (previously filed as Exhibit&#160;10.8 of our Registration Statement on Form&#160;F-1 (File No.&#160;333-229155) as filed with the SEC on January&#160;7, 2019 and incorporated by reference herein).</a></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="line-height:1.25">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-4.htm">4.5+</a></span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-4.htm">Chemomab Ltd. 2015 Share Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s registration statement on Form S-4 (SEC file number 333- 252070), filed with the SEC on January 13, 2021)</a></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="line-height:1.25">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-8.htm">4.6+</a></span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-8.htm">Tel-Aviv Souraski Medical Center (TASMC) License Agreement between Chemomab Ltd. and the Medical Research, Infrastructure, Health Services Fund of the Tel Aviv Souraski Medical Center., dated December 1, 2011, as amended on May 9, 2013 (incorporated by reference to Exhibit 10.8 of the Company&#8217;s Amendment No. 1 to its Registration Statement on Form S-4 filed with the Securities and Exchange Commission on February 10, 2021)</a></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="line-height:1.25">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-9.htm">4.7+</a></span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-9.htm">CMC Collaboration Agreement between Chemomab Ltd. and CMC ICOS Biologics, Inc., dated June 7, 2015 (incorporated by reference to Exhibit 10.9 of the Company&#8217;s Amendment No. 1 to its Registration Statement on Form S-4 filed with the Securities and Exchange Commission on February 10, 2021)</a></span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>
            <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
              <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:rgb(0, 0, 0);font-weight:normal;font-style:normal">139</span></span></span></div>
              <div style="page-break-after:always">
                <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
              </div>
            </div>
            <table cellpadding="0" cellspacing="0" style="font-family:Arial;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921058967/tm2114615d1_ex1-2.htm">4.8</a></span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921058967/tm2114615d1_ex1-2.htm">Controlled Equity Offering<sup style="vertical-align:text-top;line-height:1;font-size:smaller">SM</sup>&#160;Sales Agreement, dated April 30, 2021, by and between the Company and Cantor Fitzgerald &amp; Co. (incorporated by reference to Exhibit 1.2 of the Company&#8217;s Registration Statement on Form S-3 filed with the Securities and Exchange Commission on April 30, 2021)</a></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="line-height:1.25">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-9.htm">4.9+</a></span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-9.htm">Employment Agreement, dated September 1, 2021, by and between Chemomab Therapeutics, Inc. and Dale Pfost (incorporated by reference to Exhibit 10.9 to the Registrants registration statement on Form S-1 filed with the SEC on January 13, 2023)</a></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="line-height:1.25">&#160;</div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="line-height:1.25">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-10.htm">4.10+</a></span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-10.htm">Employment Agreement, dated November 8, 2021, by and between Chemomab Therapeutics, Inc. and Donald Marvin (incorporated by reference to Exhibit 10.10 to the Registrants registration statement on Form S-1 filed with the SEC on January 13, 2023)</a></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-11.htm">4.11+</a></span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-11.htm">Consulting Agreement, dated April 18, 2022, by and between Chemomab Ltd. and Dr. Adi Mor (incorporated by reference to Exhibit 10.11 to the Registrants registration statement on Form S-1 filed with the SEC on January 13, 2023)</a></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="line-height:1.25">&#160;</div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="line-height:1.25">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323003334/exhibit_1-2.htm">4.12</a></span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323003334/exhibit_1-2.htm">Sales Agreement, dated October 16, 2023, by and between the Registrant and&#160;Roth Capital Partners, LLC (incorporated by reference to Exhibit 1.2 of the Company&#8217;s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on October 16, 2023)</a></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891324002290/exhibit_99-1.htm">4.13</a></span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891324002290/exhibit_99-1.htm">Securities Purchase Agreement by and between the Company and the Purchasers, as identified therein, dated July 25, 2024 (as filed with the SEC on July 25, 2024 as Exhibit 99.1 to our Report of Foreign Private Issuer on Form 6-K and incorporated by reference herein)</a></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">&#160;</td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">&#160;</td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891322001304/exhibit_21-1.htm">8.1</a></span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891322001304/exhibit_21-1.htm">List of Subsidiaries (incorporated by reference to Exhibit 21.1 to the Registrant&#8217;s annual report on Form 10-K for the year-ended December 31, 2021, filed with the SEC on March 30, 2022)</a></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">&#160;</td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">&#160;</td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_11-1.htm">11.1</a></span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_11-1.htm">Amended Insider Trading and Blackout Policy</a></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_12-1.htm">12.1</a></span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_12-1.htm">Certification of the Chief Executive Officer required by Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a)&#160;of the Securities Exchange Act of 1934, as amended</a></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_12-2.htm">12.2</a></span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_12-2.htm">Certification of the Chief Financial Officer required by Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a)&#160;of the Securities Exchange Act of 1934, as amended</a></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_13-1.htm">13.1&#8224;</a></span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_13-1.htm">Certification of the Chief Executive Officer Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_13-2.htm">13.2&#8224;</a></span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_13-2.htm">Certification of the Chief Financial Officer Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;</span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_15-1.htm">15.1</a></span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_15-1.htm">Consent of Independent Registered Public Accounting Firm</a></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891324001124/exhibit_97-1.htm">97.1</a></span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891324001124/exhibit_97-1.htm">Chemomab Therapeutics Compensation Recovery Policy (incorporated by reference to Exhibit 97.1 to the Registrant&#8217;s annual report on Form 20-F for the year-ended December 31, 2023, filed with the SEC on March 28, 2024)</a></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="line-height:1.25">&#160;</div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="line-height:1.25">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">101.INS</span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inline XBRL Instance Document</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="line-height:1.25">&#160;</div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="line-height:1.25">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">101.SCH</span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inline XBRL Taxonomy Extension Schema Document</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">101.CAL</span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">101.DEF</span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">101.LAB</span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inline XBRL Taxonomy Extension Label Linkbase Document</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">101.PRE</span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width:8%;vertical-align:top;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">104</span></span></div>
                  </td>
                  <td style="width:92%;vertical-align:bottom;font-family:'Times New Roman'">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>
            <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman'"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">+ Indicates management contract or compensatory plan.</span></span></div>
            <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman'"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8224; The certifications furnished in Exhibits 13.1 and 13.2 hereto are deemed to accompany this Annual Report on Form&#160;20-F&#160;and will not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 or the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates it by reference.</span></span></div>
            <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman'"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">++ Portions of this Exhibit (indicated with [***]) have been omitted as the Registrant has determined that (i)&#160;the omitted information is not material and (ii)&#160;the omitted information would likely cause competitive harm to the Registrant if publicly disclosed.</span></span></div>
          </div>
          <div style="line-height:1.25;font-family:Times New Roman;text-align:center;margin-top:12pt;margin-bottom:3pt"><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">140</span></span></div>
          <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
            <div style="break-after:page;margin-top:0pt;margin-bottom:0pt">
              <hr style="border-width:0px;clear:both;margin:0pt 0px;width:100%;height:2px;color:rgb(0, 0, 0);background-color:rgb(0, 0, 0);margin-bottom:12pt"/>
            </div>
          </div>
          <div style="text-align:center;line-height:1.25;font-family:'Times New Roman';font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="SIGNATURES"><span>SIGNATURES</span></span></span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>
          <div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman'"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The registrant hereby certifies that it meets all of the requirements for filing on Form 20&#8209;F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.</span></span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>
          <table border="0" cellpadding="0" cellspacing="0" style="font-family:Arial;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:50%;vertical-align:top;font-family:'Times New Roman'">
                  <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>CHEMOMAB THERAPEUTICS LTD.</span></span></span></div>
                </td>
                <td colspan="2" style="vertical-align:top;font-family:'Times New Roman'">&#160;</td>
                <td style="width:12%;vertical-align:top;font-family:'Times New Roman'">
                  <div style="line-height:1.25">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width:50%;vertical-align:top;font-family:'Times New Roman'">
                  <div style="line-height:1.25">&#160;</div>
                </td>
                <td style="width:4%;vertical-align:top;font-family:'Times New Roman'">
                  <div style="line-height:1.25">&#160;</div>
                </td>
                <td style="width:34.19%;vertical-align:top;font-family:'Times New Roman'">
                  <div style="line-height:1.25">&#160;</div>
                </td>
                <td style="width:12%;vertical-align:top;font-family:'Times New Roman'">
                  <div style="line-height:1.25">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width:50%;vertical-align:top;font-family:'Times New Roman'">
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Date: April 4, 2025</span></span></span></div>
                </td>
                <td style="width:4%;vertical-align:top;font-family:'Times New Roman'">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>By:</span></span></span></div>
                </td>
                <td style="width:34.19%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman';white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>/s/ Adi Mor</span></span></span></div>
                </td>
                <td style="width:12%;vertical-align:top;font-family:'Times New Roman'">
                  <div style="line-height:1.25">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width:50%;vertical-align:top;font-family:'Times New Roman'">
                  <div style="line-height:1.25">&#160;</div>
                </td>
                <td style="width:4%;vertical-align:top;font-family:'Times New Roman'">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Name:</span></span></span></div>
                </td>
                <td style="width:34.19%;vertical-align:bottom;font-family:'Times New Roman';white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Adi Mor</span></span></span></div>
                </td>
                <td style="width:12%;vertical-align:top;font-family:'Times New Roman'">
                  <div style="line-height:1.25">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width:50%;vertical-align:top;font-family:'Times New Roman'">
                  <div style="line-height:1.25">&#160;</div>
                </td>
                <td style="width:4%;vertical-align:top;font-family:'Times New Roman'">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Title:</span></span></span></div>
                </td>
                <td style="width:34.19%;vertical-align:top;font-family:'Times New Roman'">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Chief Executive Officer</span></span></span></div>
                </td>
                <td style="width:12%;vertical-align:top;font-family:'Times New Roman'">
                  <div style="line-height:1.25">&#160;</div>
                </td>
              </tr>

          </table>
        </div>
        <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:3pt"><br/><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">141</span></span></div>
        <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
          <div style="break-after:page;margin-top:0pt;margin-bottom:0pt">
            <hr style="border-width:0px;clear:both;margin:0pt 0px;width:100%;height:2px;color:rgb(0, 0, 0);background-color:rgb(0, 0, 0);margin-bottom:10pt"/>
          </div>
        </div>
        <div style="line-height:1.25">&#160;</div>
      </div>

  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

      <tr>
        <td style="width:100%;vertical-align:top">
          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab Therapeutics Ltd.</span></span></div>
          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">and its subsidiaries</span></span></div>
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25">&#160;</span></span></span></div>
          <div style="text-align:center;line-height:1.25;font-weight:bold"><span id="ConsolidatedFinancialStatements"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Consolidated Financial Statements</span></span></span></div>
          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2024</span></span></div>
        </td>
      </tr>

  </table><a id="a_001"></a>
  <div style="line-height:1.25">&#160;</div>
  <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
    <div style="page-break-after:always">
      <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
    </div>
  </div>
  <div style="line-height:1.25">&#160;</div>
  <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab Therapeutics Ltd. and its subsidiaries</span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="line-height:1.25">
    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Consolidated Financial Statements as of December 31, 2024</span></span></div>
    <div style="line-height:1.25;font-weight:bold">
      <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/>
    </div>
    <div style="line-height:1.25;font-weight:bold">&#160;</div>
  </div>
  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Contents</span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="text-align:right;text-indent:12pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Page</span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="line-height:1.25">
    <table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

        <tr>
          <td style="width:90%;vertical-align:top">
            <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#ReportofIndependentRegist">Report of Independent Registered Public Accounting Firm <strong style="box-sizing:border-box;font-weight:bolder;color:rgb(0, 0, 0);font-style:normal;font-variant-ligatures:normal;font-variant-caps:normal;letter-spacing:normal;orphans:2;text-indent:0px;text-transform:none;widows:2;word-spacing:0px;-webkit-text-stroke-width:0px;white-space:normal;background-color:rgb(255, 255, 255);text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-size:13.3333px"><span style="box-sizing:border-box;color:rgb(33, 37, 41)">(PCAOB ID&#160;<span style="box-sizing:border-box"><ix:nonNumeric id="Fxbrl_20250325185550517" name="dei:AuditorFirmId" contextRef="C_20240101to20241231">1057</ix:nonNumeric></span>)</span></strong></a></span></span></div>
          </td>
          <td style="width:10%;vertical-align:top">
            <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F- 2</span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:90%;vertical-align:top">&#160;</td>
          <td style="width:10%;vertical-align:top;text-align:right">&#160;</td>
        </tr>
        <tr>
          <td style="width:90%;vertical-align:top">
            <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#ConsolidatedBalanceSheets">Consolidated Balance Sheets</a></span></span></div>
          </td>
          <td style="width:10%;vertical-align:top">
            <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F- 3</span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:90%;vertical-align:top">&#160;</td>
          <td style="width:10%;vertical-align:top;text-align:right">&#160;</td>
        </tr>
        <tr>
          <td style="width:90%;vertical-align:top">
            <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#dStatementsofOperationsf">Consolidated Statements of Operations</a></span></span></div>
          </td>
          <td style="width:10%;vertical-align:top">
            <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F- 4</span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:90%;vertical-align:top">&#160;</td>
          <td style="width:10%;vertical-align:top;text-align:right">&#160;</td>
        </tr>
        <tr>
          <td style="width:90%;vertical-align:top">
            <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#Equity">Consolidated Statements of Changes in Equity</a></span></span></div>
          </td>
          <td style="width:10%;vertical-align:top;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F- 5</span></span></td>
        </tr>
        <tr>
          <td style="width:90%;vertical-align:top">&#160;</td>
          <td style="width:10%;vertical-align:top;text-align:right">&#160;</td>
        </tr>
        <tr>
          <td style="width:90%;vertical-align:top">
            <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#Cashflows">Consolidated Statements of Cash Flows</a></span></span></div>
          </td>
          <td style="width:10%;vertical-align:top">
            <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F- 6</span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:90%;vertical-align:top">&#160;</td>
          <td style="width:10%;vertical-align:top;text-align:right">&#160;</td>
        </tr>
        <tr>
          <td style="width:90%;vertical-align:top">
            <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#Notes">Notes to the Consolidated Financial Statements</a></span></span></div>
          </td>
          <td style="width:10%;vertical-align:top">
            <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F- 7- F- 26</span></span></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="line-height:1.25">&#160;</div>
  <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
    <div style="page-break-after:always">
      <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
    </div>
  </div>
  <p><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><img src="image00001.jpg" alt="image00001.jpg"/></span></span></p>
  <div style="line-height:1.25">&#160;</div>
  <div>
    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Somekh Chaikin</span></span></div>
    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">KPMG Millennium Tower</span></span></div>
    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">17 Ha&#8217;arba&#8217;a Street, PO Box 609</span></span></div>
    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tel Aviv 61006, Israel</span></span></div>
    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">+972 3 684 8000</span></span></div>
    <div style="line-height:1.25">&#160;</div>
  </div>
  <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="ReportofIndependentRegist"></span>Report of Independent Registered Public Accounting Firm</span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">To the Shareholders and Board of Directors,</span></span></div>
  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab Therapeutics Ltd.:</span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="text-align:justify;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Opinion on the Consolidated Financial Statements</span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We have audited the accompanying consolidated balance sheets of Chemomab Therapeutics Ltd. (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations, changes in equity, and cash flows for each of the years in the three-year period ended December 31, 2024, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.</span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="text-align:justify;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Going Concern</span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1C to the consolidated financial statements, the Company has incurred recurring losses and negative cash flows from operations that raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1C. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="text-align:justify;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basis for Opinion</span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="text-align:justify;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Critical Audit Matters</span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Critical audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="text-align:justify;margin-right:42.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20240325173623987" name="dei:AuditorName" contextRef="C_20240101to20241231">Somekh Chaikin</ix:nonNumeric></span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="text-align:justify;margin-right:42.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Member Firm of KPMG International</span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="text-align:justify;margin-right:42.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We have served as the Company&#8217;s auditor since 2015.</span></span></div>
  <div style="text-align:justify;margin-right:42.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20240325173629952" name="dei:AuditorLocation" contextRef="C_20240101to20241231">Tel Aviv, Israel</ix:nonNumeric></span></span></div>
  <div style="text-align:justify;margin-right:42.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">April 4, 2025</span></span></div>
  <div style="text-align:justify;margin-right:42.5pt;line-height:1.25">&#160;</div>
  <div style="text-align:justify;margin-right:42.5pt;line-height:1.25">&#160;</div>
  <div>
    <div style="text-align:justify;line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:8pt"><span><span>&#169; 2025 KPMG Somekh Chaikin, an Israeli partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.</span></span></span></span></div>
    <div style="text-align:justify;line-height:1.25">&#160;</div>
    <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
      <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">F - 2</span></span></span></div>
      <div style="page-break-after:always">
        <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-bottom:10pt"/>
      </div>
    </div>
  </div>

  <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab Therapeutics Ltd. and its subsidiaries</span></span></div>
  <div style="text-align:right;line-height:1.25">&#160;</div>
  <div style="line-height:1.25">
    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="ConsolidatedBalanceSheets"></span>Consolidated Balance Sheets as of</span></span></div>
    <div style="line-height:1.25;font-weight:bold">
      <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/>
    </div>
  </div>
  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In USD thousands (except share and per share amounts)</span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="line-height:1.25">
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

        <tr>
          <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;vertical-align:bottom">
            <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;vertical-align:bottom">
            <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note</span></span></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Assets</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current assets</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000038" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,071</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000039" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,292</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Short-term bank deposit</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000040" name="us-gaap:DepositsAssetsCurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,195</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000041" name="us-gaap:DepositsAssetsCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,492</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted cash</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230213102216110_Fact_0000000000040" name="us-gaap:RestrictedCashCurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">76</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230213102216110_Fact_0000000000041" name="us-gaap:RestrictedCashCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">76</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other receivables and prepaid expenses</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000042" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,698</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000043" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,037</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total current assets</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000044" name="us-gaap:AssetsCurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,040</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000045" name="us-gaap:AssetsCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,897</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-current assets</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Long-term prepaid expenses</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000048" name="us-gaap:PrepaidExpenseNoncurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">385</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230131220311598" name="us-gaap:PrepaidExpenseNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">559</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment, net</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000052" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">250</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000053" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">303</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease right-of-use assets</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000054" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">289</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000055" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">392</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total non-current assets</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000056" name="us-gaap:AssetsNoncurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">924</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000057" name="us-gaap:AssetsNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,254</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total assets</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000058" name="us-gaap:Assets" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,964</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000059" name="us-gaap:Assets" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,151</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current liabilities</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade payables</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000060" name="us-gaap:AccountsPayableTradeCurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">666</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000061" name="us-gaap:AccountsPayableTradeCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">516</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued expenses</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000062" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,563</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000063" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,423</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Employee and related expenses</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000064" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">874</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000065" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">823</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease liabilities</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000066" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">115</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000067" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">76</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total current liabilities</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000068" name="us-gaap:LiabilitiesCurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,218</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000069" name="us-gaap:LiabilitiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,838</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-current liabilities</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-current<span style="font-weight:bold">&#160;</span>operating lease liabilities</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000070" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">209</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000071" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">316</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total non-current liabilities</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000072" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">209</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000073" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">316</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Commitments and contingent liabilities</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"><ix:nonFraction id="Fxbrl_20250325185935895_Fact_0000000000072" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20241231" unitRef="usd" xsi:nil="true"></ix:nonFraction></td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"><ix:nonFraction id="Fxbrl_20250325185935895_Fact_0000000000073" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20231231" unitRef="usd" xsi:nil="true"></ix:nonFraction></td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total liabilities</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000074" name="us-gaap:Liabilities" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,427</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000075" name="us-gaap:Liabilities" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,154</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Shareholders' equity</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:top;width:64%;vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ordinary Shares <ix:nonFraction id="Fxbrl_20230201163052384" name="us-gaap:CommonStockNoParValue" contextRef="C_20231231" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="Fxbrl_20230131220607422" name="us-gaap:CommonStockNoParValue" contextRef="C_20241231" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> par value - Authorized: <ix:nonFraction id="Fxbrl_20230131221114549" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20241231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">4,650,000,000</ix:nonFraction> and <ix:nonFraction id="Fxbrl_20250325191129849" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20231231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">650,000,000</ix:nonFraction> Ordinary shares as of December 31, 2024, and&#160; December 31, 2023, respectively&#160; (*)</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issued and outstanding: <ix:nonFraction id="Fxbrl_20240325094937707" name="us-gaap:SharesOutstanding" contextRef="C_20241231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230213101830930" name="us-gaap:CommonStockSharesIssued" contextRef="C_20241231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">377,132,220</ix:nonFraction></ix:nonFraction>, and <ix:nonFraction id="Fxbrl_s_20250325190508979" name="us-gaap:SharesOutstanding" contextRef="C_20231231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20250325190508980" name="us-gaap:CommonStockSharesIssued" contextRef="C_20231231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">284,094,700</ix:nonFraction></ix:nonFraction>&#160;Ordinary shares of December 31, 2024 and 2023, respectively (*)</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230131221528825" name="us-gaap:CommonStockValue" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230131221535249" name="us-gaap:CommonStockValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additional paid-in capital</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000086" name="us-gaap:AdditionalPaidInCapital" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,160</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000087" name="us-gaap:AdditionalPaidInCapital" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,675</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated deficit</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000088" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">102,623</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000089" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">88,678</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total shareholders&#8217; equity</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000090" name="us-gaap:StockholdersEquity" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,537</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000091" name="us-gaap:StockholdersEquity" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,997</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total liabilities and shareholders&#8217; equity</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000092" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,964</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000093" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,151</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>

    </table>
  </div>
  <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
  <div style="line-height:1.25">
    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(*) 1 American Depositary Share (ADS) represents 20 Ordinary Shares.</span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="line-height:1.25">
      <table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;color:#000000;width:100%">

          <tr>
            <td style="width:50.00%">
              <div>
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">____________________________</span></span></div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chief Executive Officer and Director&#160;&#160;&#160;</span></span>
              </div>
            </td>
            <td style="width:50.00%">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">__________________</span></span></div>
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chief Financial Officer</span></span></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height:1.25">&#160;</div>
  </div>
  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Date of approval of the financial statements: April 4, 2025</span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the consolidated financial statements.</span></span></div>
  <div style="text-align:justify;line-height:1.25">&#160;</div>
  <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
    <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">F - 3</span></span></span></div>
    <div style="page-break-after:always">
      <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-bottom:10pt"/>
    </div>
  </div>

  <div style="text-align:right;line-height:1.25">Chemomab Therapeutics Ltd. and its subsidiaries</div>
  <div style="line-height:1.25">&#160;</div>
  <div style="line-height:1.25">
    <div style="line-height:1.25;font-weight:bold">Consolidated Statements of Operations f<span id="dStatementsofOperationsf"></span>or the year ended</div>
    <div style="line-height:1.25;font-weight:bold">
      <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/>
    </div>
  </div>
  <div style="line-height:1.25">In USD thousands (except share and per share amounts)</div>
  <div style="line-height:1.25">&#160;</div>
  <div style="line-height:1.25">
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

        <tr>
          <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;vertical-align:bottom">
            <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">December 31,</div>
          </td>
          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;vertical-align:bottom">
            <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">December 31,</div>
          </td>
          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;vertical-align:bottom">
            <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">December 31,</div>
          </td>
          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">Note</div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">2024</div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">2023</div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">2022</div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25;font-weight:bold">Operating expenses</div>
          </td>
          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">Research and development</div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">9</div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25;font-weight:bold"><ix:nonFraction id="FFact_0000000000094" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,327</ix:nonFraction></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25"><ix:nonFraction id="FFact_0000000000095" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,381</ix:nonFraction></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20240325095930537" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,977</ix:nonFraction></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:52%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">General and administrative</div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">10</div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><ix:nonFraction id="FFact_0000000000096" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,412</ix:nonFraction></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><ix:nonFraction id="FFact_0000000000097" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,078</ix:nonFraction></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20240325095935768" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,556</ix:nonFraction></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:52%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25;font-weight:bold">Total operating expenses</div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25;font-weight:bold"><ix:nonFraction id="FFact_0000000000098" name="us-gaap:OperatingExpenses" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,739</ix:nonFraction></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25"><ix:nonFraction id="FFact_0000000000099" name="us-gaap:OperatingExpenses" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,459</ix:nonFraction></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20240325095940813" name="us-gaap:OperatingExpenses" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,533</ix:nonFraction></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:52%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">Financing income, net</div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold">(<ix:nonFraction id="Fxbrl_20230131223230473" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">794</ix:nonFraction></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold">)</div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20230131223237304" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,238</ix:nonFraction></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
            <div style="line-height:1.25">
              <div style="line-height:1.25">)</div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20240325095946273" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">353</ix:nonFraction></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
            <div style="line-height:1.25">
              <div style="line-height:1.25">)</div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:52%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25;font-weight:bold">Loss before taxes</div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25;font-weight:bold"><ix:nonFraction id="Fxbrl_20230207212310873_Fact_0000000000102" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">13,945</ix:nonFraction></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20230207212310873_Fact_0000000000103" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">24,221</ix:nonFraction></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20240325095953001" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">28,180</ix:nonFraction></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:52%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">Tax benefit</div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">11</div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><ix:nonFraction id="Fxbrl_20230131223639023" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><ix:nonFraction id="FFact_0000000000101" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20240325100001097" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">534</ix:nonFraction></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
            <div style="line-height:1.25">
              <div style="line-height:1.25">)</div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:52%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25;font-weight:bold">Net loss for the year</div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><ix:nonFraction id="Fxbrl_20250326102131457" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">13,945</ix:nonFraction></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><ix:nonFraction id="FFact_0000000000103" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">24,221</ix:nonFraction></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20240325100006496" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">27,646</ix:nonFraction></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>

    </table>
    <div>&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

        <tr>
          <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">Basic and diluted loss per Ordinary Share</div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">13</div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><ix:nonFraction id="Fxbrl_20230131213305203" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20240101to20241231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000104" name="us-gaap:EarningsPerShareBasic" contextRef="C_20240101to20241231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.039</ix:nonFraction></ix:nonFraction></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20230131213312166" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230101to20231231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000105" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20231231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.103</ix:nonFraction></ix:nonFraction></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_s_20240325100011534" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20240325100011535" name="us-gaap:EarningsPerShareBasic" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.121</ix:nonFraction></ix:nonFraction></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:52%;padding-bottom:4px;vertical-align:bottom">
            <div style="line-height:1.25">Weighted average number of Ordinary Shares outstanding, basic, and diluted (*)</div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;vertical-align:bottom">
            <div style="line-height:1.25">13</div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><ix:nonFraction id="Fxbrl_20230214141238310" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20240101to20241231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000106" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20240101to20241231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">359,048,638</ix:nonFraction></ix:nonFraction></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20230131213329528" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20230101to20231231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000107" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20230101to20231231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">234,998,859</ix:nonFraction></ix:nonFraction></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_s_20240325100018414" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20240325100018415" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">227,589,288</ix:nonFraction></ix:nonFraction></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>

    </table>
  </div>
  <div style="line-height:1.25">
    <div style="line-height:1.25">&#160;</div>
    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(*) 1 American Depositary Share (ADS) represents 20 Ordinary Shares.</span></span></div>
  </div>
  <div style="line-height:1.25">&#160;</div>
  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the consolidated financial statements.</span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
    <div style="text-align:center"><span style="font-weight:normal;font-style:normal">F - 4</span></div>
    <div style="page-break-after:always">
      <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-bottom:10pt"/>
    </div>
  </div>

  <div style="text-align:right;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Chemomab Therapeutics Ltd. and its subsidiaries</span></span></div>
  <div style="text-align:right;line-height:1.25">&#160;</div>
  <div style="line-height:1.25">
    <div style="line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Consolidated Statements of Changes in Equity<span id="Equity" style="margin-top:0pt;margin-bottom:0pt"></span></span></span></div>
    <div style="line-height:1.25;font-weight:bold">
      <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/>
    </div>
  </div>
  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In USD thousands (except share amounts)</span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

      <tr>
        <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Ordinary</span></span></span></span></div>
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Shares (*)</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
          <div style="line-height:1.25">
            <div style="line-height:1.25">&#160;</div>
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Treasury</span></span></span></span></div>
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Shares</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Additional</span></span></span></span></div>
          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Paid In</span></span></span></span></div>
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Capital</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accumulated</span></span></span></span></div>
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Deficit</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">Total</span>&#160;<span style="font-weight:bold">Shareholders&#8217; </span></span></span></span></span></div>
            <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">Equity</span></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Number</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Number</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span><span>USD</span></span></span></span></strong></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:16%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Balance as of January 1, 2022</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230207232832534" name="us-gaap:SharesOutstanding" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">228,090,300</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208004148281" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208004108785" name="us-gaap:SharesOutstanding" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208004208753" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230207232638785_Fact_0000000000128" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,639</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20230207232638785_Fact_0000000000129" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">36,173</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230207232638785_Fact_0000000000130" name="us-gaap:StockholdersEquity" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,466</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:16%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share-based compensation</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208004236209" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208004232608" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230207232932528" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,211</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208004229458" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230207232938175" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,211</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:16%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Issuance of shares, net of issuance costs</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325100655099_xbrl_20230207233201211" name="cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">2,576,400</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325100655099_xbrl_20230208004904248" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325100655099_xbrl_20230208004910523" name="cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325100655099_xbrl_20230208004901083" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325100655099_xbrl_20230207233210018" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">267</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325100655099_xbrl_20230208004950211" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325100655099_xbrl_20230207233216009" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">267</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:16%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Exercise of options</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230207233039147" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,970,000</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208004521301" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208004621028" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208004724885" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230207233033563" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">143</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208004807831" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230207233028090" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">143</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:16%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Treasury shares at cost</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208004938057" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20230207233301376" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal" sign="-">11,640,460</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20230207233406606" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,218</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208004934609" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208004932393" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20230207233411324" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,218</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:16%;padding-bottom:2px;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Net loss for the year</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208004352160" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208004349447" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208004345432" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20230207233044479" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">27,646</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20230207233049858" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">27,646</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:16%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Balance as of December 31, 2022</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230207234506438" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">232,636,700</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208004359870" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20230208004449318" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal" sign="-">11,640,460</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20230208004357072" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,218</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230207233106443" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,260</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20230207234203847" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">63,819</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230207233116634" name="us-gaap:StockholdersEquity" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,223</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>

  </table>
  <div>&#160;</div>
  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

      <tr>
        <td style="vertical-align:bottom;width:16%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Balance as of January 1, 2023</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230207234515566" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">232,636,700</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208004830175" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20230208004835440" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal" sign="-">11,640,460</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20230208004846448" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,218</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230207233129314" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,260</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20230207233133644" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">63,819</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230207233141194" name="us-gaap:StockholdersEquity" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,223</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:16%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share-based compensation</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208004855201" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208004852649" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230207233154315" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,491</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208004943313" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230207233147476" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,491</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:16%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Issuance of shares, net of issuance costs</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230207233201211" name="cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">51,458,000</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208004904248" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208004910523" name="cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208004901083" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230207233210018" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,924</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208004950211" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230207233216009" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,924</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:16%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Sale of treasury shares at cost</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325100724019_xbrl_20230208004938057" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325100724019_xbrl_20230207233301376" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">11,640,460</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325100724019_xbrl_20230207233406606" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,218</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325100724019_xbrl_20230208004934609" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20240325100724019_xbrl_20230208004932393" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">638</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325100724019_xbrl_20230207233411324" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">580</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:16%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Net loss for the year</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208005011611" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208005008418" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208005005802" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20230207233416622" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">24,221</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20230207233422744" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">24,221</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
      </tr>
      <tr>
        <td style="vertical-align:top;width:16%;padding-bottom:4px;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Balance as of December 31, 2023</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230207233430996" name="us-gaap:SharesOutstanding" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">284,094,700</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208005022333" name="us-gaap:StockholdersEquity" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230207233657770" name="us-gaap:SharesOutstanding" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230207233728393" name="us-gaap:StockholdersEquity" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230207233439472" name="us-gaap:StockholdersEquity" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,675</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20230207233445148" name="us-gaap:StockholdersEquity" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">88,678</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230207233450251" name="us-gaap:StockholdersEquity" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,997</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>

  </table>
  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

      <tr>
        <td rowspan="1" style="vertical-align:bottom;width:16%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:16%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Balance as of January 1, 2024,</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325100756924_xbrl_20230207234515566" name="us-gaap:SharesOutstanding" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">284,094,700</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325100756924_xbrl_20230208004830175" name="us-gaap:StockholdersEquity" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325100756924_xbrl_20230208004835440" name="us-gaap:SharesOutstanding" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325100756924_xbrl_20230208004846448" name="us-gaap:StockholdersEquity" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325100756924_xbrl_20230207233129314" name="us-gaap:StockholdersEquity" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,675</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20240325100756924_xbrl_20230207233133644" name="us-gaap:StockholdersEquity" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">88,678</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325100756924_xbrl_20230207233141194" name="us-gaap:StockholdersEquity" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,997</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:16%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share-based compensation</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325100645650_xbrl_20230208004855201" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325100645650_xbrl_20230208004852649" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325100645650_xbrl_20230207233154315" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">617</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325100645650_xbrl_20230208004943313" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325100645650_xbrl_20230207233147476" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">617</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:16%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Issuance of shares and pre-funded warrants, net of issuance costs</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230207233006128" name="cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">93,037,520</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208004339738" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208004626295" name="cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208004335122" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230207233012248" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,868</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230208004332317" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230207233018475" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,868</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:16%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Net loss for the year</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325100739987_xbrl_20230208005011611" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325100739987_xbrl_20230208005008418" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325100739987_xbrl_20230208005005802" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20240325100739987_xbrl_20230207233416622" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">13,945</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20240325100739987_xbrl_20230207233422744" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">13, 945</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:16%;padding-bottom:4px;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Balance as of December 31, 2024</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325100745487_xbrl_20230207233430996" name="us-gaap:SharesOutstanding" contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">377,132,220</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325100745487_xbrl_20230208005022333" name="us-gaap:StockholdersEquity" contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325100745487_xbrl_20230207233657770" name="us-gaap:SharesOutstanding" contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325100745487_xbrl_20230207233728393" name="us-gaap:StockholdersEquity" contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325100745487_xbrl_20230207233439472" name="us-gaap:StockholdersEquity" contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,160</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20240325100745487_xbrl_20230207233445148" name="us-gaap:StockholdersEquity" contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">102,623</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325100745487_xbrl_20230207233450251" name="us-gaap:StockholdersEquity" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,537</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>

  </table>
  <div style="line-height:1.25">&#160;</div>
  <div style="line-height:1.25">
    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(*) 1 American Depositary Share (ADS) represents 20 Ordinary Shares.</span></span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
  </div>
  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The accompanying notes are an integral part of the consolidated financial statements.</span></span></span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
    <div style="text-align:center">
      <div style="margin-top:10pt;margin-bottom:10pt">
        <div style="text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-style:normal;font-weight:normal">F - 5</span></div>
        <div>
          <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt"/>
        </div>
      </div>
    </div>
  </div>

  <div>
    <div>
      <div style="text-align:right;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Chemomab Therapeutics Ltd. and its subsidiaries</span></span></div>
      <div style="text-align:right;line-height:1.25">&#160;</div>
      <div>
        <div style="line-height:1.25">
          <div style="line-height:1.25;font-weight:bold">
            <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Consolidated Statements of Cash flows <span id="Cashflows" style="margin-top:0pt;margin-bottom:0pt"></span>for the year ended</span></span></p>
            <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/>
          </div>
        </div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In USD thousands</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

            <tr>
              <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash flows from operating activities</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss for the year</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000149" name="us-gaap:ProfitLoss" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">13,945</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000150" name="us-gaap:ProfitLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">24,221</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240325104742349" name="us-gaap:ProfitLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">27,646</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Adjustments for operating activities:</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Depreciation</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000151" name="us-gaap:Depreciation" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">53</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000152" name="us-gaap:Depreciation" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">67</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325104746496" name="us-gaap:Depreciation" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">58</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000153" name="us-gaap:ShareBasedCompensation" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">617</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000154" name="us-gaap:ShareBasedCompensation" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,491</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325104750812" name="us-gaap:ShareBasedCompensation" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,211</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in other receivables and prepaid expenses</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000155" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">487</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000156" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">903</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240325104755091" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in trade payables</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000157" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">150</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000158" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,172</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325104759425" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">352</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in accrued expenses</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000159" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,860</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230201002431792" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325104804410" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,823</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in employees and related expenses</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000161" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">51</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000162" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">737</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325104808746" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">907</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in operating leases</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000163" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">35</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230201002424683" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240325104815058" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">11</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net cash used in operating activities</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000165" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">15,386</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000166" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">23,611</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240325104819434" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">20,370</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash flows from investing activities</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Investment in deposits</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000167" name="cmmb:PaymentsForInvestmentInDeposits" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,297</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000168" name="cmmb:PaymentsForInvestmentInDeposits" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">15,882</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325104823921" name="cmmb:PaymentsForInvestmentInDeposits" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">19,601</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Purchase of property and equipment</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000173" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000174" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240325104839642" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">68</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net cash provided by investing activities</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000175" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,297</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000176" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,879</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325104844087" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,533</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash flows from financing activities</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise of options</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000179" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230131235658097" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325104931102" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">143</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Purchase of treasury share</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230201000241409" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000182" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240325104937430" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,218</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sale of treasury share</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325104521419" name="us-gaap:ProceedsFromSaleOfTreasuryStock" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325104453631_xbrl_20230201000241409" name="us-gaap:ProceedsFromSaleOfTreasuryStock" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">580</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325104453631_Fact_0000000000182" name="us-gaap:ProceedsFromSaleOfTreasuryStock" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance of shares net of issuance costs</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000183" name="us-gaap:ProceedsFromOtherEquity" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,868</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000184" name="us-gaap:ProceedsFromOtherEquity" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,924</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325104942102" name="us-gaap:ProceedsFromOtherEquity" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">267</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net cash provided by (used in) financing activities</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230201002754453" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,868</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000186" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,504</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240325104946388" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">808</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in cash, cash equivalents and restricted cash</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230201002721687" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,221</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000188" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,228</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240325105003435" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,645</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash, cash equivalents and restricted cash at beginning of the year</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000189" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,368</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000190" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,596</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325105007045" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,241</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash, cash equivalents and restricted cash at end of the year</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000191" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,147</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000192" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,368</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325105011131" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,596</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Supplementary cash flows information:</span></span></span></div>
        <div style="text-align:justify;line-height:1.25;font-weight:bold">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

            <tr>
              <td style="vertical-align:bottom;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">A.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <span style="font-weight:bold">Cash paid and received during the year for:</span></span></span></div>
                <div style="line-height:1.25">&#160;</div>
              </td>
              <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:top;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income taxes received</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214142748754" name="cmmb:IncomeTaxesReceived" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20230214143241770" name="cmmb:IncomeTaxesReceived" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">187</ix:nonFraction></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325105045604" name="cmmb:IncomeTaxesReceived" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">351</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:top;width:64%;padding-bottom:4px;vertical-align:bottom">
                <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest received</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207233819452" name="cmmb:InterestReceived" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">814</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207233829491" name="cmmb:InterestReceived" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,463</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325105050333" name="cmmb:InterestReceived" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">972</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">&#160;B.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Significant non- cash transaction:</span></span></span></div>
        <div style="text-align:justify;line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

            <tr>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:64%;padding-bottom:4px;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Right-of-use asset recognized with corresponding lease liability</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;border-bottom:#000000 double 4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%;border-bottom:#000000 double 4px;vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000193" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;border-bottom:#000000 double 4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%;border-bottom:#000000 double 4px;vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000194" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">392</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;border-bottom:#000000 double 4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%;border-bottom:#000000 double 4px;vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325105059739" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the consolidated financial statements.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
      </div>
      <div style="line-height:1.25">
        <div style="margin-top:10pt;margin-bottom:10pt">
          <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-style:normal;font-weight:normal">F - 6</span></span></span></div>
          <div>
            <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always"/>
          </div>
        </div>
        <div style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab Therapeutics Ltd. and its subsidiaries</span></span></div>
      </div>
      <div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="Notes"></span>Notes to the Financial Statements as at December 31, 2024</span></span></div>
        </div>
      </div>
    </div>
  </div>
  <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:10pt;text-align:center"/>

  <ix:nonNumeric id="Fxbrl_20250325232417636" name="us-gaap:NatureOfOperations" contextRef="C_20240101to20241231" escape="true">
    <div>
      <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Note 1 - General</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt">&#160;</td>
            <td style="width:30pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>A.</span></span></span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Chemomab Therapeutics Ltd. (hereinafter - "the Company") is an Israeli-based company incorporated under the laws of the State of Israel in September 2011. The Company&#8217;s registered office is located in Kiryat Atidim, Tel Aviv, Israel.</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:65pt">&#160;</td>
            <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>i.</span></span></span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company is a clinical-stage biotech company discovering and developing innovative therapeutics for conditions with high-unmet medical need that involve inflammation and fibrosis.</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:65pt">&#160;</td>
            <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>ii.</span></span></span></span></td>
            <td style="width:auto;vertical-align:top">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The wholly owned subsidiaries of the Company are: Chemomab Ltd. ("Chemomab"), Chemomab Therapeutics Inc. and Chemomab Therapeutics (Israel) Ltd.</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt">&#160;</td>
            <td style="width:30pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>B.</span></span></span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company relies on one supplier for the production of the CM-101 used in its product development. If this supplier fails to deliver or experiences production delays, the Company will be required to seek an alternative solution. Switching suppliers may cause manufacturing delays and higher costs, potentially delaying the product's development and impacting the Company&#8217;s operational results and financial position.</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt">&#160;</td>
            <td style="width:30pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>C.</span></span></span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Going concern uncertainty</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. However, the Company has incurred recurring losses from operations as of December 31, 2024 of approximately $<ix:nonFraction id="Fxbrl_20250325233240211" name="us-gaap:OperatingIncomeLoss" contextRef="C_20240101to20241231" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal" sign="-">103</ix:nonFraction> million and negative cash flows from operating activities in 2024 of $<ix:nonFraction id="Fxbrl_20250325233246707" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20240101to20241231" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal" sign="-">15.4</ix:nonFraction> million with currently no products approved for sale.</span></span></span></span></div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As of December 31, 2024, the Company had cash, cash equivalents, and short-term deposits of $<ix:nonFraction id="Fxbrl_20250325233301811" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="C_20241231" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.3</ix:nonFraction> million. The Company&#8217;s current cash resources are sufficient to meet its planned expenditures through the end of March 2026. These indicators raising substantial doubt about its ability to continue as a going concern. The Company will be required to raise additional funds to support its operations and continue as a going concern. While management believes that the Company can raise additional funds, there can be no assurance that these efforts will be successful or sufficient.</span></span></span></span></div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
      <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></span></span></span></div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>

  <ix:nonNumeric id="Fxbrl_20250325165827031" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_20240101to20241231" escape="true">
    <div>
      <div style="line-height:1.25">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Note 2 &#8211; Summary of Significant Accounting Policies</span></span></span></div>
        <div>
          <div style="line-height:1.25">&#160;</div>
          <ix:nonNumeric id="Fxbrl_20250325170749806" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_20240101to20241231" escape="true">
            <div>
              <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">A.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Basis of Preparation</span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;).</span></span></span></div>
            </div>
          </ix:nonNumeric>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <ix:nonNumeric id="Fxbrl_20250325170755069" name="us-gaap:UseOfEstimates" contextRef="C_20240101to20241231" escape="true">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">B.</span></span></span></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">Use of estimates</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</span></span></span></div>
          </div>
        </ix:nonNumeric>
        <p style="margin:0pt">&#160;</p>
      </div>
      <div><ix:exclude>
        <div style="text-align:justify;line-height:1.25">
          <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 7</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right;margin-top:10pt"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2024</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
          <p style="margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Note 2 &#8211; Summary of Significant Accounting Policies (cont&#8217;d)</span></span></span></strong></p>
          <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
        </div>
      </ix:exclude></div>
      <ix:nonNumeric id="Fxbrl_20250325170802129" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="C_20240101to20241231" escape="true">
        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">C.</span></span></span></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">Foreign currency</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The currency of the primary economic environment in which the operations of the Company are conducted is the U.S. dollar (&#8220;dollar&#8221; or &#8220;$&#8221;), thus; the dollar is the functional currency of the Company.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The transactions and balances of the Company denominated in U.S. dollars are presented at their original amounts as the U.S. dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Monetary assets and liabilities denominated in a non-U.S. dollar currency are translated using the current exchange rate and nonmonetary assets and liabilities and capital accounts denominated in a non-U.S. dollar currency are translated using historical exchange rates.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Statements of operations accounts denominated in a non-U.S. dollar currency are translated using the exchange rates in effect on the transaction dates, except for depreciation, which is translated using historical exchange rate.</span></span></span></div>
        </div>
      </ix:nonNumeric>
      <div style="line-height:1.25">&#160;</div>
      <ix:nonNumeric id="Fxbrl_20250325170807416" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_20240101to20241231" escape="true">
        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">D.</span></span></span></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">Cash and cash equivalents</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Cash equivalents are short-term liquid bank deposits that are readily convertible to cash with original maturities of three months or less at the date acquired.</span></span></span></div>
        </div>
      </ix:nonNumeric>
      <div style="line-height:1.25">&#160;</div>
      <ix:nonNumeric id="Fxbrl_20250325170815861" name="cmmb:ShortTermBankDepositsPolicyTextBlock" contextRef="C_20240101to20241231" escape="true">
        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">E.</span></span></span></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">Short-term bank deposits</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Bank deposits with original maturities exceeding three months but less than one year are classified as part of short-term investments. These deposits are recorded at cost, which approximates their market value, including accrued interest. Interest earned on these deposits is recognized as financial income. As of December 31, 2024, the range of interest rates paid on these deposits was between <ix:nonFraction id="Fxbrl_20250325184652403" name="cmmb:PercentageOfShortTermDeposits" contextRef="C_20240101to20241231_srtRangeAxis_srtMinimumMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.24</ix:nonFraction>% and <ix:nonFraction id="Fxbrl_20250325184700941" name="cmmb:PercentageOfShortTermDeposits" contextRef="C_20240101to20241231_srtRangeAxis_srtMaximumMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">5.75</ix:nonFraction>% (2023: between <ix:nonFraction id="Fxbrl_20250325184705304" name="cmmb:PercentageOfShortTermDeposits" contextRef="C_20230101to20231231_srtRangeAxis_srtMinimumMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.22</ix:nonFraction>% and <ix:nonFraction id="Fxbrl_20250325184709274" name="cmmb:PercentageOfShortTermDeposits" contextRef="C_20230101to20231231_srtRangeAxis_srtMaximumMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">6.65</ix:nonFraction>%).</span></span></span></div>
        </div>
      </ix:nonNumeric>
      <div style="line-height:1.25">&#160;</div>
      <ix:nonNumeric id="Fxbrl_20250325170822565" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="C_20240101to20241231" escape="true">
        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">F.</span>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <span style="font-weight:bold">Restricted cash</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Restricted cash is primarily invested in highly liquid deposits. These deposits were used to secure office lease payments.</span></span></span></div>
        </div>
      </ix:nonNumeric>
      <div style="line-height:1.25">&#160;</div>
      <ix:nonNumeric id="Fxbrl_20250325170829453" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_20240101to20241231" escape="true">
        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">G.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Property and equipment</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Property and equipment are stated at cost less accumulated depreciation. Maintenance and repair expenses are charged to operation as incurred. Depreciation is calculated based on the straight-line method and&#160; the estimated useful lives of the assets and commences once the assets are ready for their intended use.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Annual rates at depreciation are as follows:</span></span></span></div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
          <div style="margin-left:36pt">
            <ix:nonNumeric id="Fxbrl_20250325170224477" name="cmmb:ScheduleOfAnnualRateOfDeprecationTableTextBlock" contextRef="C_20240101to20241231" escape="true">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td colspan="1" rowspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" rowspan="1" style="vertical-align:top;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>%</span></span></span></td>
                    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Computers</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000214" name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" contextRef="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">33</ix:nonFraction></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:88%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Laboratory equipment</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000215" name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" contextRef="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Furniture and equipment</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000216" name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" contextRef="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">7</ix:nonFraction></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="4" style="vertical-align:top;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Leasehold improvement - <ix:nonNumeric id="FFact_0000000000217" name="cmmb:AnnualRatesOfDepreciation" contextRef="C_20240101to20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">over the shorter of the lease term or the estimated useful life of the improvement</ix:nonNumeric></span></span></span></div>
                    </td>
                  </tr>

              </table>
            </ix:nonNumeric>
          </div>
        </div>
      </ix:nonNumeric>
      <div style="line-height:1.25">&#160;</div>
      <div><ix:exclude>
        <div style="line-height:1.25">
          <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 8</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right;margin-top:10pt"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2024</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
          <p style="margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Note 2 - Summary of Significant Accounting Policies (cont&#8217;d)</span></span></span></strong></p>
          <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
        </div>
      </ix:exclude></div>
      <ix:nonNumeric id="Fxbrl_20250325170838965" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="C_20240101to20241231" escape="true">
        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">H.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Impairment of long-lived assets</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company&#8217;s property and equipment are reviewed for impairment in accordance with ASC 360, &#8220;Property and Equipment&#8221;, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less selling costs. During the periods ended December 31, 2024, 2023 and 2022, no impairment losses have been recorded.</span></span></span></div>
        </div>
      </ix:nonNumeric>
      <div style="line-height:1.25">&#160;</div>
      <ix:nonNumeric id="Fxbrl_20250325170845711" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_20240101to20241231" escape="true">
        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">I.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <span style="font-weight:bold">Research and Development</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Research and development costs are charged to operations as incurred. Most of the research and development expenses are for subcontractors and salaries.&#160;</span></span></span></div>
        </div>
      </ix:nonNumeric>
      <div style="line-height:1.25">&#160;</div>
      <ix:nonNumeric id="Fxbrl_20250325170853037" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_20240101to20241231" escape="true">
        <div>
          <div style="text-indent:36pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>J.&#160; &#160; &#160; &#160;&#160; &#160; Income taxes</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income,&#160;tax-planning&#160;strategies, and results of recent operations.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the income taxes expense.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50 percent likely of being realized.</span></span></span></div>
        </div>
      </ix:nonNumeric>
      <p style="margin:0pt">&#160;</p>
      <div style="margin-top:0pt;margin-bottom:0pt"><ix:exclude>
        <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt">
          <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 9</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right;margin-top:10pt"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2024</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
          <p style="margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Note 2 - Summary of Significant Accounting Policies (cont&#8217;d)</span></span></span></strong></p>
          <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
        </div>
      </ix:exclude></div>
      <ix:nonNumeric id="Fxbrl_20250325170901014" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="C_20240101to20241231" escape="true">
        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">K.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Fair value of financial instruments</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>ASC 820, Fair Value Measurements and Disclosures, relating to fair value measurements, defines fair value and established a framework for measuring fair value. The ASC 820 fair value hierarchy distinguishes between market participant assumptions developed based on market data obtained from sources independent of the reporting entity and the reporting entity&#8217;s own assumptions about market participant assumptions developed based on the best information available in the circumstances. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>In addition, the fair value of assets and liabilities should include consideration of non-performance risk, which for the liabilities described below includes the Company&#8217;s own credit risk.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:</span></span></span></div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Level&#160;1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></span></span></div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities.</span></span></span></div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The carrying amounts of cash and cash equivalents, short-term deposits, trade payables, other receivables, and prepaid expenses approximate their fair value due to the short-term maturity of such instruments. None of the Company&#8217;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.</span></span></span></div>
        </div>
      </ix:nonNumeric>
      <div style="line-height:1.25">&#160;</div>
      <ix:nonNumeric id="Fxbrl_20250325170907896" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="C_20240101to20241231" escape="true">
        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">L.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Share-based compensation</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company accounts for share-based compensation as an expense in the financial statements based on ASC 718. All awards are equity classified and therefore such costs are measured at the grant date fair value of the award and graded vesting attribution approach to recognize compensation cost over the vesting period. The Company recognizes compensation cost for an award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant-date value of such award that is vested at that date.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The fair value for the Company&#8217;s stock options granted to employees, consultants and directors was estimated using Black-Scholes option-pricing model at the grant date, using the inputs detailed in Note 8(C).</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</span></span></span></div>
        </div>
      </ix:nonNumeric>
      <div style="line-height:1.25">&#160;</div>
      <ix:nonNumeric id="Fxbrl_20250325170915750" name="cmmb:GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock" contextRef="C_20240101to20241231" escape="true">
        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">M.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Government-sponsored research and development</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Chemomab records grants received from the office of the Israel Innovation Authority (the &#8220;IIA&#8221;) as a liability, if it is probable that the Chemomab will have to repay the grants received. If it is not probable that the grants will be repaid, Chemomab records the grants as a reduction to research and development expenses.</span></span></span></div>
        </div>
      </ix:nonNumeric>
      <p style="margin:0pt">&#160;</p>
      <div><ix:exclude>
        <div style="text-align:justify;line-height:1.25">
          <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 10</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right;margin-top:10pt"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2024</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
          <p style="margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Note 2 - Summary of Significant Accounting Policies (cont&#8217;d)</span></span></span></strong></p>
          <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
        </div>
      </ix:exclude></div>
      <div>
        <ix:nonNumeric id="Fxbrl_20250325171008896" name="cmmb:SeverancePayPolicyTextBlock" contextRef="C_20240101to20241231" escape="true">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">N.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Severance pay</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Pursuant to Section 14 of the Severance Compensation Law, 1963 ("Section 14"), all employees of the Company are entitled only to monthly deposits, at a rate of <ix:nonFraction id="Fxbrl_20230215220314714" name="cmmb:PercentageOfMonthlyDepositsRate" contextRef="C_20240101to20241231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">8.33</ix:nonFraction>% of their monthly salary, made on their behalf with insurance companies. Upon release of the policy to the employee, no additional liability exists between the parties regarding the matter of severance pay and no additional payments shall be made by the Company to the employee. This plan has been accounted for as a defined contribution plan. Severance costs amounted to approximately $<ix:nonFraction id="Fxbrl_20230215220321806" name="us-gaap:SeveranceCosts1" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction>&#160;thousands, $<ix:nonFraction id="Fxbrl_20230215220329094" name="us-gaap:SeveranceCosts1" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction> thousands, and $<ix:nonFraction id="Fxbrl_20240325101644612" name="us-gaap:SeveranceCosts1" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">142</ix:nonFraction> thousands for the year ended December 31, 2024, 2023 and 2022, respectively.</span></span></span></div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="line-height:1.25">&#160;</div>
      <ix:nonNumeric id="Fxbrl_20250325171015865" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="C_20240101to20241231" escape="true">
        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">O.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Concentrations of credit risk:</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Cash and cash equivalents and short- term deposits are invested in banks. Management believes that the financial institutions that hold the Company&#8217;s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</span></span></span></div>
        </div>
      </ix:nonNumeric>
      <div style="line-height:1.25">&#160;</div>
      <ix:nonNumeric id="Fxbrl_20250325171023616" name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="C_20240101to20241231" escape="true">
        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">P.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Leases</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Under Topic 842, the Company determines if an arrangement is a lease at inception. Right-of-use (ROU) assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company's incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be 9% in 2024 and 2023 and 5% in 2022, The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>When determining the probability of exercising such options, the Company considers contract-based, asset-based, entity-based, and market-based factors. For lease agreements, the Company has elected the practical expedient to account for the lease and non-lease maintenance components as a single lease component. Therefore, for those leases, the lease payments used to measure the lease liability include all the fixed considerations in the contract. The Company's lease agreements generally do not contain any residual value guarantees or restrictive covenants.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>ROU assets for operating leases are periodically reduced by impairment losses. The Company uses the long-lived assets impairment guidance in ASC Subtopic 360-10, Property, Plant, and Equipment to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize.</span></span></span></div>
        </div>
      </ix:nonNumeric>
      <p style="margin:0pt">&#160;</p>
      <div><ix:exclude>
        <div style="text-align:justify;line-height:1.25">
          <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 11</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right;margin-top:10pt"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2024</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
          <p style="margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Note 2 - Summary of Significant Accounting Policies (cont&#8217;d)</span></span></span></strong></p>
          <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
        </div>
      </ix:exclude></div>
      <ix:nonNumeric id="Fxbrl_20250325171031922" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="C_20240101to20241231" escape="true">
        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">Q.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Segments</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company has one reportable segment, focused on the research and development of therapeutics for conditions with high unmet medical needs involving inflammation and fibrosis. The Company&#8217;s chief operating decision maker ("CODM") is its chief executive officer of the company. The segment is managed on a consolidated basis, and the CODM uses total operating expenses and consolidated net loss to assess performance, forecast future financial results, and allocate resources.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>In evaluating the Company's financial performance and making strategic decisions, the CODM regularly reviews operating expenses by function. Furthermore, the CODM is provided only with the consolidated expenses, as presented in the income statement disclosures (see Notes 9 and 10&#160;with respect to salaries, professional services, consultants and subcontractors). This includes a review of budget versus actual expenses and direct program spending, which encompasses clinical costs, consultant fees, manufacturing expenses, and other direct external costs.</span></span></span></div>
        </div>
      </ix:nonNumeric>
      <div style="line-height:1.25">&#160;</div>
      <ix:nonNumeric id="Fxbrl_20250325171038815" name="us-gaap:ConsolidationPolicyTextBlock" contextRef="C_20240101to20241231" escape="true">
        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">R.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Principles of consolidation</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The consolidated financial statements include the accounts of the Company and its Subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.</span></span></span></div>
        </div>
      </ix:nonNumeric>
      <div style="line-height:1.25">&#160;</div>
      <ix:nonNumeric id="Fxbrl_20250325171048100" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_20240101to20241231" escape="true">
        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">S.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Loss per ordinary share</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Basic Loss per ordinary share are calculated using only weighted average ordinary shares outstanding. Diluted loss per share, if relevant, gives an effect to dilutive potential ordinary shares outstanding during the year.&#160; Such dilutive shares consist of incremental shares, using the treasury stock method, from the assumed exercise of share options.</span></span></span></div>
        </div>
      </ix:nonNumeric>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>

  <ix:nonNumeric id="FFact_0000000000244" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" contextRef="C_20240101to20241231" escape="true">
    <div>
      <div>
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 3 - Cash and Cash Equivalents</span></span></div>
        <div>
          <div style="line-height:1.25">&#160;</div>
          <div style="line-height:1.25;margin-left:36pt">
            <ix:nonNumeric id="Fxbrl_20240325103135178" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" contextRef="C_20240101to20241231" escape="true">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In USD</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000235" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20241231_srtCurrencyAxis_currencyUSD" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,545</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000236" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20231231_srtCurrencyAxis_currencyUSD" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,718</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In NIS</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000237" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20241231_srtCurrencyAxis_currencyILS" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">525</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000238" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20231231_srtCurrencyAxis_currencyILS" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,574</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In other currencies</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325103200378" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20241231_srtCurrencyAxis_currencyXXX" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*<ix:nonFraction id="Fxbrl_20250325144319085" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20231231_srtCurrencyAxis_currencyXXX" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000241" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,071</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000242" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,292</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </ix:nonNumeric>
          </div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25;margin-left:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">* Less than 1 thousand</span></span></div>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>
  <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 12</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right;margin-top:10pt"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2024</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>

  <ix:nonNumeric id="FFact_0000000000252" name="cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock" contextRef="C_20240101to20241231" escape="true">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 4 - Other Receivables and Prepaid Expenses</span></span></strong></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
    <ix:nonNumeric id="Fxbrl_20250325144838679" name="cmmb:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" contextRef="C_20240101to20241231" escape="true">
      <div>
        <div>
          <div style="line-height:1.25;margin-left:36pt">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Government institutions</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000245" name="cmmb:ReceivablesFromGovernmentInstitutions" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">263</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000246" name="cmmb:ReceivablesFromGovernmentInstitutions" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">289</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Prepaid expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000247" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,435</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000248" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">748</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000249" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,698</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000250" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,037</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>
        </div>
      </div>
    </ix:nonNumeric>
  </ix:nonNumeric>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left">&#160;</p>

  <ix:nonNumeric id="Fxbrl_20250325145701936" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="C_20240101to20241231" escape="true">
    <div>
      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Note 5 - Property and Equipment, Net</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="line-height:1.25;margin-left:36pt">
        <ix:nonNumeric id="Fxbrl_20250325145709940" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_20240101to20241231" escape="true">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Cost:</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Computers</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000253" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">68</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000254" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">68</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Furniture and equipment</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000255" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000256" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Laboratory equipment</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000257" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">400</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000258" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">400</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Website development</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000259" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapSoftwareDevelopmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000260" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapSoftwareDevelopmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Leasehold improvements</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000261" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000262" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230201032006902" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">529</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000264" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">529</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Less - accumulated depreciation</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20250325145509779" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">279</ix:nonFraction></span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="FFact_0000000000266" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">226</ix:nonFraction></span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230201033845372" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">250</ix:nonFraction></span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000268" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">303</ix:nonFraction></span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </ix:nonNumeric>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>

  <ix:nonNumeric id="FFact_0000000000294" name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="C_20240101to20241231" escape="true">
    <div>
      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 6 - Leases</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On May 10, 2020, Chemomab entered into an office and lab space lease agreement (the "Agreement") for a <ix:nonNumeric id="Fxbrl_20230131233210356" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_20200510" format="ixt-sec:durwordsen">three-year</ix:nonNumeric> term in Atidim Park, Tel Aviv, with an option to extend for an additional <ix:nonNumeric id="Fxbrl_20230131233301410" name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="C_20200501to20200510">three years</ix:nonNumeric>. On October 24, 2021, the Company signed an amendment (the "Amendment"), under which it returned the previous space on December 12, 2021, and leased a larger space in the same location for <ix:nonNumeric id="Fxbrl_20230201000916081" name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="C_20211001to20211024">three years</ix:nonNumeric> through October 2024. In September 2024, the Company extended the agreement through October 2027. The annual lease and management fees are approximately $<ix:nonFraction id="Fxbrl_20230131234005244" name="cmmb:AnnualRentAndManagementFees" contextRef="C_20211001to20211024" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">112</ix:nonFraction> thousands, and a bank guarantee of approximately $<ix:nonFraction id="Fxbrl_20240325135011021" name="cmmb:BankGuaranteesToPropertyOwner" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">76</ix:nonFraction> thousands was issued to the property owner in 2023.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On September 30, 2024, the Company signed an addendum to the rent agreement stating that, as of January 1, 2025, the Company has an early termination period of 120 days for the lease agreement.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div><ix:exclude>
        <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
          <div style="margin-top:0pt;margin-bottom:0pt">
            <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 13</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right;margin-top:10pt"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2024</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
          </div>
        </div>
        <div style="line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Note 6 &#8211; Leases (cont&#8217;d)</span></span></div>
        <div style="line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt">&#160;</div>
      </ix:exclude></div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25">The above operating leases are included in &#8220;Operating lease right-of-use assets&#8221; on the Company&#8217;s Consolidated Balance sheets as of December 31, 2024 and 2023 represent the Company&#8217;s right to use the underlying asset for the lease term. The Company&#8217;s obligations to pay lease payments are included in the current liabilities as &#8220;Operating lease liabilities&#8221; and in the non-current liabilities as &#8220;non-current operating lease liabilities&#8221; in the Company&#8217;s Consolidated Balance sheets as of December 31, 2024 and 2023. Based on the present value of the lease payments for the remaining lease term of the Company&#8217;s existing lease agreement, the Company recognized operating right-of-use assets and operating lease liabilities of approximately $<ix:nonFraction id="Fxbrl_20250326210718797" name="cmmb:OperatingRightOfUseAssetsAndOperatingLeaseLiabilities" contextRef="C_20231212" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">392</ix:nonFraction> thousands on December 12, 2023.</div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the year ended December 31, 2023, the Company recognized an increase in right of use assets of $<ix:nonFraction id="Fxbrl_20230131234513790" name="us-gaap:OperatingLeaseImpairmentLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">392</ix:nonFraction> thousand.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2024 and 2023 amounts of operating right-of-use assets were $<ix:nonFraction id="Fxbrl_20230214143811730" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">289</ix:nonFraction> thousands and $<ix:nonFraction id="Fxbrl_20230214143818906" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">392</ix:nonFraction> thousand, respectively. The operating lease liabilities amounts were $<ix:nonFraction id="Fxbrl_20230214143827206" name="us-gaap:OperatingLeaseLiability" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">324</ix:nonFraction> thousands and $<ix:nonFraction id="Fxbrl_20230214143833566" name="us-gaap:OperatingLeaseLiability" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">392</ix:nonFraction> thousand, respectively.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As most of Chemomab&#8217;s leases do not provide an implicit rate, Chemomab uses its incremental borrowing rate based on the information available at the commencement date of each lease in determining the present value of lease payments. Chemomab&#8217;s incremental borrowing rate is a hypothetical rate based on its estimation of its theoretical credit rating. The rate was <ix:nonFraction id="Fxbrl_20250325212645077" name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="C_20230101to20231231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230131234937485" name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="C_20240101to20241231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">9</ix:nonFraction></ix:nonFraction>% in 2024 and 2023.</span></span></div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Maturities of lease liabilities under non-cancellable leases as of December 31, 2024, are as follows: (in thousands):</span></span></div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
      <div style="margin-left:36pt">
        <ix:nonNumeric id="Fxbrl_20240325105733072" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="C_20240101to20241231" escape="true">
          <div>
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325112906183" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">120</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2026</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325112921124" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">120</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2027</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325112940611" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">106</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;padding-bottom:4px;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total future minimum lease payments</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000290" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">346</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less imputed interest:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000291" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;padding-bottom:4px;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present value of operating lease liabilities</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000292" name="us-gaap:OperatingLeaseLiability" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">324</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>
        </ix:nonNumeric>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>

  <ix:nonNumeric id="Fxbrl_20250325145247048" name="us-gaap:CommitmentsDisclosureTextBlock" contextRef="C_20240101to20241231" escape="true">
    <div>
      <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Note 7 - Commitments and Contingent Liabilities</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">A.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Exclusive License Agreement (hereinafter- &#8220;the License Agreement&#8221;)</span></span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In December 2011, Chemomab entered into a License Agreement with the Medical Research, Infrastructure, Health Services Fund of the Tel-Aviv Souraski Medical Center (&#8220;Fund"), pursuant to which it was granted with an exclusive license to certain inventions (as defined in the License Agreement) including patents, knowhow and products and the right to sublicense to third parties the rights granted, pursuant to and subject to certain terms and limitation fully set in the License Agreement.</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Chemomab has agreed to pay the Fund a non-refundable and non-creditable sublicense fees as a percentage of all Attributed Income (as such term defined in the License Agreement) and shall further pay the Fund royalties from sales made by sublicensee.</span></span></span></span></div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Royalties in percentage of Net sales or Service Income (as defined in the License Agreement), subject to certain additional terms set forth therein.</span></span></span></span></div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
      <div><ix:exclude>
        <div style="line-height:1.25">
          <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 14</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right;margin-top:10pt"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2024</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
          <p style="margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Note 7 - Commitments and Contingent Liabilities (cont&#8217;d)</span></span></span></span></strong></p>
          <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
        </div>
      </ix:exclude></div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In addition, with respect to each Licensed Product (as defined therein), Chemomab has agreed to pay the Fund the following non-refundable, non-creditable amounts:</span></span></span></span></div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt">&#160;</td>
            <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(a)</span></span></span></span></td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="Fxbrl_20230215222406006" name="us-gaap:LongTermPurchaseCommitmentDescription" contextRef="C_20240101to20241231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_usgaapCapitalAdditionsMember">$100 thousands upon submission of a New Drug Application (&#8220;NDA&#8221;), Biological License Application (&#8220;BLA&#8221;) or equivalent for each Licensed Product to the United States Food and Drug Administration (&#8220;FDA&#8221;), $100 thousands upon submission of a similar application for each Licensed Product to an equivalent foreign regulatory agency in Europe and one hundred thousands dollars upon submission of a similar application for each Licensed Product to an equivalent foreign regulatory agency in Asia. Payment in the aggregate shall not be more than $300 thousands per Licensed Product, provided that for each jurisdiction, payment shall be made only once.</ix:nonNumeric></span></span></span></span></div>
            </td>
          </tr>

      </table>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt">&#160;</td>
            <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(b)</span></span></span></span></td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="Fxbrl_20230215222519809" name="us-gaap:LongTermPurchaseCommitmentDescription" contextRef="C_20240101to20241231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_cmmbCapitalAdditionsOneMember">$200 thousands upon the grant of FDA or equivalent agency marketing approval in Europe and/or Asia for each Licensed Product. Payment in the aggregate shall not be more than&#160;$600 thousands per Licensed Product, provided that for each jurisdiction, payment shall be made only once.</ix:nonNumeric></span></span></span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As of December 31, 2024, no payments were made to the Fund.</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In addition to the payments described above, <ix:nonNumeric id="Fxbrl_20230215222713212" name="us-gaap:OtherCommitmentsDescription" contextRef="C_20240101to20241231">upon the occurrence of either (i) closing of a public offering of the ordinary shares of Chemomab; or (ii) a Change of Control Transaction, Chemomab shall pay the Fund a cash payment equal to one percent (1%) of the proceeds raised by Chemomab in its initial public offering, or 1% of the consideration received by Chemomab or its shareholders at the closing of a Change of Control Transaction (after deduction of amounts paid as liquidation preference to the shareholders of Chemomab on account of their investment in Chemomab, if any), but in any event not more than&#160; $3,000 thousand.</ix:nonNumeric></span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As of December 31, 2024 none of the above occurred and as such, no commitment exists.</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt">&#160;</td>
            <td style="width:30pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>B.</span></span></span></span></td>
            <td style="width:auto;vertical-align:top">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Chemomab partially financed its research and development expenditures under programs sponsored by the Israel Innovation Authority (&#8220;IIA&#8221;) for the support of certain research and development activities conducted in Israel.</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In return for the IIA&#8217;s participation, Chemomab is committed to pay royalties at rate of <ix:nonFraction id="Fxbrl_20230201002925810" name="cmmb:PercentageOfRoyaltyPaymentsOnSaleOfProduct" contextRef="C_20240101to20241231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_usgaapCapitalAdditionsMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction>% of sales of the developed product (linked to U.S. dollar), up to <ix:nonFraction id="Fxbrl_20230201002935951" name="cmmb:MaximumPercentageOfPaymentsOfRoyalties" contextRef="C_20240101to20241231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the amount of grants received (100% plus interest at LIBOR). In addition, the IIA may impose certain conditions to transfer technology or development out of Israel.</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Chemomab did not receive any grants from the IIA in the years ended December 31, 2024, 2023 and 2022.</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Since Chemomab &#8217;s incorporation through December 31, 2024, Chemomab received $<ix:nonFraction id="Fxbrl_20230201002951961" name="cmmb:CumulativeAmountsOfGrantsReceivedAndRecognized" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,227</ix:nonFraction> thousands from the IIA, which was recognized as a reduction of research and development expenses.</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As of December 31, 2024, Chemomab had no commitment&#160; to pay royalties.</span></span></span></span></div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
      <div><ix:exclude>
        <div style="line-height:1.25">
          <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 15</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right;margin-top:10pt"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2024</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
          <p style="margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Note 7 - Commitments and Contingent Liabilities (cont&#8217;d)</span></span></span></span></strong></p>
          <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
        </div>
      </ix:exclude></div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt">&#160;</td>
            <td style="width:30pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>C.</span></span></span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In June 2015, Chemomab entered into a license agreement with subcontractor (&#8220;the Subcontractor&#8221;), under which the Subcontractor granted to Chemomab certain licenses to use proprietary rights of the subcontractor, materials and know how in the techniques and use of the same, for purposes of research and development of Chemomab 's product CM-101, as well as commercialization thereof. Further to the agreement, the Subcontractor also provides manufacturing services of intermediate and active pharmaceutical ingredients. According to the related manufacturing agreement, the manufacturing of the product is carried out by the Subcontractor in accordance with Chemomab's specifications and timeline.&#160; From time to time, Chemomab and the Subcontractor have been signing additional agreements for additional manufacturing and final process lock of the product for clinical use. Under the agreement, Chemomab is also obligated to pay the Subcontractor royalties determined as a percentage of net sales of each licensee product.</span></span></span></span></div>
              <div>&#160;</div>
              <div>
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>During 2024, 2023 and 2022, Chemomab recorded expenses related to the above agreements in the amounts of $<ix:nonFraction id="Fxbrl_20230213125722009" name="us-gaap:RoyaltyExpense" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">418</ix:nonFraction> thousand, $<ix:nonFraction id="Fxbrl_20230213125731080" name="us-gaap:RoyaltyExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,832</ix:nonFraction> thousands and $<ix:nonFraction id="Fxbrl_20240325141025378" name="us-gaap:RoyaltyExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,222</ix:nonFraction> thousand, respectively. The expenses were recorded under research and development expenses.</span></span></span></span></div>
              </div>
            </td>
          </tr>

      </table>
      <div style="text-align:justify;line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt">&#160;</td>
            <td style="width:30pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>D.</span></span></span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As of December 31, 2024 and 2023, the bank imposed restriction on a bank deposit in the amount of $<ix:nonFraction id="Fxbrl_20230213125744104" name="us-gaap:RestrictedInvestments" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">76</ix:nonFraction> thousand, for the purpose of securing lease payments under an office lease agreement.</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt">&#160;</td>
            <td style="width:30pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>E.</span></span></span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In&#160; 2022, the Israeli Tax Authority ("ITA") notified the Company that it had initiated a routine VAT audit covering the tax years 2017 through 2022. The ITA raised several claims, primarily regarding the recoverability of VAT related to the Merger Agreement expenses and the classification of the Company as a holding company. The Company accrued a provision for expenses&#160;of $<ix:nonFraction id="Fxbrl_20250325180625658" name="us-gaap:AccretionExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">638</ix:nonFraction>&#160;thousands in the year ended December 31, 2022. On December 29, 2024, the Company and the ITA reached a settlement agreement stipulating that the Company would pay $<ix:nonFraction id="Fxbrl_20250325173724868" name="us-gaap:AccruedIncomeTaxes" contextRef="C_20241229" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">538</ix:nonFraction> thousand. The amount was paid in January 2025.</span></span></span></span></div>
            </td>
          </tr>

      </table>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>

  <ix:nonNumeric id="FFact_0000000000385" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" contextRef="C_20240101to20241231" escape="true">
    <div>
      <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Note 8 - Share Capital</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt">&#160;</td>
            <td style="vertical-align:top;font-weight:bold;width:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>A.</span></span></span></span></td>
            <td style="vertical-align:top;width:auto">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Right attached to shares</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold;margin-left:72pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Ordinary shares</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>All of the issued and outstanding ordinary shares of the Company are duly authorized, validly issued, fully paid and non-assessable. The ordinary shares are not redeemable, and each ordinary share is entitled to one vote. The holders of the ordinary shares have the right to vote and participate in shareholders' meetings, the right to receive profits, and the right to participate in the accumulated earnings when the Company is dissolved.</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">1.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Voting</span></span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The holders of ordinary shares are entitled to vote on all matters submitted to shareholders for a vote.</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div><ix:exclude>
        <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
          <div style="text-align:left;margin-top:0pt;margin-bottom:0pt">
            <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 16</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right;margin-top:10pt"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2024</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
          </div>
        </div>
        <div style="line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Note 8 - Share Capital (cont&#8217;d)</span></span></span></span></div>
        <div style="line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt">&#160;</div>
      </ix:exclude></div>
      <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">2.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Dividends</span></span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The holders of the ordinary shares are entitled to receive dividends, when and as declared by the Board of Directors, and out of funds legally available.</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Since its inception, the Company has not declared any dividends.</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="line-height:1.25">
        <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="vertical-align:top;font-weight:bold;width:36pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">B.</span></td>
              <td style="vertical-align:top;width:auto">
                <div style="font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">Financing rounds</span></div>
              </td>
            </tr>

        </table>
        <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
      </div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:72pt">&#160;</td>
            <td style="vertical-align:top;width:18pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1.</span></span></span></span></td>
            <td style="vertical-align:top;width:auto">
              <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On March 15, 2021, the Company entered into Securities Purchase Agreements with certain purchasers, pursuant to which the Company agreed to sell approximately $<ix:nonFraction id="Fxbrl_20230213133908909" name="cmmb:ProceedsFromSaleOfAdss" contextRef="C_20210301to20210315_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">45.5</ix:nonFraction> million of its American Depositary Shares (ADSs)&#160;in a private placement transaction, (or "The Private Placement"). The Private Placement closed on March 22, 2021, at which time the Company sold to the purchasers <ix:nonFraction id="Fxbrl_20230213133843633" name="cmmb:NumberOfWarrantsPurchaseUpAdss" contextRef="C_20210301to20210322_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">2,619,270</ix:nonFraction> ADSs together with warrants to purchase up to <ix:nonFraction id="Fxbrl_20230213133849363" name="cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" contextRef="C_20210301to20210322_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">261,929</ix:nonFraction> ADSs at an exercise price of $<ix:nonFraction id="Fxbrl_20230213133830904" name="cmmb:SaleOfStocksPricePerShare" contextRef="C_20210301to20210322_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">17.35</ix:nonFraction> per ADS. The warrants will expire five years from the date of issuance, and if exercised in full, will provide to the Company proceeds of approximately $<ix:nonFraction id="Fxbrl_20230213133820824" name="cmmb:ProceedsFromSaleOfAdss" contextRef="C_20210301to20210322_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.5</ix:nonFraction> million. 20 Ordinary Shares are equal to 1 American Depositary Share (ADS).</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:72pt">&#160;</td>
            <td style="vertical-align:top;width:18pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2.</span></span></span></span></td>
            <td style="vertical-align:top;width:auto">
              <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On April 30, 2021, the Company entered into an At the Market Offering Agreement (the "ATM Agreement") with Cantor Fitzgerald &amp; Co., ("Cantor"). According to the ATM Agreement, the Company may offer and sell, from time to time, its ADSs having an aggregate offering price of up to $<ix:nonFraction id="Fxbrl_20230213133808746" name="cmmb:AggregateOfferingPriceOfAtMarketOfferingAgreement" contextRef="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">75</ix:nonFraction> million through Cantor or the ATM Agreement. From April 30, 2021, through December 31, 2022, the Company issued <ix:nonFraction id="Fxbrl_20230213133801744" name="cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" contextRef="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">699,806</ix:nonFraction> ADSs at an average price of $<ix:nonFraction id="Fxbrl_20230213133754484" name="cmmb:SaleOfStocksPricePerShare" contextRef="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">22.75</ix:nonFraction> per ADS under the ATM Agreement, resulting in gross proceeds of $<ix:nonFraction id="Fxbrl_20230213133747440" name="cmmb:ProceedsFromSaleOfAdss" contextRef="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,917</ix:nonFraction> thousand.</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:72pt">&#160;</td>
            <td style="vertical-align:top;width:18pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3.</span></span></span></span></td>
            <td style="vertical-align:top;width:auto">
              <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On April 25, 2022, the Company filed a prospectus supplement with the SEC for the issuance and sale of up to $<ix:nonFraction id="Fxbrl_20230213133711976" name="cmmb:ProceedsFromSaleOfAdss" contextRef="C_20220401to20220425_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">18,125,000</ix:nonFraction> of its ADSs in connection with the reactivation of the ATM Facility and pursuant to General Instruction I.B.6 of Form S-3, which, subject to certain exceptions, limits the amount of securities the Company is able to offer and sell under such registration statement to one-third of our unaffiliated public float. During the year ended December 31, 2022, the Company issued <ix:nonFraction id="Fxbrl_20230213133726969" name="cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">130,505</ix:nonFraction> ADSs at an average price of $<ix:nonFraction id="Fxbrl_20230213133719951" name="cmmb:SaleOfStocksPricePerShare" contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.11</ix:nonFraction> per ADS under the ATM Agreement, resulting in gross proceeds of $<ix:nonFraction id="Fxbrl_20230213133734136" name="cmmb:ProceedsFromSaleOfAdss" contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">275</ix:nonFraction> thousand. During the year ended December 31, 2023, the Company issued <ix:nonFraction id="Fxbrl_20240325123733602" name="cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" contextRef="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">772,900</ix:nonFraction> ADSs at an average price of $<ix:nonFraction id="Fxbrl_20240325123743170" name="cmmb:SaleOfStocksPricePerShare" contextRef="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">1.83</ix:nonFraction> per ADS under the ATM Agreement, resulting in net proceeds of $<ix:nonFraction id="Fxbrl_20240325164632464" name="cmmb:ProceedsFromSaleOfAdss" contextRef="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,371</ix:nonFraction> thousand.</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
      <div><ix:exclude>
        <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
          <div style="margin-top:0pt;margin-bottom:0pt">
            <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 17</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right;margin-top:10pt"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2024</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
          </div>
        </div>
        <div style="text-align:justify;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Note 8 - Share Capital (cont&#8217;d)</span></span></span></span></div>
        <div style="text-align:justify;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt">&#160;</div>
      </ix:exclude></div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:72pt">&#160;</td>
            <td style="vertical-align:top;width:18pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>4.</span></span></span></span></td>
            <td style="vertical-align:top;width:auto">
              <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On September 19, 2022, the Company entered&#160; into a share purchase agreement (the &#8220;Repurchase Arrangement&#8221;) with Dr. Adi Mor, co-founder of Chemomab Ltd., then Chief Scientific Officer and a director of the Company and Professor Kobi George, co-founder of Chemomab Ltd. (together with Dr. Adi Mor, the &#8220;Co-Founders&#8221;), whereby the Company agreed, subject to the requisite court approval required under Section 303(a) of the Israeli Companies Law, 5759-1999 (the &#8220;Companies Law&#8221;), which the Company received on November 14, 2022, to repurchase up to <ix:nonFraction id="Fxbrl_20230213133614438" name="cmmb:RepurchaseOfAmericanDepositaryReceiptsShares" contextRef="C_20220901to20220919_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">582,023</ix:nonFraction> of the Company's ADSs owned by the Co-Founders, for consideration not to exceed an aggregate amount of $<ix:nonFraction id="Fxbrl_20230213133621142" name="cmmb:RepurchaseOfAmericanDepositaryReceipts" contextRef="C_20220930_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">2,500,000</ix:nonFraction>, depending on the market price of the ADSs at the time of any repurchase. Accordingly, on November 16, 2022, the Company repurchased <ix:nonFraction id="Fxbrl_20230213133633159" name="cmmb:RepurchaseOfAmericanDepositaryReceiptsShares" contextRef="C_20221101to20221116_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">582,023</ix:nonFraction> ADSs (the "Treasury Shares") from the Co-Founders at an average price of $<ix:nonFraction id="Fxbrl_20230213133700406" name="cmmb:WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" contextRef="C_20221101to20221116_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember" unitRef="USD_Per_Share" scale="0" decimals="4" format="ixt:num-dot-decimal">2.0848</ix:nonFraction> and for total consideration of approximately $<ix:nonFraction id="Fxbrl_20230213133643190" name="cmmb:TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" contextRef="C_20221101to20221116_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,218</ix:nonFraction> thousand.</span></span></span></span></div>
              <div>&#160;</div>
              <div>
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On November 17, 2023, the Company sold the Treasury Shares for an aggregate consideration of approximately $<ix:nonFraction id="Fxbrl_20240325170937255" name="us-gaap:ProceedsFromSaleOfTreasuryStock" contextRef="C_20231101to20231117" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">580</ix:nonFraction> thousand.</span></span></span></span></div>
              </div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:72pt">&#160;</td>
            <td style="vertical-align:top;width:18pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5.</span></span></span></span></td>
            <td style="vertical-align:top;width:auto">
              <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In October 2023, the Company filed a prospectus supplement with the SEC for the issuance and sale of up to $<ix:nonFraction id="Fxbrl_20240325171010296" name="cmmb:ProceedsFromSaleOfAdss" contextRef="C_20231001to20231031" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">2,863,664</ix:nonFraction> of its ADSs in connection with the reactivation of the ATM Facility and pursuant to Rule 415(a)(6) under the Securities Act of 1933 Form F-3, which, subject to certain exceptions, limits the number of securities the Company may offer and sell under such registration statement to one-third of our unaffiliated public float.</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:72pt">&#160;</td>
            <td style="vertical-align:top;width:18pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>6.</span></span></span></span></td>
            <td style="vertical-align:top;width:auto">
              <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In October 2023, the Company entered into an At the Market Offering Agreement (the "Roth ATM Agreement") with Roth Capital Partners, LLC, (&#8220;Roth&#8221;). According to the Roth ATM Agreement, the Company may offer and sell, from time to time, its ADSs having an aggregate offering price of up to $<ix:nonFraction id="Fxbrl_20240325171044931" name="cmmb:ProceedsFromSaleOfAdss" contextRef="C_20231001to20231031_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRothCapitalPartnersLlcMember_usgaapSubsidiarySaleOfStockAxis_cmmbMarketOfferingAgreementMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">2,863,664</ix:nonFraction> through Roth or the Roth ATM Agreement. From October 30, 2023, through December 31, 2024, the Company sold <ix:nonFraction id="Fxbrl_20240325171233284" name="cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" contextRef="C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRothCapitalPartnersLlcMember_usgaapSubsidiarySaleOfStockAxis_cmmbMarketOfferingAgreementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">2,303,009</ix:nonFraction> ADSs at an average price of&#160; $<ix:nonFraction id="Fxbrl_20240325171244020" name="cmmb:WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" contextRef="C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRothCapitalPartnersLlcMember_usgaapSubsidiarySaleOfStockAxis_cmmbMarketOfferingAgreementMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">1.11</ix:nonFraction> per ADS under the Roth ATM Agreement, resulting in net proceeds of $<ix:nonFraction id="Fxbrl_20240325171253164" name="cmmb:TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" contextRef="C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRothCapitalPartnersLlcMember_usgaapSubsidiarySaleOfStockAxis_cmmbMarketOfferingAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,348</ix:nonFraction> thousand.</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:72pt">&#160;</td>
            <td style="vertical-align:top;width:18pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>7.</span></span></span></span></td>
            <td style="vertical-align:top;width:auto">
              <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On July 25, 2024, the Company entered into Securities Purchase Agreements with existing and new investors of the Company (the "Purchasers"), pursuant to which the Company agreed to sell $<ix:nonFraction id="Fxbrl_20250325215406745" name="cmmb:ProceedsFromSaleOfAdss" contextRef="C_20240701to20240725_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction> million of its ADSs in a private placement transaction, (or "The Private Placement"). The Private Placement closed on July 30, 2024, at which time the Company sold to the Purchasers <ix:nonFraction id="Fxbrl_20250325215437317" name="cmmb:NumberOfWarrantsPurchaseUpAdss" contextRef="C_20240701to20240730_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">4,148,867</ix:nonFraction> ADSs together with pre-funded warrants to purchase up to <ix:nonFraction id="Fxbrl_20250325215503211" name="cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" contextRef="C_20240701to20240730_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">3,948,300</ix:nonFraction> ADSs at an exercise price of $<ix:nonFraction id="Fxbrl_20250325215530459" name="cmmb:SaleOfStocksPricePerShare" contextRef="C_20240701to20240730_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="ILS_per_Share" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction> per ADS, resulting in net proceeds of $<ix:nonFraction id="Fxbrl_20250325215545276" name="cmmb:ProceedsFromSaleOfAdss" contextRef="C_20240701to20240730_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,071</ix:nonFraction> thousand. The Pre-Funded Warrants were classified as equity, since the warrants are not considered as an ASC 480 liability, are indexed to the Company&#8217;s own Ordinary share, and meet all the equity classification conditions pursuant to ASC 815-40. The Private Placement did not include any warrant coverage or other dilutive terms.</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
      <div><ix:exclude>
        <div style="line-height:1.25">
          <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 18</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right;margin-top:10pt"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2024</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
        </div>
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Note 8 - Share Capital (cont&#8217;d)</span></span></span></span></div>
        <div style="text-align:justify;line-height:1.25;font-weight:bold">&#160;</div>
      </ix:exclude></div>
      <div style="line-height:1.25">
        <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="vertical-align:top;font-weight:bold;width:36pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">C.</span></td>
              <td style="vertical-align:top;width:auto">
                <div style="font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">Share-based compensation</span></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
      <div style="line-height:1.25">
        <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="vertical-align:top;font-weight:normal;width:36pt">(1)</td>
              <td style="vertical-align:top;width:auto">
                <div style="font-weight:normal"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Share-based compensation plan:</span></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company maintains (i) the 2011 Share Option Plan (the &#8220;2011 Plan&#8221;), (ii) the 2017 Equity-Based Incentive Plan (the &#8220;2017 Plan&#8221;) and (iii) the Chemomab 2015 Share Incentive Plan (the &#8220;2015 Plan&#8221;).</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As of December 31, 2024, a total of&#160;<ix:nonFraction id="Fxbrl_20230207224906305" name="cmmb:NumberOfStockReservedForIssuance" contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">28,443,060</ix:nonFraction> of our Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20230207223247056" name="cmmb:NumberOfStockAdssResveredForIssuance" contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,422,153</ix:nonFraction> ADSs) were reserved for issuance under the 2015 Plan, of which <ix:nonFraction id="Fxbrl_20230207225529762" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">3,445,520</ix:nonFraction> Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20230207223254041" name="cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">172,276</ix:nonFraction> ADSs) were issued pursuant to previous options exercise, and <ix:nonFraction id="Fxbrl_20230207225556251" name="cmmb:NumberOfOptionsIssuableOutstanding" contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">9,134,900</ix:nonFraction> Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20230207223300376" name="cmmb:NumberOfAdssOptionsIssuableOutstanding" contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">456,745</ix:nonFraction> ADSs) were issuable under outstanding options and restricted shares ("RSAs"). Of such outstanding options and RSAs, options to purchase <ix:nonFraction id="Fxbrl_20230207225618055" name="cmmb:NumberOfOptionsVestedAndExercisable" contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">6,677,380</ix:nonFraction> Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20230207223309640" name="cmmb:NumberOfAdssVestedAndExercisable" contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">333,869</ix:nonFraction> ADSs) had vested and became exercisable as of that date, with a weighted average exercise price of $<ix:nonFraction id="Fxbrl_20230207224602275" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.31</ix:nonFraction> per Ordinary Share (or $<ix:nonFraction id="Fxbrl_20230207223316544" name="cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">6.17</ix:nonFraction> per ADS). During the year ended December 31, 2024, options to purchase <ix:nonFraction id="Fxbrl_20230207224845387" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">200,000</ix:nonFraction> Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20230207223324626" name="cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">10,000</ix:nonFraction> ADSs) were canceled.</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>During 2024, the Company issued <ix:nonFraction id="Fxbrl_20250325215807778" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember_usgaapStatementClassOfStockAxis_cmmbRestrictedOrdinarySharesMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">6,443,900</ix:nonFraction> restricted Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20250325215819491" name="cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember_usgaapStatementClassOfStockAxis_cmmbRestrictedOrdinarySharesMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">322,195</ix:nonFraction> restricted ADSs) under the 2015 Plan.</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As of December 31, 2024, a total of <ix:nonFraction id="Fxbrl_20230207225827725" name="cmmb:NumberOfStockReservedForIssuance" contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">23,061,380</ix:nonFraction> of our Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20230207225729518" name="cmmb:NumberOfStockAdssResveredForIssuance" contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,153,069</ix:nonFraction> of our ADSs) were reserved for issuance under the 2017 Plan, of which <ix:nonFraction id="Fxbrl_20230207225858382" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">22,915,400</ix:nonFraction> Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20230207225738550" name="cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,145,770</ix:nonFraction> ADSs) were issuable under outstanding options. Of such outstanding options, options to purchase <ix:nonFraction id="Fxbrl_20230207225916606" name="cmmb:NumberOfOptionsVestedAndExercisable" contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">11,460,260</ix:nonFraction> Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20230207225743877" name="cmmb:NumberOfAdssVestedAndExercisable" contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">573,013</ix:nonFraction> ADSs) had vested and became exercisable as of that date, with a weighted average exercise price of $<ix:nonFraction id="Fxbrl_20230207225929980" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.13</ix:nonFraction> per Ordinary Share (or $<ix:nonFraction id="Fxbrl_20230207225750293" name="cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.63</ix:nonFraction> per ADS). During the year ended December 31, 2024, options to purchase <ix:nonFraction id="Fxbrl_20250325215036218" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">131,260</ix:nonFraction> Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20250325215042778" name="cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">6,563</ix:nonFraction> ADSs) were canceled.</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt">&#160;</td>
            <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(2)</span></span></span></span></td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The expenses that were recognized in the consolidated statements of operations for services received from employees and service providers are as follows:</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="line-height:1.25;margin-left:72pt">
        <ix:nonNumeric id="Fxbrl_20240325123602369" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" contextRef="C_20240101to20241231" escape="true">
          <div>
            <table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Research and development</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000338" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20240101to20241231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">401</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000339" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">407</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325160020593_Fact_0000000000339" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">448</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>General and administrative</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000340" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20240101to20241231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">216</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000341" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,084</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325160020594_Fact_0000000000341" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,763</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Total share-based compensation expenses</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000342" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">617</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000343" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,491</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325160020595_Fact_0000000000343" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,211</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>
        </ix:nonNumeric>
        <p style="margin:0pt">&#160;</p>
      </div>
      <div><ix:exclude>
        <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
          <div style="text-align:left;margin-top:0pt;margin-bottom:0pt">
            <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 19</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right;margin-top:10pt"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2024</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
          </div>
        </div>
        <div style="line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Note 8 - Share Capital (cont&#8217;d)</span></span></span></span></div>
        <div style="line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt">&#160;</div>
        <div style="line-height:1.25">
          <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

              <tr>
                <td style="width:36pt">&#160;</td>
                <td style="vertical-align:top;font-weight:bold;width:36pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">C.</span></td>
                <td style="vertical-align:top;width:auto">
                  <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Share-based compensation&#160;</span><span style="font-weight:bold">(cont&#8217;d)</span></span></span></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
      </ix:exclude></div>
      <div style="text-align:justify;line-height:1.25">
        <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="width:36pt;vertical-align:top"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(3)</span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The number and weighted average exercise price of options are as follows:</span></div>
              </td>
            </tr>

        </table>
        <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
      </div>
      <ix:nonNumeric id="Fxbrl_20240325123629767" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock" contextRef="C_20240101to20241231" escape="true">
        <div>
          <div style="line-height:1.25">
            <div style="margin-left:72pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Weighted average</span></span></span></span></div>
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>exercise price</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Number</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>of options</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Weighted</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>average</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>remaining contractual life (in years)</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Weighted</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>average</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>exercise price</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Number</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>of options</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Weighted</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>average</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>remaining contractual life</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(in years)</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Outstanding at January 1</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000345" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.33</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000346" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">35,191,540</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="FFact_0000000000347" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20220101to20221231" format="ixt-sec:duryear">7.42</ix:nonNumeric></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000348" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20211231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.38</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000349" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">27,003,260</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="FFact_0000000000350" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20210101to20211231" format="ixt-sec:duryear">8.12</ix:nonNumeric></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Exercised</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250325222230065" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_20230101to20231231" unitRef="USD_Per_Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250325222216181" name="cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1" contextRef="C_20230101to20231231" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250325222250292" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.07</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20250325222305533" name="cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,970,000</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Forfeited</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250325222118860_xbrl_20250325221717788" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_20230101to20231231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.39</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20250325222118860_xbrl_20250325221737036" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20230101to20231231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">20,373,620</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250325222118860_xbrl_20250325221754569" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.32</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20250325222118860_xbrl_20250325221806508" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,240,120</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;padding-bottom:2px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Granted</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000360" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20230101to20231231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.07</ix:nonFraction></span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000361" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20230101to20231231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">15,055,180</ix:nonFraction></span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="FFact_0000000000362" name="cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" contextRef="C_20230101to20231231" format="ixt-sec:duryear">5.86</ix:nonNumeric></span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000363" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.16</ix:nonFraction></span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000364" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">11,398,400</ix:nonFraction></span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="FFact_0000000000365" name="cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" contextRef="C_20220101to20221231" format="ixt-sec:duryear">7.8</ix:nonNumeric></span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;padding-bottom:4px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Outstanding at December 31</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000366" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20231231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.16</ix:nonFraction></span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000367" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20231231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">29,873,100</ix:nonFraction></span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="FFact_0000000000368" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20230101to20231231" format="ixt-sec:duryear">5.99</ix:nonNumeric></span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000369" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.33</ix:nonFraction></span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000370" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">35,191,540</ix:nonFraction></span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="FFact_0000000000371" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20220101to20221231" format="ixt-sec:duryear">7.42</ix:nonNumeric></span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:72pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Weighted average</span></span></span></span></div>
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>exercise price</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Number</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>of options</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Weighted</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>average</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>remaining contractual life (in years)</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Weighted</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>average</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>exercise price</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Number</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>of options</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Weighted</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>average</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>remaining contractual life</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(in years)</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Outstanding at January 1</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325121853866_Fact_0000000000345" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20231231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.16</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325121853866_Fact_0000000000346" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20231231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">29,873,100</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="Fxbrl_20240325121853866_Fact_0000000000347" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20230101to20231231" format="ixt-sec:duryear">5.99</ix:nonNumeric></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325121853866_Fact_0000000000348" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.33</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325121853866_Fact_0000000000349" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">35,191,540</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="Fxbrl_20240325121853866_Fact_0000000000350" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20220101to20221231" format="ixt-sec:duryear">7.42</ix:nonNumeric></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Exercised</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250325221902891" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_20240101to20241231" unitRef="USD_Per_Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250325222019555" name="cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1" contextRef="C_20240101to20241231" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250325221840311" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_20230101to20231231" unitRef="USD_Per_Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250325221924813" name="cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1" contextRef="C_20230101to20231231" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Forfeited</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250325221717788" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_20240101to20241231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.19</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20250325221737036" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20240101to20241231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">667,820</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250325221754569" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_20230101to20231231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.39</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20250325221806508" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20230101to20231231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">20,373,620</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;padding-bottom:2px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Granted</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325121853884_Fact_0000000000360" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20240101to20241231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.03</ix:nonFraction></span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325121853884_Fact_0000000000361" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20240101to20241231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">2,845,020</ix:nonFraction></span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="Fxbrl_20240325121853884_Fact_0000000000362" name="cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" contextRef="C_20240101to20241231" format="ixt-sec:duryear">8.56</ix:nonNumeric></span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325121853884_Fact_0000000000363" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20230101to20231231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.07</ix:nonFraction></span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325121853884_Fact_0000000000364" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20230101to20231231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">15,055,180</ix:nonFraction></span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="Fxbrl_20240325121853884_Fact_0000000000365" name="cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" contextRef="C_20230101to20231231" format="ixt-sec:duryear">5.86</ix:nonNumeric></span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;padding-bottom:4px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Outstanding at December 31</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325121853889_Fact_0000000000366" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20241231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.15</ix:nonFraction></span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325121853889_Fact_0000000000367" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20241231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">32,050,300</ix:nonFraction></span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="Fxbrl_20240325121853889_Fact_0000000000368" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20240101to20241231" format="ixt-sec:duryear">7.34</ix:nonNumeric></span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325121853889_Fact_0000000000369" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20231231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.16</ix:nonFraction></span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325121853889_Fact_0000000000370" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20231231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">29,873,100</ix:nonFraction></span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="Fxbrl_20240325121853889_Fact_0000000000371" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20230101to20231231" format="ixt-sec:duryear">5.99</ix:nonNumeric></span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
      </ix:nonNumeric>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="width:36pt;vertical-align:top"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(3)</span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The number of&#160;RSAs is as follows:</span></div>
              </td>
            </tr>

        </table>
        <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
      </div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;margin-left:72pt">
        <ix:nonNumeric id="Fxbrl_20250325221214720" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" contextRef="C_20240101to20241231" escape="true">
          <table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Number of RSAs</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>RSA</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Unvested at beginning of the year</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250325221306195" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_20231231" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:top;width:88%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Granted</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250325221342084" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="C_20240101to20241231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">6,443,900</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Vested</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250325221358846" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="C_20240101to20241231" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Forfeited</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250325221420994" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="C_20240101to20241231" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:top;width:88%;padding-bottom:4px;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Outstanding at December 31, 2024</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250325221313724" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_20241231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">6,443,900</ix:nonFraction></span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </ix:nonNumeric>
        <p style="margin:0pt">&#160;</p>
      </div>
      <div><ix:exclude>
        <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
          <div style="margin-top:0pt;margin-bottom:0pt">
            <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 20</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right;margin-top:10pt"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2024</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
          </div>
        </div>
        <div style="line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Note 8 - Share Capital (cont&#8217;d)</span></span></span></span></div>
        <div style="line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt">&#160;</div>
        <div style="line-height:1.25">
          <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

              <tr>
                <td style="width:36pt">&#160;</td>
                <td style="vertical-align:top;font-weight:bold;width:36pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">C.</span></td>
                <td style="vertical-align:top;width:auto">
                  <div style="font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-weight:bold">Share-based compensation&#160;</span><span style="font-weight:bold">(cont&#8217;d)</span></span></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
      </ix:exclude></div>
      <div style="line-height:1.25">
        <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="width:36pt;vertical-align:top">&#160;</td>
              <td style="width:36pt;vertical-align:top"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">4)</span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Fair value measurement:</span></div>
              </td>
            </tr>

        </table>
        <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
      </div>
      <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The fair value of the options is measured at the grant date using the Black-Scholes Option pricing model and the assumptions used to calculate the fair value of the options are as follows:</span></span></span></span></div>
      <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
      <ix:nonNumeric id="Fxbrl_20240325123652785" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_20240101to20241231" escape="true">
        <div>
          <div style="margin-left:72pt">
            <table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;font-weight:bold;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024 grants of Options</span></span></span></span></td>
                  <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Weighted average share price (in U.S. dollar)<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(a)</sup></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000373" name="us-gaap:SharePrice" contextRef="C_20241231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.04</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Exercise price (in U.S. dollar)</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000375" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="C_20241231_srtRangeAxis_srtMinimumMember" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.03</ix:nonFraction>-<ix:nonFraction id="FFact_0000000000376" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="C_20241231_srtRangeAxis_srtMaximumMember" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.05</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Expected life of options (in years)<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(b)</sup></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="FFact_0000000000377" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20240101to20241231_srtRangeAxis_srtMinimumMember" format="ixt-sec:duryear">5.5</ix:nonNumeric>-<ix:nonNumeric id="FFact_0000000000378" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20240101to20241231_srtRangeAxis_srtMaximumMember" format="ixt-sec:duryear">6.1</ix:nonNumeric></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Expected volatility<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(c)</sup></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000379" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_20240101to20241231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">89.29</ix:nonFraction>%-<ix:nonFraction id="FFact_0000000000380" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_20240101to20241231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">92.98</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Risk-free interest rate<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(d)</sup></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000381" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_20240101to20241231" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.1</ix:nonFraction>%-<ix:nonFraction id="FFact_0000000000382" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_20240101to20241231" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.5</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Dividend yield</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000383" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20240101to20241231" unitRef="Pure" decimals="INF" format="ixt:num-dot-decimal">0</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </ix:nonNumeric>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:72pt">&#160;</td>
            <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(a)</span></span></span></span></td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The weighted average share price is based on the Company's Ordinary Share closing price on the stock exchange as at the grant date</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:72pt">&#160;</td>
            <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(b)</span></span></span></span></td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Expected life for the periods presented was determined according to the simplified method since, at the date of grant, the Company did not have enough history to make an estimate. This method effectively assumes that exercise occurs over the period from vesting until expiration, and therefore the expected term is the midpoint between the service period and the contractual term of the award. The simplified method is applicable to service conditions.</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:72pt">&#160;</td>
            <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(c)</span></span></span></span></td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Expected volatility is based on historical volatility over the most recent period commensurate with the expected term of the option. As the Company has a short trading history for its ordinary shares, when the Company's trading period is shorter than the expected term, the expected volatility is derived from the average historical share volatilities of several unrelated public companies within the Company&#8217;s industry that the Company considers to be comparable to its own business over a period equivalent to the option&#8217;s expected term.</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:72pt">&#160;</td>
            <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(d)</span></span></span></span></td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The risk-free rate for the expected term of the options is based on the Black-Scholes option-pricing model on the yields of U.S. Treasury securities with maturities appropriate for the expected term of employee share option awards.</span></span></span></span></div>
            </td>
          </tr>

      </table>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>
  <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 21</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right;margin-top:10pt"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2024</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>

  <ix:nonNumeric id="Fxbrl_20250325142201448" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" contextRef="C_20240101to20241231" escape="true">
    <div>
      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Note 9 - Research and Development</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="line-height:1.25;margin-left:36pt">
        <ix:nonNumeric id="Fxbrl_20250325142211689" name="cmmb:ScheduleOfResearchAndDevelopmentTableTextBlock" contextRef="C_20240101to20241231" escape="true">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Consultants and subcontractors</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325111304537" name="cmmb:ConsultantsAndSubcontractorsExpense" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,994</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000386" name="cmmb:ConsultantsAndSubcontractorsExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,014</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000387" name="cmmb:ConsultantsAndSubcontractorsExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,052</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Salaries and related expenses</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325111310016" name="us-gaap:OfficersCompensation" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,715</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000388" name="us-gaap:OfficersCompensation" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,362</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000389" name="us-gaap:OfficersCompensation" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,867</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Lease and maintenance</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325111315367" name="cmmb:RentAndMaintenanceResearchAndDevelopmentExpense" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">101</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000390" name="cmmb:RentAndMaintenanceResearchAndDevelopmentExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">137</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000391" name="cmmb:RentAndMaintenanceResearchAndDevelopmentExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">245</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share-based compensation</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325111320717" name="cmmb:ShareBasedCompensationResearchAndDevelopmentExpense" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">401</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000392" name="cmmb:ShareBasedCompensationResearchAndDevelopmentExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">407</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000393" name="cmmb:ShareBasedCompensationResearchAndDevelopmentExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">448</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Other expenses</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325111247489" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">116</ix:nonFraction></span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000394" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">461</ix:nonFraction></span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325111250767" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">365</ix:nonFraction></span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325111258130" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,327</ix:nonFraction></span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000396" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,381</ix:nonFraction></span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000397" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,977</ix:nonFraction></span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </ix:nonNumeric>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>

  <ix:nonNumeric id="Fxbrl_20250325141555128" name="cmmb:GeneralAndAdministrativeDisclosureTextBlock" contextRef="C_20240101to20241231" escape="true">
    <div>
      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Note 10 - General and Administrative</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="line-height:1.25;margin-left:36pt">
        <ix:nonNumeric id="Fxbrl_20250325141625498" name="cmmb:ScheduleOfGeneralAndAdministrativeTableTextBlock" contextRef="C_20240101to20241231" escape="true">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Salaries, fees and related expenses</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325110603691" name="us-gaap:SalariesAndWages" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,085</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000400" name="us-gaap:SalariesAndWages" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,545</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000401" name="us-gaap:SalariesAndWages" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,435</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Professional services</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325110618011" name="us-gaap:ProfessionalFees" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,115</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000402" name="us-gaap:ProfessionalFees" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,139</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000403" name="us-gaap:ProfessionalFees" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,596</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share-based compensation</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325110622931" name="cmmb:ShareBasedCompensationGeneralAndAdministrativeExpense" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">216</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000404" name="cmmb:ShareBasedCompensationGeneralAndAdministrativeExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,084</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000405" name="cmmb:ShareBasedCompensationGeneralAndAdministrativeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,763</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Fees to directors</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325110632753" name="us-gaap:NoninterestExpenseDirectorsFees" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">284</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000406" name="us-gaap:NoninterestExpenseDirectorsFees" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">258</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230201004651041" name="us-gaap:NoninterestExpenseDirectorsFees" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">231</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Directors' and Officers' Insurance</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325110648131" name="us-gaap:GeneralInsuranceExpense" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">538</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000408" name="us-gaap:GeneralInsuranceExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">648</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000409" name="us-gaap:GeneralInsuranceExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,084</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Lease and maintenance</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325110658345" name="cmmb:RentAndMaintenanceGeneralAndAdministrativeExpense" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000410" name="cmmb:RentAndMaintenanceGeneralAndAdministrativeExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">81</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000411" name="cmmb:RentAndMaintenanceGeneralAndAdministrativeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Other expenses</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325110704195" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">124</ix:nonFraction></span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000412" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">323</ix:nonFraction></span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000413" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,423</ix:nonFraction></span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250325141611203" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,412</ix:nonFraction></span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000414" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,078</ix:nonFraction></span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000415" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,556</ix:nonFraction></span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </ix:nonNumeric>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>

  <ix:nonNumeric id="Fxbrl_20250325204325897" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_20240101to20241231" escape="true">
    <div>
      <div>
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 11 - Income Taxes</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="vertical-align:top;width:34pt;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax rates</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;margin-left:70pt">
          <div style="text-align:justify;line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ordinary taxable income in Israel is subject to a corporate tax rate of <ix:nonFraction id="FFact_0000000000418" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_20240101to20241231_srtStatementGeographicalAxis_countryIL" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction>%.</span></span></div>
          <div style="text-align:justify;line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Capital gain is subject to capital gain tax according to the corporate tax rate in the year the assets are sold.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s US subsidiary, Chemomab Therapeutics Inc. ("Chemomab Inc.) is taxed separately under the U.S. tax laws.</span></span></div>
          <div style="text-align:justify;line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab Inc. is subject to a federal flat tax rate of <ix:nonFraction id="FFact_0000000000419" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_20240101to20241231_srtStatementGeographicalAxis_countryUS_usgaapIncomeTaxAuthorityAxis_usgaapDomesticCountryMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">21</ix:nonFraction>% and state tax as applicable.</span></span></div>
        </div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
        <div><ix:exclude>
          <div style="line-height:1.25">
            <div style="line-height:1.25">
              <div style="line-height:1.25">
                <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 22</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right;margin-top:10pt"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2024</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
              </div>
            </div>
          </div>
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 11 - Income Taxes (cont&#8217;d)</span></span></div>
          <div style="line-height:1.25;font-weight:bold">&#160;</div>
        </ix:exclude></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="vertical-align:top;width:34pt;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">B.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax assessments</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:70pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2024, the Company&#8217;s tax reports through December 31, 2019 are considered closed to audit inspections by the Israeli Tax Authority (&#8220;ITA&#8221;) due to statute of limitation rules effective in Israel.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;text-indent:36pt;line-height:1.25">
          <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

              <tr>
                <td style="width:36pt">&#160;</td>
                <td style="vertical-align:top;width:34pt;font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">C.</span></td>
                <td style="width:auto;vertical-align:top">
                  <div style="font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">Losses for tax purposes carried forward to future years</span></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="line-height:1.25;margin-left:70pt">
          <div style="text-align:justify;line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2024, 2023, and 2022, the Company and its subsidiaries had approximately $<ix:nonFraction id="Fxbrl_20230213140532094" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_20241231_srtStatementGeographicalAxis_countryIL" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">176</ix:nonFraction> million, $<ix:nonFraction id="Fxbrl_20230213140537759" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_20231231_srtStatementGeographicalAxis_countryIL" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">165</ix:nonFraction> million, and $<ix:nonFraction id="Fxbrl_20240325142108415" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_20221231_srtStatementGeographicalAxis_countryIL" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">159</ix:nonFraction> million, respectively, in net operating loss carryforwards, which are available to reduce future taxable income with no limitation on the period of use.</span></span></div>
          <div style="text-align:justify;line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On March 27, 2020 and December 27, 2020, the President of the United States signed and enacted into law the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) and the Consolidated Appropriations Act, 2021 (CAA). Among other provisions, the CARES Act and the CAA provide relief to U.S. federal corporate taxpayers through temporary adjustments to net operating loss rules, changes to limitations on interest expense deductibility, and the acceleration of available refunds for minimum tax credit carryforwards. The CARES Act also includes provisions for a carryback of any net operating loss (NOL) arising in a taxable year beginning after December 31, 2017, and before January 1, 2021, to each of the five taxable years preceding the taxable year in which the loss arises (carryback period).</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab Therapeutics Inc., a wholly owned subsidiary of the Company, filed an application with the US Internal Revenue Service to carryback net operating losses. Chemomab Therapeutics Inc received $<ix:nonFraction id="Fxbrl_20230213140710654" name="cmmb:ReceivedAmountOfChemomabTherapeuticsInc" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">351</ix:nonFraction> thousands in December 2022 on account of 2016 and 2017 and received the remainder $<ix:nonFraction id="Fxbrl_20230213140716671" name="cmmb:ExpectsToReceiveAmountOfChemomabTherapeuticsInc" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">183</ix:nonFraction> thousands in 2023. Accordingly, a tax benefit in the total amount of $<ix:nonFraction id="Fxbrl_20230213140722797" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">534</ix:nonFraction> thousands was recorded in the Company&#8217;s statement of operations during 2022.</span></span></div>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-indent:36pt;line-height:1.25">
          <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

              <tr>
                <td style="width:36pt">&#160;</td>
                <td style="vertical-align:top;font-weight:bold;width:34pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">D.</span></td>
                <td style="vertical-align:top;width:auto">
                  <div style="font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">Deferred taxes</span></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;text-indent:-1.1pt;margin-left:70pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In respect of:</span></span></div>
        <div style="text-align:justify;text-indent:-1.1pt;margin-left:72pt;line-height:1.25">&#160;</div>
        <ix:nonNumeric id="Fxbrl_20250325204425105" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_20240101to20241231" escape="true">
          <div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;margin-left:72pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net operating loss carry-forward*</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325113127688" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,755</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000422" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,258</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000423" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,550</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom">
                      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation expense</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325113134551" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">351</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000424" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,163</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000425" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,774</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development costs</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325113142383" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,103</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000426" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,041</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000427" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,858</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom">
                      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325113151187" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000428" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000429" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gross deferred tax assets</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325113158306" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,219</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000430" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,471</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000431" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,195</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom">
                      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less - Valuation allowance</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240325113204191" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,219</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000432" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,471</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000433" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,195</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </div>
                    </td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:64%;padding-bottom:4px;vertical-align:bottom">
                      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net deferred tax assets</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325113212847" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230201010225989_Fact_0000000000426" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230201010225989_Fact_0000000000427" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="text-align:justify;text-indent:-1.1pt;margin-left:72pt;line-height:1.25">&#160;</div>
            <div style="line-height:1.25;margin-left:72pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">* This excludes capital losses of approximately $<ix:nonFraction id="Fxbrl_20250402185453246" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,224</ix:nonFraction> thousands for which the company will create a full valuation allowance.</span></span></div>
          </div>
        </ix:nonNumeric>
        <p style="margin:0pt">&#160;</p>
        <div><ix:exclude>
          <div style="line-height:1.25">
            <div style="line-height:1.25">
              <div style="line-height:1.25">
                <div style="line-height:1.25">
                  <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 23</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right;margin-top:10pt"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2024</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
                </div>
              </div>
            </div>
          </div>
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 11 - Income Taxes (cont&#8217;d)</span></span></div>
          <div style="line-height:1.25;font-weight:bold">&#160;</div>
        </ix:exclude></div>
        <div style="text-align:justify;margin-left:70pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. A valuation allowance is provided when it is more likely than not that the deferred tax assets will not be realized.</span></span></div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:70pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has established a valuation allowance to offset deferred tax assets on December 31, 2024, 2023 and 2022 due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. The net change in the total valuation allowance for the year ended at December 31, 2024 was an increase of approximately $<ix:nonFraction id="Fxbrl_20230201010356964" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_20240101to20241231" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction> million.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;text-indent:36pt;line-height:1.25">
          <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

              <tr>
                <td style="width:36pt">&#160;</td>
                <td style="vertical-align:top;width:34pt;font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">E.</span></td>
                <td style="width:auto;vertical-align:top">
                  <div style="font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">Roll forward of valuation allowance</span></div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div>&#160;<div style="margin-left:72pt">
          <ix:nonNumeric id="Fxbrl_20240325113717888" name="us-gaap:SummaryOfValuationAllowanceTextBlock" contextRef="C_20240101to20241231" escape="true">
            <table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td rowspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:right;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at December 31, 2021</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000438" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,030</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Currency translation Income</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000439" name="cmmb:CurrencyTransactionLossValuationAllowance" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,316</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
                </tr>
                <tr>
                  <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income tax expense</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000440" name="cmmb:IncomeTaxExpenseValuationAllowance" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,481</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at December 31, 2022</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000441" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,195</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Currency translation Income</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230201010936607" name="cmmb:CurrencyTransactionLossValuationAllowance" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,295</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income tax expense</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000444" name="cmmb:IncomeTaxExpenseValuationAllowance" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,571</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:88%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at December 31, 2023</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325112211572_Fact_0000000000441" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,471</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Currency translation Income</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240325112219753_xbrl_20230201010936607" name="cmmb:CurrencyTransactionLossValuationAllowance" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,459</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:88%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income tax expense</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325112200162_Fact_0000000000444" name="cmmb:IncomeTaxExpenseValuationAllowance" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,207</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at December 31, 2024</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000445" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,219</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </ix:nonNumeric>
        </div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
        <div style="line-height:1.25">
          <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

              <tr>
                <td style="width:36pt">&#160;</td>
                <td style="vertical-align:top;width:34pt;font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">F.</span></td>
                <td style="width:auto;vertical-align:top">
                  <div style="font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">Reconciliation of theoretical income tax expense to actual income tax expense</span></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:70pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A reconciliation of the Company&#8217;s theoretical income tax expense to actual income tax expense is as follows:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25;margin-left:72pt">
          <ix:nonNumeric id="Fxbrl_20240325113734351" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="C_20240101to20241231" escape="true">
            <table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss before income taxes</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240325113300491" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">13,945</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000447" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">24,221</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000448" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">28,180</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Statutory tax rate</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325113309002" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_20240101to20241231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000449" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_20230101to20231231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000450" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_20220101to20221231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Theoretical tax benefit</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240325113316316" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,207</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000451" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,571</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000452" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">6,481</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in temporary differences for which deferred taxes were not recognized</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325113329731" name="cmmb:ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">858</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230213113429979_Fact_0000000000453" name="cmmb:ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,177</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230213113429979_Fact_0000000000454" name="cmmb:ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,696</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax rate differential</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325113338019" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230213113425908_Fact_0000000000453" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230213113425908_Fact_0000000000454" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">20</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-deductible expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325113354492" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">148</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230213113423827_Fact_0000000000453" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">346</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230213113423827_Fact_0000000000454" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">744</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325113401417" name="cmmb:LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,192</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230213113421604_Fact_0000000000453" name="cmmb:LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,392</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325114521690" name="cmmb:LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,879</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Actual income tax expense (Benefit)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;border-bottom:2pt solid black">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;border-bottom:2pt solid black">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325115329121" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;border-bottom:2pt solid black">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;border-bottom:2pt solid black">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325115408857" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;border-bottom:2pt solid black">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;border-bottom:2pt solid black">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240325115419350" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">534</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>

            </table>
          </ix:nonNumeric>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25">
          <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

              <tr>
                <td style="width:36pt">&#160;</td>
                <td style="vertical-align:top;width:34pt;font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">G.</span></td>
                <td style="width:auto;vertical-align:top">
                  <div style="font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">Accounting for uncertainty in income taxes</span></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:70pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the year ended December 31, 2024, the Company did not have any unrecognized tax benefits and does not expect that the amount of unrecognized tax benefits will change significantly within the next 12 months. The Company&#8217;s accounting policy is to accrue interest and penalties related to unrecognized tax benefits as a component of income tax expense.</span></span></div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>
  <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 24</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right;margin-top:10pt"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2024</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>

  <div>
    <ix:nonNumeric id="Fxbrl_20250325140934102" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_20240101to20241231" escape="true">
      <div>
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Note 12 - Related Parties Balances and Transactions</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>A.</span></span></span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Balances with Related Parties:</span></span></span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The following Related Party payables are included in the consolidated Balance Sheets:</span></span></span></span></div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;margin-left:36pt">
          <ix:nonNumeric id="Fxbrl_20250325140945214" name="cmmb:ScheduleOfRelatedPartyPayablesTableTextBlock" contextRef="C_20240101to20241231" escape="true">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Employees, consultants and related expenses</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000459" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">531</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000460" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">490</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accrued expenses</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000461" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">75</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000462" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">74</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000463" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">606</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000464" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">564</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </ix:nonNumeric>
        </div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>B.</span></span></span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Transactions with Related Parties:</span></span></span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The following transactions with related parties are included in the consolidated Statements of Operations:</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25;margin-left:36pt">
          <ix:nonNumeric id="Fxbrl_20250325140954486" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" contextRef="C_20240101to20241231" escape="true">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Salaries and related expenses</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325105700969" name="cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,718</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000466" name="cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,795</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000467" name="cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,409</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share-based payments</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325105708763" name="cmmb:RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">427</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000468" name="cmmb:RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,304</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000469" name="cmmb:RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,466</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Professional Services</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325105715263" name="cmmb:RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">284</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000470" name="cmmb:RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">258</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000471" name="cmmb:RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">231</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Research and development</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325105723270" name="cmmb:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000472" name="cmmb:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000473" name="cmmb:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325105729174" name="us-gaap:CostOfRevenue" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,465</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000474" name="us-gaap:CostOfRevenue" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,393</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000475" name="us-gaap:CostOfRevenue" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,142</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </ix:nonNumeric>
        </div>
      </div>
    </ix:nonNumeric>
    <p style="margin:0pt">&#160;</p>
  </div>
  <div>
    <div>
      <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 25</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right;margin-top:10pt"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2024</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
    </div>
  </div>

  <ix:nonNumeric id="Fxbrl_20250325135500617" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_20240101to20241231" escape="true">
    <div>
      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Note 13 - Net Loss Per Share Attributable to Ordinary Shareholders</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Basic net loss per share is computed by dividing the net loss available to common stockholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares of were dilutive. Diluted net loss per share is the same as basic net loss per share of ordinary share, as the effect of potentially dilutive securities is antidilutive.</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The following table sets forth the computation of basic and diluted net loss per share attributable to ordinary shareholders for the periods presented:</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="margin-left:36pt">
        <ix:nonNumeric id="Fxbrl_20250325135622835" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="C_20240101to20241231" escape="true">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In USD thousands, except share and per share data</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Numerator:</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:64%;padding-bottom:4px;vertical-align:bottom">
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Net loss</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325110200438" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20241231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">13,945</ix:nonFraction></span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000478" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">24,221</ix:nonFraction></span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000479" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">27,646</ix:nonFraction></span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:64%;vertical-align:bottom">
                  <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Denominator:</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_s_20240325110207874" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20240101to20241231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20240325110207874" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20240101to20241231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">359,048,638</ix:nonFraction></ix:nonFraction></span></span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_s_20230215224008037" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20230101to20231231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230215224008037" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20230101to20231231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">234,998,859</ix:nonFraction></ix:nonFraction></span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_s_20250325234313474" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20250325234313474" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">227,589,288</ix:nonFraction></ix:nonFraction></span></span></p>
                    </div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:64%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr style="background-color:rgb(204, 238, 255)">
                <td style="width:64%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;</span></span></span></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Net loss per share attributable to ordinary shareholders, basic&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>and diluted</span></span></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_s_20240325110215226" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="C_20240101to20241231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20240325110215226" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="C_20240101to20241231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.039</ix:nonFraction></ix:nonFraction></span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230131213444247" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="C_20230101to20231231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000482" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="C_20230101to20231231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.103</ix:nonFraction></ix:nonFraction></span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230131213458553" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000483" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.121</ix:nonFraction></ix:nonFraction></span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
              </tr>

          </table>
        </ix:nonNumeric>
      </div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;text-indent:0.55pt;margin-left:35.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The potential number of ordinary shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented since including them would have been anti-dilutive are as follows:</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="margin-left:36pt">
        <ix:nonNumeric id="Fxbrl_20250325135633684" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_20240101to20241231" escape="true">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Number of shares</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Outstanding options to purchase ordinary shares and RSAs</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20250325234340730" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20240101to20241231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">38,494,200</ix:nonFraction></strong></span></span></p>
                    </div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250325234328859" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20230101to20231231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">29,873,100</ix:nonFraction></span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000486" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20220101to20221231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">35,191,540</ix:nonFraction></span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </ix:nonNumeric>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>
  <div>
    <p style="margin-top:10pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman, Times, serif;font-size:10pt">F - 26</span></p>
  </div>
  <div>
    <hr style="border:none;border-bottom:4px solid #000000;border-top:1px solid #000000;height:10px;width:100%;color:#000000;text-align:center;text-align:center"/>
  </div>
</div></div></div></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>exhibit_1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div>
      <div style="text-align: right; line-height: 1.25; font-weight: bold;">
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <div style="text-align: right; line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u>Exhibit 1.1</u></div>
      <div style="text-align: center; line-height: 1.25;">THE COMPANIES LAW, 1999</div>
      <div style="text-align: center; line-height: 1.25;">A LIMITED LIABILITY COMPANY</div>
      <div style="text-align: center; line-height: 1.25;">----------------</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">ARTICLES OF ASSOCIATION</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">OF</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
      <div style="text-align: center; line-height: 1.25;">Therapeutics</div>
      <div style="text-align: center; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25;">
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">As Amended on June 10, 2024</div>
      </div>
      <div style="text-align: center; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Preliminary</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zaed3cc8c6a5e48658fc0e5616d6fe650">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">1.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-variant: small-caps;"><u><font style="font-weight: bold;">Definitions; Interpretation</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(a) In these Articles, the following terms (whether or not capitalized) shall bear the meanings set forth opposite them, respectively, unless the subject or context requires
        otherwise.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z209abc46519a483389f7fa3bf5ca788a">

          <tr>
            <td style="width: 8.33%; vertical-align: top;">&#160;</td>
            <td style="width: 33.33%; vertical-align: top;">
              <div style="line-height: 1.25;">&#8220;Articles&#8221;</div>
            </td>
            <td style="width: 58.33%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">shall mean these Articles of Association, as amended from time to time.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.33%; vertical-align: top;">&#160;</td>
            <td style="width: 33.33%; vertical-align: top;">&#160;</td>
            <td style="width: 58.33%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8.33%; vertical-align: bottom;">&#160;</td>
            <td style="width: 33.33%; vertical-align: top;">
              <div style="line-height: 1.25;">&#8220;Board of Directors&#8221;</div>
            </td>
            <td style="width: 58.33%; vertical-align: bottom;">
              <div style="text-align: justify; line-height: 1.25;">shall mean the Board of Directors of the Company.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.33%; vertical-align: bottom;">&#160;</td>
            <td style="width: 33.33%; vertical-align: top;">&#160;</td>
            <td style="width: 58.33%; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8.33%; vertical-align: top;">&#160;</td>
            <td style="width: 33.33%; vertical-align: top;">
              <div style="line-height: 1.25;">&#8220;Chairperson&#8221;</div>
            </td>
            <td style="width: 58.33%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">shall mean the Chairperson of the Board of Directors, or the Chairperson of the General Meeting, as the context implies;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.33%; vertical-align: top;">&#160;</td>
            <td style="width: 33.33%; vertical-align: top;">&#160;</td>
            <td style="width: 58.33%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8.33%; vertical-align: top;">&#160;</td>
            <td style="width: 33.33%; vertical-align: top;">
              <div style="line-height: 1.25;">&#8220;Company&#8221;</div>
            </td>
            <td style="width: 58.33%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">shall mean <font style="font-weight: bold;">Chemomab Therapeutics Ltd</font>.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.33%; vertical-align: top;">&#160;</td>
            <td style="width: 33.33%; vertical-align: top;">&#160;</td>
            <td style="width: 58.33%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8.33%; vertical-align: bottom;">&#160;</td>
            <td style="width: 33.33%; vertical-align: top;">
              <div style="line-height: 1.25;">&#8220;Companies Law&#8221;</div>
            </td>
            <td style="width: 58.33%; vertical-align: bottom;">
              <div style="text-align: justify; line-height: 1.25;">shall mean the Israeli Companies Law, 5759-1999 and the regulations promulgated thereunder. The Companies Law shall include reference to the Companies Ordinance (New Version), 5743-1983, of
                the State of Israel, to the extent in effect according to the provisions thereof.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.33%; vertical-align: bottom;">&#160;</td>
            <td style="width: 33.33%; vertical-align: top;">&#160;</td>
            <td style="width: 58.33%; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8.33%; vertical-align: top;">&#160;</td>
            <td style="width: 33.33%; vertical-align: top;">
              <div style="line-height: 1.25;">&#8220;Director(s)&#8221;</div>
            </td>
            <td style="width: 58.33%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">shall mean the member(s) of the Board of Directors holding office at a given time.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.33%; vertical-align: top;">&#160;</td>
            <td style="width: 33.33%; vertical-align: top;">&#160;</td>
            <td style="width: 58.33%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8.33%; vertical-align: bottom;">&#160;</td>
            <td style="width: 33.33%; vertical-align: top;">
              <div style="line-height: 1.25;">&#8220;External Director(s)&#8221;</div>
            </td>
            <td style="width: 58.33%; vertical-align: bottom;">
              <div style="text-align: justify; line-height: 1.25;">shall have the meaning provided for such term in the Companies Law.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.33%; vertical-align: bottom;">&#160;</td>
            <td style="width: 33.33%; vertical-align: top;">&#160;</td>
            <td style="width: 58.33%; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8.33%; vertical-align: bottom;">&#160;</td>
            <td style="width: 33.33%; vertical-align: top;">
              <div style="line-height: 1.25;">&#8220;General Meeting&#8221;</div>
            </td>
            <td style="width: 58.33%; vertical-align: bottom;">
              <div style="text-align: justify; line-height: 1.25;">shall mean an Annual General Meeting or Special General Meeting of the Shareholders (each as defined in Article 23 of these Articles), as the case may be.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.33%; vertical-align: bottom;">&#160;</td>
            <td style="width: 33.33%; vertical-align: top;">&#160;</td>
            <td style="width: 58.33%; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8.33%; vertical-align: top;">&#160;</td>
            <td style="width: 33.33%; vertical-align: top;">
              <div style="line-height: 1.25;">&#8220;NIS&#8221;</div>
            </td>
            <td style="width: 58.33%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">shall mean New Israeli Shekels.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.33%; vertical-align: top;">&#160;</td>
            <td style="width: 33.33%; vertical-align: top;">&#160;</td>
            <td style="width: 58.33%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8.33%; vertical-align: top;">&#160;</td>
            <td style="width: 33.33%; vertical-align: top;">
              <div style="line-height: 1.25;">&#8220;Office&#8221;</div>
            </td>
            <td style="width: 58.33%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">shall mean the registered office of the Company at a given time.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.33%; vertical-align: top;">&#160;</td>
            <td style="width: 33.33%; vertical-align: top;">&#160;</td>
            <td style="width: 58.33%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8.33%; vertical-align: bottom;">&#160;</td>
            <td style="width: 33.33%; vertical-align: top;">
              <div style="line-height: 1.25;">&#8220;Office Holder&#8221; or &#8220;Officer&#8221;</div>
            </td>
            <td style="width: 58.33%; vertical-align: bottom;">
              <div style="text-align: justify; line-height: 1.25;">shall have the meaning provided for such term in the Companies Law.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.33%; vertical-align: bottom;">&#160;</td>
            <td style="width: 33.33%; vertical-align: top;">&#160;</td>
            <td style="width: 58.33%; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8.33%; vertical-align: bottom;">&#160;</td>
            <td style="width: 33.33%; vertical-align: top;">
              <div style="line-height: 1.25;">&#8220;Economic Competition Law&#8221;</div>
            </td>
            <td style="width: 58.33%; vertical-align: bottom;">
              <div style="text-align: justify; line-height: 1.25;">shall mean the Israeli Economic Competition Law, 5758-1988 and the regulations promulgated thereunder.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.33%; vertical-align: bottom;">&#160;</td>
            <td style="width: 33.33%; vertical-align: top;">&#160;</td>
            <td style="width: 58.33%; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8.33%; vertical-align: bottom;">&#160;</td>
            <td style="width: 33.33%; vertical-align: top;">
              <div style="line-height: 1.25;">&#8220;Securities Law&#8221;</div>
            </td>
            <td style="width: 58.33%; vertical-align: bottom;">
              <div style="text-align: justify; line-height: 1.25;">shall mean the Israeli Securities Law 5728-1968 and the regulations promulgated thereunder.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.33%; vertical-align: bottom;">&#160;</td>
            <td style="width: 33.33%; vertical-align: top;">&#160;</td>
            <td style="width: 58.33%; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8.33%; vertical-align: top;">&#160;</td>
            <td style="width: 33.33%; vertical-align: top;">
              <div style="line-height: 1.25;">&#8220;Shareholder(s)&#8221;</div>
            </td>
            <td style="width: 58.33%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">shall mean the shareholder(s) of the Company, at any given time.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%- % -%-->
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(b) Unless the context shall otherwise require: words in the singular shall also include the plural, and vice versa; any pronoun shall include the corresponding masculine,
        feminine and neuter forms; the words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; shall be deemed to be followed by the phrase &#8220;without limitation&#8221;; the words &#8220;herein&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221; and words of similar import refer to these Articles in their
        entirety and not to any part hereof; all references herein to Articles or clauses shall be deemed references to Articles or clauses of these Articles; any references to any agreement or other instrument or law, statute or regulation are to it as
        amended, supplemented or restated, from time to time (and, in the case of any law, to any successor provisions or re-enactment or modification thereof being in force at the time); any reference to &#8220;law&#8221; shall include any law (&#8216;<font style="font-style: italic;">din</font>&#8217;) as defined in the Interpretation Law, 5741-1981 and any applicable supranational, national, federal, state, local, or foreign statute or law and shall be deemed also to refer to all rules and regulations
        promulgated thereunder; any reference to a &#8220;day&#8221; or a number of &#8220;days&#8221; (without any explicit reference otherwise, such as to business days) shall be interpreted as a reference to a calendar day or number of calendar days; any reference to a
        business day or business days shall mean each calendar day other than any calendar day on which commercial banks in New York, New York or Tel-Aviv, Israel are authorized or required by applicable law to close; reference to a month or year means
        according to the Gregorian calendar; any reference to a &#8220;Person&#8221; shall mean any individual, partnership, corporation, limited liability company, association, estate, any political, governmental, regulatory or similar agency or body or other legal
        entity; and reference to &#8220;written&#8221; or &#8220;in writing&#8221; shall include written, printed, photocopied, typed, any electronic communication (including email, facsimile, signed electronically (in Adobe PDF, DocuSign or any other format)) or produced by any
        visible substitute for writing, or partly one and partly another, and signed shall be construed accordingly.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(c) The captions in these Articles are for convenience only and shall not be deemed a part hereof or affect the construction or interpretation of any provision hereof.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(d) The specific provisions of these Articles shall supersede the provisions of the Companies Law to the extent permitted thereunder.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Limited Liability</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z3782a99127864efb9527a98290b3cd8b">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">2.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">The Company is a limited liability company and each Shareholder&#8217;s liability for the Company&#8217;s debts is therefore limited (in addition to any liabilities under any contract) to the payment
                of the full amount (par value (if any) and premium) such Shareholder was required to pay the Company for such Shareholder&#8217;s Shares (as defined below) and which amount has not yet been paid by such Shareholder, subject to the provisions of
                the Companies Law.</div>
            </td>
          </tr>

      </table>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Company&#8217;s Objectives</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zadddec6cb7074dccb2e93bfa18aa46c9">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">3.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-variant: small-caps;"><u><font style="font-weight: bold;">Objectives</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;">The Company&#8217;s objectives are to carry on any business, and do any act, which is not prohibited by law.</div>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z8bf092dc9ef24743a2885fda1e32df22">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">4.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Donations</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;">The Company may donate a reasonable amount of money (in cash or in kind, including the Company&#8217;s securities) to worthy purposes, as the Board of Directors may determine in its
        discretion, even if such donations are not made on the basis or within the scope of business considerations of the Company.</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Share Capital</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z3152c17f9d55486cb5076dbd8e21cb41">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">5.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Authorized Share Capital</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(a) The authorized share capital of the Company shall consist of 4,650,000,000 Ordinary Shares without par value (the &#8220;<font style="font-weight: bold;">Shares</font>&#8221;).</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(b) The Shares shall rank <font style="font-style: italic;">pari passu</font> in all respects. The Shares may be redeemable to the extent set forth in Article 18.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">- 2 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zbd25986043d9420dbcd663e4379f2cfb">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">6.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Increase of Authorized Share Capital</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(a) The Company may, from time to time, by a Shareholders&#8217; resolution, whether or not all of the shares then authorized have been issued, and whether or not all of the shares
        theretofore issued have been called up for payment, increase its authorized share capital by increasing the number of shares it is authorized to issue by such amount, and such additional shares shall confer such rights and preferences, and shall be
        subject to such restrictions, as such resolution shall provide.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(b) Except to the extent otherwise provided in such resolution, any new shares included in the authorized share capital increase as aforesaid shall be subject to all of the
        provisions of these Articles that are applicable to shares that are included in the existing share capital.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zab551f4ef2844ad78b972d8c9f0f23aa">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">7.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Special or Class Rights; Modification of Rights</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(a) The Company may, from time to time, by a Shareholders&#8217; resolution, provide for shares with such preferred or deferred rights or other special rights and/or such restrictions,
        whether in regard to dividends, voting, repayment of share capital or otherwise, as may be stipulated in such </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">resolution.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(b) If at any time the share capital of the Company is divided into different classes of shares, the rights attached to any class, unless otherwise provided by these Articles,
        may be modified or cancelled by the Company by a resolution of the General Meeting of the holders of all shares as one class, without any required separate resolution of any class of shares.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(c) The provisions of these Articles relating to General Meetings shall apply, <font style="font-style: italic;">mutatis mutandis</font>, to any separate General Meeting of the
        holders of the shares of a particular class, it being clarified that the requisite quorum at any such separate General Meeting shall be two or more Shareholders present in person or by proxy and holding not less than thirty-three and one-third
        percent (33&#8531;%) of the issued shares of such class; provided, however, that if (i) such separate General Meeting of the holders of the particular class was initiated by and convened pursuant to a resolution adopted by the Board of Directors and (ii)
        at the time of such meeting the Company is a &#8220;foreign private issuer&#8221; under the US securities laws, then the requisite quorum at any such separate General Meeting shall be two or more Shareholders present in person or by proxy and holding not less
        than twenty five percent (25%) of the issued shares of such class.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(d) Unless otherwise provided by these Articles, an increase in the authorized share capital, the creation of a new class of shares, an increase in the authorized share capital
        of a class of shares, or the issuance of additional shares thereof out of the authorized and unissued share capital, shall not be deemed, for purposes of this Article 7, to modify or derogate or cancel the rights attached to previously issued
        shares of such class or of any other class.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zcf2952dcc0e04d5d96785efc64fcb8fb">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">8.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Consolidation, Division, Cancellation and Reduction of Share Capital</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(a) The Company may, from time to time, by or pursuant to an authorization of a Shareholders&#8217; resolution, and subject to applicable law:</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">(i) consolidate all or any part of its issued or unissued authorized share capital;</div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">(ii) divide or sub-divide its shares (issued or unissued) or any of them and the resolution whereby any share is divided may determine that, as among the holders of the shares
        resulting from such subdivision, one or more of the shares may, in contrast to others, have any such preferred or deferred rights or rights of redemption or other special rights, or be subject to any such restrictions, as the Company may attach to
        unissued or new shares;</div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">(iii) cancel any authorized shares which, at the date of the adoption of such resolution, have not been issued to any person nor has the Company made any commitment, including a
        conditional commitment, to issue such shares, and reduce the amount of its share capital by the amount of the shares so canceled; or</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">(iv) reduce its share capital in any manner.</div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">- 3 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(b) With respect to any consolidation of issued shares and with respect to any other action which may result in fractional shares, the Board of Directors may settle any
        difficulty which may arise with regard thereto, as it deems fit, and, in connection with any such consolidation or other action which could result in fractional shares, may, without limiting its aforesaid power:<br>
        <br>
      </div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">(i) determine, as to the holder of shares so consolidated, which issued shares shall be consolidated;</div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">(ii) issue, in contemplation of or subsequent to such consolidation or other action, shares sufficient to preclude or remove fractional share holdings;</div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">(iii) redeem such shares or fractional shares sufficient to preclude or remove fractional share holdings;</div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">(iv) round up, round down or round to the nearest whole number, any fractional shares resulting from the consolidation or from any other action which may result in fractional
        shares; or</div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">(v) cause the transfer of fractional shares by certain Shareholders of the Company to other Shareholders thereof so as to most expediently preclude or remove any fractional
        shareholdings, and cause the transferees of such fractional shares to pay the transferors thereof the fair value thereof, and the Board of Directors is hereby authorized to act in connection with such transfer, as agent for the transferors and
        transferees of any such fractional shares, with full power of substitution, for the purposes of implementing the provisions of this sub-Article 8(b)(v).</div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="za07d38dabe044206bef9a625c2ab4f85">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">9.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Issuance of Share Certificates, Replacement of Lost Certificates</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(a) To the extent that the Board of Directors determines that all shares shall be certificated or, if the Board of Directors does not so determine, to the extent that any
        Shareholder requests a share certificate or the Company&#8217;s transfer agent so requires, share certificates shall be issued under the corporate seal of the Company or its written, typed or stamped name and shall bear the signature of one Director, the
        Company&#8217;s Chief Executive Officer, or any person or persons authorized therefor by the Board of Directors. Signatures may be affixed in any mechanical or electronic form, as the Board of Directors may prescribe.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(b) Subject to the provisions of Article 9(a), each Shareholder shall be entitled to one numbered certificate for all of the shares of any class registered in his or her name.
        Each certificate shall specify the serial numbers of the shares represented thereby and may also specify the amount paid up thereon. The Company (as determined by an officer of the Company to be designated by the Chief Executive Officer) shall not
        refuse a request by a Shareholder to obtain several certificates in place of one certificate, unless such request is, in the opinion of such officer, unreasonable. Where a Shareholder has sold or transferred a portion of such Shareholder&#8217;s shares,
        such Shareholder shall be entitled to receive a certificate in respect of such Shareholder&#8217;s remaining shares, provided that the previous certificate is delivered to the Company before the issuance of a new certificate.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(c) A share certificate registered in the names of two or more persons shall be issued to the person first named in the Register of Shareholders in respect of such co-ownership.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(d) A share certificate which has been defaced, lost or destroyed, may be replaced, and the Company shall issue a new certificate to replace such defaced, lost or destroyed
        certificate upon payment of such fee, and upon the furnishing of such evidence of ownership and such indemnity, as the Board of Directors in its discretion deems fit.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z7b1c64d1143e4082af1beb3e1db241e5">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">10.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Registered Holder</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">Except as otherwise provided in these Articles or the Companies Law, the Company shall be entitled to treat the registered holder of each share as the absolute owner thereof,
        and accordingly, shall not, except as ordered by a court of competent jurisdiction, or as required by the Companies Law, be obligated to recognize any equitable or other claim to, or interest in, such share on the part of any other person.</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">- 4 -</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zf3b6a6b670cc48edadd059403740359f">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">11.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Issuance and Repurchase of Shares</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(a) The unissued shares from time to time shall be under the control of the Board of Directors (and, to the extent permitted by law, any Committee thereof), which shall have the
        power to issue or otherwise dispose of shares and of securities convertible or exercisable into or other rights to acquire from the Company to such persons, on such terms and conditions (including, inter alia, price, with or without premium,
        discount or commission, and terms relating to calls set forth in Article 13(f) hereof), and at such times, as the Board of Directors (or the Committee, as the case may be) deems fit, and the power to give to any person the option to acquire from
        the Company any shares or securities convertible or exercisable into or other rights to acquire from the Company on such terms and conditions (including, inter alia, price, with or without premium, discount or commission), during such time as the
        Board of Directors (or the Committee, as the case may be) deems fit.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(b) The Company may at any time and from time to time, subject to the Companies Law, repurchase or finance the purchase of any shares or other securities issued by the Company,
        in such manner and under such terms as the Board of Directors shall determine, whether from any one or more Shareholders. Such purchase shall not be deemed as payment of dividends and as such, no Shareholder will have the right to require the
        Company to purchase his or her shares or offer to purchase shares from any other Shareholders.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z1efeb79450dd4b8696a0ef332db4b77e">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">12.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Payment in Installment</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;">If pursuant to the terms of issuance of any share, all or any portion of the price thereof shall be payable in installments, every such installment shall be paid to the Company
        on the due date thereof by the then registered holder(s) of the share or the person(s) then entitled thereto.</div>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z62f2e624d91943ab9fcc0dc156c969b9">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">13.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Calls on Shares</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(a) The Board of Directors may, from time to time, as it, in its discretion, deems fit, make calls for payment upon Shareholders in respect of any sum (including premium) which
        has not been paid up in respect of shares held by such Shareholders and which is not, pursuant to the terms of issuance of such shares or otherwise, payable at a fixed time, and each Shareholder shall pay the amount of every call so made upon him
        or her (and of each installment thereof if the same is payable in installments), to the person(s) and at the time(s) and place(s) designated by the Board of Directors, as any such times may be thereafter extended and/or such person(s) or place(s)
        changed. Unless otherwise stipulated in the resolution of the Board of Directors (and in the notice hereafter referred to), each payment in response to a call shall be deemed to constitute a pro rata payment on account of all the shares in respect
        of which such call was made.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(b) Notice of any call for payment by a shareholder shall be given in writing to such shareholder not less than fourteen (14) days prior to the time of payment fixed in such
        notice, and shall specify the time and place of payment, and the person to whom such payment is to be made. Prior to the time for any such payment fixed in a notice of a call given to a shareholder, the Board of Directors may in its absolute
        discretion, by notice in writing to such shareholder, revoke such call in whole or in part, extend the time fixed for payment thereof, or designate a different place of payment or person to whom payment is to be made. In the event of a call payable
        in installments, only one notice thereof need be given.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(c) If pursuant to the terms of issuance of a share or otherwise, an amount is made payable at a fixed time, such amount shall be payable at such time as if it were payable by
        virtue of a call made by the Board of Directors and for which notice was given in accordance with paragraphs (a) and (b) of this Article 13, and the provision of these Articles with regard to calls (and the non-payment thereof) shall be applicable
        to such amount or such installment (and the non-payment thereof).</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(d) Joint holders of a share shall be jointly and severally liable to pay all calls for payment in respect of such share and all interest payable thereon.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(e) Any amount called for payment which is not paid when due shall bear interest from the date fixed for payment until actual payment thereof, at such rate (not exceeding the
        then prevailing debitory rate charged by leading commercial banks in Israel), and payable at such time(s) as the Board of Directors may prescribe.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(f) Upon the issuance of shares, the Board of Directors may provide for differences among the holders of such shares as to the amounts and times for payment of calls for payment
        in respect of such shares.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">- 5 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z36fbdf5d564d469eb999ea333246f1c7">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">14.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Prepayment</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">With the approval of the Board of Directors, any shareholder may pay to the Company any amount not yet payable in respect of his or her shares, and the Board of Directors may
        approve the payment by the Company of interest on any such amount until the same would be payable if it had not been paid in advance, at such rate and time(s) as may be approved by the Board of Directors. The Board of Directors may at any time
        cause the Company to repay all or any part of the money so advanced, without premium or penalty. Nothing in this Article 14 shall derogate from the right of the Board of Directors to make any call for payment before or after receipt by the Company
        of any such advance.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zbad2d8b3a6724d46bc4e5c297b248689">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">15.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Forfeiture and Surrender</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(a) If any shareholder fails to pay an amount payable by virtue of a call, installment or interest thereon as provided for in accordance herewith, on or before the day fixed for
        payment of the same, the Board of Directors may at any time after the day fixed for such payment, so long as such amount (or any portion thereof) or interest thereon (or any portion thereof) remains unpaid, forfeit all or any of the shares in
        respect of which such payment was called for. All expenses incurred by the Company in attempting to collect any such amount or interest thereon, including, without limitation, attorneys&#8217; fees and costs of legal proceedings, shall be added to, and
        shall, for all purposes (including the accrual of interest thereon) constitute a part of, the amount payable to the Company in respect of such call.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(b) Upon the adoption of a resolution as to the forfeiture of a Shareholder&#8217;s share, the Board of Directors shall cause notice thereof to be given to such shareholder, which
        notice shall state that, in the event of the failure to pay the entire amount so payable by a date specified in the notice (which date shall be not less than fourteen (14) days after the date such notice is given and which may be extended by the
        Board of Directors), such shares shall be ipso facto forfeited, provided, however, that, prior to such date, the Board of Directors may cancel such resolution of forfeiture, but no such cancellation shall stop the Board of Directors from adopting a
        further resolution of forfeiture in respect of the non-payment of the same amount.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(c) Without derogating from Articles 51 and 55 hereof, whenever shares are forfeited as herein provided, all dividends, if any, theretofore declared in respect thereof and not
        actually paid shall be deemed to have been forfeited at the same time.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(d) The Company, by resolution of the Board of Directors, may accept the voluntary surrender of any share.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(e) Any share forfeited or surrendered as provided herein, shall become the property of the Company as a dormant share, and the same, subject to the provisions of these Articles,
        may be sold, re-issued or otherwise disposed of as the Board of Directors deems fit.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(f) Any person whose shares have been forfeited or surrendered shall cease to be a shareholder in respect of the forfeited or surrendered shares, but shall, notwithstanding, be
        liable to pay, and shall forthwith pay, to the Company, all calls, interest and expenses owing upon or in respect of such shares at the time of forfeiture or surrender, together with interest thereon from the time of forfeiture or surrender until
        actual payment, at the rate prescribed in Article 13(e) above, and the Board of Directors, in its discretion, may, but shall not be obligated to, enforce or collect the payment of such amounts, or any part thereof, as it shall deem fit. In the
        event of such forfeiture or surrender, the Company, by resolution of the Board of Directors, may accelerate the date(s) of payment of any or all amounts then owing to the Company by the person in question (but not yet due) in respect of all shares
        owned by such shareholder, solely or jointly with another.</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(g) The Board of Directors may at any time, before any share so forfeited or surrendered shall have been sold, re-issued or otherwise disposed of, nullify the forfeiture or
        surrender on such conditions as it deems fit, but no such nullification shall stop the Board of Directors from re-exercising its powers of forfeiture pursuant to this Article 15.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">- 6 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z07ee45cbe4ea451482e39d20d24c7def">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">16.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold; font-variant: small-caps;">Lien</font>.</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(a) Except to the extent the same may be waived or subordinated in writing, the Company shall have a first and paramount lien upon all the shares registered in the name of each
        shareholder (without regard to any equitable or other claim or interest in such shares on the part of any other person), and upon the proceeds of the sale thereof, for his or her debts, liabilities and engagements to the Company arising from any
        amount payable by such shareholder in respect of any unpaid or partly paid share, whether or not such debt, liability or engagement has matured. Such lien shall extend to all dividends from time to time declared or paid in respect of such share.
        Unless otherwise provided, the registration by the Company of a transfer of shares shall be deemed to be a waiver on the part of the Company of the lien (if any) existing on such shares immediately prior to such transfer.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(b) The Board of Directors may cause the Company to sell a share subject to such a lien when the debt, liability or engagement giving rise to such lien has matured, in such
        manner as the Board of Directors deems fit, but no such sale shall be made unless such debt, liability or engagement has not been satisfied within fourteen (14) days after written notice of the intention to sell shall have been served on such
        shareholder, his or her executors or administrators.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">(c) The net proceeds of any such sale, after payment of the costs and expenses thereof or ancillary thereto, shall be applied in or toward satisfaction of the debts, liabilities
        or engagements of such shareholder in respect of such share (whether or not the same have matured), and the remaining proceeds (if any) shall be paid to the shareholder, his or her executors, administrators or assigns.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z8c38b778e4ba4441931e6ea74d12d6a2">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">17.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Sale After Forfeiture or Surrender or For Enforcement of Lien</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">Upon any sale of a share after forfeiture or surrender or for enforcing a lien, the Board of Directors may appoint any person to execute an instrument of transfer of the share so
        sold and cause the purchaser&#8217;s name to be entered in the Register of Shareholders in respect of such share. The purchaser shall be registered as the shareholder and shall not be bound to see to the regularity of the sale proceedings, or to the
        application of the proceeds of such sale, and after his or her name has been entered in the Register of Shareholders in respect of such share, the validity of the sale shall not be impeached by any person, and the remedy of any person aggrieved by
        the sale shall be in damages only and against the Company exclusively.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zdf31c6b98d714cf2a9f506c08d2c973f">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">18.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Redeemable Shares</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">The Company may, subject to applicable law, issue redeemable shares or other securities and redeem the same upon terms and conditions to be set forth in a written agreement
        between the Company and the holder of such shares or in their terms of issuance.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">- 7 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Transfer of Shares</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z4a8d6688988c4fed899c249ba2353c7c">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">19.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Registration of Transfer</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; text-indent: -0.05pt; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; text-indent: -0.05pt; margin-left: 35.45pt; line-height: 1.25;">No transfer of shares shall be registered unless a proper writing or instrument of transfer (in any customary form or any other form satisfactory to the
        Board of Directors or an officer of the Company to be designated by the Chief Executive Officer) has been submitted to the Company (or its transfer agent), together with any share certificate(s) and such other evidence of title as the Board of
        Directors or an officer of the Company to be designated by the Chief Executive Officer may require. Notwithstanding anything to the contrary herein, shares registered in the name of The Depository Trust Company or its nominee shall be transferrable
        in accordance with the policies and procedures of The Depository Trust Company. Until the transferee has been registered in the Register of Shareholders in respect of the shares so transferred, the Company may continue to regard the transferor as
        the owner thereof. The Board of Directors, may, from time to time, prescribe a fee for the registration of a transfer, and may approve other methods of recognizing the transfer of shares in order to facilitate the trading of the Company&#8217;s shares on
        the Nasdaq Stock Market or on any other stock exchange on which the Company&#8217;s shares are then listed for trading.</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z4222bdcfefb7436a9c625622fff047b8">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">20.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Suspension of Registration</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">The Board of Directors may, in its discretion to the extent it deems necessary, close the Register of Shareholders of registration of transfers of shares for a period
        determined by the Board of Directors, and no registrations of transfers of shares shall be made by the Company during any such period during which the Register of Shareholders is so closed.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">- 8 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Transmission of Shares</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zfecc309aff374461b850ad0b87eda9a7">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">21.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Decedents&#8217; Shares</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">Upon the death of a Shareholder, the Company shall recognize the custodian or administrator of the estate or executor of the will, and in the absence of such, the lawful heirs
        of the Shareholder, as the only holders of the right for the shares of the deceased Shareholder, after receipt of evidence to the entitlement thereto, as determined by the Board of Directors or an officer of the Company to be designated by the
        Chief Executive Officer.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z0ae66650624742fab2fd18f13cc9eaba">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">22.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Receivers and Liquidators</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(a) The Company may recognize any receiver, liquidator or similar official appointed to wind-up, dissolve or otherwise liquidate a corporate Shareholder, and a trustee,
        manager, receiver, liquidator or similar official appointed in bankruptcy or in connection with the reorganization of, or similar proceeding with respect to a Shareholder or its properties, as being entitled to the shares registered in the name of
        such Shareholder.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(b) Such receiver, liquidator or similar official appointed to wind-up, dissolve or otherwise liquidate a corporate Shareholder and such trustee, manager, receiver, liquidator
        or similar official appointed in bankruptcy or in connection with the reorganization of, or similar proceedings with respect to a Shareholder or its properties, upon producing such evidence as the Board of Directors (or an officer of the Company to
        be designated by the Chief Executive Officer) may deem sufficient as to his or her authority to act in such capacity or under this Article, shall with the consent of the Board of Directors or an officer of the Company to be designated by the Chief
        Executive Officer (which the Board of Directors or such officer may grant or refuse in its absolute discretion), be registered as a Shareholder in respect of such shares, or may, subject to the regulations as to transfer herein contained, transfer
        such shares.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: center; margin-left: 35.45pt; line-height: 1.25; font-variant: small-caps; font-weight: bold;">General Meetings</div>
      <div style="text-align: center; margin-left: 35.45pt; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z97840e4909e64927ad4ab149e27c48e2">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">23.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">General Meetings</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(a) An annual General Meeting (&#8220;<font style="font-weight: bold;">Annual General Meeting</font>&#8221;) shall be held at such time and at such place, either within or outside of the
        State of Israel, as may be determined by the Board of Directors.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(b) All General Meetings other than Annual General Meetings shall be called &#8220;<font style="font-weight: bold;">Special General Meetings</font>&#8221;. The Board of Directors may, at
        its discretion, convene a Special General Meeting at such time and place, within or outside of the State of Israel, as may be determined by the Board of Directors.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(c) If so determined by the Board of Directors, an Annual General Meeting or a Special General Meeting may be held through the use of any means of communication approved by
        the Board of Directors, provided all of the participating Shareholders can hear each other simultaneously. A resolution approved by use of means of communications as aforesaid, shall be deemed to be a resolution lawfully adopted at such general
        meeting and a Shareholder shall be deemed present in person at such general meeting if attending such meeting through the means of communication used at such meeting.</div>
      <div style="line-height: 1.25;"><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">- 9 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z6270047ecf9042af84a331d4e75c6bb7">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">24.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Record Date for General Meeting</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;">Notwithstanding any provision of these Articles to the contrary, and to allow the Company to determine the Shareholders entitled to notice of or to vote at any General Meeting
        or any adjournment thereof, or entitled to receive payment of any dividend or other distribution or grant of any rights, or entitled to exercise any rights in respect of or to take or be the subject of any other action, the Board of Directors may
        fix a record date for the General Meeting, which shall not be more than the maximum period and not less than the minimum period permitted by law. A determination of Shareholders of record entitled to notice of or to vote at a General Meeting shall
        apply to any adjournment of the meeting; <u>provided</u>, <u>however</u>, that the Board of Directors may fix a new record date for the adjourned meeting.</div>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z362512a31c9f45e28a44b0334e069136">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">25.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold; font-variant: small-caps;">Shareholder Proposal Request</font>.</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;">(a) Any Shareholder or Shareholders of the Company holding at least the required percentage under the Companies Law of the voting rights of the Company which entitles such
        Shareholder(s) to require the Company to include a matter on the agenda of a General Meeting (the &#8220;<font style="font-weight: bold;">Proposing Shareholder(s)</font>&#8221;) may request, subject to the Companies Law, that the Board of Directors include a
        matter on the agenda of a General Meeting to be held in the future, provided that the Board of Directors determines that the matter is appropriate to be considered at a General Meeting (a &#8220;<font style="font-weight: bold;">Proposal Request</font>&#8221;).
        In order for the Board of Directors to consider a Proposal Request and whether to include the matter stated therein in the agenda of a General Meeting, notice of the Proposal Request must be timely delivered in accordance with applicable law, and
        the Proposal Request must comply with the requirements of these Articles (including this Article 25) and any applicable law and stock exchange rules and regulations. The Proposal Request must be in writing, signed by all of the Proposing
        Shareholder(s) making such request, delivered, either in person or by registered mail, postage prepaid, and received by the Secretary (or, in the absence thereof, by the Chief Executive Officer of the Company). To be considered timely, a Proposal
        Request must be received within the time periods prescribed by applicable law. The announcement of an adjournment or postponement of a General Meeting shall not commence a new time period (or extend any time period) for the delivery of a Proposal
        Request as described above. In addition to any information required to be included in accordance with applicable law, a Proposal Request must include the following: (i) the name, address, telephone number, fax number and email address of the
        Proposing Shareholder (or each Proposing Shareholder, as the case may be) and, if an entity, the name(s) of the person(s) that controls or manages such entity; (ii) the number of Shares held by the Proposing Shareholder(s), directly or indirectly
        (and, if any of such Shares are held indirectly, an explanation of how they are held and by whom), which shall be in such number no less than as is required to qualify as a Proposing Shareholder, accompanied by evidence satisfactory to the Company
        of the record holding of such Shares by the Proposing Shareholder(s) as of the date of the Proposal Request; (iii) the matter requested to be included on the agenda of a General Meeting, all information related to such matter, the reason that such
        matter is proposed to be brought before the General Meeting, the complete text of the resolution that the Proposing Shareholder proposes to be voted upon at the General Meeting, and a representation that the Proposing Shareholder(s) intend to
        appear in person or by proxy at the meeting; (iv) a description of all arrangements or understandings between the Proposing Shareholders and any other Person(s) (naming such Person or Persons) in connection with the matter that is requested to be
        included on the agenda and a declaration signed by all Proposing Shareholder(s) of whether any of them has a personal interest in the matter and, if so, a description in reasonable detail of such personal interest; (v) a description of all
        Derivative Transactions (as defined below) by each Proposing Shareholder(s) during the previous twelve (12) month period, including the date of the transactions and the class, series and number of securities involved in, and the material economic
        terms of, such Derivative Transactions; and (vi) a declaration that all of the information that is required under the Companies Law and any other applicable law and stock exchange rules and regulations to be provided to the Company in connection
        with such matter, if any, has been provided to the Company. The Board of Directors, may, in its discretion, to the extent it deems necessary, request that the Proposing Shareholder(s) provide additional information necessary so as to include a
        matter in the agenda of a General Meeting, as the Board of Directors may reasonably require.</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">- 10 -</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">A &#8220;<font style="font-weight: bold;">Derivative Transaction</font>&#8221; means any agreement, arrangement, interest or understanding entered into by, or on behalf or for the benefit
        of, any Proposing Shareholder or any of its affiliates or associates, whether of record or beneficial: (1) the value of which is derived in whole or in part from the value of any class or series of shares or other securities of the Company, (2)
        which otherwise provides any direct or indirect opportunity to gain or share in any gain derived from a change in the value of securities of the Company, (3) the effect or intent of which is to mitigate loss, manage risk or benefit of security
        value or price changes, or (4) which provides the right to vote or increase or decrease the voting power of, such Proposing Shareholder, or any of its affiliates or associates, with respect to any shares or other securities of the Company, which
        agreement, arrangement, interest or understanding may include, without limitation, any option, warrant, debt position, note, bond, convertible security, swap, stock appreciation right, short position, profit interest, hedge, right to dividends,
        voting agreement, performance-related fee or arrangement to borrow or lend shares (whether or not subject to payment, settlement, exercise or conversion in any such class or series), and any proportionate interest of such Proposing Shareholder in
        the securities of the Company held by any general or limited partnership, or any limited liability company, of which such Proposing Shareholder is, directly or indirectly, a general partner or managing member.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(b) The information required pursuant to this Article shall be updated as of (i) the record date of the General Meeting, (ii) five business days before the General Meeting,
        and (iii) as of the General Meeting, and any adjournment or postponement thereof.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(c) The provisions of Articles 25(a) and 25(b) shall apply, <font style="font-style: italic;">mutatis mutandis,</font> on any matter to be included on the agenda of a Special
        General Meeting which is convened pursuant to a request of a Shareholder duly delivered to the Company in accordance with the Companies Law.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(d) Notwithstanding anything to the contrary herein, this Article 25 may only be amended, replaced or suspended by a resolution adopted at a General Meeting by a supermajority
        of at least 65% of the total voting power of the Shareholders.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zf34f755bf42c43ebad34d05cc4f9fa33">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">26.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Notice of General Meetings; Omission to Give Notice</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(a) The Company is not required to give notice of a General Meeting, subject to any mandatory provision of the Companies Law.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(b) The accidental omission to give notice of a General Meeting to any Shareholder, or the non-receipt of notice sent to such Shareholder, shall not invalidate the proceedings
        at such meeting or any resolution adopted thereat.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(c) No Shareholder present, in person or by proxy, at any time during a General Meeting shall be entitled to seek the cancellation or invalidation of any proceedings or
        resolutions adopted at such General Meeting on account of any defect in the notice of such meeting relating to the time or the place thereof, or any item acted upon at such meeting.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(d) In addition to any places at which the Company may make available for review by Shareholders the full text of the proposed resolutions to be adopted at a General Meeting,
        as required by the Companies Law, the Company may add additional places for Shareholders to review such proposed resolutions, including an internet site.</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">- 11 -</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Proceedings at General Meetings</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z6fa465676aa8419f82b1ea144eba9de6">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">27.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Quorum</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(a) No business shall be transacted at a General Meeting, or at any adjournment thereof, unless the quorum required under these Articles for such General Meeting or such
        adjourned meeting, as the case may be, is present when the meeting proceeds to business.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(b) In the absence of contrary provisions in these Articles, the requisite quorum for any General Meeting shall be two or more Shareholders (not in default in payment of any
        sum referred to in Article 13 hereof) present in person or by proxy and holding shares conferring in the aggregate at least thirty-three and one-third percent (33&#8531;%) of the voting power of the Company; provided, however, that if (i) any such
        General Meeting was initiated by and convened pursuant to a resolution adopted by the Board of Directors and (ii) at the time of such General Meeting the Company is a &#8220;foreign private issuer&#8221; under the US securities laws, then the requisite quorum
        shall be two or more Shareholders (not in default in payment of any sum referred to in Article 13 hereof) present in person or by proxy and holding shares conferring in the aggregate at least twenty five percent (25%) of the voting power of the
        Company. A proxy may be deemed to be two (2) or more Shareholders pursuant to the number of Shareholders represented by the proxy holder.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(c) If within half an hour from the time appointed for the meeting a quorum is not present, then without any further notice the meeting shall be adjourned either (i) to the
        same day in the next week, at the same time and place, (ii) to such day and at such time and place as indicated in the notice of such meeting, or (iii) to such day and at such time and place as the Chairperson of the General Meeting shall determine
        (which may be earlier or later than the date pursuant to clause (i) above). No business shall be transacted at any adjourned meeting except business which might lawfully have been transacted at the meeting as originally called. At such adjourned
        meeting, if the original meeting was convened upon request under Section 63 of the Companies Law, one or more shareholders, present in person or by proxy, and holding the number of shares required for making such request, shall constitute a quorum,
        but in any other case any shareholder (not in default as aforesaid) present in person or by proxy, shall constitute a quorum.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z40f30ccf1d0748aa853885dccde60af4">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">28.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-variant: small-caps;"><u><font style="font-weight: bold;">Chairperson of General Meeting</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">The Chairperson of the Board of Directors shall preside as Chairperson of every General Meeting of the Company. If at any meeting the Chairperson is not present within fifteen
        (15) minutes after the time fixed for holding the meeting or is unwilling or unable to act as Chairperson, any of the following may preside as Chairperson of the meeting (and in the following order): a Director designated by the Board of Directors,
        the Chief Executive Officer, the Chief Financial Officer, the General Counsel, the Secretary or any person designated by any of the foregoing. If at any such meeting none of the foregoing persons is present or all are unwilling or unable to act as
        Chairperson, the Shareholders present (in person or by proxy) shall choose a Shareholder or its proxy present at the meeting to be Chairperson. The office of Chairperson shall not, by itself, entitle the holder thereof to vote at any General
        Meeting nor shall it entitle such holder to a second or casting vote (without derogating, however, from the rights of such Chairperson to vote as a Shareholder or proxy of a Shareholder if, in fact, he is also a Shareholder or such proxy).</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="ze07a34da80ef44239c629761b12f5d8e">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">29.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Adoption of Resolutions at General Meetings</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(a) Except as required by the Companies Law or these Articles, including, without limitation, Article 39 below, a resolution of the Shareholders shall be adopted if approved
        by the holders of a simple majority of the voting power represented at the General Meeting in person or by proxy and voting thereon, as one class, and disregarding abstentions from the count of the voting power present and voting. Without limiting
        the generality of the foregoing, a resolution with respect to a matter or action for which the Companies Law prescribes a higher majority or pursuant to which a provision requiring a higher majority would have been deemed to have been incorporated
        into these Articles, but for which the Companies Law allows these Articles to provide otherwise (including, Sections 327 and 24 of the Companies Law), shall be adopted by a simple majority of the voting power represented at the General Meeting in
        person or by proxy and voting thereon, as one class, and disregarding abstentions from the count of the voting power present and voting.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">- 12 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(b) Every question submitted to a General Meeting shall be decided by a show of hands, but the Chairperson of the General Meeting may determine that a resolution shall be
        decided by a written ballot. A written ballot may be implemented before the proposed resolution is voted upon or immediately after the declaration by the Chairperson of the results of the vote by a show of hands. If a vote by written ballot is
        taken after such declaration, the results of the vote by a show of hands shall be of no effect, and the proposed resolution shall be decided by such written ballot.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(c) A defect in convening or conducting a General Meeting, including a defect resulting from the non-fulfillment of any provision or condition set forth in the Companies Law
        or these Articles, including with regard to the manner of convening or conducting the General Meeting, shall not disqualify any resolution passed at the General Meeting and shall not affect the discussions or decisions which took place thereat.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(d) A declaration by the Chairperson of the General Meeting that a resolution has been carried unanimously, or carried by a particular majority, or rejected, and an entry to
        that effect in the minute book of the Company, shall be prima facie evidence of the fact without proof of the number or proportion of the votes recorded in favor of or against such resolution.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zdbc9c8190bfa468bb754e57beb3f31c4">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">30.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Power to Adjourn</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">A General Meeting, the consideration of any matter on its agenda, or the resolution on any matter on its agenda, may be postponed or adjourned, from time to time and from
        place to place: (i) by the Chairperson of a General Meeting at which a quorum is present (and he shall do so if directed by the General Meeting, with the consent of the holders of a majority of the voting power represented in person or by proxy and
        voting on the question of adjournment), but no business shall be transacted at any such adjourned meeting except business which might lawfully have been transacted at the meeting as originally called, or a matter on its agenda with respect to which
        no resolution was adopted at the meeting originally called; or (ii) by the Board of Directors (whether prior to or at a General Meeting).</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z7a18506be562437e8650b22f29670ee6">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">31.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Voting Power</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">Subject to the provisions of Article 32(a) and to any provision hereof conferring special rights as to voting, or restricting the right to vote, every Shareholder shall have
        one vote for each share held by the Shareholder of record, on every resolution, without regard to whether the vote thereon is conducted by a show of hands, by written ballot, or by any other means.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z175ba01c676b4edca34b4033d7f681cb">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">32.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-variant: small-caps; font-weight: bold;"><u>Voting Rights.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(a) No shareholder shall be entitled to vote at any General Meeting (or be counted as a part of the quorum thereat), unless all calls then payable by him or her in respect of
        his or her shares in the Company have been paid.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(b) A company or other corporate body being a Shareholder of the Company may duly authorize any person to be its representative at any meeting of the Company or to execute or
        deliver a proxy on its behalf. Any person so authorized shall be entitled to exercise on behalf of such Shareholder all the power, which the Shareholder could have exercised if it were an individual. Upon the request of the Chairperson of the
        General Meeting, written evidence of such authorization (in form acceptable to the Chairperson) shall be delivered to him or her.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(c) Any Shareholder entitled to vote may vote either in person or by proxy (who need not be a Shareholder of the Company), or, if the Shareholder is a company or other
        corporate body, by representative authorized pursuant to Article (b) above.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(d) If two or more persons are registered as joint holders of any share, the vote of the senior who tenders a vote, in person or by proxy, shall be accepted to the exclusion
        of the vote(s) of the other joint holder(s). For the purpose of this Article 32(d), seniority shall be determined by the order of registration of the joint holders in the Register of Shareholders.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(e) If a Shareholder is a minor, under protection, bankrupt or legally incompetent, or in the case of a corporation, is in receivership or liquidation, it may, subject to all
        other provisions of these Articles and any documents or records required to be provided under these Articles, vote through his, her or its trustees, receiver, liquidator, natural guardian or another legal guardian, as the case may be, and the
        persons listed above may vote in person or by proxy.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">- 13 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Proxies</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zbd7f991e748348568aab85d72eb9cde4">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">33.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Instrument of Appointment</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(a) An instrument appointing a proxy shall be in writing and shall be substantially in the following form:</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" align="right" style="width: 95%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;" id="z30900a186b9f44f0b1c0d482873cea16">

          <tr>
            <td style="width: 18.71%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#8220;I</div>
            </td>
            <td style="width: 33.7%; vertical-align: top; border-bottom: #000000 2px solid;">&#160;</td>
            <td style="width: 4.89%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">of</div>
            </td>
            <td style="width: 42.7%; vertical-align: top; border-bottom: #000000 2px solid;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 18.71%; vertical-align: top;">&#160;</td>
            <td style="width: 33.7%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-style: italic;">(Name of Shareholder)</div>
            </td>
            <td style="width: 4.89%; vertical-align: top;">&#160;</td>
            <td style="width: 42.7%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-style: italic;">(Address of Shareholder)</div>
            </td>
          </tr>
          <tr>
            <td colspan="4" style="width: 100%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Being a shareholder of [&#9679;]. hereby appoints</div>
            </td>
          </tr>
          <tr>
            <td style="width: 18.71%; vertical-align: top;">&#160;</td>
            <td style="width: 33.7%; vertical-align: top; border-bottom: #000000 2px solid;">&#160;</td>
            <td style="width: 4.89%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">of</div>
            </td>
            <td style="width: 42.7%; vertical-align: top; border-bottom: #000000 2px solid;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 18.71%; vertical-align: top;">&#160;</td>
            <td style="width: 33.7%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-style: italic;">(Name of Proxy)</div>
            </td>
            <td style="width: 4.89%; vertical-align: top;">&#160;</td>
            <td style="width: 42.7%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-style: italic;">(Address of Proxy)</div>
            </td>
          </tr>
          <tr>
            <td colspan="4" style="width: 100%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">as my proxy to vote for me and on my behalf at the General Meeting of the Company to be held on the ___ day of _______, _______ and at any adjournment(s) thereof.</div>
            </td>
          </tr>
          <tr>
            <td colspan="4" style="width: 100%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td colspan="4" style="width: 100%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Signed this ____ day of ___________, ______.</div>
            </td>
          </tr>
          <tr>
            <td colspan="4" style="width: 100%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td colspan="4" style="width: 100%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25;">(Signature of Appointor)&#8221;</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; clear: both;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;">or in any usual or common form or in such other form as may be approved by the Board of Directors. Such proxy shall be duly signed by the appointor of such person's duly
        authorized attorney, or, if such appointor is company or other corporate body, in the manner in which it signs documents which binds it together with a certificate of an attorney with regard to the authority of the signatories.</div>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(b) Subject to the Companies Law, the original instrument appointing a proxy or a copy thereof certified by an attorney (and the power of attorney or other authority, if any,
        under which such instrument has been signed) shall be delivered to the Company (at its Office, at its principal place of business, or at the offices of its registrar or transfer agent, or at such place as notice of the meeting may specify) not less
        than forty eight (48) hours (or such shorter period as the notice shall specify) before the time fixed for such meeting. Notwithstanding the above, the Chairperson shall have the right to waive the time requirement provided above with respect to
        all instruments of proxies and to accept instruments of proxy until the beginning of a General Meeting. A document appointing a proxy shall be valid for every adjourned meeting of the General Meeting to which the document relates.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z347b0c781c6c4ac19e511b84e10b04d7">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">34.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Effect of Death of Appointor of Transfer of Share and or Revocation of Appointment</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(a) A vote cast in accordance with an instrument appointing a proxy shall be valid notwithstanding the prior death or bankruptcy of the appointing Shareholder (or of his or
        her attorney-in-fact, if any, who signed such instrument), or the transfer of the share in respect of which the vote is cast, unless written notice of such matters shall have been received by the Company or by the Chairperson of such meeting prior
        to such vote being cast.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(b) Subject to the Companies Law, an instrument appointing a proxy shall be deemed revoked (i) upon receipt by the Company or the Chairperson, subsequent to receipt by the
        Company of such instrument, of written notice signed by the person signing such instrument or by the Shareholder appointing such proxy canceling the appointment thereunder (or the authority pursuant to which such instrument was signed) or of an
        instrument appointing a different proxy (and such other documents, if any, required under Article 33(b) for such new appointment), provided such notice of cancellation or instrument appointing a different proxy were so received at the place and
        within the time for delivery of the instrument revoked thereby as referred to in Article 33(b) hereof, or (ii) if the appointing Shareholder is present in person at the meeting for which such instrument of proxy was delivered, upon receipt by the
        Chairperson of such meeting of written notice from such Shareholder of the revocation of such appointment, or if and when such Shareholder votes at such meeting. A vote cast in accordance with an instrument appointing a proxy shall be valid
        notwithstanding the revocation or purported cancellation of the appointment, or the presence in person or vote of the appointing Shareholder at a meeting for which it was rendered, unless such instrument of appointment was deemed revoked in
        accordance with the foregoing provisions of this Article 34(b) at or prior to the time such vote was cast.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">- 14 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Board of Directors</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zeb4417b95a644d5f8629ef08912208d7">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">35.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Powers of the Board of Directors</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(a) The Board of Directors may exercise all such powers and do all such acts and things as the Board of Directors is authorized by law or as the Company is authorized to
        exercise and do and are not hereby or by law required to be exercised or done by the General Meeting. The authority conferred on the Board of Directors by this Article 35 shall be subject to the provisions of the Companies Law, these Articles and
        any regulation or resolution consistent with these Articles adopted from time to time at a General Meeting, provided, however, that no such regulation or resolution shall invalidate any prior act done by or pursuant to a decision of the Board of
        Directors which would have been valid if such regulation or resolution had not been adopted.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(b) Without limiting the generality of the foregoing, the Board of Directors may, from time to time, set aside any amount(s) out of the profits of the Company as a reserve or
        reserves for any purpose(s) which the Board of Directors, in its absolute discretion, shall deem fit, including without limitation, capitalization and distribution of bonus shares, and may invest any sum so set aside in any manner and from time to
        time deal with and vary such investments and dispose of all or any part thereof, and employ any such reserve or any part thereof in the business of the Company without being bound to keep the same separate from other assets of the Company, and may
        subdivide or re-designate any reserve or cancel the same or apply the funds therein for another purpose, all as the Board of Directors may from time to time think fit.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z6c4054989a3745aea5dfb8f63aa81796">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">36.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Exercise of Powers of the Board of Directors</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(a) A meeting of the Board of Directors at which a quorum is present in accordance with Article 45 shall be competent to exercise all the authorities, powers and discretion
        vested in or exercisable by the Board of Directors.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(b) A resolution proposed at any meeting of the Board of Directors shall be deemed adopted if approved by a majority of the Directors present, entitled to vote and voting
        thereon when such resolution is put to a vote.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(c) The Board of Directors may adopt resolutions, without convening a meeting of the Board of Directors, in writing or in any other manner permitted by the Companies Law.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z57c0f6901dac4147a8229e326e323bf9">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">37.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Delegation of Powers</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(a) The Board of Directors may, subject to the provisions of the Companies Law, delegate any or all of its powers to committees (in these Articles referred to as a &#8220;<font style="font-weight: bold;">Committee of the Board of Directors</font>&#8221;, or &#8220;<font style="font-weight: bold;">Committee</font>&#8221;), each consisting of one or more persons (who may or may not be Directors), and it may from time to time revoke such
        delegation or alter the composition of any such Committee. Any Committee so formed shall, in the exercise of the powers so delegated, conform to any regulations imposed on it by the Board of Directors, subject to applicable law. No regulation
        imposed by the Board of Directors on any Committee and no resolution of the Board of Directors shall invalidate any prior act done or pursuant to a resolution by the Committee which would have been valid if such regulation or resolution of the
        Board of Directors had not been adopted. The meetings and proceedings of any such Committee of the Board of Directors shall, mutatis mutandis, be governed by the provisions herein contained for regulating the meetings of the Board of Directors, to
        the extent not superseded by any regulations adopted by the Board of Directors. Unless otherwise expressly prohibited by the Board of Directors, in delegating powers to a Committee of the Board of Directors, such Committee shall be empowered to
        further delegate such powers.</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(b) The Board of Directors may from time to time appoint a Secretary to the Company, as well as Officers, agents, employees and independent contractors, as the Board of
        Directors deems fit, and may terminate the service of any such person. The Board of Directors may, subject to the provisions of the Companies Law, determine the powers and duties, as well as the salaries and compensation, of all such persons.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(c) The Board of Directors may from time to time, by power of attorney or otherwise, appoint any person, company, firm or body of persons to be the attorney or attorneys of
        the Company at law or in fact for such purposes(s) and with such powers, authorities and discretions, and for such period and subject to such conditions, as it deems fit, and any such power of attorney or other appointment may contain such
        provisions for the protection and convenience of persons dealing with any such attorney as the Board of Directors deems fit, and may also authorize any such attorney to delegate all or any of the powers, authorities and discretions vested in him or
        her.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">- 15 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z4a763165c32149d4a76e22e8f651cb31">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">38.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Number of Directors</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(a) The Board of Directors shall consist of such number of Directors (not less than three (3) nor more than eleven (11), including the External Directors, if any were elected)
        as may be fixed from time to time by resolution of the Board of Directors.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(b) Notwithstanding anything to the contrary herein, this Article 38 may only be amended or replaced by a resolution adopted at a General Meeting by a majority of at least 65%
        of the total voting power of the Company&#8217;s shareholders.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zef5b5b41ad45444e953e2c0ca31e804d">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">39.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Election and Removal of Directors</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(a) The Directors, excluding the External Directors, if any were elected, shall be classified, with respect to the term for which they each severally hold office, into three
        classes, as nearly equal in number as practicable, hereby designated as Class I, Class II and Class III. The Board of Directors may assign members of the Board of Directors already in office to such classes at the time such classification becomes
        effective.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">(i) The term of office of the initial Class I directors shall expire at the Annual General Meeting to be held in 2022 and when their successors are elected and qualified,</div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">(ii) The term of office of the initial Class II directors shall expire at the first Annual General Meeting following the Annual General Meeting referred to in clause (i) above
        and when their successors are elected and qualified, and</div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">(iii) The term of office of the initial Class III directors shall expire at the first Annual General Meeting following the Annual General Meeting referred to in clause (ii) above
        and when their successors are elected and qualified,</div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(b) At each Annual General Meeting, commencing with the Annual General Meeting to be held in 2022, each Nominee or Alternate Nominee elected at such Annual General Meeting to
        serve as a Director in a Class whose term shall have expired at such Annual General Meeting shall be elected to hold office until the third Annual General Meeting next succeeding his or her election and until his or her respective successor shall
        have been elected and qualified. Notwithstanding anything to the contrary, each Director shall serve until his or her successor is elected and qualified or until such earlier time as such Director&#8217;s office is vacated.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(c) If the number of Directors (excluding External Directors, if any were elected) that comprises the Board of Directors is hereafter changed by the Board of Directors, any
        newly created directorships or decrease in directorships shall be so apportioned by the Board of Directors among the classes as to make all classes as nearly equal in number as is practicable, provided that no decrease in the number of Directors
        constituting the Board of Directors shall shorten the term of any incumbent Director.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(d) Prior to every General Meeting of the Company at which Directors are to be elected, and subject to clauses (a) and (h) of this Article, the Board of Directors (or a
        Committee thereof) shall select, by a resolution adopted by a majority of the Board of Directors (or such Committee), a number of Persons to be proposed to the Shareholders for election as Directors at such General Meeting (the &#8220;<font style="font-weight: bold;">Nominees</font>&#8221;).</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">- 16 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(e) Any Proposing Shareholder requesting to include on the agenda of a General Meeting a nomination of a Person to be proposed to the Shareholders for election as Director
        (such person, an &#8220;<font style="font-weight: bold;">Alternate Nominee</font>&#8221;), may so request provided that it complies with this Article 39(e), Article 25 and applicable law. Unless otherwise determined by the Board of Directors, a Proposal
        Request relating to an Alternate Nominee is deemed to be a matter that is appropriate to be considered only at an Annual General Meeting. In addition to any information required to be included in accordance with applicable law, such a Proposal
        Request shall include information required pursuant to Article 25, and shall also set forth: (i) the name, address, telephone number, fax number and email address of the Alternate Nominee and all citizenships and residencies of the Alternate
        Nominee; (ii) a description of all arrangements, relations or understandings during the past three (3) years, and any other material relationships, between the Proposing Shareholder(s) or any of its affiliates and each Alternate Nominee; (iii) a
        declaration signed by the Alternate Nominee that he or she consents to be named in the Company&#8217;s notices and proxy materials and on the Company&#8217;s proxy card relating to the General Meeting, if provided or published, and that he or she, if elected,
        consents to serve on the Board of Directors and to be named in the Company&#8217;s disclosures and filings; (iv) a declaration signed by each Alternate Nominee as required under the Companies Law and any other applicable law and stock exchange rules and
        regulations for the appointment of such an Alternate Nominee and an undertaking that all of the information that is required under law and stock exchange rules and regulations to be provided to the Company in connection with such an appointment has
        been provided (including, information in respect of the Alternate Nominee as would be provided in response to the applicable disclosure requirements under Form 10-K or 20-F or any other applicable form prescribed by the U.S. Securities and Exchange
        Commission (the &#8220;<font style="font-weight: bold;">SEC</font>&#8221;)); (v) a declaration made by the Alternate Nominee of whether he or she meets the criteria for an independent director and, if applicable, External Director of the Company under the
        Companies Law and/or under any applicable law, regulation or stock exchange rules, and if not, then an explanation of why not; and (vi) any other information required at the time of submission of the Proposal Request by applicable law, regulations
        or stock exchange rules. In addition, the Proposing Shareholder(s) and each Alternate Nominee shall promptly provide any other information reasonably requested by the Company, including a duly completed director and officer questionnaire, in such
        form as may be provided by the Company, with respect to such Alternate Nominee. The Board of Directors may refuse to acknowledge the nomination of any person not made in compliance with the foregoing. The Company shall be entitled to publish any
        information provided by a Proposing Shareholder or Alternate Nominee pursuant to this Article 39(e) and Article 25, and the Proposing Shareholder and Alternate Nominee shall be responsible for the accuracy and completeness thereof.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(f) The Nominees or Alternate Nominees shall be elected by a resolution adopted at the General Meeting at which they are subject to election. Notwithstanding Articles 25(a)
        and 25(c), in the event of a Contested Election, the method of calculation of the votes and the manner in which the resolutions will be presented to the General Meeting shall be determined by the Board of Directors in its discretion. In the event
        that the Board of Directors does not or is unable to make a determination on such matter, then the method described in clause (ii) below shall apply. The Board of Directors may consider, among other things, the following methods: (i) election of
        competing slates of Director nominees by a majority of the voting power represented at the General Meeting in person or by proxy and voting on such competing slates, (ii) election of individual Directors by a plurality of the voting power
        represented at the General Meeting in person or by proxy and voting on the election of Directors (which shall mean that the nominees receiving the largest number of &#8220;for&#8221; votes will be elected in such Contested Election), (iii) election of each
        nominee by a majority of the voting power represented at the General Meeting in person or by proxy and voting on the election of Directors, provided that if the number of such nominees exceeds the number of Directors proposed to be elected as set
        forth above, then as among such elected nominees the election shall be by plurality of the voting power as described above, and (iv) such other method of voting as the Board of Directors deems appropriate, including use of a &#8220;universal proxy card&#8221;
        listing all Nominees and Alternate Nominees by the Company. For the purposes of these Articles, election of Directors at a General Meeting shall be considered a &#8220;Contested Election&#8221; if the aggregate number of Nominees and Alternate Nominees at such
        meeting exceeds the total number of Directors to be elected at such meeting, with the determination thereof being made by the Secretary (or, in the absence thereof, by the Chief Executive Officer of the Company) as of the close of the applicable
        notice of nomination period under Article 25 or under applicable law, based on whether one or more notice(s) of nomination were timely filed in accordance with Article 25, this Article 39 and applicable law; <u>provided</u>, <u>however</u>, that
        the determination that an election is a Contested Election shall not be determinative as to the validity of any such notice of nomination; and <u>provided</u>, <u>further</u>, that, if, prior to the time the Company mails its initial proxy
        statement in connection with such election of Directors, one or more notices of nomination of an Alternate Nominee are withdrawn such that the number of candidates for election as Director no longer exceeds the number of Directors proposed to be
        elected as set forth above, the election shall not be considered a Contested Election. At any General Meeting at which Directors are to be elected, each shareholder shall be entitled to cast a number of votes with respect to nominees for election
        to the Board of Directors up to the total number of Directors to be elected at such meeting. Shareholders shall not be entitled to cumulative voting in the election of Directors.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;"> <br>
        </div>
        <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">(g) Notwithstanding anything to the contrary herein, this Article 39 and Article 42(e) may only be amended, replaced or
          suspended by a resolution adopted at a General Meeting by a majority of at least 65% of the total voting power of the Company&#8217;s shareholders.</div>
        <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;"> <br>
        </div>
        <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">(h) Notwithstanding anything to the contrary in these Articles, the election, qualification, removal or dismissal of External
          Directors, if so elected, shall be only in accordance with the applicable provisions set forth in the Companies Law.</div>
        <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;"> <br>
        </div>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">- 17 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <br>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zbd1c5dfe198e4e0eb412f2393622f368">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">40.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Commencement of Directorship</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">Without derogating from Article 39, the term of office of a Director shall commence as of the date of his or her appointment or election, or on a later date if so specified in
        his or her appointment or election.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z002178abd9db41c3bf734e172111647d">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">41.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Continuing Directors in the Event of Vacancies</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">The Board of Directors (and, if so determined by the Board of Directors, the General Meeting) may at any time and from time to time appoint any person as a Director to fill a
        vacancy (whether such vacancy is due to a Director no longer serving or due to the number of Directors serving being less than the maximum number stated in Article 38 hereof). In the event of one or more such vacancies in the Board of Directors,
        the continuing Directors may continue to act in every matter, provided, however, that if the number of Directors serving is less than the minimum number provided for pursuant to Article 38 hereof, they may only act in an emergency or to fill the
        office of a Director which has become vacant up to a number equal to the minimum number provided for pursuant to Article 38 hereof, or in order to call a General Meeting of the Company for the purpose of electing Directors to fill any or all
        vacancies. The office of a Director that was appointed by the Board of Directors to fill any vacancy shall only be for the remaining period of time during which the Director whose service has ended was filled would have held office, or in case of a
        vacancy due to the number of Directors serving being less than the maximum number stated in Article 38 hereof the Board of Directors shall determine at the time of appointment the class pursuant to Article 39 to which the additional Director shall
        be assigned. Notwithstanding anything to the contrary herein, this Article 41 may only be amended, replaced or suspended by a resolution adopted at a General Meeting by a majority of at least 65% of the total voting power of the Company&#8217;s
        shareholders.</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z151df0a27c0845bcbdfc75a6254a36ff">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">42.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Vacation of Office</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">The office of a Director shall be vacated and he shall be dismissed or removed:</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(a) ipso facto, upon his or her death;</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(b) if he or she is prevented by applicable law from serving as a Director;</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(c) if the Board of Directors determines that due to his or her mental or physical state he or she is unable to serve as a director;</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(d) if his or her directorship expires pursuant to these Articles and/or applicable law;</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(e) by a resolution adopted at a General Meeting by a majority of at least 65% of the total voting power of the Company&#8217;s shareholders (with such removal becoming effective on
        the date fixed in such resolution);</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(f) by his or her written resignation, such resignation becoming effective on the date fixed therein, or upon the delivery thereof to the Company, whichever is later; or</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(g) with respect to an External Director, if so elected, and notwithstanding anything to the contrary herein, only pursuant to applicable law.<br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">- 18 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zaefc9ea2fb944f21bd4e76783d6ec99a">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">43.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Conflict of Interests; Approval of Related Party Transactions</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(a) Subject to the provisions of applicable law and these Articles, no Director shall be disqualified by virtue of his or her office from holding any office or place of profit
        in the Company or in any company in which the Company shall be a shareholder or otherwise interested, or from contracting with the Company as vendor, purchaser or otherwise, nor shall any such contract, or any contract or arrangement entered into
        by or on behalf of the Company in which any Director shall be in any way interested, be avoided, nor, other than as required under the Companies Law, shall any Director be liable to account to the Company for any profit arising from any such office
        or place of profit or realized by any such contract or arrangement by reason only of such Director&#8217;s holding that office or of the fiduciary relations thereby established, but the nature of his or her interest, as well as any material fact or
        document, must be disclosed by him or her at the meeting of the Board of Directors at which the contract or arrangement is first considered, if his or her interest then exists, or, in any other case, at no later than the first meeting of the Board
        of Directors after the acquisition of his or her interest.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(b) Subject to the Companies Law and these Articles, a transaction between the Company and an Office Holder, and a transaction between the Company and another entity in which
        an Office Holder of the Company has a personal interest, in each case, which is not an Extraordinary Transaction (as defined by the Companies Law), shall require only approval by the Board of Directors or a Committee of the Board of Directors. Such
        authorization, as well as the actual approval, may be for a particular transaction or more generally for specific type of transactions.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Proceedings of the Board of Directors</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zfaf2a0c4253e453ca6e3e4586ce5407d">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">44.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-variant: small-caps;"><u><font style="font-weight: bold;">Meetings</font></u>.</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(a) The Board of Directors may meet and adjourn its meetings and otherwise regulate such meetings and proceedings as the Board of Directors thinks fit.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(b) A meeting of the Board of Directors shall be convened by the Secretary upon instruction of the Chairperson or upon a request of at least two Directors which is submitted
        to the Chairperson or in any event that such meeting is required by the provisions of the Companies Law. In the event that the Chairperson does not instruct the Secretary to convene a meeting upon a request of at least two Directors within seven
        (7) days of such request, then such two Directors may convene a meeting of the Board of Directors. Any meeting of the Board of Directors shall be convened upon not less than two (2) days' notice, unless such notice is waived in writing by all of
        the Directors as to a particular meeting or by their attendance at such meeting or unless the matters to be discussed at such meeting are of such urgency and importance that notice is reasonably determined by the Chairperson as ought to be waived
        or shortened under the circumstances.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(c) Notice of any such meeting shall be given orally, by telephone, in writing or by mail, facsimile, email or such other means of delivery of notices as the Company may
        apply, from time to time.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(d) Notwithstanding anything to the contrary herein, failure to deliver notice to a Director of any such meeting in the manner required hereby may be waived by such Director,
        and a meeting shall be deemed to have been duly convened notwithstanding such defective notice if such failure or defect is waived prior to action being taken at such meeting, by all Directors entitled to participate at such meeting to whom notice
        was not duly given as aforesaid. Without derogating from the foregoing, no Director present at any time during a meeting of the Board of Directors shall be entitled to seek the cancellation or invalidation of any proceedings or resolutions adopted
        at such meeting on account of any defect in the notice of such meeting relating to the date, time or the place thereof or the convening of the meeting.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">- 19 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z2d5e1d82faa74119935b9a677552b146">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">45.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-variant: small-caps;"><u><font style="font-weight: bold;">Quorum</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"><br>
        Until otherwise unanimously decided by the Board of Directors, a quorum at a meeting of the Board of Directors shall be constituted by the presence in person or by any means of communication of a majority of the Directors then in office who are
        lawfully entitled to participate and vote in the meeting. No business shall be transacted at a meeting of the Board of Directors unless the requisite quorum is present (in person or by any means of communication on the condition that all
        participating Directors can hear each other simultaneously) when the meeting proceeds to business. If within 30 minutes from the time appointed for a meeting of the Board of Directors a quorum is not present, the meeting shall stand adjourned at
        the same place and time 48 hours thereafter unless the Chairperson has determined that there is such urgency and importance that a shorter period is required under the circumstances. If an adjourned meeting is convened in accordance with the
        foregoing and a quorum is not present within 30 minutes of the announced time, the requisite quorum at such adjourned meeting shall be, any two (2) Directors, if the number of then serving directors is up to five, and any three (3) Directors, if
        the number of then serving directors is more than five, in each case who are lawfully entitled to participate in the meeting and who are present at such adjourned meeting. At an adjourned meeting of the Board of Directors the only matters to be
        considered shall be those matters which might have been lawfully considered at the meeting of the Board of Directors originally called if a requisite quorum had been present, and the only resolutions to be adopted are such types of resolutions
        which could have been adopted at the meeting of the Board of Directors originally called.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z823aa35d21324131a7eeeb547c283968">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">46.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Chairperson of the Board of Directors</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">The Board of Directors shall, from time to time, elect one of its members to be the Chairperson of the Board of Directors, remove such Chairperson from office and appoint in
        his or her place. The Chairperson of the Board of Directors shall preside at every meeting of the Board of Directors, but if there is no such Chairperson, or if at any meeting he is not present within fifteen (15) minutes of the time fixed for the
        meeting or if he is unwilling to take the chair, the Directors present shall choose one of the Directors present at the meeting to be the Chairperson of such meeting. The office of Chairperson of the Board of Directors shall not, by itself, entitle
        the holder to a second or casting vote.</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z621f1d2e6b90445092d36daab3cca4d2">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">47.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Validity of Acts Despite Defects</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">All acts done or transacted at any meeting of the Board of Directors, or of a Committee of the Board of Directors, or by any person(s) acting as Director(s), shall,
        notwithstanding that it may afterwards be discovered that there was some defect in the appointment of the participants in such meeting or any of them or any person(s) acting as aforesaid, or that they or any of them were disqualified, be as valid
        as if there were no such defect or disqualification.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">- 20 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Chief Executive Officer<br>
        <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z193699cd09da4c63bc654fb3ed63cac6">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">48.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Chief Executive Officer</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">The Board of Directors shall from time to time appoint one or more persons, whether or not Directors, as Chief Executive Officer of the Company who shall have the powers and
        authorities set forth in the Companies Law, and may confer upon such person(s), and from time to time modify or revoke, such titles and such duties and authorities of the Board of Directors as the Board of Directors may deem fit, subject to such
        limitations and restrictions as the Board of Directors may from time to time prescribe. Such appointment(s) may be either for a fixed term or without any limitation of time, and the Board of Directors may from time to time (subject to any
        additional approvals required under, and the provisions of, the Companies Law and of any contract between any such person and the Company) fix their salaries and compensation, remove or dismiss them from office and appoint another or others in his,
        her or their place or places.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Minutes</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z4c9d555f5514491597136ea0acd57158">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25; font-variant: small-caps;">49.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-variant: small-caps;"><u><font style="font-weight: bold;">Minutes</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">Minutes of each General Meeting and of each meeting of the Board of Directors and any Committees thereof shall be recorded and duly entered in books provided for that purpose.
        Such minutes shall, in all events, set forth the names of the persons present at the meeting and all resolutions adopted thereat. Any minutes of the General Meeting or the Board of Directors or any Committee thereof, if purporting to be signed by
        the Chairperson of the General Meeting, the Board of Directors or a Committee thereof, as the case may be, or by the Chairperson of the next succeeding General Meeting, meeting of the Board of Directors or meeting of a Committee, as the case may
        be, shall constitute prima facie evidence of the matters recorded therein.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Dividends</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z8263153af6ff435ea1d468309e1611f2">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">50.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Declaration of Dividends</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">The Board of Directors may from time to time declare, and cause the Company to pay dividends as permitted by the Companies Law. The Board of Directors shall determine the time
        for payment of such dividends and the record date for determining the shareholders entitled thereto.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="za39f07b4c9284ee795a3e361454fd44a">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">51.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Amount Payable by Way of Dividends</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">Subject to the provisions of these Articles and subject to the rights or conditions attached at that time to any share in the capital of the Company granting preferential,
        special or deferred rights or not granting any rights with respect to dividends, any dividend paid by the Company shall be allocated among the Shareholders (not in default in payment of any sum referred to in Article 13 hereof) entitled thereto on
        a <font style="font-style: italic;">pari passu</font> basis in proportion to their respective holdings of the issued and outstanding Shares in respect of which such dividends are being paid.</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z7903b727aad841edb3ee7aa5e8468f79">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">52.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Interest</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">No dividend shall carry interest as against the Company.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z2b15a3a7fbcd4e62b57cae95511f83db">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">53.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Payment in Specie</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-right: 0.05pt; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-right: 0.05pt; margin-left: 35.45pt; line-height: 1.25;">If so declared by the Board of Directors, a dividend declared in accordance with Article 50 may be paid, in whole or in part, by the distribution of
        specific assets of the Company or by distribution of paid up shares, debentures or other securities of the Company or of any other companies, or in any combination thereof, in each case, the fair value of which shall be determined by the Board of
        Directors in good faith.</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">- 21 -</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z806c62fddfdb4e62b7aca878a98d8cf0">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">54.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Implementation of Powers</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">The Board of Directors may settle, as it deems fit, any difficulty arising with regard to the distribution of dividends, bonus shares or otherwise, and in particular, to issue
        certificates for fractions of shares and sell such fractions of shares in order to pay their consideration to those entitled thereto, or to set the value for the distribution of certain assets and to determine that cash payments shall be paid to
        the Shareholders on the basis of such value, or that fractions whose value is less than NIS 0.01 shall not be taken into account. The Board of Directors may instruct to pay cash or convey these certain assets to a trustee in favor of those people
        who are entitled to a dividend, as the Board of Directors shall deem appropriate.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z4445f887c2634543a88dddd264d6c27e">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">55.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Deductions from Dividends</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;">The Board of Directors may deduct from any dividend or other moneys payable to any Shareholder in respect of a share any and all sums of money then payable by him or her to the
        Company on account of calls or otherwise in respect of shares of the Company and/or on account of any other matter of transaction whatsoever.</div>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z3dd9ece4c1594c548bab85d10f9ecd80">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25; font-variant: small-caps;">56.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-variant: small-caps;"><u><font style="font-weight: bold;">Retention of Dividends</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(a) The Board of Directors may retain any dividend or other moneys payable or property distributable in respect of a share on which the Company has a lien, and may apply the
        same in or toward satisfaction of the debts, liabilities, or engagements in respect of which the lien exists.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(b) The Board of Directors may retain any dividend or other moneys payable or property distributable in respect of a share in respect of which any person is, under Articles 21
        or 22, entitled to become a Shareholder, or which any person is, under said Articles, entitled to transfer, until such person shall become a Shareholder in respect of such share or shall transfer the same.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z59421a1a3c644dedb82e12c837897119">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">57.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Unclaimed Dividends</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">All unclaimed dividends or other moneys payable in respect of a share may be invested or otherwise made use of by the Board of Directors for the benefit of the Company until
        claimed. The payment of any unclaimed dividend or such other moneys into a separate account shall not constitute the Company a trustee in respect thereof, and any dividend unclaimed after a period of one (1) year (or such other period determined by
        the Board of Directors) from the date of declaration of such dividend, and any such other moneys unclaimed after a like period from the date the same were payable, shall be forfeited and shall revert to the Company, provided, however, that the
        Board of Directors may, at its discretion, cause the Company to pay any such dividend or such other moneys, or any part thereof, to a person who would have been entitled thereto had the same not reverted to the Company. The principal (and only the
        principal) of any unclaimed dividend of such other moneys shall be if claimed, paid to a person entitled thereto.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z32dabfc2f03e44e28bd2cd5557a9f597">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">58.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Mechanics of Payment</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">Any dividend or other moneys payable in cash in respect of a share, less the tax required to be withheld pursuant to applicable law, may, as determined by the Board of
        Directors in its sole discretion, be paid by check sent through the post to, or left at, the registered address of the person entitled thereto or by transfer to a bank account specified by such person (or, if two or more persons are registered as
        joint holders of such share or are entitled jointly thereto in consequence of the death or bankruptcy of the holder or otherwise, to any one of such Persons or his or her bank account or the person who the Company may then recognize as the owner
        thereof or entitled thereto under Article 21 or 22 hereof, as applicable, or such person&#8217;s bank account), or to such person and at such other address as the person entitled thereto may by writing direct, or in any other manner the Board of
        Directors deems appropriate. Every such check or other method of payment shall be made payable to the order of the person to whom it is sent, or to such person as the person entitled thereto as aforesaid may direct, and payment of the check by the
        banker upon whom it is drawn shall be a good discharge to the Company. Every such check shall be sent at the risk of the Person entitled to the money represented thereby.</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">- 22 -</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Accounts</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="ze9f25320c25946a59598f4008c577023">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">59.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Books of Account</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">The Company's books of account shall be kept at the Office of the Company, or at such other place or places as the Board of Directors may think fit, and they shall always be
        open to inspection by all Directors. No shareholder, not being a Director, shall have any right to inspect any account or book or other similar document of the Company, except as explicitly conferred by law or authorized by the Board of Directors.
        The Company shall make copies of its annual financial statements available for inspection by the shareholders at the principal offices of the Company. The Company shall not be required to send copies of its annual financial statements to the
        Shareholders.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z2141a85b3caf4e39aac938e5a483becb">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">60.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-variant: small-caps;"><u><font style="font-weight: bold;">Auditors</font></u>.</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"><br>
        The appointment, authorities, rights and duties of the auditor(s) of the Company, shall be regulated by applicable law, provided, however, that in exercising its authority to fix the remuneration of the auditor(s), the Shareholders in General
        Meeting may act (and in the absence of any action in connection therewith shall be deemed to have so acted) to authorize the Board of Directors (with right of delegation to a Committee thereof or to management) to fix such remuneration subject to
        such criteria or standards, and if no such criteria or standards are so provided, such remuneration shall be fixed in an amount commensurate with the volume and nature of the services rendered by such auditor(s). The General Meeting may, if so
        recommended by the Board of Directors, appoint the auditors for a period that may extend until the third Annual General Meeting after the Annual General Meeting in which the auditors were appointed.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z51dd2a6c08e5424abf63d7c6ee785c34">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">61.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-variant: small-caps;"><u><font style="font-weight: bold;">Fiscal Year</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">The fiscal year of the Company shall be the 12 months period ending on December 31 of each calendar year.</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Supplementary Registers</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z7f028d4bd0724770b9b65fe68e50b4ce">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">62.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Supplementary Registers</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">Subject to and in accordance with the provisions of Sections 138 and 139 of the Companies Law, the Company may cause supplementary registers to be kept in any place outside
        Israel as the Board of Directors may think fit, and, subject to all applicable requirements of law, the Board of Directors may from time to time adopt such rules and procedures as it may think fit in connection with the keeping of such branch
        registers.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">- 23 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Exemption, Indemnity and Insurance</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zc92dd9eacb7549b5b90fc08a3609c178">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25; font-variant: small-caps;">63.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-variant: small-caps;"><u><font style="font-weight: bold;">Insurance</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">Subject to the provisions of the Companies Law with regard to such matters and to the fullest extent permitted by the Companies Law, the Company may enter into a contract for
        the insurance of the liability, in whole or in part, of any of its Office Holders imposed on such Office Holder or expenses incurred or to be incurred due to an act performed by or an omission of the Office Holder in the Office Holder&#8217;s capacity as
        an Office Holder of the Company arising from any matter permitted by law, including the following:</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(a) a breach of duty of care to the Company or to any other person;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(b) a breach of his or her duty of loyalty to the Company, provided that the Office Holder acted in good faith and had reasonable grounds to assume that act that resulted in
        such breach would not prejudice the interests of the Company;</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(c) a financial liability imposed on such Office Holder in favor of any other person; and</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(d) any other event, occurrence, matters or circumstances under any law with respect to which the Company may, or will be able to, insure an Office Holder, and to the extent
        such law requires the inclusion of a provision permitting such insurance in these Articles, then such provision is deemed to be included and incorporated herein by reference (including, without limitation, in accordance with Section 56h(b)(1) of
        the Securities Law, if and to the extent applicable, and Section 50P of the Economic Competition Law).</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zb2aa12dbf9b242518c2dee2e722ea84c">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">64.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-variant: small-caps;"><u><font style="font-weight: bold;">Indemnity</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(a) Subject to the provisions of the Companies Law, the Company may retroactively or pursuant to an advance undertaking, indemnify an Office Holder of the Company to the
        maximum extent permitted under applicable law, including with respect to the following liabilities and expenses, provided that such liabilities or expenses were imposed on such Office Holder or incurred by such Office Holder due to an act performed
        by or an omission of the Office Holder in such Office Holder&#8217;s capacity as an Office Holder of the Company:</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">(i) a financial liability imposed on an Office Holder in favor of another person by any court judgment, including a judgment given as a result of a settlement or an arbitrator&#8217;s
        award which has been confirmed by a court;</div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">(ii) reasonable litigation expenses, including legal fees, expended by the Office Holder as a result of an investigation or proceeding instituted against him or her by an
        authority authorized to conduct such investigation or proceeding, or in connection with a financial sanction, provided that (1) no indictment (as defined in the Companies Law) was filed against such Office Holder as a result of such investigation
        or proceeding; and (2) no financial liability in lieu of a criminal proceeding (as defined in the Companies Law) was imposed upon him or her as a result of such investigation or proceeding or if such financial liability was imposed, it was imposed
        with respect to an offense that does not require proof of criminal intent;</div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">(iii) reasonable litigation costs, including legal fees, expended by an Office Holder or which were imposed on an Office Holder by a court in proceedings filed against the Office
        Holder by the Company or in its name or by any other person or in a criminal charge in respect of which the Office Holder was acquitted or in a criminal charge in respect of which the Office Holder was convicted for an offence which did not require
        proof of criminal intent; and</div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">(iv) any other event, occurrence, matter or circumstance under any law with respect to which the Company may, or will be able to, indemnify an Office Holder, and to the extent
        such law requires the inclusion of a provision permitting such indemnity in these Articles, then such provision is deemed to be included and incorporated herein by reference (including, without limitation, in accordance with Section 56h(b)(1) of
        the Israeli Securities Law, if and to the extent applicable, and Section 50P(b)(2) of the RTP Law).</div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(b) Subject to the provisions of the Companies Law, the Company may undertake to indemnify an Office Holder, in advance, with respect to those liabilities and expenses
        described in the following Articles:</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">(i) Sub-Article 64(a)(ii) to 64(a)(iv); and</div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">(ii) Sub-Article 64(a)(i), provided that:</div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 106.35pt; line-height: 1.25;">(1) the undertaking to indemnify is limited to such events which the Directors shall deem to be foreseeable in light of the operations of the Company at the time that the
        undertaking to indemnify is made and for such amounts or criterion which the Directors may, at the time of the giving of such undertaking to indemnify, deem to be reasonable under the circumstances; an</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 106.35pt; line-height: 1.25;">(2) the undertaking to indemnify shall set forth such events which the Directors shall deem to be foreseeable in light of the operations of the Company at the time that the
        undertaking to indemnify is made, and the amounts and/or criterion which the Directors may, at the time of the giving of such undertaking to indemnify, deem to be reasonable under the circumstances.</div>
      <div style="text-align: justify; margin-left: 106.35pt; line-height: 1.25;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">- 24 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; margin-left: 106.35pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z678009542c274596965a8aefdfa47fc5">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">65.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-variant: small-caps;"><u><font style="font-weight: bold;">Exemption</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">Subject to the provisions of the Companies Law, the Company may, to the maximum extent permitted by law, exempt and release, in advance, any Office Holder from any liability
        for damages arising out of a breach of a duty of care.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z56ee76f3128646e3a52caaf2924c4252">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">66.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">General</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(a) Any amendment to the Companies Law or any other applicable law adversely affecting the right of any Office Holder to be indemnified, insured or exempt pursuant to Articles
        63 to 65 and any amendments to Articles 63 to 65 shall be prospective in effect, and shall not affect the Company&#8217;s obligation or ability to indemnify, insure or exempt an Office Holder for any act or omission occurring prior to such amendment,
        unless otherwise provided by applicable law.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">(b) The provisions of Articles 63 to 65 (i) shall apply to the maximum extent permitted by law (including, the Companies Law, the Securities Law and the Economic Competition
        Law); and (ii) are not intended, and shall not be interpreted so as to restrict the Company, in any manner, in respect of the procurement of insurance and/or in respect of indemnification (whether in advance or retroactively) and/or exemption, in
        favor of any person who is not an Office Holder, including, without limitation, any employee, agent, consultant or contractor of the Company who is not an Office Holder; and/or any Office Holder to the extent that such insurance and/or
        indemnification is not specifically prohibited under law.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Winding Up</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z8f9f789b8e084548bf24bc29b4198764">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">67.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Winding Up</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">If the Company is wound up, then, subject to applicable law and to the rights of the holders of shares with special rights upon winding up, the assets of the Company available
        for distribution among the Shareholders shall be distributed to them in proportion to the number of issued and outstanding shares held by each Shareholder.</div>
      <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">- 25 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Notices</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z45ed07e0718744d8bab79cb49d124389">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">68.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Notices</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;">(a) Any written notice or other document may be served by the Company upon any Shareholder either personally, by facsimile, email or other electronic transmission, or by
        sending it by prepaid mail (airmail if sent internationally) addressed to such Shareholder at his or her address as described in the Register of Shareholders or such other address as the Shareholder may have designated in writing for the receipt of
        notices and other documents.</div>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;"><br>
        (b) Any written notice or other document may be served by any Shareholder upon the Company by tendering the same in person to the Secretary or the Chief Executive Officer of the Company at the principal office of the Company, by facsimile
        transmission, or by sending it by prepaid registered mail (airmail if posted outside Israel) to the Company at its Office.</div>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;">(c) Any such notice or other document shall be deemed to have been served:</div>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">(i) in the case of mailing, forty-eight (48) hours after it has been posted, or when actually received by the addressee if sooner than forty-eight hours after it has been posted,
        or</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">(ii) in the case of overnight air courier, on the next business day following the day sent, with receipt confirmed by the courier, or when actually received by the addressee if
        sooner than three business days after it has been sent;</div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">(iii) in the case of personal delivery, when actually tendered in person, to such addressee;</div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">(iv) in the case of facsimile, email or other electronic transmission, on the first business day (during normal business hours in place of addressee) on which the sender receives
        automatic electronic confirmation by the addressee&#8217;s facsimile machine that such notice was received by the addressee or delivery confirmation from the addressee&#8217;s email or other communication server.</div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;">(d) If a notice is, in fact, received by the addressee, it shall be deemed to have been duly served, when received, notwithstanding that it was defectively addressed or failed,
        in some other respect, to comply with the provisions of this Article 68.</div>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;">(e) All notices to be given to the Shareholders shall, with respect to any share to which persons are jointly entitled, be given to whichever of such persons is named first in
        the Register of Shareholders, and any notice so given shall be sufficient notice to the holders of such share.</div>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;">(f) Any Shareholder whose address is not described in the Register of Shareholders, and who shall not have designated in writing an address for the receipt of notices, shall
        not be entitled to receive any notice from the Company.</div>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;">(g) Notwithstanding anything to the contrary contained herein, notice by the Company of a General Meeting, containing the information required by applicable law and these
        Articles to be set forth therein, which is published, within the time otherwise required for giving notice of such meeting, in either or several of the following manners (as applicable) shall be deemed to be notice of such meeting duly given, for
        the purposes of these Articles, to any Shareholder whose address as registered in the Register of Shareholders (or as designated in writing for the receipt of notices and other documents) is located either inside or outside the State of Israel:</div>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">(i) if the Company&#8217;s shares are then listed for trading on a national securities exchange in the United States or quoted in an over-the-counter market in the United States,
        publication of notice of a General Meeting pursuant to a report or schedule filed with, or furnished to, the SEC pursuant to the Securities Exchange Act of 1934, as amended; and/or</div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">(ii) on the Company&#8217;s internet site.<br>
        <br>
      </div>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;">(h) The mailing or publication date and the record date and/or date of the meeting (as applicable) shall be counted among the days comprising any notice period under the
        Companies Law and the regulations thereunder.</div>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">- 26 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Amendment</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zd5a817f24404413d83cbb4535a62b1fb">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">69.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Amendment</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;">Any amendment of these Articles shall require, in addition to the approval of the General Meeting of shareholders in accordance with these Articles, also the approval of the
        Board of Directors with the affirmative vote of a majority of the then serving Directors.</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Forum for Adjudication of Disputes</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="za47478247265436f83e31e087e09328f">

          <tr>
            <td style="width: 0px; vertical-align: top;">&#160;</td>
            <td style="width: 32pt; vertical-align: top;">
              <div style="line-height: 1.25;">70.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold; font-variant: small-caps;">Forum for Adjudication of Disputes</font>.</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 35.4pt; line-height: 1.25;">(a) Unless the Company consents in writing to the selection of an alternative forum, with respect to any causes of action arising under the U.S. Securities Act of 1933, as
        amended, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the U.S. Securities Act of 1933, as amended; and (b) unless the Company
        consents in writing to the selection of an alternative forum, the competent courts in Tel Aviv, Israel shall be the exclusive forum for (i) any derivative action or proceeding brought on behalf of the Company, (ii) any action asserting a claim of
        breach of a fiduciary duty owed by any director, officer or other employee of the Company to the Company or the Company&#8217;s shareholders, or (iii) any action asserting a claim arising pursuant to any provision of the Companies Law or the Securities
        Law. Any person or entity purchasing or otherwise acquiring or holding any interest in shares of the Company shall be deemed to have notice of and consented to these provisions.</div>
      <div><br>
      </div>
      <div style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">- 27 -</font></div>
      <div>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <br>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-11.1
<SEQUENCE>3
<FILENAME>exhibit_11-1.htm
<DESCRIPTION>EXHIBIT 11.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">


  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right;"><u><font style="font-weight: bold;">Exhibit 11.1</font></u><br>
    </div>
    <div>
      <div class="BRPFPageHeader">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: center; margin-right: 1.5pt; line-height: 1.25; font-weight: bold;">Chemomab Therapeutics Ltd.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; margin-right: 34.6pt; margin-left: 33.15pt; line-height: 1.25; font-weight: bold;">Insider Trading and Blackout Policy</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">
        <div style="line-height: 1.25; font-weight: bold;">Adopted by the Board of Directors on November 14, 2019, as amended on April 3, 2025 <br>
        </div>
      </div>
      <div class="BRPFPageHeader">
        <div style="line-height: 1.25;">
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <!--PROfilePageNumberReset%Num%2%%%-->
          <div style="text-align: justify; margin-left: 10.1pt; line-height: 1.25; font-weight: bold;">POLICY STATEMENT</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 34.9pt; margin-right: 21.45pt; margin-left: 10.1pt; line-height: 1.25;">This document sets forth the policies of Chemomab Therapeutics
            Ltd. (the &#8220;<font style="font-weight: bold; font-style: italic;">Company</font>&#8221;) prohibiting &#8220;insider trading&#8221; and the procedures to be followed by directors, officers and employees
            of the Company before engaging in any trading involving securities of the Company (the &#8220;<font style="font-weight: bold; font-style: italic;">Policy</font>&#8221;).</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 34.9pt; margin-right: 21.45pt; margin-left: 10.1pt; line-height: 1.25;">Insider trading is prohibited by U.S. federal law and Company
            policy. Any director, officer or employee of the Company, while having knowledge of material non-public information about the Company, is prohibited from:</div>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z939f8e930eeb49c18f3768702395763d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 62.5pt;"><br>
                </td>
                <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">A.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>trading in securities of the Company or of any other company, while in possession of material non-public information about such other company obtained in
                    connection with employment by or service to the Company;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="z962b9ea558c64ec6b6224b94486c6d3a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 62.5pt;"><br>
                </td>
                <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">B.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>disclosing this information to anyone else (other than to another director, officer or employee of the Company who has a need to know in order to perform his or
                    her duties on behalf of the Company); or</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="za73ad8e86d0c45f0916ce4ac3d4a941a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 62.5pt;"><br>
                </td>
                <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">C.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>recommending to anyone else that they trade in any of the Company&#8217;s securities (i.e., &#8220;tipping&#8221;).</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 34.9pt; margin-right: 14.45pt; margin-left: 10.1pt; line-height: 1.25;">For purposes of this Policy, any references to a director,
            officer or employee of the Company includes a reference to such person&#8217;s immediate family members, any other persons who reside with him or her, and any entities with which he or she is affiliated. The prohibitions and restrictions in this
            Policy apply equally to such family members, persons who reside with the director, officer or employee, and affiliated entities.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="z343e6ea68eb54c119038981b314e4783" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 20.05pt;"><br>
                </td>
                <td style="width: 25.05pt; vertical-align: top; font-weight: bold;">I.</td>
                <td style="width: auto; vertical-align: bottom;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Penalties</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 34.9pt; margin-left: 10.1pt; line-height: 1.25;">The criminal and civil penalties for illegal insider trading by any individual are
            extremely serious. These include:</div>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z0a0d19a0ede1401e9f68cb079e0e883c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 62.5pt;"><br>
                </td>
                <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">A.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>a prison sentence of up to 20 years and a fine of up to $5 million;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zf8937541761b40479c37b5882cbce7ff" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 62.5pt;"><br>
                </td>
                <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">B.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>a civil penalty of up to three times the profits made (or losses avoided) by the trading; and</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="za316c492d64e4028bc0aaeb6b5a3ec22" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 62.5pt;"><br>
                </td>
                <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">C.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>disgorgement (payment to the government) of the profits made (or losses avoided) including profits (or losses avoided) by a &#8220;tippee.&#8221;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 34.9pt; margin-right: 14.45pt; margin-left: 10.1pt; line-height: 1.25;">These penalties are cumulative (i.e., can be imposed together)
            and a &#8220;tipper&#8221; can be liable for the same penalties as a person that made the trade, even if the tippee made no profit.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; margin-left: 45.1pt; line-height: 1.25;">Company employees are also subject to removal and/or termination for violating this</div>
          <div style="text-align: justify; margin-left: 10.1pt; line-height: 1.25;">Policy.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">2</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <table cellspacing="0" cellpadding="0" id="z4e6ffa8248cb4cfb8c5394a4141447b6" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 15.5pt;"><br>
                </td>
                <td style="width: 29.6pt; vertical-align: top; font-weight: bold;">II.</td>
                <td style="width: auto; vertical-align: bottom;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Definitions</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z49444d91187b41ccb333faee136785dc" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 62.5pt;"><br>
                </td>
                <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">A.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>Material Non-Public Information</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 34.9pt; margin-right: 17.5pt; margin-left: 10.1pt; line-height: 1.25;">Information is material if there is a reasonable likelihood that
            the information, if disclosed, would affect the market price of the security upward or downward or that an investor would want to know or would consider the information important in making a decision to buy or sell the security.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; margin-left: 45.1pt; line-height: 1.25;">Examples of material information may include, but are not limited to:</div>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z69d47abcabae40558ba4595f23086c9c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 48.5pt;"><br>
                </td>
                <td style="width: 31.55pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>quarterly earnings or revenue information;</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" id="z7c56ad3052cd4507b07fed0bd3741096" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 48.5pt;"><br>
                </td>
                <td style="width: 31.55pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>results of the Company&#8217;s clinical trials and pipeline status;</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" id="zffcf65b22d43416fa580c44f18337207" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 48.6pt;"><br>
                </td>
                <td style="width: 31.45pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>new collaboration or licensing arrangements or other significant business development activities;</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" id="z08d1d638e9ff415f8ac02ae20e2ec407" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 48.5pt;"><br>
                </td>
                <td style="width: 31.55pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>significant write-downs in assets or increases in reserves;</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" id="zddc887d5d8e744b390344c43d469a538" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 48.6pt;"><br>
                </td>
                <td style="width: 31.45pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>modifications to the cost structure of the Company or a significant product candidate;</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" id="za1f7a9c0996f4470ac69046a60e671a0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 48.45pt;"><br>
                </td>
                <td style="width: 31.6pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>changes in leverage or liquidity or non-compliance with financing agreements;</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" id="z036180a1e46143d2a10f2eb76c8effbf" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 48.6pt;"><br>
                </td>
                <td style="width: 31.45pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>proposals, plans and arrangements (even if preliminary in nature) concerning a merger, acquisition or divestiture;</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" id="z764ae249dd0949c38ad514af5408c8bf" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 48.6pt;"><br>
                </td>
                <td style="width: 31.45pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>proposals, plans and arrangements (even if preliminary in nature) concerning any financing, refinancing or securities offering;</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" id="z6e29321f5e044d3eaf5853ac1d4bba38" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 48.5pt;"><br>
                </td>
                <td style="width: 31.55pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>an important development in the Company&#8217;s businesses or prospects,</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" id="z2347aa37e5fd448184171dcaac5649c1" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 48.5pt;"><br>
                </td>
                <td style="width: 31.55pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>changes in key management; or</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" id="z852683d6a0e04ea5bd23b6878f68afff" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 48.6pt;"><br>
                </td>
                <td style="width: 31.45pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>developments regarding significant litigation or governmental or regulatory investigations (including decisions or settlements in those matters).</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 34.9pt; margin-right: 45.9pt; margin-left: 10.1pt; line-height: 1.25;">Information is non-public if it has not been made widely available
            to the investing public. Information must be reported in a widely distributed press release, in Securities and Exchange Commission (&#8220;<font style="font-weight: bold; font-style: italic;">SEC</font>&#8221;) filings, or in other reports made available to all shareholders in a Regulation FD-compliant method before it is considered public information. In the case of the Company&#8217;s earnings releases or any other important
            announcements of previously non-public information, trading is not permitted until the time the market opens one (1) day following the date the press release or other public disclosure is issued. For purposes of this Policy, the &#8220;market&#8221; is the
            Nasdaq Capital Market (&#8220;<font style="font-weight: bold; font-style: italic;">Nasdaq</font>&#8221;).</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 34.9pt; margin-right: 38.65pt; margin-left: 10.1pt; line-height: 1.25;">When in doubt about whether information about the Company is
            material and non- public, any director, officer or employee of the Company should consult with the Chief Financial Officer or his or her designee before making any decision to disclose such information (other than to directors, officers or
            employees of the Company who need to know it) or to trade in or recommend securities to which the information relates.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">3</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <table cellspacing="0" cellpadding="0" id="z2854116d31bc432ba28cd0ce63364a61" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 62.5pt;"><br>
                </td>
                <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">B.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>Trading</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 34.9pt; margin-right: 17.6pt; margin-left: 10.1pt; line-height: 1.25;">The term &#8220;trading&#8221; applies to purchases, sales, gifts, pledges or
            any other transfer or commitment to transfer any stock or other securities of the Company, including the Company&#8217;s ordinary shares and American Depositary Receipts. Trading includes, without limitation, the exercise of stock options pursuant to
            a broker-assisted cashless exercise, selling stock acquired from an option exercise or selling or buying the Company&#8217;s securities in street name or within an IRA or other retirement account.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 34.9pt; margin-right: 17.2pt; margin-left: 10.1pt; line-height: 1.25;">The mere exercise of a stock option for cash (i.e., purchasing and
            holding the stock) is not considered a trading transaction. This Policy also will not apply to the delivery of shares owned by the option holder to the Company or the withholding of shares otherwise issuable upon exercise of a stock option by
            the Company, in each case to satisfy the exercise price payable, or the tax withholding requirements arising, upon the exercise of an option. However, as previously noted, sale of stock in connection with a stock option exercise, for example, a
            broker-assisted cashless exercise of an option or any other sale for the purpose of generating the cash needed to pay the exercise price or tax withholding of an option, or the sale of shares received upon exercise of an option, will be subject
            to this Policy and is considered trading.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 34.9pt; margin-right: 21.45pt; margin-left: 10.1pt; line-height: 1.25;">&#160;Gifts are subject to this Policy (except where such gift is for
            family or estate planning purposes, where securities are gifted to a person or entity subject to this Policy);</div>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z4f42770e534a4f36a237307fc9eacaf7" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 20.05pt;"><br>
                </td>
                <td style="width: 25.05pt; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-weight: bold;">III.</td>
                <td style="width: auto; vertical-align: bottom;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Other Restrictions</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 34.9pt; margin-right: 38.65pt; margin-left: 10.1pt; line-height: 1.25;">In addition to trading while in possession of material non-public
            information, this Policy prohibits all of the following activities:</div>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z6849027c744b496f9845eb62e7ee42fb" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 48.6pt;"><br>
                </td>
                <td style="width: 31.45pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>engaging in &#8220;short sales&#8221; and &#8220;selling against the box&#8221; (a variation of selling short) with respect to securities of the Company;</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" id="z2015deecded64486a3b322ecb883323e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 48.45pt;"><br>
                </td>
                <td style="width: 31.6pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>buying or selling puts, calls or other derivative securities on the Company&#8217;s securities;</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" id="z839aa90206ab4a63b0584f5bc91d0eeb" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 48.5pt;"><br>
                </td>
                <td style="width: 31.55pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>transferring securities including as gifts;</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" id="z32dedb21ccdf45e28acc559d4af0d5a1" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 48.5pt;"><br>
                </td>
                <td style="width: 31.55pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>trading in securities of the Company on a short-term basis;</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" id="zbe757cc92f544f3997154dadb41fcc6b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 48.5pt;"><br>
                </td>
                <td style="width: 31.55pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>holding Company securities in a margin account and/or pledging securities; and</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" id="z740c79b235624a9d9cc46924ed0b5ff8" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 48.6pt;"><br>
                </td>
                <td style="width: 31.45pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>entering into hedging or similar transactions with respect to Company securities.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 34.9pt; margin-right: 28.85pt; margin-left: 10.1pt; line-height: 1.25;">Directors, officers and employees of the Company also are
            prohibited from trading in the securities of companies with whom the Company does business or proposes to do business (e.g., suppliers, customers, competitors, and/or potential acquisition targets) if the person has obtained material non-public
            information about that company in the course of his or her services to the Company (and is prohibited from disclosing that information other than to another director, officer or employee of the Company who has a clear need to know in order to
            perform his or her duties on behalf of the Company). For example, trading or giving tips concerning a company that is being considered for acquisition or with which the Company is in acquisition negotiations, or is involved with ongoing
            business relations, is prohibited by this Policy when the director, officer or employee has non-public information about the potential transaction or the company&#8217;s current business.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">4</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <table cellspacing="0" cellpadding="0" id="zf3d0e14ad37248b49c81102624282f27" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 20.05pt;"><br>
                </td>
                <td style="width: 25.05pt; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-weight: bold;">IV.</td>
                <td style="width: auto; vertical-align: bottom;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Black-out Periods and Blackout Persons</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 34.9pt; margin-left: 10.1pt; line-height: 1.25;">&#8220;Blackout Persons&#8221; (as defined below) are required to observe the following guidelines
            whenever contemplating trading in Company securities:</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="zf93a70fa7a9a4b3caac77a27ec4a3e22" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 62.5pt;"><br>
                </td>
                <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">A.</td>
                <td style="width: auto; vertical-align: bottom;">
                  <div style="font-family: 'Times New Roman',Times,serif; text-align: justify;"><font style="font-weight: bold;">Blackout Persons may not
                      purchase, sell, gift or otherwise transfer Company securities during the period from and including the time the market closes on the twentieth (20</font><sup style="font-weight: bold; vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup><font style="font-weight: bold;">) calendar day of the third month of any calendar quarter until the time the market opens following the release of quarterly financial information (each, a &#8220;</font><font style="font-weight: bold; font-style: italic;">blackout period</font><font style="font-weight: bold;">&#8221;).</font></div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zcf2789574e584a008b67995b8f3f12ec" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 62.5pt;"><br>
                </td>
                <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">B.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>Notwithstanding the above, in a period where the trading window would otherwise be closed due to sub-paragraph A above, and absent any other material non-public
                    information, the Company may determine that it is not in possession of material non-public information and may determine that the trading window will remain &#8220;open&#8221; during all or part of the period otherwise &#8220;closed.&#8221;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="zce3a75fd807b49a7ba4905e2483ed161" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 62.5pt;"><br>
                </td>
                <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">C.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>The Chief Financial Officer or his or her designee may, at his/her sole discretion, close the trading window at any time by notification to the Company.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="z0c5cfe043b724b2f93d91eb06bade8c7" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 62.5pt;"><br>
                </td>
                <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">D.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>The Chief Financial Officer, or his or her designee, may define other black-out periods than those automatically created by sub-paragraph A above and, if this is
                    done, so communicate it to the Company and directors.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zb9e1dbb262854aa4a0d515cc3d027f37" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 62.5pt;"><br>
                </td>
                <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">E.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>The following persons are considered &#8220;Blackout Persons&#8221; for purposes of this Policy:</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z78d7c235bbaf491cbef65407525fb194" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 89.05pt;"><br>
                </td>
                <td style="width: 26.25pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>Directors;</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" id="z7083232dd81341f08b37af6e1fc0562c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 89.05pt;"><br>
                </td>
                <td style="width: 26.25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>Officers of the Company who are required to file reports under Section 16 of the Securities Exchange Act of 1934, as amended (the &#8220;<font style="font-weight: bold; font-style: italic;">Exchange Act</font>&#8221;);</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" id="z3d92d8587ab5423d90f2af24f53bfad0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 89.05pt;"><br>
                </td>
                <td style="width: 26.25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>All members of the legal and financial departments with access to financial reports or forecasts prior to their public release;</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" id="z5786cb186cb141eebadb8473f43bae62" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 89.05pt;"><br>
                </td>
                <td style="width: 26.25pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>All accounting personnel;</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" id="z1beef521231545a5a121b16e2005e6e4" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 89.05pt;"><br>
                </td>
                <td style="width: 26.25pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>All investor relations and corporate communications personnel;</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" id="za41ed3fbed4c4b569db3fb6fc072029c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 89.05pt;"><br>
                </td>
                <td style="width: 26.25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>Any other persons designated by either (i) the Board, (ii) the Chief Financial Officer, or (iii) the Corporate Secretary; and</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" id="z00ac921dff9748e6aebe09e9e2d63317" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 89.05pt;"><br>
                </td>
                <td style="width: 26.25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>Any such person&#8217;s immediate family members, other persons who reside with him or her, and entities with which he or she is affiliated.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z3abf70abcb9a44f7944d5edfc5f2debc" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 20.05pt;"><br>
                </td>
                <td style="width: 25.05pt; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-weight: bold;">V.</td>
                <td style="width: auto; vertical-align: bottom;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Pre-Clearance Procedures for Certain Persons</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 34.9pt; margin-right: 21.45pt; margin-left: 10.1pt; line-height: 1.25;">In addition to complying with the prohibition on trading during
            black-out periods, the following individuals (&#8220;<font style="font-weight: bold; font-style: italic;">Pre-Clearance Persons</font>&#8221;) must consult the Chief Financial Officer or
            his/her designee in writing before actually trading at any time in any of the Company&#8217;s securities (even when the window is &#8220;open&#8221;):</div>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="ze382ae30be034fa78c50137a2b29bb7b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 48.5pt;"><br>
                </td>
                <td style="width: 31.55pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>Directors;</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" id="z6ac9f68ec86b4fe48ce9e44b39233074" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 48.5pt;"><br>
                </td>
                <td style="width: 31.55pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>Officers of the Company who are required to file reports under Section 16 of the Exchange Act;</div>
                </td>
              </tr>

          </table>
          <div> <br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">5</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <table cellspacing="0" cellpadding="0" id="zb9bc91014a274ca5bdb16c4360959397" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 48.5pt;"><br>
                </td>
                <td style="width: 31.55pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>Any other person designated by either (i) the Board, (ii) the Chief Financial Officer, or (iii) the Corporate Secretary; and</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" id="z643447eccf9b409ab3290cc67b4d4b7d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 48.5pt;"><br>
                </td>
                <td style="width: 31.55pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>Any such person&#8217;s immediate family members, other persons who reside with him or her and entities with which he or she is affiliated.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 34.9pt; margin-right: 17.65pt; margin-left: 10.1pt; line-height: 1.25;">The Chief Financial Officer or his or her designee will be able
            to provide advice based on the specific fact situation and is/are authorized to approve exceptions to guidelines A and B above under &#8220;Black-out Periods,&#8221; if in his/her judgment it is clear that no law or regulation would be violated by the
            proposed requested trading given the particular facts.</div>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zd936ef69b2414ed88270bf67706f90c8" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 20.05pt;"><br>
                </td>
                <td style="width: 25.05pt; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-weight: bold;">VI.</td>
                <td style="width: auto; vertical-align: bottom;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Pre-Planned Trading for Blackout and Pre-Clearance Persons</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 34.9pt; margin-right: 21.45pt; margin-left: 10.1pt; line-height: 1.25;">The SEC has promulgated Rule 10b5-1 pursuant to the Exchange Act
            which provides an affirmative defense to persons making a purchase or sale who demonstrate that a purchase or sale was completed pursuant to a binding contract, instruction or written trading plan that meets certain requirements and that was
            entered into at a time during which the person is not aware of material non-public information about the Company (a &#8220;<font style="font-weight: bold; font-style: italic;">Rule 10b5-1
              Plan</font>&#8221;). Blackout Persons and Pre-Clearance Persons will not be subject to the black-out periods and, if applicable, pre- clearance procedures set forth above for trades that are executed pursuant to a valid Rule 10b5-1 Plan that was
            adopted outside of a blackout period (and when the person was not otherwise in possession of material non-public information about the Company) and was pre-cleared by the Company&#8217;s Chief Financial Officer.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; margin-left: 45pt; line-height: 1.25;">Such Rule 10b5-1 Plans must:</div>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z7db1fc6a9de547c8affa4a3728236fe2" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 45pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>have been submitted to and pre-approved by the Chief Financial Officer and/or his or her designee;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z8d1d49c796b140468e96863785a02bca" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 45pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>include a &#8220;Cooling Off Period&#8221; for</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zcdda710431bf47978d33defa9f12e022" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 81pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top;">o</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>directors and officers that extends to the later of 90 days after adoption or modification of a Rule 10b5-1 trading plan or two (2) business days after filing the
                    Form 20-F or Form 6-K (or the US domestic filing equivalent thereof, if applicable) with financial results covering the fiscal quarter in which the Rule 10b5-1 trading plan was adopted, up to a maximum of 120 days; and</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z034db3c479ed4baa964f9d6d40b7e1a6" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 81pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top;">o</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>employees and any other persons, other than the Company, that extends 30 days after adoption or modification of such Rule 10b5-1 Plan;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zf4ca5cb315e3494086918d7498c03b90" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 45pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>for directors and officers, include a representation that the director or officer is (1) not aware of any material nonpublic information about the Company or its
                    securities; and (2) adopting the Rule 10b5-1 Plan in good faith and not as part of a plan or scheme to evade SEC Rule 10b-5;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z6e97ecfda8e34c93b46298b2535d4292" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 45pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>have been entered into in good faith at a time when the individual was not in possession of material nonpublic information about the Company and a blackout period
                    was not otherwise in effect, and such individual has acted in good faith with respect to the Rule 10b5-1 Plan;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zd9c6c98205414a5ea4ff980910a63a9b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 45pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>either (1) specify the amounts, prices, and dates of all transactions under the Rule 10b5-1 Plan; or (2) provide a written formula, algorithm, or computer program
                    for determining the amount, price, and date of the transactions, and (3) prohibit the individual from exercising any subsequent influence over the transactions; and</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zee385b83516e460b8827c1162362b4b5" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 45pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>comply with all other applicable requirements of Rule 10b5-1.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">6</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: justify; text-indent: 34.9pt; margin-right: 21.45pt; margin-left: 10.1pt; line-height: 1.25;">The Chief Financial Officer may impose such other conditions on
            the implementation and operation of the Rule 10b5-1 Plan as he or she deems necessary or advisable. Individuals may not adopt more than one Rule 10b5-1 Plan at a time except under the limited circumstances permitted by Rule 10b5-1 and subject
            to pre-approval by the Chief Financial Officer.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 34.9pt; margin-right: 21.45pt; margin-left: 10.1pt; line-height: 1.25;">Although non-discretionary Rule 10b5-1 Plans are preferred,
            discretionary Rule 10b5-1 Plans, where the discretion or control over trading is transferred to a broker, are permitted if pre-approved by the Chief Financial Officer or his or her designee(s).</div>
          <div style="text-align: justify; text-indent: 34.9pt; margin-right: 21.45pt; margin-left: 10.1pt; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 34.9pt; margin-right: 21.45pt; margin-left: 10.1pt; line-height: 1.25;">The actual transactions effected pursuant to a pre-approved Rule
            10b5-1 Plan will not be subject to further pre-clearance for transactions in the Company&#8217;s shares once the Rule 10b5-1 Plan or other arrangement has been pre-approved.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 34.9pt; margin-right: 21.45pt; margin-left: 10.1pt; line-height: 1.25;">You may only adopt more than one Rule 10b5-1 Plan at a time if
            the adoption of an additional Rule 10b5-1 Plan is under the limited circumstances permitted by Rule 10b5-1. You may only amend a Rule 10b5-1 Plan outside of quarterly trading blackout periods when you do not possess material nonpublic
            information. Any amendment of a Rule 10b5-1 Plan must be preapproved by the Chief Financial Officer at least 30 days before you trade under an amended Rule 10b5-1 Plan with directors and senior management subject to a longer &#8220;cooling-off
            period&#8221; as required by Rule 10b5-1 for certain amendments (i.e. those that change the amount, price, or timing of purchases or sales). However, previously scheduled trades under the Rule 10b5-1 Plan before its amendment may continue until the
            amended Rule 10b5-1 Plan takes effect.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 34.9pt; margin-right: 21.45pt; margin-left: 10.1pt; line-height: 1.25;">The Company reserves the right to publicly announce, or respond
            to inquiries from the media regarding, the implementation of Rule 10b5-1 Plans or the execution of transactions made under a Rule 10b5-1 Plan. The Company also reserves the right, from time to time, to suspend, discontinue, or otherwise
            prohibit transactions under a Rule 10b5-1 Plan if the Chief Financial Officer or the Board of Directors, in its discretion, determines that such suspension, discontinuation, or other prohibition is in the best interests of the Company.
            Transactions prohibited under Section V of this Policy, including short sales and hedging transactions, may not be carried out through a Rule 10b5-1 Plan.</div>
          <div style="text-align: justify; text-indent: 34.9pt; margin-right: 21.45pt; margin-left: 10.1pt; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 34.9pt; margin-right: 21.45pt; margin-left: 10.1pt; line-height: 1.25;">Compliance of a Rule 10b5-1 Plan with the terms of Rule 10b5-1
            and the execution of transactions pursuant to the Rule 10b5-1 Plan are the sole responsibility of the person initiating the Rule 10b5-1 Plan, and none of the Company, the Chief Financial Officer, or the Company&#8217;s other employees assume any
            liability for any delay in reviewing and/or refusing a Rule 10b5-1 Plan submitted for approval nor the legality or consequences relating to a person entering into or trading under a Rule 10b5-1 Plan.</div>
          <div style="text-align: justify; text-indent: 34.9pt; margin-right: 21.45pt; margin-left: 10.1pt; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 34.9pt; margin-right: 21.45pt; margin-left: 10.1pt; line-height: 1.25;">The transactions prohibited under this Policy, including among
            others short sales and hedging transactions, may not be carried out through a Rule 10b5-1 Plan or other arrangement or trading instruction involving the potential sale and/or purchase of the Company&#8217;s securities.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="margin-left: 10.1pt; line-height: 1.25; font-weight: bold;">FURTHER INFORMATION ABOUT INSIDER TRADING AND BLACKOUT POLICY</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-indent: 34.9pt; margin-right: 21.45pt; margin-left: 10.1pt; line-height: 1.25;">The Company will post this Policy on its website at <u>www.chemomab.com</u> and update it as necessary to ensure that Company employees and directors are informed about this Policy.</div>
          <div class="BRPFPageHeader">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">7</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            </div>
          </div>
          <div style="margin-left: 39.95pt; line-height: 1.25; font-weight: bold;">APPENDIX A</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD. </div>
          <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">INSIDER TRADING GUIDELINES</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; margin-left: 10.1pt; line-height: 1.25; font-weight: bold;"><u>Pre-Clearance Procedure</u></div>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z327f3b1ee1fb4379ac7fa791426705c3" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 27.55pt;"><br>
                </td>
                <td style="width: 17.55pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>All &#8220;Pre-Clearance Persons,&#8221; as defined in Section V of the Company&#8217;s Insider Trading and Blackout Policy (the &#8220;<font style="font-weight: bold; font-style: italic;">Policy</font>&#8221;), must request written approval from the Chief Financial Officer or his/her designee before trading at any time in any of the Company&#8217;s securities or
                    exercising options or warrants, including during a period not deemed a &#8220;Blackout Period,&#8221; as defined in Section IV of the Policy.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="z91b887382f394fd9aea54644cd2dec3b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 27.55pt;"><br>
                </td>
                <td style="width: 17.55pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>The Chief Financial Officer or his/her designee shall provide advice based on the specific fact situation and is authorized to approve exceptions to the Blackout
                    Period, if it is clear that no law or regulation would be violated by the proposed trade given the particular facts.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zb5017ca6271546f4be0b7c8d351c377c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 27.55pt;"><br>
                </td>
                <td style="width: 17.55pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>The Chief Financial Officer or his/her designee shall record the date each request is received and the date and time each request is approved or disapproved.
                    Unless revoked, a grant of permission will normally remain valid until the close of trading two business days following the day on which it was granted. If the transaction does not occur during the two-day period, pre-clearance of the
                    transaction must be re-requested.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zb0920ff4defa428a99040a9abc59a8fc" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 27.55pt;"><br>
                </td>
                <td style="width: 17.55pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>Pre-clearance is not required for purchases and sales of securities under a pre-existing written plan, contract, instruction or arrangement under Rule 10b5-1
                    under the Securities Exchange Act of 1934 (&#8220;<font style="font-weight: bold; font-style: italic;">Approved 10b5-1 Plan</font>&#8221;). With respect to any purchase or sale under
                    such an Approved10b5-1 Plan, the third party effecting transactions on behalf of the Pre-Clearance Person should be instructed to send duplicate confirmations of all such transactions to the Chief Financial Officer.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; margin-left: 10.1pt; line-height: 1.25; font-weight: bold;"><u>Pre-Clearance Factors for Consideration</u></div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 21.8pt; margin-right: 4.4pt; margin-left: 10.1pt; line-height: 1.25;">When reviewing a proposed trade, the Chief Financial Officer or
            his/her designee should consult the Policy and consider, among other things, the following factors before granting approval.</div>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z5d032a25c9db47f88be1d6f459543c14" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 27.5pt;"><br>
                </td>
                <td style="width: 17.6pt; vertical-align: top; font-weight: bold;">1.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="font-weight: bold;">Is a blackout period in effect?</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="z19e5a4b76b564751b7b458ce900d975f" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 62.5pt;"><br>
                </td>
                <td style="width: 17.55pt; vertical-align: top;">a.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>All &#8220;Blackout Persons,&#8221; as defined in Section IV(E) of the Policy, are prohibited from trading in the Company&#8217;s equity securities during a Blackout Period.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z9a7c491f40bd45c1933c0a660b1a05d7" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 27.5pt;"><br>
                </td>
                <td style="width: 17.6pt; vertical-align: top; font-weight: bold;">2.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="font-weight: bold;">Is the trade a prohibited transaction?</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z2f3b09cd178e4b86b669f44dece78556" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 62.5pt;"><br>
                </td>
                <td style="width: 17.55pt; vertical-align: top;">a.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>Pre-Clearance Persons, including any such person&#8217;s immediate family members, other
                      persons who reside with him or her and entities with which he or she is affiliated, are prohibited from engaging in the following transactions in the Company&#8217;s securities unless advance approval is obtained from the Chief
                    Financial Officer or his/her designee:</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z405540bedcc14f64b915f5d4a0100ad2" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 100.55pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">i.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div><font style="font-weight: bold;">Short-Term Trading: </font>Pre-Clearance Persons who purchase
                    Company securities may not sell any Company securities of the same class for at least six months after the purchase;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">8</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <table cellspacing="0" cellpadding="0" id="zda23a1ab2b804d68976bd330ce5ae077" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 100.55pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">ii.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div><font style="font-weight: bold;">Short Sales: </font>Pre-Clearance Persons may not sell the
                    Company's securities short;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="zd347e95f8c224696a0c8cd2bceeed284" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 100.55pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">iii.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div><font style="font-weight: bold;">Options Trading: </font>Pre-Clearance Persons may not buy or sell
                    puts, calls or other derivative securities on the Company&#8217;s securities;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z0c0acc7f80f1470b91cd545be4118765" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 100.55pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">iv.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div><font style="font-weight: bold;">Trading on Margin or Pledging: </font>Pre-Clearance Persons may
                    not hold Company securities in a margin account or pledge Company securities as collateral for a loan; and</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zc6bc1e7d649e40d7922b4a2827c63de0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 100.55pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">v.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div><font style="font-weight: bold;">Hedging: </font>Pre-Clearance Persons may not enter into hedging
                    or monetization transactions or similar arrangements with respect to Company securities.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zeaf06bfb88ba4185a7fe773bbfe735b0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 27.5pt;"><br>
                </td>
                <td style="width: 17.6pt; vertical-align: top; font-weight: bold;">3.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="font-weight: bold;">Does the trade qualify for an exception to the Policy?</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z20c6ad939c864716b263345ed22f5eaf" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 62.5pt;"><br>
                </td>
                <td style="width: 17.55pt; vertical-align: top;">a.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>The only exceptions to the Policy are set forth below. Please note that the following are not exceptions from applicable pre-clearance requirements.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zb4e72159edb6424cb9ca89acfa1c6283" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 100.55pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">i.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div><font style="font-weight: bold;">Stock Option Exercises: </font>The Policy does not apply to the
                    exercise of an employee stock option, or to the exercise of a tax withholding right pursuant to which an employee elects to have the Company withhold shares subject to an option to satisfy tax withholding requirements. The Policy does
                    apply, however, to any sale of stock acquired upon such exercise, including as part of a broker- assisted cashless exercise of an option or any other market sale for the purpose of generating the cash needed to pay the exercise price of
                    an option;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zc2cd96d6607a444d964e483fe97e75e8" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 100.55pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">ii.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div><font style="font-weight: bold;">Employee Stock Purchase Plan: </font>The Policy does not apply to
                    purchases of Company stock in any employee stock purchase plan resulting from periodic contribution of money to the plan pursuant to an election made at the time of enrollment in the plan. The Policy also does not apply to purchases of
                    Company stock resulting from lump-sum contributions to any such plan, provided that an employee elected to participate by lump-sum payment at the beginning of the applicable enrollment period. The Policy does apply to an election to
                    participate in any plan for any enrollment period, and to sales of Company stock purchased pursuant to the plan;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z8a08950ffb5a45f0aed5d48f6a95aec3" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 100.55pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">iii.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div><font style="font-weight: bold;">Blind Trust Transactions: </font>The Policy does not apply to any
                    transaction executed by a trustee of a blind trust established for the benefit of one or more persons subject to the Policy; provided that (a) the trustee is not a person subject to the Policy, (b) on the date such Company securities
                    are deposited into the blind trust, the beneficiaries who are subject to the Policy are not in possession of Material Nonpublic Information and are in compliance with the Policy in all respects, (c) the written agreements setting forth
                    the terms of the blind trust are approved by the Chief Financial Officer or his/her designee prior to the deposit of any Company securities into the blind trust and (d) the Pre-Clearance Person does not, at any time, provide Material
                    Nonpublic Information to the trustee. For purposes of this exemption, a &#8220;blind trust&#8221; is a trust in which the beneficiaries have no control over any transaction executed by the third- party trustee; provided that the trust documentation
                    may contain guidelines to be followed by the trustee in connection with the disposition of Company securities; and</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z7940ceb71f4542bfa9047217e49004c6" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 100.55pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">iv.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div><font style="font-weight: bold;">Approved Transactions: </font>The Policy does not apply to any
                    transaction specifically approved in writing in advance by the Chief Financial Officer or his/her designee.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zab2195a5edae4209888919d953f07f0b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 100.55pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">v.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div><font style="font-weight: bold;">Rule 10b5</font>-1 trading Plan: The Policy does not apply to any
                    transaction conducted pursuant to a Rule 10b5-1 trading plan that complies with the requirements outlined above.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zd47f30edfbe54efb9a55d0625ad981ac" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 100.55pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">vi.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div><font style="font-weight: bold;">Gifts</font>: gift transactions for family or estate planning
                    purposes, where securities are gifted to a person or entity subject to this policy</div>
                </td>
              </tr>

          </table>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
    </div>
  </div>
  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">9</font>
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>4
<FILENAME>exhibit_12-1.htm
<DESCRIPTION>EXHIBIT
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="text-align: right; line-height: 1.25;"><img width="624" height="15" src="image00002.jpg"></div>
    <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u>Exhibit 12.1</u></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14a OF</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">THE SECURITIES EXCHANGE ACT OF 1934</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">AS ADOPTED PURSUANT TO SECTION 302</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">OF THE SARBANES OXLEY ACT OF 2002</div>
    <div style="line-height: 1.25;">I, Adi Mor, certify that:</div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="line-height: 1.25;">1. I have reviewed this Annual Report on Form 20-F of Chemomab Therapeutics Ltd.;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
      statements were made, not misleading with respect to the period covered by this report;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
      registrant as of, and for, the periods presented in this report;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over
      financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the
      registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the
      reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">c. Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as
      of the end of the period covered by this report based on such evaluation; and</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">d. Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal
      quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the
      registrant&#8217;s board of directors (or persons performing the equivalent functions):</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability
      to record, process, summarize and report financial information; and</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z351d06bc0d0d48b29a4dbb87a1761ca1">

        <tr>
          <td style="width: 50%; vertical-align: middle;">
            <div style="line-height: 1.25;">Date: April 4, 2025</div>
          </td>
          <td style="width: 50%; vertical-align: middle;">
            <div style="line-height: 1.25; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
            <div style="line-height: 1.25; font-weight: bold;"> <br>
            </div>
            <div style="line-height: 1.25;"><u>/s/ Adi Mor</u></div>
            <div style="line-height: 1.25;">Adi Mor</div>
            <div style="line-height: 1.25;">Chief Executive Officer</div>
            <div style="line-height: 1.25; font-style: italic;">(Principal Executive Officer)</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="line-height: 1.25;"><img width="624" height="15" src="image00002.jpg"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>5
<FILENAME>exhibit_12-2.htm
<DESCRIPTION>EXHIBIT 12.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><img width="624" height="15" src="image00002.jpg"></div>
    <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u> <br>
      </u></div>
    <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u>Exhibit 12.2</u></div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14a OF</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">THE SECURITIES EXCHANGE ACT OF 1934</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">AS ADOPTED PURSUANT TO SECTION 302</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">OF THE SARBANES OXLEY ACT OF 2002</div>
    <div style="line-height: 1.25;">I, Sigal Fattal, certify that:</div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">1. I have reviewed this Annual Report on Form 20-F of Chemomab Therapeutics Ltd.;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
      under which such statements were made, not misleading with respect to the period covered by this report;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and
      cash flows of the registrant as of, and for, the periods presented in this report;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and
      internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
      relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable
      assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">c. Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure
      controls and procedures, as of the end of the period covered by this report based on such evaluation; and</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">d. Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the
      registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit
      committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the
      registrant&#8217;s ability to record, process, summarize and report financial information; and</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="za5c281ecaf6a431e8e548f9a889e011c">

        <tr>
          <td style="width: 50%; vertical-align: middle;">
            <div style="line-height: 1.25;">Date: April 4, 2025</div>
          </td>
          <td style="width: 50%; vertical-align: middle;">
            <div style="line-height: 1.25; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
            <div style="line-height: 1.25; font-weight: bold;"> <br>
            </div>
            <div style="line-height: 1.25;"><u>/s/ Sigal Fattal</u></div>
            <div style="line-height: 1.25;">Sigal Fattal</div>
            <div style="line-height: 1.25;">Chief Financial Officer</div>
            <div style="line-height: 1.25; font-style: italic;">(Principal Financial Officer)</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <img width="624" height="15" src="image00002.jpg"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>6
<FILENAME>exhibit_13-1.htm
<DESCRIPTION>EXHIBIT 13.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div class="BRPFPageHeader">
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
    <div style="text-align: right; line-height: 1.25;"><img width="624" height="15" src="image00002.jpg"></div>
    <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u>Exhibit 13.1</u></div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">PURSUANT TO 18 U.S.C. SECTION 1350,</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">AS ADOPTED PURSUANT TO SECTION 906</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">OF THE SARBANES-OXLEY ACT OF 2002</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">I, Adi Mor, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report on Form 20-F of Chemomab Therapeutics Ltd. for
      the fiscal year ended December 31, 2024 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in such Annual Report on Form 20-F fairly presents, in all material
      respects, the financial condition and results of operations of Chemomab Therapeutics Ltd.</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zb6e906321bb74b5f84e12d40b6333ac9">

        <tr>
          <td style="width: 49.84%; vertical-align: top;">&#160;</td>
          <td style="width: 50.16%; vertical-align: bottom;">
            <div style="line-height: 1.25; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.84%; vertical-align: middle;">&#160;</td>
          <td style="width: 50.16%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49.84%; vertical-align: top;">
            <div style="line-height: 1.25;">Date: April 4, 2025</div>
          </td>
          <td style="width: 50.16%; vertical-align: bottom;">
            <div style="line-height: 1.25;"><u>/s/ Adi Mor</u></div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.84%; vertical-align: top;">&#160;</td>
          <td style="width: 50.16%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Adi Mor</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.84%; vertical-align: top;">&#160;</td>
          <td style="width: 50.16%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Chief Executive Officer</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.84%; vertical-align: top;">&#160;</td>
          <td style="width: 50.16%; vertical-align: bottom;">
            <div style="line-height: 1.25; font-style: italic;">(Principal Executive Officer)</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><img width="624" height="15" src="image00002.jpg"></div>
    <div class="BRPFPageFooter">
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>7
<FILENAME>exhibit_13-2.htm
<DESCRIPTION>EXHIBIT 13.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: right; line-height: 1.25;"><img width="624" height="15" src="image00002.jpg">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u> <br>
      </u></div>
    <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u>Exhibit 13.2</u></div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">PURSUANT TO 18 U.S.C. SECTION 1350,</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">AS ADOPTED PURSUANT TO SECTION 906</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">OF THE SARBANES-OXLEY ACT OF 2002</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">I, Sigal Fattal, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report on Form 20-F of Chemomab Therapeutics Ltd.
      for the fiscal year ended December 31, 2024 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in such Annual Report on Form 20-F fairly presents, in all material
      respects, the financial condition and results of operations of Chemomab Therapeutics Ltd.</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z8e26db4d2283423296feee78aa97db1a">

        <tr>
          <td style="width: 49.84%; vertical-align: top;">&#160;</td>
          <td style="width: 50.16%; vertical-align: bottom;">
            <div style="line-height: 1.25; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.84%; vertical-align: middle;">&#160;</td>
          <td style="width: 50.16%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49.84%; vertical-align: top;">
            <div style="line-height: 1.25;">Date: April 4, 2025</div>
          </td>
          <td style="width: 50.16%; vertical-align: bottom;">
            <div style="line-height: 1.25;"><u>/s/ Sigal Fattal</u></div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.84%; vertical-align: top;">&#160;</td>
          <td style="width: 50.16%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Sigal Fattal</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.84%; vertical-align: top;">&#160;</td>
          <td style="width: 50.16%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Chief Financial Officer</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.84%; vertical-align: top;">&#160;</td>
          <td style="width: 50.16%; vertical-align: bottom;">
            <div style="line-height: 1.25; font-style: italic;">(Principal Financial Officer)</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><img width="624" height="15" src="image00002.jpg"></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div class="BRPFPageFooter">
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>8
<FILENAME>exhibit_15-1.htm
<DESCRIPTION>EXHIBIT 15.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div class="BRPFPageHeader">
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
  <div style="line-height: 1.25;">
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u>Exhibit 15.1</u></div>
  </div>
  <div style="line-height: 1.25;">
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Consent of Independent Registered Public Accounting Firm</div>
  </div>
  <div style="line-height: 1.25;">
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">The Board of Directors<br>
      Chemomab Therapeutics Ltd.:</div>
    <div style="line-height: 1.25;">&#160;</div>
  </div>
  <div style="line-height: 1.25;">
    <div style="text-align: justify; line-height: 1.25;">We consent to the incorporation by reference in the registration statement on Form F-3 (No. 333-281750 and No. 333-275002) and registration statements on Form S-8 (No. 333-266868 and No. 333-259489)
      of our report dated April 4, 2025, with respect to the consolidated financial statements of Chemomab Therapeutics Ltd.</div>
  </div>
  <div style="line-height: 1.25;">
    <div style="line-height: 1.25;">&#160;</div>
  </div>
  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z3ceb879e19ff4827af482156a471ded7">

      <tr>
        <td style="width: 100%; vertical-align: middle;">
          <div style="line-height: 1.25; font-style: italic;">/s/ Somekh Chaikin</div>
        </td>
      </tr>
      <tr>
        <td nowrap="nowrap" style="width: 100%; vertical-align: middle;">
          <div style="line-height: 1.25;">Member Firm of KPMG International</div>
        </td>
      </tr>

  </table>
  <div style="line-height: 1.25;">
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">Tel Aviv, Israel</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
  </div>
  <div style="line-height: 1.25;">
    <div style="text-align: justify; line-height: 1.25;">April 4, 2025</div>
    <div style="line-height: 1.25;"><br>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>cmmb-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<schema xmlns:cmmb="http://www.anchiano.com/20241231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2024" xmlns:cyd-af="http://xbrl.sec.gov/cyd-af/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" targetNamespace="http://www.anchiano.com/20241231" elementFormDefault="qualified">
  <!-- INTEGIX by Ez-XBRL -->
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"/>
  <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"/>
  <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <import namespace="http://fasb.org/us-gaap-ebp/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/ebp/elts/us-gaap-ebp-2024.xsd"/>
  <import namespace="http://xbrl.org/2020/extensible-enumerations-2.0" schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/cyd-af-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/cyd-af/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd"/>
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.anchiano.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>0001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>0002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
        <link:definition>0003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/StatementsOfOperations" id="StatementsOfOperations">
        <link:definition>0004 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/StatementsOfChangesInEquity" id="StatementsOfChangesInEquity">
        <link:definition>0005 - Statement - Consolidated Statements of Changes in Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
        <link:definition>0006 - Statement - Consolidated Statements of Cash flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/General" id="General">
        <link:definition>0007 - Disclosure - General</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>0008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/CashAndCashEquivalents" id="CashAndCashEquivalents">
        <link:definition>0009 - Disclosure - Cash and Cash Equivalents</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpenses" id="OtherReceivablesAndPrepaidExpenses">
        <link:definition>0010 - Disclosure - Other Receivables and Prepaid Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
        <link:definition>0011 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/Leases" id="Leases">
        <link:definition>0012 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/CommitmentsAndContingentLiabilities" id="CommitmentsAndContingentLiabilities">
        <link:definition>0013 - Disclosure - Commitments and Contingent Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ShareCapital" id="ShareCapital">
        <link:definition>0014 - Disclosure - Share Capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ResearchAndDevelopment" id="ResearchAndDevelopment">
        <link:definition>0015 - Disclosure - Research and Development</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/GeneralAndAdministrative" id="GeneralAndAdministrative">
        <link:definition>0016 - Disclosure - General and Administrative</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>0017 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactions" id="RelatedPartiesBalancesAndTransactions">
        <link:definition>0018 - Disclosure - Related Parties Balances and Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholders" id="NetLossPerShareAttributableToOrdinaryShareholders">
        <link:definition>0019 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>9960701 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>9960702 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/CashAndCashEquivalentsTables" id="CashAndCashEquivalentsTables">
        <link:definition>9960703 - Disclosure - Cash and Cash Equivalents (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesTables" id="OtherReceivablesAndPrepaidExpensesTables">
        <link:definition>9960704 - Disclosure - Other Receivables and Prepaid Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
        <link:definition>9960705 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/LeasesTables" id="LeasesTables">
        <link:definition>9960706 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ShareCapitalTables" id="ShareCapitalTables">
        <link:definition>9960707 - Disclosure - Share Capital (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ResearchAndDevelopmentTables" id="ResearchAndDevelopmentTables">
        <link:definition>9960708 - Disclosure - Research and Development (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/GeneralAndAdministrativeTables" id="GeneralAndAdministrativeTables">
        <link:definition>9960709 - Disclosure - General and Administrative (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
        <link:definition>9960710 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables" id="RelatedPartiesBalancesAndTransactionsTables">
        <link:definition>9960711 - Disclosure - Related Parties Balances and Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables" id="NetLossPerShareAttributableToOrdinaryShareholdersTables">
        <link:definition>9960712 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/GeneralDetails" id="GeneralDetails">
        <link:definition>9960713 - Disclosure - General (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" id="SummaryOfSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9960714 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails" id="SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails">
        <link:definition>9960715 - Disclosure - Summary of Significant Accounting Policies (Schedule of Annual rates of Depreciation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/CashAndCashEquivalentsDetails" id="CashAndCashEquivalentsDetails">
        <link:definition>9960716 - Disclosure - Cash and Cash Equivalents (Schedule of Cash and Cash Equivalents) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails" id="OtherReceivablesAndPrepaidExpensesDetails">
        <link:definition>9960717 - Disclosure - Other Receivables and Prepaid Expenses (Schedule of Other Receivables and Prepaid Expenses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/PropertyAndEquipmentNetDetails" id="PropertyAndEquipmentNetDetails">
        <link:definition>9960718 - Disclosure - Property and Equipment, Net (Schedule of Property and Equipment, Net) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/LeasesNarrativeDetails" id="LeasesNarrativeDetails">
        <link:definition>9960719 - Disclosure - Leases (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails" id="LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails">
        <link:definition>9960720 - Disclosure - Leases (Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails" id="CommitmentsAndContingentLiabilitiesDetails">
        <link:definition>9960721 - Disclosure - Commitments and Contingent Liabilities (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ShareCapitalNarrativeDetails" id="ShareCapitalNarrativeDetails">
        <link:definition>9960722 - Disclosure - Share Capital (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails" id="ShareCapitalShare-basedCompensationExpensesDetails">
        <link:definition>9960723 - Disclosure - Share Capital (Schedule of Share-based Compensation Expenses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails" id="ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails">
        <link:definition>9960724 - Disclosure - Share Capital (Schedule of Number and Weighted Average Exercise Prices of Option) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ShareCapitalScheduleOfUnvestedRSADetails" id="ShareCapitalScheduleOfUnvestedRSADetails">
        <link:definition>9960725 - Disclosure - Share Capital (Schedule of unvested RSA) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails" id="ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails">
        <link:definition>9960726 - Disclosure - Share Capital (Schedule of Assumptions Used to Calculate the Fair Value of the Options) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails" id="ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails">
        <link:definition>9960727 - Disclosure - Research and Development (Schedule of Research and Development) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails" id="GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails">
        <link:definition>9960728 - Disclosure - General and Administrative (Schedule of General and Administrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
        <link:definition>9960729 - Disclosure - Income Taxes (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails" id="IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails">
        <link:definition>9960730 - Disclosure - Income Taxes (Schedule of Significant Components of the Company's Deferred Tax Asset) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails" id="IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails">
        <link:definition>9960731 - Disclosure - Income Taxes (Schedule of Roll Forward of Valuation Allowance) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails" id="IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails">
        <link:definition>9960732 - Disclosure - Income Taxes (Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails" id="RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails">
        <link:definition>9960733 - Disclosure - Related Parties Balances and Transactions (Schedule of Related Party Payables) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails" id="RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails">
        <link:definition>9960734 - Disclosure - Related Parties Balances and Transactions (Schedule of Transaction With Related Parties) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails" id="NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails">
        <link:definition>9960735 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Computation of Basic and Diluted Net Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails" id="NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails">
        <link:definition>9960736 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Weighted Average Number of Shares) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cmmb-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cmmb-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cmmb-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cmmb-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
    </appinfo>
  </annotation>
  <element name="AdditionalWorkOrderAmount" id="cmmb_AdditionalWorkOrderAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AggregateAmountCommitmentToPay" id="cmmb_AggregateAmountCommitmentToPay" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AggregateAmountOfCommitmentPaid" id="cmmb_AggregateAmountOfCommitmentPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AggregateOfferingPriceOfAtMarketOfferingAgreement" id="cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AmericanDepositarySharesMember" id="cmmb_AmericanDepositarySharesMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AnnualRatesOfDepreciation" id="cmmb_AnnualRatesOfDepreciation" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AnnualRentAndManagementFees" id="cmmb_AnnualRentAndManagementFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AtmAgreementMember" id="cmmb_AtmAgreementMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BankGuaranteesToPropertyOwner" id="cmmb_BankGuaranteesToPropertyOwner" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" id="cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" id="cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="CantorMember" id="cmmb_CantorMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CapitalAdditionsOneMember" id="cmmb_CapitalAdditionsOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CashAcquiredInMerger" id="cmmb_CashAcquiredInMerger" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CashPaidAndReceivedDuringYearForAbstract" id="cmmb_CashPaidAndReceivedDuringYearForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" id="cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ConsultantsAndSubcontractorsExpense" id="cmmb_ConsultantsAndSubcontractorsExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CumulativeAmountsOfGrantsReceivedAndRecognized" id="cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CurrencyTransactionLossValuationAllowance" id="cmmb_CurrencyTransactionLossValuationAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract" id="cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EarningsPerShareCalculationNumeratorAbstract" id="cmmb_EarningsPerShareCalculationNumeratorAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EffectOfReverseCapitalizationTransaction" id="cmmb_EffectOfReverseCapitalizationTransaction" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="EffectOfReverseCapitalizationTransactionShares" id="cmmb_EffectOfReverseCapitalizationTransactionShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EstimatedFairValueOfNetAssetsAcquired" id="cmmb_EstimatedFairValueOfNetAssetsAcquired" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ExpectsToReceiveAmountOfChemomabTherapeuticsInc" id="cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FinanceIncomeExpensesNet" id="cmmb_FinanceIncomeExpensesNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FormerChemomabSecurityHoldersMember" id="cmmb_FormerChemomabSecurityHoldersMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GeneralAndAdministrativeDisclosureTextBlock" id="cmmb_GeneralAndAdministrativeDisclosureTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock" id="cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IncomeTaxDisclosureLineItems" id="cmmb_IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IncomeTaxDisclosureTable" id="cmmb_IncomeTaxDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="IncomeTaxesReceived" id="cmmb_IncomeTaxesReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncomeTaxExpenseValuationAllowance" id="cmmb_IncomeTaxExpenseValuationAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IncrementalBorrowingRateOfLeases" id="cmmb_IncrementalBorrowingRateOfLeases" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="InterestReceived" id="cmmb_InterestReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="InvestorsMember" id="cmmb_InvestorsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LaboratoryEquipmentMember" id="cmmb_LaboratoryEquipmentMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LienOnBankDeposit" id="cmmb_LienOnBankDeposit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="LongTermLeaseDeposit" id="cmmb_LongTermLeaseDeposit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" id="cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="MarketOfferingAgreementMember" id="cmmb_MarketOfferingAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MaximumPercentageOfPaymentsOfRoyalties" id="cmmb_MaximumPercentageOfPaymentsOfRoyalties" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember" id="cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NatureOfOperationsDisclosureAbstract" id="cmmb_NatureOfOperationsDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfAdsIssuedAndOutstandingAfterMerger" id="cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfAdssOptionsIssuableOutstanding" id="cmmb_NumberOfAdssOptionsIssuableOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfAdssVestedAndExercisable" id="cmmb_NumberOfAdssVestedAndExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfOptionsIssuableOutstanding" id="cmmb_NumberOfOptionsIssuableOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfOptionsVestedAndExercisable" id="cmmb_NumberOfOptionsVestedAndExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfOrdinarySharesConsistedInDs" id="cmmb_NumberOfOrdinarySharesConsistedInDs" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfStockAdssResveredForIssuance" id="cmmb_NumberOfStockAdssResveredForIssuance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfStockReservedForIssuance" id="cmmb_NumberOfStockReservedForIssuance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfVestedAndExercisable" id="cmmb_NumberOfVestedAndExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfWarrantsPurchaseUpAdss" id="cmmb_NumberOfWarrantsPurchaseUpAdss" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OperatingRightOfUseAssetsAndOperatingLeaseLiabilities" id="cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="OrdinarySharesNoParValuePerShareMember" id="cmmb_OrdinarySharesNoParValuePerShareMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OtherAccountsReceivableAndPrepaidExpensesTextBlock" id="cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement" id="cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="PaymentsForInvestmentInDeposits" id="cmmb_PaymentsForInvestmentInDeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="PercentageOfMonthlyDepositsRate" id="cmmb_PercentageOfMonthlyDepositsRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfRoyaltyPaymentsOnSaleOfProduct" id="cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfShortTermDeposits" id="cmmb_PercentageOfShortTermDeposits" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ProceedsFromSaleOfAdss" id="cmmb_ProceedsFromSaleOfAdss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ReassessmentOfRightOfUseAsset" id="cmmb_ReassessmentOfRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ReceivablesFromGovernmentInstitutions" id="cmmb_ReceivablesFromGovernmentInstitutions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ReceivedAmountOfChemomabTherapeuticsInc" id="cmmb_ReceivedAmountOfChemomabTherapeuticsInc" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RecoverabilityOfVatAmount" id="cmmb_RecoverabilityOfVatAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" id="cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" id="cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" id="cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" id="cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RentAndMaintenanceGeneralAndAdministrativeExpense" id="cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RentAndMaintenanceResearchAndDevelopmentExpense" id="cmmb_RentAndMaintenanceResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RepurchaseArrangementMember" id="cmmb_RepurchaseArrangementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RepurchaseOfAmericanDepositaryReceipts" id="cmmb_RepurchaseOfAmericanDepositaryReceipts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RepurchaseOfAmericanDepositaryReceiptsShares" id="cmmb_RepurchaseOfAmericanDepositaryReceiptsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RestrictedOrdinarySharesMember" id="cmmb_RestrictedOrdinarySharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RothCapitalPartnersLlcMember" id="cmmb_RothCapitalPartnersLlcMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SaleOfStockLineItems" id="cmmb_SaleOfStockLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SaleOfStocksPricePerShare" id="cmmb_SaleOfStocksPricePerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SaleOfStockTable" id="cmmb_SaleOfStockTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="SaleOfStockValueOfSharesIssuedInTransaction" id="cmmb_SaleOfStockValueOfSharesIssuedInTransaction" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ScheduleOfAnnualRateOfDeprecationTableTextBlock" id="cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfGeneralAndAdministrativeTableTextBlock" id="cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" id="cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfRelatedPartyPayablesTableTextBlock" id="cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfResearchAndDevelopmentTableTextBlock" id="cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember" id="cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeverancePayPolicyTextBlock" id="cmmb_SeverancePayPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" id="cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" id="cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" id="cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice" id="cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationGeneralAndAdministrativeExpense" id="cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ShareBasedCompensationResearchAndDevelopmentExpense" id="cmmb_ShareBasedCompensationResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ShareholdingPercentageImmediatelyFollowingMerger" id="cmmb_ShareholdingPercentageImmediatelyFollowingMerger" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShortTermBankDepositsPolicyTextBlock" id="cmmb_ShortTermBankDepositsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SignificanAccountingPoliciesLineItems" id="cmmb_SignificanAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SignificantAccountingPoliciesTable" id="cmmb_SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="StockAndWarrantsIssuedDuringPeriodNewIssues" id="cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockAndWarrantsIssuedDuringPeriodValueNewIssues" id="cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" id="cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger" id="cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesStockOptionsExercised1" id="cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TaxAssetsAcquiredThroughMergerValuationAllowance" id="cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" id="cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="TwoThousandsFifteenPlanMember" id="cmmb_TwoThousandsFifteenPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandsSeventeenPlanMember" id="cmmb_TwoThousandsSeventeenPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" id="cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>cmmb-20241231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#StatementsOfOperations" roleURI="http://www.anchiano.com/role/StatementsOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#StatementsOfCashFlows" roleURI="http://www.anchiano.com/role/StatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#OtherReceivablesAndPrepaidExpensesDetails" roleURI="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#PropertyAndEquipmentNetDetails" roleURI="http://www.anchiano.com/role/PropertyAndEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails" roleURI="http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails" roleURI="http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails" roleURI="http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails" roleURI="http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails" roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails" roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaap_DepositsAssetsCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_24"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_RestrictedCashCurrent_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_DepositsAssetsCurrent_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsNoncurrent_6" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_6" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_7" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_6" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_8" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_11" xlink:to="loc_us-gaap_Liabilities_12" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_12" xlink:to="loc_us-gaap_LiabilitiesCurrent_12" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_12" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_12" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_12" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_13" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_12" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_14" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_12" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_15" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_12" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_17" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_17" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_17" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_11" xlink:to="loc_us-gaap_CommitmentsAndContingencies_20" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_11" xlink:to="loc_us-gaap_StockholdersEquity_21" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21" xlink:to="loc_us-gaap_CommonStockValue_21" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21" xlink:to="loc_us-gaap_TreasuryStockValue_22" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21" xlink:to="loc_us-gaap_AdditionalPaidInCapital_23" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_24" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementsOfOperations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_2" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" xlink:to="loc_us-gaap_OperatingExpenses_3" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4" order="10" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_10"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_PaymentsForInvestmentInDeposits" xlink:label="loc_cmmb_PaymentsForInvestmentInDeposits_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfTreasuryStock" xlink:label="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaap_ProceedsFromOtherEquity_16"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_ProfitLoss_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_Depreciation_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_ShareBasedCompensation_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4" order="30" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7" order="60" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8" order="70" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_10" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_10" xlink:to="loc_cmmb_PaymentsForInvestmentInDeposits_10" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_10" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_11" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_13" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_13" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_13" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_13" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_14" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_13" xlink:to="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_15" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_13" xlink:to="loc_us-gaap_ProceedsFromOtherEquity_16" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ReceivablesFromGovernmentInstitutions" xlink:label="loc_cmmb_ReceivablesFromGovernmentInstitutions_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xlink:to="loc_cmmb_ReceivablesFromGovernmentInstitutions_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_2" order="10" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/PropertyAndEquipmentNetDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2" order="10" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_4"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_4" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ConsultantsAndSubcontractorsExpense" xlink:label="loc_cmmb_ConsultantsAndSubcontractorsExpense_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RentAndMaintenanceResearchAndDevelopmentExpense" xlink:label="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShareBasedCompensationResearchAndDevelopmentExpense" xlink:label="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_5"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_0" xlink:to="loc_cmmb_ConsultantsAndSubcontractorsExpense_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_0" xlink:to="loc_us-gaap_OfficersCompensation_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_0" xlink:to="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_0" xlink:to="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_0" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_5" order="40" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaap_SalariesAndWages_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="loc_us-gaap_NoninterestExpenseDirectorsFees_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="loc_us-gaap_GeneralInsuranceExpense_5"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_7"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_0" xlink:to="loc_us-gaap_SalariesAndWages_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_0" xlink:to="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_0" xlink:to="loc_us-gaap_ProfessionalFees_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_0" xlink:to="loc_us-gaap_NoninterestExpenseDirectorsFees_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_0" xlink:to="loc_us-gaap_GeneralInsuranceExpense_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_0" xlink:to="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_6" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_0" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_7" order="60" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_0" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_0" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6" order="10" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2" order="10" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_4"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostOfRevenue_0" xlink:to="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostOfRevenue_0" xlink:to="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostOfRevenue_0" xlink:to="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostOfRevenue_0" xlink:to="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_4" order="30" use="optional" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>cmmb-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#StatementsOfChangesInEquity" roleURI="http://www.anchiano.com/role/StatementsOfChangesInEquity"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails" roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#CashAndCashEquivalentsDetails" roleURI="http://www.anchiano.com/role/CashAndCashEquivalentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#PropertyAndEquipmentNetDetails" roleURI="http://www.anchiano.com/role/PropertyAndEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#LeasesNarrativeDetails" roleURI="http://www.anchiano.com/role/LeasesNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#CommitmentsAndContingentLiabilitiesDetails" roleURI="http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#ShareCapitalNarrativeDetails" roleURI="http://www.anchiano.com/role/ShareCapitalNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#ShareCapitalShare-basedCompensationExpensesDetails" roleURI="http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails" roleURI="http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#IncomeTaxesDetails" roleURI="http://www.anchiano.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails" roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails" roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/DocumentDocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AmericanDepositarySharesMember" xlink:label="loc_cmmb_AmericanDepositarySharesMember_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_OrdinarySharesNoParValuePerShareMember" xlink:label="loc_cmmb_OrdinarySharesNoParValuePerShareMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="loc_dei_EntityInformationFormerLegalOrRegisteredName_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_48"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_49"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_51"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_52"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_53"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications_54"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial_55"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer_56"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_57"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_58"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtRestatementRecoveryAnalysisFlag" xlink:label="loc_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag_59"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentInformationTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_cmmb_AmericanDepositarySharesMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_cmmb_OrdinarySharesNoParValuePerShareMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_1" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_6" xlink:to="loc_dei_AddressTypeDomain_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_6" xlink:to="loc_dei_BusinessContactMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_6" xlink:to="loc_dei_AddressTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityCentralIndexKey_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_AmendmentFlag_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentType_14" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentRegistrationStatement_15" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_16" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentFiscalYearFocus_17" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentPeriodEndDate_18" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentAnnualReport_19" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentTransitionReport_20" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentShellCompanyReport_21" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityFileNumber_22" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityRegistrantName_23" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_24" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityTaxIdentificationNumber_25" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityAddressAddressLine1_26" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityAddressAddressLine2_27" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityAddressCityOrTown_28" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityAddressCountry_29" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityAddressPostalZipCode_30" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_CityAreaCode_31" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_ContactPersonnelName_32" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_LocalPhoneNumber_33" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityInformationFormerLegalOrRegisteredName_34" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_Security12bTitle_35" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_TradingSymbol_36" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_SecurityExchangeName_37" order="270" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_38" order="280" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityVoluntaryFilers_39" order="290" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityCurrentReportingStatus_40" order="300" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityInteractiveDataCurrent_41" order="310" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityFilerCategory_42" order="320" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntitySmallBusiness_43" order="330" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityEmergingGrowthCompany_44" order="340" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentAccountingStandard_45" order="350" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityExTransitionPeriod_46" order="360" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_IcfrAuditorAttestationFlag_47" order="370" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityShellCompany_48" order="380" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityPublicFloat_49" order="390" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_50" order="400" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_AuditorName_51" order="410" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_AuditorLocation_52" order="420" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_AuditorFirmId_53" order="430" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_WrittenCommunications_54" order="440" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_SolicitingMaterial_55" order="450" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_PreCommencementTenderOffer_56" order="460" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_57" order="470" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_58" order="480" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag_59" order="490" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementsOfChangesInEquity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaap_TreasuryStockCommonMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_14"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_EffectOfReverseCapitalizationTransaction" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransaction_15"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_EffectOfReverseCapitalizationTransactionShares" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_16"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_17"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_23"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_TreasuryStockCommonMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_RetainedEarningsMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquity_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharesOutstanding_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_11" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_12" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_13" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_14" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cmmb_EffectOfReverseCapitalizationTransaction_15" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_16" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_17" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_18" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_19" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_20" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_21" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_22" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_23" order="150" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_SignificanAccountingPoliciesLineItems" xlink:label="loc_cmmb_SignificanAccountingPoliciesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_SignificantAccountingPoliciesTable" xlink:label="loc_cmmb_SignificantAccountingPoliciesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_IncrementalBorrowingRateOfLeases" xlink:label="loc_cmmb_IncrementalBorrowingRateOfLeases_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_8"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_PercentageOfMonthlyDepositsRate" xlink:label="loc_cmmb_PercentageOfMonthlyDepositsRate_9"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_PercentageOfShortTermDeposits" xlink:label="loc_cmmb_PercentageOfShortTermDeposits_10"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cmmb_SignificanAccountingPoliciesLineItems_0" xlink:to="loc_cmmb_SignificantAccountingPoliciesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmmb_SignificantAccountingPoliciesTable_1" xlink:to="loc_srt_RangeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MaximumMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MinimumMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SignificanAccountingPoliciesLineItems_0" xlink:to="loc_cmmb_IncrementalBorrowingRateOfLeases_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SignificanAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_SeveranceCosts1_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SignificanAccountingPoliciesLineItems_0" xlink:to="loc_cmmb_PercentageOfMonthlyDepositsRate_9" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SignificanAccountingPoliciesLineItems_0" xlink:to="loc_cmmb_PercentageOfShortTermDeposits_10" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AnnualRatesOfDepreciation" xlink:label="loc_cmmb_AnnualRatesOfDepreciation_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_LaboratoryEquipmentMember" xlink:label="loc_cmmb_LaboratoryEquipmentMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_cmmb_AnnualRatesOfDepreciation_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3" order="20" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_ComputerEquipmentMember_3" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_cmmb_LaboratoryEquipmentMember_4" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_5" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_6" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/CashAndCashEquivalentsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD" xlink:label="loc_currency_USD_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_ILS" xlink:label="loc_currency_ILS_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_XXX" xlink:label="loc_currency_XXX_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_CurrencyAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_1" xlink:to="loc_currency_AllCurrenciesDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_USD_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_ILS_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_XXX_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_1" xlink:to="loc_currency_AllCurrenciesDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/PropertyAndEquipmentNetDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_LaboratoryEquipmentMember" xlink:label="loc_cmmb_LaboratoryEquipmentMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_12"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_ComputerEquipmentMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_cmmb_LaboratoryEquipmentMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_12" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/LeasesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_ILS" xlink:label="loc_currency_ILS_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_8"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AnnualRentAndManagementFees" xlink:label="loc_cmmb_AnnualRentAndManagementFees_9"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_BankGuaranteesToPropertyOwner" xlink:label="loc_cmmb_BankGuaranteesToPropertyOwner_10"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ReassessmentOfRightOfUseAsset" xlink:label="loc_cmmb_ReassessmentOfRightOfUseAsset_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_13"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:label="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_16"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1" xlink:to="loc_srt_CurrencyAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_1" xlink:to="loc_currency_AllCurrenciesDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_ILS_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_1" xlink:to="loc_currency_AllCurrenciesDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LeaseExpirationDate1_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_cmmb_AnnualRentAndManagementFees_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_cmmb_BankGuaranteesToPropertyOwner_10" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_cmmb_ReassessmentOfRightOfUseAsset_11" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_12" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_OperatingLeaseLiability_13" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_14" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_15" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_16" order="110" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalAdditionsMember" xlink:label="loc_us-gaap_CapitalAdditionsMember_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_CapitalAdditionsOneMember" xlink:label="loc_cmmb_CapitalAdditionsOneMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaap_LeaseAgreementsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_EUR" xlink:label="loc_currency_EUR_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_ILS" xlink:label="loc_currency_ILS_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentDescription" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentDescription_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaap_OtherCommitmentsDescription_21"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct" xlink:label="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_22"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_MaximumPercentageOfPaymentsOfRoyalties" xlink:label="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_23"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized" xlink:label="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_26"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement" xlink:label="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_28"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AggregateAmountCommitmentToPay" xlink:label="loc_cmmb_AggregateAmountCommitmentToPay_29"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AggregateAmountOfCommitmentPaid" xlink:label="loc_cmmb_AggregateAmountOfCommitmentPaid_30"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AdditionalWorkOrderAmount" xlink:label="loc_cmmb_AdditionalWorkOrderAmount_31"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_LienOnBankDeposit" xlink:label="loc_cmmb_LienOnBankDeposit_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedInvestments" xlink:label="loc_us-gaap_RestrictedInvestments_33"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RecoverabilityOfVatAmount" xlink:label="loc_cmmb_RecoverabilityOfVatAmount_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxes" xlink:label="loc_us-gaap_AccruedIncomeTaxes_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionExpense" xlink:label="loc_us-gaap_AccretionExpense_36"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_OtherCommitmentsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" xlink:to="loc_us-gaap_CapitalAdditionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" xlink:to="loc_cmmb_CapitalAdditionsOneMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" xlink:to="loc_us-gaap_LeaseAgreementsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_srt_CurrencyAxis_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_7" xlink:to="loc_currency_AllCurrenciesDomain_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_7" xlink:to="loc_currency_EUR_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_7" xlink:to="loc_currency_ILS_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_7" xlink:to="loc_currency_AllCurrenciesDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_12" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_12" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_13" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_srt_StatementScenarioAxis_15" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_15" xlink:to="loc_srt_ScenarioUnspecifiedDomain_15" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_15" xlink:to="loc_srt_ScenarioForecastMember_15" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_15" xlink:to="loc_srt_ScenarioUnspecifiedDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentDescription_20" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_OtherCommitmentsDescription_21" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_22" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_23" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_24" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_25" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_26" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_27" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_RoyaltyExpense_28" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_AggregateAmountCommitmentToPay_29" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_AggregateAmountOfCommitmentPaid_30" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_AdditionalWorkOrderAmount_31" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_LienOnBankDeposit_32" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_RestrictedInvestments_33" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_RecoverabilityOfVatAmount_34" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_AccruedIncomeTaxes_35" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_AccretionExpense_36" order="170" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalNarrativeDetails">
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_SaleOfStockLineItems" xlink:label="loc_cmmb_SaleOfStockLineItems_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_SaleOfStockTable" xlink:label="loc_cmmb_SaleOfStockTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_CantorMember" xlink:label="loc_cmmb_CantorMember_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RothCapitalPartnersLlcMember" xlink:label="loc_cmmb_RothCapitalPartnersLlcMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_InvestorsMember" xlink:label="loc_cmmb_InvestorsMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_7"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AtmAgreementMember" xlink:label="loc_cmmb_AtmAgreementMember_8"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RepurchaseArrangementMember" xlink:label="loc_cmmb_RepurchaseArrangementMember_9"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_MarketOfferingAgreementMember" xlink:label="loc_cmmb_MarketOfferingAgreementMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_14"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RestrictedOrdinarySharesMember" xlink:label="loc_cmmb_RestrictedOrdinarySharesMember_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_19"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_TwoThousandsFifteenPlanMember" xlink:label="loc_cmmb_TwoThousandsFifteenPlanMember_19"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_TwoThousandsSeventeenPlanMember" xlink:label="loc_cmmb_TwoThousandsSeventeenPlanMember_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_28"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement" xlink:label="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_29"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ProceedsFromSaleOfAdss" xlink:label="loc_cmmb_ProceedsFromSaleOfAdss_30"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" xlink:label="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_31"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfWarrantsPurchaseUpAdss" xlink:label="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_32"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_SaleOfStocksPricePerShare" xlink:label="loc_cmmb_SaleOfStocksPricePerShare_33"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfStockReservedForIssuance" xlink:label="loc_cmmb_NumberOfStockReservedForIssuance_34"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfStockAdssResveredForIssuance" xlink:label="loc_cmmb_NumberOfStockAdssResveredForIssuance_35"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfAdssOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfAdssOptionsIssuableOutstanding_36"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfOptionsIssuableOutstanding_37"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfVestedAndExercisable" xlink:label="loc_cmmb_NumberOfVestedAndExercisable_38"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfAdssVestedAndExercisable" xlink:label="loc_cmmb_NumberOfAdssVestedAndExercisable_39"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfOptionsVestedAndExercisable" xlink:label="loc_cmmb_NumberOfOptionsVestedAndExercisable_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_41"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_44"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_45"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_46"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceiptsShares" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_47"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_48"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_49"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfTreasuryStock" xlink:label="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_50"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_SaleOfStockTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_cmmb_CantorMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_cmmb_RothCapitalPartnersLlcMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" xlink:to="loc_cmmb_InvestorsMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" xlink:to="loc_us-gaap_PrivatePlacementMember_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" xlink:to="loc_cmmb_AtmAgreementMember_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" xlink:to="loc_cmmb_RepurchaseArrangementMember_9" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" xlink:to="loc_cmmb_MarketOfferingAgreementMember_10" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_14" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_14" xlink:to="loc_us-gaap_ClassOfStockDomain_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_14" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_14" xlink:to="loc_cmmb_RestrictedOrdinarySharesMember_15" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_14" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_us-gaap_PlanNameAxis_19" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_19" xlink:to="loc_us-gaap_PlanNameDomain_19" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_19" xlink:to="loc_cmmb_TwoThousandsFifteenPlanMember_19" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_19" xlink:to="loc_cmmb_TwoThousandsSeventeenPlanMember_20" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_19" xlink:to="loc_us-gaap_PlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_25" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_26" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_27" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_28" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_29" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_ProceedsFromSaleOfAdss_30" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_31" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_32" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_SaleOfStocksPricePerShare_33" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_NumberOfStockReservedForIssuance_34" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_NumberOfStockAdssResveredForIssuance_35" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_NumberOfAdssOptionsIssuableOutstanding_36" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_NumberOfOptionsIssuableOutstanding_37" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_NumberOfVestedAndExercisable_38" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_NumberOfAdssVestedAndExercisable_39" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_NumberOfOptionsVestedAndExercisable_40" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_41" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_42" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_43" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_44" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_45" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_46" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_47" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_48" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_49" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_50" order="260" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharePrice_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9" order="80" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9" xlink:to="loc_srt_RangeAxis_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9" xlink:to="loc_srt_RangeMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9" xlink:to="loc_srt_MinimumMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9" xlink:to="loc_srt_MaximumMember_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9" xlink:to="loc_us-gaap_AwardTypeAxis_14" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_IncomeTaxDisclosureLineItems" xlink:label="loc_cmmb_IncomeTaxDisclosureLineItems_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_IncomeTaxDisclosureTable" xlink:label="loc_cmmb_IncomeTaxDisclosureTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IL" xlink:label="loc_country_IL_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_country_US_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_17"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ReceivedAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_18"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_21"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_0" xlink:to="loc_cmmb_IncomeTaxDisclosureTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_1" xlink:to="loc_srt_StatementScenarioAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_srt_ScenarioForecastMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_1" xlink:to="loc_srt_StatementGeographicalAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_5" xlink:to="loc_srt_SegmentGeographicalDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5" xlink:to="loc_country_IL_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5" xlink:to="loc_country_US_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_5" xlink:to="loc_srt_SegmentGeographicalDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_10" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_10" xlink:to="loc_us-gaap_DomesticCountryMember_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_10" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_15" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_0" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_16" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_0" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_17" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_0" xlink:to="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_18" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_0" xlink:to="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_19" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_20" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_0" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_21" order="70" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_8"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_us-gaap_RelatedPartyMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_8" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_Default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_2" order="10" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_Default" order="10" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>cmmb-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AdditionalWorkOrderAmount" xlink:label="loc_cmmb_AdditionalWorkOrderAmount_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AdditionalWorkOrderAmount" xlink:label="loc_cmmb_AdditionalWorkOrderAmount_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AdditionalWorkOrderAmount" xlink:label="loc_cmmb_AdditionalWorkOrderAmount_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AggregateAmountCommitmentToPay" xlink:label="loc_cmmb_AggregateAmountCommitmentToPay_4"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AggregateAmountCommitmentToPay" xlink:label="loc_cmmb_AggregateAmountCommitmentToPay_5"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AggregateAmountOfCommitmentPaid" xlink:label="loc_cmmb_AggregateAmountOfCommitmentPaid_6"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AggregateAmountOfCommitmentPaid" xlink:label="loc_cmmb_AggregateAmountOfCommitmentPaid_7"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement" xlink:label="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_8"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement" xlink:label="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_9"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement" xlink:label="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_10"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AmericanDepositarySharesMember" xlink:label="loc_cmmb_AmericanDepositarySharesMember_11"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AmericanDepositarySharesMember" xlink:label="loc_cmmb_AmericanDepositarySharesMember_12"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AnnualRatesOfDepreciation" xlink:label="loc_cmmb_AnnualRatesOfDepreciation_13"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AnnualRatesOfDepreciation" xlink:label="loc_cmmb_AnnualRatesOfDepreciation_14"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AnnualRatesOfDepreciation" xlink:label="loc_cmmb_AnnualRatesOfDepreciation_15"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AnnualRentAndManagementFees" xlink:label="loc_cmmb_AnnualRentAndManagementFees_16"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AnnualRentAndManagementFees" xlink:label="loc_cmmb_AnnualRentAndManagementFees_17"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AtmAgreementMember" xlink:label="loc_cmmb_AtmAgreementMember_18"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AtmAgreementMember" xlink:label="loc_cmmb_AtmAgreementMember_19"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_BankGuaranteesToPropertyOwner" xlink:label="loc_cmmb_BankGuaranteesToPropertyOwner_20"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_BankGuaranteesToPropertyOwner" xlink:label="loc_cmmb_BankGuaranteesToPropertyOwner_21"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_22"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_23"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_24"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_25"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_26"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_27"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_CantorMember" xlink:label="loc_cmmb_CantorMember_28"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_CantorMember" xlink:label="loc_cmmb_CantorMember_29"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_CapitalAdditionsOneMember" xlink:label="loc_cmmb_CapitalAdditionsOneMember_30"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_CapitalAdditionsOneMember" xlink:label="loc_cmmb_CapitalAdditionsOneMember_31"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_CapitalAdditionsOneMember" xlink:label="loc_cmmb_CapitalAdditionsOneMember_32"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_CashAcquiredInMerger" xlink:label="loc_cmmb_CashAcquiredInMerger_33"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_CashAcquiredInMerger" xlink:label="loc_cmmb_CashAcquiredInMerger_34"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_CashPaidAndReceivedDuringYearForAbstract" xlink:label="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_35"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_CashPaidAndReceivedDuringYearForAbstract" xlink:label="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_36"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_CashPaidAndReceivedDuringYearForAbstract" xlink:label="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_37"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" xlink:label="loc_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_38"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" xlink:label="loc_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_39"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" xlink:label="loc_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_40"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ConsultantsAndSubcontractorsExpense" xlink:label="loc_cmmb_ConsultantsAndSubcontractorsExpense_41"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ConsultantsAndSubcontractorsExpense" xlink:label="loc_cmmb_ConsultantsAndSubcontractorsExpense_42"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ConsultantsAndSubcontractorsExpense" xlink:label="loc_cmmb_ConsultantsAndSubcontractorsExpense_43"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized" xlink:label="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_44"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized" xlink:label="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_45"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized" xlink:label="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_46"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_CurrencyTransactionLossValuationAllowance" xlink:label="loc_cmmb_CurrencyTransactionLossValuationAllowance_47"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_CurrencyTransactionLossValuationAllowance" xlink:label="loc_cmmb_CurrencyTransactionLossValuationAllowance_48"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_CurrencyTransactionLossValuationAllowance" xlink:label="loc_cmmb_CurrencyTransactionLossValuationAllowance_49"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract" xlink:label="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_50"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract" xlink:label="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_51"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract" xlink:label="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_52"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_EarningsPerShareCalculationNumeratorAbstract" xlink:label="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_53"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_EarningsPerShareCalculationNumeratorAbstract" xlink:label="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_54"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_EarningsPerShareCalculationNumeratorAbstract" xlink:label="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_55"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_EffectOfReverseCapitalizationTransaction" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransaction_56"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_EffectOfReverseCapitalizationTransaction" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransaction_57"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_EffectOfReverseCapitalizationTransactionShares" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_58"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_EffectOfReverseCapitalizationTransactionShares" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_59"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_EffectOfReverseCapitalizationTransactionShares" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_60"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_EstimatedFairValueOfNetAssetsAcquired" xlink:label="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_61"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_EstimatedFairValueOfNetAssetsAcquired" xlink:label="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_62"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_EstimatedFairValueOfNetAssetsAcquired" xlink:label="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_63"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_64"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_65"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_66"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_FinanceIncomeExpensesNet" xlink:label="loc_cmmb_FinanceIncomeExpensesNet_67"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_FinanceIncomeExpensesNet" xlink:label="loc_cmmb_FinanceIncomeExpensesNet_68"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_FinanceIncomeExpensesNet" xlink:label="loc_cmmb_FinanceIncomeExpensesNet_69"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_FormerChemomabSecurityHoldersMember" xlink:label="loc_cmmb_FormerChemomabSecurityHoldersMember_70"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_FormerChemomabSecurityHoldersMember" xlink:label="loc_cmmb_FormerChemomabSecurityHoldersMember_71"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_GeneralAndAdministrativeDisclosureTextBlock" xlink:label="loc_cmmb_GeneralAndAdministrativeDisclosureTextBlock_72"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_GeneralAndAdministrativeDisclosureTextBlock" xlink:label="loc_cmmb_GeneralAndAdministrativeDisclosureTextBlock_73"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_GeneralAndAdministrativeDisclosureTextBlock" xlink:label="loc_cmmb_GeneralAndAdministrativeDisclosureTextBlock_74"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock" xlink:label="loc_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_75"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock" xlink:label="loc_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_76"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock" xlink:label="loc_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_77"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_IncomeTaxDisclosureLineItems" xlink:label="loc_cmmb_IncomeTaxDisclosureLineItems_78"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_IncomeTaxDisclosureLineItems" xlink:label="loc_cmmb_IncomeTaxDisclosureLineItems_79"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_IncomeTaxDisclosureTable" xlink:label="loc_cmmb_IncomeTaxDisclosureTable_80"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_IncomeTaxDisclosureTable" xlink:label="loc_cmmb_IncomeTaxDisclosureTable_81"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_IncomeTaxesReceived" xlink:label="loc_cmmb_IncomeTaxesReceived_82"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_IncomeTaxesReceived" xlink:label="loc_cmmb_IncomeTaxesReceived_83"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_IncomeTaxesReceived" xlink:label="loc_cmmb_IncomeTaxesReceived_84"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_IncomeTaxExpenseValuationAllowance" xlink:label="loc_cmmb_IncomeTaxExpenseValuationAllowance_85"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_IncomeTaxExpenseValuationAllowance" xlink:label="loc_cmmb_IncomeTaxExpenseValuationAllowance_86"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_IncomeTaxExpenseValuationAllowance" xlink:label="loc_cmmb_IncomeTaxExpenseValuationAllowance_87"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_IncrementalBorrowingRateOfLeases" xlink:label="loc_cmmb_IncrementalBorrowingRateOfLeases_88"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_IncrementalBorrowingRateOfLeases" xlink:label="loc_cmmb_IncrementalBorrowingRateOfLeases_89"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_IncrementalBorrowingRateOfLeases" xlink:label="loc_cmmb_IncrementalBorrowingRateOfLeases_90"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_InterestReceived" xlink:label="loc_cmmb_InterestReceived_91"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_InterestReceived" xlink:label="loc_cmmb_InterestReceived_92"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_InterestReceived" xlink:label="loc_cmmb_InterestReceived_93"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_InvestorsMember" xlink:label="loc_cmmb_InvestorsMember_94"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_InvestorsMember" xlink:label="loc_cmmb_InvestorsMember_95"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_LaboratoryEquipmentMember" xlink:label="loc_cmmb_LaboratoryEquipmentMember_96"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_LaboratoryEquipmentMember" xlink:label="loc_cmmb_LaboratoryEquipmentMember_97"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_LaboratoryEquipmentMember" xlink:label="loc_cmmb_LaboratoryEquipmentMember_98"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_LienOnBankDeposit" xlink:label="loc_cmmb_LienOnBankDeposit_99"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_LienOnBankDeposit" xlink:label="loc_cmmb_LienOnBankDeposit_100"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_LongTermLeaseDeposit" xlink:label="loc_cmmb_LongTermLeaseDeposit_101"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_LongTermLeaseDeposit" xlink:label="loc_cmmb_LongTermLeaseDeposit_102"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_LongTermLeaseDeposit" xlink:label="loc_cmmb_LongTermLeaseDeposit_103"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" xlink:label="loc_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_104"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" xlink:label="loc_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_105"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" xlink:label="loc_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_106"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_MarketOfferingAgreementMember" xlink:label="loc_cmmb_MarketOfferingAgreementMember_107"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_MarketOfferingAgreementMember" xlink:label="loc_cmmb_MarketOfferingAgreementMember_108"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_MarketOfferingAgreementMember" xlink:label="loc_cmmb_MarketOfferingAgreementMember_109"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_MaximumPercentageOfPaymentsOfRoyalties" xlink:label="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_110"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_MaximumPercentageOfPaymentsOfRoyalties" xlink:label="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_111"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_MaximumPercentageOfPaymentsOfRoyalties" xlink:label="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_112"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember" xlink:label="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_113"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember" xlink:label="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_114"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember" xlink:label="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_115"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NatureOfOperationsDisclosureAbstract" xlink:label="loc_cmmb_NatureOfOperationsDisclosureAbstract_116"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NatureOfOperationsDisclosureAbstract" xlink:label="loc_cmmb_NatureOfOperationsDisclosureAbstract_117"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NatureOfOperationsDisclosureAbstract" xlink:label="loc_cmmb_NatureOfOperationsDisclosureAbstract_118"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger" xlink:label="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_119"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger" xlink:label="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_120"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfAdssOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfAdssOptionsIssuableOutstanding_121"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfAdssOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfAdssOptionsIssuableOutstanding_122"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfAdssVestedAndExercisable" xlink:label="loc_cmmb_NumberOfAdssVestedAndExercisable_123"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfAdssVestedAndExercisable" xlink:label="loc_cmmb_NumberOfAdssVestedAndExercisable_124"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfOptionsIssuableOutstanding_125"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfOptionsIssuableOutstanding_126"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfOptionsIssuableOutstanding_127"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfOptionsVestedAndExercisable" xlink:label="loc_cmmb_NumberOfOptionsVestedAndExercisable_128"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfOptionsVestedAndExercisable" xlink:label="loc_cmmb_NumberOfOptionsVestedAndExercisable_129"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfOptionsVestedAndExercisable" xlink:label="loc_cmmb_NumberOfOptionsVestedAndExercisable_130"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfOrdinarySharesConsistedInDs" xlink:label="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_131"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfOrdinarySharesConsistedInDs" xlink:label="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_132"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfOrdinarySharesConsistedInDs" xlink:label="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_133"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfStockAdssResveredForIssuance" xlink:label="loc_cmmb_NumberOfStockAdssResveredForIssuance_134"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfStockAdssResveredForIssuance" xlink:label="loc_cmmb_NumberOfStockAdssResveredForIssuance_135"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfStockAdssResveredForIssuance" xlink:label="loc_cmmb_NumberOfStockAdssResveredForIssuance_136"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfStockReservedForIssuance" xlink:label="loc_cmmb_NumberOfStockReservedForIssuance_137"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfStockReservedForIssuance" xlink:label="loc_cmmb_NumberOfStockReservedForIssuance_138"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfStockReservedForIssuance" xlink:label="loc_cmmb_NumberOfStockReservedForIssuance_139"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfVestedAndExercisable" xlink:label="loc_cmmb_NumberOfVestedAndExercisable_140"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfVestedAndExercisable" xlink:label="loc_cmmb_NumberOfVestedAndExercisable_141"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfVestedAndExercisable" xlink:label="loc_cmmb_NumberOfVestedAndExercisable_142"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfWarrantsPurchaseUpAdss" xlink:label="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_143"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfWarrantsPurchaseUpAdss" xlink:label="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_144"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfWarrantsPurchaseUpAdss" xlink:label="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_145"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:label="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_146"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:label="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_147"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:label="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_148"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_OrdinarySharesNoParValuePerShareMember" xlink:label="loc_cmmb_OrdinarySharesNoParValuePerShareMember_149"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_OrdinarySharesNoParValuePerShareMember" xlink:label="loc_cmmb_OrdinarySharesNoParValuePerShareMember_150"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:label="loc_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_151"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:label="loc_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_152"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:label="loc_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_153"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement" xlink:label="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_154"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement" xlink:label="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_155"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement" xlink:label="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_156"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_PaymentsForInvestmentInDeposits" xlink:label="loc_cmmb_PaymentsForInvestmentInDeposits_157"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_PaymentsForInvestmentInDeposits" xlink:label="loc_cmmb_PaymentsForInvestmentInDeposits_158"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_PaymentsForInvestmentInDeposits" xlink:label="loc_cmmb_PaymentsForInvestmentInDeposits_159"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_PercentageOfMonthlyDepositsRate" xlink:label="loc_cmmb_PercentageOfMonthlyDepositsRate_160"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_PercentageOfMonthlyDepositsRate" xlink:label="loc_cmmb_PercentageOfMonthlyDepositsRate_161"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct" xlink:label="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_162"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct" xlink:label="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_163"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct" xlink:label="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_164"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_PercentageOfShortTermDeposits" xlink:label="loc_cmmb_PercentageOfShortTermDeposits_165"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_PercentageOfShortTermDeposits" xlink:label="loc_cmmb_PercentageOfShortTermDeposits_166"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_PercentageOfShortTermDeposits" xlink:label="loc_cmmb_PercentageOfShortTermDeposits_167"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ProceedsFromSaleOfAdss" xlink:label="loc_cmmb_ProceedsFromSaleOfAdss_168"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ProceedsFromSaleOfAdss" xlink:label="loc_cmmb_ProceedsFromSaleOfAdss_169"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ReassessmentOfRightOfUseAsset" xlink:label="loc_cmmb_ReassessmentOfRightOfUseAsset_170"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ReassessmentOfRightOfUseAsset" xlink:label="loc_cmmb_ReassessmentOfRightOfUseAsset_171"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ReassessmentOfRightOfUseAsset" xlink:label="loc_cmmb_ReassessmentOfRightOfUseAsset_172"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ReceivablesFromGovernmentInstitutions" xlink:label="loc_cmmb_ReceivablesFromGovernmentInstitutions_173"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ReceivablesFromGovernmentInstitutions" xlink:label="loc_cmmb_ReceivablesFromGovernmentInstitutions_174"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ReceivablesFromGovernmentInstitutions" xlink:label="loc_cmmb_ReceivablesFromGovernmentInstitutions_175"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ReceivedAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_176"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ReceivedAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_177"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ReceivedAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_178"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RecoverabilityOfVatAmount" xlink:label="loc_cmmb_RecoverabilityOfVatAmount_179"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RecoverabilityOfVatAmount" xlink:label="loc_cmmb_RecoverabilityOfVatAmount_180"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RecoverabilityOfVatAmount" xlink:label="loc_cmmb_RecoverabilityOfVatAmount_181"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_182"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_183"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_184"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_185"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_186"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_187"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_188"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_189"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_190"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_191"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_192"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_193"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_194"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_195"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_196"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_197"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RentAndMaintenanceResearchAndDevelopmentExpense" xlink:label="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_198"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RentAndMaintenanceResearchAndDevelopmentExpense" xlink:label="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_199"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RentAndMaintenanceResearchAndDevelopmentExpense" xlink:label="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_200"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RepurchaseArrangementMember" xlink:label="loc_cmmb_RepurchaseArrangementMember_201"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RepurchaseArrangementMember" xlink:label="loc_cmmb_RepurchaseArrangementMember_202"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RepurchaseArrangementMember" xlink:label="loc_cmmb_RepurchaseArrangementMember_203"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_204"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_205"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_206"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceiptsShares" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_207"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceiptsShares" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_208"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceiptsShares" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_209"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RestrictedOrdinarySharesMember" xlink:label="loc_cmmb_RestrictedOrdinarySharesMember_210"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RothCapitalPartnersLlcMember" xlink:label="loc_cmmb_RothCapitalPartnersLlcMember_211"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RothCapitalPartnersLlcMember" xlink:label="loc_cmmb_RothCapitalPartnersLlcMember_212"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RothCapitalPartnersLlcMember" xlink:label="loc_cmmb_RothCapitalPartnersLlcMember_213"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_SaleOfStockLineItems" xlink:label="loc_cmmb_SaleOfStockLineItems_214"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_SaleOfStockLineItems" xlink:label="loc_cmmb_SaleOfStockLineItems_215"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_SaleOfStocksPricePerShare" xlink:label="loc_cmmb_SaleOfStocksPricePerShare_216"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_SaleOfStocksPricePerShare" xlink:label="loc_cmmb_SaleOfStocksPricePerShare_217"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_SaleOfStocksPricePerShare" xlink:label="loc_cmmb_SaleOfStocksPricePerShare_218"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_SaleOfStockTable" xlink:label="loc_cmmb_SaleOfStockTable_219"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_SaleOfStockTable" xlink:label="loc_cmmb_SaleOfStockTable_220"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_SaleOfStockValueOfSharesIssuedInTransaction" xlink:label="loc_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_221"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_SaleOfStockValueOfSharesIssuedInTransaction" xlink:label="loc_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_222"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_SaleOfStockValueOfSharesIssuedInTransaction" xlink:label="loc_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_223"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock" xlink:label="loc_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_224"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock" xlink:label="loc_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_225"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock" xlink:label="loc_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_226"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock" xlink:label="loc_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_227"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock" xlink:label="loc_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_228"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock" xlink:label="loc_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_229"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" xlink:label="loc_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_230"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" xlink:label="loc_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_231"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" xlink:label="loc_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_232"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock" xlink:label="loc_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_233"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock" xlink:label="loc_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_234"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock" xlink:label="loc_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_235"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock" xlink:label="loc_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_236"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock" xlink:label="loc_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_237"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock" xlink:label="loc_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_238"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember" xlink:label="loc_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_239"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember" xlink:label="loc_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_240"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_SeverancePayPolicyTextBlock" xlink:label="loc_cmmb_SeverancePayPolicyTextBlock_241"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_SeverancePayPolicyTextBlock" xlink:label="loc_cmmb_SeverancePayPolicyTextBlock_242"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_SeverancePayPolicyTextBlock" xlink:label="loc_cmmb_SeverancePayPolicyTextBlock_243"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_244"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_245"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_246"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_247"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_248"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_249"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_250"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_251"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_252"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_253"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_254"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_255"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_256"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_257"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_258"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShareBasedCompensationResearchAndDevelopmentExpense" xlink:label="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_259"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShareBasedCompensationResearchAndDevelopmentExpense" xlink:label="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_260"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShareBasedCompensationResearchAndDevelopmentExpense" xlink:label="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_261"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShareholdingPercentageImmediatelyFollowingMerger" xlink:label="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_262"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShareholdingPercentageImmediatelyFollowingMerger" xlink:label="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_263"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShortTermBankDepositsPolicyTextBlock" xlink:label="loc_cmmb_ShortTermBankDepositsPolicyTextBlock_264"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShortTermBankDepositsPolicyTextBlock" xlink:label="loc_cmmb_ShortTermBankDepositsPolicyTextBlock_265"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShortTermBankDepositsPolicyTextBlock" xlink:label="loc_cmmb_ShortTermBankDepositsPolicyTextBlock_266"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_SignificanAccountingPoliciesLineItems" xlink:label="loc_cmmb_SignificanAccountingPoliciesLineItems_267"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_SignificanAccountingPoliciesLineItems" xlink:label="loc_cmmb_SignificanAccountingPoliciesLineItems_268"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_SignificantAccountingPoliciesTable" xlink:label="loc_cmmb_SignificantAccountingPoliciesTable_269"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_SignificantAccountingPoliciesTable" xlink:label="loc_cmmb_SignificantAccountingPoliciesTable_270"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_271"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_272"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_273"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_274"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_275"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_276"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_277"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_278"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" xlink:label="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_279"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" xlink:label="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_280"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" xlink:label="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_281"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger" xlink:label="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_282"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger" xlink:label="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_283"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger" xlink:label="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_284"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_285"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_286"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_287"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance" xlink:label="loc_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_288"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance" xlink:label="loc_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_289"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance" xlink:label="loc_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_290"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_291"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_292"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_293"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_TwoThousandsFifteenPlanMember" xlink:label="loc_cmmb_TwoThousandsFifteenPlanMember_294"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_TwoThousandsFifteenPlanMember" xlink:label="loc_cmmb_TwoThousandsFifteenPlanMember_295"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_TwoThousandsFifteenPlanMember" xlink:label="loc_cmmb_TwoThousandsFifteenPlanMember_296"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_TwoThousandsSeventeenPlanMember" xlink:label="loc_cmmb_TwoThousandsSeventeenPlanMember_297"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_TwoThousandsSeventeenPlanMember" xlink:label="loc_cmmb_TwoThousandsSeventeenPlanMember_298"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_TwoThousandsSeventeenPlanMember" xlink:label="loc_cmmb_TwoThousandsSeventeenPlanMember_299"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_300"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_301"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_302"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IL" xlink:label="loc_country_IL_303"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_country_US_304"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_EUR" xlink:label="loc_currency_EUR_305"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_ILS" xlink:label="loc_currency_ILS_306"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_ILS" xlink:label="loc_currency_ILS_307"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD" xlink:label="loc_currency_USD_308"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_XXX" xlink:label="loc_currency_XXX_309"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_310"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_311"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_312"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_313"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_314"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_315"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_316"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_317"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_318"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_319"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard_320"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_321"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_322"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtRestatementRecoveryAnalysisFlag" xlink:label="loc_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag_323"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_324"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_325"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_326"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_327"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_328"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_329"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport_330"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_331"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_332"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_333"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_334"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_335"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_336"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_337"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_338"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_339"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_340"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_341"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_342"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_343"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_344"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_345"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_346"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="loc_dei_EntityInformationFormerLegalOrRegisteredName_347"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_348"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_349"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_350"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_351"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_352"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_353"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_354"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_355"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_356"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_357"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_358"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer_359"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_360"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_361"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial_362"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_363"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications_364"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_365"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_366"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_367"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_368"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_369"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_370"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_371"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_372"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_373"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_374"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_375"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_376"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionExpense" xlink:label="loc_us-gaap_AccretionExpense_377"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxes" xlink:label="loc_us-gaap_AccruedIncomeTaxes_378"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_379"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_380"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_381"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_382"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_383"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_384"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_385"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_386"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_387"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_388"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_389"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_390"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_391"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_392"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_393"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_394"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_395"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_396"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_397"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_398"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_399"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_400"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_401"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_402"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_403"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_404"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_405"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_406"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_407"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalAdditionsMember" xlink:label="loc_us-gaap_CapitalAdditionsMember_408"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_409"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_410"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_411"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_412"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_413"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_414"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_415"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_416"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_417"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_418"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_419"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_420"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_421"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_422"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_423"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_424"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_425"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_426"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_427"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_428"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_429"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue_430"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_431"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_432"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_433"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_434"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_435"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_436"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_437"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_438"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_439"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_440"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_441"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_442"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_443"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_444"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_445"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_446"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_447"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_448"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_449"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_450"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_451"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_452"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_453"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_454"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_455"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_456"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_457"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaap_DepositsAssetsCurrent_458"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_459"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_460"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_461"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_462"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_463"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_464"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_465"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_466"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_467"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_468"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_469"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_470"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_471"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_472"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_473"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_474"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_475"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_476"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_477"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_478"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_479"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_480"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_481"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_482"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_483"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_484"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_485"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="loc_us-gaap_GeneralInsuranceExpense_486"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="loc_us-gaap_GeneralInsuranceExpense_487"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_488"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_490"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_491"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_492"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_493"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_494"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_495"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_496"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_497"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_498"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_499"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_500"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_501"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_502"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_503"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_504"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_505"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_506"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_507"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_508"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_509"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_510"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_511"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_512"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_513"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_514"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_515"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_516"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_517"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_518"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_519"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_520"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_521"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_522"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_523"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_524"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaap_LeaseAgreementsMember_525"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_526"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_527"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_528"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_529"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_530"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_531"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_532"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_533"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_534"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_535"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_536"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_537"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_538"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_539"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_540"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_541"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_542"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_543"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_544"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_545"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_546"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_547"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_548"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_549"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_550"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_551"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_552"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_553"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_554"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_555"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_556"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_557"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1_558"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1_559"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_560"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_561"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_562"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_563"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_564"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_565"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_566"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_567"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_568"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentDescription" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentDescription_569"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_570"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_571"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_572"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_573"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_574"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_575"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_576"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_577"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_578"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_579"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_580"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_581"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_582"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_583"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_584"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="loc_us-gaap_NoninterestExpenseDirectorsFees_585"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_586"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_587"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_588"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_589"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_590"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_591"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_592"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_593"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_594"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_595"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_596"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_597"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_598"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_599"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_600"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_601"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_602"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_603"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_604"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_605"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_606"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_607"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_608"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_609"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_610"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_611"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_612"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaap_OtherCommitmentsDescription_613"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_614"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_615"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_616"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_617"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_618"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_619"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_620"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_621"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_622"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_623"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_624"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_625"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_626"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_627"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_628"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_629"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_630"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_631"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_632"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_633"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_634"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_635"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_636"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_637"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaap_ProceedsFromOtherEquity_638"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaap_ProceedsFromOtherEquity_639"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfTreasuryStock" xlink:label="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_640"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfTreasuryStock" xlink:label="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_641"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfTreasuryStock" xlink:label="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_642"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_643"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_644"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_645"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_646"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_647"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_648"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_649"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_650"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_651"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_652"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_653"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_654"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_655"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_656"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_657"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_658"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_659"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_660"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_661"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember_662"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_663"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_664"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_665"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_666"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_667"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_668"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_669"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_670"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_671"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_672"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_673"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_674"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_675"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_676"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedInvestments" xlink:label="loc_us-gaap_RestrictedInvestments_677"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_678"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_679"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_680"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_681"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_682"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_683"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_684"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaap_SalariesAndWages_685"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaap_SalariesAndWages_686"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaap_SalariesAndWages_687"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_688"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_689"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_690"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_691"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_692"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_693"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_694"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_695"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_696"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_697"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_698"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_699"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_700"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_701"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_702"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_703"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_704"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_705"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_706"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_707"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_708"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_709"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_710"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_711"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_712"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_713"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_714"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_715"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_716"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_717"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_718"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_719"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_720"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_721"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_722"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_723"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_724"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_725"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_726"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_727"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_728"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_729"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_730"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_731"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_732"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_733"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_734"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_735"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_736"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_737"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_738"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_739"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_740"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_741"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_742"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_743"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_744"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_745"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_746"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_747"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_748"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_749"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_750"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_751"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_752"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_753"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_754"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_755"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_756"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_757"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_758"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_759"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_760"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_761"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_762"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_763"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_764"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_765"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_766"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_767"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_768"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_769"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_770"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_771"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_772"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_773"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_774"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_775"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_776"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_777"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_778"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_779"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_780"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_781"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_782"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_783"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_784"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_785"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_786"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_787"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_788"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_789"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_790"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_791"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_792"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_793"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_794"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_795"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_796"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_797"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_798"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_799"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_800"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_801"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_802"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaap_TreasuryStockCommonMember_803"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaap_TreasuryStockCommonMember_804"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaap_TreasuryStockCommonShares_805"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_806"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_807"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_808"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_809"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_810"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_811"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_812"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_813"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_814"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AdditionalWorkOrderAmount_0" xml:lang="en-US">Additional work order amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AdditionalWorkOrderAmount_1" xml:lang="en-US">Additional Work Order Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_AdditionalWorkOrderAmount_2" xml:lang="en-US">Additional work order</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AggregateAmountCommitmentToPay_0" xml:lang="en-US">Aggregate amount commitment to pay.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AggregateAmountCommitmentToPay_1" xml:lang="en-US">Aggregate amount commitment to pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AggregateAmountOfCommitmentPaid_0" xml:lang="en-US">Aggregate amount of commitment paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AggregateAmountOfCommitmentPaid_1" xml:lang="en-US">Aggregate amount of commitment paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_0" xml:lang="en-US">It represents as a aggregate offering price of at the market offering agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_1" xml:lang="en-US">Aggregate Offering Price Of At Market Offering Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_2" xml:lang="en-US">Aggregate offering price of at the market offering agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AmericanDepositarySharesMember_0" xml:lang="en-US">American Depositary Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AmericanDepositarySharesMember_1" xml:lang="en-US">American Depositary Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AnnualRatesOfDepreciation_0" xml:lang="en-US">Annual rates of depreciation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AnnualRatesOfDepreciation_1" xml:lang="en-US">Annual Rates Of Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_AnnualRatesOfDepreciation_2" xml:lang="en-US">Annual rates of depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AnnualRentAndManagementFees_0" xml:lang="en-US">Annual rent and management fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AnnualRentAndManagementFees_1" xml:lang="en-US">Annual rent and management fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AtmAgreementMember_0" xml:lang="en-US">ATM agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AtmAgreementMember_1" xml:lang="en-US">ATM agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_BankGuaranteesToPropertyOwner_0" xml:lang="en-US">Bank guarantees to property owner.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_BankGuaranteesToPropertyOwner_1" xml:lang="en-US">Bank guarantees to property owner</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_0" xml:lang="en-US">The amount of of asset held for sale recogized prior to the completion of merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_1" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Asset Held For Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_2" xml:lang="en-US">Asset held for sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_0" xml:lang="en-US">Amount of accrued liabilities to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_1" xml:lang="en-US">Accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_2" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_CantorMember_0" xml:lang="en-US">Represents about Cantor.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_CantorMember_1" xml:lang="en-US">Cantor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_CapitalAdditionsOneMember_0" xml:lang="en-US">FDA or equivalent agency marketing approval [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_CapitalAdditionsOneMember_1" xml:lang="en-US">Capital Additions One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_CapitalAdditionsOneMember_2" xml:lang="en-US">FDA or equivalent agency marketing approval [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_CashAcquiredInMerger_0" xml:lang="en-US">Cash acquired in merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_CashAcquiredInMerger_1" xml:lang="en-US">Cash acquired in Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_CashPaidAndReceivedDuringYearForAbstract_0" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_CashPaidAndReceivedDuringYearForAbstract_1" xml:lang="en-US">Cash Paid And Received During Year For [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_CashPaidAndReceivedDuringYearForAbstract_2" xml:lang="en-US">A. Cash paid and received during the year for:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_0" xml:lang="en-US">It represents as a change in temporary differences for which deferred taxes were not recognized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_1" xml:lang="en-US">Change In Temporary Differences For Deferred Taxes Not Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_2" xml:lang="en-US">Change in temporary differences for which deferred taxes were not recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ConsultantsAndSubcontractorsExpense_0" xml:lang="en-US">Consultants and subcontractors expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ConsultantsAndSubcontractorsExpense_1" xml:lang="en-US">Consultants And Subcontractors Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ConsultantsAndSubcontractorsExpense_2" xml:lang="en-US">Consultants and subcontractors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_0" xml:lang="en-US">The cumulative amounts of grants received from the IIA and recognized by the company, as of the balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_1" xml:lang="en-US">Cumulative Amounts Of Grants Received And Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_2" xml:lang="en-US">Cumulative amounts of grants received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_CurrencyTransactionLossValuationAllowance_0" xml:lang="en-US">Amount of increase (decrease) in the valuation allowance due to currency transaction loss.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_CurrencyTransactionLossValuationAllowance_1" xml:lang="en-US">Currency Transaction Loss Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_CurrencyTransactionLossValuationAllowance_2" xml:lang="en-US">Currency transaction income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_0" xml:lang="en-US">Earnings Per Share Calculation Denominator For Basic Net Income Loss Per Share Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_1" xml:lang="en-US">Earnings Per Share Calculation Denominator For Basic Net Income Loss Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_2" xml:lang="en-US">Denominator:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_EarningsPerShareCalculationNumeratorAbstract_0" xml:lang="en-US">Earnings Per Share Calculation Numerator Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_EarningsPerShareCalculationNumeratorAbstract_1" xml:lang="en-US">Earnings Per Share Calculation Numerator [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_EarningsPerShareCalculationNumeratorAbstract_2" xml:lang="en-US">Numerator:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_EffectOfReverseCapitalizationTransaction_0" xml:lang="en-US">The amount of effect due reverse capitalization transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_EffectOfReverseCapitalizationTransaction_1" xml:lang="en-US">Effect of reverse capitalization transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_EffectOfReverseCapitalizationTransactionShares_0" xml:lang="en-US">The number of shares isued due to effect of reverse capitalization transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_EffectOfReverseCapitalizationTransactionShares_1" xml:lang="en-US">Effect Of Reverse Capitalization Transaction Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_EffectOfReverseCapitalizationTransactionShares_2" xml:lang="en-US">Effect of reverse capitalization transaction (In shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_EstimatedFairValueOfNetAssetsAcquired_0" xml:lang="en-US">The amount of estimated fair value of the net assets acquired.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_EstimatedFairValueOfNetAssetsAcquired_1" xml:lang="en-US">Estimated Fair Value Of Net Assets Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_cmmb_EstimatedFairValueOfNetAssetsAcquired_2" xml:lang="en-US">Net acquired assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_0" xml:lang="en-US">The amount expects to receive of Chemomab Therapeutics Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_1" xml:lang="en-US">Expects To Receive Amount Of Chemomab Therapeutics Inc</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_2" xml:lang="en-US">Expects to receive amount of Chemomab Therapeutics Inc</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_FinanceIncomeExpensesNet_0" xml:lang="en-US">The net amount of finance income earned and finance expenses incurred during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cmmb_FinanceIncomeExpensesNet_1" xml:lang="en-US">Financing expenses (income), net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_FinanceIncomeExpensesNet_2" xml:lang="en-US">Finance Income (Expenses), Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_FormerChemomabSecurityHoldersMember_0" xml:lang="en-US">This represents former Chemomab security holders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_FormerChemomabSecurityHoldersMember_1" xml:lang="en-US">Former Chemomab Security Holders [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_GeneralAndAdministrativeDisclosureTextBlock_0" xml:lang="en-US">The entire disclosure of general and administrative expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_GeneralAndAdministrativeDisclosureTextBlock_1" xml:lang="en-US">General And Administrative Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_GeneralAndAdministrativeDisclosureTextBlock_2" xml:lang="en-US">General and Administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_0" xml:lang="en-US">Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_1" xml:lang="en-US">Government Sponsored Research And Development [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_2" xml:lang="en-US">Government-sponsored research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_IncomeTaxDisclosureLineItems_0" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_IncomeTaxDisclosureLineItems_1" xml:lang="en-US">Income Tax Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_IncomeTaxDisclosureTable_0" xml:lang="en-US">Disclosure of information pertaining to income taxes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_IncomeTaxDisclosureTable_1" xml:lang="en-US">Income Tax Disclosure [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_IncomeTaxesReceived_0" xml:lang="en-US">It represents income taxes received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_IncomeTaxesReceived_1" xml:lang="en-US">Income Taxes Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_IncomeTaxesReceived_2" xml:lang="en-US">Income taxes received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_IncomeTaxExpenseValuationAllowance_0" xml:lang="en-US">Amount of increase (decrease) in the valuation allowance due to income tax expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_IncomeTaxExpenseValuationAllowance_1" xml:lang="en-US">Income Tax Expense Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_IncomeTaxExpenseValuationAllowance_2" xml:lang="en-US">Income tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_IncrementalBorrowingRateOfLeases_0" xml:lang="en-US">It represents incremental borrowing rate of leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_IncrementalBorrowingRateOfLeases_1" xml:lang="en-US">Incremental Borrowing Rate Of Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_IncrementalBorrowingRateOfLeases_2" xml:lang="en-US">incremental borrowing rate of leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_InterestReceived_0" xml:lang="en-US">The amount of interest received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_InterestReceived_1" xml:lang="en-US">Interest Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_InterestReceived_2" xml:lang="en-US">Interest received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_InvestorsMember_0" xml:lang="en-US">Investors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_InvestorsMember_1" xml:lang="en-US">Investors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_LaboratoryEquipmentMember_0" xml:lang="en-US">Laboratory equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_LaboratoryEquipmentMember_1" xml:lang="en-US">Laboratory Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_LaboratoryEquipmentMember_2" xml:lang="en-US">Laboratory equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_LienOnBankDeposit_0" xml:lang="en-US">Lien on bank deposit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_LienOnBankDeposit_1" xml:lang="en-US">Lien on bank deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_LongTermLeaseDeposit_0" xml:lang="en-US">Long-term lease deposit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_LongTermLeaseDeposit_1" xml:lang="en-US">Long Term Lease Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_LongTermLeaseDeposit_2" xml:lang="en-US">Long-term lease deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_0" xml:lang="en-US">Represents losses and benefits for tax purposes for the year, for which deferred taxes were not recorded.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_1" xml:lang="en-US">Losses And Benefits For Tax Purposes For The Year For Which Deferred Taxes Were Not Recorded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_2" xml:lang="en-US">Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_MarketOfferingAgreementMember_0" xml:lang="en-US">Market Offering Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_MarketOfferingAgreementMember_1" xml:lang="en-US">This member stands for market offering agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_MarketOfferingAgreementMember_2" xml:lang="en-US">Market offering agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_MaximumPercentageOfPaymentsOfRoyalties_0" xml:lang="en-US">The maximum percentage of royalties payable on the amount of the grant received (dollar linked), plus interest at annual rate based on LIBOR.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_MaximumPercentageOfPaymentsOfRoyalties_1" xml:lang="en-US">Maximum Percentage Of Payments Of Royalties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_MaximumPercentageOfPaymentsOfRoyalties_2" xml:lang="en-US">Maximum percentage of payments of royalties (as a percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_0" xml:lang="en-US">This represents Merger Agreement with Chemomab, an Israeli limited company and a clinical-stage biotech company inclued proposed merger of CMB Acquisition Ltd, wholly owned subsidiary of our company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_1" xml:lang="en-US">Merger Agreement With Cmb Acquisition Ltd Subsidiary Of Ours And Chemomb [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_2" xml:lang="en-US">Merger agreement with Chemomab, an Israeli limited company and a clinical-stage biotech company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NatureOfOperationsDisclosureAbstract_0" xml:lang="en-US">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NatureOfOperationsDisclosureAbstract_1" xml:lang="en-US">Nature Of Operations Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_NatureOfOperationsDisclosureAbstract_2" xml:lang="en-US">NATURE OF OPERATIONS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_0" xml:lang="en-US">Number of ADS issued and outstanding after the merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_1" xml:lang="en-US">Number of ADS issued and outstanding after the merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfAdssOptionsIssuableOutstanding_0" xml:lang="en-US">Number of ADSs options issuable outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfAdssOptionsIssuableOutstanding_1" xml:lang="en-US">Number of ADSs options issuable outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfAdssVestedAndExercisable_0" xml:lang="en-US">Number of ADSs vested and exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfAdssVestedAndExercisable_1" xml:lang="en-US">Number of ADSs vested and exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfOptionsIssuableOutstanding_0" xml:lang="en-US">It represents number of options issuable outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfOptionsIssuableOutstanding_1" xml:lang="en-US">Number Of Options Issuable Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_NumberOfOptionsIssuableOutstanding_2" xml:lang="en-US">Number of options issuable outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfOptionsVestedAndExercisable_0" xml:lang="en-US">It represents number of options vested and exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfOptionsVestedAndExercisable_1" xml:lang="en-US">Number Of Options Vested And Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_NumberOfOptionsVestedAndExercisable_2" xml:lang="en-US">Number of options vested and exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfOrdinarySharesConsistedInDs_0" xml:lang="en-US">Represent the number of ordinary shares consisted in one American depository share (ADS).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfOrdinarySharesConsistedInDs_1" xml:lang="en-US">Number Of Ordinary Shares Consisted In Ds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_NumberOfOrdinarySharesConsistedInDs_2" xml:lang="en-US">Number of ordinary shares represented by each ADS (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfStockAdssResveredForIssuance_0" xml:lang="en-US">Number of stock option ADSs resvered for issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfStockAdssResveredForIssuance_1" xml:lang="en-US">Number Of Stock Adss Resvered For Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_NumberOfStockAdssResveredForIssuance_2" xml:lang="en-US">Number of stock option ADSs reversed for issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfStockReservedForIssuance_0" xml:lang="en-US">It represents number of stock resvered for issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfStockReservedForIssuance_1" xml:lang="en-US">Number Of Stock Reserved For Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_NumberOfStockReservedForIssuance_2" xml:lang="en-US">Number of stock reserved for issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfVestedAndExercisable_0" xml:lang="en-US">It represents number of vested and exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfVestedAndExercisable_1" xml:lang="en-US">Number Of Vested And Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_NumberOfVestedAndExercisable_2" xml:lang="en-US">Number of vested and exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfWarrantsPurchaseUpAdss_0" xml:lang="en-US">Number of warrants purchase ADS's.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfWarrantsPurchaseUpAdss_1" xml:lang="en-US">Number Of Warrants Purchase Up Adss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_NumberOfWarrantsPurchaseUpAdss_2" xml:lang="en-US">Number of warrants purchase ADS's</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_0" xml:lang="en-US">Operating right-of-use assets and operating lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_1" xml:lang="en-US">Operating Right Of Use Assets And Operating Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_2" xml:lang="en-US">Operating right-of-use assets and operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_OrdinarySharesNoParValuePerShareMember_0" xml:lang="en-US">Ordinary Shares, No Par Value Per Share [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_OrdinarySharesNoParValuePerShareMember_1" xml:lang="en-US">Ordinary Shares, No Par Value Per Share [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_0" xml:lang="en-US">Other accounts receivable and prepaid expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_1" xml:lang="en-US">Other Accounts Receivable And Prepaid Expenses [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_2" xml:lang="en-US">Other Receivables and Prepaid Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_0" xml:lang="en-US">Payment on commencement of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_1" xml:lang="en-US">Payment On Long Term Purchase Commitment Commencement Of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_2" xml:lang="en-US">Payment on commencement of agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_PaymentsForInvestmentInDeposits_0" xml:lang="en-US">The amount of payments for investm,ents in deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cmmb_PaymentsForInvestmentInDeposits_1" xml:lang="en-US">Investment in deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_PaymentsForInvestmentInDeposits_2" xml:lang="en-US">Payments for Investment in Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_PercentageOfMonthlyDepositsRate_0" xml:lang="en-US">Percentage of monthly deposits rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_PercentageOfMonthlyDepositsRate_1" xml:lang="en-US">Percentage of monthly deposits rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_0" xml:lang="en-US">The percentage of royalty payments on sale of product developed with funding received from the IIA.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_1" xml:lang="en-US">Percentage Of Royalty Payments On Sale Of Product</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_2" xml:lang="en-US">Royalty payments on sale of product (as a percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_PercentageOfShortTermDeposits_0" xml:lang="en-US">Percentage Of Short Term Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_PercentageOfShortTermDeposits_1" xml:lang="en-US">percentage of short term deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_PercentageOfShortTermDeposits_2" xml:lang="en-US">Percentage of short term deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ProceedsFromSaleOfAdss_0" xml:lang="en-US">Proceeds from sale of ADS's.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ProceedsFromSaleOfAdss_1" xml:lang="en-US">Proceeds from sale of ADS's</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ReassessmentOfRightOfUseAsset_0" xml:lang="en-US">Reassessment Of Right Of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ReassessmentOfRightOfUseAsset_1" xml:lang="en-US">Represent the amount of reassessment of the right of use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ReassessmentOfRightOfUseAsset_2" xml:lang="en-US">Reassessment of the right of use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ReceivablesFromGovernmentInstitutions_0" xml:lang="en-US">Government institutions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ReceivablesFromGovernmentInstitutions_1" xml:lang="en-US">Receivables From Government Institutions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ReceivablesFromGovernmentInstitutions_2" xml:lang="en-US">Government institutions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_0" xml:lang="en-US">The received amount of Chemomab Therapeutics Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_1" xml:lang="en-US">Received Amount Of Chemomab Therapeutics Inc</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_2" xml:lang="en-US">Received amount of Chemomab Therapeutics Inc</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RecoverabilityOfVatAmount_0" xml:lang="en-US">It represents recoverability of VAT amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RecoverabilityOfVatAmount_1" xml:lang="en-US">Recoverability Of Vat Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RecoverabilityOfVatAmount_2" xml:lang="en-US">Recoverability of VAT amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_0" xml:lang="en-US">Related party expenses related to professional services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_1" xml:lang="en-US">Related Party Transaction Professional Services From Transactions With Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_2" xml:lang="en-US">Professional services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_0" xml:lang="en-US">Related party expenses related to research and develeopment expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_1" xml:lang="en-US">Related Party Transaction Research And Development Expense From Transactions With Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_2" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_0" xml:lang="en-US">Related party expenses related to salaries and related expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_1" xml:lang="en-US">Related Party Transaction Salaries And Related Expenses From Transactions With Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_2" xml:lang="en-US">Salaries and related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_0" xml:lang="en-US">Related party expenses related to share based payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_1" xml:lang="en-US">Related Party Transaction Share Based Payments From Transactions With Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_2" xml:lang="en-US">Share-based payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_0" xml:lang="en-US">General and administrative related rent and maintenance expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_1" xml:lang="en-US">Rent And Maintenance General And Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_2" xml:lang="en-US">Rent and maintenance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_3" xml:lang="en-US">Lease and maintenance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_0" xml:lang="en-US">Research and development related rent and maintenance expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_1" xml:lang="en-US">Rent And Maintenance Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_2" xml:lang="en-US">Lease and maintenance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RepurchaseArrangementMember_0" xml:lang="en-US">This member stands for Repurchase Arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RepurchaseArrangementMember_1" xml:lang="en-US">Repurchase Arrangement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RepurchaseArrangementMember_2" xml:lang="en-US">Repurchase arrangement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RepurchaseOfAmericanDepositaryReceipts_0" xml:lang="en-US">Represents the amount of repurchase of american depositary receipts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RepurchaseOfAmericanDepositaryReceipts_1" xml:lang="en-US">Repurchase Of American Depositary Receipts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RepurchaseOfAmericanDepositaryReceipts_2" xml:lang="en-US">Repurchase of ADSs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_0" xml:lang="en-US">It represents repurchase of American Depositary Receipts shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_1" xml:lang="en-US">Repurchase Of American Depositary Receipts Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_2" xml:lang="en-US">Number of shares repurchase of ADSs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RestrictedOrdinarySharesMember_0" xml:lang="en-US">Restricted Ordinary Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RothCapitalPartnersLlcMember_0" xml:lang="en-US">Roth Capital Partners Llc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RothCapitalPartnersLlcMember_1" xml:lang="en-US">This member stands for Roth Capital Partners, LLC</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_RothCapitalPartnersLlcMember_2" xml:lang="en-US">Roth Capital Partners, LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_SaleOfStockLineItems_0" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_SaleOfStockLineItems_1" xml:lang="en-US">Sale Of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_SaleOfStocksPricePerShare_0" xml:lang="en-US">Per share amount received by the company for each share of common stock issued or sold in the stock transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_SaleOfStocksPricePerShare_1" xml:lang="en-US">Sale Of Stocks Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_SaleOfStocksPricePerShare_2" xml:lang="en-US">Share price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_SaleOfStockTable_0" xml:lang="en-US">Different names of stock transactions and the different attributes of each transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_SaleOfStockTable_1" xml:lang="en-US">Sale Of Stock [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_0" xml:lang="en-US">Represents the amount of sale of stock value of shares issued in transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_1" xml:lang="en-US">Sale Of Stock Value Of Shares Issued In Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_2" xml:lang="en-US">Issuance and sale of of ADS upto</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_0" xml:lang="en-US">Tabular disclosure of the annual rate of deprecation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_1" xml:lang="en-US">Schedule Of Annual Rate Of Deprecation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_2" xml:lang="en-US">Schedule of annual rate of deprecation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_0" xml:lang="en-US">Tabular disclosure of general and administrative expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_1" xml:lang="en-US">Schedule Of General And Administrative [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_2" xml:lang="en-US">Schedule of general and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_0" xml:lang="en-US">Schedule of other accounts receivable and prepaid expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_1" xml:lang="en-US">Schedule Of Other Accounts Receivable And Prepaid Expenses [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_2" xml:lang="en-US">Schedule of other accounts receivable and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_0" xml:lang="en-US">Tabular disclosure of related party payables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_1" xml:lang="en-US">Schedule Of Related Party Payables [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_2" xml:lang="en-US">Schedule of related party payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_0" xml:lang="en-US">Tabular disclosure of research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_1" xml:lang="en-US">Schedule Of Research And Development [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_2" xml:lang="en-US">Schedule of research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_0" xml:lang="en-US">This represents security holders of Anchiano as of immediately prior to the merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_1" xml:lang="en-US">Security holders of Anchiano as of immediately prior to the merger [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_SeverancePayPolicyTextBlock_0" xml:lang="en-US">Disclosure of accounting policy for severance pay.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_SeverancePayPolicyTextBlock_1" xml:lang="en-US">Severance Pay [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_SeverancePayPolicyTextBlock_2" xml:lang="en-US">Severance pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_0" xml:lang="en-US">It represents Share Based Compensation Arrangement By Share Based Payment Award ADS Forfeitures In Period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Ads Forfeitures In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_2" xml:lang="en-US">Options to purchase ordinary shares cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_0" xml:lang="en-US">It represents Share Based Compensation Arrangement By Share Based Payment Award ADS Outstanding Period Increase Decrease Weighted Average Exercise Price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Ads Outstanding Period Increase Decrease Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_2" xml:lang="en-US">Weighted average exercise price of ADSs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_0" xml:lang="en-US">Weighted average remaining contractual term for option awards granted during the period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants In Period, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_2" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_0" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award, Options, Acquired In Merger, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_1" xml:lang="en-US">Weighted average price of shares acquired in merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_2" xml:lang="en-US">Acquired in Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_0" xml:lang="en-US">General and administrative related share-based compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_1" xml:lang="en-US">Share Based Compensation General And Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_2" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_0" xml:lang="en-US">Research and development related share-based compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_1" xml:lang="en-US">Share Based Compensation Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_2" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_0" xml:lang="en-US">shareholding percentage immediately following the merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_1" xml:lang="en-US">Shareholding percentage immediately following the merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ShortTermBankDepositsPolicyTextBlock_0" xml:lang="en-US">Short Term Bank Deposits [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ShortTermBankDepositsPolicyTextBlock_1" xml:lang="en-US">Disclosure of accounting policy for Short-term Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ShortTermBankDepositsPolicyTextBlock_2" xml:lang="en-US">Short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_SignificanAccountingPoliciesLineItems_0" xml:lang="en-US">Significan Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_SignificanAccountingPoliciesLineItems_1" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_SignificantAccountingPoliciesTable_0" xml:lang="en-US">Significant Accounting Policies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_SignificantAccountingPoliciesTable_1" xml:lang="en-US">Disclosure of iinformation about significant accounting policies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_0" xml:lang="en-US">it represents number of shares and warrants issued during period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_1" xml:lang="en-US">Stock And Warrants Issued During Period New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_2" xml:lang="en-US">Issuance of shares and warrants, net of issuance costs (In shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_3" xml:lang="en-US">Issuance of shares and pre-funded warrants, net of issuance costs (in Shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_0" xml:lang="en-US">Value of stock issued in lieu contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_1" xml:lang="en-US">Stock And Warrants Issued During Period Value New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_2" xml:lang="en-US">Issuance of shares and warrants, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_3" xml:lang="en-US">Issuance of shares and pre-funded warrants, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_0" xml:lang="en-US">Number of new stocks of American Depository Shares ("ADS") issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_1" xml:lang="en-US">Stock Issued During Period American Depository Shares New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_2" xml:lang="en-US">Number of ADSs issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_0" xml:lang="en-US">Number of options acquired, including both vested and non-vested options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_1" xml:lang="en-US">Stock Issued During Period Shares Stock Options Acquired In Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_2" xml:lang="en-US">Acquired in Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_0" xml:lang="en-US">Number of share options (or share units) exercised during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_1" xml:lang="en-US">Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_2" xml:lang="en-US">Stock Issued During Period Shares Stock Options Exercised 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_0" xml:lang="en-US">Amount of increase (decrease) in the valuation allowance due to tax assets acquired through merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_1" xml:lang="en-US">Tax Assets Acquired Through Merger Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_2" xml:lang="en-US">Tax assets acquired through merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_0" xml:lang="en-US">It represents Total consideration of repurchase of american depositary receipts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_1" xml:lang="en-US">Total Consideration Of Repurchase Of American Depositary Receipts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_2" xml:lang="en-US">Total consideration of repurchase of ADSs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_TwoThousandsFifteenPlanMember_0" xml:lang="en-US">2015 plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_TwoThousandsFifteenPlanMember_1" xml:lang="en-US">Two Thousands Fifteen Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_TwoThousandsFifteenPlanMember_2" xml:lang="en-US">2015 plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_TwoThousandsSeventeenPlanMember_0" xml:lang="en-US">2017 plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_TwoThousandsSeventeenPlanMember_1" xml:lang="en-US">Two Thousands Seventeen Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_TwoThousandsSeventeenPlanMember_2" xml:lang="en-US">2017 plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_0" xml:lang="en-US">It represents weighted average price of repurchase of american depositary receipts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_1" xml:lang="en-US">Weighted Average Price Of Repurchase Of American Depositary Receipts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_2" xml:lang="en-US">Weighted average price of repurchase of ADSs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_IL_0" xml:lang="en-US">Israel [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_US_0" xml:lang="en-US">U.S. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_EUR_0" xml:lang="en-US">Euro [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_ILS_0" xml:lang="en-US">Israel, New Shekels</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_currency_ILS_1" xml:lang="en-US">NIS [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_USD_0" xml:lang="en-US">USD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_XXX_0" xml:lang="en-US">Other currencies [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AddressTypeDomain_0" xml:lang="en-US">Address Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag_0" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorFirmId_0" xml:lang="en-US">Auditor Firm Id</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorLocation_0" xml:lang="en-US">Auditor Location</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorName_0" xml:lang="en-US">Auditor Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_BusinessContactMember_0" xml:lang="en-US">Business Contact [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode_0" xml:lang="en-US">City Area Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelName_0" xml:lang="en-US">Contact Personnel Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract_0" xml:lang="en-US">Cover [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate_0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAccountingStandard_0" xml:lang="en-US">Document Accounting Standard</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAnnualReport_0" xml:lang="en-US">Document Annual Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag_0" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag_0" xml:lang="en-US">Document Financial Statement Restatement Recovery Analysis [Flag]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus_0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus_0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems_0" xml:lang="en-US">Document Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable_0" xml:lang="en-US">Document Information [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate_0" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentRegistrationStatement_0" xml:lang="en-US">Document Registration Statement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentShellCompanyReport_0" xml:lang="en-US">Document Shell Company Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport_0" xml:lang="en-US">Document Transition Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType_0" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1_0" xml:lang="en-US">Entity Address, Address Line One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine2_0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown_0" xml:lang="en-US">Entity Address, City or Town</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCountry_0" xml:lang="en-US">Entity Address, Country</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesAddressTypeAxis_0" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode_0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey_0" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus_0" xml:lang="en-US">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany_0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod_0" xml:lang="en-US">Entity Ex Transition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber_0" xml:lang="en-US">Entity File Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory_0" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode_0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInformationFormerLegalOrRegisteredName_0" xml:lang="en-US">Entity Information, Former Legal or Registered Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent_0" xml:lang="en-US">Entity Interactive Data Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPublicFloat_0" xml:lang="en-US">Entity Public Float</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName_0" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany_0" xml:lang="en-US">Entity Shell Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness_0" xml:lang="en-US">Entity Small Business</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber_0" xml:lang="en-US">Entity Tax Identification Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers_0" xml:lang="en-US">Entity Voluntary Filers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_0" xml:lang="en-US">Entity Well Known Seasoned Issuer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_IcfrAuditorAttestationFlag_0" xml:lang="en-US">Auditor Attestation Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber_0" xml:lang="en-US">Local Phone Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_PreCommencementIssuerTenderOffer_0" xml:lang="en-US">Pre-commencement Issuer Tender Offer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_PreCommencementTenderOffer_0" xml:lang="en-US">Pre-commencement Tender Offer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle_0" xml:lang="en-US">Title of 12(b) Security</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName_0" xml:lang="en-US">Name of Exchange on which Security is Registered</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SolicitingMaterial_0" xml:lang="en-US">Soliciting Material</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol_0" xml:lang="en-US">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_WrittenCommunications_0" xml:lang="en-US">Written Communications</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CurrencyAxis_0" xml:lang="en-US">Currency [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember_0" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember_0" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis_0" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember_0" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioForecastMember_0" xml:lang="en-US">Forecast [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioUnspecifiedDomain_0" xml:lang="en-US">Scenario [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis_0" xml:lang="en-US">Geographical [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis_0" xml:lang="en-US">Scenario [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis_0" xml:lang="en-US">Title of Individual [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_0" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent_0" xml:lang="en-US">Trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccretionExpense_0" xml:lang="en-US">Accretion Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedIncomeTaxes_0" xml:lang="en-US">Accrued Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_0" xml:lang="en-US">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_0" xml:lang="en-US">Recognized liability for royalties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0" xml:lang="en-US">Less - accumulated depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital_0" xml:lang="en-US">Additional paid-in capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_0" xml:lang="en-US">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_1" xml:lang="en-US">Additional paid in capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_0" xml:lang="en-US">Exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Adjustments for operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_0" xml:lang="en-US">Share-based compensation expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0" xml:lang="en-US">Outstanding options to purchase ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets_0" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets_1" xml:lang="en-US">Total assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract_0" xml:lang="en-US">ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent_0" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent_1" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0" xml:lang="en-US">Current assets:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract_1" xml:lang="en-US">Current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrent_0" xml:lang="en-US">Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsNoncurrent_1" xml:lang="en-US">Total non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract_0" xml:lang="en-US">Non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0" xml:lang="en-US">Basis of presentation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" xml:lang="en-US">Basis of Presentation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2" xml:lang="en-US">Basis of Preparation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_0" xml:lang="en-US">Business Acquisition [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_0" xml:lang="en-US">Prepaid and other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalAdditionsMember_0" xml:lang="en-US">New Drug Application and Biological License Application [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract_0" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xml:lang="en-US">Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_0" xml:lang="en-US">Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_0" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_1" xml:lang="en-US">Cash equivalents, and short-term deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1" xml:lang="en-US">Change in cash, cash equivalents and restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain_0" xml:lang="en-US">Class of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies_0" xml:lang="en-US">Commitments and contingent liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock_0" xml:lang="en-US">Commitments and Contingent Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember_0" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockMember_1" xml:lang="en-US">Ordinary shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockNoParValue_0" xml:lang="en-US">Common Stock, No Par Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued_0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue_0" xml:lang="en-US">Ordinary Shares no par value - Authorized: 650,000,000 shares as of December 31, 2021 and 500,000,000 shares as of December 31, 2020; Issued and outstanding: 228,090,300 shares at December 31, 2021 and 9,274,838 shares at December 31, 2020</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue_1" xml:lang="en-US">Ordinary Shares no par value - Authorized: 650,000,000 shares as of December 31, 2023, 2022 and 2021;Issued and outstanding: 284,094,700, 232,636,700 Ordinary shares at December 31, 2023 and 2022, respectively and 228,090,300 Ordinary shares at December 31, 2021</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue_2" xml:lang="en-US">Ordinary Shares no par value - Authorized: 4,650,000,000 and 650,000,000 Ordinary shares as of December 31, 2024, and December 31, 2023, respectively (*) Issued and outstanding: 377,132,220, and 284,094,700 Ordinary shares of December 31, 2024 and 2023, respectively (*)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_0" xml:lang="en-US">Deferred taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember_0" xml:lang="en-US">Computers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_0" xml:lang="en-US">Concentration of credit risks</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_1" xml:lang="en-US">Concentrations of credit risk</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_0" xml:lang="en-US">Principles of consolidation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfRevenue_0" xml:lang="en-US">Related Party Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CostOfRevenue_1" xml:lang="en-US">Total related party expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_0" xml:lang="en-US">Incremental borrowing rate based on credit rating</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_0" xml:lang="en-US">Deferred Tax Assets, Capital Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_1" xml:lang="en-US">Deferred tax asset capital closs carryforward</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_1" xml:lang="en-US">Gross deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_0" xml:lang="en-US">Research and development costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_1" xml:lang="en-US">Net deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0" xml:lang="en-US">Net operating loss carry-forwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_0" xml:lang="en-US">Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0" xml:lang="en-US">Share-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0" xml:lang="en-US">Less - Valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1" xml:lang="en-US">Balance at December 31</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2" xml:lang="en-US">Balance at January 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_3" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepositsAssetsCurrent_0" xml:lang="en-US">Short-term bank deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation_0" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DomesticCountryMember_0" xml:lang="en-US">Federal [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract_0" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic_0" xml:lang="en-US">Basic and diluted loss per Ordinary Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic_1" xml:lang="en-US">Basic loss per Ordinary Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted_0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted_1" xml:lang="en-US">Diluted loss per Ordinary Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_0" xml:lang="en-US">Earnings per ordinary share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_1" xml:lang="en-US">Loss per ordinary share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_0" xml:lang="en-US">Net Loss Per Share Attributable to Ordinary Shareholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0" xml:lang="en-US">Statutory tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0" xml:lang="en-US">Corporate tax rate (as a percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1" xml:lang="en-US">Corporate tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0" xml:lang="en-US">Employee and related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_1" xml:lang="en-US">Employees, consultants and related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain_0" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0" xml:lang="en-US">Fair value of financial instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0" xml:lang="en-US">Functional currency</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1" xml:lang="en-US">Foreign currency</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_0" xml:lang="en-US">Furniture and Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_1" xml:lang="en-US">Furniture and equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_0" xml:lang="en-US">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_1" xml:lang="en-US">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_2" xml:lang="en-US">Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xml:lang="en-US">General and Administrative Expense [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_0" xml:lang="en-US">General and administrative [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralInsuranceExpense_0" xml:lang="en-US">Insurance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralInsuranceExpense_1" xml:lang="en-US">Directors' and Officers' Insurance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_0" xml:lang="en-US">Impairment of long-lived assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0" xml:lang="en-US">Loss before income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xml:lang="en-US">Loss before taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" xml:lang="en-US">Loss before income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3" xml:lang="en-US">Loss before taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5" xml:lang="en-US">Loss before taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_0" xml:lang="en-US">Net loss per share attributable to ordinary shareholders, basic and diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1" xml:lang="en-US">Net loss per share attributable to ordinary shareholders, basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_1" xml:lang="en-US">Net loss per share attributable to ordinary shareholders, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract_0" xml:lang="en-US">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_0" xml:lang="en-US">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_0" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_0" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_0" xml:lang="en-US">Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_0" xml:lang="en-US">Income taxes paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_1" xml:lang="en-US">Income Taxes Paid, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_2" xml:lang="en-US">Income taxes paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_0" xml:lang="en-US">Tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_1" xml:lang="en-US">Actual income tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_2" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_3" xml:lang="en-US">Income tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_0" xml:lang="en-US">Theoretical tax benefit on the above amount Decrease (increase) in tax refund resulting from:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_0" xml:lang="en-US">Income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_1" xml:lang="en-US">Tax rate differential</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_0" xml:lang="en-US">Theoretical tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_1" xml:lang="en-US">Non-deductible expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_0" xml:lang="en-US">Change in trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_0" xml:lang="en-US">Change in accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0" xml:lang="en-US">Change in employees and related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_0" xml:lang="en-US">Change in leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1" xml:lang="en-US">Change in operating leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0" xml:lang="en-US">Change in other receivables and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseAgreementsMember_0" xml:lang="en-US">2020 Lien [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseExpirationDate1_0" xml:lang="en-US">Lease expiry date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_0" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_1" xml:lang="en-US">Leasehold improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeDisclosureAbstract_0" xml:lang="en-US">Lessee Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_0" xml:lang="en-US">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_0" xml:lang="en-US">Lessee, Lease, Description [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_1" xml:lang="en-US">Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0" xml:lang="en-US">Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1" xml:lang="en-US">Schedule of maturity of lease liabilities under our non-cancelable operating leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xml:lang="en-US">Total future minimum lease payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1" xml:lang="en-US">2027</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1" xml:lang="en-US">2026</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0" xml:lang="en-US">2023</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1" xml:lang="en-US">2025</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0" xml:lang="en-US">2022</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1" xml:lang="en-US">2023</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2" xml:lang="en-US">2024</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0" xml:lang="en-US">Less imputed interest:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_0" xml:lang="en-US">Lessee, Operating Lease, Option to Extend</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_1" xml:lang="en-US">Lease term, option to extend</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_0" xml:lang="en-US">Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_0" xml:lang="en-US">Lease term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities_0" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities_1" xml:lang="en-US">Total liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_0" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_1" xml:lang="en-US">Total liabilities and shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAssumed1_0" xml:lang="en-US">Liabilities assumed, net of non-cash assets received in Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAssumed1_1" xml:lang="en-US">Liabilities assumed, net of non-cash assets received in Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent_0" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent_1" xml:lang="en-US">Total current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_0" xml:lang="en-US">Current liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_1" xml:lang="en-US">Current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrent_0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrent_1" xml:lang="en-US">Total non-current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_0" xml:lang="en-US">Non-current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount_0" xml:lang="en-US">Payment for licensed agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_0" xml:lang="en-US">Category of Item Purchased [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentDescription_0" xml:lang="en-US">Description of application payment for licensed product</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NatureOfOperations_0" xml:lang="en-US">General</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xml:lang="en-US">Net cash provided by (used in) financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0" xml:lang="en-US">Cash flows from financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1" xml:lang="en-US">Net cash provided by investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0" xml:lang="en-US">Cash flows from investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2" xml:lang="en-US">Cash flows from operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Cash flows from operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NetIncomeLoss_0" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_NetIncomeLoss_1" xml:lang="en-US">Net loss for the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_0" xml:lang="en-US">Significant non- cash transaction:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1" xml:lang="en-US">B. Significant non- cash transaction:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoninterestExpenseDirectorsFees_0" xml:lang="en-US">Fees to Directors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_0" xml:lang="en-US">Financing income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_1" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_2" xml:lang="en-US">Financing expenses (income), net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_3" xml:lang="en-US">Nonoperating Income (Expense), Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_0" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_1" xml:lang="en-US">Schedule of Unvested RSA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OfficersCompensation_0" xml:lang="en-US">Salaries and related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses_0" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses_1" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract_0" xml:lang="en-US">Operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss_0" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_1" xml:lang="en-US">Operating Income (Loss), Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_2" xml:lang="en-US">Net Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_3" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_4" xml:lang="en-US">Net loss for the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss_0" xml:lang="en-US">Decrease in the carrying amount of the right-of-use asset due to impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss_1" xml:lang="en-US">Increase in the carrying amount of the right-of-use asset due to impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability_0" xml:lang="en-US">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability_1" xml:lang="en-US">Operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability_2" xml:lang="en-US">Present value of operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability_3" xml:lang="en-US">Present value of operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_1" xml:lang="en-US">Operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0" xml:lang="en-US">Non-current operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1" xml:lang="en-US">Non-current&#160;operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_1" xml:lang="en-US">Operating lease right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentsDescription_0" xml:lang="en-US">Decsription of occurrence for payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentsLineItems_0" xml:lang="en-US">Other Commitments [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentsTable_0" xml:lang="en-US">Other Commitments [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense_0" xml:lang="en-US">Other General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense_1" xml:lang="en-US">Other expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_0" xml:lang="en-US">Due to Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_1" xml:lang="en-US">Related Party Payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherResearchAndDevelopmentExpense_0" xml:lang="en-US">Other expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_0" xml:lang="en-US">Purchase of treasury share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_1" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis_0" xml:lang="en-US">Plan Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain_0" xml:lang="en-US">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0" xml:lang="en-US">Preferred shares par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued_0" xml:lang="en-US">Preferred shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0" xml:lang="en-US">Prepaid Expense and Other Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xml:lang="en-US">Other receivables and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1" xml:lang="en-US">Other accounts receivable and prepaid expenses, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_0" xml:lang="en-US">Prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseNoncurrent_0" xml:lang="en-US">Long-term prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrivatePlacementMember_0" xml:lang="en-US">The Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_0" xml:lang="en-US">Proceeds from preferred shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants_0" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants_1" xml:lang="en-US">Exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromOtherEquity_0" xml:lang="en-US">Proceeds from Other Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromOtherEquity_1" xml:lang="en-US">Issuance of shares net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfTreasuryStock_0" xml:lang="en-US">Proceeds from Sale of Treasury Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfTreasuryStock_1" xml:lang="en-US">Treasury stock at cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfTreasuryStock_2" xml:lang="en-US">Sale of treasury share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_0" xml:lang="en-US">Exercise of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_0" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfessionalFees_0" xml:lang="en-US">Professional services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss_0" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProfitLoss_1" xml:lang="en-US">Loss before taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProfitLoss_2" xml:lang="en-US">Net loss for the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_0" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_0" xml:lang="en-US">Property and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_0" xml:lang="en-US">Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_0" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_1" xml:lang="en-US">Property Plant And Equipment Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0" xml:lang="en-US">Property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_0" xml:lang="en-US">Annual rates of depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0" xml:lang="en-US">Schedule of Property And Equpment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_1" xml:lang="en-US">Schedule of property and equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain_0" xml:lang="en-US">Related and Nonrelated Parties [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyMember_0" xml:lang="en-US">Related Party [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_0" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_0" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0" xml:lang="en-US">Related and Nonrelated Parties [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0" xml:lang="en-US">Related Parties Balances and Transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract_0" xml:lang="en-US">Research and Development [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_0" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_1" xml:lang="en-US">Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0" xml:lang="en-US">Research and development expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1" xml:lang="en-US">Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_0" xml:lang="en-US">Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashCurrent_0" xml:lang="en-US">Restricted Cash, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedCashCurrent_1" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashNoncurrent_0" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedInvestments_0" xml:lang="en-US">Bank restricted deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems_0" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember_0" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember_1" xml:lang="en-US">Accumulated deficit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0" xml:lang="en-US">Right-of-use asset recognized with corresponding lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1" xml:lang="en-US">Right-of-use asset recognized with corresponding lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RoyaltyExpense_0" xml:lang="en-US">Royality expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalariesAndWages_0" xml:lang="en-US">Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SalariesAndWages_1" xml:lang="en-US">Salaries and related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SalariesAndWages_2" xml:lang="en-US">Salaries, fees and related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0" xml:lang="en-US">Sale of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0" xml:lang="en-US">Schedule of Weighted Average Number of Shares Excluded From Computation of Diluted Net Loss Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1" xml:lang="en-US">Schedule of weighted average number of shares excluded from computation of diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_0" xml:lang="en-US">Schedule of components of cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_0" xml:lang="en-US">Summary of the effect of share-based compensation on the statements of operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1" xml:lang="en-US">Schedule of the effect of share-based compensation on the statements of operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0" xml:lang="en-US">Schedule of Significant Components of the Company's Deferred Tax Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" xml:lang="en-US">Schedule of significant components of the company's deferred tax asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0" xml:lang="en-US">Schedule of Computation of Basic and Diluted Net Loss Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" xml:lang="en-US">Schedule of computation of basic and diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0" xml:lang="en-US">Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1" xml:lang="en-US">Schedule of reconciliation of theoretical income tax expense to actual income tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_0" xml:lang="en-US">Schedule of net assets acquired based on their estimated fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_0" xml:lang="en-US">Schedule of Transaction With Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" xml:lang="en-US">Schedule of transaction with related parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0" xml:lang="en-US">Summary of assumptions used to calculate the fair value of the options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" xml:lang="en-US">Schedule of assumptions used to calculate the fair value of the options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_0" xml:lang="en-US">Summary of number and weighted average exercise prices of option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_1" xml:lang="en-US">Schedule of number and weighted average exercise prices of option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_1" xml:lang="en-US">Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesCPreferredStockMember_0" xml:lang="en-US">Series C Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeveranceCosts1_0" xml:lang="en-US">Severance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation_0" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation_1" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1" xml:lang="en-US">Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" xml:lang="en-US">Unvested at beginning of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xml:lang="en-US">Outstanding at December 31, 2024</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1" xml:lang="en-US">Vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_0" xml:lang="en-US">Exercise price (in U.S. dollar)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0" xml:lang="en-US">Dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0" xml:lang="en-US">Expected life of options (in years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_0" xml:lang="en-US">Expected volatility, maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_0" xml:lang="en-US">Expected volatility, minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0" xml:lang="en-US">Risk-free interest rate, maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0" xml:lang="en-US">Risk-free interest rate, minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0" xml:lang="en-US">Weighted Average Remaining Contractual Life in Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0" xml:lang="en-US">Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1" xml:lang="en-US">Options to purchase ADS cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xml:lang="en-US">Outstanding at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xml:lang="en-US">Outstanding at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_0" xml:lang="en-US">Weighted average exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0" xml:lang="en-US">Number of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xml:lang="en-US">Outstanding at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xml:lang="en-US">Outstanding at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0" xml:lang="en-US">Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0" xml:lang="en-US">Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_0" xml:lang="en-US">Share Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice_0" xml:lang="en-US">Weighted average share price (in U.S. dollar)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding_0" xml:lang="en-US">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding_1" xml:lang="en-US">Beginning balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding_2" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SoftwareDevelopmentMember_0" xml:lang="en-US">Website Development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SoftwareDevelopmentMember_1" xml:lang="en-US">Website development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis_0" xml:lang="en-US">Class of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_0" xml:lang="en-US">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems_0" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_0" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_0" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable_0" xml:lang="en-US">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity_0" xml:lang="en-US">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity_1" xml:lang="en-US">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity_2" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity_3" xml:lang="en-US">Total shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1" xml:lang="en-US">Shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract_0" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_0" xml:lang="en-US">Reverse stock split conversion ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" xml:lang="en-US">Number of shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0" xml:lang="en-US">Exercise of Options, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1" xml:lang="en-US">Exercise of options (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_0" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_1" xml:lang="en-US">Sale of treasury share at cost (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0" xml:lang="en-US">Issuance of shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0" xml:lang="en-US">Exercise of Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1" xml:lang="en-US">Exercise of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_0" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_1" xml:lang="en-US">Sale of treasury share at cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems_0" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember_0" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventMember_1" xml:lang="en-US">Subsequent event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract_0" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_1" xml:lang="en-US">Events After Balance Sheet Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable_0" xml:lang="en-US">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_0" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_0" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_0" xml:lang="en-US">Sale of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_0" xml:lang="en-US">Schedule of Roll Forward of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_1" xml:lang="en-US">Schedule of roll forward of valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract_0" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract_1" xml:lang="en-US">Supplementary cash flows information:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_0" xml:lang="en-US">Capital losses carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockCommonMember_0" xml:lang="en-US">Treasury Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TreasuryStockCommonMember_1" xml:lang="en-US">Treasury share [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockCommonShares_0" xml:lang="en-US">Treasury Stock, Common, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates_0" xml:lang="en-US">Use of estimates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_0" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1" xml:lang="en-US">Net change in the total valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xml:lang="en-US">Weighted average number of Ordinary Shares outstanding, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2" xml:lang="en-US">Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1" xml:lang="en-US">Weighted average number of Ordinary Shares outstanding, basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2" xml:lang="en-US">Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AdditionalWorkOrderAmount_1" xlink:to="lab_cmmb_AdditionalWorkOrderAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AdditionalWorkOrderAmount_2" xlink:to="lab_cmmb_AdditionalWorkOrderAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AdditionalWorkOrderAmount_3" xlink:to="lab_cmmb_AdditionalWorkOrderAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AggregateAmountCommitmentToPay_4" xlink:to="lab_cmmb_AggregateAmountCommitmentToPay_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AggregateAmountCommitmentToPay_5" xlink:to="lab_cmmb_AggregateAmountCommitmentToPay_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AggregateAmountOfCommitmentPaid_6" xlink:to="lab_cmmb_AggregateAmountOfCommitmentPaid_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AggregateAmountOfCommitmentPaid_7" xlink:to="lab_cmmb_AggregateAmountOfCommitmentPaid_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_8" xlink:to="lab_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_9" xlink:to="lab_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_10" xlink:to="lab_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AmericanDepositarySharesMember_11" xlink:to="lab_cmmb_AmericanDepositarySharesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AmericanDepositarySharesMember_12" xlink:to="lab_cmmb_AmericanDepositarySharesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AnnualRatesOfDepreciation_13" xlink:to="lab_cmmb_AnnualRatesOfDepreciation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AnnualRatesOfDepreciation_14" xlink:to="lab_cmmb_AnnualRatesOfDepreciation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AnnualRatesOfDepreciation_15" xlink:to="lab_cmmb_AnnualRatesOfDepreciation_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AnnualRentAndManagementFees_16" xlink:to="lab_cmmb_AnnualRentAndManagementFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AnnualRentAndManagementFees_17" xlink:to="lab_cmmb_AnnualRentAndManagementFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AtmAgreementMember_18" xlink:to="lab_cmmb_AtmAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AtmAgreementMember_19" xlink:to="lab_cmmb_AtmAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BankGuaranteesToPropertyOwner_20" xlink:to="lab_cmmb_BankGuaranteesToPropertyOwner_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BankGuaranteesToPropertyOwner_21" xlink:to="lab_cmmb_BankGuaranteesToPropertyOwner_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_22" xlink:to="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_23" xlink:to="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_24" xlink:to="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_25" xlink:to="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_26" xlink:to="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_27" xlink:to="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CantorMember_28" xlink:to="lab_cmmb_CantorMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CantorMember_29" xlink:to="lab_cmmb_CantorMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CapitalAdditionsOneMember_30" xlink:to="lab_cmmb_CapitalAdditionsOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CapitalAdditionsOneMember_31" xlink:to="lab_cmmb_CapitalAdditionsOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CapitalAdditionsOneMember_32" xlink:to="lab_cmmb_CapitalAdditionsOneMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CashAcquiredInMerger_33" xlink:to="lab_cmmb_CashAcquiredInMerger_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CashAcquiredInMerger_34" xlink:to="lab_cmmb_CashAcquiredInMerger_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_35" xlink:to="lab_cmmb_CashPaidAndReceivedDuringYearForAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_36" xlink:to="lab_cmmb_CashPaidAndReceivedDuringYearForAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_37" xlink:to="lab_cmmb_CashPaidAndReceivedDuringYearForAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_38" xlink:to="lab_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_39" xlink:to="lab_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_40" xlink:to="lab_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ConsultantsAndSubcontractorsExpense_41" xlink:to="lab_cmmb_ConsultantsAndSubcontractorsExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ConsultantsAndSubcontractorsExpense_42" xlink:to="lab_cmmb_ConsultantsAndSubcontractorsExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ConsultantsAndSubcontractorsExpense_43" xlink:to="lab_cmmb_ConsultantsAndSubcontractorsExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_44" xlink:to="lab_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_45" xlink:to="lab_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_46" xlink:to="lab_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CurrencyTransactionLossValuationAllowance_47" xlink:to="lab_cmmb_CurrencyTransactionLossValuationAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CurrencyTransactionLossValuationAllowance_48" xlink:to="lab_cmmb_CurrencyTransactionLossValuationAllowance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CurrencyTransactionLossValuationAllowance_49" xlink:to="lab_cmmb_CurrencyTransactionLossValuationAllowance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_50" xlink:to="lab_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_51" xlink:to="lab_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_52" xlink:to="lab_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_53" xlink:to="lab_cmmb_EarningsPerShareCalculationNumeratorAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_54" xlink:to="lab_cmmb_EarningsPerShareCalculationNumeratorAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_55" xlink:to="lab_cmmb_EarningsPerShareCalculationNumeratorAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EffectOfReverseCapitalizationTransaction_56" xlink:to="lab_cmmb_EffectOfReverseCapitalizationTransaction_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EffectOfReverseCapitalizationTransaction_57" xlink:to="lab_cmmb_EffectOfReverseCapitalizationTransaction_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_58" xlink:to="lab_cmmb_EffectOfReverseCapitalizationTransactionShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_59" xlink:to="lab_cmmb_EffectOfReverseCapitalizationTransactionShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_60" xlink:to="lab_cmmb_EffectOfReverseCapitalizationTransactionShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_61" xlink:to="lab_cmmb_EstimatedFairValueOfNetAssetsAcquired_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_62" xlink:to="lab_cmmb_EstimatedFairValueOfNetAssetsAcquired_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_63" xlink:to="lab_cmmb_EstimatedFairValueOfNetAssetsAcquired_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_64" xlink:to="lab_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_65" xlink:to="lab_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_66" xlink:to="lab_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_FinanceIncomeExpensesNet_67" xlink:to="lab_cmmb_FinanceIncomeExpensesNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_FinanceIncomeExpensesNet_68" xlink:to="lab_cmmb_FinanceIncomeExpensesNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_FinanceIncomeExpensesNet_69" xlink:to="lab_cmmb_FinanceIncomeExpensesNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_FormerChemomabSecurityHoldersMember_70" xlink:to="lab_cmmb_FormerChemomabSecurityHoldersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_FormerChemomabSecurityHoldersMember_71" xlink:to="lab_cmmb_FormerChemomabSecurityHoldersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_GeneralAndAdministrativeDisclosureTextBlock_72" xlink:to="lab_cmmb_GeneralAndAdministrativeDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_GeneralAndAdministrativeDisclosureTextBlock_73" xlink:to="lab_cmmb_GeneralAndAdministrativeDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_GeneralAndAdministrativeDisclosureTextBlock_74" xlink:to="lab_cmmb_GeneralAndAdministrativeDisclosureTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_75" xlink:to="lab_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_76" xlink:to="lab_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_77" xlink:to="lab_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_78" xlink:to="lab_cmmb_IncomeTaxDisclosureLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_79" xlink:to="lab_cmmb_IncomeTaxDisclosureLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_80" xlink:to="lab_cmmb_IncomeTaxDisclosureTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_81" xlink:to="lab_cmmb_IncomeTaxDisclosureTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxesReceived_82" xlink:to="lab_cmmb_IncomeTaxesReceived_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxesReceived_83" xlink:to="lab_cmmb_IncomeTaxesReceived_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxesReceived_84" xlink:to="lab_cmmb_IncomeTaxesReceived_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxExpenseValuationAllowance_85" xlink:to="lab_cmmb_IncomeTaxExpenseValuationAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxExpenseValuationAllowance_86" xlink:to="lab_cmmb_IncomeTaxExpenseValuationAllowance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxExpenseValuationAllowance_87" xlink:to="lab_cmmb_IncomeTaxExpenseValuationAllowance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncrementalBorrowingRateOfLeases_88" xlink:to="lab_cmmb_IncrementalBorrowingRateOfLeases_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncrementalBorrowingRateOfLeases_89" xlink:to="lab_cmmb_IncrementalBorrowingRateOfLeases_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncrementalBorrowingRateOfLeases_90" xlink:to="lab_cmmb_IncrementalBorrowingRateOfLeases_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_InterestReceived_91" xlink:to="lab_cmmb_InterestReceived_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_InterestReceived_92" xlink:to="lab_cmmb_InterestReceived_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_InterestReceived_93" xlink:to="lab_cmmb_InterestReceived_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_InvestorsMember_94" xlink:to="lab_cmmb_InvestorsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_InvestorsMember_95" xlink:to="lab_cmmb_InvestorsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LaboratoryEquipmentMember_96" xlink:to="lab_cmmb_LaboratoryEquipmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LaboratoryEquipmentMember_97" xlink:to="lab_cmmb_LaboratoryEquipmentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LaboratoryEquipmentMember_98" xlink:to="lab_cmmb_LaboratoryEquipmentMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LienOnBankDeposit_99" xlink:to="lab_cmmb_LienOnBankDeposit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LienOnBankDeposit_100" xlink:to="lab_cmmb_LienOnBankDeposit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LongTermLeaseDeposit_101" xlink:to="lab_cmmb_LongTermLeaseDeposit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LongTermLeaseDeposit_102" xlink:to="lab_cmmb_LongTermLeaseDeposit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LongTermLeaseDeposit_103" xlink:to="lab_cmmb_LongTermLeaseDeposit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_104" xlink:to="lab_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_105" xlink:to="lab_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_106" xlink:to="lab_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MarketOfferingAgreementMember_107" xlink:to="lab_cmmb_MarketOfferingAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MarketOfferingAgreementMember_108" xlink:to="lab_cmmb_MarketOfferingAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MarketOfferingAgreementMember_109" xlink:to="lab_cmmb_MarketOfferingAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_110" xlink:to="lab_cmmb_MaximumPercentageOfPaymentsOfRoyalties_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_111" xlink:to="lab_cmmb_MaximumPercentageOfPaymentsOfRoyalties_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_112" xlink:to="lab_cmmb_MaximumPercentageOfPaymentsOfRoyalties_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_113" xlink:to="lab_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_114" xlink:to="lab_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_115" xlink:to="lab_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_116" xlink:to="lab_cmmb_NatureOfOperationsDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_117" xlink:to="lab_cmmb_NatureOfOperationsDisclosureAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_118" xlink:to="lab_cmmb_NatureOfOperationsDisclosureAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_119" xlink:to="lab_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_120" xlink:to="lab_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfAdssOptionsIssuableOutstanding_121" xlink:to="lab_cmmb_NumberOfAdssOptionsIssuableOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfAdssOptionsIssuableOutstanding_122" xlink:to="lab_cmmb_NumberOfAdssOptionsIssuableOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfAdssVestedAndExercisable_123" xlink:to="lab_cmmb_NumberOfAdssVestedAndExercisable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfAdssVestedAndExercisable_124" xlink:to="lab_cmmb_NumberOfAdssVestedAndExercisable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOptionsIssuableOutstanding_125" xlink:to="lab_cmmb_NumberOfOptionsIssuableOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOptionsIssuableOutstanding_126" xlink:to="lab_cmmb_NumberOfOptionsIssuableOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOptionsIssuableOutstanding_127" xlink:to="lab_cmmb_NumberOfOptionsIssuableOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOptionsVestedAndExercisable_128" xlink:to="lab_cmmb_NumberOfOptionsVestedAndExercisable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOptionsVestedAndExercisable_129" xlink:to="lab_cmmb_NumberOfOptionsVestedAndExercisable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOptionsVestedAndExercisable_130" xlink:to="lab_cmmb_NumberOfOptionsVestedAndExercisable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_131" xlink:to="lab_cmmb_NumberOfOrdinarySharesConsistedInDs_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_132" xlink:to="lab_cmmb_NumberOfOrdinarySharesConsistedInDs_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_133" xlink:to="lab_cmmb_NumberOfOrdinarySharesConsistedInDs_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfStockAdssResveredForIssuance_134" xlink:to="lab_cmmb_NumberOfStockAdssResveredForIssuance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfStockAdssResveredForIssuance_135" xlink:to="lab_cmmb_NumberOfStockAdssResveredForIssuance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfStockAdssResveredForIssuance_136" xlink:to="lab_cmmb_NumberOfStockAdssResveredForIssuance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfStockReservedForIssuance_137" xlink:to="lab_cmmb_NumberOfStockReservedForIssuance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfStockReservedForIssuance_138" xlink:to="lab_cmmb_NumberOfStockReservedForIssuance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfStockReservedForIssuance_139" xlink:to="lab_cmmb_NumberOfStockReservedForIssuance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfVestedAndExercisable_140" xlink:to="lab_cmmb_NumberOfVestedAndExercisable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfVestedAndExercisable_141" xlink:to="lab_cmmb_NumberOfVestedAndExercisable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfVestedAndExercisable_142" xlink:to="lab_cmmb_NumberOfVestedAndExercisable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_143" xlink:to="lab_cmmb_NumberOfWarrantsPurchaseUpAdss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_144" xlink:to="lab_cmmb_NumberOfWarrantsPurchaseUpAdss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_145" xlink:to="lab_cmmb_NumberOfWarrantsPurchaseUpAdss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_146" xlink:to="lab_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_147" xlink:to="lab_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_148" xlink:to="lab_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OrdinarySharesNoParValuePerShareMember_149" xlink:to="lab_cmmb_OrdinarySharesNoParValuePerShareMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OrdinarySharesNoParValuePerShareMember_150" xlink:to="lab_cmmb_OrdinarySharesNoParValuePerShareMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_151" xlink:to="lab_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_152" xlink:to="lab_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_153" xlink:to="lab_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_154" xlink:to="lab_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_155" xlink:to="lab_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_156" xlink:to="lab_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PaymentsForInvestmentInDeposits_157" xlink:to="lab_cmmb_PaymentsForInvestmentInDeposits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PaymentsForInvestmentInDeposits_158" xlink:to="lab_cmmb_PaymentsForInvestmentInDeposits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PaymentsForInvestmentInDeposits_159" xlink:to="lab_cmmb_PaymentsForInvestmentInDeposits_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PercentageOfMonthlyDepositsRate_160" xlink:to="lab_cmmb_PercentageOfMonthlyDepositsRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PercentageOfMonthlyDepositsRate_161" xlink:to="lab_cmmb_PercentageOfMonthlyDepositsRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_162" xlink:to="lab_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_163" xlink:to="lab_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_164" xlink:to="lab_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PercentageOfShortTermDeposits_165" xlink:to="lab_cmmb_PercentageOfShortTermDeposits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PercentageOfShortTermDeposits_166" xlink:to="lab_cmmb_PercentageOfShortTermDeposits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PercentageOfShortTermDeposits_167" xlink:to="lab_cmmb_PercentageOfShortTermDeposits_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ProceedsFromSaleOfAdss_168" xlink:to="lab_cmmb_ProceedsFromSaleOfAdss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ProceedsFromSaleOfAdss_169" xlink:to="lab_cmmb_ProceedsFromSaleOfAdss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ReassessmentOfRightOfUseAsset_170" xlink:to="lab_cmmb_ReassessmentOfRightOfUseAsset_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ReassessmentOfRightOfUseAsset_171" xlink:to="lab_cmmb_ReassessmentOfRightOfUseAsset_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ReassessmentOfRightOfUseAsset_172" xlink:to="lab_cmmb_ReassessmentOfRightOfUseAsset_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ReceivablesFromGovernmentInstitutions_173" xlink:to="lab_cmmb_ReceivablesFromGovernmentInstitutions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ReceivablesFromGovernmentInstitutions_174" xlink:to="lab_cmmb_ReceivablesFromGovernmentInstitutions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ReceivablesFromGovernmentInstitutions_175" xlink:to="lab_cmmb_ReceivablesFromGovernmentInstitutions_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_176" xlink:to="lab_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_177" xlink:to="lab_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_178" xlink:to="lab_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RecoverabilityOfVatAmount_179" xlink:to="lab_cmmb_RecoverabilityOfVatAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RecoverabilityOfVatAmount_180" xlink:to="lab_cmmb_RecoverabilityOfVatAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RecoverabilityOfVatAmount_181" xlink:to="lab_cmmb_RecoverabilityOfVatAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_182" xlink:to="lab_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_183" xlink:to="lab_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_184" xlink:to="lab_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_185" xlink:to="lab_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_186" xlink:to="lab_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_187" xlink:to="lab_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_188" xlink:to="lab_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_189" xlink:to="lab_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_190" xlink:to="lab_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_191" xlink:to="lab_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_192" xlink:to="lab_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_193" xlink:to="lab_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_194" xlink:to="lab_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_195" xlink:to="lab_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_196" xlink:to="lab_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_197" xlink:to="lab_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_198" xlink:to="lab_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_199" xlink:to="lab_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_200" xlink:to="lab_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseArrangementMember_201" xlink:to="lab_cmmb_RepurchaseArrangementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseArrangementMember_202" xlink:to="lab_cmmb_RepurchaseArrangementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseArrangementMember_203" xlink:to="lab_cmmb_RepurchaseArrangementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_204" xlink:to="lab_cmmb_RepurchaseOfAmericanDepositaryReceipts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_205" xlink:to="lab_cmmb_RepurchaseOfAmericanDepositaryReceipts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_206" xlink:to="lab_cmmb_RepurchaseOfAmericanDepositaryReceipts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_207" xlink:to="lab_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_208" xlink:to="lab_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_209" xlink:to="lab_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RestrictedOrdinarySharesMember_210" xlink:to="lab_cmmb_RestrictedOrdinarySharesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RothCapitalPartnersLlcMember_211" xlink:to="lab_cmmb_RothCapitalPartnersLlcMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RothCapitalPartnersLlcMember_212" xlink:to="lab_cmmb_RothCapitalPartnersLlcMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RothCapitalPartnersLlcMember_213" xlink:to="lab_cmmb_RothCapitalPartnersLlcMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStockLineItems_214" xlink:to="lab_cmmb_SaleOfStockLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStockLineItems_215" xlink:to="lab_cmmb_SaleOfStockLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStocksPricePerShare_216" xlink:to="lab_cmmb_SaleOfStocksPricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStocksPricePerShare_217" xlink:to="lab_cmmb_SaleOfStocksPricePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStocksPricePerShare_218" xlink:to="lab_cmmb_SaleOfStocksPricePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStockTable_219" xlink:to="lab_cmmb_SaleOfStockTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStockTable_220" xlink:to="lab_cmmb_SaleOfStockTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_221" xlink:to="lab_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_222" xlink:to="lab_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_223" xlink:to="lab_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_224" xlink:to="lab_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_225" xlink:to="lab_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_226" xlink:to="lab_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_227" xlink:to="lab_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_228" xlink:to="lab_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_229" xlink:to="lab_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_230" xlink:to="lab_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_231" xlink:to="lab_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_232" xlink:to="lab_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_233" xlink:to="lab_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_234" xlink:to="lab_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_235" xlink:to="lab_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_236" xlink:to="lab_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_237" xlink:to="lab_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_238" xlink:to="lab_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_239" xlink:to="lab_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_240" xlink:to="lab_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SeverancePayPolicyTextBlock_241" xlink:to="lab_cmmb_SeverancePayPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SeverancePayPolicyTextBlock_242" xlink:to="lab_cmmb_SeverancePayPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SeverancePayPolicyTextBlock_243" xlink:to="lab_cmmb_SeverancePayPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_244" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_245" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_246" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_247" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_248" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_249" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_250" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_251" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_252" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_253" xlink:to="lab_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_254" xlink:to="lab_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_255" xlink:to="lab_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_256" xlink:to="lab_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_257" xlink:to="lab_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_258" xlink:to="lab_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_259" xlink:to="lab_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_260" xlink:to="lab_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_261" xlink:to="lab_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_262" xlink:to="lab_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_263" xlink:to="lab_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShortTermBankDepositsPolicyTextBlock_264" xlink:to="lab_cmmb_ShortTermBankDepositsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShortTermBankDepositsPolicyTextBlock_265" xlink:to="lab_cmmb_ShortTermBankDepositsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShortTermBankDepositsPolicyTextBlock_266" xlink:to="lab_cmmb_ShortTermBankDepositsPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SignificanAccountingPoliciesLineItems_267" xlink:to="lab_cmmb_SignificanAccountingPoliciesLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SignificanAccountingPoliciesLineItems_268" xlink:to="lab_cmmb_SignificanAccountingPoliciesLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SignificantAccountingPoliciesTable_269" xlink:to="lab_cmmb_SignificantAccountingPoliciesTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SignificantAccountingPoliciesTable_270" xlink:to="lab_cmmb_SignificantAccountingPoliciesTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_271" xlink:to="lab_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_272" xlink:to="lab_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_273" xlink:to="lab_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_274" xlink:to="lab_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_275" xlink:to="lab_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_276" xlink:to="lab_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_277" xlink:to="lab_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_278" xlink:to="lab_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_279" xlink:to="lab_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_280" xlink:to="lab_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_281" xlink:to="lab_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_282" xlink:to="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_283" xlink:to="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_284" xlink:to="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_285" xlink:to="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_286" xlink:to="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_287" xlink:to="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_288" xlink:to="lab_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_289" xlink:to="lab_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_290" xlink:to="lab_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_291" xlink:to="lab_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_292" xlink:to="lab_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_293" xlink:to="lab_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TwoThousandsFifteenPlanMember_294" xlink:to="lab_cmmb_TwoThousandsFifteenPlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TwoThousandsFifteenPlanMember_295" xlink:to="lab_cmmb_TwoThousandsFifteenPlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TwoThousandsFifteenPlanMember_296" xlink:to="lab_cmmb_TwoThousandsFifteenPlanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TwoThousandsSeventeenPlanMember_297" xlink:to="lab_cmmb_TwoThousandsSeventeenPlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TwoThousandsSeventeenPlanMember_298" xlink:to="lab_cmmb_TwoThousandsSeventeenPlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TwoThousandsSeventeenPlanMember_299" xlink:to="lab_cmmb_TwoThousandsSeventeenPlanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_300" xlink:to="lab_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_301" xlink:to="lab_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_302" xlink:to="lab_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IL_303" xlink:to="lab_country_IL_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_304" xlink:to="lab_country_US_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR_305" xlink:to="lab_currency_EUR_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_ILS_306" xlink:to="lab_currency_ILS_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_ILS_307" xlink:to="lab_currency_ILS_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_USD_308" xlink:to="lab_currency_USD_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_XXX_309" xlink:to="lab_currency_XXX_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain_310" xlink:to="lab_dei_AddressTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_311" xlink:to="lab_dei_AmendmentFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId_312" xlink:to="lab_dei_AuditorFirmId_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation_313" xlink:to="lab_dei_AuditorLocation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName_314" xlink:to="lab_dei_AuditorName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember_315" xlink:to="lab_dei_BusinessContactMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_316" xlink:to="lab_dei_CityAreaCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName_317" xlink:to="lab_dei_ContactPersonnelName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_318" xlink:to="lab_dei_CoverAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_319" xlink:to="lab_dei_CurrentFiscalYearEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAccountingStandard_320" xlink:to="lab_dei_DocumentAccountingStandard_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport_321" xlink:to="lab_dei_DocumentAnnualReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag_322" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag_323" xlink:to="lab_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_324" xlink:to="lab_dei_DocumentFiscalPeriodFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_325" xlink:to="lab_dei_DocumentFiscalYearFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems_326" xlink:to="lab_dei_DocumentInformationLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable_327" xlink:to="lab_dei_DocumentInformationTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_328" xlink:to="lab_dei_DocumentPeriodEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentRegistrationStatement_329" xlink:to="lab_dei_DocumentRegistrationStatement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentShellCompanyReport_330" xlink:to="lab_dei_DocumentShellCompanyReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_331" xlink:to="lab_dei_DocumentTransitionReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_332" xlink:to="lab_dei_DocumentType_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_333" xlink:to="lab_dei_EntityAddressAddressLine1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2_334" xlink:to="lab_dei_EntityAddressAddressLine2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_335" xlink:to="lab_dei_EntityAddressCityOrTown_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry_336" xlink:to="lab_dei_EntityAddressCountry_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_337" xlink:to="lab_dei_EntityAddressesAddressTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_338" xlink:to="lab_dei_EntityAddressPostalZipCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_339" xlink:to="lab_dei_EntityCentralIndexKey_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_340" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_341" xlink:to="lab_dei_EntityCurrentReportingStatus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_342" xlink:to="lab_dei_EntityEmergingGrowthCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod_343" xlink:to="lab_dei_EntityExTransitionPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_344" xlink:to="lab_dei_EntityFileNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_345" xlink:to="lab_dei_EntityFilerCategory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_346" xlink:to="lab_dei_EntityIncorporationStateCountryCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationFormerLegalOrRegisteredName_347" xlink:to="lab_dei_EntityInformationFormerLegalOrRegisteredName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_348" xlink:to="lab_dei_EntityInteractiveDataCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_349" xlink:to="lab_dei_EntityPublicFloat_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_350" xlink:to="lab_dei_EntityRegistrantName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_351" xlink:to="lab_dei_EntityShellCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_352" xlink:to="lab_dei_EntitySmallBusiness_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_353" xlink:to="lab_dei_EntityTaxIdentificationNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_354" xlink:to="lab_dei_EntityVoluntaryFilers_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_355" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag_356" xlink:to="lab_dei_IcfrAuditorAttestationFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_357" xlink:to="lab_dei_LocalPhoneNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer_358" xlink:to="lab_dei_PreCommencementIssuerTenderOffer_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer_359" xlink:to="lab_dei_PreCommencementTenderOffer_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_360" xlink:to="lab_dei_Security12bTitle_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_361" xlink:to="lab_dei_SecurityExchangeName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial_362" xlink:to="lab_dei_SolicitingMaterial_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_363" xlink:to="lab_dei_TradingSymbol_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications_364" xlink:to="lab_dei_WrittenCommunications_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis_365" xlink:to="lab_srt_CurrencyAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_366" xlink:to="lab_srt_MaximumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_367" xlink:to="lab_srt_MinimumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_368" xlink:to="lab_srt_RangeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_369" xlink:to="lab_srt_RangeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember_370" xlink:to="lab_srt_ScenarioForecastMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain_371" xlink:to="lab_srt_ScenarioUnspecifiedDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_372" xlink:to="lab_srt_StatementGeographicalAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis_373" xlink:to="lab_srt_StatementScenarioAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis_374" xlink:to="lab_srt_TitleOfIndividualAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_375" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent_376" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionExpense_377" xlink:to="lab_us-gaap_AccretionExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxes_378" xlink:to="lab_us-gaap_AccruedIncomeTaxes_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_379" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_380" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_381" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_382" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_383" xlink:to="lab_us-gaap_AdditionalPaidInCapital_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_384" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_385" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_386" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_387" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_388" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_389" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_390" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_391" xlink:to="lab_us-gaap_Assets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_392" xlink:to="lab_us-gaap_Assets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_393" xlink:to="lab_us-gaap_AssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_394" xlink:to="lab_us-gaap_AssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_395" xlink:to="lab_us-gaap_AssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_396" xlink:to="lab_us-gaap_AssetsCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_397" xlink:to="lab_us-gaap_AssetsCurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent_398" xlink:to="lab_us-gaap_AssetsNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent_399" xlink:to="lab_us-gaap_AssetsNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_400" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_401" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_402" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_403" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_404" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_405" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_406" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_407" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalAdditionsMember_408" xlink:to="lab_us-gaap_CapitalAdditionsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_409" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_410" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_411" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_412" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_413" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_414" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_415" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_416" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_417" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_418" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_419" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_420" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_421" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_422" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_423" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_424" xlink:to="lab_us-gaap_ClassOfStockDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_425" xlink:to="lab_us-gaap_CommitmentsAndContingencies_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_426" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsDisclosureTextBlock_427" xlink:to="lab_us-gaap_CommitmentsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_428" xlink:to="lab_us-gaap_CommonStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_429" xlink:to="lab_us-gaap_CommonStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNoParValue_430" xlink:to="lab_us-gaap_CommonStockNoParValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_431" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_432" xlink:to="lab_us-gaap_CommonStockSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_433" xlink:to="lab_us-gaap_CommonStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_434" xlink:to="lab_us-gaap_CommonStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_435" xlink:to="lab_us-gaap_CommonStockValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_436" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_437" xlink:to="lab_us-gaap_ComputerEquipmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_438" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_439" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_440" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue_441" xlink:to="lab_us-gaap_CostOfRevenue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue_442" xlink:to="lab_us-gaap_CostOfRevenue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_443" xlink:to="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_444" xlink:to="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_445" xlink:to="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_446" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_447" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_448" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_449" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_450" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_451" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_452" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_453" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_454" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_455" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_456" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_457" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsCurrent_458" xlink:to="lab_us-gaap_DepositsAssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_459" xlink:to="lab_us-gaap_Depreciation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_460" xlink:to="lab_us-gaap_DomesticCountryMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_461" xlink:to="lab_us-gaap_EarningsPerShareAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_462" xlink:to="lab_us-gaap_EarningsPerShareBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_463" xlink:to="lab_us-gaap_EarningsPerShareBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_464" xlink:to="lab_us-gaap_EarningsPerShareDiluted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_465" xlink:to="lab_us-gaap_EarningsPerShareDiluted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_466" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_467" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_468" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_469" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_470" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_471" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_472" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_473" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_474" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_475" xlink:to="lab_us-gaap_EquityComponentDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_476" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_477" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_478" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_479" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_480" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_481" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_482" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_483" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_484" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_485" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralInsuranceExpense_486" xlink:to="lab_us-gaap_GeneralInsuranceExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralInsuranceExpense_487" xlink:to="lab_us-gaap_GeneralInsuranceExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_488" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_490" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_491" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_492" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_493" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_494" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_495" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_496" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_497" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_498" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_499" xlink:to="lab_us-gaap_IncomeStatementAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_500" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_501" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_502" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_503" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_504" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_505" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_506" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_507" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_508" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_509" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_510" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_511" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_512" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_513" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_514" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_515" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_516" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_517" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_518" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_519" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_520" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_521" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_522" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_523" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_524" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAgreementsMember_525" xlink:to="lab_us-gaap_LeaseAgreementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseExpirationDate1_526" xlink:to="lab_us-gaap_LeaseExpirationDate1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_527" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_528" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_529" xlink:to="lab_us-gaap_LesseeDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_530" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_531" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_532" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_533" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_534" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_535" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_536" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_537" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_538" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_539" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_540" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_541" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_542" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_543" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_544" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_545" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_546" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_547" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_548" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_549" xlink:to="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_550" xlink:to="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_551" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract_552" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_553" xlink:to="lab_us-gaap_Liabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_554" xlink:to="lab_us-gaap_Liabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_555" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_556" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_557" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAssumed1_558" xlink:to="lab_us-gaap_LiabilitiesAssumed1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAssumed1_559" xlink:to="lab_us-gaap_LiabilitiesAssumed1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_560" xlink:to="lab_us-gaap_LiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_561" xlink:to="lab_us-gaap_LiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_562" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_563" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_564" xlink:to="lab_us-gaap_LiabilitiesNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_565" xlink:to="lab_us-gaap_LiabilitiesNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_566" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentAmount_567" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_568" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentDescription_569" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations_570" xlink:to="lab_us-gaap_NatureOfOperations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_571" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_572" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_573" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_574" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_575" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_576" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_577" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_578" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_579" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_580" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_581" xlink:to="lab_us-gaap_NetIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_582" xlink:to="lab_us-gaap_NetIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_583" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_584" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoninterestExpenseDirectorsFees_585" xlink:to="lab_us-gaap_NoninterestExpenseDirectorsFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_586" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_587" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_588" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_589" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_590" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_591" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficersCompensation_592" xlink:to="lab_us-gaap_OfficersCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_593" xlink:to="lab_us-gaap_OperatingExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_594" xlink:to="lab_us-gaap_OperatingExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_595" xlink:to="lab_us-gaap_OperatingExpensesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_596" xlink:to="lab_us-gaap_OperatingIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_597" xlink:to="lab_us-gaap_OperatingIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_598" xlink:to="lab_us-gaap_OperatingIncomeLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_599" xlink:to="lab_us-gaap_OperatingIncomeLoss_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_600" xlink:to="lab_us-gaap_OperatingIncomeLoss_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss_601" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss_602" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_603" xlink:to="lab_us-gaap_OperatingLeaseLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_604" xlink:to="lab_us-gaap_OperatingLeaseLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_605" xlink:to="lab_us-gaap_OperatingLeaseLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_606" xlink:to="lab_us-gaap_OperatingLeaseLiability_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_607" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_608" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_609" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_610" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_611" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_612" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDescription_613" xlink:to="lab_us-gaap_OtherCommitmentsDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_614" xlink:to="lab_us-gaap_OtherCommitmentsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable_615" xlink:to="lab_us-gaap_OtherCommitmentsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherGeneralAndAdministrativeExpense_616" xlink:to="lab_us-gaap_OtherGeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherGeneralAndAdministrativeExpense_617" xlink:to="lab_us-gaap_OtherGeneralAndAdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_618" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_619" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherResearchAndDevelopmentExpense_620" xlink:to="lab_us-gaap_OtherResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_621" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_622" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_623" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_624" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_625" xlink:to="lab_us-gaap_PlanNameAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_626" xlink:to="lab_us-gaap_PlanNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_627" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_628" xlink:to="lab_us-gaap_PreferredStockSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_629" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_630" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_631" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_632" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseNoncurrent_633" xlink:to="lab_us-gaap_PrepaidExpenseNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember_634" xlink:to="lab_us-gaap_PrivatePlacementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_635" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants_636" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants_637" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherEquity_638" xlink:to="lab_us-gaap_ProceedsFromOtherEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherEquity_639" xlink:to="lab_us-gaap_ProceedsFromOtherEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_640" xlink:to="lab_us-gaap_ProceedsFromSaleOfTreasuryStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_641" xlink:to="lab_us-gaap_ProceedsFromSaleOfTreasuryStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_642" xlink:to="lab_us-gaap_ProceedsFromSaleOfTreasuryStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_643" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_644" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees_645" xlink:to="lab_us-gaap_ProfessionalFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_646" xlink:to="lab_us-gaap_ProfitLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_647" xlink:to="lab_us-gaap_ProfitLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_648" xlink:to="lab_us-gaap_ProfitLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_649" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_650" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_651" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_652" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_653" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_654" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_655" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_656" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_657" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_658" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_659" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_660" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_661" xlink:to="lab_us-gaap_RelatedPartyDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember_662" xlink:to="lab_us-gaap_RelatedPartyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_663" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_664" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_665" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_666" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_667" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_668" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_669" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_670" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_671" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_672" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_673" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent_674" xlink:to="lab_us-gaap_RestrictedCashCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent_675" xlink:to="lab_us-gaap_RestrictedCashCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent_676" xlink:to="lab_us-gaap_RestrictedCashNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedInvestments_677" xlink:to="lab_us-gaap_RestrictedInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_678" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_679" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_680" xlink:to="lab_us-gaap_RetainedEarningsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_681" xlink:to="lab_us-gaap_RetainedEarningsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_682" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_683" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense_684" xlink:to="lab_us-gaap_RoyaltyExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalariesAndWages_685" xlink:to="lab_us-gaap_SalariesAndWages_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalariesAndWages_686" xlink:to="lab_us-gaap_SalariesAndWages_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalariesAndWages_687" xlink:to="lab_us-gaap_SalariesAndWages_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_688" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_689" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_690" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_691" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_692" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_693" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_694" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_695" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_696" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_697" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_698" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_699" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_700" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_701" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_702" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_703" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_704" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_705" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_706" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_707" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_708" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_709" xlink:to="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_710" xlink:to="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_711" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_712" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember_713" xlink:to="lab_us-gaap_SeriesCPreferredStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1_714" xlink:to="lab_us-gaap_SeveranceCosts1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_715" xlink:to="lab_us-gaap_ShareBasedCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_716" xlink:to="lab_us-gaap_ShareBasedCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_717" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_718" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_719" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_720" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_721" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_722" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_723" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_724" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_725" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_726" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_727" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_728" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_729" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_730" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_731" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_732" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_733" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_734" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_735" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_736" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_737" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_738" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_739" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_740" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_741" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_742" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_743" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_744" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_745" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_746" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_747" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_748" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_749" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_750" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_751" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_752" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_753" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_754" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_755" xlink:to="lab_us-gaap_SharePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_756" xlink:to="lab_us-gaap_SharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_757" xlink:to="lab_us-gaap_SharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_758" xlink:to="lab_us-gaap_SharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_759" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember_760" xlink:to="lab_us-gaap_SoftwareDevelopmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember_761" xlink:to="lab_us-gaap_SoftwareDevelopmentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_762" xlink:to="lab_us-gaap_StatementClassOfStockAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_763" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_764" xlink:to="lab_us-gaap_StatementLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_765" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_766" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_767" xlink:to="lab_us-gaap_StatementTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_768" xlink:to="lab_us-gaap_StockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_769" xlink:to="lab_us-gaap_StockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_770" xlink:to="lab_us-gaap_StockholdersEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_771" xlink:to="lab_us-gaap_StockholdersEquity_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_772" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_773" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_774" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_775" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_776" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_777" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_778" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_779" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_780" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_781" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_782" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_783" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_784" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_785" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_786" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_787" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_788" xlink:to="lab_us-gaap_SubsequentEventLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_789" xlink:to="lab_us-gaap_SubsequentEventMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_790" xlink:to="lab_us-gaap_SubsequentEventMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_791" xlink:to="lab_us-gaap_SubsequentEventsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_792" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_793" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_794" xlink:to="lab_us-gaap_SubsequentEventTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_795" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_796" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_797" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_798" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_799" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_800" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_801" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_802" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember_803" xlink:to="lab_us-gaap_TreasuryStockCommonMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember_804" xlink:to="lab_us-gaap_TreasuryStockCommonMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares_805" xlink:to="lab_us-gaap_TreasuryStockCommonShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_806" xlink:to="lab_us-gaap_UseOfEstimates_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_807" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_808" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_809" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_810" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_811" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_812" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_813" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_814" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>cmmb-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#BalanceSheetsParenthetical" roleURI="http://www.anchiano.com/role/BalanceSheetsParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#StatementsOfOperations" roleURI="http://www.anchiano.com/role/StatementsOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#StatementsOfChangesInEquity" roleURI="http://www.anchiano.com/role/StatementsOfChangesInEquity"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#StatementsOfCashFlows" roleURI="http://www.anchiano.com/role/StatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#General" roleURI="http://www.anchiano.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#CashAndCashEquivalents" roleURI="http://www.anchiano.com/role/CashAndCashEquivalents"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#OtherReceivablesAndPrepaidExpenses" roleURI="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpenses"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#PropertyAndEquipmentNet" roleURI="http://www.anchiano.com/role/PropertyAndEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#Leases" roleURI="http://www.anchiano.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#CommitmentsAndContingentLiabilities" roleURI="http://www.anchiano.com/role/CommitmentsAndContingentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#ShareCapital" roleURI="http://www.anchiano.com/role/ShareCapital"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#ResearchAndDevelopment" roleURI="http://www.anchiano.com/role/ResearchAndDevelopment"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#GeneralAndAdministrative" roleURI="http://www.anchiano.com/role/GeneralAndAdministrative"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#IncomeTaxes" roleURI="http://www.anchiano.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#RelatedPartiesBalancesAndTransactions" roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactions"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#NetLossPerShareAttributableToOrdinaryShareholders" roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholders"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#CashAndCashEquivalentsTables" roleURI="http://www.anchiano.com/role/CashAndCashEquivalentsTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#OtherReceivablesAndPrepaidExpensesTables" roleURI="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#PropertyAndEquipmentNetTables" roleURI="http://www.anchiano.com/role/PropertyAndEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#LeasesTables" roleURI="http://www.anchiano.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#ShareCapitalTables" roleURI="http://www.anchiano.com/role/ShareCapitalTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#ResearchAndDevelopmentTables" roleURI="http://www.anchiano.com/role/ResearchAndDevelopmentTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#GeneralAndAdministrativeTables" roleURI="http://www.anchiano.com/role/GeneralAndAdministrativeTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#IncomeTaxesTables" roleURI="http://www.anchiano.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#RelatedPartiesBalancesAndTransactionsTables" roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#NetLossPerShareAttributableToOrdinaryShareholdersTables" roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#GeneralDetails" roleURI="http://www.anchiano.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails" roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#CashAndCashEquivalentsDetails" roleURI="http://www.anchiano.com/role/CashAndCashEquivalentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#OtherReceivablesAndPrepaidExpensesDetails" roleURI="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#PropertyAndEquipmentNetDetails" roleURI="http://www.anchiano.com/role/PropertyAndEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#LeasesNarrativeDetails" roleURI="http://www.anchiano.com/role/LeasesNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails" roleURI="http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#CommitmentsAndContingentLiabilitiesDetails" roleURI="http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#ShareCapitalNarrativeDetails" roleURI="http://www.anchiano.com/role/ShareCapitalNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#ShareCapitalShare-basedCompensationExpensesDetails" roleURI="http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails" roleURI="http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails" roleURI="http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails" roleURI="http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails" roleURI="http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#IncomeTaxesDetails" roleURI="http://www.anchiano.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails" roleURI="http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails" roleURI="http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails" roleURI="http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails" roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails" roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails" roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails" roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20241231.xsd#ShareCapitalScheduleOfUnvestedRSADetails" roleURI="http://www.anchiano.com/role/ShareCapitalScheduleOfUnvestedRSADetails"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/DocumentDocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AmericanDepositarySharesMember" xlink:label="loc_cmmb_AmericanDepositarySharesMember_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_OrdinarySharesNoParValuePerShareMember" xlink:label="loc_cmmb_OrdinarySharesNoParValuePerShareMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="loc_dei_EntityInformationFormerLegalOrRegisteredName_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_48"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_49"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications_51"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial_52"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer_53"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_54"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_55"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtRestatementRecoveryAnalysisFlag" xlink:label="loc_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag_56"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentInformationTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_cmmb_AmericanDepositarySharesMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_cmmb_OrdinarySharesNoParValuePerShareMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_1" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_5" xlink:to="loc_dei_AddressTypeDomain_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_5" xlink:to="loc_dei_BusinessContactMember_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_1" xlink:to="loc_dei_DocumentInformationLineItems_8" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityCentralIndexKey_8" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_AmendmentFlag_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_DocumentType_11" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_DocumentRegistrationStatement_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_CurrentFiscalYearEndDate_13" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_DocumentFiscalYearFocus_14" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_DocumentPeriodEndDate_15" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_DocumentAnnualReport_16" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_DocumentTransitionReport_17" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_DocumentShellCompanyReport_18" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityFileNumber_19" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityRegistrantName_20" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityIncorporationStateCountryCode_21" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityTaxIdentificationNumber_22" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityAddressAddressLine1_23" order="150" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityAddressAddressLine2_24" order="160" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityAddressCityOrTown_25" order="170" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityAddressCountry_26" order="180" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityAddressPostalZipCode_27" order="190" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_CityAreaCode_28" order="200" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_ContactPersonnelName_29" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_LocalPhoneNumber_30" order="220" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityInformationFormerLegalOrRegisteredName_31" order="230" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_Security12bTitle_32" order="240" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_TradingSymbol_33" order="250" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_SecurityExchangeName_34" order="260" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_35" order="270" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityVoluntaryFilers_36" order="280" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityCurrentReportingStatus_37" order="290" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityInteractiveDataCurrent_38" order="300" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityFilerCategory_39" order="310" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntitySmallBusiness_40" order="320" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityEmergingGrowthCompany_41" order="330" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_DocumentAccountingStandard_42" order="340" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityExTransitionPeriod_43" order="350" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_IcfrAuditorAttestationFlag_44" order="360" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityShellCompany_45" order="370" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityPublicFloat_46" order="380" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_47" order="390" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_AuditorName_48" order="400" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_AuditorLocation_49" order="410" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_AuditorFirmId_50" order="420" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_WrittenCommunications_51" order="430" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_SolicitingMaterial_52" order="440" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_PreCommencementTenderOffer_53" order="450" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_54" order="460" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_55" order="470" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag_56" order="480" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaap_DepositsAssetsCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_31"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AssetsAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_DepositsAssetsCurrent_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_RestrictedCashCurrent_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_AssetsCurrent_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_7" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_8" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7" xlink:to="loc_us-gaap_AssetsNoncurrent_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_Assets_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_15" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_16" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_17" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_18" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_us-gaap_LiabilitiesCurrent_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_21" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_21" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_21" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_CommitmentsAndContingencies_24" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_Liabilities_25" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26" xlink:to="loc_us-gaap_CommonStockValue_26" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26" xlink:to="loc_us-gaap_AdditionalPaidInCapital_27" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_28" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26" xlink:to="loc_us-gaap_StockholdersEquity_29" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_31" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/BalanceSheetsParenthetical">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaap_TreasuryStockCommonShares_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockNoParValue_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_SharesOutstanding_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_TreasuryStockCommonShares_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementsOfOperations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_OperatingExpenses_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasic_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementsOfChangesInEquity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaap_TreasuryStockCommonMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_12"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_EffectOfReverseCapitalizationTransaction" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransaction_13"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_EffectOfReverseCapitalizationTransactionShares" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_14"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_15"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_23"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_TreasuryStockCommonMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_RetainedEarningsMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockholdersEquity_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_SharesOutstanding_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_10" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_11" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_12" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_cmmb_EffectOfReverseCapitalizationTransaction_13" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_14" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_15" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_16" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_17" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_18" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_19" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_20" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_NetIncomeLoss_21" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockholdersEquity_22" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_SharesOutstanding_23" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_PaymentsForInvestmentInDeposits" xlink:label="loc_cmmb_PaymentsForInvestmentInDeposits_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfTreasuryStock" xlink:label="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaap_ProceedsFromOtherEquity_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_25"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_CashPaidAndReceivedDuringYearForAbstract" xlink:label="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_25"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_IncomeTaxesReceived" xlink:label="loc_cmmb_IncomeTaxesReceived_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_26"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_InterestReceived" xlink:label="loc_cmmb_InterestReceived_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1_31"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_ProfitLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_Depreciation_2" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_ShareBasedCompensation_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_5" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12" xlink:to="loc_cmmb_PaymentsForInvestmentInDeposits_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_16" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_16" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_16" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_16" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_16" xlink:to="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_16" xlink:to="loc_us-gaap_ProceedsFromOtherEquity_19" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_16" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_20" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_22" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_23" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_24" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_25" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_25" xlink:to="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_25" xlink:to="loc_cmmb_IncomeTaxesReceived_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_25" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_26" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_25" xlink:to="loc_cmmb_InterestReceived_27" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_30" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_30" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_30" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_30" xlink:to="loc_us-gaap_LiabilitiesAssumed1_31" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/General">
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NatureOfOperationsDisclosureAbstract" xlink:label="loc_cmmb_NatureOfOperationsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_us-gaap_NatureOfOperations_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/SummaryOfSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/CashAndCashEquivalents">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpenses">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:label="loc_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0" xlink:to="loc_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/PropertyAndEquipmentNet">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/Leases">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/CommitmentsAndContingentLiabilities">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapital">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ResearchAndDevelopment">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/GeneralAndAdministrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_GeneralAndAdministrativeDisclosureTextBlock" xlink:label="loc_cmmb_GeneralAndAdministrativeDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_cmmb_GeneralAndAdministrativeDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactions">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholders">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShortTermBankDepositsPolicyTextBlock" xlink:label="loc_cmmb_ShortTermBankDepositsPolicyTextBlock_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_12"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock" xlink:label="loc_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_13"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_SeverancePayPolicyTextBlock" xlink:label="loc_cmmb_SeverancePayPolicyTextBlock_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_19"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cmmb_ShortTermBankDepositsPolicyTextBlock_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_10" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_11" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cmmb_SeverancePayPolicyTextBlock_14" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_16" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_17" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_18" order="170" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_19" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock" xlink:label="loc_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/CashAndCashEquivalentsTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" xlink:label="loc_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0" xlink:to="loc_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/PropertyAndEquipmentNetTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ResearchAndDevelopmentTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock" xlink:label="loc_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/GeneralAndAdministrativeTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock" xlink:label="loc_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock" xlink:label="loc_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NatureOfOperationsDisclosureAbstract" xlink:label="loc_cmmb_NatureOfOperationsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_SignificantAccountingPoliciesTable" xlink:label="loc_cmmb_SignificantAccountingPoliciesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_SignificanAccountingPoliciesLineItems" xlink:label="loc_cmmb_SignificanAccountingPoliciesLineItems_5"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_IncrementalBorrowingRateOfLeases" xlink:label="loc_cmmb_IncrementalBorrowingRateOfLeases_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_6"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_PercentageOfMonthlyDepositsRate" xlink:label="loc_cmmb_PercentageOfMonthlyDepositsRate_7"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_PercentageOfShortTermDeposits" xlink:label="loc_cmmb_PercentageOfShortTermDeposits_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cmmb_SignificantAccountingPoliciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SignificantAccountingPoliciesTable_1" xlink:to="loc_srt_RangeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MaximumMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MinimumMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SignificantAccountingPoliciesTable_1" xlink:to="loc_cmmb_SignificanAccountingPoliciesLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SignificanAccountingPoliciesLineItems_5" xlink:to="loc_cmmb_IncrementalBorrowingRateOfLeases_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SignificanAccountingPoliciesLineItems_5" xlink:to="loc_us-gaap_SeveranceCosts1_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SignificanAccountingPoliciesLineItems_5" xlink:to="loc_cmmb_PercentageOfMonthlyDepositsRate_7" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SignificanAccountingPoliciesLineItems_5" xlink:to="loc_cmmb_PercentageOfShortTermDeposits_8" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_LaboratoryEquipmentMember" xlink:label="loc_cmmb_LaboratoryEquipmentMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_7"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AnnualRatesOfDepreciation" xlink:label="loc_cmmb_AnnualRatesOfDepreciation_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_ComputerEquipmentMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_cmmb_LaboratoryEquipmentMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_7" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7" xlink:to="loc_cmmb_AnnualRatesOfDepreciation_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/CashAndCashEquivalentsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD" xlink:label="loc_currency_USD_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_ILS" xlink:label="loc_currency_ILS_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_XXX" xlink:label="loc_currency_XXX_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_CurrencyAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_1" xlink:to="loc_currency_AllCurrenciesDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_USD_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_ILS_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_XXX_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ReceivablesFromGovernmentInstitutions" xlink:label="loc_cmmb_ReceivablesFromGovernmentInstitutions_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0" xlink:to="loc_cmmb_ReceivablesFromGovernmentInstitutions_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/PropertyAndEquipmentNetDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_LaboratoryEquipmentMember" xlink:label="loc_cmmb_LaboratoryEquipmentMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_10"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_ComputerEquipmentMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_cmmb_LaboratoryEquipmentMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/LeasesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_ILS" xlink:label="loc_currency_ILS_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_6"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AnnualRentAndManagementFees" xlink:label="loc_cmmb_AnnualRentAndManagementFees_7"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_BankGuaranteesToPropertyOwner" xlink:label="loc_cmmb_BankGuaranteesToPropertyOwner_8"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ReassessmentOfRightOfUseAsset" xlink:label="loc_cmmb_ReassessmentOfRightOfUseAsset_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_11"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:label="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1" xlink:to="loc_srt_CurrencyAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_1" xlink:to="loc_currency_AllCurrenciesDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_ILS_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_LeaseExpirationDate1_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_cmmb_AnnualRentAndManagementFees_7" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_cmmb_BankGuaranteesToPropertyOwner_8" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_cmmb_ReassessmentOfRightOfUseAsset_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_OperatingLeaseLiability_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_13" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_14" order="100" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseLiability_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalAdditionsMember" xlink:label="loc_us-gaap_CapitalAdditionsMember_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_CapitalAdditionsOneMember" xlink:label="loc_cmmb_CapitalAdditionsOneMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaap_LeaseAgreementsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_EUR" xlink:label="loc_currency_EUR_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_ILS" xlink:label="loc_currency_ILS_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentDescription" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentDescription_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaap_OtherCommitmentsDescription_16"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct" xlink:label="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_17"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_MaximumPercentageOfPaymentsOfRoyalties" xlink:label="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_18"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized" xlink:label="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_21"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement" xlink:label="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_23"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AggregateAmountCommitmentToPay" xlink:label="loc_cmmb_AggregateAmountCommitmentToPay_24"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AggregateAmountOfCommitmentPaid" xlink:label="loc_cmmb_AggregateAmountOfCommitmentPaid_25"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AdditionalWorkOrderAmount" xlink:label="loc_cmmb_AdditionalWorkOrderAmount_26"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_LienOnBankDeposit" xlink:label="loc_cmmb_LienOnBankDeposit_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedInvestments" xlink:label="loc_us-gaap_RestrictedInvestments_28"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RecoverabilityOfVatAmount" xlink:label="loc_cmmb_RecoverabilityOfVatAmount_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxes" xlink:label="loc_us-gaap_AccruedIncomeTaxes_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionExpense" xlink:label="loc_us-gaap_AccretionExpense_31"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_OtherCommitmentsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" xlink:to="loc_us-gaap_CapitalAdditionsMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" xlink:to="loc_cmmb_CapitalAdditionsOneMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" xlink:to="loc_us-gaap_LeaseAgreementsMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_srt_CurrencyAxis_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_6" xlink:to="loc_currency_AllCurrenciesDomain_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_6" xlink:to="loc_currency_EUR_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_6" xlink:to="loc_currency_ILS_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_10" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_10" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_srt_StatementScenarioAxis_12" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_12" xlink:to="loc_srt_ScenarioUnspecifiedDomain_12" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_12" xlink:to="loc_srt_ScenarioForecastMember_12" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_15" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentDescription_15" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_us-gaap_OtherCommitmentsDescription_16" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_18" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_19" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_20" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_21" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_22" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_us-gaap_RoyaltyExpense_23" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_AggregateAmountCommitmentToPay_24" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_AggregateAmountOfCommitmentPaid_25" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_AdditionalWorkOrderAmount_26" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_LienOnBankDeposit_27" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_us-gaap_RestrictedInvestments_28" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_RecoverabilityOfVatAmount_29" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_us-gaap_AccruedIncomeTaxes_30" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_us-gaap_AccretionExpense_31" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_SaleOfStockTable" xlink:label="loc_cmmb_SaleOfStockTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_CantorMember" xlink:label="loc_cmmb_CantorMember_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RothCapitalPartnersLlcMember" xlink:label="loc_cmmb_RothCapitalPartnersLlcMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_InvestorsMember" xlink:label="loc_cmmb_InvestorsMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_6"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AtmAgreementMember" xlink:label="loc_cmmb_AtmAgreementMember_7"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RepurchaseArrangementMember" xlink:label="loc_cmmb_RepurchaseArrangementMember_8"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_MarketOfferingAgreementMember" xlink:label="loc_cmmb_MarketOfferingAgreementMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_12"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RestrictedOrdinarySharesMember" xlink:label="loc_cmmb_RestrictedOrdinarySharesMember_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_16"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_TwoThousandsFifteenPlanMember" xlink:label="loc_cmmb_TwoThousandsFifteenPlanMember_16"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_TwoThousandsSeventeenPlanMember" xlink:label="loc_cmmb_TwoThousandsSeventeenPlanMember_17"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_SaleOfStockLineItems" xlink:label="loc_cmmb_SaleOfStockLineItems_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_23"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement" xlink:label="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_24"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ProceedsFromSaleOfAdss" xlink:label="loc_cmmb_ProceedsFromSaleOfAdss_25"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" xlink:label="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_26"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfWarrantsPurchaseUpAdss" xlink:label="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_27"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_SaleOfStocksPricePerShare" xlink:label="loc_cmmb_SaleOfStocksPricePerShare_28"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfStockReservedForIssuance" xlink:label="loc_cmmb_NumberOfStockReservedForIssuance_29"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfStockAdssResveredForIssuance" xlink:label="loc_cmmb_NumberOfStockAdssResveredForIssuance_30"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfAdssOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfAdssOptionsIssuableOutstanding_31"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfOptionsIssuableOutstanding_32"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfVestedAndExercisable" xlink:label="loc_cmmb_NumberOfVestedAndExercisable_33"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfAdssVestedAndExercisable" xlink:label="loc_cmmb_NumberOfAdssVestedAndExercisable_34"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_NumberOfOptionsVestedAndExercisable" xlink:label="loc_cmmb_NumberOfOptionsVestedAndExercisable_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_36"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_39"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_40"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_41"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceiptsShares" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_42"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_43"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfTreasuryStock" xlink:label="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_45"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_cmmb_SaleOfStockTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_cmmb_CantorMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_cmmb_RothCapitalPartnersLlcMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5" xlink:to="loc_cmmb_InvestorsMember_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5" xlink:to="loc_us-gaap_PrivatePlacementMember_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5" xlink:to="loc_cmmb_AtmAgreementMember_7" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5" xlink:to="loc_cmmb_RepurchaseArrangementMember_8" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5" xlink:to="loc_cmmb_MarketOfferingAgreementMember_9" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_12" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_12" xlink:to="loc_us-gaap_ClassOfStockDomain_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_12" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_12" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_12" xlink:to="loc_cmmb_RestrictedOrdinarySharesMember_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_us-gaap_PlanNameAxis_16" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_16" xlink:to="loc_us-gaap_PlanNameDomain_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_16" xlink:to="loc_cmmb_TwoThousandsFifteenPlanMember_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_16" xlink:to="loc_cmmb_TwoThousandsSeventeenPlanMember_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_cmmb_SaleOfStockLineItems_20" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_20" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_20" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_20" xlink:to="loc_us-gaap_PreferredStockSharesIssued_21" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_20" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_22" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_20" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_23" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_20" xlink:to="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_24" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_20" xlink:to="loc_cmmb_ProceedsFromSaleOfAdss_25" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_20" xlink:to="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_26" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_20" xlink:to="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_27" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_20" xlink:to="loc_cmmb_SaleOfStocksPricePerShare_28" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_20" xlink:to="loc_cmmb_NumberOfStockReservedForIssuance_29" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_20" xlink:to="loc_cmmb_NumberOfStockAdssResveredForIssuance_30" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_20" xlink:to="loc_cmmb_NumberOfAdssOptionsIssuableOutstanding_31" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_20" xlink:to="loc_cmmb_NumberOfOptionsIssuableOutstanding_32" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_20" xlink:to="loc_cmmb_NumberOfVestedAndExercisable_33" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_20" xlink:to="loc_cmmb_NumberOfAdssVestedAndExercisable_34" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_20" xlink:to="loc_cmmb_NumberOfOptionsVestedAndExercisable_35" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_36" order="160" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_20" xlink:to="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_37" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_38" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_39" order="190" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_20" xlink:to="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_40" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_20" xlink:to="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_41" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_20" xlink:to="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_42" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_20" xlink:to="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_43" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_20" xlink:to="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_44" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_20" xlink:to="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_45" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger" xlink:label="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_9"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_15"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_16"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xlink:to="loc_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_15" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_15" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_15" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_15" xlink:to="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_RangeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MinimumMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MaximumMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_SharePrice_7" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_8" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_10" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_11" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_12" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_13" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_14" order="70" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ConsultantsAndSubcontractorsExpense" xlink:label="loc_cmmb_ConsultantsAndSubcontractorsExpense_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RentAndMaintenanceResearchAndDevelopmentExpense" xlink:label="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShareBasedCompensationResearchAndDevelopmentExpense" xlink:label="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_cmmb_ConsultantsAndSubcontractorsExpense_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_us-gaap_OfficersCompensation_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaap_SalariesAndWages_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="loc_us-gaap_NoninterestExpenseDirectorsFees_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="loc_us-gaap_GeneralInsuranceExpense_5"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_us-gaap_SalariesAndWages_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_us-gaap_ProfessionalFees_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_us-gaap_NoninterestExpenseDirectorsFees_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_us-gaap_GeneralInsuranceExpense_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_IncomeTaxDisclosureTable" xlink:label="loc_cmmb_IncomeTaxDisclosureTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IL" xlink:label="loc_country_IL_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_country_US_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_8"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_IncomeTaxDisclosureLineItems" xlink:label="loc_cmmb_IncomeTaxDisclosureLineItems_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_13"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ReceivedAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_14"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_17"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_cmmb_IncomeTaxDisclosureTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_1" xlink:to="loc_srt_StatementScenarioAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_srt_ScenarioForecastMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_1" xlink:to="loc_srt_StatementGeographicalAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4" xlink:to="loc_srt_SegmentGeographicalDomain_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4" xlink:to="loc_country_IL_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4" xlink:to="loc_country_US_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_8" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_8" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_8" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8" xlink:to="loc_us-gaap_DomesticCountryMember_8" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_1" xlink:to="loc_cmmb_IncomeTaxDisclosureLineItems_11" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_11" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_11" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_12" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_11" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_11" xlink:to="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_11" xlink:to="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_11" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_11" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_17" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_CurrencyTransactionLossValuationAllowance" xlink:label="loc_cmmb_CurrencyTransactionLossValuationAllowance_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance" xlink:label="loc_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_IncomeTaxExpenseValuationAllowance" xlink:label="loc_cmmb_IncomeTaxExpenseValuationAllowance_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_cmmb_CurrencyTransactionLossValuationAllowance_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_cmmb_IncomeTaxExpenseValuationAllowance_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" xlink:label="loc_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_6"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" xlink:label="loc_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_us-gaap_RelatedPartyMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_CostOfRevenue_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_EarningsPerShareCalculationNumeratorAbstract" xlink:label="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20241231.xsd#cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract" xlink:label="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalScheduleOfUnvestedRSADetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 0L!W0# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH ***Q=;UNST6SFNKN>*%8HG?,CA1\H)[_ $__ %8JHQ<FHQ5V^@I2
M44V]EN1^(O$6G>&-,N-6U298+2V1I))'(4!5&2<D@?K7Q?K?_!0S]GC0=0N-
M-O\ QAID5S;.T<J-=0@JRG!!!F!Z^WXU^)7_  55_P""Q/A_X*V/B/X;V=[#
M]LN(;FUCDAD&X-AD&"IR#WK^#;XK_MK_ !(\9>.-<UFP\5ZO%;WM[--&L=[.
M%"LX(X#XQS7U&5\+8[,$FJ<E>SCY[.VJMU[^>QY6*S6C0M9IKKY;?+:_4_U9
MC_P4G_9J R?&NE?^!<'_ ,>KNO!?[<WP*\=7 MM"\4Z?=2E@H$=Q$W)('\,K
M>O\ GO\ Y#4W[4/Q5\DO_P )AK6=I/\ Q_7&?;/[S';'-?4W[*G_  4A\;?!
M[Q E]KGB34[F*.8,1/=SL,*PR,,Y';\L5Z5?@;,*4;^SF[6NK6Z*_P"/X[BI
M9I"I3<W:]KQ2MJM-OD_GTMU_UZ] \2:;XCM5O--G2>%U#!D(/49]>_:N@K^)
MW]AK_@X,\.>)?$&@_#R]N(VGOI;>V,DLG<E4SDDY^]]/QYK^P'X3?%32?B1X
M9TC6[*[@F_M&TAN L<BL1YB!\8SG/)_&OE,9EF+P4FJU-Q2=OP7_  ?N.^GB
M*<U"\K2DMO,]AHHHKSCH"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOU/J:<%3A&$59))?@%%%%06%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\LG&=QQC.?\ ]8'?ZYKMM$T\>&=MU:WCNY^8@.<Y&">.O;H<_P \?<\0^ 6
MH48_5L-[RCU2\NW:_P#P-#S8\45752G*"=2SC9Z=.G;3IY+U_M ^%?[6_A'Q
M4;:RBNX6FF**N95)Y/3^7YGM7VYIU]%J%I#=1,I690XP0>&&1TK^&CX5_M(Z
M_P"#/$EBZSSB*&:/)WG& Z_[0_SQ]?Z4/V.?VL!\3(+'3KZ^4[(HX\-)D\*H
M_O'N.V:_D/Q#\,\7D%6IB,-1G[*+DZUTW9KI&_SVT_7Z;+LWAB&J=624I64;
M/;9:]?\ A_4_56BJUK=0W<:R0N'4@'(.>HSVJS7XLTXMIIIK=/='OW"BBBD
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MY17(^"]?C\1:):ZC'()!.@8,#G/"GCD^M==7YS.+A)Q>\79GNQDI14ELU?\
MX 4445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS7]T4*,)0A5?,IVB_==NBZ+^M?(_+YX3EG#V:^&5W>^BT>B_KSZ#H94N%)B
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MA/AK^S3XW\86/VZ]T*[#X!&86/\ 3WST_.O4?^&./%6H'R)M"NM@R!^X;I^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW4Y( !;MTR.G'I7VU'^R!XVO;&2\ET&[\]<E<POGCZJ/0?3O7MW[.W[&>O\
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M!RK%._?^M?[)W[07[$O@3X[Z3?:;KUG;2)=I(KEH5;.]2#V[Y_0=>E?QR_\
M!2S_ ((M:9X)UJ:X^'/AM[OS9FD8VMMG[QR<[0>Y]??Z_L>0\<T<-2HX=2E&
MI&,(N5]-+7;?WO[SYS,,L3G[:"OI:VLM6UM?LC^,\F58OM"JX!' P>PSZ?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHSGIS12335T[KN@"BBBF 4444 %%%% !1110
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M:]NHK3VU6UO:3MVYG;[MA<L?Y5]R_KHON.3T;P3X<T%$CTO3;>U6/ 411*N
M!@=!76 8& , 445$I2EK)MOSU!)+9)>BL%%%%2,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMQ;+/LV2E?N;CU XZ<>U?R+^*/\ @NY^TQ;>+=5TZVUV]\N"YE10+N3C#8&
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M%% !1110 4444 %%%4K^_@T^!KBX8)&@R2>!@<]\4TFVDE=O1(+VW+A( )/
M'4UQ7BGQMHOARREN+K4+:(QJQ*O*BG@'U;VKYP^-/[8OPG^$^DZ@_B'7;6SE
M2&79OFB7Y@IQ]Z1>0?\ ]5?QQ_\ !0W_ (+(:E;^(]<TOX?>*?-MMTZ0K!=C
M&-S*.4=O\^U>WE.38C'XB$'"4(<T6W)6NM-%?JTS&=:G",I<R?*KM7V7?H?T
M#_MJ_P#!3GPQ\#[:ZV:C:RLB28V3(W08['/?G\AUK^7/]J#_ (+RQZV=2T?3
MKV5&<RJKQ2N.NY1C:P^N1_C7\_7[0'[<'Q;^+U[<IK^I74\,LSA=TTC_ "LW
M'WN.G8=^O-?)DNCPZU&=4U0EF?YG9CQD\GG@G_\ 77ZS0X<I4:5"C2@H2A*+
MDYKTOYVZ:O\ 0^4Q&:8?V\IR<I*5HQ47O*ZLMM6?7GQU_;'^(OQJO9[S2_%6
MK6JF4R!8[RX08)#<XDZ<<]>.*^8'^.'Q9VG2QXPUS?G;O^WW(Y)8?\]<]L#_
M .M7&B;3[%C'IS \[7P1@<$=,]1GGW/M701)HY@6Y8K]I//;K[Y.>.<<>AZ<
M5])A<@RJFI3G*E[6I%1JN\=5IMYZ=3R\5G->E=0A/EM^ZAUB]+-K3?\ $O1^
M,?B9<@M?^*]6G#@\27L['GZR'D9SV_/FL.]U/QCO:?\ MR^+>OVB4G_T+_/X
M5G:AK\<!VJ^!D@=/P_H1],]^(K/65F?$K?(>N3P>N.?IUKZG Y?DV"PBY'32
MLW9RB[W2OY]_ZL>)&MFU6JL3._O;IQUM=+;2VFK^Y];P/\0OB-IL@BM/$NJP
M;FXV7DR\?@XS_D=.3V%IXY^+\\"2IXUUQ5(R/^)A=#'?_GH1^&#^E<GJ<5M<
M2)+!A@O)P/3\,>HS[=*MKK:1VPM8&!E48"CCGT_/_'TK@S&AE6)H-WIIP5[2
M<=].^G]=-CU%FF+I*$81E)W2DTG[NV_5:KY'I_@[X[?%GP5XCTS4[GQEKDL5
MI=13.K7]RP(C=6(.9.<_E^>:_H9^!G_!=N;X<>#-(\/:E?SS7%I''"[R2R,Q
M951<DL>N1G\SUQ7\T%B]K<*1J)^9LX!Q^O<\]NP]>E2?\(WH\TIDS\N0V<\?
MSQ_AGBOCL9DU*M1A5PGL^?[+235]-]-=OO/2P^/J0J4ZF);DIM<J6CZ?\'J?
MZ4O_  3N_P""N?A[XTZ/#)>7\$32(AQ-*JGYMH/#-GH>O'TK]\/ 7Q[\->+H
MX'CU6RS,%.//C[_C_3U]Z_QXOAG^U!\0O@5>6UOX,OI[>U1U#>5*Z@*".N#C
MMC_&OV$^ W_!8;XH: +"/5/$D\6PQ!MUVXQ@C/!8>^.G3WK\[S+))\]9U</-
MUK7YE%\K>FVGH]/RN?1TL;+26LH.UDMX[7O_ $M].K/]1>UU.SO45[:>.8$9
MS&X8#\1FIIY_*7/X#WR,_A[?Y%?ST?\ !,G_ (*5^$OBSX;LXO%/B2*:_GBB
M5!)<(S-(P3CF3)Y)'_ZC7] 6C:O8>)=.AU*QD66VN$5XW4Y!! /!!/8]J^"J
MT,30JU(5=-?=5MEIO^/S/7PU6E4Y92V^TG\NG33N:,-P9HR<=/\ ]?7'^-4Y
MYP\%PH7'[M^W7 SS^'\ZTD@5%*CC/7OGZ]/TQ56YMU2WN&P.8GZ>X_"KIN*B
MU*_,[6]?Z_X<Z'*C[]HM)_#_ %_7ZG\67_!<42?VAXA(+ %;KL?]H8^A%?P*
M>()9%^(6M[B2/MDO7I][T.?YY/\ +_00_P""VZ6CW?B)9,;MEUUQGG?Z\G\*
M_@3\46MM'\0=;9\!?MDO)P."P[?YXK]4X>PZQ.%H1G'FCR>\[>:ZGQ^/K0I2
MKQG=J3T7W+3SVU9Z!^RM)M_:1\$28^[K-H?_ "*AZ]N_^-?ZT/\ P3VU)9_A
M%X)CV8VZ19#..O[I/;K^''Y5_DX_LJ1V\G[2_@=5P4.L6F>A_P"6@_7Z]/0#
M)K_6Q_8$L+"'X.>!WA W_P!CV><8!SY0^O3\J\#/L/AL-4Q453DI.3Y)=]M;
M_?\ \-MW82M-4\-&GI3:C=/5M:)?Y?YGZ0#H/H/Y4M(.@^@_E2U\,>T%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%&:,TKJ]KJ_;J 4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *]W_QZW'_
M %QD_P#037^>?_P<9ZJ;?XH7D.W[UQ..,]VG'I_GM[?Z&%W_ ,>MQ_UQD_\
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M ./R]/<?K574&2)_F_UHZ#U// SVX_I[FSHW@GQ;XZE^QZ7;RS\D* K-UZ=
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MOO0-ZT^D50H '04M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4E&5^:R?/=6;LO/^K_?]4T5'%(LL:R+R& /KVSVJ2ORQIIM-6:T:/8"BBBD
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M9@FU]5J^?N/I;R]!\T?YE]Z/T1HKS_P3\0]#\;Z5;ZMI5S'+;7*JT;*X((8
M@Y''<=O6N^#*0""#GIS7'4I5*4N6I"47V::_,(RC+X6GZ#J***S*"BBB@ HH
MHH ***,T %%-WK_>7\Q1O7^\OYB@!U%&<].:* "FEL-C'I^M0W%S%;0R32,
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M7QV'JT)>S=.5&:M=37*_-_A]_K8])\TH+DE:6GO?=?\ K^GO*VY0?6G4@&
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M;Q,=KJQYB4D<$]QU/H>AKV56##(.17\P7[)'[;]GX,>SLO&&KE0/+C599O\
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MK,Z>$H4FG"%FMOP_R_1W"BBBO..D**** "BBB@ HHHH **** "BBB@ HHHH
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MOCWX1N[^Q,^FR7]JSEHRR[6GASU!'3/X?B3^V8[%4<GRR52UXJ#:MM>R^_\
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M7:2NU;X-M'LKZGU]*O3FHI3C*36Z>^VWW]+G8T9STYJ*7=LXJ"'>I^;(&?\
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MA^%<O\3_ -K_ ,!?L^_ W2'\2:C!:7#>%[;R3),D9WFQ3;C)'=AW'\Z_SO\
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MA7WP].EZ'\0/$CB2:6"W59[DK]YD4##2'O\ AVQ7]Z/[-_[2?A7XK^$M*O\
M3KZ.X:[AC<,)5;.Y0?6OPW,,EQ5"/MU0G"#;O!Q=X1767WGM8?'1=1T*CM)6
M49MZ3>FB\_1?\'[!>18U+N0JCJ3P!7D7Q!^+/A;P9I\]S>ZU8VYBC=B);F%,
M%5SSN<>_3\ZX+X]_';P[\-O"6LW=]>102064\BDR*#E4.#ZCI_3WK^%'_@I3
M_P %5?%6I:MXB\+^ ?%$R74,US"B0W3Y'++QLE'IGZ]_7BP6#E*I"I5@W"ZM
M"VM3NEY]/^'.Z<TD];:;]%Z]OT/V1_X* ?\ !;^S^ 6MW7A[0[^&]1GDAWVT
MB2KQO&<H7[+Z^N,U_,U^UC_P6?\ $OQ<TJ[@M;NZA,XDP8W=3\Q/H!Z_C7X:
M_%+XT_$/XBZM->^/-1N+VX>9G5II'8_,Q/\ &['U[]17E?VRR9=UT-R<G!_#
M/^/X<9K]UX9X9PD\-2Q5."P[G%2J*HE=>KV6G4\"OF,G75*#>C2YKZ/9_=?\
M_D?=FC?MW^-$$C/JVHC<Q)!GFSUSZGOP?\YT+K]N[QE,-O\ :VHJ./\ EO-C
M^?\ ^OFOSZ-[HZNODIA1G.%P.?\ @(]N?\:?>ZIHQ@ B7Y\?W><C]?\ /2O=
MQF28)./).BV_BDK:O3^M#R\17JT\0YJ$YOFW6RORM7U?]:'WQ_PW3XR6%D&K
MZC\P(SY\W^/;J?\ "OKG]CS_ (*X^)_V?O&$6LW.H7MROVA&VR2R.,;E[-D=
MB#Q7XGV=WI<ULZ,H,I!VC'))QCM_GVS6,-'E:=I5&$!!7CIQG SZ =.V.OKX
M=3AS#8J%>%.DIM)+F2O?9=EU_P"&V)AC*O-*MRRC.-GJM_EIK^A_IF_L8?\
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MRJ2OSZ"DK\SYM=&=M-32?/+F=]&NUBO=_P#'K<?]<9/_ $$U_GQ_\'%$:_\
M"T+I]V,74_'KEIL]_?\ /-?Z#EW_ ,>MQ_UQD_\ 037^>C_P<7K<_P#"U;DJ
M2$^V3DXZ%09_?CG/_P"NON.!:,:^=4X2:2Y9;_+^OF>;G,8RPC4U=<RTZ[K[
M_P#.Q_(_=O\ :+^>(C:H9ESCV_\ U]#QR/2O0/V881!^TK\/P&!_XGMG[_\
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ME?W6_P#!(;_@J9JOQ7&C^%KVY=OL<<%J#(^<[%1.Y/8') ZU_ K?M;RV$H8
MW&W /4YZ=^1VZ?\ UZ_9W_@C9X]D\#^/8'NYS'&U\FW+;1@R+@<_I[9Z<U_/
MG&&11HU:\(4G>K*3;2>OI^6GIT/M<KQDY4E*I5Y73LH1>]M-%KKY):W[6:/]
M4OX?>*!XIT>&_#!M\:-P>Q&0>,UW]?'?['?BV'Q5\/+"]CEWA[:%LY)!RGK^
M'TK[$K\&Q5)T:]2DU;DE:W:Q]O0G[2E"5^:\4[][I/\ .X44F1G&>:6N=2BV
MTFFUO;H;!1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *P/$E\VGZ9/.O5%)'X _YZ]ZWZ\J^,/B6R\*^#=3U:_94M[>WD=V8@ !58
M]3]#[^G>ML/'GKTHO[52"_\ )D14^"7H?QR_\'$/QNOM+\'7,44DBA8I4X)'
M3>/\_P#ZJ_@]D\:7/BF]=YE9M\CC>P)_C[G\^WZ\5_5U_P %\/VB_!7Q'T_4
MM%T>XBEN8'GA8+(K$,K.".GY>GZU_)QX8?3;6S>:10'#%L\9/)..F/3O]:_H
MGA' XC"1O.$I8=TO=TT3:B_ZO]_0^)S-TWATN6]3G>M[.]T6+RU-MJVE1K_R
M\W<"L/3<X&<=, '/_P"NO] +_@A_^P;HWB;X=^%_B=+%#]HCCM+C<57=GY7/
M/_ <>_Y5_%)\ /V</%W[1OBG2;?PG:R7)M[Z D(C/PL@/8C'_P!?FO\ 3\_X
M(_?!?Q)\&OV?-$\/:_ \%U#9VH964J?EBP>">!_7OWKP./<1F%&A>&+2PTI6
M5*VU[)KOL>CD>'HRH0]I#][=/I?2UG:U]++Y'Z\>'=+71='L--3[MI;Q0*!Z
M1H%'\JV7) R/\]Z%R%&>N.:4C/!%?B#?O.^NNOGJ?3M/ELG9VLF11N6//^>_
MI^E34T*%Z4ZAN[T6A--2C&TY<S[_ *?(****184444 %%%% !1110 4444 %
M%%% !5:\_P"/6X_ZY/\ RJS5:\_X];C_ *Y/_*FMUZK\P/XR_P#@MI?O'?>(
MXPA/R7(S_P!]G^OYU_ _XNO'B\>ZVZ@DF\EX[\D'C'^?;FO[Z/\ @MD]J+OQ
M&'QO*777G^_^.1Q7\#7BJ:V3XA:T9<;#>S8_,?Y'UX-?OW!<5.C@(R5TXQNK
M[K1???Y?C?XG-G:557LGOTWY.K[ZGIW[,&J)IG[0'@_5[EO*CM]5M7+.0%&V
M13SG'YG^M?UJ_P#!0']MZUT#]E?PIINB:Q$;B+P_#"R6\Z[P1!( "$;(]_7\
M*_CKLH[S3=2@UW26:*2U=94=201MP<C![_YSVZ;XB?&GQ_\ $;2K;POJ6I7-
MW;1J+:.)G=P!C:  6([],=>Q[_<YOD>#E;$*"C5BN:,GTT5]OZW^?E8+%K$5
M(0<U:C96OOMZ:[K3]3B?'_CK6?BOKDNIE[B\NI)I"J9>1V)9B HY)]!@'L:]
M)^$?P"^(WCO4+>U?PIJS02RHBR&RN"K*Q SDQ^G7MC\C^A7_  3E_P""97Q.
M^,?C7PSXEET>>[\-O=V\MR&MV>-HVD5CNR2 -I(Z9ZU_H6?LU_\ !+?X"^%/
M!?AU]3\&Z<NJ)96QN':T@#>:L8WDYBZ[AW].M?E^>9S/+)1="M'VD=+1?56_
M"WRZ]T?3T\/"2>TE.SO_ ":+=?UYWV/XM_@-_P $.+OXJ^#(O$6HZ?<VTSQ(
MYCDBE5LL,D;6 ]#]"/S]#?\ X(#B"9D^QS'!Q_JWQZ>A_P ^PK_0K\)?L_?#
M[PAI@TO1])M[:U50@C2-%7 &.BH.N>N/PK:;X,>#&8L=-@))SGRU_P#B:^1C
MQCB%*;][FF_?=]VK+^O3JCM^H5'%+G3C9?=9?\'\#_.MUO\ X(+-8Z9+<QV4
MQ=$)P$<G[I/3'/Z8K\IOVI/V!?&O[/,4TND>'-3NU3?S%:SR  '(X"-P/KVK
M_6EN/@CX)N8FAETV HPP1Y:^F.ZU\W?%S]@;X&_$G1M1CUGPM87<SVTWE[[:
M%R'*-C[T1[X]\_A6E/C7$PA*,'.-23CRROMM?^KB_LM27+4<90TYE;?;\;W_
M  /\;B_;7M+N6&J:?<V<\9.8IXGC888<88 C\!_2JLFJ2ZFNUXF0H.#@\$=^
MF>#_ )Q7]7W_  5%_P""1?B7P;XN\0>,/!_AQK3PO:R7,H\BUVH$4LXQM"@<
M _0<8Z5_,?XQ\+Q^#M2N]/NX#'+;3R0R KM^9'*D<CU!Z?RZ_K629^LPP=&5
M6M&O45.-UHW%V5[K7TZ^7<^1S;"1RZ;2BY^T:<$MTKK33^K;:6/9?V,/C5KG
MPJ^+VB:NNH74-K:W4#[/.=8\+(AZ9''!["O]+;_@EE^V1!\<?#NDV$VH1RM;
MV4$/^M!.4CQ@\DY^7GIVK_*MFU:+28#?V+>7<IDAUX(*X/MW&?\ /']3G_!
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MP06DT/P]JFLP6<[2VD4LJ((W))49' '/?H,9[U_I'ZQX9TK7X/)OH$EC(Z$
MC!S@<@\'V]?I7 W_ ,#_  1J-G/8W&F6[P3JRNIC0Y# C'*\]>]:83CC$TZ;
MCB'.J[\R:\K6=OZ^XWCEGLJ4J=-J,F[M[[V_X/6S]'K_ (]WQL_9<\?_  ?U
MC4[.U\+:K-%932(K"SN"I5#UR(\5\@W\NJ177D:U82V,Q?!2XB:-N/9U!SD'
MZXK_ %X?C?\ \$U/@1XVL=0N'\(:?-=3QS,S?98"2S*<=83DYQ_B:_AB_P""
ML_\ P2I\7^#?&FJ>(/ &@/9:%923S'R+8B-40L>J!1C&,\=.:][+^+,5BZJF
MZ_+3LH^R=KZV3VVO\_R/,Q6$5.E)?PY)W]I:U]%IYZ_?Z:'\W5P+K2VM;W3+
MJ2&1)$ES;NRGY2#U4YZ 'M7]4W_!('_@JWJWPA_X1OX:ZIJ$H@N9;6UDEN9B
M %!"<ESQC.#^=?RO2V-WX>UBZT+6U83V4AAD5P1ADXS@YYX/'Z5>TSQKK/@S
M6;?6O#]S);2VD@EB>-BI4J0<@J0>O3].:^MJY=ALVR^>)]E[2ZE9+>Z2U\^O
MZZ.YXV%S#$8:KR2J/5I7[[6\_P#)]+G^TK\#/C;X5^*OA#1-3T[6[*\NKZTA
MF>*&XBD<,Z!BNU6)!Y[C\.!7T3&NT>QQC^?]:_SC?^")G_!4GQ'HGC*PT7XE
M>)YYM-@GA@CBN+I]BK^[7 $CL!W/ [GZ5_H$?!7XT>'?C)X<MM=\/SI-;20Q
MON1@X^9<CD ?A[5^%YM@:N"Q$X2@XPYG9VTWV7I_6A]G@YQFE.3_ 'K6OI9?
M\-\O0]MHHHKR3O,'Q0<:!JIQ_P N<_\ Z+:O\V?_ (+C>()8?BUXF@$)($UY
MSMSCYC[=?\XXQ7^DQXGQ_8&JY_Y\Y_\ T6WUK_-]_P""WD>GR?%KQ,KJID\Z
M[]#U)_QZ<_6OL>#:$,1F#C-)Z:7Z;:_>U_P=CQLYK>RHT]&^:=OQ7Y?J?RMZ
M3J<CZI>AH\@SR=1P,LW?'8]SP?SK[S_86\3V_P ._CKX>\8/*D)M+R"7)(4#
M;-&WKZ+G_"OB:TCLK;4[UF4#,SD?@6Q@^H_EQ6E9>*;_ $#4EOM.G>(QME"O
M&,'/48]*_?J>24?J#4H*<90<966T6EY::??<^1Q.+FJT84?<DFGSOS_K_@[G
M]*?_  59_;]OO'OP_P! T?2]5D M]+L[?;!.<?)!"@&$8^AX/;.*_EPO-6\0
M>,-7:>VM[O4;N9R0JJ\KL6;T"D]_Z5[)K7B+Q7\7)K+2IKB:[9WC@127?DE5
M  W$9]>GO7[Q?\$O?^"2WC7X@>-O#?BOQ-H#W?AJ::VED\VU+(8RZ,<E@R_=
MSV_GQ\7BOJ>1TY_5G&'+=I)]='\]]/1'LX.4\2X^VO6;Y;R5[+;IY?D?E_\
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MN)[BSA:5(TBD9B41W^Z%]0.U?Z/C?!OP<V,Z=!QC'R)V&.R#UK#\2? +X?\
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M56261\)&%' 9R ,*#Z<=/7S+PQX7E\;R1>'M-C:34YF$8"KEMS$+G ]\#O\
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M3F98SNSD'&#R2?Z?X&IX;5<?:BW/7;G^?)QZ?YQ5>>&:']Y<'AN1D=N<=?\
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M<W35QT2UMV_J[^ARWE=5RBK>Y'3_ ,!_-,]NHHHK\J/<"BBB@ HHHH ****
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M'^>G;Z,;O2V6?*R<C:W!Z$],?GGO7TK^RM^T#JWP(\<Z#;6+RQK<:M:QG8Q
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MP4C0'.5SR1S[]N:_3:"WBMT5(HU0*H&% ';VJGI.DV>C6<=E91K%!$H5548
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M[]J_L/A'Q#R_.*4.?%0G*2CRQ<]8WLOZ[GR6)P,</&<80Y9326VLM?\ @?\
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M *_2WU& E"ZBE[RBFW;?X5\N_7;N>VT445^;GK!1110 4444 %%%% !1110
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M4>VT>[2_/\CV?KN&YE'VL;O5*ZUO:W7K<]VHKP.+XZ^&I)-GVN#/_79,>O\
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M^2%NK6]_<6Z\&-V7;Z 8_P#U_P#UJ]\_8H3=^U+X*##DZQ;#KZSQCK7W_'V
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MS>_^?K7^>#X\N7C^)7B#RP2?[0GX]O,_QQ_G%?Z(?_!95X_[,\5#'/V>Z_\
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MGA[4%5HY()5^=<C#)@_PGCO[@"O\W?\ X+A?L>Z?\$?B+<0Z3"OEM=S$F-,
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M:2':H#9*1$] #VQ^?K7],48VQH!V11^0%?SV_P#!*-+H>%_"YD<E?L5IA<Y
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MYL<A#QL?EW!CU'IGT(]^_P#3]^SG\!=%\ ^&+*VN]-A2^ACC^<Q@-N5?IQR
M?I^!K_/GQE\<J]3ZQEV'J2E5GS1LIZPYO=3LO(^ZRO*4VJDTDDHZO[5K72]3
MV3X8> +'PQHNGK'%&K+;1 C: 1A%[8]3W_05[" %&  ![56MH1"BHHPJ# ]
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MX^M>H5Y!\$(9$^&_A$MT_L:P/K_R[1''X8X/^)KU^OYEQ"4:U1*7-[SU^?\
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M-XC2A_9U%.GS2=/25_3^OGH3P]3FDVY\R=K+LO=_JWEWL?Z4]F2;:#VBC_\
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M'C&%6675IMN2]FW;MLOGY?U;PL!3JO%\[;FI33MVM;??RL?Z7.C_ /(+L/\
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MD>*^PJ_G'&5JE;$5'4FYM3:N_7]#]+HQ4:<;*U]6EW"BBBN4U"BBB@ HHHH
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MU3^VEH?A'2)_^$4UNWNY6B<%8)@3DAAC@@Y_/C!':OYV/CY^USXI\<>(+AM
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M3LWLM=3^,+_@MW+.-1\1)M.TI<Y(]"6Z^I'K_D_P6^)99=.\?ZW- I+M=S9
M]<@'C@#@?T^O]\7_  6UN8$O?$2%1N,=SSG_ 'OSQGK_ (U_!7XAN(4\?ZV9
M0&7[9-][G^+N/Z>GY5^W<$T74I8>-17C)14;K37EVO;;7[SY',8I5*T(:2J.
MS:Z[.[6W]?,]#_97NIM0_:3\#FX7:QUBU!R.?]<O'^?7VK_6=_8 TU+?X/\
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M\K%$+<*-QR0IQ@#OV^E1P<[9WAV]EO\ ?O\ UW.W,(REAI**NWTZVNMOR/\
M/UN!Y.I/(GW]Q..XY/J>GK_]>LZ;4;B[US3[*0%5FGBC.<X^9U'3@=#C_P"O
MDUU/B[3)?"_CJ\T*\4B2"9D(88.5=@>#]/SSC@U7_L@3^*-&EC4;1=VY./3>
MI]_3].M?U'AL1!X-2IV7)%7MWMUM;\?4^!<(1Q:CB*:IQ:>_K_2_#J?T(_\
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MSK]1?^"4T-J/VK?!Q9U\S^T[0XS_ -/4/;_/Y5^6*W26>I7I/ ,TIQ]6(_\
MK\<?I7Z/_P#!*%[BX_:W\&R*S;#JEH<9XP;J _A]?I7ZSF<92R^O[-\MJ#<G
M\M?Z1\AAX-XR'MIN#O%J_JOO=OZN['^N=\&SGX;^$L#@:+88(_Z]HN*]/KRW
MX,'_ (MIX1SU_L73_K_QZQ5ZE7\\U?XD_P#$S]&I_!'6_NK7Y?U_PP4445F6
M%%%% !7Y>?\ !45V3X(:L5Z_9+CC_MD.E?J'7Y@?\%06"_!'5RPR/L<__HJO
M1RJ2CC\,Y;*I%_=)?H95Y1C1J2E\,8MN^UD?Y;_[>R-/XUOG;.?M\WM_RT;_
M /5Q7P;)>S+I\<3 A!CGH.PSG_$=LCTK] OV]75O&E^RC _M"4XZ?QMV_P#U
MU\!ZE)')I421J XQTZ]OY_R ]L_TYD4J[P\JE.+5)TU9+9JROO>WG\C\TS22
MQ&*HV_A^T6VT%IKKYW7_  4?M%_P2]ED/B[PUY0R#?VG3/\ STC/;\/T^E?Z
M@7[();_A3?AC<,'^SX#^:)7^85_P2GV0>*/#8F&XF_M<$GG_ %L8_G^N:_T_
M?V2&5O@]X:*@ &PMR .G$:#_  _"OQGC]S>+O*ZCSNRZ?UU/K,CC*$JD>;G@
MDN5_+T5OZOT/I^BBBOS@^D"BBB@ JK>G%I<'_IB__H)JU5:].+2X/_3)_P"5
M./Q+U7Y@?R+_ /!9RYN%L/%:*ORF"\'Z$^O^?Y_YWOBR>:+XG^(70$G^T9\C
M_@:\]_7VQU[\_P"B9_P68N[=--\6(RC<8;S&<\?*QY_SS^M?YWWBBXBA^)_B
M)W7(.HW! /\ OCK^?3CC\:_HO@K"QGA,#4]DI6C!R=NMHZ[?>]CY[.'_ +-6
M7]U6_KY$^MJD^ES/,0K^42 ?]WI^?I[=L5_3A_P;"A!\9GR?^8@GMP'A_+W^
MAK^8/Q*DES82R0DJ@0\#@8V\=O;J:_IR_P"#8>-S\8RH8@_;X^GKOBX/8?Y]
M*R\2Z+IX>E>=HR@VD_LVMHM.^NE_QN>5PUB)2C6M+G<&ERW>FL5^/]=S_2QL
M\?9H2#G,4?\ Z"/\:@U:,RZ==QCJ\$BC\4-/TY&2T@#<GRH_T0?YS5QU#JRD
M9# @_C7\].REO=)K7\S[2+;BFU9M7:['\7__  6:^!VK7MIXL\10Z?-)&D-Y
M)Y@C)& C'KQGH?2OX)M:%W:>,M<M;B)H_*O[J,AA_=E<'K[#K^'U_P!:[_@J
M5\.]!N?V>?&FJ3V$#S+IMVWF&,%L_9Y3UX/X>M?Y4?QIM;6/XH>+8;:-4$>L
MWJ@ 8Z7$H]QU_P >]?M?!&*E6PZA&JW.'+%1VMHKK7HD?"\3\CBU]7_>/:6O
M=>O;KIOY'G6FKYFH1AQA2W)_%?R]>G:O[@/^#;BV@BU(>6P)+=L?[7;MR 1^
M?-?Q VCB&49(!R.>G;MZ]OY>]?V&?\&\GQ4L?"&LHE[,@WR!5#L.-VX=<]^F
M.>V*]7C##3K9=5ITJCE5E%/V766U^_\ EO:^EO-X8JPP];E=GS/66W(]-/+=
MG]_R?<7_ '5_D*=7)>$/$UOXGTN&_MV#(Z*1M(/50>H_S^%=;7X!.$J<Y0FK
M2B[279]C]-34DFM4PHHHJ!A1110 4444 %%%!.!F@ KY+_;$U?3K7X(>.XI[
MA$D;1+\ %@/^6+>HSZD?Y-?5CS *YXX5CCGL*_F]_P""N7[;FD?"'1/$?A&Z
MO%AEOK2[MD0R8Y:-UZ;O8G\.W?V<ERZ>88V&'BW&32:MUU2M_6QQ8NM35%RT
MG%-)^MUU_KU/\Z/]M;4GM_VJO'D]L/,4ZS=D$<Y'GN/\>E>4>&L:]XKTI+K"
MNUU#\IZG)']3Q]<5J?'OQ1;^*_C#XB\5?ZR&]OII@WW@0\C-G.3_ )XZXQ@>
M!)Q>^.]#E@^6-;R E1Z;LXQ^GYFOZ<X9RZ65Y3+V\.5[<\E:Z:5M-/Z=]3XC
M-)?6,3":O&"BDY:?W?=MLK_UJ?VY_P#!$KX;PV7B30+U8R QMF!Q[CKP/P_+
M@=?[?]&M5MK"U4=H(_\ T #^7\J_CS_X(O7ULUQX:B$8$@CM03CGC'ZXYK^Q
MFR_X]+?_ *Y)_*OP/CNLY9M.,9WA9Z=.G]?.Y]=D\8PPJ48V5[Z;/17_ #^9
M8/0_0_RK\Q/^"C@/_"AO'I_ZA%[_ .BV-?IV>A^A_E7YC_\ !1E2?@/X\/II
M%[_Z+->/PY#GQT5>WG;T_P CHQ[_ '2_Q)_<T?Y*7QT(_P"&@_'>\X_XG5[C
M_OY_]?\ R*;\#'W?'+PQ&/N'4K?)[??4=?\ /K4?Q^B>;]H'QUL."=:N_P ?
MWGZX'UQ4OP!7R_C=X7C;ECJ, ![_ .L7OQC%?NV%P<9Y5%RK\M7GT=M;6BNJ
MVV77YGS=2,5CG+=NFER]M%KYV7]=_P#35_X)1V,,7A7PLZD$FQM3_P".1_KQ
MCIR:_H03A$'HJ_R%?SY_\$IK69/"OA9V;(-E:<=,?NT__5^E?T%Q\(@]$7^0
MK\2XOI.EFTHM\WN+6UMK=/Z_ ^EP"C&@E&7-=M_Y_=M;I\Q]%%%?*G:%%%%
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M5G4HTHM;5-_7Y:[7OYCR?$.KB*D73Y'&,;^>L7VM_P .?95%%%?GA].%%%%
M!1110!\[?M4$CX(^.2/^@)?_ /HAJ_R _P!O4-<?M6^.T<<#6;P>O_+>4]#P
M/Q_I7^OY^U0?^+(^.<]/[$O_ &_Y=V[U_D$_MYSQC]J[QV .?[9NP/\ P(D^
MN.#[>E?H_A[KC:BY^6[CI_-JM._G\UY'BYW+DPSG;X8M\VONV:=_P['R9J%O
M)!<Q+&&*DJ#@?US[_CVK^F3_ (-];=1\=M*8D9%Y:G&1U#K]?IC\*_FTNKR
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M![!7N_\ CUN/^N,G_H)K_/,_X.,&E/Q6N5V_(;N?)Z8'[X_S_'CO7^AG=_\
M'K<?]<9/_037^>O_ ,'%]U"OQ1NXBHWM=7(4]<9,W?KZ?7Z<5]OP%*FL[I>T
MASQL]/G'4\G.(*>$DFNOG;^OS/Y%[AH-/NI9H65I"Q)48S]../R[5ZC^R_J4
M<_[1?@*YNF"*FMV9)/0#S2>>WZ9Z&O$;[3[I-1GG=B8F9L#MU^G^?:M3X?:X
M?"/Q#T+Q$6*)I][%.Q^[@(S'V^M?TAG. PM7*)5Z=.-9N'(E'[%XKUV^[3>Q
M\'A>2CC+J=VMIOOI[O2_;[^I_L=?L&>*]%O?V?O -G;7L4LR:+9J55P6SY?3
M'Y#'KWZ"ON<'/(Z&OX]/^"+'_!0+3_BG)X;^'\5^9I;**TM3'YN[& %Z9]\=
M!_2O[ [23S;:"0?QQ(W_ 'T,U_)^=8-X+&U8?S2<K=KN_P#G]Q^B9?7G7H*4
MX\KV7FE_7YEBBBBO(.X**** "BBB@ HHHH HZD<6-R?^F3_^@FOY7?\ @LUJ
M,J_##QE&O/\ HUYQ_P!L9A].OI_.OZH=3_X\;GM^Z?\ ]!-?RQ?\%EK6+_A6
M'C*1I$S]EO.-PSS!*<?YQG\Q7U7"E#V^.LI\C5G?M9K_ #_X*/.S%VIPTN^;
M\FO\S_-JU'49(?'7B,L",ZI=GTZW$OKZ^I_GTZ>'49YB,J0I(YQ]?Y=Q_*L'
M5[$WGCCQ$T0P$U.[.0,]+A_Z@_7W[>A^ M$?QAKUMX8LTS=32+&N!ELL=O;/
MUK^N>%\7AL'@*4:[C5<=ZDMVU;O_ ,#IY'Y9G>$JXC%UG3I2M;7^ZM.OE_6Y
MEK)"0"7P2/\ /:BOT L?^">?Q!U"T@O([>XV7$:R+^Y;HRAA_P L_>BOJ5GF
M6Z?NZ?3[7^#S_K3OK\>\JG?^+;7:RT^'3^NZ[L_V":***_SS/Z4"BBB@ Z]1
M49AB;[T:'ZJ*DHIIM;-KT A^SP?\\8_^^!_A3A%&O*HH^@%244<S[O[P"BBB
MD 4444 %%%% !1110 4444 %%%% !113 I!SGU_'Z_SK.<Y1<>6#DF[-]OZ_
M$!]%%%: %>$?&SX0:1\4M"GTS488W5HG'* ]0>/\^_2O=Z:RAAAAD&NG"8JM
M@J]/$4)RA4IRYH2B[--=>A,HQG%QFE*+T:?4_D/_ &SOV*]6\+>(;J7PGHTT
M\:RR,I@A.,Y8C! ]!GCGZ=OS0G\"^-O#-PZ>)M+NK&SC) DF1U&T=QG ]_\
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MY'50@XZ<XX'8?IUSZ5Q6J:I/YQ$<4H&>0 ?;C\??'>MKPWX;U;Q4^RV2?/\
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M%?CTDIS]I)7G_-U/="BBBF 4444 %%%% !1110 4444 %%%% !1110 4444
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MO^%?O5'#*O1E4A%5DZ=U'NK)K_AN[U/EJ.#IX.?NU+Q_*]MM>F_ETLC^\/\
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M0 ,+<3#  P.BCUS]*^>/#^K*=9TR2=]J)<0$D]!AEY[\]Z_<7_@KG^P7XO\
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M_7EJ?,9Y6A"C4BM=/>E_*K+^ON\BEXE=[>PFCA&8]AR0?;@8^G'Y^M?TY?\
M!L/*R_&1CW^WQGUP=\1Y]?7_ /77\Q6M3I'I\L,F&<KC)YXY[\GO_0=Z_I]_
MX-CH?+^,9<CAK^,@=2,M">_(Q_GM6GB;B>:&'I*'.N1J_P!W3N^^G0\;AR:C
M"NTN1N2::_Y>;*_S[Z[K0_TI=.<O:0$_\\H__01T_P ]JO5GZ8P-G!C_ )XQ
M_HHS_.M"OY_G\4M+:['WE)MTX-[N*OZGYZ_\%*-$O]?_ &;/&EAIT#SW,NF7
M2HB*68DV\W0#)]/SK_*&_:6^&?BKP/\ $SQ?>:_IL]E!+K%\Z/*C(I#7$C*<
ML.>H]!_7_8^^)OA"W\:^&+W1;F!9XKF)HV1UW AE8=#]?_U]O\_O_@X8_9FL
M?A=9W.J:3HZ6LERTDK/! $+%F.3\JCD\DG//:OT?@7'TL/*I0NE7JS7L_P";
M:*=O1]_Q6AXN<8)XMQ7*[):SM?EO9?\ #V/Y#[_4W0-+ 2V.<@Y]>X/3L,]>
MYK]D/^"6?[2+?#;Q7I\5Y?BT62]B0;Y=G#2 9[?WA_C7XXZ)I$TNG,TX(8$C
M#]<9Z<__ %OIUK4\+>(M5\(>*-'N=/NI;=8[^W=O+<K\HF4G('\_Q]C^KYEA
M'B<"Z\$U4A&UTNK2O\_ZNSY:GA5A*CIT8WO).4]NWR_X)_L<_L+_ !*M/'_P
MGTG5([M9Q-;0,&#!LYB#=:^Z001D<BOY-/\ @C)^VQI5Q\,O"W@[4-1C:]>"
MTB/FS98G8J<Y;)Y]O3G-?U8:!J=OJFFVEY!-'(L\$;C8P;.Y W;Z_P">_P#/
MF>X"6#Q4G*3;JMSU3ZV_SW^78^WP%:52E&+C\*2;\[+?^K_,W**"<#-(&!Z5
MX#G%246[2>R^[_,] 6BBBJ **BEE$:DGC'.:CAG$O3UQV_I_G]15<LK<UG;N
M4H2<7-)\J=F_N_S+-!Y&**0L%&6( '4FI)./\6>*-%\)Z?<7VL7<=K"L3L7D
M8(.%SG).*_SS/^#AOXS>'M>^)%Q'H6K17*&ZF!\J4$'F48X/IQCO_+^N_P#X
M*N?%=OAW\&-4U#3]46VG6UN.8IMK@B,'L0>__P!<5_F,_MK_ !%\0?&#QG>Z
MA=:K/>*E[*V7E,G21LX[9Y_^O7Z;P!EM2KC:>.47-0?(U;17Y=7I;2^W_#GC
M9E.C&FZ7,H2;OZ[:6^7SU6MSXT:W35KF268Y#$G<><Y&>IZ>G^16]\.;;;\3
M/#>F6@WF?4((PHZG+X[<G_\ 5ZUS7F_V=;+&QRX4@GIZ?Y^O'O7UA^QQ\%=7
M\?\ QH\$ZI#;S3VR:Q92/A&9=HE!()P1W_$5^YY[F-' 9=*FZJ<E3O[/SY4^
MCW^[L?,TJ,*E92K3M2O9)[/:TOS?X>:_O._X(]_!/6-%T?PKK]QI\T4,UM:2
MAVC8#!"G.?U_K7]4]JI2VA4]5C4?D*^'?V#_ (=:/X7^ W@E%T^**[CTBS#O
MY85]RQ+G)P._M_\ 7^Z@,# & *_E3.,;+'8VK5DMI-+KHO/\_D?;86C&C2BH
MNZ:37HTOT2]!#T/T/\J_,;_@HRQ'P'\>#_J$7O\ Z+85^G)Z'Z'^5?F+_P %
M&O\ D@WCT=_[(O,?]^V_QKJX>;6.A;OJN^L=#+'_ ,%=/>6OS1_DF?M"2O!\
M?_'+1]3K-WGV_>#/'^>,^M+\ )#)\;/#$CC#_P!H6^!_VT'^>AIG[0,JP_M
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MC0QE6<H*5G%W[:J[^[\#P<_7-@YQ<N2+@U)^3:7^9\HWZJ+B(MPP*]_?\O\
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MG_Z]?S%QYDU3#8NKBU=PYN5Z6UT2_%^?;<_0,GJ\M.%'F]HW%2YNUTM+??\
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M "BBB@ HHHH ***0LJ_>('UH 6BJ<][;0(S--&-HSRP],UP\OC_28[MK9KR
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MX=ENX9EN88\VY8'.Y1SM_#\\=>G^C=_P1(^"WCVU^$FB7VJWU\X2"U<B9GY
M3/<#MQG&/QKP\[RZM@F[T.6FW;F5TM;=?Z^;1VX*4Y4_WK=[[[W5EK^1_4O!
M)'+&LL9RKC*G.<@\C_/6IJR]'MI+33[:"4[GCC56)ZD@8K4KYZ,5%6BK+LCK
M,'Q0<>']6/\ TY3?^@&O\W[_ (+=WDG_  MKQ*A!VF>ZYXXR_7V_/TXZ&O\
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M?=_+R_0_U\-'UFQURT2[L95FAD (=2"#D ]NGJ/SK2(*G(Z']/;_  K\*_\
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M_/G'T&6<-XS%8JG3JTI0A)I\UNMUIOUON>=B<RP]*FYJ:?3[[:V?EWW/'/\
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M(;:0-;8)<@MC ZYSGW_'W[5H:,)=9DCTXJT]VQ"E@-SL>YS[G\_UK]"O@/\
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MKG%JK77*E9J/9Z;[[:_\$^ZO#UJ+31K"WV@>5;1)C']U%'X=,=J*T%F5 %
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M]2NVDDD,4.9I#UX!SEOR^M?OC\(_C-I?C[2;*[M[F%FN(T;:'!(+*#C&3_\
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MM7^#1'_J_P"T[/H.,?:8,\?Y]O2ORH1);C4[W:2,32=#CC<3Q^>.W)K]._\
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M.5!X/M@8/TJS+9Z8LL-[!(!+"RRKC@Y3YAT/M@U_5U_P4*_X(2^*O ^GZ_\
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M=#^'.^D74)<1MF!N&(R1C\.G>O>_@Q^TCXU_9QNUU3P)=7$=T&WGRI74AA]
M>>GMQ]*Z#]JC]FKQ/^S'XQNO!5]IM[-)#-)"93#(<;&QG.W@],]>!FOD1;^;
M36WWUO)AAG$J'@'.>".WI]>M?I<\RI9M0H<]&G&K."O-6<J3:2LG^?S[GS*I
M5\!7Y8W<&_=CK^\6F_=ZK73H?N'\'/\ @N/^TEI?B/3[/4]6OH[)98U<O=2
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M7J6?^"8O[ 7A#]F?0M)U#3-+CMKN>R@DFS J'S6C5FSU.=S>W?M7[?A%"[5
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MOLZL'&^VCV_X/]=#IA6IU$W"2:3L[=SHZ***XC4**** "BBB@ HHHH ****
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M-74^#_Q&4^:^EW'F$\_NY,^N?N>OOUK_ $2[;_@A[9PAPVEV_P W3]S'QQ[
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MYZ_>4_RKD&^"'PO9S(WA#1BY.2QL+8DGZ^57N87B'$X6E"E!>[%6TD^EG?\
MK[F<M?#^V<6IN-NB\K6_(_RJ_P!G/_@F#^TCX<^/GA'6KWP9J<5G::K;222-
M:W 556522281TP>?4U_I;?L6>"M9\)?"WPEIVJVSV]Q:Z9:12(ZD,&2-01@@
M$?Y/?%?4-O\ !3X96LZ74'A+1XYT(9)%L;8,I'.01$"/P->CV6FV6GQ+#:6\
M<,: !41550!TP  !CL*X,?F=7&M/6G_-9_%MOKK_ $M32C2]E%IR<O-_*Y='
M0?04M%%>8;!1110 4444 %?C#_P4W^#/B+XF>'+Z#1;"2[D>TD4*B,WS;#Z
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ME+EON_N_R_JY_DU>*/\ @E%^TA<6DAB\$ZD7*G_ETN>3@^D'?IZ9Z]J_?_\
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M$.TVVM6:-2PC@1#DYST)]37VAI?A/P_HT:Q:;IEK:(GW5AA1 /IM45T0
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M)=]=>Y_)]_P4'_X(N?#"^LM5\2>"_#D,^K7HGG<PVBEC*V\CE,GJ!S_+C/\
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M^T+XY^ ?B.VUSPI>W%K=6\T3*T<CIC8P(^[CUK^^C_@B3_P50_X6)X8LM/\
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MO:U^M@HS13"F3G-95)323A'F=TFO*ZN_NN,?1116BOU **** "BBB@ HHHH
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MM5?J@&+NYS^H_P _YQ3Z**FG#DCRW<NMW^7IV ****L HHHH **** "BBB@
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M)UZWLVDHW2BUI;:WY_*Q\9F,,4U%T^:=2GT?RMWZ>?709Y0D<2?Q YZ\\GZ
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M=P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY9/K7-4JN$+T[\[WCTBVT[JV^G7R\CU*.)C.3FDHTZEEHK:>[=V^=PN(\D&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_/U^;X)+C8RN3GW)]?KGVY_EBJ6RZ\W=SCVS@_\ ZCU/]>E-M1N$D"R1L@)
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MY'3]P?QYQC^7\ZZ/PG^P'?B\0W^B[D#J?GA'3([$'W_EVK^CW^R=._Y](/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q=0T
M*PU(@W,*R$?W@#C],U1'A+2 FS[-'C&,8&/T%=*TB)PQP?2G @C(.173#$XJ
MG%<E6K&*VM*22V??T^_N2X1E\44[=T<ROA/24&!;1@>P']0::WA'2&.3:Q'Z
MJ#^?%=315K'XQ._UBK=[^_+7;S\OZT$H03NHJ^U[&!;^'--MR#' BX.> /TX
M]:VXHDB4*@P!_G%245A4KUJW\6I.?7WFW^9226B5D%%%%9#"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH Q[R*5G&S(QC/Z>GJ/\\U?M598\-U_SZ59QGJ,_A16TJKE!0:6G5?(
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF*6OBCX??M$:?XDNH+8ZC$\DKA=OF@DYX]S7V787 NK2"<'<)$5@1WR ?ZT
M7*0D#J0/J<4M?/OQ>^)\/@8*9;A8<XZMM],CK[\4 ?0.1ZBEKYC\!?&C3?$D
MD$2W\4CR,!MW@G]#W_\ KXKZ5MI1-#'(.0ZA@?8@&@">C..O%%>9>-_$T^B0
MR/$2-JL>/89]1_7\* /2]Z_WE_,4;U_O+^8_QK\]];_:'U6SU&2U1V^1V& Q
MZ#//WO\ '\ZY+5?VIKW3/ENKGRB<8#/@G)QW..W%:4Z<ZDE!+5]] ;MN?IKO
M7^\OYC_&C>O]Y?S'^-?F!8?M1ZK>R#R9F=3T(<G.?<'TKIK?]H[5VOK>!Y&
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M\G-0\4>*OB)?W&J^)+^?4)1/(Y>=RY(W^K<YYZ=SGZU>M[.WF40VJ!)5&"5
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "HIE+Q.O]Y2*EHH ^4_B)\,]1\07,S1!BKEN
MBD]<^@/7/_ZJ^;==_9^UVTLKV>!)$V13-D+CLS=<9X[_ (_C^GA13U4'\*Y#
MQ>PCT740(U_X]INW^PWY>_>NU5YUHQH:*.B^ZUOU?W(5M;W;WWUMZ=K>1_,'
MJ6C^*5^-Z>'VN9R&O#'L);G]ZJ]/4_\ UN]?K'X8_9^\03Z3I]PRR-YEO$V2
MIYRBGK]3DG_"O@Z_6.3]J*)B!_R$<]!WN%]L\<\#T]*_H3\(0Q_\(YI/R+_Q
MYP=O^F25GB*<:?*H\U[:WU6RV_KK;H:2A*%F[>\KJVMMM'YZGR5\/_@WJVA:
MM!=3*^U'4\KV!'M^O?%?:MI&8K>&,]511^2@5*(T7D(H_"GUSMM[MOU("N0\
M=F0>%=9,1VN+&YVGODPOC'XUU]<?X\9E\)ZV5ZBPN2/J(7_S[T@/YC+O4O&,
M7[35^#J-Q]C_ +1.V/>=N//E[#V/^37]!_P'NKFXT>V\^0N?LZDY_P!U:_GE
M;4K^?]J#4+>2-A$-28;B#T^T2_Y_&OZ)_@? D6CVFW^*WCR/3('3_P#54N:4
ME&SN];VTZ=?F0ZD5-4W\35U]UU]Y]#UP/Q-:1/!FN-$Q5Q8W!4CKGRSC]:[Z
MO/\ XGDCP7KA'7[#<?\ HL_Y]^E6M6EW99_-5IVL>+9/V@M4@74+C[.-28!-
MYV@><W&,G],5_0%\ #>G1H/M<C2-Y*<MD]!SV]S[5_/UH5W*/VB=4$@(3^TG
MY[']Z_\ ^KV_"OZ%?@;)&^CVY0@GR$X&.X&>GTJZE.5-J]FFKW6J ^@Z***S
M ^ ?VYK^]L?!$[V<K1OY4O*\'H>_;VYK^>K1-?\ %^H^.K*Q74;@Q37P4IN;
M!&\Y'3./\GTK^A_]M^*)_!4PD./W,G4#NI_S[?C7\_WA"V9/B?I/DJ&0ZDH)
M49P-Y]^>!S^E=N'J8>FG*:?/:VU^W_#B:;V=N_?Y'[1> /@7J^K>$-+O?+9I
M9K>-V<J23N'<D'//?_)[?0/V?]=L=;M;QTDV12JYR#P-W^?_ *U?8/P7A4>
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M ,%*O$%[H^A!K29X24R"IV]0V.A_S^M?K]7XZ_\ !3*WAFT)1(V/D/7T&?\
M'G_(J0/SE_98\1^*-2\;Z29+^=H#=1Y4L<8,@_\ K_\ Z^*_I[\&%SX<TLN2
M6^R09)]?+!K^8_\ 9-1(O%VDK'@C[3'^CK^'U'M]*_IR\''/A[3#_P!.L/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI<3QPHLBB3<P9%PP(Z@@COVK[,K-IK1JP!1112 **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"CJ-O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?\BUI'_7G!_Z*2M:LYR48SBH\J5M+75K =-1116(!7(^.\_\(GK>/^?&X_\
M1,E==7(^.\GPGK>.OV&XQ_WYDH _F"OYG_X::U ,<J-1(QVXN)<]<\5_0E\
MW1M'M2HQ_HZ#ICH@/]:_GLU&"5?VF=1=P=O]I$YQ_P!/$N>V#_6OZ$/@ 8_[
M'M=I_P"7=.OKM&??/0?YX>EGWZ?A_P $F2J>TBU;DY=>^T?Z_P CZ<KS_P")
MREO!>N =?L-Q_P"BS7H%<#\32?\ A#-<QU^P7&/^^#2*/YEK.TN8OVA-5D#M
MM_M)N >WG2?_ *OUK^@G]GEV;1;<.23Y,9YZ<!17X':5F7]H/5%D&%_M)NO_
M %V?N?4?K^5?T!? :**/1[?8<_N$_/:I]JZE54*+IRNY.5[[V6FGWK^M3.$_
M:7DDTEIJFNU]_/KUNMCZ-HHJ![B)&VLPSGU_SGTKE-#X-_;CE1/!,VX?\L9!
MR..AK^?/PA8W5Y\4M(E@D98UU.,D D=&;_\ 7^=?O_\ MU*\W@>8Q?,/)DZ>
MN&Q7\_G@_6!HGQ TZXO&$4,5^K.S<  .<GMV]_6NNE6A2@[+]YWL_*_SWZ_=
MH<]6E.4E.F[3T5G>UKK_ "7],_JP^"J&+X>Z"KGD64()/4D*<_SKUC</4?G7
MPA\/_P!I3P!9^!]'M(]:M1<Q6L2.@E0'=@\8W9%=SI/[3W@&>>.SDURV^T2,
M%1/.3)8\8P&S^6?2N9\S]YIZ]?N_S-U>ROO97]>I];T5Q7A_Q9I^NI'-9SI*
MD@!5E((YQTY/'/\ ^NNUJ1A7SY^TKN_X5CKI4X(LYO\ T6U?0=?/O[2JN_PP
MUY4&3]CF_P#0& _G35KJ^UU?TZ@?D#^P@93\7-;#L2O]J2CDG_GH>!7[*?&3
MP!;>-/!E]IBVZ/-<6K("5!/,>.N#SD^E?C?^PC:W<?Q<ULRHP']J2GD8!'FC
MV SU/_ZZ_?4QB6%4;NB]1_LBM9.FIKDYE&ROO?9:Z_?_ )DNTHVNFGNU_P .
M^A_--XZ^'U_^S;XHGUABUJES>M*& * AY">P'\_7GC%?LE^RC\38_&'@NSN7
MN!*[1Q DMEB2N.,D_C7QI_P4B^&WB#Q'IT4N@V$MPT7SDQ(3]WZ C.?S'3M7
M@_['OQ;O?!-YIG@W6;@VMUYD<7D2.5;[P7&TX/?I7J*-&K0W5DKZO5M*/]=O
M1F4(>RM&-VM//M?[OZW/Z#D<.H8=#^7X4^L;P_="]TBQN0=PF@C?/^\@-;->
M,]W;N;E'4;A;:RN)F.!'$S?D"?Z5^0?[4/Q13QE/J/@.TF_TB?S(5"MSDDJ<
M 9[GGC-?IO\ $G5I]/T34#'D8M9<^Y"-[?7C_(_GXD\4+K/[2JZ=<3;E?4-I
M4L"/^/@9P#Z__7KIPU:%)RY]I*VF^Z_X),X\T>6]K[G6?!/]BKQ#<W-UJ$L<
MS+=/),I9#_&68=4QU([]^@KWJ\_8@\5O,3$9U3/ "]N.VW^I'ZU^M/PZ\-66
MF:#ILT,:?O+6)LA5YS&I[?7]!^/I'EI_<3_OD?X5;Q3@[4M(]^O3[]OZZ3"E
M&$%#=+OKKY=M3\&_$G["_B2WM9]3F69OLD9FRR?\\U9LYV'L.GTKSKX ?$.\
M\)?%J#P+/<2*;:Y2(HS$#A]G3I_".W\J_H$\801R>&]63RT^:SG'W1_SR?VK
M^;[Q98)X4_:!O]=A_=NMZ7R!@<3N?IW[#IGZU4:U:M?WHI?:YNJ]W;^ONNQR
MY81<FKI+U]-[^1_29X?E$^F64H<-O@C;KGJ@/Y\_E6[7R?\ LZ_$2;Q=I5NL
MDN_RXD4<Y PH'OZ?UXKZPKBG?F=]_P @IS52"FEHPK\P?^"FS,OP?OBK%?W4
MW3@_=3']:_3XG R>!7Y6?\%1+B3_ (4Y?"VRSF&7&/7"_P"3^'M22D]DWZ*Y
M9\5?\$NI=/DTZX2]ACG)E.=X!Y+#GG_/ZU^^^C>']&:WCGBLX5+*#D(!W..F
M#_\ K^E?SO?\$K8;V6RF:X1QF?('(_B'/3_/Y5_1QH*E-/B7&,*H_G71-5HT
MH.3M%_"MGI;7U_R%I=]]+_H:<-O# ,1(%'L,?RJ>BBN:[8PHHI#G!QZ4 >+?
M'Z01_#3Q&Q[6$Y_)3_D>]?SV_LGWRW/[0>NQ\#&K/UR/^6B>WO\ RK]^/VA6
MG/P\\1)@F,V$^>W5>1Z?Y![5_.?^S_XCTSPE\<];O+JX2$G4W)+D#^-/4]\5
MT4?8V;JQDUIJO7T=M.O_  !._2WSN?U#>$DV6$.,?ZM>A.?NCUYKKLYZ<U\9
M>%/VE? 5IIL7VS6[6-UC7.9D'11UR?Z?UKO-"_:-^'^MW(M[/6[65R=NT3(W
M/3U/^?TQGR\SY+\O2XSZ1HK$T77++6K=9[.994*@@J0>O^?PZ"MNI *_-?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %<WXCTV74M.N[:,D&>&2,8ZC<K8QT_+UKI**NG4=.2DMUW _(:?\ 8QUV
M7XU)X[S*;=;HS8P<8\U7SG&.V>V:_6'0+)M.TBQLF^];P1QGZJH']*UMJ_W5
M_P"^13JNM7E6LY):=D))+8****Q&%8WB&P.IZ/?V*];BWDC'_ T9?Z]ZV:*
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M7EL\2X'.6!'^'O7X@:C_ ,$[?&!\::GKUG+<1+=W3S*4W#&3TX7^9_\ K?T
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MEL8[4ZBIG%3CRRVT\MG<! , #K2T44TE%)+9:( HHHI@%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
F444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image00001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  U &P# 2(  A$! Q$!_\0
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@"BBBO..H**** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image00029.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00029.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" &+ H(# 2(  A$! Q$!_\0
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M_NO_ -\U4LV#ZG=D9^ZO45HXJA:_\A2[_P!U: +]%%% !1110 4444 %%%%
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M%2+G(XXH ?CBF1_=/^\:DJ./[I_WC0!)1110 4444 %%%% !1110 &J.C_\
M'JW_ %T:KQJCH_\ QZM_UT:@"\:BN/\ CW?Z&I345Q_Q[O\ 0T 2+]U?I2TB
M_='TI: "D-+2&@".7_71?4_RJ6HI/]=%]3_*I: "J%K_ ,A2[_W5J_5"U_Y"
MEW_NK0!?'2B@=** "BBB@ HIK=>.?Z4C$^X]Z 'T'H>U,QA<>M"GD@]?3TH
MH#5;?L)".Q"'!I_]IPXY28?\ --TO_46_P!'_G5]^A^E %(:G"1PDW_?!H_M
M.'.-DW_?!JU:G-NF?2D8_P"E)_NF@"L=3A'5)O\ O@T@U.$C(2;'^X:O2?<;
MZ&F6Q_<)]* *G]J0!MNR;/\ N&E_M.'&=DW_ 'P:LL?])3Z&I'^X?I0!2&IP
MD<)-_P!\&C^TX?[DW_?!JW;\PIGTI&/^DK_NF@"K_:4/]R;_ +X- U.$\[)O
M^^#4NHHTVGW,:2>4SQ,JR9QM)!YJ'0+:2ST;3[::;SY(;=$:7.?,(4#=GWH
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MDKCGK[UK:%J'B[6-,COK%M(BMIB3&DH?<!FMCP?I%[I%O.NI20RW5S=O<,T
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M?ZZ+ZG^52U%+_KHOJ?Y5+0 50M?^0I=_[JU?JA:_\A2[_P!U: +XZ44#I10
M4444 %(S!>IQ2U3U6Z2RL9;F4$QQ*78#J: +6X4!P?Y5R:>*)1#+'/I[1W^Y
M!%;K)N$F_P"Z2>PK8TG5$O+/SI8C 8W,4R$YV2#J/<>] !IL(-O;C<PR'[^]
M7C %!^>3I_>JEI<T9M[8AQC#_P ZOM-&0<.* ([>$&%3ODZ?WJ&B N4&^3[I
M_BI;6:,0)EQTI&FC^U(=PQM- #Y( $;YY.A_BIEO"/)3YY.G]ZI))XRC8<=#
M3+>:,0H"PZ4 -:$?:4^>3[I_BJ1H0$/SR=/[U1M-']I0[QC::E>:,H<..E #
M((084^>3I_>I&A_TE?G?[I_BIUO-&(4^<=*1IH_M2_./NF@"#4X(#IMU]I>3
M[/Y3^;\W\.#G]*@\/0V1T'3AICR_81;IY'S?P;1M_2K&I7%LFG737)#0+$YD
M7U7!R/RJMX<N+*30M.EL (K)[:,P)TVIM&!^5 %V2$">+YY.I_BJ0PC:=SR=
M.?FJ.2:,SQ?..]2--'M.7!XYH Q?",.G#P_:_P!C/-]@RYC.XCG>V?US6N\(
M\Z+YY.A_BK*\(7>FR^'K2324$-BQ?RU(P1\YSQ]<UJO-'YT7SCH: )# /[\G
M_?501PC[,F'D]?O58,\6/OBL'7/%.C>'+.W;6+Y+;SB5C!!8L?H 30_,J$7)
MV2/,_ /@^P\7V=[J>NW6IS7CWT\99+MD 56P  .U=4?A-X< .)-5Z?\ /\]5
MO@?*C>&)YAN5)+^X==ZE<@MD'!KT<RQ[3\PZ5$8JQTU*\Z<G&,FCB_#OPWT'
M1]4M]4LOMK7<2LJ--<M)@-UZUUKPXN$VN^=IZM3[>5!"GSCI2-*GVE3O& IJ
MTK'/.I.;7.[V'-$%4Y=^F<;JYSQ1JMYI<>EV^EQI+>7TWDQF=B$7C/.!6UK%
M_%9:7=79PXAB9]O3.!G%<39KX@\0WN@ZE>P:?!I]O*+E0DA+X*G Z>]:0BVN
M:VARU)I/V:W9HY\;&48CT;/./G?_  ITJ^-Y(70QZ.-P(_UC_P"%=5YJ&=3N
M'W:F\V/^\*?MGMRH/8)=68/@O2)]*\.V=G=R9EA4JWEM\IY[5L/"!+&-SG/&
M":6UEC$7W@#DT22QF:([AWK*3YG<UC'E5B Q[-7M_F8_NVZ_A5_L:I-(KZO;
M[3G]VW]*NYQ0RCE?B-/KT'A^8^'+2QN96'[S[6^U53N?0\5R_@O29K#Q)9M9
M:;X?TF.5&FN!;S-+-<J1_#GH,\FNP\;0VFI:%?:;=RW$220^8TD*,Q4 ^W7G
MM7'^%RVL>*M*GU&\1I+!&%LEO9/#NRN#O8C&,=O6FMP9ZE(H="K %6&"#WJM
M;Z;:6ZOY%M#'O&UMJ 9'I5LTO:D'0@@MHH(UC@1(XEZ(@P!3T^^_U%25&GWY
M/J* 'TR?_5FI*CF(*8'K0 Z@O@XP:S/$5K=:AH-[:Z=<?9[R6(I%+_=;UK"^
M&>AZQH>BRP:[<B:5I=T<?F&01CO\QZYZT =:G^ND_"I:BC_UTGX5** &O]T_
M2DB^ZOTI7^Z?I21?<7Z4 .-1C_6J/:I&J,?ZY?\ =H EIIZ-3J0]&H ;%_JU
M^E/IL7^K7Z4Z@!DGWD^M.]*;)]Y/K3O2@!:CCZ'_ 'C4E1Q_=/\ O&@"2BBB
M@ HHHH *RK_7+2RU6ST^4L;BZW% !P !DD^E:IZ5QNH^&-1FU^*^AU$>092[
MQM&"RJ5QM4TM1HT(/%=G()VDBGAC2-I8V=1^^4'!*X]_6E7Q1";5F-I="[$@
MB^R$#S"2,COCISUK&7PSJ5S 8;H01BV@:& ARWF$G.X^G:IFT;5GF.K-# -1
M\]9/LPD^4J%VXW8ZGK3>XCI]/U*WO[&.ZB;;&W!W\%3W%1Z/(GV5OG7F1L<U
M7\/Z2;'25MKP([M(TKA>@+'.!4^CPQFU/R+@2,!Q0!H>8G]]?SJ*X=3;OAEZ
M>M/,$?\ <7\JBGAC$#X1>GI0!*LB;1\Z_G3O,3^^OYTQ88]H^1?RI?(C_N+^
M5 #O,3^^OYTAD3^^OYTGD1_W%_*D,$7'R+^5 #9'7SHOF7OW]JE\Q/[Z_G4$
MD4?G1 JN.>U2>5%_<7\J '^8G]]?SJC:$'5+S!S\JU<\B/\ N+^54[-0NIW8
M7CY5H T!11BB@ HHHH *KZA"9[.6(!"74K\XR.?458HH X6S\)75O;RRHUM%
MJ/F))$%+,@"= <G//UKH] TY[&QD2[*O/<3-/-@?+N;KCVK7HH RM*VFWML*
MO1^WO6BRKM/RCIZ5FZ6S"V@Q&6^_CD>M7C+(0?W+#C^\* %MU'DK\J]/2D91
M]H7Y5^Z>U-MY)/)7]RW3U%(TDGVA?W3?=/\ $* )I%41M\J]#VIMNH,*':O3
MTIKRR;#F%NA_B%)!(_DIB%L8X^84 *P ND&T?=/:I'5=C$*.GI4#2/\ :$/D
MMG!_B%2-))L/[EAQ_>% "VZ@PI\J]/2FLH^TCY5^[Z4D$DGDIB$]/44UI'^T
MK^Y;[I[B@!-4,<.FW4TD0DCCB=W0#[P )(_&H/#LUO>:%IUS:VX@@FMXY(X2
M/]6I4$+^%2:C<RP:?<RBV:0QQ.X3(^; SBHM#O9+S1;"Z-FUNTUNDGDY&4R
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M?YAT]:?Y,?\ <%13PQB!R$'0T 2B1-H^9?SIWF)_>'YTQ88]H^04OD1_W!0
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M"RF7)P4^8$ >W>O2=W4^G6N/NO&5M)=3+8:3?:G! Y22YAB!0$=0"?O8]J2
MJ_"SQ99ZUI/V19K47,$CHD<,?E^9&IXDV8XS75Z[;-?Z/=VL1 >6,J.<<TW0
M[ZQUC3XK_32CP2 @,$VL.Q!'4&M Q_W3CC&:8'G]II&HPVK3VME+%';RQR)9
M22[C(5^\0>V:Z;PY8NMA<&]BV275P]PT6<E QR%/N*VMI]J7:?;'I0!E:5;Q
M"VME"X #\9]ZT&@C"G"]O6J&FS(MO;EMW ?^'WJ\UPA4_>Z?W30 VV@C,"';
MV]:1H(_M*#;_  GO2VTZ"!/O=/[II&G3[2A^;[I_A- $CV\8C;Y>Q[TVWAC,
M*?+V]:62X0QM][H?X33;>=! GWNG]TT (T$?VA!M['O4CP1A#\O;UJ-IT^TI
M][[I_A-2/.FTCYNG]TT -@MXS"GR]O6D:WB^TJ-O\)[TMO.@A3[W3^Z:1IT^
MTK][[I_A- $.IK;0:;=R7$1>!87:1?[RXY%0^'Q9W6AZ=/91&*UDMT>&/IL0
MJ"!4VI7D4.G74KQM(D<3N4V_>P"<5%H%_#=:'I]S'"T$<UO'(L6W[@*@X_"@
M"U)!'Y\7R^O>G-!$$Y7C'(S3))T\^(_-W_A-2&X3_:X']VDP,?PG)87GA^UN
M-+@,%DQD\N(\8PY!_4$_C7)_!F-6TG5 W/\ Q-+GO_M&KLGC[2])\/Z5<265
MVKW[R);V5O$7D.UR&.!^?XU4^#2S0Z#>2W=K<6IGU">5(YHRK[6;()':DWJ=
M,8M4I2Z,]"^SQ@_=_6H[>&/R8SM[>M2^<A_O=/[IJ*WD4PQXW=/[M4U<Y?,\
MZ\?>)-(OM'O--M)'FNQ*D8$:,1NW@D9KT.WA0VL>Y3G8._M7'_#0H=&GR"?]
M,G'*9_BKMC,@4XW=/[IK6K)+W$MC"C%OWV]Q+>",PH2O;UIK01_:4&W^$]Z6
MWG00H/FZ?W336G3[4GWONG^$UD=!*\$85OE[>M,MX(S GR]O6GO.A5OO=/[I
MIEO.@@3[W3^Z: $:"/[0@V]CWJ;[/&/X?UJ%IT^T(?FZ'^$U-YZ?[7_?)H A
MM8(S#]WN>]$D$8FB&WN>]%K.@A_BZG^$T23H9HOO=3_": (7C5-8MMHQ^[;^
ME7UJ@TBOK%MC/^K;J/I5[.WK0!S_ ,0+>\N_"&I0:9YGVMXL((W"$^VX],^M
M<MX%AL4U6U$6@W%G<K'@RR7HE"G'/&><^M=7XZLGU+PMJ%M%=):EH]QE<X3:
M.2&/H1UKSCP5HVGQ^.K.;2I]!6*)I)@UI*&E<,N#%CT!YS2B-GLVW'Y5@>,Y
M7AT.9D=D0R()&!Q\A/-=":AD@66-DE"NC#!5AD$>F*8CG/!A4#4HK5RUA%.!
M;L3N&,<@'ZUT2[O,;!7WS26MK%:PB*WC2*,=$08 I\?WG^HH XG5%N&2[6U=
M%N3N\HGH&[5A>$H=9@L)QK3DOO\ W:R'+*??V->FW5C!<##QK[XK+O='RK&W
M?D#HYH0'@%UX*U4>*)=1U*X3281)N6_CD V$GL.X/I751>)-6\,30Q>,)(+O
M29E_<:M;*2/I(H_G74^/]$#Z+))?F6.*TS,KQ+N^H_&N9\/^+=.D2TT<6+F#
MB%O,(DY/3CN#4."W1U0Q%UR5O>C^1V.GWD%[ MUI]U#/ P!66%L_3D5OV6L2
M*H6YP5 QO Y->9WWA.]T;49M0\#30V;L!]HT^8GR9S[?W35G2O&T;W3Z?K]C
M-H^JI&7"2']U-CKL;H?I0I-;A/#IKFINZ/64E\^/?'(C<>G-2(KJ 04&1W%>
M;>&/$0UG[2;:*6UDBP3DYR#T_&M#3_B!&_B#^R)K20L"4$P/5AUR/2K6IS69
MW>)".2N*R]6T.PUB2W_M2TM[KR3OC+KRI'^>E7K>^MYU!20#G&#Q4W_+1?I0
M(X_XEVNOW'AY(O##[9Q(/,6,A7*>BG\JV?"\.J1:!91ZU(CZBL?[YASS6SMY
MR,?X4UC@$8_*@!(]_EK@KC'%._>>JTV"0-&H7/3/3%2@Y% $,GF;DY3K3_WG
M'W*63[R?6G>E #/WGJE,CW[3ROWC4]1Q]#_O&@ _>>J4HSCYL?A3Z3% #)#C
M^5<EKOB7P9+-<6FLWVESRV9)DAG42-&?H176RG&,@$$XKROQ==:3=:Q?W&F)
M=6-[;@VMQJ\<&^W5\?<E7^(#N>U)C1VO@O5/#^JZ9]H\*FT-F2"WD1A!D^HQ
MUKH^U<=\.Y[6#2UT."9+BXTN*,37$:_)(7!8,OK789I]"1:***!B&J.C_P#'
MJW_71JO&LW28MUNYWL/WC=#B@#2)XK \7>([3P[IHGO5D?S#L18QRQ^M;)@_
MZ:2?]]50UG1[34M/D@U"/[3#G=M?L1Z4 2Z)JL&KZ;!>6>XPR+D9'(K0!XYJ
ME8Z?#9VL4%MF*&-<(BGA:L>1_P!-)/\ OJ@";-%0_9_^FDG_ 'U1Y'_323_O
MJ@##US_D:O#7^_<?^BZZ'_&N9UR''BCPV/,D^]<<[O\ IG6O:6$D+R&2ZF?<
MV0"W2@#0S5"U_P"0I=_[JU9^S_\ 323_ +ZJI9KMU.\&2>%ZT :-%%% $$GS
M0N 0,J1SV)]:\\\)2^*/#^@P:9)X;\]H&8&6.X4!\L3G!->A2<*2!SCUZ_6N
M(F\4:S'*ZQGPP &( ;5 #^/'6IZAT+'PFBFCT343<B-)7U"9VAC?<(<X^7/K
M7;D@=:Y#X8Z;-IVB71N;BSGENKR2Y8VDF^-=V.,]ZZ'6C,-+N3:%5N!&?++-
MM ;MS5O<2+N0#2;U]:\XMS<V=JFG7CRP7$\T0GF2X\P;3UPV.*Z?PO-<2:7.
MBR"?R+F2"-Y&R613QDTAE_2_^/>V^C_SK0;HWT-9>E&;[/;;E7=A_P"+WJ^3
M-ALJO0_Q4 /MO]0GTI&_X^4_W33+<R^2N%7I_>I&,OVA?E7[I_BH GD_U;?0
MTRWSY*Y]*:YFV-\J]#_%26YF\E/E7I_>H <W_'TO^Z:DD_U;?2J[&;[2ORK]
MT_Q5(QFV'*KT_O4 .M_]0F?2FL?]*7_=--@,ODI\J]/[U-8R_:E^5?NG^*@
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M3_=- #7:;8V8TZ'^*DMVE,*8C3I_>J>3_5M]#3+;_4)]* (6:7[0G[M,X/\
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MK2G[2A\J3[I[4 3O&@1OE'3TIEM&A@3*CIZ4KRG8W[J3IZ5';RD0I^ZDZ>E
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MF:UN9));FUDEN\.6VN&P#S]T]L<5;;RUNWTZ.YD.B_:D&\S'&"@.W?G^][T
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M8I(O]6OTIU #)!\R?6G>E-D^\GUIWI0 N*J2VT=S \<HR"3CV^E6ZCC^Z?\
M>- %+2;5[19D?D;LJ?45HBDQ2B@ HHHH *ADMXWE25U5I(\[&(Y7/6IA10!2
MATRSB>=X[6!&G_UI5 #)_O>M,_L?3Q9&S^QV_P!D)W&'RQMSZXK0HH CBB2&
M-8XE5$484*, "JFC\6K?]=&J\:HZ3_QZM_UT;^= ')>$)5,.I1X(87\IY_"M
MZ3[C?2O.M.B\;FXU4Z!+H2Z=]ODV"Z5S)GC/2IIV^)<;$/+X;VL,9"/0!WDF
MXQXB(S[UCZA'M\4>&7;EC-(#]?+:L/9\3"O^O\,?@CU%IR>+U\;^'SXFDTAK
M/?)Y8LE8-OV'KF@#NO'5O+>^$-4M[:(S3R0D)&O)8Y%>00Z=K*PQHV@:GE55
M3^ZXZ5[XH..:@O+8W"JHD:/:<Y'>I<5+<WHXB5'X3P:>VU2*YMXGT/4UEFW"
M-?*Y; R:G_L_6.^@:F?7]U7K&N@GQ1X;&3G=< 'T_=UI0R+9R);,\DK2$DL1
MTJ?91-_[0JG%_"/3KRQ76I;^QFLOM$ZE%F&"0!UKM[7_ )"=WC^ZM7-I/)JG
M:_\ (4N_]U:T6FAQSDYRYF7,44ZB@CE%HHHH&%1S<*2=H &<DXQ4E,E 88;H
M>H]: ,9?$>ER6EU<PW*RQ6TGE.8U)R_H/4_2M#3KR'4;9+FV;=$W3(PRGN".
MQKD#H]W;1WLMO8_+'J*74<,> 70#G;[UN>&[&1--G%]$8S<W#W'E$X9 QR <
M=Z!LO:7_ *FW^C_SJZ_(/TK+TF&/[+;  XPXY;GK5XP(,\'H?XJ%N2QOVF&V
MMT:XFCB7IF1@H/YU5DU.P\Y";ZTZ'_ELO^->>^.-+L]7^(WA+3=1C,UC)!<.
M\!=@K,%X)Q6T?A?X.$@!T2(@C_GJ_!_.INW<ZE3I1BN=O7LD4]"GBN/C)XD>
M"6.5/[.MQN1@PSSQD5Z' /W2?2L#0?!V@Z!+<3:1IL=K),FUW5F.X#IU-;D$
M"&%, ]/[U$%9$5IQFTX=$EJ/;_CZ3_=-2O\ ZL_2JK0)]I3@_=/\5/:WC"-P
M>G]ZJ,26W'[E/I36'^E+_NFH[>WC\E.O3^]2-;H+A< XVG^*@#B/C-X9U?Q3
MX<2PT"XEMKB5_+DD$NQ%C/4L/XN@Q6I\,M*U#1_"&GV>LO<27Z)B8S2^9R..
M#Z>U;VI6@FT^YBC)1Y(G57R?E)'6H-#L?LNAV%O+*;B2&!(VF!_UA"@;OQHL
M#?1F!\3S_P 2S31_U$(/_0A79X.TXZD<5YCI^D77BN]N;B_U6X2VM]1=%M$
MV#RVXYZUZ1]GCVD8/3'WNE:S244C"DW*3D^IG>%[2_M-$MH=5F\^\4N9),YW
M?,2OZ$5J'/G1?0UD>%M+.GZ':VMS<?;)8RY:?<3NRY(_0X_"M)X4,T?!Z'H:
MR-RV:AMO^/=/I2&W3T/_ 'U4=O A@3@]/[U $K_\?,7^Z:E;[I^E5'@3[0G!
MZ'^*I6MX]IX/3^]0 ZU_U"?2D;_CZ3_=-1VT"&%#@]/[U(T"?:4X/W3_ !4
M69/NM]*9;?ZA/I37@3:W!Z?WJ9;P)Y"\'I_>H D;_CY3_=-353:!/M*#!^Z?
MXJF^SQ^A_P"^J "T_P!2/J:)?]?#]345K AAZ'J?XJ)($\^+@]_XJ &3?\A>
MV_ZYM_2KJUGM&J:Q;X!_U;=_I6@O2@!:*** "BBB@ J-/OR?45)4:??D^HH
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M\T<C*5*'H&H QM824>,_#K.^8RUQ@?\ ;.NGV@L"0"1WQ7-:VTO_  E'AO\
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MD8X%+0>: .<\:-C3[:.60QVLEPD<[;MN$)YY[4SPI)*VDW"0.3%%=21V[/\
M-F('Y<'N/>NAN8([F%HKB-)(V&&5AD&D@MTMXTCA58XD&U448 'M1?H!Y[+H
MOC*XF,FG>)[.VMG),4#60<H,\C)ZU#IG@CQ3::]=:S+XFMY;Z>%8'?[& -BD
MD#'XUW6EC,%OUZ/VZ<UHD84_2DE9W-'5;BXHXV/2?%Q4%?$=MC_KS%!TGQ:)
M!_Q45KG'_/F*Z^V&85..WI2-_P ?*=?NGM6OM&<OL5:QR1TGQ>%Y\1VW3_GS
M%)'I/BWRU_XJ*VQCI]C%=E)_JV[\'M3+?_4)D'..A%+VC[![&/<YOPIH5UHJ
M7*75Y'=3W4QN'<)M^;&.@KH&278<E.E/8?Z4F <8/-22?<;Z>E*4G)W9I&*C
M'E6Q7A$_DIADZ4?OOM"99/NFIK?_ %"<=O2FL/\ 2D./X2.E245=4'_$ON?M
M3(+?RG\WC^#!S^E5_#HA_L'3AI;+]@%NGV?<#GR]HV_I5[5&BCTVZ>Y7= L3
MF1<=5P<_I4'AY[5]"TY].0I9- A@3&-J%1M&/I0!/()?.BRR=Z>1-M.YH\8Y
MI9.9X>#U/:I?X3G/2@#G_"2VBZ#:KHK@Z>-_E[@2?OMNY^N:UV\XS1?,AX-9
MW@^2QG\/VLFE1&*R)?RT(P5(=L_KFM9A^_BX/0]J  B;^\M0VXF^SIADJV3_
M )Q45L,6Z9!''I0!$_G>>GS)G!I["?:?F3I2L/\ 2$X/0]JE;[IX[4 5[<3>
M0F&3I2,)OM"?,OW34UK_ *E.O3TI'_X^4X/W<=* $<3;6^9.E,MQ-Y*?,G2I
MW^ZW';TIMO\ ZE<@CCN* (7$WVA,,F<&I,3]V2E8?Z2G!^Z>U2T 5+83>5PR
M=32R";SHLLG>I+7B+OU/:EE&9XC]>U %1@_]KV^_'^K;I^%:"]*HS?\ (8MN
M/^6;\_E5\4 %%%% !1110 5"J R2'+=1T-35&GWG_"@!?+']YOSJ.>,",\M^
M=3U'.,QX]Z #RP3]YOSI?+']YOSIU+0! D8,LG+=N]2>6/[S?G34_P!9(?I4
MM $3QC:WS-T]:2- 57ENGK4DGW6^E)&,*/I0 AC']YOSJ/RQYJ\M]WUJP:BZ
M3*?;% #O+']YOSIIC&#\S?G4M-)^]0!'%&/+7YFZ>M.,0_O/^=.B_P!6OTIU
M $$D0W)\S=?6G^6..6_.EDZI]:=0 WRQ_>;\ZCC0;3RWWCWJ>HHS\K?6@!WE
MC^\WYTY5VC&2?J:6B@ HHHH **** "F,Q![4^N>\52SB2QMH)Y;<74NQY8SA
ME &>#VH W]V3@=15+1S_ **W7_6-6;X9O[JZT-)& GG21HLDXW!3C-7=)>;[
M*?W0SO;(W=* +4UHDMQ',6;<G04:A!'<V,T-PHDB=<,I_B%.+S_\\A_WU3)F
MF,,F8QT]>M $\0"1JJC    I^:@5IMH_=#_OJEWS?\\A_P!]4 39H//2H=\W
M_/(?]]4F^;_GDO\ WU0 Z3_7Q?C_ "J7-57:;S(CY0SSWZ5)OF_YY#_OJ@";
M-4;7_D*7G^ZM6-\W_/(?]]55LRQU*[WJ%^5>AH T112<T4 +1110 4444 %(
MW2EH/2@#.&EVV<X?C.,,<<TK:9;[2%\P$C&=Y_QJ\QQZ\>E<CX@O+>[M 9I;
MZUC21D6W ,4EQ)_"%/4B@#=M]*A2%5D,C.!R=YI_]F6K$$>9_P!_#7%7L6K0
MS6L^HD3VEK ID"7923=GGA?O'%=ZC9C5^2& ('>@"L^F6YC8(9,D$ [SQ3;?
M2X5A57,C,.IWFL'Q!>PW]JKRRW]HJL42V"F&6>3MM[D?I63>S:A LTES>.+V
MPBA>- _#EFP<@=>/Y4@L=O\ V7;$?\M,_P#70_XTDFF6^&VF0,1Q\YX_6KF<
M(6/7&XCUXKD_%5[>7GAF[N=.DN-/-ODN9HMKMCLOM[T^H&_;Z7 L*JYD9U&&
M(<\T[^S;7<#^\R/^FA_QKD]8%ZFL)>7"^9ID,47W+HH^3C)V \\UVFY2H< D
M;=W3)HZ!UL4[C2K9X'0J[!E(*ER0<^O--M-(MH+2&'#*L2!=J,0!@=N>E8GB
MN^O;OPS/>:;+<Z<L#9?S8=DCX8=,]O>J.N7EPFH7%RES(DUG)!'#$&^5P^-V
M1WII =?_ &9:Y'$G'3]X?\:4:9;8Q^\_[^'_ !JVI(7H>!G%9FJZB8-UO#!<
M-/+$QCD5,QJV#C<W04@#3]%MK.SC@5"JQYX1B!R2?7WJQ_9=N2"1)Q_TT/\
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MQ>(-$DCO&CLGN!&T"#&_Y2?F/IQ67I-Y<-K=E<&YD=[R::*:$ME55>F!V_\
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MC QQGK3L#VN>IZE:6]];/;WD2RP/PRL.OI3(4M-.M?*C,4$,*YVY "#UKE_
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M!T4VC:=<26TDUK$S6P'E'^Z.U:)./?Z5Y-#XMU^"&\U>XNK233K?56T\6$<
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M;PEH^C:A)>Z?;&.=P0/G)5 >H49P!6A<:59W&IVVH30AKNW5DBDSRH/6KU%
M%#4M)L]2-L;V$2FVE$T63C:X[U> Q2T4,#F]4\$Z%J7F&XM"'DG^TL\;E6\S
M&-V1[5!<> -"GM;:&6*X;[,S-%)Y[;UW=?FZUU=%) 96A:!IVA6K0:;#Y8=M
5SN6+.Y]6)Y-:M)2]J "BDHJK"/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image00030.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00030.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" &2 BT# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[?\ Y[Q?]]"C[-!_SQBZ_P!P4OV:'_GC%_WP* $^UV__ #WB_P"^A2?:[?\
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M 'P* )T=74,C!E/0@Y%+5/1P!I\8'0%O_0C5R@ HHHH **** "BBB@ HHHH
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3^*J6D_\
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MQN7&\Y7I_#[5=[T PHHHH A7_CZ?_=%2U$O_ !]/_NBI: *FD?\ (/C^K?\
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M_P"?J3U_WJ-1VA_-^!T.R;M+_P".T>7-_P ]?_':PO\ A$-+_P"GS_P*D_\
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MY]JWO^$6L5T0:3NG^RB<7 );YMV[=U],USOB3P+=3VUM::#<_9(CYB7$Y?\
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MN?\ [Z-28YI:LAR<MR/R5_O/_P!]&HKJ$"$_,_4?Q'UJU4-Q_J_Q%(145?\
M3IP7N,;5QGA>_0]S[5:6('C+_P#?1JOI^9B\[3&1BQ0@<* /;U]ZNCY>M ,9
MY*_WG_[Z-))"NQOF?I_>-#7$*EMTBC:,MD]*&N(OF7S%W [3ST/I0%REL<1Q
MH'7+@@[F_D.]6X[<B-0SMD #AB!5:.17:WV,IY8=,_D>U:--B1$(% ^\_P#W
MT:/)7^\__?1J6BD,JPQ*99OF?J/XC4WDK_>?_OHTV#_73?45-0!'Y*_WG_[Z
M-)Y*_P!Y_P#OHU+10!4$ -TPW/\ ='\1J40*#G=)_P!]&A?^/I_]T5+0!4T<
M8T^/KU;J?]HU<JGI'_(/C^K?^A&KE !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !37ZCKCVIU,D;:P]_TH8'C O[:
M?6]5&K:U'IUY!>M&((;!9 JC&T[\<DU[%:'=%&=S-\HY;J>.M>17%[=^&KS4
MUANI8; W;3'?I#2"(L1P'QR/>O7;.3?!"VX-O0-D#&<CKBA; ]RQ1110 G\5
M4M)_X]W_ .NK?SJ[_%5+2?\ CW?_ *ZM_.@"Q=?ZAZFJ&Z_U#U-0 4444 %0
MVW^H3Z5-4-M_J$^E $U%%% !4,/^OE_"IJAA_P!?+^% $U%%% !4'_+T<_W/
MZU/4!YNC_N_UH YNZU35Y->O;+2K2SDCM@F]YY&'+#/  J4S^*/^?/2_KYK_
M .%+HW_(W:_G_IC_ .@"NBP?6DKFDI<ME8Y6"SUFZU^PO-2ALXH;19!^X=F+
M%ACO72S?>B^M38J*<?-'_O4TK$.7,3#^M+2?XTM A*AN1\AZ'D'GMS4U07 ^
M5NO;^= $>F9\AMS.WSM]]=N*M/VJIIZD0G>LR_.2/-;<?_U4S][--.%F(124
M"A>G YH0Y;DFP/<RAE+*5 (*\=?7O4K1*<DH 2=QX[]C]:(8MLFXN[-M .3Q
M]:F;[I^E.Y*17M440KM7;U-6:AM?]0M34AA1110!#!_KIOJ*FJ&#_73?45-0
M 4444 0K_P ?3_[HJ6HE_P"/I_\ =%2T 5-(_P"0?']6_P#0C5RJ>D?\@^/Z
MM_Z$:N4 &:,U%<R)#&9)&5$7DLQP!4#7< +[IXE*8#?,,KGH#[T 7#THJJ+J
MW\Q0)XLE]F-PY;T^M66.!SZ4 'TI:X>Q\<+=LLDFCWUOIC7!M5O79"A<-@94
M'(!/<BMV'Q!I<M_=VB7T7VFU&Z49P$4=3F@#:R",@C%+7&ZA\0- M+>UG^TM
M,D\_V91&I)5\$C([9QUJ]X9\4Z7XCMVDTRX#MLWR1$?,G49]^G:@#I,T$\5Q
M?ASQ_HFNR.D4I@<3/#$LV 9=GWF '1?<UIQ^*]$?3Y;X:C ;:-_*9\XPWIC^
M5 '0 TI..M<_IOBG1=2N8[>QU&">=T+HB]2HZCZCTZU+>^(M+M+Z2QFO$%VL
M+3&('DJ 3^?'2AZ M=C;R*,@=:X71?B1X>U>>.**=X6FC22+S1M!W$J![<BN
M@_X2#2EOKFS-[$MS:H7EC)QM &2<]Z -K(]:,BL5=?TQ]#_M=+N,Z?C(G[,/
M;U]JK'Q9H?\ H>-2@'VKF(@Y]N?[OISWH Z/-&:REUG3R$ O(OG=XE^<?>3[
MP_#O56U\3Z/<Z=<WT-_&UM;'$K=-GI^?;UH WLCU%+FN=F\4Z/!;6MW+?Q"W
MNN(G&3N]\=AZFM]&5T#*P9&&01WH ?1110 4444 %,D[#%/IDF?44F!Y5KLK
M:GI.N7DFMZL^B6\Y@N$AB0#:"-P4YSM'?O7IFFF+[#:BU/[CRE\O/=<#'Z8K
MD=5T'PJVI3_:]32U\UQ)/8B]6.*5O5H^N3WKKC-;VEH9LA;>-!@J,C:.F,4(
M'N6Z6N8A\66USI=O?65O<SB=V2.';M=MO4X/]:D'BNR-Q F)/)ECW^?P%4\_
M*??@TP.B_BJEI/\ Q[R?]=6_G3K.[%S9Q715H4==P$@P<>I]*BTB1/LSG>N#
M*Q'(]: +=U_J'J:J]U(GD-\Z_G4OF)_ST7\Z 'T4SS$_YZ)^='F)_P ]$_.@
M!]0VW^H3Z4_S$_YZ)^=0VSH(4RZ]/6@"S13/,3_GHGYT>8G_ #T3\Z '-54#
M,DO..:G,L?\ ST7\Z@1T,LWSK^= 6[G/P^,K&0MY5M?RHK%=Z6[%20<'!Q[5
M+_PEUK_SXZE_X#-_A3O KI_PC-J=Z_ZR7^+_ *:-70>:G]]?SI:]#5N";7*<
M[_PEUK_SXZE_X#-_A41\6VHF9A8ZEG:/^79O7Z5T_FI_?7\Z9YJ_:#^\7&SU
M]Z:3ZAS0_E_$YGPQ.UYK>M7IM;F&"9HPAF0J6PH!P#75)S^=,+QGJRG\:57C
M'1U'XT)61G)MO8EJEJCM':ET.&7)7Y=W/T[U:,J?\]%_.J>ILK6K!6+-S@1L
M Q^A[4"0JK<LKE)4YV;=R]/[V:-MR6XD39YFX#'\'I4\3JL:;F ..Y&:?YD?
M]]/SI#OJ5%CN^-TL9Y.[Y>O]VHYTO1"?WL6[9M^Y_'GK]*N^8G&&7IQS56\F
M8-&L<BA6^]QG_P#532%S#(E>'?# RQD!6/R$C<3S]<_I5RW1E:0LQ8,V0/[H
M]*CAX.Z68,Y&" PV_45.)(^SI^=,74DI&^Z?I3?,3_GHGYTC2)M/[Q.GK2&-
MM?\ 4K4U5[:1!"N77\ZE\Q/^>B?G0 ^BF>8G_/1/SH\Q/^>B_G0 R#_73?45
M-5>*1!++\Z=1WJ7S$_YZ)^= #Z*9YB?\]$_.CS4_YZ)^= #%_P"/I_\ =%2U
M761?M3G>N-H[U*9$_P">BY^M %?2/^0?']6_]"-7*IZ1_P @^/IU;I_O&KE
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M?M$7VC/F)]P_Q>AY_*H+P?O+4,V/WHQ\F[]>WUI6MH!*=L: JA(.WD9ZX^M
MQMM<P2M--%*I5@&&<#C'WL^GO4VF BW(/F??8_O#R>>M,@MXFMH_W",IC"<H
M!\O]W'I[5<C7:,8Q0Q=!U0S_ 'HO]ZIS4%Q]Z+_>H FI:0?UI: "HKG_ %+?
MA_.I:BN?]2WX?SH E%% HH *1ONGZ4M(WW3]* (K7_4+4U06I_<)4U "T4E%
M $4'^NF^HJ:H(?\ 73?45-0 M%)10!B0_P#(V7/_ %[)_,UM"L6W.?%=UC_G
MV3^9K:ILF/D5=(_Y!\?U;_T(U<JGI'_(/C^K?^A&KE(H**** "BBB@ HHHH
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M /WP/\:/[;G_ .@1?_\ ? _QK6\^+_GH*//B_OBBZ*L^YBIK,XDD_P")1?\
M)'\ _P :D_MJ?_H$7_\ WR/\:T8IHQ++EQU%2^?%_P ]%HNNPK/N9/\ ;4__
M $";_P#[X'^-']M3_P#0)O\ _OD?XUK>?%_ST%'GQ?\ /0470<K[F%I+3W&O
M75U+:3VT?DK&/-'WN3TKH1VJMYL?VICO'W!4OG1Y^^*EZLJ*LK$.D?\ (/C^
MK?\ H1JY5/1R#I\9!R,M_P"A&KE PHHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!/XJHZ2!Y$G
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M4 )M'H/RHVCT'Y4M% $"@?:GX'W14NT>@_*HU_X^G_W14M %32/^0?']6_\
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M_P"/"/ZM_P"A&KE4](.=/C//5NO^\:N4 %%%% !1110 4444 %%%% !1110
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M]G_"HXFO_.E_<P 9&#O//Z4 :5%4MU__ ,\[?_OL_P"%&Z__ .>=O_WV?\*
M+M1?\O7_  #^M5]U_P#\\[?_ +[/^%,Q?B4OLM^F/OG_  H T!THJENO_P#G
MG;_]]G_"C=?_ //.W_[[/^% %VH+C[T?^]4#/?X_U=M^+G_"HKAM0_=?N8#\
MW)WG_"@#2_QI:H[K_P#YY6^/]\_X4NZ__P">=O\ ]]G_  H NU%<?ZIOJ/YU
M7W7_ /SSM_\ OL_X4R3[>Z$;+?\ [[/^% &A15+=?_\ /.W_ .^S_A1NO_\
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MN,D[>G))JS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *3O110 O:D%%%
MP-%%%"$PI***0"T444(8E+115$A2BBBIZC"BBBF 4444 %%%% !2&BB@!111
M128!1110 4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
8* "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image00031.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00031.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" %@ G,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#ZIHHHH **
M** (YI8X(FDF=4C'5F. *A-_:+ )C<1"(G ?<,&L'XDJ6\)W(5=Y+Q@*3@-\
MPXKA[B%UTS8(K>.9M64&SE/[N'Y>A]CUK6%-25V2Y69ZLVH6:[-US"-XRN6'
MS#VJ7SH]S+N7<HW$9YQZUYW=6UA+JURNKK;1K'I:E C85#DYV4N@7;Q&634I
M?+DDTE2#(<;L%OZ8INDK:"YCOIK^UA1&EGB19/NDL!N^E'VZU$WD_:(O-/\
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M CRU#?4XJ/?<?\\U_P"^JL45 ROON/\ GFO_ 'U09)01O4 $@<&K%0W72/\
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MW5<?VA-R>H_E10,WM/\ ^/&#_<%6*@T__CQ@_P!P5/0(**** "BBB@ HHHH
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M\;!D89!'0TZ@ HHHH **** "H;?K)_O5-4-O]Z7_ 'J $'_'Z?\ KF/YU/4
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MNND?^^* )6^X?I4=I_Q[I]*D;[A^E1VG_'NGTH EHHHH \;_ &L,GX0W6/\
MGXB_K7PR5P@)-??7[1FAZCXB^&MQ8:-!]HNGGC8("!P,YZU\C'X.>.,9&C-_
MW\7_ !KLH2C&#;>HF>>NN<$'K0?E8''Y=Z] /P<\<[O^0.W_ '\7_&GR?!_Q
MQMV_V.W'_31?\:TYH-.741YYEB,+P":=%G=V^4YKT%/@YXW7!.C,0><>:O\
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M;UK2^/7BG4O!WP[N]7T5T2[CD15+KN&"<=*U?B$ )?#(' _M:'^1KC?VK_\
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M4 >15^AG[.__ "1WPW_UP_J:_/.OT,_9W_Y([X;_ .N']30!Z/1110 4444
M%0W72/\ WQ4U0W72/_?% $K?</TJ.T_X]T^E2-]QOI4=I_Q[I]* )&^Z:Y?4
M=-^T>(?.^R2>7\A9_.VK(1TX]JZD]*XC6M4N(?&5M;1WJ21$KFU5,-%G^,L>
MQH \W_;,_P"2<V'_ %^K_*OB]N#US7VA^V8?^+<6/_7ZO\C7QAM]:UIIM60"
MQM\N#ZTA^]Q1@!N#D8H'R\UHVVD .#U-:NB$JS-D+@9Y%984DC%:UK RND98
M .,\UTX:BZDKWL:49.,N8(0)!,7(]169<_ZPX.?>K5V?+=PIX%4"=QYK7'SB
MDH+<4I7-WP(?^*UT'T^VQ?\ H0K]$_'$L47A#43<$B-H=APN[KP./QK\[? J
M_P#%9:$W'_']$,?\"%?H]XA\LZ'<B>T:\A,9#P+U<=P*\J3N2SSGP/X?ATSP
MCKWAZXU.=1 RN]V@VR!64,#N[^E=C\-;6&R\)6L%M?1W\2%@MP@/S\]_?UKB
M/AY?V?\ P@OB1TM+F"..>1"\_.\$87!/4#I6_P"'=8CT#X8-J,@AD^RJYV0)
ML#-G@8_+FI$:'Q#_ -=X:_["T/\ (UQO[5__ "1W4/\ KM%_Z%5C5_%\&NMX
M)B:&9+NYO+>Y.$/EC*DXW=*K_M7?\D=U#_KM%_Z%0!\'&O7_ -E/_DLFF?\
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MY)XC^+UM:ZWJFD0Z)K-PUA/Y,D]J!@MUXK)TWXO?8U+W.@^(YV7<<,%(QVH
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M0XXK>\1>&XM6\/7&DVL[Z?%-C+VX (&<D?C7+^*M#L].UCPA/'#']K6]2$S
M8)4(1T% '.?M;_\ )(Y_^OF/^=?"U?=/[6__ "2.X_Z^8_YU\+4 >^?L:_\
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M:UAN!AF@^4@9_K4 <MXKUBUU6'PA/;2#,^I02K&3\P!![5SW[5__ "1W4/\
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M_G7PK0![Y^QK_P E,NO^O)_YBOH+X\_ZOPI_V%!_Z U?/O[&O_)3+K_KR?\
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M2K\NS\J=;90AB,KU->K/DE448;(F-[6$N)<Q+&< KQD=3578.N<C%2RLLCD
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M3-*S_P ^5Q_-:]JS2>X!1112 YG5<?VA-UZC^5%&JG_B83<GJ/Y"B@#>T_\
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M:]DTWQ-<:BN81%Q=F%@P(^0@[2/RKIM*N#=:?#*Z@,R_,!TS1S,"S&NU%7T
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M:BK+M$5P5VCWX%=**** "H;?K)_O5-4-OUD_WJ $'_'Z?^N8_G4]0#_C]/\
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M>.".42@PMALUYE_PR[X._P"?W5?^_H_PKWRFR$A3C/3M33:V \$_X9=\&_\
M/YJO_?T?X5*?V8_"&T*M[J@ _P"FH_PKT%=9U**-;H.LZM*ZR6VW!C5<\9]:
MCD\83>9YGD,B*A<+C(;/0'T-5&I*.S \^_X9=\'$\WFJ?]_1_A2?\,N>#?\
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M'4US^I:I;V5_/;26:-$H5CM RS'.3^ %=+67J&AV=_>)<W"%G7&1G@XZ?SH
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M )['\J5V _R5H\E:9Y4W_/;]*/*F_P">WZ478#_)6CR5IGE3?\]C^5'E3?\
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MF/\ Q<N#_L&G_P!#-=23Z&N6D_Y*3 3WTX_^AFJCU$SJJ***D84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!D>)M M
M?$-G%!>/-'Y,JS1O"^UE8="#6+_P@5O_ -!G6O\ P*/^%=C13NPL<=_P@<'_
M $&=:_\  H_X4?\ "!V__09UK_P*/^%=C11=A8X[_A [?_H,ZU_X%'_"C_A
M[?\ Z#.M?^!1_P *[&BB["QQW_"!V_\ T&=:_P# H_X4G_"!6_\ T&=:_P#
MH_X5V5%%V%BEI&GC3+"*U6>>=8^CS-N8_4UR=OX*O--\37=]H^KO;:;?3&XN
M[-HPP:0C!*GMGBNYHHN*QY5#\'[9+RWN&U*8^5;S0%-@PQ?.&/NNXXKL?#OA
M#3M$LXQ#&K7PMEM9+O&'D4# S728YHIN;>X**1YO=_#1O["TJTT[5I;6\TYY
MO*N@@)*2YWJ1]#6I/X#MFL_#-K!</%%H<PF08SYA YS7:44<[#E1QWC'P2GB
M35;>]>\>!H;6:VVJN<B08S^%9,WPOMYH8XI+^7:ND?V5PHY&<[_K7H]%"FUL
M#BF>72_#&X9M,NO[3BDU&UMQ9R2S6ZNLL0/'RGHP]:V;?P%%'I?B:S^V/C6Y
M-[,% \KY0,#\J[BBFZDF'*CSR]^'6=;M-3LKR,2K;Q6UPL\ D$BIT(ST-.O/
MAM;77AW5-+:[<?:[\ZA')M'[I\@@8[CBO0:*'4D^HN5'F6L_#>\U?0K73+C4
MK>-%E\R=X;54).004Q]T\5T_C3PG#XG\'3:#-/)$KHBK,.64KC!^O%=-12<V
MW=CLCS:/X5V<5SJ<T=Y(OVW3!IP7:,1\8+CW-.O/AO)++>I!JC1VE]IL5A<Q
MF,$DQKA7![5Z/13]I(7*CDO#G@V/1?$DVK)=/*TEA!8^61P!&/O?C4X\,%9]
M23[8YL+XLTD.T9#-UP:Z:BDIM;#LCC5\%ET?[5?/+*6B"MM PD9R!5VZ\,!]
M=.HP2H/,V^:DD8;.WT/:NEHJO;3[BY4<9XLTVZO_ !+I*VCO /)E5I@N0N1T
MJ&;P#&_E(MZXB6%(BI4'[ISD>F37<8I:I5YQ228<JZG)7/A$S2:BHO76WO"C
M,FT':RXY!_"I-2\(PW\>I+).Z_;/+Y ^X4]*ZFBI]M/N/E1Q[>";<R7[I<R*
MUS;K N/X,=3^-96L>'?[,T"_A4RW-U?,BIY28V.. >.E>BTF!5+$3ZL7*CD+
MCPBUWI>F6;7/E0VRJ6P@W[AR<-VS6KX@T5M32Q,%P8)K242(^,YXQBMNBH]K
M)N]Q\J.77PHGS;KER6O/MAX[XQBJ=AX'2VN#(]X[J%EC4%1G:^>I[D9KM**K
MVT^XN5&#9Z 4\,OHUU<--$T9B#XP0O:LL>"V>WFCN-0DD:2..('8!M5#Q794
M4E5FKV8[(P[SP_%=WES/)(<36WV8KCI[UE_\(5$FDV5O'<L;FTD:19G4-N)Z
MY%=A10JLULPY485_X?6]\.KI4LH4?*6=$ S@YZ4_5]&DN=/CM;"X6T0#:X$8
M97&.F*VJ*7/(=CE(_"DEFUI)I=^]O+#"('8J&WKG-=)-;F>T>%Y'!="I=3@C
M(QD>]3T4I3<MQ)6.-'@*W&/^)SK7'_3T?\*7_A [?_H,ZU_X%'_"NQHI78SC
MO^$#M_\ H,ZU_P"!1_PH_P"$#M_^@SK7_@4?\*[&BB["QQW_  @=O_T&=:_\
M"C_A1_P@=O\ ]!G6O_ H_P"%=C11=@<;_P (%;GKK.M'_MZ/^%7] \)6FC:E
M)?I=7MU<O'Y6ZYFW[5SG KHZ*+L5D%%%%(84444 %%%% !1110 4444 %%%%
( !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image00032.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00032.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" $_ A0# 2(  A$! Q$!_\0
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MJK!-<K8K;PSLJ ]#6D7IJ<ZB[G<:/I-I#L>\ECV,-VW-9&NZO$MTR68!$;<
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M@#H0 ?I26URHJ[L1W]];:/I,^I7;*+:($\]S7RW\0/'%]XMU)YI9&6S4D01
M\8'K73_'CQ=)=:L="L9&%G;??V]&->0.YVD=CVKEE)MGH4:2CJRU%<$/G..U
M27TGF0*PY(ZUF;B&#=QTJY'*LEK(.^*5KFW4AW9J:W3S&V#N:I*>@JW;/LF5
MASZBA:,MZG?V/PWU*\\,RZU"T9@B&2N>:X34%0MR-N.,#L:['1/&^HZ7H%[I
MZDM:SC"C/2N)EE$P.[KG-4S.,FGJ4"#&"1^=,O)D+1K;G&1\^:L,/E/>LN8G
MS>.U"+23U+T#*,]Z<\BL,$#/K5))<"I8V5NM VA2=AR#2HRD_6C,:*<BHT<
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ML+::"WD5P3&>E79&?.[Z#&N/+G(.0C]Q5J._<0R#8N,;5P*IY.W;(F&SP*>
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MXA==?99YKF6<LF1P6KHO$G-BO^]7/8^7T.*F6PUJ['B'[0_B*-X[7187W/\
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MHFP,*>W6B.A-G<KL=RY7@5&%S4\PSPGW:9D=J&,KMG=C/%12$;?6K+K^55Y
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M4YI(REH/APK':,'%5;Y6ENX5W9'4BK(<$]#E>:JVW[V>64_>S@4Q1+W '%-
MW+R,\TB@D\T_HN!US02WJ#,R<#I44D:R*V1DX[5(_'3FH\<$]*!+<SIP+.YA
MD)XZ8-:F[*[ASNYJO=0K=0X89*C(J.PG\V/:1B0'&VD:2]XL+CHV:"3TI6(7
M.X<]J9]3\WI2,W>PF"TF.V*CP9-RJI)'I3Y7"(Q)PV.@Y_&K&C?ZS='T/=QC
M-:P@Y$5)J*,W<YF&^,C [UUOPYDW:G<#_9K&\0YCF1HEY/7BM;X;C_B9W#$$
M#96U.FXS.:O-2IFM\2SMT=#_ +=>>1R;\9XKO_B<=ND1_P"_7FXD/;%5B%[P
ML*M"XO+8JPI(Z&J*297/>K$39'-<ECK+2G ZU)"QY(JFQ]#5J/Y(P#WHL!/E
MFQ3E!'6H P/W<T_<:9+9+VS2!CTQ2;BHY%-\XY''3I0+5L>X!8'\Z0@#H*%^
M;\:-VTXIE7:%=C@=L4&3/4YII&3\U-$?!Q0.X_S,'FJ\[ ?-U-2-POO4> >U
M)HJ*6XU)ODSWIXD 4#'6F; #G]*=C(SC\*G1;C=A2.P-1,>[_A22%@>1Q4+L
MSM@9P.Q&*+WV)Y%N.+X7^53Z7AM0MCWWC^=9TCR%260@9Z@5;THXU2T)/!<8
MK:C\>Q%>*Y-SVA/NT4Q=P'%%>H>/8Y[XA'_BE[D]N.M>.H^8Q@CIZU[UJVGP
MZK9O;76?+<<XKG5\!Z0O C?\ZRQ%!R9T8>NJ:/+$DZ98?G5A9!C[P_.O3QX$
MT@_\LW_.G#P-I']QOSKF^JR.GZ[$\T648^5@/QJ>*0'JR_G7HR^"-)'\#_G2
MKX+TM3PC?G3^J2#Z[$\^#C/I^-2;\CY2N?K7H!\(:;_=;\ZIZQX=LM-TV>[@
MM7N985+B,'D@=:/JDA?7(G%@C^*E,@#[>1Z5G^&O&^GZ_P"'-2UVQ\.72VFG
M,RS N"21UQ70_#*^TSQ[H[:K:Z5/96Y;:IE8$OCT]*/JD@^N1,Y.6//3WJ0<
MK\I'XFN\'AG33N*HS<XX-1?\(OIZV\A"N^W+[-W(([4_JD@^N1.&!S]WD]*&
M.PDLPXZX-2>"?$?AWQ5I>I:A-;MID.GW!MI1(X^8@XS5B_U70[+QWI?AAK"1
MGOX_/AN@WR@4OJ<@^N1*JN#&?F&>_M2!0L?#!@>O-=Y_PBNF!F!5LCDY-*OA
MC3&RO+$<X!Y%/ZK(/KD3SQRP7#$#TINX8ZBO1?\ A$M-_NN?QZ4O_"(Z9_<;
M\Z3PD@^N1/-6DPP#.<$UL3>'[9[+[2NJ?/C(C##K77GPAIIXV-CZTS_A"-*)
MY63_ +ZK6GAW$RJ8A2V.&@T6%HD::\<3,V",]JFUC0[?2;9+F'4%N'+K\A/3
MFNS;P1I3=?.S[/35\#:0'#E)7.00&;/(K=TEN8>U>QT$;9L(^^8@<_A7S]J$
MG_$UNMKC/G'BOH81J(?+(PH7: /2N5D\ :,\[S%'W.VX\TJM%S0Z%94W<\@2
M8JA+LIQVS4-U<I"NY]KEA@<]*]C7X?:*5^:-SSZU'+\.-$DQF-^/>N7ZK(]&
MGF$8/8\-@N;A9UB3AB<G/(Q75P_+M"N.F37I,'PZT:&0R;79OK5M/!.DC^%_
MSH>%D.>9QELCSQ"1@JP'KS4T(55(R"WUKT/_ (1'3,?<;\Z7_A$]-!R%8?C4
M_5&82QJ9YO<W2P0/D@-C'XTW3V_T4$XW-V%>AS>#-+DD5RC;AZGBN7O+_P #
M:3=R)=:D(71MK@YV@^E/ZI(:QL4C-23YP,_7VI\CKV(S[UTFB)X8UWS8=)N3
M,R_,5&00/7FKMGI&@ZB\L=G,L[6[;)55L[3Z&CZI(EXR)Q<;?-MR"W7KTI-^
M7ZC Z^]=OJ6B:+IMB]U>N+>V!PSL<8JQ;^&-+FB26+]Y&ZY5E/!%'U.0?6T<
M #D_*P'IS5:]39()8B%D_B/K7I8\)Z<#G8WYTDWA/395P4;\Z7U20UC4CS7S
M9'CW1X9NXS1-/)'"-JCG[QSTKT>+P?ID7W5<?C3V\*::5*[6 -/ZI(IXV+/.
M-*L?[3N#%-,L-F1_K<\YK1U#11:30I;ZCYL9]&^[79KX.TSR/*"OL/H<4B>"
MM*5<!9?Q>NBG1Y58Y*M?G.1_X1VVU.;;/JKJ$'WF:M/P/;K8^)KRS@G$\*Q<
M-G.:V'\$:2>@F'? ?K6CHWAZRT>=Y;-&5W7:2QR:V5/6YBYW5C ^*DBIHT?0
M9?O7EZR _P 0_.O<]<T:TUNV%O? F-3D8K$'@/1Q@+&X XSFL*U!R>AO0KJ"
MU/+HIE*G:P(%21S@'YF _&M#7M?\$^'KF>'4HKI(K=_+>4*0I8]!6UX5B\,^
M(KAHK6VN8I=N\"8$!E]16/U21O\ 6HG-&8'&&'/O5Z-OE7<P-=)H-AX4US4-
M0MM+D\R>P?RYQG[AJ]KVD^'_  ]I,VI:E(T5K'RSD\"CZI(7UM'**Z@'H"/4
MT\$*-S']:[.P\/:/J5E#>VNYX9T#HV>"#5E_"NFB-MX8*O).>E'U20?6HG!2
MMT&X9(SUJ)91TSS7=66@:-?P^?:OYT0^7<I]*KZ[IOA_0-+EO-6F2WLT^\[G
MG\*/JDAK%11RJ-D=<4K%=XRRY[\\58TW6_"US'',8[F"TD;;#-(IQ(:KW7BG
MP?:>+K?P_?+/;7DY C9QA),^]'U60/%1#(())%)Y@& .*W/&=QX7\%Z6=0UQ
MC%;,<*%R>:G\,V^C^*=)BO[2*98)!NC9A@L*/JLB?K43F'=6QS@^]*GWN"#V
MK3\67WAGPOJ%G!K,4R?:G$4<F"5W'MQ6AXBC\.:!9Q37C,//&(85.6E/L*/J
MLAK%HYMPHYR.N*;(0@SFMZUN/#=UX>EUFVCEFA@!$L0^^A'8BG>"_P#A&_&6
ME'4-':1[=7*-GC!'44?56'UN)S+/^\A5NC-@D]JU-3\.6]O;^?%J1EE;!" ]
M*[1O"6F2*0T1Z\'-0?\ "$:5N)Q,?^!UK3P]C&>);V.)BT.W<PA]1<2R<%=P
MPM2W6B6^DWVG^1?K<NTHW 'IS78?\(1I(!&V4D]]_2G6O@K2;659(D<NK;@6
M;-;*DD[F<JSDK7.DW8 ^7/ [T4Y0 ,;3QQ16MC&XNVE%%**HE!28YIU)1<8F
M**6BFP$)Q69XAGC@T2_>:40H(6^<]N*U,57O+6*ZA:*XB26)AAE?D&E<-#Y%
M^%MIY_PR\9RC69;,^?*PMP<;Q_\ 7K:\+^(-5TC]G))?#H<WB7!%P%!+Q1[N
M2!]*^BXO#>AI$T46F6:QMU41 ;OK4UGI&GV<+06FGVT4<W#HJ *P]Z+@>0>!
M[S4[+3;_ %6[OY'\,266^3$OF31-CJ/0^U8'@?Q!(/BAI::5>ZA)H-_92,XN
MR22P'6OH&UTC3;.U>"TL;>*%R=\:I\I_"F0Z)I<&QXM/M5"="$Y&?3VHN%D?
M(45LES\-_$)C-QN773E8\C<N[K77>/S9V_C/PREM>W$<,>ELR3$DL&"],^M?
M2$>A:7%&\4>GVJK(V]E$8P3ZTR;0-+G9#)IEI*4X#/&#CZ4<S%9'SUHO]O>)
M_@S:Z_!JE^=3T>Y9W5&(,\2G[I_"O9/AV1K=K#XF/VJW>[B56MY6X7'?%3ZS
MX2ENI+0:+>+I5A&Q-Q;11C;-]:ZJT@CBMDBA4+$@P !CD47"Q,@//-.Q2=,4
MM%QV%I"!2K10 F/2C%+1387&E<TH%+12O808]*0BEHIH8WGM1CUIU% Q,44M
M% B.3G@9YXR*\$_:>TFPL/ EO+;6L,<DE[&99,89N:]]8=.<5Q/Q ^'^F>/(
M88-8EN5@A8,(XWP"1T- :!:Q:=X?\(0:NEHD=S]B12\*\G*C\Z\>^%.M0>%?
MC!J&DK+<-I>NK]HBEN%(/FG^$9KV*Y\"0/!I4*ZA>B'3B#&GF</CIN^E5?%O
MPUT?Q9K-CJMW/<0W-F!]G: [=N.M%PLC(^.9M]6\-W7A^>2YADEB,P:W0MN9
M>@/I3_V=_%+>(/A[!#.?],TUOLDJ,,-QT)%=/X=\&V^C7E[,+ZZNY;M,-]H;
M<%^E9_@_X9Z7X3UZ\U32YKKSKUB\\;291C]*6H'<(QZ<CM4N/>HX\]<]\?2I
M<4[@)1U[4N**5P#%)FE-%&X(3%&*"<4HHL"8FW%-88YZGWJ2D/2G<#PS]JI;
M:U^&Z*%BC=[R,XP,L<]:[FUU2WTOP%IUV#!+>-:(L6W 9^!P*UO%7@_1_%4<
M:ZW;?:$CY52>*A;P5HTEKIT!A<1V1#0?-T-*XSPKPWJ1\$?&M))K:73-'\0Q
MXD69OO2^M>E_%BZM]>M9?#ZVS:A;R0,\HMVY5L?+TKJO$G@K1?$EY;W.KVOV
MB2'F(L?]61W%2>'_  KIFARSW6GI('E&)"S9-%Q'G?[-/B8W_A:;0+^14U/2
M9FA$3GYMG;BO2/%4.L36+?V+<V\(V-YAE3)/%5-"\":%HVL2:MI]H8KZ8DR2
M9Y;-=*Y#9&/9AZBBX'F7PDM_$JZ3&;F\M&L_/8NGE8;KS7)_M3+=?\4M<3([
M^'X;Q6O0N<=>-WM7O4,,<*$0QJBDYP!4&IV=G?6S6E_#'<02C#1R+N4TQ&1'
M/X>OM&LEW6<EC(J&%1@\XX KS'X\^&8?$6C75]IDD)U;1MMQ L; .%7K7I&B
M>$=$T2<2V-LRJS?(K'<JGV':IH?".E6VL7.HK QN+I#'*6;*E?I2N,\!^)_B
M*'QI\ 8M9NALDAVP>7(,,S@@%A7K/A/Q ^E?#_PR;>Q?4%DM4!: ?=X[UM:I
M\/\ PYJFFPZ;<Z<K6D)W+$IV@D]ZU_#FBV7A^R2PTM6CMUZ(QR%IA8\A_:.O
MXI="\+F8I"\FHQ.87^\HR*F^(^5^*GP\N9-IT]1@R'E%..">U>C^*/ ^B>);
MCSM8M?M#( 5!.,&I[GP]I-]HT>FW$7G6T0"H&'S)]#1<#ROX4[TN?B5/,RK8
MM<2%'/W#\IY%6?V69+>7P#>+;R1L?M\K%4^M>FCPQI8T<:,D/EVA'S(O\0]S
MWJ'PKX-T7PRSKHEJ;7.2R*>"?6@&CHU&3R<T[ [?E38UPW-24,!,8]J,4X44
)@$Q12T4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image00033.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00033.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" #= SD# 2(  A$! Q$!_\0
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MLDK#?CL>>1ZT >^-J=@(8YVOK41R':CF5=K'VYY-2W%U;V<7F7=S%#&>CR.
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M\2WMUK,\4TTELT^8I2 <)L[8QVKC%:^U'X5:C\1[GQ5?0^(H[EG2%9L11X?
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M_H/PK\+:%KW]JZ;9S).KL\<33$Q(3U*KT%5Y?@YX-GUQ]2DL)<O-]H>W\UA
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **3-&: %HKEH?&$,WBV\\/I87OVJUA\]I-G[LKVP?>H=
M"\=6&K:/J6IM;W=I:6#M'*TZ8)*]<#O0!U^?6BN;\.>)XM>L[B>WMKJ)H1N,
M$J8=@1E2/J*Q=)^(T6I2 P:%K(M_.\AYC#\L; X.?:@#OJ*C5\]JCDN(XY(T
MDD1'D)"*QP6/M0!8HSBJE_=_8K*:Z=))%B0N4098X[ >M-L;O[=9PW4:.D<R
MAU60;6 /J/6@"YFEK-T?4UU2"62*">+RY6B99EVG([CVJZLA9B K<4 2T4Q6
MSZ_C3P<T %%%&: "BDS1F@!:*** "BBB@ HHS29H 6BC-% !11FDS0 M%)FE
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK/CN*<:Y+XDR:W
M;^&Y;CPW=1P:C"0\:2+N67'53]: .KWXH#_-C!_*O-M4\<W,_P *UUO2%0:Q
M<0E4B89"3+PV1[8-7-+\96>D>'](/BG5 ]_<PK,\@BPHW>O8#- '?T5SZ^*]
M).K?V<+L-.$,C$#*(,9Y;H#45OXTT:XTZZOH[EOLT#;&=D(W'_9_O?A0!TM,
MWX.*Y3_A/_#:Z?#>2:JB1S2&)%<$.7'\.WKFGKJSZPNG:IH>H*=*#,;K<O&T
M>N>010!U8-(3BL3P_P"(]/UWS_[,E:586VEMA /NI[CWK$USXBZ-HOBI]%U-
MI+=H[;[0UPR_NU'3F@#M2V/QZ4F_'7BN*L_&6FZKK=F-/UNW6U\EY'@="&E
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MFLWUWI$%A=0WFG&Q>.Y;;L;=D,*MF[N>HE;\ZB:[NN<3R9[Y-)X5C]H96L>
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M$T=3R@9[)3=E7FCJ/918$4F2O2/ANNW2IO\ KI7 E*]"^'HQI<W_ %TK'$?
M7%G5'H:Y_6/%FE:1<"WOYR)^Z1H9"OUQTKH3TKC+&\TS1-;O[6^OK$3WDOFQ
M*Q'F-G^%L_I7GFAT^GZA;7]NMQ:3)+$_ 93T]C5C _YYFN:\%VFHP#49=5L;
M2S::X+1);-N4IV)]":ZG\Z %HHHH 0]ZX#XF36L4FG_VA8&\AW%HXU<J7D'W
M5QW&:] /2N*\?2-:2Z=>!+>80R;EAEF$1)]030!-\/94ETF9S MO<><?/C5R
MX5_0$]JZT<UQOPU$W]C7#SW-M*TMR\@C@?>(0?X">YKJ+N[2SM_,F)]@.K?2
M@!;@L7PF,XK,N)+V&[5XYK?[)C!#'!S7/:MKOV7QG;I+<&&W>U\Q8VX+&O,_
MB?XD_MJ%4T2]EMFC<AXP,$FNS#X655^1K3PSFSTKQMK>CVL+R7!D^TQC*-%U
MS]:X*U^)>MB^BM_($T4V!'O&#6+97$^K:!:1W9!DB<+*V>36IKVG26%U:W=K
M$9$"C:G4I[UZD,#3IZ3/0IX:,=S6TSQKJ>F>(I+6_)EMW;(7J5'M6WJ^LR:W
M86]S##+'&CD-&3@GWKB+>QN8H8[UHY)4ER2S#YE-:L7BA+719;>X1ED&=S-'
MR/3%.IA8)IP0Y45?1">)KT)X?N=D1DD,19(R.M<+IFJ1>)&M9Y-T$NQ8#&P^
M48]*UM4U&_M6MKRZ4BQ!W+$>I2J]A;V6Y8=/.U9IOM!4C[F3G KLIQY(Z&T(
MRB[$]S:BVO)+9@(IE.6..HHA\0ZEI*M9Z:R6T.=P)'WCWKJO$>FRW4T-U;H'
MWIM8@<CWKE_[(N)9$3R)9'4[=Y'%:\T*L+5#25-/1H[_ ,.>*3J"10F46\\8
M!EW'"$^U=1+KCV#QMJ46]I#B-X>=PKR;4?#E]#;,RD&(K\X!Y%7M)\6M;W-O
M%?Y:QB@V!ARP(KRZ^"4G>GJ<53#6=['8^-_%MUI$]G%9Q!UG7>S.?NCTI^D:
MO!X@4S1S%&QC&[!5JXB"Y/B'Q/'<NA-HJ\*>@4=S5V:V.C:Q]IC+?9;@8)0<
M(?>E'#04;/<N.&O'8T_%?Q0CT&1;2SC>[F@(69LXY_K6SHWQ"LM5-L5GC@DF
M7/D/PP->,:IX=G>XN[V?4K.2)9/,V9^8U4U+PKJFK6-O=Z)R2/W<R'OFK^I4
MN6[W)EAH15V?2\.L1SKND/D(#]X]#6O&ZLH92&!&00:\'UC6;_PO\-_LNIW'
MG:E*H0..H/KCVJS\$?&MY?1?V9J,OVIX^4F'\5<%3"M)R1RSPRMS(]P.>].C
MZU@>*]8ETC31<Q1JY+ 8SW-5=!\2RWMZMO+#'N(R2D@8C\*Y'3ER\QRJA)KF
M.PI33(SGKWI]8@)4,WWJF]:@F^]51W,ZFPV@4@IPJF9(****#1"BBDI105<4
M4M-I:!H6BBC%(L**6B@!II*4TE!(5#-;13NC2H"R<JWI4U!H!["=>?6D-*#\
MP'/-'?IBG<BVMQM20U&31$ZAE!/S-T%)O0B*]XM4M(M+4&X4444 %%%% "5X
MSKZ_\3V[_P!\U[,:\=UT?\3N[_WS73A?B)GL5H5JW&.E00BK<29&:]2)@R6/
MZ59B6HHD)ZU<B48JT38<B^M3(5#!<]:%7-9>N:U#I$EO%Y$EQ=7!VI&@SCW-
M1.:BM2X4W-V1N;5; ()'K4T(4,0"#Z9-<9J7B6.P>2'4;J*&;:"L:'+55\2Z
M\FFZ7;WUO."\B<*6YSV)K.*=1VB=3PDHJ\ST:)69?G&W^M2F/>,$9'2O$[;X
ME:W9Z2S7$,-Q,3\CJ<X'N*L:1\4+^\WVU\T5NS ^7,H[^E:/ 5][&2A!O1GL
MJQ;5"XP!TI)D.P[CM7^\37A%MX^\2:;'=B>>.ZV-E&/7%9FI>/M<U_1+G,KV
MY5LF2,XQ1'+Z\K:#Y*:>K/??W0!#NI]L]:Y;Q]J%W;Z%(OARYM_MBGY][CY5
M_P :\9M_$FMQVP5]0,H9,!L<BN88WLD\PMYY9 W+L[$$UWT\EK/5D>WH0>IT
M.K?VOJNR2[>:YD VJ4;(]^*G\*6.@H\Z:[/\H4CR0>0>_--\/SWFD:?<!!';
MR3K@R.V6 ]A6-9QVJO,7=FCD.6/]TUM' 5)*TEH=,\31CI'<[6^\3Z7H$-DF
MA6Q-EGI&W(_WJZ+2?B/8R0SM>SJN%S&F.<^E>66MNOFR?9Y@83_L9XJIK-M]
MD^SRNJO\V48#&3ZD4O[*A>U]3-XJZNT=G)\7-3-]L6PB>$'!!X8C->I?#?Q;
M;ZYKL$5D$*O$3(.Z-Z5\P,CW$SW1<?>XQQN([5ZI^SF_G?$2XF==NZ @(. M
M<N8Y=&C2<H]#*G64W8^I%YYS7G6N+G5I_K7HP'-<!K*YU6;ZUX6#^)E5-C/1
M?:IXTIZ+4JK7J)'/<%6I56A14BBIN%QRBG[:%Z4\"H;&-VT8J7%*5XX'/:I<
M@*^WFF,M6%5BHW]?:C90I#*CK43)FKOEX!SSFHI%"G+$ =.M:*0RB\=0LGM6
MDR CIFH63TIK4#,=*B:.M%X^*A,=/E SBE,*5>:/GGI4>SVY_G2Y1IE%DKO/
M 2[=-D_W\UQK1X!R,5VO@CY=.E_WJY<6K0+CN=+7D.N7$?\ ;E]#"DBVQD/G
M$6'F2EN^UZ]=SVQ7B.K'31XCUI+W4;H7+S[8[>%9/W9_#CGI7FFAZAX6U>#4
MK$_9H+N&*#]WFY3:S5M^8?\ 9_.LCPOI%II-@!9),GG 2,LLC.0?J:V?S_.@
M!]%%% #6..O%<+XXMGNM>TU+;^SOM'EN<:@A9"HZX[9KN6^]Q^7K7F_BKPY+
MJFI?V5?ZWJ+K>;I%2*-56)1VW=>>E &Q\-[N.ZT^]\LZ>1%<LA-C'LCS_7ZU
MLW8\WQ!9H2-J1L^#W-8WPU2WAT>>UMIY91;3&)EE0*R$=N.OUK:F_P"1D@QV
M@/\ .A^0'%?$*PM+S5[<SH6N0G[O#8)KCK[P_:J-P0QSH-S!CDUVWCJS^UZU
M"5.)E3=&2>AK#D#O((;R0&X7G<O?ZU[N$J.,%8]_"07(C@6DFB8P0#]XS;F
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MPV,3()T.Z(,<AV[5X[\)['4#\6+&^>>3,A9IT1CLS70VU])-:SV%ZQO()?\
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MN!\1,8_$46HRR>9,Q\MHN_U%3V]WJ>I7LUS/*C2L,K K<+18P0:EHFL1S_\
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MMF@#6L\P<;E:,9 ^M9.$E*T3+DE&7NC$_LN.U,$LB22K)L48P0345QHD::G
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M!M@I##5[PMC .!TI_P#PI#3?-##4KL+CE<#FO8]M&VCG8?6ZO<\?D^".F/\
M=U&Z0=P *@E^!>F.JC^U;P%>^!7LI^M'XT^=A]=J_P QXY!\#M/@W>7J]YS_
M +(IDOP*T]YC(=8NQD8P%%>S"N4\?Z_J'ARPMKG3K&*^\V9862239MR>#2YV
M/Z[6_F.'?X&V#6ZQ'5[PX.=Q S5=?@+8*KK'K5Z%;G&!74CQOJD,NM:?>Z1%
M'K.GVWVN.)9<Q3Q>H;L:WM U?4]5\'P:K)80Q7\T/FQ6PERISR 31S,?UZOT
MD>?-\"]/::*0ZO=[HUVYP.136^!6FLS.-6NU8GK@5VO@/QHGB?0;F]N;8V-U
M9RM#<VY.?+([@]P:/AUXMNO%]O?WDFGBRM(+A[>'+Y>3:<9([4^=B^O5_P"8
MXS_A1M@&#?VQ=GVVCFI;;X)Z;&[EM0NG5AAEQ@5Z^O>GE<TN=@\;6>\CQB'X
M'6"22@ZO>O"W2-@/EK8\,_">ST*^FN8]1N9W<8'FX.*].VTNT54:TH_"S&=:
M=323./'@>U#%Q<RAV.2144W@6"2)D6^G0M_$!DUVN!1@>E#JS;NV9<J/,+7X
M3V<.H27<FIW4\C+MPZC J]X2^&]GX:\1R:I:W]R^]<>0WW.:]!P/2D(Z8XIN
MM4:LV+E5[C.0H/>O(_$OP6MM>UJZU"?7;N-KA]_EHBD+7IVOW=S8Z+=W=G"D
M]Q#&9%C=MH;'O7"Z1\0-4=M#EUK1([6PUEO*MIH9O,*2$<!AZ'UJ83E!WB-I
M/<Y[_A0EF$P->O/^!1J:OP?!'2A"%N+PW##^)H5%=?X+\1ZKKMUJL>HZ;%91
M6-P;<,DN\NP]JKZ+XQN+OQQJ/AC5;#['<PIYUM*K92XC]?J/2M/K5;N+DB<W
M)\$O#[KM9W'N(Q69??L_Z-<L-NHW$:CH%45VUEXQGOOB%<^&[*QW6UI")KB\
M9L=?X5'>NON)O)MWE895%+$#K@5?UVNOM$^SAV/&8/V>M!3_ %VH7<GUQ5NW
M^ ?AV,G?<W+CMD]*]9LKI;JTBFC!"RJ&4-UYKDIO%M]?:Y>:=X8TU-0^P,$O
M)I9-B*W]Q?4TGC:TMY#5.*V,63X.:)Y2)!-+$R?=8**AN_A$;B177Q#=1%5P
MNV-<BKVI_$:\TR/2+N^T.:WTR[NC:7#R-\]LV<!B.ZGUK5\?>,7\,1:6ME:C
M4+O4+A88T+[54'^(GTJ/K-5]1J*1Q<_P/-R29O%FJL?08%0K\ K 7$<TNOZC
M+LY(;'->RQO+Y"M*H64KDJO(!]!7)Z%XU%[IVO7>J6,FG#2IFC='()8 <'\:
M7M:G<U522V.3F^!^DAM]MJ-S%)_>*AJHR_ #3YI&=M=U#YNH4 5WWAWQ3=WM
MV;/5--%I?26_VNU1)-WFQ=N>S>U6? WB67Q1I,]U/8O82PW#P-$YW$%3WH]M
M4[ASOJ>=Z=\![.Q;":_J3P9YC8\&I=1^!&EWC9BU>_@&<E5Q@UZ#/XBEDOKR
MWTJS-U]C&R5]V%\T]$!]NYJ/PEXCGUJZU"RU&R-CJE@X66,-N4@]"#1[:IW$
MY'FT?[/&D>8QN=8U"92/N@@8]ZT+CX(6D]I;V[>(-2$,'W5R#GTKI]<\:W<'
MC>U\.:'I\&I2;0]XQN KVX/0[>IXKL)+J%)"IGBW]DWC/'6DZDNH_:2Z'C;?
ML_Z6VX/J]\<\G*BJT?[.>D+.KR:W?L!R%P!7M;WT$<(GDNX5A8X61G 5C['O
M7/>-O&*^'-)2]M[7^TAQD0N.%)QFI<V7[>=MSD[;X-:= LB?VC</$ZX*.@(/
MN177_#_PH?"6G2V@OY;U9)-X,BA0@] !6W;ZA%-"I\R)9?+$C0F0!D!&>:S-
M4\36]@UO,OEW%BS;9[B&0-Y&?NE@.WO2YF]#.4W+<Z44M11-OP000>1CTJ6D
M2%%%% !1110 4444 %%%% !1110 4444 &*3%+10 F*J:M!'<:=<PSIOB>-E
M9?48JY574K87EG-;M))&)%*[XSAESZ&@#YTTZ"&QT3P_>'39='CAU3#:P)-P
M*ER A YP>G->G^!--L[?QGXPN8H!%*;A0S@] 5ST[9ZT^S^%NE00V=O<W^I7
MMC;2^<MI<3;HF?.02.^#S4S_  ZM#J-]>)K&K1F^D$EPB385\=OI0!S?BF%/
M"WQ"B\76V^+3Y"EKJBCE-C?=EQVP>]+8VZZQ\8=/UB<M-;RV<AM5R0JJIP'
M]Z[*3P38W!U%;VYNKJTOX1!):S29C51TP*9'X&L8M>T[5+>ZNXFT^(6\$"O^
M[5,=,4 =:O)'/O4E- [TZ@ HHHH ,4444 &**** "BBB@!K=*\N^+-C;R^(?
M"<S:3_:<WVAU,(<*77;TYXKU)A7*>*O!EMXCU*QO;B_O[:6S),(MY-@4GO\
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C4 %%%% !BBBB@ HHHH *,444 &*,444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image00034.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00034.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" $@ G$# 2(  A$! Q$!_\0
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M** "BBB@ HHIK'B@!U%9&BZW9:S',VG7(F\B4Q2X_@8=0:6VUNRN=7N=+@N
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M9["86(PY$HQY1]:OWIB4VVKVN,3L-MS!R5/^T*MLIMF++;W'A_4K>]=KN01
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M/I4\J>J"W5&3-/::SJ4S%9+:1V+>?.N D8'0?6NW^%VG>1!=7@!19FVJN,9
M[UY]?7#WUU_I\\<TBP>6;=1M*L*]'^%UC>6^E&6]F8[\;8S_  BM8:$U_@.[
MC.1^%.I%Z"EK8\\**** .?\ &6AQ>)O#MUI<TS0+,!^\7JI%>7:QX#_LIK/6
MM3\<7D(LU\F&ZP"J#W/I7I7CVUO[OPK>P:0SK<E?X#AG4=0#ZUX3=6%^LD5K
MXCMM0L/A_-CSH)B9)&E'7..<&@#U+X16>F6]AJ]SI.JRZP;BX+RW4@^61O\
M9]JSM/NK_3-:U--+C%P03(UN3Q[X/K5GX+QPP:7JR:1;RV_AY9\V*R+M..^/
M:L'7IVL_$#ZGI,[0Q295G8?*[=P!ZU$U?<ZL-'F+M[L>TCOTGA\V23>\#\G=
M_=ID-O\ 8Y+>]FT\&\\S=F,Y103T-9&FZI]JLO)M[(2WXE\U&V\]>216Y##?
MZGK$ALB9]/=09,_*!(.U9/0ZWIH/UB\CF:[N)@;>X@ 6(QCY&S_"?>I]+>87
MMDNGQ*]R83)-)*>']AZ4[S8K>:2WFM)IIXCYCVJ#Y/K5::"33;BWU&>.6:&>
M)@D4?6//:DV9IW=KFGI6E1ZO937D*>1?+,24;E,U5U2RU6/[1;3Z?!-=7@VQ
MS0<!![U<^'=_!!8&RGN4\]W,D0SR0?YUI^-+_4M*AM;O2K4W*J^V:->I!J7<
MSDVI6.;.I2PQV?APP-:WG1GSQ(._/O3+JTL=,O#I,-\ZV\J%IE<9"'T&:I3:
MWJ.L7,LEQ8QP2P,! #PZU<U.6]EN)([VUM(/.B 69R#D^@/K5_";1C8XJSO;
MNPU"6TM6>XWL4VA>57V/I77^&?$\5O&%GTN..1'\L2 ?,![UU&C^&8;30W2-
M@;R5=QGQ\P/M7D^GO=V^IZAI\DI::>3!=AU7---,TC:IH;JWL[^(KR&ZNI8K
M8.9UQRK@=JZ?Q.AU'0+37+ -'?VRYC$9R!]:SIO"VFP:2]Q'=S2"--N-V?F-
M<7K'B#4M$B?2HGV^<FW:O(R?3WJ>1-B]ES/0]@\%W=U?>'[>XOYXIYWSN*=/
MQ]ZXKQ18'P_XOL=8BF^260B5>^#7,6-IXE\.0V,@\R.RE.X@'(3W-;M]/<ZS
MK%LT3V]S=P86-R?W<JGJ,>M3&*38E3LS<U7Q(9];LC! 6T]"&>5AD?45U,FJ
MV1B$R7"/&V,L.<?6N)M$U&TNKZPN8K6)&7.6Y 7VK)L=/G\F>VEN'MFD/(;G
M>N>,5GR79$HZ'M^5EL#Y9#(R<'L>*\"N[C^PYKYY-.%Q>RS,%R<M&O\ >6O=
M-/@":'#!E@OD[,GKTKRG2[;R_&DEA<V[W,T(+PW+=/H:ZU[J,<.^63*'A?Q'
M=:9I3WOVQI[,_*EI+S*6SW]JH>(WU35M6BO-0@C"@801?>0'UKM[KP/9+I]_
M>7CA;R0&3<IP$QR,5Y]X6DU-=9AGM[*XOUB8AW[,*<9V.J,H[F;:7>H30+I]
MM=(FR5A(H3D9]:UC+#<K/IZ;(+I%Q)*IVK)["M34TDA75C9:-LDNFWNW\:4F
MEZ;I+>$9&N8'&HL2Z&0]&]C5N5S53TN4/#TNIVMK<VUG<?8;:S(<%EVB0^E6
M[[S/$EI<ZAJGVVVEA38J(,H_H:Q3?S&QB_M.>5&;Y?+=/DP.^:M:MJ-PD<,6
MEWD\UGM_>*HX4^U"6MPBE>Y@Z=:P:7K5D;Z,RQ,<@^A/K79:I<6-KO6Z6.WG
M+AX[F)ONCVIJZ=>3^$6^P+:R)(=TTTQ!<+GG'I78:!#X0O(X[1?(GN%B!D\W
M_P"O2G/H15JVT.2T;5;6/4)=EY)&-N5FDY8D]Q[5@R7*W^NI_:4DEV(Y/FBV
M\.M=7XBT_2]%L-5OK>W$LTY$4*%@VSW%<GX9\.-J/B*"VMM6=+H)YTAQT]J$
MM+L::Y;LZR.V?6]*N9-+LK/38H20%(S(0.]<[//KM\8)XUG^Q_ZE44_(Q]:U
MO$_A2?2;F\N%U"7$T.=P/WL=0!6UX?UB;6_!\=EX>L3 T:;"TI^Z1W^IJ%(S
MYM-#E+/58?#>H3Z:;5+F_N%P\N[J3V_"L37FU^U?R+R6XTVQ(+QJG0GZU>L]
M&>TUZY34[F(:L1YMN'Y^8=L^]>ASH/%7A-C/&#<QQD,,9 <=JIM71<G='F&A
M^(]>.BB*UO[J:Y=M@C SQ7H6G&#P_P""99;VTD+R-ND3.&F<UP7A.9])UPF\
M1X)EZ@#  J?QKXCGUJY-E;R/'"C !^G/K4R@GJ@2UNCJ?A_>V.I>*+5M.MS8
M9!,L"],UVWQ<1G\'7*1X#,P +'&*YSP!;^'=,U/3[2UNS/J93<[==Q-=-\6(
M_-\'W<6]5=B-I;IFK@NAR3_BH\%TC5;^RNDBMKEH[4,!+D97'UK<U:;3FU"&
M.WN!=6Y.^4QCI]#6%-;_ &-(55Q=-*FUT0?*A]ZN^4D&D"UTR'R)]VZ0./F;
MZ'TK7EU/142QJE_:7=G-9:/;26QWAEG<Y<X]/2MC3;U$LX[JRTEI6B3;<S$Y
MV-_>KG-.O;/1I9KG5HGN8[E=BQ1<E36]I=SY$S6>N7ZZ?IPC,RQ(1ND';=0U
M;84W;8O:UI,GBN2UFM&8L\>6F?A5 K,N[9/#TL L;B&9[D^7,A/!'<UVG@W6
M-*_L.=7O,H09!)C "#M7E6H7L7B'Q1<3PP+;62G:IS@;?6IC<RA)N]S;\6>(
M["_L8-(@NGAD1P905!!4>]$^O6MPOV#3+>">TDCVE?XD(_BKM+7P/X1CT5;O
M4)XW#19:4N!@5YEKMMHXNG_X1I9H0O,=P#_K .U.W<5.?,['3:1';:=HTD^K
MR+%-'_QYR+SEO2L[PGXPF\.'4-2AT][R!S^^=4^XWUK-OKQ[O2+4"$D'Y=N/
M]6?[U6M&OM5CTN^TJW6V>QV>:\H&/P-"B:5*=SKM4^*D5Y8K':6VUYH^)<Y\
MO/<#UKRV5I+EY%R\EUOW"0\YJ5(?.A$L:B!#G8PZ&IX_(@V7"LQ&<&//);UJ
ME!1"G3Y=C5N=&6QTNTG@D,_VO_CXC/1&]JU?"OCO4= C.G3VYEMM^8I'X 7Z
MT7FLVK^%+BQDMU2Z(!BE'5C74:'XC\)3>'K6UU.*);F&/_5RK\Q(K*=Y,*CM
M&S1DW N?%6NFZ2]@=(5W0Q2?=/J/K4^L0PSV]K;:&'N90_[Z(KD1L/7VKFM;
MUN#6-2M8M)TQ[:6-\%83A67L:]G\*V$5AID>+<0W$OS2 ?>)]S7-4?(C&3]F
ME(\<O;6^FU*YB2(6D[)M=,;5P*]V\**X\*V2,%W^3@@'KQ7.?$>&W3P]=7<D
M*&2$@IQ@N?3-=/X7G\[PS8R^3Y1:$,8_0XZ5I2ES(Y\35]HDSBTMKR?P[?V9
MB2RN/-)A9FQP3UK/\&^%K[3M.OY]9NUNY,F2"4MNVXKGO&=U?WUU>N^I*A:7
M8D:M_JE[DBMGPKX[T6UTZ/1[]G5E4QBX.2K^]*6YIK&*:.)FO8+S4KF:%6&J
MW#;$8+@''>O0H]-L%T32[A8(1(6 NY7'S'U!JOJ4-@WA_3M6M(8I);2Y)418
M!<9JKJM_IVK7CO8M)')Y?F?9#PI>JW+E-U'8T--BW:MJ-QH$S6L,8W-"Q_UO
MK@4S4M+35##KFCSI)9P(5FB8\Y_BKF-*GO+:^:Z!:>ZG'E-;H.0IZD4ZZ6_M
M!)!I=R8]%WA;A6&';/4#W%')K<CV>MR[<:E)H7V1M-NO,T*Z;;<*P_>(3[^E
M:>DW^D:1'>_V1))<WY;= 6.2Q/:L'QKX<M;?P[9ZAHUQ<30[L%3T)]ZYR"Y^
MSW=K=6C[9H@&QT^;TJW%-&D8*<=#M;_4-2>"Z;Q/I;N\Q'E^6,B(=ZT=:AT>
MWT2V2STP73;E9$;HY/\ .HM'\5Z]>V=Y+>:.9;1DP6Q@'\*JZC+-J5M86UE'
M]FDM4.TJXZGL/>L;6,DFG874M#N;);&XDWL5!D:WCX2,'L?:G-I4I M+]8H;
M>?\ TGS8V_=Q>@^M;/A6Y?5=%ETG5;J..Z4;7!^\1[FM;Q580WWAL6-M+#&T
M8'E^8>#BDWT!MWL<[X7\4+';PZ7+!/Y^\K&X7&Y.Q-=UJEDNHZ9);2,4$B[6
M8=J\UU-KB>XM+BZ,5O<:;'O*P])O:GW?BR_U?36O(Y#IRQLH\AAS)]*B4+C<
M#3FM!H6@WVG-)'+,IW1C.&93ZFN<MTO='L?[2 :W2+B&W<Y\QCWQZ5I_O_$G
MB>Q^UVDD=@(<8)VF5O>ME_"K7NI.TVH+-9J"D<0.3&::?*BXZ(\_\..]WJK!
MVMEO))?,GED.,#T%>V>#KJ&YMI3:L)(D;:'!R#7D7_".Z6GB!M)GD>*Z8_Z\
M\+SVKTKX?:=#H\UY86MUYT4>"5'\+5=[M6,L1\)W"]J.]"\#FEK<X S1244
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M*BC.R2NS(\#^ ;J&_M-0UCY/)^94/))KM?&D$<_AR\\Y$.U2ZY[&N@Z F1L
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M11M<VNF7$V+:]AF0,T;G[GK3M/TB&]TFWU"QNA;VX):="<8/K]*>QF_,T;Z
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MWUK/NPR3(TBD<?+QP*ZJ;LA-:6-SPKIL6I^)@NW$<;^8P4<?2O3_ !/XLL-
MC()\RZP L2]A7D^@Z[+H'VEHT\QI1A2.U,TVWGUF:>YN&,TJ_O)';HH[5G*#
MF]29Q26IJ^(?%6NZ^JP00-!$>04.#^-6-"TV[M[BSN=8N/,1%W(CG.*OV>CS
MZE,LFG+FVB48=3PQIU^?[2\36.G22QB!<&0(><^E:-1C'W4<[;EHCHK>&\\1
M-YD;BTTZ%L+(@^=S4<G@^2:5!>:E,]JC;@H/W_\ >KM%2.&-8XE"1I\JJHQB
MJI$@D=F88/W5KAE5ES6)CHSA=<T2Q_MZ*U5!%9M"68#UKG0]MX<TQ)H[3[1J
M<LIV,X^Z,\5TVNNNIZ[*;=FVV\.UV7^]7,R7M[JDT$$\*,(E*A_;^]6VK.BG
M<Q=8U"[&L_VA>;'N'3H.B9KJ[70;:W\)27,H,TLH\TY]:Y75#;SR20YWE2%5
M\8S7I#1FZ\)"*,@MY&T8]J4G9%2=CS[1E-UL#^460G )Z"G+")6EVQ;SR YX
MVFLF.X,4ALX(RL['!<]L>E:$9>7]YO,CJFP;#@?C[UFT]V&Z/4O@XS?V9=(V
MT%'QD#&34WQL>Y3P/<&S4O/YBX ]*C^#[12Z;.T0(&<,#ZUK_$U@GA:X=F"J
MA!.>]=L7[AP/^*?.8N&L-%9IW/VRY8(JJ?N>I-3Z3:ZU>QS:#I4T<\$I#R3-
M4]_-HQFAOF1_(D_=2 <G=ZXK,O-1DTJ]2XT&4I'&NTDC!?\ "LU<]+H7[#0]
M>T./4;5PEOYWRO,3PX]JYVVF.FSRZ8P@S<MAYI.5C'K6CJGB76KF.!+J0O@Y
M96[YK$UZUCBD$:.'DD&YDSG;GUKHC%VU$MSH=4LY_!NH)';7JSP7D.5EA/%=
M)ITOA6/P4T^HJCZSR8L_>9NU>9PQ^;]FMVDE:*/Y0I;(!-6KVT>W8Q3R(9(O
MF3'I5.*ZD\O,SI=-\3SV<<L5[8Q2VUP,>6RY,1]16+9L;;4%FMI@$!+''1L_
MPXJ'3)S+>*9'P<$?,*UH+;3YW@1DE5A+ABA^\3WJE&RT-&^56)+GPWJ-\?M-
MO;D02'+<XVTR>W@@L)[6XC/G,X"IGICN*E.K3VFM3Z<\\KVX.TD-@+Z5G:E!
MY?F>3*TKYY8GE15PNS%NZU.AM]3;3(9[ +!=K=QA"7&2G_ZJR;U]-TJ>&+2I
M);B2$9N&;IN/8"J* PPK) _FSM@X'\)]ZM6NIV!6\LM8M4:\:,N+B$XVFMHV
M6YSRO?0>LOVK=@[90<C/&:S[][?*A&:&XSG&<@U+;3:=;^&FDQ)->[\+,W11
MZ5DM;75[(,(0LA'[TCM[5E4DEJC:E=JTB26!;TSQ33>2[C*QKR"?4U9_X1K4
M9]-AFG=&6-@&R<&-?7WK;T_1K?30&N(9'24!1+C@&KMW;$VKNEV&92$$9X)%
M<M2NY*R+5-)W-;4EMAX2B6!%1TPIF')<>XKW?P:4_P"$4T_RN5\D?RKYPL9!
M]FD,A6.1FVE6;.[\*^D_"NP>&K$1X \H<#O6%.^MSFQ.ED<5=8^W3X_OFGKM
MC0O*ZJH[DUFZUJ4-E>7 '[R7<<@=%^M<IJNL37DX@9@54;R$/RXKGE&[+A%M
M'3ZOXNT[3E,4#_:;P\"-.@^IKE]4U74=:M9FDD-LJC:(\8S6=8V47GSW91WW
M]L=JTEG!O/+EB;"CY=R\#VJW%):'1"(:5:!+.WLI(LQR?ZQ%/4>N:U+ZQ32[
MV&'3YFCB(\U1US[9IFB3:??7C6T\C6TB_>;/6O0+73=-EL8T55>%>0Y.3GZU
M-QN\7<XS2[=M26:\CC*R1#E7Z>YJC>W+P02P8<FX'W.OY5KW%])HTUY! !/:
M2,<QXPQ/M4%K=_9)+>1H@V&W%6&64&E:Y46]RUH9%EK5BMD'CB9 )B1W]*D\
M56LE[XG'DM]F9(RW _U@J*7R[:.XNH-0$Q=LE6&"OM6?<^)[H7$-U9J)]@VM
MO6E9D.+YKH6.?=8RB.6X2-#AX^@JI>P1)8/<F1TG P8\9^4]Q[U<?5?[:21)
M(A:W*#+*HP&'O6II][:#4$6_,)18L+(XX;VHTN/6+N<OIMLL22W/G&3:F6CD
M:H9(GMX?.G$)2;K(/OXJAX[:'^TGGT]PEG'U1>"QK-M;B[U>6&^=5%M:$+M4
M]??%:*-T:)N1V7B:UTYM*L]0LHLX(0D<$G' K/OK&ZTZUM[N\PT-P<,F?F&>
M@K.O;Q9Y42Y>1X&<%43@*_8U+K,>L6RK)>L9(X\/$W4"HMT9,GH5)-:M+:QN
MK><2\/Q&Q/'O7?? BXEO9M5GF);!"*3Z5Y+XDU.2^UJ%EM592@+K&/U->R_
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M:TN3OGD0R!P<!,^GT]*SK>T*7<3WT*H=WIC"U<U*UM[4C^R[F6Y1#OQ)V/\
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M:='!-<--]H,8\E<KMZFH/#%IJ?B33Q<W ^RQ1C88]A#8%7)M'O;>"6:W,C1
M8+[3DT),&UW,"WM))YM]Z76 MRJG&14^H2QM++:VB_(JY#>E/BCO-45%D@N(
M+6-L-\AR?<5%/;W5K,UM#%))&YQYVSG%5J0Y)(]VADD7X/[H_P#6"VP*^?\
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MJ=D\G$D+#&T>U:*10-;(-KJ\9R[9Y-)Q8].X:HF) MS\]P' 7:>%%7'FB@9
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54H%-0L)S;W #I2T451(4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image00035.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00035.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" $\ IL# 2(  A$! Q$!_\0
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MN8 0TN_'S.>23GWH="*:3>X>T9ZG:^)=#N]/FO[76-.FL83MEN([E&CC/HS
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M% !01GK110 =>M%%% !1110 48&,8X]*** # (P1Q1110 4444 &.<]Z***
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MK\L%O#=Z=':E8BSE)E9V!7@$\E<=\BK>A:+=R^ [V&[PFJZM#+-.7&-LDJD
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MC.AANH(8D49W INSG_OH45(T.1\N_KZ?\$(N=]?ZW-FBBBN,U"BBB@ HHHH
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M=2S2.#:W"6LJ!#N\QMNT =\[A@U(NOVG]KIITD=U#-(SK$TL#*DI498*QX/
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M 4H, 1J0_P Q4 #CCW;K7PQ\2WEO"+BV-S:#4-5DDLX;F+>$N'!AE0R H&4
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M>^A'F-*P=V(! SD=!P,UTW@_7$\1Z&NI0F%H9)YXXWA?>CHDKHK ]\A0?QH
MJ?\ "(6W_05\0?\ @UG_ /BJ/^$0MO\ H*^(/_!K/_\ %5TM% '-?\(A;?\
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M !5>Y_X^+7_?/_H)JQ5>Y_X^+7_?/_H)H L4444 %!Z&B@]#0!7T[_CQM_\
M<%6*KZ=_QXV_^X*L4 %%%% '%PZ!?6_B:XU"]\73&W:[5XK(6UJ@"D86)F,>
M\\E@"&!P<=<D]I7BNO:+]D^-VC7!_MV^GF;S8Y'F!C1=Y+*JB+;L0,>K!L'
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M?\A*Z_ZXG_T):])I, HHHI %%%% !1110 4444 %%%% !1110 4444 %%%%
M%>;_ (_;?Z/_ $JQ5>;_ (_;?Z/_ $JQ0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !5;3/^/&+\?YFK-5M,_X\8OQ_F: +-%%% !7E$5W:1_&
MZ2$RW$MQ*^%,EN=L9%N"41S-TQSQ$1ENO.:]7KS./[9)\99&34I9K.,;6A6T
MG98F\K_5E]GE+G(8G=N/RC'2@"CXWU&.#XO>'[<:Q>PNWDJ]K$A*[6D.#_K
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M "5*S_[!47_HR6L<OPL<56]G)VT.V<N57/=_^&@/AU_T&I?_  #F_P#B:/\
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MXV,MJK3!2SGF4@[22"%4$$GI[>K4 96JZ!IVJZEI]_>PN]WI[,UM(LK+Y98
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M)P<#\*\<^)\UK9?$?3]0-C/<W=K#%(L:W2Q>?AV8;08V8A2N6VL!R,U[!97
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M.1D>OLEK-]HM89MCQ^8@?8XPRY&<'WH EKFY_P#DI%E_V"9__1T-=)7-S_\
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MR<Y(*/T%>KUY;JLNH_\ "RHI=3OK1;2"XMHHH(9IAY?F-((RP$>TL^",$X'
MSS7J5 '">*KKQ')XCTJVLK.]M;;[8";NVD$L)@&TL94VY#-RBC.!EF)X J73
MVU=OB7'_ &Q#I\:#3)_(-K*[DKYT7W]RC!Z=,]Z[:N;G_P"2D67_ &"9_P#T
M=#0!TE%%% !1110 4444 %(_W&^E+4;0J<Y+\_[1IH&244Q8@"""_'JQ-/I
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MR;-E[?R3H.<Y"L2 ?>MVBB@ HHHH *KW/_'Q:_[Y_P#035BJ]S_Q\6O^^?\
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ML?UH L4444 %!Z&BB@"OIW_'C;_[@JQ5:.VDBC5$N&"J,#Y13O*F_P"?EO\
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M$BM+'"I5L[GD4,@'KD,"/:L^X\765M'(9XY8VBOGLI5; V;4,C2'G[GEC?\
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; 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image00036.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00036.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" ,! F(# 2(  A$! Q$!_\0
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MM/-ND1&+ /YGEKA/E.68* >O49A\0V \5>"#IEY<P:==7<4+2A2)1"X9790
MPSR".M32:/93>(=4U*>]B9+^PCL'A& 556D).[/?S.F.,4 %CXWT*_ANI;.X
MNIA;QK,R)8SEY(V.%>)-FZ5"> R!@?6H(?'VB3ZGI=E;_P!H32:BDKQ.FGS;
M8_+8(ZR?+F,AC@A@,=\9&>/L?A=9V7AV;2;>^\-Q+F$)-%HJ1M<)&V=EWME
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MV'A"STFQU^VDO;=%C:\U"$W*S#^(,GF*Q!Z??R..37/:/X#&DC3FLO$%K#)
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M,4AQD<,QZ#_$TBVZ9W/^\;U?G_\ 54J*$4*HP!2T  &.E%%% !1110 4444
M%%%% !1110!!->6T'F^=<0Q^4GF2;W V+S\Q]!P>?:GV]Q#<H7MY8Y5#%"48
M, P."..X->4>(/ _B6_U?7]5CEL7?5H;G3VM3E2EN8\0DR=#AEW;<<>:W)JS
MJVD:SH_A&WLX(YGN+CQ#YKQV<[1F2"29F*EUY4%3R?UH ]2IBS1O*\:2(TB
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MLL8=,[3R,C%-N?\ CVE_W#_*BW_X]XO]T?RIV5KBOK8DHHHI#"BBB@ J%?\
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M'Y<;Q@9X$CC X_*G_#WP=_PAWA5=&74[B_9%*)<3#E5YVJ%)( 7../:I]/\
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MBJUO+,]S,DGE[$QC;G)SS32N)LLT444AA1110 4444 ))]QOI2TDGW&^E+0
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MRVB6$MP=HW MN0X3(/4CJ,TSQ_<6Y^(?A"[BN7VS(H 0'#HTJ[2,2*7.2,J
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MH!.3CKZTM%-R;5@"BBBD!P7QE\*6/BCP;<PWC20%'20RP*HD;##Y=Q!XYS^
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M^E+22?<;Z4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M =2?0&N9_P"%>^$/^A;TO_P'6K.G^"O#6FWL5W8:'I]O=1'='+'"%93C'!H
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M_ Z+_P"*H_X3SPC_ -#/HG_@=%_\56W]@L_^?2W_ ._8_P */L%G_P ^EO\
M]^Q_A0!B?\)YX1_Z&C1/_ Z+_P"*H_X3SPC_ -#/HG_@=%_\57+>,];TK2-;
M:ZNM $D^DO%'%*9$1&2Y#;WV@$D*(CQ@D]A7H@L+,C(M+?\ []C_  H Q/\
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M''*&;:WRR#JI_IZU)0 4444 %%%% $<$$-NK+;Q1Q*S%R$4*"QZGCN:DHHH
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MTK3S<-.;"T,[@JTAA7<P/4$XSW/YU<HH I/I6G/&J/86C(I!53"I P,#''H
M/PJQ;P1VX<0KM#N7;G.6/4U+10 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[M8KB(2JDBAU$L31N ?56 93[$ U#JVHVND:7=:AJ,ODV=K&TLTFTMM4#).
M"3^ H MT5F:UKVFZ+IBW^IW(AMG94C(1G:1F^ZJ(H+,Q[* 3[5+H^J6VL60N
MK,7*Q%BF+FVDMW!'7*2*K#\10!>HHJ*WN(;E6:WFCE57:-C&P8!E.&!QW!!!
M% $M%%4M)U2SU>U>XTZ;SH4ED@9MI7#HQ1A@@=&!'IZ4 7:*** "BBB@ HHH
MH **** "O.?&/@N]U[Q/J.HVI%I=P65J^E7^0?*NXGF.",YVD.%88P58BO1J
M* / KOP)XDU71M#;Q!I>H! ;Y[K3M,FL9)+>::X,B2*UP#&?E) 92'7C'4UM
M:AX+U-_$%[)#H4DEY-J-G/9ZY)<PF2UBCCA64L=V_+;'7"J0V?FP,5['3))H
MX\!V )Z#J3^% '@GBOX?Z_?6%_;:;X?$>NR3WLL^N_:8O].@D639!DN)#G=&
MNUP$79D'@5TT?A/7$\*W&F7%E]JU+^V;2\DO_,C'VV-9HW+$%LJ8T79MZ80;
M<YQ7J7GD_=AE/X ?S-'G-_SPE_\ '?\ &@#R&P\):CH<UK<:;X4 >Q\0W%]+
M]D>VC:]MY!,$9"77)02*"LA4CG&:Y/Q/X>O9+,:=K&C_ &@1Q:E>WUN(X+IK
M2":Y+I-'YDT:+)M5\.&9AC&PU]%><W_/"7_QW_&LS5]$TC69H9=8T&SOY8/]
M4]U;12M'R#\I;..0#QZ"@##\9:>_B'X7/:>'+?S!=6]N]K%E8_DWHPZD ?**
M9J7A)M2\?W^KW%NA5-,ABL+B0AUAN0\Q+A,\,H9<-CN0#UKLO-8=+>7_ ,=_
MQH\YO^>$O_CO^- 'A>B> M;TSPMJ%NNDZI)J%RMO!J$<_P#9DD5VH?,DD"@!
M9),9.ZY&2" <UJ>&? U]IM]X8N=1\.QW7V(W\(9OLK262R3!X'XVJ JAAB,?
M+NX7%>P><W_/"7_QW_&CSF_YX2_^._XT >/:+\+85/AX:GX>LY$&B2P:F)?+
MD$MU^[\OS!D^85^?:W(7L1Q53_A =<N-6\.SZW!K%PEMIUC#&]C-9%[*>+_6
M;WF!< G!+0ME@""#Q7MGG-_SPE_\=_QH\YO^>$O_ ([_ (T >3:5\/KFWO=+
MOGT>!;YM7U!K^=FC9GLI?/V*QR=R$M&=G."<X!S6EH?A*2/X)7?AI_#L%G?&
MQEMVM2("EQ/LP)05)4[F (9L-QR!7H_G-_SPE_\ '?\ &CSF_P">$O\ X[_C
M0!XUKO@&ZCMOL]MX4@OBVD06FFO#+#$NDW0W%Y "PV99E;?$&8E>G2NS\(>$
MFLO%&N:SJ]ND^H22Q+:WDA#'8+:)'9!GY-S*V>A.!GC%=EYS?\\)?_'?\:/.
M;_GA+_X[_C0!YKI?@_Q3IOC:34)-0TN^AFL;L27'V%HF::1T**^9GS@*H!"X
M"IMQR#4WPG\.ZEHEW.]YIUW8Q-90P2_;)X9FDF0MDP^6S;(.3A#M SPB\Y]$
M\YO^>$O_ ([_ (T><W_/"7_QW_&@#QB]\"^)(;OQ'?6%G$USI]UYWAX"5%\Q
M9)3-,.3A<[RG)'W?>EN_AQ?Q>(-$$\6K7>GV=E9P6TVGO9JUI+$29&8SCS$#
M'!+0MN(R"#Q7LWG-_P \)?\ QW_&CSF_YX2_^._XT >&-\.];\OQ6TUKJT^M
M7EM?11W0EL5M+P2DF,,0%G8@%0!*2JX.#C%;[^#]0;P/J^D:QIE[J-Z]]'<F
M[M&MF:_Y#*7CF<(50 (T;X4JHV^WJGG-_P \)?\ QW_&CSF_YX2_^._XT <9
M+I-Q+\-=/T_5_#QGND2(R6&CRQVK6[*V5:$F150H0#P_4<$BN3E\+^--4MHV
MO#*EW_9>I6D,]Q<QB:(221F!)6BXW[5(+("!CJ3U]?\ .;_GA+_X[_C1YS?\
M\)?_ !W_ !H \;/@W5$CU&_\.^%QH(M5L[BRTKSX%^T7<,A+R?NW*+NC)CW%
M@6S\V,5C:K\,?%$L"644;MI]FJ7H$5Q$6NII3%]JB D!3/R2GYUVMYF#G+8]
M]\YO^>$O_CO^-'G-_P \)?T_QH \I_X0R>#POX?MET74]1TNTU"6YN]$U"2S
M\R165@H"1LMOM5B&$8(7'N,5/)X1UA_A-_8<%HUI?G5!<)%'-&S0Q?;O-#!F
MRI*IS@YZ8P>E>GBYCSAR4/HXVU-0!YQK7P\CGFTI)&N]86;5A>:K<7DD8>9!
M;R1@,$"*4Y1=BK@@G(.37-0^$[K0KR*Z;1%TQ]/NKJ[OO$,4\8$]EMD*PC:3
M*<*8QL9 J>7\N<"O;*1T61&1U#(PPRD9!'I0!\Y^%_"C75E<Z9-HKV7B&\MM
M-G<0PP6PEM8KA3)+YB3.S2')+,WELV!A0:ZSQ'\/97\<64UK8:@-#@BMTL%T
MC[%$+!TD9GSYR[T5L@EH3N(R"#Q7I^BZ#H^A+*NB:5I^G+*09!:6R0AR!@9V
M@9Q6E0!XC+X'NVA\26W_  C=^=/NITN%<II[7MS+YQ<AF,FR> <';-AL''..
M-/4/"?B6_P!-TE8+*STZ[C\/WEDXM'$$5O-(T6Q%"L2H(4\KD#UZ5ZQ)*D7^
ML8+GH.YIGGY^[%*P]=N/YXH \2A^'ESJ'B[2IX_",>C>%HY8Q=Z5)+ 4E=89
ME:9HXW9"#O1#U9^K# KL-+\,ZO;_  KU?0+918WK->Q6*";:L<32N8E#)G8-
MA &.5'88Q7>^<W_/"7_QW_&CSF_YX2_^._XT >*:A\/[G4],UB&P\'P:1ILR
M6*QZ3*UNPEGCFS+.%1FC7]V=N<AF Y'2N\\>:9>)_P (I-H6D27L.DZBLSVE
MFT,16(02H-@D=%X++QD<5U_G-_SPE_\ '?\ &CSF_P">$O\ X[_C0!YEKGAW
M6=9UK5-=@TF:TNTM+&?3XKF:(/\ :8)96:-BCLHW*VW.2,/UX..8M_AMK3>)
MK;4]<@U6YENS%>/+IKV(:RN3*SR!FF&]5 *+NA;)5,$'BO=/.;_GA+_X[_C1
MYS?\\)?_ !W_ !H Y3P[X72W\;>(]=O[)#<SW*&QG=@Y2+[/&C;!D[,LK ]"
M<#.1BN.U7PMK>HIX@TW2]$O+#1;ZRO/.LM1NH)K:6Z?F-[<!G:/+;F.=B\YV
MYKUSSF_YX2_^._XT><W_ #PE_P#'?\: /*CX.NKO3?$D,?AN*QM+WP]#96U@
M_P!G"K.AG)3:C%!AG5LYQSG.<XR8?A=);6.K16GAVRMFN;K2BIMQ#$6AC\HW
M RI! W*Q(_B/(S7M?G-_SPE_\=_QH\YO^>$O_CO^- 'B_B#X>:GY-[8Z=ILB
M>'$UK[4FEV M/WL#6RKF..<&'B7<VQP.Y'.*TM:\'WBP^#CIVCW^HW>FQ+$O
M]KFSN(H%+J6,WS@K(H'RO!G&,<C%>K><W_/"7_QW_&CSF_YX2_\ CO\ C0!P
M/PX\/W>B>)=>D_L=K/3[EC*MU>);F[GE:1F(\R%V,D8!ROF .,XYJ7PG::WH
M$=]H#:+</#-=W4\.KP3P^3MF=Y 74N) X+!2 C#C.:[GSF_YX2_^._XT><W_
M #PE_P#'?\: /$K7P+K*:5<6UAX=_LJ[70[JROYUN8C_ &O=.H"/E7RWS!F\
MR7:PW8[FKNM?#"-Y/$AL/#]I^]TF V!!08OU\S=*N3\LO^KS(<$_WCS7L'G-
M_P \)?\ QW_&CSF_YX2_^._XT >*>%=$U&\U.*]TG1%@O[76-1>;69)H]LL6
M^91;D!O,8%RN5*[0!D'-5]'\ Z^VF:K#/I<]FNH'3GGB5[2#=+'<E[AU%OM
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M;PH9))'.%10,DD]@!0!+138Y$EC22-@Z. RLIR"#T-))-'')&DDB*\A*HK,
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M10 4444 %%%% !1110 5#!_K;C_KH/\ T%:FJ&#_ %MQ_P!=!_Z"M $U%%%
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MB'+E4&"P.6('%3>.[B]M/"&J3Z5)>Q7T<68GLK1;J8-D?=B8@.?8FO/M#O\
MQ5K/PPU7^T[:[O\ 5&N_($<]DHD6/*@L(R(1N7+'[QP1]XXQ0!U'P>M+>V\&
M1O9:LFJV]U*URDZGE5< A'^8_.!C/N:[>N$^$D.J66C7%CK%I?K-')YIN[NW
MBM_M#/G(6..1PNT*O3 Y&!UKM3=VPO!:&XA%T4\P0[QO*YQNV]<>] ',?"__
M )%FX_["NH_^EDU=;7)_# 8\,W&?^@KJ/_I9-764 (P)Z,5^E1J&,CCS&P,=
MA_A4M1I_KI/PIH3) ,#DY]Z***0PHHHH **** ,.15_X3B!O[*=G_LZ0?VED
M[4'FI^YQTR?O?\!K<K#D:/\ X3BW7^U)%F_LZ0C3<':Z^:G[[/3(^[Z_-6Y0
M 4444 %%%% 'D7BKXMW6B>(;[34TN"5;>0QAS*06Q^%8TOQLNY% .CV_#!O]
M:W8Y]*XGXG?\C[K7_7PU<O0![#_PN^\_Z UO_P!_3_A7HWPV\62^+]'N;V:U
M2V,4YA"HQ;/RJ<_K7RQ7T#^SS_R*>H?]?Q_]%I0!ZG1110 4444 5[#_ %#?
M]=9/_0VJQ5>P_P!0W_763_T-JL4 %%%% !1110 4444 %%%% !1110 4444
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M3&AE$I1?-52H?'(!QD9].!^5<E\++_3-1\*K<:)/?SVC3,-]\5,F[ R,K\I
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M!@_0U>.SO!UL-.G"6K36S%&G)--GLU?-_P =O^1\D_ZX1_RKU['Q!_O^%/\
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M8$(_O?I7CO\ PS1X\_YZ:)_X%O\ _&Z]C*\PP]##J%25GKW-IQ;=T>)UZ!\
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M10 4444 %%%% $+*T3%HAN4G)3^HI\<J29VGD=5/!'X4^F211R_ZQ <=#W%
M#Z*C$*CN_P#WVW^-+Y2^K_\ ?9_QH ?13/*7U?\ [[/^-'E+ZO\ ]]G_ !H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(*ENA ##LU2Q^ [)+34M/.HZD^B7PESIC-'Y,32-N9HVV>8#N)(!<@$\#I@
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M.JG!'%=%7.Z)X5@TOQ!?ZU)?7E]?W<:PE[A85V1ABP0>7&F0,]7W-@#FNBH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *\_\1:IJT_Q!BTW3[G5[?2K.S2XO9+!;,JC.[;?-,X+;-L;<1 MS]*]
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MG6?D6\300Q^0NV.-AM9%&,!2  0."*E@L+.W:1H+2WB:1%C<I&%WJHPJG Y
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M&EZ7JUVL5^\EQ>,GR2 GH" 0<8(.<9Z9XZUTM9J:'IZ7*SK"?,5PXS(Q (
MXSC VCCID UI4 %%%% !1110 4444 %%%% !1110 445'--% NZ:2.,9QEV
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M^M<^NL:=J/B71+FSNXGA:SNV!)VG&Z$9(.".AZ^E '5T5#]KMQUGB_[['O\
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M,'!'2@#'T[5=>OK43+H^G1G<5:-M28LI![XA(Y&#]"*M?:?$'_0*TS_P8O\
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MR82'"!K6-6)R1C:6!SE6'X&NKU"S@U"QN+.[3S+>XC:*1,D;E88(R/8UR_\
MPKCPKYAD;2PTAVY9II"3M8L/XO5CT]: *MAJ-Y,WE3^,M,^T;]H$5NFU@3\F
M"6Y)4KP.^:UK:UU>ZA6:U\3030M]UX[-&4]N"&JO#\//"T,21QZ3$$1/+"[W
M(VXQZUNZ)I-EH>EPZ=I4"V]G""(XU)(&22>ON: ,_P#LW7O^A@3_ , 4_P#B
MJQ;^]U&SUB"QD\66*R,422)K(&7=)GR@H!_BV/U[+7<5E:GX>TS5+M+F^MO-
MG0QD-O8?ZMF9. <<%F/XT 5O[-U[_H8$_P# %/\ XJC^S=>_Z&!/_ %/_BJF
M\2>)=+\.1V\FL7!@CG;8C;"P)R/0>AS] 3T!K-;XA>%5MQ*VN62\99#(-R<J
M#N'48W#/ISZ&@!=535M,T^:[O/$T4,,8^:1[!2JY.!G!Z9(JOX=.M:MI<<Z^
M)[.:9?W5Q]FL@T:S #>JDG)&>A[C!KI=2L;;5M/>UO%=[:8#<JNR%AUQD$''
MJ/PIFBZ18Z+:M;:9 ((6D,A7<6^8X]2>,  #H  !0!0_LW7O^A@3_P  4_\
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MB@ HHHH **** "D90WW@#]12T4 ,$48.0BY^GXT^BB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** *>IZ78ZI$D>I6D%U&A8JLR!@"R,AZ^JLP^
MA-9[>$O#S.[-HNGEGW;LP+SN()SQW(!K<HH ;&BQQJB#"* H'H!3J** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1)\0_P#8.N/_ $6U %WP_P#\@'3<=/LT?_H(J_5#P_\ \@#3?^O:+_T 5?H
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M PO&NM3^']!EU&VMEN3$Z[U9L )GYC^5<AXP,]]XV\":C!]J-C.V45(3^[)
M<[SG@$;>.?N&MKXM-;CP;*+MHUC,\0!D'R@[@03P<8QG/M7-^+VM%\3?#>WF
MN;"2\A=6 8&5BI"+O0Y'4C@X.>O !H V?B%H^M7EAX@GCU5(=+.G-L@PY(90
M2WW2I&1D9W'KRO'/81Z? 54YN.Q_X^)/]D_WO]D?KZG-7QC_ ,BCKG_7C/\
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M5T5P21P"&(!_$UY_-I-Y:>#]/TD:=?LC7[.YAC6+:F&//E%]O)P"0>1VPIH
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MQG/WFYS\W8$]^,9H ?X1N9I/%OB>&>ZGG6.93&K[]L:G/RC/ _KUZ5J>.O\
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M>0>A%=I(BR(R2*&1AAE89!'I7&^,O#6BV_@[Q%+%I=F)&L+ABQB#<[6;//\
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M>(=)G\MMC^59%MK>AQ-P:Z.N"_X5;HAD+?:M3"F9YRBSA58L&!!PO(^=OSH
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MC7O[6 L6'V%I(23\F456&\#//S!OPV'&"10!T%%<C)<>*Y+C'V&)(UVLI#*
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M]2P(/XG JY87.NOJT<=_;)#;;FYC 8,N#@DY.#G;QQ_%U'0 Z"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KBM9^&GA_5M0O[VY2Z6XO=_FM%,5^
M\B*<#T^3./5W_O&NUHH X[2/AUH>DZW#JMH;W[7#))*A>X+@%U"L"#U&%'7I
MV[5V-%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
144 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image00037.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00037.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" %^ H,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WZ/2=.O\
M7]<DOM/LKJ19HE#SP)(0/)7C)'2K7_".:'_T!-+_ / ./_XFGZ=_R&M>_P"N
M\7_HE*TJT2T)9E?\(YH?_0$TO_P#C_\ B:/^$<T/_H":7_X!Q_\ Q-:M%.R
MRO\ A'-#_P"@)I?_ (!Q_P#Q-'_".:'_ - 32_\ P#C_ /B:U:*+(#*_X1S0
M_P#H":7_ . <?_Q-'_".:'_T!-+_ / ./_XFM&&>*<.8)8Y0C%&V,&VL.H..
MA'I4E%D!E?\ ".:'_P! 32__  #C_P#B:/\ A'-#_P"@)I?_ (!Q_P#Q-:0F
MB,YA$B&8+O,>X;@OKCKCWIVY=^S<N_&=N><>N*+(#+_X1S0_^@)I?_@''_\
M$T?\(YH?_0$TO_P#C_\ B:U:*+(#*_X1S0_^@)I?_@''_P#$T?\ ".:'_P!
M32__  #C_P#B:U:0,I9@K*67J >1]:+(#+_X1S0_^@)I?_@''_\ $T?\(YH?
M_0$TO_P#C_\ B:U:;-)'!$TLSI'$HW,[L%51ZDGI19 9G_".:'_T!-+_ / .
M/_XFC_A'-#_Z FE_^ <?_P 36HK!E#*05(R"#D$4M%D!E?\ ".:'_P! 32__
M  #C_P#B:/\ A'-#_P"@)I?_ (!Q_P#Q-:M%%D!E?\(YH?\ T!-+_P# ./\
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M_P# ./\ ^)K4=E1&9V"JHR6)P /4TV.:*54:*6-PZ[T*L#N7U'J/>BR S?\
MA'-#_P"@)I?_ (!Q_P#Q-'_".:'_ - 32_\ P#C_ /B:TI)HHY(XY)8TDD)$
M:LP!<CDX'?\ "GT60&5_PCFA_P#0$TO_ , X_P#XFC_A'-#_ .@)I?\ X!Q_
M_$UJT460&5_PCFA_] 32_P#P#C_^)H_X1S0_^@)I?_@''_\ $UJT460&5_PC
MFA_] 32__ ./_P")H_X1S0_^@)I?_@''_P#$UJT460&5_P (YH?_ $!-+_\
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M/_H":7_X!Q__ !-'_".:'_T!-+_\ X__ (FM6BBR RO^$<T/_H":7_X!Q_\
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M!E?\(YH?_0$TO_P#C_\ B:/^$<T/_H":7_X!Q_\ Q-:M%%D!E?\ ".:'_P!
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MJVWV?&TJB8*MN.% _AQUYS7KOAOP_8^';.:#3Q,QGF:XGFGE,DLTK=7=CU/
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MN_O?**/%'AFP\21V8OFNH9K*;S[:XM9C%+"^,$JP]02#4.47),:3L>=1^/\
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MK7_GO'^='VZU_P">\?YTGV&U_P">$?Y4?8;7_GA'^5'[OS#47[=:_P#/>/\
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M= V6;V5W?:<1=AGG2WE$;B1=O[LDG(ZU83XGZQ!K#6>I^%X;>*"_L[*ZECU
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M7WJ@$3>JAHE<>]/4!^D_%70)]'T6YU>0Z==ZE;)<M;B-YEME=RBF215PH+#
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MSR\?,W)QY9Z]<UGP>#]374#?W.HVUS=J(2!*KE)6CD9LN.B@ANBC@@'FB[[
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M9KNWFWE@OER!MQ R1QZ#FN3TW0M:6+5IKUU^W7%D;:)S<F0-(S,6?!X08*8
M_NTRZ\&2Q7$3:?<R@QPJ!,9?+8R9C3.% &%BCP!W)YS1=]@.UN(O.MY8LD>8
MC)G'3(QFN&TGX:Z/HFAZ-:6C+"^G7=M>W%VR9:[: '&_).T<GIP.U(VA^(Y#
M.\K,9'9.!?MLD82,S,PXVH5*J%7!XK2TNPUS3[35KB7-_J<SD0Q37(\@KN."
M!CY<*1P>3C'O2=GN@.4OOAK97ND+_P 57*NDJ\DI "^2':X,VX88*#D[#G/
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M8M]<=ZDN/#^L+'<YO9Y$17:(K<,K,=L:J3CDXQ(^/4@4^9]@.WP?2AOE4EN
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M],&W\1Z[::?<ZMJ$QDBL2DM[8"(B1,LR,BY0<#*D#+'Y>N#6[JGB:^L]8U&
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M]$D6BN\=\P1L1,B[F'3YL 'IFJVE^-]"U3RA83SR/)/%;^6]N\3HTBEHRRN
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MIZ 29A_NR?F*,P_W9/S%1T46 L,8O)C^5\9..14>8?[LGYBA_P#41?5JCI)
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MU6&SU6TDG+S6D<NRYBB:,G,"N.%/8DCZ>]&L:[J4D=PMIJ"2"W6;R]1@AP"
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M=SMYT8?SS\QE_P!9WY;KSU'.*SM4TRPM+NTN#,(K6.8_9XXF,DC73J$&!G&
M &V^HSVI-L!=6OM%L[G2EN-&MS%<^<3+-;*AM@#R2",C<Y ^IS4NEWOA^^AG
MA;3[6$7$1N;I7M0(I" "^7V[79=PSZ5?O='TS4=/:WU!OM44MN+-W>;EU!!/
M(/WLC)(YS67.?#6GW.HQ3-*K"*6.5&\PQHK /(L?\()!4D#FC4"M-K?AV\5X
M-0TJ-]/M0HMTFL"Q4%=SL(ROR1JI3YNGS5I2>*]#T^U WO#;QS?9(U2W8*S+
MP0@ Y5>^.E07VF>'K-H!>/<_Z0Q!E,LCK-OVC;(XX(.Q1@GM4R:=H:V_]NB2
M? _TIKDS,6QM'!'T XZ\"EJ!=U/Q%INF7%S#=RR*UM$LLS",E4#'"@MTW,>@
MZFJUMXNTFZB:2W:ZD13&N1;/R[@%4 QDM@CBH)9O#VL236Y,LLUS,DLH6.17
MBDB.U2W'[O!7'.!UJO\ V5I>MWT.H6=W>".)@9)R\D9D4*RH(W.!M!9CD9IW
M?0#2'BS2"H?SY1%Y)F,IA8(H"%RI;& ^T$[>M)#XLTF614$EPC8D9Q);NGEJ
M@!9GR/E&&!S[TA\-Z'Y>S9B!H_EA%P?+ VA2P7.,[5 +>GUI][H6CW;@W1WB
M5I)5C-QA79P0S 9Y.#CCV]*+R LZ)KEEK</FZ>9WBP?G>%D7@X(R>_\ 2M.L
M[3+6&QWK'?231O@11RRA@@7@A?7D\GZ5>66-FVK)&S<\!@3QUJD^X'C'Q5_Y
M'S4O]V'_ -$I11\5?^1\U+_=A_\ 1*45Q%GM*_\ (3U[_KYA_P#1*TM36"J^
MLZ^&4,//BX/_ %Q2K_DQ?\\T_*MJ<U&-A-:F516KY,7_ #S3\J/)B_YYI^57
M[5"L95%:ODQ?\\T_*CR8O^>:?E1[5!8RJ*U?)B_YYI^5'DQ?\\T_*CVJ"QE4
M5J^3%_SS3\J/)B_YYI^5'M4%C*HK5\F+_GFGY4>3%_SS3\J/:H+&516KY,7_
M #S3\J/)B_YYI^5'M4%C*J2+[LO^[_45H^3%_P \T_*G+#& W[M>GI0ZJ"QD
M45J^3%_SS3\J/)B_YYI^5'M4%C*I,#;MP-OICBM;R8O^>:?E1Y,7_/-/RH]J
M@L973I1@8Q@8^E:ODQ?\\T_*CR8O^>:?E1[5!8YS4M*M=1:)YQ*DL1;9)#*8
MW&X889'8X&:L6MM#:6L5M;1K';Q($1!T"CM6WY,7_/-/RH\F+_GFGY4>T78+
M&5WSQGUHZ=*U?)B_YYI^5'DQ?\\T_*CVJ"QE45J^3%_SS3\J/)B_YYI^5'M4
M%C.?_41?5JCK7,4>Q1Y:XY[4WR8O^>:?E0JJ"QE45J^3%_SS3\J/)B_YYI^5
M'M4%C*HK5\F+_GFGY4>3%_SS3\J/:H+&516KY,7_ #S3\J/)B_YYI^5'M4%C
MFM2T>SU&2.2X659$5D#PRM&2K8W*2O4' J[!%'!!'# BQQ1J$1%'"J!@ 5L>
M3%_SS3\J/)B_YYI^5'M%V"QE45J^3%_SS3\J/)B_YYI^5'M4%C*H_+%:ODQ?
M\\T_*CR8O^>:?E1[5!8RL8[#IBBM7R8O^>:?E1Y,7_/-/RH]J@L95%:ODQ?\
M\T_*CR8O^>:?E1[5!8RJ*U?)B_YYI^5'DQ?\\T_*CVJ"QE5(?^/9?]\_R%:/
MDQ?\\T_*G>5'L \M,9]*'506,BBM7R8O^>:?E1Y,7_/-/RH]J@L95%:ODQ?\
M\T_*CR8O^>:?E1[5!8RJ*U?)B_YYI^5'DQ?\\T_*CVJ"QE45J^3%_P \T_*C
MR8O^>:?E1[5!8RJ*U?)B_P">:?E1Y,7_ #S3\J/:H+&54EM_Q\1_6M'R8O\
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M-)&N2&,/F_,N=Q^7&6Z9P*ZM='L5F\T0#?YLDV=Q^_(-KGKW%5H/#6EV^1#
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MV?V0R)$%*Y9V9\#J27/'MBJ5QX!CN"?-OEQ*S&X5+555@7C;"#/R<1A<\G%
M"Z'HWAI+&*.XU"#4)]S6\DDEUD-( PD15)X&9'^4=V^E2:UHVB:9;6\5PFJW
M,K1?9X8K>1Y9BJ,) 1C^X<$'MG'.:1O!&^XB=M0!1'1V7[*IW%)FE7G/&68;
ML==HZ5LZII%U=SVMU;:C]FO8H'MWE\@.'5]I8A2?E;*@@\_0T6 R$M/#1QJ\
M5[*TC6[7:8O&#[-B[G"9R&*HN3C/YFK]O:Z5]JN==CGFEENK;S9(7GWH44<#
MRSP #V'&<]ZSG\"6<=IY,$[K&H(XC#2,HB6-5W'KA0WU+FGZ3X8+Z/J27>ZU
MEU&4MY>%8V\'F%Q",''.6S@]6]J )_#>E:;;37,[7%M-J1N9+^X$+X\IF4KC
M;G( 4D<]R3WIVD#2=1NCKBQ7=M(Y\]#=MY8;]WL\U5STVD#/O3K?PK%;0WHM
MKCRI[FUEMS*L0!#2.SM(>>3EAQ_LU3;P4&ALH5O(H(885@EBM[4(LJK*LG R
M=N[8H;KD#M0 Y_#WA8MM:X0 @6OE_;2%W^64Z;O]9L)&>M6M0TKPW=7LUW>2
M6S2VPA,NZX 6(1,2FX9P!G.<]< 'I56?P5 UO:1K.-D4+13CR%)FW.'9@<_(
MS$8)YX-9EMX :ZTZ%M4NU%XV'>,0C9DNTCJ^&!<EGZY'W1QUR =-!X;TH3P7
M4*R':5D3;,2C$,SJ^,X)S(QS[UIZ?9P:?8P6EHFRWA0(BYS@#WJ2WACMK>*"
M%%CBB0(B*,!0!@ #TJ2F!\^_%C_DH&J?2'_T2E%'Q8_Y*!JGTA_]$I14#/<=
M-_Y#6O\ _7>+_P!$I6EGV%9NG?\ (:U__KO%_P"B4K1JH["8N?849]A2450"
MY]A1GV%)10 N?849]A244 +GV%&?84E% "Y]A1GV%)10 N?849]A244 +GV%
M*#UX'2FTH[_2D 9]A1GV%)13 7/L*,^PI** %S["C/L*2B@!<^PHS["DHH 7
M/L*,^PI** %S["C/L*2B@!Q/RC@4F?84'[HI*0"Y]A1GV%)13 7/L*,^PI**
M %S["C/L*2B@!<^PHS["DHH 7/L*,^PI** %S["C/L*2B@!<^PHS["DHH 7/
ML*,^PI** %S["C/L*2B@!<^PI<_+T'6FTO\ "/K2 ,^PHS["DHI@+GV%&?84
ME% "Y]A1GV%)10 N?849]A244 +GV%&?84E% "Y]A2J?F' IM.3[PI )GV%&
M?84E%,!<^PHS["DHH 7/L*,^PI** %S["AF"XW;1DX&3C)JO?AFT^Z5 2YA<
M*!U)VG&*^?\ PW\/O$5GX5\.23R7%I->7^F-+;68D,EH$#^9<2>9D"4[@&(&
MT8'%2V!]$9]A1GV%>$ZCJGQ"BTG2X+:UUY]0M7E8W6P;;I%NMH65 G)\H;LD
MJ"#QDU+J=Y\0$D\01VC:S<6PU&)OM@A,31VI9]T<,6PMN7Y,NFX%>1SFBX'N
M/7^$49]A7DGCQ+V[^%^BV>M:;J&M:S<H(VN+>VF46[E2#<21IALJ#D*1RWI7
MIF@KLT/3DWW,FRVC7?<J5E;"@9<'D,>I'K30%_/L*,^PI**8"Y]A1GV%)10
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MY2QI"(QMP"S./G(XYW8XJO<:_KD4]X+.:[N&@$JI%):C:T0AS'.S!1\S2,H
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MU&1XCMP<(H4$F1FPH'J>]=;IL\MUIMI<7%N]K--"DDD#_>B8J"4/N"<?A3T
MM;V]:-[>M-HHL [>WK1O;UIM%%@';B?_ -5)N/\ D4E%,#Y^^+/_ "4#5/\
MMC_Z*2BD^+'_ "4#5/I#_P"B4HK,9[CIW_(:U_\ Z[Q?^B4K1K.T[_D-:_\
M]=XO_1*5HU4=A,*5?O#/K2450'SM]L\9:5%IFC::^NP:D;.[NXK2&)7W2_;R
M$:;<"1$4;KQP16]JUW\0HW\01V0U>XC&H0LER(C'MMF=]\<*;"<J-GSKNRO(
MYKV4VEN;X7A@C^UB,PB;;\X0G.W/IGG%35-@N>,G_A897[2]]JK36EOIK)%#
M:A(KIVF9;C>K+NR(\%AQ@\U9D.IVOB33==U:VO=M_J%[<)98.X>3 5M(BO\
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M^B4K2P/[WZ5FZ=_R&M?_ .N\7_HE*T:J.P,7 _O?I1@?WOTI**H0N!_>_2C
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M)89;6R@ADA0Q1LB8*J3DC/H3S]:8B]1115 %%%% !2_PCZTE+_"/K0 E%%%
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M7SO,@D\UBH(<N69AD#RU/7^$#VJBEUX?O,1V>EWLWV>(2VTD/[LR"(E2(V+
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/B/ =%!XC4?WO:BI&?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>image00019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" &3 LP# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P"K_P ,V:M_
MT,>G_P#@._\ C1_PS9JW_0QZ?_X#O_C7TU17=]>K=S#V$.Q\R_\ #-FK?]#'
MI_\ X#O_ (T?\,V:M_T,>G_^ [_XU]-44?7JW</80['S+_PS9JW_ $,>G_\
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M (#O_C7TU11]>K=P]A#L?,O_  S9JW_0QZ?_ . [_P"-6?\ AF'6/^ACT_\
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M_P#&OJ.BCZY6[A["'8^7/^&9-8_Z&33O_ =_\:!^S)K!./\ A)-._P# =_\
M&OJ.G1C+BE]=K=P]A#L?+O\ PS#K'_0QZ?\ ^ [_ .-'_#,&L?\ 0QZ?_P"
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M&8=8_P"ACT__ ,!W_P :3_AF#6/^ACT__P !W_QKZJQ1BCZ]7[A["'8^5?\
MAF#6/^ACT_\ \!W_ ,:7_AF'6/\ H8]/_P# =_\ &OJG%&*/KU?N'L(=CY5_
MX9@UC_H8]/\ _ =_\:/^&8-8_P"ACT__ ,!W_P :^JL48H^O5^X>PAV/E;_A
MF'6/^ACT_P#\!W_QI/\ AF#6/^ACT_\ \!W_ ,:^JL48H^O5^X>PAV/E7_AF
M#6/^ACT__P !W_QI?^&8=8_Z&33_ /P'?_&OJG%&*/KU?N'L(=CY5_X9@UC_
M *&/3_\ P'?_ !H_X9@UC_H8]/\ _ =_\:^JL48H^O5^X>PAV/E;_AF'6/\
MH9-/_P# =_\ &D_X9@UC_H8]/_\  =_\:^JL48H^O5^X>PAV/E7_ (9@UC_H
M8]/_ / =_P#&E_X9AUC_ *&/3_\ P'?_ !KZIQ1BCZ]7[A["'8^5?^&8-8_Z
M&/3_ /P'?_&E_P"&8=8_Z&/3_P#P'?\ QKZIQ1BCZ]7[A["'8^5?^&8-9_Z&
M/3__  '?_&C_ (9@UC_H8]/_ / =_P#&OJK%%'UZOW#V$.Q\K?\ #,.L?]#'
MI_\ X#O_ (T?\,PZQ_T,>G_^ [_XU]4\48H^O5^X>PAV/E7_ (9@UC_H8]/_
M / =_P#&C_AF#6/^ACT__P !W_QKZJQ1BCZ]7[A["'8QJ***YC4*1F"*68@*
M!DDG  I:S_$7_(O:K_UZ3?\ H#545=I 65N[9[3[4EQ"UKMW><) 4QZ[NF*F
M5E=0RD,K#((.017SAIL\OA3X7S:5=L3HGB+0VNM/=CQ!=>5F6#Z-]Y??-=?J
M'B;6FU73/#^C/J5M%:Z);W<DFG627,LCN,*"'X5!CG')/I7;+!._NO3]#-5.
MYZQ/?VEO>6UI/<11W5UN\B)FPTNT9;:.^!UJR.>E>-:E+X@UK7?ABU]G1?$$
MRWJ3LT()B(0 LJ'C) R <@9J]_PF'B/3K34M"-[;W&L0Z_!HT.K/;@8CE7?O
M9!\N]1D8Z$XJ)81V7*]?^#8:F>LW7E65G-=ZA/';6L*&2221L!%'4D]A5F%;
M1[5;E'5[=D$@EW?*5(SNSZ8YKR#Q9J>LV>G>/?">M:D-72+P^U_;WCPK%(H;
M<C(X7"GD9!P.*N?#GQ/?^([.]\NX%EIVC:9' FG2P@37#&$$3ON&1&>B@=<$
MGTJ'A9<G/?\ ICYE>QZI8R6-_:175D\-Q;2KNCEB8,KCU!'!%2/:QM]T%3[5
MX/HL^LZW-\)Q;:R^EF\TVYE(M+:((KJ@R0F-O(.,8P.W6NZLO$FJ-?\ Q)AE
MN@R:*B&S)11Y>;;>2>.?FYYJ9X:4=G_5[ I([*:%HC\W([$5'7DMQXSUR?3/
M"W]H:Q<:;!J&@_;3=VEBL\ES=\?)MVMM7!!P ,YQD5Z!X"AUIO!NEW'B1IGU
M::$2W*RHJ-&QYVX4 #'Y^M*5!PC>3!23+UMJ>GW4QAM;^TGF'6..96;\@<T^
MUO[2\DN8[2XBF>VD\J=4;)B?&=K>AP17SUX&\/W6NZ!HB:/X;^R7MOJ\ES)X
MB+HF(UG8LJX.]B1\N#Q6_OUVSD^)^L:)K*Z?'IVI27 @^S)(+AEB4D.6Z+CC
MC!]ZZY8**;BI:K_.W2Y"F]['M^:3->9^)/%%W>6]E'I&JZE;ZF-,6_GM--T]
M+C;N4%6D=^%7J,=35.Z\2>*;WPEX3UY6N[72+NQ:;4[K2K1+B:*7^$^6V?W?
M4G:":P^JRM=LKG1[-8Q[?WC#KP*MYKQ?6O&NK7FL:)H^@ZI?W-K+I(U&34M+
MTZ.::Y);8I"-\J+D$GOGCBO0OA_?:QJOA&TF\4636FJ'?'-&R>67 8@/MS\N
MX8..V:QJ4)0CS2*4D]#:@U6PN+N2TM[ZUENH_OPI,K.OU4'(J6\OK6QA\V]N
M8+:(G >:0(N?3)KR6'P]HM[\1-%@\%:5;6=MX>N'FU'4K=-H9RI'V8-UD8DY
M;).,>M:_QOMX;RR\)6UU"D\$OB"T1XW7<KJ=V01W%7[&//&-]Q<SLV>AVE[;
M7D7FV=Q#<19QOB<.,_45/FO);NPTSPA\8O#\7AR.'3X-1LKIM3M(/DB,<:@I
M*R#A2#D;N_2LZR\;:L?%?AN>QU;4=2T/6;][7-UIJ6]NR%6*F%A\Y(V]3D$<
MT?5G+6#TM?\ /_(.>VY[7FC->.^ +J]T^;Q]K&M>)IQ86&J74<HE@0HNU$Q)
MP,C P-H..*=X+\5ZVWQ TK2KR_U*_P!,U2PFNE?4=/CM&#)M(:(+SL(;HW/3
MFE+#23=GM_PX^<]5OM3LK#9]OO+:UWYV^=*J;OID\T))'+&LD#I)$XRKHVX$
M>QKRKXQI$_Q$\""?0VUY/+OLV"JC&3]VO.'(7CKSZ5D0P^)O O@M&L(H-(GU
M?Q+&MIITA$T=G!+QY9(XZC<0O3H*TAAKQBT]7_F_\B7/5GMN:,UYG</XH?Q?
M9>#HO$SQRQV#ZE=:H+*+S9<R;4C1#\JJ.YY-9>B>.-=630[O6+F%["+5[G0=
M3>.,*DD@_P!3.#_#R,$ XR:%AY-73'S+J>LW5[:VLMO'<W$,,ER_E0K(X4RO
MC.U0>IP"<"DU"^M=-LI;S4+B*VM81NDEE;:J#U)KQ^U\3:OJM]X1U.Z>%[+5
MO$DT=E');H3%:)&X0JQ&06*D[NN#Z5F>--0\0^*/A_X[U9]7CM]+L[J:P33/
MLRE6CB=5+,_W@Y/([>U7'"MR2D_ZO83GH>](X=59"&5@"".X-3Q+M&3U->*Z
MYXI\23^)K[1M";4[=-)T^V>,6%@ER9II(]P\TN?E3@#"\GGFK'B3Q-XPMH-&
MU#6#J'A_1Y--26\N+&Q2Z-M=Y^<3JV2L8&.5'U-9O#2T5UJ/G1['-,D$323.
MD<:#<SN<!1ZDU7L=3L;_ '?8+VUN=OWO)E5\?7!KEOB),ES\(]?FCN%N8Y=)
MD=9U&!(#'G<!Z'K7 _#GP[=7?B+PAK&F>%_^$<LK"P*WET6C5M0WQJ%&Q"<C
M/S9:HIT%*FYR=K Y:V/<B<49KP[2_%_BR+X<ZKXTOM4AG6U^T6UM8"V54=A-
MY:RR/UX]!@8%;4FN^(O!WB'3+;6]6&OVNI:?=717[,D+PRPQ^8=FSJA''.2#
MCFF\++577_#;ASH]7S64_B/1TUU-%;4[,:NZ[EL_-'FD8S]WKTYKRW3O$WBJ
MQT7PAXJU+68;ZSUZ[MX)]+6V1$@6?.SRG'S%EXSN)SSTIO@#S]&\4_$/6;VZ
MO;]+;5?*DM[:Q6229C&FUAM&[@'& <8R::PUDVWM^=[!SGM.:JZIJ5GI5C+>
MZG=0VEI$,O-,X15^I->>:IXDU?Q)XLT;0M O+G0+>ZT^749IY[,?:<+($"!)
M!A>>22,XQ7$>,M4U?Q+X MX-3OT6ZT[Q3%I<\T,"[+DK,H27:<@$9R5Z$BBG
MA7)KF=@<^Q[UI>I6>K:?#?:;<Q75G,-T<T3;E<=.#4<FL:;'>BSDU"S2\/ @
M:=1(?^ YS7):EXFETS3-6TFUM=6GU:PT^:1+V33S';RR)&6!#* F2<<#OD5E
M_"?P?X:NO GA[59=-L[_ %&XACOI;^:,23/<'YF8N><ALCVQ4>R2BYRVZ#N[
MV1Z?FC->(WWBWQ5+X6\0^-K;5XH+/2K^6"/2#:HT<L44@1@[GY][<D$$ <<5
MLW>I^)M?\>Z[H^DZY_9%A9Z;:WL;+:I+('D#?+EN-O'/?CC%5]5DMVOZM_F+
MG/5<T9KQC1O&?B/Q7:>!]-M;^+2KW6+.XN[V]B@61L0MMVQJWR@L>3G.*M>,
M?$'B+3/$>B>%+;4-2FF-@]Y=ZA8:?'+<S8?:H6,_(H]3@]NF:/JL^;ENKZ_@
M'/U/7<T9KQJ3Q/XTEM/!%E>2?V/JFJ7]S974DUJN7C1&*2A"<*Q !QG&?:LC
MQIKGB)?!7C_1+W66GN=%N+5$OXX5CDGAF*_(X' 89ZC&:<<))M*Z_IV!S/?,
MUE:;XCT;5-2NM/T[4[.ZO;7_ %\$,H=H^<<@=.>*9IUAJ%KH+6MQK$UU>E6V
MWLD"*RYZ?*H"G%>(^!K[5_#GPLT9M+U!/MFN:O\ V?%+-;(5L]\TF^3@ N3C
M.&)&:FG04XMIZW2_/_('*S/H;-&:\@U#Q+XB\.3>-=&N]5&I3Z;H9U:ROWMT
M21"=PV.JC:<%<CCI7:_#U=;GT:+4_$.J)>2ZA#%<1V\4"QQVH*Y*J1RV<C)/
M<<5,Z+A'F;&I7=C=;5].6\^R-J%F+K.WR3.H?/IMSFGQZE9R:E+IZ7,1OHHQ
M,\ ;YU0G 8CT)!KYXU;19-?\0_$C3K'PD-6U*YU!8[?4V:.-;)C$F&+D[A@_
M-\M=1#I&N3?%>]T_3]=-A=0^';1+B]6!9I)65F' ?@ G))()^E;O"Q2^+I?\
MO\R5-]CVG-&:\@T[QO>ZG\.O#DU[JUS9Z_J4\D"C3K%;B:Y\IF5]B-\J\ $L
M>!5*P\4^--1\%ZC]@%W<W^F:VUC=31VL8O#:  EEB)V>:,@8Z>U9_59ZW>SL
M/G1[9FC->)ZCX\U >'_#MMH6LWNIW&J7\UM->KIR"[@6-=S1^2<+Y@X&2/4X
MKM_AEJ/B"^L]3B\26]XOV>YV6=S=VZP2W$)4$%D7@,#D<8SZ5,\/*$>9C4DW
M8ZB35].BO5LY;^T2\;A8&F42'Z+G-72V!DUXC\;M#AMK&_O$\+V$6FO)%=7^
MO1,INX,.-SHF 21@<[NYXKO_ (D:E86GPTUBYO9KD64UD8A);G]ZWF#:NWW)
M84.BFHN+W#FWN=+8ZE9:@'-A=VUT(VVN895?:?0X/!JWFOG;P!J(\"ZU-_PD
MNE"Q\2SV]GIEGI&G0A$O(\_Z\-G:[Y)W'^''O7K7Q5\1-X8\!:MJ$.3=^7Y%
MJHY+32?*F,=>3G\*JIAG&HH1UOL)3NKG46EY;WD9DM)X9XPQ0M$X<!AU&1W%
M1WVI6=@UL+VYA@-S*((?,;;YDAZ*OJ3@\5X9\)==T_PK>:_HNFB\DLETQ=5@
M6ZMI(&>>./;<!0X!.XA6X]327#^(M5TWX;:]KFMQ7L6IZU:W!LUMT1;<L&*B
M-AR0!P=V:MX3EFTWI_P+BY]#W74M0M=,L9;S4;B*VM(1F2:5@JH,XY)^M$>H
M6DEZUG'<PM=K&)FA#@N$)P&QUP?6O!/'&H>(?%/PV\;:U+J\<&EV]W+91Z4+
M92ICBE5=QD^]O)Y].V.:Z/Q1J=_'K_B^VLIX[5K?PFEU%.D"&56!?(WXSC Z
M9XSD<T?5';5Z_P##?YASGK-Y?6MD8?M=Q#!YT@AB\QPN]ST49ZD^E6,UXO!)
MJ6E>!OATUSJ7]HF_U+3U'VJVC)@C:+[JG'4?WS\WO2:EXG\57.A^+?%ECK$-
MG::%>3P0Z6;5&29(2 WF.?F#-SC!&..M3]5;=D_ZO8?.>TYHS7E+ZOXE\2^.
M[K2=)UHZ-IXT:VU$%;5)95DD+<#<,8]<^G&*J:=XWOM6\">&C<ZK=VGB#4))
MD*:78+<2W(B9E9E5LJ@X!)/':I^K3M>X<Z/5]0U&STY8&O[F*W6>58(C(P7?
M(WW4'J3V%2W%S#:Q[[F6.%,A=TC!1DG &3W)KP>[U_4O$'@WP\^M.9+NR\:0
M61D>(1.ZHYP74<!L'G''%=M\?.? L&?^@K8_^E"4WAW&:@WJV'-I<]'S2YKR
M35-2\5ZIXH\<VFF>(%TRRT.*&:W5;2.5G=H2Y5BP^[D?7GK4-GXL\0^*KOP5
MI=AJ$>CS:II#:K>744"RLQ7:NQ%?( ).3[4?5I6O=?TKASGIRZ_I+*[+J5IM
M2Z^Q,3* !/\ \\O]_P!NM:6:^>]#NK[3-$O%F>UN+N3Q]Y$\I@5E<DKN95;.
MT]\CD=J[KPW>>(_%WB+6KR#7?[,TO2M5>PCL(K5)#,L>-YD9N06SQC&/>G4P
MW*F[Z IW/2LTC.%4EB  ,DGH*\2\7>.]3L]1EU3P_K%_?:?!JL5C)"=.1;(
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_;__ !-'_"UO!/\ T'[?_OV__P 37R#13_LFE_,P^LR['U]_PM;P3_T'X/\
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MH_LFE_,P^LR['V%:_$_P==7$<%OKD#RR-M1=C\G\JC_X6MX)_P"@]!_W[?\
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MQUR,8%<+136$III]A>TE:P5J:S_R#]#_ .O0_P#HUZRZU-9_Y!^A_P#7H?\
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M"/\ S^:Q_P!]I_\ $T?VC2[/[@LNZ/GBMD?\B2W_ &$Q_P"B37MW_"G/"/\
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M_OM/_B:M:M\)O"U[J5Q<W%WJRRRMN8(ZXSCMQ4/,*7,GK]P[*VZ/FZBOH?\
MX4YX1_Y_-9_[[3_XFC_A3?A'_G\UC_OM/_B:O^T:79_<*R[H^>**^A_^%.>$
M?^?S6?\ OM/_ (FC_A3GA'_G]UG_ +[3_P")H_M&EV?W!9=T?/%%?0__  IO
MPC_S^:S_ -]I_P#$T?\ "G/"/_/YK/\ WVG_ ,31_:-+L_N"R[H^>**^A_\
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M^T:79_<%EW1\\45]#_\ "F_"/_/YK/\ WVG_ ,31_P *<\(_\_FL_P#?:?\
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M9C9Q\W=2>.@[4)XA;I!:!S]]HNI6%E#>7ME+!;3';'(^ &.-V/7H0?H16CX
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M=LT.DVPBW_ZR1CN=_JQK9HJ)UIS5I,')L5?OK]12R_ZU_P#>-(OWU^HI9?\
M6O\ [QK+J+H(C;74GL<UYVWPWA/A"\T\NDFJ7*M$US*[NBQFX\THJD_*#QD
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MK21;9O,(0*&^;@8//09^M%PY6;%%<WJ/B<Z;#JC7EF/-M%#1QPS!S,2&(0G
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M7IQ39;/P_;13B-!=^5#YJ2&Y*^:?/*8P/]C#<<]^E<]_8^H_] V]_P# =O\
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M<, DL.U5+&VF\O2%UG1[QM @:YCD2T@G N)<)Y4[PD^8 1O&#D!N>XKU@
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MFED\M6\OY<Y8+WS@[&(.,=,XS74&LBST#2[6>VN;*W$+0PI%&8I&"M&H^0$
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MSB[#:S% 8_<+E0JYSGK5MM4U6VO$.IZEJMQ$D;BZ>UB?:UL+=2LL8V_ZPRY
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M(4444 %%%% !1110 ^#_ %Z?6HZEM_\ 7Q_6HJ74K[(M%%%,D**** "BBB@
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MBB@#I-'_ .0?%^/\ZNU2T?\ Y!\7X_SJ[7#+XF>W2^!!1112- HHHH ****
M"BBB@ ILO,; >AIU(_W3]* .6^QW'_/,_F*/LEQ_SS/YBK^**ZN=G%]3AW*'
MV.X_YY_J*/LEQ_SS_45>8A5+,0% R23@"LEO$V@HQ5]:TT,.H^TI_C33D]D+
MZI#N6/LEQ_SS_44?8[C_ )Y_J*JGQ1H'_0;TS_P)3_&C_A*- _Z#>F?^!*?X
MT[3[!]5I]RU]CN/^>9_,4?8[C_GF?S%5?^$HT#_H-Z9_X$I_C1_PE&@?]!O3
M/_ E/\:+5.P?5:?<M?8[C_GG^HH^R7'_ #S/YBJR^)M!9L#6M,)_Z^4_QK7C
M97C5XV5T89#*<@_0TFY+= L)#N4EM)]P/E]_44LEI.9'(C/+'N*O#J/K2N/G
M;ZU/.Q_5(;7,[[)<?\\S^8H^R7'_ #S/YBK]%/G8?4X=RA]CN/\ GF?S%'V2
MX_YYG\Q5^BCG8?4X=RA]DN/^>9_,4?8[C_GF?S%7Z*.=A]3AW*'V.X_YYG\Q
M4GV6?[/CRSG?GJ/2K=/_ .67_ OZ4N=@L)!=3-^QW'_/,_F*/LEQ_P \S^8J
M_11SL/J<.Y0^R7'_ #S/YBC['<?\\S^8J_13YV'U.'<H?8[C_GF?S%'V2X_Y
MYG\Q5^BCG8?4X=RA]CN/^>9_,4?9+C_GF?S%7Z*.=A]3AW*'V.X_YYG\Q3Y+
M6<K'B/HN#R/6KE/<?*GT_K2YV'U2'<S?LEQ_SS/YBC[)<?\ /,_F*OT4^=A]
M3AW*'V.X_P">9_,4?8[C_GF?S%7Z*.=A]3AW*'V2X_YYG\Q1]CN/^>9_,5?H
MHYV'U.'<H?8[C_GF?S%'V2X_YYG\Q5^BCG8?4X=RA]CN/^>9_,4^XM9VF<A.
M">.15S%/E_UC?6ESNX?5(VM<S?L=Q_SS/YBC['<?\\S^8J_11SL/J<.Y0^QW
M'_/,_F*/LEQ_SS/YBK]%/G8?4X=RA]CN/^>9_,4?9+C_ )YG\Q5^BCG8?4X=
MRA]DN/\ GF?S%'V.X_YYG\Q5^C%'.P^IP[E.&TG69"8^ ?45']CG_P">?ZBM
M*/\ UB_6FXI<[N/ZI"UKE#['<?\ /,_F*/L=Q_SS/YBK]%'.Q?4X=RA]DN/^
M>9_,4?8[C_GF?S%7Z,4^=A]3AW*'V2X_YYG\Q1]DN/\ GG^HJ_11SL/J<.Y0
M^R7'_/,_F*/L=Q_SS/YBK]%+G8?4X=RG':SA9,QGE<#D>HIGV2?_ )YG\Q6D
M@^5_I3,4<[N'U2'<H?8[C_GF?S%'V.X_YYG\Q5^BGSL/J<.Y0^QW'_/,_F*/
ML=Q_SS/YBK]%'.P^IP[E#['<?\\S^8H-G<'K&3^(J_1BESL/J<.Y0^QW'_/,
M_F*/L=Q_SS/YBK]%/G8?4X=RA]CN/^>9_,4GV.?_ )Y_J*T**.=A]3AW*<MK
M.=F(^B =13/LEQ_SS/YBM&3^'_=%-I*;&\)!]2A]DN/^>9_,4?8[C_GF?S%7
MZ*?.Q?4X=RA]CN/^>9_,4?8[C_GF?S%7Z*7.P^IP[E#['<?\\S^8H^QW'_/,
M_F*OT4^=A]3AW-#2T9+&-7&&&<C\:MU!9?\ 'LE3US2W.N*Y4D%%%%(H****
M "BBB@ HHHH *1_NGZ4M(_W3]* ,:DI:.XK<D^;_ (U^,KS5/$-SHMI,\6F6
M3>6Z(<>=(/O%O4#H!7G$5C<2V_GQ6LKP"18O,6,E=YZ+GU/85N_$6UEL_'>N
MQ3J5;[4[C/=6.0?R-:/@KQ;::'IJV%];RW%I-?+/=1J!S&%&TK_MJX!'_P!>
MOHX+V5%.DKG WS2]YG(16DTM\ME';NUVS^4(=OSE\XVX]<U"X5&97 #*2I![
M$=17I4?CG2%%LXL6#QW_ -JES "SCSS)O#[N&VD+C!Z=<5+'XXT(7BR26EQ(
MRI&);@VL6^Z"O(6B9<X52'5=PY^2E[>K_('+'N><MIURLT,+6KB6:,31H5Y=
M",AA[8!JNR;,;UVY 89&,@]#]*]%'C317M-.C:PFB>U@$4A6-7$_[IT .>0$
M+ KCKDY&<4#QCH]T;?\ M-;QU2TLH]JV\;>4\#@LJ\C*N!U[>E"KU>L Y8]S
MSC"$X^7/I7H?P@\97>@>(K73YIGDTF\D$+Q,<B-CPKKZ<]:M>,=3TZ[\#HNG
MW%E&TLBSM BKO;=)(P48.5*AANR.<#!KBO"=K+>^*=(M[=2TCW<> !GHP)_0
M&FY*O2ESJP*\9*S/L<<,,^M+)]]OK1_'^-$GWV^M?.'>)16+XP?54\.W;>'F
MB74_E\KS"HR-PW!2WR[BN=N[C.,UQUK\0'M[2UABAN-0FNLP6CW86&62[6<1
M26\BH-H*!@VY<@@$T@/2Z*\ROO'FL\6\5AI]EJ8U2VLVMKJ1R5AE=U$A8+M(
M;9PRDCD]Q4DGQ(NPNN7$.@R26.FK=@3;RH,EOU#$C #G(&,D<9ZT70'I-%<!
M;>-M676Q9:CI%C'$FI0Z;++#=LYW31>:C*"@R , Y[]*/ _BZ^UYK"VA@@*I
M:17-Y-=W&)6\QG"B,*H#$;.3P.<47 [^G?\ ++_@7]*;7B?Q)^(?B+0?&-]I
MNFW$"6D0C**T"L1E 3R?<UM1HRK2Y8FE.FZCLCVRDKYN_P"%L^+?^?NU_P#
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M"8(P\H);[1;?N<<D#YOG(/&>F:3K23LXAS/L<)N'K4T=O-*A>.&1T 9BRJ2
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M.* /1L>U!!'4$5Y+:Z?XJM-3$JQZA-97NJVJS1,Q)MUC2(^:O/\ JVPZL/4
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M:>\32;HZ9&LE\4*P*QPH<\ GV&<GV%<AI=CXHLHULFFE6*PC_=/$X=+HF52
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M-B],#YOI5#4/%VH7$8@M+:2&5[9)7*QG?#)^Z8CGJI#D=!T/H: /0:*5QAV
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M3KBZ:ZN+&VEN63RVE>,%BN",$_0D?0T 8,WBZ9&G4Z;)"UO \LI>56V8*8&
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MK2 ;1113 **** "BBB@ HHHH *=+_K&^M-ITO^L;ZT@&T444P"BBB@ HHHH
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M_P#0;?\ [\I_A1_PMKQO_P!!M_\ ORG^%<I=Z/>V>CV>IW,21V=X2("9%W.
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MU8KX\[0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KF/'4<LWAS5(X,^:]K*J8]2AQ73U2U"'S
M(SQ50ERR3!['YQH,(H/! P:6N]^,G@JX\'^*[ADC;^RKR1I;67' R<F,^X_E
MBN"K]-P]:->FJD'HSRI1<79A1116Q(4444 =#X&O&LM;=Q>Z;:QR6\D4HU)&
M>WG1L9B<*">?7VZUW_AG4?!6DZK?26VI1QZ=)=!)K28.T;P^3@F,%"SCS"P
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M1_PSOK'_ $&[/_OR]?67D+Z"C[.OH*[?[<QG\WX$?5X=CY-_X9WUC_H-V?\
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M0['R;_PSOK'_ $&[/_OR]'_#.^L?]!NR_P"_+U]9?9U]!1]G7T%/^W,9_-^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
G**** "BBB@ HHHH **** "BBB@ HHHH **** $-%%% "T444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>image00020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" &P K0# 2(  A$! Q$!_\0
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M$5U-;K8^4KOFJ2?F%%%%,R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** ,37?"VBZY"8]1T^!R6W>8J[7!]=PYJSH&AZ=H%C]DTFV2W
MASN;')8^I)Y)K2HHL4YR:Y6] HHHH)"BBB@ HHHH ***I:OJEGI%C)=ZA/'#
M"BDY=@,X'09ZF@:3;LB[17DOA[XPV][K7D:K;16=C*3Y4P<DQCMO[<^U=_H?
MBK1-=N9(-*U"&XFC&XHN02/49ZCZ4DTS6IAZE/XD;=%%%,Q"BBB@ HHHH **
M** "JUE?6M]YWV.>.;R)##)L;.QQU4^XJS7#?"S_ )FK_L.7/_LM7&-XN78E
MO5([FBBBH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P=>\(Z'
MKID?4M.ADG==IF VN/0Y'>L[PC\/]'\,WC7=L)KB[(*K+.V[8OHH[?6NOHI6
M6YHJTU'E3T"BBBF9A1110 5SOC/Q;I_A:P:6\DS<LC-# H+,Y ]N@SWKHJ^?
MOCM]L;Q?$9H9%M_LZQVSKP'[MD^H/:ID[(Z<)1C6JJ,MB7PI\6]235&EUPFZ
ML).76&(#R?3;Z_C7IG@WQ_IGBF^DM+2*XAG6/S5$JC#IG&1CZCBOF2**9-T$
M65DZN<\'Z>]>I_L_V<\FOWEXT,AMX;;R1*5PJL6'R@]">*B,G>QZF-P=&--U
M$K,]XHHHK4\(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@L-.B$5M",*N<_4D]S5VBDDD7.K.:M)W"BBBF9A1110 4444 %%%% !1110
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M?_1HMF$ [,X/4^W3ZUUTO8^RESRL^UC*7-S*R/558,H92"I&00>#2T  #
M'  KSWP]\6= U[XCZCX,LH[P:C9>8#,R#RI&3APISGCW'.*Y#4]"HHHH ***
M* "BBB@ KA_%'PTT?7]<?64O-7TC5)4$5Q<Z5>-;M<(!@*^,@\=\9]Z[BJ&N
MV4^HZ1<VEG?SZ=/*NU+J *7B.>H# C\Z .<\3?#K1?$%II27,NHVUYI:>79Z
MC:W;1W40P ?WG.[.!G=G--D^'6ES:3HMA=7VKW0TK44U.*>XNO-EDF4DC>S
MY7GH,>V*XCX66_B6]\4>)VU3QGJU]:Z#J4EDEM)'$$N%\H$%R%!!RV>,=!69
M\&_B=>6?@_P?;>(;#5[R#5+I[$:W/*'5KAI7V(03O(P -W3C':@#U&]\!:7<
MZWK&IQ7&HV<VK6ZV]XEG<&%9"I&V7@9$@ QN!''6H/#/PYTO0]>_MN:^UC6-
M66-H8KK5;LSM"AQE4& %SCKC/O6+KOQ=L]+U35E31[RZT;1YUM=2U*.6,""0
MXR%B+;Y NX;B!QSUKTR-UDC5XR&1@&4CH0: '4444 %%%% !0>E%% ')Z?K\
MT5W,+L%X&<X(ZIS_ "KJ+>>*XC$D#JZGN#7&7%O]GU&X@<8^8LI]0::J36K^
M9:R-&W?'0UZ%2A"=G'0\JEB*E.ZEJ=S17+VGB62,[;Z+<!P7C[?45OV5];WJ
M;K:57]1W'X5R3HSI_$CNI8BG4TB]2S11161N%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7&:_KD\]Y):63F.&,[6=>K'OSZ5V9Z5Y;;YCNI%D^^)"&^N:[<%3C.3<NA
MM1BF[LR+WQ%HMIK!T^^GD\\$*\A4E$8]BW:NG6&6T826<KQGJ"K<'^E>!:W,
M8]2U*.[&)S<2%PW4Y)KVWPI]HB\)Z4E[N%PMNH8-U'IG\,5]!CL'&A3A.+O<
MTA+F;3.Z\.:J=1@=)@!<1'#8Z,/6MBN(\(N?[>D"_=:(Y_,5V]?-8FFJ=1I&
M-2*C*R"BBBN<S/"OC+X&GM9[[Q!I\D1M)W5IX&X978@%AZ@GFO)1!/;F4*^=
MJC>1U^@K['U"SM]0LIK2\B6:WF4HZ-T(KS/6_@[I\K+)HEY-9R$_.)3YJL/Y
MC%92AK='LX/,(PAR53RGP.&B\6Z(VDL5NFN$4%!G*D_-GVQG-?55<OX)\%:9
MX3LPEK&LUX<F2Z=!O;/8>@]JZBKBK(XL;B(UYWCL@HHHJCC"BBB@ HHHH **
M** "BBB@ HHHH **** (+ZUBOK&XM+E=\%Q&T4B^JL,$?D:^-OA5KDOP/^,F
MK>&_$C-%H]VX@>9A\JC.89_]W!P?3)]*^T*\S^-?PETSXF:7&7D%GK5JI%K>
M 9&#_ X[KG\1V[@@'I44B2Q))$ZO&X#*RG(8'H0?2G5\6:?JOQA^"I_L^2RG
MO=&C;$:R1&YML?[#KR@]LCZ5;G_::\=:HPL-(T'3HM0?Y0(H))I,^R$_T- '
MT?\ &#XA6'P[\(W&H7+HVH2*8[*VS\TLN../[HZD_P!2*\7_ &._"EW/=:SX
MYU96+W9:WMG<<R$MNE?\P!_WU6%X/^"WC7XD>(DU_P"*-U=6UF2"T<[8N)5_
MN*@XC7\O8=Z^M-*T^TTG3;:PTVWCMK.VC$4448PJ*.@% %JBBB@ HHHH ***
M\P\:>,O%EM\1HO"_A+3]%N6&F?VE(^HS/'E1(4*J5XSTZCUH ]/HK@?#'Q-T
MK4/AY!XJUS;H\#2O;R1N_F_O5<H5C*C,F2#C R?2MJS\<^&KOPW<Z]%J]N-*
MM25N)I<QF%ACY75@&5N1\I&>10!3\%^$[CP_J7BZYGN8IEUO46O8U12#$I0+
MM;/4\=JY#2_A3J-EX$\$Z"VIVC3Z!K":E+*(VVRHLCOM4=0?G')]*[&S^(_A
M2[\,W'B"+5T72K>3R99I8I(RKG&%V,H8DY& !SD8I\/Q#\+2^&[O7DU5!IEG
M(L5S(T3J\#LP4!XRN]3EAU'?/2@#AM6^#@;Q7JFI:?#X9O+75;K[5.-8TO[3
M-;L<;O*<,,J<9VMP":]BC18XU1%"HH"J , "N7TGXA>%=7N-2@TW68+B73HS
M-<*JMD1CJZY'SK_M+D5F^!/BEX>\7Z+=:E!)-916J/+<?:XGC2.,,RAO,("'
M(7/!.,\T =Y17*>%?B%X6\53W$&@ZO%=3VZ>8\91XV*?WU# %E_VAD4_PSX^
M\,>*+V.TT#5X+ZY>V^V>7&K96+(7+9'RG)'RG!]J .HHHHH **** ,O7--^V
MP^9" +F/[A]?8US*7)5O+G4I(O56&"*[JJMY86UXN+B)6/9NA'XUT4:_(N66
MQR5\,YOF@[,^??%&FZEH&MW&HZ>;@P32&5)DRP!/)1QZ?TKMM$O9;O3;/4X%
M>VFE0,4Y&#W'TXKL;KP]+'EK&8D?W'_QK$NEE@?9=1-&WOT/TKT85HU%9'D3
MP\J3;EH='X>UU=0;[/< )=*,^SCVK=KR\RM:W4=Q$</&VX5Z9:RB>WBE7HZA
MA^-<.+HJFU*.S/3P.)=5.$]T24445R'>%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5%=7,%I"9;J:*&(<%Y'"J/Q-2UY?\
M1SI=OXZTF[\9VC7/AA;&5(S);M/;Q71<<R( 1DIPI(]:J*YG83=CTFXO+:WA
M66XN(8HF("N[A5)/3!-/2:)Y6C21&D4!F0,"0#T)'O7C^O'PU:^,K.X\4:?Y
MGA6328X])\VR>2VB?>=Z^7M.V0KLQD X&!5JR\1:)X;^*VN#4)C90WNGZ?'9
M@V\A#@>8 HPIQC<O!QC-5[/L+F/55N8&N7MUFB-P@W-$'!91ZD=<4X31F8PB
M1#*JABFX;@#T./2O%(=6\,7OQ4\W2;:*SO-.GN#^[MW2YU6Z*,"F_;@1#G[Q
MP6Q@ #)L_#*XU*7XK:M<:MHFK6=[>Z5#)<R72IL1Q))A5VN?DQA5 Y^4D@9I
M^RTN',>RT445D4%<%XNTR2SOVO(E)MYCEB/X6]_K7>TV1%D0I(H96&"",@UM
M0K.C+F1<)\KN>3-:V%Q<I<W%I;RW"?=D>,%A^-7+B[&.M=A=>$].F<L@EAR<
MXC?C\C5C3_#VGV3ATB,D@Z-*=V/Z5Z,L=3:OJ;^VCNBCX-TR2WBDO+E2LDPP
MJGJ%_P#KUTM%%>74J.I)R9SRDY.["BBBH)"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ KY$\*%+3]M#4%Z![JY QZM 3_6OKNOD;
MQ$3IG[:-DZ%4\^Y@SQU#P!3_ #H ^B?BWXQ'@3P#J>O"-99X5"6\;='E8[5S
M[<Y/L*\F_9M^-&L>.?$%_H?BDVSW7DFYM988_+R 0&0@<'@@@^QI/VU]1:#P
M)HM@I(%U?F1O<(A_JPKQ_P"$^GR^!?C_ .%+5Y3LNXH6+-@;EN+?./\ OIL?
MA0!]8_&CQL? 'P_O]:@C26\!6"U1_NF5C@$^P&3^%><?LT?&+5O'NHZGHWB<
MV[W\,8N;>6*/R]Z9 92!QP2I!]S63^V[J)B\->&]-5F'GW4D[ ="$0 ?^AUY
MS\&=/;P)^T=I6DR2LRS0B(L?XO-MPX_\>(_*@#Z;^.GCR3X>^ +G5K1(I-1E
MD6VM%DY7S&S\Q'<  G'M7$_LS_%W5/B"^JZ7XD\AM2M%6XBFA38)(R<$%1QD
M''/O[5R?[;VHG[+X5TI&.7DFN&7L<!5'\S7(_ FQ/@?]I+^P&D=@T$EJ3GJ3
M")1G\10!]HUXU\0OA@GCKXK&;6K&5M#_ + :WBO$EV^3=>;E2 &!)"DGD8KV
M6B@#P;6/!WBS6/ /ANS?36L-5\+:D"8]/N([<7L2*5$UNV"J,0<X8#G=ZU%=
M?#O5]0\#:U-8:?JRZU=:G:7[V^OW\,KWH@(^5C&-JY''.<[1G%>_44 >/>/=
M(\4?$#P?83QZ'=:%J.F:K#>QV9OHA-.B#!*R*"J/\QVDY^[SUKBO'?AZ?3?@
MW\0-5OK/7[:^U(6:2-K5[#<2RB.5 I_=#"@9QR22 .E?2U9^OZ+IWB'29],U
MJTCO+"?;YD,F=K8(89Q[@'\* /,O#.C>(M:^)6G:]JNA)H5EI6D/IZ$7*2_:
MG<CE O\ RS '&<'IQ6!H_@WQ5J'P5U7X?7VCG3KNV1OL]])<H\%VWV@RA0%R
MP!'!R.]>]HH1%5!A5& /04M 'C^DZ3XE\1_$#1]>U7PVOAVUT73;BT\LW,<C
M74DBA=JA/^6:XR"<?2MWX!^&[OPM\+M(T[5=/6QU1/-:YC^4L6,C$%BI()QM
M[^E>AT4 %%%% !1110 4444 %175M%=1&.= ZGU[5+133:U0FDU9GGWB/1Y=
M/):,%[8]&[K[&NXTOC3;7/\ SR7^0J>1%D0I(H93P01D&E4!5 48 X %;5:[
MJ049=#FHX6-&I*<=F+1116!U!1110 57MKVUNFD6VN8)FC.'$<@8H??'2N=^
M*<&J7/P[U^'0?-.I/:,(1"<.?4+[D9 ]Z\OU)?#=_P##+5X?AQIDD&I):VZW
M\=K9R07#0AQYD98@%GV[\\D]:TA#F5R7*S/;X]3L)8VDCO;5XU8(6652 QZ#
M.>OM4MU=6]G%YEW/%!'G&Z5PHSZ9->$^,KGP9+\/I+CP38Q6]O!J>G/>>18O
M%@+*"-P*@L5 .<9/K6O\3O&?@S6-"LI5M;76;F:26VM)+RTE,%LQ4!Y) 5S@
M CH"2< >HKV3;5A<Y[#-/###YLTL<<7'SNP"\].:DKYG\??:W^'^D:=IEGK.
MK>&M,MK5K;4(D&RZG$J@M(K,' 4 A1M/+<\#-?2=K*9[6*5XI(6D0,8Y,;D)
M&<'!(R/:IG3Y4G<<97=B6BBBLR@HHHH **** "BBB@ HKSKP+X2TC4_!^D7M
M]'=2W4]NKR.;V8;F/4X#XKK=&\-:9HUR\^GQ3)*Z;"7N9)!C.>C,1VJYQ49.
M-]B4VU<V****@HX2Z^)^C6GB2XTBYL]4C6WO(["6^, -LD\@!12P;/.1V[UU
MT>K:=+J4FGQW]H]_&NY[99E,J#U*YR!^%>4ZA\--3/C/4_$]O%9SWHUB&]M8
M)YV\J: 1JCAUQM5P<LK8)! YK-_X5[JFA:]J.JZBIOM)MKB\U-9K:8?:'\R-
MP8S&(][G#;?]9C@$ 5NX4WLS/FDMT>N1^*?#\DDJ1Z[I3O"I>15O(R44=2>>
M .]5/&'B^Q\.:)>7^4O9+41,]M#*OF!9'"JQ'8<YSWQ7@G@;1IM?T^_T*-;.
MYO[SP^UG!?6UPLL5G&I!6.95B4JQ)ZDLW!KM;[P#XJU>U\137\.EV]UJ5E86
MT4,5RSJA@EW-N8H.HY''?'O0Z48NS8N=M:(];&LZ6=2?3AJ5E_:"+O:U\]?-
M5<9R4SD#'M6=I?C+P[JFEW&HV>LV+6-M*T4TSS*BQL&*_,21C)'&>HY'%>?3
M?#_Q%=_$B'7+XV,MM;ZL;I9A.0S6IC*B/R@F 5[DL=U9K?#'Q$OA.VTR"'2X
M;C2M7>_MVBE 6^C9I"/,W1D(RAP!D..*7)#N/FEV/7]0\0:58:?'>7&HV203
M+FW9KA%6<XR A)PQ/M63I_C?39OA_;^+M0WV&GR6XG97^=DR<!>.I)P !ZUY
MW%\,]:LX]!G@L-*OF@M[RWGL=1N"\<#3R;_,C81@'']T*.#@$5T7_" :A<_!
M:P\*37%O!JMI%$4D&7B$L<@=<]"5) %')!6U"\NQU&A^+K;4K&[N[VPU+1+>
MV"LTFKQ+;J5;HP.XC'U(([U'K'C.RL+_ $2"V47T.JI<217%O*K1@0QF0\]\
MXQQ7+>+O#_C'QGX5%OJ=MI6G7UI>07<$4%TTL=QLR6#EH\+DD$95AD<YK/T7
MX=ZS:G0Y72")X+C4;BZC-R) K7$.Q=A6-!@MR0% 'O0HPW;!N70[SPWXRTK6
M=&T6\FN;:PN-6A6:WL[BX02MGL!GYOPKI:\6T?X=:_I^H^#)K>WTZ&YTVUM[
M:_O&N/-$D<;$M&(FCZ\_*X92,U[34323]UE1;>X45'<PI<V\L$P)CE4HP#$$
M@C!Y'(_"N;_X0/P__P ^UU_X'3__ !=2K=1N_0ZBBN*UKP3H=OHU_-#!=+)'
M;R.C?;I^"%)!^_70>$G:3PKHSR,6=K*$LQ.23L'--I6N@3?4U:***D84444
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MZ K]22N=\9^++7PI!8/=6=_>RWUR+6""RC#R/(02!@L!T![UT5</\4/"$WC
M>'K=0IM+74EN+L><T3^4$8'8R\[LD=Q3A9R][8)7MH:FC>-M"U3P_'K)O8[&
MS:5K=_M[+ T<JDAHVW'&X$=,UHZCK^CZ9Y7]I:MI]IYJ[X_/N4CWKZC)Y%>/
MWOPR\1IHF@V]H-/>30YKJ&.,2*@NX9?NS,6C=5EQG=E3G)((S7'>+],71+_^
MR)8XVAL]'M;6[L[B\"RWFUFD6.W9H6+XSMR@0YX-;*E&3]UF;G);H^E?[:TO
MRY)/[2LMD;(CMYZX5GQM!.>"<C [Y%8VE^-=,NH]9EU"6'2X--U%].:6[G1$
MD=0#D$D 9STZ\5Y[K7@?Q+JEWJ[6%MIT6FZQ>6&J'[1*R30&(1[H2@4C/R_>
MSVQBK&L> ?$D_P!OCM_L4ME>:_<:A-;M<&(R0O&%C._8Q4JP)*@<CC-2H1ZL
M?-+L>CW7BK0[;6=.TJ?4[5+[4(S+:QF0?O5&!P>G.>!WYQG!J[;:QIMU<7-O
M:ZA9S3VO^OCCG5FA_P!\ Y7\:\J\.?#O6M%N_!5PUMI=V^F6,VGWA:0AHPT@
M998R5.XJ!P#CKUK'T7X0Z[#:ZAI]Y<P1@:==V-K?Q3C]YYQSEXQ$&]R6=B#G
M'6CDA_,'-+L>J:3XST[5_%TVB:8\5VD5D+S[9;SK)&<R%"GRD\@BH&\>V#^(
MIM(L-/U?46MYUMKJZM+7?;V\AQ\KOD<C(S@''>N>^&_@_6-'\5MJNIZ9HVF0
MG2(M/\G3I"VYT?.]LJO4?ETYJWX?T/Q3X7\0ZI;Z9;Z7>Z#J6I-J!GFN'CGM
M_,(\Q=@4A^G!R.O-#C"[L-.1UUYXATV%-26&]M;F[L(7FFM8IU,JA1GE<Y'X
MUS_ASXA6.L74<<T!L(6TB#5WGN)5"1I*2-I/8C'7I7":!\+=<TW6KC[2\%Q;
MQ"^>VNUN55I&N%88D3RMQ^\,YD(XR!4X^&FK'2VM[VRL[Y#X>LM-, O&AS/#
M)N)#A#@#@@X.2,$4^2&UQ<TNQ[%87MKJ-I'=:?<P75M)RDT$@=&^C#@U8KFO
MAUI>J:-X1LK+7I+:2_C+ES;H%4 L2H.%4$@$9; R<FNEK%JSL6M@HJIJNG6V
MJV36EZKO Q!(21HSP<CE2#6%_P ('X?_ .?>Z_\  Z?_ .+H5NH._0ZBBOF3
MXQH_A_QA]BT>YO+:U^SQOL%U(WS'.3DL3VHKT:>6NI!34MS"5?E=K'NOPS_Y
M)_H/_7HG\JZ:N9^&?_)/]!_Z]$_E735Q5OXDO5FT/A04445D4%%%% "*JKG:
M ,\G I:*"<#)P /6@ HK$O/$VGV[E$+SL.OE+D?GTJNOBRV)&ZUNE7N< X_6
MM50J-742E"78Z.BJ6G:I::@#]FE!8<E",,/PJ[6;3B[,336X4444A!1110 4
M444 9_B/_D7M4_Z]9?\ T U!X/\ ^12T3_KQ@_\ 1:U/XC_Y%[5/^O67_P!
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M/6*-<;408Z8'2GT4AB!5&,*!C@<4M%% !1110 5\^?MI:2;OX=Z9J*+DV-^
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M:I_UZR_^@&H/!_\ R*6B?]>,'_HM:G\1_P#(O:I_UZR_^@&H/!__ "*6B?\
M7C!_Z+6J^R+J:]%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** *NK?\@J\_P"N+_\ H)KF?A!_R370/^N'_LQKIM6_Y!5Y_P!<
M7_\ 037,_"#_ ))KH'_7#_V8ULOX3]5^3(^T=A1116)84444 %%%% !1110
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M4E#A@SKY8!_V<OQVVBMB.\N/[951=3->&[:-[,_<6WR</C'I@[L\GCVKJJ*
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M&[5?^_-O_P#&ZZBBES,?*CE_^$<U;_H;M5_[\V__ ,;H_P"$<U;_ *&[5?\
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MYM__ (W1_P (YJ__ $-VJ_\ ?FW_ /C==111SL.5'+_\(YJ__0W:K_WYM_\
MXW1_PCFK?]#=JO\ WYM__C==111S,.5'G_C&RUO0O"^IZI;^*M2EEM8&E5)(
M8-K$=CA,U>TO1-8O-,M+E_%FJ*TT*2$"&# )4'_GG[U8^*G_ "3KQ#_UZ/6S
MX<_Y%[2_^O6+_P! %:W_ ':?F1;WK&1_PCFK?]#=JO\ WYM__C='_".:O_T-
MVJ_]^;?_ .-UU%%9<[+Y4<O_ ,(YJ_\ T-VJ_P#?FW_^-T?\(YJ__0W:K_WY
MM_\ XW7444<[#E1R_P#PCFK_ /0W:K_WYM__ (W1_P (YJ__ $-VJ_\ ?FW_
M /C==111SL.5'+_\(YJ__0W:K_WYM_\ XW1_PCFK_P#0W:K_ -^;?_XW7444
M<[#E1YKKWPFM-?OOMFKZYJ5S<[ F\K$ORCH,!0.]%>E45M'%UHJRD0Z4'K8*
M***YS0**** "BBB@ HHHH *X35/^2S:)_P!@J?\ ]#%=W7":I_R6;1/^P5/_
M .ABMJ.[]'^1$^AW=%%%8EA1110!Y5\8OBA_PB1&E:*(Y=9D3>[N,I;J>A([
ML>P_$U\ZZMXFUS5YGDU+5[ZX9^H:9@OTVC@"F^*]0EU;Q/JM]<,6DGN9&R>P
MW$ ?@ !657U&$PD*4%IJ>?4J.3)//F_Y[3?]_#_C1Y\W_/>;_OX?\:CKU_PQ
MX;T*6?P2][I<4\5WI=W=7:9/[YH\E2>>HQ6E>K"BKM$QBY;'DGGS?\]YO^_A
M_P ://F_Y[S?]_#_ (UZAKG@[3--\/\ B.^@@6>UDGLKC2[DDY%O,QRH^GW3
M]*VO$_A?2[7X@:+I4?A[1H-)GU"*+S(;DM/*I3+*Z;LJ,]\#H*Q^N4^B+]G(
M\5\^;_GO-_W\/^-'GS?\]YO^_A_QKH+?0AJGQ%.AV:".*746@55Z)&'.?R4&
MN]\7>$=*C\4>%+BPT633]*O-0;3[BTF1UWE9<!OFYPZ=_:M)XBG"2BUNKDJ#
M:N>1>?-_SWF_[^'_ !I/-EW9\V7=TSO.:]K;P/H4?Q,\]["/_A%S:B46VX[1
M*9/(\O.>N_GK4-GX,T2^T7QK!'80IJ$.I7%MITH)S'Y:;P@Y[A2._6LOKM+M
MV*]E(\;\^;_GO-_W\/\ C1Y\W_/>;_OX?\:],U_PMIEC\)["6&Q7_A(S/;">
M;)WYF#.J8Z?=*]JT/B%X,T_1/#$=Q9:,\=SHL]O'>S2HX2^5T!8YZ$!^#M]:
MI8NDVE;=V%[.1Y'Y\W_/>;_OX?\ &CSYO^>\W_?P_P"->F^)O["3P?X7O+7P
MMI=O<ZWY@D=&DS#MD"_)ENX]:OZ]X<\/Z!>^,]7DTB.[MM-NH+2ST]G9859T
M4EFP<GKTS0L5#K'\N]A^S?<\C\^;_GO-_P!_#_C1Y\W_ #WF_P"_A_QKU[1_
M#/A_5=8\&ZNFDI#8:O%="YTWS&:,20J>4).<'TJEKOA#2K'P_P"+-4L[=9;&
M2"UO-)G).8DD<AT'/4'*G/M26,IM\MOZO87LW:]SR[SYO^>\W_?P_P"-;FA^
M,_$6AW"S:=K%XA4C,<DADC;V*MD5S]%=DJ<)*S1"DUL?7/PG^(4'C?39$G1;
M?5[4#SX5/RL#T=?8^G:N]KX]^#6HR:;\2M%:)B%N)?LT@'\2N,8_/!_"OL*O
MFL=AU0JVCLSNHS<XW84445Q&H4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !6'XL\0P^'[ 2,HDN9/EBBSU/J?85N5XW\2KI[CQ3-&Q.R!%11Z<9
M/\ZZ\#05>JHRV.3&UW0I.4=S+U3Q!JFI2E[J\EP>B1L54?0"LSS'_P">C_\
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M?5Q?,KH****0SE?BI_R3KQ#_ ->CUL^'/^1>TO\ Z]8O_0!6-\5/^2=>(?\
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MP7=#]EB^S.9O+F6\NYKFX.Z65B[$#')J&NL_X0#7?[EK_P!_O_K4?\(!KO\
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M/J?SKF9H6Z*J;CZG\Z-Q]3^= %NBJFX^I_.C<?4_G0!;HJIN/J?SHW'U/YT
M6Z*J;CZG\Z-Q]3^= %NBJFX^I_.C<?4_G0!;HJIN/J?SHW'U/YT 6Z*J;CZG
M\Z-Q]3^= %NBJFX^I_.K,?W%^E #J*** "BBJOF-_>- %JBJOF-_>-'F-_>-
M %JBJOF-_>-'F-_>- %JBJOF-_>-'F-_>- %JBJOF-_>-'F-_>- %JBJOF-_
M>-'F-_>- %JBJOF-_>-'F-_>- %JBJOF-_>-'F-_>- %JF3M(L+F%%>4*2JL
MVT$^F>U0>8W]XT;V_O&@#Q+QWX_F'B711J.A7%E<:/=FX>)Y@?-!4K\IQC'/
M6O6?"&M7VO:?]MO-)DTR%\&)99-SN/7&!@?6I=2TG3]3N+6?4+."YFM6WPO(
M@)0U?WM_>-=5:M2G3C&$+->9G&$DVVRU157S&_O&CS&_O&N4T+5%5'F*(SN^
MU%!+,3@ #O0DQ=%='W*P#*1T(/0T 6Z*J^8W]XT>8W]XT 6J*J^8W]XT>8W]
MXT 6J*J^8W]XT>8W]XT 6J*J^8W]XT>8W]XT <_\5/\ DG7B'_KT>MGPY_R+
MVE_]>L7_ * *Y_XGLQ^'GB'))_T-ZV= =AH.F8)_X]8O_0!6S_A+U_1$?:-B
MBJOF-_>-'F-_>-8EEJBHX22IR<\U)0 4444 %%%% !1110 4444 %%%% !39
M?]6:=39?]6: *M%%% !7">+%U6Q\>Z7K.G:+=:I!#82V[K RKAF;/4^U=W15
MTY\CO:Y,E='%_P#"7:]_T(NK_P#?^*C_ (2[7O\ H1=7_P"_\5=I15^TA_(O
MQ_S%RON<7_PEVO?]"+J__?\ BH_X2[7O^A%U?_O_ !5VE%'M(?R+\?\ ,.5]
MSB_^$NU[_H1=7_\  B*C_A+M>_Z$75_^_P#%7:44>TA_(OQ_S#E?<XO_ (2[
M7O\ H1=7_P"_\5'_  EVO?\ 0BZO_P!_XJ[2BCVD/Y%^/^8<K[G%_P#"7:]_
MT(NK_P#@1%7#?$[Q3K0DT2\;1;W1)[2=Y(I9Y%82' ROR]L=?K7MM8NO>';3
M7-0TJ>_'F16$C2K"1P[$ #/L,9Q6^'KTJ=12E!6^?^9,X2<;)EOP_?3:GHEE
M>W5J]I//$'>%NJ$_YS5^BH;RX2TM99Y/NQKG'K[5R/WI>ZC5)[$Q( R2 /4U
M"+JW+8$\1/IO%<#?WMUJ$I>=SMSP@/RK^%4/,A\[R?.B\[^YO&[\J]&&7-KW
MF="H::L]3HKA]&U>?3Y DK-);$X93R5]Q7;HZNBNA#*PR".XKCKT)479F4X.
M#%HHHK @**** "BBB@ HHHH **** "BBB@ HHHH *M1_ZM?I56K4?^K7Z4 .
MHHHH *IU<JG0 4444 %%%-DD2,9=E7ZG% #J*A^U0?\ /9/SI/MEO_SV3\Z5
MT.S)Z*B6XA;[LJ'\:E) &20!ZFF*P45&9XAUE3_OJF?;+?\ Y[)^=*Z'9D]%
M-CD23_5NK?0YI68+]X@?4TQ"T4SS8_\ GHG_ 'T*7S$_OI_WU1<+#J*175CA
M64GV-([K&,NRJ/<XHN.S'45#%=032;(I [8SQ4V1ZC\Z2:>P--;A14+74"YS
M*G3/!S51-7MI,^6LK@=PE)SBMV4J<GLCSGX\:_J%CI]OI5K')#:7BDS7(Z/C
M_EF/3U/M6WI_BS74L+5$\$:K(JQ(H=9XP& 4<UN^(;/2O%&CW&EWS!1(/EW<
M-&_9A[BM:V:*VLX(FFC(CC5-VX#. !79]9I.C&'*KJYC[*:FVSE/^$NU[_H1
M=7_\"(J/^$NU[_H1=7_[_P 5=>+F ])XC_P,4X31'I+&?^!"LO:T_P"5?>_\
MQ\DNYQW_  EVO?\ 0BZO_P!_XJ/^$NU[_H1=7_\  B*NS5@WW2#]#2L0HR2
M/>G[2'\B_'_,.67<XO\ X2[7O^A%U?\ [_Q4?\)=KW_0BZO_ -_XJZ\W, ZR
MI^=,-[;#K.GYTO:T_P"1?C_F')+N<G_PEVO?]"+J_P#W_BH_X2[7O^A%U?\
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M6CRG]/UH 913_*?T_6CRG]/UH 913_*?T_6CRG]/UH 913_*?T_6CRG]/UH
M913_ "G]/UH\I_3]: &44_RG]/UH\I_3]: &44_RG]/UH\I_3]: &44_RG]/
MUH\I_3]: &44_P I_3]:/*?T_6@!E%/\I_3]:/*?T_6@!E%/\I_3]:/*?T_6
M@!E%/\I_3]:/*?T_6@!E%/\ *?T_6CRG]/UH 913_*?T_6CRG]/UH 95J/\
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MFD(W>:&4KDGC&./6N[HI.K)[AR(****S*"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>image00021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" %1 PD# 2(  A$! Q$!_\0
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M&K^JUND2?:0[GHE'^>M>=_\ "WO"_P#SVN/^_1H_X6]X7_Y[7'_?HT?5*_\
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MA;_GM<?]^C1_PM[PM_SVN/\ OT:/JM;^4/:Q[GH=+GBO.O\ A;_A?_GM<?\
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M@Y(].M9^FWUO!J=W))=2FVD.[#PAQ,,Y(<$U['_PI/1_^@A>X_"C_A2>C_\
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M8/MP:=NYQ^%<[:^((SI\]Q($/ERF-$0G)]/QH7Q+ P9UAF\@'8)/5L XQ^-
M'1;A1NKFQK5PUO)F%(Y&NOLZ!CD(, Y/YT^;4KI7O55H0;./+;AS(V,Y ]*
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M;"U*%Q\2H86U\2Z/=QG3'CBA24[6N&D.%Q_=&>]177Q/6UT:.ZET:[^UI?\
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MP!R,=0/6K5]]O-\;NP+;&1-L;+][GGZ<4 ;^_P!:7>*XU[[6XY+=+IRLLSL
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M,"WB@;]W%R\P/WA_^NM'1+VZNKFX^TJ5155HE*;3SU^M;3(":-HH 5>1S2T
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MO["LVVCS)&\M0APX)*=E/TJU+H]G+"\4T?R-$(BN?X0<_P ZQXM/U"&.-[.
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M?% \1Y5I?LK_ &<';NW#); (_#FN@FMH9DV2Q(ZYW8(XS0+:$)M$:[>XQUH
MYT:S=M:2.SQ1,UUY.\$,L2X')-.FU*Z22[47D0^RQY52F#.<9W?3Z5O+9VZP
M&$01^4>"FW@T?8K;,9\B/,8VK\O0>E '*QZY??V7Y[2XD2104D0*Q!QU&>!S
MUKL(6WH&]0#C'2H7LK9RA>%&V=,BIU 48'% "D U!=AQ;R>3CS=IV$],XXJ>
MD(R.: .0C,OV6T9TN]@DVW@!.\MCC'^SFG?:7BM]1BN8KN0^;F$*#RI P0:Z
MW:*0*!T&* .:M1J/]HV;R+++;1QLN0P&XXZL#W[5';7NKW3.%'DJ'8[WBY(
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MAQ76E03GFA5 ''KF@#E&O]5BF2VAA=46$@O(F?FQD$'OFI[6YU*19B&D5W5
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MC5/^@79_F:/^%T:I_P! NS_,T?V7B.P?6(=SW?[5#_ST%)]JA_OBO"#\:=4
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M!\:M4)_Y!EGZ'D\&E_X75J@ZZ59C\33_ ++Q'8/K,.Y[M]J@_P">@H^U0?\
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MI\MKJ>ISW$TTD<'E1LC8? PG5>O\Z3O?X@T[%BXM[.+Q)':B!8[:Z@6-68Y
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M_H$67_?L4?\ "'^'_P#H$6?_ '[%']JT_P"0?U=GS''XD:*/]Q;VZ3JOEQS
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M\JF)5<6_V:([MQP2"2QZGIP*PUD11]]:^N/^$0\/_P#0&LO^_8I/^$/\/_\
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M.:?YC_\ /+_QX4 /VC;@53;3+5I)7,.3*,.,G#?4=*L^8_\ SR_\>%)YC_\
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MJ??-1S4GK8KW[E#^T[__ )_;G_OX:/[2O_\ G]N?^_AK8F\*W+M<-92QO!$
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MWR?\\C_WT* )<"C ]*BWR?\ /(_]]"C?)_SR/_?0H DVJ>HI<"HM\G_/(_\
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M#(6ZYQV]NE '16&JVE^66VE5W0 R*#DIGL:OUS^E>'[?2KZXNK>20M,BQE<
M+@=#QWK<$@&<X&.Y- $F*,4SS1C^0]:/-';GUH ?BC%,$JDD97(ZC/2E\P#J
M#0 [%&*3>._%() >F?RH =BC%)O%(9 .HH =BC%(K9[&G4 )BC'UI:* &E<T
MN/I2T4 (>.35.?488+^VLY=PGN Q08SPO6KC=*R-6TG[=?V5XMS+;SVN[:4Z
M,&Z@C\* %MO$.GS1NSSI$4;:P=AQS@?G1'XCTF3R_+OH&\R3RDPV2S>@K)_X
M0S3O-MI7:9S")."<>87_ +W';M3])\)V.ER64D1W-:;MFX#^(#K^5 &G<>)-
M(MKF2WGOH4FC.&0GD&FW7B?2+7S!+>1[HRH95Y(STX%9]UX2L)YY979]\KR.
M<XZN,'\J@3P3IT*W(BED3S663=@%D8'.0?Z4 :FJ>)]-TY7,LN]HV19$3EDW
M="1Z5))XDTM<!+N*1VC,B*K9W#%8LG@BS:ZN;G[9=?:)R&+L02"#FB/P+IL6
MU5FN"F,R+N'SMV;/]!0!KVOB;3YQ%OE$1EVA%<_,Q89 Q3H_$^CRW*V\=_ 9
MF;8%W=3Z?G65)X-LY-@$\R,CK)N!&[Y5QP>U21^"[%-A1W!0( 0 /NMN';UH
M V;G6].M9IHKB[BCDA3>ZL>0OK5*Z\5Z5 EJ4N%F:Y=5C6,Y)R<9/H*I7/@F
MRN-6N;^6>=I)SR,\*,YP/;BD7P/8I=B>.>9/W@D9%QAL'('3@9H U;GQ%I]I
M/-%>3I 8Y!'EC]XD9JC;>,+&YUB2PCCF_=L5:8C"9 R?T(HOO"%E>7L]S*[[
MYF+.,#&2NW^51OX-M#'M%Q<*<DA@V",J%_D* -"3Q1HT<<<CZA $D!*'=UQU
MI)/%&CQJC/?0A7&5.>M9-IX#TZVA2(22NJC:-V/[P;/3U%3_ /"%V'[SYY"&
M(.& ('S%O3U- &H?$.EB.%S>1;)E9XR#]\+UQ]*@B\4Z7)$9OM"K;>6LHE;@
M$-TXZUF'P'8->17#3W!\MBPCW#:"<YQZ=:>W@JV:.,&ZGWQ1K'&YQE=O3VH
MVH]<TV2\CM([N)KF0!EC#9)!&:T0<US5AX.L;&:"2%WW0R+(OU P/YFNE Q0
M M%%% $-Y_QZR_[M21_ZM?I4=Y_QZR_[M21_ZM?I0 ZBBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *]K_K+C_?JQ5>U
M_P!9<?[]6* &,/6J%G%?"^NVNY8GM6(^SHJX9/7-:!7-+@4 8GB6VO+NS6WL
M&5'=OFD<G"@<]JR5MM7-UYRI(8YY5\U"^ F%^\/;VK:\17TNGV8DMD9Y6.
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M7DR6\#SS-MCC4LS8Z 4 0:>MREC"MZZ276W$C(,*6]JYO5;&_EU:]:-)#$X
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MF99K:(F*(2R[7[9[>M/U#6H[>XABCC:0NP5V(^5<C(S0!25-;^9GE9R!D)@
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MXC!QG<Q&>/PI&UNU#[(R\DA8J%5#D8&>:$TR$733$LS Y5<_<.,?RJ"#0;.
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M/;N1T/X5NFDQ0!0;38)8=MPHE9E"NQXW<8IL&CV<(PD.25*[F.20>HK1Q2T
M9(T.R$<:-$75&W#<Q.3ZGWITFCV[^<0K*\H4%@WW=O3'Y5J44 9W]D613:T
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1** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>image00022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" %% N<# 2(  A$! Q$!_\0
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MS,1T:NJW$=3GG'%<M6,$X^R+C>VI+13-V>F,>M/'2IL,**** "BBB@ HHHH
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M]CCM5-_!GAV2[%P^E0/*8_+).2&&,<\]<=ZZ&RMH;*TBMK:-8H(E"(B]% Z
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MX_)MXX@2=BA03U.*D"CM1TK*4FUJ;I6T,KQ,3_9+?]=8_P#T,5K+VK)\3?\
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M@E%^1H]E/L#DCIL?C1CFL'3_ !;HE_=);6M_$\[_ '4Y!-;JG-0TX[H:=PP
MIQ@5D>$_^0)%_OR?^AFM@_=-8_A/_D!Q?[\G_H9IK83-BFDCG&-U.Q4-UO\
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MWP*/LT/_ #RB_P"^!4YJCK%ZNGZ?-=/R(U)QZT*\GRH4K15V3_9H?^>47_?
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M44@&R=*J67_'U=?[PJW)TJI9?\?5U_O"FMA/<NK0QQU_"A:J:P9AI=T;0$W
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M)_\ )/K+_KK+_P"AF@#NZ*** "BBF]* %[]ZI6Y_XF5U_NK7A7BCXG>)M/\
M$FIV=M/;K!!.R1@Q D**R1\5O%23.XGMB6P/]2* /I@4M>,_"GQYKOB3Q0UC
MJDL+VX@:0!8]O->R#M0 ZBBB@ I#UI:0]: %[51E_P"0DG_7,U>[51E_Y"2?
M]<S3B!=3I10G2BD V3I52Q_X^KK_ 'A5N3I52R_X^KK_ 'A36PGN75JKJUT;
M'3;JZ6-I3#$T@C7JV 3@?E5I:&4.,,,CTI#.%T'Q_'=^!U\1ZC9W$:;MC0VT
M;2L.?0#FL+PGXDLO$OQCN;FPCNXTBT8*PN8&B8YE!X# 9%>J0P16\82"-(HQ
MT5%"@?@*X92?^%WN,DXT/C/;]\* .]HHHH **** /E3XI?\ )0-8_P!\?RKE
MJZGXI?\ )0-8_P!\?RKEJ /3/V?_ /D<[G_KV/\ .OHBOG?]G_\ Y'.Y_P"O
M8_SKZ(H **** "BBB@ K-U+_ )"&G_[Y_E6E6;J7_(0T_P#WS_*FMQ2V+\?W
M!3Q3(_N"GBDQA1110 5!-]ZIZ@F^]0!%[UCZJ0+_  Y XK8JO=VD5R!OX8=&
M'6DU<J+LSG989WF)27"]JM,5"C..*O\ ]D1_\]GI1I,'.6D_.L^0U<T8DI!=
M<5-.KRQ@0N%(.3[UMQ6%O&I4)NSW/6H&TF'/RR.OXT<@E-&9:HT:'SI-Q)R*
MY_QIXHLO#-O;27T4LD=PVP!1T'J379?V3%QNE<CZUR/Q0D\/Z3X9G&M@SK,"
M(H6/+OV(^E355H7.K!*%2O",HMWZ%#7/%6D:5X=BO9)Q-#*,PQH?FD]OI6]H
M=];ZGI=K>VRL(IDW*I&"OM7SQHMDVDW^E:EXETZX;0I6)16)*CGK_6OIO2+2
MPO;*&ZTZ4M9RINB9/N@>@J8XB>(?O:6Z?J>KF^"HX&,8P;=WOT]"O=/*BCR$
M5C1$6:#=,H#UJC3(Q_RU;/2E&EQ<9D<_C6MCP.==#%AQS]>]6.D9*@%@.!ZU
MJ2Z=;OC&4(]*8-+B'25_SHY0YT8T$EPTV)$ 3O[5I:3C[<^W'W:L?V;&?^6K
MU/:VD=MGR\DGC)II"<DT6/2IX?NBH/3Z5/!]P5:,B6HYON5)4<WW* *%\"UK
M(%R6QVKG;EG2-4CQ')_$&&<UU6:Y_4 R:@Y=&((X.,U$D:T[$%N TZ%% (ZM
MVJ.4LD!$96.4G[S#(:G6[.A?[005_A 4YIS+(FPR(_E=@16>IKU*ZL_F1^7C
MS1PQ' JS+YK;2F0 <,2,YJ-&<7)W%!#_ '=O-2R!S K!)&C#=*%<&-9)I%?R
MV,<><E01DUF^(-431=)FU!P1:P#+ +DD^E72;@S+L4K%W!3FJWB":UMM-NKC
M4!Y6GI&?-\P<$?3U]J4D[&M#6I&,E=&+8>(K34-%;61J*)8*NZ12<8]C[U+X
M4\1IXALGGTU\6Z,5V["&4UX)<6DUR+V_TVRNQH"S@N!G&/\ /Y5[_P" AI&K
M:'!)X?C*6L<>UT4D,&]&]ZXZ4YSDDU_P?,]_-,NI8.@IQ?-=_=Y,U&AF1A+]
MI=@_W@S9S4B17'F-CYX,<*%R11]FF5$%O"4*_>W+FK31SR &*.028Y(&*[%$
M^=E+01690IG5BN..^*B3<9G+.)$QPH7I31'=C8(]Z#^(%<YJPR2329@B<8'/
M&*?*3=#8ABW)*X&[.*AE:1YE\AEV=UV\TZ2.8QA8]\<@/)*DBK=FK&YAPC%@
M?F;;@46#1:EC1HG%S*Y1U0CN*VH>],).3DD\\"GP]ZV4;(YI.[+%%%%,0444
M4 %%%% !1110 R3J*H:+_J9O^NK?SJ_)5#1?]3-_UU;^=6MF2]T:(I:0=*II
MJ5JZW+)<PLMJ2LY#<1D#)W'MQ4(HMR?ZMOH:X;X)_P#)/K+_ *ZR_P#H9J_X
MCUS7HXK6;PKHMMK-I/'O:4W@A STQD'/'.:S?@8SO\-].:50DA>0NH.=IWG(
MH [ZBBB@ /2D'6E/2D'6@#Y(\<_\CIK?_7T_\ZQ/XJV_'/\ R.FM_P#7T_\
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M!_\ L!_^UA0!WU%%% !1110!\J?%+_DH&L?[X_E7+5U/Q2_Y*!K'^^/Y5RU
M'IG[/_\ R.=S_P!>Q_G7T17SO^S_ /\ (YW/_7L?YU]$4 %%%% !1110 5FZ
ME_R$-/\ ]\_RK2K-U+_D(:?_ +Y_E36XI;%^/[@IXID?W!3Q28PHHHH ****
M &OVQZUS?B?PG:>(;J&:[EFC:&&6!?+(Y608-=-133MJA-)G$GP!IQBC3SYR
M$DMY0<*"3"NU1T[BHU^'6FBW,(FN-OV46HSCA0X?/UR*[JFU7M9VW%R1/.KK
MX9Z7]HN)[G4;T6Q215A8KLBWA=Y!QWVCK4.K>"?#5SL,VJO#/F.6*3<N0%0)
MP",$$#FNI\:P7MWI7V/3H5D>YD"2,Y^58^^:YS3O#]Q))I,>HZ=$3:7$B.W4
M&(K\GX"MX.\;RD2XI="W/HVCR7NFW5AK(M)].MS;GR2FV2$D$JPQP,CMBJ&F
M?#_P_%;S6]IJ#-!<R":(*5+)ABQ .,D9-2:AX9D,7B?[)I\8>8Q"W"@#*C[V
M*9)H-Y.FERV<,B36D$C1NRB/Y\<*5'&#514>DA6\C87PKI,EG:6OVIW6"\;4
M%^9>7W9.?;-9,WPZ\//=7[-<MY&J,[I'N4%)&()9&ZYRHI+*RU.SALKF73I2
MS6TD4D4;<QNS9'X57O=!UQUL1#:1G^S85,9=^6D+9;:.G3CGUH4-?B'9=C2B
MT'1IEG%[K;7\QL6L99964,(\DY.!5/2O!F@6*6K3:W-='S$:-Y9%^8*A0*,#
MI@TFH>')9K/Q$UKIHCENBC1*H )X&['XYXI9M*F6337FTI[Z%+62(H45,2$C
M' .!]:KE727]6)TOL7(/AOI_V!+:2_O)XH[>6VB+;<K'(P8@<=B.*-6^&>D:
ME.T\DUPER9$D20!3LVH$( QCD#FNG\*VLUEHMI;7;$W$:8;G..<@>^.E;%<S
MJ2BW9FBBCB#X TS>&5IE"W$5P$0!5W(I4#Z$,:V?#&B#P]IQL8KJ>XA\QI(O
M. S&&.2O'89K>HJ)3E+=C44MAJTZBBI&%%%% !1110 QQ\V:XZT\!Z7;Z2;*
M'S$#79O&EV@2LVXM@G'(YKM**:DT)I,\[C^&.FH)4FU"_FAV,D4;E<0@OO;'
M'.3ZT:MX*T&XU.YO;G4Y([9I 9[;>HC\X(5#GN#@]*[^[9DMI61-[JI*J/XC
MV%>76OA[5UAOEU"PA<7\+2. VXB8'Y2??'I712]Z[<K$2BNQ)IG@WPY9^4TN
MOS7,L(BBADDD4%$0Y5!@>OXU%%\.O#J0:M"-<N&-S$L=P\CHSQJ#D')'!]^M
M;TGAN'S?#I338?W2GSR!PIV#K[YK(M] NVT[6K66UD)N93A#&H#(7'\77IV-
M:12EKS"LNQMZ7X6T_2[C4)8M5N?*O;9(9HWD'8;5D#=<D5C6OPQT>PCD,6KW
MR7D$B3"Z:12\+*."<C!X]:'T75L:E ]N98X(X4MI-W^N13G'U&<58U2RU74Q
MJ;06#1KJ$T2;9GQB-5&XG'8]*2IZ_$%EV)+KPOHW]H7DMUK<@^WM!/+$74!Y
M$/RN.._M567P+X<=-;6WU6:W-Y=+=SF.8?N2.=@]%)))'J:=I^@7DEQH2ZAI
MT1:QG>-Y.H,0'R=>351-!OUT?6X392-/--N1-HPR[R>&ZGCUJE37\_\ 5PMY
M%^S^'FD/IT,=AJMU]E%G)8N8V5A+&S9(/'4'I4I^&6EM=2/]KO/L[!B+?<-H
MD90I?IUP!6GX3L)H-2U"[%HUA:3!%CMR1U48+8'3-=8O2N>522=KE**:.?\
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M?]\4]0NB3 _K1Q4?GQ?WZ//B_OBIMW0R3'-&!FH_/B_OBC[1$/XQ0D["T)0
M#Q2U"+B+^^*7[1%_?%.P$M%1?:(_[PH^T1_WA3LQDM%1?:(O[PI/M,7]\468
M7)J*A^TQ?WQ1]IB_OBBS"Y-147VB+^^*/M$7]\468$M%1?:(O[XH^T1?WQ2
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MK+_Z&: .[HHHH #TI!UI3TI!UH ^2/'/_(Z:W_U]/_.L3^*MOQS_ ,CIK?\
MU]/_ #K$_BH ]&^ G_(]/_U[-7T:*^<?@)_R/3_]>S5]&YQ0 M%-SGIBES0
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M+AAZFC3/$6G:CK6HZ39W'F7]@R_:$*D;<],'&#6[7*VV[LV5DK(!T%9NI?\
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M_P#>K6K)A_UT?^]6M64]RD%%%%0,**** (Y*HZ+_ *F;_KJW\ZO2=15'1?\
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M1_85M_STO/\ P*?_ !HT"YM9HS]:Q?["M?\ GI>_^!3_ .-']A6O_/2]_P#
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C %%%% !1110 4444 %%%% !1FBB@!,THHHI(!:***91__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>image00023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" $W L$# 2(  A$! Q$!_\0
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M<DU>6+S3Y2,C;>3@U#-&Z'[^)>RU/*F.[,:QTX:4PMK"*.WLV.Z5SVK35HW
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M0DY0AEY<TZ.)S_J9,$CY@PQ5:XB*1MYGS$="M4HM*Y+I\NX3[%0B#YOFQDU
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M%^T782=MJ@]16%2+^R$UL:EC=PR0QPBV$<GF [O49K]#_"G_ "+&E#TMH_\
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M>>E076E^?&VY450,*HXQ6@]T B^9\F_H350B-97<W/S8SY>>30!S<OA.>_\
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M%:P0Y['JWPCM);/P;;P7#VQE21PRVI_=IS]T?2NU)Q7'_"U='7P?9KX<\[[
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M*NW5Y% RBXD$6X\$\4.0S"3?E1T(Z4W>XCEP+30M.-C=7#%W7&X=17'6\>I
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MK&2>YS3IMZG,C'!YR*<<DY;\A5F^M/L[87YD_O54 V_=.:%*YBV*1A:3/-.
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M=ZE2ML)(W+*XM;>P!,ZB$MDD'I5R22"5R8&#Q2C(QVKCM3@631M-@@50+M,
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M2\S5STU)D+A'49"MR#ZU)91P/(?MVY01@#WH5A/;AG8*\;9"^M69[L7BJBQ
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M?:RLRDQJH]:]:D&Y7 /.#7A?BCPVT-S<-(OEYDWJ<UC6O:R-:>Y4\.BY,P9
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M&M>*K33EVP,9),_/CM2*5B[/86FII#>7,)B:$EXQT/TK!TR_ANVO-1U^-H!
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M-2:/+A\!O 93!TR3C_II3E^!/@5,8TU^/^FE>H@@=#FD!!Y'-.X^9WN>73?
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MB@ HHHH **** "BBB@ HHHH **** #%,V^YI]% #"@.*38/?V]JDHH CV8!
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M-_&(I/8>HHT&9\>KW$NI65X&Q9S2-"L>.H'0UUX&3SU[US<7AZ2"XTB"%_\
M0;%3@M]YB:Z5?Q_&D ;,#'-!0''48Z4_%&*0QJCFG444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1BBB@ Q1110 4
M444 %&*** "BBB@!,'M^M-*DG^F:** '8HP>]%% "XHHHH :13J**0!1113
***** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>image00024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00024.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" $F OH# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M975<%_K5H/GIS["@/G% #Q12 TM !1110 4444 %%%% !1110 4444 %%%%
M!11030 9HS24F?>@!V:*2BD M%)FEI@%%%% !110: #-%-IU( HS13<T .S1
M3:7- "T4AS29Q0 ZBDS2@YI@%%%% !11FB@ HHHH **** "B@TE*X"YHS244
M &:,T4N:+@%%%% !1113 **** "BBB@ HHHH **** "BBB@ HHHZ4K@%%&:0
MT +129I<TP"BC-%*X!1113 **** "BBB@ HHHH **** "JUW_P >MQ_UR;^1
MJS5>['^BS_\ 7-OY&@#R?]F;_D2-2_["=Q_Z%7L%>/\ [,O_ ")&I?\ 83N/
M_0J]@H **** "BBB@ HHHH *:U*3[4M &5KT.HW&ESQZ/<1V]\P_=RR+D+7D
M&C:G\1]0\;:EX?;7-,1].1)))!!_K W;VKW+!'3BO*?"*X^/'C$X_P"72 F@
M#U*U61+>-9B#*%&\@8!/<U,*:F=HSU[TO- "T4BG-+0 4444 %%)FC- #7/I
MSCM7(>*/B/X6\,ZF;#7-5BM+H('V-Z'O77L,U\B_':PM-3_:,T2RU&(2VD_E
M1R1_WE/:@#W4?&KP"<9\00#/3.1FE_X73X _Z&*V_.O!['X06EKXU\6RZE9V
M3Z+!;3/:0K,"R$#Y3@5S5U9>%OAYX7\/R:OH":YJ.M(;F8S-A88LXVICO0!]
M.#XU^ .?^*AM_P!:=_PNOP!_T,-M7PCXQ_L677KB3PU!<V^FN0T<-Q]^/U'T
MK!;@]* /T,_X77X _P"AAMJ%^-'@%B OB&V)K\\J?'UR.,=Z:5W8#]$!\7/!
M;<+K,)[YJ-_C%X&C?;+K<*-[YKXJ^'VH:<=3:+7)62%DQ$>RMZT[5&L-3N)H
M(0H,;X60#[PKL]A2Y=]3JI4HUGRQW/M ?&KP#T_X2"W_ %I?^%T^ 0>?$%L*
M^$]4T)K-!(,,M9ZB+[.P=1O[>U33PRDG=F5>A4HRY9JQ]^?\+I\ ?]##;4?\
M+K\ ?]##;5^>K"FXKFE&ST,C]#/^%U^ /^AAMJ/^%U^ /^AAM:_/*EI6 _0S
M_A=?@#_H8;:D_P"%U^ /^AAMJ_/0#-/"'TJH0<M@/T)'QF\!L#C7[<@4W_A=
M/@#H?$-N*^ %VK"P(^:JQZG-=%?#QIQ3)3NS]"?^%U> /^AAMJ4?&;P&03_;
MUOCUK\]%&6K5BB06_)&36V!P4<2VFQ2ERGWJ/C1X /\ S,-L*#\:/ (_YF&W
MKX$DMPQR@X J)=@4AE&?6M*N6NF_>V$IW/T!_P"%S^ NWB"WI#\:? (Z^(;:
MO@6U4MG"@BHI(0[MMP,4JF6\M/FBQJ6MC[_'QJ\ ?]##;4?\+J\ #_F8;:OS
MW9<'&*9BO.E!QW+/T,_X77X _P"AAMJ0_&OP#V\06Y^E?GI2K]X<=Z@#]1;"
M\AU"RBN[1Q)!,@>)A_$#7G^L_&OP7HNJ76G:CJ+17=N^R1-F<-Z5TGPU'_%
M^'_^O./^5?&.NQ:2_P"T#J*^(X)9M*%\QG2!2QQV_#UH ^G/^%_?#\L!_:KG
M/I&:7_A?W@ 8']K/_P!^SQ7C?Q%T>RU7PCK5QHFAZ%J-A!B2SO-*?;/;(/\
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M?\+_ / '_06;_OV:/^%_^ /^@LW_ '[-? M*.: /OG_A?_@#_H*M_P!^Z/\
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M^@KCKZ42S[0I\M20@'>O*KM1]U%PDY2YC-'+>U=E;KIMEX.DN @FO9VV9/\
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M[7P_XNDN#G_14X]*]Q_9W:RU"SO-6EUBXU'7&D>.7S9#N6,'Y?D/2O#OVO\
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M_:\!_P"%I+GI]E0#!YHJ-.06/#:;3C28K,!**4TE !1110 4ZFTM "T4E+0
M=Z=CBF]ZD0;B!ZGIZU6G4!N:0]*Z1?#4@TMKV=TB4#(4GDUSP3+;?P%$6I/W
M28R3(\45:FM7C0%A5;&!6M6C*D[2*$%6K>X$0(V@U5I:5.HX; .=LMG%,I^T
MD8ZTC+1RRFN9H!M%*:2L@ 5(C%>14?>GJI9L"KI2E&7N;@]2Y%=9PKCBI<':
M20=IJ@ZLC?,,>U3B\D\L(3E>U>]ALQE%<M8RE#L/X\P8'%.D8;F^7J1BBVG7
M[KCCUJ68Q;?D()R*[?<J4G),G6Y^BOPU_P"1#T#_ *]$_E7P5\:?^2I>(_\
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MI-7(K^[*QX;(I4\TRKMUL=0ZG!QR*I5MB(<DK(Q3$-)2FDK!C"BBBD 4444
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M@8#@]!5_%5[O_CTN/^N3?R- 'D_[,WR^"=2"@!?[2G  '0;J]A Q7C_[,O\
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M41I<OO,4::B[GZ*? _\ Y)7X<_Z]5KNA7"_ _P#Y)7X;_P"O5:[JF:"T444
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M7P3\:?\ DJ7B/_KZ:@#C%Y/X8KM_"NJQ79L=/OD#HL@4OTPOI7#KUJ6&5X9
M\;$,#D'T-5&3B[HQKT_:Q<3U_P ;66FZ3HUQ:J@>:1P]NYY*KZ5S5C#<64*Z
MA8SB57 5XN[>U-TS5?\ A(;>/3[[YK@C"RL>GI2:7?GPEJ4T%_;^;D87O^-=
M<4EK+J>?"E*$>1[G::#K,N^VO-4F#Z/&"MPK=8O8#UJ2X\36>I>9#IAN$5B5
MC5TSN3L37%Z3?6,UY<7&I^;#"061!T=OI6=8ZW=6&N->VAVY./)<=5KDG0C&
M?,F=^!DHOEJ([KP_X2#^((/M/[Z(C,DX? 3Z5U,T>D1O]B*O/# 6?=(=Q/\
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MTW.VHDK'Z*_ _P#Y)5X<_P"O45W5<+\$?^25^'/^O5:[JN1[C"BBB@ HHHH
M*1ONFEH/2@#-UIX(](O'NY3#;K$QDD4X*+CDCWKP&3PUX?O/ =QXE\WQ=+I;
MR,'A^T$LZ9QOQ_=KW[68+6YTF]@U @64D3+,2<87'-> ?9]0MO!4K67C8CP$
MLAMFD%J3.L><%1_L\]: /<_!(L%\*:6-&=FT[R%\@MUV^_O6W(,KQS65X3M+
M&Q\-Z=;:0ZR:?'"H@<'(9<<'\:UF]NM ',Z]XOT_1-;T_2KD2O=WG,04<8SC
MDUM:A-'#:3M/(D:[#\S,%QP:YOQKX3_X2B2T66Z$%O"X8E%^<XYP&ZBK?B[P
MSIOB/0Q8:DLS6\:[DVN5.0.,F@#A?V9<'P5J6""/[3GP1W^:O8:\;_9?B2#P
M'?0Q9"1ZC.JY.> U>R"@ HHHH **** "BBB@#SSX^?\ ))?$/_7"OSO%?HA\
M?/\ DDOB'_KA7YWB@ I*6DH *LZ;_P A&U_ZZK_,56JSIO\ R$;7_KJO\Q0!
M^G?A_P#Y .G?]>\?_H(K0K/\/_\ (!T[_KWC_P#016A0 4444 1XXKG=8\-Q
M7UU]IBFEM[C&"\9ZBNE%)MJ)P4MR)P4]S!T/0H-+9Y$9Y9G^](YR37Q]^UY_
MR5-?^O9*^WMM?$/[7O\ R5,?]>RTX1Y58<(*"LCPZBBBJ*"E4XYI*7M51;3N
M@'M*SC#'-/2 O'N!Q4(Y-/5RO&:WISC*7[P3)?* X((;]#22V[1J&)X-*UP3
M'M(_&HS*Q&"<UM5=%*R!;EW1;U].ODG0?=/(]177^.]7L=5TVQEMBOF;<,.Z
M^U<!N.[/>EW''-<#W,YT5*7,A"/RJ6WA\TX! /O46: VT\5K"U]34EE@:/J/
MQJ!O:IFG9E"YR*B:G6Y4_=$)1FBBL;C"BDI: "BBB@!***6@ '!JVDZB$JZ
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M[\B@#\U2C#L?RHVM_=/Y5^E7_"">%?\ H :?_P!^11_P@?A;_H V'_?H4T[
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M_P#?H5U4<9[/XE<3B?FQ.LI.!;R?]\&H$A<R?/!-M[X0U^EP\/Z/G_D%V?\
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M1?B!IVJW]M:K:WD!F=H=\J859%ZI]:[9%V_2@!]%%% !1110 4444 %5KO\
MX];C_KDW\C5FJUW_ ,>MQ_UR;^1H \H_9E_Y$G4O^PG<?^A5[!7C_P"S+_R)
M.I?]A.X_]"KV"@ I&;;Z?B:6N$^.%S/:?#/6)K2:2&4( 'C;##) X- ';F1#
M_&G_ 'U4-Q';SPM'.L4L3##*^"#7E>@_"72+O1-/N)]4UMI9H$=S]L;!)'-:
M(^#FB_\ 04UO_P #&H RO#FB:3_PNGQ*GV"Q\E+2(JI1< ^P[5ZW$T<:!59
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MT<FHP2S7$PD1ECP$'>NR\M?[HI=H]!F@##UV#5);%4T6Y@MYPP#M*NX,O?\
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MS6UZJV.K00M/%+'!:JX"#^($]2?>OI?O_P#6JM>7$-E!+/<ND4$8W,[<!0*
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M8OXK/66N_P"THMC3!RRQXPQQZ5]&,!W YJEI^I66H-.+*>*<PN8Y-G)5AU%
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MBC2WDEI)/,H#E0N0P7M]:ZSPKXTN+C2;?[;;7%Y,'DBDN;=<QY0]36Q!\/\
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M"Y6-L@$BM9_AWX6=44Z5$ J[1@D9'H>:UM#\.Z9H2S+I-JMN)CNDP2=Q]>:
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M'8O:-=07%G*D@WJ<\J *T%\7>+]6_M2[LOL5KI,:2QJ78>9"RC@XZDFO0O\
MA!?#GV1K7^S4\@RB;9N. P.01SQ5J'PIHL.I2W\5@BW,JE),9PP(Q]WIGWH
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M-Y]J]9;P1X>:S-J=-B,)F\_DG._USUJ63PEH<D\\LFG1,\\0A<D9#(.@QTH
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MTE=(:YCET>7[/&TA;R8AM6=O[P'>O/?'UPUMX^U:[M]5-C-9Z8DC>6,&1MW
M)]*]ACL+:/R=EO&ODY$>!]S/I4-QHVGW,CR7-E;RR2##L\8)8>A]J /'[+Q!
MXCUSQ3')#KEII\=OY;"UE!_TJ,CD@=ZIS^*8Y-;OU_MB:ZTFZMIXY%NQ@;QT
M4+V],U[<-(T_[1#.+*V\Z$;8W\L90>@J%O#VD-(\C:79EW^\QA7)_2@#YY00
M)HNIB76)SF*V6WAFY6/)ZJ.^*ZR/5-4CCU%K36[J]BT*>*66%!EIXF'S*?QK
MUR30]*D"B33;1@H"KF(< =*I:AX=BE9/L/EV(=LW(AC ,ZCL3B@!OA?[1_8L
ME[+//.]SNN(XY>L8(R%KA=$UN^N8KW6EUB9]4A27?HQ'RY7I@=J]81%6-54?
M*H  ]*JQZ58QW<EU'90+<R?>D" ,?QH \+U#Q)KD>E--IGB1O*N!'+/(Z[FM
MI&;!C'H*-6O9+O6+>RF\3WA@LKY=TX.."F>?;->X#1--$4D8T^U$<C;W01 !
MF]30=#THQNATZUVR?>'E#F@#R#3-=U:'P7-J\VNRWSRZ@;.:=!\MO%N(W >N
M,<U4.I3MJ^CQS:C'*T$DR6.HSCET*G!;UP>]>WPZ78P6DEK#9VZ6TGWXA& K
M?44PZ-IK10QM86ICA&V-3$/D'H/2@#B_A7J=Q=1ZE;7UQ<W%Y!+EY7??$0?^
M>;>GM7H@JK9:?:6$/E65O%!'G<5C7:,U;Q0 4444 &*,444 &*,444 &****
M #%&*** #%&*** #%&*** $Q2XHHH ,48HHH 3 HQ110 N*,444 &**** #%
M&*** #%&*** # HQ110 TC/%&VBB@!U&*** #%%%% "8&<]Z7%%% !BBBB@
MQ1BBB@ P*3 HHH 7%&*** #%&*** #%%%% !BBBB@ Q1BBB@ Q1BBB@ Q28H
MHH 7%)BBB@ Q00*** $QS2@8HHH 7%&*** "BBB@ Q36 -%% "X!I<444 %%
M%% !1110 4444 %%%% !1110 8HQ110 4444 !&:;BBB@!V**** "C%%% !1
)110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>image00027.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00027.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" $% U,# 2(  A$! Q$!_\0
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M_P#"T_&__0RZC_W\IN-@/T=YHYK\XO\ A:?CC_H9=1_[^4?\+3\<?]#+J/\
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MX7^)(;436L]D=0U..2#5 YPD2.V28_>N\M?!\UKXUT/5+<Q"TL; VDA P[L
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MRW .7ESRS=![5J.&A979R[,,X]!5"\=;=PUO&K(OWXV//X5!I^IJ\[RW8+(
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MH &8 <TTRC'4#N.1S5?4K2._L;BTF9Q',A1MC;3@^AKQGP3X(L!\2->MGO\
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M!5J_IE])87<<\)^93G![U0%.S1RJ6@I)-69V<GB6.]U*TN19Q)=1G##&5?\
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M6_\ GAIG_@&G^%<2*=M]J8':?\+*UO\ YXZ9_P" :?X4?\+*UO\ YX:7_P"
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M?\\=,_\  -/\*XBEII7 [7_A96M_\\-+_P# -/\ "C_A96M_\\-,_P# -/\
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MOV8@AE'W<D=3]:^:P[#^6:&D9L;B2!T![4 /CGEB+&*1T+#:=IQD>E0]Z**
M+%K.T$F^,_-VJ2"5A=)+_K)-X;!YW'/2JJFO5/V>/!#>,?'UGY\>[3;%A<7!
M(X)'1: :3.?\:>*;[6K6VM=2M%M9K7Y<C()!Z#%<A"ADE5!_$:[?XWIY7Q4\
M1)A0JW&% Z!<<"N(MY#%,C@]#D41C&.A/+RIV/0+*QEME@!CW8P<XYKZA_9H
M"#2-7$8P/M S_P!\U\NP^*;-=/$EPCO<-A6C!P *^COV1;E;WPUKD\<?EJ;S
M &<G[M=M2I#V"IQ//P]*?M>:1[[V%>;_ !NN+6#0+#SK=GNFNU6UG2;R?(D[
M-N[5Z/7!?&2."7PS&MS<6D*><!ON(#,H_P" CO7"CT@^$]G]C\,3L(8A=R3,
M\LJW(G,\GJS"L&^\>>(--UJ*PU6/P[;3F0 QFY)D5">./7VK2^!LDC^%KA6M
MH852Y95DAA,4<H]0#S7">.],\/3^*-:U.*6>*ZLKV!;TE06DW=D!YP/:F![;
MK>A:?X@TM['5X!/;/R5SQGU%9GAOP7I'AN\,^E1RJ=FQ49\J@]1Z5T=NRF&/
M8<IM !/'';\:L[1^- 'C]YI&GZ7^T'H<FG6D-M)=:?.\[1KCS&]37L*]!7EG
MB#_DX#PS_P!@V?\ G7J= !1110 4444 (U?#_P"V!_R50?\ 7HE?<#5\/_M@
M?\E4'_7HE 'AIH%!H% "U]>_L3_\BUKW_7PO\J^0J^O?V)_^1:U[_KX7^5 '
MTK1110 4444 <;XMN7@OM/0R&&U=\R2XSCVJJ;Y6\2V0T^X$RR#;)$HR%'KF
MKWBJZ/VFRLUCC;[2_)E' 7_&J5OY>CZ[;0V\$*VTX( 4?.#_ (5PS2]K<\N?
MQV.9^/7!\+X_Y^9?_19KX6O&_P!,GX_Y:-_.ONKX]#_D5NW^DR_^BS7PG>_\
M?MQ_UT;^==R/43=B6RNI;:=)(2P=#N4@XYKV[1%T?QYI4%QJ\16[A CG>, ,
MWH:\)4X%=;\/_$TWA_50R;3;RD)*C="/6B*BG=G!CZ$JE/FINTD-^(7AD^&=
M9>V!S"XWQ]_E-<BPKV'XZQP2G3+NVF25)8A]TYQ7C[#FKJ--^Z:8*<YTDY[B
M**Z;P/X>7Q'K"6+3K!E2Q)[XKF5./>M+1M1FTR^@NK9BDL9R"*E;IF]7FY'R
M.S.@\;>$)_#[)(,R6SY"R8QS7(;0"<_A7L_BO7SXC^'9N+AX4F1P?+/#$^H%
M>-D#&?SK:M-2>ASX*I.<+5=T;7A_PU>:NZM%&RVY;!F(^45H^,?!LF@QP.DX
MN$D7)91]T^E=/\.'N[C3X[ MMMR3)_\ 6KM;DZ4\'V36)8A&S;AD]:\FI7G"
M>AYM?,ZD,3[-+0\N^%X*GQ)D?\PR3/Z5PF/ES7K&@_V?_;OB@:0"MI_9D@ /
M<\5Y1BNZ,N:/,>W"?/'F&4E*W6DIEA1110 M&:2EH ,T9HQ1B@ S6AHFJW6B
MZI;:AI[+'=6[B2-BN=K#O6?BEH ]!\=?%?Q%XYT.UTSQ"\$R6\OFK(J;6)]Z
MX.7:#\M145HI*P"YKT?]GIB?C!X='_38_P#H)KS?->C?L\'_ (O%X<_Z[G_T
M$UGH!] ?M'?\AV__ .P(_P#Z'7QTK<5]B_M'?\AR_P#^P(__ *'7QQ0.Y=L)
MVMYUD0D$&N^ATRRUVW\\?)*PQ\O0M7G"Y[5U?@O5C:7J0RMB%S@Y[5U82<(S
MM-'HX&K'F]G4V9@:M9FRO)(6ZH<50KH_&RQC6)3"X=6.<CO7.5%:W.[''B(J
M%1I;!5FT56?#=*K5-"^U\U>%<552D82V)+R((?EZ57"YXJ]>LIC7::I]QBM\
MQIPC5]P(>9>L]-DF>,/^[5^C-TI-2T]K.X:/=OQT8=#5_3EENX1YC#RX1@<]
M*UY)=,>V(O>9(UPN.]<4X<L%(]6EA8U*?,QV@C'PL\2?]?,/\ZX:N]THJ?AC
MXFV<+]JAQ^=<&162/-DN5V0RBBBF2%+244 +FC-)10 N:,T48H  <&MKPIXF
MU/PMK$>J:-,L-[&,+(5W8_.L7%% '=?$#XCZU\0/[-_X2$P;[-2J21K@MGUK
MB9,!R%.1G@TS-(3FKNK *#7OG[&HS\2KS_KS;^=>!5[[^QI_R4F\_P"O)OYU
M-P&_M#<2ZUC_ *##?^@BO"%8K]T<U[M^T1_KM:_[##?^@BO!LXI)V [SX3^-
M'\)>(EDF42Z7<XAO(&&59#WQ7L7BOX/^'=9T#4M2\,B5-353=[-W[ORSSQ7S
M&OTSZU]._LY^.DU:SN?"^O7$,9BM6%K.QVEEQ]TGO2:Y7S(EKL?,DJF-V1A@
MJ=I^M1UI^)+7[%KVHVP8.(YW4,.AYZUEU5[ZE#T&ZO1_#/P]_MGPZFH)<KOD
M8JL8YZ>M><(<#(KO?AKXMNM$NEM4.Z"=@"&YP?45I2E:5V<F,]HJ?-2W./U?
M3YM-OIK6Y4K+&<$&JUO"T\R11AG=S@*HR2?2NV^+AC;Q1+*DL<ID0$M&<C-<
MIH<DL6J6TENVV:-PR-[CI2K2W:-:51RI*3W.^\(?">]UHNNIW*:6P7*I,/F8
MX]*X#6--ETW4+FTF5@\+E3D8Z=Z^A_#\5_?PIX@OYT::=P0'; XJ'XH7'P_N
M_#M_J)*7&O8\D+"<8?UQZ5Y,,9+VEK71A1KRFVCRWQK_ ,D\\&#T27_T*N :
MN_\ &W_)/?!O^Y+_ .A5P#5Z;VT.T2DHHI %+244 +FC-)10 N:2EQ1B@!5.
M*[7X??$OQ'X#$R>'[B..*9@TB.@8,17$TM &]XHUZ;Q3X@OM7U!(X[FZ;>ZQ
M#"Y]JP^A..E-HJ^96V ?O)/-?8G[%G_(DZQ_U^?^RU\<"OL?]BO_ )$G6?\
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MYF@#*4XJ:*=XI \3/&PYRAP15\>'-9_Z!EW_ -^S1_PCFL_] R[_ ._9I]+
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M_P#OZ:7_ (9_^'G_ $!F_P"_IKU>B@#RC_AG_P"'G_0&;_OZ:/\ AG_X>?\
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MO3H--8W-I@RQ^:1C/3ZUI+\!OATV?^)5G;U_?$XIWBC1+F\\97<UO9W8NIQ
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M<,41NP.WI^-<Q;^-M>MO#<VHWW]F-*+F143<<M&I[*.2?>@#U3>#*RA@2.2
M>12^8@;9O!DQG;GFO(8_&^I?V\?[/T*T6XO6C7SY+GC!3=RO^%0R>/M0_M=+
MBWT&UDNY D E^T\8+;2=OIF@#V96R.:<#FO*;_XAZK!91I;V=B+\221-YCGR
MG=3C8F.2U>EZ7+-+90/=*$G>-6=1T4GM0!<HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D8 CGF
MEHH ;M Z#%)@Y]*?10 T X[BDQN7!'Y]Z?10 S;QC&/Y4N#_ )[TZB@!N/7\
M\T?A[4ZB@"O<V\5Q$T4Z+)&XPRL,Y%/A18XU2,;44!0OH!4M% #<?C2J,4M%
M #'[UYAXRGU30/B!!KATW4=5TIK-K98K(Y\IR>I7OGUKU$C/6DV#MD?C0!P?
MP>T_5+'P_<OJJ301W%T\]K:3MODMXV/W237>'I2@8H;[M &#XOUF70M NM1B
MA$[0!3Y;-@8)QG-8GAKQH^L^(Y-/^RJD'EAHY V3D#D$5U.KZ7:ZOI\EE?Q"
M:VDX9"<!A5;2_#FEZ7=-<V%G'#.R",LO]T=J /+F\0Z?K?[1&EP:?([S6-A-
M#.'C*A6SVSUKVL=*\HUN-$^/_ALI&B9TV<DJH&3GOZUZN.!Q0 AKR;6M(T_6
M/CQ%#JME;WD4>DET29=P!W=0#7K)KS1S_P 7_3_L#G_T*@#H_P#A O"G)_X1
M[3>?^F(YIW_"!>%-N#X?T[W_ ' KIQ10!RP\!>%!C'A[31CTA%?'7[5.F6&D
M_$O[-I=G#:0_9D8I$NT$G/:ONT]*^'_VO_\ DJH_Z]$H \-H%% H 6OKW]B?
M_D6M>_Z^%_E7R%7U[^Q/_P BUKW_ %\+_*@#Z5HHHH **** "BBB@ HHHH 9
M( >O3%<GXDTWPSJE\AU::WCOHQL5A/Y<F#V/M75R@GI7BOQ$M;*Y\;:N(IM(
MAD&G;IC>9W$CNI[&@#T+3]%\/6NOM]E\K^TDM1$80^2(?=?3WIT?@_0X;.XL
MX[(&UNCEHRQ(&.Z_W:\BLM7^P:AHVIZ?*]I<&PACN//7<\T6_;EC^H]JUKOQ
MOK\\AL-*U2Q9C>2I'?SC:C!?NI0!Z)-X(T*=%\^U=]D!AW-(<E#U!-7-$ATG
M2M+<:=<1_88AM8F7<JX[$]JFT-[B6VS>7<<]P57S$096-L<X]17EVK6]OH=[
MKNLZ(HO-*>0P:KIL+;P5/_+55SP0<YH ] TWPKH$5\=3T^!293YH$<G[LGNP
M'2F:CX>\.V%Y+K=\B6VY@TKL^V-V[$KTS7!ZEXFO?#\5U:6-_%;P6_V:2RMV
MBP7C?JGZ]:?K>IG7?">JW6HZO;-;LNV33'0!K9E<8YSGWYH [A_!_AU-/U8S
M6@:TU'$UT7<E7(Y#>V*LZ'X>T>":'4;$-*6B"Q.\A<!?85YK'XL\2W,6H2VE
M[I5K865L8S;70^?:J\.!WS^5=P]QJ5Y\-[:]TBY2"_%JDX>&/Y6P,E0/2@#;
MU;P_I^J7<%Q?1M,\'1=Q"GZCO6;=^ O#]US+9,#O+_*Y !;J!]:YC0/$6L7U
MY<1?;9FW1B^MM\& T07YD/N6XKG3XS\6'26U$ZQI4%M=W"1(C#,EN2V"N* /
M0K?X<^&K>ZCN8[)_.CX4^8>,#'\N*CC^&GA>&=98K!P48.O[T]<YK OM>\21
M^-ETFUOK%+:S\HR&Z&UKI6')7UQ[5M:]K%Y)XM;2H=5CTD0QI-&94#"YR>1D
MT 4M=^':27D+:.+>*VR7D25FW*Y/,BD=Z] TZ+[+:0PF1Y"B!2[]6QW->2ZC
MXQUN6>^DLKQ$D1I8GLO+!:!8_NR@YYSUJG=^-M<FUFTM+'7[!8;CR!(7B^9"
MP^;'- 'N&_VHWGL*\/L/%>KMJES>KJ_VHV=E,$ME4!)G5L G\.:GT_Q'XLFN
MM$M[G7=+$.IW.T/" \BKC.WT!S0![2&(ZCFFO* K,?NJ,DGM7C'BKQ#KB_V_
M8MK$D$T2@P26J*R[0><G/#>N:?J7C.\T[5[2VM-;@N8_+$$XEC"QHQ3(.<Y)
M)H ]>L[R&]MUGM)%EB;D,IZU8+9'%>!Z/XWUKR)I9=8TX6UGY1,%O$!OW-A@
M:U+?QOXC5M6U-I;)K&$M&MCG]]'CH^/0=30!ZY;:A;7,\\,$\<DT!VRHAR4)
MZ9]ZM!SG@<8KQWP?<301^-Y['5H;R^*)=+=1(.?DR. ><=*B_P"$VUFYCN%L
M=6M9)380W!&T HQ.'"YQS[&@#V%;V WQM!*GVE5WM'W ]:G63+<"O";SQIK#
M:Q:1V.JV,"3K#&99X,3E6^\"?4&K&H>-=:N+*WM[75XXI1-);I<QQAO,=6P-
MWH,9YH ]L:3+=./ZU%]JAW1YEB_>':H#9W$=0/4UBZU<ZA;>&T:RA:_NVC42
M"-@I88^9@>E<I\-;6TGT'3M2U*.6UDL)I4A^T2#&6/7KSZ4 >BR7<,<R0R2(
M)7!*QEOF8#N!27=];VD#37<J00J 6=S@#ZUY%H^H7X\:R:DS)?:A+=2P/8,N
M'MXU'RE#G@']:E^)&N7>J6<ND7?_ !)8I;-KDK. QG*G_5YZ9[T >K6FH6]V
MSBTE28QXW;3]W/2K)<_W217@UIXUNH/#MRD.KVD5Y$RB$VT0S, @.TD^G>K;
M>-]>N6EN8M<T^*..2WC6)4!W&3AL]\B@#V:6]MX;R*U>5$N)03'&3RP'6H(]
M;TYYV@2]@>82^245N0_]VO'KGQ[J5C?XDNK&^:V,T&1'^\!!'[S/8 'I[5B'
M7KS0=3U5M-US2KEY;AI3<31#+-LSO _2@#Z,\T #(ZG%#/MQD'\Z\AL_&NJ6
MNFZE]HOH;^ZCM8+D%$QY/F'#''<#K6]X7\1:K/#<0R0/K-JD_EI?P$*K1D#Y
MCZX]J .YAOK:>:2*">*22+_6*C@LGU%2M+@# .3TKSG3_P"R(_%EYJ6AB.:X
M@A,1@@D^>Y?U()[5G^(?%6NQ>(&C6\@TR(6B7$5A*@:25]^&3/?- 'IEEJ=I
M?Q-+8SQW$:.8V:-MVUAU%7"^T XXKPCP_P"(;CPVT\UC+;&WN;VX_P"):!@A
M@,\'ZU9A\5>+VL;">;7-(2'4+M$!5=SQ*W48]J /;MPR *S[C6;&"XG@ENH4
MG@3S)8R_*)_>(KSF'Q3JBZ-8ZN;[[39VMU+97HBCRTG.U&'XUF>)KB71]>U*
MY6YLVU9='5I9IX_]8-X^4CITH ]DCG66%)8F#HR[E/8BHH=0M9;R6TCFC:ZB
M4-)$#\R9Z$BO%M/\?ZU:6JZA=:E97L!N'MH[6WCP" N011I&MSV&J>)-:BOH
MM1OIK*&7=%&!Y63@Y]=OO0![3>ZC:6+0+=W$<+7#^7#O.-[^@JR&R,$8.<5X
MMK&K2WNE64^HSP:A]BU2,V5X%P)\KD@?0\5T?PVUW7M:U*YN=4N[!["128[:
M)LRP,#T:@#T2YGBMH6FG=8XE&YF8X J@FO:6SA!J-F78X"^:,DUC>-)2^I>'
M[5\"SN+K$OH2 2 ?J:X:ZB\'^=XU&K?85"RX3:V'#;> N#USZ4 >P-.B+N=@
MB]"6(&/_ -=07NIV=CL%Y=00%_N^8X7=]*\BEFU#5?A]I>@SP7-[JK6QFE1)
M@DT0!/E%\X]LU7U[Q#8:]X1\*W%Q'8W6K0WBV\MO.^ ' (93CM0![')JMA'#
M#)+>0+'+_JV,@ ?Z'O5BVN8KF$2V\BR1'^)#QFO%KK0%\/VF@0:VUIYUUK?V
MB& 292W0C[BY/(KT+PONA\5^(+.%<62M'(N.BL1R!0!UZYQS2TB]*6@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW^%?07[-OBB+X?:-JMMXCTO5HI;B9739:.V0!]* /K:BO+#\;?#HS_H.M_\
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MZ4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MF_Y9Q_\ ?(KC/#O@6+0M<>[T_5+U-.9VD33<_NE8]3ZUVZ8H 8T$7_/*,_\
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MLL% )'0G%% $U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% #60'K1L HHH -O\L4;!110 AC4]A0(U'3BBB@ \L?E3
M7A1DVLJE?[I&0:** %6,;>/Y4OEC\?6BB@ \L#TI=@_I110 WRA^'ICBG; .
.G7UHHH 7 ]**** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>image00028.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00028.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" $" IT# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BC-%
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M* "BBB@ HHHH **** "FNV!TSSBG'I7+?$B<VWA6ZD^VW=B,@&>TCWR*/84
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M\)Z?K<<!MUNX]XB)R5]JS?BT/)^%WB4* %6QD  XP,5F?L\_\D>\-_\ 7O\
MU- 'HU%%% !1110 4444 %%%% !112,P% "T5'O'X>M*KAAD4 /HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG_?Y?\:/[4T__G^M?^_R_P"->9_\*"\"_P#/K??^!C_XT?\ "@? O_/K?_\
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M;W/B#3DN)X.$?."1Z'U%=+IMI:Z98P65C$EO;PKMCB7C:![4 7J*:AW#-.H
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MU?Y3V(->#^-OC7XQ\4WVIZ%;M';V-Y(UNENJ[710<?>]:V/V9])N_#GB6_\
M$6L7MM8Z)91-!<LTP^=ST&.] $+>&_"WPKTVSL/'B1:EKES=1W$EO -WV>$>
MI[YKZZ\*:EIFK^'[*]T)HVTR6,&#8N J^F*^7?VCM)\*^(M<TS7K#Q3:)+>%
M()(P=^%_O\=*Z3P?\9/!_@*33/!NE"XOM-M\1RZGGY3(QY('IF@#Z4/'0<_2
MD4YZ@?7UKRC]HOQ%K>C_  R:_P#"QD#S,HDGB&6CB/\ $*X7]D?Q/XGUO^UK
M;6;BXN]-B :&>;DA\\@&@#Z4%+34]J=0 4444 %%%% !1110 4444 %&***
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M7@+_ *"-S_X"O_A1_P +Z\!?]!&Y_P# 5_\ "O1O[(TP_P#,.LO^_"_X4O\
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MCCWX- 'N&!Z#\J-@SQ^..]5='D:;3;260[G>%&8^I(!)J[0 #BBBB@ HHHH
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M ZAH&H&2RU\BP>Y>X:W:V0D[CTW]: /0UXIU-7VZ4Z@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!NS_:-&SW-.HH :$'?FC;
M3J* &A0,4;!C'-.HH ;LYSF@( ,4ZB@!-M)L&.].HH 9Y8SU_"EV#;CFG44
M(%Q2;!C%.HH ;L[Y.:4+CH32T4 )BEHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>image5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 0W!WT# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-<T779-=FTW1M)U"+6TCECN48:='90WWVF4/.HVMY8*;FSQB@#Z[_P""7?\
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M.IZ%J5GDG:#OEN@ I/0YR!GGO7T!/:03IS9Z4JCDR P^80O4LI;+Y_B4<MR
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MY?=UR.N>*E\VTW^9]GTO9_SZXAVXZ;?L^_=[8K[)_P"%8^!^^@VC'LS LP]
MK$Y '8#I1_PK'P1_T ;7=_STPWF?7?G=GWS0!\8H-/B<RBTTARV?DQ ^S/0^
M6'S'MZY/W<9-2*^G#(G;39%;CR5MOM;CKPDD1Q;G_:?(QQW%?97_  K'P/VT
M&T4]V4%6/J&8')![@]:<OPS\$HP:/0K6,@Y^0,F[V;!&X>QS0!^3/[6,.G6G
MPHNK^U@>)TU*U7:A6(ME)3D7&T(@^7&T@DY]J]3_ &=/^)M^S-H4TY<(-7U
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MXEZR7$R1*,#/WG('3WH O45XIK'[1/P=T.].GWWC;2OMHQ_H]M*+J4Y)7 6
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MTNTE);;\B_Z4K(?FYRO;\@#ZA=6=<!VC/!W+C(]N01^E$:LBX9VD.?O-C/Z
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MX5[O^$3M=WF9W_\ +4QEO]7'_P \_EQ7I%>:_"G'_")6N H^<\+"T(_U<?\
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M$K#^E8_P^\76WC+0[37;:X:6.[B618R5.!(F1P"1TYX ]#G-=RJ-(V1N7'_
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M[>ZK+<QM8/9>'Y8BL&V7?F.TM0I).S&_)!Z5K^"?B/XDN==U74->\.^.=/\
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M XZXZWPG^UQ^S/XZO)--\/\ Q@^'>KWT>4>ULO$%A/+@':P*!P<9P".>OX4
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MT:;>&."\U.WTR'<(7VEY[J1(E4'!.XXQG/%?QU:+=?M[^*?C#X@TWX4?MK?
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ME=R5FN5V=[:^EF_QL%%%%(H**** "BBB@ HHHH **** "BBB@ HHHH ****
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ML_AO'!H?@33['28;K4+'30)UF=$BNKJ*W;9L9FSL<A2P(Z%N*\$U?]G'69_
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M^D_"SX;R>%;JVE>]U75=;MK>\@=&B\M5M)+Z*:7*/(QVKU4+U(% 'M/[/O\
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MG[YV+EA#'<1I]XYQ@#MC!KZLJ&;S]A\CR]_;S,XS[X_SGVHNUL%SP_7/V??
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MFKX*^*[/P+XZ\>QV7C#4(YYK/P_:Z;J5]?3Q6S1I/(@M;65,1M+&#ENKC'L
M?7U%?%&A?\%"/V6-;OETP_$%](U!S&%M];T36=+5O-)";;B\L8;9]Q'1921W
MP""?JG2_'O@S6=-LM7T_Q/H<VGZC'YME<'4[.,7$>XINB62968%@0, Y(XH
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M2^V?;-)T+3-/NO+):/S[6TBAEV%N2N]#@GDB@#J:*** "BBB@ HHHH ****
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M#TH 6BBB@ HJM)=P12")W(<XP-K'.>G(&/S-6: "BBB@ HHHH **** /CO\
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M>N<\1Z%\&? N@&1XM,U'49)"7FN=5U">>:9L %I8Q<>4IQ@ 1HH(_A[U:O\
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M>22<]<?H-\8/^"HWA_X,:!H+^)OAGXMU[5-1T#2M2GB\+HUW;-+?6$%TRPW
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M;6-G"[2WMSAC!;I)+M)7%94W_!3?QI/I>C^!8&\++X_\6JEA8:IIVLV]_?\
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M[>PM(F)+9C@BC)8Y.20H))/7U[U^>'Q]TIKGXD:5=&.6$1QW \ZVF"2#,D'
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MZB@#)AT+1K:/RK/2M,LU ^46NGV<(3_=5(54?E50Z(I+)-!87\#$Y%[9VSL
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MR\K_ *[4"OW@"=O;I7T%#\"OBT8534[?0KJ3&'^RW=VD#'O@EHY #^!%)?\
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M(!()W&!TCR#C'S8P#U X_1'0OV8-"N4CN?&4T]_<QC>L-I.+>))#P<"-(MP
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M_P">GS5Z?7F_PKW#PE:;O,SO/^L\O=_JX_\ GF2M>D4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.Z+1].1O5;2('_T&M%+&SC "6ENH'0"&/ ^GR\=:M447=K:V[= (A!"#D0Q
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MHJCD >5<<;<'/UQU_.N8_8\F0? _3+J]@69FU:["MRQR(K?CRRH48SU'7TI
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M4_,3G'?K7T;X5^ 7A?2T0ZE8V^INN/FO[>.X<X]R./Q'\S7T&H50 2#C@?\
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M$^PYH =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445&SX.
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MX!_^M0!]XT5\_P /P+NEB:.7XJ?$J0LP(D77RCKC/&?)/KS]*D/P,E,:Q_\
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M ?Y;?_!RI8PG]K7XDRI>HMP?$FM[8\+N5_M5P!WW?*<'\..U>F_\$C_V//\
M@I;\8(-*3X ?MTP_"6";3IGM+6XD:]2WA%C*_E>3,2B?NP4R!E<YX(K^E?\
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M (?ZSX6\*:M\&/B)!K'B58TN/-AM[>WTV66=H /.\_<Z@8;<47N,<9KTZ?\
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M%&,$ #H.P .<U+_@J[^SWJ7P;/Q?\%:B^H:6]@+^&SOKK3K>[,;+N4,D5U<
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M*9)8TRR\#YL<\5^''QF_X*X?LU?#9-#\<>*_V;_BQJGAW6]6TN"#6O#ES=W
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M_9=\$^*]+\4:%\++9]5TNU:UL;FZ>._AA@+QO@Q7\DNX[HD.XJS<>_(!\<^
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MK]M(+63.Z[-M,X/R-'"8RJ@_*.6;D#OWJ7S;CS=GV;]UG'F^8O3_ '.OM^M
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M["Y$JW/A(X^I1EB(TO:-VE/DMRN"CR*IS5>\FQ9YA'(A=Y5& 3^\POXC'/\
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MGXNUKQWK-V+8^=?PF)(?(W[UC_UH"L7'&X8Q]:_2RRMS*/M%Q]HM8\!1;M<
MQ *,9" #DC&>.O';G7DTFVDE$QW!QG&,<9Q_+%5I=#BD?>US=''2,2 )D=,
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M"ESGD<BE=/9I]0OTZA1113 **** "BBB@ HHHH **** "BBB@ HHHH ****
M(Q#$',@10YZMCGCWJ2BB@ HHHH **** "BBB@ HHHH *\^^(WPZT?XDZ%/HF
MK[D22&:.*95#-"TR@&10P/(P*]!K/U&6TAB$EY>BRC7)\QIEA''7+-Q@9YH
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MC8C<89^<L<_-^%=M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2LG>\DV=Z/A5\6]V3X:\&$9S_P C%>!L_P"__9>ZE_X59\7LG_BG?!V.<?\
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M0*S("))%/S# X-(@@;X6_%HPA!X8\'B0')D/BB_.>F/E.EXXY_.G6_PM^+2
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M'\LGAOP7+$>JMXANP^?:3^RRX[]",]^@J.3X5_%QY28O#?@^%?[I\37Y&?\
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MX]*]*I2BXR<79M.UUJODS+5:--/LTT_FF%%%%2 4444 %%%% !1110 4444
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MT-\!='UG0;GX.^(O%2^,] U6S6RED\0-%J'B,0W4 B*6EW*^R,(A"VX^SL%
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M;2+5M>CM=O0PM7MM4U**[L[=9[6.>&>)+N.=04\R-E5Q'P<J2, '(Q7\(_\
MP4D_X(8_\%!?'GQ/\2_$7X7ZGK7QET[5M4DN+7PAJGBG3--LHH[F[#@+_:6J
M^4/(1MZCRA]P  =:_OCR/455>V1B6:.*3G/S(H(]\X/3M^=>%CLHPF80<*JM
M=WN]=[=TULNVO6Y^@\$^(&<<!YA#,LJI4)UX>SY)3IMRISINZG%JI&5[]&JD
M=/A6K/\ /+_8C_X-^OV_'^,W@KQE\;/ VG?"OPQX<U!KZ_@CUO0/$#7L?DO"
M(<6.I_+\T@?+0O\ =QC)X_NT^!WP$T?X1^"+/PW87<@F%C;P7,ULD%O^]AC=
M"<0K@\N?XB>.#7OD@$8P)50?\\T1<MWP!QZ4V- P+!I$QV/RY]>AQ_GVJ<MR
M' Y4G4P\8Q<D^>HXRO9I)J-HI6WO;S/>X_\ &[Q#\1E&GGF)G/!QY$Z%/DIT
MZK@XRA-J52KK%V7NJFG:S3U;^'?&'P0\?^!/'EW\3? NEQ?$J\U.**"?PYJ%
MS;:>+5+:26176[O9'B<R^>1@1@C9SD'CY0_:FTK]LOXN#1-,\'? Z\\+:8;1
M;;7XM-\9:.EM(3-(9&>"-(?M \E@."<@8ZU^SH;:@SN;/H,]OK^5,??(08YO
M+&.00">:]14J4J3@HQ4):\Z4KZM/71O7;5?D?E,JD:L/95.6G4D^9U%*4:B?
M;W>:+MLN6'9O8_'7X1_LY_!'X1^#A9?$C]G/3?&/C&^CDN]3MW^&[ZT+C4;P
MF><3:K#IUW;R.9I"'E+D$Y)]_2/@K\&-:L?B%9>*_"OP5\/_  F\(B]BGALK
M>QL+!K2WWAD46<<=K,IC7'R^6&&,5^I Q@9()'?BL._1E=G<O)'D_NU&W]0<
MGTX_I6,<'A;OGC",;II.-O>T2]Z*O?SE<G$X_'4L+"C2^M8MN2BHRQ-1Q2_F
M<$[6_P ,92M<LS7$.GV<MY?7:)!;1-/<7+'RX(HHP6DDD<DB-$4%F9B%4 DD
M#I\I>._VZ?V/_AS?1V?Q!_:2^$W@^[$QA%MJWCW0;-S* Q,<J37:%2 K95L<
M@UZ3\;?!GC3QU\+_ !IX;\&>(O[#U36_#&L:993&/<8[B\L9H(F#C]XI5W^\
MH)SS7^?A^UA_P0Y_;\NOB5KFKWWAR[^--KKVJ3OIUX9O$%U;Z/YCSRBZDB6P
MN(0H3,6"0 7 SZ\V8XZ6"@G2H2K65V[QY;:;6O-O33W4MG>S9^J^%W W#G&%
M6K1X@XBI<.2O&*=6=--2:6LW4;=F](\E.6[YN0_T!OAY^U3^S=\641OAM\;O
MAMXWWX"?\([XMT?5'9B 0!]DNI"6.17OHD7 R3SSGJ,'D'=Z'(P:_P T7X&_
MLO?&;_@GMXZT?XA?'+XMZE\-=(T*X@OKOP'X?NKFVN+J*VD$DD"V=S<:8LC.
MJF,!TY(QGU_H/\#?\'4G[$MQJ]AX9U3P;\58-/#V]B^OWUCI:@E=D#3LC:H5
MQD;B/-(ZDYKRL#G^'Q%6V)Y<).3481E;W[M7NO>:::W<EH_2WU''G@7F>0.E
M6X3QDN+,#.G.K/$X6%&4(*+C9*5&M*[DF]'%2T=HG]3-W?0?<\PQGH"S>2N2
M<?>;@_3K68UO)++%(JF0 DATG3:..K#^(<]!C^E>&_ 3]H;X4_M&^'=-\6^
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MU[:72O:^NGFV_P 3X:K5<YR<6^5Z*Z2;7GO9OU"BC.>E&<=:1B%%)D>HI<T
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MA)G.:N,\54A@HSDG*,I*I5Y4E\,:<7!:?SU%J];:'WSXA^-7@W0F9&U."[D
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MBG2O,KH$MQ*I.&<NHVCGG!&3]/\ &J\Z.SD?90 T;@W <;HR1V &21U!']*
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ME6",@@]",?G2T4$E4V=N224R3_M'_&E-G >JG_OIO\:LT53G-Z.4FNS;\O\
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MS=S]/_"&N:SKVCVUQK>B7&@:C) KW%O)-:3^5(0,JK6UQ<H<'/.\CWZ9\O\
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M]:3R;F_TOPKJD^EQMRK2>://80AN2Q!PN37ZL_"#]H7X5?'"U>Z^'>OC5#%
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M=/G?RXY/D<;9%W+]QNU?%'P]D,OQQUQ\!!]ELAY:2J(^)[H9$/W@3[GGIVH
M^[J*** "BBB@ HHHH ***/\ /0_THO;5Z( HHHH ***0LHZD"@&[:O1=WH+1
M2*P89&?Q&*C\^'?Y?FIOSC9N&[_OG.: 3NKK5$M)@'J!^5!(4$DX Y)]*SY-
M5LXY%B#O*[' \F-Y5!_VF0%5'N3_ $J7.,?BDEY7U^[<:;Z7^1H^W;I5=;6!
M93,%/F, "=S8P.G&<5*'R,D%<],@]_PZTCRJB[CN(Y^ZI8\>P&?I2C5A)^[-
M7WM>TDN[B[27S06;V3U=EY_,<V_^#;U'WL^O/3VI#(JD!B-Q.. ?\_\ UZSI
MM8L;=9'GD:!8U9F>='AC 49.7D4+T[UYQK'QC\!:.DHN?$.F?:4XCMH[I)YI
M'Y^58H\N6X/ !..2,5P8K,\+A&G4KTEHV^>HHI)?RI[R=M%?<[<-E.8XR?+A
M<+B*LVXI*-&I4CJ[;16GK<]:)P,]JCDGCB4/(VU3GD^W6OSE\5?M/_%.'Q[:
M6_AOPA'>>"3!<FZUJ>Z,!CF#1?9P+.0I)()$,K;E7 V\]:\<^(7[0OQSUS7C
M8Z+9V=CHIC0&ZAU("5F<D2+]F6X20;0 =Q&T].QKX_'>(F383VO+*I4E#W5!
M0;3>GO\ ,D[QUMI?N^Q^BY5X1\59FZ,O80HT9PYZDYNSAKK%P=GS6UM>_2W4
M_3KQAXI\%PZ==V.OWT?V2XC99X$=PSH<@C,9#J<9^Z1C-?'-AXX^$7PX;4;;
MX8^%YA)<W5W<S2S7.HSPR75Q*\L[G[3>;@KRNYP@"\X48&*^;KO59H+2"_\
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MI%!1110 A&X$'.#Z<'\ZCCB6+.TN<DGYF+=3GC/2I:* "BBB@ HHHH ****
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M%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***AE$Q
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MUK3KY#_8_P!7^/NH>![JT^/=A86>MZ6;2TTY[&TN+07,"K*)99%G)W,<1\J
M!GIS7UY0 4444 <IXEU6;0[&ZOG2_O(EAE(MM/M!/<?<8#9\RDMGD#(YXZ<U
M_*#^W-\(?'/BCQ#KNL:_XQU_QOHEY<RM9>'?B&BQ:'H3RS@V]XL=Q>WT1&FN
M4N(U-N 3"!QG-?UPW84VMP'4LOD3;@HRQ7RVR%_VB.GOBOXA?^"B^B?LWM\1
M?$S7_P (_P!I*^\12ZA.L<RRZM'X9O[Q[D!(5^SW*$V]Q*0@$>UMK#:0<&@#
M]4_^".?P8\2>&;OQ-/?_ !@\)>)+!]+;;X=\*V.G0+9+]JMB([AK,QLZ*/EP
MZ$$XSST_H3@TJ>UEC-K=QP6P7$EO':Q@2MQABX.0<9]?O5_-/_P0R\.6^C3>
M*91\ ];^&MM+HS"PU&^_X2/?>_Z7:D"X.JZE=1$LGSDQJ#D>F17])FM^(+;P
MSI#ZIJTUO:VT6!NE;8H^5F"DL1SA>^?ZT =117RH_P"UU\-8-6_L>4W<DNX*
M+J'RFM&9F*[5?<26!7)'H1W//OUGXLT_4].T_5;.\M(;748O-@%W)L=EW%/E
MP<'E3STH ZVBJWG%K?S4>(Y7*OG,9]R0?\BFVDLDJL9'@<@X'D$D?CDGF@"W
M1110 4444 %%%% !1110 4UG5!EV"@=V( _,TZJ.H:=::I;26=[$98)05=0[
MQD@C! 9&5AD>AH S%\5: U\=.75+-KP,5,"W$1DR.HV!MW48Z5T&X8!R,'H?
M6O&M,^#?PUT76O[4L/#EQ#J(<O\ :VO]0D0L>2<2W+IR>V,9KUQK6WEC2-E)
MC0#:-[<8''(.3@>IH M9HIB(L:A$&%7@#)/ZGFGT %%%% !1110 4444 %%%
M>5^,=)^(EZTI\-Z^FF1%F\LI'"\JJ3QQ+%(. > : /5**Q= @U2WTV"/5[IK
MR]5%$L[*JEVQR2$51R>>@K:H **** "BBB@#,U=8WL9A($9=K</(T0^XW\2@
MFOC#P']G7XW:VD5F4/V2S/G(N^,_OKOI*<$X[C''6OL_5YDAL9G=G0!6Y158
MYVMV?(KXP\!W4D_QNUS;+"\7V6S #$"?/G76=RKA1UXXY_*@#[BHH)P,U")U
M+;<-U]/R_.FDWLF_Z_X)$IPA92DHN6BOU)J*B:4*VU@P']\C"_G2F0=B,>IZ
M?I64ZU.'Q22=[6Z_<_SV\RDU)M1U:=FNJMY?KL244@93T(_.D+J.K*/J0*:J
M0DN92BUW4DU]Z=BK/L_N'456>]M(_OW,"GT:5!_,_P#UJRI_$NBV^XOJ=B N
M2P-S%E0!DD_-V[_UKGJX["4=*F(HQ?;VD+KU7,F:T\/B*KM3HU9_X:<G^2-Z
MBO/KSXC^#K4&1_$5@!']]4N[<_\ ?66X_#].37":G^T+X#LI!#%JMK*_S#?Y
M\31\<<D-U_$],X.#6,LVR^";GBJ4;*_QIZ:;-75]=%?4];#<-YYB^58?+,;4
M<O\ J'J12^<HI'O3!C]UMOX _P Z0[0!YA4D=V _E7RWJ?[2^AV\>ZR-M<'!
M.X$,AQT"[7Z_G]#7F&K?M2ZSJ4ACT'1XRT/R/)<0S")FZY0I( 1@\'US7D8K
MC#)\+#FE6E+72T?/>ZYG9WT;78^@P?AGQ9C&I++9TX2=I.M445&S6KC+1:VU
M2^\^X;B63=NM[V!0I \ER@!QVWG)&>G KG]:\4:;X<LY-3UA;.*.)&=Y+>5)
M7&T$D@D+GCMG';M7YZ^)OC+XT\36DMK=ZQIVAR2J4$ME\EY&,  HLN]-V,')
M7WKR+2M3\1:41YWC_7]=93DP7ZZ>X?')4HMLHP>1QT^E?)YAXFY?23CAJ=1.
M]O:2<-/^X34N9>2FF?=Y;X'9W6<)8RO1IK1SIQC4FGLVE73A&*MO+V<M^J/T
MO\._&OP9XFO9K.SU;:461F%RL$485 68;_-). .]<]X_^*GANUTB^L]"\5Z7
MI6J2IL@N8WMG>.0,#G;NYZ$8).>:_-.7XI^$FO)[75/$>C:%<8</*+N"WF=L
M$%90QVJ'/#%5!YXP<5Q.L?%+PIHR32Z4\OBV1\@1^'/^)E+)R3F0'=M''5<'
M/' -?'5O$^%6$W+VR;<HMTZC6R6MN=VN_LVU[,^WP7@&HXR#QL\3&*4)0P\*
M+G"<-&Y*LZ:C-V2;=XN.[?;[T\)?'K7/#-O>6WB'6#XN\]\PWEOY226X ;Y1
M&@.0=V<[@01C->*^*/&WCS5?%4WB/0/B9KNBV$R(HT4KYT491V;=Y;S"--P<
M)N"C[G/2OE"S\??$3Q9N@\+^#FT2'.6G\3V5Y;#!. 59' Z9SP>W'>NQL_#/
MCNZAV^*O$\-O'(,-;:2L"VP0@;MLDT+3;N@Y?@=,&OFL5QQG&)C[/!5\3R[0
MT2?+H^64M&E?KIT=M3[K!^$G"65UU6K0PWMG&[A4J.JW!):RI1]K#GT^%N+L
MNA[SK_Q0\27.F+;:UXY6<*J^:[:BMH[!2"PDAB?H>ZY([<UX9X@^*?A&Q ,O
M]HZ]=!OEC\/:7;ZG=L_/*SF6.1#C.64Y[5F1_!3X76=V-7:]%YJLCAV;4]6N
MO*,C'_GC#*J?>/ VA=W&,#%>M:-X4EAMV70[;0Y,(-@C2223 Q_JSRQ//4MR
M#^%>)+$\39C.]154UHI2G6JOET=FE*FM=K-S2\KZ_0T,-PADU!QH1P]-QGK%
M4L-@VVW&VE6-:7:S4$WI:S/&['XB>(_$4GV?PWX$\76:'(^V>*I;O3+, G P
M!]I09'(&.@SWQ5J]\&?$740+N\\4V&AA@=UKHUM'JD^WK@S21V\BG!VCT.37
MT=X?^%_C769_-DTJT**#@XOD<9_NH&6,CKDD>F#CIZGHWP4\8-//]KO;33K!
M(PSQJ%^T%>=^/.5N<=..N:[\-PWGV)Y7*A6G&?O?#*$925O=C%13\[<WSW1Q
MXKQ#R/*.;DQ6"H^SC:<:G)7FXWC;WYJNXN_2-"*\E>Y\06/P[ANO^0Q>ZYJL
MD9_>3:NUQ!;2#.<I;FXEB6,=" H&<\<FF20_#70]7M]/DM_"-K?9C4,([,79
M<[<,0T8=G.<DD\GZU]DVOA3X51ZW<Z1=:QXNAU43"*^: 6;V<LQ ^YYMNVU2
MK*#L(]<"NE\7?LK_  Q6S'B?2/"$?BK61 EQ;SZC<7Q=W*!T$D=E/ N[D!@%
M'3'U]C#\&\05HKD^I<E.2<H.\ZL'=63:A*:V=UKMKU/E:WC'D-.;]K@L75E4
M4O9.-&A0IRO;WXU&XP=M)04E'F_E73YJ%I?C#V5]J4EH0-L6GVQVE<<*J1N%
MQC@?Y-.AT%[J0-'9ZLTV<LQMY9I#@\@QEB%SR3@_+UYQ7W1\'_ ,MYH5G+XC
M\':3H<OEQ[X+4Z@CQX"Y %W,[9'N<^N>M?0^G^%O#=@P-G8VRR#/S85F]#G.
M>W%?28+PUS'$VJXFO@8*4E*25.I&4;\OPQE"*;TM?W;Z:K1+Y+,?':AAG*&"
MRS$2J15G>6&IQ=EI[:5",T_1\UM='J?E(GAK7)I(DM]%U=R&^\UC+)QCU.2G
MU'KZ5UUI\+O&>I!6B\-7#_[=Q!*B#(]?*<C/M_*OU+2SLU^Y;6Z_[L:#^0H+
M01N(E:*-B,A. 3CJ=H&#]<9KZ.CX8X"D^>M4A-\T?X=.7-+9->]*VKW7?J?*
M8CQYSJI;ZOE>&I/;WZ\IJSMS7<:<).^OVOPT/S-B^!WCJ7KH$,0[NR2E%'<Y
M, SCOFL>^^%]UHVJ64-]XNT>PGE92UDUA!OB.X#868*S]B2P!P<8/2OU*:2(
M':\D>3_"20>>V.*YS4?!'A;69XKV_P!*M[F>/!24Y!!!SGY2,\YQFNU>'^!I
MN$L':E4A/G?MN:UFUHE32LUYN273N<,_&3-\;S4\TPRAAI0:BL'%2;DXV2E]
M8WBO[LHNZUOL<W\.]#C\-:+86\VJVEX\MM#(KQ6D-H#YJ!P0L>0>O![U\A_'
MB=(?B)I3K TK^7<8,9+/_K8?X#@'ZY_2OT%AM;>".***%%CA18XUV@[410JK
MDY)P  ,FOSG_ &@%N'^)ND1@#R/+N22^5B'[V#&73# ^@!YYS7WN7818&E&E
M=24$E%Q<UM;=2F^W<_%,RJ5<QK5:TI6G4J^TOK3:][FU=/2]K:)6N?:OPGF:
M?PC:NR.A\PC$BA3CRX^< D?U]:]+KS#X1HL?@^T53&1O/^K9W7_5Q]W).:]/
MKN;NV^_]=V1%-1BG=M))MN[;MJ[V5_6R]$%%%%(84444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444C$@$@9(' Z9-
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MH I36\EPJF.>:R;()\M8BWN#N1ASWZ_X/6U!0I-*]P",$R! ?S15Q^&*M44
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M'O*UM+:/SZ_D=E+V56E[>%6+YDFDI1DI+3:UG?[_ )&A11168!1110 4444
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MA>-L\D-*R%H\GL%PF>.!6^GQZ\7Q.#/;V4N#S'%.GEG'_33R 1G&?N]_PKR
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M(KC0+E9",B.WE$SD=R 0O2M%?VB_#ZRA+C1-7A!QC]TA(SW(+CO7P_H'Q/\
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M3STUZ=]-JVO]-N'\FVO[6XD&?W<5U'+(,=<JKEN/<9K0_P ]Z\;\&?!+X?\
M@?7YO$'A[1KZRU.8S%[B?5+Z[B;S0P?$-Q=2QC(8@808SQBO9*%&.ONI7MT7
M2SZ>?]=62M?1N7=N[U^:7Z^HTJ"<\Y^I_P _Y^M 4 YYS]3_ )_S]*=157?Z
M$66]EO?;KM?U()HY9.$E\L=P%SG\>WUJ@UW:64PMW:0RMC&YF;)//&3Z^G\J
MU&W_ ,.WWW9_I4+VT,C^8Z*7&/F^G^>])Q3WBI:[-Z)JUG9J2]-/F7&2?NRN
ME'9QBDVVEUTNN[>NYX+XO\'_ !RU+7);OPM\2K'1M%:8O'ILNBV=PZPELK&9
MY$,A(& 3G/!Z\5[1H%MJ]IIT$.M7J:A?JBB:Y2-8E=@,,0B * 3S@ 5M?3I1
M5=+6Z[ZM_>V_NV+G5YX1CR4TH[2BFF]+:N[3^X*C,2EMV6SS_$<<^W2I*,]N
M]*YE>WET^_I\PHHHH *_/#X]6UN?B/I,[KB18[C#&9X!S+!GYU!/.!V]:_0^
MOSR^/%S"OQ(TJ'S'$S1W&%C52QQ+;YYD'E\<9Y_"@#[#^%!SX2M2"&_>'E96
MF'^KCZ.P!->E5YM\*MW_  B5KN\S/F'_ %@CW?ZN/_GG\M>DT %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4QXXY0!(BN!T##.*?6/K&OZ
M+H,23:SJEGI<4K%(I;R9(5=AC(4N0"1D9^HH UU4* J@!1T Z"EK*TR\AU")
M;RSU*#4+.?YX)(-CQLG3Y74G<,@\_P"-6Y(KAI R7/EQC&8_+4Y]?F)R,]*
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M?FM6*SO=M[+W=.5/36]KMW6][:Z)'P?;?!?XG+:XU?2?#^HW:KA9=/MH[$$
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MOTB4'*SOR-/[*BTUY\T>RVV7F?G!+X \8V1/V6P\0N%ZK]DN-BGJ5VB/Y\=
MPX.<@5EMX2UYI?,U+2M9'.6#Z;<>7GN?+,9/![=P.M?IO4$EK;S$F6"*0GKO
M13GZY'-3*I*?\23G;;;3YVO:W1>0Y)V7):+T3DU=VTV\].NE[:6/S*N+:ZMU
M,4XN[.VQAFDL;A@J\#[B[2G'KT[UCZ9<:_H_B?1V\):#+XH22YQ=2BVD;[-'
MY;'S"PSY?S!5R>.>:_3J;PYH-P")]'T^4'@^9:Q-D'URM16GA?P_I\@EL-)L
M[%\\FSA2WS_O>6%R/;I5^UM34%?5^^FHV:TLEU=NG,V)PEHXSDMM$H)-W5W\
M#>MM5?796.4T6XUG5/#+'4M+;3+@0IB!W4$_(^X<X QQ\OI^=?,?P^A:#XU:
MVLD:J_V:T.1"<X,]UC,P8JQ[\=.O<5]FZYM339@9'B4*WS1C+#Y6]2/SS7QA
M\/74_&O6]LOFC[+9\O.WF?ZZZX,.2J^V.I..F,YQ<$I<R;;5E;ET??5-]]K=
M-2_>NMK6UT=[^2N[+YL^Y)$W#EF ')"]_P *^3OCNT;O/'$FYS&H&Z-F!/E@
M<C&3[GOVKZT.<' R?0]*^>_BKX#U[Q;)*NFW:V6]0%D\G>!A0N?-QN'U[<]<
M"OG.(E7>$MAZ<*DY2LU*+;Y5O9\LE;NK7>A]+PG/ T,YH8C'2G3HTO?E*$HJ
M3<90LK2W3MJEN?G)+H,BHT]U.4Y+&%$)Z$D@1 EN.F.N/:MG1-/EU.7['H^E
M7=S=,&13]CFD&[D= @V_4M@?H/KCP1^R[%;2077BO57U;!1IHH[FY16Z%E#+
M(AYY[ ?ICZ<T/X?^$_#A5M)T>VMY$X$A&Z3ICEVW,3COGG/-?FE3@#$9TG/$
M^SH0=O?@JD>:+M>T&FV^NUC^@,]\;LOH83ZIE-/%8G$0I\M*=2$*6&A*R2C4
M2ESU$K=+)[]CX&\*? /QWK<I;4K9]+MF&0SQJ6.3P%'F+L/U!X[5[YX<_9FT
MZQDBN-1U*2X9,$I)$K \\CDG_./4U]7@!1A0 !Q@#%+7U^3>'V2Y3"',JF*G
M%6?M':+[[6D]=KO0_),Q\5>+L?!THXV.%IM.-J%*'/9].><9/;32UNYS6C^&
M-$T2..&SL+=&C"@2"WC5OE &<A1UQG_$<UJW:(5/F7/V<?PE"%.>PQ[^@Y/U
MYK0J.2**7B2-7P<_,H/(Z'ZCM7VU'#T*$(TZ-*G3A%)1C&$;+SVW\]_,_.ZU
M?$8FI*MB*U2M4E)R<YRDWK9ZW;OJKOI?H9-O$7W;KN5U & ZNJGZ[OO?A^&*
MXGQ_<?$+3]&>7X?VNF7NJ><H$5["60QD-N8@7$7(( ^]^'%>F")%& O'IV'T
MIX 7@#%:.G!M/WDU_*^7332VJL[:Z=@I8BK&2YX4IP_DDN9].MDKWZV?3>RM
MYW\/+SQ]?:(LGCVRL;+6#*X>.P4I%Y85=I4>=-@DD]6_G7=Q6QB=W$\S[SG;
M(VY5]E'&![?3TJU10XQ=EKI:SYI7T[N_6VO052:G+F4(07\L%9?Y7]$EY$3L
M0P&<#O\ *3]3G^M *L< DY[X]O[W_P!;_&I2,]1GZBD  X  ^@I2ITY_%%M^
M<G;II;LVM5^)C::E=-6O?9M]-%[UEUUMOT&[".0V/P_^O4<D99U.&.#GAL?I
M^?\ G J>BE"E3IWY8V3UMS2MTVUTVZ#G'VBM+NGLKZ--;I]O7LT(.@^E+116
M@PHHHH **** "CKP:** $  & ,"EHHH 0C((R1GN.#^%-6,+SR3ZGD_R%/HI
MW=K=!.*;3:NUMY!1112&%?FS\?L'XK:," 1Y5WPT;2C_ %UO_P LUP3]>WXU
M^DU?GK\>4B_X6)I4C1Q;A'<8=V,1'[V#_EJH+#I]#B@#[!^%0 \)6F H^<\+
M"T(_U<?\#DG\:])KS3X4$'PC:X*D>8?NRM,/]7'T=@":]+H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "F/(D2EY'2-!R7=@B@>I9B /Q-..<''
M!QP3Z]JP=9TNTUG3[K2=5FC-O>IY3"/$<I&0V%+%N?E]* )KKQ!I%K$\K:C8
M/L!)1;ZT#< D_>F'I7Q!\=OVH/A!IM[:^&]?\+ZMXSNH92QL]*N+.'[*'(3S
M&GFOK6)PY7A5D<_+R.:ZSQ7^Q'\-/%D[W$OB3QSI9D9V9=(UI+5"7ZG MV''
M;ZU\Q^.O^"3WPM\07%MJ%E\5/BQ97,4N]UNM:CO[=PIW "*.TB=>X)+D$>E
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/F+]J3X):W\>OAWJ_@C1-?OO"UW?V5S;1:K:7/V=HWE1U1]ZQRN "1DA<X]^
MGXVZ7^R#_P %1?A-%JWAKX<2?L]^)_#>N6-[H-SJOBC6/&TVNPZ;JD$EC<W:
MB*6&T%W%;3/+&?+*>:J_*PX/]%]% 'X^?\$[?^"?_P 8/V6]>\4>,?B7\28=
M2U7Q9:2+>:1H%PUUIL,\MS#<,B?;[!)EB4HP!64MPHSUK]@5!50I8N0,%FQE
MO<X &?H *=10 4444 -<;E(P#D=#TKX[^*O[/?C3Q[XLLM8TWQ<=(TR!)A+9
MQ&(%S(T94EFM97^4*1PXZ^XK[&HH ^7-"_9ET>"RBBU_7]7U*=&RVV2 1]%_
MB$".<D'J>.U>DZ3\%/ 6DJ@33&N63H]Q-(Q/U 8#]*]:HH YR'PEX=MVC:+2
M;16C"A#Y2G 48'4')'J<FM](8HP!'%&@' "HJ@8^@%244 %%%% $4LT<*;Y#
MM4=\$_H 34#WD8@:X17EC4%B5&#@=>&*FKG7J*0@$$$#!X(QP: /,D^+?A%M
M1FTHSWB7L$HB>,V5R5WD X$BQE#]X<[L5Z+:W(NH4F6-T210Z;P 65@"IP.1
MD'.#@BHX].L(I&ECL[9)'.YI%A0.Q]2VW)/O3WM=\@<33(!C$:/MCX[%<<_X
M4 62 1@C(]",_P ZP9=/L;JY;S]#A=E VW,\%K(A.?<,_'4G'?\ +?KG=>\3
M6'AZ%9KV.\=7) ^S6=Q<GC .1"C$=1VH \S^($GQGLKFSA^&VG^%I; (//&H
MB>/RSO;*A8F08"X/R@]3WKT'PDWC)M.A;QDNC)J)C4RKH_VCRE?'(_?\Y'?'
M&<XXHT'QEI?B'<;*.\7!Q^_L[F YP#R)8U(SFMG4M0CTV!KRYG2&UC7<Y,3N
MP &3]TYZ>Q]* -2BO.-*^*_@G6KY=.T_49YKEG"!38W2)N)P!YC1A!SWSCWK
MT4.K+O4Y7!/ /;V]: '45%',LI(4.,==R,OY$@9J6@ HHHH *@\D^;YGFMC.
M=FU,?3.W=^M3T4 )M4<A1GZ"@*!T4#Z #^5+10 4444 %%%% &-KS!=.F)C$
MORM\AW?W3_=(-?&7P]9F^-.MG9)$OV6TPG[KRQ^_NN1EC+ST.?PR>OV?KGF_
MV?-Y3A'VM\Q<(/NGN2*^+_A^&'QLUSS2CR?9;/+B)B2//NL?O@Y1N>>!QUYS
MR ?<](5!Y(S_ )_6EHI-)Z-)K?57_,!OW1\J_@ !2\XZ8/O2T4PUO>[_ *Z]
M_P 1J[_XMOMMS_6G444"2LDKMVZO5_,****!A1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %?GS\=\_\+#TO;OSY=Q]S9N_U
MD'_/7Y/\_6OT&K\]_CQ@_$+2\@$>7<<-&TP_UD'\"X/^?>@#Z_\ A5N_X1*U
MW;\^8?\ 6>7N_P!7'U\KY?RKTFO-/A0 /"-K@*/WAX6)H1_JX_X&)(KTN@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH JQVOER&3SIFSGY&?*#/H
M,<?G4KPQ2,&>-693E21D@^HJ6B@  P, 8 HHHH 0@,,$9'H:I'3XA)YD;21<
MYV1D*A/N,<Y[\\U>HH **** "BBB@ HHHH **** "BBB@ HHHH **** &/&D
MB[9%#KZ,,BA(TC7;&H1?11@4^B@ HHHH **** "BBB@ HHHH **** "BBB@
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M7R3N95(/%=U=?#'POX@$5IK_ (=TS5;"U/\ HMK=Z=#!!;@ J/*C12I 7C&
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MA;#]XQX^Z.1GVKT?Q5H^HZSI5Y9Z=?FRFFMI8UQE0[,A 1I%^:-6Z%U!*Y)
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M@C(*D$$9SD$=*^4O!WP%\<>#?$%Q>0^-[R[L+G4)[PVT_GW(59YVF,8::5L
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M44 %%%% !1110 4444 %%%-?<5.PA6[$C(_*@!U%? ?QL_X*=?L0?LX:_?\
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M $?C0!/16<MWABIGCE/;RHF;'UVEOZ=#3A)>JX!A6:,\^8I$>T'U1B22!^=
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MURN<G'7K[5;B\T*?.9"W^RNT#USR<T 2T5$)HBY02(7')4,-PS[5+0 4444
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MOB;PY^SVWPR\&:8]RTE[XAGM=(L1#>W-J46X@?4KV\:?RH9"/*CVC# G) H
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M ?O%L]3M)0IZ'Y5G9Q@^N.: -^BN/NO&GA'2[G[/?>*]'CGD/RV\FI6.]<\
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M%\)Z-]OS\LE_";E%4G)"K)Y@7) X  P*ZN;3M+TVUA-YI'A^&0N0HATN,P@
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M !(L9O$.CW7P^U2U@3[0;G^Q+&QE52"VYDELK>9CQG&TM_*OEWXO_P#!3_\
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M$70O%FAZ9]F\.:[XOT-[3^T;^*>"/S)S-$Y8M"LKD,9CG.03S7[#?![]I_\
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MVN\898QM &<XVCY1^ Q5TQN9 XF<+S^[ 7:?TS^M $U%%% !59HK@RAQ<8C
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M^28Q+&\2VMK=73?NR&38">F!0!\S?!3X!>-M(GL-3\8^!+WPZT4$-S-+9?M
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M*-L+F>^\,ZYX>CM=3LY[9));A#<ZE;C3/.AV/AHKDC</W9)Q77_'/P_^R_\
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M*7_!5O\ :CNO .GZUX=^#6L^ 99S9N^K&WEU6*=)'0NFR[TA$03 E-PY0-N
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MH1Y+;C)DD8%?NUI_@WPMI5D-.T[0=+L[(+L^S065O'%M[@HL8!SWR#FJNI^
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M !'TX:3XY\+:+XHL%#^7;:UI]O?Q1&0 .T27".$9@HR1@G ]*[2B@#Y/\/\
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M_P $W=>&G3^+?$/Q+FT3X@LX:TA\)0-H/AN%9=SSQW6F_;;AKF19$A\N1;I
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M^W_'>/J?@ZY^*>JZYDRWOA[Q;\,;31M#MXNMRJ:G&+^1EB3>8V-HF\J"0N:
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M3XEQ_$?7/C9;:3<F]%Y)HFG^$;R. ,7WO&L,6KE@,GI@_6OMSX1?\$\OAO\
M"_7=6U[QEJFC_$-]2L]0MH8+GP/=7;6UQ>P2Q17#))<73#[/)(LQ.%(VYW+C
M-?L7-9V^XS)9VSS]=[HH;/\ OA2U99@+R8MK"*VE)_>2- NQQGY@'*\[AG![
M]30!^)GB+_@F-X;\2ZM=ZQI?Q.U#PK&TK36VD^&/#5_IMFP+%A%=P)<$2*.
M5^3C<,<USGCK_@GC\2?$_P .]5^'NCZQ\'-.MKRVN;2/Q+?_  =O;SQ&$D0Q
MBYDU1M>B!N2/G>4H,N2<=:_>+RK:UP/L&]V^\T$"D?4GCK_C5\0PO'M,*;&&
M2C(,<CH1B@#\XOV#?@+/^R!\#M(^$_B;Q?>^-M1T[2X=/EUFQ\.7MO!*\40B
M,B1127BA"1D 2M@?Q5\)?%;_ ()K_&FY^)\_QA^&?Q6T 3+JJZQ'HNN>!;V4
MLBW N6@\PZS:%G9 47"9R1\O0'^@A+.UB79';PHH_A6-0/R I9;6&8!74X4@
M@*2O*\CI0!^-=U\#OVJ_CMI%CX-\??%CP[\.?"VG*J:K;:9X&U*VU#6H(U$?
MV>RNYM::.&0N5DW>3,-J$;><UQNE_P#!.%/ _B2$^#O'^NN;B&1KS7O$.G7%
M[;)/E.(UAFM=@D)+8,C<+UK]N[F&S+Q++8_:"&^1S"LFPX/S%CR![_X5;-M;
MO%Y;6\9B//EM&NW(Z97&* /P ^(W_!-[XH:YK+ZEJGQ;\/ZUI,\:Q6\-_P"&
MI;FSB<%BWE02ZNS(Y!4,V1GCIR:C\)?L%?$3X1:;J,UMX@T?Q&-8W7%K80>'
M;G^SU!3RQ$]I'JD@V$IROR]3]:_?N72M.EC$3V5JR*<JK01LJGU"D8%>=^+O
M$>D^##";[1]5U5&4/!#HVGK+Y2[B F%DCYR,_0C/L ?CI\+_ -DOXS7ND:GI
M7B?1O@KX(T^_N[YA?Z=\([N/7O(N)Y2EQ_:8UYL7+HPD,AC'SL6P.E<CXE_X
M)!:4\TWB3P[\;O$^M^(69[A-/U^QN;_PT\Q);RWTYKF+-N2=I0SCY>-W>OV4
MC^+6GW\0G/A3Q=;6\8QY%YHD89E7@8WS$X8 8_"FV/QDT"[N/L%GX)\7(YRB
MN-#00AL8#9$N, \T ?CQX2_X)=F^6ZLO&\^G^"A/;3Q+XE\":1_8]\\KQ,J.
M5BNKF4B20@.F<LI*Y!.:O>&/^"</BSX/0ZWI_@GQCX9^)%MXAA:TDD^*G@NZ
MUNYL(C(DWG6)N-5M<S@QJ@9%/R,_'-;'[=6C_P#!2?XF6:6'[&_QALOASJL6
MHV4S)XO\'6"6?V2&[A>ZA^TM8Z@^7MUD16V=6SQ6Q^RQ_P /#?A[H5]I_P"U
MEX_LO&_B&YL!!HFI^"?"UEJ<=GJ7F1-]HN(WT_30D?DK,O1QN<#'(P >?7__
M  2P\3^.='N;/Q'\7SX.$TZ7']B^$_!>HZ7X=G(#G$]K%J,B2,N=L9,HPKL,
M')KG[;_@F'KUAI__  @MQ'X9N_#S'RW\:GP5<76J+&S;FG\N/46N6=<G@'/'
M%<!\?OA]_P %I/$7Q=T;Q3\#?VD=%\/_  OMENAJ7A[7?!&FC49O,GMGM_*M
M&TNZC;9#'.K,9A@NO7.1^N?[.'Q!^,GA3P#9VG[0FI:EXQ\:1P*MW>Z1X=M=
M/BEF7[S+;VZ6R<C@#8/TH ^#_B;_ ,$YM \4> 8/!FAW'@SQ+J-O'!'!+J?@
M:[6>WFB*;+B,7.HJ89H67S$<GY'4'L*X#X1_\$U/BK\.=#\1Z/K/QHA\-:3K
MEDUH((O#MYJ/V=?/BE"VR66K#R,>7C+*0%XQS7[)VOQ=T&*[>X;P1XNB#;OW
MQ\.PQ[@<_P#+59MS9Z9/7/O6O_PM?PUJ:/%_PB?B+S&'RK-HT;ECSP%9\,>I
MH _+;3?^"=UC#\-=;\.0^.M&\=WVH7<,_P#:&O\ @J^FF@*17"D1K<:B,*QD
M4GG.5 ->=?L[?\$U/B5\&OB-?^-M/^*D>D:==&V_XE&G>%+VSLPL$L[DH(]4
M9-SB3;]SIBOW2\)W-IJ5I)+'I-SIRY4^5>Z?'9.V0<$(A(;'.3VR*ZXPQ%0I
MC0J.@VC'\J /+O#?B6ST/2+/2M3O=7U+4;6/9<7W]BZB8YWR6W+^[DXP0/OG
MIU].E'C+2(H6EGGN6ZD1IIUV)\=0!#Y9=CCL!S75^1".!$@'^Z*B:QLV<2-:
MP-(.CF)"PQZ$C(H Y;_A/?#2VWVJ>YN;2/&2M[8W5K*!_M131JX/J"..]:&D
M>(/#>KR9TF_LKF9@3MA=3+ZG*?>'OD<5POQ=MXU\-W<T5M TWDR$.V$.<'^(
M*Q'K_C7G_P %[-XKU)G>$DH_R)"@()0C_6@ M_7O0!].T444 >7_ !"^*WAC
MX7V0U3Q7+JHL&#D?V3H.I:Q,OEX+ETT^&=E&&&"R@'G%<7\)_P!J'X/?&J\U
M#3_ >NZA=WNEW'V6]MM3T/5-&EAGV))L*:C;P$G9(IR!CFK/QK^"/_"Y=)@T
M>[\5:MH%K"TISI$US9RR"4("LDMI<VTC@!. S''.,9->:_!W]D'P]\&?MK^'
M_$%W/<:C-Y][>744L]Y<2%%CWO=3W4TV_:B@,&XQ0!V_QF_:P^!?P!EL8/BA
MXRBT"XU*?[-8VRV=U>W%S/L>3RX8;6.221MB.V%4G"FNE^&_[0/PL^*VAS^(
MO"'B!I=)MS&)+G5+&[T;_6AV0HFH1P.X(1B2H(&.M>(?&?\ 8C^'OQKCC'B>
M?[5<Q2^=%>ZA;R:C>6LFUE\RQN)[CS;*7#%?,@9&V$KT)SUGP2_9S\&_ O0[
M[PEIT.I^(+.^VRF758Y[^WB-NKJJ(;RXN/+!$IPJX''?% 'KR_&;X8/?OI:>
M,]#DODV[[>.^@>10Q91D*YQDJ1^%=?#XI\/7$:RP:M9S1N,AHY5<?CMSC\<5
M\@Z+X9T-/B]JL*^"="%N+:U*SS:7:Q*29;C($HMV)(X/7C(K[!M= T2&%5BT
MC385(Y2"WB\O'H,(H(_"@"O/XG\.D%&UJT0GC,=S&&';UX(/Y$>U5Y/$7A^&
MRE#ZU (WAD03S3H5&Y2NXL2!QGUZ5HGPWH!))T?3LDY)^RQ<GU^[3I/#VA2Q
M>3+I&GR0XQY;VL+)CTVE2* /P!^.G_!(W0OC;\3H?B#XT^(WA_Q/X<37K;6&
MT#4M,MYH#%;WL=X(O,EO\, $'1.>U>T_%7_@E9^R-\5O"&C:5H6A?#WPKXF\
M/)&]IK%IHEL)5N$B\DOQ/'G<&;HX_'%?LK_PCVA&/R?[(T_R@,"/[+%L ] N
MW _*J!\(:$KJUOI6EP+NRZKI]N=X],[,CZB@#\:O!/[ ?BSX3> -3\->&/B9
M\./&$-Q<6[Q>%_&7A>+4O#LL4"3*/-L_[:MU:11)Y:/YH"J[#'/'S_\ $S]A
MOXK^/K32M&\.>&/A3^S_ *Y8WKSWOQ+^#ITWPI=:U!(4"02V46M3SAK8H\BN
M96R9R H(-?T0CPUH '.CZ<2.I^R0C/X;:SYM T"9Q#_PC6GR[.=TUE"(QG^Z
MVQN?7T_"@#\2?%7_  3$E\3^$/A]=^)_VC==\5>-O".FK';OXTNH=?M;ZX2Z
MFG39FYB*1$LH*^<W.XYYX]PM9_\ @H/HNA67@*ULO@_I_AW2[*#2-+\5/I\*
M :;:PK;6EU/8?\)&KRO]G1)) &3<Q. ,XK]3Y/#>CNL(.@Z0_E#"!K>+$7.<
M1_NN!WXQS6C+I&EW,:Q7&G6<J!0OER01N@ 4*% 9<;0. ,=* /D'X.>$_'?A
M'1H+SXG?&;0_$.J"W'G2Z%8OHVB^>8\$QV\FHWP6,/\ ='G-QWKX9_:J_P""
M?_BW]M?Q>8OB7^TQXH\-_!^R0'1]*^'6KKHFIK=2R-]K:XOYKR]@E#1);!%6
MR0H0V2V>/V-?P_X><?87T/16M@=H@:VA(P.0/)\K;U[>M3-X6T1(%MK33--M
M(58MY<=C;F/)XX3:%!.!S[4 ?SMZE_P0J^%WA]O#\OPK_:_^-^A2Z#&H=_$7
MBVWU1+J5)6DWR?8X-,+KC:N"S' ZBO6->_X)U^-]0UC1/$+?';POXZU?P[9V
M%G93>*=(.HVDHTR"."'[;;SZVIF.V%1+\ZA\-@ $5^Z">&-!\L))I&FR'&&)
MLX0#_P !VX%1MX:\,VJ,ZZ%IB#DD)90@GN3PGN2: /R#^)/[$?BKXX^ IO"W
MQ*\>_ CPZMS:^1//X0^'8TB=0R;&,;OXCNHU;K@[2 ?6L>P_8$UJ/P[HWA"U
M\8_#"U\/:-)9O/J]AX96#5KFRLF5I=]S%K>%:6)"&<QL!DDJ>E?L*-*\*W0V
MR^'['RCP6FL8?+P>YRIXYK0_L7PU:P/LTK3EB:-E,<=K#B16!S&%"X;<#MV]
M#G% 'XP_%[_@GG+XXTJP@^!?QYL/!>O::RO?W-M%]LE<!&1A$UGJED;=C(P.
M9#(,#&.<@\/?L >+K3X5:MX7USXI:9XB^,ES=VSZ+X^U;3)KZ[L+"..=+RWC
M']J^8JW$KVSD"Y4$Q+D-CC]BM&T3PM;O<2:=X3MM-=@?,D32X+<S#(_B106Y
MY_#/:ORP_;Y^'G_!2[Q3:Q+^Q#XO^&O@&Y69VDO_ !386LER(L#8D:2Z!J1.
M3G=\XY [4 ?&?C#_ ()1?&J^TO2KC7?B]X&GUV"_DFN-:U3PDZ&6U!1HH4ED
M\0(X,?SD$RL!N!QGK[EXJ_X)XWOB?PQ\.K&3QY\//$VK^$]/6VNGU;0K;4+9
M)5NYI\6<4FK;X8\.IVB5_F).X$XKU?\ 8/\  _\ P4KT:PDTS]NGQEX"^([)
M,K07/A[2[18Q$01(NQ=#TX#E1R.O%?JX/#WAFR"M!X:L4W#=B#3X%(SV.%'/
M'XT ?EAXP_80E^(OABQT;Q)\9K7P0EKI=KIXMO"=LVD62I;6Z6ZL(?[0E !5
M Q 8#))&!7BVD?L'_$+P9HR^!?"7BOX">*/#<2_9H_$_CCP&FO>(Y8%^5;B;
M4/\ A);9WN"OS&3RQEN<#@5^X#:1H5W$7GT&V< 8\N6RB9B!VP0?3@>M1)H7
MAR*VW1^'+-$Q_J5L( V/3:%_3TYH _#SQS_P2QT#QY#X=GU/XT:+=7FD:MI6
MIWVBRVHE\..EA>0W,T$&EC5%\E"L3)&&ED" @'=C!]^\<?L%_"7Q=9^%K?1=
M3^'^B7GAY8UDO-/\/VR7$SQ^6-ZRQWBE&S&2"2V"<BOU*A\+^&2/,3P_ID3,
M/FW6$"L0W4-\G/O4L?A7PW$28]"TM">I6R@&?KA.: /,?AEX?TCX?^$].T27
MQ>VI0Z=8PV@N+B_C942"+8!$NX^7&H'[M,G8H YQSZ%9^*?#+(%CUVSN%QP[
MW,;@^^[.#]?3BM/_ (1[0]AC_LFP\LY!3[-%M.>N5VX-1)X7\.Q+LCT33$7I
MM6SA X^B4 5Y?&/A>W5WFUS3H4C5F=Y+F.-%502QW,0./8T:%XQ\,>)GECT#
M6K#57@!,HL[A)M@! ).PG') K.\2>&/#TF@ZN&T72R1IUWM9[. [2('PV=AY
M'8]1VKYK_9SL(=.\0>(5M5@5&21=EI&-H'GJ<'"K@=.F>0* /LJB@=!10 44
M44 07%S;VJ&2YFC@C'5Y7"*/J6(%/BFBG020R)*C<AT8,I^A'%?+W[6.M:MH
M?PTU2[T>\N+*Z2TF9)K9 \@8 X(!(Y%:W[/-_K.H^$]+N]4U2YOGDMHBPG7:
M<M%W 8\@X..W2@#Z&EDG1T$<'F*3AFWA=H]<'D_3_&E>ZABQYDBJW]P,&;\
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M/#DWAE[6>XAD\N.2[&K7L4L"R,JS(J+YL>Y0PSFO)?!7_!)OQM\/M;U$F_\
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M[J7&H6L3$]. \JD\U1FU96"7"RZ;=63@,EQ'+#+'L!Z^9O*8SW!P.OT_$_\
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M)NO^%G:CO\DP^1;[=I8R9\R?J,XZ8[>M?3%O_J8_]W^IKYJLD;_A9FHMYTC
MPV^(R%VC]Y,<C W9.><DU]*V_P#J8_\ =_J: )J*** "B@G@\9]O6N>U76=1
ML!_HGA[4M48G ^R26BX]SY\\?'Y_TH Z&BO-W\7^*54E?A_K[\\*)])!_6_%
M-C\:>)Y!M/PY\21,#RTESH^P^F-M\30!Z517G#>,O$T7WOAWXBFS_P \;C2.
M/8[KX<_I2Q^,?$TY&WX>^(;<'O<7&D\>_P EZWZ=O>@#L;J],+%5B6,@_P"N
MG 2+W)<D#IQUZU';:WILA,+:II<ETO+06]];O( >G[L2E^<>G4'TKY3_ &A_
M"OQ ^,'@^\\(>'K7QMX)U"YB>)==T:YT-'C+9^=3=27*C /&8OUK\D_A3_P2
M?^._PP^*M]\5;W]HGXN^+I=1:V#^'KO6?#CI!';2SS >0NFV\0#_ &C8=LA)
MV]<#- ']#QU:SC+"XECM5!XDN9HH4<<_,C.Z@KP>0<4IU.SGA9[*ZL[PC.!#
M<0S#([?NW;GM[5^3W[6/['OQ:_:1\%^&_#>A_$'XH_#._P!&TC^S[C4-&O\
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M,ETCPPUVOG66G-=8.U9(8F8C(SA2N.N/\FKLV@Z-.@C?3;/8.0J01H.F/X5
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MV/O < YXZ5]Z5\)_L8%O[*\0;O,_Y#FMX#^3P/[0N, >63P.V?FY^;'?[LH
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MH PM,TRPT"UAT^RM+>VLH%VVT%I:;%B3).WY 0.23VK<!R 1T(!'&/T[4M%
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M^^]@N!U(/J:\Z\:_M'?&_0-1NYOB-H_[0J:M.TBI8^&#KL.G0W+DX6-[:ZM
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MA^-KF?QQJWB?0-.\7V[,-.N[W5KV&>VMI_WDL 46"@L6BCZKU7KS0!ZQIO\
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M@O/$OB+Q%X)TO4[<;]3MI]1T;6HHY1_K%TVRALXTE /"+<+@]#WH ^D/@O\
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M92U?XMZ)I.CV/Q,U;P[%IK*95\J6YM]058FC\N[A6>+S%)(?!;[P!KX'O?\
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M<]J (TRZ*9(PK'JIPV/;-/VKUVC/T%4Y;M+17EO9;>U@0%C+),JJ% R2Q8@
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M^7PGX9U?7YI[&UMK2XO]>\,V>HV\MQ'!&DTT[6-A(AWR!F8(F.N !6;\+O\
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M@=(_X*!?$>T^%BV^FVT^L_$R/3^+[QIH-[;Z++>K%]Z5=*A@E$3N,MM0$ G
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ML> ?V6_V6[MO/N)X9O#WP[L?#+W#2R/+YLS3ZU,WGR,Q:5R06<LW!-=C\/O
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MM72;2:L_-=GW7D?FSX=_X):_LV^&_%L7C"U7Q3/J,-VMXD5QJK&W$JOO7Y5
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MQ;0B25!Y:L?*^;$;;F ]B>.] 'T7#=03DB)RQ7K\K#'_ 'T!5BDP!T _*EH
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M9&+9SSYC-TZ<_P"->X6&E:=ID2PV%G!:Q( %2&-4  &  % JR=\*?\M+AO\
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M(\D$BJ HGE:1$V%UP[ 9"GC)ZUZQ%J=EJ5J+C3M2MWB=0RSQ,DJ\]#UY]/\
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M+=#YFZ>221]S(@8;I'D;M_>Q7-_#_P"'>F>$[64[;ZXNIV1WDU$P.Z-R2(C
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M!/XC7>D:A>1WD5GX..M>*%M8@50QR1W26Z0MF-FV+P 0>K5_1LJ(@VHBJO\
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MKGN "1^>1562R$L/DO+(1C&X;5;_ ,= % '(>./B1X0^'M@VH>*M9M-(M?E
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MQ5C1OBA\-;ZVEU'1_&_AR[LTC$ES-)XAMI%@BR/F8-.P7YB!QQSQ7Y#^'/\
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M3Y^8^#V'8 _0#5OB7X!\+0,_B7QSX<TU4'SS7^I6=JJ^Y+28'^?6L?4_BO\
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M.!PP_BW(#G.: /HFWMXK6%(($"11@*BJ   !C@# J:LFRU[1M2 -AJ=E=YY
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MF578)D>H[5L? #_@H_X*_:%\1'P7+HMGX0UIOGBM8O%EG?WLBHZQN1#';1.
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MGB3]J'58GOO'$GQ/T[XB0$_V9HOAS1=?B\%7,RX,2WZ(MQ 8FERLFZ]0;!U
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MEEU*XLO'^E*EM86^9+NX23:Z3&&!'D"QEB^W Y(- 'VU^Q;J?[7-W+XHTO\
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M_K,/PDM \6X:O\<_"'C@Q* /E-GI%S9O+QP=H'4G'2@#^ACX"0/;_#[3XY/
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MXQM/.3],_A6]&K&35W*%[<RMJEI\FM=U=7TOO;6\DGRR<>9-77;YW7WGS_\
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MF2%0I+@E1U !)_(<FGT4 01%&3,0* XP&4K^AY_S^61JVEV>JQ&WU"W,T9#
M?(7 W<'"C.#[].*WJ*J,G'5;]S#$4(XB#C-Z/=23E%]=5=:^::?J>*0_!/P2
ME]+J!LFDEDD\P++&C*IP!@+LRHXZ9]^>WJ6F:;::9#';VD"0QH BJL8'RCCM
M]/Q^O39HK25:<[*6J2LOZM;[_P#A^3#Y7AL+)3HQC"2NVXQ:YFW?^9V\K?>1
M^8N[;ALYQ]UL?]]8Q^M2445D_)?KKU/3=NBMIKUU[[*WIKZA1TZ"BC.>E3I=
M;7Z=[>7404A/U_ $TM%#O;1V?>U_PT PM<T/0M>L9K/7]/LKVRE5DFAOHDEA
M9",,&60;2".#D5\?^._V;?V<-/L;K5;+X0^#Y;I$DF%W::%9(=XW-Y@F6!N<
MY.0>,?6OMJ2..52DJ*Z'JK#(-?!/[6O[2WA3X->$=<BO])OIDM;6[1ETZWNI
MGPB2*=D=M;S-N]!CTP.E?4<*0Q-7,,/2I2KU'&<)5N6K&C35%27/*=FG9?RQ
MZ>>^-9Q46Y*.M[)IN[Z;:_.YQOP;\:^"K36=6\+V'BKPIX>DFLM0LK"U2^MK
M>XM+F2WFC@VQFX3YHW*@!54DC (KP[QY^RA^UYXE\2OJO@7]HC4[;0[FX,GD
M6<UP(EA9]P"E-716&W_9^@K\R?V:O@7X2_:N^-$NL:!\4?B=X1NYKNYOUMUA
MO4A7RM]R8PLMI 8P0FT$GC.:_I&^!_P-OOA+I\=G<^.?$GBL(B('UJY,A&P8
MR%(R"<<\_IQ7UW&,LKPV(K5L/7IRQ-6C1A+"U:%2<8J%^6=*M%J-Y7=U)MJR
MN84H2?*I0BXIWYE*,^VE];=--UWOLOP ^&GCOX:^%K73_'GC2\\8:JL/^DWD
MZ2EVE?+M_K)[@D@G&=QZ5]#QR+*NY0P!_O*5/Y'FI**_+)S<Y.4MY.[MHODN
MAV^BLNRO^K;_ !,/Q*B/H&L[\ #3;SYL9V_N'Y'N.HKYA_9U93KWB0+>O<X2
M3Y&5U"_OTZ;B?TKZA\1$C0=9P-Q_LV\P,9S^X?C'>OE_]G9YFU[Q)YELD(V2
M8*Q-'D^>G<]?_KU('US1110 4444 ?+_ .U8\:?#?4S*T:K]EFR9(FE7[K=5
M4C/T]>:UOV?B&\)Z84P5^SQ<JI1>8^/D.3]/2N4_;"6-OA=JOF3-"/LDWS+(
M(ST;^(\#Z^U=%^SB%'@G2 KF0?9H?G)W$_N^I(ZT ?2=%%% !1110 <]_P"6
M/ZFBHT8-G!SC_:S_ /JJ2HIOF@G9K?>[>_=V;N%^VOIK^044458#2X4X.?KC
MBF^;'G;NY_2E8MG 3</7<!^G7BH)(P<B-@'(.%)XS^&,?G_.K2B][KSNFNF]
MDVM^OWF%2=6.L%&5I)-24HM^4&[*3>NQ.'4G'/U(P*5CP0&53VS_ (5\Y>//
M"_Q0OI-_AS63;J)D;:')&P2 L"!<)QLR#VY/%=-X'TWQQ802?\)%J,-V4C'
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M?!=];1W:NA/EW<)TPN5RX;:P'S*.F,5]1>"O%O[/_P #/"TT7A>UO/"WATO
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MM9@".V<'H.YH <=*L6;>T"M)VE;)E&>H$A^8 ]\'L/2K:QJB&-6/?[S;R/\
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M#Q#9PZ+>?$KQW9>&X[>.TET/2XO#EI#<P)&L;>==Q:0E_OE5<R.ERK[B6!%
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M_9Q^&]]XSU+X%Z-XKM?M<2_V?X>T+3KS49V:*:021-(J-M^4KPV"Q'X/U?\
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M\JTA6%2SLY*J% Y;_='84 =%1110 4444 %%%% !1110 4444 %%%% !7/\
MB9Y?[(O(X8(IY'A<*EPBM;DX.!+N5EP>^5/':N@K\\?VT/\ @H?\'_V.==\*
M>#OB/H/BG5K_ ,<6\<NFS:'%8O:0K-<R6B_:VN;NWD7]Y&Q.P'Y>G- 'Y!_M
MF>$O$T_QDGN+OX>Z1+&UY$RZGX%^%7AGQ7JJI\I5AJ%U#I]RMP%P6'G I)D!
MB1FO$_A_\7?'GPY^*D,&E_!+XI_$BV@NE1;?7_AU8:;?RJIVY:."XU(HV.2
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M7[/WQQM_C)I\VI16T+1P7-S!'=VJQ31W*VTSQ"?<J1A?-5 ^T9"YZGBOEO\
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M;HMQJEI'YCJB%[B%-S,<*!\V<DD8]<BO"_"-WX6\?^'H[30]7M[>6YA"QM'
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MCV%?DI\4/^":/_!<CP/XHO\ Q)X2_;9.MV"WDMVB0Q7MO!M9S*4_LZ&UFM6
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MX[4 ?2M%8>G>)= U:%)]/U?3[F.0 H8KJ%B0>F 'S^E;2LK#*LK#U4@C\Q0
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MN,8YW5\K^#/^"G'[0UMK,]J_P;UCXA65PS)');6\NEO:(3D2L;32Y-W0*06
MRV<U[5H?[5OQV\<^++#4O^%@>&OA=:B,B3X6ZW#;7.NZF9)(_P!_;W%WIRW2
MI:A3$X7@M<*3VH \)_9S_P""-8T[X;VFB?&/7WL=4TZ_N+^TTWPK:1Z;?AY%
MBVB;6!=7L$JEDP@"+M(8G[PKL?BE^S-^UYX8TR/P5\%_"?C&]\.:';FST/5[
MWXF:5!<"(EY/-\IFMW0AW/&!TSZ5]R?'3XC?%BQ^#FG^)/"FL:E8>)9#>B6;
M1]+35%F\N&V:(M$Z(L*EGD(=8R>>AV\? O[-?[2?[<'B;3_BC_;>EZ/J_P#8
MMW-'HM_J>KWEIJI06$,BL-'_ +#:W5Q(6Q$LSJ?[W/ !YU\+?V/_ -OW4H+B
M3XP>)_&UU8O<W#'2+CQW;W\<=J9G\JW5A>RIL2':@P,  C':N^\(?L$?%'5?
MB-'%KO@K7/#W@5[L;_$>G>+].DU%(,C]^L$>^;>/O8"$_P Z\W^ O[4O_!0I
MCXO\;?$[4Y)/!.@>)-?B?1]2\+V.ES-I^GZE<QI%:W(TQ'FC-O$JPSD@R+MD
M/4UZ[\1/^"GWQ=UWP3/KWP;^&>HZ>[6[-;ZCKBB#0D8#"S-?BQN@(@?F+>41
MCM0!U&B_L8?M=:)XLU$:)\5?B)IWA6S%U)HRR^+A(+AHE<V<4L*W,9592J(V
M4  8YX%86O\ [.__  4@UK4X;B/Q]XFTZSTF8RP06?BU(VU10"@CG<:F0F00
M^67&5Q5GP+^W!\;[CP]%KL_Q#\->.O$L=M]JG^'^B6]BUW<2I&9'T^TN+>Q^
MT33N08HAY*EVV]":XC5_^"I7[4&O7P\/1?LR>-?A/=^88K3Q!XUMKRST[4G7
M/-H9=)DCDWJ-Z@  J"?:@#T[4?@G^VC=>';B#6[_ ,6W6LK"Z0VJ_$73K=KA
M@IVGS))V"%VXY/'YU\F> _V5?^"CMQ\0([GQUXE\??#+X=B\$DNHZ3\0;77M
M1@LP^XLD6G7IED8)G 6#)/0$U]'6/[>?[2L%BVD:M\+K/Q%K]XI^QZY8,\D=
MJ7&(RT T54?8WS8;KWXJ'XQ?%7]O/0/@M=_$"'XG6O@ZX33WO5MO^$&TG5)(
M?D\P1^3=62JQ0?+RO..E &+X/L/V\/%GQ"L_ ^G:OX^;PCIVIQ>=XIUR/5=/
M>]L+28-*QNKV>&)VGA0_WMS-P"37[>^ O#VK^%-"L4UK4=1U._$"I?SZC?K*
MD;[4W.N[/\0(^\>/K7Y!_LP?M=?M>?$/P]<1ZYH=IJTVEZ/>7[ZU+:)IDFHM
M8V<MQMBL8-)$*2W)BPD:N0'; S46F_MR_&OQ)?:]%K.H0^!-1\.AY+'P/K.E
MV[7WCF991#_9>E/-9+,9RK-<CRD9MD+$CK@ _;Y;M+QMD,<5S!U>1)D<(W8$
M#/)YJR)K:$>6KQ(PY\O>J\_C7X"?\/$/CMK^N)X*OM)\/?L]7$H>2#Q#XSN(
MX3J"1,J;[>PN]*5'60R!LAOEX ZU5^)W[5_[8-GI6F:3X*E;Q])-.P?XB>"M
M#@U2QD$H3;$]O'IR0+]G_P!86#G(DYH _H%AFFD9M\ 1 ?D<2*P<?W@!_+_"
MFW*S,#ME\N/'(1&,GO@@]?3CBOPKTK]HW]M'X8Z5X6N?$WB"/XE7/BZ!+J/2
M9?#]IH=UX<W3/;_9+XVEA.Y<&/S27 ;9(.P%=7\4?^"DOQ,^!&I:7X$\=?#G
M5/$/B_Q!96%[8WWA@"]L+0:M;Q7-K%<$V4!$D"S*DP,9PZMU[@'[2QL\4 ,"
MS7) X$S%&/UW <_TXJP)D15:?RX&.!M9UZGC&>.YQ[U\K_ ?XA_$7QQX$M/%
M7B[3[JUN[FP6Z:T5"+E&EAW@?9_)A4NI;[N!R.>E?B5\4/BQ^T3IWQ:\1R>+
M/VAO$&@>#[2XOIM,T#Q3I"^#;21HG=[.STW5+%YIKZZD<1Q6D#*HNIFCB8@2
M$T ?TP-)&B&4D; ,[E&>/PIL%S%< F)BP!P<@C^=?SF?#K]M?]H#2]*UO4K#
MP_\ &OQG:Z):F6-)O!8GT;4U$L<?^CZJ\LTK1G<&$HAR1MR.2*] \*_\%'_B
MUXSL+R/7TTKX#O:N%6^\:R6]N9RH;*>5>V$:ACCG!;;F@#]]!.AD,8#[ACDH
MP7G_ &NGZU+@>@_*OYW]+_X*:_M W'C"?P)X?T;2_B39HL1C\>>'IEFTZ1YW
MDC,7EVVDM;YA$8=L2G(D&1@#/O?B;]K/]I3X,Z-9^._%6D7GQ!T_69+>WB\,
M:#8YO]-;4G2&*9A%8AG^QM,LCJV 1&0< F@#]IJAFA$R[=SQG^]&=K?@<&OP
M$\7_ /!0O]HG1KC2_$5CH6LV^D&837?AS6]$BT^XN8&1O]&@N$LIY#(&96R
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M2"/S%?&G['C7]QX6\0+JS1W$BWMO@_98H ?]?D[(_E/;J*^RT1(QM1%1?10
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MI8J_8K)^&M+<_P#;-.HYZ8S[U\]_M(>#_"?B7X9^)M)UN_M]"@N[,1M>JEO
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ML%S#&S(C$+((44-G #8_*OJOP)^TAI&NV$$^NK9:'<R1YE@,P?RV9,E2, @
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MA!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<@*"0 )!P3G)Q6YIOP.^'^GJIETR74)U;=]HO+F>20MQU <+UR?N]_2O7Z*
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MKH^$H-+EC=W +?:)TWJ0?XBV1Z]Z^H_&?_!1C]G_ ,*:Y/H7B32_[6CAE,,
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MSDX+B8#MD@U\C^-_V.?@7\2_%(T[PQ^V-%X T:*^21?"?@75;30[9H(9E<V
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MI6D^,_MNHW7PR\6>&=#TV?[/<MJ0T>YN2[;BI2/3M5NV90$8GY/\*]Z\-_\
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MCJT=A9:3*JME3<_95(4JRC&2_F9.<].U>'?$7X.:.!<77AOXH6KNS[H[);V
M(HR?E!6= @'3D>@[UE?"GP+;Z=J?G^*M:T&ZMUP!/>7ME(XPRYQ(TS 9'4'F
MMI/D2CRV4M9<W,X[+56C%:=^5AB*M)13I<O/I\4[.^EDKN,;/16W?1H_1OPS
MXGT[Q-IT>H6#YB<X *[#T4_=.#T(YQC\JZ0,#P""1V!!KRK1_$_PVT:R6"S\
M0^&8&QC*:C9 9VCCY9 #T/3^E;_AK6],U>YNGT_5M.U%/-X^Q2I+MPJG!9)'
M!//H.OXUSW2=N9:[:J_32UD[;V?7\LHU(NR<ESVU2VOU2=VG\FV=LP##!&0?
M\]ZYRZT>%YFD4F-B3\RLP/.1G&"H_P ^Y/25&T>XY+,/4 UK3FX.][?\.OT_
MJYSXS"PQ=/DDKZ_S..CWU3/#?$O@3P_?PW2W^HW-MY\<B-(+H0CYUQGYL 8[
M8Y'Y5Y3X7^!?@'3;ZXOQX@N;F3EQ&]ZLP!+#JNUCZ_=_I7O'CWX?6_BO2KVU
M8S&66"18#O!VR["(V!XQA\'/^3\J^!_@+XZ\)ZY<7MUJ!EL'9MBRW"G8I;(P
M#<$+^*X'OS7TN!Q-/DDUBG3F^177)S+;2*EHO-K5KOH?SUQWD-6AC:%1\!4>
M)Z*DDZLYS7LXSE9RFN2=6?(O>TDD[,]%U8R:)J$5MX<4W0V-PPVQG:5VY9BC
M9],<8)SSTS;#Q+\2)=5-K<>'76P 3;<I+#Y9W$[L!;EI,XQP5Q_7;UKPKK5_
M>P6UIJD=O*$8';*AD)RO1A(N "0<=_:K&A?#;XC:9J'VI]>DN[-MN("V2N"2
M3O,Y!R".-N?6JQ>)IP34YRK7VDY0M)Z6YH^ZV]%K%..UNR^8P.2Y_4S"G'+N
M%,7E.5JI%3>$O4H4W9-IT)14]VERJ;75[GL&AZ"]S;Q7%SY\4[@%T:0;02H.
M  2>.V2?>M&Y\':9<7=M=72M-+;/OB+NXVM@@'Y, G#8YXK<T>*>WM8UO!B<
M* ['.<XYR>?Y_P JV@RMT(-?/5*\Y2O]FVEE9=-GKI\S^F,JRRA2P5&#NJW+
M3=12O\4%%ZT_=Y7W6MK[R1GKB&2.%-@15P%(<MQZ'[O/N<XS[5:,NUL$KCL
M"*FP.N!GZ5$\6\Y#$'T/3O\ _6_*L>:,K)JUE:^]W??1+4]NK%J,?80C&4;<
MR5DI=V]O+=R$#XRY!5?7KGOTY^G0?A7*>++W7#H=Y-X1M[:\UA$D%O%=JRPM
M(H^4.<H<;O?^M=@HVJ%ZX&*7 '0 ?A6=&U":E%<UI<S4M8RUV<59)/R7K<T7
M-97;YK+7JG;HUVZ'X@?%*[_X*K^(]?N=,TCP5X B\&R73HDTLZ?\>;2'#$+=
MM/D1\YVYZX K]/O@/H7Q,TGPQIJ_$0:)%JB6\8NH=+$N%E\OY@ID'(#\<GUX
MKWV3(! "X[9Q^/\ D?G4*NK':)$+>BL,\=>Y_I7JXWBC%U\'_9M+*Z,:2DYR
MG0PWLXWE:+:DT_?TUDEK?7ST@I*,K2?*_BO>3OW;>JO_ ,'S+=%1*K _C^GY
MG-.,D88*77<>BY&3^%>+1J3JIN5*=-K=27ET)MK9>]I?1#Z\R^*WVO\ X1'5
MO(QL^R2;\[,?<?/WOFZ>G\Z]-KRSXM)$WA/53).8F%I)@!&.?E;^(<#\?K6H
MCY<_8HQ_9?B/_5[O[?U[=L\W[W]I76<[^,YSG;\OIVK[VKX+_8I)_LKQ"-S,
M!KVNX+3++D?VC<]E&5XP=IY&>>E?>E !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M6?,;F%S+YLDD0Y\F.%68^P;.?>M"JUU-)#&7CB,S <*.I- %6[UC3=/@^TZE
M>6^G0@9+WLT=N%'N9& _^O6;:>,?"^H1SRZ=K^DWRVZEIOLM_;2>6H."6(DP
MHR0,D@9KX _X* 7;_P#"%Z<LPAAMY]0TJ.[$^HW5@!!)>VZS?/;HS<(3QQGO
MP:^>=.^!_@GQ]^S?\2M&^'1O+KQ=JOAI(X/[#UC4KZ\6<WEHS^4B2)(6P&&5
MP>OH<@'[!)<:=K0:>+48/L\9Q(T4\&0QZ?OXI25Z'@D9Q[5+#>Z7:%T.NV3P
MJ,F*2\@E=/4LQE9\'WP.OI7XR?L$?LH_%;P7\&/B'X'\>R^)]+?5]8M;JRO-
M9.I_VDJ10WZ;;>"ZEWO&?-4L5F7!"C!XK/\ A'^RS\0_AU\<OB'K&M2>*-0\
M(W&A6WV/4=3_ +2ALS*D]^TRH))I(<JKQ$[6S@C\0#]G;/6?#6HW-PF@ZWH\
MUU"^V[AL)K6>=9-H.V54?<K;=O!P<$5\1?M*? +P/\7?$ZW'BOXN6'@6-D@C
METZ>.UL=2=8XTCW0ZK]LMKJ#S NY"C@KD$8 %?!/[']K9VW[2?QFCAUN:[3_
M (3$8M+6]O+OR?\ B6Z?^[>.0JD9/)VKQR#WK[J_;9_9I\-_&+X1ZW=0^"]6
M\4^(I-(D2VL;*_U*PO+AUM%2,(UB6E5FPH!5<Y.?H -\,_L??L?:SX:3X;^(
MM:MOC!926XLFT/QEXWU#QI876Z/9LDTO5=2U"WE5R<^6RLI!V\CBOG"V_P""
M:7Q?^&OB6\O_ -GS]H'3/ 7A^XDD6V\()X0L9-+TZU9\I!:PR2R11B)0$39$
MFU1@8%?/W[,W[+OQ'_9W_9OL?&'@+X5>+O#OQ3T[3$NK?P_>7>MZWJ*WD"AT
MB(U)&GD<,N &BR>AP>GKI_;(_;&O]+M=)T7X%?%C_A*%")>7>J^$I;#31)C$
MC1W"0S,PW\C]VO&.!0!U-]_P2_\ %GBC5(O$GQ5^/6H^)/$3.)F=-(VV4+J1
M@6T OXHH4! ;9'$HW$G&3FO3]3_X)N^&/$]G;P>)_&>BZ_=6UM%;6USJOAJQ
MO;N.&&,10(LUQ<M*OEHJJH4G:  .@KRZ32?VZ/B=X>DUS6?$6J^"-9AA8V&E
M#0FN2KKN95=G2W)R_',9X/0\5R7@GX=_M]:AX*UWQ;XV\:SWWCO1KC4H_#NB
MRZ1)8QWUM933)I9=XXMP\^".'<1!)C).6ZD ^BM4_P"":W@(^ Y/"]M?^'])
MOS:-;KXAL_"6G-J,;E,"99/-CF#K]X'SLYY!%?-?A_\ X),^-OA_J,FL:'\=
M?^$X@O \+:-\0-).H:5:17(,;2V=KJ%WJ=M%-;*YDM6CBC,<B*R,A (\4@^,
M?_!0[5[)K+XQ:/\ %'PC_P L[A_!'@5_%$$8!P3#-=#2&D4 $J2%R.>*]#TS
MXL?\%%[O^S="\,>%O%5QX>N[BVM)==\0^'KC3;Z*RF=8I;J6S2TNHU>.%FE*
M?:<9&W<!\U '?I_P21FOO%>B>*M>^.FM+;Z==F[N_#6FV<X\,WP:-T-M>Z>F
MJPV,UJ"^X)-;,@9$.S(!'OFJ_P#!/?X=RZG87?A7QYX;\'^([2U>!)=#T72+
M.:<';NDGL+6]A$[[U0EW5RI)&1N->U> OAO\5]'^&7B.X\9>)[_Q?KVKZ2JI
MI']GG3I+>Y,T,C+')"\DK, '7B-3CMVK\$_''[(/[2_@C]K'1_VG-"\'>./$
M5GH5KJNF_P#"$6.H>(Y1>C4;FRN%N1$JO 1$++9S W^MP"!D4 ??OQ/_ ."9
M'Q-\57QD?]IS0=)B"XCN+_PII#W1YX&V:[4KM&,,KY.?6L;X>?\ !*"XMM4M
MM2^)7Q^N/B1:Z;,KVMA;:819>0I5S +:/4?LZ*S;B5567YLGDG/D/Q/^"O[1
M7[6MU9:]KG@'QW\)CIB1K!92MK32R21 '>R*+,$'W!STYKTC0_$G_!0+X+>$
MK3X?>%OA]J7C;PYI%L;6+6;R"^L]2MX6+N6MHDTZ\-\R[BP,MRA)^7.* -+]
MI?\ 9&^.WBKQ[H>@_L\Z_J7PM\$6EGI.GW,VBV]QIUO,UM:P07=U+:66V"1Y
MY$>60O)EV<ECG)/ZD?LY_ 2_^$/@2P\.^+_$MIXW\30:?';7'B2XL88;V6Y$
M(1YV):23<6RQRV<YK\A= \??M-Z=I.HZ[/JOQZD\5B:ZG'AR7X30I!%=>8[?
M9+.Y.JM)<VZ/^[AG-NC2QA7,:D[1ZAX*U#]O[Q;HD?CM8-<TC4Y8A=#0_$^B
MS:5J"EEW>6]NMM,%?'5<$!N!ZT =GX?_ .">'QH^&?QI\1_%[X5?&OPU'J>N
M/J>S3;WPMIL3V7]I+*A=KG%R\Y@64G8\8$I7#8S4'C+_ ()=>-/CYK-KXB_:
M2^-T^OZWH]R;_P -W/A*RD\*OI>H%7B\UCHEWI_VM?(FF39,"I+!MH(!KYX\
M1_$C]LC0=2>7PO-\?)/&<LOE_9;#X107WALW,K[62756U(21618D27(LRR19
MD$;$8KDM:^(G_!5AM5TB/Q5X?UVSBN[C;IU_X:T:ZU81L8V(?7(Y-/M%T^,H
M&W,C3XEVH <DT ?8&J_\$L;I-&DTFW^)$?BB#RFBAD\763ZC/&FW"H+F^N;R
M48]=W'4>M<W#_P $JO%U_P"#O^$-?]H:_P#"NG-!]G_LGPU:2K:QIC;Y4;P:
MA:.$7[H(0<8&,5Y[8^-_^"E;O;:+J%MK-Y;7:JK:C;:%,Z0*^%)FQ:* R#EA
MNXKUGP_X!_;LT*]CUC_A-[Z\",)O[.DT%E#'AC'YFUCZKG:?Q[@&=X3_ ."3
MMYH*M;3>/8('AB<6_B-!=76IF94(CGEAFF49+X9P9R,YY/?C?&W_  2B^*?B
MNVN=)E_:1T>_L;GY(KW4/!6F3ZQI"@DB;3;YKB2[MIQQ'YD4T3[&8;L$@]/K
M'QX_;\TR[N=%_P"%9^,-;BO1)8_VC#HEQ';VHN,P_;%=+-PZP;O-VD@$)C<,
MUY%JNK_\%(/!=VDGAN#Q-K$?B"3RI[J+PU-)/X>C<&;SDMS!(ERP91%MD>(?
M,3D'@@'MW@C_ ():^)?!'POU?P#??&:3XAIJEW;71NM>MI8)K1[>.X0+;7,E
MW=S11GSLF.-T0[1D<"N'E_X)2?$S4M,CT+4/VK-2\(^$XI9)K;PQX9TO[%-Y
MDNT2^?KMGJ5IJ%PDBI&@CE#+'M)7!<Y]'6Z_;2L/A#JFN^,/$?CG6M8^U6HC
MBT?P/&_B:!9(;@RI;:*DL27,095\R4SH5;8NW#9KYMT[Q=^W-I]J->^&/A[X
MG>*/$EY.\%Y9?$OP9+X-@LHHSF&>W:V.M><6+OD-%'PJ\G/ ![IX&_X)/_\
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M1R,\'N/2N%T_PCH/AMR^BZ0S&4[V8S22#=TZMNQT'Y5VD+3&,&6-(SCA58L
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MP#9KROQ/^U=^R/\ VC+I7C+X>^$M0\*[VCEOH-/CU8O;YP670[2SDNGRIXB
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M*U*-S%]BU6SO-/N'D7.8XH[F*-I'X)VH"< G&!0!]E$9ZC/U%-"J#D*H/J%
M-?F_\4?^"H_[,OPZMT:UUG6?$]W*X6.#2?#VN7$+)P"_VJWL)XAR1@$\C)'2
MNN^&_P#P46_9T\=>'8->U/Q'<>$//F:)8->TS4K&/Y51MPN+RTMD;[W('3OU
M% 'WI17S]8?M4?L]ZC9_;K;XL>#?L^"VZ76K*$D#/(2256/3THTS]J'X&ZVS
MC1?B+X9U-8Y'B;[)J=O*Y>-BKA8T9F;# @8!SC(ZB@#Z *J1@J"/0@$?D:3:
MN,;5QZ8&*^2?%7[<G[-/@N[ELO$OC^/3)H69)#-IM_Y2E3@YE$.S (ZYQWZ5
MU/AG]KG]G+Q;")]%^+'A*9#&9<3ZG;VK[54N?DF=&SM!XQGC% 'T< !T 'T
M%+TZ"O-?"GQ?^'/CB>2W\)^*=-UZ2($R?V;*+I4 (&6:+<H&2!G..17I((8
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MJ<'C.*U(?&GQ#,6ZY^' M92I(C;Q#8L"P'"AP@')XJ.;FN^5;=7;:VJUUO\
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M\9:9 8QCDCS(!OYP,"@%=M);MV7S/IRBODF;XR_M$1S*B?LU7$D1SNF'CK2
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #74.I4Y
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH "<
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M:,=+::M7<E]UO,5KJ7L^:6MK1CO&RW7,Y6OWBU?[5W8_45G5UW$YD4<I'(P
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M6TGF*SX(V9^4YZ5]@Q3R7,J26WV>>VV_-*ETQ(SR,1JI1LCG.?3UX_&/3O\
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M/E;C[K[W[63/TTCU;3)XFFM]0LKF-49RUO=P3 JJEC@QR,#P#7P#JG_!1_\
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M$?"W2(?&'Q?_ &R?"OC7PWY?]I3"'P?X5T. V<O^D*D=S:3@R1B!@J3':9%
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M7X]?L]?MZ_"/5M+T/QYJ7@ZULKFT&M.U_:^'M6AO'BN$:"W757#21@!]Q16
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MH **** "BBB@ HHH)P,G@4 5I[N"W*K*Y4MT&"?Y4UIY]Z^5;^9$V#YGF*N
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M&D5MK D<E3S@9Z#G%7**I-K[[C4FE9/2Z?S6Q1BL(DA$$S272@8S<MYC'ZG
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MH!^5,,,1<2%%+CHV.>?>@!B.X81^5)M55 D8KAL<>N<\9/'?M4]%% !1110
M4444 %%%% !113))%C0NYPJC)X)_04 /HJJEY \;2HS%5Z_*P.<9Z$9KX:_:
MR_;Q^'?[).GZ-J7C?3YY[?6[N2TM7626%?,B,8;)6VE&/W@ZXQ[T ?=]%?F?
MXA_X*8_"[PQX)\$>/M3TP?V!XVTT:I9SVNIK=R06QN9K;,L,%N\JMNA<[75&
MQCCFD7_@K1^QH&M(YOB(89YX87FB;3;W-O)(H+Q',8+&,DKD ;B.@H _3&BO
MRXT+_@KY^QGXD\>+X!TKQ]YFI/<_9DFGL;RU@9^@S)-$L8!/<OP.M<AX?_X+
M'?LRZG\0M0\$:I?_ -DPV$ETAUCS)KJ*7[-OY2)+=02^WY0LC$Y&,T ?KM17
MYL:__P %:/V(O#6G7&I:O\3[BT@MDWRM-X?U5$QD#Y7:$*W7L3Q4GAW_ (*L
M_L<>+_!NH^./#7Q(AU#1=+N(;>ZF>SN;<(\RRLN3(@[0N<>@H _2.BORJTS_
M (+.?L!WMY_9=Q\9+.VU7>8_L26%S<-O'\(:,<D^PK#N?^"V'["-GJ\6E7/Q
M%OHS/<QVL4Z^'M8DC:2601IEDMBJJ6898M@#D\4 ?KC17RYX5_;(_9^\9^!=
M:^(V@>-H;WPKX?T\:IJ]\EK-NM+-I(HA*T&#+_K)D4KC(SS7SM+_ ,%<?V%H
MK:^O'^+,HMM-N/LMW.WA_5%ABG^;Y#*8MF?D;'/.#C- 'Z645^:GAW_@K7^P
M_P"*VF30/BJ+YHE!^72+Y59CGY1(4VYX[9Q_.BO_  5K_8]L]:?1_$'CHZ*S
MS".RGEL+R1+M2%Q(/W2A!N)7!8],YH _3FBOCB\_;W_9:LM"7Q%+\3M)&FO;
MK=(Y9!*8602*WD^9YN2A!V[<]J^5=+_X+$?LU:MXR_L.VO"?#7VDQ?\ "5&6
M41>0&P;C[&ULK8 ^;;YGXT ?KC17XZ>+?^"X/[#>BZM'H>@>/QXFU4W<5M-:
MV]G=PF$-*L<C[A%(&\I2S8[[3V.:]?T[_@J]^R!?Z;%=GQV\5W-&&CL_[-OB
M2Y .PR>5@<9YQV]Z /TLHK\V[?\ X*G_ +*-RK0)XPE;4S\T.GQZ=?2/+$/O
M2!UA.-OR\;>_7BN4\2?\%A_V*O",UE8>(OB#-I>JWTX@BLKK2=1A7<Q 4^?)
M L9R20<=,<GF@#]3Z*\M^%/QA\#_ !D\+Z?XN\#ZO!JFD:G#'<6LT;#+QRQ^
M8IVG##Y>>E>@WFJV5BZ1W#LK2'"[8W<9QGDJ#B@#1HK/BO7G=?)@+PD9,I.W
M'I\I&>>?\]="@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX.6Z9Y[T >DWMO+=6,L%U:6MYYL3QR0N@>)E=2K+B0'@J3G]*_*#XB_\$Q_
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MR8U  61\;I>%'^L+'(SUYKK(H((!M@ABA4]1%&L8/U" 9IZKM &2V.YY-.H
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M_$77(]%MKV*3[)FVEF%Q/$D;/$#&3Y>/,4;FX&: /AGPW_P3O3Q+X3TOX?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 QVCC4ERB+W+8 _'/%>(?&7]GOX2_M :)#H?Q)\*:+XFT
M^W,IMQ?V%I>F!YM@>2%IXY C_(OS =17N#HD@VNBNOHP!'Y&A$2,;4147T4
M#\A0!^<NA_\ !,3]G'PUI&OZ3IEMJXM-:W_9X;R6RFMM"5XA'Y>BP_9%6SC4
M@R!5S^\9GZFOF+X7?\$4?V<_A[XQO?$^IZWX\^)CW>LW>J+;>*-9TR\TNU%S
M=R72V,=G)IY;[+;"3R(X]_$2*M?MP0&&" 1Z$4Q(HXL^7&B9))VJ!R>IX]:
M/SIU+_@EE^R'JGC7_A-KCX?6*3_:/M!T2&QTQ-#SG)C^R"RW>7VQYM:&N_\
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M=[N('<#RLUU::5I,ZQR'3;3CE-]O%N7CM\IP<'M4AT?2BXD.G69<# ;[/%N
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MI,6N7<97.JZP8;[4I&&#YCG8&+DC)^7G/2O5(+*QCB"VUI!;ICY1'!'$5X[
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M(-!DC\H1M,R[)B,*!DB@#^EI+N.9"\ :8 XPHVG\-^VID<E-SHT?JK8)'O\
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M:7>6)08 QY<^67D="!7H .0#Z\T %%%% !1110 4444 %%%% !1110 4444
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M]#<1K;>'[*YA=\22"XAC,2X/S89R7YP,#GFOA[]LK]@'3_VUO!<OA;Q3X_\
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MOEX%\*_%V/XV:7^TG\>YO$L>JC6%TO4?%GVG3S.)O/\ *91$F8]WR_>Y'&:
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M(@'&Y8QD?]\KFGQ31S)OC.Y3WP1^A -<?87OC&63_B8:5:01#^%)%=C[[@Y
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M+6R%8O*;?&H!.["DCWH _:36?&_A#P\H;6O$VAZ9DX5;S4[.!V/^RDDRL??
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MXC88^3C][@J.O?\ QI/@.<Z+J'+']]%C=,LQ'^L[J!M^A% 'O5%%% !1110
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MMG:K^TCX+\*:SXU^$'C_ ,.>'K'3;228:;KMC:M$[00!GWW<UI=LBNX8YV'
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M '& .E:"QQIDHBJ3U*J!G\J?10 A 888 @]01D4@1%&U44#T"C%.HH ****
M*[6MLT@E:")I1D"0HI8 ]><9["A;2U60S+;Q+*0 9 BAR!T!;&:L44 %%%%
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MD'),CN1M Z_+M/;G.>W;LMS'>.Z>1,L:9^<$#)'/ X/.>]49].OV<2Q:M<@
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M['>O4OBS^R#^S[\<](M]"^*OP^TSQAIEH0;>WU!ID$152BE6@DC;(4D9ST-
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MQ7I$,L%P 3@)>WK&1MK$D@]-P/5J^H?"$G@.2V63PHWA]E?EGTI+2/<W3E8
M,'@>_2@#DM4^,,=MD:5X3\4ZFV/E#:+JEH"<=,RV>!SQ7':Y\8?BS'I+WGA'
MX'ZCXDU+86BTRYUZWT/S&YVH;B^M1''G');@?S^D);J&'JVYNR)@L?8#U/:G
MPS><@?RY(\\[9%VD?4>O]* /"_!7Q&^+&N+&/%?P=F\)3,I,L?\ PDEEJ@C8
M*3M#V\*JW/&0?TJKX^\>?%C23 /"WPCO?$X>0+*8?$]CI7EIACO_ -(A?=R,
M8'KFOH2B@#YFTCXK_%6VM&N?$OP9U/2(@R ^7X@MM7FR<D[8K2V+D <GC&:[
MFQ^,>CRV:SZCH7BNQF)(:"/PUK5T%P <F2*RVXY//M7KY 88(R/0TFU=NW:-
MIXQCC!H \FA^-7@>20I/<:G8*,[I-0T?4+)$ ZM(UQ!&$4=RV !R<5KVOQ6^
M&>J.+6U\<>&)YY/E%LNK633YQG!A,I?/J"N>HKJ[OP[H-^)%O='TZZ64%9!/
M:0R!U888,&0[@1U!ZUP=[\%/AC=,TT/@W0;"\)W+>6.GP6LZM_>\R!4?/OF@
M#PCQ_P"&?%%QXXT_Q1X-T^\U."".9&GM-3MTL0))(G!>% "Q.PX.\<9]17TS
MX*N?$-SI$+Z_;+;78.UH]V\[550/FW,,]<\\XKQGQ=\*;73]-<>&_&>K^']8
MWCR'75;R6!8P&RIT^2[\A\':0Q7( ( PQKE- N_C;X(M3//KEA\1K,,6^Q8C
ML;^-%]/(MYFD+*0 "XY![T ?8E%?-^@_M&Z1=SR:?XI\*^)?!6HP/Y;/K]G]
MDTRX; (DLKR1P9X.=OF>6OSAACBO6-,\5VNL>7<6>I6,UM)AE-C/%=QE,\;G
MR"IQ]X#H?6@#N**IF\C<8@DAED_NE]HS]1G_ #WKSKQQ\:OA1\,K(W_Q#^(7
MA+PA:H5#S:SK-K;1J6(4 EG+#+$+RHYXH ]1HKQ/P'^TA\!OBA-);_#WXL^!
M_%TT2[Y(M%URUNW5<A<E0P/4@?4UT/C'XK?"WP%;?VIXT\>>'/#5H#M^T:KK
M$%K#D@MT+G/"D_=/ - 'I=%>$^&/VDO@/\0)7M/!'QB\"Z[=1'$L6F:W:7,B
M[LA=R[E*\JWY8KTZR\0:).3&/$NE7K$X"PWEKNSZ820G_(]: .HHK*N]0TK1
MK1[Z_P!0M[*R53(]U=W*I"J8W%C)(VT+CG.<8KR&Y_:(^!$>J)I?_"V/! UA
MBP2P?Q%:I(<,JO\ ('*Y#,HP>Y[T >YT5AZ9XBT;5[ :EI^JZ=>V9W8NK*[B
MN+?  ;_6H=O0@GV(-<=-\1_!:W\NGOX\\/I=HXC:P&HV+70<XPAC29I%;D<%
M0>: /1;DXB;YBO!Z.(ST_O'@8ZYK"AN(I4$%Y 9(.ADGD$J$9QDL!M/'O[5$
MBRW*I=PZD\-@RA]LT*2QS(5SO61F.4D'S*1Q@\5----+&1:0VTEGT$L!$KE?
M40E N>^-W^- 'Q3^VCX)F\7^%+3^QWT2&33+S3[Z-=8O[/2K-S9W,,X1Y[V:
M&+8WEXSNYSCO@_G=XQ\ ?%CXR^%Y?#]O^U%\,?V9K;385S?Z3K&F:Y]L";8_
M*N!I_B&S\L'.\LQ !0 \FON#]O\ L=8N?!&F_8%UAK>._P!*:^ATW2_MCRVB
MWENUS')&K (K1!U9N=HR>U?%XT#1O$WPQUS1_AY^SK%XOUBXTQ8]0U&X2ZBU
M2#$D6Z:ULH[*Y$LI<;?+\V/"L23D8(!-\/O@KXR^#7PIURYF_:5^#7[4E]+?
M6BJVK+IVD&W&RYW'^V-2\27D$3,2/W9(9L C[IS]:?LC^#?$SSW7C74+KPAI
M,ETR0#PUX7U+3]<LX_(+/YBW>F7DT(:7S,%=N5"#UK\U/!?[.?Q0\(>"M<\3
M>-/ 4?@_P6NH0"XL-:N=1M=0:=UG:(6NA2V/V:Z1520-(TR%"R  [R:_0K]B
M>[MYKFZA\/Z?KT&CJT2QW$VBC3=+,WSA_*ECD*R,,+N^7H5H _432[_5[J25
M+[2A9Q(V(KCST<3+@?/Y0PR<Y&TG/'O7QU^T+^S=X8^*7BA?$.N_%:[\%2QK
M!_HMM=V]H (8T53F5L@L%#9QUK['A^W6<K&YN9;R.1LQQQ0+B$8 VF0'+="<
MG^E?GU^U9\ _B]\4_%J7_@C5([/2VCM@T+ZI?6>=D,:R QVT3KDLK9YY[]:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %?FS^WI\2+GX>Z7:FQ^#)^,
M%]<Z>9+>QG\2Z;H$2.9)E%N9=1M+B, E0=YVCYSTP37Z2.2%8C.0,\#)_ =Z
M\P\3^&O"'B^WO8_&^B07EA IC-QJMG'$D,.W<3%<D[U49)W CG/UH _ENM$_
M;#^/>DZQ86G['VE? [PE>W-[$-4\&>*-!\4^,/LK2/&+VSUC1%1;>XE0">-6
MM&:!VVL"RFO5/V./V']#^!OQ*L?&GC#Q3^UC?W$4PFGN_B[\3[2X\.^80 _F
M6-WX=LW$8)("FXR/6OO;XJ>-/V%_A%XAO-%MM2^*-[J[7#F72OAG\1_$D*_:
M93ODABL;+7;1$82,4,:H K @"LWP+KW[,OQ#U6&*/X1_M:WTL[J5B\7>(/%]
M_I[;N09+:[\1W,)7H3F,COSQ0!^L_@[QKX#UR"*U\.>(/#U_/!%"CV^F:G9W
MDJXC"C>+=S\YVG/ R037H=>*_"GX?^ _#FEI=^$_ B^%TD*G9J-MY6K$A!@S
M-)OD(P>,R'YMQZ]?94,Q9O,1%4'Y2K%B1CN,#% $M%9EQJ7V>X6W^QWLN['[
MV*'=$,_[61T[^E?+G[5VL?'GPY\/]5U7X(7=LWB6.UGDLK6>RCG'FJK&-?FM
M;HGG:.8CSV- 'UM17Y\?LV_$[]HO5].9_C#I>L?VA%I]S+A]!BL;2:ZCMI&B
M2*=8(&8O,%"#R\MD @D\?*'[1G[37[9WA_Q]X?L_ 7AW7M%\.'5FCU"!/#$.
MHR:C9^3<$10RS63%"75&WJX.!CO0!^U&H[?LK[@2/0'!^ZWL?Y?X5YKH(7_A
M([DJBJ-D76V?=]Y^LV K?0?G7C/P?^)'Q8\8?#N;4M7\.21^)HQ:A;/Q0AT1
M9A)'*99%$=K*>&"@XC( /X'N/A]J?BN\UZZ'B;2O#NFW8$>8M*\075^^W<X!
M-O)96J+R#C'7H>F: /H:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@".6/S5V[W3G[R':WYUYU\0?A3X.^)^D)HGC'38M8LHC(8TNX
MXY]IE"A^)%8<A0.E>B3+(R$12&)L_>"A_P#QT\&B%9%0"60RMG[Q4)_XZ.!5
MPK3IRCR3<91]^+2U72Z=O/:X7/CWPK^PS\ O"&JR:QI7@_28[MIQ/&XTZS4Q
ML-N,%8@>-HQR*^N=/LDT^TM[*)8UM[6&.W@2- JI%$H2-0/14 '%7J*JI7J5
M5[[YM;W:5T^MFEI?KW"UKZ;N["OAW]L;']F>'\G'_$\T7G!/_,0MN_;Z]NO:
MON*OA[]L7_D&>'_E+?\ $\T7@9_Z"%OV'7Z?AWJ(6YES<MKZ\W-R_/EU ^EO
MA:6_X172]Q<_Z*GWKE)A]Q.BJ 1_2O2Z\U^%P/\ PBVE\,/]%3K D7\"?Q*2
M3_6O19ED=,12>4V?O;0WZ'BJJ14)N*=UW_I+\@):*QK[[2^G7MM;7:G4&MY!
M!)M"E9"/D.T9Z'M7Y?OHO[:WA3XH:_JDGBV_U?P/=:FDVG:99:6;YX;(1Q*T
M*F6W4*2ZN<!\?-G-9@?JS17PI\7?B3\7-4^&&K:3X&\/?$/2?'$MBL=IJD?A
M998DN@Z;G4^82!@-@JAZCBOB[]DK5_VZ=/\ B5)IGQEM?&.M>'+GS)(=5U.P
MN["WM0LT86-H_LPB)9&)Y?@+P.: /T^^/:PMH^DB:?R!]JDPVQGR<1\<$8KT
MKX>;1X.T0(^]?LORO@C<-[<X/(KQGXYV'BR73M(FT[6;.)#)\]M=Z?;3!3MC
M+8:1&(;G!X'3\*]?^':WD/@W1A?2QSW MOWAMXDC0G>_W40*JCZ ?2@#NZ*K
MP3^<"?*ECP2/WB[<X.,_0]JL4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 9J.02%<1LJMSRPW#\JDQ[?I11%R3N^71Z:7T_O)Z,#RCX@?!?X?
M_%'3Y--\;^'].URVD&&CN[2"9.""/EE1QE2!CCL#7C_AC]B/]GGPC?KJ6A^!
M=)LKI)!(DD5A8QE6!R""EN#U_'WKZWHKLAC\93BH0Q%2,5=**:LK[VTTV!ZN
M[NW\_P"NG]796L[6&QM;>RMD$=O:PQP0H!@)%$H1% ' "J  /2K-%%<;;>KZ
M@5+_ /X\KK_KA+VS_">U?%NJ$CQWI&"P_P!/;[LZ1 _NY.JL"7^@Z'YCQ7VC
MJ&?L-WC&?L\N,G SL.,GM7QA>.?^$YTL7-F'/VYMCPCS@#Y<F"Q8#;WZ=,T
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MRQG@\'N?K].+?P&!&B7^0P)EBSNA6'G]YV4\_4]/T ![U1110 4444 %%%%
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MXKS/Q_\ %#P_\.],N)8K*2_N(4?;IVEQ0)*64$!%1C#'G/OB@#^3%](_:O\
M"/Q,TCQ%;7?Q$\.>/CKUE)K\TNCZE=>';Y&O(_[1MK>:>18Q'<(9(XV%J"-P
M8*,5_2U\$/&_QA\;^!M/T_4M%70=6^Q1I)KEZTRR-+Y:@S"V>V56.<MM+@=L
M\UZ7X)TGQ!XVFA\0>)H-*?1)R+BVL)+2%;Z$D;X?,98B"R$J6Q*>G6O?[>V@
MM8UBMXDBC08544+@?@!0!\HZ-^RU9:IK#^)OBWXGO/B'KXN7GM9_+ET>VM(A
M(6MK7[+;7,D,ZVT6R'>Z@RA-S@$XKZET[2M/TFWCM=/M8;6"-51(XD5 %4
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M;21"5X]5MMUQ&"H)!%K]I0D<G@GIUYH ^[EGA9BJR*6'4 \\5)D'H17P2O\
MP4,_9QFU6ST8^(=9MVU"[@LK6_FT:[AM+B:YE6&)5GDMU7$KN IR,Y^E?;/A
MV_TK6--MM7TB0S6E[$LL4I+9=& 93M8\<'T'6@#>HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0WQ?_P""INA_"WQA+X0@^$GC_5KJ/4%L/MEII5O-:%FG6#S-XOD;8-Q8DJ"
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M7 ""(J?FZ'S 6QQ_#S7U&ARBGDY ZXS^../RH =1110 4444 %%%% !1110
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M\J(I8L.!T!&3[ 9ZFO-_B%>^()M%N[?P1KVBZ?KIAE6U:\NK;8LY0B(LK%N
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M<C&!N( !^E=90 45$TT2-L:158XPI.#STI99H8%+S2QPH.2TKK&H^K.0/UH
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M;_M!>$TC^%7[4NM>*O%-G*BPZ#:ZC+)9W*E&'F.BSH&8.JJ"7_B/U'%?LO\
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M0<_T_&O1_AV$/@_19%4@M;$Y8AF/[QNK#&3^% ';  = !] !_*EHHH ****
M"BBB@ IKL54D*6QV'7]>*=1UX--;J^U]0*A,;IOE'D]SYC+QW/4XK'O-=TVR
M2413Q3W*(66-9$.6YQGYAC_ZPIOB**Q>S=+N6../:<[R,8Y)X[?YZUY-8CX>
MV-W,T]]I,<Q !:2XA#=6(RI((ZD?Y-=^&H4ZJ;FZO*M53@M7LG:\N9Z7T2Z:
M,^'XBX@J9;B*>%PKRNABJR]W$X[$1A3B[;<MERNZ^*>FRWV\,^)'[0WQ)\.Z
MO/96OA*"YTU6Q#<0F+>T9_B;S+M><YQ@=*P-(\3VOQ,M?/\ $>DBWN)<^9%(
MT:X897&5E8]NS?\ U_2OB+X.\,>-TE71_&>AZ<R(4RDEO(Z-R3R+A-I&1U_+
MI7EO@'X(^'O#\DEUKOQ-34YDN)71%U&W$(4R,R)CSGP%4A=IQTKZ_ PP%*C>
M,>=22YH.G4]I%I+6RIO5/JFTGNUU_C_BW(?%?B+BBKC<RXGR2?#L95)4L&L5
M"G2BHN*A*$Y5I0O9.UDF[W26J/>_AWX7T+PZ]M]D6.TMXRA'[Y3M Q_><M_/
M_#V^?QCX=L!_I&J0*!@<RQGDG '!ZGCT[5\6^/OB?I?@^VN(]%T#3?$1@5U2
M4:A K2; 0IW8(RW7//7 K@O#?B+P1\1+B"+7+&TT&61U:14ND7!')4R,H#9/
MIUSTYXSQ>44L7+VSGRP4?<IJ4(R<=[N[FXOREKY'VF#\6H\'87!9%E<<LQF.
MG.%">(K8J4J,:J48>\U45XW=V[Q2[M'Z'Q>,-$OU*6>HP9(_U@DC.T9Z]2!Z
M<C\:U[.Y$D9*3B^!YW!HG ]LI@?G7S[H7A[X7>'-(N?L&H:-+-+;A0EQ-!-N
M.0>45E9^G(!_2N^\#75F+6X-E]A\@.J[=/MVC5N"!E-[%N,X(XQUS7RN.P>"
MIQFX5L31J4M/>IRLUNVI.#27^)*_2ZU7]!\/\09KBJ.&K9K5RV=7$P4XQRVL
MJE.E%I:2?M*E._?5M=FSOM66-=-OYF7:5MI254@N0!G@9QWX_(U^7&G?M.>!
M?A3\0O&L>M^$_&FH%-3WO-I.G-<1M^XA&1\ZYZ=NN/K7Z>RV@NH[ID$^Z:$H
MH;*J&(.,*PXZ\Y//3-?.6B?#CXCZ%XC\0:I:Q:7>VFH7?GVT.JVL%TNWR8TV
MIF9-BY4_>'?/2IRG%97SNGB,97K1<4E34IX?VKNN:$ZZHUG3C%7=U2<7:W4_
M1,+7J58IJ4875E*;>VBO&::23Z;WT6G3XZUS_@L;^RGX3U0Z3XBA^(/AV97$
M<AO/#\@C1B1R20S$<YX'3I7Y8_MI_P#!:'QS/;ZY:?LKR>(/%#LMTNEI)X>M
MI(I0=_V<8GC1SD%<Y&X^V:_8K]H?]CJ7]HC1]4M_%?@GPOINLW44D$6M:9I^
MG174>$\N*5)"S,K !6'S9!^E?BYI'_!%[]K_ .''BDZA\-_BI$FB07+26OVR
M"VENA"CED4S+K$()"@+Q&.O K^L_"RA]'_"T*>/XABH9K["-)X7,\TP^(R]U
MY6;JQF\&JE)Q:MSNFG%/2#9RXR-:4)>S<Y/5REMJK:*3^-/RFEYH\P_85_X*
MJ_';6_'MC!\>O!E[903RNESYGAC3$)9E; 1H09 Q?:!G^+KS7[@^/_VE?V6_
MB3I%K#\0?A-XL\0BYBVLEOH02)MRC< T+)@$'C)^AK\2OBM^R_\ MW?"QGUO
MP[I6E_$+5=-E6ZN(X=)VW6R%P\SK,FI29D107&T'D#&>_)>%OVP_VQM+FB\*
M>-?"?B#P@S$6KW=Q<SV%O;X^0NHN  57G[K\ =>:_4.)O"'@SB^-/.N"\VRG
M#_5J7-45#/I862BTI15.=.C*I527PWA3WT6YR49UJ<+5(SJ-[2G3=2-M';5\
MSMVBY)=^_P"OO@V7]C+P!K<7B/X?_LJ>*;.87 O!J,5JK3"9Y/.:4(^IX!\P
MDX*=>PKW/PQ^U5X'^)7Q7M]!T?P9\0[#5)]0C@CBU'3;*"R1WD"HKR2R&(*N
M>I)P /6OCG]G;X2_M ^*;W2_&^F?M(G4A<M'?OX3DU6*6UW2.97M)H3J0W[6
M/E/A1]!G%?K%8_#_ .+'B.\A/B73M T$N4$NJ:-;V\=P.FZ53%<.Y;^('=G]
M!7\M\40P^48ZM0J8YUJN'I5<*L1B<XK8N:BI).,</B4I5(/EOS49M-+X+M%T
MG*:^%QC>ZA[.R6UU=-V^=M/F?3*12-H<I>6YL_+MG>2)!;&0JL99EPJNF2!C
M"GZ$"ODV>31=0\;Z7A;^&X@OF(:1(55V"2#)VY)Y^G?M7UI9:0-%T":TGN9+
MIH;.57NFXE8+$0S9;.&.,Y.>?I7R%)+ITWCO3A:33SNM^V_[3&TX7Y)/N,JH
M%(_O9/''?-?B.*<95FXUFKR;37+%3[^Z]=?+;J=O*^6RNGIJ[NUK>:WVW_R?
MVY8@"SM@,D"),9ZXQ5JJMC_QYVW '[I.@('3T/(JU04>!?'?X:?\+#\/75M:
MZIJ>FZJ+1XK%M/F\D^9\Y4G<K1YW,.6]NPKY[_9&^$_QJ^#_ (>URR\:W.J>
M(+B;5M8GTPZM=:?,_P!BN+ZXELE#6OE#:L+Q!=WS #YN17Z 8!Z@?E2T ?BA
M^T]^S%^UA\6?%.HZQX2MM&TJUN;N::+?KM[:SHCR%A^[ANO*# $< 8]!7WA\
M&_AC\6?"WPV70O&7B2"TOHM(D@>;39?M,T<WV1D#^9=0RJ=KX))SD9/U^MWM
M;>1MSPHS9SDCG/K5/5D5=(U% HV_8KD;>V/*;_/O0!\A?!KPSXG\*^)M3;5O
M&E[XBANBR1PSI9,(29-P.8;6%A@#&<_CW'V=&28T)Y)45\J_#:"U_P"$COF+
MK;ON?"K&S;SNZ$J<?B?YD5]51X$:8.1M&#C&?PH ?1110 U@64@,5)_B'4?G
M4*P,#DS2.?5L<?0  58HJE)I66GR5^G6U^BTV)E&,K<RO9W6K6OR:&;3@#><
M^O'-.P< 9/'?CG]*6BH:3WO][7Y/3Y#2MM?:V[>WJ_QW"FMNQ\N,^_\ G^=*
M2<<#)],X_4U4G9S&V0PX)VJ"#T/\0JX1YFMM_7\#*M55.$FU-OE;]U-;?WK6
M3UZ7?D0SWL5O@R3HAR!AF7&3VQD$>G-0RZM;JHQ/&-W\603^&,C\QZ_CY'JN
MOZ5IUXQU'2KFY428R;2>4<G@C;$V<=<=SBEN/B3X#L;?SKG2KJ*)1EFDT:]5
M5!]S!S[X_E@5WO U9J'LJ4JCD[W@TK[-I6UV^:_ ^$GQ=AJ;KK$YA@LLY9<O
M+BZE6I))-+GYX*VJZ1LU:[T/5HKZ&0EOM+,=IZ[<9QVP,=.?PXKQ[Q/>0OJD
MT<VI&VC$8YA(+GE@<[U9, 8Z<_I7.7G[0'PW$4EMH\Z?;CNVVQTZ[#' /2/R
ME8\D#(X&>>2*^*_BU\1_B]K&ID^%?#3SZ:RD"Y31;^3=\QXPKH0 N#DYSVZ5
M]1D60U*U3VF(_P!EIQC;]Y*/-HX_#JI._>S=M[6N?AGB_P",V2\.\-XJGA'#
MB6NK.=++:6-Q*ES.*<6Z+G)5$M;=K*W4];^(M]#;E3I?B.\FG\^/$2?9R2=Z
M\$,@&.F<<@=#GIZW\%=1\03G=>SS+ L6<A4^8 K][(ST_NXY[9R:^&_"</Q!
MGN8;SQ#X9CC=7$NXZ)=NS.#N V^8Q4ENY''4^WUKX(^(?B33GBMKOPI>PV^W
M89(M*O&!'&/N1X0<#KG%?19GD-.GAG*EB*-6<HVM4J4J>CY5[L)>\Y=K];6/
MYG\&_$C*<PXGCGF)R'-LHJ2KVCS8'-913Z-JW-&+YK2YFU8^UQJ>GIM#W:;\
M8V'&\GN<8S]>,?SJ<SI, T9=D/0XP/R_7\.]?,%[XLTV^U"W>6VO;&XV\2+I
MEXD@Y7(\TH.G<=>_:O=O#LTUYI$)M+R3ASF2Y@E9B-JX')0C'OZGW%?G.+R^
M>%G%RFK;22<9N+?1\J\[_/<_T&X3XVP/%>)K8&EC,-2=%7=Z>*C)I*.LO:.Z
MWMR<K:>I\9?M@F--:\*M+9?:2($Q<2W$$$4'^D2<OYLT0('7D$<\^E?17PRU
MS0XO">E)>^+/"WG#3[8*JZKHP>#]TN(WQ*/GC&%.>01SDYKR+]I_X&Z[\7AI
M<$&F+K-O;VP@N5CN(+0'][*Q5EF<D\,?S^E?,VF_L(?"G2M/,=_\*M6:\D5F
MN3I]_ @>>3)D;<MI*,LV23D\YQS7OX?"87'9;A56Q\L/]5<W*G3E@ZTI*4KW
M]A5Q%"I%)6;O**;>J9^A5)*'LXQ?/&"<>>$I.,ME=KIM?5:7;=SX^_X*/Z-X
MTUJ3Q+)JOQ,T;4OAW(U_YFA:=JNE?:FLF,FZ)< +NV9 _>G]:^5/V.?V2O\
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MD(4C''*=Z]"\/^#O#_AZVCBTRS50%&99,R2R$\EV9\G<QR3C ] *ZOIP!@4
M0V]M!:QK#;Q)#$H 5(U"J .F .*FHHH A)G\P (ACYRQ8AO;Y<8_7\JFHHH
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MB@#\?H/'W["/[5FIC3O$O[+WC.QT[4Y?+?7FMY] C'G-@R_:K.\@:,9.<JW
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M\2^&?&MK+'=KK=AXU\0R32WR,)#>26U[J4]F999LRNOD>7N)P@% '4?M$_\
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M1 .#G_D(VW3MGZ\9QGC-?"4HTHR;JN-.+=YSA&W;5[M_KZEW;[OLCZ:^&/\
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MEE)7BJ3BX.WQJ\HOW;J*NXZ^;7SV,/\ 8[_8[TS4X;'QMIFJ?$;P3 \K7O\
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MS;\,TB?Q!?F18BP+[3),T39W#[J@$,?;(KZA3 1<8Q@8P<C\#WKY=^&GVO\
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M/-[\>M7GO_[-\+^ KW7[ISMB4WALDD9A\HW2VI4 ]#D]Z84^*7C8M::S\/\
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M*^4JTJ=:7-5I4JC3O%RIQ;7_ ($FUKYL_=,-3G1I1@Y)M)7<;I.R[7=ODV(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG^M>F5YC\*MG_"+:7M\K/V5/]7Y^?N)U\WC\J].H **** "BBB@#Y[_:"_Y
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M>)@W_ 8OF/(//MTXKM=+L_L, 41VZ(!\BVJ!5"=5 PJYX[U<M[2.&-5:.)I
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M*GI[9_G^=?,/P[16\27A,J1G>WRN&);YQP-H(S]>*^JHP/+0<$;1VX_4?TH
M\I3PYH%[>;KZPOWW.2\[^:(.>I,N_./?'UZYJAK'PT^#X@GN-5TK2554=Y)9
M)U24@#)(?>#N].>M>SE$*E2J[2,8P,8/X5\_?$#X&6OB]9)+'4;C3+EF#AX[
MF38Q#;MKHP==C=& 7."<8H ^9_'?A3X(WERMIX<G_L^^,I56349BF[#9&P3L
MI'L1Z^E=S\/OAY?:;I\LNF7]O?\ W"@_M.ZC8+\V!Y"*ZMZ9)R.@IH^!NN>$
MDDN9].TC7%C'R,7N2V>/FDP8FY']SG)[BNJ\,VOQ1E1[?PY:Z'H$(X8[96R1
MG;_Q\><W<_=X]: ..\2>,O%'AR\%G?Z)>26R<^=%=73QL,X/RF( < <CGI7K
MGP\U?PQXPL\W&CSK<1DI*7N)I6!P",*V-@P>@^O&37)Z_P""?VA-3=4&M^&[
MB('/[Z%0%SZ%+<$G@<?IUSZG\+O"?CGP]#(/%U_IET[R;D2PB5512 -N?)C)
MY!Y))P>M '76&C:3;3@V%M<HH8?ZV,S@$'G#R,2H';T'%=T../2D  Z #Z#'
M\J6@!&Y!'J#_ "KR[QA\,M)\:)LU$2KM;<&CEEAP<$<B-EW?>[GWKU*F_/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-R.MO^&^\]HHKQH>+/BSY9+> M"\WLH\07FPCODG2\@^@QS53_A,_B[N\O\
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M>"]"=22 JZ]=%QC'++_9W ]*=_PD'Q0 5F\&:#\XR NO718<XPX_L[Y32O\
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M[=LT"/2J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BD) &20!ZGBF)+')GRY$?!(.U@>1U''I0!)13'D2,;I
M'5%'4L0!^M*K*XRK!@>A!R/TH =1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 449QR>!4:S1.2J2(S*<, P)!]".QH DHJ%YT1PA$A)QRL;,O/^T!BIJ
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M\7Z;\+?%?C'1_P#A9%_:O-%I6C6]]?VLWV9HX[EQ>VT,]K$JRS1*JRSHYW<
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M_KCBJ;7EW$2)I;*/'4N61<=3EFP!\N>3@9K\LOB%_P %%_B+\)/&MCI'CO\
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MC'M3[/7]-NPITZZT_4(6P$;2[VWO,@]#B!V& .3SP*_S(O\ @Y ^+OQ8T?\
M:Q^(N@Z3XH\4:1H4?B76(E&GZKJ-C;QPI=S@%3;7$8 51Z8 ]A7Z[_\ !O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGB75KV)#INN?"+X5Z=XCT2\\L,HO=2U,Z?ICI*[NCIF*8NHD);C!_1+X+_\
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M%2+R[N*UO&F2-_/8[HU^5U/\1Q^TGPP^#?P\^#OAZT\+^ /#]OHND64$=O!
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M/6OT[\!? GX6?#01?\(?X3T[3'A7:DQABFN,%=IS/)&96)!.26SR37KH 48
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M!O+;VP0/EYQZC-?C/^TA^W]\8]+\=W7PT\/:1%\ 2\RV.G>-?B6(K*UU3S,
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MZN_X(K_\$</V,?VM_P"QG^+_ (?\7:FUYITT\HL_%%[IT?F+8RS*5%A=PR*
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MU+XU^!K.]N'V1VLNI6XN?,P3M,1?>&P#P5[&@#[2AN(K@$Q,6 .#\K+_ .A
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M?I_UR:I7ABD(9T5F4Y!(Y'TJ.2*63<F]/)=&1D*DL0PV_>SZ$]OSH _S?_\
M@Y;O(9/BW8VZS2^8/..T^1M&;IP,$8?GODX_45^K/_!K;:30?#6[DDF,BOJ+
ME5+PMMQ;6PP GS#U&<'GZ5^]G[4W_!(O]D+]K[6X_$'Q<\*SWNI1Y_TFSBTP
M2N"^\AVNK"X)&XG SW/K7M7[)W[ 7[/'[&6CG1O@IX;_ +&MFD,LDDD5BLTL
MA55+2-:6MN&.U0,XZ4 ?;-(2!U('UX_G2U#/&94VC9_P-=R_ED?SH E!!Y!!
M'MS2U%#&8D"'9G)/R+M7\LG^=2T %%%% !1110 4444 (% Y"@$]P *JWMC9
MZC ]K?6T%W;R AX;B))8G!ZAD<,I!''(JW5:>Y\KY5CDD?L%5MIST&[! S^E
M 'Y'?M+?\$H_ /Q8\1:EX_\  FN:AX>\87EQ/>0Z?<WOV;PO'<2LSJGV&UMG
MQ"K'[H4C':NI^'O_  3<U'PEX>-DO[0WQ/\ #5W>V;V6MV7AC_A&KG2KZSN8
M&@OK%1J^ASS1P7,+R0%T9)41R4=6 :OU%^UK#%YMZ8[, 98R2J%'_ C@?YQ1
M#?V-T"(+J"XX.5BD60D8YX4D]* /CG]GW]B/X-?L[7&HZAX)T_4;[6=5;S-1
MU'Q#<Q7K7TWSDR30(/(7<S,2(XD'., 5]4:3H%KI8E>/1]&L&>21]FBV<-D'
MWLS;I%BCB5G?(+L<EGR223SL+=Z?"^W<EN[''[P>5N/MNQG\*T00P#*000""
M.00>A!H I1O>O)EHXXX<_=;/FX_ E<_T]Z>@NC(?.%N8NVT,7]LYX_+O5NB@
M J$RN) @A<J<_O!MVC]<_I4U% $,UO%< "52P!R/F9?_ $$BE\I%B\I<J@&.
MIZ>F37.:OXJT/0"'UC7--L(WX1;B5(WR.N26'J.PJ/3/&'AO5LFS\0Z1>QN<
M(L%S$6Y['$A).>O ZB@#;CT^V\MX7Q<QN6+++MD4[CR,'(P,XQ^?I7XZ_M<_
M\$I_#7Q,\4:M\9/@Y<3:3\8+JYN-3M3K.MZC!X;%^[M*@>PM=Z"'?@%1'C;D
M5^RBQHJ9MPB;_F# 94[N<\'G/7K4$<EZ)-DD*NF<><K!1]=F2?\ .: /QR\(
M?\$[M4\9^'M-T/XEVUS\/M>M!!)>^*/ 5W:2KJ$MOM>2)TU5+W_1[QE,<H%N
MC>7(2I5L$>[Z-_P3,^ D=K]G\4Z3<>)Y47$-]=7;P7+2# \V4V:VR%B,Y  '
MS'CT_22BG=[7;79MZ[?/H0Z<=TN5K9QW7=J]TI/O:]]3\Q->_P""67P2\00C
M2V\1^+])\+F433^%+&32[C2[F5#^ZDDFO[&YOE,2EU01W*@B1MP.!7UM\&?V
M>_!7P%\/V_ACX?V=S#I]N J&]:%E/S;B6\M5.">N *^A:*EI<W-;6UKZ[!&G
M&#NE[W63UD_-O=OS,B\B+QQ^?9/=L&4XMWV!3D$L=TB< C/T]36E&H\H*%:,
M8 VDY9?QR>?QJ6BFM'=)7[VUT*LM=%KH]-UYC$38",DY]:?111=L$E%*,59+
M9=@HHHH&%%%% !1110 4444 %%%% !1110!%,I="JRM"3T==N1]-P(KP/XQ?
ML^>#/CEX8O\ PGXWMH[S3;^VFMY;NV$=KJ6V964N+F"-'#9/#!Z]_95<%6 (
M/4'H:1(TC7;&H5?0=* /P_\ !G_!'O2M+\:2:AKOCS4E\+VLTEQH<6F7BRZI
MIEQ$2^GW*?:]/:%Y;641R 2M(C%?F5AD'Z3;_@F=X"USQ!X?\0_%#XL?$WXL
MGPE="]\.Z9XE'ANQM=,G$3P*T#Z%I.FSOMAD>,>=*^5/.37Z7.ZQHSNP1$4L
MS,<*J@9))/  ')JE::KIM^[I97UK=O'_ *Q8)DE9,''S!"2.3CF@#B_"WPS\
M$^%["&QTKPU8P);11PQ2W5O!=W05!@%;B999%]PK $XR*Z8:?,LOEV]S=V<
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M,3S.3#<F4(B[F(@$1F8[02%"%CT R17!Z;^W#^SCK4MS;:3XUGN[FU!\R%]
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MHEQ!LV*^2R$\#'>@#\T--_:M_:@TFV?Q3\,OBKXG_:(N+X&";P2?AOI&@SZ
MT0R+I[S3?[1N)TF,A0+)$JCR,@_,<>5:Y^UW^WZE]<ZYKGQ&TCP[#(XF?P-J
MVDV^DZWHR@ &SM$BT@R:G(=ID5IS$Q+A#P :_0[]E+_@IK^PO^UAJ-WX=_9[
M^-4FL>(;1XTO+9? -QHER#,76+?--X;M+=U9HY -KD@@YX.:_2"V\"37VZ\N
MK^QU$2DO!-<Z+H\DI XRS/I^[.<_YZ@'X1^"/V[_ -IKQ)X/O+B#PO\ %;Q!
MJ=H+F W6J?#RVTU)YH&:,R:?'$LRWMHS+FUG=4-Q#LD9%+XKF;_]KK]N6_\
M"\ESIVN1?#V_\EG5?'GAJTT>WA(R0LH.EW(4KC!^0\\&OZ%HO!VJQPM''J5M
M;,,B(6^G:<B*,D+\HLP!@8R ,>E0W/@O59M/,,D^EWUT5YDO],T^6-F_VE^Q
MD<]_EQ0!^1?[!G[;OQV^*?CU?!/Q6^'WQDN5A2Z2;Q?/\/H--\"73PP2$366
MM1/$98)'4- WV==X*\ FOVTAO&N45[=%.X9*2L4D3V90#@_C[9K@(?#'B.*"
M.&TU<Z;(N QM+/3HH,#J$5+7(!' X]/2M!/#'B0 9\8:F&[[8-/Q_P"D@]Z
M.]&<#/7'./7O2UY]_P (YXL6=2OB^^>#(W*\5EO(XSC;:8JQJ>A>)9(66P\4
M:C$^.'$5B7SZ_/;%?TQ[4 =S17FT^D^)M,T?4+R?Q7J4\]M8W,Z"2&PQYD43
M,N=ELIZCU_.O,/@I\0?$WBC6-9L?$&H_;8[17^SYCAC*D2JG_+-$).#TYZT
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M.<#:.<9/8T[0O&/QZ\13>3J'PTT_P+$1D7=]K-GKR]<8,-I);N#SGKVZ5]$
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M'=,HD:)I<L;=3GY371> _P!A#X%>*K"9+3XTZQ\5-)8M';K)XELM5AMY"/F
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M 9KZ5)P,G@5$L\+L425&<9RH.2,=>* '1L[("Z;&/5<[L>V1UI]%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%12&8
M$>4B,.^YRN/I@'- $M%1O(8TW%&8@9*H-QSW Z9]!ZUC77B#3K2)I+FZMK,J
M"2M[,L&W']XG.,<YH W:*X6Q^)/@C4KH6&G^*-"U"_W;39V.IVT\ZD=08U??
MQSGCM72:AKNC:39O?ZKJ=CIUG&N^2XO+F&")%R!DM(X&,D=,T :IZ'Z'^5<G
M, ;]L@'@?>C:8=3_  K@C_\ 5_=-2Z)XT\)>)DE;P_XCT?6!$=LAT^^@N-C'
M. P1R03@_E5.2Y1M4>+8X("_,TGDH<EL89"6;IGIW^N0#KX?]4G Z=E*#J?X
M3R*EJ*'_ %2=.G9BXZG^(\FI: "BBB@ HI,@=2*,CU% "T5')+'&"7D5!ZD]
M*SS<QV[B2XU&+RG.$1@B\L?E 8')Z@<^OK0!J44U75E#*P*GD,#QCZUYY\2_
M'%YX&\,7FNZ7H<_B6[M@VS2[)F,\I$4CC;Y:2-]Y OW3RU 'HM%?S;^)/^"T
M_P"U3X<_:#O_ (5Q_P#!/7XK:OX0A6S%MXTM4U8Z?*\]S=0R?,NB&/\ =QPQ
MR-^^/RR#IP3^C/Q3_;G^*/P]^$&B?$BQ_9I\8^)=7UK19-4_X132_MDM_8RK
M+<1K9W06Q+I*1"K\IG:Z\<T ?I5,LKH5B<1N<X9EW ?AD5YW)X,UZ74SJ!\7
M7Z(7+?8X_,6W )SM"&0\#T]OKG\3/V0?^"OW[1'[1'BBY\.^./V$?B9\+(DU
MV_TN#5-8.J&U>VM[^:U@O7>?2+8*DT2+-@%@%;AF'->@?ML?\%4?CK^R[J^J
MZ+X*_8G^*'QA-A+-%#J/A6#4;FTNO+) >-H--F&U\<$$_2@#]6=7^'^NR%I;
M?QWKUJ7/S*C32H 2,A$1U*GK@YXXZ\U1T_X;>(8W\Q?B'XCF8#)6Y>?RSVX5
MG&/H#Q^%?(7[/G[;WQ9^,_PUO?&>M?LW>+/ NKVOAV^UE/#NM->17]Q=6EA+
M>)I\<<E@C&XN)(Q!&NW)=P *_,>X_P""WG[75M\>='^$K?\ !-GXS+H&I:Y+
MI4OCF\@UBVT6U@2.=Q>M,-%:/RF,0 RX'SCG- '[C?$;]E[X>_%O2GT;XKZ9
MH7C+2G<.T>M:5;W;[\%00]WYR D,<G9D\5YY\,?V /V<?A)K5OK_ ,-_!NB>
M&KRVF6X@FTC2M,M'CE1MRNDEM;(P(?!!![>M>^_"[XA:Q\1O#-IJ?B#P]'X0
MU&[M[><Z5<3O<S1&527C=9H(3NC(4'Y>IKUVWA-O&%9T; ZJBQCUZ#C_ !ZT
M >4?\*W\1->F=_'>L+;!MT=M"\B $<J&.\AAGA@ ,CCC-7KOP-XCNFB(\::A
M (2"HA$B^8 ",2_O?FZYX[C->HY'J/SHR/4<^] 'EK>!?$CJ%;QC>,!C@K*<
MX]?WOIQ]*[30](N]+@$5SJ,E\0?ON&&>/]IV]N];V1G&1GT[T9&<9&?3O0 M
M%%% !61K^/[#U;<,K_9UWG@GCR'SQWK7K(U\XT/5CQQIUW]XX'^H?J><"@#Y
M7^!SA?$>MBTL\@B3S'*>3@><.<2+\WT'U/2OKU<[5R,' XZ_K7R3\"I6E\0Z
MZ&,/"R?ZJ4R'_7+U#;<?K]*^MQ]T?0?RH 6BLNZU>SL=QO7^R1("QGGQ'#@=
M?G8XX[^E<4?B9X7U&ZEL?#OB7POJEU;OY=U NM0BY@EP#L,*"0[L,#@[3R*
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MK[T 345Y=\0O&NL^"/#=SK&E:,_BJZ@@DD2T@9HGE9 2%'E1RG+' 'R_G7X
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MM1S^?YUU\;A4 >9'8=6RHS[X!XI_F1_WT_[Z'^- '#_V1XX_Z&32O_!3-_\
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MW3U'Y<4ZB@ HHHH 0D#DD >YQ_.D))4[,%L';GIGMG%(\:2+MD4,OH>E,9)
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MYS-:65O;R'<,'YHD4\CK0!N4444 %%%% !1110 4444 %%%% !1110 4444
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MW7A;0KQ0LMBBH.BP,]LOTVP-&..U11>$=!A39':,JYSC[1.3S[F3/;UKI:*
M.>_X1;1?^?9__ BX_P#CE'_"+Z+_ ,^S_P#@1<?_ !RNAIA?K@9 [_7VJ)3C
M"W,]7LMV]M;=E?5[!N<S_P (;X?\WSOL<GF9SG[5<]<^GF[?TK4LM&T^P?S;
M6%HW]3+*_48Z.["M'?\ SZ\_GCZ>]*N>IS^?'7T[5G&O"<DHMROH]K+7=VN^
MN_PCLUOII=>8^BBBMQ!7+>-&*>&M49>"+=R./]EO6NIKE/&W_(L:K_U[2?\
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M4(;.^N5";Q"EI<"8C&0/*\LR ].-O>L[1O$]]J3DW.BRV-O@D2-+OF. 2/\
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MVW;OL\.[U\M,_P O>IZ* &&.,@ QH0.@**0/H"*8;>W88,$1'H8T_P *FHH
M8D<<0VQHJ*.RJ /TI]&:*+@%)WSQ^7/YTM%)I/=;-/[M0*MU+<1*#;VWVAB>
M5\Q8\=.<MUJM>W%_'8O-;6P-V$)6%F#@-V!(QGMT(K3I"<=C^ K3VD().5.#
M47>3?/>2[-<UK>D5^=WO9):WW[[::Z'Y3_M!?'G]OKP?XNEL/A%\$M"\7>'5
MD0)J-S!*&V%5+';]L0MC)&0 ,+D<U]<?L]^/_CQXQ\-:=>_%_P"'UGX7U>:"
M%KQ;29(8X9&5?- MGEFD 5B0!OZ=Z^E7O DHB\BX;) WK'E!GU;/'Y5:)..
M"?0G'Y]:[*F8X;$4VJ>"PL;)+F@YMQT6R33YG:^KEYH4N9N[;22TBHI::=E=
M[>I3CNWDD:/RT^4'!$JL20.!M'(R:?"\[L?-MS&.Q,BOD?0#CZ?_ %Z<?LT!
M#N(HG./FP <GMG&3FIPRD9!!'UKAJ^RDXOEY8I+26FNEW9M[V3U^Y .HHHI
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M7^5?GY\!)$DU?5=AW8UK4@?W2P\B]F[)D'I^/4]J_0.#_4Q_[B_RH EHHHH
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M"A0;54R1,H/R#C&>PSZ5\>>%9Q\*_&#6NK7EQ<-KMP]M L!>1$8EI<OYX7:
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MKF0HB#^]@*.W?CV_2LT7EP7_ '*"X3/14,0"^N]LJ<=>.O:@#41$C 5$5 .
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MS^'WA#1?#NC6'Q"T==/LO*LIGLO#U_:W?[R0A_,?[1=[=S;3YH5N.F,9]&\
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MKF4M_:"S^8^_SR"/+&W;D$Y-?;UO8LMK##=2K=7$:X:X>)06//.SD+^%:-%
M%>WBFB!$DWF\G'R!,#L./3]:6XCAEB=)Q&492I\S;MP01SNX[U/63K%GIEY:
MO%JNT6Q!#[IFA&._SJZ$?7(H ^*_'.CW/PB\2VOBG2FUW6/[0U*V@:UT:T:^
M6)+VX2)FD1Y@B1QB3<[ ?*JEL<5]@Z#?S:KI%A?^?);>9$LDL-Q$JS %1\LB
MY.PY/.,\_05X/\;&TY/#T46C>+M%T);9[>0RW$SW<J)$Z%BB0)=2L^T84%""
MV,\=/-?AU\8WTT2:78ZQK7Q#U22/RK:&VTS[+9Q2 @[FDNK6PRH52OWSU&:
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M'WC/X?Z#K%EXRU:VU6ZNKJ&2WDMIC,L<:>;N4G:N,[E 'M0!],4444 %%%%
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M?_!#3=.U&_N_&6E,NF1&2>&&^M'N&PZIM2/S@-V3T)_&OA2?_@FS^S@VI#Q
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MAW8ZGIN^;\ZGH **** "BBB@ IH92< @GTI'*X^;I^/]/K4!1Q\T!4Y/\><
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M"#7]#V+)#JEE-%*!(DJ7]O)&R/\ ,&5O-/&.>.,8'-?S)?L(_P#!*-?%4?\
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M'E[O,YQYV_[_ 'W?N_RY_#-?0O@K_D6-)_ZX'_T8] '4T444 %%%% !1110
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MQ@A^'NIVQ+S?#G3?"&A^(K])E&X6=U>7@M;J*5QCGRBP# CDD4 =+X)_8?\
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M3>(8]&2SUK6/#*VMHNI72Z9%;:18>(K6VN(HK80K&S(/.558C+&@#T7X9_\
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M0.]<K\,?V*/A'\+]97Q'HUG>WVJ)$Z17FM7U_JUW"CE6*13:A=3O$K%5+*K
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M)9[+P[X]2RTY6$2#;%!_9[X4CJ QY!YYK]-?&,=RVDX2":Z<>8?+@@$CGA<
M+D8SGC'IZU\Z^&?'U]X3U34TN/AUXUN UQE)K/36ECE^1!E09 %&5(P,CCWS
M71E%?&X&DZF5XG%TL9/EBOW]"%."3CLI>^Y?S?$OD?8864G%.*E&?)%\S=.*
M7P^<G?;X;+L^A^<O[0W_  2?\$6_A/4M4T[XZ?M8:E<6]JY2PTOXD+BX9(>-
MT":1*[LY'S$9R2<#IC\6_AA_P3_TBV\?6UYXLT;]J[6-)&H)YG]I>);B4O'Y
MP#,XD\/,>1\QR/\ "OZ9OCG^W)J_PMLKRZ@_9N^+7C".VB,G^@Z,3;2 1A\%
MO,8 =F.T@$'.>E?BOXS_ &S/VF_V@-:N[SP?\+/BM\,M#O)9I(=,LM"_TNUA
M<L503Q>1+NC&!D,.1^-?T?P?FWBSF.4/ O.Z>&PM1PE3Q>(SO)Z-6*Y>54XP
M]O[>":=^;D@M%>2O8X\?3@DI)?O)P;E9N2;Z2:4W!^EKOIV/TQ^&W_!*_P"$
M,^AVVLZ3\3OV@?"GG0+(+,^+[6*2V5XR<*#H\3HR X!(!SVKI[C_ ():>"+J
M;-G^TW^U4I5N5L_BA'"D?.1A/[,./:OP.^&__!;;XA_LV_$2?PQX[\'?&;XG
M2V\\U@NAZE;"!))VWV\:;GN+A\B1E(RI.1C&:^A_B3_P7:_:)U2TAU+X>_L?
M>,/#5LR^8+C5[V:V\U2 RE5_LJ96P.?O <_EZ68>&OTBL16C5P.<X3-,%*%X
M8RIQ#D7(TU\%JF,^M-I=53DG>^FHL-6@H0=%J[TFK5.9M*-^5RC;7RT7H?K]
M<_\ !+'PE<6#6UQ^U'^U:T93:SR?$]?-7C& YTP#@# ..#[\UH_ S]F;PI\"
MO'MAINC>-_BIXVEL+R)$O_&OC"'69)S"Z@/,191%R^/GYYR<=J^1_P!A?_@J
MI\7/CWHT:_$KX'^(K&\:YN;9S;@2E1%<2PJ%065MO^51ACM+=^<U^F/A=KO7
M_B1!K,?@OQ+H]K-=I+YNI130P(KN&RT6]H\#)SVZ'KBOQ?BC(_%C*)8C"YW7
MRZ=.-&K.O*MF.$K4^2#2G[&.&Q$9.=GHG%RETCN=,H\\>:-[1EM>*DI6335[
MIO1ZZKNSZN\03Y\.ZPY7##3+PA XR2+=\ -C )/&2.*^1OV>M0DF\3Z^LT+Q
M8$FTW%U')N(F7[BX4]!ZG]>/KCQ!E="U99(4*_V==\AL9'DOU( ( [^GY5\G
M_ V*)/$^M&")!GS,^3_I./WO\3/@H,]QW[<U^1?5\15G3]M6I0A%WDZ//9O1
MI*_-:_5.^G;6VC32M=ZI*Z<&]+<U[76O6UM-C['^S[I$F\Z88'^K5_W9SSR,
M<D>M/NK:.[MI;689BFC,;^I5A@]>]3)]U?IZ8_2G5U;:;^8CY7N/V0/A-/XG
MO/%@MKZ'5[ZX%U/+#]C0&4*J@@_9=_1!U8GWK5^(/[+OP_\ B3I1TOQ!=ZWQ
M:I:1WMM<VZWL,4<2Q1^5,]N^PHJC;\N!@<5])T4>B2]$EY=+#;;=WKT^X^/O
M@W^Q-\'?@I=VNI^'HM6U;5[1TDCU;7Y;2\OVD0@AY)X[6%BQ(Y/>NC^(/A'0
M-/U*TU*UT/1[6\DO[8O=VEO#9W;%KA-Q:=]Q8MDY 'S9(!YKZ>KY^^)*P&>Q
M\F22607MJ2BK]KQ_I$?5)"0H]2!\O4=,T"/:M"XTJS _YY+W#?PCN.#]16O6
M3H>1I=F""/W2\%=IZ#JHX'T[5K4 %%%% "$ X)&<=*6BBBX?+??S"BBB@ I"
M<#)S^ I:Y3Q%>W5K!(T-ZUE@,1*84=1C/]XX/IS32NTN[2^]G/B<1'#4G5E&
M4DND$F_5IN.GH[G0330M&T;JSAU*E0A;(8$<X!XYYKS[5? ?A?4KB.>]\,65
M[(KEEGFBA+1G!&_YH\@X)'7/-95I!XOO"9$\43&,J2I_LFV1!P3GS%8D_B.>
M,XJCJ=GX[2RNA#XK9KC;^Y4:?!N#9'1<_,<<8^ON:ZZ+E1ES*/*D[2G.I!<M
M[):*<)*_3?I==_D<YS?+E1Y\PX=J9WR0G.E35*B_LIVBJM>'O75]).[LDC2\
M0>&=(TS0Y3IUC!;L"%^SQ/%$F"&_N@=/U!.,5\LZ]X.^$L<S:[XSTS3C='/-
MVD$BXC8MD2,ASRV2,YQVP<UO:SX>^.^JJ\,'B>6.$R9\R728<XXX";6# C/.
M[TQZUZ!X8^"^I:KH\:>--4L]5N-[;_M.E0XP0,_NFPJY.>G)[\5])@,SPU+"
MU(XC$2G:=TN7WM4M(OF;2O?L_P!?YVXKR7B#C+&T\3PKP!ALN5."IQ>9QP]-
M<\7=R]E+%PAR]KOFOTV/./ ?QU^!GA[5(=(T%;6VG,@MT_L_3IG8,WR?>@@9
M<<\D>_2OL'3]?L->AAN;"Z=8'4.5FMI8]R8Z?/MQU'!&/QP:\@@_9W\#:?*+
MFQT_2;6\4[A<P:7;JX?KN!!&.>?;\*V+SP=KFC:=<3Z9XE=%@3<L*VD9&,@
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MUU<7.GRZUIPM!+).[S1JS[95C#%D 63 7[IH V?#7[>WP U_XA0>"O"7P_\
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MP1I^J7,8<I(L:B4%E.>K*I!('7))KYM^$7@W0/ _Q/UJU\/:/9^']#MK:WF
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MM>VST9\Y?$/X&M+=1R:)J>D:/#@?NF*PXP3DX &?0_EQ75^ ?A'X=MK!8O$
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MOP3UZ\U,9<W22V^)6O?L!*:\!^(,D'VFT MC WVRVS+([6JM^^CX$D8)8GC
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MM_(L##DC9II5(MWUTT.U'QYUO4-06WTG0_ML#2@>;/<K;0["0"PECCDW8&2
M<!L=<5[#;>(YM8TJ<7%I:VTKQ LBZ@S88E<C[J%N_7'N*^?+']CWP]IY46OB
MOQ1"ZG!,5W 2<<,#O@(Y&>1S^E=M:? +2O#5I/,?$WB.Y4)\T4]Q 0XRO!*Q
M*>H'0CUZ\4L54R:7+'#0<'[O)RQ=[Z-:1E!.[:W6A[?!V*\;.:53BS)LOC%M
M^T:S/#XA*]KJ[PG*N1MV491;T1[AX,:*VM9PS1J693A92V>6/;_/-3^,[^,:
M1<QKF1)()4E5%RP1@!][JG^\.1BL7X=:'IME83QVK3R*'3)G<LQ(W<Y//7K_
M $KT?R8BIB:WS&1@E@K @YXYY/XU\WBI1AB9SCS2G"7-+G5OY7M>Z?32[ZG]
M%Y0LVJY=0]HL)AYNFGHO:6]Y=(2IT_+1OS1^25C^RS^R]\2_&7BO6/&D>J6N
MK-?YN9[3XC>)=*V.((OF:VMKR"&W(&#A .!DU\#_ +3/[(OP+LO&9A\%?MA6
M'PQT^,PK_8NM_&37YKB,A%5DW76JF1,D' 'W0<#I7]&.L?#OPAK:7*:CH%K*
M+@$3-&/L[R\8RSPF-B2.-Q.>@Z<U\<^-?^":7[)'Q%UJ77?$?PQ2XU"60R23
MOK.K!B^>6")>[.N3C&,8&#S7W_"'B+BLLG4K1S?/,OY*:HQPRI*M@4E:+<*-
M>M2:ORWBZ<)*S>NNOO.$YTU&M*'-RQYI0<DYM)6U@HV7]V5[[.7?\VM/_P""
M;G[-'Q(^#KC6OBFOQ0U>XTAB^LQ_%_Q2=.NI6@)\W?#J+KL=CGA.A[U_)W\8
MOV-/!'PP^-D\'_"=^!&T'3]=5CH>B^-;O6=3N((KQ0;2X^T^5)B5!Y<K;F(4
MEL-C!_T-]$_9'^"OP]\--H/A#P.8K."T>W@B;4[S8$6,JN2UVO P.>O/XU_-
M;\>?^"0WPG\??%O4/%HB\":5>0ZJVI8N_%6O03(\%U]H_>HETT38*#<@!W#(
MP:_JGP,\<JF3X[,7C\XSO-\)-1GR8K#T8K#N;DG]7A3Q>(G2ATC^ZIM=)72M
MPXN$>2"4(J;=KQO#2T5[Z;Y&OF]3B/V5'_9*TW3;-+G]EW0O%&I6EHO_ !-M
M/\2ZG%J;R 1@S1I;6AS(W.1YO0GD]_V[^#_[.O[)7QL\*76L:OX%\7_#^.T\
MD+I<_P 1O%.EQ2&19#\D<5_ KK'LQG9P&YH_8'^ _AKX8V%UX?CU/X=:E;+8
M"U,.E.][<%5DAX\W4(FDR-@^9&!X.3@G/Z<O\+? D\7ER:%"R289O*EEBC)'
M<")U&.3C QC(]<_D/C-XF_VIQ'F*P^;<48"BY4Y4VLYS6O&5TI<LL+C<5"GA
MXZV2IQFK6:L]"\/2G!1?+#FV?NI-MVL[PB^^[[7V/@CX!?!GX;?#/XM:O8?#
M6"6+3E@LW6XF\::UXCG=O-N!AH-2DE5  %P1(=Q/(!%?HOXN60>%]25I/G^S
MO^\(V?PMSQTINA>"?#/APEM%TFWLV;&9 &:0XY&78E_UQZ5+XTV_\(UJF_.W
M[.^[;U^ZV<9K^?,WSF6<XBG7D\14=.C3I.MBO>JU7"*BYRJ-N4KVOK)_@=UW
MRI-+3M;LO)/[_P!#XB^ ZR+K&J^9<+<'^VM2P4D,NT?;9L Y^[C].E?H#!_J
M8_\ <7^5?GW\!/L_]KZM]G\W']MZGN\W;G/VV?.W;^F>WO7Z"0?ZF/\ W%_E
M7DB):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *ADG2,@,')/]U&8?B5!Q
M^-344 )PR\C((SAAZ^H-<AXB\*:!JUM*MYX7TO6FD5@T-S!  VX'/S2*0"<_
MK7844 ?-A_9YTZ.?^T="\0^(/#%SN\Q+.SO0;&)\[@GDQ*@,?\)4,,KQQ6R=
M"^,7AN,#2M>TOQ)$HVB&]LI8YBN!R9I+\*6XZE?7 KWJB@#P>V\=?%73#GQ'
M\.Q-:C[U]IFH12L"/2SB\^9MPR1CIC'.:Z"U^+V@,"NH:9XFTZ91F03>'=7,
M*^I%Q]D$9 YSSP,'H:]8JK=0K.FQK>&X4Y#)/C;@^Q5LY[C% 'FD?QK^&CRM
M _B:TMYD;:\5T'MI$;T=90I4_4"MU?B7\/VA^T?\)CX>6$#)=]4M$ &,G.Z4
M8QW!I\WP[\#W<C7%WX2T"2YD.99&TZV=G;IEG,>6.!U-,D^&GP_DA:W?P=X>
M,+ AD_LNTP0>H/[J@#%E^-_P>@SYWQ,\$Q8Z^9XBTU<8Z];@5&?CI\&@%)^)
M_@?#D*I_X2/3/F+$!0/](Y)) 'KVK/D_9Z^"LTADF^&_A29B<D2Z3:.ISS]U
MHR*A;]G+X(.RL?AIX4^1@R@:5:A5*G*D*(\ @],=* .SMOB;\/;Q/,L_&7AV
M\7&1]EU6TG)!Z;1'(Q/X55N?BMX M3ME\26!E.<0QR"29L=UB7+L.V0.I%2:
M9\+/AWHZA=.\':!; # \O3;88'M^[K1D\ ^"I)%F?POH9F3A9?[.MA(HR#@/
MY>X#(!Z]A0!S%U\5?!\T#&*37[A2",Z=H.J73$?[(AMGSG@=\_R\V\2>);;7
MK9[?3OA'>^*6D&V-M4L)-+?)Z/YE]9+Y;*?FR>A%?1MGI&F:>H6RL;:V5?NB
M*)$QCIC K1H ^!D^#?Q.\27'G:-9WOPF ;>LL6KPZDC#D;/(LWM64<@X)XVX
M/-:NJ? SXPV>DO%?^.;SQ\I=3_9R&32YR &R1=7=Y<1@8.TC9SV]*^Y** /B
M?P3IVK>#%*2_ A1J2MNGU>>^L]0NY4'3]]%;?/M(9E1>?F/7->V6OQG\-6RI
M:7^A>+-+OE^6>*+P?KDME ^>@O(K(6[IMY+JVWJ,C%>V4QXTE4I(BNC<,K ,
MI'N#Q0!YNGQ9\"1(&O/$^G0NPW"&<FVN$W8(22WE(E5P#AE*@@\$9JW'\3/!
MTD?VEM?T>"RQN-S<ZC;VX"]<E964C\3QU(K3N/ ?@N[E,]UX6T*>9CEI9=,M
M7D)/.2S1DD^^:BNOA[X(O;=K6Y\+:));LI0Q'3[?85/!& G0T <Z?CC\'1(8
M3\3?! E4D-&?$6F;P1U!7[1D?E2'XY?!Q65&^)W@@.QPJGQ'IF6/H!]HY-80
M_9L^!WVA[K_A7'AHSN26<Z=;GEN3QL[T2?LU_ Z26.=_AOX9,D3;D;^SK<8.
M".FS!ZGK0!WUG\1O 6H0FXL?&'AV[@7&9K?5;26,9R1ETE(&0#CGG%4+GXK?
M#ZV<Q-XITJ24#[D%U'.V>P"QLQ)SV YJQI_PQ^'^E6IL]/\ ".@VMLVW,46G
M6RJ=H(&0(QG )_.G1?#/P%!<?:H_"FBB;@[_ +# <$$D$ I@'D\T 8;?%;02
M)#;V^O:BNUO+^R>&M7EAE)!VJ+E+=XB&X&[.,'/2N,N/BAX]GF,7A7X3ZA?*
MYQ]JOKP:4JKV=H[N"-FY ^7(//M7T!;6MM9Q+!:P16\*#"QPQK&B@= %4  "
MK% 'SG%J?[06N7*P-HF@>%+-U):YN"FJ2)G@ +;WD+9P2<^P[C%12_ J\\1W
MGVOQMXR\1:LQVYLK.\:TT91DE@EA)YY4D\,PEY&T=N?I&B@#SSP_\+/ ?A:!
M5TCPOI*7"\O=M9P&ZG?^_+*4RS8 7/H *[*W6Y&%6"&TB7Y5C55;Y5X&"A4
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MX]:2MG9^(=)6:QN;:^L;/6_#T^J6+W%E/'<0Q31_;;=6C:2)5;D#'?%?>M%
M'XJ:3^PA^T;XANK"U\3?$[PI\.O#VDL&%E\/?!L^E'68E4QK;Z@8=;N/,B((
ME(9!\Z*3TKE/&7_!*74?%'C/3M8M/%][:2V]M.DGBJT@^R:BCR-$VQ0USYY6
M8J&8@GE!GMC]UJ* /PFT+_@E?XTL_%4S7'C[4S;PQP/!XHO)#=7=Q(K/^ZDA
M6]68)" I&3SYA Q@UZ)\0_\ @G?\4_%>G6>@:E\8-'O].LK?[+82W'@_4KNY
M@BWNW,HUS&X,[,"%7MTQ7[*T4 ?B%X<_X)2:[HGA:]T'6/BIINN1WWVF0W4W
MA2ZDDMUN2[B...34Y) (E8(HW=%&*N>"O^":OCWX5Z?')X4\=>%?&]I H\KP
MWXD\&WB6$JC.(7BFUJ- I''TK]L:* /Q>T[_ ();7]Q<ZCXCUOQUYFH:E;70
M3PVEC*-#TZ>YC<(;.W^WNJ?9G8&'#G:54\XS5/P#_P $R/BIX:N-6BA^.MWI
MND:BC1R:9-IUU=6DD)D#B(QIJB@*"JGI_"/P_:VB@#\@-?\ ^"<7B,Z!>Z3:
M>*M"U.YNDD'VLZ%) 2[J1N82:GG/?[W->D_LM_L>_$7X!RZ7<ZY\0WOM+L'@
M=]#L=.N%A:.%E)B4+?W P57:/D/!'%?IM10!$DBSQ;EWJ''&Y61AD>C $&HX
M+80%B)9I-W:1MP'TX%6:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$=@@\Y<;6^4 ]LX-?6WB,D:!K)'4:;>$9&1_J'['@U\D_L_RQR^)M?%Q(L;
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M$:L5[M>C[?FMM:2LUO>RDD*?LY*R@XM?#).\D_/F;7X/<_-;]D;]@/0/V?\
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M:_[!EY_Z(>ODG]GB5H_$OB)5C9P5D!8%,+^_4Y^<AOP'^-?6WB3_ )%_6O\
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M>[)WA"0"!MZ].^1_^HCYZN?@SX\'B"6\L/&5[:Z:RILMQYC1@[F)^19UP=I
MZ<8]*]["8FE[#V56<6G[]JEFG:RZR7-VLM>NVB_*\]R7B"GF=.ME> G2P,(1
MIIX.M##U8+>\%&,MG_<2M>VY9CUKXXSZ[Y*V6E2Z6)L#?A7\L-U)5EYQUQ^F
M*]_T4ZU]F5M;2VB?9EA;;C\W&02<\8STYXX'<X'AWPOJVCI']NU:6_=5P6D4
MX)VXR 78CUY]/PKNHQ(H"OW[$$@_YX]_2N'&5*<Y+V+I\J2=J<>771O3E[.V
MSZ:L^NX9P^-H4I/-(8N5>4DKXBHIRY/=Y5)J<EWU=D_Y.@B/&^52-F7NWO\
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M7^5?GI^S[_R%M7_[#FJ?^ED]?H7!_J8_]Q?Y4 2T444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!_\ '* +U%4CJ6G#K?V0^MU /YR4G]J:;_T$+'_P+M__ (Y0!>HJC_:FF_\
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M%4O[2T_&?M]ECU^U08_]#I/[4TW_ *"%C_X%V_\ \<H O451_M33?^@A8_\
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MVW5UI[HT<DMM-D$&+SX=Q]1AG'TK$M;#PXDWG)9V=M+DGS&FML@^ORR'GTH
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M;B9)VS%]H(<[@37Z%?"GXX_%WX>>$+.S\0_\$YK9O'<%K$BQ>%6T_4M->Z5
M$D36['2KRT978+)Y@G(^;.[O50O-M)6M_-[J^^7*G\FR>5.RC*[M[W,U!)Z*
MR<FD]?33IHS]7?"OP=^'7B;1X]5T'7-<O=.O8/\ 1YY&F@=4E3Y72.=(Y$8
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ML VZG?Z9<W$*2!]SDNL.$(.,8-?G7\;/B=JGQ+^-=MJ^N:=XS^.?PL^VV_\
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M7\VF]'I?S;[GGGA7X(?"'P--%<>$/ASX2\.3P,K0S:5H]K:21LN-I1XT# C
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML;JZ\+V\$CLVI2ZU#82:G,M[YC0JDUG$B_9"RL2[8]?\+?MU?LE_'+PCI_\
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M >,"O5=.\-:5HL*VVB6L.EVRXQ:VB"&U! QE;=-L2D@ $A>@ KH**?Z=U?\
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MKK?C'X2WW@B]UHA_!S>")+G7M/OKIT,BQZI>Z/\ :((8#;[W\V9X4\Q4&[)
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MMM"Y]\#_ #WJ:@!" >H!^HHP.N!GZ4M% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
>444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>image00002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 0X!W\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
,B@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001534248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Chemomab Therapeutics Ltd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Kiryat Atidim, Building 7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tel Aviv<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">6158002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well Known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">U.S. GAAP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">377,132,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Somekh Chaikin<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tel Aviv, Israel<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm Id</a></td>
<td class="text">1057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Kiryat Atidim Building 7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tel Aviv<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">6158002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Sigal Fattal<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">492-5563<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cmmb_AmericanDepositarySharesMember', window );">American Depositary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CMMB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of Exchange on which Security is Registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cmmb_OrdinarySharesNoParValuePerShareMember', window );">Ordinary Shares, No Par Value Per Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, no par-value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of Exchange on which Security is Registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmmb_AmericanDepositarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmmb_AmericanDepositarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmmb_OrdinarySharesNoParValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmmb_OrdinarySharesNoParValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6,071<span></span>
</td>
<td class="nump">$ 9,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Short-term bank deposit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,195<span></span>
</td>
<td class="nump">10,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">76<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other receivables and prepaid expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,698<span></span>
</td>
<td class="nump">1,037<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,040<span></span>
</td>
<td class="nump">20,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Long-term prepaid expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">385<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">250<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">289<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">924<span></span>
</td>
<td class="nump">1,254<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,964<span></span>
</td>
<td class="nump">22,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade payables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">666<span></span>
</td>
<td class="nump">516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,563<span></span>
</td>
<td class="nump">3,423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee and related expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">874<span></span>
</td>
<td class="nump">823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">115<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,218<span></span>
</td>
<td class="nump">4,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current&#160;operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">209<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">209<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingent liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,427<span></span>
</td>
<td class="nump">5,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Shareholders' equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary Shares no par value - Authorized: 4,650,000,000 and 650,000,000 Ordinary shares as of December 31, 2024, and December 31, 2023, respectively (*) Issued and outstanding: 377,132,220, and 284,094,700 Ordinary shares of December 31, 2024 and 2023, respectively (*)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">116,160<span></span>
</td>
<td class="nump">105,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(102,623)<span></span>
</td>
<td class="num">(88,678)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,537<span></span>
</td>
<td class="nump">16,997<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 16,964<span></span>
</td>
<td class="nump">$ 22,151<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">1 American Depositary Share (ADS) represents 20 Ordinary Shares.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common Stock, No Par Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">4,650,000,000<span></span>
</td>
<td class="nump">650,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">377,132,220<span></span>
</td>
<td class="nump">284,094,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">377,132,220<span></span>
</td>
<td class="nump">284,094,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11,327<span></span>
</td>
<td class="nump">$ 18,381<span></span>
</td>
<td class="nump">$ 16,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,412<span></span>
</td>
<td class="nump">7,078<span></span>
</td>
<td class="nump">11,556<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,739<span></span>
</td>
<td class="nump">25,459<span></span>
</td>
<td class="nump">28,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Financing income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(794)<span></span>
</td>
<td class="num">(1,238)<span></span>
</td>
<td class="num">(353)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,945<span></span>
</td>
<td class="nump">24,221<span></span>
</td>
<td class="nump">28,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(534)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13,945<span></span>
</td>
<td class="nump">$ 24,221<span></span>
</td>
<td class="nump">$ 27,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per Ordinary Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.039<span></span>
</td>
<td class="nump">$ 0.103<span></span>
</td>
<td class="nump">$ 0.121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per Ordinary Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.039<span></span>
</td>
<td class="nump">$ 0.103<span></span>
</td>
<td class="nump">$ 0.121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of Ordinary Shares outstanding, basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">359,048,638<span></span>
</td>
<td class="nump">234,998,859<span></span>
</td>
<td class="nump">227,589,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of Ordinary Shares outstanding, diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">359,048,638<span></span>
</td>
<td class="nump">234,998,859<span></span>
</td>
<td class="nump">227,589,288<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Number of shares has been retroactively adjusted to reflect the share reverse split effected on March 16, 2021 (refer to Note 1)</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">1 American Depositary Share (ADS) represents 20 Ordinary Shares.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Ordinary shares [Member]</div></th>
<th class="th"><div>Treasury share [Member]</div></th>
<th class="th"><div>Additional paid in capital [Member]</div></th>
<th class="th"><div>Accumulated deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 97,639<span></span>
</td>
<td class="num">$ (36,173)<span></span>
</td>
<td class="nump">$ 61,466<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">228,090,300<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,211<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues', window );">Issuance of shares and pre-funded warrants, net of issuance costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues', window );">Issuance of shares and pre-funded warrants, net of issuance costs (in Shares)</a></td>
<td class="nump">2,576,400<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="nump">1,970,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Sale of treasury share at cost</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1,218)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,218)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Sale of treasury share at cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(11,640,460)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(27,646)<span></span>
</td>
<td class="num">(27,646)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1,218)<span></span>
</td>
<td class="nump">101,260<span></span>
</td>
<td class="num">(63,819)<span></span>
</td>
<td class="nump">36,223<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">232,636,700<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(11,640,460)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,491<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues', window );">Issuance of shares and pre-funded warrants, net of issuance costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,924<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues', window );">Issuance of shares and pre-funded warrants, net of issuance costs (in Shares)</a></td>
<td class="nump">51,458,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Sale of treasury share at cost</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,218<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(638)<span></span>
</td>
<td class="nump">580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Sale of treasury share at cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11,640,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(24,221)<span></span>
</td>
<td class="num">(24,221)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">105,675<span></span>
</td>
<td class="num">(88,678)<span></span>
</td>
<td class="nump">$ 16,997<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">284,094,700<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284,094,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">617<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues', window );">Issuance of shares and pre-funded warrants, net of issuance costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">9,868<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues', window );">Issuance of shares and pre-funded warrants, net of issuance costs (in Shares)</a></td>
<td class="nump">93,037,520<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,945)<span></span>
</td>
<td class="num">(13,945)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 116,160<span></span>
</td>
<td class="num">$ (102,623)<span></span>
</td>
<td class="nump">$ 13,537<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">377,132,220<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">377,132,220<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">1 American Depositary Share (ADS) represents 20 Ordinary Shares.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>it represents number of shares and warrants issued during period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the year</a></td>
<td class="num">$ (13,945)<span></span>
</td>
<td class="num">$ (24,221)<span></span>
</td>
<td class="num">$ (27,646)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments for operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">617<span></span>
</td>
<td class="nump">1,491<span></span>
</td>
<td class="nump">3,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Change in other receivables and prepaid expenses</a></td>
<td class="num">(487)<span></span>
</td>
<td class="nump">903<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Change in trade payables</a></td>
<td class="nump">150<span></span>
</td>
<td class="num">(1,172)<span></span>
</td>
<td class="nump">352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Change in accrued expenses</a></td>
<td class="num">(1,860)<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">2,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Change in employees and related expenses</a></td>
<td class="nump">51<span></span>
</td>
<td class="num">(737)<span></span>
</td>
<td class="nump">907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Change in operating leases</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(15,386)<span></span>
</td>
<td class="num">(23,611)<span></span>
</td>
<td class="num">(20,370)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_PaymentsForInvestmentInDeposits', window );">Investment in deposits</a></td>
<td class="nump">2,297<span></span>
</td>
<td class="nump">15,882<span></span>
</td>
<td class="nump">19,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">2,297<span></span>
</td>
<td class="nump">15,879<span></span>
</td>
<td class="nump">19,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Purchase of treasury share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,218)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfTreasuryStock', window );">Sale of treasury share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">580<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Issuance of shares net of issuance costs</a></td>
<td class="nump">9,868<span></span>
</td>
<td class="nump">2,924<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">9,868<span></span>
</td>
<td class="nump">3,504<span></span>
</td>
<td class="num">(808)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(3,221)<span></span>
</td>
<td class="num">(4,228)<span></span>
</td>
<td class="num">(1,645)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of the year</a></td>
<td class="nump">9,368<span></span>
</td>
<td class="nump">13,596<span></span>
</td>
<td class="nump">15,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of the year</a></td>
<td class="nump">6,147<span></span>
</td>
<td class="nump">9,368<span></span>
</td>
<td class="nump">13,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_CashPaidAndReceivedDuringYearForAbstract', window );"><strong>A. Cash paid and received during the year for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_IncomeTaxesReceived', window );">Income taxes received</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_InterestReceived', window );">Interest received</a></td>
<td class="nump">814<span></span>
</td>
<td class="nump">1,463<span></span>
</td>
<td class="nump">972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>B. Significant non- cash transaction:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset recognized with corresponding lease liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 392<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_CashPaidAndReceivedDuringYearForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_CashPaidAndReceivedDuringYearForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_IncomeTaxesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents income taxes received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_IncomeTaxesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_InterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_InterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_PaymentsForInvestmentInDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payments for investm,ents in deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_PaymentsForInvestmentInDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfTreasuryStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of an equity stock that has been previously reacquired by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfTreasuryStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NatureOfOperationsDisclosureAbstract', window );"><strong>Nature Of Operations Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">General</a></td>
<td class="text">
    <div>
      <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Note 1 - General</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt">&#160;</td>
            <td style="width:30pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>A.</span></span></span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Chemomab Therapeutics Ltd. (hereinafter - "the Company") is an Israeli-based company incorporated under the laws of the State of Israel in September 2011. The Company&#8217;s registered office is located in Kiryat Atidim, Tel Aviv, Israel.</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:65pt">&#160;</td>
            <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>i.</span></span></span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company is a clinical-stage biotech company discovering and developing innovative therapeutics for conditions with high-unmet medical need that involve inflammation and fibrosis.</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:65pt">&#160;</td>
            <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>ii.</span></span></span></span></td>
            <td style="width:auto;vertical-align:top">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The wholly owned subsidiaries of the Company are: Chemomab Ltd. ("Chemomab"), Chemomab Therapeutics Inc. and Chemomab Therapeutics (Israel) Ltd.</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt">&#160;</td>
            <td style="width:30pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>B.</span></span></span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company relies on one supplier for the production of the CM-101 used in its product development. If this supplier fails to deliver or experiences production delays, the Company will be required to seek an alternative solution. Switching suppliers may cause manufacturing delays and higher costs, potentially delaying the product's development and impacting the Company&#8217;s operational results and financial position.</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt">&#160;</td>
            <td style="width:30pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>C.</span></span></span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Going concern uncertainty</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. However, the Company has incurred recurring losses from operations as of December 31, 2024 of approximately $103 million and negative cash flows from operating activities in 2024 of $15.4 million with currently no products approved for sale.</span></span></span></span></div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As of December 31, 2024, the Company had cash, cash equivalents, and short-term deposits of $14.3 million. The Company&#8217;s current cash resources are sufficient to meet its planned expenditures through the end of March 2026. These indicators raising substantial doubt about its ability to continue as a going concern. The Company will be required to raise additional funds to support its operations and continue as a going concern. While management believes that the Company can raise additional funds, there can be no assurance that these efforts will be successful or sufficient.</span></span></span></span></div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
      <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></span></span></span></div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NatureOfOperationsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NatureOfOperationsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
    <div>
      <div style="line-height:1.25">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Note 2 &#8211; Summary of Significant Accounting Policies</span></span></span></div>
        <div>
          <div style="line-height:1.25">&#160;</div>

            <div>
              <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">A.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Basis of Preparation</span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;).</span></span></span></div>
            </div>

        </div>
        <div style="line-height:1.25">&#160;</div>

          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">B.</span></span></span></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">Use of estimates</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</span></span></span></div>
          </div>

        <p style="margin:0pt">&#160;</p>
      </div>
      <div></div>

        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">C.</span></span></span></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">Foreign currency</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The currency of the primary economic environment in which the operations of the Company are conducted is the U.S. dollar (&#8220;dollar&#8221; or &#8220;$&#8221;), thus; the dollar is the functional currency of the Company.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The transactions and balances of the Company denominated in U.S. dollars are presented at their original amounts as the U.S. dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Monetary assets and liabilities denominated in a non-U.S. dollar currency are translated using the current exchange rate and nonmonetary assets and liabilities and capital accounts denominated in a non-U.S. dollar currency are translated using historical exchange rates.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Statements of operations accounts denominated in a non-U.S. dollar currency are translated using the exchange rates in effect on the transaction dates, except for depreciation, which is translated using historical exchange rate.</span></span></span></div>
        </div>

      <div style="line-height:1.25">&#160;</div>

        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">D.</span></span></span></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">Cash and cash equivalents</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Cash equivalents are short-term liquid bank deposits that are readily convertible to cash with original maturities of three months or less at the date acquired.</span></span></span></div>
        </div>

      <div style="line-height:1.25">&#160;</div>

        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">E.</span></span></span></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">Short-term bank deposits</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Bank deposits with original maturities exceeding three months but less than one year are classified as part of short-term investments. These deposits are recorded at cost, which approximates their market value, including accrued interest. Interest earned on these deposits is recognized as financial income. As of December 31, 2024, the range of interest rates paid on these deposits was between 4.24% and 5.75% (2023: between 4.22% and 6.65%).</span></span></span></div>
        </div>

      <div style="line-height:1.25">&#160;</div>

        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">F.</span>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <span style="font-weight:bold">Restricted cash</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Restricted cash is primarily invested in highly liquid deposits. These deposits were used to secure office lease payments.</span></span></span></div>
        </div>

      <div style="line-height:1.25">&#160;</div>

        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">G.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Property and equipment</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Property and equipment are stated at cost less accumulated depreciation. Maintenance and repair expenses are charged to operation as incurred. Depreciation is calculated based on the straight-line method and&#160; the estimated useful lives of the assets and commences once the assets are ready for their intended use.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Annual rates at depreciation are as follows:</span></span></span></div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
          <div style="margin-left:36pt">

              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td colspan="1" rowspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" rowspan="1" style="vertical-align:top;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>%</span></span></span></td>
                    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Computers</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>33</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:88%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Laboratory equipment</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>10</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Furniture and equipment</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>7</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="4" style="vertical-align:top;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Leasehold improvement - over the shorter of the lease term or the estimated useful life of the improvement</span></span></span></div>
                    </td>
                  </tr>

              </table>

          </div>
        </div>

      <div style="line-height:1.25">&#160;</div>
      <div></div>

        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">H.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Impairment of long-lived assets</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company&#8217;s property and equipment are reviewed for impairment in accordance with ASC 360, &#8220;Property and Equipment&#8221;, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less selling costs. During the periods ended December 31, 2024, 2023 and 2022, no impairment losses have been recorded.</span></span></span></div>
        </div>

      <div style="line-height:1.25">&#160;</div>

        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">I.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <span style="font-weight:bold">Research and Development</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Research and development costs are charged to operations as incurred. Most of the research and development expenses are for subcontractors and salaries.&#160;</span></span></span></div>
        </div>

      <div style="line-height:1.25">&#160;</div>

        <div>
          <div style="text-indent:36pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>J.&#160; &#160; &#160; &#160;&#160; &#160; Income taxes</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income,&#160;tax-planning&#160;strategies, and results of recent operations.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the income taxes expense.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50 percent likely of being realized.</span></span></span></div>
        </div>

      <p style="margin:0pt">&#160;</p>
      <div style="margin-top:0pt;margin-bottom:0pt"></div>

        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">K.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Fair value of financial instruments</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>ASC 820, Fair Value Measurements and Disclosures, relating to fair value measurements, defines fair value and established a framework for measuring fair value. The ASC 820 fair value hierarchy distinguishes between market participant assumptions developed based on market data obtained from sources independent of the reporting entity and the reporting entity&#8217;s own assumptions about market participant assumptions developed based on the best information available in the circumstances. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>In addition, the fair value of assets and liabilities should include consideration of non-performance risk, which for the liabilities described below includes the Company&#8217;s own credit risk.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:</span></span></span></div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Level&#160;1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></span></span></div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities.</span></span></span></div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The carrying amounts of cash and cash equivalents, short-term deposits, trade payables, other receivables, and prepaid expenses approximate their fair value due to the short-term maturity of such instruments. None of the Company&#8217;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.</span></span></span></div>
        </div>

      <div style="line-height:1.25">&#160;</div>

        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">L.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Share-based compensation</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company accounts for share-based compensation as an expense in the financial statements based on ASC 718. All awards are equity classified and therefore such costs are measured at the grant date fair value of the award and graded vesting attribution approach to recognize compensation cost over the vesting period. The Company recognizes compensation cost for an award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant-date value of such award that is vested at that date.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The fair value for the Company&#8217;s stock options granted to employees, consultants and directors was estimated using Black-Scholes option-pricing model at the grant date, using the inputs detailed in Note 8(C).</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</span></span></span></div>
        </div>

      <div style="line-height:1.25">&#160;</div>

        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">M.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Government-sponsored research and development</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Chemomab records grants received from the office of the Israel Innovation Authority (the &#8220;IIA&#8221;) as a liability, if it is probable that the Chemomab will have to repay the grants received. If it is not probable that the grants will be repaid, Chemomab records the grants as a reduction to research and development expenses.</span></span></span></div>
        </div>

      <p style="margin:0pt">&#160;</p>
      <div></div>
      <div>

          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">N.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Severance pay</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Pursuant to Section 14 of the Severance Compensation Law, 1963 ("Section 14"), all employees of the Company are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made on their behalf with insurance companies. Upon release of the policy to the employee, no additional liability exists between the parties regarding the matter of severance pay and no additional payments shall be made by the Company to the employee. This plan has been accounted for as a defined contribution plan. Severance costs amounted to approximately $50&#160;thousands, $86 thousands, and $142 thousands for the year ended December 31, 2024, 2023 and 2022, respectively.</span></span></span></div>
          </div>

      </div>
      <div style="line-height:1.25">&#160;</div>

        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">O.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Concentrations of credit risk:</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Cash and cash equivalents and short- term deposits are invested in banks. Management believes that the financial institutions that hold the Company&#8217;s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</span></span></span></div>
        </div>

      <div style="line-height:1.25">&#160;</div>

        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">P.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Leases</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Under Topic 842, the Company determines if an arrangement is a lease at inception. Right-of-use (ROU) assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company's incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be 9% in 2024 and 2023 and 5% in 2022, The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>When determining the probability of exercising such options, the Company considers contract-based, asset-based, entity-based, and market-based factors. For lease agreements, the Company has elected the practical expedient to account for the lease and non-lease maintenance components as a single lease component. Therefore, for those leases, the lease payments used to measure the lease liability include all the fixed considerations in the contract. The Company's lease agreements generally do not contain any residual value guarantees or restrictive covenants.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>ROU assets for operating leases are periodically reduced by impairment losses. The Company uses the long-lived assets impairment guidance in ASC Subtopic 360-10, Property, Plant, and Equipment to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize.</span></span></span></div>
        </div>

      <p style="margin:0pt">&#160;</p>
      <div></div>

        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">Q.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Segments</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company has one reportable segment, focused on the research and development of therapeutics for conditions with high unmet medical needs involving inflammation and fibrosis. The Company&#8217;s chief operating decision maker ("CODM") is its chief executive officer of the company. The segment is managed on a consolidated basis, and the CODM uses total operating expenses and consolidated net loss to assess performance, forecast future financial results, and allocate resources.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>In evaluating the Company's financial performance and making strategic decisions, the CODM regularly reviews operating expenses by function. Furthermore, the CODM is provided only with the consolidated expenses, as presented in the income statement disclosures (see Notes 9 and 10&#160;with respect to salaries, professional services, consultants and subcontractors). This includes a review of budget versus actual expenses and direct program spending, which encompasses clinical costs, consultant fees, manufacturing expenses, and other direct external costs.</span></span></span></div>
        </div>

      <div style="line-height:1.25">&#160;</div>

        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">R.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Principles of consolidation</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The consolidated financial statements include the accounts of the Company and its Subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.</span></span></span></div>
        </div>

      <div style="line-height:1.25">&#160;</div>

        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">S.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Loss per ordinary share</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Basic Loss per ordinary share are calculated using only weighted average ordinary shares outstanding. Diluted loss per share, if relevant, gives an effect to dilutive potential ordinary shares outstanding during the year.&#160; Such dilutive shares consist of incremental shares, using the treasury stock method, from the assumed exercise of share options.</span></span></span></div>
        </div>

    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
    <div>
      <div>
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 3 - Cash and Cash Equivalents</span></span></div>
        <div>
          <div style="line-height:1.25">&#160;</div>
          <div style="line-height:1.25;margin-left:36pt">

              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In USD</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,545</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,718</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In NIS</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">525</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,574</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In other currencies</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*-</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,071</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,292</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>

          </div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25;margin-left:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">* Less than 1 thousand</span></span></div>
        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Receivables and Prepaid Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock', window );">Other Receivables and Prepaid Expenses</a></td>
<td class="text">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 4 - Other Receivables and Prepaid Expenses</span></span></strong></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>

      <div>
        <div>
          <div style="line-height:1.25;margin-left:36pt">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Government institutions</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">263</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">289</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Prepaid expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,435</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">748</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,698</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,037</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>
        </div>
      </div>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other accounts receivable and prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">
    <div>
      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Note 5 - Property and Equipment, Net</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="line-height:1.25;margin-left:36pt">

          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Cost:</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Computers</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>68</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>68</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Furniture and equipment</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>33</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>33</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Laboratory equipment</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>400</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>400</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Website development</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>14</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>14</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Leasehold improvements</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>14</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>14</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>529</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>529</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Less - accumulated depreciation</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(279</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(226</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>250</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>303</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>

      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">
    <div>
      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 6 - Leases</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On May 10, 2020, Chemomab entered into an office and lab space lease agreement (the "Agreement") for a three-year term in Atidim Park, Tel Aviv, with an option to extend for an additional three years. On October 24, 2021, the Company signed an amendment (the "Amendment"), under which it returned the previous space on December 12, 2021, and leased a larger space in the same location for three years through October 2024. In September 2024, the Company extended the agreement through October 2027. The annual lease and management fees are approximately $112 thousands, and a bank guarantee of approximately $76 thousands was issued to the property owner in 2023.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On September 30, 2024, the Company signed an addendum to the rent agreement stating that, as of January 1, 2025, the Company has an early termination period of 120 days for the lease agreement.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div></div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25">The above operating leases are included in &#8220;Operating lease right-of-use assets&#8221; on the Company&#8217;s Consolidated Balance sheets as of December 31, 2024 and 2023 represent the Company&#8217;s right to use the underlying asset for the lease term. The Company&#8217;s obligations to pay lease payments are included in the current liabilities as &#8220;Operating lease liabilities&#8221; and in the non-current liabilities as &#8220;non-current operating lease liabilities&#8221; in the Company&#8217;s Consolidated Balance sheets as of December 31, 2024 and 2023. Based on the present value of the lease payments for the remaining lease term of the Company&#8217;s existing lease agreement, the Company recognized operating right-of-use assets and operating lease liabilities of approximately $392 thousands on December 12, 2023.</div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the year ended December 31, 2023, the Company recognized an increase in right of use assets of $392 thousand.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2024 and 2023 amounts of operating right-of-use assets were $289 thousands and $392 thousand, respectively. The operating lease liabilities amounts were $324 thousands and $392 thousand, respectively.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As most of Chemomab&#8217;s leases do not provide an implicit rate, Chemomab uses its incremental borrowing rate based on the information available at the commencement date of each lease in determining the present value of lease payments. Chemomab&#8217;s incremental borrowing rate is a hypothetical rate based on its estimation of its theoretical credit rating. The rate was 9% in 2024 and 2023.</span></span></div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Maturities of lease liabilities under non-cancellable leases as of December 31, 2024, are as follows: (in thousands):</span></span></div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
      <div style="margin-left:36pt">

          <div>
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">120</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2026</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">120</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2027</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">106</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;padding-bottom:4px;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total future minimum lease payments</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">346</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less imputed interest:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(22</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;padding-bottom:4px;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present value of operating lease liabilities</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">324</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>

      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingent Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments and Contingent Liabilities</a></td>
<td class="text">
    <div>
      <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Note 7 - Commitments and Contingent Liabilities</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">A.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Exclusive License Agreement (hereinafter- &#8220;the License Agreement&#8221;)</span></span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In December 2011, Chemomab entered into a License Agreement with the Medical Research, Infrastructure, Health Services Fund of the Tel-Aviv Souraski Medical Center (&#8220;Fund"), pursuant to which it was granted with an exclusive license to certain inventions (as defined in the License Agreement) including patents, knowhow and products and the right to sublicense to third parties the rights granted, pursuant to and subject to certain terms and limitation fully set in the License Agreement.</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Chemomab has agreed to pay the Fund a non-refundable and non-creditable sublicense fees as a percentage of all Attributed Income (as such term defined in the License Agreement) and shall further pay the Fund royalties from sales made by sublicensee.</span></span></span></span></div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Royalties in percentage of Net sales or Service Income (as defined in the License Agreement), subject to certain additional terms set forth therein.</span></span></span></span></div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
      <div></div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In addition, with respect to each Licensed Product (as defined therein), Chemomab has agreed to pay the Fund the following non-refundable, non-creditable amounts:</span></span></span></span></div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt">&#160;</td>
            <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(a)</span></span></span></span></td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$100 thousands upon submission of a New Drug Application (&#8220;NDA&#8221;), Biological License Application (&#8220;BLA&#8221;) or equivalent for each Licensed Product to the United States Food and Drug Administration (&#8220;FDA&#8221;), $100 thousands upon submission of a similar application for each Licensed Product to an equivalent foreign regulatory agency in Europe and one hundred thousands dollars upon submission of a similar application for each Licensed Product to an equivalent foreign regulatory agency in Asia. Payment in the aggregate shall not be more than $300 thousands per Licensed Product, provided that for each jurisdiction, payment shall be made only once.</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt">&#160;</td>
            <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(b)</span></span></span></span></td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$200 thousands upon the grant of FDA or equivalent agency marketing approval in Europe and/or Asia for each Licensed Product. Payment in the aggregate shall not be more than&#160;$600 thousands per Licensed Product, provided that for each jurisdiction, payment shall be made only once.</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As of December 31, 2024, no payments were made to the Fund.</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In addition to the payments described above, upon the occurrence of either (i) closing of a public offering of the ordinary shares of Chemomab; or (ii) a Change of Control Transaction, Chemomab shall pay the Fund a cash payment equal to one percent (1%) of the proceeds raised by Chemomab in its initial public offering, or 1% of the consideration received by Chemomab or its shareholders at the closing of a Change of Control Transaction (after deduction of amounts paid as liquidation preference to the shareholders of Chemomab on account of their investment in Chemomab, if any), but in any event not more than&#160; $3,000 thousand.</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As of December 31, 2024 none of the above occurred and as such, no commitment exists.</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt">&#160;</td>
            <td style="width:30pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>B.</span></span></span></span></td>
            <td style="width:auto;vertical-align:top">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Chemomab partially financed its research and development expenditures under programs sponsored by the Israel Innovation Authority (&#8220;IIA&#8221;) for the support of certain research and development activities conducted in Israel.</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In return for the IIA&#8217;s participation, Chemomab is committed to pay royalties at rate of 3% of sales of the developed product (linked to U.S. dollar), up to 100% of the amount of grants received (100% plus interest at LIBOR). In addition, the IIA may impose certain conditions to transfer technology or development out of Israel.</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Chemomab did not receive any grants from the IIA in the years ended December 31, 2024, 2023 and 2022.</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Since Chemomab &#8217;s incorporation through December 31, 2024, Chemomab received $1,227 thousands from the IIA, which was recognized as a reduction of research and development expenses.</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As of December 31, 2024, Chemomab had no commitment&#160; to pay royalties.</span></span></span></span></div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
      <div></div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt">&#160;</td>
            <td style="width:30pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>C.</span></span></span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In June 2015, Chemomab entered into a license agreement with subcontractor (&#8220;the Subcontractor&#8221;), under which the Subcontractor granted to Chemomab certain licenses to use proprietary rights of the subcontractor, materials and know how in the techniques and use of the same, for purposes of research and development of Chemomab 's product CM-101, as well as commercialization thereof. Further to the agreement, the Subcontractor also provides manufacturing services of intermediate and active pharmaceutical ingredients. According to the related manufacturing agreement, the manufacturing of the product is carried out by the Subcontractor in accordance with Chemomab's specifications and timeline.&#160; From time to time, Chemomab and the Subcontractor have been signing additional agreements for additional manufacturing and final process lock of the product for clinical use. Under the agreement, Chemomab is also obligated to pay the Subcontractor royalties determined as a percentage of net sales of each licensee product.</span></span></span></span></div>
              <div>&#160;</div>
              <div>
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>During 2024, 2023 and 2022, Chemomab recorded expenses related to the above agreements in the amounts of $418 thousand, $4,832 thousands and $5,222 thousand, respectively. The expenses were recorded under research and development expenses.</span></span></span></span></div>
              </div>
            </td>
          </tr>

      </table>
      <div style="text-align:justify;line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt">&#160;</td>
            <td style="width:30pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>D.</span></span></span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As of December 31, 2024 and 2023, the bank imposed restriction on a bank deposit in the amount of $76 thousand, for the purpose of securing lease payments under an office lease agreement.</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt">&#160;</td>
            <td style="width:30pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>E.</span></span></span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In&#160; 2022, the Israeli Tax Authority ("ITA") notified the Company that it had initiated a routine VAT audit covering the tax years 2017 through 2022. The ITA raised several claims, primarily regarding the recoverability of VAT related to the Merger Agreement expenses and the classification of the Company as a holding company. The Company accrued a provision for expenses&#160;of $638&#160;thousands in the year ended December 31, 2022. On December 29, 2024, the Company and the ITA reached a settlement agreement stipulating that the Company would pay $538 thousand. The amount was paid in January 2025.</span></span></span></span></div>
            </td>
          </tr>

      </table>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Share Capital</a></td>
<td class="text">
    <div>
      <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Note 8 - Share Capital</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt">&#160;</td>
            <td style="vertical-align:top;font-weight:bold;width:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>A.</span></span></span></span></td>
            <td style="vertical-align:top;width:auto">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Right attached to shares</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold;margin-left:72pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Ordinary shares</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>All of the issued and outstanding ordinary shares of the Company are duly authorized, validly issued, fully paid and non-assessable. The ordinary shares are not redeemable, and each ordinary share is entitled to one vote. The holders of the ordinary shares have the right to vote and participate in shareholders' meetings, the right to receive profits, and the right to participate in the accumulated earnings when the Company is dissolved.</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">1.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Voting</span></span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The holders of ordinary shares are entitled to vote on all matters submitted to shareholders for a vote.</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div></div>
      <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">2.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Dividends</span></span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The holders of the ordinary shares are entitled to receive dividends, when and as declared by the Board of Directors, and out of funds legally available.</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Since its inception, the Company has not declared any dividends.</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="line-height:1.25">
        <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="vertical-align:top;font-weight:bold;width:36pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">B.</span></td>
              <td style="vertical-align:top;width:auto">
                <div style="font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">Financing rounds</span></div>
              </td>
            </tr>

        </table>
        <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
      </div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:72pt">&#160;</td>
            <td style="vertical-align:top;width:18pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1.</span></span></span></span></td>
            <td style="vertical-align:top;width:auto">
              <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On March 15, 2021, the Company entered into Securities Purchase Agreements with certain purchasers, pursuant to which the Company agreed to sell approximately $45.5 million of its American Depositary Shares (ADSs)&#160;in a private placement transaction, (or "The Private Placement"). The Private Placement closed on March 22, 2021, at which time the Company sold to the purchasers 2,619,270 ADSs together with warrants to purchase up to 261,929 ADSs at an exercise price of $17.35 per ADS. The warrants will expire five years from the date of issuance, and if exercised in full, will provide to the Company proceeds of approximately $4.5 million. 20 Ordinary Shares are equal to 1 American Depositary Share (ADS).</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:72pt">&#160;</td>
            <td style="vertical-align:top;width:18pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2.</span></span></span></span></td>
            <td style="vertical-align:top;width:auto">
              <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On April 30, 2021, the Company entered into an At the Market Offering Agreement (the "ATM Agreement") with Cantor Fitzgerald &amp; Co., ("Cantor"). According to the ATM Agreement, the Company may offer and sell, from time to time, its ADSs having an aggregate offering price of up to $75 million through Cantor or the ATM Agreement. From April 30, 2021, through December 31, 2022, the Company issued 699,806 ADSs at an average price of $22.75 per ADS under the ATM Agreement, resulting in gross proceeds of $15,917 thousand.</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:72pt">&#160;</td>
            <td style="vertical-align:top;width:18pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3.</span></span></span></span></td>
            <td style="vertical-align:top;width:auto">
              <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On April 25, 2022, the Company filed a prospectus supplement with the SEC for the issuance and sale of up to $18,125,000 of its ADSs in connection with the reactivation of the ATM Facility and pursuant to General Instruction I.B.6 of Form S-3, which, subject to certain exceptions, limits the amount of securities the Company is able to offer and sell under such registration statement to one-third of our unaffiliated public float. During the year ended December 31, 2022, the Company issued 130,505 ADSs at an average price of $2.11 per ADS under the ATM Agreement, resulting in gross proceeds of $275 thousand. During the year ended December 31, 2023, the Company issued 772,900 ADSs at an average price of $1.83 per ADS under the ATM Agreement, resulting in net proceeds of $1,371 thousand.</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
      <div></div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:72pt">&#160;</td>
            <td style="vertical-align:top;width:18pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>4.</span></span></span></span></td>
            <td style="vertical-align:top;width:auto">
              <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On September 19, 2022, the Company entered&#160; into a share purchase agreement (the &#8220;Repurchase Arrangement&#8221;) with Dr. Adi Mor, co-founder of Chemomab Ltd., then Chief Scientific Officer and a director of the Company and Professor Kobi George, co-founder of Chemomab Ltd. (together with Dr. Adi Mor, the &#8220;Co-Founders&#8221;), whereby the Company agreed, subject to the requisite court approval required under Section 303(a) of the Israeli Companies Law, 5759-1999 (the &#8220;Companies Law&#8221;), which the Company received on November 14, 2022, to repurchase up to 582,023 of the Company's ADSs owned by the Co-Founders, for consideration not to exceed an aggregate amount of $2,500,000, depending on the market price of the ADSs at the time of any repurchase. Accordingly, on November 16, 2022, the Company repurchased 582,023 ADSs (the "Treasury Shares") from the Co-Founders at an average price of $2.0848 and for total consideration of approximately $1,218 thousand.</span></span></span></span></div>
              <div>&#160;</div>
              <div>
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On November 17, 2023, the Company sold the Treasury Shares for an aggregate consideration of approximately $580 thousand.</span></span></span></span></div>
              </div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:72pt">&#160;</td>
            <td style="vertical-align:top;width:18pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5.</span></span></span></span></td>
            <td style="vertical-align:top;width:auto">
              <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In October 2023, the Company filed a prospectus supplement with the SEC for the issuance and sale of up to $2,863,664 of its ADSs in connection with the reactivation of the ATM Facility and pursuant to Rule 415(a)(6) under the Securities Act of 1933 Form F-3, which, subject to certain exceptions, limits the number of securities the Company may offer and sell under such registration statement to one-third of our unaffiliated public float.</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:72pt">&#160;</td>
            <td style="vertical-align:top;width:18pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>6.</span></span></span></span></td>
            <td style="vertical-align:top;width:auto">
              <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In October 2023, the Company entered into an At the Market Offering Agreement (the "Roth ATM Agreement") with Roth Capital Partners, LLC, (&#8220;Roth&#8221;). According to the Roth ATM Agreement, the Company may offer and sell, from time to time, its ADSs having an aggregate offering price of up to $2,863,664 through Roth or the Roth ATM Agreement. From October 30, 2023, through December 31, 2024, the Company sold 2,303,009 ADSs at an average price of&#160; $1.11 per ADS under the Roth ATM Agreement, resulting in net proceeds of $2,348 thousand.</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:72pt">&#160;</td>
            <td style="vertical-align:top;width:18pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>7.</span></span></span></span></td>
            <td style="vertical-align:top;width:auto">
              <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On July 25, 2024, the Company entered into Securities Purchase Agreements with existing and new investors of the Company (the "Purchasers"), pursuant to which the Company agreed to sell $10.0 million of its ADSs in a private placement transaction, (or "The Private Placement"). The Private Placement closed on July 30, 2024, at which time the Company sold to the Purchasers 4,148,867 ADSs together with pre-funded warrants to purchase up to 3,948,300 ADSs at an exercise price of $0.0001 per ADS, resulting in net proceeds of $9,071 thousand. The Pre-Funded Warrants were classified as equity, since the warrants are not considered as an ASC 480 liability, are indexed to the Company&#8217;s own Ordinary share, and meet all the equity classification conditions pursuant to ASC 815-40. The Private Placement did not include any warrant coverage or other dilutive terms.</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
      <div></div>
      <div style="line-height:1.25">
        <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="vertical-align:top;font-weight:bold;width:36pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">C.</span></td>
              <td style="vertical-align:top;width:auto">
                <div style="font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">Share-based compensation</span></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
      <div style="line-height:1.25">
        <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="vertical-align:top;font-weight:normal;width:36pt">(1)</td>
              <td style="vertical-align:top;width:auto">
                <div style="font-weight:normal"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Share-based compensation plan:</span></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company maintains (i) the 2011 Share Option Plan (the &#8220;2011 Plan&#8221;), (ii) the 2017 Equity-Based Incentive Plan (the &#8220;2017 Plan&#8221;) and (iii) the Chemomab 2015 Share Incentive Plan (the &#8220;2015 Plan&#8221;).</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As of December 31, 2024, a total of&#160;28,443,060 of our Ordinary Shares (equal to 1,422,153 ADSs) were reserved for issuance under the 2015 Plan, of which 3,445,520 Ordinary Shares (equal to 172,276 ADSs) were issued pursuant to previous options exercise, and 9,134,900 Ordinary Shares (equal to 456,745 ADSs) were issuable under outstanding options and restricted shares ("RSAs"). Of such outstanding options and RSAs, options to purchase 6,677,380 Ordinary Shares (equal to 333,869 ADSs) had vested and became exercisable as of that date, with a weighted average exercise price of $0.31 per Ordinary Share (or $6.17 per ADS). During the year ended December 31, 2024, options to purchase 200,000 Ordinary Shares (equal to 10,000 ADSs) were canceled.</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>During 2024, the Company issued 6,443,900 restricted Ordinary Shares (equal to 322,195 restricted ADSs) under the 2015 Plan.</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As of December 31, 2024, a total of 23,061,380 of our Ordinary Shares (equal to 1,153,069 of our ADSs) were reserved for issuance under the 2017 Plan, of which 22,915,400 Ordinary Shares (equal to 1,145,770 ADSs) were issuable under outstanding options. Of such outstanding options, options to purchase 11,460,260 Ordinary Shares (equal to 573,013 ADSs) had vested and became exercisable as of that date, with a weighted average exercise price of $0.13 per Ordinary Share (or $2.63 per ADS). During the year ended December 31, 2024, options to purchase 131,260 Ordinary Shares (equal to 6,563 ADSs) were canceled.</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt">&#160;</td>
            <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(2)</span></span></span></span></td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The expenses that were recognized in the consolidated statements of operations for services received from employees and service providers are as follows:</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="line-height:1.25;margin-left:72pt">

          <div>
            <table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Research and development</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>401</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>407</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>448</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>General and administrative</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>216</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,084</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,763</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Total share-based compensation expenses</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>617</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,491</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3,211</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>

        <p style="margin:0pt">&#160;</p>
      </div>
      <div></div>
      <div style="text-align:justify;line-height:1.25">
        <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="width:36pt;vertical-align:top"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(3)</span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The number and weighted average exercise price of options are as follows:</span></div>
              </td>
            </tr>

        </table>
        <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
      </div>

        <div>
          <div style="line-height:1.25">
            <div style="margin-left:72pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Weighted average</span></span></span></span></div>
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>exercise price</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Number</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>of options</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Weighted</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>average</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>remaining contractual life (in years)</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Weighted</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>average</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>exercise price</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Number</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>of options</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Weighted</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>average</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>remaining contractual life</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(in years)</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Outstanding at January 1</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.33</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>35,191,540</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>7.42</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.38</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>27,003,260</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>8.12</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Exercised</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.07</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(1,970,000</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Forfeited</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.39</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(20,373,620</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.32</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(1,240,120</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;padding-bottom:2px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Granted</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.07</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>15,055,180</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5.86</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.16</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>11,398,400</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>7.8</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;padding-bottom:4px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Outstanding at December 31</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.16</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>29,873,100</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5.99</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.33</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>35,191,540</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>7.42</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:72pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Weighted average</span></span></span></span></div>
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>exercise price</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Number</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>of options</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Weighted</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>average</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>remaining contractual life (in years)</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Weighted</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>average</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>exercise price</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Number</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>of options</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Weighted</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>average</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>remaining contractual life</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(in years)</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Outstanding at January 1</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.16</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>29,873,100</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5.99</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.33</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>35,191,540</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>7.42</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Exercised</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Forfeited</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.19</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(667,820</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.39</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(20,373,620</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;padding-bottom:2px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Granted</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.03</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,845,020</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>8.56</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.07</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>15,055,180</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5.86</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;padding-bottom:4px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Outstanding at December 31</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.15</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>32,050,300</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>7.34</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.16</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>29,873,100</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5.99</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
        </div>

      <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="width:36pt;vertical-align:top"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(3)</span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The number of&#160;RSAs is as follows:</span></div>
              </td>
            </tr>

        </table>
        <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
      </div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;margin-left:72pt">

          <table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Number of RSAs</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>RSA</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Unvested at beginning of the year</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:top;width:88%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Granted</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>6,443,900</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Vested</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Forfeited</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:top;width:88%;padding-bottom:4px;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Outstanding at December 31, 2024</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>6,443,900</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>

        <p style="margin:0pt">&#160;</p>
      </div>
      <div></div>
      <div style="line-height:1.25">
        <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="width:36pt;vertical-align:top">&#160;</td>
              <td style="width:36pt;vertical-align:top"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">4)</span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Fair value measurement:</span></div>
              </td>
            </tr>

        </table>
        <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
      </div>
      <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The fair value of the options is measured at the grant date using the Black-Scholes Option pricing model and the assumptions used to calculate the fair value of the options are as follows:</span></span></span></span></div>
      <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>

        <div>
          <div style="margin-left:72pt">
            <table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;font-weight:bold;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024 grants of Options</span></span></span></span></td>
                  <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Weighted average share price (in U.S. dollar)<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(a)</sup></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.04</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Exercise price (in U.S. dollar)</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.03-0.05</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Expected life of options (in years)<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(b)</sup></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5.5-6.1</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Expected volatility<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(c)</sup></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>89.29%-92.98</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Risk-free interest rate<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(d)</sup></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>4.1%-4.5</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Dividend yield</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                  </td>
                </tr>

            </table>
          </div>
        </div>

      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:72pt">&#160;</td>
            <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(a)</span></span></span></span></td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The weighted average share price is based on the Company's Ordinary Share closing price on the stock exchange as at the grant date</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:72pt">&#160;</td>
            <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(b)</span></span></span></span></td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Expected life for the periods presented was determined according to the simplified method since, at the date of grant, the Company did not have enough history to make an estimate. This method effectively assumes that exercise occurs over the period from vesting until expiration, and therefore the expected term is the midpoint between the service period and the contractual term of the award. The simplified method is applicable to service conditions.</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:72pt">&#160;</td>
            <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(c)</span></span></span></span></td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Expected volatility is based on historical volatility over the most recent period commensurate with the expected term of the option. As the Company has a short trading history for its ordinary shares, when the Company's trading period is shorter than the expected term, the expected volatility is derived from the average historical share volatilities of several unrelated public companies within the Company&#8217;s industry that the Company considers to be comparable to its own business over a period equivalent to the option&#8217;s expected term.</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:72pt">&#160;</td>
            <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(d)</span></span></span></span></td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The risk-free rate for the expected term of the options is based on the Black-Scholes option-pricing model on the yields of U.S. Treasury securities with maturities appropriate for the expected term of employee share option awards.</span></span></span></span></div>
            </td>
          </tr>

      </table>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Research and Development</a></td>
<td class="text">
    <div>
      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Note 9 - Research and Development</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="line-height:1.25;margin-left:36pt">

          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Consultants and subcontractors</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>7,994</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>14,014</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>13,052</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Salaries and related expenses</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,715</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3,362</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,867</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Lease and maintenance</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>101</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>137</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>245</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share-based compensation</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>401</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>407</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>448</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Other expenses</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>116</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>461</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>365</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>11,327</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>18,381</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>16,977</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>

      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and Administrative Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_GeneralAndAdministrativeDisclosureTextBlock', window );">General and Administrative</a></td>
<td class="text">
    <div>
      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Note 10 - General and Administrative</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="line-height:1.25;margin-left:36pt">

          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Salaries, fees and related expenses</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,085</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,545</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3,435</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Professional services</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,115</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,139</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,596</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share-based compensation</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>216</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,084</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,763</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Fees to directors</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>284</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>258</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>231</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Directors' and Officers' Insurance</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>538</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>648</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,084</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Lease and maintenance</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>50</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>81</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>24</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Other expenses</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>124</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>323</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,423</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3,412</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>7,078</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>11,556</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>

      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_GeneralAndAdministrativeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_GeneralAndAdministrativeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
    <div>
      <div>
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 11 - Income Taxes</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="vertical-align:top;width:34pt;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax rates</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;margin-left:70pt">
          <div style="text-align:justify;line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ordinary taxable income in Israel is subject to a corporate tax rate of 23%.</span></span></div>
          <div style="text-align:justify;line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Capital gain is subject to capital gain tax according to the corporate tax rate in the year the assets are sold.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s US subsidiary, Chemomab Therapeutics Inc. ("Chemomab Inc.) is taxed separately under the U.S. tax laws.</span></span></div>
          <div style="text-align:justify;line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab Inc. is subject to a federal flat tax rate of 21% and state tax as applicable.</span></span></div>
        </div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
        <div></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="vertical-align:top;width:34pt;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">B.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax assessments</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:70pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2024, the Company&#8217;s tax reports through December 31, 2019 are considered closed to audit inspections by the Israeli Tax Authority (&#8220;ITA&#8221;) due to statute of limitation rules effective in Israel.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;text-indent:36pt;line-height:1.25">
          <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

              <tr>
                <td style="width:36pt">&#160;</td>
                <td style="vertical-align:top;width:34pt;font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">C.</span></td>
                <td style="width:auto;vertical-align:top">
                  <div style="font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">Losses for tax purposes carried forward to future years</span></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="line-height:1.25;margin-left:70pt">
          <div style="text-align:justify;line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2024, 2023, and 2022, the Company and its subsidiaries had approximately $176 million, $165 million, and $159 million, respectively, in net operating loss carryforwards, which are available to reduce future taxable income with no limitation on the period of use.</span></span></div>
          <div style="text-align:justify;line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On March 27, 2020 and December 27, 2020, the President of the United States signed and enacted into law the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) and the Consolidated Appropriations Act, 2021 (CAA). Among other provisions, the CARES Act and the CAA provide relief to U.S. federal corporate taxpayers through temporary adjustments to net operating loss rules, changes to limitations on interest expense deductibility, and the acceleration of available refunds for minimum tax credit carryforwards. The CARES Act also includes provisions for a carryback of any net operating loss (NOL) arising in a taxable year beginning after December 31, 2017, and before January 1, 2021, to each of the five taxable years preceding the taxable year in which the loss arises (carryback period).</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab Therapeutics Inc., a wholly owned subsidiary of the Company, filed an application with the US Internal Revenue Service to carryback net operating losses. Chemomab Therapeutics Inc received $351 thousands in December 2022 on account of 2016 and 2017 and received the remainder $183 thousands in 2023. Accordingly, a tax benefit in the total amount of $534 thousands was recorded in the Company&#8217;s statement of operations during 2022.</span></span></div>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-indent:36pt;line-height:1.25">
          <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

              <tr>
                <td style="width:36pt">&#160;</td>
                <td style="vertical-align:top;font-weight:bold;width:34pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">D.</span></td>
                <td style="vertical-align:top;width:auto">
                  <div style="font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">Deferred taxes</span></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;text-indent:-1.1pt;margin-left:70pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In respect of:</span></span></div>
        <div style="text-align:justify;text-indent:-1.1pt;margin-left:72pt;line-height:1.25">&#160;</div>

          <div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;margin-left:72pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net operating loss carry-forward*</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">40,755</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">38,258</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">36,550</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom">
                      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation expense</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">351</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,163</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,774</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development costs</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,103</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,041</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,858</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom">
                      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gross deferred tax assets</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">44,219</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">43,471</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">41,195</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom">
                      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less - Valuation allowance</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(44,219</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(43,471</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(41,195</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </div>
                    </td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:64%;padding-bottom:4px;vertical-align:bottom">
                      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net deferred tax assets</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="text-align:justify;text-indent:-1.1pt;margin-left:72pt;line-height:1.25">&#160;</div>
            <div style="line-height:1.25;margin-left:72pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">* This excludes capital losses of approximately $14,224 thousands for which the company will create a full valuation allowance.</span></span></div>
          </div>

        <p style="margin:0pt">&#160;</p>
        <div></div>
        <div style="text-align:justify;margin-left:70pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. A valuation allowance is provided when it is more likely than not that the deferred tax assets will not be realized.</span></span></div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:70pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has established a valuation allowance to offset deferred tax assets on December 31, 2024, 2023 and 2022 due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. The net change in the total valuation allowance for the year ended at December 31, 2024 was an increase of approximately $0.8 million.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;text-indent:36pt;line-height:1.25">
          <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

              <tr>
                <td style="width:36pt">&#160;</td>
                <td style="vertical-align:top;width:34pt;font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">E.</span></td>
                <td style="width:auto;vertical-align:top">
                  <div style="font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">Roll forward of valuation allowance</span></div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div>&#160;<div style="margin-left:72pt">

            <table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td rowspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:right;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at December 31, 2021</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">36,030</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Currency translation Income</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,316</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
                </tr>
                <tr>
                  <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income tax expense</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,481</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at December 31, 2022</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">41,195</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Currency translation Income</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(3,295</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income tax expense</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,571</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:88%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at December 31, 2023</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">43,471</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Currency translation Income</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2,459</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:88%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income tax expense</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,207</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at December 31, 2024</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">44,219</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>

        </div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
        <div style="line-height:1.25">
          <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

              <tr>
                <td style="width:36pt">&#160;</td>
                <td style="vertical-align:top;width:34pt;font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">F.</span></td>
                <td style="width:auto;vertical-align:top">
                  <div style="font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">Reconciliation of theoretical income tax expense to actual income tax expense</span></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:70pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A reconciliation of the Company&#8217;s theoretical income tax expense to actual income tax expense is as follows:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25;margin-left:72pt">

            <table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss before income taxes</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(13,945</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(24,221</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(28,180</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Statutory tax rate</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Theoretical tax benefit</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(3,207</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(5,571</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(6,481</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in temporary differences for which deferred taxes were not recognized</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">858</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,177</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,696</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax rate differential</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">20</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-deductible expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">148</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">346</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">744</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,192</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,392</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,879</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Actual income tax expense (Benefit)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;border-bottom:2pt solid black">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;border-bottom:2pt solid black">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;border-bottom:2pt solid black">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;border-bottom:2pt solid black">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;border-bottom:2pt solid black">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;border-bottom:2pt solid black">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(534</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>

            </table>

        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25">
          <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

              <tr>
                <td style="width:36pt">&#160;</td>
                <td style="vertical-align:top;width:34pt;font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">G.</span></td>
                <td style="width:auto;vertical-align:top">
                  <div style="font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">Accounting for uncertainty in income taxes</span></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:70pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the year ended December 31, 2024, the Company did not have any unrecognized tax benefits and does not expect that the amount of unrecognized tax benefits will change significantly within the next 12 months. The Company&#8217;s accounting policy is to accrue interest and penalties related to unrecognized tax benefits as a component of income tax expense.</span></span></div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties Balances and Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties Balances and Transactions</a></td>
<td class="text">
      <div>
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Note 12 - Related Parties Balances and Transactions</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>A.</span></span></span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Balances with Related Parties:</span></span></span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The following Related Party payables are included in the consolidated Balance Sheets:</span></span></span></span></div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;margin-left:36pt">

            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Employees, consultants and related expenses</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>531</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>490</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accrued expenses</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>75</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>74</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>606</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>564</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>

        </div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>B.</span></span></span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Transactions with Related Parties:</span></span></span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The following transactions with related parties are included in the consolidated Statements of Operations:</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25;margin-left:36pt">

            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Salaries and related expenses</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,718</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,795</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,409</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share-based payments</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>427</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,304</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,466</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Professional Services</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>284</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>258</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>231</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Research and development</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>36</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>36</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>36</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,465</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>4,393</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5,142</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>

        </div>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Ordinary Shareholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share Attributable to Ordinary Shareholders</a></td>
<td class="text">
    <div>
      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Note 13 - Net Loss Per Share Attributable to Ordinary Shareholders</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Basic net loss per share is computed by dividing the net loss available to common stockholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares of were dilutive. Diluted net loss per share is the same as basic net loss per share of ordinary share, as the effect of potentially dilutive securities is antidilutive.</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The following table sets forth the computation of basic and diluted net loss per share attributable to ordinary shareholders for the periods presented:</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="margin-left:36pt">

          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In USD thousands, except share and per share data</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Numerator:</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:64%;padding-bottom:4px;vertical-align:bottom">
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Net loss</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>13,945</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>24,221</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>27,646</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:64%;vertical-align:bottom">
                  <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Denominator:</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>359,048,638</span></span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>234,998,859</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">227,589,288</span></span></p>
                    </div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:64%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr style="background-color:rgb(204, 238, 255)">
                <td style="width:64%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;</span></span></span></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Net loss per share attributable to ordinary shareholders, basic&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>and diluted</span></span></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.039</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.103</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.121</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
              </tr>

          </table>

      </div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;text-indent:0.55pt;margin-left:35.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The potential number of ordinary shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented since including them would have been anti-dilutive are as follows:</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="margin-left:36pt">

          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Number of shares</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Outstanding options to purchase ordinary shares and RSAs</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>38,494,200</strong></span></span></p>
                    </div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>29,873,100</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>35,191,540</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>

      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (13,945)<span></span>
</td>
<td class="num">$ (24,221)<span></span>
</td>
<td class="num">$ (27,646)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text">
            <div style="font-size:10pt;font-family:Times New Roman">
              <div>
                <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman';font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Risk management and strategy</span></span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>
                <div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman'">
                  <span style="font-size:10pt;font-family:Times New Roman"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>We maintain a cyber risk management program designed to identify, assess, manage, mitigate, and respond to material risks from cybersecurity threats&#160;to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic, or competitive in nature, and our clinical trial and related data (&#8220;Information Systems and Data&#8221;).</span></span></span></span>
                </div>
                <div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>
                <div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman'"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The underlying processes and controls of our cyber risk management program incorporate various practices and standards for cybersecurity and information technology. We conduct an annual assessment performed by a third-party service provider of our cyber risk management program. The annual risk assessment identifies, quantifies, and categorizes material cyber risks to our Company. In addition,&#160;we, in conjunction with the third-party cyber risk assessment vendor, develop a risk mitigation plan designed to address such risks, and where necessary, remediate potential vulnerabilities identified through the annual assessment process.</span></span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>
                <div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman'"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>In addition, we maintain various policies to help identify, address, and mitigate risks from cybersecurity threats, including, for example in areas such as information security, access on/offboarding, and access and account management. We monitor threat intelligence as well as other information obtained from governmental, public, or private sources, including external consultants engaged by us. We also partner with IT and cybersecurity providers, such as cybersecurity consultants. We leverage these third-party providers and solutions to support our cybersecurity risk management strategy and processes, which include, for example, maintenance of an IT assets inventory, periodic vulnerability scanning, identity access management controls, endpoint protection, endpoint detection and response, remote monitoring management on certain devices, encryption of certain data, critical data backups, infrastructure maintenance, incident detection and response, cybersecurity strategy, and cyber risk advisory, assessment and remediation.&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;</span></span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>
                <div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman'"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Our assessment and management of material risks from cybersecurity threats are integrated into the Company&#8217;s overall risk management processes. For example, (1) cybersecurity risk is addressed as a component of the Company&#8217;s enterprise risk management program and identified in the Company&#8217;s risk register; (2) the security department/security management works with management to prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business; or (3) our senior management evaluates material risks from cybersecurity threats against our overall business objectives and reports to the audit committee of the board of directors, which evaluates our overall enterprise risk.</span></span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>
                <div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman'"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>We have implemented third-party risk management processes to manage material risks from cybersecurity threats associated with reliance on vendors, critical service providers, and other third parties we engage, such as software-as-a-service providers, data hosting companies, and contract research organizations. These processes include, for example, conducting risk assessment for certain vendors, reviewing vendor security assessments and questionnaires, and conducting annual reviews of vendor audits and reports.&#160;Depending on the nature of the services provided, the sensitivity of the Information Systems and Data at issue, and the identity of the provider, our third-party risk management process may involve different levels of assessment designed to help identify cybersecurity risks associated with a provider.</span></span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>
                <div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman'">
                  <span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 3. Section D Risk Factors in this Annual Report on Form 20-F, including &#8220;Cyber-attacks, security breaches or other disruptions to our information technology systems, or those of third parties upon which we rely, or our data could irreparably damage our reputation and our business, expose us to liability and materially and adversely affect our results of operations.&#8221;</span></span></span>
                </div>
              </div>
            </div>
          <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>We maintain a cyber risk management program designed to identify, assess, manage, mitigate, and respond to material risks from cybersecurity threats&#160;to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic, or competitive in nature, and our clinical trial and related data (&#8220;Information Systems and Data&#8221;).</span></span></span></span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 3. Section D Risk Factors in this Annual Report on Form 20-F, including &#8220;Cyber-attacks, security breaches or other disruptions to our information technology systems, or those of third parties upon which we rely, or our data could irreparably damage our reputation and our business, expose us to liability and materially and adversely affect our results of operations.&#8221;</span></span></span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text">
            <div style="font-size:10pt;font-family:Times New Roman">
              <div>
                <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman';font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Governance</span></span></span></div>
                <div>
                  <div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>

                    <div style="font-size:10pt;font-family:Times New Roman">
                      <div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman'"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The audit committee of the board of directors oversees our cybersecurity risk exposures and the steps taken by management to monitor and mitigate cybersecurity risks. The cybersecurity stakeholders, including member(s) of management assigned with cybersecurity oversight responsibility and/or third-party consultants providing cyber risk services brief the audit committee of the board of directors on cyber vulnerabilities identified through the risk management process, the effectiveness of our cyber risk management program, and the emerging threat landscape and new cyber risks on at least an annual basis. In addition, cybersecurity risks are reviewed by our board of directors at least annually, as part of our corporate risk oversight processes.&#160;</span></span></span></div>
                    </div>

                  <p style="margin:0pt;text-align:center">&#160;</p>
                </div>
                <div></div>&#160;<div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:Times New Roman;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman">Our Chief Information Security Officer (&#8220;CISO&#8221;) is responsible for oversight and administration of our cyber risk management program, and for informing senior management and other relevant stakeholders regarding the prevention, detection, mitigation, and remediation of cybersecurity incidents.</span>&#160;<span style="font-size:10pt;font-family:Times New Roman">Our CISO is a Certified Information Systems Security Professional and has prior experience selecting, deploying, and overseeing cybersecurity technologies, initiatives, and processes directly or via selection of strategic third-party partners.</span></span></span></span></div>
                <div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:Times New Roman;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                <div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:Times New Roman;margin-top:0pt;margin-bottom:0pt">
                  <span style="font-size:10pt;font-family:Times New Roman"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">We have developed an incident response plan&#160;that is designed to escalate certain cybersecurity incidents to members of management, including the CISO, depending on the circumstances. Such members of management work with the Company&#8217;s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified. In addition, the Company&#8217;s incident response plan includes reporting to the audit committee of the board of directors for certain cybersecurity incidents.</span></span></span></span>
                </div>
              </div>
            </div>
          <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">
                    <div style="font-size:10pt;font-family:Times New Roman">
                      <div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman'"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The audit committee of the board of directors oversees our cybersecurity risk exposures and the steps taken by management to monitor and mitigate cybersecurity risks. The cybersecurity stakeholders, including member(s) of management assigned with cybersecurity oversight responsibility and/or third-party consultants providing cyber risk services brief the audit committee of the board of directors on cyber vulnerabilities identified through the risk management process, the effectiveness of our cyber risk management program, and the emerging threat landscape and new cyber risks on at least an annual basis. In addition, cybersecurity risks are reviewed by our board of directors at least annually, as part of our corporate risk oversight processes.&#160;</span></span></span></div>
                    </div>
                  <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman">Our Chief Information Security Officer (&#8220;CISO&#8221;) is responsible for oversight and administration of our cyber risk management program, and for informing senior management and other relevant stakeholders regarding the prevention, detection, mitigation, and remediation of cybersecurity incidents.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman">Our CISO is a Certified Information Systems Security Professional and has prior experience selecting, deploying, and overseeing cybersecurity technologies, initiatives, and processes directly or via selection of strategic third-party partners.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">We have developed an incident response plan&#160;that is designed to escalate certain cybersecurity incidents to members of management, including the CISO, depending on the circumstances. Such members of management work with the Company&#8217;s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified. In addition, the Company&#8217;s incident response plan includes reporting to the audit committee of the board of directors for certain cybersecurity incidents.</span></span></span></span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Preparation</a></td>
<td class="text">
            <div>
              <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">A.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Basis of Preparation</span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;).</span></span></span></div>
            </div>
          <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">B.</span></span></span></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">Use of estimates</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</span></span></span></div>
          </div>
        <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency</a></td>
<td class="text">
        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">C.</span></span></span></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">Foreign currency</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The currency of the primary economic environment in which the operations of the Company are conducted is the U.S. dollar (&#8220;dollar&#8221; or &#8220;$&#8221;), thus; the dollar is the functional currency of the Company.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The transactions and balances of the Company denominated in U.S. dollars are presented at their original amounts as the U.S. dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Monetary assets and liabilities denominated in a non-U.S. dollar currency are translated using the current exchange rate and nonmonetary assets and liabilities and capital accounts denominated in a non-U.S. dollar currency are translated using historical exchange rates.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Statements of operations accounts denominated in a non-U.S. dollar currency are translated using the exchange rates in effect on the transaction dates, except for depreciation, which is translated using historical exchange rate.</span></span></span></div>
        </div>
      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text">
        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">D.</span></span></span></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">Cash and cash equivalents</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Cash equivalents are short-term liquid bank deposits that are readily convertible to cash with original maturities of three months or less at the date acquired.</span></span></span></div>
        </div>
      <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ShortTermBankDepositsPolicyTextBlock', window );">Short-term bank deposits</a></td>
<td class="text">
        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">E.</span></span></span></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">Short-term bank deposits</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Bank deposits with original maturities exceeding three months but less than one year are classified as part of short-term investments. These deposits are recorded at cost, which approximates their market value, including accrued interest. Interest earned on these deposits is recognized as financial income. As of December 31, 2024, the range of interest rates paid on these deposits was between 4.24% and 5.75% (2023: between 4.22% and 6.65%).</span></span></span></div>
        </div>
      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted cash</a></td>
<td class="text">
        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">F.</span>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <span style="font-weight:bold">Restricted cash</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Restricted cash is primarily invested in highly liquid deposits. These deposits were used to secure office lease payments.</span></span></span></div>
        </div>
      <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text">
        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">G.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Property and equipment</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Property and equipment are stated at cost less accumulated depreciation. Maintenance and repair expenses are charged to operation as incurred. Depreciation is calculated based on the straight-line method and&#160; the estimated useful lives of the assets and commences once the assets are ready for their intended use.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Annual rates at depreciation are as follows:</span></span></span></div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
          <div style="margin-left:36pt">

              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td colspan="1" rowspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" rowspan="1" style="vertical-align:top;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>%</span></span></span></td>
                    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Computers</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>33</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:88%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Laboratory equipment</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>10</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Furniture and equipment</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>7</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="4" style="vertical-align:top;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Leasehold improvement - over the shorter of the lease term or the estimated useful life of the improvement</span></span></span></div>
                    </td>
                  </tr>

              </table>

          </div>
        </div>
      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text">
        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">H.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Impairment of long-lived assets</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company&#8217;s property and equipment are reviewed for impairment in accordance with ASC 360, &#8220;Property and Equipment&#8221;, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less selling costs. During the periods ended December 31, 2024, 2023 and 2022, no impairment losses have been recorded.</span></span></span></div>
        </div>
      <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">
        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">I.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <span style="font-weight:bold">Research and Development</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Research and development costs are charged to operations as incurred. Most of the research and development expenses are for subcontractors and salaries.&#160;</span></span></span></div>
        </div>
      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text">
        <div>
          <div style="text-indent:36pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>J.&#160; &#160; &#160; &#160;&#160; &#160; Income taxes</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income,&#160;tax-planning&#160;strategies, and results of recent operations.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the income taxes expense.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50 percent likely of being realized.</span></span></span></div>
        </div>
      <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value of financial instruments</a></td>
<td class="text">
        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">K.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Fair value of financial instruments</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>ASC 820, Fair Value Measurements and Disclosures, relating to fair value measurements, defines fair value and established a framework for measuring fair value. The ASC 820 fair value hierarchy distinguishes between market participant assumptions developed based on market data obtained from sources independent of the reporting entity and the reporting entity&#8217;s own assumptions about market participant assumptions developed based on the best information available in the circumstances. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>In addition, the fair value of assets and liabilities should include consideration of non-performance risk, which for the liabilities described below includes the Company&#8217;s own credit risk.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:</span></span></span></div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Level&#160;1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></span></span></div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities.</span></span></span></div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The carrying amounts of cash and cash equivalents, short-term deposits, trade payables, other receivables, and prepaid expenses approximate their fair value due to the short-term maturity of such instruments. None of the Company&#8217;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.</span></span></span></div>
        </div>
      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based compensation</a></td>
<td class="text">
        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">L.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Share-based compensation</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company accounts for share-based compensation as an expense in the financial statements based on ASC 718. All awards are equity classified and therefore such costs are measured at the grant date fair value of the award and graded vesting attribution approach to recognize compensation cost over the vesting period. The Company recognizes compensation cost for an award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant-date value of such award that is vested at that date.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The fair value for the Company&#8217;s stock options granted to employees, consultants and directors was estimated using Black-Scholes option-pricing model at the grant date, using the inputs detailed in Note 8(C).</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</span></span></span></div>
        </div>
      <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock', window );">Government-sponsored research and development</a></td>
<td class="text">
        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">M.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Government-sponsored research and development</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Chemomab records grants received from the office of the Israel Innovation Authority (the &#8220;IIA&#8221;) as a liability, if it is probable that the Chemomab will have to repay the grants received. If it is not probable that the grants will be repaid, Chemomab records the grants as a reduction to research and development expenses.</span></span></span></div>
        </div>
      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SeverancePayPolicyTextBlock', window );">Severance Pay [Policy Text Block]</a></td>
<td class="text">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">N.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Severance pay</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Pursuant to Section 14 of the Severance Compensation Law, 1963 ("Section 14"), all employees of the Company are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made on their behalf with insurance companies. Upon release of the policy to the employee, no additional liability exists between the parties regarding the matter of severance pay and no additional payments shall be made by the Company to the employee. This plan has been accounted for as a defined contribution plan. Severance costs amounted to approximately $50&#160;thousands, $86 thousands, and $142 thousands for the year ended December 31, 2024, 2023 and 2022, respectively.</span></span></span></div>
          </div>
        <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of credit risk</a></td>
<td class="text">
        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">O.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Concentrations of credit risk:</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Cash and cash equivalents and short- term deposits are invested in banks. Management believes that the financial institutions that hold the Company&#8217;s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</span></span></span></div>
        </div>
      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">P.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Leases</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Under Topic 842, the Company determines if an arrangement is a lease at inception. Right-of-use (ROU) assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company's incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be 9% in 2024 and 2023 and 5% in 2022, The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>When determining the probability of exercising such options, the Company considers contract-based, asset-based, entity-based, and market-based factors. For lease agreements, the Company has elected the practical expedient to account for the lease and non-lease maintenance components as a single lease component. Therefore, for those leases, the lease payments used to measure the lease liability include all the fixed considerations in the contract. The Company's lease agreements generally do not contain any residual value guarantees or restrictive covenants.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>ROU assets for operating leases are periodically reduced by impairment losses. The Company uses the long-lived assets impairment guidance in ASC Subtopic 360-10, Property, Plant, and Equipment to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize.</span></span></span></div>
        </div>
      <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text">
        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">Q.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Segments</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company has one reportable segment, focused on the research and development of therapeutics for conditions with high unmet medical needs involving inflammation and fibrosis. The Company&#8217;s chief operating decision maker ("CODM") is its chief executive officer of the company. The segment is managed on a consolidated basis, and the CODM uses total operating expenses and consolidated net loss to assess performance, forecast future financial results, and allocate resources.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>In evaluating the Company's financial performance and making strategic decisions, the CODM regularly reviews operating expenses by function. Furthermore, the CODM is provided only with the consolidated expenses, as presented in the income statement disclosures (see Notes 9 and 10&#160;with respect to salaries, professional services, consultants and subcontractors). This includes a review of budget versus actual expenses and direct program spending, which encompasses clinical costs, consultant fees, manufacturing expenses, and other direct external costs.</span></span></span></div>
        </div>
      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text">
        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">R.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Principles of consolidation</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The consolidated financial statements include the accounts of the Company and its Subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.</span></span></span></div>
        </div>
      <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per ordinary share</a></td>
<td class="text">
        <div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">S.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Loss per ordinary share</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Basic Loss per ordinary share are calculated using only weighted average ordinary shares outstanding. Diluted loss per share, if relevant, gives an effect to dilutive potential ordinary shares outstanding during the year.&#160; Such dilutive shares consist of incremental shares, using the treasury stock method, from the assumed exercise of share options.</span></span></span></div>
        </div>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_SeverancePayPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for severance pay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_SeverancePayPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ShortTermBankDepositsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for Short-term Bank Deposits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ShortTermBankDepositsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock', window );">Schedule of annual rate of deprecation</a></td>
<td class="text">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td colspan="1" rowspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" rowspan="1" style="vertical-align:top;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>%</span></span></span></td>
                    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Computers</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>33</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:88%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Laboratory equipment</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>10</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Furniture and equipment</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>7</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="4" style="vertical-align:top;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Leasehold improvement - over the shorter of the lease term or the estimated useful life of the improvement</span></span></span></div>
                    </td>
                  </tr>

              </table>
            <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the annual rate of deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of components of cash and cash equivalents</a></td>
<td class="text">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In USD</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,545</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,718</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In NIS</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">525</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,574</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In other currencies</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*-</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,071</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,292</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Receivables and Prepaid Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock', window );">Schedule of other accounts receivable and prepaid expenses</a></td>
<td class="text">
      <div>
        <div>
          <div style="line-height:1.25;margin-left:36pt">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Government institutions</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">263</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">289</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Prepaid expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,435</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">748</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,698</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,037</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>
        </div>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of other accounts receivable and prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, Net</a></td>
<td class="text">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Cost:</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Computers</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>68</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>68</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Furniture and equipment</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>33</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>33</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Laboratory equipment</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>400</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>400</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Website development</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>14</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>14</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Leasehold improvements</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>14</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>14</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>529</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>529</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Less - accumulated depreciation</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(279</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(226</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>250</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>303</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturity of lease liabilities under our non-cancelable operating leases</a></td>
<td class="text">
          <div>
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">120</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2026</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">120</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2027</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">106</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;padding-bottom:4px;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total future minimum lease payments</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">346</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less imputed interest:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(22</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;padding-bottom:4px;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present value of operating lease liabilities</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">324</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of the effect of share-based compensation on the statements of operations</a></td>
<td class="text">
          <div>
            <table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Research and development</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>401</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>407</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>448</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>General and administrative</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>216</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,084</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,763</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Total share-based compensation expenses</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>617</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,491</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3,211</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>
        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of number and weighted average exercise prices of option</a></td>
<td class="text">
        <div>
          <div style="line-height:1.25">
            <div style="margin-left:72pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Weighted average</span></span></span></span></div>
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>exercise price</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Number</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>of options</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Weighted</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>average</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>remaining contractual life (in years)</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Weighted</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>average</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>exercise price</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Number</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>of options</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Weighted</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>average</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>remaining contractual life</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(in years)</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Outstanding at January 1</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.33</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>35,191,540</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>7.42</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.38</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>27,003,260</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>8.12</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Exercised</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.07</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(1,970,000</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Forfeited</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.39</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(20,373,620</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.32</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(1,240,120</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;padding-bottom:2px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Granted</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.07</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>15,055,180</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5.86</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.16</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>11,398,400</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>7.8</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;padding-bottom:4px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Outstanding at December 31</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.16</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>29,873,100</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5.99</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.33</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>35,191,540</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>7.42</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:72pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Weighted average</span></span></span></span></div>
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>exercise price</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Number</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>of options</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Weighted</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>average</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>remaining contractual life (in years)</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Weighted</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>average</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>exercise price</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Number</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>of options</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Weighted</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>average</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>remaining contractual life</span></span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(in years)</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Outstanding at January 1</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.16</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>29,873,100</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5.99</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.33</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>35,191,540</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>7.42</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Exercised</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Forfeited</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.19</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(667,820</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.39</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(20,373,620</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;padding-bottom:2px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Granted</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.03</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,845,020</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>8.56</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.07</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>15,055,180</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5.86</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:28%;padding-bottom:4px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Outstanding at December 31</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.15</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>32,050,300</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>7.34</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.16</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>29,873,100</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5.99</span></span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
      <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of Unvested RSA</a></td>
<td class="text">
          <table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Number of RSAs</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>RSA</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Unvested at beginning of the year</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:top;width:88%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Granted</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>6,443,900</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Vested</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Forfeited</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:top;width:88%;padding-bottom:4px;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Outstanding at December 31, 2024</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>6,443,900</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used to calculate the fair value of the options</a></td>
<td class="text">
        <div>
          <div style="margin-left:72pt">
            <table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;font-weight:bold;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024 grants of Options</span></span></span></span></td>
                  <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Weighted average share price (in U.S. dollar)<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(a)</sup></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.04</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Exercise price (in U.S. dollar)</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.03-0.05</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Expected life of options (in years)<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(b)</sup></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5.5-6.1</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Expected volatility<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(c)</sup></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>89.29%-92.98</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Risk-free interest rate<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(d)</sup></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>4.1%-4.5</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:88%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Dividend yield</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock', window );">Schedule of research and development</a></td>
<td class="text">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Consultants and subcontractors</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>7,994</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>14,014</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>13,052</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Salaries and related expenses</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,715</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3,362</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,867</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Lease and maintenance</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>101</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>137</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>245</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share-based compensation</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>401</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>407</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>448</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Other expenses</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>116</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>461</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>365</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>11,327</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>18,381</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>16,977</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and Administrative Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock', window );">Schedule of general and administrative</a></td>
<td class="text">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Salaries, fees and related expenses</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,085</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,545</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3,435</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Professional services</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,115</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,139</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,596</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share-based compensation</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>216</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,084</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,763</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Fees to directors</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>284</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>258</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>231</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Directors' and Officers' Insurance</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>538</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>648</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,084</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Lease and maintenance</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>50</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>81</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>24</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Other expenses</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>124</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>323</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,423</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3,412</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>7,078</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>11,556</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of significant components of the company's deferred tax asset</a></td>
<td class="text">
          <div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;margin-left:72pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net operating loss carry-forward*</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">40,755</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">38,258</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">36,550</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom">
                      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation expense</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">351</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,163</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,774</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development costs</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,103</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,041</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,858</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom">
                      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gross deferred tax assets</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">44,219</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">43,471</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">41,195</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom">
                      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less - Valuation allowance</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(44,219</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(43,471</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(41,195</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </div>
                    </td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:64%;padding-bottom:4px;vertical-align:bottom">
                      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net deferred tax assets</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="text-align:justify;text-indent:-1.1pt;margin-left:72pt;line-height:1.25">&#160;</div>
            <div style="line-height:1.25;margin-left:72pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">* This excludes capital losses of approximately $14,224 thousands for which the company will create a full valuation allowance.</span></span></div>
          </div>
        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Schedule of roll forward of valuation allowance</a></td>
<td class="text">
            <table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td rowspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:right;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at December 31, 2021</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">36,030</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Currency translation Income</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,316</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
                </tr>
                <tr>
                  <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income tax expense</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,481</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at December 31, 2022</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">41,195</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Currency translation Income</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(3,295</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income tax expense</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,571</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:88%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at December 31, 2023</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">43,471</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Currency translation Income</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2,459</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:88%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income tax expense</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,207</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at December 31, 2024</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">44,219</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of theoretical income tax expense to actual income tax expense</a></td>
<td class="text">
            <table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss before income taxes</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(13,945</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(24,221</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(28,180</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Statutory tax rate</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Theoretical tax benefit</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(3,207</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(5,571</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(6,481</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in temporary differences for which deferred taxes were not recognized</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">858</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,177</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,696</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax rate differential</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">20</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-deductible expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">148</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">346</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">744</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,192</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,392</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,879</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Actual income tax expense (Benefit)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;border-bottom:2pt solid black">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;border-bottom:2pt solid black">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;border-bottom:2pt solid black">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;border-bottom:2pt solid black">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;border-bottom:2pt solid black">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;border-bottom:2pt solid black">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(534</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>

            </table>
          <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties Balances and Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock', window );">Schedule of related party payables</a></td>
<td class="text">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Employees, consultants and related expenses</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>531</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>490</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accrued expenses</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>75</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>74</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>606</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>564</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of transaction with related parties</a></td>
<td class="text">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Salaries and related expenses</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,718</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,795</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,409</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share-based payments</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>427</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,304</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,466</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Professional Services</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>284</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>258</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>231</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Research and development</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>36</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>36</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>36</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,465</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>4,393</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5,142</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Ordinary Shareholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of basic and diluted net loss per share</a></td>
<td class="text">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In USD thousands, except share and per share data</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Numerator:</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:64%;padding-bottom:4px;vertical-align:bottom">
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Net loss</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>13,945</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>24,221</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>27,646</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:64%;vertical-align:bottom">
                  <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Denominator:</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>359,048,638</span></span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>234,998,859</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">227,589,288</span></span></p>
                    </div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:64%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr style="background-color:rgb(204, 238, 255)">
                <td style="width:64%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;</span></span></span></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Net loss per share attributable to ordinary shareholders, basic&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>and diluted</span></span></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.039</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.103</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.121</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
              </tr>

          </table>
        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of weighted average number of shares excluded from computation of diluted net loss per share</a></td>
<td class="text">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Number of shares</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Outstanding options to purchase ordinary shares and RSAs</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>38,494,200</strong></span></span></p>
                    </div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>29,873,100</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>35,191,540</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NatureOfOperationsDisclosureAbstract', window );"><strong>Nature Of Operations Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (103,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash flows from operating activities</a></td>
<td class="num">(15,386)<span></span>
</td>
<td class="num">$ (23,611)<span></span>
</td>
<td class="num">$ (20,370)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash equivalents, and short-term deposits</a></td>
<td class="nump">$ 14,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NatureOfOperationsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NatureOfOperationsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SignificanAccountingPoliciesLineItems', window );"><strong>Significan Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_PercentageOfMonthlyDepositsRate', window );">Percentage of monthly deposits rate</a></td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SignificanAccountingPoliciesLineItems', window );"><strong>Significan Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_PercentageOfShortTermDeposits', window );">Percentage of short term deposits</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">6.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SignificanAccountingPoliciesLineItems', window );"><strong>Significan Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_PercentageOfShortTermDeposits', window );">Percentage of short term deposits</a></td>
<td class="nump">4.24%<span></span>
</td>
<td class="nump">4.22%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_PercentageOfMonthlyDepositsRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of monthly deposits rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_PercentageOfMonthlyDepositsRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_PercentageOfShortTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>percentage of short term deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_PercentageOfShortTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_SignificanAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_SignificanAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Schedule of Annual rates of Depreciation) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Annual rates of depreciation</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cmmb_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Annual rates of depreciation</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Annual rates of depreciation</a></td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_AnnualRatesOfDepreciation', window );">Annual rates of depreciation</a></td>
<td class="text">over the shorter of the lease term or the estimated useful life of the improvement<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_AnnualRatesOfDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual rates of depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_AnnualRatesOfDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cmmb_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cmmb_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Cash Equivalents (Schedule of Cash and Cash Equivalents) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">$ 6,071<span></span>
</td>
<td class="nump">$ 9,292<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">5,545<span></span>
</td>
<td class="nump">6,718<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_ILS', window );">NIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">525<span></span>
</td>
<td class="nump">2,574<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_XXX', window );">Other currencies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Less than 1 thousand</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_ILS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_ILS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_XXX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_XXX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Receivables and Prepaid Expenses (Schedule of Other Receivables and Prepaid Expenses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ReceivablesFromGovernmentInstitutions', window );">Government institutions</a></td>
<td class="nump">$ 263<span></span>
</td>
<td class="nump">$ 289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">1,435<span></span>
</td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other accounts receivable and prepaid expenses, Total</a></td>
<td class="nump">$ 1,698<span></span>
</td>
<td class="nump">$ 1,037<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ReceivablesFromGovernmentInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government institutions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ReceivablesFromGovernmentInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net (Schedule of Property and Equipment, Net) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 529<span></span>
</td>
<td class="nump">$ 529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less - accumulated depreciation</a></td>
<td class="num">(279)<span></span>
</td>
<td class="num">(226)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property Plant And Equipment Net</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cmmb_LaboratoryEquipmentMember', window );">Laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Website development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cmmb_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cmmb_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 10, 2020</div></th>
<th class="th"><div>Oct. 24, 2021</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 12, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lease term, option to extend</a></td>
<td class="text">three years<span></span>
</td>
<td class="text">three years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_AnnualRentAndManagementFees', window );">Annual rent and management fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_BankGuaranteesToPropertyOwner', window );">Bank guarantees to property owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289<span></span>
</td>
<td class="nump">$ 392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 324<span></span>
</td>
<td class="nump">392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities', window );">Operating right-of-use assets and operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Increase in the carrying amount of the right-of-use asset due to impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Incremental borrowing rate based on credit rating</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_AnnualRentAndManagementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual rent and management fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_AnnualRentAndManagementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_BankGuaranteesToPropertyOwner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bank guarantees to property owner.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_BankGuaranteesToPropertyOwner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating right-of-use assets and operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest:</a></td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 324<span></span>
</td>
<td class="nump">$ 392<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingent Liabilities (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 29, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Decsription of occurrence for payments</a></td>
<td class="text">upon the occurrence of either (i) closing of a public offering of the ordinary shares of Chemomab; or (ii) a Change of Control Transaction, Chemomab shall pay the Fund a cash payment equal to one percent (1%) of the proceeds raised by Chemomab in its initial public offering, or 1% of the consideration received by Chemomab or its shareholders at the closing of a Change of Control Transaction (after deduction of amounts paid as liquidation preference to the shareholders of Chemomab on account of their investment in Chemomab, if any), but in any event not more than&#160; $3,000 thousand.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_MaximumPercentageOfPaymentsOfRoyalties', window );">Maximum percentage of payments of royalties (as a percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized', window );">Cumulative Amounts Of Grants Received And Recognized</a></td>
<td class="nump">$ 1,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royality expenses</a></td>
<td class="nump">418<span></span>
</td>
<td class="nump">$ 4,832<span></span>
</td>
<td class="nump">$ 5,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedInvestments', window );">Bank restricted deposit</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxes', window );">Accrued Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Accretion Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_CapitalAdditionsMember', window );">New Drug Application and Biological License Application [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentDescription', window );">Description of application payment for licensed product</a></td>
<td class="text">$100 thousands upon submission of a New Drug Application (&#8220;NDA&#8221;), Biological License Application (&#8220;BLA&#8221;) or equivalent for each Licensed Product to the United States Food and Drug Administration (&#8220;FDA&#8221;), $100 thousands upon submission of a similar application for each Licensed Product to an equivalent foreign regulatory agency in Europe and one hundred thousands dollars upon submission of a similar application for each Licensed Product to an equivalent foreign regulatory agency in Asia. Payment in the aggregate shall not be more than $300 thousands per Licensed Product, provided that for each jurisdiction, payment shall be made only once.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct', window );">Royalty payments on sale of product (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=cmmb_CapitalAdditionsOneMember', window );">Capital Additions One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentDescription', window );">Description of application payment for licensed product</a></td>
<td class="text">$200 thousands upon the grant of FDA or equivalent agency marketing approval in Europe and/or Asia for each Licensed Product. Payment in the aggregate shall not be more than&#160;$600 thousands per Licensed Product, provided that for each jurisdiction, payment shall be made only once.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amounts of grants received from the IIA and recognized by the company, as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_MaximumPercentageOfPaymentsOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum percentage of royalties payable on the amount of the grant received (dollar linked), plus interest at annual rate based on LIBOR.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_MaximumPercentageOfPaymentsOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of royalty payments on sale of product developed with funding received from the IIA.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481639/420-10-35-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due. This amount is the total of current and noncurrent accrued income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the terms of a significant arrangement with a supplier (excluding an unconditional purchase obligation) to acquire goods or services over a period of time beyond one year or the normal operating cycle, if longer, which may include identification of the goods or services to be purchased, pricing, effects on pricing of failing to reach minimum quantities required to be purchased, cancellation rights, and termination provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the nature and terms of commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments which are not defined as or included in marketable (debt, equity, or other) securities whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478600/954-210-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_CapitalAdditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_CapitalAdditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=cmmb_CapitalAdditionsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=cmmb_CapitalAdditionsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="10">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 15, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 30, 2024 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Jul. 30, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 25, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 17, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 16, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 19, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 25, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 22, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStockLineItems', window );"><strong>Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ProceedsFromSaleOfAdss', window );">Proceeds from sale of ADS's | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,863,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options to purchase ADS cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">667,820<span></span>
</td>
<td class="nump">20,373,620<span></span>
</td>
<td class="nump">1,240,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfTreasuryStock', window );">Sale of treasury share | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 580,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 580,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmmb_TwoThousandsFifteenPlanMember', window );">2015 plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStockLineItems', window );"><strong>Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues', window );">Number of ADSs issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfStockReservedForIssuance', window );">Number of stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,443,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfStockAdssResveredForIssuance', window );">Number Of Stock Adss Resvered For Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,422,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfAdssOptionsIssuableOutstanding', window );">Number of ADSs options issuable outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">456,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfOptionsIssuableOutstanding', window );">Number of options issuable outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,134,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfAdssVestedAndExercisable', window );">Number of ADSs vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfOptionsVestedAndExercisable', window );">Number of options vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,677,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted average exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted average exercise price of ADSs | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,445,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options to purchase ADS cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod', window );">Options to purchase ordinary shares cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmmb_TwoThousandsSeventeenPlanMember', window );">2017 plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStockLineItems', window );"><strong>Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues', window );">Number of ADSs issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,145,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfStockReservedForIssuance', window );">Number of stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,061,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfStockAdssResveredForIssuance', window );">Number Of Stock Adss Resvered For Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,153,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfAdssVestedAndExercisable', window );">Number of ADSs vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">573,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfOptionsVestedAndExercisable', window );">Number of options vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,460,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted average exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted average exercise price of ADSs | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,915,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options to purchase ADS cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod', window );">Options to purchase ordinary shares cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cmmb_RestrictedOrdinarySharesMember', window );">Restricted Ordinary Shares [Member] | 2015 plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStockLineItems', window );"><strong>Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues', window );">Number of ADSs issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,443,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">The Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStockLineItems', window );"><strong>Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ProceedsFromSaleOfAdss', window );">Proceeds from sale of ADS's | $</a></td>
<td class="nump">$ 45,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,071,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues', window );">Number of ADSs issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,948,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfWarrantsPurchaseUpAdss', window );">Number of warrants purchase ADS's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,148,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,619,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStocksPricePerShare', window );">Share price per share | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cmmb_AtmAgreementMember', window );">ATM agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStockLineItems', window );"><strong>Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement', window );">Aggregate offering price of at the market offering agreement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ProceedsFromSaleOfAdss', window );">Proceeds from sale of ADS's | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,125,000<span></span>
</td>
<td class="nump">$ 15,917,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,371,000<span></span>
</td>
<td class="nump">$ 275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues', window );">Number of ADSs issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">699,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">772,900<span></span>
</td>
<td class="nump">130,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStocksPricePerShare', window );">Share price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="nump">$ 2.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cmmb_RepurchaseArrangementMember', window );">Repurchase arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStockLineItems', window );"><strong>Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RepurchaseOfAmericanDepositaryReceipts', window );">Repurchase of ADSs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares', window );">Number of shares repurchase of ADSs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">582,023<span></span>
</td>
<td class="nump">582,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts', window );">Weighted average price of repurchase of ADSs | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts', window );">Total consideration of repurchase of ADSs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,218,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cmmb_RothCapitalPartnersLlcMember', window );">Roth Capital Partners, LLC [Member] | Market offering agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStockLineItems', window );"><strong>Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ProceedsFromSaleOfAdss', window );">Proceeds from sale of ADS's | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,863,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues', window );">Number of ADSs issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,303,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts', window );">Weighted average price of repurchase of ADSs | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts', window );">Total consideration of repurchase of ADSs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,348,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents as a aggregate offering price of at the market offering agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfAdssOptionsIssuableOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of ADSs options issuable outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfAdssOptionsIssuableOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfAdssVestedAndExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of ADSs vested and exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfAdssVestedAndExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfOptionsIssuableOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents number of options issuable outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfOptionsIssuableOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfOptionsVestedAndExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents number of options vested and exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfOptionsVestedAndExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfStockAdssResveredForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock option ADSs resvered for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfStockAdssResveredForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfStockReservedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents number of stock resvered for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfStockReservedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfWarrantsPurchaseUpAdss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants purchase ADS's.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfWarrantsPurchaseUpAdss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ProceedsFromSaleOfAdss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of ADS's.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ProceedsFromSaleOfAdss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RepurchaseOfAmericanDepositaryReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of repurchase of american depositary receipts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RepurchaseOfAmericanDepositaryReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents repurchase of American Depositary Receipts shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RepurchaseOfAmericanDepositaryReceiptsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_SaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_SaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_SaleOfStocksPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by the company for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_SaleOfStocksPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents Share Based Compensation Arrangement By Share Based Payment Award ADS Forfeitures In Period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents Share Based Compensation Arrangement By Share Based Payment Award ADS Outstanding Period Increase Decrease Weighted Average Exercise Price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stocks of American Depository Shares ("ADS") issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents Total consideration of repurchase of american depositary receipts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents weighted average price of repurchase of american depositary receipts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfTreasuryStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of an equity stock that has been previously reacquired by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfTreasuryStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in the weighted average exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cmmb_TwoThousandsFifteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cmmb_TwoThousandsFifteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cmmb_TwoThousandsSeventeenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cmmb_TwoThousandsSeventeenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmmb_RestrictedOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmmb_RestrictedOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cmmb_AtmAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cmmb_AtmAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cmmb_RepurchaseArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cmmb_RepurchaseArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cmmb_RothCapitalPartnersLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cmmb_RothCapitalPartnersLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cmmb_MarketOfferingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cmmb_MarketOfferingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Schedule of Share-based Compensation Expenses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses</a></td>
<td class="nump">$ 617<span></span>
</td>
<td class="nump">$ 1,491<span></span>
</td>
<td class="nump">$ 3,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses</a></td>
<td class="nump">401<span></span>
</td>
<td class="nump">407<span></span>
</td>
<td class="nump">448<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses</a></td>
<td class="nump">$ 216<span></span>
</td>
<td class="nump">$ 1,084<span></span>
</td>
<td class="nump">$ 2,763<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Schedule of Number and Weighted Average Exercise Prices of Option) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning</a></td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="nump">$ 0.33<span></span>
</td>
<td class="nump">$ 0.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercise</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">0.19<span></span>
</td>
<td class="nump">0.39<span></span>
</td>
<td class="nump">0.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">0.03<span></span>
</td>
<td class="nump">0.07<span></span>
</td>
<td class="nump">0.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end</a></td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="nump">$ 0.33<span></span>
</td>
<td class="nump">$ 0.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning</a></td>
<td class="nump">29,873,100<span></span>
</td>
<td class="nump">35,191,540<span></span>
</td>
<td class="nump">27,003,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1', window );">Exercise</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,970,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(667,820)<span></span>
</td>
<td class="num">(20,373,620)<span></span>
</td>
<td class="num">(1,240,120)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">2,845,020<span></span>
</td>
<td class="nump">15,055,180<span></span>
</td>
<td class="nump">11,398,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end</a></td>
<td class="nump">32,050,300<span></span>
</td>
<td class="nump">29,873,100<span></span>
</td>
<td class="nump">35,191,540<span></span>
</td>
<td class="nump">27,003,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Life in Years</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">7 years 4 months 2 days<span></span>
</td>
<td class="text">5 years 11 months 26 days<span></span>
</td>
<td class="text">7 years 5 months 1 day<span></span>
</td>
<td class="text">8 years 1 month 13 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm', window );">Granted</a></td>
<td class="text">8 years 6 months 21 days<span></span>
</td>
<td class="text">5 years 10 months 9 days<span></span>
</td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards granted during the period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Schedule of unvested RSA) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at beginning of the year</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">6,443,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at December 31, 2024</a></td>
<td class="nump">6,443,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Schedule of Assumptions Used to Calculate the Fair Value of the Options) (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Weighted average share price (in U.S. dollar)</a></td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">89.29%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">92.98%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in U.S. dollar)</a></td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in U.S. dollar)</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The weighted average share price is based on the Company's Ordinary Share closing price on the stock exchange as at the grant date</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Expected volatility is based on historical volatility over the most recent period commensurate with the expected term of the option. As the Company has a short trading history for its ordinary shares, when the Company's trading period is shorter than the expected term, the expected volatility is derived from the average historical share volatilities of several unrelated public companies within the Company&#8217;s industry that the Company considers to be comparable to its own business over a period equivalent to the option&#8217;s expected term.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The risk-free rate for the expected term of the options is based on the Black-Scholes option-pricing model on the yields of U.S. Treasury securities with maturities appropriate for the expected term of employee share option awards.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Expected life for the periods presented was determined according to the simplified method since, at the date of grant, the Company did not have enough history to make an estimate. This method effectively assumes that exercise occurs over the period from vesting until expiration, and therefore the expected term is the midpoint between the service period and the contractual term of the award. The simplified method is applicable to service conditions.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development (Schedule of Research and Development) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ConsultantsAndSubcontractorsExpense', window );">Consultants and subcontractors</a></td>
<td class="nump">$ 7,994<span></span>
</td>
<td class="nump">$ 14,014<span></span>
</td>
<td class="nump">$ 13,052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Salaries and related expenses</a></td>
<td class="nump">2,715<span></span>
</td>
<td class="nump">3,362<span></span>
</td>
<td class="nump">2,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense', window );">Lease and maintenance</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense', window );">Share-based compensation</a></td>
<td class="nump">401<span></span>
</td>
<td class="nump">407<span></span>
</td>
<td class="nump">448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other expenses</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">461<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total</a></td>
<td class="nump">$ 11,327<span></span>
</td>
<td class="nump">$ 18,381<span></span>
</td>
<td class="nump">$ 16,977<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ConsultantsAndSubcontractorsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consultants and subcontractors expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ConsultantsAndSubcontractorsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development related rent and maintenance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RentAndMaintenanceResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development related share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ShareBasedCompensationResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative (Schedule of General and Administrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and Administrative Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Salaries, fees and related expenses</a></td>
<td class="nump">$ 1,085<span></span>
</td>
<td class="nump">$ 2,545<span></span>
</td>
<td class="nump">$ 3,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional services</a></td>
<td class="nump">1,115<span></span>
</td>
<td class="nump">2,139<span></span>
</td>
<td class="nump">2,596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense', window );">Share-based compensation</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">1,084<span></span>
</td>
<td class="nump">2,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseDirectorsFees', window );">Fees to Directors</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">258<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralInsuranceExpense', window );">Directors' and Officers' Insurance</a></td>
<td class="nump">538<span></span>
</td>
<td class="nump">648<span></span>
</td>
<td class="nump">1,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense', window );">Lease and maintenance</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other expenses</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">323<span></span>
</td>
<td class="nump">1,423<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total</a></td>
<td class="nump">$ 3,412<span></span>
</td>
<td class="nump">$ 7,078<span></span>
</td>
<td class="nump">$ 11,556<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General and administrative related rent and maintenance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General and administrative related share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralInsuranceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralInsuranceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseDirectorsFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noninterest expense related to directors' fees which are fees paid by an Entity to its directors. Directors' fees may be paid in addition to salary and other benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseDirectorsFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Net change in the total valuation allowance</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ReceivedAmountOfChemomabTherapeuticsInc', window );">Received amount of Chemomab Therapeutics Inc</a></td>
<td class="nump">351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc', window );">Expects to receive amount of Chemomab Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (534)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Deferred tax asset capital closs carryforward</a></td>
<td class="nump">$ 14,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Capital losses carryforwards</a></td>
<td class="nump">$ 176,000<span></span>
</td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="nump">$ 159,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. [Member] | Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount expects to receive of Chemomab Therapeutics Inc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ReceivedAmountOfChemomabTherapeuticsInc">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The received amount of Chemomab Therapeutics Inc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ReceivedAmountOfChemomabTherapeuticsInc</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Schedule of Significant Components of the Company's Deferred Tax Asset) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred taxes</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry-forwards</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 40,755<span></span>
</td>
<td class="nump">$ 38,258<span></span>
</td>
<td class="nump">$ 36,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">351<span></span>
</td>
<td class="nump">1,163<span></span>
</td>
<td class="nump">1,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,103<span></span>
</td>
<td class="nump">4,041<span></span>
</td>
<td class="nump">2,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,219<span></span>
</td>
<td class="nump">43,471<span></span>
</td>
<td class="nump">41,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less - Valuation allowance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(44,219)<span></span>
</td>
<td class="num">(43,471)<span></span>
</td>
<td class="num">(41,195)<span></span>
</td>
<td class="num">$ (36,030)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">This excludes capital losses of approximately $14,224 thousands for which the company will create a full valuation allowance.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Roll Forward of Valuation Allowance) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at January 1</a></td>
<td class="nump">$ 43,471<span></span>
</td>
<td class="nump">$ 41,195<span></span>
</td>
<td class="nump">$ 36,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_CurrencyTransactionLossValuationAllowance', window );">Currency transaction income (loss)</a></td>
<td class="num">(2,459)<span></span>
</td>
<td class="num">(3,295)<span></span>
</td>
<td class="num">(1,316)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_IncomeTaxExpenseValuationAllowance', window );">Income tax expense</a></td>
<td class="nump">3,207<span></span>
</td>
<td class="nump">5,571<span></span>
</td>
<td class="nump">6,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at December 31</a></td>
<td class="nump">$ 44,219<span></span>
</td>
<td class="nump">$ 43,471<span></span>
</td>
<td class="nump">$ 41,195<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_CurrencyTransactionLossValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance due to currency transaction loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_CurrencyTransactionLossValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_IncomeTaxExpenseValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance due to income tax expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_IncomeTaxExpenseValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Theoretical tax benefit on the above amount Decrease (increase) in tax refund resulting from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (13,945)<span></span>
</td>
<td class="num">$ (24,221)<span></span>
</td>
<td class="num">$ (28,180)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Statutory tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Theoretical tax benefit</a></td>
<td class="num">$ (3,207)<span></span>
</td>
<td class="num">$ (5,571)<span></span>
</td>
<td class="num">$ (6,481)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized', window );">Change in temporary differences for which deferred taxes were not recognized</a></td>
<td class="nump">858<span></span>
</td>
<td class="num">(1,177)<span></span>
</td>
<td class="num">(1,696)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Tax rate differential</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Non-deductible expenses</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">346<span></span>
</td>
<td class="nump">744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded', window );">Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards</a></td>
<td class="nump">2,192<span></span>
</td>
<td class="nump">6,392<span></span>
</td>
<td class="nump">6,879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Actual income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (534)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents as a change in temporary differences for which deferred taxes were not recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents losses and benefits for tax purposes for the year, for which deferred taxes were not recorded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Parties Balances and Transactions (Schedule of Related Party Payables) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employees, consultants and related expenses</a></td>
<td class="nump">$ 874<span></span>
</td>
<td class="nump">$ 823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,563<span></span>
</td>
<td class="nump">3,423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employees, consultants and related expenses</a></td>
<td class="nump">531<span></span>
</td>
<td class="nump">490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Related Party Payables</a></td>
<td class="nump">$ 606<span></span>
</td>
<td class="nump">$ 564<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties Balances and Transactions (Schedule of Transaction With Related Parties) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty', window );">Salaries and related expenses</a></td>
<td class="nump">$ 1,718<span></span>
</td>
<td class="nump">$ 2,795<span></span>
</td>
<td class="nump">$ 2,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty', window );">Share-based payments</a></td>
<td class="nump">427<span></span>
</td>
<td class="nump">1,304<span></span>
</td>
<td class="nump">2,466<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty', window );">Professional services</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">258<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty', window );">Research and development</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total related party expenses</a></td>
<td class="nump">$ 2,465<span></span>
</td>
<td class="nump">$ 4,393<span></span>
</td>
<td class="nump">$ 5,142<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party expenses related to professional services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party expenses related to research and develeopment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party expenses related to salaries and related expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party expenses related to share based payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Computation of Basic and Diluted Net Loss) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_EarningsPerShareCalculationNumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13,945<span></span>
</td>
<td class="nump">$ 24,221<span></span>
</td>
<td class="nump">$ 27,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">359,048,638<span></span>
</td>
<td class="nump">234,998,859<span></span>
</td>
<td class="nump">227,589,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">359,048,638<span></span>
</td>
<td class="nump">234,998,859<span></span>
</td>
<td class="nump">227,589,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Net loss per share attributable to ordinary shareholders, basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.039<span></span>
</td>
<td class="nump">$ 0.103<span></span>
</td>
<td class="nump">$ 0.121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Net loss per share attributable to ordinary shareholders, diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.039<span></span>
</td>
<td class="nump">$ 0.103<span></span>
</td>
<td class="nump">$ 0.121<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Number of shares has been retroactively adjusted to reflect the share reverse split effected on March 16, 2021 (refer to Note 1)</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">1 American Depositary Share (ADS) represents 20 Ordinary Shares.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share Calculation Denominator For Basic Net Income Loss Per Share Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_EarningsPerShareCalculationNumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share Calculation Numerator Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_EarningsPerShareCalculationNumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 17: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Weighted Average Number of Shares) (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Outstanding options to purchase ordinary shares</a></td>
<td class="nump">38,494,200<span></span>
</td>
<td class="nump">29,873,100<span></span>
</td>
<td class="nump">35,191,540<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>94
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( "^*A%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( "^*A%JZ.LQ)\P   "L"   1
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M7^:S%I6L;J2X?9]<?_F=A)TW=F//R[CF/XR/@FT#?_Y%^P502P,$%     @
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M3@H\W/[O#;#"Q([A[8N_ 5!+ P04    "  OBH1:X-17>4 '  "V(P  &
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MG7LEN/G\B?#T('T:#K)#&V085V=PB:>J\8:6!^!NBO%P=I;@3O06@>5[Q<[
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M-C@9&1+5EN>V@W+E*MQ<HJF7KEF9&PV4#3#S"RGQH6.+9G='YG\!4$L#!!0
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MV@EQU #9(PU0UP!Q#: YTL#L&IA\#]9( ZMK8'$-3&>D@=TUL/D>_)$&3M?
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MAN"<< U0SU>,R=<+_8+VX'[Q/U!+ P04    "  OBH1:U+^T3_(%   ?#0
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M6/0&B\@[.8HLW\@@ST^=W0C'NX'&#S'4: URRG!1;H+#JH)=.']+AIS4I],
M,/XT+7K#RV2X^(GA?"'>6Q-J+WXU)97W :9@,5)9#%0N%P\BOJ%B(H[GAV(Q
M6RP?P#L>0SN.>,<_P?L@0^=(?*S$QQ8Q<A-X\4;Y0EO/"W]?Y#XXM,4_^Z)/
MV,O]V#PJ)[Z5!9UEF 5/;DW9^9-'\Q>SUP\P7X[,EP^A/U24APT_V$!B+HY$
MCW!P,3FXPAC;1N;B2XU/+75!%5[\$<J)>(HOI(RL CD89:$F<66;5IIM]DPH
M+Z01U]Y)TNJ(6[\415H5RA36M199Q<<.#> $&VNY\<)6\?DF8)%?$@),Q VU
M@9H<FQ>S^7S"C 9_3QZ]6LQ?OO88])7RX -<6U6J(.:A;1$] >-WY;8RB(N@
M( Z'X@N0+]9J?=B[F1RHR<$.;HQ"%$B4*J0^\@%*(W*%/!7U&$V)IK!K<LJL
M$'*)J5Y#K5I^5<;8M63EX*#N\@<YA+DI56JKC0JUJ*$ 1YUI(*4-E>Q/& +K
M4(.P,FNK@:),I24$,&D2G%4J=]8K#^8]]4UMM=X*NS$P]EWN$:ITBL;4#K%)
M1R=BK&\J:3:\9\\.Q?[:7QL,&KO>O_PT9?)9!#RXO)].AUY@(@;_".3:%N\N
MIH.9M<Z67=+;@>O[H_EL+CJ?RJ>"'S8-:8;$AXFXYNTHUAVD5-J+8+%-(_U.
MP 7=8I(5F8+\KBOLD%M_>"\W&Z6UR F$OW>*NPE(GN@;][34:#"3JNJM[AAD
M(FY0Q*+FH@\</)1V*PH)\G@R706QZ&*7)(\QB5QUXF;P 11:=)8)2G(!XR;>
MO9.97_QNV!% @3#BZ/?]. ]VT"YT$Y0&AXWOV\9(4\ 17/K8A1CUR<%;RT#H
MS (18C+Q)^!H#MLX;++H6[[?A.!5&2?K#L[SW#(Y+VJ)!.5$!NRIE7$FD3VQ
MNN<$RJ 0^:96<:0,K%L-#!_CP4U!J__DT!+2>^HCX%6\!!V]\:)6,E<:P< 6
MO<(;#!^]&K"=\U%-\LY#]+R?B'=V@TRZ^V6O)9L6G6.RCOB!N4+R/4 K9YN[
MC()&'"D</$F5AL,G$FU1L5N%0264\O%\=HSC5^MA:@VM4O\4TM>BPMWF/CHK
M"5\XQF &W,?SYY/E"!5U([(U 6Z,'?K$)P)K+@T:WTM-$W&QG^Z/&2@CJ<-$
MC=M_#6O#W<G,?6U=.,( -.C$V#L^\5I.QA#W2W//,^&B%U$3'D3T!2:&M5KQ
M*N:LX=MDG'0M#8L8SRUK)8Y=[@IGNU4=2>,K.W\O'7H'L;R(GCW+) MHL)A!
M)Y5/4XGS6L;A$J7M<DQ/CFMF=)3Z9LO.N0.5Z8B+^T.KW@MKKT*P+UB62=?A
MJ,+A%E6(-0&)B]YV.\B4#WO\6BL=U0,'3^SSG!5T'?. 8V&W<@6D:3^!6&%'
M<4?.0\%SU#E,+(TP,*,*O1+\&)GO"A3(5YUF\;RK4<K#WI$O+=#YM"IT5X((
MGS+EO[B'IN7HK.&;;B]&J>DY"I0"XD))]R'D.]HSV7<GFNY<6AMRJW@U]SSI
M)J3[Z_AUO/U?I$OOW?;TTP'MLU(HAJ8*IK/)R^>9<.DZGEZ";>,5.+<!%^KX
M6.,7##G>@/7*0K;[%W8P_B8Z_Q]02P,$%     @ +XJ$6J6<DHF'%0  VSL
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M$I2,IU)F':FC(X>&;B\'4_:W+$S.U$_4W!T/?9(G$TP,T76GIK8ZNCD^Q9F
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M10I59_9[@1&QL\DU8DXKCJ2X7*0K)MRKYY]?%7N?\K6VX::O]"3%+ODGBQ0
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MQI.4@.S:NC.T:%PK+84VC>FFI7D)4=H L[X2YHA[PVXPO*W97U!+ P04
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M-_GCSB>9BAQ 'YZHC$&2_SJ3[J9O6S/_26>SW'\8^\#U4H*[2[' UJ/1V>G
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M=O0SG 7N,ER:65@5:E"?5)GHBOQ3 R30TK-@[D53L0,]C#/2=#3OH4W,V0&
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M3,:P ?+W" )JL4R!:;M:1[!17Y@;D!#R"7=W]DMMU?URYCKU$WY/#Y__@PP
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M3^EG] \^=HQEPPR\4^(/7MIJ%MP$M(0MVPO[H X?H8LG=WB%$L:O]-#*9DE
MB[VQJNZ4T8.:R_;/GKH\G"C<1!<4DDXA\7ZWAKR7=\RR^52K ]5.&M$<X4/U
MVN@<E^Y2UE;C*4<].W\ P2R4=,6TY6#HD@DF"R28+.D7S:1A/GUF&EHTYY3"
MHH->MM#)!>@XH?=*VLK0][*$\AP@1#][9Y-G9Y?)5<0[*(8TC0<TB9+L"E[:
M!Y]ZO/05P1_/HJ5_+3;&:N3^?BGP%C9[&=:]HXEI6 &S !^* ?T(P?S-+_$H
M^O6*TUGO='8-_?_=V%7HEQW_K"Q0O,NW]-66R6)(^L,#M]7/JA/ZI0*Z50)[
M I<[>GX1#3NRC7"X&BB7A=AC^2!!+2H5B*\$+[U\9X2N7?V;"<$"@7H#VA7)
M.>,JQBTI^;J^0R"U-^BU^8E[7S="'0',P-O!E\VD;>/3G8OPA/W0@"%Y&I/L
M-B*+HM#[TX-Q3L89&44CDH\RLAR2L\)Z33KLOQ2>K3==ZO\S,VN+/VR>Z+W:
MTM\:T,S#3<B?P#0%]R(OD)>3>"&CN"17TWK.K?'2-(<+:8T'X_B&)(/Q;8YK
M%MV2=871OG6MU\5_]$&1+!FC:!IE3F@T(BNMMF#<J&""KK%R.=8>26[P/$<X
MO*L'+&BFB\J;+>$1YU'CL$@ZZCZ'E)-LD-ZF)!_$64)?>J[A2;.M0>_\2#&8
M_;VT;=_M=_NIM6B;]3_B[<B[9WK'\8H%;%$U&H[S@.IVC+2,58UOW1ME<1!X
MLL+)"]H)X/E6X>/L&&>@G^7S'U!+ P04    "  OBH1:)EK@:$T$  "S"P
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M*[),URJ,']9NJX!]K[A>8=8EJ72E'5NSPP)AI4 K6/E0O(>;KWW>57>^1Y%
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M8Z6T6JN-!&=$<?++SFLZ\X.$@9U1,4;*5Y&4KT;/?]V=IG>,(4J.0_J1Q/<
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M]8(-Y-22RSRPYB'[(:YQ^0S6!=5L=-&R)"I"]DA!#UDK"RU.JN2'^10+MXE
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M<C3*,=+=5'>.54V8I+FR;BZ#6;N'$+1/</L+I>S6\0WZI[7X"U!+ P04
M"  OBH1:T6VO#7@"  !_!0  &0   'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6Q]5,%NVS ,O?LK! T8-J"H'=M)TRXQD+1=MT.QH%FWP["#8C.Q4%GR)#GI
M_GZ4['AID>8BBQ+Y^$CZ:;)3^LF4 )8\5T*:*2VMK:_"T.0E5,R<JQHDWJR5
MKIA%4V]"4VM@A0^J1!A'T2BL&)<TF_BSA<XFJK&"2UAH8IJJ8OKO'(3:3>F
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M\GQN])89GTUH/NBD=M5$3BC?E#LTM"NH#O,O0)(L.[GG:PGV=!XA@?JMJ!@
MECU ^@) DK(;K;"V[(,JH?P;("(V(Z5T1VF9'D6\AN*,39(W+(W3[ C>9)0X
MZ? F+TJT%H!="UM(;9T!]N-R;='0#_'SD-X>+3N,YDTRLRTO8!&2"RR81PCS
MUZ^2:?S^"-=LY)H=0\_OR'2ED\!T15U&9P0^^UCZ-C$I^%I(@8(ZYNBV#=/.
M,*75VX*K J3O(2._&HY";?HB>TCB41*')5(SSH,DC0,*IKO@(DCB:7"OD4M6
M.?1W2_^H:%PS,&[Y,SD8;3#)IH%O!!--ZQ!*)A0"@>,L.$G3X#18^9,4LD<N
M72?_'QW[XH-)FK%#MQWM&:$!L^GL;EFAG<+>$^/J^*)<]D;ZD]X_1S?<;(2R
M='A%I?'9Q7G(3&_Q?H*Z[6RUUD@F[<*:7D4P/H'V*ZUQ-_$'C.]L_AM02P,$
M%     @ +XJ$6JPMZ*SJ!   J T  !D   !X;"]W;W)K<VAE971S+W-H965T
M,CDN>&ULW5?;;N,V$'WG5Q NTMJ +.MN>9L82#;;;0OL!?%F%T71!UH:VT1D
MT4M2=O+W'5**[&05(2]]*6S+(C5SYG)F2.K\(.2=V@!H>K\M2G4QV&B]>S.9
MJ&P#6Z9<L8,2GZR$W#*-0[F>J)T$EENE;3$)/"^9;!DO!_-S._=9SL]%I0M>
MPF=)5;7=,OEP!84X7 S\P>/$#5]OM)F8S,]W; T+T+>[SQ)'DQ8EYULH%1<E
ME;"Z&%SZ;ZZF1MX*?.5P4"?WU$2R%.+.#/[(+P:><0@*R+1!8/BWA[=0% 8(
MW?C>8 Y:DT;Q]/X1_3<;.\:R9 K>BN(;S_7F8I .: XK5A7Z1AQ^AR:>V.!E
MHE#V2@^-K#>@6:6TV#;*Z,&6E_4_NV_R\!J%H%$(K-^U(>OE-=-L?B[%@4HC
MC6CFQH9JM=$Y7AI2%EKB4XYZ>K[8, GT+=MQS0HZ_,*6!:C1^40CMI&89 W.
M58T3O(#C!_2#*/5&T7=E#OE3@ DZU7H6/'IV%?0B7D/FTM!W:. %40]>V$8:
M6KSPI4BUR.XVHLA!JE_HN^\5UP_TH]! _[Y<*BVQ/O[IBKM&C;I13<^\43N6
MP<4 FT*!W,-@_O-/?N+]VN-SU/H<]:'/%]B#>54 %2NJ-T!AM<)J-B-E>!N;
M>LQI)K;8HXK9,L>OD52::<#FT<I(8P]+^UAU1=CK0W>$?P&3% S3I/L6V8/M
M$J1AL&=@N#67T%P"<KNX1N]%I5B9J][1#7K"9+:A.,(NW./JLC/ADLCS\3<E
M4922]U!BW(6583EV#S<\FV6 !'Y"?,=+T;HS34+R19CZ?S&K<&_N09'$GZ)>
M-/-)Z 2^3WM(CEN2XU>37%8V-<;A@UU0T!&VQR#62/X]R(PKH#O),VAX-=YU
M<=IKLIO3;\\,DJ<&R<?:M]:L(L\U<)4V^P OUYB]TK94A5DM^ KHD)?T 2E3
MHQ_5_BM#CX45GI38\?*ITM@E96Y0F*9_LK+";8GZQ'/#D(2QX\]\)XX\,G6C
MP$RF))@ZGH?$)QY)73\@[QK'<S*V'\_%RAOZSFSJH:!'1CB'F\<*.#IO(&9D
M&'A.. V=)*@?XV1@5(+(<_QF[KUD9:V <'[L>#$ZDWHD=M,$)TWI^DXX2YW(
M,]ZEST,Y:;%:/)@Y*=KT/8,QFW5'^+_D/WIZ.2V''OY?F[+G_->?4\9]9#Q)
MIDYZI/O'&CCA&WUST@@I#TR)Q4EW#?3S'9,P0'FT8<LCC#HCZENZDG;I2EZ]
M=-V6>U"&HYO%9=>*U(O4O2(="P$Q<<U?7-9$MJ8P]B6L>6DKH=DC#?<G.4V<
M* J=&0;]U>H\X6?<D\GZX''4[\O7M,W7]-7Y8@H/PG5]T\IL.%K0C!595>#.
M;2-9,2[IGA55N_\W_="5WG[#)A2Z-BFQ^\:GE_K*;H!U&]I&NG47+LU%43 Y
MHD,V,N48M67_@J"MXS%>8I3<X8$%#=C6/';T29?2X7*$!1F/$]<_RN\%IH$7
MYHPVS$8DG;G![&P\"]Q92L[(#5=WXY4$H!Q)QGK15)JL#?,1B5S_;!RY,8I=
M\SW/\3Q"'S@4V%[DK(O#R<GI>0MR;=\1%"XL5:GK@W0[V[Z&7-:G[Z-X_0[S
M@4FL1D4+6*&JYTYQ&Y;U>T$]T&)GS^)+H?%D;V\W^"H%T@C@\Y7  VDS, ;:
ME[/YOU!+ P04    "  OBH1:>TN:C<@"   G!@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6R555%OTS 0?O>OL(*$0 I+XJ1)-]I(ZP8"B8EI92"$
M>'"3:Q/AV,%VUO'O.2=M5J2N$B_VG7WWW7<YWV6V5?J7J0 L?6R$-'.OLK:]
M" )35-!P<Z9:D'BS5KKA%E6]"4RK@9>]4R,"%H9IT/!:>OFL/[O5^4QU5M02
M;C4U7=-P_6<!0FWG7N3M#^[J367=09#/6KZ!)=C[]E:C%HPH9=V -+625,-Z
M[EU&%XO$V?<&7VO8F@.9NDQ62OURRL=R[H6.$ @HK$/@N#W %0CA@)#&[QVF
M-X9TCH?R'OU]GSOFLN(&KI3X5I>VFGM3CY:PYIVP=VK[ 7;Y3!Q>H83I5[H=
M;./,HT5GK&IVSLB@J>6P\\?==SAPF(;/.+"= ^MY#X%ZEM?<\GRFU99J9XUH
M3NA3[;V17"U=4996XVV-?C:_ P-<%Q7ELJ37\(!5:O&;6_KJ"U\),*]G@<4P
MSC@H=I"+ 9(] QDQ>J.DK0Q])TLH_P4(D-](DNU)+MA)Q&LHSF@<^92%+#F!
M%X])QSU>_+])_[A<&:OQI?P\EO8 FAP'==US85I>P-S#]C"@'\#+7[Z(TO#M
M"<K)2#DYA9XOL1O+3@!5:ZH/Z9=/](]Q/HEZG/-W!*?@2D>.BU@.:%:@74E.
M**Y8;HG=PLC]\IK:2G4&69N3VI62!IN*2VOZ%$VW*O!!N;HH;4CFGY\G)$K\
M,,(M]L,)(TLNN*YAL-<@N(62PB..+@.&,#^+)B3VXY2A/$TS\@FPDWMC-[@L
M2"X+(%$8(6!&6#(ARXIK>.,:OJ2%:AP2=W.$)&B4A!E)DBGY;"M,=HP312E)
MTHC$Z01E/V89B:9^/$74U#_/,GKL(00'S=N WO0CRF#,3MJAC\?3<0I>#LW_
M9#Z,T!NN-[4T5, :7<.S;.)1/8RE0;&J[4?!2ED<++U8X20'[0SP?JV4W2LN
MP/AOR/\"4$L#!!0    ( "^*A%KC1TB)[@(  ( &   9    >&PO=V]R:W-H
M965T<R]S:&5E=#,Q+GAM;)55VV[;, Q]UU<('K +X-7W-.V2 $DO6X$5+9IU
MPS#L0;'IV*@M99+2='\_4D[2%$@#[,46*?+P',JB!RNE'TP%8/E3VT@S]"IK
M%Z=!8/(*6F&.U (D[I1*M\*BJ>>!66@0A4MJFR .PU[0BEIZHX'SW>K10"UM
M4TNXU=PLVU;HOQ-HU&KH1=[&<5?/*TN.8#18B#E,P=XO;C5:P1:EJ%N0IE:2
M:RB'WC@ZG:04[P*^U[ R.VM.2F9*/9!Q50R]D A! [DE!(&O1SB#IB$@I/%G
MC>EM2U+B[GJ#?NFTHY:9,'"FFA]U8:NAU_=X :58-O9.K;[ 6D]&>+EJC'OR
M51>;]CR>+XU5[3H9&;2U[-[B:=V'G81^^$I"O$Z('>^ND&-Y+JP8#;1:<4W1
MB$8+)]5E([E:TJ%,K<;=&O/LZ#-(T*+A0A9\7&"!VE@MJ%/\_3<Q:\!\& 06
M"U%XD*]!)QUH_ IH%/-K)6UE^(4LH'@)$"##+<UX0W,2'T0\A_R()Y'/XS!.
M#^ E6]F)PTO^7_;%$W[P!OBO\8Q\N?V]KP$=?+H?GF[2J5F('(8>7A4#^A&\
MT=LW42_\=(!\NB6?'D(?3?%F%LL&N"KY?$>(>"%D'^N#N/M9_P2A.= QLOU+
M/!IH9Z#I> X8='#T2.@1L_OI.;>56AHD;@Y:4]$(78/Q>0E@G% -C;!0<.B.
MRK#(#_L9B_TLS5CBITG&;K4JP=#HP.:0E#IW<5%$<5%R0M$G/3:MA(:/=*\+
MGJN6\ 2-"Q9'/0>+I/WC7L(NJ;A5O*@U#A2E#8MI+^NS.(G8^<;[SA&\*4NL
M1]:5-$LM9 XL2_JLE_;7H%\!2[I8FIP69!<3LG[$L%$WML*^/>M#5X*MB_P4
MGZ@PBMFQ'QXC6N1G68_O^ZJ"G:G0@IZ[V6=0Y5+:;D!LO=OQ.NZFRG-X-YNO
MA9[7TO &2DP-CXXSC^MNWG6&50LW8V;*XL1RRPI_$: I /=+I>S&H +;G\[H
M'U!+ P04    "  OBH1:+])&G<D$  #S"P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970S,BYX;6RU5EMOVS84?N>O(+QNBPLEUM67+#$0)[L4:+L@3KN'80^T
M=&P1I4B/I.)XOWZ'E.*ZB*+E93! DQ)YOG/Y^.E<[)3^8DH 2Q\K(<WEH+1V
M>SX:F;R$BIDSM06);]9*5\SB4F]&9JN!%?Y0)49Q&(Y'%>-R,+_PSV[U_$+5
M5G )MYJ:NJJ8WB] J-WE(!H\/;CCF]*Z!Z/YQ99M8 GVT_96XVITL%+P"J3A
M2E(-Z\O!572^&+O]?L-G#CMS-*<NDI527]SB77$Y")U#(""WS@+#OP>X!B&<
M(73C[];FX #I#A[/GZS_XF/'6%;,P+42?_#"EI>#Z8 6L&:UL'=J]QNT\63.
M7JZ$\2/=M7O# <UK8U75'D8/*BZ;?_;8YN$U!^+V0.S];H"\ES?,LOF%5CNJ
MW6ZTYB8^5'\:G>/2%65I-;[E>,[.W\E<54#OV2,8>G+/5@+,\&)DT;3;,,I;
M,XO&3/R"F2BF'Y2TI:$_RP**;PV,T*>#8_&38XNXU^(-Y&<TB0(:AW':8R\Y
M!)IX>\E_!DION,F%,K4&^N?5REB-U/BK*^;&8MIMT5V7<[-E.5P.\#X8T \P
MF/_P730.?^KQ-SWXF_99GR_Q^A6U *K6U/"-Y&N>,VDI1K%5$J0U[HTMP3]A
M<O^C<6P$K:&@%J-DQH#MBJH?%_,.U0JTRSUY>>&JXH;$#3'YM+Q!7U1MF"Q,
M[^HC"@U*BF:6RPW%,AB:,ZWWIR@P.Z:+MR0-@TF6D60:Q-F4).,@RT*R+)F&
M4W?_"A\PR@+SUQH>W1Q(DD4D"J)Q@N-DDI([K C3>4D1%1/S@/*S13%Q"336
MD"2(PH2D09A&) ZF"/0[YE*3*"0S$B7D5^T\>YY00](TB*,929,@G40D1<Q9
M1MX#[CZEGYFH&[>80+EC,@=RTAX8XJPYXV;-L:%/1Q?*J?O1M_2^Y 9CS$5=
M@,O4EELF?-K $X!MMUH]<I0G$'OZ)D*L./V:;HI9I;N28QZ.J((:(P3-4<0M
M4$;7-:X>GKM^UD/C[$#C[-4TU@IQVC*[=0=D%U][ ;IOX;>46S#A;%-FZ3&'
MG;)$Y(UC6)B$Y+K&&LA\3U$/I!&-8XUJD),H2*(Q'9)615RAGH@W#M)IU(<1
M(T9;[UZ,)(@])3HPLB";]&(D#J-A5R]&'*39K!L#X<-)'T;:4I_VT&)\H,7X
M];2 7,F<"]ZXVJB:TF!1\ 3ESSRE5KF/>=WYLHM _:[\WX+WW@G)"I#W<.0O
M&"15$LQ25_&3V%U;+PSQ-(BF(<Z6EMG:*KWWT:%< D'L[X^&^Z,LN3TKD+#F
MUA,)*XG&&MK@I.'HD%R73&Z<&]0"?D8TMF&TX&N4'V0,'*O%L2;ABQWNH%)9
M7RS\&/T#!7&BB1<CFGBL*!C/QCBY;[T]V+6<":>I(2:.?%3R%/N#&GLQ[#2>
MBF9(E*+2IV,R25.?,(1TNJV<)E..SA[[QKJ4@^Z8H:B%#QSM4]S;IH.NM:J.
MOC.M_AA4_6@6X^U-_#B=S,C52Z2B)XO&V-#K\DF6I&38=0M&1XU8!7KCVTT$
M5K6T34]V>'KH:*^:1N[K]J8=_L#TADM#!:SQ:'@V01G438O9+*S:^K9NI2PV
MB7Y:8E<.VFW ]VNE[-/" 1SZ_/F_4$L#!!0    ( "^*A%J9+PQ? @,  %('
M   9    >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;(U5;6_:,!#^[E]A9=*T
M2:QY#] !4FDW;1\J(6@W3=,^F.0@49TXLTTI_WYG!U*8(*H4.3[[[KF[Q[[S
M:"ODD\H!-'TI>:7&3JYU?>VZ*LVA9.I*U%#ASDK(DFD4Y=I5M0266:.2NX'G
M)6[)BLJ9C.S:3$Y&8J-Y4<%,4K4I2R9W4^!B.W9\Y[ P+]:Y-@ON9%2S-2Q
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MN6Y.01@#_7[!N7J8F WJ=C?Y#5!+ P04    "  OBH1:-\%/IRP#  #,"P
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M;@ZX#E#O9XS)]41O4/6'T3]02P,$%     @ +XJ$6D<MQ\R/ @  LP8  !D
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M0>]40;\0],W<YY-E9CK$$D]&G&T0UZV5F[XPN(Q:33"A^LEZDES=)4HG)U]
M81'H[$_,.=:0S]%9"!*35)RC2_3C*41GG\[1)T0H^KYD:X%I(D:N5*&U@1L7
M8>[R,,&1,#YZ8%0N!9K1!)(:??@+?=!@X*HQEP,/W@<^#1H='_ 6^=X%"KS
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M:C5R!@Y*88$+JF[XYAM4?GJ&+^%4VB?:5+&>@Y)"*IY58*T@(ZQ\XX<J#UN
M3G</P*\ _GL!004(K-%2F;4UP0K'D> ;)$RT9C,-FQN+UFX(,U]QIH2>)1JG
MXDO0.9#H>*9_C[2@@/@"76%5"*(>3=O.HTN"YX02173H'4M!H.M"H!^<G2:8
M)4#Q7".O<Q!8$;8L0?($'4] 84)UZQ3=S2;H^.@$'2'"T.V*%Q*S5$:NTB:,
M%#>I!%^4@OT]@B>0G*&@\PGYGM]M@(_?#P]>PEV=NCI_?IT_W_(%>_,G)0":
M$)E0+@L!Z/?Y7"JA?\\_3>9*MFXSF]FR0YGC!$:.WI,2Q!J<^..'3NA]:;+Z
MG\A>& ]JXT$;>[PG_1<E*K0H4T+6<<?W(G>]K;N5^4#=W5IW]RW=O2;=):K7
MJKN5^4#=O5IW[RW=89/NWJYN+WRENY7Y0-UAK3MLU7W+%:9H42BS-W0!(UF1
M(6JK2HX?]7F@&HM N&,KZ+ZVU;KP@;;ZM:U^JRVS[Q')\D)!JBN: KV$&C8Y
MZ>\X.?7]5TY:USK0R:!V,FAU,C643*$UIH4M_[RNX^5GHL_%O\G?8&?#!Z8R
MO/#7$//Y.0>E;'?K$#,7B"LLEH1)+6*A4=Y97Z=0E(=RV5$\M^?:G"M]2MKF
M2M]C0)@ /;_@7#UUS%%9WXSB?U!+ P04    "  OBH1:T394Z08'  "_(0
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M*KH_M3$Q&Y6PR.O6/J\38U<+6T4+2K2Z68;]K9H3VF+9-'*M'_<ZC?R9/*%
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MFB,+[B[D/%C20I^@C6H.JKFHYJ&:CVK!Z-MS9..'Z+01JL6HEE!:)V.TMJ%
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MNG'5EO5KXK+^][^%4GJ79Z^?/Q1#DQ,*+=I'-1/5+%2S4<U!-1?5/%3S42U
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MJH6H%J%:C&H)I7523V_+Y/49>.Y01VOE4<U -1/5+%2S4<U!-1?5/%3S42U
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MI56HU@M4/[_=;LN7+^H)OF_SK[O5N?H?4$L#!!0    ( "^*A%J\[K:_8 ,
M "4.   9    >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;,57;4_;,!#^*U:&
M)B8!>24MK*T$#=N0AH3HV#Z@?3#)M8E(XLQV6]BOW]E)0U-"!%*D?6EMYY['
M=\_Y_#):,_X@8@!)'K,T%V,CEK(X-4T1QI!1<<0*R/'+G/&,2NSRA2D*#C32
MH"PU'<ORS8PFN3$9Z;%K/AFQI4R3'*XY$<LLH_SI'%*V'ANVL1FX21:Q5 /F
M9%30!<Q WA;7''MFS1(E&>0B83GA,!\;9_9I8%L*H"U^)K 66VVB0KEG[$%U
M+J.Q82F/((50*@J*?RN80IHJ)O3C3T5JU',JX'9[P_Y%!X_!W%,!4Y;^2B(9
MCXVA02*8TV4J;]CZ&U0!'2N^D*5"_Y)U96L9)%P*R;(*C!YD25[^T\=*B"V
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MVFLUTR5-8.Z9>Z-!;<&+W[[ICX./'9J'K>9A%WK\<*@21;*&#1."B8TM'^9
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M<.:0/)QPOB/T.XL!.'K*TIPMM)CSXE+761A#AMF$%)"++VM",\Q%EVYT5E#
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M$&.75Q-:M9&L*">*1R9Q/BF7,4ZUP)4 WJ\8DR\;]8%F3I[^#U!+ P04
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M&FMD,PVKOD6C7HR;0%EHB;,,<7KZC+'XBU *7JB$148DA4>M)5M6FBQS"EK
MKS)E'(.HGLY$GE*IX&:!,9M6:")6,!-%B0![]-A](HHE0'@*,<LK35-X6^86
M;F*J"<NQ]1Y>%S'<O+N%=^"",N0*&(=7SK2ZPT%L_Y:)2B&1&KL:O35[=I/&
MLUGM67#",S^ #X+K3,&<IS3=)W!1IE:KX$VK67"6,:;)/83^'01>$'5L*+X<
M'G; YY?#@S/>A.W)AY8O/'7R54$ET4(^=&E;8Z-NK,E>#ZHD"9TXF)X4E1OJ
M3+__SN][/W3I<DVR^97(]C2+6LVB<^SVMN08QEV*U<B^19KTO)GZX2CJC=W-
MKA3'5D$4!/Z^U;S#:M"/^JW5WN9[[>9[9P\\IEQ@!CEYY+UK'ODUR>97(MM3
MK=^JUC][Y)_LIX:F[\D&K\N: J^*)>9*3'/B+3$VN:M2F.DP:24V&S*^!M[$
M"Y2(L%9 #K+K/DF37>_,QX\E'5H\G=_M9_^/KJ.M0;V=> I[(R\:]L/A07P>
M6P9A-!H-A[W108QV6 :#WG 4#(?=<3IH%1_\'Q5/ZT]5E^;G]_LYZ-1\<+'F
MQY:G-.^P/*_YL-5\>%%BNUZ@SNH%!SM[]>Z]\,"CN,O*]\(#OSNM=K+FGL^C
MUN?1?^3SZ5"9C2[RNLOJV.M.JU->^Z8 WQ_9J0']?\L:S^T=:ZY61A0L*36O
M 2U%7<_GWX"D?V)1BK<.U<&2WM3[H#/:Z"<I7EF%O3)G&NAJA=-HBU7A!R*3
M#/R^+5]\N$$L+H<DST)3\&_Q$OGPB!4)2PB'F)9",=T6G7#S&"]ND=XF>*X5
MLAS4I>J^*]F[.Y4QDJ_MDT1AOJBXKC_[[6C[['FRQ?[1N/<0H\;',S/S4.I$
M^(BH'SS_+%V_OU"-->,*<KK";7CW [S2LG[2U!TM2ENS+X7&%X!M9O@,I-(8
MX/Q*H&Q-QRS0/BRG?P-02P,$%     @ +XJ$6A>FV@:P @  \@8  !D   !X
M;"]W;W)K<VAE971S+W-H965T-3@N>&ULK57+;MLP$/P50@6*%&A#O9Q790%V
MW*(%FL2(T>90]$!+:XL():HD92=_WR4E*TYJ&SGD(O&Q,]P=DL-D+=6]+@ ,
M>2A%I8=>84Q]0:G."BB9/I8U5#BSD*ID!KMJ276M@.4.5 H:^OX)+1FOO#1Q
M8U.5)K(Q@E<P540W9<G4XQB$7 ^]P-L,W/)E8>P 39.:+6$&YF<]5=BC/4O.
M2Z@TEQ51L!AZH^!B$MMX%_"+PUIOM8FM9"[EO>U\SX>>;Q," 9FQ# Q_*[@$
M(2P1IO&WX_3Z)2UPN[UA_^IJQUKF3,.E%'<\-\70._-(#@O6"',KU]^@JV=@
M^3(IM/N2=1?K>R1KM)%E!\8,2EZU?_;0Z; %"$[V ,(.$+X$Q'L 40>(7@N(
M.X"3FK:E.!TFS+ T47)-E(U&-MMP8CHTEL\KN^TSHW"6(\ZDUWBR?DBMR104
MF15, 1D9H_B\,6PN@!A);E3.*SP2[70A10Y*DZ,9GL"\P1"Y('=.7LC): 4*
M3PNY;LHY$N*4 ^D/Y&@"AG&!K4]$N[&$&BS ID&S+MEQFVRX)]D@)%>R,H4F
M7ZH<\N<$%"OORP\WY8_#@XP3R(Y)%'PDH1_&.Q*Z?#T\V@&?O!X>'J@FZC<S
M<GSQ'KXO92WD(P"9&9G=DYO:7:W?5V WX\\NO0_R6<NYT#7+8.BAIVA0*_#2
M]^^"$__S+JW>DFSR1F3/=(Q['>.#.MXT1AM6X;%?$NE$U/8BU(W*"O08(C<W
M8O]!;A<8N 6L]:[2Z"P^C]&-$[K:%NW_P/#\[#0*7@9.=C .@O-@$#\%ML72
M+3<H02V=JVJ2R:8R[<WH1UOC'J-Q.X-[,8Z&/G(^1I]HVM?@BJDE1U$$+)#2
M/S[%M%3KL&W'R-IYSEP:=##7+/!1 F4#<'XAI=ET[ +],Y?^ U!+ P04
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ME()*;@4=QNSL:.ZOI!14<K^5.8QY&D*',2D%E<P*.EQ5],08DU)0R:P@JJH
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( "^*A%K@U%=Y0 <  +8C   8
M          " @28(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    "  OBH1:Y53CE"D&  "L&@  &               @(&<#P  >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ +XJ$6GTFX>V2 @  +P<
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M965T-RYX;6Q02P$"% ,4    "  OBH1:I9R2B8<5  #;.P  &
M    @($ ,@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @
M+XJ$6H[/>1Q@ @  9P4  !@              ("!O4<  'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( "^*A%JWU$+'9 (  )(%   9
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M970Q-"YX;6Q02P$"% ,4    "  OBH1:8RG-M[P"   T!@  &0
M    @($^<0  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (
M "^*A%J9X-8'X@(  ) &   9              " @3%T  !X;"]W;W)K<VAE
M971S+W-H965T,38N>&UL4$L! A0#%     @ +XJ$6D'%B@O>"0  $QD  !D
M             ("!2G<  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M% ,4    "  OBH1:<2^#5S0#  #7!P  &0              @(%?@0  >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( "^*A%HF6N!H300
M +,+   9              " @<J$  !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&UL4$L! A0#%     @ +XJ$6C&\0J)F @  B 8  !D              ("!
M3HD  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  OBH1:
M/*4S.!$"  #=!   &0              @('KBP  >&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;%!+ 0(4 Q0    ( "^*A%J2>$X:&0P  '@R   9
M      " @3..  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%
M  @ +XJ$6DFV:\G=%@  FT4  !D              ("!@YH  'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  OBH1:EC?-&X,"  !Q!0
M&0              @(&7L0  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+
M 0(4 Q0    ( "^*A%IWAG'[;0(  &8%   9              " @5&T  !X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ +XJ$6M%MKPUX
M @  ?P4  !D              ("!];8  'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6Q02P$"% ,4    "  OBH1:;]]80*H"  #=!0  &0
M@(&DN0  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( "^*
MA%IJ+T+/@ (  ',%   9              " @86\  !X;"]W;W)K<VAE971S
M+W-H965T,C@N>&UL4$L! A0#%     @ +XJ$6JPMZ*SJ!   J T  !D
M         ("!/+\  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
M    "  OBH1:>TN:C<@"   G!@  &0              @(%=Q   >&PO=V]R
M:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( "^*A%KC1TB)[@(  ( &
M   9              " @5S'  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL
M4$L! A0#%     @ +XJ$6B_21IW)!   \PL  !D              ("!@<H
M 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  OBH1:F2\,
M7P(#  !2!P  &0              @(&!SP  >&PO=V]R:W-H965T<R]S:&5E
M=#,S+GAM;%!+ 0(4 Q0    ( "^*A%H?<3U,70,  'P(   9
M  " @;K2  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @
M+XJ$6C[9(\'O @  Z@@  !D              ("!3M8  'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6Q02P$"% ,4    "  OBH1:31RPZ%T#  #Z#@  &0
M            @(%TV0  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4
M Q0    ( "^*A%HWP4^G+ ,  ,P+   9              " @0C=  !X;"]W
M;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ +XJ$6N:Q+RGE @
M*PH  !D              ("!:^   'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6Q02P$"% ,4    "  OBH1:1RW'S(\"  "S!@  &0              @(&'
MXP  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( "^*A%K!
MEWN,P@,  ' 3   9              " @4WF  !X;"]W;W)K<VAE971S+W-H
M965T-# N>&UL4$L! A0#%     @ +XJ$6E(BZ6I7!   "Q<  !D
M     ("!1NH  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
M"  OBH1:T'GR*.@"   E"0  &0              @('4[@  >&PO=V]R:W-H
M965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( "^*A%K1-E3I!@<  +\A   9
M              " @?/Q  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L!
M A0#%     @ +XJ$6A'?VN;A$0  \2$! !D              ("!,/D  'AL
M+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    "  OBH1:O.ZVOV #
M   E#@  &0              @(%("P$ >&PO=V]R:W-H965T<R]S:&5E=#0U
M+GAM;%!+ 0(4 Q0    ( "^*A%IZ@*;FM@0  (T7   9              "
M@=\. 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ +XJ$
M6FX-V<R5 @  DP8  !D              ("!S!,! 'AL+W=O<FMS:&5E=',O
M<VAE970T-RYX;6Q02P$"% ,4    "  OBH1:C9V/E48&  #W%   &0
M        @(&8%@$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0
M   ( "^*A%K7%_A;2 ,  )0*   9              " @14= 0!X;"]W;W)K
M<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ +XJ$6I04L!F> P  . P
M !D              ("!E" ! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q0
M2P$"% ,4    "  OBH1:GAHP !P$  !]$P  &0              @(%I) $
M>&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( "^*A%J#7_>8
M(@0  #,/   9              " @;PH 0!X;"]W;W)K<VAE971S+W-H965T
M-3(N>&UL4$L! A0#%     @ +XJ$6L)R9;<9 P  ' D  !D
M ("!%2T! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    "  O
MBH1:CA^D&2L$   B#0  &0              @(%E, $ >&PO=V]R:W-H965T
M<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( "^*A%K;@)O@VP(  -H)   9
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M;',O+G)E;'-02P$"% ,4    "  OBH1:#WE:Y<X$  #!)@  #P
M    @ 'P1@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ +XJ$6A,G[+KO
M 0  I2(  !H              ( !ZTL! 'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ +XJ$6F(CYQC8 0  2"(  !,
M ( !$DX! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $( 0@ %$@  &U !
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>103</ContextCount>
  <ElementCount>288</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>34</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0005 - Statement - Consolidated Statements of Changes in Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/StatementsOfChangesInEquity</Role>
      <ShortName>Consolidated Statements of Changes in Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0006 - Statement - Consolidated Statements of Cash flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0007 - Disclosure - General</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/General</Role>
      <ShortName>General</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0009 - Disclosure - Cash and Cash Equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/CashAndCashEquivalents</Role>
      <ShortName>Cash and Cash Equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0010 - Disclosure - Other Receivables and Prepaid Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpenses</Role>
      <ShortName>Other Receivables and Prepaid Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0011 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0012 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0013 - Disclosure - Commitments and Contingent Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/CommitmentsAndContingentLiabilities</Role>
      <ShortName>Commitments and Contingent Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0014 - Disclosure - Share Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ShareCapital</Role>
      <ShortName>Share Capital</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0015 - Disclosure - Research and Development</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ResearchAndDevelopment</Role>
      <ShortName>Research and Development</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0016 - Disclosure - General and Administrative</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/GeneralAndAdministrative</Role>
      <ShortName>General and Administrative</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0017 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0018 - Disclosure - Related Parties Balances and Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactions</Role>
      <ShortName>Related Parties Balances and Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0019 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholders</Role>
      <ShortName>Net Loss Per Share Attributable to Ordinary Shareholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9960701 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9960702 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9960703 - Disclosure - Cash and Cash Equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/CashAndCashEquivalentsTables</Role>
      <ShortName>Cash and Cash Equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/CashAndCashEquivalents</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9960704 - Disclosure - Other Receivables and Prepaid Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesTables</Role>
      <ShortName>Other Receivables and Prepaid Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpenses</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9960705 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9960706 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/Leases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9960707 - Disclosure - Share Capital (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ShareCapitalTables</Role>
      <ShortName>Share Capital (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/ShareCapital</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9960708 - Disclosure - Research and Development (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ResearchAndDevelopmentTables</Role>
      <ShortName>Research and Development (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/ResearchAndDevelopment</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9960709 - Disclosure - General and Administrative (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/GeneralAndAdministrativeTables</Role>
      <ShortName>General and Administrative (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/GeneralAndAdministrative</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9960710 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/IncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9960711 - Disclosure - Related Parties Balances and Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables</Role>
      <ShortName>Related Parties Balances and Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactions</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9960712 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables</Role>
      <ShortName>Net Loss Per Share Attributable to Ordinary Shareholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholders</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9960713 - Disclosure - General (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/GeneralDetails</Role>
      <ShortName>General (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/GeneralAndAdministrativeTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9960714 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9960715 - Disclosure - Summary of Significant Accounting Policies (Schedule of Annual rates of Depreciation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Schedule of Annual rates of Depreciation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9960716 - Disclosure - Cash and Cash Equivalents (Schedule of Cash and Cash Equivalents) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/CashAndCashEquivalentsDetails</Role>
      <ShortName>Cash and Cash Equivalents (Schedule of Cash and Cash Equivalents) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/CashAndCashEquivalentsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9960717 - Disclosure - Other Receivables and Prepaid Expenses (Schedule of Other Receivables and Prepaid Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails</Role>
      <ShortName>Other Receivables and Prepaid Expenses (Schedule of Other Receivables and Prepaid Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9960718 - Disclosure - Property and Equipment, Net (Schedule of Property and Equipment, Net) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/PropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Schedule of Property and Equipment, Net) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/PropertyAndEquipmentNetTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9960719 - Disclosure - Leases (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/LeasesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9960720 - Disclosure - Leases (Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails</Role>
      <ShortName>Leases (Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/LeasesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9960721 - Disclosure - Commitments and Contingent Liabilities (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingent Liabilities (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/CommitmentsAndContingentLiabilities</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9960722 - Disclosure - Share Capital (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ShareCapitalNarrativeDetails</Role>
      <ShortName>Share Capital (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/ShareCapitalTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9960723 - Disclosure - Share Capital (Schedule of Share-based Compensation Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails</Role>
      <ShortName>Share Capital (Schedule of Share-based Compensation Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/ShareCapitalTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9960724 - Disclosure - Share Capital (Schedule of Number and Weighted Average Exercise Prices of Option) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails</Role>
      <ShortName>Share Capital (Schedule of Number and Weighted Average Exercise Prices of Option) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/ShareCapitalTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9960725 - Disclosure - Share Capital (Schedule of unvested RSA) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ShareCapitalScheduleOfUnvestedRSADetails</Role>
      <ShortName>Share Capital (Schedule of unvested RSA) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/ShareCapitalTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9960726 - Disclosure - Share Capital (Schedule of Assumptions Used to Calculate the Fair Value of the Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails</Role>
      <ShortName>Share Capital (Schedule of Assumptions Used to Calculate the Fair Value of the Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/ShareCapitalTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9960727 - Disclosure - Research and Development (Schedule of Research and Development) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails</Role>
      <ShortName>Research and Development (Schedule of Research and Development) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/ResearchAndDevelopmentTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9960728 - Disclosure - General and Administrative (Schedule of General and Administrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails</Role>
      <ShortName>General and Administrative (Schedule of General and Administrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/GeneralAndAdministrativeTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9960729 - Disclosure - Income Taxes (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/IncomeTaxesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9960730 - Disclosure - Income Taxes (Schedule of Significant Components of the Company's Deferred Tax Asset) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails</Role>
      <ShortName>Income Taxes (Schedule of Significant Components of the Company's Deferred Tax Asset) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/IncomeTaxesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9960731 - Disclosure - Income Taxes (Schedule of Roll Forward of Valuation Allowance) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails</Role>
      <ShortName>Income Taxes (Schedule of Roll Forward of Valuation Allowance) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/IncomeTaxesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9960732 - Disclosure - Income Taxes (Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails</Role>
      <ShortName>Income Taxes (Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/IncomeTaxesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9960733 - Disclosure - Related Parties Balances and Transactions (Schedule of Related Party Payables) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails</Role>
      <ShortName>Related Parties Balances and Transactions (Schedule of Related Party Payables) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9960734 - Disclosure - Related Parties Balances and Transactions (Schedule of Transaction With Related Parties) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails</Role>
      <ShortName>Related Parties Balances and Transactions (Schedule of Transaction With Related Parties) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9960735 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Computation of Basic and Diluted Net Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Computation of Basic and Diluted Net Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="zk2532902.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9960736 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Weighted Average Number of Shares) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Weighted Average Number of Shares) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cmmb-20241231.xsd</File>
    <File>cmmb-20241231_cal.xml</File>
    <File>cmmb-20241231_def.xml</File>
    <File>cmmb-20241231_lab.xml</File>
    <File>cmmb-20241231_pre.xml</File>
    <File doctype="20-F" isDefinitelyFs="true" isUsgaap="true" original="zk2532902.htm">zk2532902.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image0.jpg</File>
    <File>image00001.jpg</File>
    <File>image00019.jpg</File>
    <File>image00020.jpg</File>
    <File>image00021.jpg</File>
    <File>image00022.jpg</File>
    <File>image00023.jpg</File>
    <File>image00024.jpg</File>
    <File>image00027.jpg</File>
    <File>image00028.jpg</File>
    <File>image00029.jpg</File>
    <File>image00030.jpg</File>
    <File>image00031.jpg</File>
    <File>image00032.jpg</File>
    <File>image00033.jpg</File>
    <File>image00034.jpg</File>
    <File>image00035.jpg</File>
    <File>image00036.jpg</File>
    <File>image00037.jpg</File>
    <File>image5.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="523">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="14">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="46">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="1">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>100
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "zk2532902.htm": {
   "nsprefix": "cmmb",
   "nsuri": "http://www.anchiano.com/20241231",
   "dts": {
    "schema": {
     "local": [
      "cmmb-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/ebp/elts/us-gaap-ebp-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cmmb-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cmmb-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cmmb-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cmmb-20241231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "zk2532902.htm"
     ]
    }
   },
   "keyStandard": 229,
   "keyCustom": 59,
   "axisStandard": 14,
   "axisCustom": 0,
   "memberStandard": 23,
   "memberCustom": 11,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 103,
   "entityCount": 1,
   "segmentCount": 34,
   "elementCount": 573,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 523,
    "http://xbrl.sec.gov/dei/2024": 46,
    "http://xbrl.sec.gov/cyd/2024": 14,
    "http://xbrl.sec.gov/ecd/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation",
     "longName": "0001 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets",
     "longName": "0002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:DepositsAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.anchiano.com/role/BalanceSheetsParenthetical",
     "longName": "0003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:CommonStockNoParValue",
      "unitRef": "USD_Per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:CommonStockNoParValue",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:CommonStockNoParValue",
      "unitRef": "USD_Per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:CommonStockNoParValue",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.anchiano.com/role/StatementsOfOperations",
     "longName": "0004 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.anchiano.com/role/StatementsOfChangesInEquity",
     "longName": "0005 - Statement - Consolidated Statements of Changes in Equity",
     "shortName": "Consolidated Statements of Changes in Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.anchiano.com/role/StatementsOfCashFlows",
     "longName": "0006 - Statement - Consolidated Statements of Cash flows",
     "shortName": "Consolidated Statements of Cash flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.anchiano.com/role/General",
     "longName": "0007 - Disclosure - General",
     "shortName": "General",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.anchiano.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "0008 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.anchiano.com/role/CashAndCashEquivalents",
     "longName": "0009 - Disclosure - Cash and Cash Equivalents",
     "shortName": "Cash and Cash Equivalents",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpenses",
     "longName": "0010 - Disclosure - Other Receivables and Prepaid Expenses",
     "shortName": "Other Receivables and Prepaid Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.anchiano.com/role/PropertyAndEquipmentNet",
     "longName": "0011 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.anchiano.com/role/Leases",
     "longName": "0012 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.anchiano.com/role/CommitmentsAndContingentLiabilities",
     "longName": "0013 - Disclosure - Commitments and Contingent Liabilities",
     "shortName": "Commitments and Contingent Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.anchiano.com/role/ShareCapital",
     "longName": "0014 - Disclosure - Share Capital",
     "shortName": "Share Capital",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.anchiano.com/role/ResearchAndDevelopment",
     "longName": "0015 - Disclosure - Research and Development",
     "shortName": "Research and Development",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.anchiano.com/role/GeneralAndAdministrative",
     "longName": "0016 - Disclosure - General and Administrative",
     "shortName": "General and Administrative",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "cmmb:GeneralAndAdministrativeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "cmmb:GeneralAndAdministrativeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.anchiano.com/role/IncomeTaxes",
     "longName": "0017 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactions",
     "longName": "0018 - Disclosure - Related Parties Balances and Transactions",
     "shortName": "Related Parties Balances and Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholders",
     "longName": "0019 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders",
     "shortName": "Net Loss Per Share Attributable to Ordinary Shareholders",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "9960701 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "9960702 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "cmmb:ScheduleOfAnnualRateOfDeprecationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "cmmb:ScheduleOfAnnualRateOfDeprecationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.anchiano.com/role/CashAndCashEquivalentsTables",
     "longName": "9960703 - Disclosure - Cash and Cash Equivalents (Tables)",
     "shortName": "Cash and Cash Equivalents (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesTables",
     "longName": "9960704 - Disclosure - Other Receivables and Prepaid Expenses (Tables)",
     "shortName": "Other Receivables and Prepaid Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "cmmb:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "cmmb:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.anchiano.com/role/PropertyAndEquipmentNetTables",
     "longName": "9960705 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.anchiano.com/role/LeasesTables",
     "longName": "9960706 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.anchiano.com/role/ShareCapitalTables",
     "longName": "9960707 - Disclosure - Share Capital (Tables)",
     "shortName": "Share Capital (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.anchiano.com/role/ResearchAndDevelopmentTables",
     "longName": "9960708 - Disclosure - Research and Development (Tables)",
     "shortName": "Research and Development (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "cmmb:ScheduleOfResearchAndDevelopmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "cmmb:ScheduleOfResearchAndDevelopmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.anchiano.com/role/GeneralAndAdministrativeTables",
     "longName": "9960709 - Disclosure - General and Administrative (Tables)",
     "shortName": "General and Administrative (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "cmmb:ScheduleOfGeneralAndAdministrativeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "cmmb:GeneralAndAdministrativeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "cmmb:ScheduleOfGeneralAndAdministrativeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "cmmb:GeneralAndAdministrativeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.anchiano.com/role/IncomeTaxesTables",
     "longName": "9960710 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables",
     "longName": "9960711 - Disclosure - Related Parties Balances and Transactions (Tables)",
     "shortName": "Related Parties Balances and Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "cmmb:ScheduleOfRelatedPartyPayablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "cmmb:ScheduleOfRelatedPartyPayablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables",
     "longName": "9960712 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Tables)",
     "shortName": "Net Loss Per Share Attributable to Ordinary Shareholders (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.anchiano.com/role/GeneralDetails",
     "longName": "9960713 - Disclosure - General (Narrative) (Details)",
     "shortName": "General (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:OperatingIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:OperatingIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails",
     "longName": "9960714 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)",
     "shortName": "Summary of Significant Accounting Policies (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:SeveranceCosts1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "div",
       "cmmb:SeverancePayPolicyTextBlock",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:SeveranceCosts1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "div",
       "cmmb:SeverancePayPolicyTextBlock",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails",
     "longName": "9960715 - Disclosure - Summary of Significant Accounting Policies (Schedule of Annual rates of Depreciation) (Details)",
     "shortName": "Summary of Significant Accounting Policies (Schedule of Annual rates of Depreciation) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "cmmb:ScheduleOfAnnualRateOfDeprecationTableTextBlock",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "cmmb:ScheduleOfAnnualRateOfDeprecationTableTextBlock",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.anchiano.com/role/CashAndCashEquivalentsDetails",
     "longName": "9960716 - Disclosure - Cash and Cash Equivalents (Schedule of Cash and Cash Equivalents) (Details)",
     "shortName": "Cash and Cash Equivalents (Schedule of Cash and Cash Equivalents) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20241231_srtCurrencyAxis_currencyUSD",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails",
     "longName": "9960717 - Disclosure - Other Receivables and Prepaid Expenses (Schedule of Other Receivables and Prepaid Expenses) (Details)",
     "shortName": "Other Receivables and Prepaid Expenses (Schedule of Other Receivables and Prepaid Expenses) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_20241231",
      "name": "cmmb:ReceivablesFromGovernmentInstitutions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "cmmb:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock",
       "cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20241231",
      "name": "cmmb:ReceivablesFromGovernmentInstitutions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "cmmb:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock",
       "cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
     "longName": "9960718 - Disclosure - Property and Equipment, Net (Schedule of Property and Equipment, Net) (Details)",
     "shortName": "Property and Equipment, Net (Schedule of Property and Equipment, Net) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.anchiano.com/role/LeasesNarrativeDetails",
     "longName": "9960719 - Disclosure - Leases (Narrative) (Details)",
     "shortName": "Leases (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_20200510",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20200510",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails",
     "longName": "9960720 - Disclosure - Leases (Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases) (Details)",
     "shortName": "Leases (Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
     "longName": "9960721 - Disclosure - Commitments and Contingent Liabilities (Narrative) (Details)",
     "shortName": "Commitments and Contingent Liabilities (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:OtherCommitmentsDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:OtherCommitmentsDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.anchiano.com/role/ShareCapitalNarrativeDetails",
     "longName": "9960722 - Disclosure - Share Capital (Narrative) (Details)",
     "shortName": "Share Capital (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_20231001to20231031",
      "name": "cmmb:ProceedsFromSaleOfAdss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231001to20231031",
      "name": "cmmb:ProceedsFromSaleOfAdss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails",
     "longName": "9960723 - Disclosure - Share Capital (Schedule of Share-based Compensation Expenses) (Details)",
     "shortName": "Share Capital (Schedule of Share-based Compensation Expenses) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails",
     "longName": "9960724 - Disclosure - Share Capital (Schedule of Number and Weighted Average Exercise Prices of Option) (Details)",
     "shortName": "Share Capital (Schedule of Number and Weighted Average Exercise Prices of Option) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "unitRef": "USD_Per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
      "unitRef": "USD_Per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.anchiano.com/role/ShareCapitalScheduleOfUnvestedRSADetails",
     "longName": "9960725 - Disclosure - Share Capital (Schedule of unvested RSA) (Details)",
     "shortName": "Share Capital (Schedule of unvested RSA) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails",
     "longName": "9960726 - Disclosure - Share Capital (Schedule of Assumptions Used to Calculate the Fair Value of the Options) (Details)",
     "shortName": "Share Capital (Schedule of Assumptions Used to Calculate the Fair Value of the Options) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:SharePrice",
      "unitRef": "USD_Per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:SharePrice",
      "unitRef": "USD_Per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails",
     "longName": "9960727 - Disclosure - Research and Development (Schedule of Research and Development) (Details)",
     "shortName": "Research and Development (Schedule of Research and Development) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "cmmb:ConsultantsAndSubcontractorsExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "cmmb:ScheduleOfResearchAndDevelopmentTableTextBlock",
       "div",
       "div",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "cmmb:ConsultantsAndSubcontractorsExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "cmmb:ScheduleOfResearchAndDevelopmentTableTextBlock",
       "div",
       "div",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails",
     "longName": "9960728 - Disclosure - General and Administrative (Schedule of General and Administrative) (Details)",
     "shortName": "General and Administrative (Schedule of General and Administrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:SalariesAndWages",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "cmmb:ScheduleOfGeneralAndAdministrativeTableTextBlock",
       "div",
       "div",
       "cmmb:GeneralAndAdministrativeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:SalariesAndWages",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "cmmb:ScheduleOfGeneralAndAdministrativeTableTextBlock",
       "div",
       "div",
       "cmmb:GeneralAndAdministrativeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.anchiano.com/role/IncomeTaxesDetails",
     "longName": "9960729 - Disclosure - Income Taxes (Narrative) (Details)",
     "shortName": "Income Taxes (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails",
     "longName": "9960730 - Disclosure - Income Taxes (Schedule of Significant Components of the Company's Deferred Tax Asset) (Details)",
     "shortName": "Income Taxes (Schedule of Significant Components of the Company's Deferred Tax Asset) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails",
     "longName": "9960731 - Disclosure - Income Taxes (Schedule of Roll Forward of Valuation Allowance) (Details)",
     "shortName": "Income Taxes (Schedule of Roll Forward of Valuation Allowance) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "cmmb:CurrencyTransactionLossValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails",
     "longName": "9960732 - Disclosure - Income Taxes (Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense) (Details)",
     "shortName": "Income Taxes (Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails",
     "longName": "9960733 - Disclosure - Related Parties Balances and Transactions (Schedule of Related Party Payables) (Details)",
     "shortName": "Related Parties Balances and Transactions (Schedule of Related Party Payables) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_20241231",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "cmmb:ScheduleOfRelatedPartyPayablesTableTextBlock",
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails",
     "longName": "9960734 - Disclosure - Related Parties Balances and Transactions (Schedule of Transaction With Related Parties) (Details)",
     "shortName": "Related Parties Balances and Transactions (Schedule of Transaction With Related Parties) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails",
     "longName": "9960735 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Computation of Basic and Diluted Net Loss) (Details)",
     "shortName": "Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Computation of Basic and Diluted Net Loss) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "us-gaap:IncomeLossFromContinuingOperationsPerBasicShare",
      "unitRef": "USD_Per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare",
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails",
     "longName": "9960736 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Weighted Average Number of Shares) (Details)",
     "shortName": "Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Weighted Average Number of Shares) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "strong",
       "span",
       "span",
       "p",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "strong",
       "span",
       "span",
       "p",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2532902.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade payables",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r35"
     ]
    },
    "us-gaap_AccretionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccretionExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion Expense",
        "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r725"
     ]
    },
    "us-gaap_AccruedIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedIncomeTaxes",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Income Taxes",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due. This amount is the total of current and noncurrent accrued income taxes."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r40",
      "r74",
      "r376"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 10.0
      },
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails",
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recognized liability for royalties",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less - accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r104",
      "r385"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r545",
      "r812"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid In Capital [Member]",
        "verboseLabel": "Additional paid in capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r702",
      "r703",
      "r704",
      "r706",
      "r763",
      "r815"
     ]
    },
    "cmmb_AdditionalWorkOrderAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "AdditionalWorkOrderAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional work order amount.",
        "label": "Additional Work Order Amount",
        "verboseLabel": "Additional work order"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of warrants",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r25",
      "r68"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_AggregateAmountCommitmentToPay": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "AggregateAmountCommitmentToPay",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount commitment to pay.",
        "label": "Aggregate amount commitment to pay"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_AggregateAmountOfCommitmentPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "AggregateAmountOfCommitmentPaid",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount of commitment paid.",
        "label": "Aggregate amount of commitment paid"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "AggregateOfferingPriceOfAtMarketOfferingAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents as a aggregate offering price of at the market offering agreement.",
        "label": "Aggregate Offering Price Of At Market Offering Agreement",
        "terseLabel": "Aggregate offering price of at the market offering agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r591",
      "r602",
      "r612",
      "r645"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r594",
      "r605",
      "r615",
      "r648"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsDetails",
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "auth_ref": []
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r595",
      "r606",
      "r616",
      "r640",
      "r649",
      "r653",
      "r661"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation expenses",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r244"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_AmericanDepositarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "AmericanDepositarySharesMember",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "American Depositary Shares [Member]",
        "label": "American Depositary Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_AnnualRatesOfDepreciation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "AnnualRatesOfDepreciation",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual rates of depreciation.",
        "label": "Annual Rates Of Depreciation",
        "verboseLabel": "Annual rates of depreciation"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_AnnualRentAndManagementFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "AnnualRentAndManagementFees",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual rent and management fees.",
        "label": "Annual rent and management fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding options to purchase ordinary shares",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r83",
      "r105",
      "r123",
      "r156",
      "r160",
      "r169",
      "r170",
      "r175",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r290",
      "r294",
      "r309",
      "r375",
      "r452",
      "r528",
      "r529",
      "r545",
      "r566",
      "r726",
      "r727",
      "r772"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r110",
      "r123",
      "r175",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r290",
      "r294",
      "r309",
      "r545",
      "r726",
      "r727",
      "r772"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:",
        "terseLabel": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r175",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r290",
      "r294",
      "r309",
      "r726",
      "r727",
      "r772"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_AtmAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "AtmAgreementMember",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM agreement [Member]",
        "label": "ATM agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm Id",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r574",
      "r575",
      "r598"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r574",
      "r575",
      "r598"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r574",
      "r575",
      "r598"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "cmmb_BankGuaranteesToPropertyOwner": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "BankGuaranteesToPropertyOwner",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bank guarantees to property owner.",
        "label": "Bank guarantees to property owner"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of presentation",
        "terseLabel": "Basis of Presentation",
        "verboseLabel": "Basis of Preparation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r575",
      "r598"
     ]
    },
    "cmmb_CantorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "CantorMember",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about Cantor.",
        "label": "Cantor [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalAdditionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalAdditionsMember",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Drug Application and Biological License Application [Member]",
        "documentation": "Contractual obligation to increase property, plant and equipment either through construction or future purchases."
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_CapitalAdditionsOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "CapitalAdditionsOneMember",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FDA or equivalent agency marketing approval [Member]",
        "label": "Capital Additions One [Member]",
        "verboseLabel": "FDA or equivalent agency marketing approval [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsDetails",
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "verboseLabel": "Cash and Cash Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r102",
      "r520"
     ]
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r379"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash and cash equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Restricted cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r72"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash equivalents, and short-term deposits",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of the year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of the year",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r58",
      "r121"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Change in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r58"
     ]
    },
    "cmmb_CashPaidAndReceivedDuringYearForAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "CashPaidAndReceivedDuringYearForAbstract",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Cash Paid And Received During Year For [Abstract]",
        "terseLabel": "A. Cash paid and received during the year for:"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents as a change in temporary differences for which deferred taxes were not recognized.",
        "label": "Change In Temporary Differences For Deferred Taxes Not Recognized",
        "terseLabel": "Change in temporary differences for which deferred taxes were not recognized"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation",
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r106",
      "r107",
      "r108",
      "r123",
      "r145",
      "r146",
      "r148",
      "r150",
      "r158",
      "r159",
      "r175",
      "r188",
      "r190",
      "r191",
      "r192",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r309",
      "r405",
      "r406",
      "r407",
      "r408",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r440",
      "r461",
      "r483",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r685",
      "r700",
      "r707"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingent liabilities",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r76",
      "r378",
      "r439"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsDisclosureTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingent Liabilities",
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "verboseLabel": "Ordinary shares [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r556",
      "r557",
      "r558",
      "r560",
      "r561",
      "r562",
      "r563",
      "r702",
      "r703",
      "r706",
      "r763",
      "r811",
      "r815"
     ]
    },
    "us-gaap_CommonStockNoParValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockNoParValue",
     "presentation": [
      "http://www.anchiano.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, No Par Value",
        "documentation": "Face amount per share of no-par value common stock."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.anchiano.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r440"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.anchiano.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary Shares no par value - Authorized: 650,000,000 shares as of December 31, 2021 and 500,000,000 shares as of December 31, 2020; Issued and outstanding: 228,090,300 shares at December 31, 2021 and 9,274,838 shares at December 31, 2020",
        "terseLabel": "Ordinary Shares no par value - Authorized: 650,000,000 shares as of December 31, 2023, 2022 and 2021;Issued and outstanding: 284,094,700, 232,636,700 Ordinary shares at December 31, 2023 and 2022, respectively and 228,090,300 Ordinary shares at December 31, 2021",
        "verboseLabel": "Ordinary Shares no par value - Authorized: 4,650,000,000 and 650,000,000 Ordinary shares as of December 31, 2024, and December 31, 2023, respectively (*) Issued and outstanding: 377,132,220, and 284,094,700 Ordinary shares of December 31, 2024 and 2023, respectively (*)",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r380",
      "r545"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computers [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of credit risks",
        "terseLabel": "Concentrations of credit risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r89"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principles of consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r522"
     ]
    },
    "cmmb_ConsultantsAndSubcontractorsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "ConsultantsAndSubcontractorsExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consultants and subcontractors expenses.",
        "label": "Consultants And Subcontractors Expense",
        "verboseLabel": "Consultants and subcontractors"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Costs",
        "totalLabel": "Total related party expenses",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r123",
      "r175",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r309",
      "r528",
      "r726"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "CumulativeAmountsOfGrantsReceivedAndRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amounts of grants received from the IIA and recognized by the company, as of the balance sheet date.",
        "label": "Cumulative Amounts Of Grants Received And Recognized",
        "verboseLabel": "Cumulative amounts of grants received"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsDetails",
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "cmmb_CurrencyTransactionLossValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "CurrencyTransactionLossValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance due to currency transaction loss.",
        "label": "Currency Transaction Loss Valuation Allowance",
        "terseLabel": "Currency transaction income (loss)"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r583",
      "r672"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r583",
      "r672"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r585",
      "r674"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r585",
      "r674"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r587",
      "r676"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r585",
      "r674"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r578",
      "r667"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r579",
      "r668"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r579",
      "r668"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r577",
      "r666"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r577",
      "r666"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r577",
      "r666"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r580",
      "r669"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r582",
      "r671"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r582",
      "r671"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r583",
      "r672"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r586",
      "r675"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r584",
      "r673"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r581",
      "r670"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental borrowing rate based on credit rating",
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Capital Loss Carryforwards",
        "verboseLabel": "Deferred tax asset capital closs carryforward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development costs",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carry-forwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation expense",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails",
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less - Valuation allowance",
        "periodEndLabel": "Balance at December 31",
        "periodStartLabel": "Balance at January 1",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_DepositsAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositsAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term bank deposit",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r23"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r575",
      "r598"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r575",
      "r598",
      "r641"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r575",
      "r598",
      "r641"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "currency_EUR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "EUR",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted loss per Ordinary Share",
        "terseLabel": "Basic loss per Ordinary Share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r143",
      "r145",
      "r148",
      "r149",
      "r150",
      "r155",
      "r285",
      "r288",
      "r303",
      "r304",
      "r372",
      "r391",
      "r523"
     ]
    },
    "cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share Calculation Denominator For Basic Net Income Loss Per Share Abstract",
        "label": "Earnings Per Share Calculation Denominator For Basic Net Income Loss Per Share [Abstract]",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_EarningsPerShareCalculationNumeratorAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "EarningsPerShareCalculationNumeratorAbstract",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share Calculation Numerator Abstract",
        "label": "Earnings Per Share Calculation Numerator [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted loss per Ordinary Share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r145",
      "r148",
      "r149",
      "r150",
      "r155",
      "r285",
      "r288",
      "r303",
      "r304",
      "r372",
      "r391",
      "r523"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per ordinary share",
        "terseLabel": "Loss per ordinary share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r152"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholders"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share Attributable to Ordinary Shareholders",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r151",
      "r153",
      "r154"
     ]
    },
    "cmmb_EffectOfReverseCapitalizationTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "EffectOfReverseCapitalizationTransaction",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of effect due reverse capitalization transaction.",
        "label": "Effect of reverse capitalization transaction"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_EffectOfReverseCapitalizationTransactionShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "EffectOfReverseCapitalizationTransactionShares",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares isued due to effect of reverse capitalization transaction.",
        "label": "Effect Of Reverse Capitalization Transaction Shares",
        "verboseLabel": "Effect of reverse capitalization transaction (In shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statutory tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r536"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate tax rate (as a percent)",
        "terseLabel": "Corporate tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r253",
      "r276",
      "r536"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails",
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee and related expenses",
        "terseLabel": "Employees, consultants and related expenses",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well Known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r98",
      "r114",
      "r115",
      "r116",
      "r127",
      "r128",
      "r129",
      "r131",
      "r136",
      "r138",
      "r140",
      "r157",
      "r176",
      "r177",
      "r180",
      "r202",
      "r274",
      "r275",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r288",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r329",
      "r390",
      "r397",
      "r398",
      "r399",
      "r415",
      "r483"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r591",
      "r602",
      "r612",
      "r645"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r588",
      "r599",
      "r609",
      "r642"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "ExpectsToReceiveAmountOfChemomabTherapeuticsInc",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount expects to receive of Chemomab Therapeutics Inc.",
        "label": "Expects To Receive Amount Of Chemomab Therapeutics Inc",
        "terseLabel": "Expects to receive amount of Chemomab Therapeutics Inc"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of financial instruments",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Functional currency",
        "verboseLabel": "Foreign currency",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r595",
      "r606",
      "r616",
      "r649"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r595",
      "r606",
      "r616",
      "r649"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r595",
      "r606",
      "r616",
      "r649"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r595",
      "r606",
      "r616",
      "r649"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r595",
      "r606",
      "r616",
      "r649"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Equipment [Member]",
        "terseLabel": "Furniture and equipment [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_GeneralAndAdministrativeDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "GeneralAndAdministrativeDisclosureTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of general and administrative expenses.",
        "label": "General And Administrative Disclosure [Text Block]",
        "verboseLabel": "General and Administrative"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 10.0
      },
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails",
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "terseLabel": "General and administrative",
        "totalLabel": "Total",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r463"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_GeneralInsuranceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralInsuranceExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance",
        "terseLabel": "Directors' and Officers' Insurance",
        "documentation": "The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales)."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Government Sponsored Research And Development [Policy Text Block]",
        "verboseLabel": "Government-sponsored research and development"
       }
      }
     },
     "auth_ref": []
    },
    "country_IL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "IL",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Israel [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "currency_ILS": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "ILS",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsDetails",
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Israel, New Shekels",
        "terseLabel": "NIS [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r574",
      "r575",
      "r598"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of long-lived assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r65"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails",
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss before income tax",
        "negatedTotalLabel": "Loss before taxes",
        "positiveTerseLabel": "Loss before income taxes",
        "positiveVerboseLabel": "Loss before taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r79",
      "r82",
      "r373",
      "r387",
      "r525",
      "r528",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share attributable to ordinary shareholders, basic and diluted",
        "terseLabel": "Net loss per share attributable to ordinary shareholders, basic",
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r80",
      "r117",
      "r130",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r145",
      "r148",
      "r149",
      "r285",
      "r288",
      "r304",
      "r372",
      "r781"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Net loss per share attributable to ordinary shareholders, diluted",
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r117",
      "r130",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r145",
      "r148",
      "r149",
      "r150",
      "r288",
      "r304",
      "r372",
      "r781"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r182",
      "r183",
      "r306",
      "r307",
      "r308",
      "r394",
      "r396",
      "r468",
      "r518",
      "r539",
      "r783"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r183",
      "r306",
      "r307",
      "r308",
      "r394",
      "r396",
      "r468",
      "r518",
      "r539",
      "r783"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r253",
      "r254",
      "r262",
      "r271",
      "r536",
      "r761"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r253",
      "r254",
      "r262",
      "r271",
      "r536",
      "r761"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_IncomeTaxDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "IncomeTaxDisclosureLineItems",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_IncomeTaxDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "IncomeTaxDisclosureTable",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information pertaining to income taxes.",
        "label": "Income Tax Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r249",
      "r253",
      "r259",
      "r260",
      "r261",
      "r263",
      "r269",
      "r277",
      "r279",
      "r280",
      "r281",
      "r410",
      "r536"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails",
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails",
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "positiveTerseLabel": "Tax benefit",
        "positiveVerboseLabel": "Actual income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "verboseLabel": "Income tax benefit",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r95",
      "r139",
      "r140",
      "r156",
      "r161",
      "r170",
      "r252",
      "r253",
      "r278",
      "r392",
      "r536"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Theoretical tax benefit on the above amount Decrease (increase) in tax refund resulting from:"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_IncomeTaxExpenseValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "IncomeTaxExpenseValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance due to income tax expense.",
        "label": "Income Tax Expense Valuation Allowance",
        "verboseLabel": "Income tax expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r250",
      "r251",
      "r263",
      "r264",
      "r268",
      "r273",
      "r404"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Tax rate differential",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r256",
      "r536",
      "r758"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Theoretical tax benefit",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r536"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "terseLabel": "Non-deductible expenses",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r758"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income taxes paid",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes paid",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r120",
      "r270",
      "r271"
     ]
    },
    "cmmb_IncomeTaxesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "IncomeTaxesReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents income taxes received.",
        "label": "Income Taxes Received",
        "verboseLabel": "Income taxes received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in trade payables",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 60.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in employees and related expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 70.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in leases",
        "terseLabel": "Change in operating leases",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r688",
      "r698"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in other receivables and prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "cmmb_IncrementalBorrowingRateOfLeases": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "IncrementalBorrowingRateOfLeases",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents incremental borrowing rate of leases.",
        "label": "Incremental Borrowing Rate Of Leases",
        "verboseLabel": "incremental borrowing rate of leases"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r595",
      "r606",
      "r616",
      "r640",
      "r649",
      "r653",
      "r661"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r576",
      "r665"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r576",
      "r665"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r576",
      "r665"
     ]
    },
    "cmmb_InterestReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "InterestReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of interest received.",
        "label": "Interest Received",
        "terseLabel": "Interest received"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_InvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "InvestorsMember",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investors [Member]",
        "label": "Investors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment [Member]",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseAgreementsMember",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2020 Lien [Member]",
        "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723"
     ]
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease expiry date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r327"
     ]
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r328"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r328"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "verboseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases",
        "terseLabel": "Schedule of maturity of lease liabilities under our non-cancelable operating leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "verboseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "verboseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2022",
        "terseLabel": "2023",
        "verboseLabel": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less imputed interest:",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Lease term, option to extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease term",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r123",
      "r175",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r291",
      "r294",
      "r295",
      "r309",
      "r438",
      "r524",
      "r566",
      "r726",
      "r772",
      "r773"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r77",
      "r382",
      "r545",
      "r701",
      "r715",
      "r765"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAssumed1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAssumed1",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities assumed, net of non-cash assets received in Merger",
        "verboseLabel": "Liabilities assumed, net of non-cash assets received in Merger",
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r17"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r101",
      "r123",
      "r175",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r291",
      "r294",
      "r295",
      "r309",
      "r545",
      "r726",
      "r772",
      "r773"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r39",
      "r40",
      "r41",
      "r42",
      "r123",
      "r175",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r291",
      "r294",
      "r295",
      "r309",
      "r726",
      "r772",
      "r773"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_LienOnBankDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "LienOnBankDeposit",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lien on bank deposit.",
        "label": "Lien on bank deposit"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermPurchaseCommitmentAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for licensed agreement",
        "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Category of Item Purchased [Axis]",
        "documentation": "Information by category of items purchased under a long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermPurchaseCommitmentDescription",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of application payment for licensed product",
        "documentation": "Describes the terms of a significant arrangement with a supplier (excluding an unconditional purchase obligation) to acquire goods or services over a period of time beyond one year or the normal operating cycle, if longer, which may include identification of the goods or services to be purchased, pricing, effects on pricing of failing to reach minimum quantities required to be purchased, cancellation rights, and termination provisions."
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents losses and benefits for tax purposes for the year, for which deferred taxes were not recorded.",
        "label": "Losses And Benefits For Tax Purposes For The Year For Which Deferred Taxes Were Not Recorded",
        "terseLabel": "Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_MarketOfferingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "MarketOfferingAgreementMember",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Market Offering Agreement [Member]",
        "documentation": "This member stands for market offering agreement.",
        "terseLabel": "Market offering agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r187",
      "r205",
      "r245",
      "r305",
      "r340",
      "r393",
      "r395",
      "r402",
      "r430",
      "r431",
      "r489",
      "r491",
      "r493",
      "r494",
      "r496",
      "r515",
      "r516",
      "r531",
      "r533",
      "r535",
      "r540",
      "r541",
      "r542",
      "r543",
      "r554",
      "r728",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779"
     ]
    },
    "cmmb_MaximumPercentageOfPaymentsOfRoyalties": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "MaximumPercentageOfPaymentsOfRoyalties",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum percentage of royalties payable on the amount of the grant received (dollar linked), plus interest at annual rate based on LIBOR.",
        "label": "Maximum Percentage Of Payments Of Royalties",
        "verboseLabel": "Maximum percentage of payments of royalties (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r187",
      "r205",
      "r245",
      "r305",
      "r340",
      "r393",
      "r395",
      "r402",
      "r430",
      "r431",
      "r489",
      "r491",
      "r493",
      "r494",
      "r496",
      "r515",
      "r516",
      "r531",
      "r533",
      "r535",
      "r540",
      "r541",
      "r542",
      "r554",
      "r728",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.anchiano.com/role/General"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r96"
     ]
    },
    "cmmb_NatureOfOperationsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "NatureOfOperationsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Nature Of Operations Disclosure [Abstract]",
        "verboseLabel": "NATURE OF OPERATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails",
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "terseLabel": "Cash flows from operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r60"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails",
      "http://www.anchiano.com/role/StatementsOfChangesInEquity",
      "http://www.anchiano.com/role/StatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "negatedLabel": "Net loss",
        "negatedTotalLabel": "Net loss for the year",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r60",
      "r81",
      "r99",
      "r111",
      "r112",
      "r116",
      "r123",
      "r130",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r139",
      "r140",
      "r147",
      "r175",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r285",
      "r288",
      "r304",
      "r309",
      "r389",
      "r460",
      "r481",
      "r482",
      "r564",
      "r726"
     ]
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r595",
      "r606",
      "r616",
      "r640",
      "r649"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant non- cash transaction:",
        "terseLabel": "B. Significant non- cash transaction:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoninterestExpenseDirectorsFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoninterestExpenseDirectorsFees",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees to Directors",
        "documentation": "Noninterest expense related to directors' fees which are fees paid by an Entity to its directors. Directors' fees may be paid in addition to salary and other benefits."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Financing income, net",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Financing expenses (income), net",
        "totalLabel": "Nonoperating Income (Expense), Total",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Schedule of Unvested RSA",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "cmmb_NumberOfAdssOptionsIssuableOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "NumberOfAdssOptionsIssuableOutstanding",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of ADSs options issuable outstanding.",
        "label": "Number of ADSs options issuable outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_NumberOfAdssVestedAndExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "NumberOfAdssVestedAndExercisable",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of ADSs vested and exercisable.",
        "label": "Number of ADSs vested and exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_NumberOfOptionsIssuableOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "NumberOfOptionsIssuableOutstanding",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents number of options issuable outstanding.",
        "label": "Number Of Options Issuable Outstanding",
        "verboseLabel": "Number of options issuable outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_NumberOfOptionsVestedAndExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "NumberOfOptionsVestedAndExercisable",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents number of options vested and exercisable.",
        "label": "Number Of Options Vested And Exercisable",
        "verboseLabel": "Number of options vested and exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_NumberOfStockAdssResveredForIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "NumberOfStockAdssResveredForIssuance",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock option ADSs resvered for issuance.",
        "label": "Number Of Stock Adss Resvered For Issuance",
        "verboseLabel": "Number of stock option ADSs reversed for issuance"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_NumberOfStockReservedForIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "NumberOfStockReservedForIssuance",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents number of stock resvered for issuance.",
        "label": "Number Of Stock Reserved For Issuance",
        "verboseLabel": "Number of stock reserved for issuance"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_NumberOfVestedAndExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "NumberOfVestedAndExercisable",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents number of vested and exercisable.",
        "label": "Number Of Vested And Exercisable",
        "verboseLabel": "Number of vested and exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_NumberOfWarrantsPurchaseUpAdss": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "NumberOfWarrantsPurchaseUpAdss",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants purchase ADS's.",
        "label": "Number Of Warrants Purchase Up Adss",
        "verboseLabel": "Number of warrants purchase ADS's"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficersCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salaries and related expenses",
        "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating Income (Loss), Total",
        "terseLabel": "Net Income (Loss)",
        "negatedLabel": "Net loss",
        "negatedTotalLabel": "Net loss for the year",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r525",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713"
     ]
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease in the carrying amount of the right-of-use asset due to impairment",
        "terseLabel": "Increase in the carrying amount of the right-of-use asset due to impairment",
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails",
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities",
        "totalLabel": "Present value of operating lease liabilities",
        "verboseLabel": "Present value of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current operating lease liabilities",
        "verboseLabel": "Non-current\u00a0operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails",
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "OperatingRightOfUseAssetsAndOperatingLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating right-of-use assets and operating lease liabilities.",
        "label": "Operating Right Of Use Assets And Operating Lease Liabilities",
        "verboseLabel": "Operating right-of-use assets and operating lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_OrdinarySharesNoParValuePerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "OrdinarySharesNoParValuePerShareMember",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ordinary Shares, No Par Value Per Share [Member]",
        "label": "Ordinary Shares, No Par Value Per Share [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "OtherAccountsReceivableAndPrepaidExpensesTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other accounts receivable and prepaid expenses.",
        "label": "Other Accounts Receivable And Prepaid Expenses [Text Block]",
        "verboseLabel": "Other Receivables and Prepaid Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsDescription",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decsription of occurrence for payments",
        "documentation": "Description of the nature and terms of commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 60.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other General and Administrative Expense",
        "verboseLabel": "Other expenses",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r814"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due to Related Parties, Current",
        "totalLabel": "Related Party Payables",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r545"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other expenses",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r593",
      "r604",
      "r614",
      "r647"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r596",
      "r607",
      "r617",
      "r650"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r596",
      "r607",
      "r617",
      "r650"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment on commencement of agreement.",
        "label": "Payment On Long Term Purchase Commitment Commencement Of Agreement",
        "verboseLabel": "Payment on commencement of agreement"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_PaymentsForInvestmentInDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "PaymentsForInvestmentInDeposits",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of payments for investm,ents in deposits.",
        "negatedLabel": "Investment in deposits",
        "label": "Payments for Investment in Deposits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of treasury share",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "cmmb_PercentageOfMonthlyDepositsRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "PercentageOfMonthlyDepositsRate",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of monthly deposits rate.",
        "label": "Percentage of monthly deposits rate"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "PercentageOfRoyaltyPaymentsOnSaleOfProduct",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of royalty payments on sale of product developed with funding received from the IIA.",
        "label": "Percentage Of Royalty Payments On Sale Of Product",
        "verboseLabel": "Royalty payments on sale of product (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_PercentageOfShortTermDeposits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "PercentageOfShortTermDeposits",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Short Term Deposits",
        "documentation": "percentage of short term deposits.",
        "verboseLabel": "Percentage of short term deposits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred shares par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r197"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r197"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 10.0
      },
      "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails",
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other receivables and prepaid expenses",
        "totalLabel": "Other accounts receivable and prepaid expenses, Total",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r178",
      "r179",
      "r521"
     ]
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term prepaid expenses",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from preferred shares",
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromOtherEquity",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Other Equity",
        "verboseLabel": "Issuance of shares net of issuance costs",
        "documentation": "Amount of cash inflow from the issuance of equity classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "cmmb_ProceedsFromSaleOfAdss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "ProceedsFromSaleOfAdss",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from sale of ADS's.",
        "label": "Proceeds from sale of ADS's"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfTreasuryStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfTreasuryStock",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails",
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Treasury Stock",
        "verboseLabel": "Treasury stock at cost",
        "terseLabel": "Sale of treasury share",
        "documentation": "The cash inflow from the issuance of an equity stock that has been previously reacquired by the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r7"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional services",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r528",
      "r564",
      "r813",
      "r814"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Loss before taxes",
        "verboseLabel": "Net loss for the year",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r111",
      "r112",
      "r118",
      "r123",
      "r130",
      "r136",
      "r139",
      "r140",
      "r175",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r285",
      "r288",
      "r289",
      "r292",
      "r293",
      "r304",
      "r309",
      "r373",
      "r388",
      "r414",
      "r460",
      "r481",
      "r482",
      "r537",
      "r538",
      "r565",
      "r695",
      "r726"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Type [Axis]",
        "verboseLabel": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r327"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r90",
      "r93",
      "r94"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r103",
      "r386"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 30.0
      },
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Property Plant And Equipment Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r327",
      "r374",
      "r386",
      "r545"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r90",
      "r93",
      "r384"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentSalvageValuePercentage",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual rates of depreciation",
        "documentation": "Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property And Equpment, Net",
        "terseLabel": "Schedule of property and equipment, Net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r327"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r187",
      "r203",
      "r205",
      "r235",
      "r236",
      "r237",
      "r245",
      "r305",
      "r338",
      "r339",
      "r340",
      "r393",
      "r395",
      "r402",
      "r430",
      "r431",
      "r489",
      "r491",
      "r493",
      "r494",
      "r496",
      "r515",
      "r516",
      "r531",
      "r533",
      "r535",
      "r540",
      "r541",
      "r542",
      "r543",
      "r554",
      "r558",
      "r724",
      "r728",
      "r764",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r187",
      "r203",
      "r205",
      "r235",
      "r236",
      "r237",
      "r245",
      "r305",
      "r338",
      "r339",
      "r340",
      "r393",
      "r395",
      "r402",
      "r430",
      "r431",
      "r489",
      "r491",
      "r493",
      "r494",
      "r496",
      "r515",
      "r516",
      "r531",
      "r533",
      "r535",
      "r540",
      "r541",
      "r542",
      "r543",
      "r554",
      "r558",
      "r724",
      "r728",
      "r764",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779"
     ]
    },
    "cmmb_ReassessmentOfRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "ReassessmentOfRightOfUseAsset",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reassessment Of Right Of Use Asset",
        "documentation": "Represent the amount of reassessment of the right of use asset",
        "verboseLabel": "Reassessment of the right of use asset"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_ReceivablesFromGovernmentInstitutions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "ReceivablesFromGovernmentInstitutions",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government institutions.",
        "label": "Receivables From Government Institutions",
        "verboseLabel": "Government institutions"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_ReceivedAmountOfChemomabTherapeuticsInc": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "ReceivedAmountOfChemomabTherapeuticsInc",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The received amount of Chemomab Therapeutics Inc.",
        "label": "Received Amount Of Chemomab Therapeutics Inc",
        "terseLabel": "Received amount of Chemomab Therapeutics Inc"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_RecoverabilityOfVatAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "RecoverabilityOfVatAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents recoverability of VAT amount.",
        "label": "Recoverability Of Vat Amount",
        "verboseLabel": "Recoverability of VAT amount"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r588",
      "r599",
      "r609",
      "r642"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails",
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r204",
      "r333",
      "r334",
      "r377",
      "r383",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r457",
      "r459",
      "r488"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r333",
      "r334",
      "r335",
      "r336",
      "r377",
      "r383",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r457",
      "r459",
      "r488"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r464",
      "r465",
      "r468"
     ]
    },
    "cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails": {
       "parentTag": "us-gaap_CostOfRevenue",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party expenses related to professional services.",
        "label": "Related Party Transaction Professional Services From Transactions With Related Party",
        "verboseLabel": "Professional services"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails": {
       "parentTag": "us-gaap_CostOfRevenue",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party expenses related to research and develeopment expense.",
        "label": "Related Party Transaction Research And Development Expense From Transactions With Related Party",
        "verboseLabel": "Research and development"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails": {
       "parentTag": "us-gaap_CostOfRevenue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party expenses related to salaries and related expenses.",
        "label": "Related Party Transaction Salaries And Related Expenses From Transactions With Related Party",
        "verboseLabel": "Salaries and related expenses"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails": {
       "parentTag": "us-gaap_CostOfRevenue",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party expenses related to share based payments.",
        "label": "Related Party Transaction Share Based Payments From Transactions With Related Party",
        "verboseLabel": "Share-based payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails",
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r204",
      "r333",
      "r334",
      "r377",
      "r383",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r457",
      "r459",
      "r488",
      "r771"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties Balances and Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r334",
      "r337",
      "r411",
      "r412",
      "r413",
      "r466",
      "r467",
      "r468",
      "r486",
      "r487"
     ]
    },
    "cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "RentAndMaintenanceGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General and administrative related rent and maintenance expenses.",
        "label": "Rent And Maintenance General And Administrative Expense",
        "verboseLabel": "Rent and maintenance",
        "terseLabel": "Lease and maintenance"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_RentAndMaintenanceResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "RentAndMaintenanceResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development related rent and maintenance expenses.",
        "label": "Rent And Maintenance Research And Development Expense",
        "terseLabel": "Lease and maintenance"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_RepurchaseArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "RepurchaseArrangementMember",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Repurchase Arrangement.",
        "label": "Repurchase Arrangement [Member]",
        "verboseLabel": "Repurchase arrangement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_RepurchaseOfAmericanDepositaryReceipts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "RepurchaseOfAmericanDepositaryReceipts",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of repurchase of american depositary receipts.",
        "label": "Repurchase Of American Depositary Receipts",
        "verboseLabel": "Repurchase of ADSs"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_RepurchaseOfAmericanDepositaryReceiptsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "RepurchaseOfAmericanDepositaryReceiptsShares",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents repurchase of American Depositary Receipts shares",
        "label": "Repurchase Of American Depositary Receipts Shares",
        "verboseLabel": "Number of shares repurchase of ADSs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails",
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "totalLabel": "Total",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r518",
      "r528",
      "r780"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "verboseLabel": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/ResearchAndDevelopment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development",
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r517"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r589",
      "r600",
      "r610",
      "r643"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r590",
      "r601",
      "r611",
      "r644"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r597",
      "r608",
      "r618",
      "r651"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Current",
        "verboseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r689",
      "r699"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r690",
      "r699"
     ]
    },
    "us-gaap_RestrictedInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank restricted deposit",
        "documentation": "Investments which are not defined as or included in marketable (debt, equity, or other) securities whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r505"
     ]
    },
    "cmmb_RestrictedOrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "RestrictedOrdinarySharesMember",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Ordinary Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r68",
      "r381",
      "r400",
      "r401",
      "r409",
      "r441",
      "r545"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "verboseLabel": "Accumulated deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r127",
      "r128",
      "r129",
      "r131",
      "r136",
      "r138",
      "r140",
      "r176",
      "r177",
      "r180",
      "r274",
      "r275",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r288",
      "r296",
      "r298",
      "r299",
      "r301",
      "r302",
      "r317",
      "r319",
      "r397",
      "r399",
      "r415",
      "r815"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use asset recognized with corresponding lease liability",
        "verboseLabel": "Right-of-use asset recognized with corresponding lease liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r544"
     ]
    },
    "cmmb_RothCapitalPartnersLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "RothCapitalPartnersLlcMember",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Roth Capital Partners Llc [Member]",
        "documentation": "This member stands for Roth Capital Partners, LLC",
        "terseLabel": "Roth Capital Partners, LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royality expenses",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "us-gaap_SalariesAndWages": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalariesAndWages",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold",
        "verboseLabel": "Salaries and related expenses",
        "terseLabel": "Salaries, fees and related expenses",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "cmmb_SaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "SaleOfStockLineItems",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Sale Of Stock [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_SaleOfStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "SaleOfStockTable",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Sale Of Stock [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_SaleOfStocksPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "SaleOfStocksPricePerShare",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by the company for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale Of Stocks Price Per Share",
        "verboseLabel": "Share price per share"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r206",
      "r705"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r141",
      "r206",
      "r686",
      "r705"
     ]
    },
    "cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "ScheduleOfAnnualRateOfDeprecationTableTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the annual rate of deprecation.",
        "label": "Schedule Of Annual Rate Of Deprecation [Table Text Block]",
        "terseLabel": "Schedule of annual rate of deprecation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Weighted Average Number of Shares Excluded From Computation of Diluted Net Loss Per Share",
        "terseLabel": "Schedule of weighted average number of shares excluded from computation of diluted net loss per share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of components of cash and cash equivalents",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of the effect of share-based compensation on the statements of operations",
        "terseLabel": "Schedule of the effect of share-based compensation on the statements of operations",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Significant Components of the Company's Deferred Tax Asset",
        "terseLabel": "Schedule of significant components of the company's deferred tax asset",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Computation of Basic and Diluted Net Loss Per Share",
        "terseLabel": "Schedule of computation of basic and diluted net loss per share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense",
        "terseLabel": "Schedule of reconciliation of theoretical income tax expense to actual income tax expense",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r536",
      "r758"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "ScheduleOfGeneralAndAdministrativeTableTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of general and administrative expenses.",
        "label": "Schedule Of General And Administrative [Table Text Block]",
        "terseLabel": "Schedule of general and administrative"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of other accounts receivable and prepaid expenses.",
        "label": "Schedule Of Other Accounts Receivable And Prepaid Expenses [Table Text Block]",
        "verboseLabel": "Schedule of other accounts receivable and prepaid expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r327"
     ]
    },
    "cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "ScheduleOfRelatedPartyPayablesTableTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party payables.",
        "label": "Schedule Of Related Party Payables [Table Text Block]",
        "terseLabel": "Schedule of related party payables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r464",
      "r465",
      "r468"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Transaction With Related Parties",
        "terseLabel": "Schedule of transaction with related parties",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "ScheduleOfResearchAndDevelopmentTableTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/ResearchAndDevelopmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of research and development expenses.",
        "label": "Schedule Of Research And Development [Table Text Block]",
        "terseLabel": "Schedule of research and development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of assumptions used to calculate the fair value of the options",
        "terseLabel": "Schedule of assumptions used to calculate the fair value of the options",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of number and weighted average exercise prices of option",
        "terseLabel": "Schedule of number and weighted average exercise prices of option",
        "documentation": "Tabular disclosure of the change in stock options."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r568"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Exchange on which Security is Registered",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "auth_ref": [
      "r172",
      "r173",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r427",
      "r428",
      "r429",
      "r490",
      "r492",
      "r495",
      "r497",
      "r503",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r519",
      "r534",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r555",
      "r558",
      "r730",
      "r782",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r171",
      "r172",
      "r526",
      "r527",
      "r530"
     ]
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Preferred Stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r691",
      "r692",
      "r729"
     ]
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "cmmb_SeverancePayPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "SeverancePayPolicyTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for severance pay.",
        "label": "Severance Pay [Policy Text Block]",
        "verboseLabel": "Severance pay"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents Share Based Compensation Arrangement By Share Based Payment Award ADS Forfeitures In Period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Ads Forfeitures In Period",
        "verboseLabel": "Options to purchase ordinary shares cancelled"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents Share Based Compensation Arrangement By Share Based Payment Award ADS Outstanding Period Increase Decrease Weighted Average Exercise Price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Ads Outstanding Period Increase Decrease Weighted Average Exercise Price",
        "verboseLabel": "Weighted average exercise price of ADSs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalScheduleOfUnvestedRSADetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "terseLabel": "Forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalScheduleOfUnvestedRSADetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalScheduleOfUnvestedRSADetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodStartLabel": "Unvested at beginning of the year",
        "periodEndLabel": "Outstanding at December 31, 2024",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalScheduleOfUnvestedRSADetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price (in U.S. dollar)",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility, maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility, minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life in Years"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails",
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited",
        "label": "Options to purchase ADS cancelled",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards granted during the period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants In Period, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Outstanding at the end",
        "periodStartLabel": "Outstanding at the beginning",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price",
        "documentation": "Change in the weighted average exercise price of options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Outstanding at the end",
        "periodStartLabel": "Outstanding at the beginning",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238"
     ]
    },
    "cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangements By Share Based Payment Award, Options, Acquired In Merger, Weighted Average Exercise Price",
        "documentation": "Weighted average price of shares acquired in merger.",
        "terseLabel": "Acquired in Merger"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "ShareBasedCompensationGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General and administrative related share-based compensation.",
        "label": "Share Based Compensation General And Administrative Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Share-based compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r213",
      "r232",
      "r233",
      "r234",
      "r235",
      "r238",
      "r240",
      "r241",
      "r242",
      "r243"
     ]
    },
    "cmmb_ShareBasedCompensationResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "ShareBasedCompensationResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development related share-based compensation.",
        "label": "Share Based Compensation Research And Development Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average share price (in U.S. dollar)",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life of options (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapital"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Capital",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r69"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.anchiano.com/role/BalanceSheetsParenthetical",
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_ShortTermBankDepositsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "ShortTermBankDepositsPolicyTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short Term Bank Deposits [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for Short-term Bank Deposits",
        "verboseLabel": "Short-term bank deposits"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_SignificanAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "SignificanAccountingPoliciesLineItems",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significan Accounting Policies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_SignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "SignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Table]",
        "documentation": "Disclosure of iinformation about significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r122"
     ]
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SoftwareDevelopmentMember",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Website Development [Member]",
        "terseLabel": "Website development [Member]",
        "documentation": "Internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation",
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r106",
      "r107",
      "r108",
      "r123",
      "r145",
      "r146",
      "r148",
      "r150",
      "r158",
      "r159",
      "r175",
      "r188",
      "r190",
      "r191",
      "r192",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r309",
      "r405",
      "r406",
      "r407",
      "r408",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r440",
      "r461",
      "r483",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r685",
      "r700",
      "r707"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r44",
      "r47",
      "r48",
      "r98",
      "r114",
      "r115",
      "r116",
      "r127",
      "r128",
      "r129",
      "r131",
      "r136",
      "r138",
      "r140",
      "r157",
      "r176",
      "r177",
      "r180",
      "r202",
      "r274",
      "r275",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r288",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r329",
      "r390",
      "r397",
      "r398",
      "r399",
      "r415",
      "r483"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r427",
      "r428",
      "r429",
      "r490",
      "r492",
      "r495",
      "r497",
      "r503",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r519",
      "r534",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r555",
      "r558",
      "r730",
      "r782",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsDetails",
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails",
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r157",
      "r319",
      "r341",
      "r403",
      "r426",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r440",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r459",
      "r462",
      "r463",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r483",
      "r559"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r141",
      "r206",
      "r686",
      "r687",
      "r705"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsDetails",
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails",
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r157",
      "r174",
      "r319",
      "r341",
      "r403",
      "r426",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r440",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r459",
      "r462",
      "r463",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r483",
      "r559"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r592",
      "r603",
      "r613",
      "r646"
     ]
    },
    "cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "StockAndWarrantsIssuedDuringPeriodNewIssues",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "it represents number of shares and warrants issued during period",
        "label": "Stock And Warrants Issued During Period New Issues",
        "verboseLabel": "Issuance of shares and warrants, net of issuance costs (In shares)",
        "terseLabel": "Issuance of shares and pre-funded warrants, net of issuance costs (in Shares)"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "StockAndWarrantsIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock And Warrants Issued During Period Value New Issues",
        "verboseLabel": "Issuance of shares and warrants, net of issuance costs",
        "terseLabel": "Issuance of shares and pre-funded warrants, net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "StockIssuedDuringPeriodAmericanDepositorySharesNewIssues",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stocks of American Depository Shares (\"ADS\") issued during the period.",
        "label": "Stock Issued During Period American Depository Shares New Issues",
        "verboseLabel": "Number of ADSs issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails",
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Number of shares issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r43",
      "r44",
      "r68",
      "r405",
      "r483",
      "r499"
     ]
    },
    "cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options acquired, including both vested and non-vested options.",
        "label": "Stock Issued During Period Shares Stock Options Acquired In Merger",
        "verboseLabel": "Acquired in Merger"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of Options, shares",
        "terseLabel": "Exercise of options (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r43",
      "r44",
      "r68",
      "r219"
     ]
    },
    "cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised1",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "negatedLabel": "Exercise",
        "label": "Stock Issued During Period Shares Stock Options Exercised 1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Treasury Stock Reissued",
        "terseLabel": "Sale of treasury share at cost (in shares)",
        "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r44",
      "r68"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of shares",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r43",
      "r44",
      "r68",
      "r415",
      "r483",
      "r499",
      "r565"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r43",
      "r44",
      "r68"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of Options",
        "terseLabel": "Exercise of options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r44",
      "r47",
      "r48",
      "r68"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "terseLabel": "Sale of treasury share at cost",
        "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r26",
      "r43",
      "r44",
      "r68"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets",
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total shareholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r47",
      "r48",
      "r62",
      "r442",
      "r458",
      "r484",
      "r485",
      "r545",
      "r566",
      "r701",
      "r715",
      "r765",
      "r815"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Shareholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Roll Forward of Valuation Allowance",
        "terseLabel": "Schedule of roll forward of valuation allowance",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowElementsAbstract",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplementary cash flows information:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "TaxAssetsAcquiredThroughMergerValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance due to tax assets acquired through merger.",
        "label": "Tax Assets Acquired Through Merger Valuation Allowance",
        "verboseLabel": "Tax assets acquired through merger"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital losses carryforwards",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r770"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "auth_ref": []
    },
    "cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents Total consideration of repurchase of american depositary receipts.",
        "label": "Total Consideration Of Repurchase Of American Depositary Receipts",
        "verboseLabel": "Total consideration of repurchase of ADSs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock [Member]",
        "verboseLabel": "Treasury share [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.anchiano.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_TreasuryStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockValue",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r44",
      "r47"
     ]
    },
    "cmmb_TwoThousandsFifteenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "TwoThousandsFifteenPlanMember",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2015 plan [Member]",
        "label": "Two Thousands Fifteen Plan [Member]",
        "verboseLabel": "2015 plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_TwoThousandsSeventeenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "TwoThousandsSeventeenPlanMember",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 plan.",
        "label": "Two Thousands Seventeen Plan [Member]",
        "terseLabel": "2017 plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "currency_USD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "USD",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "USD [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r87",
      "r88",
      "r91",
      "r92"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Net change in the total valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails",
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of Ordinary Shares outstanding, diluted",
        "verboseLabel": "Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r150"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails",
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of Ordinary Shares outstanding, basic",
        "verboseLabel": "Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r150"
     ]
    },
    "cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.anchiano.com/20241231",
     "localname": "WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents weighted average price of repurchase of american depositary receipts.",
        "label": "Weighted Average Price Of Repurchase Of American Depositary Receipts",
        "verboseLabel": "Weighted average price of repurchase of ADSs"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "currency_XXX": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "XXX",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other currencies [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-4"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478600/954-210-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481639/420-10-35-4"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479365/842-20-25-6"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>101
<FILENAME>0001178913-25-001205-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178913-25-001205-xbrl.zip
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M[6C-J/RCBDHN%7U?D>OL!#M2\@B< ASV$S 9P7_8?S^2 'N0#*B&,C,PKZO
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MM&EO<T)O!*DELZ?BHM]N@T)?<U83?6/C]\[XE?LS>X96P+3$@G4"<$3S()E
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MP7S0JI)6[].RN8?Q/FV9)U\"DJN%_W^\#O_@TN@]73KB4,\W>.K)NQ/NAYL
M#P,5]];BL$X\'74BS^?[+YCZXCD,) F*-QQ6)WRVVCIYQ5)$?J!928IVZ"@(
M$=OB8) ZE<IGYW<<PBB H:M19>2&9Q*X2%>3*EXU/)L"LNAJ$[#0X'M8\_94
M.28&?I0.D7F;'V(I3K%Y=S+U/.$I)/@:LV_045$V#7%_?M;=HI'_-=!DS2-.
M\GT3QA%T4&Q[G= 0'^L3ARPP_>PF[TZ6)!"G"0M"T-N/O;E@]=+LE(03AZ=
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M4))-2.]P[BWB!"<:]9E>$.3V4E8,1@YKDI%YX'9<>0>D:1?.-;0I8O_%B-_
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M>&UL[5U)<^,XEK[WK\CQG)TN;]U=%97=(<MVA:.=EL-25M;,A0&3D,1)BM0
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M6V<M"9[&((:T=3R9CY<@7$#\$-[];T*ZD:63UT1K\I+5"J#-9#[U%Z$_]UU
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M,[><Z1(& 54"@W C1>AA!>>B6[Z2,;-[/\B57UR>MRWF7'3+1;+^BO,NC)_
MBK5/ZHHZ%]WRE.*&[T:(3-+V/!Y3NR#:C"./3RVWIG/1+0?*2)B!CP>/++G4
MIDG)D)A_1AWGHEL.M"/OYW^HPN)<YGY0+>]<=,N#6!U?*!)ZX5QTRX=V.AZ3
MCQ,TB]Y9(CFCM'/1+2_:[3;;'U(49D6=BVYYT4Z?SQ&.0?#?_EJX]>LJ.)?=
M\B,Z9R,$ 8>X:A'GLEN>DU\[B6"#HS"$ >=PKROJ7';+>ZCG5?"\C$(^2]PO
MYER:X3FE)O2>?(#H$2Y ,$$9_X,(>D)6*=>$<]DM%YI"-T&$FO.+UYD?,S7
M^\6<RVYY#1$5J9_@=+-ZC0(&33MEG,MN>4HQ '<?;NHGQIG>NJ+.I0E.\IV(
MK?\*"4^80D V*O0>,$X$P@2CCG-I@JO\'@6$20"4BK2(KVC<*^M<FN K^34Z
MNP30Q4:$1.9MEE?%N>J6MQ1G"CDXJ//!&R375)"3(CB&ZJHX5Z;N.VA,Q.Y%
M)) I=DHZ5R9N/=,5"()"1<LE;J>D<V6"_]P1?K$@B^LW%+W'R_RJRB6RMH9S
M94;+MG75)+LA] #R&+2R*SA7)FXW=Q];)46F\>$/ZD%QYZI;/O3@SM$H\7S2
MSBB.(9%>4P&"K>1E5W"N3/"DJBZ%OXLJ!9TK$]SG.7D-?/<^B #_B*R4<ZZ,
M<)UHM:(*B<C]D1DS)TE,HQBHN,/G/9R*SG6W'"A?9!S!J%+"N>Z6O^1=/>;1
M&WR"BE+.=<<VF:R[>Q^M'ECGRDX9Y[I;7O*=B*DQ#.FJ2<)<E\1B=;5EG>N.
M;R>I8S]E U\)[T<^8-T%#@LZU]WRBV<$Z5C T$W-/S/JL(0F\SE3W&97<*Z[
MY1E[/6<"OC+!!]6<:S-6FGN?G&BK^ ZA"(TC(IZZ I8GKNA<F['?Y!2\I&P7
M9K9#-WJ#:#,*0;#!/I:'(6C$N=YRIJUKW0CM@@/(+7K+O?R4?&?G*%I).[ 5
M'4=2CF2?(D06UI<34B_!A*HH=5=/-WSJ1?B+&T08>E].8I3 [9<1N;Y\Q'=!
M.BY?3C!<I ;<;D:"X[\I')D2Y^ZHR'BI,8>F&Y0LC]\M1"FBZW'6NK69!ECG
M*7R(KI[475AROG$#QR?M6%?@/#>_4G?=Z+M:JH4/E&F@'1P\!Z:0.@^^'B>4
M<?3(D7T(M<X/T*YMR:3R$ S+<; _1L':?OJFJZ^M)S%KZG(0TW?Q*-!QG1X+
MA!=#1GC@.5F@NAPRJGW_RP+4U3& 8CIM%BBOAXR2Y^Y9 /SKD %R/$4+?'\[
M!GP';J8%NK\? [I])]4"W,_' *[.O77+SX\!8;U?;(EQT$)+G6MMB6S0P@K+
M,[=$-VBA1=*3MP0[:&%&Z/];PART-,/U'"XA#EJ>X?H<EQ '+=)P_)5+@(.6
M:ECNSB6Z08LU?#_I[35^R!CWW:U+5(,695C>VB6Z08LSCS4.WR6RHQ!E9/W"
M2]2#EFGJ7,M+9(,68PX<U$M8@Q9=6/[M);HCD%HX7O$ES".076I\ZDMX1R"\
ML%WQM_KZX:-D>_"7* <MSC B $IP@Y9F&!$$);@C$&B8D0<ER$'++_R0A1+C
MH"497K1#B7#00@T_3*+$> 2BS7Z<18GM".29O4B-$MHQR#*"T(ZML7[(6/="
M1$I0@Q9@:L),2F"#%EX.@E5*6(,66YBA+B6\00LL];$R);9!"RK\()L2XZ!%
M%9FXG!+IH 46N4">$NN@!1CU:)\2-T.Z^?5L-\5V!UFW>>\G]9,8NASEH@->
M1NCJE/24R)J5=KN^8'\)M[-)I=>&**3S+9MTNZZ><11[1 BS,->6-Y\N?"OQ
M,],(,\L:IW:&(, )VJ0T9.0(J6;6,9ZD>^1Y?G9V/@/?>PCS%W:$"+CUG#;1
MVTU0O-"G4D+HW0$4$O&.G=*=7\%I$]3=W_YLGZ"ZV0E)UF[^HDWQ^"#G6-PO
M[+3))]&(7HF$$LRRSKEY1DE&+!5QO=L$T;?^4L5C&G^8DG>S_\*7:/B5&FN7
M3UPWX"?XGO["Y[P2]=ME']<(*P\I;8YKKX%V6<R;<8[_27#VLM\L8K"#[_0)
MO?RF5I?XHW%;REG2&0]OW)%[HQO39\KH>[W%^W+^O[, TNV+9C6T*]573I+>
MDMYL=;2E.FM%.7,Z@_8L\CCT\HG$#?9ZHW:4DZHWIE\#Z16JVV3JT,YQZ&_Y
M0XIW'Q"Y/N9N:.6VVF5NUWXP:\++::Q=#GC=\[MS(7F!ONC 5FZK71YY[?.K
M"2^GL789ZIL ?H)Q]L(H?8V2@V6G7#53O8'L.5Q-U)YRD*D).IJ,.6R$@I%@
M*)?LSY?#(KP>+TL=95?^"B&U]>#J-%=' 8RGW+(LS4-#A"+EEV6I'AJB9.K(
MC.=\:)#M2,=!8VGFE68\M$;_=@RXZA1UEFX_Y?E25MA9EHQ%-_ =+9YE.5HT
M8JW1[%F6JJ4)V$8J/LLRN*C@5E8/6I;-I3.L6Z6B91E>E!$W441:EOBE \P[
M&DS;TL!HY\4L7:9MN6&T\R>F4M.VW#&ZIYRIWK0MK8SV*6?J.6W+,=,$^8%6
M5)11QH278;): ;29S*?^(DR3WE2CK9Y3=V8B*=*C. V"I!?V "LY(+)L766'
MA_T]<CP-Y2NK>AX*":T9&9:/H61-/:YD&,45[3WY;ZNY)_\X+]1YE.%4N/.[
M.6J8WE-[)8Q0]!5\^*MDQ:5IIXP9JL@N%U)5+:/'L4_K[#5R&V-L0W)THO2D
M!<%-A%#T3O;2"SE\)_-'PC/8!G%1/:?-2QN-K(;T]D).8CB.<(SK7OAEE'04
MS?6,@23\UJ7#L2!#\#4*XV6PR;/KXY?ZM]IEJJDZVTD0-UU&*)Y!M"KZD2'M
MH%+5K\Z ^5&)/=5>?V28QM'8)Q4@[X[5/N.RSC!Y0""#?DLM<S7T'0+8YXI#
MA+#'0BU\9T-Q)5EJ4VI],$HP\B."S)8!++,]M9Y7L6!AF=%)*^):>45@>;)&
M+S!UE]!+ @(CSSY.Y@M/Y@0*@JZ?JN6;: Q:B]C/*"*R1[QY#BC9H4?MT6O9
M$$9Q9>,AC4R2IB!X(\NH>#(J7U5-P-6WI'K394CUS-7!DNB9%8Q'KVV7.'/H
MA'&FDDT8CVECDG.S*9X0:K*4MK7M040I$L:^2=0VCH@Z8"0Q1"4M,O&J=354
M*6=LY4?P2E/!1V@CIHA?P7@HY'V""(-,$"13>^]_T$_B,$YV):?-([A-Z$_%
M7.IA];!:H^@M2PX@!,"IY;1Y&]?.[;FO<>S%*"0E03#D?74&;=>EN\T8"%F_
MZ?L=-\"@S2PKB 3LZ][0='U-P"MNDAW1PSJ5H"+YBMAWA)2!'0J[M-<#9\LU
M1P16*#)9IN+2,K-<&<LR=9<6P'R9S.+@A\Y/+DGEM0$-V!C@)2&2_J&$OH&
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MT3Q^!PC>PC<81'*+@5G'N-E?O]G<M.'?O-F\9UR_(7Y^.7Y%\YF41ZZ;K)*
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M(S^;I4?"[4'1V-O[?)K;&3,_IN$!#Z'GO_E>0LY5]A:I+:O)<JE*YG<_7K[
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MZI!4$!S>J7X]HQW2S('_^#]02P,$%     @ +XJ$6E,RW0VVH0  ["H( !4
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M]3=VB]J(6=>&^:#&@(H=?3(**G8TSRBHV-%1VT;DQ_PZY._\Y%-L_2FT66T
M:T=?N0%K*>C$K'PD=!)%+.0+]QIC42BS^)J259A4,24['?K[MP0D[.@[SR3L
MZ$;/).SH4''U.,ND[XS4.'6^$/P7AB%CY>:=B20.;Q%(V=&](R-E1V>/C)0=
M[2UOOG$;PIQ!\:>IS)S1JMPZJ@$\.QIY,'AVM.Q@\.SHU::+PX<\*Q_3C?P&
MNIRWPM-7NW]K*2S$8/#LZ,CF=[A;R*;R$\DPQ/ML?DWS>-U^8VO> H"VHQ,=
M@[:D ]V"MJ3C&I^\?<QIB0MXY\S750)HEC35$- LZ9LAH%G2-32/"(F+2YHO
MN<CH#@K4I0&,)<UB!XP=/7(#NU0P?@MNA.SL9]LP:2O=O[44S&$0:';TQR#0
M[&B)>HO#1*9^63[-BC(IU^S6L1VB066 :D<W.(%J1R,X@6I'0U0A:@^+!V18
M'>#:T1K.X-K1),[@VM$U^)0!I(T?0FYF\]_"4I]%M[4"0+*E<>Q!LA0^P2HD
M6QHF9>G60UHV0PV#-3 '%<+2'-\2^I1$?$UI%"G0L;A9O9V$M4\ ;5O:ZY71
MMJ4)7QEM6UI5B4D=^D:<TUKF?]2WH"-LZ>Q7WQ&VK(%7WQ&V[ PE.-@!AC1A
MSQM%"7E]8;D7#O\0=($MV^45=X$M6^GU=H&E8"=MR/#Z]S0L\"_BQ-TR]=X?
M ,J#VG[CI#RHW3=.RK9L/I'>.\E*PH*WM@6:[,AJU+LAH&#+?O-(P9;EY9&"
M+9O)(P5;UL[NE[56F#D!;3, WY:EX@F^+2O#"_QWEN+ZW)"5\*V8H&/GPB!*
MA*8*P+*EQ2W#LJ5I+<.RI0WE-V;SR9+0) JETT1(-^S8=-5^BVA6&\#:TGM.
MP-K2<$[ VM)E)I_3)T+ITP8 MZ7!G .WI;N< [>EM< :22*PR[>]A+O6,EVM
M^W>68N[<Y.6CR,"#NP:PHHJK-.J IJD#P"QI)?O +.DE^\#L:";N=,$>=EUU
MQ1Y7E04@=K2.!2!V-$JC\>(:)E/ECF^ 9KL"0+*C-ZQ"LJ,1K$*RL]8WOJ -
M#[];#@#86;,/!V I(DNC89$;BR__/"+,U"0K7X\F +:=5=LY;#MKNG/8EE;\
MZ)'$:^9JEV7K,.4QO,&@H23BV?10)CM?GO1L!N!;TA.^X%O2+K[@6])$U7?;
M#L_ZXC=K!PA8TEO^"%C2<OX(6-*2U8?-'Z_U9'1@P_?O+$6F&35%2SI[S!0M
MZ?<*2?.&[#K<,%_7OFRZVP#@MC6\,^"V=;LSX+:UNOI2H#_T[E8 O&V=[A2\
M;7WN%+PE7;Z=AQ.-N>@Q";-\ O^>+I<D3D""TPWLEW-ZE_/XG?I#HR.:!%J6
M-/S(:%F* 72+J<?QX@\6$\/,AYHJ ,N2)K8-RY+VM W+DFZL7&+.\B6:#SQ)
M67WS=[K9\YJ9/(<4;&-\]3PG"<8R+J;9-0%1:TW38/DS0-^2AGVM]"WIZ==*
MWY*F/P)7(VPK1\7RP;%L.?R_GPF^^2/Q!"?Q@HB88H2=]0[144<!@BZU9'_\
MJTOK+K5D%?VK2^LNM621'<I Q/']E864D^O1#N0;L@R3# B>Y1F+Y;\.4WSG
M;KT[CP%S_\Y2%*U_=25TI27+]5]=^<Y21+%.]$4'?):HA>*=$]\[#;).V@0!
M7>=H1_ E=IVCW<27V'5#[D0.=&T_J#&@,N2NPC&5(:UYQU2&M*(/<GT_H"F@
M,:3EZHZ&I8AQWFE8M-@>\U1L9T1LJ\;YZV6>IBPSO#Y;5=]V@(!%.\D/ 5O6
MBH@BUL@A79B>KQK4!:"V;(/!@=K2Q(,#M:1GDT66S-'[7%R*H^SAMQ)27'6Z
MS)I4!JB6]*@+J);T9/6U<O]S>C?.SIH TI(6'!2DI8AV/ E,%LL,!-R)\7Q-
MJ[.OC^29_;)]Z,V; -B6=)IKV)8TF6O8EO27:]B6M%GG-YG_K@7LV^T  4M:
MSA\!2]K/'P%+.M$? 4N:$C^\_[6=)W%YE<_"B,@![0$A2UIU-(0L1?H;$2&+
MNGD? /\<^V/+&5Y/1MT- B6+>GLLE"SJ]+%0LJCO31#(T^'X[=%DZJ: AD6M
M[Y.&1=WODX8="^ N?!&)M(38WCW2?+UXY+*+6IM?7>#)D2X=8]]V@( ="\ C
M 3L:WQ\!2_'B[O(R3%EFW9@E8LLS=%D^)@3&X2T"*3M:?F2D[.CYD9&RH^GO
MGO.[QWQ=A%E<7";SDI#L.@TSO>^VMA) LZ.Q!X%F1PL/ LV.9FU^!=VOL_[@
M%-4 GB6-.10\2_IP*'AVM-V.(P-S8#AV$3JFS?OWEF*BC9"8'4TX0F(]M>%C
M6:Z*/WWWW<L#3;\M2/3M(G_ZCMT[T,UW2%C^P-ASYOP7]],K%87JCX"EIQ([
M LNG6PV63[> I:?64F-94TJR2((1/S70B-_<7WRZ4>%I_!D0]516QR&:7BE[
MJ/%G0-131SE U%,M'8?HT^VY#A'\&1#UU$3'(?K+7_ZB0P1_!D0]E8\244P2
M#@;^4>. '^XG<0P[[>(.&CS/T2M6 4A9[OY]W^AE?9$M21:CU\QE&B[:4#7+
M **>RWY?1.L8CU<O$[J<JAX;[94!1#;6ZTY$5SF/,J+')$L!*ALK=R>JC^%2
MM6/?*0%H;*S=[6A.UT62@>BBKW<8M4<?;2T+"&VLY>T(SY)R,Z$D/,OCM@YK
M%@$\-E9R#1[._IK0(L\RDFH&4E44\-E8UW7XP'::/!3,=;\56*,,(+*QKFL0
ML26[O$R**$S_2D)ZD<7GZM2SNN* <]C5_CR/ULS?NO(]N<774"%M6\[:*]R_
M[QLE[5"L/*(2&,.T;;!510'?L-I ?O0RR6[+97E!:4[/<AA8%A],H[2Z*P+V
M8?7&#@2,4PKBA[\1R<8VDRQ,-T52F//H: 0X#:MU:C@XJ_@]PB7\3K43TY8'
MI,-JI.TOX_PWQUF5!I3#:B7YW6DVS^F260Y7&E_!KBJ =UBMI?AXFRN>KCC@
M'%9[R0]SB=,K"F590#BL-I-?O2$+\1XBAQDNYG8'4F4=0.Q&K]T^DC1%/_PP
MVQAIC/T*]^_[1AT[$"L+)IGPQP(&2'>+ TXW^@VW?%W8H C@&59G78#Y 48P
MWX>*_^#JHKI;UI8'I,-JHK8OO^N)]!T@'583;7T9]Q@S>I<_M^TC6TH#RF$U
MT?9W^:F?$41Q0/B^;V2N8_"1HG%4,GE)VG2EOA)@'E8+;7W^.@?3+?W?R4JS
M VVO %B'U4?\TV<$WVJGTRPF+_]-] *P4Q80#JM_Q%?SY1*U7A[]SAU8&M$F
M]' U%>_?]XV7=1AVOB7ENH5O\\I6DU17!? .JY?XQR^6A"[@H[_2_+E\%!I<
M"U=9 ]"ZT%H7+[7Z;HU5I"L..%WHK,LD)1_7F@.RW6* RX6&P@_2,[ F%WG'
MTK]5$M"YT$S3+,HI3(+:Z!6:IW,YU=8$]"[T5F,#= G_(/2*+,)T1KDE3RB)
M->=_?9H /BYTVC2#+V*0]B<"NZ50K%(=^%55 *\+O7:]?DB3Z#+-0SW(1CE
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MBI/9';/Y-(N3IR1>:_M4619P6M$AZ^+-(@Q7#:SB-S5>\8O[_0@T&J>J[DK
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MI'[P87<=C)>_V)YF$25A0<X)_R_\G*[Q48-\"'(3EN1B/B>=.PAW0*"G?5B
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MND/*==0$+JYMEB&YN+97AN3BVE;I0&1PQ&;8 G!S;5MT(.M<#(SJ R_7MH?
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M5D:>Y7*QX9.B^U5F:QW []QFL(S?N45@&;]S?6\9OW-MGK,5AL0W\+\TB3#
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M.9@#VW?>)JN5;">80T-LXT3DYC\#0RGDU]?R;L6#*!L154IP10VKLET1>S2
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MO",5;\^YFU,0 7YT 'E3L(Y]2'+TMJ@*L;M:%GPS1ST;BP!%S)GTPVG08!0
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M\7E8MG2JN CBI0,L'ES@JQ.HX!KXN=@$UHZ?MQ@L(*3JE506;_JQR@K>H/-
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MW9ND^/T,.C I\5]MB0;J\BA.$2L?4*C@\412PT*Y;6V6+W9H>!J&(D^3F#^
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M^0GIY^!?,?7L&N536^E@%3=*CFB\6^;X(5YE+?-Y1&0_YEE,XC6(*NP5=?=
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M*D[X4_8KA?BU,R]6W(OHZU?87U01;;2L#W&SO//&;O06 V=0A;$MK'S ,LV
M(2?_&Z^J-Q*JY'6/!2F&*R8DIY)Q&K&W_V8BD;3SKKXP;>39<BDF_RS\L]KL
MV-'W>_ZBJDY;6M)BJMY05%-IM;HOQ)) U9;NM2'%<;-D? ZQ?./9KV)1$QR
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MW01<7-"83QF7D&">*>5DA;.U@SS@=&OH<JUW4*U:5<VW]W@L96U**3L CK/
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M#Q-S<78J;?XK ]S#N)G&U:FTMT0]C)-I7)U46^]-RQI7A'M!C*'^2*,XE]^
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M/"; 'S4W0H?K;*%62&G?W8")2?7FRJ^H4X!MS2UX:^@$D/S\$4<,(*)L\:-
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M0?_/_;GBPWXXRWCV9P,64G]!"?ILAO$,4)EVW,RQQK,[%Q#I^2G<$;KE)"1
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M\-2I)D\+<\R9]BOA3#W<-89)A;SH7WO2HG\XCS@P</;FTQA*[>_FH/D*ML\
M\N#)1AB!Z*O[YF_3+1>FVA@S4/FA&*KJ&%5)1GC<FV<6/43@-@%;VDF2GZS:
MQ8(!*)()LJI=;G 101C]0'ME^?I9FA(+1M$\XTTVRFI()"KWA&=)J(]4;87!
M("12#7&!(G>-2/ U"I--L"MJ<V*ZL.@HF*;:RT("N)(U%_O(@-:85&DX,9JR
M%#*,1)=8' PNULFA6Z?3(2.;!#4:2#%P+MG2M+#>H]7$^Y A'Q'F!TQ?FU(W
MSHNO)'=,DE8"E"GDDA"!IM0#H N]V**7=<T .A\+L43'MH), 6>:J-ACX7ZK
M+#^TRF=Q4?HL"^\Z1IN01D\SNT (PX:DNH1Q5PT3G(O= FW+,#DIS+8'(PS1
M5;1U_; -1OO9QC'*G,$ EK P#4J"&:J0,_1Y]/Y%$(_>B2'B3S#?AS>%H8\=
M#NC3WOAO^*=82$WV).,9_$2VPZ%2M]L7&+UFN>)"!#BS5+OF]G<]>89)^<G&
MVZ\R07IR@U<DDI#^!'L)I0UR])4T&>>8H@+K,C,GC,LHUX(S\XM6#IB<KH "
MG0AR?-Q6_"6A5T2]QO!'AWH=>H;SG"DE3 I=H0ABG15 R]?E2BW6&0&TH,R7
M<]AF@.F^WU6Y:'S'O :](N9,H6ET;QN'"D*!3)NQ?##3%[V@^"!VK,F4MT=?
M!TA9K6H#C83,%*UL.;%.U2&=8(J!]_,Z>OWDY0MF<!7_VL-5_,:9!4&^.5(M
MF*8DWG"S\'Y[NN+!A_YL%I[;NR<>/.C/G0Q"RO#\ZU__XL&#_FR^1&-QY63,
M(<W!JN%$?;V)R:4+X0XIXH3_JC^-]?D5K,;6&./P!;55^F@"6D>(\O#:A@H-
MQ -QB?\RVX:0"%P&<MFS/A%D,IXPI:2'=G3(>)&U:KOH^>!R+&L54SJT#&.:
M)",;?6<6<=>D092S\;1-JM .I_KN>Q'?AG'B)RE)@F)Y7Z0F#^!SKU(O>];D
MJ9V/-^X,YGUS51RHLX>O4-:A#97L29M2E&$WLHE.M[5\3B>ZK(N@+_DR2MS
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M5.?,N+$2/W87."'I,MIB7U7N7BOM1!>[_9 \_&?VPX7+'(O*T<SXT&%CCN\
M=XM!B&)_ZAH4\C-Y;'F*_I!P.6=Z6&5K)- IUDW880%RSDPGVC/$)+&0I;:
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MNX-?F1)X5 FI]4]]*@/*O_6$E(X8:1-BI!E]E9/F<[[?[LLB<''^Z(=*2>/
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M%[B+"QX%)2;L,,)'O-'N(R*DN1K9,I0,+<S0UN,8.IOP65-;+QU\+J4#.#(
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M&O1H^E<]<O*V[4M+C)AM28EG+>3M<4Y4:F\J)EF@0FK),WHWP7[V52-<:>]
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M+1FFJ7,=+%N]>H%MY#CB'!,C>Z-I\TSCC5QFRE52'B(B!+BLM>,J78(T\:_
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M2!!8SP76E:[!ZC$U:ME$7]D*)Z]YEJ=MDH.M9EE8&F:K5@LK#.5'W#+D7S3
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MB 7.K-,K3XWD8D8C_E<NJ@Z5>XF?<"O&U0;=BOR&$C:0SM"))23P\[,[CDO
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M ;E-K:F/_3$XA30PCF![-#:1,YZ\%O=[IU.%2NY *ZB#<2M[AEAOJ<Q779B
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M0Q.WL4XCGSA.(#R'<>*YC+H1%S:7@><%A :SM$X/+1WY7FI=#=+TC#5W)YP
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M-BJC\NK:I-8)SX[8EDV"UT;)QB;%4XR26L?U3JI&I(WOU!>H;4I0A8]<NU&
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M^U&?=>4\SQZS0ERJ'U;U.H,?_C]02P,$%     @ +XJ$6J@+U_P,"    AX
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M=*I>4 @4FH %XQ)B.EI;<#W2W=BJ@G\[0]1A*_XJ);1P(5IFH1ODMU_B<#;
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MB8CQ5P( ^K\"  H   !I;6%G93 N:G!G[+MW5%/OV^8;1 450:0(BD0%14!
M0)0>&R @1+K2HM($I/<2HH*@"$2Z(A!ITHD*H4/H$1 "! A%>@DM0(! $D(R
M^<Z<><^L6;-F35OK=]XS)NOS1]9^\NS<V?=SW=>=/)LYPIP&G-+3UM4&L+&Q
M 9ZRG@#F..#>/Z_^MQ[_3/*_.P<;LPG RWGX&H<O.]LEP"%>-G9>-F8;  @
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M(T]-0X5K2-MWU+8 WIGKTD."\O)&G,\(?JW$]><-R'H!, \F33I,_8$TW6M
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MSD,.L(3/0J7@GX4F\D/\E[$65_Z/9>NXK&DY+I?/^^ZI;IK!&^\?IY,[Q9@
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MBH>]56,($V9T/OV$'UNV&HPTV7WPDY-0IN$Z7E"J@;*R&C.<J,EH)+[M!BY
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M]97M[7D.%_J7Z%"3WS[19I+/7 <C7,LLZWM6SXPO4#)3.*3S(W6[)'O'&IB
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MN6%VK;=M/='F;O350J'_<QNW+UXX!+ZM\((*0!W>NVXE&93[N.-8M\CQ+29
MD/YL$Q[N\,(O9.FK7^^]6BX[#>]67#B6$@9E##(!E<B("A[NWLFS^$O[QAV4
M_T#<>P U]?U]_E%4%% LH*! 5$"DJXAT8OD" @+2.T&0+ETZ)"HB@D $1)06
M%9!.E!:IH0B1&B5 A" !0@LAM 0((67C[YG=?7;VV?WO,_^=V<S<S&0F<^X]
MYW[NY_U^W7O.YYX8B%_H0!L*0@.TMA$?^M3];@QN"'G/? F;YQLVM+::F\YL
MJ#9TF-BY5N:0K]YH:ABR%D%B>_TIN$9O+J3[#0K&!+[KD!*UK(YV!V&>@O.@
M=3#*3#%=WB3G;H"DV],7)VI"KD7*KVJ0V* 7("&H/RA)XOR(UXVS*9N.M2AY
ME?24=77B)@FL&-D\&Y@4&W.JHW)0(7D^_E!X0"&7D>BV6\J'Z"?GOKQ+"3LC
M]^HM6.!M@]D_3 H[ -WK:?_GGNI<N<P1<-8EN%\8,INI!;)814U7V+#].EH;
M/8%1K3%[0="/W1:Y;+[P<NU?*DP.X,IN[L=% @,B(\ITUSV-'>B8/(I/DM%F
MT#!8,K,.U\6 C)Z,FXI7W\&X$+"9X)H9IFA'J&S,89FCV.0 \+$)/RC9<NYC
M@6V5<S$HW&)4IAP?044QKS)6N4%M<0/.DJ><!!R;5KLZ[4Y@A-Z#L?E>E,?6
M*KP'9Z^IJ1-AFY V>&;#Q*5\V&7W!SWZ!E00!K;^@BLKFD:EWC<5(-M:< Q3
M_A/JN;V?C]E146,]";MBI'+&]:J<D6(+L=H68$\FN>3/9]1\Z#9?/YNOXO1\
MO1?T74*OIT[D(GQ) U,?E[[.P^83?H#X ].="5JY)MH+[(S)B(N#&K$#'JQ[
M9O@/)!=2>-)A+L%IH7EL;?<J_TBO[V<7GQ5'*9Z].QI<]T(^'8]-D\>@Z<*)
MWV=D3!Y8EMBHS:?$K>;[LR3OG8XP'WF3;ZRJ'*R&_;,;W99#:T75@P^P1S2!
M2:O^'_8\FMXG5VMWKP:G8V@L?7FRB8IMS4C5; [_RR+J"?"\:_23F%-D<"?H
M.=07G)0C^++*,VUS1O%BUK5. \#E8.:3K>GH'-8P*P,5T*QS=]R>7N%H_4A/
M0NI=2*3(;IYK$ C4B<J-O;,.%LZ\;9>'/&J1KZ )F3B9DE=$JZ]CMQ')7T07
M==\ER1J9_4&:6/QF,0>%%]D'-L;2B29*BG?N-=K/I%LEVAQ];7#@M=GN=G?T
M0:BF3:&EH(55N5Y/4+A/A8Y@<8F%JFO)Z1P?'7$*9$9/R$;_/Y?4A8W8[*.Z
MA[Y]<TW_T"OS]"DFUM*P(<,V\)]GVY/?[@(RV\5-@EUD-QI>S?3+!BC5\WNG
M^'ZOZ$N.Y!UMK5@43 4U*'="GS-,/[ OX/P?S=_U&&_SSE[@"]XI<KG%-;BV
M&V@.X.!1KG#^\+5A2^*NHQ*G9*G^2-/7E6?<12;[- P"J127*<M,MZOTE[<Z
M[R=>=PRQ:<+J0:I41,=*#O<Y]6Y6U,=E0Q)I@GN^?TL%QEY=UYT@>Q;ZR5\T
M3,V4?"RR$DJ _PA#S&.V/W#WLHFNRC<VP"(\]$/E*KKETYK?N/L)5AO0<=2M
MO9N02>!IMK++Y&=4F;.90*VZ,_8N!R"O!HQ)RT^$M.!Z,Y;6R>;YEE;2[]E>
MGMH/-Z.FX1R ,Z3V3J*L>?'MU,N7C4Z^RLRAH?*;N(=R9_ZJZ&<@OB\D)".K
M4/A,2W5EPRC<)3:,]95]D>G;6D UWK"I\OUL>=YN3>FXZ^O)6=.\4%R:_ (O
M?6;#RV<8G:(ZN(M'478D,^R@&*?M=@Z ;'OV$G;%#EUR19L2>^)IA[C*B!<\
ME.)\P+#PW>GY9%81%8]H,XU<%(N6R+,=?A B4)[S9E'.9:S(RK<9;?UY*CI,
MN\4FU"5KY(*N(V19W(U6ZV?" 9RD0:[2WX?P@^D(FSQU;<,8+0E(C81^*)ZZ
M\&4M#"2RYL,!()5?1;,^64!IRE2Z3?A'!'K?!.)I!J]9%^,$#0.Y6#MFX_6]
M:E.B45OBVR)IK*V$)WONM\+%N<?#M>$AKUJ'47#H,CKI['B]0\4IK3U\B;C_
MXX;A"5_VXM@ZZ+ORRXE'S^3-3BY_"0BXX7*O!7),A6U@:O; APA_16W/*$D-
MZ[:X!II]\/@J@1U]@N[*SNI=#G9TNIO1\8*_MYW&O+JL0AFNJFY(Q_/;B8A:
MN5XFPLTPS#CY^*L?L]R\U:)].ER&@PFF#*CS#1V]'#?29?T3;_*',PWWF@-'
M?=L,2NA:1&0W_& D[-[(:JQ'M;%P\8BE9CVK?[]DF-NQAXN@[,4<]@O((:X0
M+]"#IP<ENR:RF%0G!P,QI4UCR:L>5DX9Z&I]J I.F/G3KK6J,[T4_K[V23!C
M1WM[12?:"KZ>ND0U>HCI?SV. 6* ,P7RQ*_O5>5&'M@>6=EE]QNJQJEAG=NH
MPUW$Y=O%FN_>SGW&R3GHPM>CX22NY3VP^A<.Z#%$4YA =O;Z/\,7Q4SDRG8;
MXKMN1$NTQ,GO=+6#)9BJLTO3D5N."@-"1 P,163IQ)&9D6VB[!'@\;:#+HZ.
M]&N,F!BKL*/S1LO[GVE.$QNX;O:!+@^TXT';9>_]G3J6WS.[OWP_%X9/<4U9
MMXLAEIA%,]>N]<I@[$>[!L?J=]^ Y:/]2PJQFXVTQU]KAAWZCHT91U)B. #C
M.,U:EAXE3$MKQ+:A0..IZ$" B.!WS\\%4-E0NF!L"EN",&=+_<7M1R^W'UET
MXUG,BY79#;.DBSGLR$]6)YTD5>YVJ"_<*S $L@O!/T^G5OR.S#9-M/B:[M'P
M32_RC^FM SP=![9U*J;+?W[_66$A_!CWQV;<!T6DZL2J.EAK>"BV#4.5\J^O
M>G<%>:;D/>;FDRTT?51C4?!@9P)ZE8!T$J#2H9K#=X6%2HDZ,8MD+*W;NA%I
MA?SVZ)@;I("X7O%Y]M,(8H 2"":SQ99""M<F%&76.0 P;AEZ&KSN9"ZSG?CR
MKL(^QVHTZR/LHS"3+_*9_9G9T\AO&;KCRB[PF)^+NW]7?-..<[N'+R[\0T]Z
MV$/)=@XNB&!L0OG8!YCF?O[ [^+^\'V0<649GF==R-U9E-7,BN;W&6_]X 68
M3 MEH0D.A%7Q62!$_Y3IG)FLH^)MHGE7JBX1)@PZ3KJODF\D<@ 7/Y+Q*#J.
M\9.;X'3JI>$S9YZYCZ<VZ;T>TF23=)K88A!KMBFHIBA\$S+,YK7NN%/IX/61
M W@;O\6@T7@NH<;0VP>^?$F<7GPZ=5R- W ?7Q3AU;W/H#$KVC%?Z(]4[UE9
M:\AJZ!I&X!U97,W'1SR0-['LTB]X,Y&*':W_!)YG>Y$ 2[KQNQ;#Q^*70%F*
ML5<I__GJ;)XIPTVMU0A\*??GO?_7M2C_;VY\.] -,A>DG1YR #]-H 50IIA7
M>2XT^<QKRA[N5)K*GQ()^"(2R1!QY@#056A6<"8'<$N5'8U:#TZH;T$)*;UR
MATZ4\(#L8>)F0"(9;-!UO,SRZK.$AHBFMFQ;-DKR%5#C]O.\"'(Q#03CSWY0
M-J@L==H]K5 4U#_56K%M[JY,N;#.:EMB_ZDA FD_8508R<5U[.OG8HUW;HJ#
MO0>"5.CND]$1" O6N[D$D(]98O\C?6SU.&T:6JF^I L'=Z+N#UXI5[<W[.B3
MP-A5-(;:!\Z'$[+=%]:_ICK=?N/96K6%^Z>.A,Q>G.0 7-=^VX+6A]H HC)G
MQ=]MD?[6R16'=":":A.[L.2/X]"EIKW3J!.(0'\+?&ASW"+.TN36I=6]!"%S
M^]/_^ULY3@O-L_R*?!.._;VGU3]9# S<Y -@2MGN.4V/%VV,CK]Z4]![:0W[
M,=\HO5C"QS\&Z@)/_S5J&%AU7OUM)):UP,/ #>R@ZFV[_'RJ_8$VR%-W6N]2
MW??ZCAE,<3VR<C1=GHBFP(M]+)P;TBL^Z$W9/NI"WNIR!5*7_4@U:2<':WW9
MG2*^=:N9%GE26?GUM@YY851M59$_5BE_ANL<_/VQ?8QMT(-#]<5?VUOCSQ-9
M;E3&Z%+UA7<!:7I!T:[QS(K=M)^HP%2;-9M(O(/[V0$#E3Q7M<]$#@#'AGZ&
M'X(^@O&Y^-AP /BSWUV"K7[X9&\,.>)@X =CK7GHKCRJ<GQNH6:9?)M12)SP
M%G)W5\1R<,G*QS_"'P)>8#P&W2>I"6PALJN@OM!$E2+?IJJVQ0G06(DE;+N9
M ]#&(2(#NVW:9!.4:;TV?EYSU[ZXAJC\AB\2<NB,]S;7$E6^_RR[+4?23)\W
M8:#HH=@$AU#ZI2+:+ZWZ&- (S4BV++^BX%N);0X-^_7#OR,REXG6XP>%1=U,
MS^R&E1T*4L&U>O"5A[RQ"(=-_ ']?7I2_[=VSOZ6VI>;=A2>,AW-'0P-D<_6
M8 9@=4665'P5PX[-)=]!1B\^B1%C1#!5G-'=@J*_Z7Y=.?G] Y)O1:3"I*;G
M9"6_]42SY'<C6%^AOH-^#B-;<<?$#:=$/N>HIAC=[3&B_8%U,>%8ILZT EAX
MP<JR6#KA^>QRH]Y$</@XA="*U,X+U[63[X,PLKOZM\-;F3LKW(293?'?\W>A
MP\&-)IJ;WC_[+\(N&? \^ST?!P5&,_$;RFGU',"Y5?MZ+:2M5)9/'NP'RA0J
M.-2XVT]/+VIJN63(?[IW;A,JT3BD):&O.>(0 %>PS-*[<&MG*73I*MPI.IHK
M-?KJI[H$FN4[+!)'9T0L4W1(W8\REH>1H;.U8JLJ"<;42UA#<%R=,Q;'%@M_
M=_2IHV/\0O-&8YM[YJKA&J9DWD&S\JK/3_ZGR$4 <9.V ZRR'A&]",UE>2_I
MF&D+;!,9,;F::L]B'8EE$'0QOA\D=9EO$%=R,YH!X<73M"%:EWY\^16:)2VF
M29+*K6^H<8&NH_O'*FRO/(N=_%KB)^L34U\RL_NI*H\?RN]4(? T_T/*'!$9
M.^8\XO#J:YJ6_4L7GL.3\?&_GZC0PUA^2R  NY]PNGA#/*&RR1KW^^'[T_>Z
ME?@R!'>NHD$.K,CUB)7S2H^-CZP]!M.2+J3T-O'D?]\?NKF DAMB.OQ8]^]3
M+1LNV%C(L_7X7(&A32WJ.V:X28/\SH;61F36[F365]$?@]/I1X2BZPPY (D(
M'@2S]C41:$[Y"36*=EK6^K*-)99<;;C:@9$$EDZ'D<"_UIA7]-\^ K.E7J%X
M@=\P[I@_#*C#IG/@]O&]:T._O%N>S$-#,:8:> P-,T\543Z[F?,[0736QUG+
M>4BS51GW8ZWG8=@;#XOC;W/JO2+J47V$9Z 3*] PP0D9_X2[TN?BVQ?CT2@R
MQ5HY[' 8>/)3*7YSSOTSE!47U0$R8@@2H2L=&\:W-\1^D1RL.TD5DJS?11-G
M$!X\K[6 ZXC\+> 1OP*!@_7O7'C9BLNVYZ)37FOL(";H7M];$,"5O'++BM-9
ME;,[R "NEJ)3;94K$I_!%?(-*L&;3)#R1:_APALI3ZWN&A#$@-5092A6Z+I6
MJE=7SG/;\*:$ 6.Q3_<,Y$L[O^CDTG3SW)/O;IG5W=G[+,4!M,+!][;7""0+
MO,'UYI:5UZ$=#"((\3,MB[*X&V[^_;?#5)_0O&@WE:FT8[A=LXG%#"QWNGDV
M1E47'\I$E>]58R80XP9L/C'M"UZ?Z0;W\XN"+B85>"I$:D7)Z+:U4@<AF[%G
MZ.0'&]?&INR4+KI+&<W)*T4!B#Q,W7JFO'%PS QYC>)HXSUQ4D1=RO69H#EI
M*#A-RW85PSQU:G;G)=,\LB'CC_:K4X?7[9#\WX(QZCO )^(@#$:X1:G#8QCM
M'O0S052V+Q:C5]GLCT<LP5K[-NIEAU)DE$,^-:/\04#CK6$\!V BU_%$+D10
M.P9;4;"^@AUT/V?2_TB,S>]\%"IK4[)2/I2_UJOD6)7K"'?('_;SY J'YY7_
ML8S7_VIS_Y9JK';+Y-*?C&;7^R/UQB8WINQ7O=(NG%4YN7+F@TPCHB<07\+F
MDYQ9>Z8K@GNK8SKZN?9%K-Q +BH<\9,G+R^&;2]<P475:ZQJQ;9]D0Z,0(JY
MV\*8":KM2/P7V%K:K4%H'H$ROQ<=JT]'$@=M36K&9)J&E1;R[12[:H3#\>/)
MFT?0;?(KZM#S%:EYODTA&?XAW?++55YT1H&-BCB?J=4D\8B>\V=*Y/8?OSAM
MV <4-WSH<JNHC47KT<?^0-O6>JNF H!K@5T'OV3IO'T<[ST<T;,R;.V$*?O\
M2)A?<]7W'YU^25)#IJL1C1@P!W!_]MN1QXUGH\+.?>GQF5/1.)]AOSF(FZ2R
MY&_K>*Y:LX>0;K<Z$P[LH ,@J-<_5!FKP,MI/()&5=X]ITP<EB>J;=K6Z+P_
M1M$C%3;F'R926L=:_>-T TL<5[SO_EH6..[:8B#R0SJ91L2E"+!5)R+=[^"8
M]L%G$A]=K^@],%!:HR>0<OC1Y?E33 ;5)7]=<MN27K81[_1%XNQP0.#YM\O*
MUPT$,)LJJ82P8Y%#?GM<9_0LA.MN@2VJ,HEU1]W14Z=OE3U"1J6,%893RDV-
M/Y#PI&3B8&U.I)S+A,6K-UDY)C(> ?D2Y1S *.)(UIY1DI73D"Y-,4ZZL)G<
MS-P&P1 '(9UM*B/U_(>+A[=.-CW_6>UPI.F>U:D?Z V8V<CB#G+Z#/-<Q:SR
M*UU^+--$TFQ?<[*&=H/"MZFG7Y]U?5ZAB1"3V?V/@?1+X/:J&T=U(VGGI'-&
M+WAP\W[BBQ19,8HXVB5K>Z>+ P#XP 7K^N,$#1KN/JH:-3]Q''#CB:;@M@$'
M4(E;%%F5K7JY$*G1]\JA__U:PROG'5+MILZDDA&KKMRMT;.RT<+181#BK&4/
M[QQ=8YXE53M=N1BEN;@&7T2EY[$+AROU.(!#S62?X[>D\HXUIX7"G-EM62SZ
M)Z5?;YPX@"909_Y7:!-JYP<'P+<)%%I@E@L>GXC'VLZSP=G^<3X>=!_Y$*F&
M7U'*FR N8M-OG'%X(6.0H2]]]T"C^C21/A3-\@- .Q!-\\5SV2_L^?8[!A#3
MKMWLB(W![>S^MX8?OM:[F/70XK#D:MJ68%*HQKAI;? P!Y"X"V:+='O8V>G[
M'K?-J)\PV+6!3(+6[\*$V)BS[QIJ:UOR].<\1>:@S:N--.)(,#BC39W+VH*'
M[.]N+DV\/"$?VS,5ZRJA,8[[Q@&0<7L\3 \6#"(:Z_/-#R9$"M\Q-02U)-\@
MY[&FXV*VA'=A>Z;0C@NZO&2)4\UG95[X2ZQW7[C_]NM#L>"=^SOL)[B1AY/.
MZE8?$\MD/$>BBFO\T;8[9.@P&J[]=E6QOI\WLAH/=;[1M@WJ&[K1ZDJ.\5)0
M.@)L38DO"!XU,&W9K@Y@G)M+=YC:MC.^QAH7-3-?B@F&DWX@2)CM)6YH6M"1
M[3L.69CG+5<5PK_4K;VK<GI@I8'I!P8<@OY@!^G*Q"IN(+M8$$<=SV&[D_RO
M*T5%@U_LJWVM!2W8VFE,\TI$)"2_>E[B[]LS)+O7A$3>+TDL,[(,RB%%XAV5
MG!4)QEO-I'"H(6I='_J"?6/C*#IQB]_?P-);LF!\4@HK+"<0=S,V]+4&B\O<
MA24KK!)G'_C1%I!?^!#5P./DUQ#CDR=N]<KH5.Q*<@#QOKIG(B.Z4?R*]8I&
M?Z2^)8_Q"O0=$3@@TQ8UMX5&&K$':?E*A+NUR7WCM[OYGM_4 H P=-SL^S^1
MH]VFLCVFU\:"ZXLAY01<V;)KF=6S-XO;8TFK#:3%W9PP!RI;)P!$YM*+7*UU
M8.BV<0H4<^8O\D16A"VG4>D=W)&:<H0CZ6EF*N<LR#PDE#@C#Q+&/!KY\2P5
M/3&I(?^J]U 4>HH#D$$X+:!:$'0E/E^S2OKSVU7SPLTDK"@$BHG%K:?.ODQ
MI6Z][1D_.MG<VL@$L;RF4.'3E0+E,]YU./D4I[71F"8P=K%LX]U2XRCB;.H-
MPBIBF-E<!:TH2-V3G5!%4*2G$Q0Y@*NY+J%YD"W0$.@L!^  ILMLN*]#.P"-
MZK]6N"'78!070T-L.K.R<@Q1/LH'"HRA?A.OHSF ?CTFU\9NO>7V)LX@!'68
M*?20-W!;KT"=^#*;022(Q[6X7.L?!56:C)>"W^),_-MV.  57+L%O/8#PNL
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MO&ZRT0JGMKE%PB[$9>KIB95=K) 7?'_G6(P$%Q.-G1;^@UN 7N+>@$]?5#F
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M6_8EPT<SX;I%I9?:P.*)%;==!K%9HA7.)B$H-7H<NT%'9O"RDJ&#0PPAC -
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ME<"6'UQ'$7:F5Y9R4_:GW_?7ZZFXI'7]D)\DA>41Z^]-C(N3M<M3E0 ^*=8
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M9<XZ>WT_<B_?/VB+I\YS0@8T(!5GM-J&IRY('@?P_W;G)<T;&!366BG-TI.
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M0QL:FX*4*GLM-$3U8R<G=&5RYK/&*]_WW6VN'58JF H)N]A^W)K]-#01L!I
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MBS%16%@M[K3W70Z:[BZ2\BW3U6=94R'_4KJ'3V#^8X1<UF #/AA,JR"HRVS
M/ @K1,LF\!B30;V8:Z#9O,.(5],Z.D36KV:LWGM?W5#W@@A9/LL E1+U!XVA
M+8T<ZU4AAEUOG/'.H"(68[?G.C'$0PL%Y_DI6<Z^+T.-M[J+?BQ7P42"WX%/
M,,!_U$;!:4,[FD&N ,\7BZ2(H[ \M.@P,^=;".:9LOA[CIJ^T,2QE)D?FFR
M+++@R8^T-)MEP_O*0OJ&"R^]";A$\]8?;(#)RV73Z-+(N.>^HT%-R<9D2&K=
M---?SU+4^9-*H(_/USB+%*H=%.F,W)+MF*'(&1;D,Q2'KIO=6!J='79]5::\
M>[+XM?GPC_61A ;T3TPL4"  &YLMF^Z8[/#U*S(UZ[%,%EYI6)SN3W2,HL30
MYBT]2TV&\,D6,B\^ZL^Z:NZOKDYC;L-=@'_S.F=$6V4I4(O:89D&$OD@;=EM
MQVZP:ZA8K_0@>'5]RQEXIIT_S1PV\&#<3FF>V$0>7BHG/!4U"<29;0V95K8V
ML@$_&J_ .A 5W!_8@.<1#ZZC+&^WUD8%&R01GUH_NMEVPHHKDW: QD5R,(*+
MRX69[/U%GPVPF6)J$=8A..3&!<YY!L6;A/CI+#$BT!Y8.Q'[U[ZE ^'^0:1G
M*<<%=H\@E1!*&,(\8 /FS(*UEV3-H\[S4Y]F869!A%5(BHM&=J%H;W)*,8A*
M%<Z+K<TN+9^1#DUJ,Z]V3,V13$IN;51@SHPAJ?-]_ZZ_LY_B+C>@L3,CGMB-
M&29M<33R639@]MT!B%_G9%%P;CNX/GM^X&RJU-W\IS*G9S;?[G'5P/,6PL5(
M?JY:_N*NP(N!(AM18]\9QB1>#M2_K_Y2C0*;U&4,/'%+.G==WJI\N.WV7X[L
M,.2->W[?P^I-B4R)\7H8DJD4X,1%OY87K;AV:3I^W!-92$,L.&W+SKEW@*-I
MG7M1%%?KNR\V9=YK5B&./!A731$1^1DULZNVJ!Z:NG!K+'T,>YAP/K_(.G+1
M_[PX&^#,87;&<.@,12:Z#2&T>@XU$ZT#?*0LR?O!U AZ7/N74O9%44W"#@,4
MQ8^G[Y_9]OX)>C_10BQ,E2E,]/#1?GSA<N3I/K[/XH_8 'YQFNV&CGKG)Y5J
ME[4>0S,XCX4)U-,9,X0)0X 2>Z5,I@?.?G*#N>$\A1'IOQAOZX9D$N:\N1I%
M)N_F"R1%96?"LE0A-1B.]IG 6I,@')K-NR*<D4EZ:!#RHLPM*TWQ>)[X.^T0
M0)QDNX063&O:^6:R\1/$^N.G,3>O:EK6?=_C3ESMA :+=6I%1X;K<[^__B%C
M8I^;+SE''A_Y2SN26U,BD9L[YD#5,9H_^W'.!^1E&4U[G]#:U&I\.5*/^WH:
M7WC-8UD%&5C?G>8F+WB.+$-0F<73XTGRGBO_ZIJS1IKL"\MM$^ X;*<H8ZB(
MYD1'U"Y9C7$9-@JJWGK/4J<,6VW+].\MW [32?[\.UE0>WP&)[[)T-POMYUG
M [H1[S'"2BCB7HO]_#ZO5;SUDS2CGX:"+T5_<?'P(R5TP_O:)873NW8,YH@W
M;J18?GGS2'ZI3H4WDS^<CPW0CZ%.3&I']A;I6]Y_DU?BY& <,<' B-']?A/B
M7B/-G8FX:QLH"2<Z) +#]9$4LZXU4.'Q&+FZ.\6L7-;XW"V H?7\E[)3S#K
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M>_C\/K96@:SH_KWOY?VJ>+DB6?6:[*\L>UI PT*$F0U*U/@&.HBWJ7?_#VB
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M\X]99V9_?=6V"+O5 )*$X68$8><I%OBVQH&6@("""?U]_[ID#[M;)\H'45(
MT*S:[I6D;\\ESX^X#&^D9N^LW;MPWUAQT16)8QQ3HXK-X9*Z6N23+9.+M5J'
MQLS\("DX* PYAA53O%/L6WI[LCHHXEP$:F?\W)]GZHWA"@'Y^+ZBJ;L-;F_/
MN2OA+_PK"C"V(%*.F?-N WX G=4)R5\9"K:U=3!=+YH/T>OT^:YP2A6A+-)]
MGB"RA\:C*3);#(%_]=%UG-Q <=<]O*N_?GC\Q)@X_JFKDW][D_M\]DP!W!M>
M!6&<^3IK&^5YG6AZG_0T.R.UL?W\QXF;(EJOC-D Z\Q-UM-6&[3 _,OA%*3M
M^(/$QI7K#5D9.$_$7LYJA'V61Z?)U^5%C&ZUK2E<%W4 _"7<[DTY/YE]E92=
M4CKU$"N(2TNZM_9'*_5*%M]-S2VL";Z5#8B"L; J!M6?7\$)7_^U([W"!F3!
M<\K?DM3;SDDBO!^[%^ [CS1#Q9]5?#MD!;CZ'QQ1\*R/Y-<VE-F:=5QO!<,P
M"Q&B-%K+:W9=&W6P\VB&\[5FJ+0KEQYQLYB@AL#;J!QQI97. :^C:HU1^YH]
MV -@?7<.093,JEF:$<+,QJBSCI#2<LKM/(*N]4-/),M+7U,]:^5R]#\"2'D7
M34; 7V?S^+P;?D1D Q1Q=0QN$,J/=K Q1R)TW#BS.I&0"%5K[GTPFGN+YZ/^
MX1=2&.I\X]5F3\N3?<\&#FQ'B7EU# 'P!J57R:HZG[;?4C.$8X"D&.XL!88
M)9)$MVFM3&FWS[WMZ2.M/SWP,E_J%-\]USHIY%BSEQ@TE3E*5CZ\<+[S_.5V
MR0[W1 )D+8S^'-YVF240W'<74T^JB]KHW/AN@L^KB?5)^C2;>4>S!STOL,]1
MF:\=&!84N_DI<$>@O<[^M&1E6HB86Y.BBYIV8QS@1G$G[.TGGRO &SFB9DBE
M++%IXW*G%P@'=>CSM.C$F-Y5B]C,H4_)7EOF4'][;SQVC# OF)81WR!@-XE]
M9K5Y5/;)K*3>*F27QG2C*[+&]929"-9YCW.#HP''78<);W]Y%+A=D#9<>1AU
M$$+#15+2#E<W?#6U4O!Y3CP\?ECB%]Y!\X";FI!*R$CXG'LVU?9@(><'%KZ-
M]A9(?^PS$O&W4ST_;[14!L]HRH9Q"PM9CFMYZ<1?1Z365*W6%4;3WL/;)#GZ
MNY C&6JZOB"?X78J;@16Z*>_(/0E/AX()6EGXLC^<1*WN3[>U*3%_,_+I_-8
M8MXL9KRJX[0#I>^^J7?UY+&%,[T"6U5'Z.,L$H?\SG+&&<!?0:J%W[)4*3;=
M'5I'1OSP3K?%I!0C(R>_$5[IP@M@LAW4$Z2'C2DYQB7J0WT&TS0@Y+:02;Y+
M ^[&&-D4[ 0N*"HL/7HH.E1A0<U>PIV*]_!YOR2BB6V-@)_;LAD[6Q,2^ZJ7
M[ZBA\0)RB;$>DS#MI+V<99(8((7QWB7:GS8+"$J4P??)2@=V16"2%J8Q*[D)
ME[*>][XNE7Q&QS56V7OL#DV$-[$!<F,_^R9J1.K;%-#6;BVCV9CW^+">@H;@
MFX]RW@]HO;JJ2L1BYI_3'XHNB;6$9NM2N[06&/MUGD^^GY9"]T>E=,$%*/R$
M;-4'8-2$@7+2CX\DW8BC8-UK_#OH_!SG/.=%^T 3FD>NK><Z&\#5NJP1?KTE
MWZ$HYPK41,+16Y 6&#I3N5ZL4>5PA%_,2VD5-U-'[;=-_@O^\OD5#*-/1.P$
M%^>E5BR;^,;_PMZ+\"-SH^=,2'WRWN\_9FU/!DBV8-(+')]/!*;>I3M7;58?
MA,'B:+:W,B>%-.QN#06HQ_YQ[J/M5A@J6&?55OR0T,M<F P-=4_8$XL2^ S0
M5@]@^F'],MT9E_FV*P!)?^EL0';-$RQOX0SU^<M#77=U^7=8J:,AR* 0(U/E
M)4\4I,]!Q/7[=HKUD]'4Y,2"&@QA45=Q3.8$4GHQ*9M0U#T8P+(J[!1MGFI_
MN7)-MX+EMSH<9\#;4O&;.N'WRB_1=7V5,FQ7X-&\)-O+K1O<%0),=];:V[)C
M[7[!>#16IAM[;N*7H-GN%<S%$KB.58ASVL06:90?_NFMCC(79_;&_K6&0\$W
MBLJ5@LYV'Z8%'F!WUBGNYQ:_%D!DM^06XW83T6Q D4M&8]<(_9CW=/91_B*I
M0:9?ET)?Q^.9:RBB(.3&][7TH#J&VH8K^)"<<3XUV99ARY#LE$.EF#]].+"Q
M*/YHQYB%F'T>[&D+?*Z$=6I@A6>&PC.M0^8R@-..DF))2?A,CKKCHY2@_"[<
M_]#DL?#J+E.#?(!6N-I_C2%OWA(:OKJ6OS$]T(<F;X9]UBEA5,4Y6M9=@T:T
MAFY1]J\7Q"C,<YVZ0:<!677/PVN3JH^>N>D8L:D;C-VEV>H,.=UIYY75P/9.
M':<]8MU>'6O40%W94KK541GR-EC;08=,)$YCU ;JT7)I%[KQ%CX6CH/+MC6C
M#-J,<V-UZ'9OP:4E[M[LOJJ#0%;Y1FM 675GK8NK-G61H,'0_/=93.'64O/[
MOD.[KMM>W%0R@:1<&1-Q 4+<_F7,+?:)D/UY +PKA%!C^ Z8&G:ILMH60-$8
MZJJSE]B':^?46DI2A435D-?])YAPM'6AP \7*V96_ECV 7J&HXV;7!^?1?/V
M:!_K?7U3Q[^L5$);ZTLM]^7\N,73F30:":15W?]RX8;I172X I_J8 *F4#=>
MIH81>.V#[.&[6HN/]A?I>R""T%ZU!E*QM._<PXPK0A#Y&(\=I-=,>C+F=G:Y
MG781)(MXO1HZ.P630/V=&"&/5#_A&1^X:L31D:.T[8P8C0[Y<G/5 3C_X#Y#
M:RQBNC)]Y[(A5@I35PC"PFH*? Y7VIU\LQBW1XL HQ=H$0F.I(2KQ3P?$6KE
M\\.A^?NKS$"=7NJ]%<U^[<(6/+2GMHG*$K-+=:MR8 ,^"\S$[:YB=?C@SO)G
M_PC^9Y<HF>^ZVT;.[2)LV!GW8!V!W7C&@9#7YE)Y7@<WMU1.]\X/1HLVKO32
M3-L5*Y9HB$=Y8T3'$/**07](/3K4=$R;B(&/Y >(^O^UGY"^DL"3QG4^8(L"
MJR_'SRE]AY\RT)!N,H_V;IWKKB #4;XOC:'>T(O.@*<*K\#H71'N1$)_(.2(
M*AMPW-^+NF/V\Q3_5-<< X.5@'-OJ^(M<CXL6L05B*I;!ECT!?R9P0[2=!+N
M6R1[7MK(;20W[H+*$O\>UB"]$&L#-L2*2O:P(A3(R1@=^.,;D<U [R4 R >X
M;*W"@JM"<D99-X)CEBD8#3^,:D?O 158ZY9 D0?^<X?AWO3 33;@G>\V:TC_
MG,R!%)I6/LJZ":^>[Y,E A>VKY=;T@-WHZ7C1+FY9/'U3"UXA3?18TY[YERX
MP'9"Y*.WF][5I46N]Z\9!V\SMB%+[O\J@3'?MTJ%"U,0"\H24)N4VTCGYT%!
MIYON]/)\47?7[-8.1>#J_@0_MGDK;N8Q6NF3Z>BNE$L>7<?W-;1E6W_RN*Q?
MHWDIV:&E&A)!]UB$O3 K<&A^:N"3>G@[(5A$A!D65$)S-!/\7;_@(]H-@7L9
MPKLJJ[]L>DMY<"7'=(BS 54?(P"KB;V-P;*1K7>X?HL+=#_(]ENG,15H: 64
M(0I8YM>5]]I<O+9I?)4CW>R!Z:X$+9.7F1 U\(?61-,9&NZW9W^<+=_Q1_S+
MH,]2>DRHU@+XZN7+JM@7"PP:W:I*!C?!I2 1-2Q;=WL U+-E[P?!V_W$> "6
MPK8'=*]&8'AH/%_BLD7I$_:]DC;VX:DU>SK-UY^4#AGO.FVT6!(QV,U[A"LO
M<AS4OTPJ'!D8)A-T,> E2!Z(9*[J!U^ :A"M\9X;CM]D\V-7LW_ ,VV79=_K
MC?L)5DVH'M.D-_P W@R+87+@\;4RY4$X>&%%*FVF7R$,:*64J;4]C%F Q/MD
MO9#.G70[8M<Y#ID&US21&=BFOI?9?Z8ZL:FE^ UB&'6+ILH4XU"%S+1=/ ,X
M?-;MY8Q;U(4J-D!G0$.'L(L>DN=,S#YHT%:?$H*<R _[#W^[2R7.*'%W#_U=
M@0JZ[KE0(3PS <* =T W?P[O6ST6REU*R"I[1Q3%ZOI1AHMRF__^O(J1KU-M
MTKHB^,#@_O^3OO'_')8B*H^,P$OK+#C/0/[DF>=7;#TBB"%7@9#C\+;; :O-
MNG1-"N[^VR_.)R^MMEGHSXOR0Q[Q:ZY# G$$.$,0SS+SZT;L<[?LLP%I9^#Q
M@;-?:6.B> B4VSOK5Q'Z:.WPU@X5L4BE.S,>CNI)A=MOIZ4&Z SE:_63]9W&
MWYUUEZR7V&8J+'LT@[P]<OHN?%*,U H:X">PPFP]MWV#72BK"VAM! 4!2?!I
MVUW$KA-9:H16:5/JM^2[HJW8D<C,1_RKP]10VSW<28.1WCRB<)5OGEM_0<M(
MRMXJP6_.I\:C#/(]X\!51IHQE84!4[C)$#;@*+/=$]0AD?[2Z%KL('=&3C2?
MRHCD5!5D59-T2RRX6?G9]SM)EU^?_^\RUR9?>]QB 'K7C:,)X,';\_!PYTOP
M+?3N&&;(?=9']F?ME_7%;C;@&VY>[X)5L3F89RW,0+38SW^T^TY-G??:UHKO
MM*UUK_STHC\;\ -^'>O%T;@[>9/_=RO7_]^!"OG? KB'#4BU*\$AMM=]V !'
M!-72 6U-C?Q77[/-:Y=9/'\A);[N-KH)1W*=#Y-IW%[^+D[\;\>1D*#.A=AF
M-.(.:CAX4%>1N@<\W7O-2J9'DWC0 K=G<8>[OFSO;OSM(U&F+,T-W IBP'\@
MP"M\QS$5?1/VE[N_D"%\".5U4Z!PQE" $]2@R1_G)$5S8O3'$NW(I:*>>4<B
M[PF\#G/%M43HTOG#CWQ=.$CT+#L[N@G&SU.M>5V5)4.Y$EK8@'2U'3/FR,4N
M \27$Q'!&]SE<,E1YK^:.74LGC\ZD.T6EU'/,_/*Q&.!T?<B=V_>70QH.]H:
M':^*W:"=GAX+E2VK-L9[AJ<OY"PNB6B8YZ.$!_+1\'2&-IS$O['%.NY$5UB%
M'V>=70U,U[JG@A5"-1R]"X"G&AVD:ZXRUO>S>>_.OKT0+R1T=!#P ^#?I?"5
M%/3V.H)W-7"LT:E1_]0[17G.XO+?!/%CAYIX6%Z__7@^;]Q9JZ4Z?HV)T IG
M.F$'KU*"+?/S^K9E^F&-RNM&%3Q+?)KD;L@.G&FM)DE9CMG)$47*RODY387
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M,L;L6UW,E-#%^/ORD6\!@?LEH>8I[GEVW6YNYSH/FPA9&P*X(G_\6$V8*?#
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MW%DE3F5?[LM^#"#[K3,XWE.N1NSPCIW+A:_<2,@N"^QC&MJG1,2.US^6CJS
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MF7G+PO'_<JU=Q'K-QS6D2#3_;NI5BH!=$PG><5*UP\+D#RIKQ,^[1X1GKI&
M)ZUO06;0C%.(_59PC%9:TAR">*G^1JRWEV7_5'SIN07Q'3X?B%3W0Y'!A$ME
MYQ)K//&M [@FYS1Z62C5^5) SNTTI-8#QS'3'JH#QBL#,1[#'*7Q+YG>=[@K
M_>X20>F<NMY; S D^GFUWJ?;46V@!4@ZIFZ+".'>H,XY&=IY7ZR[9F<6OUF1
M\DF#W@$#.>)6<!_VZ/"3'KO/;>-*#\O_7GKO#'!MRIZTW>9F [A%8,,[:Z&'
M)^!O E0%D_)NS8LFWK^K.6&D-Q6"#I)N&^EP637]V]LBAGZ6W&B^'A9 3U0
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MW2N/6FCI;:?K4Q8K@#MBS;)Z0PNM8;ZA."%_=URYL$FE=-_+6Y?%=R;YM-F
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M/=.)43<\#&G",I7(R&L>M>:A+=5FU"*U'+M&$.-U-1M VXMF _2%"B"OZB+
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M/K7"O*PR$UE[>_:?<&2NH;BOE9[]&N6,V7E-_U-N=R^)_R1E><&V(Q5*-9K
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M<I+UD4C;EU7=N6"S@G/9V&L06>!AW^;#U PM0B)?)P4Q*LB>,*.C7..EDEM
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MMI.L2T0"W ;>:G%(>5W_H,^11!(D*E*"Z (0!^RB*_TG3LX]PLDW$=B2/57
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M,<9]WW.4>?2*R-M[\[*EU6;C//(<=&6>H]8Q5Z0A%3C]]9NL@EZQY0FS2U&
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M%5P7JD?S24H. T.C6W J>?TU,#,A_*3HX%O[L;43]Z*S(_@<RRD6#O\>ET$
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MX],"O*Z'6M3V82CYVQ"QB$1UY2:IJJ&)T:++Q;?-XFA35]I>A#T$TL5A$\H
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M_2<3/!AN)=U+ZO/&:VGX9X6ZEH]F;;#[M>VW=XI?6^L%2NFO_5#I,\ \XB7
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MKY+4&Y7)0^2^"5P(I$EYU<"HI>+/92^=VIR1:VWI!V9TWA_8ZV.3$_ID#I.
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M*FU5^CGH*=*=%S"3)-V! 5-A9[-J]Y8&!=G155;2$.XXT/84[NGLK788YNS
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MF<@O#--WIG2G!\*SYLX.XVA)H@ZBL9YES,-&$M$',%X1HO?//"\:GHQPRY#
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MIA7:,"F<,OAD*E(L;LMB!1<?ON>30/;#]:N)"P:^WADJ(EED>9&M#0H"B^U
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M@=J%X;@X']3>V6=&HP=VF)('<F7JZAJ$).L(X-(2A<_J%Y_WJ\74!J^F0^0
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M 7C(  CW_BUQ1Q]9];\(/ND6^H !0!7\W.S12<*BR?\@<Q,IUZ/7%;=BYQB
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M#__FF6V;*._/ )R#9AS/B<]ZZW94YG[A2+A'J#6"@"RVT:W^N>!J)=W7IQ*
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M5FAV;.<__20EZ_V'H1T<LO(#=Y ^MG4M?6'#,%:Z]_J2=R^^D6M#$:<NB*I
M2#H/6UI,-:,'.*E^H'L<'+\C]R^Q +*V9.@<;DLN/["6/CGKEOB>3^"??&$A
MB>_F<-!@R\2/T3(5Z;OC2:45B=S/U;DNB8,PX]_SU:W\@REEM= 53JIT3M5_
M.'U>#TGP4XG;0;!#=>7TO8^;!EY?%G,^,7VA"O;,(4?A&H*F*[_[K;6[C?YI
M;]0'-9S#J4R!S4FO/.LI9D/::,E%_Y66\G%;QBI6 "(QC[S@*B[Q#@ANBE[U
MD>E3\VRGKM))^&*G*U?\BI\;F+BG:][(B99)%N"/;PIS04J048MXZ!$7RXT
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MCBUGR2]% RKO&1W1BS_BY0E*1"YR6=<U5U8E34@\$1\A.NV*9Z]27_G2'%B
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M92(4R[TF\0]H+T]WRL:0"@MP84-'H[+"P6"N4V77,B/CF)>ZF%+"7I@<%<A
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MV0ZY@"Y '[^@(SK<GV2WF?@, ;UVD>G$ CP;-6IRR"L-E-A29,:C/XR&L/'
M9]<;\Z&ZG04P_\$"K%7<%M.&W6$WYXZ?ARGXO:*39H>YSKS$-_%(-'8=BA2D
M*+); ZB(7Y&..9!(Z'"F,.!9#FH:218V9H<<2^@)NX<$>5Q4-:;:<9 @?/_L
MP^QRWCUM=RK';U.QJQVH:X\3I+(;+XRCCX&>$T^CHUZOA=M3AL+9THEO=>0;
M'ML,([N ]DY4L@#EY]B-.65BX?TI9D;S"-+QR2+Z]+2[S5XWMV3URUSQ/&\Z
MF>FWOO^68Y2#)"@S=1^D4@.?('9<"!Y-U954K#I/*Q"O']1N5J.[SZ,GH?/0
MJ'T'\W'-H"O_!A5RV\<' (*/9%+#W*DG7');*1>^;4'3X#6E5VI*S"HB=$;$
M7VD[A'%IP1U3L.;YMBF7YW+R!9^'":)UT@_Y:[(.* @5NC#YSL)ID[:!9:)8
MFE._:.:2]#8ODGB(S,MC9-'O8C]CS^5]E<A-NE"KVPWVTIUM#I@3;/XQO'F$
M&_@L]+%S7#.LV9>I<E"MJ+]LN*<P(]9<F+EH4IRBO.-NFJ:I^AVK6X[:&:;]
MK=-RIDFAT,76HZRF]65'(;?Z)E<A!K0:?:!_3)JK3!KP&N T^;G>S@,U[03=
M5J65T>-@LK#9PX;-"RC3 @<S7EQ7F\$-(!!#CV:4P.MPVZ@]%?( +;#">,>>
MYP>_T^YTX&$>5RON1^=A[ MRQ_'<PFDSKX,>IJ&_Q/$[?VAP4BMRXW@[R*D6
M [VB1('LK=)X-E![=+>]9U%OX>[FYB'JW2;,G/T]LY0B[5"VP-^_"*C7%^3\
MU7],04[LFX'Q_E>1VH)!=#5O1S_T0X, *I6/NSM5XJB=E[Z7(X(13)<FEQ"@
MG7"!)J-Q'?'1[;L0JR"W"LUSQ,=GN.;Q4P0:C7GR7!EN R;X>>0.SEMG7.\C
M7W>2[IQHMF9"=UD@<-.,!C)>,)7S".DX[R4V:E[)I!SWN>F+>3)]6/;$Q"HC
MVE4968*:"3EWHJ@[3<I]RGK,BP%C#Q!GQ(33PNGFI8LK%5=&?SO<-*5U>L95
M4X.#(5.PRPP$$ODZ;2'ZJ)1+CU558H?3",H"ZDOVU:\=VB\QE<Z)NWNNF$=:
M:%)QU(80Q\MY88\M)HL\30AA8@C8.-IKI$== C-("LN>M+.>6*^G4T+U& DM
M-S&%RI.<6XS*L*\_]E"\J?XAO$P4B6')2*)S+NP<)=\ZK=D9P#_M>,U(N$"R
MXI+O: @\$SN^,C[3LG\.47PRY=S9)^<>!$MS4*Q#()N,K.J_:_#VF+4*95N%
M&](YE1PK+$ \6D09_HYJW;[!$XTY]>Y*1<3M+O5#)%NX"Y(;N^#G6VYTZD05
M3<==7=A<$/!QFAR6[CH>QA; # DVFKY=TV@IRTO8)%]-=3L:^F/Z-0:,7U^'
MLH&PZM-Z V^L\A^_*,M3*5DW*Q%?GNICN$"K>]<'-C,H1ZC:\SL36&M$NX69
M[RFMO3\?IB'7'N4.^L;7;\#M(:M=5;MW%IS?P6YTE^@&!)U/.3U+O+C-?>Z9
MU8@0K1B6R9 [I+4',S,*7<Z?<]WKO.618_4CDGY2,P0!7OZ84APJ.TS7E;"?
MOB,4=-/G?C"#5XLZS/&!? HYC7/];(.ZJ95TYYAWO5.22=<1G2SW#5NB%W>H
M3L5N"?_+8G6I<!9@@UXR[/+_./M22&\BJ0,Q1'8T'4VV\<T7KNN#'/H[J.*G
M05:+T*EZ^**HSB79<N/?.[<!/G!_$ :8#T\PW'+XCL/0#,@L0/_[AX8'6ZL#
MU84@4!U'/KS:L MY?#*0.,]LG&_L/'T\UUGK#'>/[,:1N5UW.@$^5X7>!>-.
MA/+H_$.._/JG*Q5;.>W0*'E;K#-S]9(?)4@;OW_F>)&&VIBM5K3 Z@7EK1 '
M#ZS7NNUJ2EJ!K'UB0^'(DO^A5W[&<%_WWM;S&%,G00SFZK1S-J^6N"'HL_=L
MTJ]K58IR7?!R.&8]&ID_B++XY3DX<6[BU?1K+5Y/]'RGRT-E&;EG<_Z;("JE
M^QN]#KF5+3+XZDMFY;F&F->+S2G[MJ\W8=J9CV6)V&2'#=4=_'CO.C5 =M9H
MJ.<HWP5MI?@C'%P<Z]2Q*9&ZQ(@-7@XV?VC&.&K";=\O<*@,;PG'O.K=T""!
M5G?+4%651LDEY=LGJ'-+ =U0+QB)=/^7BV6[R8"*0'U2<#/?"&$/7]3Y/M=2
MF2_=4[0DO9?XN@8]%RPT>ZFEZA,XY9A[4\21PVZO;W0S6 R\5?ZU@RVMNW;@
MB62A#DZX[1DO*6:=&59"_&!?6W/Q=6DL3[@Y8!59 )M>0+^$S_T[>P[1 3^;
M:QB>=9["3?$=PB+%O*.9L$4Z]M36,YRFY8HK_GGQ.@Z#3#N8T)=-N?$I[FHN
M,. 1W=8.BB^A -<&6(!CM(J6*K+9=\/ S>%3IC []06E+2R;2,^B=?'+\ F(
M'K-M5RRN=N!+Q+6C-^!C+  "&DS-07\BRG1]5STGC;]@\8?!R\D%YC57L,D5
M:<3EG)3.J3/_^C\^W_C_GI6K=MT['E/HS S[3M>Q8<+G'5)\9N7CKP[YB2WQ
M[C]*T"&@* Q-F^KG0J.6*9N-P4A\0>%HI@-VF@680V#$"/(TR\YJ B.7OGTA
M&X0Q8?ZK!60!+L]^8@$<7P$')57H.VYPA2V+LU;=!XFB >+![#X?J8'?%>=E
M 3YZ&;%)D1IHW]+F3WI%46_O^20'2!*J2)9:NSV%IG-\SXF62WQBGQK_K[C
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M>ZZQOE0!;H1$:TR]NB;K_;T\;SC886(J3#6 GC#TQG= 4.#F"0E#J\0'HBS
M]4R8M7R0LPMD194NT'<U=8ZQZVC\_BD WX:L@65B5[KI F\,8'R.E+?2>R\
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M<>)A )P[#(!JZE!%2V_F'?OJX\_I^:92>L&!BVV'+N$(S\1B.-Q=AFPT,AG
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M%BQ8L&#!@@4+%BQ8L&#!@L7_+^",L?\ 4$L#!!0    ( "^*A%HK28(M]PD
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M?H^ (]R^@KIGX>#Q]"Z.+>#QXJL5I '^.JEOND5OIUCKZ^C-U@:HORGTHN(
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M]0BHH>65,>RS>Q+SF+^DS2E9Z#Y@]=XG3>^;]E]/)3@VGDY-L$^OR81_$R9
M7A\$U!24]FN!@_;$?Y(CO:W 'T^R^+ONAR[];0:\_BV5IR[RZRQUUI>_9\Y_
M,DP3(7K-_^VI@C^G@-)XC'?W?W>L $[*\1% A'I1L/MK17F2]!A>ZJPDDM_P
M@EG^E7286_T(,"":S,H=+RW_+P<+-'\M(6HV-H85'TL8\R*>J<#EQ/M_>Y J
M4OJU%_I-_TTUEN./[@CR\$2K,'_)-0X!+3WTSJX59"'-L?L4;XLC=K?9Y3E1
MU(0]F-YBO"W\JB66[ZBR9\G>6P'):WKIJYM;W:-90=W?2!FWK+S7L004H476
M0,KEQWD@4\-W59M0'!%!5=]_4)D$+L+X[[_&P9/""]<8XV<H;8G*RT+>J'F-
MA '_$+O?OX[A&($/50/<(@J7:PB/A9PX[+7B.NXH#6!5<X _E04AQ+M\R@UB
MM\.)! 1LFI>P(FB/'&]]=-HSKV@8*QT8%76P41HN0A!\TQH6,:WX 9QHN (T
M0PWVJ KV)-=(#ARFM^L?-<2'4T2+^/0:SFV79U=.=:*!JE3?.V]SJF\,ZW!;
MAN)C>(N<KVB9P0?HQ(4S]#"G73&L4Z0E>6/+1T!KPAG2IU*P!:3'6: ]2B=.
M#)%]NU=20-=WH!(W4?58>UZ7_;): >T4%#>'G=@7#[IR=^?N+5PX@](<^&HU
M69U8+:X37*T37T]OXS4S3RM50XQO'#];@\#O "@60G+S5)TXKWX)/F<E5[Z)
ML-EX&^/R$5;,?:AWN<(\O/V!^O3[J.<9@5" %XEK7A?B1#)S53L[GZ29*XN[
M3EJ=5W8@@5]^<]L#JS?CE/S8$7D5N-* TFU9K;T<.M@SPE\AZL7M*RW<Q,![
MF4(]RR&7$VQ&AONREWKEQ?VE>"1""]P:L"<].R'5!==6!DE?YE@D9RW2L3^>
M4<UHA9GQ(!+M<7ZTK[R]&[$EMM4YPT-<!D<JW9GP!HYP-^I,KTJJO@T/1@X<
M9&T=E.PBQM=0MQIBY*<H>D@X D[,#3CC[W$E>HB8<4&M=A[% 9)@7]C9Z^4%
M( ]4!1NB?"75J5E1BWO;WXV-8J<3(PA6FA_T/G+\UWYG7A7I_]UJMVI>+;/\
M-&F5V?]QT9MU0V>+!ZXSV</8^5<4G7U7HK-^B%%DN:[/$-M-2',(75%:JH%*
ML$/P]*'05L8N]1U%U_W9@YB^$:8,"Y1P#_GR\Q[;5^^I.PRTQT11L@]H(.QC
ML3-(NU&'FG^V)#*N>02D^Q1\R^_ 17B /Q^Z1U0XR8:\#(>!!'B80V#SK\<J
M[Q F+*X8O"/6(.X9_4J7?)$WFSXL:CXKU,-"VUQY/LO2/N%$QW'OB<[QQH2.
M*80Z0U7WB=3RY\$_6V[=A@CVV#\"^(<V:<NO4T3,6B8K?_CL;0AU@M=,W2;6
M3)T,HWH=4(=';62<D!!1-B@J,^P$#7R49"AR-B5(V?H(5TM1LO>DU[9L00I\
M1!,DX/ZC/XG_&^P#QLVTMSQ![R]2S,\PO&/^P%3MEGK+\(+;E?K/\E^8:VQG
MIP6/K\QG_EE6]D[PJ5CKXUE*SQX%C3T"-A+OD6Z5M]Y]C]*372J;__=@CM]O
M4_GB_JJ@OB-XXJ/0EZ)SE3\'^XM-,O_'P21F&(6VDNX[#+(B7(C^^G!/94$9
MK=ZN3[>,J&23)2KS7H7GD,K::6]E@OZE_W=R(_Y7Y/ZW&*Q.NB1URR.N16NP
M*"0^&'M;.-8'3Y!9Z0[\26+VG])7.B+!AUK85BOZ;VD4$_P'0"*37PAB?@CA
M^86QR;\Q9OD%21Y/:M*$4A#JR=*9WOI#'$'4CX!)ILF4$-W#M=L<!JLXP:Y_
M\UMIL./_2&W'GUC\2>:O07T*?G9HV[4[5/Q#\'^G1N8/]N03%*^8])O'MZQ[
MA)C/4/W"/"=@PR>7#>,G(TC^P\ _Z3/(RO@G'_Z4E68Q_'W!?)0-U#_+R&FM
M>SA"GXK.C1+_F_;_Y!O57SQX_NN#TO19\<Q\NB4F$&/;3_RC9Z4)A.A*C#,F
M!>^'R,5_Y4#^GYR)^%=][I\,^/?G5/B# <.C(S&='/9!.-WWE@LBIH\ PAZ5
M*?9JWM5:Y9]JB?IW+Y&&Z# CE^$/I?3"4EJ;+V0^=O,1$/Z!M6&"7]0Q:U;V
MQ")!;J..I"N-^*ZC47@;SKU=G>OEW,V)=N\Q(A83BS&%:WIHALJT^E&[CI;U
MO6M)!V^\+9@O[$J=!^&4(WNY%&OVO8?EM(%.G[T%Q^F0,ZY?OZ'X:/-!D:_$
MD\70%($THR0?4]NRQ-ZXZ8"N+<=P.B-A<^ RM/',Y7[C++SF8N#-BE*2+J!7
M.LH3?5PC5V(MC42L(A0+E> 1,)O;#ZB(Y.]I$#S$LT *(TRS5^Y:"W^F3Q^C
MK2O9&_W9!KE8Y]"_X6.6Z2"FI+->6T9,8G71O5\?X59J59I#A2B2=DW"^_:1
M3'V]9]V&![Z6]93]MGJU4$'BK*BBYZ5BA.PC^F/RX<64GP_>H4NJ<]@+':8!
M>-9AZ9^OE<B+VPN?1$0Z 1\!E9,G$PSTV;-5)]5QQ]ST1=V]-02>'HI%$WN
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M>FTE?,L[*IOO@.DC#C<,.00ZN[MDD<!1QG_U4 ;G)9Q++:'&3#5.7QY9:Q<
M/\Q^:K'"2W+RI(L<*PC/L8PB'=JW.H7DA9+"NR]$O:F65?L3?E)+JH:A>!4F
MMG#%F\/X. T5WS\(T%:M[-+E!JM41'#;S)Y<B>6#D\JFE]BLZ:8.#\@/!<YF
MP24<R)1CRJ>'Z8C^S*?^.@=82[5=Y*@I6\0GZ4DY>U)\W,%L^W8IP2 Y@H;1
M3+>5Z&%XH]X<7P25:Q.S.BUP$0Q95I=-F0Q]IRTM?K *&J)_FY#7J[ETRZI@
M4%Y2[K?.=KVLH4K,WIA5?IA]E^^"$[JGX%$BMJI.L9(T;^>,\IGY@8\H7C5]
M7OF9:]4(I]\:CSVFM-Q]<O5T0CUE9NA)T>?*$\*G,U5(3/ \UMQ:CS1Y#_8]
M(L#N[L\Q(BR0J&UJ+@2W"F]'Y!UB*X133'&IL\!_.!D3QR75]BL+'\94JHQ>
M*-QU#*'BW/7Z/+]=EZR@[</I=Z!V%FPWT>A\P9J#(K6L,9W,SV2;/2W*Z-5]
ML"8^5*"D+VZ.Z=97V!8F(ZZ;%4+7R_U[\!)! E+VH7+6R6?O]9Y<[OA351[4
M[P')V,/FN^8GHT*A[A%P^ C0!A(_9U80EL/<;.+_/G[( 5+*!D\<4EI1:[Q-
MZ$F5L+5#LF4%$M,,_I!9QX3U5$3(5=*73'YRA&P&RYVB.=;F%)QM9L!J(4*,
MJJJG*41\!V>L^0((A'55U8)L[B3Q&S7OC73,$"^9TS_L)6C!'"JV%.M(M1 V
MC>NBBF<C1* *T W=RV%]YVBTG!R<4XIWQJ'''7SO8/C9V'[+QGJ%&W^KQ'-<
MD+!RW'#T7L\Z(3F K96DJJE&BS1Y4_REH0L;>JW#5]YW^!'<7U'%N\"PZ./H
M^C)6^=??QE1>%GL$3FK4@;X-O&*A7#"6C$QN> 046?-^OP#<3@:W>1+(3RF6
MFX$G@(98K(SYEYO>%;HW 89A+/Q^]?0UV*2A?CNJ<95Q+4YI&@\C4C)4:H\
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MPIUXXA=OFZ2S>,QSVWM:HN>/@"&^H_MG3_W_4T+\"2W\%S1:NNVE:U5!S$=
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MNKLV9KR(YCX79VB535@QA<QHA:42E& I8%#,V08E#!=5(T[FQD\!='R#-7P
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MP9#>=+V5*+!61@[S@'*2KHM?^IN@*8I++?F6)7T7J(Y:!EV>[,3Y($&Z*@5
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M/  0><^OETB<W:R^93 F*E)'< -[*XLUM[T$7P[@^C*&<6>E_2C.F1>(Y$[
MB?R_!NC_\I#?^?5UHP+=@>V._P-02P,$%     @ +XJ$6MK_UB6>;   T'P
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MG2$]!:_'?+HQE*VOCL-_:/(1-27[[$KF?V@A8NTE^?.4^MN[+%\G;U/;SU_
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M..2R"C[Z<0[^!#$<.$(6VQJAB=^5+_"';%P6I85J,JT9A0FCUH=HWEH7X>.
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M88DQ':8ZO!2'^SV7.OT(M.\<*L0DIN(\O@*PLO+#&/4=_ROL>H[<BX'[1*&
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MS?J*Z.N1;?\^.E+ML:F.6=VBL/%"S. L-RE@PQEC.LU60#:_X[,M"Q.A E>
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M*I%4P_B'AZO_/PYW,_\+4$L#!!0    ( "^*A%K/IF/J@Z,  +VM   .
M:6UA9V4P,# R,2YJ<&>TNP507%NW+MI((,'=W26$X"Z!X,'=W=W=0G!W:-S=
M:=R"0W /#HV[NURR]_[_<TZ=<V^]=^N]V36K5M<<ZUO?-\988\Q5O?IUX74=
M@"(I*B$*@("  .B]?0"O2P!A  ST.YAWT# P[V!@86'>PZ' P7WX (>!A(R
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M0UERH9G!P\MM+\HZ*RY(HO;WMP)@R2_0UX=A1_E3%521>5_1!I-> 1_'[B(
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M)#>>U222!^#CE)^N8!(QK8):L+%B<=O3\D.UQ:D"G_0^47:XIXF\W5MQ(]*
MT%.D?L;Z3CV>TK?%,^P> ^[V%> 7IT4,T_2AA:U)+]5FY7"W+IT7 U,DC\=N
MEO#((\G<HN/^;>,5]PI84VK]N_$J7Q;9\V'"IO*[A]J_7)N\ BQ_O0)XL5\>
MLN%OR)]Q?8KN9].5/8GO;G1+7IP-G0'X%@TYYH3'Z3?3?@:)<.S>B.K+M/DG
M.3P\P;$78N%/?,X;&3:6^ 5D?+T_:7%4==8B#9X=Z ^/;86KYZWY1TL7!WC5
M7D@''_#6;7S@]F29S#Y5D0I/0AG!/7RD<GS?)YK+::&?<8J^^\"B<^7S8:_G
MQ0![K8#X+/_*]^&]SDOB]#-(>"2Z3/Q,:_)?ZQR=;^L%K%;@1]';J_Q+('*3
MMX98@"$?]]RFK@9_?%'WK8((7Q6^"HJLUA;3EFJ5;W?\Y/DK@!1^;2KZ3J%%
M0/<8'IQ58,H[C\Q'V%]]J4DD5F)9/5XF7*RI^<X9#K+Z%: $"VO[N'*PE4E6
M)^I60>(,4D<1PY7/8LP 'PY5R;UMP>CST/OS/ \7$[PPWK90>^2>T3)T O5V
MXTW/@<(CZ+U8HB: T7<5;<,39#3/5X)ZY"]4=0S7_0U3"JMSJY0ME_DQK9^^
M62RC!#=B'C&<J8I!98C>5EDI^'8G3HY+"]V^Z5_$L:D(KBF.YM!%-:]>TEQ:
M\LXAA_[>Y37Y/=_Y='PJU7A32IQA*Q#;\MX,2R6$R2$/&C6KOYWU;SJDGIG/
MM+ _&7 ,7ZBPV[SI?.L_KRP\1PK_LN;]%JL5'".I_%4351 "+B#NS6<^:=ZV
M,$6N%,D*:>9(1[RDO3U<I#_9CGS_B0#X+.\%(S/Z%? %?K5Y %-WD=-278LO
M4GB$X7J%:JXO%]28Q#=%'S)\\CMH[ M?S6)>=*\4:1BMCBENHKB5@_I/K6?Z
MF>B?TO@=.=X',B)0ZY71K5!R[0_V8C=1>"O""S.\8(7YC\<VIZ1HLBY2=<8)
M@!]^[(P@;"+JQLP#R,J))4Q^(W/ \!9 E>NF2NS-\]1Y$;Z]_;?GY&\[Z_@I
M@3?7/RBH!^%[UCSB9F(Z3;+-C-J4DYCRZX#C&QND18"W57<*0*[]XE7_+ N!
M#8F]5\ 5:OLS?2[7&!'=8NRU>^:'>_E['^=3W;>$^BOA$CK_%K[ZDJB[Q.G+
M])9:W^7O5-M]NQ/^=NV#_"L 3E9,X!*E0R D[]$2>4?@+3L5,S&_?%QS@H@;
MF(![(%\?^+$]<:7.R#@SX.G]73Z8)B-X#O3$<K8F>/9T:/^NIJF%D#+]A'R/
MOA;^JHK\\\@<]7)0_Y690VLU.95?YDY&F,9%5&Q$)\W/T\6ZRH]D+4F&="_G
M/DJQ,+@.7#^O*]CWY:@?]E_R[N5@U"W;&4^)ZW]#PL@BPD$,&3Y]G>FTD@HA
M3X)A( AOEJ'S3";DI' JEPHW9RB,NQAA2HS:SR%(/9] . /E&[J6,)N$@&-G
MII38ZP;L<>/8H0- 75R+*S./82D-D_&:(C2I*]6\2.:IIM8E4TFL+!Q< P5F
M7R KC+DS(C$\$S?J?P[AEH42+:;*0<CT&<P.<XYCNE7NBLV77Y4A?M19UNJ=
M*C'O%80X,4_.9'T9;KEP_B5;0Z_A74@+=:J.XQSA.2?;:XNL<Z!#/UV5,R5:
M8HK8.D!!I<OXT9U@RBV@>S$YK* A: >U2$U-\Q0DM[2P_ I \OV-4YFIYI#'
MX9D$LB6P>#")-RX>VIBRKA2Z3H>,&(#+]YP!)D<Z:])>+7%,)!RHAES .]IE
MDY4<:!:QKGA*SUV/OUOH<30)+2WH96"F1V"?P]7S1=@L]?IZ=GU25&F.+6<N
M5:JAV;W/RN^:/'1;0"23.]/J>P[[R*(Y=74L,S#$$?LQ[AL%0DP2)R#KVVT9
ML"B2=#I[W@0X^9MUB#S$6N!0?8#XBSJ:FX*UHJINPT*X-;LV]5$%T7$_]DH,
MQ$WI*OX$Z%E 8AZFJK"G1):U!._K%. 3F7QD[PUG7A)^V,61U<K=\$//%^ZD
MDCSO]-2\4!09 O%*C^]\=%O\C"%BF\@-FMX95Q%8*E;W8:HDT17V4NO'SFTL
MON:8C;'0\]6CE@:7MI_)TAM']S5>6,XR"XH/;VKWBX.F;CC79SYXZ<L%#%1@
M!5[A.7SDB +A?BH_MF:E3-KT5&XUM@P4#!OP'_<X(8,1EZL--,AN&K/SIA_S
MTMQ(*_'2QSS2(+-(@K>(*4U]ZF3P/SS52;3Z\06'=CLFV_JPWD-)>;NV1JY]
M93@9*W4+ :_DLN^V62>UHE_.HOSL.^(WXV%%B02E$P)',0VCV!3-[7W)2AP$
M'^4VJGP3L'5PM&]W46-"$!0Y_RZF=HBRB0-D%47\],R<H>UL2C&%&J1RB,#Y
M1;XS;/'/XG3L+_VBZ?.7NM@!TE"1@[<(G*']G .^W>E."XI>%T% [V[I,0?4
MFH!ZEY*C5 56.0 <NQ_G9OFR[T!=EL40$#F,I&.UIT"B(='<')#25>G:_T(L
MB^9F<REM&&S?PGZE/\@V"=3'+<Q?GTG^PGE)3XQ_P*[*;7W4X#K)JLJ$AOO^
M)^<)GXA*53FO_ 8#<6^-?ZD&^6 >/-W9X=T\QMH[)X4!Z^>#W1AF^GTS4Z5[
MM&(09T&@^9X;E=FHY\0=?1[Q?<CJP\V_J^GI5,/+[Y[[^&MS(GA1RU7?#<F]
MM2N4CF?:M7\5H 1?JXVGOFMS)UYT5M.SVRK/O\K?*V#BK>W]"P9_;2I^S.[4
M,WBVT T7"@=CLS<][O>>#'CPJLKCS9SV'_/\OWK6+O'B6^]D//9B/F$L^W:F
MTY%]2Q(K*4&QE>E^XO[?[&GS4-^:)O[1LPCQXITMT[.&Z?<M/]'=G\=-DX<1
M\^W(WULXO(4>+S%.[Q0\!)ZA&7TE!4!GW0_UX]!C+-_='Y>O\X\'+O\B3?D'
M5>@_2/]IQ,=>'"G>;Y!(."B:42D4>%RWO%<4X(M_6"#?A^B\&+QU:R"'[#'\
MZ8C\<U40\9M$)MZ(),[].(F!G)O\<;#.]5LI5A0[+EY]X7S#+HP2%<WS?%!4
M[R>TMO^#/0F\S3M3%(,VE>_8+602O*/-(P)&WN[+/IK^7;0U6'1N_RKFKX#L
MP--]L2=:/N*7[QQK;RXJ)=)_"\P'H,:?!O)'GFTGDV36.R?K'N?KRTIW!<%Q
M$.,QD*,%N73PK)V_^U"Q,ZR_'PNX8QBH3 A;<E55^H2>0QW,RV%:)"J,D_RI
MR]EP9LK-M)M;+&B3OD"CW&;-0_4^_86J!;'-)W$37'.*<3Q)R&KVR*?6*H)O
M;E;%NX?3$W!5J8LYTRA\5:GCQXW_SWY,JI<[U^SAVVT5KG.(?SV!,XFO1JOQ
M*X#H\%I@+'OV(\,U#S6H5?NL^5WR/#0>H*OQO")BCF>."VN]W^A",A/ 29$E
MZY%^]TL\2O:3>@$:;0\$.@HR[BYAG:K)1#FU.5#<CJH1:ZRL"S4@W<=9NAX1
M_U-:T#9BL]>JH)7I/1R@QG&S@F[5,F0KH[&GT:$43>8D94!K&GPNFG2P]6U]
M '^(+($G3^FPR:4TJ0-IBN$$SRW'GM38_C*^_OO[@6V1(+^: XW1[2%='@52
MV:3/F("NP[7FVVS8%;?*08U4!NCX05+TP/=VV5?+GB9 7L.\W*$=F9]@^#:Z
M)(AH_5-@U%JWAG8'66B1B%M;"?FE^*5JI>P$,-6+MI!>.B1=A+Z\@L@-H>T$
M W 8C;V/^J%M: 6:3GTH AQAA*PXN)EMB[W?,"5Q$S>$E_A>68K%1GO9_UA1
M=L.:W3(M/$@=:@S?#O'B>Q>DX)$,;8V;K,0/0.S0 $'S[G8_RU4V//L+]=2)
M[>(8KMIP3:H$C4L@%#5P+*T_Z8.C4:OQ(]N@01T&"0*!Z?ZX1H#86<]^2WMO
MK;:H59$P=F*4L98>[8.G<]FO#3YF'J? D6,\VDB.H8PP<1ZQ!A$ ^VY?$M16
MO2%+>0D14_UGZG<)F=EX0%WL?93RUAVO/MK0!%&)98&B=B8OTOSR_'L%%$V'
M$J^0,P>A!TA/16M>P@)-WD@$!>-0BKKX&=2!=6D \VV_AI$"K\H%KHFRRMAT
M-:3]_'F^+H[YNGL$1=3OKVDK,P$7!$8>$;,\R.]8N3-ZQKE!X=7\&F=CL'3(
MA7QE\FWD>BJ"O&M9/A!6/Y <NKS-H!R&G9I!86ZU"B((S8<!B@:E^R[RY@TH
MBYI!*-VM<BPVG ^S+8!O"HHEB #]NP M;:K-87*;"U!/XDHZ'8 G:UN>,=PI
MFAFGKZ=N6*AXP8V:$W;BS&.VW54L0!6%X7=L7FCO=X8%5?)L6XN^VC/GZMKF
M:#G2U9VCE4$#'ABQ+X?^88!FY(CZ4"SF"RG4.)50J'X'<4[J_<RKV?/"2(H@
MSIV$&DX$ [UV<5C._=B(&;D[3Q$6,586-,/$,.9?,1S.LCE\I;M/Y'BN2887
M:>;:?J;5U@M/HP !J7/$BJN)[K3%C9DZ:"%EIF?P8DH'_53^<!]%G$"Z=?='
M4\?/A_[S4'/AQ,@+^[=#SF9&H3='QL@70_M-KF1EOMT,A0R[B\)CC7&2QFCE
M*5:W4$N$9A#6O+I%' F--GH9OS9YT0,5_60+I(@CG%S5W@,%ZQ#*< 8!3@C>
M$->% QO>C,?PK#1=Q48&^#P]SC!)MO#[TZ"B5 )_AAA1@ WAET'$ XCL]UG]
M>&:T-#'/,<$,I(JQ]>OKJL*FCH2S]8I?988PF'<GYOEYJ0M)@+)KL/'NKHS/
M)VTN%17,4_#P^)Z:<JM?Z3"9'>ROL^&;"@I/CF7^_);&"HBP2./__8D_[UXY
M%0FB/)4@]00@T"N0R)K"YQ]U0PT4'=JZSLOU%W'JI\7E<&3?1XSH/B$-X98F
M$LJ-NB#V:+?AGP6!>?+T$\F;KO-COXY6%QL-C.0;?;XJVMNH* "..1Q7[] 2
M0SED#L/J3]65D/:SSTPU_J";3=12H.D.<Q$QL.C+36N)[(Z)B,:T1'7S_=HR
MLQM:(([MTD?,Q =#GR%+P.N2-*^1%.YJ;,U[WEUY00OE*SQ@,7$76[1BT0$_
M4WY$:FYC(HB)L9YIF3KYQ&GK15FRW_F;HP$;&:T6-+-J<H]AA'FUI3(IOSTS
M)J,ZL3;?9FZ>MVJ!-0I=]QRTK"4S>05(A[AF0RH .UH7+_U>-+M-GI:P^+0@
M)#88?*@UXD,P=]+VKFJT6,.W]Q6@N(@ B C\]HYX9':_XCJ#O$\%&-@0S7;@
M:US0L+" &(<TP%<:]UU%R"&VQAG\Z]UDN3,\O/HIXM8KP$1-Z9US?'K)N'"?
M2+G;#1_:N'2:RO2G"HT+8:QN81S[)S'"LL2.LZ 2Y,#ZZ^9:#E=F"VMO9UNK
M1W4HJ(N2ZXK8; E/QN )<U6L!R\3MQ.#)E^F6'6[#ZSWYJ%<A*I/%'/FY:-%
MC<.Q&O#3]NDYLA;CDU[&5!4D<8A8-WQLLT">@2X5@/. %M'LX!X_RIRJXASK
ML:!O;[O334U]RY@K*46E3VJ?DPYJ\QS#59HWW"O@*Q"KT3_;,GN]UXY?@;^^
MX#U#F(P*HYMLW[1;E-HB']'!ZF@/9K.+=A$L(0OPL(MMNQ/>R3*2;/-=QV15
MQ8FRT8K3],XG66(&C\R-0_691K98^27YWX6U >(X1,_G4L#P!%4@RI?K\B'#
MSS5T_(JWP176L;'JP)YP3[%8N2'JKQ$$6/RK5YO7$]\&FF(.L"$7?P\&,NT,
MX3N1OZC'GM +L:K-4%@4!P0JXP \E#7Q'8UQQ S)&YG%>Q!Z;SE/Z';O,:?*
MKU@L>OQ[C)S*K!Z/TZ$62Q!FPI8,8SQ5V$BMP\+9 AE$BX!Q=1]I:<TK! D2
M7P'A4XO3\NU2N#LU];XT(_E>)TCOH0XLYA(W+;7%E%MJ0M7YQ]$D=@4@?KD0
M%=:=6#]Q$/;GUBW?&SK4WSR.K?Q>]S^05JZ)[VYQVM+HU\ZQ1Z\+"!E?A<UL
M-X.\=)M#A?]<T[Q<)X'?*X@0DK(\L!2KP:Y#WMC<-#,E$O?^"%-[*]Y/*6++
MTZ"6#5X6409.E@O_Q+6.'LS,24S+_\,PS(MCE; U7BY6XO-*KV&3"Z=VS5,3
M8 *:NRC:6A]5HFA)UA-?](()3M4,!WR-660-)F3(U;>GE0J9U!"?E0!D;< V
M[Q:8]&$']KJX;%X)I*$&?>SDD8 E6O:? QF=1650+WX1^\"%-%CA%\44I"O<
ME?TNON]!2Y9Y]";DJ?"KP20*!^=P=-5<Y8'&=5":/0*' S-O-FK@1PSTB!I"
M&/&=XA4WR>%M4_7\)GWNW-''\<[&G(?'V0SA'A>\P+ZV>::./242>%*(&;U
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MBG;%G2;BS)&0F6LR1\(F7L$]E=?VDM74QN,I<;+L!!6\ A8^K:M :_+;)]F
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MKBULK#]@+W_P&E/'= B >BK^*;C5"&^H(U9H*]-1@[GQ9 $@*H89Z E%]C1
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M0<$GN[**VX\2!9[SXQ[)LJU@2Z&AK ;@4MQ4VO PJ+^H4R5Q]JL9]ZN?#VP
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M&3ITI2GJT#Q/ON@"Q3T$#/6N3G8&Z]!ZBM(FEFWR67U%0*41Z(!M6LZ*I"*
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MTVM:'+1#%#%%S7NX]AW1#@$4 JJL:!^T_]WF?/IH_#F0M@(&J__!S+M6\!G
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M,"0]=L7)AK;9RR:,8W7+7>SAF>R?T.I,TI1N=_%VIRRW%WC7DZ'EVI!L,V&
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MR -] /])F=5MV-MXN%E!)+)W#\65,!:J'U$62\HL@+-L'5X]EH7^S(89%=+
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M]\PH14+Q2NNL/ /.(01$B-&\^N1*=/];[K5KS;VK05B.OP%5 *-F-$8HFFS
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MQP?2?Z/WV3=S4^K-O[GWGU0!]^YF_P]02P,$%     @ +XJ$6FI-6ZY>@P
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M29EG-*9XMYXIMWK^VH#P%: \3=X4N\0HI6]:<=V#WI],AKJ/L9(6$H8IO_V
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M4\HUWVQOQQ1838GA$\ZE%2P?Y.J-#3G8-86@B[(/D3YPA5D4"+=\=OL1Z\
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MAWBZM1R'\T3,]I$JYR+[T$"WW28_A+<&:KU&-Y#U08V^5=X%)8GY6^8%ZE>
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M7K&')? P<BMCE$3O%SGVO_OLO%(B M+V(SI(/<P(9H@!W_WZ/U!+ P04
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MI\7!C_[K0@]_+H<AG$J\^V=5N@)"ITJ^TJNN"@UO$YO#S$?]^'[KEXMX]MX
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M, W[7;9WHJM!5<1Z^5:K7H&V?_&.YXF:OP>ZC<]:U\/?]G//4YTP35A1&O7
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M;5TRAP^4TE/[,KO&!4;8+X X'=EQX[K^%T!.Y.-&O&Y/+0M+_TV^P/W\GQ?
M-^_3QKCLNZNHO[T?GG8=%6AD+B\Y,CT>5]TJ>H+2IF <MP%!1IVI)FCE(NT<
MT[6+T]"KC/G!9%L<*>VJW23.L<EC?-/(N\HV[>JX& FNG;L%_UO79]?(%/ H
MU:7@*S,I*7N_TM#!BC_<2UHMWI4;G[9VJ<KW6[1F+SGZ:)D&V(^F>5SZ>H_
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M1\EOZ[3%,XLNY)7MJ-#QD7#O5X4I<E,)\C'GQZQEFKQCQ>=EZG]$!!./ C[
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MD&NV@U>Q5ML=U$TAX 4U)(L"L;BZME,V.'QG---HA+4S=)T6RTRZN;_"QSW
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M$Q8&XR@\.:R-/CFTWP]+IUM.W]HN=R;^ 36OX=N-8M3Y/B%X8Q(O[LGDYIV
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MMA"S$81;@B'2]MBX;47EFXOOY<Y0928!9S;%+POA%V]Y(:LD*+US4(@'WYZ
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M0 H#LI#"9-+^@15#.1EK&.%,:H=(G@-C#5KD/QIR:BLC1?YCUO1_*\75^/\
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MUZBJ#0+.O!-2I9-J\.KE-/M/'YY7TI0O_(K1YN>:^A\[KS7FM=-'1I*P<,.
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M[@MOXGW0H= YW27*"0R83?Q[5?8_:O(]MKN'KRF;7\,C,.SK)?ISL;];?RQ
M165,"4'#^5_E8.H/[XO^=D*3B3'>\E^.R;$S_IDP_ -2*!#IH9HO"W_5X-;?
MM]4NE,4]>19UWW%>LD#$Z$305>5DXSG2F:?(&I"VZUY,3]5_1/3M$XGX@!G4
M<>F&V%>Q>J6P.]C0]ZK)N^I6W_@!)]GXP4>E.7>$LK[Q!"O1::[7CC2Q!M4S
M^=KXLA$&Q.2DP8!1E;SGU0%!4&=^WM1LZMBQ5$AE),2EDW[7Y9><34XK'X8
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M8EWAB&+>]GQ<J2E20S/BC K8IXJYZ;.K/X@-N"B9-5K5IF]X8D)+<Z9L\I:
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M@7G'40>>V1M[75L>EJ,X)F&(4,Q!HJI+=[?.W<I/VIZ5O'OT'"M6AISXR1I
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MN LD- _1ZQE" O2S:CF@52O5=)BZP4F?$1ZEIIX?Z#4U]O/3,D@Z<J/F31
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M^N__O .$:">\]7O?2[;\";_MK+\(&:3#="&8<8Y1/M9VKGCL?_E WW\A\0Z
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M]'(L^-O[@VQ/GX9AM2E0=D*>&1$(#C.>]&FW+3&.$1D+#L^</0\A+E"VU4L
M"0XV7R"IT1A%:>45:#6X[:RC?-S_;[E-_2TWT!+CZ!U@@]P2;1OTKCG3V-?,
MH7U:%)QA961'JD^-&"_,..\  30WHFC=\E9$6Q'CY)L+4U0N^M1?<3_O'^D[
MJ$7V7?==B?3^-:+"OA#_BR7^&Q3X>.&6Y(;V-E 7=+;J_R,6W;+CY8,W:,G_
M>4B/^B+N%!S[%Z6-+D[O=67R[<4_VA"-UH:2O[1!Y7\JAYHDQD7<RB :9:$Y
M;E5CGRH#K?^G7S7_].N/-?160#.K$_N'V:RZ]NN>*^ =X*C']&IE/&G:^0[
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M>3"VZ0E#[<7RC,AI1O=^J)=N!&I=ORWH#J +>6G>I^3P[>N-O(]1+W<?8PA
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MU5EB*N\;;EV;+ PY)88U1B8>#$=TQ1\:T;[A"<UPB".2Y@6).E=PS,3 D/.
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MC : 5.&Q<Y$7MG6\/KP4>U@-W,T*=%:.4+V)\G>1$^H%/V!Y>3BUK%2:"Q
M0CL.HF"'&RF^S%L]J"Y$/4WUB./(XHM8,C/=AZZGSS)Q,-<OQR/:RTP[I3D_
M&TVX?G;""!2>:BX72"%A.L%JY*]Y[O$HJ[V_$[.W?"S@R=RN"J2W<6*%4O>S
M%>[LS*\N):Z7 A3<2E9A!'4O^TQ;0AGYX0%LK+A".LN-L.0;U<H^[]VW3OI>
M&>%V+G-ZZN-E]-&3F]PT@>-T1YLRM(8'\*^MW-A*B)W]XYD2E &MBKNKY_M%
MXA8U_E#7#9$KQ:;J4/F:N? 5YZYT9(#8_8#C NY[W-\.PB*84"MN6&\8ELKV
M= '%[>3#!R0;W(JO)ECC1>V?/ZER?)K-$T_TW=]# ZM$E%/L !*R9ZZ@XZFI
M'P-X#X#D%"T,WIM.Y7:L*TUXN##P091P+4#X5P"QE(W[.R>CT!)D1M5YEHL*
M6,CU WSP8PP=X"7(_3="$>S"&DF182?4:)G%AZ.]*4,9F/G]M;2+&5I4P%]6
M[Y>:&.I+RXFW,94JC^#3WG6[^"Q\\\<8E?5:>Z49A-NZC:>)A#EO?[U->*9+
MJURQ]3#W@**2(2[79#[W_9[*FU_Y#U,<F0-$/IWLQRI[B%.7^A-MC6Y=2N4=
M$G$/1QMUO2%E\*89I23>65CKK7"?%9!Y5&W^I57RM9H3R3MI.^\WEGYF1[Y2
MX#0X4 OB'BGLR[Y3I7:3R4CY<(&+?,<:LV!!J;6Z9F#3@==G[OF3RF1/4]X5
M;"8&HF7]><$#5FD:6$W2&YKE74H<!QVJ>TU-:"B6.]<C3[M%)(+)Y6@J$/I\
MCS;\4D]\B8B,K^6FH'6TM+7SHWV*\H(W8Q<'9C%O3(T#XQB$:*"#(1-.45M6
MEN:65%=796(LX5E.9G6?"8T"KQIZGIWD?+BM7><\>#ZPH^3NG+NE>PGN7Z4M
MB.4*>]9_.NARRWS E[%T0V;;&!P\+<15TB/F,#=>8 M8F%-8,H)%^N@Y+LU)
MPR]V^1PR&RWEK15>\IZ!.6]9?K.E%1FI6'@E&WAH.[W3.RN.'@TKS"22P?I"
M[*4GEG.>Q'U5S[L&2QHS# ^&(]4OK%-N"%PT*\1[38X!E__[2Y[_+N^^1_H*
MA#K%?,58!9$"GY1NFSP.0O[@KY$9"<^Q8%NH:MU)9LA%&"/36(PFKD$$29]+
M"21.R'65?CK,"GSJ=@60W-@HWPIC($VHS_66^?'U56QRSB<M@I0,WA,X?J]V
MA7Y:W ]O0#OL71"*IN4-(4<OVIL6W!(OA+<=2Q7<8L+]6E SO32GB=*IQ1YS
MEM7?S5]0G+-C2X&G*H]ST";G4-+TWK5,;6WH/!%==C?N??5COP!\W-1;XOWP
MM&:WC',"D\)90@$3<201S98!4;>Q09^AJ:VHG+H^"ZR.^G!F8N3!_KE<*_.G
MX9AD!O@Q([:/_!T@:].?U@L-#_#.85W2CT>!XCFMY2)?(=W72,.>]C@6+2>:
M*T2%!YY:ZZBC"+W$49=*J2PM)OXK60BC\5J .('[4EOTR0W;NNJDCUW\U"S?
M%)GA8IR)C[\EV2Y2+O9RU50K<UM'A).&7F+M9?JSO#>_<_I_E%@$^19BKFE>
M<6 @NJP83W[&GEL2>WE$W0$6BN&HI*;RS5NNT8PNR.!N<W*R.FU-2OS/3<_V
M\)C0G,F3<I+-5J[&"5=[VT/X;UMF27#?R_@^^>^>#MAR,M09J)]@Q.VC5Z#M
M- G^*>UWA=M(57)Q[)\;\EXMY;$GQNHF3; 1%X]]8:BT):RQ0>B^>9>KAK=>
MW@O!AF?K$,!AH0_I 2X52R@_/7,O3; &[Q7A ^"Y&)+OV0$RP[$:4;*\J<"!
M^04E'8%48U/)/^ /QRJMLOBI23',U[A#9*#%T0W@?8P&V8(^*J"I&LG-.LG=
MD/;7U.8O=[=-Z+-FE&D[0;^3(,V-I4(4:?Q?+S1Z$Y*H%\7RO&\F#F9RE"2S
M7V#SK -\;1-CR@OFAT;UYPT'V<3(HP-!(0 /RQHB\LG=X^E7V:-&GPM9<:')
MYKTVO2>Y=:/EY>]'%>JF)ULJ@@2L5K+LHW)73=,E/X(W@$'UM]\C"T6XY8K2
M@$8*CL\]0QF1F/  ;NOW$W+,T]VLAK2/'+%YYEOO "&>I] "4/C^B6'+8SY>
MUUT^1\&QI9'L-KK>A$DU+^.3D[+TP/(R"YC6!R@W@( WY 1Z2,VS'NG12YOS
MU@EM:OI$!KPG?4$:DS5-[6=>=B.SW5B&=G.ADMXTL3]0#K=#8=V-#KGM\HRG
M/@--+K3^P8LHWT%OKT,G^->HDWL!TIX3I?O[@^T-GU_#1MMJ+*\4$ZAYE*Z@
M,;EZAJC3]DT32<A#A2+>W*2'%-Y5;RB'U66[O7JDPJ0\\N-^.\WD 3S]8WP>
M2YV%YXKJQK+2-&-Q?_/Y 0PST0D#>CGI&\S'EK0%93==T4_6+BM7S(?C"%*1
M+7,)[4).TL2TJEN]@ZL:8RPP+S[NB'/-AV;X>C\(R86YQY>*HJ*']CX ,HE(
M1WVD+(D^ T7HP-"YS9TJT>VT 9KT')9KV[.08W#2>2#/Y:_I1MN*.2%FCIO.
M[FO@<8^D7J6!.OE@C?-,7Y4<TVQ4RT,1/<W)4I?-Q=#3K6>6J<Q/_,ICZC.)
M0 =TFJ#H/=*N4[%D42U/^P(5!ZKP\.T1E//V&W<OAR)/)&V3_FZY0O7I]VX7
MH561_'GB](P;KU-NVD)^:+RWU:,?"ZZMB10)Q?I;8(&*QL@ELR_=C^722B5I
M !='!G5IQZEX<@5@@6%[?-3/D7VJ_@L]J=M:L-98=J+N&"^+9OK0,WNKN'>Z
MYD:,J=@(>&O$]F]O)XVY67D;QR?= [D:/8)[LP\8\@. S_?EXH^Z$?%;"> /
MB0P.Z;R!#T?MKP).KZTK1[-,0R*X%0MG%D3&A4/?>;(F!CY[1+1WPXTX]G56
MF5RS'.?/;+2>$+HOWB[%;8HYXO<:8PE^JC!L9&^H@=I90]JS]M*YS;2:2P0X
M=S W? L>M/<JL2B1Q5,GJ^RP+;M'A+Q_PC[?FKQ_!X 7(Y*)IV1YSOCB9*EF
MAV8?W L 8LO6-E;#QF84:R;U7J<;?A6<I6#E'!KL.HA,4!HMMW>AW6["AN=/
MI)K;NAUR:ORD79]*/S\N]ZYHA+561VZ-O8#@8*W$>>)+%7?L!WZ289!%7:G7
M0D!4AIN7EG/0M)][H>*!6KV.YK[;J>-(B$J:! [4U5LA5BT>ON:B(/F&-/ 6
M0;X_+M%-*U35$RGX!O5 4\U0/1XK77+[?:#?T3X5&K.A",SARU?,72H61:7*
M\3U5;T(U!>,Z!4_%M_7,HC;K,BQKPC1A,<:"0D)*]1?56%>Y&9K=WFGIT *3
M/K/JEMIOO4\T.U@V)">-S6=4$!;)2JUQ]#UT/ZK,Y7OEN@$?05B[=DO5$VG,
MWN"&O".V.OO?418!8F[%Z$BA60%HG#LG[WX?KK #NRQM=EK.$IDY]U>J&+-?
M^?3*?-U]GWYEOO,W9"+TS9JZ(-ML XLPQH]K^=>-HV7']'RB8@\IUE0\>C"[
MF]8PMX?)TQ9GZ%5Y;WI#VY"&></,GJ)GE?&4F&OMMR3&\ZG.^;9B>I02WIU2
M7=A]\2^VI'1K X[;E_,Y,-NO+<#"$.CY 1;:7V]ISBD^:>D"5)52K?!)T/QJ
MB-<'"IUJY]G&J[?J!>TM&4?YB^H\CUF'H^-Q[4F>X^Z($[P4Z)@>"7N*WQ'#
MCQK*S$5?:\QU'*C?I&/I7+]E6;^;WZ^*IM#9L.A5^3=MD8<$SC]'=UW#(;0U
M8 VQASUZ\5,G(L>*#$%1WKB BPR=.MJ<;S4MM@0O9X3=/W:5ZJ_/?;^13G1\
M#KMB-;_EEK)$1R,UV;_'L7DJE_&=-DT5GM*WKQ797"8F98Y_YD1^_[$F+OI1
M)TQ3AD']25*1,_*"!+K/ E]N/3)K!ER8OF?)VCW7TR_9FBX(.XXPU'O?4M_P
M)9?7TD$]J:"(!>HZG;A;&_(5IE=52G%09KR02;:M$MP8)+[D&L]))B@10\5P
MC-&_46$RG*>?ABMKD__ 3-!(+H*M;S4LSU,TT''=)IDW5[:H9:YD[LED9Y*_
M *&,ZCKD#*JM-;[+&C.NT11*6:_P6L$^+\Q'AQ]KT^M50DZ5AT]21=RT<?>9
M903:M1T4EM8^M/,;6!I0>S6M5%,K1O#IB-B3[@Y P;F BIWJ90AC941],3+H
M]VSTR,4OHMF]"*3W%-EK="BR*N(I-W.BVZ9-F2U 56QQG=-98!YF$I%7530U
MHJPG[.W9#6\H;I5XLAJ>B/6HSYU1E5SN?M9?.#=^D#C/1JKNNAK408UHV/'E
M'CU1XUK0:H3%KQJENL\'B%)*+[?(VB.-*=8.[!8G=G,;^"Q(L-8_; G(,#S(
MM=GJN2BWJ^TWP:.^;VZ\XIEZF$MDI!N"G#-1=.1KR]W2WBIQ<N0M+8[2,:/J
MDZH^*<\2&GHJ816G(V*L/*P:*NZ*E[([FFHNG(;'$(2&6-K5$PX^]H*##T8F
M"6:U?L^SO0#;7ZML9AC!V=IL?/U=B\)B7X>]E$B]*<I\3A](A0_8:E,^DQ+2
MJI[D[1X,WG3"4G:4BXN#EUE\"A#8C*G!&#YG&)("=5*XC?2["PM$L<SYE[+,
M5^*UIBT/?C1L^06C,(,.N[6OZC;AE6Q[>]?SYL6]&'^G$.R[93^?X>C)JNY$
MT_Q%]'P![0-88(B\AG-OZ4]6.0O#Q2;?'K_)"R[F6P,)D?XF!*M<"6FV5<%0
M+5%!C#M- @2_8$\I8A18BKV0+<:*<@%$8QF!Z>CNX6X;M/F''EC#1"&9DSR.
MCTB<Z.[OZ3B>?-[B]N^2I@]30#DTE$2X$FCK3&1%&^@^M^228,+,\YIJ'P(,
MRW9KA+VNK)]\/Y[5$+W_5F/L1<%7M#)V_]POG#]GWPE<3N<X^U4J[8%X>U\L
MS^M11BJH\_6NRS;8N[^<)?Q)UQU@F^H[I.DWX?PQX ">5&WG:DB[75+B+1D,
M >O."'*NXIR4[/F9*@-\V11K+8W!-*ZUG9VNOF2"A0/<TAS&IFJBCBZPT_PI
M0GCR+]K7Z5TC6'76I0,$!IT:7WHM/!]T$BKGK&/"OS?F?4WF=:2?)9#X+NS=
MXWQ\DDE (Z03U5=&OJK)<M-M$>07E(*H^[&_T^KC;S-3+]>$KUC&<6_->E [
MZ70:)SO&<SE&R7\R1Q3/]X&2$Y=<4N(DF>_:^W;J3#SJ["(Y5TQCD?HXX**@
M'C!N6X]R.H#BW[\#B1K5*6=7\5B!6-1Q()S%*C+QQ+,;/)IMEBY</%U?3Y#]
M?G%E8D?'>5SDV*R3JS]E:#)GJO#%J,R\5X^A?EN&'H\D]J"4ZEKD;3IS$WR4
MSG1.]M2&UIU6WG2<?U=$TC55O5XE7()"87C1-JVLS<P)*9E&R*E?OABEPFS_
MHS@])9/PO6-(*ZTOEA2'K& '?:>Q')=2!//'C\JP%K"'6 =$/7BYX?:7?G3W
M.'8ZTIV?)4,5LG40LGFNZ]=0;+ Q;7<9D_4X9NS![ [6!^FO&+YJLN[WW=VJ
M#7]EO\Q]'A66A57)?VV8^\;:S:NV:R=)3!Z8A/D$YK)<Z]B#R=6(RG5@C 9X
MGB:C4CLA?EE@ES;[-%Y+P0Y[X&IVQ+!Q3BVE/TZSI'.1RH=M#Z9XQQJ5]T^D
M55J=XUNX1QMRTH\QUA$+^$"0.]JPVB"WYCYS]]\G)8M1- D.A#?U2>M@CN6*
M4RT+]U-QXU=0+\GNRSQ:BPRGN]D)W)"W6/#X_*H245KC7:3ON"]KG=-[G\@+
M,)<-$4JWF0!HT1AP8+)T'1@.9MKB^!3">[#GZ19=D,UR2R<U'\Z3.[>+>NWS
M'V9[\KRO\X&>WRYG[!,IG[4H_UC0JDZ"GP '/!40JLO,E;0=THP2.F5I-ZF,
M4[RL1_8(=@%8\?<5#6P,J^5R4J,MK]#<NKKH+ -@93_6'6">H)E08BT+E;-@
M"R+&*I N>C^^8-/ZCI_*J*LIK,]7O<7+19IB-'.2M2WRATACG%L3_E+@=MQ8
MT?0Y46<23,W)OH!5*WVKR^+[P3 91LA!/)X5RH#V=V;ZF_7PGBKID=VX=NF3
MX4T)M[RE(^CVF$AYF+W#<B2'O7YS7^=R\F7ZY";D#A FW.(W)&EL/F$TT].1
M2/4%@U'9+VOI1DQC+#3-VXZ]RL@^>NA/[+H"-Q$]D-_Q<H5"YR*%8?$&2L"?
MF(EX7SJ\?<&EJ/)H/C[A5/^Z&2,358:7N0TPH]ZO4FIV?S;_=VHHQ\OG<_6%
M??#]]<I?8FKDV)  =V 'HE8/@_$89:<+>J6CP7[605NTPXX(K\F@<-?XI.F
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M:WMG=V\??G9^<7EU?7-[]P\N!  BPG^/_R,NG!=<KUZ_1GR-\@\NA%?._VS
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M(EZB+/ 9\ O[EM'OJ1FW9<WBQONJ[1D072AR,$Z/V"GWRD\T$ZFLS-O ^Y8
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M"<',,G!F#Z_[V,4K+$$@311E]E6\N>C7"2X[I4,28#871;.2=AEV9GV'/]I
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MVFAD(B]\I/PJ8WPB3IRF-V*CC- >KGP#!3P3V)7WO)+8HV^43&$[W:"_-Z,
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MU_XE9[XH( .MWGXM]+8W&2A@XS-ZZ+FEZ#E"()5MIFT7Q&CIN::_Q'?.$&A
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M"Z+N2RLZHQ;Q6FEU5K_&[B(-@&]FT?P;"8S8CZZBVK@06R1N[>23,%U%LX!
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MWC<W!5 !TJ&EA41@Z+#RE&"%R2=,C!&!M6,D@0A(X)"IS '^5*35,]O%,_A
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M%P%]WYU)^>1_>;+EF5.Q?3*2)S;KRE.1A*OPY-T>W[6.>:Y')$[0U7KI ;+
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ML3?LBZT-A0>?4>%GJ5?NE0RX-R.P*.-)\><CF&?Y(5JE6[:SL#/1R?1Q&92
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MR_O=@CIU#><4HJ\7K6O#D]"5G=@FK_#'XRWV>5O:E-4_S8RWWW7'S"I/'%)
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MI6Z"D DUPD=*>%Y"@,K?#+>Q8V6'=R=P=S-@6Q6 +:= GE_!/R(B6#&1 $.
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MFT5#M9C'0&SO9N$M?MW2VH>$*3% 4SE7+%</>?)>]1(Z4"%']O2]+%_<(/.
M_&B\5*B>%9=LWF7;2QU(6EHT'G!0F'OXX^W @NSL)-;78OO2?L%?PS\V\P06
M_YC?T))*O?JS&B:BV0Z2'019C9?U@W*8!^38@#=?(&W\V$-]C4OG$G9+A^=C
M#P>9E$[*.7V[Y&['W-R<,F_5\;J3%G?5O/H,T*7M*U'KG03W79#\.J=EGIQ=
M#]D<1THOSD%9'9L<B4P^ "1U_AKSMV. .RDF&#P &31II?@>/_]JA3V-M^V3
M_RSB";4C!]N![\U0:)^<L;I0CZ[V/I*?I;?P]<YV1QB%QIC(H8Y8?=VT]O=X
MZ1]:$3,A$Q8["_,R3:NNZZ/GP?IWX7<PFB@DVGB;A<H-53THEY)EM77$,4QF
ME!'^KGM]5<'@_:RK#R;@S,I59/E@]KY3  ]SW/XS2XNN"U,+Z[')CI?VSE,C
M=UB[?&3<%VBOSJ[)I?UF>\H6UERP?%=3YU?I%\RVQ5V12G>7)Z.9T,F*R4(X
M.ZLZ>+AF0"D0#U#YE2T&\_B)KRUZ@[$$>!KE;^/&.KH%"BC>=\#M(#=SITL4
MGUL_B/S5<CU,N*,^(/")D[EQ6;#'7FZH:<=7TNKX =]N2D1=NCCS++ TS%O]
MKD ^)N0[]-WTN/BR*;?X[[%-G!.DR;,MRO:W6XIF5=G4IBQV"J;=E*W_7=;V
MY<C&4%"XP_P/'?9WYN'[FUYU)O)PU:XG.&J4TX?=&UD/7%M!*(<T-O=G7I(Z
MTM^3+F37)'LK.[J'T&X6C$=9@2*=6KQ*#EI4DHS N?]JG0^.6:0\J$P;;M"L
MGMS.8GFC):6C23BRY66W^-1XYC3KNJ& G] 71KOGM"$57L5HR[)3IJ&>9@^/
M$G(-A*542RG%W4LB!<^E$T@U%VQ>1@)&(]MMH\9I;&&G2@41H/MP[(-2(=F7
M@L\VE&GR6FENN4MVFC981$>&NB.MPG+WS&/5Q(XMQS^TLJZ%=,<4_"!O>L*7
MAICA"+=[HRY_T5,9,D1A =\HNA"R^ >*!?+(VV8@VIJMZUC!?[#8)SP56#1(
M/'RO^%Z]I.=L&0\$1-PHSHW7*U)DBV!G/JL[,\)4P\IL$7(1K/RST IY5-:_
M6P33OS ZFL8!\\,#S2[$V@+_(8'?VR9$;M99*BH9=B]L^"A3 $3)4(1;;EKW
MNA++J-/$0FN, 9=*:E/W\//O")\Z71'U^$L*9L[<.46Q00Z:://)T?!3E7;A
M1)B%R>X]OK&W:&OJ:N[7OU_0WDJ6D%]$*KJS/I4LM?IBUWA5723/Y2'/C^ 7
MV5M*.>^=ANN<WZ[W7R8QV!^'UE J&>8'+ ;(Y=;.+LB%00P;VJH3UOFFV+T#
M=XR/&;D2KX>EM?JOJ/=(VW:<:56C3-$[X"9-U">;B.H!,FAA!VL=Y/HOS2\^
MRFQ<]K PF%SL_.A4*VM(R$@?'1[P@0D1FGI5B2Z$,$V57?< R>'\ML4AK6TY
MXG:)+J?,>X@],&X!9PS\>\B3].?*GP0Z9MXKNJ76\ZTM#9#1L)43>Q=Z?%3Z
MM!-WAO,G3=)8O4=5*;MI&&P (Y0/P-["YVP'2M!7_77Z."[*S!1>$EAM6YI1
MC7YCSD\;)9.\*T1J+/]Q>%7)7>>:=.ZK&89M=[ZMCIK$"I!$U>RDC;4T?RRT
M5"LY?<6KHB,!Y!#U#D(LU@ZNR/Y^[*CSL4JQLU_A)TAT92/1;:(@0J*VHGAV
MBJH%U-#B\K%R9"\A-RT+44/M(L[JU9:@46$C\4T%^X,&TBQ Y#$:++Q7!=56
M-SB*.C7;RAV="N;=,SL6&1DUE$H.RX?YS1'&P]4\RB(3NH;O+;1N'HV15)QE
M(ZC,O=X/*TQKL)>&*N!3P9>6+(LK#$ YT*A2&S:"+O*WCKM+J)-$$P^XJ"[5
M>\->&L?S9M%NF?M@YY6I/?.^PH4.#HH_)M8FIH5O(WBO:2T5\R@JJDD7P6JK
MMBRW<A<BZ(W%.XIG='GO:BZ^FAFB;09X$[OS=GZ/'V<RY?BZ>W(_=P]:2K@&
M&2O5OXMCY"OTO<D6UE<P623>N44/7ODR("1"<Z33S_1U;;*N2=<S.5B6]7Y$
M (Z!*$"-ZRE$8!M=]$B?QCAPTV0I&:H$FFXPNKA;Y.J(AB;/$'Q"(OS53 8=
M$[/I^7A3K:)IFYH)F(KAAG<^A[&-/N+RLQ58"S4UBZICE>8D1F'*+8:+Q,ZS
M(\QH-#;B<-+%J&].B<<W[T Z!8C-U$!?V]*"JU[S:(7SG]QP5'LX//A&PS9U
M(O3]+#;VZ_J>R\\;S;K@A\\U213,,D[";:^>M'4IL>URG"F86B@V/VF$H%6;
MRIXS"_]$A:QYJ4D'5ZF.H006DQC!:E8<P"VA (.Z5H,15!DK:)/R;<*O(MJW
MQL5:,O#IW-P"N Z+K9/(QTCB1QJ$KB79%)")8U0LK=_3Y+E_MR=QF^K;KM('
M/UT9#Y4*M.%;DSB9V^)W )P4[]0'!&_:Y.L%+-2H=52L6;' ]6B_8=)7JD;K
M@X"W<D^%WRQ[3:@(>3?:NUC3SOCI$PDRWW#VNG&^7;["LO5Z.HN*KEJ?@J+V
M5]RPPXW*: WST>";08>," W'O'KQHLH9C3:5WX6;E%&<M&Y9#W'K.!.K7OY<
M>*-GS$F4SHH6'E" K@A+^J3GL82OK8<:""4J@=*"!]T\RI.#K>[.0'>I>),N
MUFJH W$\RG3?@+'-#^+G];@TUQAPW#[&>/)=W>NPX33L5."9R>Z?G7K(E?Y*
M%S/0Y!Z4J?C5>4SL_ )PO.8#?R*<O=.:X3W+CQ*M;?)P0\W.\C'C 33SY5[!
M;O(A\^>3VZ@F*">X=SYT-!;[F#-5("<!6"T.=2YV?W$2.%\1/FA:F[S26SNE
M\P"9E+5YU\"'_5D=P E 9'2IO9TKA@F([W];TB#^K%@VZ+S+_[)MWC&>_5R*
MD_O-[=^RCMWWLQJ]@[I"1"3^9'\P< 5A](JV=93I-'"-T*\(1@;8GS!OH'P%
MUAB>FA36=6;X+] O8 6(^@GQ_0=N4W.,!0]8M6T-D=;&%!JBN.*5*?_&]]+_
MS_C^9TU1RZ#G&'K>'<%;$"L _,]36D,##R2:XH'*>+-X@V$"YQIKVRC4)ULT
ML(+U-&&O:/\''>=1,F]5H=*3P@ESC@M0_$W9J@'P'<\QZ&=)"FB8 9/JD^MN
MM2"FW)C2)YBK>?>2Z2B7QAOQ@,6ROQ>Y:TATG2M,_-VCNQ+O@\*:X[#"[VWN
M+/ZD L+TZ_# &\3<>9G9>E35190H'IBQ %KE#)0Q:@ # ;$S<NQ=&O&]9<*1
MK <PWG *2N+2I=EUB!GPI9OB\ODT1*Q1@1DQ'_1G_"U&JJ"Y/LT_7C$YHQ9(
MZCNE>2-:)>V1@GWS>#O_+9U@*8EIBPXI6C V.Y_')XUN,:>U9:-JI_R:3(YW
MW\>[&<R&NBSG"/W<.YL'2 ]@&(4'1BTC)V@O-E02OX?GIF4@NEZ'&JQH??$Y
M;ME0[HB"-/^!OD ]'E@WPVC.[1[ MS(?-3]X1ON.'[JM/VR/@03SST"ZE.F_
MP0+F5-%97CB$4F[J),_7V]N\?Z$W\Q;]<;(?[A!0;%M<)E"G]QJ0)ME!J';E
M, S!O\U[3@"XZC%4T+_%$4_A@1(H @SK(32KT?6#VEO]TS^Z/*^Q@AKO_M9#
M7LB;Y#IAJ-RTK/DN2?.\CX(X?ZA25+36DG(;?'7Z!['6S8=AW=R.X7Z;:GP)
MW<L5%NJ?Z,3C?<>J>S;T783]9>+MT:\;9VLO.>M[D_SR!.4 -AG8IQ C=)$L
M50A]@E!S4CA.;%9KCH"ZZ= ^-]]Q%4=(-HL%!H;F6UJMRRR@UW7G%[IEYK^!
MW@)C&'9F.J*$F,2O'R]N^5,>6#J/OT.=;.^;:+)T<#:'B5O!N[7X$]5&/!XV
M?GXFYG_)8SD([O[;X1M%'=]OZSMRR<L:U@L?::/]'T(O&GNS\4#3 UO*-Z 8
M.2+N?;>BI3!W/NB+QLM)J:&;/DG15%E'[: T?QP(Y7%0P83ZVH^P# VZ^-3^
M-)O62*>T?)I!UH[O<--!Y8,H/1?VO>DY$J.O ,/0Q>_Y*:ZKQRS_[<3W"3XB
MODM(3T7A00436&G0N^V#')"6:W[]9\VESZXFRH\>0LD;ZC8#=/G<J>5U=++.
MI_+ZDL!1I\9/GK@AGY5O+V:9P WKTP=TRFHDU =H68XJ[+;XE9"*&IN\I0?R
ME\P>O2_EB )PQO^&"D;7I54#NP3/D9GE^ +_4W^9C&=:6DR]$@J^E3LF8A;4
MAKKJE4)@4Z5/X6>N!!*BZ>!!NQ5ZJ%B2BL.)]=1IN#/9X8$'_$87QEI,?"^#
MDP-Q0D""URGU%(&YWIPZ,UE>,@W5J#%K.'V+VVS,/C/!_OQRB%'FV.XD'YGX
M*O=JW-#U9H#]O:CZ&M\O% V*&ZD[-5:NN=RHS3KS0\TK2QJ_8]%95NK*K.CU
ML*8)HX5-LXYA2UW$2>[*#,^GF- N\2]!^PVGXR+P9PI7?!7(QZF#^>YUWA#]
M(5'5T'^777[Z?+5%J? YZ7.&6/$7:E2%BD"IP-7_!,5\,P/P<Q]E^K]+O/)]
MMA8)@4:L[0Q$@H-W-C2A"!Y_3LT247TH:1+E9;M%P4]<IA&7G!,"4SMN>M5N
M>L31T.8?2#\*H=K-(76=HZXK3;$87?F<8M!^[Q6E<=SMLY[!IYE'=U;B%\TT
MR,S)*4:Y4H%50G=K,4_;(L"-:7?L4,G\^F7)<OJD\?]BZ)W&LUBGY7VSW%$B
M:9ZUT5S[LUC===]O>62OL198P3$.O0+I7D[!6<)C0$MI+\QU-HTC671IR1\9
M_+KG>@3H7RS-61$K*5GT)EH*6U2F-]#=9QXU++TRM!+!]#_2"4FE537]F<I9
M(IYV;YOU.V/$P1;UQJ!9:<!F%CX+RM'P7G\(>^MWB#P5QP/>QD8=+,^^J0P-
MD1;<0RL]NL#,VL."POVZHA4+EQA:[\&F&?X@T6:(W-TUV"N8'/0Z9(M*]?*?
MQSW^DO<":;#KUACL\L4Z*T^<SM6?+7@@36=) ]NN3+-/?]ZQ_U[FA0PRL#;R
MZ]C@'T6D4[Z_3DLA2&B(/.K/-JPTG)/<9SR5;;^*,VC\7&VBK>:Q74Q_.J\E
M3%9KWS& ) Y&%9>BS!6+!$M)1&]8K4;4A;8XW OV)X/6JLI_074C##V0[*-<
M<_/6[!PT!"X(\(WD%L>W'K R^",NT]P**R$1NY]TCVGI PMM-CRD%=5M/-^C
M78AXGQ6D9()3*IRM>COA>FJ&1  :'E+VI&03R IRX]L"JJ(RN0?UN\CD-@)L
MS"O (M3'SI%U@)*6@\#<G377]#WN9TIVJ-S=DOA6D[50(X\QA1>G!. #N&O"
MW:!OPT8,I4KTYV.TXY.41@O=L"-H1-"$W;]:2(=?ZC/;Y-9&&]\64J5M#$5]
MB;6#IH6$&#(8>"N9_*E$HZ1),?XK^AM9;_P+9TA79.)X_M#]75<F\75#P5;S
MJWH:@3W]9Z-G<>0ZU*F1;O=W)0KQ@/_+7Z-RC$7IC2)1+8OEQW3*KWA; C^0
M\$7<[+T>5@!ZZR^U+^0Q/\&/E.HU>+H6/;:-SOV&"#+!/.L"'@4]M.XHF-(H
M_UY1(@B3BIQ8N8,5MXKI=C)"GL!<07O,#=M;[E4[+6G]Z5'N7B7?,YBUVIZV
M!#[JY<!> D4]@;#&X@'GH*<"MH1HD)N[DB+3 9D%#YF, .FLW>*Z]6D*+\AB
MM$,*?CTE8/AWGO^,-5IS/"9/TNUT!D>$CGA5%=36?,HU>A$ML9UHIY?$/'#_
M_8&"_6<(B_L/>FN7>@N/L<VE]*ZL;\KW[)Z12.N_3I',/C7(0,S-G,1T68@6
M2Y5E6<M1!_LH%'EX=SQ7JIN3S,^%O O'E ]>0BMPL8YP?TYT+/6,7>](>C;"
M6#Y<\BG.P[8QU*B4=_G1T$ J9Y7(S[TUL%VS7_'4#Y9G$HL(S6]9ELN<BD+R
M?JK$?QJ=-ZV1IC04X]U-&Y(Q$(<'V'#^[->Q^>1C:Z'&N18$WQ/H5NSXO;WP
MG767]'O[\Z<Q(9;&1K0S-L@ZWO<%0>H$9T=P)XW5A7H4@68:#LI^#BJNI\:2
M5WE%4&Q-Y9V9S$QIR.;10!;"LY#60:9;JP;#\V.YDX$][)%[<*L$;[DDJZI(
MWOJ:7=.T*QE'>D6B!4[!-[G%ZXJ9RSAR::%6$^][;X8[IUJKILU\R"70'ZH5
M*=#5H*!U/. P\AC7>Z-#HD>@GJ['^\>$.TW+FJJSM1J#/G=)*@EXB2J]P)1H
M;EV Z)QYR(A/97F'8MG0^71$5/9EW$($JX^4S$YS3;./>J2O?#89XVKKG5VG
M!N1&R'TEKFJ='^SEM]^6KE F!.MW1"UF9ZX_=9V?7X#1#A8K=-/>*BM[]N;2
M$K%\HILM>=#3(/>.'==7XG"[FP/J1+Q+$?*TVH"TUQ6,!;93TNU(O%_DDV'4
M)^'IR'5)2\WWL5>%(LC)*4#:8#Q@S3]OE3JK,.*PF[>SJW6!_2H& 7&_B=OL
M&6D!_/L*74\UM,'Z!D&<B@)WT%] 7U\2(*( 49=Q "A-DJ3?X!FJR"T.5FE[
M[/+'OG#C+ T%JC!"T 6^C0:[?\'H_6R-W"L0.W0_0.J3&G)/9].TIF++L,-:
M_\&O]/9GM-_?L<5Q4<PJOK=(@#3^R1#:?+TF^(4(%2M Q%H]7I"^<,=8:BNI
M]!?SPSR<WREP9["*<<6&[X5H::!H:=[T.E/?28)EO(K#ZRFW(YQ?Q$'1YP2U
M&?KRU]F>ZJ0D)\9C7TZ$]3XVPC?'F5 8/G+T4$< 7X)50B!-!*YN=J7T%;7:
M[:"+D(4,[R)QW?\&R";3JPC#_U.T7"15&Z],I]/Y=QN^QD34\WK"T3@KQ\WD
M])_(LH>.(Y5;IN.W?E,_JO[2#SSX[]5DM_5;_J3.I(Y.I?^U6Y]'O8A@H$G5
M)]7-:9$]9EUISN@TLSC*62SE6CF_WZ@>(5U78/[#AQ=\YV8 =GHU9;8EI+FI
MQRS)-5SF^=:@>6--6R9#?;K 390W8]:RT\V@U6<Z)2()5?/3@93S>Q.!DE8Z
MO .K?1%?Z"%?2X*IY,U4 Q)Y+R=]LP_@T 1N0"MI&1-_M2BO6\BF;:./'-,6
MDM!TU,*"[8:%^:#Q^A7]X0^R[:0<(6S(3^"8AE%IN\OG_F IR9D*1.T@\?.8
M.P%??L4=]'NN,1^;,=&_^I(;:AG3X&30T(<./Z( 1E$NXXD%B&A.^T0R3G;W
M0AI5D@U3J:E+?E-^SW^*L[^ND?=T<AA[M>5*1)X!9G=W6/HP?S+8XL+*4HH=
MH5%TJ\S %<^MX8&!JC;5@SRJ(<U9[04^A1 4*_LF]=NLK=Q#Q:J+4"0JJ6T1
M YF1 B;2FFO.D6NA(P^3FM,Z=4?&R[5P%:W1A020I@_7!J**O&H%]PB [!"L
MV65Y#!T93VM;7(<<ZVH30-P@*D)8%?S2B.XVU$(5');GQ'>.;#%O^*NI3B!2
M17C ;XA,5R>L*ZJ/6\%),^?VZM:2 R1*-:_K1D(,$EVCV!M-FC@P Y>D(M_N
MKE@W*$+[]QE"TA/IRR#'*A1\92>>ERJD1)30:"^E2Q7#X"Q<B ! ?N%"',SK
MI02:N6TT6R11;<7RUC$$]0,/@.C"(=]SU54H$B!"0-=.77FF4Y2[T[[T9-P'
MR57YC[]A]Q>:?]B.^<.Y9M'MA2Y0;);=^]+0SZ(,],L<MW_8Y,P+ZX1!5.KK
M:SZ?W[]D^W@F\-I2;NY2XM?/D.=S>Q1CD-^"OG@@/_-=61.G%&]IJ=X4UW/.
M&/.L_9)?2<VI?ST'QQ@0^$E/8YA0@M.WG*G!1+IZ[] )83>MDXQ2^,UH&;J$
M0OX5A0DK/+"[RWQ>_-D2>BJ(AF,C%_# 4&8M8J*7Q30TN 81];,3XK>JP*72
M+YC4?-!WDV:DVRW4]I#RH+CM(HS_O+AFP]>Q]D,\V,-KAN#X1\WE/%;W9A3=
M.K#=9T8BL%%^U+,DJ?BC%TI&!&P/)6"IU91POPJ"?PP(E,G- 14A9*DY"STK
M7@]%:8&#A\,Q3<>E%9!1'%^R[>$.5A<P=A(IFUJF(F!F'&-P(E=,0XM)%N[N
MT=QA?QO"4HIHM8V^:O-WY6.4NYIDFBNX.3CNNM(48\R-1 2DG>UF/3JJ%2'Z
MC@0Q:CF^=I&B#G76>W?,B')O#,A_LMM?;%-$R]*3(G57L^A@(-BVI'RL=C=L
M2-QZ7<XCU;P]?1P,Q@*/B0[SK^1$JS&:HL6$I-23IDNH'GP625@:>T]ZXY'[
MGJU*D6U_46>-;9'CUYA"F3MGX_DE(S&PDBXBU"KKSH;5F)?4Y&#LI=A'L*0E
M%3KP)S"Z29;5AB/_\B72JR$3"1<JH]>;1Z.?WWNY*9$B"!'DYR:62S*:.ED!
MD?^,I[%\4(6HX3+L_R00J+ XJ5%!5*7ZDPA1#J5T-SB)4:T?S8M?T/I(!3'A
M_I7HDWO8\)^5BAK'H=J.BBOF/SO1"3*OZB_F5F=K"__.%(9#%.R[HL>=; &O
M.%I9GB&R>U]I:ZS(B978''Z>USJDSB'N]G"BNW+>>?G]G?8*K3NF/0@Z;->9
M/G'=WQR..O!_<CJ4KZ&XXG4T0Z0!WK]9',5=?U,Z $=XL%+MMO;C?S?@WXP@
M?4/C;P(5D!PK2&L!N,<=<4U6W3F)]Q+IB56024^70;]8[!?V"/@943F2@OED
M5B3[BV2V>6+A2G)6">^$IU]HEG+?49*-IL>R>C=5(4U;/)]T]>B).GH%C?8)
M+/J)B3.W\V"Y!:L4PHR79QB?DR@\?[SH$_=[0#)^1M*JH2-,1RUCTS3$-8$]
M[TOOI4;Z+? Y4I',=D)D6ZPNU#%V8$'L^EU#KUO!9)I@'YNFS\6]ZA5M+VLG
M+7[=_%U )MHU5/*(@K04QY/ILLN7.<ZWX8=0/0U_\/(TJW'1RR9[0K11!N%/
M%#%9"[%O"#*N 419ZM7G5!)M#NUUW$]%IZS8GDZU#I7?[-4_O^LA@LG&I5[^
M_5OT5TM=PL)D1Q?W]]PTKO].'JMIEBY68&.)/@QH^KZ7:A3_6;;+<GASD>D%
MH$SSQ:Y&F2V-L4=F^T *[IR(K1HHR)TA%?4."1DB0YP78G3TJ?W0=R Y8I.+
M>,!]/X^RM&+3 )L+.6J34QH$M:TJLU@,X8%89(?M]G0XJ*GR18DG"[&DU?AG
M8MA7H_G\R.,M>3PP(K<6/I ;0] .,6&W/:6R)GR?=<Z_=_% W>F8CA1EZ>Q#
M&-5QWA4Z C@BO1ENF[HZ!-/>:V-7\:ITV[V7_J2RC,.5MWM"W_P1BZSR) 48
M?+W%@035#.TY,XF*>5V)_("J77-FPO >WWX%/GT_P+R,[F#W3=%Y3U:]!KMB
MT]\L][6;A^[!M-[E E-7V,L:FN+&Q@7<M6GJ1"H?LM2[\J_ Y-_!'-#(XPS>
M%+C%QI:3.8^KX\/JO)N=1XQ0[WNUII=V1;(LH$K\*O1DZ-T+%/V(5V6H"?:V
M8:1^O=;F]-N?:3S15!_6D;-OKKK^@>,-IU_.3T[#UD^U[F9_DX,%E&(TF(ZP
MLK1SL[4L<5PYBB[$U/X9O5;:A%=)Z;:UR&VB4^C.Z/A2L/ WC*Z]$BH[L3%T
M",#(=&-_K<&BLSP_G@J>MX^<UTDF+3> \[=U&R"?]?Z4PO0@' 5O!OGA@2N:
M/P14WU% MX9ZL()R82.S14]D.![N;BA?528HO]* ;J$8,S:%S]N/_U4DF.U7
M7 URM=&845PCKB]EPLI@/(LI/8?O)-4?6''@TFP[AKJ8(I%JQ7UL _)^YNRL
MT\_41TY-^O7;L5G^1X6XQ.4[&=AI@B!%S!7X$4T6-JLK<;+P'*((1LO@WN91
M7[O9ZO?@32".+;S7VY=[^T+JH\/@ZZ2YMCJ%I-ID=?%!J;<L-M<:ZNJ'1.Q0
M_-?,\\,2S&3E?S:LZSZ!DY/D@(T[B/  O4[NW";;QL5UM&]0P-!:L_DUG#YD
MNWY[0KKW*3,>>*-7"C^CLO:';&8:3L^".N#?#D0^XH%!%3SP=-1TP98/,DL#
MGRGC330X'0TXN:4Q@JPPDIU=":^&<64X'3<T$'%'43I16B&CM@>J%SUT].NC
M%X0#/\:3]%/>_\!_I]_U0K_GXCKSG9Y9PF>D:H&IJ#XR'_1E60\K,QZUZVM<
MLQ])';75O3OSZ%8Q+R>D2;-7#&UT'+D%GR_U2."Y_\MG0_,_/?'Q-L6#@(9M
M0M^,B*"\;D"""+V.]-TC# /7=$)'$)H%W/LAAJ8_CLS'L64\;ML?A<U)B8-<
M]3149Q'?#AF(3,<>[06]\8=TW'LM!J=Q9%T]<=,Q.L_U&3TN,#I?\TG KA&7
M1;-UU1\/;DW5*PJKJ!ED$":Q$SR0ZX$56A\BA[Q^-/IP2'1IV/[:W'O<I@^\
ME.N76<Z%PH2"2EC9@R_[;K>3RD=NS#<WB$>]3A394UZ5Y0BH/.Y)SXPZCI*F
M#N.<$<L19]7X.7L.=; Q"T;83BO6HIDO>'>ELVE7$7W3/V24=,L^;<DW'G6[
MWGM\?%7E8M?0Y(K =([HR.;)N7-R]&,8C 1283D=!I.SYPJ)C<19R#PA4[22
M(:Y_(G%)MI_704)I?C9"H8#VFNM$*U_3A]%R\ISR+^93V _/5FGZXN<:&&V5
M/XY6>HG-=0;X--Y"\Z:+IPRJX ;$+6?YAZ3:KO*FG]456)$Z++<&?,O& ]3^
MC+U8>.<LK:3J(P8<S] 7FN</(*B'G!/8*K?7GUKT/HT@S#3E=?H.K.6-(G5N
MH9O4&'CM[SQA2+QOIE=3V+$B'/&I5_97F'M[+59#DQ"A7D:B=7T?!;H1A3[(
MH/D"FC]0JEMK?*&^K=OR\5JSP8RZ0X#1<R*6BRN&KMF'@@-9M6/Q7G0VUM,G
M[OI97VM4?,(:Z*0\69Q;Y1TO+\Z67<AY!)WXLW?.=\V]#0A^NW\YK&$Q[O ]
MZ/)368KHWY6;!4VWK_7-9WO\+"2)+VA"D'A52%P21<;.SA1_3KO^BME7GH/L
MN)_I6H\4):\$;_6';T%30C"VWMWZYZV\0WPC][N)EVYY2TC(.09RC>:2[YP%
M.73LNI9Z'[.SYA39Q24_\9:G55%FW_S/CL*,<.(N,KY< >SCU+#;+ZE';2]^
MK$^7?B% 4EVDR)97_]GR+4^FJ$,:Z<N01YK?2BE_+2W&G0^1%/S[YU,9 GE+
M>+N0HWSY7Z:.[K^;,O6_9;*BDL4U F<CNL&SH:,Y"L1_7?E$^^J697MPD?NU
MZ0=%1X][&6XGO;MFW4$!$ ?2VED?O'@.5"GL6KUQ"P=7?QJI^^$A;(+2V=+Y
M22U<=MF16+G]D$+J[7#.O-=E4639E'O]1 "8.7IE15[S.^E#Q+V'5VEHGCR1
MY38K,\LXN0]%GK0N3W6FRZ6B:PL>Y#?4>A*7DEQFB2*9;5&'W[T;*Y!G;R+"
MCE.TQ#5*V_R/G1!EYOC_Y ))"Y940A9G<-$1O+:-;=H6:N=E?Q*K$PX,9B-D
M9WQQZE578&T$T8*-_,I0 LI-*OLS_\'6&M=<B-S^>TNCS5@$MB08B%L?(MM%
MQ5)H"Q )]S_UK;H9?DOW^K%)C'K-.<];JUIJP0Q^,J6'REPS&ZA ?Z4<]\3&
MW;3:#".1Z)2PTG:2U.05EF?*&OJ4YS^/BB+*=FJZTD/&4X[4,D>MVL$%&I?#
M;=^QY?).)DA:VS0]GCA3G"F_1Y$N49CMJSNT7>X?KR2,E2ILY^:^I5LN?U5#
MWUVY!SN2()[Y,!A;G%32X3:"GM1A"-CKN?Y 2W21Q[9993,3TRQKOV'G[64_
M>6.L8UKJ0:]R#P_T4T4%$IWA>M2# !ZYFNY2NS^BCB#9A8<,N8"IO%M:W**S
M)$1:/GM,4^! (<T3EXRQ6W "Y9IR =_BF9H:3\I+W!20P0.4VSH><I?HM_UP
MF"+7D4V!<*]&V(LATD0OEOA6FYX6F5F6/L&]HT-$\OQEC^-&T+S45/"0,CP4
M>:P+@%5 Z*L>OT-'$TGM:'],C1<2] 6/6S$X>D,%3&UBUA\9&>J@O_I%[D&M
MJ$*OG=R#^OV\**5CZ%:F>HX2JBV4$)ZEB&B*ZX=<&YY8W;,ABT*KX?86D_1/
MGCZ8<0GQ.S)@J7!LT(A6RKI:PFV,3EO2QTP8-GM<UZ#_K-L6"F0;6Y!=W+;@
M@OMRB)#Z6O9<[VK8(LY;W,FC-E0!P9E_;,QF#]VC3UODB!OAS5$X2>R?.]'5
M]*3'5E(<N]X2O^"_$;4:L^DI]>DRTWW'O04%!QH5K HD_@F,W,$4Y:\\C0<Z
M4:MMY^J5O8N;8EH[N#2?&VGHEO-OZ4>FN\QO-I^P_ J'Q1N?2-6HYLWJ!+K[
MN#F/\J>!,R6JZK*XD] I(3GBKXT1HG$'8C7=M#-8-_D@AST'^="0T=8GH#\.
M+ZE8,KH<-$. $;I6R_L*&SVSO"BQVM!^&91&YF_MI&=LXNP-S]7=AS;G5=VY
MEF5_RI^;@7:&\H>1W_BQ$C[?G4_*ZB6YC>)G((WN%A]UIG4<J,2]YKQ\1'[%
M?7U1Y67A3N@??0\<_6SZK-_5O--&F-^(A=^Y8=@VH8?'-52$VUE,3T-#1@CB
M7^!B7A:A U&6?UI5;#GPG/2<4*@+$=LEW%"DE\-L\;F"PPG,(@H)K>4Y)0P"
MZ=NY\$W8'%\$3]US2=J9K=!A7KI7!>RAN0<6 \]!"^NP%\.\:TZOM_TA7UV(
MF>.-S.O1?S>*P]PB-:O*+1T@ZU,E9R:_-S>4.0@NI@[]T7;)3=\UUQD]>Y,[
M_BO]YJ>#P8HGLV317=*6!DR1/LY/JG_]N+&6*MBCX)Q]-F&V6,8_VBQ28JGF
MEXXHG'[D^P(MRY.8S^D^H,!8Z+I[LC[@(11&9O^JZ*UT43["^T<DDR+1JE2!
M3*C,=+C)LT59&TX:)PU'U>N4+!Q/7^Q;4Y8X/GL4GZQ?&7?+)%J%ZVTQ.'O'
M3E]:H,*J[H71,\_.+98>;E"%GTY3WV/&X_X;%>6F'UY6+&H6<M*1 \B>8_BZ
M ,FK,:;YY$T/:Z:EK;U7:^QU=D':G$[4E-VU2ZV$H%,><Q,Y]W.B>,:\W?O6
M;E6KL.BQQO?JAG#EM947%!'60<(F7 (9!J.5]%HOM#Y[+;ZY\B*WXY-2VIC:
M@JYE![TJ<QSO\VVM=S"?,DM!,.9ZXJHU-/% ^>QFLNT[A]@12>'.IM;"W4KG
M#IS(2)&.+H?YY\B7EGW7]:!Z\I'ZOQHTC,69K=):UG :#LA9E5#B&==C_4$2
MP-3<$J*GYC7I?DTHZO]A[#W#FMBZ]^&A*%@ 14$Z"D@5D=X)B'0A]%X%J=)[
M*$$L2.^]2PD=02!TI(MT0N]5"+WWA#?H.>?Y7?]/[X=<<R4S>R:SU\Q>ZU[[
M7O>N:5;FK"=4]$P]^;CC8BMM*_D#(6F^B3?)<Q:X;R$V-\-K(;]78>]R[MMD
MRA=>D/VV11;JRB>T:1> ?!FM]W$766)MMW84$]\?[NU$[XCLE0U:Q[IQ4\;1
MT'8A_#Z!Q1;C)(NM63#N\NKCPTL;2?#I>\K3#Q=T-G)WL)5?$VE2.XFRCL)X
M$V<67PJR!76/5 @3O%& ;BDH>)4R[(34[F=#TV(AL^>SKC<8<%*,]]2@W5+G
MRO3AI_$VI=,>GG2[K5LILB+M(9^<TH*@K!.[]4+9NC=B(,-?SH,Z+WY3'>@)
M>_[L/%73GK\?_LN/6!2M.U_"V2Y\DE:HZ"\^F*=_V/]:/6-9&9?+,SDZ9@.,
M6J5UB@/7I^NZYP#<)VGYK\-]$;]02VK#CH?7F!;DN1Z3)7!6=JJ&Y!2_&[%T
MIO6TY#2^.:K7T:IHSLJYVUPNBGQ8=C ]DV3TEV.(GX1 *=N>ZVBT:Y'1M%6@
MJZF7'4%Q1RD5Y=;(WLE3HT6<FBVY4.I2_R,PT7JMQ:0(JRU!XF-X))E$]#KG
M:*W82*>W<-HH ;N+ *-"<.ASYK:Q^Z5=3QRTN<['3))\;EW/;;WY7P528<=W
MEP2X7LULZTGHP*(?3^#B-Q&#16$P(?*KUTCD96L9*6<W;?&[!! R._UD1'G4
MQ4M1 1Q%\!)4T9HZ951&$X/U/+"@N1#YS5!G^\7/&G*JH &\,.O8L'2"U")E
M/7-F4WTZE@7KSL@K0)'A"FC,PWXWJ(Q*1R?)70$^*LM0A!QHIP!H'0,M6^^.
M79S0GC^OI<4\D_H!-,R[XP<,%V-4VU= KFNIE0D#QY.H=8OI"0 N#PST_L<Z
MT/3M_^?4!3E)6\,[-^46( ,W0Q^JB-^3.W@Y?X\KVWD\7?>@_Y;"8CC1V@NK
M* _[?DOR]W'"G[#VVU9QQS+E6J+P!(XVCDKH[!_:</[:(-_]@?4%JU*<:*E3
M-RUSH&PWB25KD/>!$[V<D7+B)-F<0X# F?.&0<UCUQ+)A;!DOM2O!I3)P8(K
MM?51*Z'9R4L&XTNB&YFC(:T*-7R?-.>EO<M[*VYN]>I-R]9%$# >'94*P/GY
MW/)AAB+?],$\+SVCEGHHP?I\ B7I+0?Z<CE]P8_3?]9$X<]*=YFI=2@^B3]L
M.CVI.@<=%-]<FY/4@:@D;QY/Q;J;7 '!LZ71?)2L#41[RCA;3<-,U\G1%= ,
M3[<S1U2U!A*U+LV%RO35N("=YF%[@D;@ PCV@^42'Y82\_$YUD-0NYR=^;[:
MBF'Z; 8>_Z4/QT5N=C1*SX>UCKQQJ(D5A;C4H">OHBHX1!\!0G.HEQ9#21@0
M!)WA&;_;*.]=B+@8'N5"Y?\]/3"<FOFM.O&>[%['YH.+<6I6(J)IWM^!L!FY
M6_YRQ4/27_:^/Z9N^@12CEH7IHS_S&.ER6^FO_H,#SMC(+<Q7;HL[1@W:%O[
M_N_72S:1/Q]B0?YD]$3F<38F,Q)Z5Z7V2Z&+QZ5B#6.7>@4>WS6'ZCEIXN\*
M&8?(CIDDIE0SA?BP"&K7NJ0J5 [T-34EJ^ZYMTXE!]N7_]IQHWAF:D>(1S-O
ML5>J\>,@4ZPS:'^':*V1>_1HAVC#EQG=\UGX9FQ] I96E\#J_LT&@;/&=]H:
M'41[JIJ0),WRBC<[:SI]0GLZ%'$U,,M1A\8<M[CU5>OM]<YQUV)R"JD;J<K,
MY QPZX.I+:56K;W.@*_?DR9W6\H#'SIA=587F]RI^QY65*,1F;-;V5;[X">,
M^<2Y/"T1=\RN=47DN$ VE*J@3(J8&>]V_>UO';:P98PE\F-J4G]]]-3X5/D;
MMS^''O.*_O(AX)KN7LXE@4 AD2%SEN!87R2:52J.=AL^E&R/SA2+&>/:LH_%
M[$W$2N]ZS7IM+MFYO?WT[:2X0L[XK5O[I9*7&L_?HM>O@#EU8,KH2/\\Z>D5
M8$0JNBZLQA_=4JIVJ1[EV>BMH[%SJ0YT-2USV/=??K=':N%?6@?O"#54'>&<
MV ^@V,1=,@@Y%FW#<O).[=9')Q6%9GN7&#U+&=Y.A'D1RE1*+NC5G1X)WV%_
M*8K-_12>U&0^72[T/B2/%6_!@#_PT%)$XJL^$OZL^V&W_T\']2.\7=X F(>>
MLJV-4M.8*[,]84I15>&-IEA_::Y.)A&W>57QOHX@YEPL%=A<]#JK?*C89;J*
M^)W'IB>.IV.II[5&9+!0E\-!E;#H_>W'V,7]O4U-2K%K'5GQ7_IN91#QGX9X
MVZ!J;!Y]SM1YI\N%_>(FO^^B_G&[UJE]IO50\N@>3?J-ZL"FP6Q\DI&F+\]!
M_@T*R!2W=BKW2ZPM<:J&T63>[]QW95.<I[5"+W4^:#8.?_4_NC4H\H/.^*;Z
M%> E:K,6"W0]]WK?[ISV?#<TK<DR;W.WBWPZE+S3,&OO:]>V.A-S W4X351K
M&PW^D,PE?=]D53"/USCS#&_9]B_H%_4YHJ/"!ONV.R^2;E5EZ@0SZV"')5*[
M0\9R.M^BXFU(ODH/=A+;BD.6SL?X%SENZ5E'2T%S?_(TV)'.4!_5SJ<):E'C
MYWW73;4N%IIK&SPQRD>DU;OBI9R<JP\83C>SELN":5UKM;!L%U/!XO6?.SN5
M6^^JAD@63"VWLAQ"MY.VGD0)CIC#7>(8R;5"X2PT-;G9(:PF*XHZA26_-X6F
MEF]]Q1.5'VG:HO0T-7GXGLK_(8B<MT\-_.0]L K/40D$+Q2E/8]6&;X"%IA?
MLH-[[[_SN3S4A]YD&XA_W_6[>AP6B[T9)75X5G"HVS!LMDTGL28%N#CY+)\C
M/KTI@5,^?/#JE[L;;P[!-+&I69X$<M+OV?"?*KY\++S,FW^)S .X,2I2 )=^
MR#V!?MY@V"EDM%5Y^+DQX9/&IZM5[+5TJ"D:6,.[GKJ8N_.K'PS=;7,F/:+;
M*+HE4=E5QT-GT@MVOXJBH<0%2W["262D8C3(6M_0Q7#2":NXH9?!(ER"G@K^
M.DI\'T[$#TNN@ 8'*$'Q.UL[WF /6\;*D3>IFD=/4WKK/I1]<,<UK^L[%/-_
M.2A%GF'\?\IW2U9%6>/^^^;'01&TA!:=6[/6_;NUQ/X#,+/_8$V F4=%G&KN
M"QE3D A?G[CR&&[T%:"_D1GV*E)2NCGFD*XFU74AO3V-YGWC&XHEI_3S50,&
M3@;F?+*6,'^_I_^;1T3]Y^_$'W7*,U,S9^!KFSF)5:_NEO!W")FGWTB6S+:"
M"(Z:M7V)$D\TN\N?EOK9IM).IAK%ULN+DI\=TZW>>QZ:/TFNAGXZU.GZX&=8
M:XK4]R@9;U6] ,F& ;$?+M7I\J0M@S5&WYG5F1J!DT)WA^S=A!7QM58;%G)<
M+?[=T8[1_E;64?=@C^?F7H%/I2;KQO=)H!^)Y-<+$N@I1/%>!W5X,51BSYK&
M:[YQ\@G\73(Q*6F%JZ)'UTE,4)#U[0J@A=0$O6#!2LRATIM:136BCS)FB!"C
MWWG&XS=W+9B$SS%8TW8 I_6:4B<T1?/21]3RG4\.:$9TG?EQ>)<A_M+%\&?<
M"_EY_FNV'*D1QE,10=Z1[:LA-UY[N8S/>66B66WK;RW#"!"C?C3C%^K0[;0C
MMBN@$ 36+1A@FE3[? %KD#U>>[@[ VH0)X)W1J2#=:TZ)Q$HQ&R6/WX/RQCL
M)/0FY@+&?RYP,\.<E)_6K+EZ/_G7%0#%HRV6R4RN&GRGE/_>UUC2 4^"\>;.
M&(\U:<CQ([9W\GV#+T*#7=XYG@\+46?OK55QKBLVGCV6$&9S,,(!%0,&?ZAX
ML]4<-S#&O\/=J=VI]PXZQV[0$_$XZ3FER!5 XI!&\(6_K9\J3(9O7/ *>%M
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M/3"LN.BX\&%=3YH$XZ*JP)-:W)/<\R<R^2/-!>,])RPDTZHBM!OB(.<-E2O
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ME)R_^S<R]G1(3?XK1L2VB<7^J&SJG2O _7'(B.+-85U+B$^!DATI/C$GAR<
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MCL%J5Z248NQZ9'-S6=4=I(L\4F"H50>Y*7N(-8[T*=Z-D%75F&S=YP%^6;N
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M]C5=>K>CD?EZV^DYZAX/MFY=&S['QN,XC0B\HXQ3#/U;M8 $S?!25^";2'[
MF" 4VR=' .1R!9  .M';\*%$VS\L]_=\<#S827[<+E-$/4WZ;,8MRC]N14V#
M[ST&D>)="^XU]M-F7H?50,45H"J6&P@=:SWB)2G"-UF#I"]^E7W0'_QA[C0/
M*QKZTW *70,_+"S4V:+(+;/W@X[ H9BH2![0_5<X^<\XK?I7^ Z(RJJ^ M2M
M_TPL9."=Y/S_5_M\T9-PI,JJ^6].1\#HQBG6)?\BVY9BY:/J!W:WR,D6PIS0
MV6XE)R"6WZGZ\6VA:EI#WD(G0K@TMC\B;AHG_^)P>M0 N#K^T04M$WGDF3=W
M:MVQJ@._$#T,3'Q =D[EUI]C.X##<-%U!(.HF?W9*&/_0ZEF_6>H_L.G?OA_
M/C?S+/]3T2]JX)UA-Q.6'G$3[ 6<?8GT)ZP%\-"@W^C83)Y"3@]J'6T7@8(7
MIW:#:(3CS9Q\G7:&7K:.^"<:VD>=)%IM:;11G:V3G[8:2PO/RGX84&[=]L28
MP!+'6_)QY.WHE;SE^Z-EK@1#IX6M]@?,>H$R2DWT&@F7; QQG+))5:6_N5A^
M+YO"+BJ?)RZ8VOA8>;EZ^;@[O].)M$AYJ!]"@WTQ@*=+])";N4.6'-FO^][P
M'>T,SM$[\\)IO?H#&7H6U8 ,:Z!CE%AE"43XO=&4W?']%?!N S9Y!UN<P;W=
M67=*X0JX)8/!)FYBJ,X]*$)HS;T7@V\#4$?B#S3N_*==X3UW\!,ZIZ'Z,SK?
MT,Z@G@,"#.(%,;?_70- 932( & $LH+>??PDT$E3$=3N]W@9*H3;T\L'GM9;
MH9H'29V4V+>E"4:_'IN21;BPH72W3![\K#JE?!AUT_F0%X',QG]\5L<G;)&T
M5+%)&TK1C$-_P4J??OI 75[.RAER/Z1D<H+LV)UB[HL8W1I%")IJF&=*&)]1
MCB'%GZQ\WJ44?.#LE"W#R)>^L*&F]V$9)M'Y1Z7HX[&:HM5P4JS@9K$-3F\,
MJ"XZ$TTA^[:-E4\.<5'Y+-VQ,6;*U^2UHQ+:W(R=8Z=Y@DGRDA?<IK4_82GT
M:?AVBZRQU2.G77R27SH*BT3WK).2)VU83&\4M^IEOP16 4(GZY&3S]YR/J:.
MMLZ+!@,]R=2^O^K#CN#E08-=ELZU)0HSP<,?9(?J)7UR= UHB6<RDS@91^#Z
M=X^1FDKO%XEXH.TJ7AC0V%T+_>2JR_NM?,B6_4/\?>G\ZB.!_"FT6#P*(:_A
MZD9EF?,PL7W6P]T@KL]C>4]QL6.P_#O9/>/[77VLU$RMD)F2>(L;\*"2%7]F
M58&IGZKDXC\$.WDGUQW;^=*=XN^2W@P<E3[4ITHJ7OAINW5(P$?)XKTANY4E
MF]WGGJ'RX4RY@"N5.;'QT6#RR\H7W3QC3HK"TW+<N;?,CXL/GJN'/Y=(60UB
M6+1LS,UY9RNX)B5IVZ 0)*=#YON@,D!A@-W6]G?4OL!);,+=G>[H<PO:3]85
MU4D<,UV8VR)X>RH]V=??.AIA%8WZVLN_&2T<V%T&RJ>KHJ5Q,9*4S>"V0.MT
M_1&OV(_$?B,H!'4KIFW)Q'CK<)=S95Q[CO-7%MW7!HO,/;M.[: F:6FMPM>L
M-3L0AQFWC_]FV])GLCVA0P_/G'P0E[SL)2(?SU7YKCG620"%40QZ6TDFAVM6
M]8G*2A=B".;]SCZ'[YHUSXQ-&H]Z2A3/- -J53V;._P%OO@=^>5"%5IK;<>,
M75Q4'8#23P7O#C+4I&%N!3.8**B*I+<-/A<;O.8W&9S8D%X!;$0S<)7#XAM(
M]=S_3>]JY0#L_Z[W)YWN"\[+9^6YV/F3$W=$YR'6!0]6TG<S;@D/#:GT C)_
M5WQ25T!7@5LKY<3QKR=<6>@N@@\S#RH;TV)D6D(@RCA)?V/3B&'H_HAO#!8[
M_W?5 [D-<5P+SA(?EN&?WU=*AU+%"?Y*$;R^WJ3_ITB0WLLE%H!:$B=6D9/_
M?\20T[.)#J7G37O>C;XOH)#Y9X$0/13?[/'PU*^$D-0Y#G+>X"7SS_W-YZ'E
M96K'YK?2;'*F;V(]?C"@Q;W4$5DO6I ?^/K-2-C!^&\_'A[AP*I.6^?4Q:>/
MWW?*3Y#H_B JTTLQ.[/FGLO1H6;&OO-S5IN:SB<,0N%:6_XJD-[.6)#W.0M1
M)> \N7H9:DAQ!4 P ;W4F*0.I"J9!#7SL:C]+=S<S-@Q)(1VJ&+81+S/<=:/
M^C_ZYWGFOS&<'T?0=9G'GZ1\9-@-=KPD8%7$<ARQE14G25T4?XMJJ\[N7IKG
MUNO=[*BJ:(<(04XI5P:WS2N [PW>2O.VZ$9FC;]P@B[;ER'9<9/8SQ+9_C/L
M2[(+&F$,E!H/C;&VI,ZQ5LO7&KFJ$[I@'FE]DQ-=G.*C$K_N[G-!AH4L_$74
MK$H-;+A.DV;UD O:U.@.8#P[@O-TS#4GI-E^+.L8V6L9^0DD+Z<S/3AB]YQY
MR73(6U^=9(^Z"K31H^R23AJ(=ZFN6=-Y>1:TL?791"UL-B;T"J!E&=M.&RFM
ML. HTRSKHF9J7_#<HX:#SPX>1B+%V/?'T*QL[TQAX^UNJM!"NTN:X6[HT:T(
MY["/JL?AW[S(3@2;;EMJZ;+JYXPLNZO-O+:C;K$]*POSK[TIYT85@P2;H&,2
M\,A$AJ-\.LXAJC$IJ1/9;[)H-,H,[X.B$LR0,CN- XEFU^M*70'**6Y_>8*2
MX0OT.7)2!LK0ML;5K=?^<[^@_.'SS?U(C4NA)^AFQ.>X[F,LNW2+:4+OABS,
M6U I'23*A]S6<KGS(/$1M18>*$=B8;72YXZ2C^!M'1Y\X]>FUB24TF(Q6"+^
M1D+/RMUAD7R(FJP.P9SHQ(7Y(]$"HP7!?GE@]9*A*CACLB1H'KD$C:\F]KVP
M6]U(&K,7Z'W4$_!!9Y8HJ@-*--F5\^I-^=/+"OH;LF[]&TFC)A>GU:)$U@!^
M\D6W\E1@8U^"6:'9%9"BKME*BHR0P8#;!V>S$.^N% JO6\?IB4*JF!N452*2
MG,2@<X\M<9*MMMF7)M$Y]+<:!]*Y,)&3+B9$5VH09:'%!%(?3AR'_.ZW3>G]
M5HKI=N2/2N=RR9_;AE,WL/R1/7X<)AP$?,+@^]=<%C>SVU 3+-K0;!C>M> Q
MH%[UP%.?RY6G_%;]6GG7;';EXG,4V%I'VN(+RDOYAC01JM2^B79]"K:@>V<H
M#^-^GP3;@5:2#\XT]OZW@.C+O+M15'"5@>$1"I_52V8L[S+4[\MUP25L[FY?
M5U$9@1Z/DPR<;ES,C\@_NY##%5C8TG?+G6;JAM.TT0>^+L-7@,Z3<_4*K <=
M?/">&5$K>G$-3[NT2H9TU\:8R!#F<V5LLLZ3Y(.\R[+?I>PG/M;->;6O85,/
M@9UG4,\F(:L0X\O>L^&*(=\C0.:A:;=18BT$$2)YT7^&^$<B!9!@D'3R[AT;
M35\)$[3OBU/*/\) Y;]_5&# 5@0^*[H.">+>AX_Z4:^$[_"O*FE,<D;YYL;]
M;UDZEI VFN'SU7J-9XL*E)9,<=,&"F4K(0LQ6&D8J\[-1+\?UF"GN@*^PHV.
M0G4:R9MJ:P>&I+$]AZ2#&98<U$)&9I[^OF!!#?0=_YP9\F-7M(R:EN$TGTZ]
M0?'Q_O1X+T%+()UK*POZB1('Z'*?]F2$RSRAE=&46A0R@+L'1!;D_0  EK,\
MDMQ)D MHI\#@ -K_Y#K5C#N1<3"4.<?_IPWC6=-JU)]*421HK/WT"F"-Y]68
MM.>B7[E[,)<CUVA_MGQ=KYW,*WW-KTO?+M;^IZ'&]V>N; WKCU8,/_OQ2#U,
M&12_\^_JE[(S+):BS#@"5FX3?;0A2W<=>]FLXBYDC5X0<Z:N7EH?4$'VD/KA
M7SC8M[>PDO0VM(>DI>! ^].V]):'1W1^_+:'>:HD.G=#YIW<DZ#';POOR21>
M 5 "1ZTRZX%>&[&OKX[COK%$/)V0X[=(>[1#I04)31@Y>^+WV#WC=G^N7L+X
MDVB&>X0'[7QS"I],-)SI7ZR[)S7OW=CD/R[8[X9:%K03C[-\UEG>@M?0YIC-
M]N:)?Y=S]E@\;F$VY"%JC7M']7XL?$7VF=L5,.'6!NU^?06,2:)YHJSB3FUS
MQ=L<#]) NC4I3TS'*+\<+=: 2 QG#3W,MU>5HI; ?&?/S8-MJH0YX UB&?93
M2(=GK"5F%BJ?G_3S[&Q.&?Q ']"CDVCW2L#:C_*+GJZTG"69<4J=/ \24^)R
MP^GGG;13S?S!8#N#8 Q[/]HN',HZ,>_"NDDNRZH?X;S1RX>0K?(?(G/X5?;8
M(*\-Z_U46FS@8MW&5-/=?L_<;F?8,X+X Y,)^H6 U\<G!4(K*RW6CQZQ.-,I
M6C#<;[UG']NZY"8#L<(:NP+,=9<=F:A!'M".&*NX\<X=T,["%4!1E?UIS8.\
MW=RZ-O"#:_T+?9[]M@Y!$FZ**D)^?@E9'/"@;='FTGOE@LZT^U^HHGQ\UCN/
M#6H>1S+1'F*"HU!G7P)^OGAB76M6Q8VVI\_@C.HBZ-@)#B5+[/=#6_L"T0)+
M)P&7UL(^K"2!&I<=CB=?(C"--/9<2N+BOA6%$^OK9X/I4NYEGQ_WTA DR?%<
M?%EVBS2NB2*;"5.@2Q/<.<KV:T+%VS;3*25< =K0CLB*;J=L(FX&*N_?I? 9
MWO[3%K:)P^P/BI,,GNI\YOMHI2N ]\7SYIR7973R0SQ^KK.>^=#RXG"!:#2:
M(FLAD=2 O_L6G<CS-SY]1I%KG7G%@T-^W',*'TQO<&'+X'DN'>7J86R'7\X3
M,EO7SQN]: ]O7R0@EMVA$&:JOE^!S]FTPO1;+$73,-K387(FMKDF<G;?ZFL2
M\82&!O+]U!50^A*G1.AMGJ"8.70C,^N";PJ>F'Z^!NTH<=#"0?9;K]2;V[]1
M(-^RU[WCZ$K<1?%<]S7\];GRS?:2V(<.6Y'9IE%.5(?Y3>7%#0Q70%/ I4VT
MHR=>$$-]D\%QJ0.=7Z>+KPHB!H]D1OF&@,NI271/"/&\,>D;1\UA8]7!_\97
M?%EJ*P'<$6H[*_:*PJZ,1>U%<[60^7#K56_Z9V7KT7IW$NV,O2RWN7:J"].R
MQ-*&L2:4I2%#'*5&$%V N5?*Y:F-U8VZ@M?J'\W)@?/%:C;RY[\1QF6-P^;V
M_"I)Y'8XMD^U(KC'S?U$ 5,FVE 68^$++<P[^O\%1!*[[6A=7ED&GNY87L[9
MIXG5]OFNK8!/KZ8JVM]=/>P:@US(+DWJ6C6^[Y/+* _=]<]Z8'H&0PX.:7@4
M@&"?UJ*Z.(7^<(=I 8C[OO\ A2!$Q-)QGW':O.DEG@@NY["_N9K0[8I;EY,B
M21G +IZ* 2.*4/(UTVD&]G2R2Z=5N!)\Q 7.W?\ 6@#T;-)C/XUYG)J5Y=:>
M]Q+=313V5JLL.&QYC&0KDCOD <5Z3;L7MXV8;6902/3B@!_ %&X 9/2F,<2'
M//''^%<1JTDVE:T;FUN9I(Y8Y=S/+O0N%)"A/X<8SF@#NC@X!^M&17FQN[FT
M26TBO)I(;J&"661I-QC9S\V#V!_2I%EDG;^RI+R=;.":81S"7#/L4,H+]^3^
M-'4#T56##(.11MQTK(\,74UWH-C<77^MDB!8X^\?6MB@ HHHH **** "BBB@
M JAJVFVVJ6YM[R+S(\[AR1@^H(YS5^B@"M9VL5G:QP6\82.,;5'M4)TRVW,P
M5UR<G#G_ !J_7/\ CR66'PM>O SK)\@&QMK'+ $ ]B:&P-'^S+<=-^?]\_XT
MRXTR)H'2)I%8C@[SQ7(WLEQIGA_9;V^HPW=Y((UC>0SR* ,EA5[PWJSZAK",
M\CH@L5#12':5<.021Z\4"N=$NF6X SYAP/[[?XTHTRW_ .FG_?;?XUQFK&XC
MUJ>\DNY7BCF58YK>;B ?W7B_B^M,\,^?>:E+<3PWLP%TX\\WN$ '3$?I[4#>
MAVW]F6V<?O/^^V_QI&TRVZ'S/^^S5?Q):BZTFY5Y)8]D;.KQ.4((!(Y%<-+#
M/#:: L/]H7OVJ!YIHDNBK.0H.<_THZV [U],B::)@\@1<[@7//'%2#3;8]/,
M_P"^VKB_#=].7T9VGD2UGN)U6*63<T:[>$<^N>E0ZU=W<^K20(]S<0MJ&Q8H
M9_*W*(R>&[8/:F!W?]F6V<?O/^^V_P :DMK.*V+-"#N;&2QS5/PW%Y.F*IAF
MA)8G9+-YK#\:UJ0";O\ 9-%+10,6BBB@04444 %!Z45'<QM+;R1QR-$SJ5#K
MU4D=10!&TBJK%I%"H?F;(P/KZ5F7NGZ5K\<,LZ07@B8B-T;.P]\$5Y]X1TK3
MD\&^)['6KZ\ETZ#596GN'F/F2 ;3R1S@GC J_P"#C'HG]I:U-:7&EZ/J$B)9
MV,<+NP '^L**"5+?H* .U_X1[3'>WD>T0O ,(QZBM8\=!VX%>2ZYXJ\3>3XF
MU'3+VVBM-+GB2VMY+;)F#*"0Y/*]:GU+Q5K^CZI<Z;<W=K<S3);M;W#1!%@:
M1@I!'<#/%%KAL=_JNB:?JTD+ZA;I-)#GRV)P5S2-HFG&:VEDM8R]JN(F;L*\
M^U#Q/XDM+Y]#2]M9;]-1AMC>M;@!HY$9ON9QN&/QK,NK_7;WQ9I]E=:N&^P7
M=U;2M% $%RHC!&5SQUI#6I[(DBR*"A#@\@J<BJ6IW.GK$;?4Y;=8Y@05F<+N
M%>7_  ^U+6=)L?"L4]U%/I^IS30?9O*P80"2K!^I]\U?\;VTMU\2K2.'1;;5
MR-..8KA]@0;_ +P]^U#Z"3NF=RMCI&H7L5Y&EO/,@&UT.>!TS[5HS7,,2O))
M-$L2<,Q8 +]:\^U 0^$-8TS7I+6*P@GM'M;N%7^1"!N7'OD8_&L[2].%SK'A
MVPUXL]K?13ZA)"[?)-.2-H/KA>@H?8$>F_Z)JEF\>Z.ZM9!A@&W*?QIL^DV,
M]]%>2VR-<1+A'QR!61X>L-#TK7=1L]'?RKN14FN+1&.R,'@,%Z*369HFJZUK
M>LZC<PW]K;:;8WK6;6;1 LZJ.6+]0Q["JN".WCD63YD96 )'RG-$D8DC*2 ,
MK JP/0BO&?"FJZSH6G6MVMW;MIMUK,UNUJT7W4+GY]_4G/:I9?'>MV^K0-%=
M?:]/NTN3&[6BQ1;D1F78<[F&5ZD8-)@>JZ9I%GI8<6-NL7F'+5H"O()O&?B3
M1;&PO=2N;6]_M#3FN1"D'EK#("H&&ZD?-DY]*=K?C'Q)X9DNX;RYMM38V,,\
M!CA$95Y'*G(SC QQGK3L#VN>IZE:6]];/;WD2RP/PRL.OI3(4M-.M?*C,4$,
M*YVY "#UKE_ VH^(;N[O(-?M9A!&JO!<S1I%(Y/52B$@#T-<Z^FW?BFR\2W,
M(2:Y&I"%()6(62&%A^[/H#WJ;6#<]1CFC81LKJ5D^Z0W#?2HM1L+;4;8P7T2
MRQ==IKQ[2]4N/#UU:+=67VI+%)75(I<I"NX>8ZD]0NX #ZUZ#XMUVZM]/T@:
M/+%%+JUQ';Q7$RY$0<9W;>YQVI]+AUL;BK:Z99QQ@I;P+\J\XQG^M7U^Z/Z5
MXMJDVI:]XHT72]3OHI!INJ/#(1;C9<XC# E<\$9QBNQ\5ZEK9\8:+HFBW]O8
MQ75O+++)) )&RO0*#^M#T28'87-M#<2Q--&KM WF1D_PMC&:K0:396]]->0V
MR+<R_?<#DUYMI/C'7]7OK=1/!;0VMA+=702#>;AXVQA2>BFJVE^.O%#:8NM7
M&G2RZ;-!),0Z)&EN0?EVL#N<>N13:L[ >NO/%%D2R(A R=QP<>M,N;6*ZC$=
MPBR*&#@>A!R#7B^M7>LV6M6^JZA?VE_++HAGC7RMJ(689!4'YEYX-=GX=U;7
M-=O+J[CO[6ST^VN6M&M7A!9L#&[=UR3T'I0U8#JAH]@FH&_%LGVH]7 SD^M:
M6<=>.*\/T'Q#K^F:)I&FP3W%[>:C>73?:! CR1HA/"J2 2?T%;D7B#Q3JQ31
M[@Q:->K937,TDL:R-,%P%&W.%Z\^E(#T^.:)SA'1CC< K9./6IUXKQ[PK)+I
MNC^ ;Y74W-Q(]C<8.1*C,QX]<$9'UKV%: %HHHH **** (WC5P5894@@@]\U
M3TW2K+3%=;&".$.=S8[UH8HP,YH 1>_UI:,8HH 1ONFLRXT;3[BSDMIK2-H)
M)#*R]MY/)^M:AZ<5S?CZZNK+P?JUQI[,EPD#;749*^I'N*&!-)8Z)>3V]MLM
M9IK/_5Q!@2@'MZ4^XM](@U>.\N!;17[C8C.P4M_]>N8AT#PKI^CZ/J<Q6W*M
M$T5ZDI$DLC>K#[V2>E4?"^BZ7XATO6[WQ+"+J^-U,EPTIPUNJ]%7^Z .:.@7
MT/2ED7)4L/,QDCOCUQ4%Y/9@K:W4T(,PV^6[ %P>V*X7PQ+;3^/+>33;A[FP
M71T$$KL6:10Y&23U^M5/B!HUC?:O-::=:27OB?4/+Q,S';I\:G_6#^[ZX[FE
M?8$=K:^'M'T^-XH;6*&&8>6R%OE(],5)-H6E#3%LI;:);-#OVG@ ^N:\G\;Z
MWYWB_0(KU]1@CTW48X(H_L[A;AMN&D)Q@\] /K7=^/IGN=1\/:02RVM_> 3X
M.-RJ"P7\2!3N!T4VC:=<26TDUK$S6P'E'^Z.U:)./?Z5Y-#XMU^"&\U>XNK2
M33K?56T\6$< #&,=/GZ[_:IK/Q3X@:30M3FO;+^S]3O)8I+4Q!3"BYV[6SDG
MCG/2@#U(.KYV,I(.#@YP?0UF+HVG6MW)>QVT23ODL[#CGK7G>GW6O?VI;66E
MW\-C'>V4VJS2M )6+&3"* 3TQ5.?Q)XAG\+Z?=:M=6TMOK%G<QR6T,.WR2J/
MAU;J<XY'O1:XTCT^TT?24M;FVMK>#R9CF55YSG^E.DT'3)+"*R>SB-M$=R)C
M[I]:X?PS(VG:OX2:$Y&J:;Y=PN>I0*5;'XFO3%SZYHN+R&Q(L:*B *BC 4=A
M4E)2T %%%% !1110 4444 %%%% !5>^B@FMV2[1'AX9@_3CFISUKF/B+8G4O
M#<EHE]!92RR)Y9N&VQRL#GRV/HW3BDP1KV\EI>LEQ;30SF'*AT8-M]?I67_9
M&@:G=R2)';37"MF0QOE@??VKA["WBM=0O=-O[%?#6I7FG.%FM9\VS*#@L0>A
M&1R>QJ'38U\+7^DRZQHL-M<*CQ6U]ILY,=T0N1O7J0W7/K3ZAYGI;^'],>[2
MY:TC,Z !3C@XZ9JI<:1H.GWBW4Z06TSOY@9Y-H9NYQWK,\'ZGJ]QIL.M:QJ-
MO+8W=M]H6UC@P\/.< C)? ]NM<UXRNH]?\4^')M/TL:K&8I\070:'D$9.&Q0
M]!'I<E]8R61EEN8/LL@V%V<;3GM45@NF7+0R6+6\OV4%(S$P;RP>HXKR+7/#
M]_IMG!)/IEMMOM8B:'2%DS$N%8$D^I[@>E=]HUQ;>&]+:XU+1TTAI)-GEVD;
M3[O0G:#1YC>AM7.E:1.EQ#+# 3/)ND4$ M)Z_P"]5>_TC0H+&&VODMX;9'W(
M)'V_-W.>YKS>SD,GC-61I,-KI<#&#@PCC'K75>+K"VU'XB>&8+^".XB,,Y\N
M09!..N.G%" ZW1[>RMK,+IFPV[-GY'WC/?FM*N#\*PPZ7X[UW3-*7R].6&*9
MXE;*12MGIZ9':N\H **,44KC%HHHIB"BBB@ HHHH Y_4/!^B7^F7FGW%F/LM
MY/\ :9D5BN^3CYOT%3Z#X>LM#\W[";C]Y][S92_3Z]*V:2DP,>Z\-:3<PZA'
M-:*R:@XDN1D_O& P"?R%)?>&-(U"6XEO+-)))X1;R$]T'0>V#WK9I10F%SGK
M'P=HEE;P10VF?)G^TH[N6;S,8W$GKP:6]\'Z+=S--+9CS6N/M1=6(/F$8)S[
MCM704AH QH?#6DP1Z?'%:*J:>[26R@G]V6ZU;;3+1M5743'_ *8L?E"3/.TG
M.*NTM,1G:YHNGZ[8_8]6MDN;8NKE'Z9!R*9K6@Z=K5E':ZA;AXHR#&5)5HR.
MA4CD5J4"DAF3X?\ #FF:!#*FF6_EM,VZ21F+.Y]V/-5Y?".C2:V-5:UQ> AB
M5<A2PZ,5'!/O6_2&F!B_\(OHXM(K46:>3'<&Y1<GB0G)-9D/P[\-17 F6P+.
MN\1[I&(B# A@HSP#DUUIHH&<WJGAJRFL$2TMK=9[6V:VMO.4LB(P *D9Y!P*
MYCPK\/A:7%_-K,%JR7=LMFUO&[2(44YW$GD>PKTA5 ;';K48&9'SV/%"W$]C
M+\/>'M.T..7^SXI%,I&]Y)&<D#IR346EZ*UGK6KRK(#8ZAB0Q=TDQAB/K6SG
M,DBGH#P/PJ0##<4=P>AA7W@[0[ZSLK6XLE,%F<PJ&(QSD@^H)[&M#5]%L-7T
M\V5_;K);<;5Z%".A4CH1[5H+2F@$8.G^%-&L([);:T"FSD::%BQ+!VX9B>Y/
MO63XJ\&0>)/%&FWU\Y-K9PR1E%8J^YNA!%=E3<#D]Z/(%N9EEX>TNRN([BUL
MXXI8X/LJD=H\YVXJE8>"="L;R6YM[0@R*RF-I&,:AOO84G S71=J<.E ')6O
MP[\,VS3-'I^3+$8#ND9L1DYV#)X&>U75\'Z*NLIJ:VI%TI#<.0I8# 8KT)]Z
MZ"BDV!S$W@;0);:>!K,JDMP;K*R,"DAZLISD9I+SP+X?N[&UM9K,[+;(C82,
M'P?O MG)![UT]':A <I#X2M[74]'%K'%%I&DQ-]EM5!^61OXL^U=4G2CN?K2
MKP*8"T444 %%%% !1110 4444 !IDB+(I5P"K#!!Z$4\TW^*DP.8L? OA^RU
M)+R"R/F1L7C1Y&:.,GNJDX%/UCP1H6L7CW5Y:OYLN/.\N1D$N.FX \UT0^\:
M>O2FP>CL<UJW@C0]3N8+B:V>*:"(01M!(8]J#HO':J\WP^T&2]>\$5RERX57
MD2X8%PHP >:ZWO120>10O])L[Y+47<(E^RN)8<D_*P& :H^)M&;5(;5K>417
MEK.L\#D=".H/U&:W:C8\_C1N&QQ'A7P#9Z9J%WJ-\BSW\MW)<QL&)1-W0[>A
M(]:R(/AU-<^)H;S4X[%+2WFDF7[.6!FW=MG1??'6O3(^78=E.![43<,@' )
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MRQ<)FB],;&PL;- %7QB8KA< )-@X3'RXI'?408\=R&[P^UTAOQN5\>D;'K.
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MP&4SG8#L[G?Q> '9.X=YDB6"*N#8(9^=2NGW^9(+\-*76\Q,+_GEBP")?_$
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M^C7<A!5:=SD?>_J5T*OGRRC@2Y@L^;W>^"4?V'&8_I^SX6N[NK_@)6.1>R@
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ML)WX>_9*EF4,JON:YKFHK[KKC.UF?C):M6M1!(% #".\9ZRC#7OS^= ? M
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M/FGQZ'7E\X*GI':1Q21M (&SD&/SC,#(DV'>?01MB!IKH /VIU8%OWFLZ.5
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M;+ 3Q;[][!9\MHSG7B:)O'T4ZED<ANTECZ'"CW9E2HVU$!HN&$>8,31TSX<
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M3./3P<#?7E0P30$!J) _YMRK'(5/_'>3\ZT"MEA:!JZ59IPJPO[#>S+)SQ^
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M]E7=6$A'ZT_^Y&SEU4C5E80 LE"?N:NA/B$EO&RP8Y#4A 4!A*QFI+=;1$$
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MVHY<R]5_:?7#]RSL!N+L%S,:,@M+3E/5=DQAA^IQ88/9JF^\XQ^K7O%/((6
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M@)S).>1KDO<A=Z?+/>0C;:DCA1$JJMI]/R3XW$4VN#*=.S_B>5DV"F@0]Z8
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M_&3%>?XLZTHXPIA>O&L@]%BM?^4[(ST*NY/JSVGJ[_!:]/UT/YC,LG\.[3"
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M[_X^K2;TL0X&H<L+S8@2(LR650!LB\M^K2E;V5EUT%2[I:XT4-CR0$:LJ3R
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MC4-P=P_N&@CNLO/]X\C-N3A[U[JL&G/4LU:]537'>E]^WP)\4)15D 7 P,
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MO=(^S<XT@OS(<E1 ;@&"<0D/I)^CR<3]'K6$P^$#O"V]:WF;J5<5/SW(A7^
M!&'9J4WAUH6)&KG-@SI1$J]'YZL,[C4Y/M[P)^_-3+$8?<X:%Y=3M%/\LZKU
M]><?QWN!(4;P/$^1B;M'Z>="7]Y,];I!US4!1 G]U/'P7\W(W*G$)4-$B2J3
M7"SRJ!R%R' YN_A+N+PS?EC%>!G'-__U_J&QTI%X_8-%/8I/=,ZB2PI5-6=
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MKDN$H''W7?&S2O'";&,=LIH'7"<?JO($H2NWQD\"8/(!VU1GO+XL-ML5T4<
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MMW\?WP$2*6H=CZ7=DTBV54>^ZF=TV/FD)*4#F8]DQDDJ_V9V@S&YD^JAGA#
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M9Q,1":O]++%_I$EJDOL6&.[ZZJ<1CE17>.I&N3 S\P[HE99X>3E(Z)!Q[N3
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M#I&O1"TQ2?UH$=A_P[>D0"ODTOA\7[WKU2*K9(X$3VE2#,0?OW@'=$GD"''
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MY;UIT@)!R.IY&*M,HV\#%1;#GG]:XF[LW<FF9UU"$C:54!;&/I2VL2QQ*J(
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MD^7_ $KQ6YN"FH7J/PWF'&1[UUXKX3BP>LRPKCL"!4ZGBJ9D*XW?,#^E6D&
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ML56(7O"PJT+B\MBK"DCH:HI)E<]ZL1-D<UR6.LM*<#K4D+'DBJ;'T-6H_DC
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M:5PT/D7X6VGG_#+QG*-9ELSY\K"W!QO'_P!>MKPOX@U72/V<DE\.AS>)<$7
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MO<ZO:_:)(>8BQ_U9'<5)X?\ "NF:'+/=:>D@>48D+-DT7$>=_LT^)C?^%IM
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M@=6+:"C1UZND@SZ0,TPL#-IM$51#J,+TX_K\<@E,OFPRG>I!";)P9"*Z?H(
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MR#8X$-"DL&_]_CZ&C!A70A7CG,-[05>@Q_L&P%CS3MS5]>#]?NBF3+A\]FV
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M+W)SOO*4L:FQ-3*?+!JWF"*81%VLH-8]]^>TG3H"4ECEKR#A(9]H<39[+*R
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M(6M)N;9&Q%Y3B.LJL>R>_X(E2\+GL^Y2;?R[C/<7^P%B_PN3$02>C+RIP!L
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MX"@KMH]G[73#.<2&6!F YP8JK,B4# 1.I.<39-; #_6V> ^)N76E*_A8FEI
MUE*&:#JSS>'?.XHKX>#D[!C&4;>\.G?"^RLXJXEIA3TYTO"/&VY7 *$GF!C$
MA[>F08%I$W=L663P+\+9@<YUA^QJ/QOW)]Y9#-PO)".[+3M^Z<,5F7HR35;Q
M +*8DBI6S';.0D-E5.M?V6/?_Y*V.4/Y=)@N@YPI[>@_=DXVM& I3WV_M.6P
M.2)4S"^NS$&Y;M/%!*?.ROS%]0D"B<F:?GP'V CZ?D.Y6V;WQ\PSZL.!X]:+
M O\[RAL+;#[9[")M)O@VZJ>MV1DYL-['F:\N2Z^Q-.VV]*%C8<%/[1;:U:'^
M,J #4EP#0^DA6D^NSQW>X/X0,O=, L\4PS/=20'*M;G)0U+VC$2%XEC5AX$Y
M\N!KL$&,U"BU?-H_POYL6FIT7_6X8K2(PC.89+L4:$D)6;NG[14BBK",%>54
ME:;R9J5T!8H?WQ(VDI60+2+M[D%<76D4/.N74!W $2Q[A52?[4 2RB*U5EK.
MS^6#)<]*K8GKO>9X'[*Q]D/)(QSGMOZ@'GL@7)@-/.PE?2*TG28^'G?GFX<J
M 47#CLB&Z-\ VJ>N:AT5UAN8#=JD,TN&B$1 QM&D8:26/0GU@LTQ"GI2!\KK
MB"I1.^4YTH#IS"2(-]OEU_*K@ UM%I+.&YR5B>(^LVRE$NUPEX5_U54J7PH_
M)%M"&S=9+4KQNV^4%/6L>D"0/+/Q#E;1."!48FL>W_ =#]3S,@C-:,7Z83[G
M_FZ05M;%VA2GN2V>8/EE"9HBJ)G+PI'"J*XM''1")B&>.(\3*=[6EFFPO&]_
MLF9;I^72<ZD,[+[NH-5LM9SCX* /_ROH0I;;<:(_? 'O)Y-0=1PUGATF3.Y5
MM6AY5BBT%YSV9?8&>.0YTY2Q]&$+;;$;^=F6AT(99D.XQ/Q+A?@A]'<B<$!$
M ;P&/#!WPA^E:"]*_>RLUW%DT'OW9P$J9>G7(>U%OR_R!FBU*PG>B7F,F-T9
M=FO/U9EUX"5*/ 7:''</I@XB4Q;D3S_K 2N]RX4-N)^:IW+!/M51CFE]QA\-
M+%K'B[AVHG([ RK*[ST*)$J.8D0P)DCXRD3+M'H&>![2=\+DR0<K1"X&#F.[
MN .FCS28A_:!K,8_^#)X0B/-C8969^>6":TAD>G;=?# ,>L<O8(H9H#:6A0F
M@-X'J_G/A7#K&R"PP[<]RT#CI=XCMNVH J5CT[K6F'ZS2A)B3" LYMA280/R
M 22L=<@N]!>KD,[ FZ#O,%V0F<_);FN%43%]B%-7,57ZI5[GPIGBA9<>,480
MQK^M:;9(?W+-)Z]OZ(R$Y9*Y?:,4N+2L$0M<K94]5!?$UJH2WD1\%LHI(Y,H
M?5][J44&,&O1;G%0]S=4H,L2T [:,R+V1^]S="^O[:VR;B&8'RU?77EX ]@D
MRA$[,C)2SJD;1+Y"R\?.0KL<)6XKS&"L?B&>N*4"W_R>9BNHLMZG4CP-3Z9%
M)YR9R$5TJ^6E9N8$^#OH#U@T\>-T=,>0<GQ4<<HK_5*293,@.?V' _ 4#N$8
M&.Y5/IG 3M4AH&M2DQZ:7D:9(3^E $(NFQ?)N9(+6>NB ^V4V'8ER1A'AR>T
M&]AHB0B=../?$RZSY,#=51Y99!YN_ WGCW,>Y2*'.]$'V[I9%;Y\$F>16JZM
M\8HS 7]]8"LD*JOT679-[3=2[S[>;HPA,AMS16L:092]92#S:ERAH!/WI@Q"
MBU4R I^\<TUPKN@BWM;2JSJM^OOK6'M->PMB(/AA5MF#NBA^3L#X(';V>!4#
MZ,'%3'JL[/-LMY;BX.@>V>2?N!WB>Z$A4W@D5)R[.XI/O6&?$DCQO5+!9@OR
M1]C)LX)O_LL00J>=SX: :U>Z(',3]51#SX=:):K3Y0^G U(.^@=\G=1Z"'9H
M:<<EEHW.>/@JR!&@MAQ&I_I<)A_%P1W&V3D]GE^LF#)#<=IA5?KBO+OD3 CW
M;L;V6[9N#!Y^QC:7"Z-^,M#8X1.Y9HV[.-:;:H5[1%^&BRD3CO?^H:G*-[N^
M39&<I[7PMA?CY*&.'P0%*,9]X[J4L,@X"0V,):A7V=N0@R/&<G;;GWM ^\-\
MM@1 W4<Y;]Z>(ZI+_*PCHRD!527GI0'Q!M"'O1S(5;IX3.;LO?R!!E.I>=G,
M.N]!1ZP?]2&$!<QKNRV@;M[MN%B9!2^E.!N5/*8 X0M;?98$,^T1)"5\(6"F
M#Y=F,7=H%N05VA(H*=]V>8 Y?D[:E]0@=\FYMJ_ ^',"$-XMT#/U7*KO,7C*
M[^9)_J7VSSQ]!2U;E4PLQ:46@64,TD:_V*%ZAM$OL,0^#![I,P._U3/EQ3DN
MQ'X^R;%CKS2J P!F**^4ZKRXC9=IMQ(-$33H:L9)A]^5T5E_[[K0+YX2:#.,
MC) X@N9;KKBL3ZFO&BY+8F?SV,D8Y@!3+W1^.;BG8UGBT#HG8F=Y;1C0/1'F
MKZR@\FU::BTO:!!^B)8_W2NM9JF]3RM CT17*87T4+7VAE<UJKSO+]U?MVML
M4]!#.T79=BR>/7'_=:O0TG9K%2VO+LT6U#&E8[U!DCHOYY41"_?PD^"JU[O1
M2)#^THFN,_N!9171]ZX;T_>HSYBP,_45!Z\(!/\8K</!@:O9DHF,4@+,'OQ)
MN6F$=-"PB)TYG.S]&+P2YZ^3=I#Z&*WOTLI]V*2FY#RPQ@6QM'>W'D(FJ58_
M7T:"4D]^('R7LY)Y&6.GX.?@9IAS.*K:/AL(^V/]>^ -T*9\R#6 #/;Y(IHY
MG W^9MN<7,IY4U87U"PN%-*79 UGQ9X^N]-Z74$6F)OR7R^H*.O"S2_ 23':
MB>EE _K#@_UJ6D2OE)2(8KXKX_!%-N0_\E<63;.\8/7=&Q')1JLUJW"!W29E
MHBGKTKL\S-QP/+I6\F%\OFDZ-P(JZ]7P.[I+)8?Q-P M&]7-Z1Q1V$F5@P.]
MP;@DA<22Y-<$FCS*%:^R(-A]@KPKS8\0F0Z *]7[:K83IV]Z130' [2J0?I#
MWU%Q<#<7VW=)/G'>5(CC^%>8X$GXN=AP%,JB -X Z-9EE>Q46LV),"*'J'#I
M;^#!#6,8)>:,$B6,T.'K="(GA_?.;_@QE"]++;^6#<!BEZ>'NH[5>O,O5*/^
M+%0N1L>1YCX6M;@7P]D;?F65#[1<M#][AYV(!!@1*PH(>.ME[*U/"*)2,T-7
M9:S22ARZ)799'F$-M4P0&V5 _ T%&HQ&F6,R#0V%[D-"PO.X'K2:D;"875)W
M[0"K7VIKYZ; UD3R4&( 1OTG9'=SWNSK+L&0)X6N9Z6!;,EL*LQ!\EB:'=4H
M_2@VHZIGZ7(759_6$</"DCP'&2(A.N;0PM H;2L8'QS<CY-<;19P(*Q;YH.O
MXYFC,$ ?(C%$(?.D19EE:PY*P,QL,'/*2/^]1U$^;&%6C5O'?X[P7'L@.XV_
M&+=&]+02,'.B5-?00E<^;=B[TT?*)^Q%60Z)=,(<7(*0%>#H+UY )E#C9K5;
M:Q+/*]W.4F0F<?X"[##-)D1+YS^CZF[YYA#[XLB_8!Q*[_)!/,CK] Z5X%(9
MQ/0+_;S$YLI,G6%W_)Z'>5^"V61JD,M?F%\U)0EB9;VZRH)1J-Q]H5^L2;^T
M<^E^'AK>%SVR!NH*"MJ/6\2WVRB48=X9R;">:!NF?*/XDDJ,3-X$:WD2KC//
MG/>E?=D?$@1H9[=QS6R-;<K-Q[O!6G8(TWFKPI0T%$,.&"3AV4*!I55V1G@:
MB?WN#U$Q0H17JL'#U[MMNF^  &*;N5 L8O.R:U[Y1[EOE![U% ??+RBE6;;X
MHCP3!3JPE4ECRUAX>Y;IF]>T6AM%64'G#9D6.:*-ER ]:],6HZ"$8KLE<OY+
M]IW?X:N_36_=>4VZ'KD/ CD;./)G\2(!(*,K#2]!5@W_F,(UVFV-)PW:?>:;
MJY(?]!)<#^6^U5R[Y72*\OKR^L56(;$A4>'72K>VB/7EBC(C@WD@U\TJ15F-
MX3? D09UNEQN2O+I +%YG/[VS1GQLK?O.'5'LI&=A/C<@-C%B:'E8-_R\I$@
M*3OW")I_F>L_JK+7##[8*-><HZW*P?7@$PW;_BQF10GI,@8^EMR"9FSG^>;Y
MIBFJ8@9Z;ZJ"I('CTE-RP%+YZ7P!MF=L<[U (>W&&7M[:DL5WKOA':KV #<C
MS1K?)<5CT(_&Z)MQ5OVHS0F^YDS\Y+ALK3I$W5D/*4A]JNS[%?E"5M(;N_-%
M'B6%8SC:5BL6!$3D=S,&JA<4D*AEUA%P;J;$,.T,;^7EG%^Q1A?0;?'Z#8!#
M9)/ZN @6F0@;.CI0O6]]25-)9-7+9%X_;:8X&G;/K]+C C9G7J+'I8?;)XO^
MK' Y?&6LU1N?57!!RYXF$?_A2ZH -\I:C(T\\A!;O*XQ>]W!>-R$VY"6*#[*
MZ@[?3(7#%=>G9O=I>%=Q<-2F[45*Q<FK[%"GWG"2A:?R4PVK<X-N-Q*H (@S
M^0:@%OZR=TJ;B'Q=-:0>@^A6P#/'ZU89NR1;N9&H=+;GVOXR"=9I#D'E>[A-
MD/?C*JFJ$"O9\ ..(DK0N9SX>8G@W937?R6<IOM\;P%WRZ=ET%SV \2NMRCI
M_Y1176#P*]2-H!FWS[O7G-=3"YCGOR\R-+3+O? XL_5YO&4 OOK=;ZLJGY&#
ML,@($LP%V._5B>)$S]IL:W,'IUT?SYI!:A'Q.QE8:]P[UJJRNY^& =-3,+:\
M0:I),I;:X3.#0 R2N5\R#!I.8)=-CU!!KBBQX0;/Q[6@VM,Z\9#*@S\76TYO
M $-85A"I@BV;:W9MW?M!:+EWH*UE+:6%G[9X(I_X0&&']^!HYA8(7TT6/B&6
MV;;Z\_MA-PQ7&MD-H\D1X<Q+*OS5IMNY%;X'-C+ZP<MJN1E-0R!I=-WW 2*<
M8IE5XNJ,5QH@/RP7YP:5?5?,$/NR3X@?UO;1':3N\!4O"B;CXN3B0R88NV,.
ML+[KP)0JO.\VAW'PG$A--S)F[4D':IP8^Y5Y+^T^ZM(IF+Z#XQN)N(\#FS;$
MMZA7-S=^9ED8 *[V6D(87E[@&QDR8R-*C]9Q>:894RP2%?"895P&,'W [4..
M#*E+>F:QTG1,;DF*2I]8/72\7'__S=5O5_X=K!7?,0!'U7L_7Z_ 6:*P[ON;
M$W?O=%"2]6=)%+[[5T=^_%<&L1L,';R1'N&?>EX>'[Z5@@O8<$4+=.2(G09-
M>LK(]HV)N/I&6?V#TU_.0)[3V8)^-=I<%:3Q,,?-3]4YM.J3J"1L*QAS;P"L
M85)P7_V./G6*LR^,_[92.W6<_' #?\O9<.9$)5>X,Z>;RE&-3N!*M%9?\T=1
MBP%-<J*7C%+%P%)G+L6LYW3]%OSGA4%82X?^.9E-_D^D3$*2#]MX!^J'.(?:
M%P])U4G$5!\IZD\,QY)DYZ,2,&H<N9XUS].U'*U.$W0S#QWH8@YX/9M;PZ]/
M(S>,PD6^\<-*34Q$QT:F>DE1L8@P?^/MLW:>[_4.>RC@B%4[UWQPF PG43LS
M"DPZ?P/T$&+CC;HW4:I=$?1&XQ@[&$[$H$*(5[,N)U3E<EP*[@EMOZTZ'^''
M?JK<*ZM Z+UBG[_U%XII,*-M_QDK*ZY_+8[C'=?M+-VCY_6>#^G''L'>/.GN
M+\"3<DS)D.7*%U0!/>06WJ%Z_10#UVE2&4X'AH0IFT=PTM?;-)V/D_4[ML'=
MD\5 ?KT9^S&W84LS,*I)IJ)%DA[4#A:"$(.&HO=J5NJ-J<W!>R*I1#0R(U6Z
MMZL[*?9 D-C'-'*0U8XI"U8;Z;?T\%QLB^(V)7[X\ 9(C68-ZO'US"[1':=_
MR:Q-?B[C9.NMP3_#6)2_2YA0H[<PTU/=&"SM+GOV,J5:_--@CP#YZ_)4XZP9
MP%H,<K2T&$MA1+:*,2)I.!%R@"WY*SB;[*&UD 6P3@=2#5O[;5HV-RE5T7[(
M;A;_8LQ?,.H3(-#T S$1'PNM$3W7]U8\7/+FICAS5_<]\?E4%3]"+&1CBW%<
M:0&FV9&=):H:L,8:/!?\.I,NS1>S*'AF="Z"Q6WLMAD@">U5RSX]-0_CGLNB
M OGHLK8TA/&ZRV:+=MCIXG]8(F[Z S+3.VJU7*U8D? AZXK >*J-ZIGKI-U_
M]/9H\FS_[8XZ<U&M_S%%9A3?<@A6MW!-(&(-D04WI7TK[/1%NT /BO)=7OT8
M!5US#VHCC6N[X<TMO]\SG/U::RC+7NC2^%4M&EM^23! KT--9-I(Q:MYGJ=-
MMFEE?5FZI8M!8ES&?-.!Y73\]&^;=*,RJ7)/I^XL@X+E1PF,1"2RIB$%<]$C
MUTGU=E(,0LQ:MG#EP'WS%[LU'=930SO)P98U_R_3ZAMF(3?XL;HU1]>5*@3^
MBE+1,GE6MKH!;X -$]\+&_IPH$\5'=M$1)EQ\XE4;,&=N06?3*!;F+B[C@-Y
M<5H_HYN@CHLO;4GSQ=E/7F'/^HY6EK%E@BWA('&[,M A]%Y'-=66@ZZEPZ+G
M-(T)T]4KT)"56]F:7ZI.8%\T3"]6P'C*>.5/NJ:90$BB@M^\1=VQD+SV%'5T
M&07F]H55<^OWC@!I#;?H!I\'+H4*("7=;*7_T5-%@J/RWY^>H==5KLN*<YQ-
M1$W?(A"#WQ%05!20>C9$4N2,PP[;,G;\O_FB@60P@UR9QF=S3G[7^Z2]^_KJ
MJ7NZ=@PL#'_23IW@<O+@\9PV567="E8%4I+-53^'XH$J;3[BPWMIOE*=0XZD
M6.7IKZB%_9,/U\.^[DCZZF%]2O;R2VZ78BCQ<$,P,E8*-V265-G35-_%O*B<
MQR.N#]D^'1!E;8$^T[JP9<#H@+*Z%-\;21NO5=[9+KG!@ZSCZ'\IMFL3V*E%
M-:#]V%XKB3ED&#A\Y"K^XK83_E"\(&>NKP3D30ZQ!>_I+GS#5>8V'@06],(;
MHB/]&DVH,]>B8GJ<"Z"2:0PU;DW<")Q^ET?\/#]DZ$G3LNJ^9?%+IV,2,_-U
MQTE>NK((XS*=X+KI>&WP%8="4H<Z+D=WJT2^9\Z=C*QA[&*YQFJD#E $M[S6
MEANF-O@&0%F]UC?5$K.52.XBV-W5XI3N']0S//+G^ZXW[*RL>*J75G>E1_2*
MT]S1WFSK+U4&:A]/<HR&9WD#N/OI*)3HO\2.,.'OF?U]RM7_ZS%NT-?8"M[I
MJ"A?DGSU22^_(+*9\J*[803Y/_*+8L$(0M8$"H=EN]1RVK5^:PFC![L ,;HJ
MB%2584,5>F\ BRF$TH(H0$R+:<(0;[_M*T*-[1D]S"&_-55OZ:L%6[/&%"6P
MT32UFO]"J;,,M$Y"/7M3T91]QT8((C SO&/X+BQ*]'7F&BCGX+Z \7ZH?Y$?
M;_C?D?$ASG@PV]/0%R2(S%D)VN_E /DW1M?YTCQY^9KY49U'?T4BU%!%$-0S
M4M(W#:K40P#.ZSA]H3J2 K^&Z7+68UQ3'S7_6,3Z,,I1"?^V+CT&5"T/9A[:
M+O5W5,+^V(5K#DL9MNQ!K!8.E\3*0:9-%A8/GUE#1&/\O.T28WC ^4?J@9M?
M]:46O?77=@:SHPO-=Y?/M$D%NZ2Q_K0=3*[IQ[B'-]@Z@C=M!P0 5^-R-=+3
M>@5RS"(-15?$HA4R3.M?ZKCE;&00BXB(.$E6\CANEU=\M5 ',D2W"KJ=T]YS
MN,W$+O)Z^C$W>(,R5U<3Y?B'#))"%_RTQ<# %D=>Q(SSH[LOID&DK2Z[J5L>
M=#OY?XKZ\09WXCXB;:?9I]@%3*2:LK,EF7H_?!]ZEG*KK5U&3F$F^NZHS>:Y
MM09Q[["%,$4;#O((KI.0X&Y!BT'\1.[,6HF6N1Q+R.QD<1"Y[_E9XBFBU;0<
MWT)$VLU]WIGS2G7.N([SQOQ\ZK4;^OCY++.:U5#&]!-;_VFBTJ+E@(KE)$A@
M8(=QMI:B,BUQE.UG(Y@:3E:<J^PT)E];F3]_:3L75HNGUG8)52A:.WZRB-%\
M_B._'Z];="0\%L,P]JE)JD"^:\_+0IV+?DSV]JINY#<APAFV/+A<3Z#Q??L/
M)D'[H/=W8&G;_+"E*5K+IO> IXZA4MW*G1\.NP^_4J4/Q9*WA$7EVWQ)2.GS
M,@^_20Y\QR$Y59(J/A2W: Z?5 UK7V2P6(]&I&@!RT7:]/;_\'C0><G?#S@$
M=2ED;%S1&!5F=VV'L)K\4B<W&ETR&I6M YWN,T8IY56XL>R5$7@>,N.ZQO_P
M-DAEK(:6YC4ZR#FV=S%:7)ZO6/CYS?;84ALE#5AB!&I/\OXH+%/5IB"7Q]6.
M)*$4[Z!2B].OW7"WFJ=]\*\I29CEA]8%0:*%H%3U0Q4?NM+A-9](]Z_EB(_4
MTDU5V&-UDX8J@4U#T^$T@5NRU\3W\+EJ@W?2@J\0>N^2$ :6]G7?RIP4?:=V
M3$TO&C_,<00P-\_B7NP:8ZH9(2\)0[7!(DF_H$W$I\:KI&1:Y*7VH\W7DG+;
MQL8O*N8$67R,\9ZE(C(7B'N)0!5LZ;-/OWV:'X!)<S?C^IL3WI"B,5R&0-/+
MU!.C>WORTQ+:V9X-AB5[L%-!UHGD_HKRI/\Y:N4.>_;](<0*G55)?T)PN\D&
M),Z:;/\M-F]&&Z;G#A9B554::=Q.,4#B/K@&DP'E0!E7J&&-N\[@RU2*?M^H
M"Z]]O^3\H>,1%QLGXD1T6PYV<$:@0W5WF<.U-^(8TJEMB06 INDSHFVOPX<(
M%T^/8VYE%:[8:POT:'@DE0Y^[L*%07<ABY3=EP5L^-C/ H+79;1ZA4I0L=<]
MVN 3-4-4BX;^6E8F0<Q8"$KBUJ@&37;&0_V DD(2!Q?0Q4#UNQ%*P:<,R\/>
M/%#FUD23#8UG"A7+=$ZEJ)UT)+7#T).SA!9M!UMM '2$"-ESF]A4#=3/5$8+
M/T"3R6IH(),MV;-G@R9F_65A+G)/@76!UYOZ<CO+W:W'!YM2\)WO#"\F_PEH
MKZ$CAZQ9^?\H[:V"XG""=U$( 9)@P1V"N[LM 8*[.X00=-G%/80DN(<EN"SN
M"T$6]^"N"RSN[JXY^5VI>Q_^Y^D\],M435=-SW3W]U5-=Z^C=#@[UA=;2-:Y
MO-HXWT+CK\UK7"]A7,IWU8AB\[$%FLOP>"PX8#L:ASL]34NO&7K<'@FJIH/$
M X65&S%]F<@(_QAXQOY$FH5>SQ!7:H'M%W(L'6TKW8O-'/$MC(H=4H71?WI@
M/K(7J*:O\7D49L9/F;^K;^*%0#!IV?HT'3N;V@/$#YS.!A<ZYX*R&1KR9%H;
M6[^/['YN@$L(_^X%RFG]15&-12AMXR\IK##@QU\*L3%>B6^,YEB+KQBT^^2V
M-F>QE2^U%-5KMH0AFE?0>X>*WP73P>?/_Z+XJKN)VX6L <=J]\$1G+&4G^W>
M:,(\GRG#D;?9G3^'^U6_C_L9<G.[;E:+<DQ_B>67D )*SY-^W957+RPF(5EU
MD823718+S>I/<KN]9^+%=#>H/97_A7(JBP+LM@LUIF;-C7Q/%.VJJE^)U*_S
M^L''F6WS-N.%/1J/O/29 ()OX"+LO/+7UW?=5;</>GS2)R9N&IJ6CO?M?^P"
M6JK_$7=:[IU1VD7GX\@[N[X$DS@R(+X*OJK&O/7L::4U,T@?1&Y@J,"AN$TG
M@A_'DP-(Q+O^X-KR57L%_-7YUX7A9]6DJ0ZC+9(#A (998!R>8.S9$0$87BV
M3'RLW.Q<5\MZG:BYZ)!JNI;ID"3[:Z-$9;X3,)S*_L,)]5ZDMY/39TF833F/
MY+H1PI>K8Y17 P_N1_K'&;O?(STJJIESP*V;)TU,9I^#!U9LWM^HW636G'&O
M7F"T+.C]PEG"&;N//H@F:_PO2L&"V9%MEUD6RG6/Q_BC,)]OX?9ARI>E2<(A
MT'5%UGE?U\T+Y)!N8_Q A]+[WA.-Q! U)X9R?)I!'8L+R3Z5<9X6^>L&D+FU
MZE?]-X'E-R-:=9-"9' V.G@]:7(\;LF-?AM\?YE_YC* 5!E>,UEA,&N]-<F7
MBBL=C*#W^8Y4C%T7%=S*%.G0_N: ]_ U,8/ORI&%I<KE3^UA?*IKH3)MV$[H
M['"R=IKDX(6PRU^4)>*8M16<!6-EXK\HX9ZOK(Q&31:A*89294#OH0 )<G,"
M?CF4^9?WD7U:W. /7;;VFP\]Z:Y"\QIY6J[;\!&6X!G!"C^O]O4ED<-*4!'7
M0<<(W)*1$:IK-LSC[^HXH0:9[VN^^4QX@:=9H'LZTUL8/^;@6+6(E CLJ\T&
M]WVA6 86%X:^@C&F\?"P?\P(6-'"*_#Q*=U/W_P!B.,<6F-Z^",L6EXIX\QH
M,D#HY(%)KWM@S@TM61C"<@#'OYY-B1Z"6SYE7 N-U7*!.$M/OQZ%/OT[$@!>
M4FKJ*"PL#"HS[>$J&-SF""9GF3JO9-9GGID_?F#72V94&+&5&\!VW<!D?DV[
M$_T7I=H_LN13Z*0O 2%1>%]B\E8\Y0(B^^>)6G[!,6'.TH!E)<P"V'"%AGD=
M[-KU(9 QV+W!HSP#ZE:J:S"K39?D *Y78T3W(7V;64D[[5U1I(8 %8;D-/@4
M\I6\V'VLIOW$$9.BR/GU,UAGY[:KSET9;!<-ZXB4"/^U@^ZF]TR<[SC(O9<A
M&DTM!M-&F-PZ" 6+^$G=+[3X]NN&NI^8!J(A5 ,I5(F/_JAZ3%2Q+WT3VB%U
M7\E5+S9.)2-92O%CNWQGF/<%$Z%1MFY+RNOKS49ZQHTW*[ACF)6N&!_Q1Y2'
M8=>B3_JY](YT/?.61K1-N1#X [*&W[8_.VOYY_%@AY;,!Q_<8EEL828JGZ;>
M+] O6%VAKWU!8ZYHD[-5=]Q+4LO!:-F[IO$RT=B"DBV1NENG_@/5F07,9G5!
MR<ZNS=U/"9E-!2K37),"*.L7UH1.?W#+=YO$@P4PB5_NK<0[NFGHEN3'L=>W
M)&(FOND#HCKUCXHY?YD)JWJ>XVQR@@PW=E>S2O-,MEJLR$S)0,[)B,J^'N:G
M]$T;S+3&)):SO=26?Q%_H^7FV-8X>,V2D+.!N)>'_U3*SU*NW*0DYKM 78A<
MG'ADYG&;)9G,=WTL.%Y UWS@,&>\)RY'#L\2+@OR9Y,9=? 3WU_#NNOCC^1,
ME>PBC*R,'D=N$0(]PK6XIN1RG=>\>Z$BYUL)#EMM%NQ8SBA[74105?/ZF!MO
M/C2I$;"%F3P(ZU@A3;WCIRF=IJ-G9O?U)]6HU(DMJT;#=ZPTB9$P8Q[/(.VE
ME&7:4\NY"I8&7YUSZY]#]"Y0E4;GW#T_S^'#\>Z+?F_TA0XA!Z&#@0VV32A
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MIQ_ %2&2PI';YOAE]#Y6R+RT\<@((>U<W=B2F# Z)?+-*,M:>LVB/,U9/:X
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MO8A*V6;ZW?\K)D(7>M MH?C&>RE]]\KQ8-Z6[+%L>PQ_EW3*9\4X2XGNG,3
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M L3R9\<NNGY&S\I<:=O-A35_Q#-)PWH;N.7,/*9[5H8+*6$]S,>VIMD:@/G
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M7+(Y=X_=C&N,U)I59>H><9EGJ4QQC0?:\@*^SQHC%5!1G.6L"PZE(2I'B K
M6K\M-_J(2!F\;F]]0:;(7J>OM/'/N@G,\5*M$_CFH=CA2V_N2\I]NM7IC(>Z
M4?8.=$<H1S!,/L2CWE%=W=.JT$^$ .M=86^;HF77/D0-._51AKQ[^!#O2_C4
M;?ES!Q-PA=5U_H],++ \*,9US.36ATQ.')KL];TJ=9.Y$2H0;1SL)8L<S'!V
M*Q?@FC]G-!2(%<D]7C!!6@9[#A5*\\8B-%XG3#:WH^U6[0D3"$[T\C"*_43-
M;)N94'*?/CM!-MN]\;A4')D9=E1O*,H9G+N55JN!&ZDT#T0+IC[K%YW&_;FA
M4(R;W_#(&LEU O JPJU]_IAF#=JH<IO0D_^(3K:X6GGD; E]T([TP47K5=;Q
MQ:CN[IT^=F.?^GI@5^:I)3'[YQ^Q_1"T#JA]*[PB>%G9@(DF=&;8\\+F-KY,
MP>Q/A 99)4;#J>!3+5*HP')N?U1+X=F ]HUTF#=S#H2!UE-,"I/8_?"$](1[
MAT8EBUAFH!A<<9A)#$+5P351UA0ZUNV0:1863TV/;-':XPQ6ISDH?K9JP3M^
M<OQC+#N16G$R0;:Q&>$>.0Q9\]X<K>BVCE-1*EI@61YV^FHCM$!5'5,_O9,$
MTD\;><DN&[$S1*OA>J19+>YF&=@]=133_^;GE= GL4-K?'BM4C"VQ&#WL[Z/
M,HCS=TE;+#H+LPSM4CF[=I&R22>VV;Y$G6$3O*JA)7[&4WB,$G5 6S-M>;KS
MH5F9_E4##F.J4 $PWW[%@<NS8DFC8C$%XW5%8^T)5D"BTP=^\$^738+>1DBT
M3>DXTB=+_[A5D\6TE9M$V]59,%7T#I?/-/)>=Q[M*56@NTCB0S8MS'F_#:VZ
M*@;,>511.1/'EMEP74&J7Y/)\_FMPY1Q;]Z3J;!2I0[1:?6^FZ0&75N17?:"
MC_"6<MKQ]J2L6*B&/'>N)$_.0BUBPMRQ>8P5L.Z?=A%X^+!!SU^9W/!8@&P"
M.N,!EW6(F^OM%SUQI;6-AW!D;]1<NV?G%\/TSM1_?J"PR"QB'_C#]C+Q'F%W
M?<'@5)_(9$ K+D_RXHFC*JQ3 %["/_0Y;NDL_BXR;:Q#XQVA8JG#01"DXQNZ
MK!Y)DISG?NN"&(S1S$(YRN=3JM)#A7";HVKX8'M\B:"6*OFBM=K'66WI,(^/
MVPZ>H0]^W"A1W],@TMA[).)N*_LDR=Y@#=6D?7;:&<@,4=FZLWU-?%/8ARRJ
M,4].'>N3TDOB)"=)05*^D0"QL7=L Q4C\+\H>(+@M*\)!/F*G#6QZGKPLX+F
M1;L']F4DTYIU#+_I63F".40ZN"BL6P^A@)YN/ZZ">4V\V;^DC$D;UAK ]R"F
MB?U,UB:,!#I,</6^='(S\DL[99JYHE8:'>SJ&A4>:HG*#$*V1=]B,;K=>NVM
MVD($>.XG^=ICX9TIG_),,G-9U[;4E]4NS64G)8;$WF78BI Q>M*$-J9($EH]
M)7$6-38GR;&EF88D6"MU7SIY75<,4;,B,=]+B1N&&F/SE?/1*W;1A[PH&+@L
M^O1_=Q*512W^.@!6EK8+8]S,#$K+BD2)%<V+"I]XZ]D5K9N6J<"*]NTLH!MA
MP?:[,7;485W_3Q.WJVG=.EM1[+9H!D$8>C)&_?4+WP(DIHR)>"R"6Q=DM%DI
M6,NK+I)<;2>&'37R:<P!9FX!^%6H] G5\BBZ<>F08^+WJTXJ[:T*<8]=*?89
M;R".OE?5R(K)D%T^*J7@Y =>5/*!\G8\A^$AL>:04;T,_ /S3BU[-&HVA69M
M!Z(RP3BF)G,ESM](9'"(4<AR*J.AW!J6/61F%>A /,9-_=7D&-M>0R7ZB5TL
MLCLDI93^O'L5#V96Q:VMU+ANEA@_T!YR#3S?)_'F[V**LJJW;(Q?.5"#VT 0
MOMSEU#0$^G^8U8*F#35QGF##Z2#P4<'79IWW?30-1+L5JUD*L1SAGQ-]Z*@(
M &V);UKB?SF.@'VSRKP+/DSD9U&VVF_>_>JC/=!>.+@>.-]+H\DA:NQDIDFI
MU%%>2U*(9<N-WUB;,2)HUY8;<Z8*AZAC@_^BN*JBF.ZR(^BN!/57='_53.>T
MPE,K847V2^Z;M9+%N[ZE2>).38!L VG^'>4FL][R1J#[TTJ!=VE4-(C:15YB
M2,L-Y:;X>O2>\"CS4G+'XG0!6'5W32@)HDA46A(=<:>P^R'$9@ZZZK#1<BO/
M.WX6.EI0$"7+^PC+B2U!_PRB<EHOCQ.J.9V?8@1\("#_?/?E\"+R1]^?&SZN
MX9?]">22'5ON#=[$^Q**A?9(*=;[S>5MY[?+Y1='W.2'%=R_9-AM$O42^S_Z
M3=7"^ _DS_@97[=-KB9Y+=P$E+6SXVF?*'1PL'VB'(]SO,+'("6Z5]-!8,B*
MP-VSF&=HU<.;3%4!1#4OS7:03<)[>A4G(% *U\SPVZHCAN^WT3/RY\VQW*,[
MHY/&^^)QX=Q"Q9<+E73I]*\91"U=./)#$2='@5RPCN74CNC5V:H!=\??$5GK
M2U8L8<O"T-Y,1L0>7MID=Q5-K!FZM)SYV3 3V7F^GV -J;HQ0R\%XE@L%'2,
M*OFM*N'[GC%%';1,N(3QI]$8(^L/LUH[J)6E#$ZPC0J(@:[Y$P1IQ$W*V^)6
M+&%4AA8'9NOC2YLGU17,5.?TN8Y_*O(:_U631:9GZTZ?D3#W9K^%!^A-4\0@
MB8[_<RW5=:S N\"P*6[P!Z\/VJ*!OBNDN/R?_VRQGM>DU[?P]5V3'WU631+3
MKF=7\-M.+5PP-[=8EBGNJ5Z)J>*A:[TPG5A>&)#HH1H7C/C#ZJ+R%\7$0Z!'
M/.F'?8&6:Z,1E;^K6:D=#Y\I'E$4@4(O(QDF-3K@7 [;@1U#PH>!!FX%MKYX
M#!($"0MLA5%^N]>#],?G<.]BJE5U%+BIG-,NQ5+N]$JUP2V @8QWU[MJ?[8Z
M)7G+W,P4L?VWDP1E%8?[[,7V$%#&JMP?AY%X2YQSY->YFW,%Y!#5X LK9+#W
M#D;CD^L65#]6]&CNCQ.6A-.^IIKA1]AM@GY!<[V"OG\*4;]7-B>J]:%$FBN4
M0S"Z42V&&]-44!FM1N"8,?I3;2'>3J^VF\3,C#0/E>N(/,XB0=)Y8<C@:2<5
M0;L)V-N;67U@L<#G+2%GKEKQ*$FQ _)7LL$\9-)^<?-CA8 YV1_4!CP3/*HS
M936#\7ZX>M)?%$:G;*K$/K\@Y4D(M8[_:?KG].(>D+.!.T7_]S[1,=%[O9B.
MG&&2H*1,+7GFJ\4"H\!J-P'=:>S_XA\;#A==-H:4+TWKJ<4?HYF*$ZA^<TP%
MK3]]<8?0P9;,@<*XN*Y&SU0)NU_WF= M3F'<793%#MDH.MXIK:95*,+9]9+X
M*"6/Z&Z^'K%_(VGS%6..#5O(OVNN0Y2:[2_*:;[@BB#O=$771F+'=FL<B-)^
MQ^JJJ76,-F$U-N4OBK=VD\PB"OOKK^A[L:72<&=4BUOBPZ(#Q0W-S+!9Q[\H
M?!L_O^!.K2YM[=]D_$6I9H,\OIE:MJ9#</<J\!(9UKS9D@RLW*>A^EW7.%7^
MJ>W"ULB8,<%V,0N'VTNZ O%L'1;XO0X'7$5M<;JZXXHF9/[UQ1Q[4Q_,(@3L
M^MU<Z:RM!+L) ?7/EZ>I*5H(J!!-,NN1M,AIIE@>%PK0U#_]0E&>]+8G4!#@
M9-!E5C+V+^T*T,Z67<;OC)SR:#KD_MR_\<\S;^S8U#5=-4@;'A4"PC_YK1H"
M5Z4I6"(N*=,7TJVM/>TXY-S!&E^J)8(6*0#4/G4'/=<W-Q"']<%)K+#Z,)[D
M!(=>I2/-S*B#F;\H*1O2:PIS&#A/55X!=;&.ILX__)S 6W"L(@,RFUYTO_N;
MHL01;B\\2N,3AEZZ6^J/$!7<2K_3>J4YO*0Z28'3K#'9MK1M*85M;]?OVZOK
MK1(@[@E]BLFXKF$[$T_!!-&S57^MGI[AG+G->&WU52/&B'CG(MF5;@QUKP:B
MCWY:^R/-=3:#<;SP6TT[W!RFQ;3,Z7/^HS_%'67+!+?.=FN5^ .E)BN+;5=]
M/U?<TRZI\%1DQ:TCP7"%\KE&_6.!G]DWE0QG/)U D+])TS3++'@#&+:RE<N&
M99%9N;0XMUOO[>62?_.V][/14EUH7ZM+DV(WCO:"7++)! /\-\)TL"Z-O*4+
M@M]AM1O@:"4FL\S@(#7J_TS$E**&XW?QC$Z1UH[92<TJ2[)^NLC[S!PB[_F,
M=4935K'D6+4O[F2@;;1(Z3+ ?7XH5=H6M4$9U4[E""";<0+TN;_Q14R6V7 S
M7-W'J4P=Z#='05A$6#IY\)J.[%R/&8A3 QZD=V<YA?=%\(MWB>6]$!9\60_K
MQ&.AA^7>IB:RS TMMGV6:]K+30\1+>G>B:'Z1%5H%>B6L\#*6LV:,.O>CT]9
MM41_4<R+S0>N>DSK;S'7Y@96W-TVZC15KM(Y"IIJ(^T[L=A#M99\*U2<258L
M@<EIWJ&"T]. CDX>YB3U<-A3SY5@EG!M_<\945BT,0#7/DN'D5"5D&7I8VY.
M\^T',*.AY=NE#_HNS=9FD:TECPHM4PR3W">U8K#+H>8\!Y=SD3&G^8Y/$B57
M,$M:GYY'/I*D.H,\K>9I;A*R\;89K<!PJ$I<^4R 0FY\S]BIY"+$]LRVM&_\
MHQ['Z9L.,T7!IN<\[E$E)W>+(<JA30Z5'!L.2%D_YK@A2X[/M,4>\FJYQ)HY
M0[ D343Q71**2R"%!:+(75]'U3HA??4KA#*@+L^="+K,3E$\=(JFF:;@->N)
MEUZLA>Z]3'VFOG0T7S,C..$0P-2./-)F7-KN6<@:.3+X@K-N_$4[?\Q3*FI.
M%>=/QX38HHSN<AQ(M\&]K2AS;P7U\-#T=>6^)H9O3!Q&P?37EP[>,2EP_UL,
M-WW7((L@Z? "R/WYBDJ-B*4U)5/ G*7@Y?N YK2X+@L&Z+^'QPFG9+ N-1(U
MML9I5))Z)>COF-F]Z5L;6-,;O\W7B!!Z_2NNZ179#0PK[@=) M)TH3Y<B Z;
MUM,--X"C:%82Z(T9<_1%+&?OU%$'A.?3N\JQ$#1^M.]3T:5:K"-;Z%-_K;XA
MZ9F_KUK\E-]$([Q2\YRT$+1_TR>945PZ\3SJ)SM:R5S_M<.-%,40WGJ)W\4"
M.28.B251<"&.JSHQNXEI^=1&-:ESO3S[H.0:CQ5+E&%;,))\M ,:U5A8162^
MZ(<B1? (*]Z(O\!K))Y]E#[-.4W*Y,IN3[KZG.##SZH5-(YJZG4?K"M;-!QA
M<]X=\_HGQGL%W_(1W6[$-8XS_YTW">>"74/H^V6%KWL?)?PGMYWEQ-2'W N(
MX$3J[2_?RFQ:3Q;D*VG+$Z'\3_(I@:A6Z\6G4L=Q1=<BLS_BSA$;-C979&6)
MACIUI$GNIK40!4:=Y@U1F[&<;+Q,P5VZJ@E):1^/>0^?M1E>9$>""[O9MV!<
M%S]W"^BJNO#H2N]7WL9(5*+"-3E1*52SRZ.LV@?ID":]M_,+BRO[AG7"DW=#
M#J["NZD7/Y5.@D;4_J+@PG#S GS2>F'D;3^572*$B<\6]MY3K41::6)]D8WJ
M02RL3VVR 4M9MX1%EI*I?_M/SBU45)V%:2)8N(1:ZMPH]0?>E!:A=MQ4#&J^
MG%NDEG<&@RM@/&MOE8&"J3%Z'AV%BJM ,OB1A%Y]4W-$[6U(RUN.YR-=:K[W
MU([GBH K)D'<R_W_BQ+P_3>N)?+_Z;U/L<0QU,8YMS"T3OMZ&*EYG;%B[\D;
M]L;<ZW(G\HJ9>-"GK#-IF6&ZW!G,<W)44,/8Q;4Y1Y3U#Z^@G#MP'MF=0J,%
M]]8@BW\"B<H*)2 (JQ0WRHG&2I,SW 1KS]62VJ%PQ3GDO+8U)J7//IZ%%)!;
M,]1/+4W_*,%L'_W$QACL+'FRHF*8S?6/*0S>$N"C#SN7.YY+3H0'QPFK 7=K
M47M] K5;ZDXS;WZ P8S/"_"16K6^': M.<%7\X.*6PD;#.CI@TKDTIM-X?,1
MR X+"PO,GA;#H2T0&0%]4#RT[5X^>5J+>G1<"6X1 ZW!F*6$1_TC8!MBNA)@
MJ]MQ3*G*VS#3H&X2;9FUH48KW$$JC5(FLLNB+]J(D\N5,-+DZ_UK0W!QM'O2
M-P$4T[CWP'H(@HTYTO@M.3UCSO.QHY3L*-8!.<R9P1BVI1-'&1V*\4WTP!)M
M%YB_-X+5HM-MG;&4G^*[0'Z7WB TY) @ORI-M6+67$N!VS"J;Y3Y<['(:J^I
M68JV(\G$NI>A?=JV)NI)O;S&5O2);R72]90F52JCKBFCWB2F>0FKAY0?//].
MC.R2"+7/!X=N2M)FO15H=/&RDLB]-B[I7+\]&'>F_HS&%(_@4:2EJ2Y)&32>
MUWM6%9V$+4VQ./E(YU#D _EW:;'K^\J5>HSC_7?AWZ?B'&O65["1MW%R =S;
MOC!09A!M#77P1G8VKJ9QK)1=#Y(YOB0&Z;8'<MU*^#;Y$1N:7>%U*UQU6J_:
MT.*?E#2FIQ?R)Y'I0PIYGW;D98QFET%:;+H=4*AG4"HW?*,QYHS-[../ !S#
MV1;\(J X<>%/FZ;::KBGAZD=TB@V/<X/!4#O>+X'(,-SCI<:KC(I^S[H+,I<
M_<5Z38K7YS.2O27Y%A^I]/ENTJ*@\V@?6#Q[R3AS25BDS/ 9G6_0ER[Y..%V
ME@WV**%)%A![TCW;%-)ZU>0K ^)^0R>]3';U7(LZW=J6*\G,!0/3!^@>MJD,
M/Y8D@/F!_8\\[OZG"THS/;.AD^:^=E%'!)TN:MZL1]_?+4V]O*PT^XL2',!0
M"[3GJ:2+ZS?U7&!AQSS#NVX]X+_I2"*]1W,P3$Z>S.NO'I!0?NAC=\N&RKPG
MPURGJ7+V=\?9CGCI:KPL[^S.FAZM!#!ONY*JCQ,"5K[M >*F.PK>).EY^VI"
M7\G<I$KA.29MK(6FNLPJ@!1UO9K2Q+:9P=0;#XWEFGBW'"9AW?RJ]&/VE7R^
MQQ\Z@_>@S;&YWP2.KWP>!<[XD?N*\96>IM@RV!!:K@+;.S<_UAX/"Y:SWL;<
M)F0,?^<5ZRJA$DS@90(+*L-Q;QU\#-7!9+O*M7AEP&U2%70M1_:%O;+TGM9O
M\U%^U5S9,PJO*FIHE^LCOHPG4\?*ZZMW5STHSGLB.GL60E6_[_*BC&J!14&N
M5MAY%7@%?B^RX'VW[K+MYNJ>ZGXVD.-77T=>%*_R> &VF]&S,?^GH/L/.?\7
M=%M.-E3@?:%',)+!Z\,!3TI>N&R/'HV&HLJEB8-9G3U:%PQ4";O"(UBTO[<H
M%B07_ =Q:KD$I_ZBO(J3W)CVJ"CJRF).E!0K<BCZ,$.@Q-G?X$"'),0:]\N8
M+:BUBM4T$7:=C5_4PHR5*7!,./ #%^3.F\D5[$_XBE>K-5/P<&Z*6NI.UC_C
M*[,O'+BH6GO:D]PM2XMSY8QGO;JJ_/ Z3BV =4XT&Y7M$C7VU_\WT$K)P3X;
M.Y!8_3H0=Y^?+/_7'?8+A>;4"#(RXG4:VBD>*^<W,6A*,VLSV2E"!Y88O/*T
M9R[^]Y_:0FSZU].W3L4V_6[NQS%_^>AV)S@8-IT#@LH$S!UQF!K.><DU,-SW
MM'WJJ!4-TDYTQ@4?&AYE\A?SZ[;UD EE*.0RQWR/9;->5*=]%;[YYQ?33U+%
M:$-?A+#K: D9E)UX>._=RI.9!;;NNK=" U6.)'77'D!?^WL\=T+??_BJ%\*O
M=!*Y,I_5GLA>R(J6=AH8"OHB94<* 4MND!F_A"2C[:5M>ABTG#(W5LH%%EE8
M.-S'S+? &^%QPYU6@\+B5#>5>DBV0D!@D2/*Q0JADM!V]20<Q'W..,W@L1C1
M:/7R2T&<==HZN/SJP!)G;VR=6OQX0_O'O81/2/6)M%U,@_NN4J4/_@8@-";K
M[DI*X#V9E^L!IIY_R4DNB"O!PZM-8=XP-G@6:G\M J"K/IN)FP,??FZ&#G\_
M)K3_B1M,V]7J_[%CY%WT"];?-*YK<\=7TH3&!X3S9B8F>U[,,TGR?U1Y O(:
M-B*A:U00>&SE=3KED CPCDG;)1V+;G=FEU)J;$=AE!5M6)(O4"34@Q8_'W%#
MBDR$'R8$)!$_;0[NL'W?.]'](G6&/M)3F!=8[&.G-\7BJS<,)B)-C5//#GQ5
M\52[8'F$WL9;B9Q1>8V)B5EU52;AYOZ>QF[=G$5E5M+0^9J+_7C!M*[!6*.P
MZM=+W%+3VU )0Y0TNL@+Z;FF^7CX+$3YE7737*Q"8!-P=RG#&C"=9;GUN(NV
M@Q7.\L %CVZ26JLW/DZ24)X.43)ZK$:=98![4L!+QTXK=GV^+N_O2S-+2'QD
M8)HNN4N)4YLM/%@FG;P:^)B@_3W+2 %_4C883X-#!X'@,&((72(1_?F1/?K3
M-TD>FZVBD"M_+FN-%O'="+)]]F:#(^67+/54^#I[?'O7RUAG>OBF3W%&T\0R
MM7IT>AGHK[-:!2RFRAR2FN"_DM*"94U] ><[F!?$BIJG=?$?K>RY4'TT-GW)
MFM$.$MZ3U&+Y<@FJ [!"N00-SO+X]HU81QRFB/"GMZ'OT?_[7O>_$VK[W&^$
M($K% BXBE*7<9!#7_PS+=#XE1:*HUUI'!YJ8L*(*3WQ7E4<ARV>@_V\U-\%>
M<)\5]<UV3.L_7WS9MZ7 9I^-073YN"?K&J3Q3[U]GGU![C?*W[B_0E!I1Z'R
M* (?+POF7@^0_[>M.:#JX$0%Y5\ ^C^9:?<_RO\+GM[P_0<LH_]_4\X"_\[_
M+U!+ P04    "  OBH1:P^D[4("K  !9K   #@   &EM86=E,# P,S0N:G!G
MG+IE5!Q!VZX[! L!0@CNP1T"P36$X.XP6(+#,+AK$H);\ #!&7P@R##(0(*[
MPQ &=W<8"'KR[O.=_:V]SOEQ]GYZW;^JNJJN[JJG[ZY5CW\>5P O5!55% $8
M&!B #_\NP.,\0!Z @X6-@XV%@X.-@XN+\_39BV?/\/">D3XG(GA!04I)24%*
M3DY-Q\I 3<-,2T[^BN<5,QL[)Q<G%0/O:UZ.UZP<G!S_:00#%Q?WV=-G),^>
MD7!0DU-S_&_'XV\ \5.,5T_<,3&8 $^(,3"),1Z[ 0P   8VQO\(P'\%QA/,
M?^/%?8KW#/]?!=@+P!,,3,PG6)C8V%A8_TJ#_Y4#L(BQ7S(*R.&0Z'S$97(G
M%?R<5/"4^5UM!YGNQ G+&RN/+WC/R"DHJ:A9V=@Y.+F$A$5$Q<0EY-\K*"HI
MJZCJZ1L8&AF; *UM;.WL'1R=/+V\?7S]_ /"OH9'1$9%QR2GI*:E9WS/S"HL
M*H:4E):55]35-\ :X4W-+9U=W3V]??T#@Y-3TS/(V3]SJ-6U]8W-K>V=W;W3
ML_.+2_35]=^;_W!A # Q_I_X_^0B_L?U! L+$POW/UP83WS_4X$8"YM1 .>E
MG [N1W<2)L'/3TG?)174=N QO]$](;/RF'A&SB*TRGKZ'[3_0?;_#^S+_Q'9
M_P3[;RX4@  3X]_+PR0&R )N2F(X\I_\3W%6^>7CZIA0\\%MJ_K>.,XRN3+I
MD38]X-#)01J1!]7>@3E\^)^ND(/T^@R_B=3O'3"!,6,SPI1"K>*N_) SL)7Y
M:!],S=&;;J;*Z+6 @\W;O:7"3[P3)D +J&L%3V^ODCM^JH<1I2PRPWCF4,C4
MMFEZZZS0GKB2?N,BGU"5BR6XGTKE0Q=7</GOVVTZ!8#,?X]-F@-06(=0J9+/
MWX$'0,;M(N;PTRR@%IZE=[:PO/[D1X <TNN6*LJ@->M-K>?"."YTPNPP+[KJ
M"*$E$DWQW87YLXOO(P"?<S=F[/0J4>@8BR_KIDY](%CL,U#@6_&5$,:<CMEQ
MG)26_:HKP0(HHV=IDNPY5E#&F+I!'M&^VWXN?</,8=HD:HU?#.?VMW<^818W
M9N<#4^,I:Y@Y"D>Y&TH^*V8=9BKS 3\]R/.3\=HGML("_G!V/X O>XS4<!GW
M.>9N_]W.$R=N2?WIM2FO^>RY[PB1'?-!SSA#GY0UXTOQJJ_D4W\IW/X."%!J
M2\LT8$SH:$?+@0LB#NQ=_ L@^'"^"JVW?53Y>&5E,V?=GKDKZ')L *F.PG]+
M5W1QK59*82V8H2NI^V:I@"QKT*<@==T;X*)C3,T><V'N(VZI/+W2_*+:YL\<
M%VZ086Y>L&O9/&]/ZI 0RS<J+9Q/?#HF[OL!0:B&%C.C6CI%U@7TRN;ORQY6
M='.IXVQZ8\9L4H>[U_S'^'GLAU2,2@5A//$QJ,2G9QR%_RW.\)_+DW67#"\<
M@5Y+!@^E(/ K*DZ6SZ9G^80!7%^I<WX@[8ZXFRRF0X<,W(S.*]5>V1H:#B9]
M^WT: TB/*;(O,[7X&S&YQWG7B'HPM7>\$"K2AH'6'> "-!#S7KIE$6GWMQ0.
M)2Y71;)F:)Q/# KR/.6D&BR37(I%/,-NN.OZ%XL@S>DA0ID'U&;&%Z9O(AR8
MJC%%H#+4D@J+#UQ[\/2'1)%-S;0.6X$SO-QN5@ Z%3^$Y_HC$0AH4W@_'!!W
MNPY?U6'M]DA7AAAYBWV )I<N?>+5,:G=IPZ"C]C2W;<N?DYY^LV%(=PDU^NS
M[PA'O!C-CQ6[3SP3ZH9T"8X7 !T%TO^7=(G5Y';?TNMA)5WSK]G5('B %N7.
M+M,7EL(!B>75ZB X$">;<*\JS.!48UUYBLO%;X4.0#^SQ_#BC@R\#L(W#:R,
M!L<C.O63WPS0]:WK7J=T( -&,ZW!^&V0G@@DK$E3U1H^^4EJ]+R;.GXY J%5
M;'Y?<30H:7YB8::TV1A,:7#__*I;AEJ& -2FPE=U2?I"#0Q_(B/&!:K6>M+6
MFUFA5+F7LF2^1QR5:X;]M/V33Z61!<&7-0:B][."1 =6U&]F0W#$\Y\_F>UI
M6>B4INY4?M4^+:SR@0+C-5.\ELZ>DRL-:E\DA/X6IS48^TXM%-]T6.Q;?)=D
MI-,>RS7(QFLVG)\]9L<<=D !.,?/75;]< TF&_D!+=O+H #&G177+3*LH3P
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M<IO1WO7=*BSU>*P+_D&76SG5';04H?81CMMPS#?SZ1L,UCHVS_ +2(VHVVO
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MU1%HAY!L38*NN7Z-G_\J:%O*7=?_>F0F47S6:ZB-O9<ZZ-LP'U9R<"_5!\(
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M\N?UDBR;J^K.T7A@/[PQ1^7BW86D_29ZL;1[HS <DVR^.,"M!/[<>;[4\,_
M6Z*Z7'&C7QE7E]Q"J193CLVF8IMSLHT$0KA,]W7GI!I?XL>^'6I?DC'V-+EI
MK]S<U5&PV7U>).7TRO#@MV?6XE20? EJP<P$.+:]%\\H6/Y ;)S[BI[Z828Y
M,#9_%B) _:H__MYIK6%Z*=MM(BN7L'6JH"$*-!I?.>S.^<U&-I]LI_E9>?TF
MY6_*/J<U*7Y;ZS5)&N[L'>*26EDVB:-+X1DGZIR<+*(&LUZ\V\I<%719!N+
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M*-38BOB<W36N1@?)3K,RW;*3=C<9</ 9TC!I*]CCMUV+G;=NU?;'H=:9P2V
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MF*6D0C%)%V'PWX?UG2I;FVUR;[;&=R/<G#*?7UJ3X7W]SH.LR6>IWRR6MPV
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M77N'JH^[3J:OW:=70>>)1110 8I-M.HH @GXC;YMORGGTKR#2]%C'B#4+HS
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MR[O^67^[[5EZG+*A@O!<3W-HH6.)MOS*Q[YKI]4TEH(9H+VY1S:1DDD85O\
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M5C)D=LIZ&NB\.WD'V$7K0D6A.2I;()]1Z5C-+='9%L9;Q2VURRKGS)!NQ-_
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M8YX-1*R'8U=-CCT.?4)5<11,I\CS#D[3Z50T]KE=)F\X(5+DL''S*I[BHI+
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MK6LI*BC.R2NS(\#^ ;J&_M-0UCY/)^94/))KM?&D$<_AR\\Y$.U2ZY[&N@Z
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M\\FT]HGF\^3(4[=RGD415U9DQ6IU'B[6+2>8:?:RQF%>K@=*YW5KRVE:&VM
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M&*[GQ?%>W'AV\32K>WN;XKF&*<?(6]Z\ILO%GC^)EM];6TTN8?*"82T?Y^E
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M,,4+;_\ KH:$KLF6Q[_GR?ASFV.UEAX/O7D=Q;M;QP,[*\D_S%17K%C<+?\
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MC"ABCL?$6G7! D@DG&%;L:]IOX(+VT>*[C22W9>5D''/I7C/B&PN&$-W;S+
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M*MSWH_LR-);>)(V)W2AADGV]ZJ212/#'<*\<=JR[=H;YW^M1.3>B&H+N.N#
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M<FIZ9G9N?FU]8_/WUO;.[M[IV?G%Y=7US>W='W)! =!0_RC_42[T%[E>P<!
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M^E].[@2K^6ULY02V,62/\D'/@,_$ U.>3O=&.HP%ISR?6UH%7$'!8KSB&=]
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MZ@Z07/1V]+%?DM@HL:]\.0F4=31945EQR-Y(%U^RN1_,5Z1QWLL.D_>'RQ4
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MBVY"4:ZHBI=OA,5F;(ZPD4%-=+MD4='FOR,&:(&>J5LMCXS0#;BDG&]M7<]
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MKAJLR.X\6=0^8@SZ+J/N]@ZT(V1OV%G]DEA[T;+M-%%G3O*+GG2%'![?;O[
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MQKA>+WR/K; +[^"MYNG2Y4U159T1XY-;$*EP8H>7=8AVPKN6/A;P&KU[B7*
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M6;#'G5<%E4XL4$!OCHTT4)8OL;"V^<U[C"=2M/WE,K+(16C]!S/EH+).AZN
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M617H_7(7'9>NG#_);:T7CZS@@)4;&A'ZRNH1UD.<X4<.DG-:%/+OBV7?K;J
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M'V(]E![&,C\;A @LZ3)_W(XJMUS[UF)HL;%BIU#5'N(:<KCJ\?R++-9-@:&
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M;V+P=?,*[YALN):-F#C90) ]+.?=%C5Y^A>GL,GI[Q97'#,:,P?FQ4)635?
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MK7Y$M#4&%;3J7T GN$1R'+_.<A3S0*53*O= I'EW@!I*)LC[X2EBV<N+(?@
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M//QZ2)#NJ3],&^*DX]?)>B727"WVXP]B3S88$,M++?57M%JY6W6E(\T[FW/
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M B7Q"%43$B:T="3MS! 5=?HX<Y5(U93V@775FK]>G=)0G]#KWUD1P;S8YEQ
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MHNKQ=DWNX1EY=C574E*.35*'#,Q^1I2%KEN\H>YP9)[5H<*;ED_BS_+C^V&
MQJ1[ED'FITI["Z41S8G,E@G:BR-JIJ=RV4X6GW)]$/8Q 9T?!6;SH261V4MF
MQ"'-<JE%%DSC%LQ5HGV\0#3D<05)463A]_Z?&-AYG, ^HXC.-),],]=)E4P(
M=W]_HK(I4>(W%16)1XF!E  ";:%I,^WX%4FRK)N+)?[Z\<O/_B3!,A]MRWZJ
MT>B(:>.3DCY+HT?Z_+<-,T:LBZXDKAQ?E@JN"1A@+,%7;?IT6<J*37;+ K5
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M$-1#9_MT+#5E-665=#HN8.TE%83&:2WW]!#?J;M;R['J!6+\L\/6&#R:]]N
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MZ:(O56VAYQN1BWZ1NTT%4*P901I&;<T+$7)3S%?^,N3;YT0(JJ&9GP#]"_U
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M^2Y+Z-:=[L/K9Q[<N6PO$0Y%3AM.1'8QK6  6!ZBENG.?6;8S#IV;/6Y2M8
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MR[%X@!;0WAXK8]:8&+/7U[][X?HG!U4 ABA!:>%:40TG 9[9\*'/GZ9WA!-
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M9HN*9-H&(AS1]6#8AS0?)='R<Q9BA/Z4UNB/]A.HJ!!X?\A*P=[M.*.OG:4
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M/YMA/KYDC5_;L8(2B,X(?(CYI2(M59!&)5:T9!F>?[^X-9'.+X]W\ N5#5Y
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MUN[?SE7R.K;0>:@O_PPE__JIZ(HFS+D35<*.NL9>/]IU,:JZFH9BTI/H!4H
MJF+^(6A+I1$3TFS<9A([Q$WS"75KULA^HE@PV ]715;KZ\Q^:]L5AT(OWI\"
M+]A/S2#\[J/X3YTA<@WE%@[C'31U:28O<X-+%8'B=0!W6;RCN"?)#ER+CO3
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M+^D-6&[7V-BKYW]J.[FX=D!H$SZ]T9_J(>L,<5DK9Z['R(R075I B- =FO)
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MAS:/DR[% +YK\*', 2& X/V:!]>UYV?NZA.P6DTO?;N!*&%KB;\UI'BK<Z$
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MD_N,)L^YP@(5F#P4C_@SW55X<>6.9CPO0T'$P/@_(DGAY<O3CUA CCJXV#<
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MN=1SRA_9A)1SXR/H#:SO_C!Q@;:(Y,V?2_5H]WZ9C6+H6OU(%^91FRZ-!6K
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MS"=5$ "=I&(IOB\>(D-0X'HZQ[LVZ>NA<&5&MR%.=3*0HQ6&]9ZU-]M ^[Z
MTAA<^FS;^4N[AAUBC!<T*+/LZM&F#?(2X:I-7\U&GE->U7V_]SHW$AHQ&5#)
MO'S.F"C,?T%\JRV>7S^5.[/6S;[/H\+Y<;RUVWBW>(^RLM<C@+'U0B2($P+
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M\I+.+[HT NQ;:)+BNMHM5MP.XRTY_<F]C[)H*(?,@#I/Y3%G_'F9Q)7+**(
M>-HRY[;SLF:1V[JD;Q  ZTFN4L32B>VVN'V3O9.\7^S<H=6[O8X4KM[$'P>7
M/6RU<[16W\:IR:OKED]$.H65-,;D=-Z!**,ON,&;* Y7/76$@K.X*3;1WQG'
M2+II)!N!V>:,]1@5L%ODI%9$78MGM^QNW J52S()SR@I5^Z1/]>:5 5PFNA/
MV?3]2]V0/LS4PC77XT5+,S<NZI:U3'4G*M%UEF9Y'YN5:M_Q2-353YE*D41D
M%M0E(C8')AZ?A)6@_H+G9(A2JFTK@6=L&>,/\$5?NRO9\"G89"P3=FI+\"S,
MK?/K!8&7L*JITK=@O):)0\>%A:;AOUW[FQ;V%.U[)'QW6L?ZZ)83&=0A&V!/
M^:J>')G4?K+1FVAC]G/>&G!.?<TV1HXK:8'IIRV%#B.]<DB!7[V0<$;<B,@&
M./B8Q7K'SR"NLO'1- U3KTG<BD9:6-L)$.- WS#E^:R?/409-M&LL(F"U+'*
M?<&27RA9E)^0[V@+FZL3_TJ,(B=]Z2O"V#+T17EN.R$$$&)[,Y2*8KFZZ\EF
M"<98&\@?^ 236C%^\LG5/@!MCJN,S-_I0\.L;OYP0F/KE>NGJ\HZ%R\;>S(S
M7N)0\$8;\I(%&J6.@>6<6-2'$F^/JU)+?ECX@KFRCP5P&2D!W]3YPN5!+K;A
M">JX'HTZ!T=Y1 E@[L>N2+[WT%=H25M!Q[P]9KINM\\BN$!0P2&;I0?);2GG
M9-%W07L)5 GU[32!(F*_M^[7Y7M:Y^69Q4>-/I5,B0D/X3%)DSHZGW'OAN#8
MZLG<'?C5U3*[#% 7EI=D$=?<7<"9-C5@*_#;)=GZ2K8"401:RM64-.8S%[C\
M\;V:3!RWUD?9"XEJPGDY8,[RFHZ8,3'M2+/%UWFMZLM _'6'>2%&[KZ^AV/<
MA]GRA\#6VAS@(O\:WC<%[L,YYO9@=R%X^+ TY_(YG?.2A3O:;G[S0 SU,^48
MJR"=X,&FP?9!=C<"(K]C!)PQ-Y%._CR/'['NMD7:=R;S U:.!8<I22UXU'Y(
MM1+O8 %7&0Z\Q?(H/$9<C/%,S6J;2^$"&A$;9G2+@N#*0TP@IC9UZ6'#9=#6
M5RAXAF52!B'VGRJ?1>\T'UIZRDNXL[T1M,SJNMJ_KT3"V[]<F(+7A!B;QY^(
M"O8/.)7T+,'JDZ(@\=J=HQ%L>U+$XHPT^PQY!A36=G[N=-M\,>*4L F@QKO3
M 1N6% 7J &Q$CB< UN5T8]1^6PF*^ VO9K/]YL[YE%N&53C3P>SB$'#,A#G$
M/>=1,K[-YRP^2!)@N)51*_*UV7S3?E-.]N.D359M*W@ZNPH\)>>?(9WEG;>,
M-PKH,(X ((UIG_INP$^@!5.-AZE  .;2;K;)7E--(^SW#6/?3V?V%L%?O+2X
M*\MUM7I\;4L,] G(I\NXE&!S)-Y2FG]Q&"X$D'].<R[^4C1P'$A-Y;1&TE70
MN701%Z.6,04;A),DGY8IEE)0Z-:G>YY1\F/A+OSX1J%J?ZQT2:B4!AD$"L="
MSN (X]$U:_)%W\?5IQPWD)Z=*6<VO1SNT/Q^^87'QB]:ZT$D@%./74Y"+I%G
M\A#]5XIK6WHY?B='B+_-UX'-ZK#-7*"O#O94R\2(]MWG'FV;@EQM*]<4T[G;
M7W%7.D(M10J5'Z/O_3#J[[]^#DLCCO38S-#SN%H_^\*%]$N&6>+T2*LR85X.
MPX"Y>>[Q&(&%(_(C*N/,D\"Z')%8F^R0;=WR&#;-XO+J"N?F(N4,)<I/L7;2
M>OQ")A^2?1=U>F,L2Q1CG&W7<9T!I^&$2XF>. FT%=W8Z-4RU8"ERQL\1LKS
MH.HR,ORC9^(+V)[\X[JW':XH,\VD\MN)=G1#L?V,'6,RN\UZFYYC:(=K&#]J
MECRIFZ:<'A$^Q><,26E&!_-MH]H?I%Q[>F,.KG5K+"Y;;BFV! FX)[6JYIB4
MP]M\KW:.A-U?;+(">6(/.R<9!5Q9Y[M2&3C:YG\P)[6J7;JN7W09WU71O1#_
M\75WW%G@1%BC=<)TNJP@8+I@@41*^8O-?=](!Z^@!NQZ..TQ/UFGU0!*R9!W
M\?W.9AU&OZ\]ZT/? #NW@RN9]D^D2-2#GX3;_,U%;UJ"1HXQ/D?ET)!'1^K#
M<\G/=30*E44&EU&$&L%]IDW^A)P7#\KWL3VSZRU2D];RU69S:$K3O#BYNP@*
MJ_/XHOT]N-A2KB \Q;B+V!@E(!%F4P+63A1?<"O?;-EMJ]=^/_9H0C9/*(__
MZ #!Y'88>=#L<F91=(T>)@*P!S_;!!)XZ:W7CZE\AGC'=3P&5M4!LF"+,@.J
M3&8T *:\N)XMC$59KG#"I\QC4*$O,/Y*W@L"X!@>]>9Q*1B3$T+7EJ0L<FOJ
M3D$6%JB>+K=FM:W1XQ:2F-QE-,9,WVB5D.OC99P30F%NK=[Z^B2;O]^G-!%=
M&\YYR,A;97S+W.3@[_I\)1!,2W)4/=/\)N\03#@]%STX:87[S=2U[AW/AX9V
MTN!=P9G")Q$CTDJC8@;IVR8BB4I_<-KKK\IB)&.#?$5[X77/9<_&.^8H1EN>
M)^_;M;E&>K-M"X[ 8 YM?]C/*S6[M*;&V.1[Z5E7[>4^6ST^U'-/(AM!P8J1
M\BVVF'6)@B66&B,+35:<IJU*?</)1VNAUPC"I!9F7?*U?FN+Z<+NY<P%=8T6
MN^'Y5/W0$2.Q/4R9:)S06;XFXB3+N)W7AQ@#.$-,$[ID6QJ':'O3,_13VOG3
MNE5\0IX]&OJX%_!AY82+@X</0W)3\>88[A+N)F9BN^CRZ&RC LA7ZC>L6&ZI
M73S:=<EE>@</@>/CIUQ6LH7,8>_X*#9R399=6:3(S^6<0>MEN"J%J?UFS<\3
MU:&]1R?LB5?&D0*.SW-4IT<I905/(A-,)S?X*S_.J-IJN-G'W%VF9.JV,79R
MR1J;;_/'4$L>QIDIH;M::2YX;O<^0P!U>U,%51?,>;%(;LS#((LC]"BCGR3K
MGS]',19=S%8YA;- P>63!)Y,'Z$T<(-<+DFE5;]*,<V3B:V6T@9Q=J>*Q1LG
M^@03B9L^=EV6D+]O>ERCR^TA):BXH'+Y=%^>G3)H*[RX.6N,7='Z5J;B!N:S
MX@X>56]LY9[2'030#=IP<@LLFC&^H+ (DOVF'F@B0<PAGI;KP,ZQ6&I)RC?W
MQ&>[)<LL=^PL)"FA(U%3+X7\&@( "JCRO_(YN!8,/2I[@LY:6BBK45R^ERVB
M*;O2Y6!K4 1\ZHM-,XG8+3TD19UP1BIS\%PR2ZXM- 8WJT>=.(>A)Y%U2CA&
MK_[(2+^=>B9Z?MU@NKQUS0@RF]O29;L+NIQ\.'K&F&44:H9#E\QH@'7P(%[_
MB3V&?L!QN$;".=.8,F@E"WI3;ARP.?P1&\'/D-W-07(-FMP^].A)9+V,\?V,
MA@HXYGE/";=W?'E5CW-TP@89.W9?DBP<6/?-9)5"S[H$ K!@SJY":=NY_&9#
M2=IP)CVMT7ABN#-^P8JJ>\C?G(FX.QF47F"@ %>(D["<9$30P4CJSDO",3WW
MWG%K#7/I 'VI&#AE%>46[X2P3:>.T$5/(<H1?YCGG_'%M;SZ&0<<')29I_TA
M<;P\JNH;P:=&DQBL-T-OC48=)TL7[]#>U4UQ'N%O9 Y6MA&F"'S4EF:1\'6G
M)-5,2]LM5P."7=I**ND&B,]N,\/*:X_.T.8/&Y7U]V^55O3T93_)K$B_^112
MU+0MB@=;)6=B\/1NSN8Z$LT*(V[\FO&(C']+B9O9DUCCS6#2&@QV9-C9S_*K
M[E:$2:_WA4A'WUOKFM[^2M&RMDF!RR#>&XJU7=5O2Y<LOL.2FF8VK,8\5/=P
M4N\<7M!:J7DK_?H93FRN".:&B\%N\NB<*"Q"17&.*ZE9;,O\O#?3N- R"KCH
M52&H9%J 2N3H?-].P-#L8=88&?2PG+(;Z\CTT.R1-CZVT_: 4)VPO(Y%7!EC
MMS99.K+>0IW7%K.\JB7KCM*,1IW?]:$_RK?DM>1*W]%JV9U55X(P2<2Q%M?P
MU,K0GN[RRD?3!'-H0#69* "'/4[7&CP.%$CE5!(WT;HZZ_&])ZL5R1-YH*;+
MW6Q[BES,G"3[A1FG;BS4)0\!1,VV0 !ZFQ# !+VV6NH_/CHL/*;!5A)7A,56
M$OWG'4/.$9FY3@L'@:"#<PRL#0&,N4$ _%ZSX\-+^>&Z_F'12K^"YI[=)._5
MRF6M["U9E\I\]YI]T\EL:B& C(MGITRCWSY@/*MZ_VZF\FLMZ;^V4GIL>SMM
M\%=WPBM6$(#0UM.!<-?+!T'*I\)'E!]/YY&7N3]]C K;_D3Q;IQ[]NR[G_P3
MY);(X'Z#;$?R]*E+R></B/U'YQ]//R.O\OY$..9NN^H4&8Q<N0_*^?4[P,3M
MD<']&=F>])\ \R#?O2^^\61-5RCB?XS//9EMNUH5&8W]<WS%XDNP+VV 0<1U
ME_#;'PB2?Q"E_1/A3YX^9\-<>'] 1/Z5I\)?0?Y*]/_)]?_D^A^2"U0G<OEW
M/A./N7/S$'X7JU(<6]T8D2['[Y]W8>^['Q  Y6W!=3 $\"$?VTL# HA^5'EX
M#P'D*(<.F]<?M%T2SD$ OS]"D151&/S]*0H$\/MCE%PU$O]OF04[$CZ9\=0X
M[_!>#,)^B3#(7#T*R1I<H'6CH6MJ66$ ^5T"N9HEUHZ_,JZ<B1X/CPP6C4Z
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M#>ZFVEZ0=?&(+)2 /#DG#]FE<9K9%J4F;<(#6G>0XA:EX'G++9?6;S/-L_2
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MHZU&<-2;4+?,8=A8J\_-J'D>6RT:P6J521]@AQF9BG:IF"GNOQB+N K'^V^
M:#[,UJ8>&%F 9)NYV1IQZ'Y<#8L*G@#Y/1$CNCK&@$8P(A9^(\2S,00?3##?
MR.5Y7(T*U^CY-]G^ ,ZILZTL+E--"$^%S./*M4?7FW_V<SN216WY/E:0?\QC
M+U0-&!Y<OS<LLDTRCX#:*C,B@Y?"D]<L"."JK0,'!O1*;!%X@;=:<VK.U<82
MK<%XN-]N/2U @+HOA4X?HEVC?$.2A?W0/#2B2(CY=U.92#U61>MVE&;-H]6(
MW_9WC.5K@B0&S$-QF^NP9* B1+A<A=WQ"?:X1H&MV"E$1P*I R"JMTR&.1)2
M N068@0W*YFCE4[>I!" ]%QI%K>M,TFU3G=9L.:S9BA7NX@K.1N1]!B)P,3P
M@__^S4OCB32% +P@@#=*T\'/0HF_KIX"55[]K6DPLD  FK)RCK*3L[@)FW=2
M]_"OZ,9-&IZDR,+II<7U$E_+V$SHK:V4<-&5-HT8,=_\$I#6U-?Y5A-CQF#W
M)ISMBJR(''$Z6UH@?YP:09R6NK7D\M=+)_HNJIJP=G%!-IM;Q-RVM2E21EO1
M;QI-$;X=/\L[CFMN[)?E3'6+O; 7BN12G_(A I: G:W3S_N(J)=0;K:IP-=,
MC%W,2OBLIE_TDRI:/'=&=@3'L= 1B:!(L>[BKT1EV,]<58(#+BXA*D8FJL<+
M*E>N8]IR3?Z+-@:</?7N?C;T&?9'D3*ZA!M4Y[=M3.H#U-LEN-O2DT2ETCM^
M?3N.^\-"_4KOW7R[.=[;DJQF\X7;$) 8-BP^OXO=J32>B7!8N5,:I=OU]CLE
MU)PU_9K^(2R_,W9 *2PSJ__ID,CS42 ]TZP)G.INV*KK#T9GER3]G+)]O8*D
MK5D+_*'GLV)O LIQ=#!!H>3 ]2)%-_P.>#YA/^J(Z;'' OYD_TS, --KP!R6
M',X1"##Z% EPI4V;>)F[LYNL_*N:59))8<E]'\/,ZD&T&^61.18>7/FY3*P%
M>DOZRWI5IN6+ /LVJA/BC#34Z?#LNXCW H/#)B[RL(_6T5_"AH=Y%P-E"M4Z
M-FMJFE <%6IFRJE'G@LXHI%5="/)R[<"X(1UZ8E)Y=G.I!=._7986PD7] ^0
M(  <W9*\D@%Z &L,23GR4A ^'9\ JF,["8ITH9? %*L-"Y4MACC2VDJ?+Q"&
MH0@M);_5'M\W/8D/IDAW2\BJ%/3*?+ST.-<,''VF?GGY3K72<&G>/Z"Y0I\?
MZKKT]CR_F]79"(@L5[ \8--Y*>W(A$" /(A'7&FHB>&?*!PO6%+1:YF!+0L!
MH,R[Z<C.,1\;5?8M@G+\3;"RMBF_/Q6;;(==C<\9F3X6YM;$6.PT!%%=<9,K
M&+I$-J*BPM<::1XT?A$F;*[P5,)90,W9775&$^# -!D@H]\3_"5T1"W(]P/N
M4=<5P=:W0O*Q*9$.Q] 4.FV/G8V/KQ=6>2HKX@I^,EI+:P$[X"A\$(U2B$.7
MZ8$LI-MW'RL)W2:!EZH%B/C6B2YLKY#WTYJN:Q&+H$@IDRM?2\8'<9>0LBY&
MMB7"(M[M+4QA(2GL^TQ# 2\R&:(=91T_/JIS6/?;@,3&VH@6)@6OGRK%>>:C
M=-@<'*\0>)&AH.)@VP&N(V*E0.UE>[96XYW^H 5EI (CVF3"WLHOU^KL?)\<
MVW<3WVI>"\B&V#)/;LZ*)R# *8OO=RWF_Q!I/-\Y1N-L#!^& !;.=4M@97,H
M94W@AQ9STWX,I%VZ'^GQ?,EIU2/ENS&/6M5E:)(8R:1_YU=RTS[PDR;%%7KH
MF>%E]7%?Y-OTVWT#NKL2"(!R-__Y^+<["N7L8T"#>X2CM9NKEX/:VN(00%1&
M"P1@\/9E'1.?7YXB@L"^3)<3.ATC\(/GN-H[%<Z7N;GY>B5"1%<C9*%'Z.Q+
M31RX_@+&APZDW/>H+9N7W%SDU;LZ6'9IZ/C31]>8ZU2U*;+H^DB%;ME54.<9
M,Y*8:9$3=3C4- .W(64XL#&:I8ZA'X?(YM.VL8WTJ!T]V&,N8L6&.EBE,5";
M65DU!%BXJE47^Y,!@4#8D%<XRUY_KOXA<S2\;WIRV[MS+XH,^Z[C26+B2X/<
MH%0U+EFCCF^5[:-H(IGOZ+W+WA*.<I?.Q:1WAF>ZQ*ZSYG53L-_!8,Y[NR6S
ML"CV5ZANVZ2U)SH1_)G:/&0JDI2G>()XW3Y4%S2U5IM64NLSLSUE3_W&"5.8
M'0QZ.2=ZH1QQ>S8ZE&ES!4^\T[7,*N\;4]7<=Q&\.=7!6$O>&=+K,-8N'Y%)
M<[,.]/1W;T32WU#=[ ;BII_B(=+EE(HIB_]\Z<:N#Z$1>=].AY[/;K"3AGVQ
M2\,WTM6,KCZ$6Y&K8+RY5/TUR0<_A=.OOW;4Z+B\" 'D-=?9=6"M@J@$4>A_
MG:]'OF5%Z>@@Z&4</W"0? ?DLA,<<$;1%E*R$;^^U),%VE0P<??D--L*=:A3
M2[Q^A]"[IA]/DUUXE*BHVX6DX,BG#CS)^]*=4%76^3I:%SG>=-3G5G3$0WYK
MC#:%W5N.16.9Q7URY1#K4-UQ1<] !XJZL#&:_+5K0I(@J.,>&D3V#M5]A'HN
MU!D*2$J33A4QR^;X'*'4?,6K+DZM,%9-Z^>VA[._(/R]9$U;S!>QQQT]'N=S
M(55 *3^Z)/EC*)^!!!YO)MA2!>B!N&0)=[MIUC2\YL35*;%+MQ2X[Q$ )S/K
M/8D43O91F#A324_+]DW"^>B4#3N338\)2B\22AXJ'^G,?MVM^NSL 3*Z1#2E
MK5JOW8JKXUKLF'9U?4;>Q&#G'NR&YXGV5C=A>=ZL:TR7+TYIQ=+'9\6ZL&1X
MB2T[*%FH43G^9_HL_F)=6:\'\]MN9H?A4YWC76KFFHAW-KTNUP0_RX^H;O('
M2!!R$V5A1QDE0P_.O%B9+@WP,P3Z5TQ<H ?WAEC0+D!+0XXZP@@95IE(FK(O
M$.^+FYR=4#OP?ZE"IRS9)DO9O+<3.Y,*+0P-R5:2P%$UA-JG+USP9X0 "K\=
MSI!(00"'% ^UDG+0B'M>UJ,)'L9Y/W'[&[](:*U'>DHD6=>]=?M)[J^' XB>
M"B5LK"#U1 675_J-, ]*UW&8XM=N*0X/EYK<^[ROH.\;"E^X+79I6SRDRB"1
M5>9Q<=$(>S81^R8%)I :U8 !]<E+"1)>/V6X"][DTDY/7[H'CLKJ-TR37TBD
M,C?V)[#KY*P,AFKV(J<!^!WL$ ZQ8Z\[P!>D3<""Y</%+[U2I3*RGH84%!^&
MV-E9%.W8\Y K[SW69T^+-JV.A(R5_,0PM;5//ICIC3"%(PU-OUT4UG7B7'@2
M Q;V%.@<:G,MSU4)8HI;N*15Y_*+K"[56-NVC/OWR*[91QU66;FL+6@Y_LJ:
MI1U-?H-6)9&"+KI%S,A#NG"BQ3_S/;M0EG]5P5/DUF&-"B;+@/,S;I\U5$+7
M6QCC@ME&$LE>^R4M.4%N/.57U(\";&JR0>$!]?!\^ .]HOWP. YSW?H^^<Q?
M7*9&G&+Y&VEF+I5< H9E#2_GMWX(JDS<0*?4S]TDWWCNEQ*>T@VR!R8 >E=F
MW<:-MZ'CF>QD[3_W2+M[;C*2"?9Y.CI^905MH5D7O.)<P0Y&9.^^V/=FS&N\
M8.)>3+MUT-%+.MD)0K !&#"3*L61..XC]!'@J(O@]5"':4@76,)2@:W:OY [
M@W7-WO%XGK?(\RM=07/+MCC*3R,-N+I[VZ(<=FQ_,QFNK(&=WX;J]X'")XFP
M8I]3GSD]!9GRN.XN,E8HQK7'M31A8&4R.[0:(J79R7/H?7AFK0H=]5QC,9O:
MB@=-[CD4RS*BOV*1EZ0M:E^?8O8R-W<9V.YP6LIRAP""J>@-!S_S1>V@K8PI
M>DX4V..K>WQO<*H;[_!V675<8IX^L\ I,W58M99!]!,%.#A&\/&5$9$8*'_6
MG&%F_7CU/J>':K(^#,N%"BI+'WX5D8CW+#1EKZ_1M+8EK[JT[0"C9K"(@D^S
M"Y8V:'O[UT3"^D6/A9O-:>\F2-SI2!W,:-?K8D:T^G&+J8&)E]B<V!B;E08>
M#5F?.H:(F?UZ==Z@-1?GVO&^U0YJ*ZJJ4I\; 8X[<\-('N^K>Y'.V*:F,Y&L
ML:L'(0Z'5PQ#)S9]9 P[&7#?4Z-P>S*(,ELD75CA;4/B1F8=!- I4@ !6-H^
MVL8)KG&</=I  %;X8ZU6\J$,X[!2OEL+OFLB_:K.?[<.EO8GP5;Z*":.K0AG
M&[(Y;39A(_'-B=D95N^"+XR7RK'F\]$45[L%F!\<>G*3B76 2<2X?[)578WY
M@8P:SVO@\Y1C>L/M#Z7"D_6@1:&$"4E$&^8Z+D1V>>FM!JY &<%+^0>2>B_M
M7+D><9ZUH6+O,].[G[QMP8G!W8U!!9O!DE*[4L>@Z"#N')1)'P>LEXCF[)5T
MEKJL7H<NTFV$8+Z3R!:EVCX7.M1N5+0+3VUB[U%7*^83U[).-*EY"5D]F/=?
M%]9'W[RUCY\^1*S]XCCVO3BE$%V"AAUPW;)XAZIZ*:UKKY</>UO$-*_([@W(
M+O'OUG=+58MXN# *8+.%;A0^ J)%P82&'J_U=)B3H_HYSB876FDW<QA((P?L
M,JI?X> N3+'EO5FHYP/MG.-E-FF FFUB)*K'OB\O+9YH(9<QQ.#D K%/B/<L
M,24-)<MD@9M7]G;CON92,;V:_2B=.!\T9R4^268YX]_P_BQL2QH^*C/6B]DA
MY>W)>,+6"$RVWQD@E]P#K$L@><0PZ&1B64IVW7J$J6^2U04GH,^>T;^NW,$N
M3CMU.9B"7BU>=.O@(D$=)9%4R#A??F?:..\"$X9)D.0"".".08 6.O= 8=5W
M+S\N,YT:":FOP^K;_=C,:@I E<+O'R,@L5 8%D<"&6LVQO8K5+]WLYE<R/%T
MI<"&9J;G VQ#UZ#R$<\@-*N4E+JRO E_1Y*/4GT6_B70JW*49!"E*VL;^9)A
MMO;'X?EA2L[!H?[@B&!U(U2%E''_KUV?VULQ, E'2LI:K]%>Q +3;H:$FN:*
MJ=J5=.S@ %D[$F.&;Z#T;<ZS,;Z@N!=3+8(FI;M&]!)5B?6SKD5?\NO'855G
M?'P;?D<U3L\6'8U9S@%;RI0U^[#!XC)"&+48>;%3UP]HFPS[%XWXL!T5Z:!N
MHPP#+OG9RU6Y+%_<5S=;9XA$O0;F@>$S<?7B1KO)..\;JQA-?!%/O<SG)ZXP
MDA9'"SR+OYX?$!LTS5,D<'UV"F]R)_/Z\BT&GNAB%*C2X[%$Q5(75;=D7F\W
MWIC<SX38%W;._3DC#Z/'PN NXY?$-[JJF%7&D,7-39&W>$H-RIP#^/?)<QEO
M&16D+I!3,K+J*K7XX]6MDKUN3$*"30 8/R\5H\/L)8?-A5OI9^("*LH63],H
MNBSVK[Y\+#',C$>"(VH0<8VP>C>F/F<^ =I!7Z@=F2Z,EO</LR#P$X@-NI?8
MRDBGG[@;,0=%S3=),R 8HCCX266*#/?EV!-AI,6P*1:$9V@-=N0K\$;/D"/0
MK=&>3JS9]>)9.).X"\<9#(L3G=CJ-J0<(!.$3NX_[U(YIXB'<&QG^ EWM(^M
MD@ +NA\VPLLI51-XOPR')D1D6BX1>R&G^1',[]6_UP[N99<ZIZY+&=EMQ&;7
MA86C,!DZ1^7]FH2Z'EI"&T%@74'N*-!#LY <[])/B1:0;L?3VW J3W<?%D1B
MK#W-A2+<:1;X7@%I@+H9$XK)@",!U4V1N]BX@::I:Q18<1^ /VN^0JY(O$5@
M[6!_4Z#6HRD9^J0& 41?*4, +K^]WJATH?$L.2+[:][W6D9)5SQCLNT2:Z[M
M:/?E6$V-!-0,UW&%P762N\A-CZ4"L^]>L4_;AAZV0>-',&5.WN7<LT?!T3.V
M^V]O;ZG<0 "(LYO_]F<6&"?5C-_>HU+]Y=L9^0>,>'M$:.R0P?UAYH\[I9T?
M3S<*<T]T]1@3RG\;)_C;"UE%#Q! (-XK?H8__4LFM%W-B!B<YZQ+_G59^S=+
M84Z]*I\+X;.VPNP*\O_18,2E_QSXIU-=* A@6OS&,J*4G366[ RKZ*;PZ:\H
M5/_&)?WRZ_VBOSDB_3/,;_ZQKMD'/QWEF+NI,\Q0]]P)*#CP(8 ^S=#0H:Y&
MY[2*(<R/DYV#$\W5'%4GRJ%9L3_?51MZSJ[]$5SN'VZ4QY$1!%GSAO;NHZ0&
M&/JYW4?J1-[N#"(_Y65(XU"X>70*!-9_.V%;A@<2JJ9_[M>Q6>^[\U\L@)^L
M>_HW,9'SK=U)G.S,_;AA!+N+=T<-1@6;BDY\']=R#"*_%&+PC$0]F%I<TJEQ
M*%4_3S6YW#6AH0SK[29+EH<3*VO[9_GZD?D$^0I$,EY]C/[8^1[;D3U'ZO6;
M";%.,'2TLG2.]N!M&2<X)M7FTYI=GY7C%030S.Y>%OFO(/A/' 7B#')XBS$[
M6LGEN!M?8FS(*\R>R5U^D,XXS'VLJVNK;U'@.BU0#*>JPGLC1D4W)HH@J)[X
M3SHI9?UO,B_@3X)#^\_&=I1%:$^>K(][]W]G*:7D,]K6K-#JOC>N.(_SOTGJ
MOP7[_UNST[^?I_^T4M;)^3KU,\3]9]ZJGT:>(8%,!:Q4!WQ]D=>_!I3>7G#+
MJ'\[[N%;0K:R! %D75QO5CB3O)>=X&($\7'VOQK"1_V$\;W;%2&\( $F+$J
M14'FL/FO..9C.5ICKJZ.E$7U]5_$=HUWPT4IMWFWS@@5^E$]QG3.6VX3<0OL
M$A2#1C]$F\95;=]NXQ#0?A>8:;@Q0/Z1[BN8H!6>0)N>0QO=#]A*,Q9TZN-]
M61&OGW ?/>L7!+/=H^P(<V"(O\MT]?]"PK?],#FP_HC TC.<Z""8XRMHHTJ'
MRKUEMM+"-LK1OEN@2#7]XZ2T%HF1IE(K43&1*OOCZ?.]0G.[(697 8Z^G&27
MBVO@*QVF2SUWIHDEK,=C-C[#^G6;@3'BW5H6IR-@+:/GX[>+NH5J;/$X"CY8
MQS1S*JQ>^Q-5L_/XM*DQIKDYY"N.ZK! &'9L2BC[\9NC]H$"U_'7*AKG4SV$
M?=2IE'P?Q+^D17WFU6MX3(( _+9JE68SW\UPIB(51(.LOZ/Q)N<@7+HN1["+
MF<$7K#)8Z<]USBI*<Y:YVPM>25*!F"*O/HFK61LBVX7"\:O&N#D,*E2D?DN,
MTNJ.IKGR>\=?P<06MH,G(L,%3?,F7QMX"T9@/.1V1<)-^F8GIB9.:P_JH@HO
MU7']Z:EZ8;5*^IKY^#3GBRR19"N^3,B,BF!ZO2+T*XY?&T<:-LT"!?J:+.G,
M Q9;5P1QTE>QY(9:]9#_1=I;!L2U+(VB@P77X![<@^L@@0"#NP[N+L'=@KL-
MA!!<@PY.<'<(#H-["!(L:" OV7N?[^Y]OG._]^Z[/];ZT;VZJKNJ:W5U574U
MP!&J>7!F]1ZH(>L:Y/JB99W!.LE*<@6;UDGP8A: 86*.J+Z8-WI$&6V_>2Z6
M4;)B)^PN3QY?]KX=&GIL3,790WZ9PR+XW5#XR<N&%Y>+95%UC#H>N)AHUSHB
MSFP0TG)/)0_K.+L2T&XB_ EPAA!7$0N"IN%'^_(]5L+"A@%P6<5NFV/,-SMJ
M;7$\SQLX60BRVV1#V\O-4[ -X#Z;Q4O4%-KI6S5Z433H*X)RK1/\)_8BJ%Z.
MPGN\D#)WV=FOFBW1)3'2,+??%T2;VN/0Q3!YGK!$E504*QMGY[JA$L#>#Z65
M11L)ACX;/ 845D\O\A7^)3DL&9E1_U%,/VYZ)PX8WU'QO;PQ_<.;1D70M1LP
MU_FGHZU%0;0X:)>Q)FAQ7/R>WM:6Z$G2]^;1O^\GH$ ;\LGF!]V82T$,J[ID
M#$M":X6>C;[H0OE'>5-HHPJW+3P$UCKT:N1(8FQ.&_&)ZS/[R7[+>_5HDX@%
MLH546]8]>5!<@A#;*P"6FZ(*J8V5$HL0!V-SJN:'JBJ\[050EAP1"2)WJ'#<
M\YX)#@MD:6E3F'>-='LD. MV)4<8\XWB$M'A]7!;IOM=+=QA5E7Q[8;D/##?
M%'@!3!UPWNMHZ_\RPVPSQAKL68L8)LN-4%Q0H;NQO%$9;^KEZ YMC1_'JWAK
M.J^,C0RKG,7YGUV K!S?C&:KC-7D&!D,Q7@AVWSJ\JR/&U5$).72UIWUI27%
MU\^]4%M13K]68Z?AP*_<W?DF-!H9X]G:!I3"9#W(+S98VQD(M0VC;[*S-^'D
MOV#&L"3-N^]',$L_YL>8-PD\YR _($8&9I_+4=:4*-#(4A9;G'[;8ZG\*N=@
M;7-0TRB2]U)-\\5\I24G\Z<(H1(Z68P4)D\AVI <7]*N/\Y@1%,]OC;6+OLJ
M^Q.@1C3_41CDH(KZ!9-8+*+5&>=0XZL1ZXP!>$7)%K-A4,J##&@WL#/(*4,&
MV!'[/GE'- T;0[Y6O#CBD?*AV)M+&C:F)R^491)!RTV6_$YR$I/!*AHZ5'PB
M%A&'"VN9.B9Q=']$L&Q@!9*^Q?NTS#H8XAIAK3[$.)<5&%EJJ'_[25MIRJ%"
M1.7-M#")WBJ^NN[6Z(\E%LYG0@>_#;G"]ZQ3>:WG!"=7P1REMH[ IKVTW0;
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M8!\$]5%+?R!-"]L79Z)%_NJZ'LO)Q9N(UU<^X6%_+4ZS#4Q+\("%I^-F\^P
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M51F7("<_@.4Z;X.M9MA><E2!%$9R\'$2N?BKMRV$ &]A;R]X3G2J&LC(= _
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M"&ZW?'H_#H&/RI-.R>5.:5WEFCM7"-AVE$%_G^PLVM%7.(4'BPHT)94T=%)
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M>YL:9_%K)AO$Q3G2N;C&X>I>?ZJ)@I'1 IN/ A$5'%&:'M>6+]]9\E!T,:/
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MEI4Y<&OS$GTW1S,U(;?7ISKV"4\%VYE+:6^0/:S5LXF&:1F?)SR@994H1VA
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MMI#]C(#\@H'T&9L[*(TC]FG XYPZ3X*A?NLQ=*U!^IC2.'"0)"TY>F0+EX<
M*5CB@@KK6@M9TU<AT03]M-#"J"7*U^3S0 OZ(VI6OF]R9G;<?9_MB]VX^U(9
MHVEUH!K4,9!.2;,":[L#I9,:DV6[$(2=)Q0Y0V'K%4#^(TQ\JHP1AW,1@B:1
MYR':T[05RF=U#6!M^0^O09>O-&))#%WID9 H['2^_&33;)AZG,RUMVKB.[L_
M2[34FXL[%([&NL2*&"GV/"&L>+"%>D6O=%/ 9F$KB2'3%-4H6I+DS5/Q?9RG
M.^&/&?>EUQ>+72#;=5,;5W(:X5#%X%$:0^Q'**GY?/VO9TV+U\&%[A+0U,CJ
M^?BX> ZQS0PF?'N9CDA,K&^< F=P%6T7+=6*ELFM:K"VB7]@4R-NY:GA:>IU
M.T,9%E:W,;;\/@/)- 6:/)?>ZP^+DBR3,:DMF8D:/U .5F=KQ#H MBB(P2\"
M&;*"#? ?&&3,;UPRYL$GX?XBD-$C4TB2B=;CZ9,GWTJ%C\>)Y,#*'WP9R$T8
MKEF[J0.87#297"898MZKXC-&9.#_8LA[_JWX-V>D>[:G^* )>T,>#CN#7T@#
M#"5A$ %%M>U>J+8N$C77ZTQ#!\KE=9!H=Z-#BF/Q2)'%03/ON9_E$TQ3??PS
MHS')^3DVYS4T^:1MN;+@MV\'GL="60Z OIJ1N)Q\EQ5BM((:/P@^KG;9=<%$
M:V2L-(\$.ZU9IMV'1/:L3AJ?BO63B6WGJ_!8EY>$Y21OAVLOO"*01:Y8ER._
M ]2("NR4&AQG[S8)I^""[@#&%FSXYYPDWTF%3&)%#.WENFT_PE*$2$L=MY<L
M<>5)ATW".7#+ED:V4](VZY;2I<C5#8Y?2[PDXLTS"V=CY-I\]"3P]:L.XQ,D
M00_M\4<OW!^MN7U=K4YVT=^EY9*FV+#^8"'T+5'2GK=N/>VQ);@=Q44 5"I?
MCFSC]BP<'&3<9B. $:KSM!(RX:V]04P^[8EY?)N;#R:*)\+)K5$25R(X+[.=
MR".^SF&DZ$&*"M5(ZO?;3I-EUV,.X9Y+()3##XS=U &RC9ILX2/TD[N-(T-W
M/K>PE.XU2>=E.[:M#">6)#H2R@R%$BV1,<L*1=N-0%A^!"2O;S?6I\,)>:+@
MF-&7P_,;9%7VRP(I<T)W *Q28))9W,'(E13=\U-JY&_,P\,IZP@K:Z&4K6!]
M932=%MS^UKF1IBN%PTMQA)DNR"C'"<,HEX\882T;MD62^_N\9I^(M+C10IHO
M9)7](V, AY1?I)ZYI?/:H)JJM[),CV1PI-93NRO>4)M%*F""DSYW0(CB#HJM
M&S[UT;@R3_@6/0$,[<0-ERQ&?#>X>A,FVE'GQ+ORP<$FR"1 0X?FL?B6/YGS
MSE%JL)W/9%J&$[(!+#KXA?>#T?+TVQ\,[*I_]/8C2!BSF_+:Y"X_O[E^D! 4
MD*Y6<TWW_L7%#XGHH9J8:N7F!4,1=L/]DZ'C]F+O04Q$N6A_Q2[:^NM!G/2Y
M^389BO7-,^9>PEOS<CO+?H"Z5T7^ J""(G1^EC<9?@=X)4;\ST;V/PR3\>BA
M3N:A][UR97L_@NH#^@=;]L,(!O?H'U2M/P"@&$#(;V,2'M ],)X_PAC\)S*1
M(H1!+Q-^@\]!:J @.\L6VG%^"67X/P'_Y1U?V/+\^':O]#T<@"'\LZ/Z_XG\
MO[RO6@'99]%<GI1T%S4$]O^.'%8&P'\[>W\<_B$_N^C_,3_[OX^X0';6('%Z
M0]+!;#>6*X@RV2@:I O9+L[<.[8X_V;':'G.U<3*%T8OX[13 4@Z2645)3YP
M@H[TI;K!I&K?>Z#'/^$<!CJV]- L\R+R9#6U,]JZ\#_X'CP*ENS79^I].2((
M0_KY63KI>E]3L]@"DR;8R(X4NWR[GX-5Q)1.SI X'"!$7OUJ0L@!DGT3K#5;
M!IPY<W-S:V0]0O:=W-IZP12:'F\ERT>A)#AA6PE_#@-,^ F)#7$1KW#> 93?
M=>7UNI2.!7"7TL)PY?-=G-!^AMT4U$S3!YF&3_;2:' 4LJ(S?^*RS7?:+\S=
M3<<VKF[XK-XZ.[NM)S-C_=H>0ODN;<6J8K!E_;4Q(F(! )-+NJN_3O^=KO;A
M%62YM>Y$PG6RR)JVC-.U<")V7(#=Q #5A!^9,J"%\:!3]^8Z<J009.D<3^H8
M4&UC1M=SM4CW'9R2GE#U9?# )RUV]IIE@EN8JH?T='\6FI1<  $&6^2O/G[4
M8CE Y(Q) :I_[2#=<9;T$/$2X_Q+3>VW_Q?= X/)X(W+D@E=ZMQF6WG'8=_:
M2+)1JEW.43MQU+O23'7NN)8&/A40U.FI;/+(I*)Y?\H[Q.6W!Y>O$&:$:</7
M+:R!<EFJ<:[$C!&%+Q?= JV)'%LFAMC)&-8;A+&H)"^U$D7BRPX$/F6K394;
M5L;!)BU8H*8,572C;PM9[1$--A\A(_CTRMOD'D3N([X'%Y8>Y.!T<\H'JD-Z
M2E;,4:*V*O:Q4)!^"\3PD]<'%UG\NJ8D#&?2=E0(4]I=D@>VFSNY&).UQ#ZE
M$'N+,VK+SHEIN03U"N)DA1NWZ,G(;TD DR_D2>HNE8;A2"/]?*,>!0V4/L&O
M3I=%%6;*RN P&WBQ'O&2C'&X6QS>IB1]@H(URU;UI0<6/=" ](SZ7AMLR/LW
M-OH'$P",C;L5XBY>1/>%!&*U;;X95,I!KAIB>W6] F_PJ1^_Y8ZG#W$LID(7
MGCXI^;)<VJ2M;&<\$1?;:8$2T\@<G,W?[V4U9U>ZK+V;Q)-?L-RE6$2K:$\3
MX2#'CK#Q,YR=\<M!$KEN7:SY(C+<^*)NTNKRF3<#\M$M>?B*]R^-T*WV=>[V
MEKD2D<YG"F0%)3HT8 /U#[T7)='13]E1Q8BW @1G5P.O)3ULBCSBNAAP5U;.
M)U=<<[Y<A&U7\+WI0X7:I>P -W*5,2[\]?=8(+W);1GE' M$6%L\V\QVG>B+
MC4<.JI8"[9\VITMLRC%"JROM*!8+1$#2 9WTD3*'X7PD+P$3&]BSLV%;H'[N
MY1AG]N*!8?2(Y[T13W,C//UJ)3-<:LOG5-I:.!9UQ8W(^WA$F>U=H[/=YP>1
M,^#I5C.%L&/_EGC-5;,IC&[IG<&GU"S4@ &.;S/>*"OI)L[KN578ESR:%<N&
M$P:,[:W$&-7F8TC#NQ\)+S+0@UIL"F_2O]9.P)+5\!2Q8IO$RG8+.F4'&W"!
MY!4 @\VS8JTVKH;JT]QX9?]2OZ5.PL$[@,N46.A(HYUW/AA@+[>65AM?.N^B
M?ZK67&F8]$' FB8QE,&0\Q7")<+@J9//J<^XFY9L^E-Q/E,(?QDKBS,)"'.R
MN_Y18BNJOOQ!L)C*EU[2Z!4%\$U2E27AX<;A[*FUCL\G.3\Z\3&AC:G0F71,
M%]\KS;FDQX14A@ITB<,RB@=L";M:Z!FA5IW(B!CZTSG'APZOFWRJ\ 11-]$Y
M>V*(4<AOACT)/.?DIDKI D @AF?1^!PR PF,.9NAO_#&9A-"IE6E?P_V8CN.
M**5[N '^$:UBM.22+5[7$(V6:J8<;+X([KMX2B)W* ,VS :[D 29TP!_T"$\
MSUW-M+5M;TO_>DL25MWD>PX5#.'/3EL1CXGF62H1#E.4*RK(5)4HV 5TX-<,
M.+7Y/)AJ?K/#W(NA<H\GI,U<(M1)>?P\"F).1<9P;--7A '7\O@=$UD-7[&H
MM G"N F,$_T&*!=(-LQEG+Z./0-9]%.T]EJ.P-RTGX!"%"7HM>,L"#))PG2"
M,ZRH6GIL!28;R*:U^!UAS>;?XJ K3X[>C9Z0X(@9K+Q77* GD^D7:6<1)PJK
M&6_?0UP#)$.UUY]S) P7-0H=+?B%.HK 0GPF5JOI_*>>/9LE8I15D4C1\C:G
M.DX96??">+>R__'3BT)+ 0/OY;'S0J3(6ZL2(NOY1::K/&%9OO(/4S^DIVL2
MV2!&+AHD^!XY ,Y/?JDYWR,_:K(FPGZ.U%;.9.$H<@)#(5%)#,Z9'V2,1F$9
M:2CYI<]1DO??X;>(F^7N6=*L%@.CT6()^0+V<'>[8^FJ2FL(GXGWB>^I6:;C
MNBN:_SKC8,:K+<O&1W-X5 %V YF9D85PH3= D9C6$!W&@\_DKTW0N)N@XHQ<
M1ZSQJC$F>H$#MOR7H5$1^HK,*T(3:P&R,7K>F+24RM?N%,/IS3O;6V1E?"09
M9K0;$7BCZ6AGH&5UM:;)'\OBB-TW\2(#*_;YV\Y0.]SCG9.=W(_Z?K2*F7N3
M\A_JH[EK3(Y4G4I&:DPZ#I\,7H/)=+Y#6F,B9?&YR%OTW:MZI)QVAXP%(U0Z
M\5.,IH0M\OOJ$"5*+;Q(^]O'.*7PNVM5 V3LY4^Q 8)U#!("24SIR;U0*U)F
M:&Q'8P!#F6)BT$9/@(&M"OK::9I#. :W^[M\H0ARVU6A@8EL*9;1M4F JISP
M /\Y8 ?_R'NWH$Q3E&)W<KA2\KQ1+TN'/1(OP H24;[*3_YAIU3@H*^.QYFS
MT]G" S^$4:QXJ_AE-#ZF!L#K$\'8M-'+MYA9P5V3M=^+#A0A9LB^(RS#?:XJ
MY0D*<+64DWSPB0>*Y7*>]^7%'Z00AO_^E"N8H0B0)XUOFS=O)#<'A$L#C$^4
M[_6QOU@G_WX4$_GD[^;,_V0H%L-7_3VPA '<Y'5>%N%HM.VJ_]%_M=Z)'R5_
M_6U..B9\*WC[!=L6^Q!]V.-AXBQ;1)E\83R4@[299=57'79!:P<%JOIC:L%#
MWZ-=MI)04^).$=W7FBLQA6HWHSGV>B4MUMR:Y>G25M_X6YM$6Q"W-LMY*^#;
M1?+R6PNU^"I[NCQ8>[TWB#I@@MHE--.H4S11U@2DS%^W ]TS%';(W#9(X"EO
MPMBZZDF5,NKC2#]Y@@GEI2H(,<A03QX3OZ^FTO]X!FMJ8JA"2FT^/ALI_%JP
ML)*CY04&%;3,.V?=[@PR=E.GA-NC=A;Q>*)']RLW3\$=<<X%%VV>[[B3?/$D
M1I' !'PULT#))YA7E8XDA_1_*C_2W7>ME2.\A9EO$7& JKC;YKL\#[ BY4@$
MJS!MQ<L&;%'X+WYD_=523-7WS^" /U[_= %2U0/U.F*'KR-E.+I3?7N!CK4F
MQLV"WS%@@[%'ER-JTA''$R"M0\R4"5SSMK75"3P;PS_-V!L!"V&A-2G1XG(-
M;2V^'Z+HV:$^39G-Q2]Y_-*39)(V3(V)@[2,HW8>)^SF-/W2_/+'DB4&J&O6
M61>DJY/CU).6PX&,731D*][Y!JT3A6!<5=I[8+*&K^2LVL*.=JDF\A*/GTXR
M?\3[L4N'(=].GGQ).8YY$RLP;%B3%P]$W-O=/DCJ38M<:, +@?A4IMDE'3"1
MJ8U33W.;VVS%]D2YOE<W9_IDN%%^)47U$S6KPTQO?E? .M"1"?R$K=3HG>"P
MKS)WL"]YH^G[2*%:8:]/6)99\?KW6ZO31[W#5;- !0A0M)D3-4B-UK##-T\"
MTQ9367>ZZ7@XVB+IC7];/I"G3NIE5 T:=1-M5 NY\V#'AO#'-V3I2-^T"'_U
M]C#JQ+SPIY!BWI;Y=#; :J^L!J#@BD$PH@^X5BYZ&:DC[P \[Y+/<8(64+(W
M,#4+#K$C>[LYZ*X>!^VVR8<<FEE@-5R6-]83 +^D?(E1_S) ;9B8^]-PI1OT
M14TG=3Z1A':^""?G*?FFO?A\ XH_''0V3O+N.&+/3S&X$Q(,DF9+)Y8GT3$>
MI.M&:K8#;NXT%FFM8$]9'Y5N0K\7O3)- (:3.D$[%=CY!U:6?L G'YP2B$?6
M4ZES NL"^):>J_&3$+PR C.@( 3,7'X64K\#K%-.20\T:!OK]+391IG:+I[[
MT_,?$8A38/*76C)4D$"5@O+WL+CVSF'/$Q@<6I.?.=38*P$&.\@==%^JOL9*
M]_Q/#B<E?6X!27:E!_-W@+3?=!WA_NE;QRXP)>^4$#<LU73REFP0&+4>0XRC
M;32DNOQ9B-3OEG#4YPX@TI1_\ROB#A"2E_3X(^'&OI< +Y7ZY5S:':!K85QT
M9T[C#M"N>@?X_L'K7\I'G_ZK[GH(NZ"(PNO=)0_E'7VW.P":F=@=(%U/_?9&
M]@[0._&7B@\HF=8B^:?9=C]$4UV_7;.D(MUZ."I?_:"Z Q#)_KDH/4[I_[><
MU+>..^W'=1^P+G_,B'Z;]KK6H_I3B4CL?S3_C^;_T?P_FO]'\_^7-*<_Q-)$
M7:G_31C?%J%UF7L]+63BY8#.&T(6>$R!3TFK>O/-DE'&ZV[A_P%02P,$%
M  @ +XJ$6J?'^;X4NP< G/('  H   !I;6%G934N:G!G[+MW.-MQVS<<16TI
MK3VB16EMM5>HFJW589.B:A5%[4C0VJLH6D7,TJ*QU8P=JJU-;4'M$2N"2%Z]
MKON^G_M]WNM]CONXG[_>XWF3X_PCW]_Y.[_GYWON_!+2;]("X(J^MIXV@(R,
M#/#TX@T@30,T_W[ZWWK]%?*_*X.,U 9@HJ:0IPHA)[L!N,1$1LY$1NH"@
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M[/_].% ,021 Q]UO1V<\.V P/ZA<Z#\Q9OP[X^N]>DS)YB(+R$IYB+!P#9B
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M+5YY$=P%8OY]'T.'!!IYW8%,\01FZ#4&,,]II6ZS]OGP]U"IV9.]AAC VVW
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M<#'&'YK,V[1E@PO/<OR 60>C!X>?[?%P#/5>_=U**G*^KC*:W>RVG6,A9!"
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MJE\)!R&T^-^?X)L"HZ$&!0&6'39&ULU6(L),A2G/39^6A*8K&!L!>,?V_Y
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MQVRJZK2QM3+$TNF-;.%2+?!1KY"2[PW./XF5<ZK&@=)O4!Y[SDZA\OH'WI
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M)0.9QPUB3\K<G&#$C?2?&-]GSH,B\82V3  A$XLFL%P@BW%,ZFKEQNI$[<)
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MZER>+03AKQ =^T@&1T@$4LP6!E>X"3Y*ZB@8 +MZ@V7'\Z1D_MY]-?,YT=>
M:JUO5^GJV)Z3RKP'1NXZ70*8B.:K%9$V A/>]VC,"7!T_E(NV -SR_H]X[\F
MJ^FZG$@*:B//YE9G\M@RSJ!B/K=[F5'\J*'MP96IG(;QRR5P(!FA@@-&]K6S
MT:0\O',=C0S(6?^HFN9MK\!<<!2IF)0-DPJ42^I&34<4P+I5E0CB1?/.O#1#
MKK#[9H[I<D5242P7KMF%U.VG'[%V,8-C18L<DKBH\TV,:0C2?O\.2J("#^]
M,-2:V: 4!)OPT['YH*#L>^P)G./.CP?6O]BB\G5=GSU^>OT3,#W^,PAGL$\0
M9@U3%7+*OH&#%9:34;!;DT<ES4/Z&)]8- T/W;\EKI9Z1Y.E<4P F.=!*VI
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MS7OAONY]:6N7@ $SX'J!Z=F%3T7ST:+.C+&^ZCC6/N:@-,SL#H.!\1<RPH+
M<!+>=!=ZH1NK=4@]$B.<4+FA/B[?SB>T[\"GHCBCP6Y4:1"S-6F59!I=[7M1
M@QQ>LA?+,C+:GBC2;OP5T"^7X3,MY=I7?G*LVD]X.4]\Z.P>\P=Z&+A_=B7#
MM<W#"KV*!P1%B0\XNYPG3*0=CW=:_=Q6T#.FMT'@&:,[/Z06--_LF#X]:/84
MW'>57$<2E60R%3BL_NK)U;0>;9^+G31SJ;_8[6B_6=FG3G5<5&SA/-*8F+R0
MG+[NXUO7E@+!_[X25M3_5OEE[[07G22H-G'$J,XRP^^-;:ZTA-&:K>CS/;!]
M%.  1$MDQ3&$!)ZU2*(OQ'2+-M/7\[ZWI&4[.%GW\R>DL64K?K -!D7 :PFN
MFJNO*@JVGQN:3KF]6W8S?[]@;[<2N@%XH@07)4>4G*V3RD:('R0*K[CGZ^Y9
M9[)+4#XR!K]PB-6(]6BV+''_UBPF5ZL[N)3:*C$>WWI?8\RIQ%+7N>5G!=RP
M/@IHO\Q,D._P@2DE68W957VR!%G,[[4Y3:N+\%L]HI:_SEJ2D-UB.HZHLB;R
MW(]ITN]64K*VH0-^,+BVT=WL]V;0)8^T5 H\)T?B,W^3LEUP5O#NMIF]!7Y-
MCC=%[\)Y=N/T_#2)]W;(:NP%OCQ+%?@8TN9^')S6 5?H^R%)VT\N"1L@'E@>
M(LLCK:=AZNL;VCSEI1>8<8;(Y9;%"7TFTN&6C6MPT_&00E0&..1=O,^TQ.=*
M_LSU..W-QHH."#54\!* &>E!K^PH9:A(N1UKU)GX-!@4:-<=&W]SSVZ&Y\-?
M7 +N ]<0V\CC'4DDL1J(.*[HBI_[= GH?6EF]ST>2SCX:3=_">"AX&FZ6,KT
MV=]ZI2B##9#!>C55;(Q= B)\1XTP^2*@W?(/I8E- 3)',/?%TX5^0@_N"3R$
MU=]U)%+64L_B6K&9^G4G27?^'9E4=TT:W9,&VY@?"=_Z?X?6,+;@047+U1*I
M#-%$+O=\\$D*Z[D .;VRW[D3(K6Z3./ZM0[02^G#77L@262Z&QFJU:5=?Q&@
MT5F[X!%\]7I5<DNH&$3&+^Z#G&%_J,@BEJ"T>*)N:FDQ";/IN 93433*2SY:
M7,9$U<V_F(&+U]M"4!J>*?C:TD02!_COB25"%#;M;Q*- VJD@,+/51$Y([[N
MD?6DGV:<OQ]("_L&[JFD%NX<(C]=T2$;T0XG331HQ9N$N?I*+_R'"V^+80HS
MM*-.F)<:V=<ZRV ^0A*9Q'Q/E/D9@>,SR5__@^^ONE\"IL]-"\A_:1&X89#P
M1[(KV7+$0.M"I>U:*@>(-/:'"'5R7JK7.:W%%A.!A@H95LW")7/BDC\W$DFN
M<+[#^17Z-& X3'";S-'8H!OI-63WUB_R6Y>$;7"]^N]'&1^)9\4<?.-(UUK]
M$"2#ZH-9)_:(*&79=\4+7'+=?@<U?PBZT/;>OC?M -K#'I@T\<F"*A Z<O-J
MYSY'/C%Y?EMH]P3AM\QKVW&62E'O3#K$G<!_U\1LDI]/9[U:)><K_EXA.=KL
MS(/VQ?U].-<F=#6^&2?IJ5L[3]HL-3$%BJU< A@(DGH16KCU$*>3.[Q]3+>&
MT:\!U$]VA]HIBC9;O6)H:#_$YRM&:5A> O1@8H:RAJV 4^7-JU3/BF'MBJ<A
MZH[FXRX!43)';1-K"7:.YEG7[&BO+7SFCH&6GT=MIK!\^V74U4#>SK.RXQ"S
ML)P3$]?[]UX,#1[O1F_K)/M+Q^IX/T!]$^)XVJ\:*Q-8EDNDP)EVB2F .A4E
M$.]_\U<)I=M_W;N6H7 M8VMD)XH((&RZ.I4131K&L:^Q%?NU8372.D,G!H>+
M7P88)+U^7%_X$.0Y!'^M^O"+;J&U!":M/F/#Q BXO=S(5K%^@?&2*NPC ,=!
M?-TG<]TE]]Q_"7KT1?S!QF1/$3=[%\0^%6:]Q244Y%,?2WP3.<A;%R[T96N&
M1_X[ER@\$@H+=,@P[+.5MFC83I96EF5KD=4Y1L@L<&:^$Q+:5U?Q,\J=\M8H
M[ ;-[8 (VFB24I^A,\IZ<5"GGL61&QO5G+-=0BW2_O0LDB=.ZB1BUS3'"<@I
MDS&P_X7=)*.82TX7^NZ%T.M#O\^9]WZ3.DY_/SO>,D*"158O 6&R[YEJ/EO\
M][CK!AGK?^]T. C8I2)$O"<^UR)5$6X2"YL!9S9P*>^?V3\3PA']9T*3U\QA
M%%&;J6HTS"_H,]:^^7W+%W5/7IQ,_E;O6S5C!'_F7L_ID*F&5GFT+]7W=%/"
M,)_]B#'',.OIS+I.4HAA05G P=\#_^IM",JST]_TLRJ;I1.,9^+G1$V#^EKT
MS0*F<*EVML3-&W=R<[;I-2O0FY_:[L,[%_&@J+)'$M-_=>G4=@_]=O^9MWQ9
M%@AI4*!7W=?7(:%)OY6/<;0OO\_:-F^H-0$;65[TWK)3/M#NJ.A'SF*>@OJX
ME1]]V9.M3A2(G;SKY-JNOB$U$1*DKS;<)O!QB;+6!2A[ZU5&C,JL-3\I?6(A
MN;2VVK*MR8S <).PJH@NC;\?VXY9J*P5,T[*TM@^U/&>^%:L4?$D<PG;N"CO
M.WEV<(7%+)< *O*#.0)L6[.Q(07*IN_<J_4\*^69V2#C2V+7Q]=Q PG!H%&J
MSI$;!-,^$+5+306+T\EY799J!N/ C9!G7.QWOVK-"WZ$=R*9X,YL=U45G>+N
MKU[74WIH]O@B8?4T2J[<??1H#UJQ /]DMX:C3\>G4%RH,F3ET0*G)(DU;#:M
MP.\C*JIL.+(U5=1GIV&I]=>^K\3+AP;,Q8]:RUR5-E<=[ML3WZ38-0SZ2":Q
MZC)31^4+;DUNK-L0K4"-#JY._RK T@>F)YUMU00()SM/L,P%ER!'V8L^O>O>
M:6.\34U1BW4N]BZ['DR_^7+<Q#IDX7-]YHCV&9ABDFGM.XAC?5)WA;#O@L'[
M![^QPU;PTL [*N!%H!L4=!&@(YW+K,HW#H/+\K[)>C5/F+TSM_-)U2TWJ:]E
MN8>1/-(TDA(LG=/-<?KE&O<'+DUBS58F0,7?M!?ORV W)=U8_-U)YR[!R"]7
M[% ID$7/NJ2@; R1CTN-S-3NXI0/[EK_WN?_-W5:U,BH^&^>\Y44-Y7TE$ V
MX,5%<X02N3W1PAJ*Q\Z^&G\62W-[EAFR5%QWXX.$HD<7\"4&Z5R+F.M#0Z)J
M/\P<(VYOG2HBDNY<V&]]+K0W]SQT7:GDHVBLZ-&?%04@F=S,M 8.^P\TT'Q"
M(_HM#4J5LYLS.'+4@P57-.H9">6AX7D0OPFJ@P9TGID(\>?2:G!+,!5L:V14
M1_EK8)4NIG=K0/:;AT(Q"_H9TYBM#29\[19&RNRI:%6^8;Z"CL1,H8AHK%$T
MV,V!XYPO#;<9]BA0TI4K+MGU9EFF6)7P6)Z $2W 0VOK6/5XXA.:9W ^1,D^
M?P&P=HC56V"[XZ'21UB-(D&HPCK>,@FC)YTZ);9%%C5.K)ESZS)XPM^+F73_
M-7;N_^OJO#:_X>JVM[C4M#--TO\*=(6$VCPF[."DS7 ,P>\G!&8JW,8=38T;
MFVIJ4'4S4ESCJ*K!6TYO/OD[H)!Q^^SPCF8@S@!TCW!J@.?*NE+]@)[$6A)S
M:U]4R_MJVA'IS=. 3P+6[H=O@\0NAJ5B"]W,-LO1"3O#(F,1%!M;__R B+.^
M0O_C7/,>&\Y8N>P2T[JXD:7X5._IOO1_GK6W+[0NZMPR=.2:?""IFFWC$(@,
MG-(BGLB1?Q&DD[)L/Z7*R!KL_@#.#*UY^+8[7CA.JX,,##PI3KI:2#,<9U!2
MA(%C&:[P1N>++[2B)P/WB>&;A$%HG'3_/FAI_>%;^MN <T9IFP)6U5XTU[_.
MV-V?"+XF"[& *CWLS)_-DJ059_-AR2R+*8Y7UC(MDS4^\WO_X!3QEP!*#&P1
MMWP) '>JTMB P@]OI&9+X9?300K]]=K3(\I'=U<0+D9M#RX!H;Z7 #>LI'8K
M7C#W5Z#(_Y0<H3*V4K@?X1'IF'$YQ-_Z*!,S;K7JNZ6?<UPH.;0K]IWJ*\7J
MJ>$QCT?69Y9WC'N^&_;DI]M]_#NF@\X5G?N#TI":Y\2_*KQK6ZQC[- OHE3H
M:-0TC[9:#$RRUJ2M2_3YO"VLSI\4P]A4%W5TECBW)"XQHD9<;6&]!-RH(]60
M'Q/2R#SS1"5V7DN=43V,4C0!*[[;R=@6R/IXV&V6\7I,KA3=GR-R$7(E%8[3
MO01$(RN78E7ZNB7C8,*3#LV6\MPL59,NQ^)WS@+2B%N0H^7Z7/6OOW@;4&IR
MNU_S8!A+)W_7X$0S%ZQX6ALQDE8J:5M7-/1\JMO2R7)07T+#1KZ(5B.HH]QB
MKC7PI?C?G/L"N?H9!><:IX=Q6>*VY5F4C=8F^<)$$5"R^;_%>4-_".3%!\,O
M7[3?%Q>;';O^H,VT38K)%IE\;>,TSFR,Q0[^-#'\\/J3FCS@>/4IN64J47J!
M)-TC.):YBL.>F;SQMIYD,FG2>46JK3J[!"0Q6'_^PT=QOQ?@AHCU3$>$RP3Y
M*Y0=#[%J3#[XQGP)T*JLS];[[+7,_[)]+?NSJ6[P/Z"HQ71FL;J%5>S6?H_,
M3"$$N18Z2K0CU5T"WD,BI)Q0(]UEDETHGPQ7.YK%P>GSY<B:BT_X_[@UXB9T
MFJ/F^4.,?6P3^@H1L'Z>ZT#[^"C$;9E6B-452!5LGV/^4GI%=,,$@@=CBF_1
MB&^K/E^EROR03NJ:\1(7Z[8(1-E7OH/\FET0XZ^K?YWW^T_I8S7^3T4W/CYG
M7GM,Y,#)!3NZ$/ERMU"TE15[KC5_7,NN/SG(,>%_]EB#4J5D,1_Q/O?%4[_)
MXM9TJ^J\Q&\_2].S-._++:74-3E-<;+E&TIO%#)-O-I)T:\Z?5\#Z;<^XQ'<
M N'T]\/9TR!"9OBEK'R=V+52&]YF>^,'NUUZCV*_WMJQ2<7MG#P@V.+Z3*,M
M)UK45F-?0<VJ!,O*=#T!0E-,G^ KS^+\?2K<<<O1QV6J^*-67^V4WLYKO)<
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M9_HM+3/^K-FS6?7U\4K"3/V6(6;!<DJ\,55S/6#G@.+ DDP=><4%L]/(E1_
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M<PD!?[*'QR4%V8C)X,4G2IDL&I!T#3Y?FT^^P'K)77F,/JI+KVUT)/I1S26
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M\,'9?12O'*;/O:'036'PPQ[ =?J/\$BT_R\RA:-@NR(<4A$L8_S3?]^BHR5
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M(VA@E58"*E^I;^M1M:<$K7DU\H72KD['@5%8CFC'SNS=IYQ3CO@.BUU%ZQ:
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M^Y%^IH9-KSNZ,48=A/U$;X091QW/@YYD&B!QQ9NP-[FTV")'9Y@7,$E67SR
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M.E,3R[ &Q)H^R])3+WNVRZ>+C1/F&ZF/=6ZV&_[W9[E9N,1(_PK;!/'V_@H
MH[]=Y)T.X6 IW8!PBEOI!@9/]PBT6:QH.Y(6!#9-4N4"=B+N7FO3>ZHB*\0?
M'+!8?]A"'K860YXZUQ,HEQ$L>+GQ&XA.77 3+=7BRGT5X?BYV_UPAVR>:KQF
ML)B<^3?\!F@M!]: C$,Z5()B;423GD_BO<@2L\?)*A#S$($CON2;"!^/,"[W
M5\DRE"'\^?]0?^0'Z7$B\G%$&A<.:ES>.CPIX/"%T<^'U;K!'1(I0>Z3J^;J
M_B.TW>9Z@HXB5;6I4I$*S,[8B/\F45D2?SKU&:++(E6,U@A:QB?%T9(<=^OK
MHW6^4SAWICL%O!2CENM5&W,AZ8[@Q!OBQM%W>NNARIBX X$*MTS+W?K=0%7!
MGZ7U<WP8VMWF,"NKL.\/#P4OK/2L'SMI?Q-LR1_P8JHZ:7GBA/@"LH,<+W":
M8.@Z*X*/L6)HK8.AHN7'QXZ5KI:S<5_=<D\:,%FQ1W//;K^RE+E[.K[ =VXA
ME][6H8&MP&U=>N$I"E']*\"9+0PQSJ?2%6/M@J3%RY8$Y^JK#FZ?")>U3'][
MQJ#G8>],W=#<K&!/VJ8C,6G&G"6/9UH=S-P-!46]]J*63,-;5MC:?G5=&.TD
M7 'BCCN0CW9F_(.F-J-5^(V?3+375:4"QH1)SK1!.8P-!_'>\HR/OX773^:G
M<*9@LGP(6SV$IQ$2YO@00K7JG=WKM'B/-\:,1Q'OXCPQFP]<L;ZN"U[QXOVM
M+I/BTE.&MMY1ZF;I7XRKS)*;M#X%CV/_8H+Z8#=P01NQE6L5"+SHAKZFM<2<
M?DVZ9H77HZ_=IWIB(,>4)P82+VQ/Z0*;F6Y<C#X-T>J5C!?:V.E+H\*KUS6W
M3+S&<"=T6%&WS!S=O>EZ;U%(C?/W.'<\PO15Y U%7E^?Z8N?-R>>,@$B[5M!
M-JXNGS-T^+-'7HO8A!2^"''[\6M-+%H&;A<*A'WZ4O5%01.]/ARI(&,;OQ?X
M[_=I:J-'TUN!VDA*1?PXN#0B)&(6W'0 !UP!:MT[Q-<NX:QN2EW-)2YCZ:^H
M ^J)4]/B!S:_-Q2;J6VEWE>0>.N7I$ZW>N;I'X<INY99@49^0J=PGJWR>M47
M2Q?C&X-1WW"(=51B@[CD2-MT .<-YGQ!LC</"]T]8J5UDE_S2'^R)V?&O45?
M$BEW+M61@UXXW<9JL#D:%3<O:?_N%]B2,] JH6CPTDM.RXFBZN4F27JR72<2
M6TEH@+G"WQ1RH5,;T7-]N5J)C7"F40Y+G,W>GK+H1PX]Y_P^SB\?0_C:WOZI
MS5"3W5FEO0*L5=DH3':(^Y01)ZX M"_6#?NI$SXIB4#:*G>)'&U--Y^VA@3D
M52N-%K]75M\:;!KCULN/;)%QZ.(<D#C^N*A7V76=.!KFL]Z^#28EU1Y5!UE'
M&40DT!.$U@'%6,)291%)"ZF5&V!NW.K+*=Z&'#T,S6P.!S_<04:/RWN1VM_%
M^G?+.Y4TF?LWM-@0H\@D9-U9OQ<U;J?_/K ;F JB\(]K6_Z\?P6H1Z6(?6K&
MJ/!8TC?O<WAF%NTUWS9PH"71\KMWG9Q<I#V@2B('H5W"4T50!?(UV&VG/Y2F
M6FC^6(4VN(V8Q?<D@>_SG@YWUWE@FZ<:4ICO&Z3W$+E6ST/3@GG3Q9BT=I9T
MR+APZ,%Q+2PEW:M;^$(259J75*$.S<_=' VD9RI!$D@<\R0RN.1?:+YQWZ"Q
M[W9%I>>PI?4BI&RQ]0312S\_AQW 1$0)Q>!!Z]5>:NAO):?]1&5<7AXB/M![
M[*C:MSE3OV0<^R$K.?U!PRVY!V4Q.NM>D: &U($]1N*1#6R^S))0^I?V'N[9
M*A,"_Z+4!I=FG$I.YP6J75BY KPX%:0RUS19%(^FC7B#=[X&JD*\*%H^UE2?
M]G4.*B?4G34TXNVWO6+M*<N-C7G!:/;C#.6<E" %4UB]%,FV2*C9=WA=#IZY
M;,-KT"O)%$BG$EZ$EYGX)]K^M]X#V+.B= 5X4_A7N6N"RVBT:+=.1TC!1"!(
MCCR462&L3=6\8=IKPK]=?_%IV/)N2S8'=<Y*^9(JNZ+@[/+&G,'<XHLI=U4I
MXN0J:X=AB<9_@VMD_HI3&RI5OZ_'Y0U<',5P-64/^6;HAV;[_7*=N^E2;)HM
MN]P>_)PL&%2GRLS1B7A;15968NF2,^)>&/'1X3,D3&BA_7/RXP$'$T5 !8J=
M_ OL1@1?Q"*H61A75NW*4LB *U@#Q>4*S(R.CB=4=7'OVO V$H=KTDMS+3C0
M:K7]LQ--Y]!)(YT('[ CE(;0=A A )7![,2K2&[F'<=WW4<+Q@=0$S@VGTPV
MA!6++%LMM#6$0L\<V510(M_5!JP_Y[G=!Y_\^SDQF5JM^'2(?\D:L0/Q73Y8
MT,'67ICQE)@>6H8(!;"?\]'3^5[K>9XJ#AVE "YZHW3K@H9=G]L9L@$O!OE3
MBCVEQF8!1 7$"'(^B$A%6HIWQNB?O5%Q7"='HQ+M/F8,*G^T=15Z*\ P_(?&
M^SO *>USH?9Q(D%'BRY^?V+&/)SM)DCC!=O)RJ(\K$=BI/9Y&96/+IU7Y4[0
MW-"QE^GJ;Z5$X:_"PI\3 ?\37[M,4'G(0U#;&!0A'@I#YE\!\DVRE=45A$@4
MN W_>W4S'O;1,=&(YL7 O>2*#!6''9SZ=]GS,DP,-NNZ/AXGYSKW/:*SX--_
MC#)JLZ#MT!FM7/PL;$_I"=U,^^#WZYI^;#'CCW!)V!A"N8H]!FF.<\30;^B/
M]P#C.)S@SB%?<.O5;XS ^D'BPZ\>2Z@DJ5T!G%(IV-(:554FNO\O]MXSJ*GH
M>QL-HO0B2I4J11 $I+=0%.E"I'=0JG3I/2@**%6Z4I7>0@"!T /2N]1(0N\M
MD%!"*('K[S_OS)WWWO^=N?.^,_?3_?!\.'/V.C/GG+W6\^RSSEYK<)P!Z[66
MA.;$@(\6IW ^A*+3&P!2UDJ$H"Y,VVW2LC-U0)DN/<ZC!1YX\8RW4ZCG>[\V
MX#I%2J X8_;%IW0?LCLA1T^5+:Z=(UQI\8\TT/S881P6H]$[RKW4P\&!#R]R
MD4>WGR74B]+OA 3\=)9";Z;SM3U^(XD.Y!YFKQ_3[GO^[3W_DSN!MO^BG9<M
M$MIMZYBZNM0-_=*2OD+)6\L?O=BWT)V[+*'FF6=CE- IRK;:L89Q1@=C#]>H
MFQHQ_+__MG'7JG-8F_;*IT];$_W^7#3)9XV.##A S[Z7"[>_)M=?B6!P2>G%
M"JW:)G8(Q.DJTB27X MPE -HT4_:K,,I9I]9OQMKL8*7Y:"I8,I_'B+3(3UW
M]1SKF8NEU9WY@?<NW%T5C88R?88XQNE-1+6W?73,LAJ:^!#DR590Q)_S59PZ
M4)GC!N YCCQ>R2OG_'0E@9GJRY/ ,I1X2E&.D^/?^.O>1;4R)##BS4GFJ7P\
ME32Y&.3DH)7*]B!4X"IM/[62-?]JT@?E%>N@&% .TDH:[B]<O'_DKG4[P9[O
M$SD+8=FZ0ONJ8_.]DCQ^Y5("/&5S#]N7=\'_&\H(GN"X6ZO#:Q6F-?GOD5)7
MZ:O?2=V^J+ >E4?^N%00][A/-LQ%]!XJ. NW6T+1KBE_SGL+9%^U_9A/=<BV
MU7DW:+7O4*?A5^JUM=(PU>S00&S Z^<DI,0D'5!"2X<,^,\U$7;?0OF]?_NS
M$]8R]^)C#S0U)!+20Z>YA)6$P3+,ICWEO",+\X28<-Y86!\MW5Z(^Z(@OG?%
M6F1ND?S1+]#GD&I8&2#@5S^.<EB QT4BN6: )&A,0H63XJTR1B\)1=MIP]_6
MC#== =W'2QL?SWJ$T+*Y% BK+WQ\@FDHDN@2037%]1D-@$W[:+E;A)5QHH06
M?V4V?(!Z4C_'W2"O.&M\_@ML;WM4E7)+\DO$17!S< /SW.<1L:&$MLJ#AWK@
M>?P_TKSS$E^(<>YA5+J'R=QO7DM**)>&.A:#H'BMP^J?=;#FUMA9#XMSX9,=
M$U8%V2*WULS%WP)V >L4VVWA_XRY9TX>8<*+%S(CVV3*\8TKPDC*I7M,^2K)
MD$5?0CG;A=E;:;18\L>8SJY_HG,+2@\>A#?^&^M6@$_J3=W+KT^*_#FU%7G<
M;1IR]%<E4USR$5/&[-$%9IR;6[/ *(XR-:_@EY_HG 1N$*N1V !B").> *I=
MRF_+! 3@NM4S>QM;&I.?U-9#>% NC*;R[HUU-<FJ0QL?W_\([[;YCOV%0^.W
MW%;*3B*(S737A/9685JKH&BR:YY0@0FS\"Q+_]K&^.#>#]2M/,[$D."SWQ%X
M 2B:NF)GK0O\%'-0B*D^!*7-YW^.8( LO8BQU*HIZ$-.ALL'J5H&JWU/,0#E
MR=(3_>-V2OAKSEBFVJ#5K;7T_EB@^:K"\'=6-80_)\,_@DW&F<W*20YK9+CX
M#?3\6)7CMV.3V**./0;]\^8N.;#H7!!3'RC8=RW<M%^W; ^ZHE.YQ/[7JJ&X
MTFK,[S-D@_8ZB?XNLP'O,=.0FK%LG]NV-><U!3'6;D4C^F0I&K(V_!4\UB'S
MQ_-1MD9+ "#NFXFPQ-!;Q#M2YLN2IOS/<!@G6A63;JO=C#=4_I)8S-SVL0<G
MIN/E5M@?5O!VI2E:F*N7YV]5Y&.=G%_JJ)8_I*-PJAN /2=> )(9O5J+N-)8
MA7!:TIU'(/O[9@./^[JC4L\"-[[8D)T?>>--;G/6R:"[,,>6V:;8K>X%7UQ1
M;>[8Z'T#[&AT LX:W:3%=I'0>_7F:UC%"WLH<>QE*>XUH45)*4P+*Y*^ F*\
M4L;,7&<&>GO=7A2LP=[Y.W/5S&)<\N#>]BO+X)]FR4PHP!B1IZ^M#7@ZY##.
M;YP\O+2;D]41+QR /2ZW";+70SP;NA\=\RJ74=1@.*5)L8P8>]C'63N.=L9J
M:">NJ6(BT$270#/).PX8V,<;P%MV$FMA$DN!C !INKN?V.C73Z'R>(9+[NM_
M\N3.-9\+= 4$P"?UV=Q->J75(!S8ORA?VSS#&]@D;J.]&IKM_!V6^7"6FY,H
M^EGUS+\XCBQ<\824P:*O18):<1E,J>1%'7C_Y3WK<+]&@?+U78N0_%\[*66V
M8C_B6\X]J[5$U#3\L2A<+G8>M!::CX29XKU7L^UL$"LFE<OMXD.[*\OG=O6Y
MP)Z@C9PRFH(%W"_.=A7.B;,H?L1!?;864*OD68FKK?,GD =]\DBY0()JF=^3
M(I*! =EE7VLU,&O01]Q'_!K__ORB$/8]=B$F*5OCF.-2I:XID;;A6^T6[],X
M8\K6+<!S$MEMH1]X#<=+'7QH)\+V7@<?>"H$ HORDK2L3)\2"9-R]BY'\N)\
MF(<(!6;SXW2.0L?1BX5?O54X&R1-CYV7E1/R6:_LL>!^+;SRI2D^SF!*KYA[
M+P,LAH'$OZ)4X5L=&?8'RP1WV$B?1X@$LU^OM1)*.L3#Y/$-*Q%$>Q=[04?_
M-+1S7L"47Z5.Q**J5!WC:-O+^2])6-H0 ,&EH#F);.\X*%4--L,_=2 YQT?9
M@MS0'E!ZX=%S5U:A7:CTOZTP0E)W<-NA.C21VD339H&Y4.==3^TM+5*P=XI\
M $>NZP(]$96HT _QW@T9_WE6SL\W ,4*U__Y E1HF/B\^.AM44_ W[&*?N#6
MQWSM#CHC0$4%J0H]0.D]E6'9?XV[C2S\6JC\3+/W+J-'16&Y+#''9J[F4#5%
M7;3A--W7" J @X\:OYBXDGS:PUI\;"K+K@3>\)[ ZFV-!S\4GY?I7QAN_Z=[
M&=%3B1RJB[4LMUZVPGOJ*;0::M[G3R4O!&[!YH3?_WY&!<;V/D@^%Y82EE:?
M.#_.[;GJO78<=Y1=8V\7_'<OMY^2&8F<?4V4T0P4N\CQ+]\N>$_QDFJ+6*EI
M,^-_**G_*_:F__,]QQYU\N_ OB]%9(Y>_((C_?[OKN==&^JR P[S9 =B_9X*
M,[$"MV17-:]WU:M"TM2LKE6,TO[GC2+_3V"!&2R<!Y)]%0 )OGKD;,+I7:/M
MP.8,551(+,3W_F=[0E>9UAK\KM9:Q+TKWMI)NVF'4%$8/E4%PS#P7>1#(Y/I
MQ6R9P4;80J2F/D_HA[3GE+>4*P^17GW*]\,8,'MF,]>,^ A]+.?G'S4M*2B]
M*?>.!5]@^?VT1-D7!AF!LJ]N'6F>0C= _T1"/D-0=V\@SI8!OOSU!L )%EH<
ME*P,K@S*7CY' )7?71Y-(1M.(3W:@;3BY/?X'#VJBNB^$OWS_2YA)<%K!-(T
M?G6B@^SJ*5X,:]DIHR_)\0AQ);P&I6G\^=/E65K<I/UL=<+*_:*[R52J2D[>
M'VRG0/'7M'-A#IB$CNPU-\.5W!!;[E7S*L^?>0=(E2J^Z,=K P+,\<M?WU&#
M]2.ZI*MSI70&@:27+$$PG.ZOE EX/:0AXD[U!\9BTFPZZ>32N15C!=QPK89F
MNYAMZ],Z$+W"4'=PC6/1E[#?WL>O.4).60YU72?A(I6FH:**(B='Q'U78A@[
M5.<U,0P3D _=/6.<_37^SJNHB=+GM]$7[5_VZ;>4 &>;#1UL._*/4H,C[B16
M2A%607')"DS^J7;OQN/%*!.WRJ$:,R59D^,D6D5.-$7=MP8T.P$,O !Y@ELJ
MQIUQ]>)B598[T=QI_H!;<]VW5MU*8 ^?\V&V\5>43+B]4%E3L=-)2+.:]NQ.
M(>I'ZDREE$-#P*\CB\6]ZHQC8.G:E7Q81BU+]99EK8 TKFQ.:\DM+.&NB8CT
M^C+=5$-89NDS<&]/>:#+<5C&-N2>-GSI[>?YG@ N;+ZAK1YXTB(#4H+L\BX.
M"FXH+T@31YNP^D RCDUDWA+(]9?8]U8I(SYS2)ES')M@E J]O.B$+K._;+(=
M*8?RBM6]HQV25=R9^EBWJ?LH.ZGU0$L$9^IQ$HIS*TAK-LJVT/B%*-5PZ" D
MO6R&P3X=Y%C7MZW*,;?9ZM.,E"L.GK"_<^W+%AZD*2_IL1MCF"->#OV0))JS
M%6CEU-8"BLMDTEU'X?E[9.X)L+95@F0\@S@[;C<#_7A^+D_9XW\JY;&?*E/B
M^V9X-^R3='@V^FC(_);&0@BRHX:E3)Q)2PL:9W6Q*!UYC^J*L<N#7O+R8H$]
MQJOZ$"](_L!)=KOB@[6Q]**$KO$+R17SD'<4ZP_9GVH,!4L5LT..N)KK$*?#
M+B0L$5-\ND6^U_ -/7EGSDSNMA+$ZE:4IW$;FK@O8T1KM'<QA?L+B"L%/-E9
M'9KSSDV/,]:&B8+ITF"YEX#XXOVQC\I)MRV0<]UY6+Y1>PSI4U3H 2V)PQXS
MU=?/.S*QRZ75>Z=,>+'67V6U)[G L*5Q58Q<>2)-J4,"8<V>C@G9+IR/OV]0
MG/>1 3S7:;RMK[]C43TFY''9_--S1AY"[\[MY,:4?&X ,=6AB)&M?B7R#F/J
M<A=,RK-C$4>CKG'KTH?O@H?R:#W=GHLR!"FQ<#]>A=.F#]R.<"FC1,BY.P+6
M?G!J,Y##/.1:U$(G(_@:X&V(KX)?FOI7O(KR&JV-H1%=J%#.U]LW@'HC\<91
MYV=Y@]X]K46D2V=.PB-B\^#PO3]^-X"$#J(.CZ3*?@]1ED3C9#/GYB$:91JW
ME8_5>!]LAIE4N,(KM=LR<Z=W\IZ"5"9_D1AV 8BFE*(+4]Q8_K91OHX-HH(2
M-T;LE2[R.N^<3_KEKD)#M]$XQZO6W8MMW'E&[B5A'*.L_A"[]/'P;C ']Y1E
M!$!X_EG73K0!*N9/K+6&QL25:=%XJ72Y) ZFO5+<T*(J0/,T0):*A%1/=A,N
M_S#Z2-S:-L3'2"59_2];6%6,B(]\"NVS/ D+?;>LWF0.M</8JK]L(H\R*-]T
M;M'-HX7R?&&DU21O<6ZYW;D>A5JM[9)3SM6P*=W?EWZIES*@F5+$@=(YQK8;
MS=IY$681\%UX8\1;L&(X7"#+A^FG"$,PT#GV8._X;Q"J]ZGYDS]!A:\LVRM\
M/!V;MDJH]%#A$GVR##ZT<4OWZ^.D6J>EF@ZJZE0>31)Y1Q$'K&PL._B]7M]2
MFA&DKJ]NSH$,+>1#KEG#?E^@(-!?*(3]H=9ZKJ89^FK#JRVL]R68%#IUY9J-
MLCAD+7DJ\?H;HYHQ[P74,'7G:F]%(,)-:- ^;URW,?+0.$:LMKG];GDV(+Z@
MFTN/;/F6+##$ Z^*B\1'/1&?#ZKLNI <W1R:/4*Z)G = 7^_>:(;;VDYW/5:
M(OYTG.]2[G)HB>8"NG-535Y:X5*]?:FR\X#W/J'^KUG_.YK#!F8[<U_"H03K
MK\,L<ZXDGR&1ZJ&,VV3?ZMCR<<_6+DQ'L.!)[Y>KK./D6O%H>X:N+"4:&N:>
M9F(H2-MC"_UF.?<AV;1?^_,>4>*0OC++'T;#5"E!^GU!#"+"DO5A@U).Q?#B
MTZ-YY^E+/@4*>0_VL)[Y=7MVGZ>N ^,AYP^F<#!,20$(YQE7L1#%HLPMHO&R
MW,1CH;TF0M&14.*W1I=Y39>K^?I#37+;NO/#T"0;UV(][Y3X]&PDP7"/$/8I
M]P)L6^B&52HLZ'B3A$NM29<IC6Z@.OD[0ISTW+3F;-S>N)10E ?\!GSH[R-_
M?>!C'IY#=FV('L>/\V@?#"]N-,P<P.H64 -RF1()A/5J1*I23L:<S;/'60ZH
MI'1;\GY@O._Y21FQ1<.8R7E\-GR:'.$9+NU_ ]A##)YQUH=O%MY'#2Z'-GRI
M@W#OBJ/2QTE%DCUOAWRT2L_LT3Q!OW#%M:A7MMN.F)7.'HIX'-$$IUC/<1K)
M$1Y?RAQ:EQUMHSH(F8(A-X!NS\<ZZ1!1,&JI#@3JM:R.03XH^0FQZ$&7OLU'
MB@OP\5PZO/)2C-ZZ375QPCRN:A/(GP#F+UY_EQ05!?F.:_^#9<\<:+Y<-(NO
M[=QBN?9?1<#9KJS#XAO%+%Q8.)_\TDOYL*V.#Q[85L[W#+QFHNTQHWS2\;#A
M&XS"8'+Z#G MF4FYU+5L,BU]Y5"IUE1/P?4@99; 2A-4ZH3>@Q5?,\YF*Y5=
MYB&UBF&1YBN7P,D724]88>?BXI'80V;JFI36]ULLY7O+)OAB+-?'AUCKTA'S
M=&#VNUW:A\_)SOO;G72Q3/U3M-(@^L%-#LWX*H^IZV !"L6.;^-6B)ITZ$BK
M0KF0%G(BQ/,&H"KJ60UEX3T!J:.F=*QY%\[:ZV<*3X1SC1R_"9SRTPM5$F:I
M3^2@HSKC+$&Y'X+]"9Z!G@6L>SE49T<][T44-51H2!D.\HG]$^QPJQ$-KEG%
MD^?N 5:Z?'^8'?O"$ K>4SP[AR_*9(?$-DU3VA?CU (@@:(=CY7;YA303BV[
MU?D>(NW^)\W9E_]"XB U_""B05@6?5VQEF/Z;]6CEO3^XD7V^I99&ROY.<G#
MQNVFP\56953VM:8Q%IB/5M #D1)T^TOA6U:V^WYU\V'4DU_':@MVSQR".[G9
M>KTFSGFQ.U-9G<X+6;(+Q<CXY&_C>@I9C<*&I")C( T[2M$_EP$G59=>XNP<
M8O2Q[-P*#B_EMU+$<ISWT+:T5];XI+4DVCU#2U309U1%!T\\/>QUT:T?W)&L
M'S_DM>L&R2W1Z0^\T?-W,:Y$LS>[R'N[5$JB<C(SOBCDZW<#Y6)7@6HOI5E9
M8KJ:1)SV*B!#HV&".7SA,U,I1R\O9^B?-XE+$"V,@=9>9AS,$K6X?2[@J%X)
M(8":KO:.&JZYKU1G7B_= ,@#?K+*COWU+#)_YJ695K$UQ;EB+A_S)<SB(4BY
MUV+^L%F<R: YN4YS4$RRR<9'3]Z? =L$O?^T?G4#=$<!0BC6K$1/^!0?!Q B
M7G7A6;_9Y? 9?GY*;A1R"91^=#8%"A$[A(NT)\U0CM,'A?1$M<Y*HGSZW]Y?
MZ.8 60%&R)5R%4,HMKR4>(,$!U8](C2(D1?WEB)C>-=0L W;;_=M=V5V(?X1
M938,"C"0OV0K+71L'5H2+(LK YZ1DKK'E#CH2]!ZC)%S@OHA0<97AF6IZ]UE
M"Y77V*9G.VX^:N?*P>UGBK$<MZ9N -_B5XQ3%M0C8[?/TI&!1Z<@Z,Z+&\"#
M:W;+==CG)S7M*;HCRLL QO$:DJ:X&P"2=850*?;1N*/)\WF1R9F!T+T@YD3B
M^+R8'U="QX0MTR:>D2S^\6>%**"Y\LG"=TO F=#%),C7RSV)MVYG(LU@,7QC
M=V>/XP_HVW,24D^)>DP(I\6Q:U!V@FZ+X2='WNIB4EG8P<XH(])T=Q(^G^1,
MNAS]#)01%&\C7_@)LK\B\&Q0Q+IYVS .[L^_'=X0?FD8%*&34.SFDJS"9W,\
MEL#F'-_:4R#6;WAR0.UMRMF ;;6[X(CYN22?0Q(>,"LNKF&];@]C#Q?KY*3:
MXP!B/M2UP1!A^D5N^NY".&II,^<VSJ?G=A3Z16\B@]_TRT&_;4U?T06N2D90
MXXE7<84/[_G:NP63I*VW?+7J+MOG4?;;WVEM"&*&WL=GI#4_7BT;;8#(/Q9,
M4 AM$>I ))P=*8T3+4-)9@R"XJF#9*N]JHQR@__4Z00^?I4PN:!;#&Y4MO2*
M<,EGM^DKO132JDGRYMR^2//)B4"8K2,7@O3'PX[-+)+Z;1_8]$0NF<7I*7@+
M9"SNAN7D,&]H%9BP*QT$L^^M?!OO20#I6 I3=K=X?8)@GEN[78S.9_W.>$7<
M_@EG4$8!X#J_ 4AXLME+#;Y=(@,+(Q>67/^%X#Y=0]M?>8:B.*7LPK[R4G6Z
M9S!8GM"GP-N1E[$\M_#]#,?X_+M-K70FU\-,O(7^\O[T3[)T,I.')%HZVO[
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M"^9X.WN<UZPIZ@8R22\]\"Q292]];P.HD&::-7$"$%VV)W*ST69Z7YQ)X>[
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MW)%PIS\L\,;*\QO K8/U>CJKZ&GW.9GWJH]CU_+,0A!BEQQD-X 5;9=*7]X
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MA='20/._\)4#-3S(<+S#OUFK^%Q(JIO#4FB5S7@].6=/8S>YY))Y-Q'G;S]
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MRKV*5L9+..L$WU&",)V0.\I[3ZBJ%,66@8A5D)U/2U6?;ABN>J,0X[W9L%7
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MI8:=ZZ*$,LELB$.8=W&$4^#:\96_>1PPL0!LJ.#I;,NG"<M?E\\<1,$Q]',
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M"^0F.FF(-X[=2#?ER7*UK_<CV>\)[PZ>:/-A@'8E8OCN,$_V>?A-FN_B'5D
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M)HV-R8<F." &_LU1BDVZ"=-<Y$SWY[E01X]DKK?$EXH-\N0EH<K-S\Q=Y ,
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M\(1#B4*#.7"[VFF'2;753J_RKZS)@!TB,2HGE?8WIPRW69:U^F //^ ;&V&
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M ^J',8YA:8G49//GZL<H5YTG @J$LKJ@'DR\I&^<#%96QI>^3GJ'YJ O#UU
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MJ:#O'(M[EV>W>2 G2RXOM"]"&%I%YD >6<*7X[)H9PI.F1,NJTU,V#=GG1\
M-< PU-R;#,?*/\1C18^\%I1,?M\!/LRXI" 6^4)_9?!&FX\:YTAI!"-N-R=D
M_@X>'=\!\):1ZQB:SIZEJ/Y3]L.EI!B,=G&%S]R2:WB5;1M\^XJW*44S/V-Z
M=9P9C^0Y&<%;=2TTY7^S[L+^!<.#:=$1?IMZ81T/D<J1R25=/_3BI%>U1,UW
M,EZK9 :=/;-99F!_O:)[E)B.L/-K$]P^%X)&I028I3O[0_F%4B)6TU9XA[1R
M*CM/6>;'8.X]6$9[=#5UK4*(*@77H-U7(+ZF_KB$4=$G0_T$^5?Z95;4Y='Y
M57]2XU(:&L0"3?[K@, HH'T+05$?VAZAU$WF=QK>QYE.2>?:8*FR-9?]R\>\
MZ<MB'CVOS\TC"Z4<?KJWE10)0SH3)F+%G!B83_O 2YE=P?<.?Y+OKF3%/%T)
MA)<N'9RZ/XJ<OBW*UDMV35EWM @;-WF[46OC?BMR&P/::%AG[1"#1BC)H&0W
M[P!1@:8![F6\17TPRO/#^AOVBZB=#F?'6]&EE_+OG!L']),08\&C6'B>].UG
M#/F&!E \$(I<R\<K>%8W5W4DO5AOKKT_IRUP,JHFRK=+^ERH'-\5EL'$<R'3
MVVP?]:5ID"/5>M_Z$:E6D=)["Z%G1I#"[:MYZ7I'B=R=*>6HK<QHL'8>3=];
M.:?$IG(&0^B7X4CZ!*&F#Z_<J0J(>MSKB835!$N7W"'E?WD"P3?"V&%V^GN%
M!9GMKQ&@ U 4ZXBBS*B,Z6D.LC=F C-B_=\2Z'D-W(/X#I3:*-=DK2YNHC:O
M1)2L-Q>J93HI1TJ"&G#V(&;1=A(5,1GQ@YSZ1!SB>HY8H#AH8_=TD6$36W6M
MUPT.97\\HR1O[S%WF5554+*X8OGE4>H[+;N6>>R<[BQYBJS_7W!#R,]&#+WO
MI=5MTTEEF\R&+XH^&W&10+Z6Z5?$R!7Y\H?&Q]D]0[K?5JQ[\UDW67X-S'5%
M'T?^[,R*TK;#E%^_N=BKDSUSO)U-VEGC_-UT 2_*VOOJ8ZU;\>W'")..IE'"
M$[AI!+N&4:VO1;)YI7_9'<!9',W+<?3O1ENEU.ERC1;6&\QG;O+@4(.AX:#4
M0OS+",^Z34LHS7"QECS.T\OJS=K+B]MT( @[V$E=GT1^$$*!<?;>;'4:>)+'
MA5R/NM!1>5>32MW/O<(2<A%#4^:YF_-8SN4"^WUY!ZK2:+"S=:KU6*]I4"_P
MXY%P[.SY/:'^$S_G/_>UX(^L9&Z'27[ALM7 <A-.GCD$>OROB:U\:#3PR6;\
MDL>@R8BUNG1ZD9()NS>=_/#0S622B+A7^\F+M;;Y#[=1/:=%4?% AIVS84FQ
M1_VO1FR(IEYKS;:7%VF&4 L9%2E421[+CRR6"S0MW &DUA=8+D?O+9VZ#Z)J
MD]J<",M8IP[T_LY74&*^M.]_!X@\%3W>"=6A%C%<;8"5:A",$GQ@]3P [Y_>
M !U#J --D9U/9SL$]]<7V<6:ZAI2#>"L+=E.D3%F!G]5/@R.I"J_L]@X/[3*
M_H[&[<EC)W4O@:KW+%E,57]).5"0B2B,^9@[C%I6&U9A^OWVZ0E1=;\X6H@?
M0V=J?AN'80H)V1"0%C4U]WM;DR@//Q9WXEWM,^D(&&AT#RF3/%62U6OQ#-^;
MB03W0C6M4;.>"L@T/QL]\M-G)()B#CW&@@.&]8UQBV#GP+8[0 PT^X"A#_J!
MSSSYK<.>'G4>MV2EB9'W3G26Q<5ABU$9B1!D!)%W5@.,_>\P(:1;X8)R6:_'
M\,V!E7PSLJ/YW:%G\:#TOU\'*:-4B$4_NO;A09%@\U]]GYM6< ;<P8.$QWKW
M@;$#C;KA^>,Q@5BG. @6A1?F^40- %GAU;R)H^KU&?(-"]&CJ90Y4D/).^RS
M)PJR&%:I&Z>)<O(7Z*0>YH[H,X:FR:TIWK]9#W2Y2!^:1[[5@JUJF"=N,&-A
MH(ULCOJ\RANO0+'9B\YH+"D<D3AT1.VD-E4<MN33K)UP1CL;GR*!0T0@2>L"
MG#U[7<6TJ2N5\,8VW;.-W6[)O<_$8JC)HW5(G4;^V?(;K8.@;(<0,S=U*O3>
MN7CWAKO?V4:>^,9UC$G?>]JRJ=PW1GTRN@89PG29SPH=^4X*AHRUL<&JRJ!X
MCE!P?>:Q.Y(47!>^R1';%N+J)+I"-53<D.OK6=29T1_85&F7"+5Y!S2QC9;8
MH/:)Q:Z';.2LU_$?XZ F-CMB?@2^0P)+OENE/:I?-22VMK14F5BR"=,6AFYQ
M2*G1$>/E_ZN&SF- -VP8[GG>N7HP!31 <][.6%*T(P98)$@E)0FK-3>W5&=:
M&8L\@_,GSNZ!Z$.<*2G1OIOKT:X=%!"%B+&U3&NIA1&^<.7T"D\10\DKMPGR
MGR04%"0 /9?9\Q7>GJL)\E=A@_;U$E^TW$..IKWM5MARO#QAPO5U=<ZSL)3;
M1\#4-HGSV#)F>?[P0-X>^5SC9Y((H@!6OB=I^8P]CMZ/TTJGJW76U8UUZM+2
M:">F8H)_/Z66*?L" /GQ."RR?^UF7SA%9V71/?WVUCZIZ>8.P/_'\]JK^B_]
M;1EHHPZ&-#Q6WZ*,LX]"5$=C:(KVL3PS'^IN+'%[_+U7#-Z\7M/$_RGB-;)M
MLZ,6T=C,DT(I3W?]_!Y8A?>@K WIUN]0Q'@@0\+;C,H=[YV4..3'04;MZB&0
M9?J\[$1D)X/6QX^S 1[&\$R34VSE^B_864^YQ+"B;( QR\"P-FV+/F\HH-SX
MK_W?2.N-$W&QH3E(+"*/!B:M_*.WE\5@-M5]=SM*AJ7DTE5@0/;&Q &+TN).
M3<]YR[$5Z#Y1#=+]4GR?+5Y\8=K^K++5R1' L5=IC_8X?-TY_3;;LH8Y")-<
MEK7ZYC4WW0A9>>>SD/9SN<K7F^:^BM3JJS,GO]FW)3!R$WM6VT+&;>:I.:RF
M?2EK<U.65Y<GP;)@2OE&U?G<@PE_0ZMQBX8;74US/>_2]O-?<DG<>[Q)):[Y
M;.3VEF]Z%L4=$PLO66((IYYL*?G?S&6?"OG@-"4FY'7N53YY)/"4=[&U8W0+
MN'@\7PEAKOUTCG:N;IN;@Z<+.Z]B8"^+(GJ-(\H-"JQ8Y(PMS@*<_"ROK&[/
MI?+KB'!BJ!=" EBW)LL %%%**%/$"T#HT2"C_#MW>+%>/4T/'^ A$7M1U-E]
M?.9P=- 397PQS!HO8#/8V'EUXMB<4UWG,FUBUFY2X^-1X]-0;5E9JV]8/,<>
MR9XN(FWC559EWK'R0^AZV93_K-GZE4#7!,)3S8^[J2+265,7SOO3(H>JT[=1
M-.*_6U12J_^D.F31EY=SR:R.):3](Z4.[%Z266$ Q&]?$BIY'UA<[ B9^'AJ
M'H[8%58TN%J5VVZK"F'G6GI[TA!7!11^3<]@4O5IMJ-7>>7?%1KEC:)(@J R
M:</Y3$5Y+!E#O9*EW%4$\N,$A%;AE2&4=P"D80A:3OMR""V*BNL/(0520,U[
MUA[6(B^F%\C!EDALF4AC_%0,^?!+^(A+%_&#L-+R-,XJO^J43EL06IX42\(.
MY',(ID+'%*!I$. H&7.TSM$<,^_DW#3I2,($><GBB;/H3%_23A^O8:_#RNL]
MX$NIHQ9C5GYM*GEX>DY0FEF<#G\PQ!*X=MK687J;%Q668QL[E.'ZC+8]PDSZ
M#_RU?\=T=6T9A==Z;?ST](3:E4MSSAMLI(&%1ERG*!= +Y7,49-C=8M0N6G?
M<ZV3Z@ZP40UK5!\47SC=I"] P#ZNX<^[>E_-K2W*,%8 %^D^MN<)^[8G\]2T
MZ62,"&LMZC\HD^\:"RX+GK@#,(EB9="4&JBT8.99S./KA(BB94C6J+N*+XT>
MM8:- R)+G\A^0)8]KWX?*(%,BE2R+5J%6 E-/D)19/N2=KO;^[KB34D;/JBB
M_"(5VDZ2DUB08ZHFYHU**V+%-XU(U_!47^:M/'8J&MV:WVP%CRQORH$9/FVL
M<1681Y]=^XV140B!7G=MT98/-/)D2J;93^@6'5?P0D7G3M9W/_K=$Q/$O?=7
M0X+%XBSBMG*8*PMEG260TNQLTPDK^]U==;^G1IM?;F\27VEREU4?P;!$AS?!
M&(?;7QTT?SKXT:<;SGK:*+ZL:XLG\W\A$,=:T>$5O^D'#2;/4ZE9\=ZZSW4,
MZ:'YQ8]>K/$UHFP"'R*;YD7%F _$OLH ;'+#RVR(4H^.>QOQ2?["7@:E;MP!
M'D"?=S<D+T!!SZ;.+46I'O9" *'6.%3Q@/R&,#=S_K_5LJ)=NVFVO-']DQ75
MITVZ1;H0F?HB(MYE6U>I\W&E+1@E.B-':'M%W%2T3\']$V0RDH$\LGBV:E.(
MSO&5Y97\*^]:D_6J,(C= Z^T-I?'G$+-5E)_-']OE3"6:V]'4E!Q>KB]_AZF
M^6] -^@66%P^+'*T8$'T=15K^.Y=;Z*_RY+\)<=X93&_<3H-4S?.W^0[P)]3
ML+JF^5;-64)SX.J*4>O?EQBQ3D6/=#;.M;3M94A(K%*MZU3U61W%TST@MJXN
M_&,BB"*M;HQ^9!+RPN4'Y7S)SK-O5CF4NKW[@C.&FJ(I5K'KG]]879J>.@??
M]L0*%#_^?Z:L_9^N:J)[UG[*A.Y\F@CO7EJ<<MFB87K_\+9DG(SFG;,+ R,W
M=YZ_:>NL=M/W9/6L^ W637,78 GW7-+A=\P2.."Y9D/**BQA'?D?;!E,6I@3
M(WA7YW-O*H.9Q!]!* CX!#(V;3@OU4&^9<K OVB:#8YH=AIDYZ(2I'H(0<]E
M%SO^!W+2][BU5M6Y99O>@)HN"? 6)U0"_!1<IVN=0$4[\* T9]C-(Z!'5YW[
MU 95_DP[GWE0TKPE79^:BI-78PO_5_SY-LI,P4@3^"9@&=)RDN4LW5(W_*I<
M_DPK[7M6FZ,F4-,\)" S4X]O/N"^7J"Y ]B(+Y4/@NK[]^*#60-?HQAZ*,DL
MH)'F<4[MH"Z3E@Z8/>D*O;IY\]Y'-AN\AWV!"^5@UA!K\67*EYE:,S))2Z"^
M.T =GO./@SZ'?T"2<)W(OOH515>\!E_?!,9?<CF/$WR^1&EA/SJ'QM(M.O,$
MNK,\MN-(U+@-_DI+Y:6+6#:]^2$9\E -Q'T],R [V]3OUSGD<@?@9IY.I^WT
M5<C,%#^YLG7B.5F7-*E=M>08!PV %V&(^8A*)?E*C"I:I@([>>V25R:]9%N)
MK949BW?@LDL4?:*HF9\>;?E=UM:B2E)28HYCB7^#KW(#W:;\/:1;I$/,,6L\
M]UW6A\NLSFY+A9Z>@-;7JFWY,@YSB%T'LU=O,T4IOW*]>_8MA?"<5&G^0X1S
M'\7"QLO*1F7@!TJKS@3[9;,U?(@X)SQERUW V5!5M\0%BS/$.*ZXEW<17VX0
MUE9NJ'7IFUZQ'I"I-?M]ASZCS$QW;%U'UL32>_(JZE*J/7)KTR2A<0.*QANS
M<4["I<W@@W>K<LT4-C14D'$>"^_$.P_27=+9JBIWXUA:_T4"WQOMG%S#LI/A
M&(3RLUWL*O=CF=)W^QP3;S2ZN7W61;RY%3W7F4I(TOX(P\N(%Q=+AS2KE17\
M$@J;*P5&,G3%T]>-G:O2YXK'Z&A%CIEKC\74QVK_>V./PRSVQ"Z,:]] 0_D]
MF>G94YW7<:^,S36SH.'-:CP7\8_!0UTRCJ$D@L0DDAJX,SF4HY,5%9(5C/YE
M>,'O0NEC2WM>9[M)Z1(/=.^$-BO[XPY:%5<^T, +4TXR>$JJ2D<+'WR0F1Y;
MNKU!<PUP>& F5&M1U0^=*C3AQGO8'H#99L^9C9 ';#$=']P_S:?FG@S3/:_[
MWQ/]C#OF";.W3X%V[HU.(4HV%^72 $/6Y.ZE('?8Y/344V7C^OE:R.V?L<!/
M3+BI3==;',-M-P-9/NVE S3:OVJ;@5:@:;'M1J:A+2]W#747=>YXTWQC\YCC
M[[8T*<0W_TT:F53_6W*(%D=;.V:V5,U6^MR[JIG>GGU('_H.8("V1[U#>(HV
M1K4]'F;AU$.T:[)%R?62RV1QP].&<!.%6C"2Z*X^8B6IC=M0&QMTM4&SS7RR
M2(O5Q>"WC7]*N&"'1X;?JO4&K^=3T?\0=G$;Y)E8/I1>Y+D.XY,AO'^*%T\^
M)]>I0IC\WKBQN%,]I%@W R.5+B](A=_< 5([O1 %KL8V/80]$[&M(Y04T.??
M;A=1O$AC[HX[P%&/)D;B8"TM4 +=U/^I@PGI)!9LV<'3;EF.AKRQ.4P]/@4_
M=UBG:R,N1[MPT+Y&1PI74D-X8F0(8AW2"Q,,"O63F(&T"CG'>TK&BI0)G60R
MB@6VMHA6XJKP3Q*4$N;N@ZRE%[25U4].)VP;1FP;#L 3AGX,?LK4G=)5E<X5
MLWE9]>5_5B<>W $B3%'F-OC(O? =GAP&%._9Q[QNM2\J@V5_ &,2P708\\4D
MM!J&C>D"3+46"MK ?8E;(G.^'A_, ]7NRF+M>(2B+\,O_DK&X0 )[(.0F2N-
M'1*YRGQ\QFA-++]AVIO%@:&MO71'R<89]2[I1;>]C-3^Y9+Y+X^M,^[%RL1.
MI%-Q+=FCH:$/Y[M9;:[EOFN7(1Z.([8U:I]=B,N;^<L-730[+OU5KP8&"QI[
M8'$)H8'R&W.#/BBZ+?M]BLR/M\H)("P=N+\V'NK;0YS8VY=9 KIZ>14B$NQ]
MW@,]5&=G;$=]:DEHR^/X":^248P[=-AUSLB8E.E+J; E;> R[,+GV?H(%D#C
M8DEX;T0"GZ.<U\,P4BB20WT4?D4U7H/'OG^=4(U:_VMBLWX;I?#QO_TLPEY!
M%R%\%Z9GOX*G];SI6]33/:I?- 2MGEROP.]U:83ZT&2S64T N_ER*LN!9KBT
M4M_4 Y$"Q=[#T.J!CY).0GHT Y)N#F^D8"7H.=_^=;0 89=>N,)89,*6TRG5
M >J/P 3]+^=\L%X)W\!3>LT, A+P*+X'P3.8UK^DB$YV+'O@6^0*.Q\ZZ(<%
M.DX[[SECCMG(A^XPX72NS4>L!&S*P6E.+N8' 5?W!9K>6F,!)43LAV3#4+]T
M6TK#FN[A;]1[M#'*61.$3(#*YD4$JD,+@\WLS%'22<CJ+2)#Z\DVKI0[ %EX
M7V97=3'AI0LQ86=P_<61 C9;Z+>9=Z,#--V%R9KJLU0X3\0[)<_/:$SY[_H[
MP)+ZQEY4X'..3Q?BK X-6,ZOTW(5<YLN,VU?%BJ5"W1(J#7(V+J-/KNIY!^^
MO_:9PBS-8I;_9V-!.[1+&!%,56[+ZS-[M#G*7QM0"[&B#S@BAX.BJQ?H3WR>
MY!C!ILNK>ZKC"/HKJP+%-^(:,CTT>;"<K5Y>G.0=VI"7<>O)<QVMV#5XY9$)
M]J_!KQN)>,W+:+XWCX345"@J>O$\+60F!DXCYC*?#8<P0K2]- P 7Y2^\GP\
M*T9(JK!.^:BN9;5+6VG7 'FS+Z5NC"]V*]V1X9LZ P6EH%QOY8$RZ4C(DXB5
MYP[;XL/?W$"4NAY[EY23XB[!\[Y(TDT+_U#Y).-IC%$II'&*ZI^9X+$7="<A
M,Y[6367;$US0,M\G3KIOQ>%*8^5(XI7O,B\H[3AJ&^-K6V#Q_G;N>*F#ZK]6
MPJ+@D7DK(5CW6!FZ>-XP\EH'J)V)7"N>$Y0VK!/163*7QL$-SQ -E;]^(%EQ
M!WAW!Z ^,"R:_:20D\!$EN5\.I#$N@KY)HCWPCI'DRH)( :GLG"/-ZTQQ_"A
M<PER+X5#2- LZH+LY+,-)4\*?#;$.2> &2D9KBWF/G[\!^<-7U'<W2U14>HQ
M%?7[KG4V3I>=C5RU@E$C?V6M&4">.3:@X0[1J9#_6OUJU>,"0SR1O=W^'94(
M<49S"VTGF1PSKXS'SWE$3$R=$K2/DA74Z[]$K^:&;>)*/(AK;W%]V[I<?*EP
M*[X)[A?6JRN &O5<9P\7F02<4CO2/P"JK'T>+!Y.89>H_PF0GV!= 4> Z4,Y
MH:[=O[;O (31U4\-#AIO'ML?7IO.!%.A%*$9Z\=ON[BA?3',/.5<]JX4HTJU
M\7< 7-E2N:KQW+6.H.F0W&&CE)9V^*JRT87EC?*\6J#A.DFP&"OEO>^QHI7!
M?:919T;%;PV3[C^$!"#_A<-Q&Z-/-4!1E_8<H=7U#H5U)IWKY5=6EU>OJR'\
M!0;N!^S&PY6SYJ]N6E<O/J"_88303;HAFRQ(:]:@TX>K&7)W (<#/XXHK50L
MG7W_>"<R":KD^2]DD[O]'/OOTBYDW']^R4M_V=W N2YW]L)IJK6NG1G?1/L*
MG!I;<Z;M8EG-$;'\:B+6=-.T_Z?G'8!H/EQQRS7:92;^^N?TV7K,7KL<1AC=
M'!_2H[QQ^7L0$^];P''U<@]S8[J4IG]R['.^>'$'Z.H0R^U=&@%'K&LWE92X
MC(G%E+AD $6B[E7NL&4+I$-Z:FARJ:)4K]^FA'R"?%$R]D$;H((RR3=/"1^?
MNU*M)<>?3US:^9LN>QGX[AW.GTJUKI>AG# BZ)_O7D7U8"EC!DW9!3HYMVY3
MBVWF$]/?!#-BP!$S;-P]* F0$%^)NQ]-CCVUMEA6)37J7R@_-VLXV'GJ*0<A
M-'QSO;_;[L!S4P]?BXA_U-)JFQ5_0D3Z5]V%8HC"-A!O/VOW'GIO&F;.;YF'
MMY?- S.HLT-!?FX$M@$.7^+#/]8EC7>J!*K052R]/_#AE7"VB4Z<^ZTV*,]^
M@7+M_4HMGN"_6O_+X$/#'-24PFXH:Y^U<640EQ%D!C)8_1=@[MOH^KP35=)[
M!XB]3BSW!'ZDC*RZ+U<C9ES("[;8I-CB^\[_Z-5[3/UGT?)(Y'JX;_)?!6@L
M"L=ESP$.V+L#5!^#G>99$-6TRVA#8F\=<Z-IKU6N5>T)F>W$&BZAL#W'/#=)
M-7Q2':^;5,P]Z$Q:W;&F%5YG_H'_CB8REN\-VM,:LLF&O+=JW1I7&PA] )>X
MVD,5_4^Z=74PV)P@+%:LCC[5#=D +892]@+;R]?;.%"MF[ D9AYD24QEO:<@
M#O,:2T+\ZPWK-5X+FG6YRN<HX:Y)1TIK\3CITP9NR?K"S,?<Y;AACWT:5+:8
M#I]-F=T!@JMW I9WK&\TG1W.[@#B0CL7IR&*JQ<^P \@D@Y1:N)[01,IC1 L
M#?Q)1L6V(90E_B$8H?6X')O>CH<&"Y14:WFPXQ"[!\J=6M?%_P;R6']-BWL/
M>0M0Y%HSY'JZ53U19]^Q[$LAD.SR/@630O]B2>QO)- ,YMBN.8QV93?_UQW-
MH!('YHP2"/'*J\R\X;E=&=*9%'_/Q/ND9+)L.GV][)P]&_CEMJYNFMGYY #^
MOM*Y7FMH[4PG=_\^+;GZZ$6V,:K=JXR;;N/#':#S-K,E\S_'.H*A2P+9$MWO
M '1L)VI!]Y$(5%(?<-J3%'<'H,2*03W@?<&X*%D,C[_.-M6*BA]OVYP+2BL_
M.5[VX?+OPD@F?!SV+]5R:-2-!8;D-H\3OH?.W7*H4RESI%=P_O&F6ZQ$.M,_
M8L:D84K:Q&!%@3#KE9J=,1'%ZU!B\H;IN%G1UNJ\VR?-P.F@^1(1L_/Z2M>3
MXVUW]T!1=%WI(7]D( ?WXYY&#"]SV/&VY\?BMZAD_9">,G1W>!(E6NG]-B5:
M4]S??2"D5LH,*WS; K)/PD?[3_0IS,>>F,P;O A2D#NO5-EI$VN=?4[J*D1M
MQ"\E*::VLO>@/)#WM@UD7QWO/XE<CPS4=J=HYSIMA+N*N"@-;9'1Y=I&RG,^
MK?A-E*(*>MRU,<WYL8,>8_;X$SLC$OJ9]2MEK/BXO\V.@I7<WM\2<\S]5D,+
MKQD^/9 E*[!LS73;=QLK#NM4@5_=YO 8,:91_?SF-OBQ+CY,\Z#[U$IG"Y0(
M(\6RCV>L/4;9I1?H<!+([;3$F@II6M1TG1CMXEE?YMU*/&6GXN]QC?%QW85D
M$49PYF 60JBL6AB44K0A@W:O4T.;V/#M#L$DP$?HX0$=PH&\!\C@(H@DHYT$
M-.-:QNM#Y.VVOQF(NSU(9U.<%<V-H/ONB&68$Y7)MDE)7=)K#S94V31GPF,-
MDZ0$:VU[PQ+!1$H@!/^D=Q*=V<+AKU'K ,CTP9-ABNFB83\E=JE6]G.<LY*H
MD/?:>@2K8W[?,"QH3^G:PE_R32C\(T.\KV:R7%LW0NJB]3%XGGD77=#E2_ZD
M?MF?+!-12\$YJ3HM#EXP9G38J5Y@I*)8941[&R6]VU-OV]]6<EOGL2,(PH@+
M8<7R0S8MP4IGT>*6K$U)5.%CM>DA_J&,MZ5%/PETY0@Z!-'_W6W&>YL7S.ID
ML)^55UWQYY^HAW-QZK-);^WL #Z2OB%OP8:E7SLD)T-7T5L$63I'N2VMRLJ:
M:5N4L0:F2V<&G0&>,K^VRNX >%?(\2C&UEJTS>87L0X+QR7*:&\=?O/XU!R1
M#)-?PRJ<4HTY0%NC,5\S\:-JQ"T]X^Y4FY*W1CJZ >7;#Z*W4F>?E(\=N"1=
M,.+\F(XKA_N-[F*]^S0I^ %ZO6 ,08E_*+GR9EE(>G("UURCP[$5,#4<P_?T
M.;SD^<)\7.#;V[8.' S_/ \2%GVA;'8*3E0^6SQ@MET]7!:6XM(4B)3MR3 !
MW'C)5?DA($;HPL8:7QW9I8-6Y7.?)P6ZQH5I-"FK38N+D!^MFB<MF<[!;!AC
M;;D*YS;!32>[>('WJ7VFTTO6ZJ-4ZR_E?C,:TBA35HK< 4B#1363A'O9*2)J
M,[C[_AW#+'"+0BGA)8Y7N(-W@(;ZJ#CKNAD@$W9*03W\77U+?5O;Y(4H_>F-
MX>X <8I3.5ZB,_O6+1<"'_J0P*B]:X52YA!(?E]7)0?BH<C3@.1S;<X(#DIT
M!^*1DU.Y!=I)WWA&G %B]\L67M3(&]::)"ECV3PH5\']Q2 MASG',CMA57;"
MUN=[P9/3[>F9/WD/*FSQB=6J9:J'F!I)E[=T2>;:5YM3+-\<(3&/T9T<(_R1
M& 81]1^-T2Z]>TMZ1S5;G<^DUK^5;J--4>X[?.+D:" =]@ E<\5T!X >?%5R
M#U]K<P0O*W:QXZ!4*QMC@6+0I%?PT^2=6)9C?&Z=CUN LG#M1C= \#&\TE\]
M$;11$%*K'HJ1@B""U/L:YQM,17D"1,Z7J^7)A%D4%4:HR=BV6#3E"1H+K&3R
MQPODA(]E[.:]RW6\FM,M1,T,#0)K=WUTR>O'WA__B&LYW_=*ON>[3:^*!B,P
M#&)R:O><[H4ZVS#D;:?\S>*@;KHIEDZO_PZ0[1J%8?^6\NJ>K/B[*9+E2O'3
M_O?CMG']Z/A&AV4!R #-UF]OAY<\:6QHS (6?' ^><*39ZYQB1 $:C[<E;4>
MEZ1P.M06M0HH8<R:+7 Q_6!*TN]WV/Z4D+'28KKAN"/&\G"V*DHQ?JXJ9\;5
M)2 @T[S\W+?EBD.@L6<]#JBBAU93>K2[Q6Z/X678@UG"%K\<+L//RD";KS%F
M&C.JFR$$A%L!LC'BMB*$>,Y!(A$KQ-L>"O.+YQ\_RN'1[!.-Z2?%E=RS"3N=
M#M-()392>Q'UF--E8!/ARZ[+ 1#)([0U*AB4H4>.%GN=9.SZ<#5JH@ZV:#L8
M_,F^4P4,,7C*03N$+$=L:;: **! 'NP^2N8OU0DQ7 J.R?*Z Y  14>YQE,W
M2Q;DU5!BWY+SA^2,F8-9@YR.I7)8;91K<X)E4MVAEP8KEHXTS_$+F=[M,WX.
M9<UD/9-8CHT9>S9_HSOR'>ZS7&.B4OUB&:[:42DJ[K(W1(IL1/RPZ'>[)@PO
MI(H8N0,X63 13,HM>(T"E5]C5@^W]&+7J%'7@>#)O'_JTUR1B@'I-O80MA'<
M/7,O:G/U/*DA;KQ@NNO^;X'/D4FQ9&7YCLBU-AIM5X%7R20CI'4>XN-Q*56%
M]OG'.;'HU*VVK#XPM?372LZ?*3AT V;;XPQ\VB%7B.Z_YP?F^F%]6I-E>DY_
MY0.J=ZLGYQ=FVYMY<JN^SPL[#2E:W!!NXM$L0R7'A3\M<KJ8_C8/N;)]> <P
M"<7Y+:=\..,T%DP[IK1&71\0T:A)FE/9F+M#N3H('[_Z.R^_-=TNE/9]BY_!
M#EX_5[X]6F\F#3^"Z^U^,5"EX_R_G?%&9^7'_U2I5.GH,]$: R!/#PBK?/T]
ME+DH&C\3<B*5]>'[LT]JKV1OGG/>V'!7RL](IK][JD1-;(2FFBZ7BUUCHH3M
M"!I]Y?&X 1I-C 9X8P1P$>M+9JZX$!^?1C UEL@2HS)-.K2S"C&3F8\NBH*
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MJ:0@?DXW/GCNG"!AH&2CO3&!D[S83\YYV<SH9Y%K36;N1 >F*K%GXO<+TI]
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MC_1AIU@U7D"1'4I?BP9)9/"V ;M.]F?/C]KYE?L9L.4;2"4:DF8?\P,XK2]
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M76/,PN]7[W_$#D7KX08*%^+U+\49C)@+WL9UV(&B&9:+OP;IH:#=\)9_WSU
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M.K24KEZG_/BS4D#JI.A%/!7.<6+_T;Q!#YBN7O PVMLDGM/O\&DUO..X]WB
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M,Y6Z9\L88&)R!^B!QK70WE# UP9ZQ5G$LC? T0WRC.K87.=*PP6PW5ZXSAW
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M73![$T!YCQ,];K)RA3;6-W< R*F16,ZD\]C-0C#^LHI"F<ZYZXRQM.C/[('
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M=GC,6Z&6;=4AQF\A>3L_\V/;#ZFL*AWZC(R,^&EM]&F2'O5:DG9ZX._L!Y]
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MS(LN5T%IGT2?0W'OP8Y\>.'U<IHKHWOFRG"JUNA'ZV.-/<=)Q+^R; #S?0^
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M' 5N9;P*'Q1*?>DU)*D@8.5A_3F($4G8E$&1!69!^B3GCVQ!P 3Z?U@@H2T
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M##@)X@5QI2H[S\9$;=W['!KT\E6L=)ZW>:"3 LI-.5Q33THSJPV'[Z:T5XZ
ME=6!%VE)QT+K&F0V_*I"82GC\KE3Y:^>]=2Q5#QZA$\KX?_K*,EO7!K1V6#U
MN_&LL=!+<ZD=FGK5< [.@(,CJY]5"%(Z)CNYMMA_PMAB4O3U@4I\K,'"!/[5
MJD$-N2^)\4IQ&#OB+TI4M.)NAC[7^EB!P;8Y!+^=5U]4R1I[NY2CW30:D/L5
MU@Z=1JK"I*=/<'%.F+CSB4=_]1JWO=J^=MGY="9TYN^_F/MIYN<[?$X>GOUC
M^&SCW4C6TM'GE"0SOL.DMC.?&9ZS" 3,82,GOF>MW%_"NE47O IN>@#DA$*^
MW>SD\)P'=$I@Y'\1]\O1B7Z";EF^3[13NCT(PNP9>T"K_/;BG2/EY]&&;1@2
M'LON[I5_P3\M]\+C 0 5I.Q@;Y]?5X=\K?1[=Y;;1J"L, NY>P9%6*4H/O[/
M!VW^ST#7%'E'LO8 H%9,7>%&CL=LT/J-D$<83U=6%R@O+!GRLWCCK#E@_SVO
M4B4.4\#E"Z5\ !"T/\.W;F5!KOS*"Q9RZP_H(,?:H5S%PU L+O>#G)!7/>)7
M?U.$+%_E.Z&@-&^ 7,Q=-)IK-KAMUT<?FV.&0$+ZM![D"238Q5C*^(CH&A6
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M:.FU:JF4^G?6IXM$+&%R3IBH_;L0GBMEQ&8O;&VKBC;N25R F7CN%2S'XQ[
M5UWO[X4+V3X'7ZM21\U8(0PIF1JO2!! #HQ,NB&ZJYR[T2I_>3JZFE3W9C]W
MU67[XQCB79=R>N#L=D.LOT#ZIL-*=M!,"O]28_W/-K@>Z&12<W"W^J(WN>#D
M"DOU@RW-_BA>U1<YJ029NJ-]>Z7^[VTSW=UEGP!;*HNJ[S%E^[24F:[%N'/Q
M2:XDE$B70]%5>5S0I?@+W_2A>X!^<KX%:VMC@U:^*(&0 Q\KP-*=V/];"@C1
M"*-/[%HU[7J_J3NDKMX/>>%C=%E8K^ZU&0\_9DR"KDKPM"I^*N9[76)A:)BJ
MK3Z:Y>  ]I[5G(!0["U+(_N313Y#2'?&7R?> W8NQ(<]!!3E>=HI8QAQE=36
MFAJ#N<WWR&3;,U==*!T+(]^VI2R 0%02$MY-\4W<N>]BDZ$R'K'+2%@X1@@Q
M&8=88O=$K[,.G8HM:WQG>K1_*J<&DXXYSJV?5W3M7EV3:=<9S28-G^-+3J;"
MI25HW _U9][F6\MEI9>4L>"H)' !7CAHIHG;^FDX"\AIIFI=_[D[*=8D4<;7
M3J,C<"_6$+Y(*=D=W>5G<"@19Q2!0-U]T(8)5WJF&.6YG$_B"S[AZVS)C*U1
M>HUN*6(2N83N4=^.<$Z$_J).=\OTIG2K\MJMOAYP/9$77D9AZ099['JN,H!;
MPN!3!4I\Y1:7^;(PJ(OLV:'\8<.,+/Y1T/5:GI>"ND-@_5C^+^Q%\ >V !*=
M(M=5"<=O^9"+7$YJJIGIGUK*V4LU&WH;&=E+WG\\/7Z_9DDM4B7*:_'DEFPQ
MF338UC;(5E\2Y[@1'A/IB+P'/$ZUEO_DY"4-^7(%[3E\46M7QM>MH"X#@56)
MCB_N9C&EQ#8\_K&+DV:\"LT!_S+=)*"2#?_V,50ZEW?"LT+LQ@C?X8>#N/C!
M*L\P&=X$U)78AJN'[5)W3K;,O,/ZL3Y,/-W'Y RZ8%ON\]SL15"-R$"B(HON
M!F_3Z"+1-X;X=:B3A(=8[C,19*9IA;:>;CKKGS(E_J+?6^LV*2TW<GKM*YP)
MZ^5Q6$9/3(5&9Z@?<KL;]#4?U29 ./GVG)<R^!R@E<U,NA19,SEUDZ:9E>$L
M<,JO 5%?&$AQOBYG'@RG7DVW4TZVL_AFO'M9BS8M68)%XKZ==O'B6DMB5U@_
MJ.'BPY(8<[P50(<@6;N6']5!$_%^M.;B=?MEN/O]E+!0,5#<\?^K@1$!(H:&
MO[@T[0L^JLC//..BV9%[PWO. .W>/MA]V[O&4L!.S>,H-_'CX,R].2*G8FAR
MWP/%Q(H:,4KSEQ33QX$T5Z=Q2AFP?TBM<Q#UG,W%Y-Z*R-$B[P$'8R5[NY3W
M@-CSW3I[XQ(ZT?A+KKA0P@\(BZ7%!J4TF\X%WIT08@PI.N3[0G?Z,M/4.>W;
MP$OHZJ*6L-VQ\-A6M<2YK.\81UOR> 2 Z_/U+]RS?MQB#1RG59?N]>\6*]MG
M5>,URX2#2*$D,:8OBP;9*5X,68YS!@SYE3,K;/I3:[4^&!>1]4JVWYM<TS"K
M/'Q106N5PA(]]:I( ^[&H<".E2_MI]M59&CFM0TFCOI&)&Y,G?QCM!(K[H*(
MUV0%>^:,TE67C;UFX(88,6+:J,4!J9:LRCX]>AJASRI^-/T+F]-26F%@5"BI
M6 ,JO:1"^(HF[2T12Z='DE8OT6W C5$\A :]_@85<O%XK$>0TA3M5RE3L&;8
M/-[_]>E2DD1_5DS'">K4S:6#P9HM]EKM/1)M*A&0K%OWGM$:K\R!IN@(4U&Y
M'3&*TFOS3]9#%[\;TB_E-YC2NCL)^I9UKOI3QP-[B#7,U(%M\46*&4.B IN
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M4]GZ[ML<-S8R^**%:IB$"MGS'46)JJWUB[K;; $Y\KMI?^HD$5GK]5=GE_<
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M@F2PK=:+M3_JV#_]]%00R>M\E>6%X3L00CFL0'&TL'W#/8 D4+P0[:_Z23'
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MFVJ2S?6M0QNH+@F_6*JN[$ENM1(B.)KR?>F-ZR9E_%"\G=<<542##->,L*3
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M;_1\?IE%)'LDY^;LS\<INSWAY:FS(6^75%E\,BTE)I3HD85.6J^*0LP\L\^
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M2 R_%.7%6[\&>I_9VDA+Z<?;M[-<DPR;Q5G5[5_LWOW7C8@0_E:<8O*)OFB
M6MW?"?21Z/G_@)1IIE<B>-L\/9Q;9O"44N3WS+P"FM<T,J_V3QC?1A.QHMU
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M+=_8+O4NBCF@BW*27VJ0F/)E>FJ5X1DP!O!*_QNL7Q'F^2U>2.*.S*B4K9'
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MOODGN7<]S6>,'/&]6L$F\.F4L+EWF':)\)?8?N1*)37Q.OZ]G+L9V9:P$JO
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M%Q,;C3[G!*HIO#[EW*KH1(=:^:.-<U^% LIF$;]>L9.^*9V%(7$.T5?I$SD
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M?S4%7I+_6L_1FOZ>VU[[=&ZA=JUKB"LF[&I]'%:,H9M4M0-%X940QU3=B/@
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M?+W=4.%-N;HR^JXLO9]RCIEA^)1-P$[\;O+A+7H9O0N'C7,\TQ*F:;J1BL$
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M$#E_]+U,43XU'O[[4YK!()_\(2GH^)O(/?&BAX[FB]Q:K;W2PFI*;/PG&SD
M@N]-1"R"LE\#W(SN@A<[65#-/=ZT05$@&FM#^+^/^DWMG8V36[):[LX,!IZ4
M0S\/QS@/'VQ>SK=#NK7  N!%;KJK['\V1KU9,.^HQMTS-@%#OYY\D5EY*N?[
M85&/:KNO/KYY4GC"\I>-O\;]ZO,L_C;<T/N9H>4U0*<V]V52><(5LB@#(1-!
M(G+"SUE-JB9M4!'D/F)6F]7;Q]P4,I95J_B%ZE"47_7Q][1G]Y(VWPT>: #_
MGL="UPM!C7'=H"AUCOD (Q)L.X*Y*M"[5#.@,A@66^Q#U&X.S[C<G@M7?WF'
M[+/+)UE[$_./_?YV5#>UE@,;G=LWJ&[-@H$U?88,SUOO5UCJDM?^GJS"EX9O
MB3=8A U8W.HSU>??JL^7@CQ2=;H&W):\2B5P85O5&8-2==JGCIQG'";FD3GJ
M7[ES=XR4%POIQX9_QFP"%#DY,35N:+-!NT4MN$N4,[I"'_ZN858\RZ1N2M(?
MB#0H2:O,Y4VRX;_(VXSAV5#_1(2FZ8,N%2-T2FOVU#FG.T7QH*N\G?:&C.T
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MH"UI0459YJXU"\55=[_U[-D!+9XK2-M0UFA+>0VZ3Z'(D)XX>;SY-#]:N/?
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M*:%WB$H7Z55:$*2)B%A .DIO1J0%"(0BO82B(+T7%41Z"R"]%T$IH29!D)X
M0H 0#O\YW_G.N2_WOMR'_9B=N=>:8XXQ]K?7G+KPNF?\YB(W)@[)0@,1B\'/
M5C,02"5<^=,K)0ZSK=IN)?;+-_WV==WGWA)\*<D4+IAF5:/GK+6BA OU[@-
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M+F9:<:R\C\Z5\%57L<GS31RQK+LO.374#&P=59V=MK *K/02.?Z -Q*F6D\
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MF\<#S@XMY)]0JRPSXK)7.R.)*KT^$D6N58@RSR0Q,)H!A[BXT<%[1;#\F9>
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M9J=6?$=]TX0W5;9=>J!UZ>\#C=-7C1RRAHU<@LN?-]Z<^D5-*&B=D&@R\)>
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M'3 (?4Q^P[%AZ>_?UHM7T3-CP<5FTL'0;O8 _<G"7(HB+B330,692OD-Y(7
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M8T0$"Y+O^VOQ4?<(X,7U]HRPS=:=XYT\I/$5,JPEO,SA=?+?X8OP$;'TC9*
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MT[0.V6I/)SG2PI1B"L\(<,/TD)1# 6?Z6<5)(%!1%\'E3!:7< Y9CBV8#HA
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M*3@AV^^*!_RC0DA? EZ.I0GP:O* FP?QABD7C>D+U2=>4KV]_D(Z/"^]DK\
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M''M\84CBX<$]F_MG!Z<&6YE,:H""2SFLOF,.XF0JZ:.>OE0W2GL_U, :K3W
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M@<;2HI_C$."'X+"LBP  _]$GE2@N"&(@ITHN^Z&E0_4@L(C4H<^N;'Q:6Q'
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M:<T,"YM_/2'69U#[ZJ0F,IL4D][&>/C5(OH. &ZQ]O]5 H>F7S(9AD#(2C%
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MCHW$P*#QY[%YK/U2>W=J(N>C/O;-<1G#1>_-3BF,KS-2+$*O$<Y243JTO4"
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MT:_TQCEV_?MI=7U7'OTM _9MTAT 08\V2 GPH<?99YU)/;(>^YS!6V#=($;
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M:R7PZDE?VE&#B_$IB:EJ-%!"G(31S,I#V%+\=DH6#P-?JZ$PQX2>VZ*U>F
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M#!ZJT1\LG@W)^LT*]S2]IH, 3,C78_>O ?:'J)$;[0 G=D8*-&+>$.B#Y;7
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M,MJ#4Z:?:YPWB>8M>S1#;N#Z3LK5%UGK4@IZTU8DIO?W4ZY/<SO^0JA&2?:
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M(KW/_#I]2%Y3YEEL-L?!P@F4%N+%=PYJ2 3OEOZPLII3\&(;7'/BG].5,H@
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MM!K#"#B%^^*F+T7!QNCHL$H\T5JGR-^']Q!R;?N]E6@&_4+04H_:6[\QI *
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M<QD5(E_R6\&9*D2>@UU.8@T>SK9+-F)WL9BY^,TZ39#J:R/Q+Y(FDHGF^]>
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M#/3=2=VW ')YTU5.:E#,!^O@^0]C;0S8+].V6XV*!BD]J:E%LX3=+9'NS$,
MUV@\_PQP925GCF\=WWUU)PLG!KHYW;W+V[2$S>^D-415_ZBS4(/6(N(]/S0+
MZU/=T5(J":"XF>:XHRCZ&NN,CNA"4>>NL9B_C=[M@;G[6*&^22Z!$@RG>.OT
M0C40#UE9 ]ZY"%SAA$>>&\D_-V?7;Q^.X>YI<O)T-3?I0A;JC&G.E&E)T'M-
M-:]NCI0V-\,3='+$"T4<#WF;W=.XD1H[S HIF<A+QS+G_3@<%Z3#L>KL8?GU
M6SP<S)=G*_;:.D%CTD,(^#Y)5[#@I=#1_F<#:NJCQ6U6K].J"6>V_\9=O=>
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MUF$ ?P'ESSM+O&,2MCK^0'WDH>4WPG"!8H-OOI](1W>,U0>[G@YV3;WA/F$
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MSAR,K"4L':&T#!E]=:&\>%#1K$RAY.,:#QSK$BO25GT8H7"3<NF.<P,;XXO
MC!4*55VF](8PM&@]W %!;WOU;A)&R>MGB]J<>/[U8S;='Q>GM"WF_JU (%"1
M+&#8O!X>=*UM[;PZ.B?2E4/CT>^T1KE&PP#:[FH3MGU(1[,\8 ?5AFH*3Y&D
M,P9];N^0.(<>V. H[1$/P*2_NFX!%.ZK1U$MI@SU$P[4J;X!.40I<:$;_I4'
M<,)MZ1/CJ@#8<5JX(K_1,M:7W?T5OCZ UP2L\229ANQQ> 8T,N[BPQ=Y7M=*
M_\3"$Z#W!N?WY%BOJ@*P'>X+V D-#1),^8Q13"Y6IO*[5ET;I3*V2[(7Y-Z
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MX+B$)[0&AMX"9$\@@0B8R#4#?T+,M2-&[D.2-O%?#IZ9-7].'71K?-ISNZN
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MDE!>.VW7^V;@DQG7"L&U-/*/-1-\PIDJ<FJZ5TL_E[YKTH=2_'8]_Z;I;E;
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M\1V6 $@F!/5FK+9N\IZ"JY&%Q5_-HAJWIN;/=>KY]LKDTH?E?N0G0'9"_S6
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MVPF2?@-.V\8!>?O[E(:]=463YUES8TAK_O9X^>>'^SK(]O791A]DH:]Y@%/
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M*/]]O^O'GM7.&:S0KR\^ &B*JU1OK;4233'B-*+&> W]C/C++AK>@3P'\>.
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MHK;,)89!SS2:>Q1OL^K_LC>%T31_YI>FB/Y$+86/_@ R97#P^6S_2MOGNFM
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M[G0*FQ2WWU(BG!9R\0F6;,CGF:[/@$8FN.S>;6U^BE8E/>IQ@STM;2< S37
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M!;@<P,Q.3K9P;X^4/^R6UA747 ,H[!6;P77;"Y_J[ZUA_U[><"!_Q>EG$!<
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M@42^F@$CC!#ZBJ*=&T6EX@V316A)_1GU-QC'Z;^$L-YYD_+4?^10P@G@HHJ
MM)VL/;2</+6MBWUJW@\D8IIAV1AB(<TP)W?G-(0]MIK':L4>&%=YX;4IH"E%
M=C'P2UJ:>(A9SM&]'9&2%6V8XS;7JM D\9)C%< YLK0N\[#@,%JB=F3"W[S:
M'&O0)+T>:JT-'T2H!0[##-OADN/M"BN7M?L_.8*>*X2F^KH(0&[AO[:6_05#
M H]@/7/GFK5YOM"^&<3P*3-B,L>UM$ .I#U%3T_(QM'+9<^\F6NS,?;0^F^'
MN<],[&6ENI/>2<Y(4.0KY3J9?0,\;W[>?=/KK"7^4Z "@<1Y=J4?&,*D?IT
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MGX/2TK:.GPT]IORX2^R<1:[&HS$SX,\3.3019Q6O".'U)F"&Q0/DZ[V;*B>
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MTV\N)FL1G0^ICL4%\4W9_I;*5<;[*^M9X!/S@'WHG[4*0H'Q<57DG;SZ:^B
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MG<?4OF98C$D;']F&8S7LZ$^9A6.)O<-_S;<7O0*IB^$0VB,PCU(^<'<2KN\
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MP-L^+R+(EU@$QK7V5/>_F-]@G>H7.KX6F)S3]6!T\RKJ9]KFZJ6?"NMW9*)
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MK]-5:0^]-[6Y'9RK"!6VD];[,GV7<?50A?HR"VMMI4]3-L4:*HUO#U[Y\)0
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M[C!Y\3&9^0=NA)4DDRR+AD2-?\-?_1-'!)*=9!*$WORJ#D!M9N^[N2TU8K*
M30@GWKY<<V@!#/][&4&KM&W,_8JL<2%T$B/(F=BOC<3(/9S(CE5<Z0#0*LNH
MKNF-$T^' ]5:?T4:?'XR]\-J06@$SXY-7XIU:$X(#*-8XML1OW-;L$2G9U5M
M;Q]/2C(ZK6=7$3U'_(DT*1+DT1A"'$<Y:)M8?5+5:,\S.V5I;U>K<&\.Y\_'
MP?NYBO?3W^ZEMW.U8;_$][%M?(W1T3(RS9# <C_>[&:S\?K;\%_WS^/0/FB1
MS^%JJ[-%!FLA095&,;7EE"TU?4G7ON//+[^V5.0W>!QM_#X*RC[F,=%Z]Y1?
MJ,,ISTGGL;[+/YXSQG;J+DJ:CK/V5@+GDKU6T7JZ^O[O5=6<A)!Q#=M/)/E:
MELH;,3HHPZ U7ULE*:6^5*CML\7FY>79HP!038<]D'Z1HK#G2I>CI"YH"CWS
M//3!C!%>K1[&F$1^PI:<91-M8&Z!KU*UZ#C1BQ1^AWQ*JM'P1#=:> QV;N^H
M*[5,VP?JPI$E\\I'Z-''9_%HA>80[V ,+I<,H9QB)%">S@D1L= 7)G/.#!1.
M_SLP*)H^+EQ^S*C4<<[C(2/7>Y;YI41C2"JDAH/&Y;/(WXIY9R>/(B5F+ P)
MT>1_C@=0K(8L29!WV_+EBA$PCW*V8=G1VQZ[;P?YV6[-?C9#[ :75OZ84]K.
M<W?3&9^YMHVT)<?&.TXO.Y5^=C,H3%\V,PBQ]8%5$WP6)V@\&UUS OC,7;+;
M6$)&.\6!#[<:0T#TAOA]G;6^$F<6U\OY4&13SM2W]>>C#ZU34U@TTQ1-A9([
MOR%_B9)!GB(IT5N4:@/,15WBMFD:-[(_Z$L@)_F"%]NBO1QWPL.F1$K76JSI
M+$Y4D VEVX!$CZ*+$R]^=:SS&?H2:$7&03@&?,[D/72J1<?Z?32\F?ZASZ+!
M649?B6".J8)L3I9!H8OER(4C=\'Y9.=02X^5:MTTO6OW7?*'/)T5VB7-  U2
M\5[/#%5W9RQ5MG !UI[.+6/+E'].-[36+C=)4Z<>&N>E'*1GIQ\/B5" 5 ^X
M',DE+KHU-]K?[@ZIHJ4(E%ZOOE7@@>A5L(KBYV<M"2W<<@,_"&+DWN5,"9GX
M-_C)/>&,K?J,EDQ<PT+ZN@MGBIJ0Y1L\9(9WX)\H@.@263L6T98C.EQ;%\4E
M*YDX>-EQ5_DE1'G!@5\F'X^PJ3J[FDG[? J*<)KA,9K.K?L"#XRN"730HW!_
MLXM+BK$3^S-O/<2S9B>R4Z@%_@0KEAD>\"%WH>Y]F[5/SEK&*Q7M%^UA%._-
MV&N'VGO>(5];V1D10(YU.#YS5NCI*7[77+?&(N$U-()^3OE$?0EGI'@69[,^
M(WED+P)YN@HJX+(+I53-)U;5\2E5 U[/71(6] 5L3:IV+T]?C,*<;[Y*REC<
M)D0LQ/5B'$X L2< 4;@)WE!Y4<C6QXH2!VS/YOY5QW$KV4,V(=XL'2'QZ7/%
MBY 02Q,3B=F%3SY[YF\AS^V%_]D)173;*?UH(JD09(M_DP*S3(G/9C!_5X<7
MGZ8:1WLT7ZVVA!]Z&BC>5#"V>5FR4]#4-&D%MJ;B-,DK:Z-CVG(>EKVEGI>;
MO-?*4"N)%5-W]N9TCRMIG&64^QVB-XGC:96V_7F=$J7?UMU@#E[BW?P?KSXU
MB/D4\!J\IN:1O;$;L;!-"*$:(OZBKTT44H)(3]HQU;/9WS9PA3$<4:!GA?^.
M5KX6RR6'*D5/B<'L1EC\W:\Q^ERR*;9\>N,Y X@Y ?,R":?2.:',!8=0?'P6
MV"VNV[I8D4X [ZZP!/@UIWK!H LM1HN,P \F_KT>8$>U1PX08YK\:41= YTW
M]%#-QP6.J G:ZZH20Y^V8'1!OJY#/5T3_^RMA=:-NJ27=P9XXI=9-6Y+? J5
M+4+4GP#$%?%0U3EJ;]-6'3INJVD'G/"#9)X$9G9[#44"3P#N\FR!F6V\2023
MPLB%&8F'W>["2LT+&3Z?B2T7-:4WDJ(AG+2K)&C;^.Q-XK4B6+EKRF^B+*&\
M[5V.Q1CKPA<7FX6PKL"SYDOFB6 V9*L"XNS&SAS<E&2'*MNH>Y);JUN\GG.3
MQ!U$JA-2%M3%?7UU:TE&")D=JC8/G.(FAR:U1A@>?U3,=ND2]$];,0[ZY@8&
MCNZYR3I8##^8(YFV%K*PQ7X4$AGJ';SSX$E+14JH-<)ZEJSD\?DKKXM@QD-"
MIVYZO[EKX?9,D<?JFO#=,O?\YV$]T]:G>07*C J9TGALM;*.F]%] B+=8Q[M
MZ3L'%R%RDZD4:Q+5E@1YLU<:ZMDFJDQ,_'J<7/Z74BAMJ/8"<TO[];GF! UM
M[R@U_-4%-WXOZ=ZSYIGT$7L& L@'Z;=8&3LGHA3"<>9;C#Q(,F_=S.R2[:08
M>T^YIWOFI]UO(L]_GMWJNS4_IMKKC\Y4<=X>DU;Q&,1]X^'":'AMIA@94<%F
M^"WT <%Q"*NW#U,(S(2&WNM;4=+Q'C]X_>C"]W35VSV_B.QPQN_(5MT3@),F
MI/L$0*Q 880L)P-C_!B*REL&CLL,R!C5>R5U!A]:%2[EQ>_-F\]CVN9P#@N0
MUCG<" <K38&2BQ>!S ]4OCM74!_1E;R8[7-\3HHSGXEJ@JUT296N]82V?UX-
MT++_&ER_R5^"&,.ME%2NHT$P\;;,MAGC ILU0;-/11OI26+-=3[,C<-L;18V
MXES+#<*)HTJP\36-R1GWRKR'QTH_Q[ZT+%];2ANOLFF$ALX>EY=7EE#_.RJ(
MZU^.Q ALW_8,?9 ^N"*9SAR^+I"6'/Y>/V;I5RMO@<S.1X'F@N2PRWJ.#LF#
MWK_.2.^FDJ\=1_AM_ST*12QNXS.2$))6[OXPF.>+Q8;:!L(KAIP;S[Y8B]P<
M& T3;>U_/:,QT6M/?#R$ Y)7CG- 6@ZD,W,6(R UJHS5<6%_!VXU3#&7X!E[
M>]TGR+.P,->I>,IV;<"#/#RGN$5>Y2H#7&)ULI6MS#,+EF^W;=$_\,QS'W=#
MC?E6KTS4--KI'7= J=8A 3G^J+K;44%H[.MB$W[*IRS9I(-&\]Y<'LPKS\GM
M!135K3$W5FS<K[C[R"ACP59G=NOH1M#Q[Q^Z :PR!?[OR]38I(G4A>A.3!(&
ME9CFB>>8E%X$=AV[A]Z;7T-+-E$(_.TS4GHI,_XUG45KP>=0=56<[!)-^9EC
M]V_<C;>T0Z.CZ2S4[ZZ"SY+B7]6R'CLLSM;S3]'%>[_9MTJ6C]<*?!O\W(@O
MNU52FSASK\LDP!&OIN1E9+33G%:QCX':S@2Y^6*K?+'>S:-+95G+T#';%K!A
M85*]G_R4;IL^,<N*DK'@>9922-HK#9DLWX-P\6(]]QE<*_I@?4-!TI)=TVWK
MT=X*/X07,1 $)V(8@C(F)/EXEE,,R#%$X.9<T3I6NG5>Y(G1'[C)8@)8;6X9
M%0)[.3X2Y/*.U[3B5_IEU94&>3Y$%Z16)<Y/,>L7A VNM2"K<U78K8*F1>+[
M),$Y<.F\BP$[\]-&%!1YVZ KR=VZ'R?BDVS_ *YXRG76\#M0 WM>>&#U" J9
M4."0<P+H O.01&L*[_J),60&UFZ$Q&D\$W5>O&01*4!M 604)JJ7E]%%FF?I
M9FN5 6ISGT+Z!A0_'V9.077&#^>@=Z;EP"KNP.J0-2XZ]@10.Q35;%_H/C%N
MI?G)$*CUYUHC>G0EL:OS@;\/O&#+)6[93(V:5XYX0]'M  -)S@E.B\"+,^5;
M6<4=&7S8?/3+7J%BI^?W;RW= @G[5O9#!&D7CB-/T9H,PWO&LA?/SG;Z>%[[
M)(H*^A[XT=8]I2_.@1V5)U2;&.21*1&9S2GN;_K["Y](8AH5OG9'-CUZWCX,
MR3MAG/%*7:?@8NX7[3R0"ZMP?(H[JV\R[#IR3!J@=T4P6CJ@9G8*WE/$\M0_
M/B6T8HLPA?79/U<8(^2@][V;8N S9(2RHS[^@7T>DGUO9[;KK.F0TN^ULWK?
M%2QJJHL!WH8(0[CQ\6D]<,5$T&]B4[MRS\)/ -$9[R=GIRG=^E1IN4\O KB,
MYF &V9:25.U\A9?SVAX;*WF'(5'2LS2GQ>W)$P#Y%T53K)WDO7J?V%5>R)=J
M.:($4WDTFA>[*-/PM'FZ=?0VX\&#I8LWK$ EB@V^P^5HHYFCK7NF'KW*VU#9
M[1"$RY\UZCTX=](SP:>8R_ +GK,F9X-]H(W!-@*?ZF0>LC5E]\._^$G-HD..
M2S$>N>?I_8VRF!@E^3.4H6[<H^KKT,IS4[K%NL*O(M^6F3F:1@/.&)MJ>MF_
M@]1I=V]&$S$&Q,0PXG9;SJE07 R1YZ3X\XXJ.HUM*1DT/'E:J^/?$&4-91_H
MK[DC8]$K<;WR)XV%Z+%-3B9B(E_MRT=#A.G ?UY:/-4S<W:4V^5L]RY]T6?O
M)!P/@E_[UUK_7/(OP]\PR)2]_O-G+5Y24M(/IF:3CJ,V^L(RB\Z?)FQ@=F;:
MR/"D%:ZBA5!TGX"9U" ?4B!4.U?UT[R(EF@FZGQ](=NL>X_DUYG^J=QXE;E?
MRUDNT]SB=^#[L)T,F_U*U*SL/3UQP= E#9^?@S:&S2KBPK?6>@X;>E83D<#3
M!2AB)X#-UGRXU@A=_GX93==3U.T]2!F7&ABWF?ZZO..'H:*/&^YQ5)^92WU\
M5$B =$2XBC"]C,+1QC&_S6;E:H4H\0D5J?$*@,\Z_HX3U/G^VT3_E]'&=HX[
M*ACL6E>?,&TV]7#J<-)OQ^/IH:F)_N3L3KP=V@IQ\02P/-&"SE_CFR*QO?N9
M<7"S7]IQA_42?\3:=H39[4#E%=?V-TS3Q1=U38T8;&<0)IV&W) T5+ZE$R.;
MPXV?P,+@8Z3@KY_#^2T_=Z=^ZS#'.+Z/85+M^PZ4B0_]TYZS5U(N",=I6!;Q
MK^/\80?VFOZ\9FD-SVG3XH@<?=^1]8V&WL!=/'-[4K2@[P0=0O*/6<@R\',
MX:(*>#-U^+?Y4IY<?GS+IX>Q$MM/"Z#J!(:TS3(W4L(6K(_%NT5%JZI"C=9J
M9UZ.Z C";Q].<#]XZ18?><7<CUFH;OX]>\ <'_TL7(TR-4\] 3#!#8;Q)+ZD
M8LLA-W5CZ<DF&5+U[=U-'(O68<W[26 D@C400C^_NC@7GBL [&I\,D!ZLC V
MGM\FSS ;V&29.&14U?BA<%O&9HW^<O+^U=3^D)AGS2UEU1Y7".O9Z.VNWXDX
MM^4)=,4)('F/K_0$<,Z1F-N5=#Z0/#1_I[<@,*ZM3A9<I(D]5:9600&W?Q$*
MW-X^;(Q?U.>%%P72[VY_+N9=FF, 2P9"R>$_1I.ZY''=W6!FDMO/3 WI4'O+
M9B)KEYZH18015BDNT..IADCDQ$K7M%<LM<G^E$N=$4/@&V.@JWA7D$8(D=HY
M*]AH>P\WU)YA9Y2K.?&>J*@>JY(CMW#&#%9=$[Y>YJT+O#=-[YD[#S(HNN]$
M8FRS@KS+P?'61P5V_Y5[Y'K>=L0R-*U^-7MR,&1X6]9>*;<\!U>Z5I1<J5C
M*Z#=M"$ 5UDK115X[+0TD0_O_\JM,V^S#P^.K&\-\MN.M1>$:[E)!#\G,66\
MQ"W:]<6+6:8?&1H%V?X?ZMXSJ*GXZ_<-@C0I M(11'J7W@F"-!$0E2Y$FM2
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M?TKR(IR.+.CD70!+O#VK,_%I,7P]DH"5\?4SY9S/M#BM$/[0JF9.0?-^KD^
M%>9[*>. ;-!;NT#F#D8\30_\V\&I\I\IF4;DC57;U0_@?-:[41Y>E?;2LOGO
M[K&(N,MP\[8J_W82/$^'"N]8IZ )9-:P"X ]LEGN%,;JH[&5>#P9'UOF/J4_
M(YTYJ5WX]9GK,!4??H7$>!G(3WT*L ,S!UA[%"A-R7,?N/YFPC=8JEK;HD_#
M\YZ45V"H6]/S3??6HZTCD;8V_Q7)?^]X]?PTQ(\"_67=/7<G3&LZY9;:,DL]
M[ZNFNIW8I)8U@#P^+&YY;(R?Q77SR&%9<,W&B8,"G!< 7S@]8:X/"CI]VRM
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M.B]8PU!?DI_3@?FTENFS("2+-T>Z18YTV^ W=0L%*\F?V.<:1>J88\X!@>M
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M,MYU:J=&HI>!WW%+J,&<"M 0M?1QY<''9/SZ*XK7V)%_[Q[]J* /:&$Z(6U
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M<5>7IW5,*-/XOQ#7TXK^2B6%D:X&O?W_[)=E8H#L\2<LCOJ*]4*LWQ<=)(V
MCV>CI2W_C\<Z_^_8D"?FT=,2N9?SE/@Q]G4!;I@'\A6R@3J)*1$OUEL@E]1
M#)1HYCSER/M$4_@L7- +\T:(E')$,6W3HB$<YU/2=G:'"FKXZEXJ^-X3D &
M^?M#FBW9RR)(U7_^'J)<YG-FG@^N3C'S@2V@.W)_^(#IG 0%\DKZ3@T<U*;C
M;EF-'7##JQ#ONCAA/3=@'L#$+OE.O$Y%#>%HW75Y5S6B9#&LU&Y*3JG=,C!4
M9')^R$.TR&&OJ=?BMMI?/*OD'+:'(H&6*H+E@7%IBLY3SWSA#Y]IQ*HPL]%
MC6 Y@DC>7N+GL#DRFT]&XJP$$*4S'F3L&]0_?O3^'?F[='-X5-WF;$+[Y:VN
MGJ=_>4)(WD6/)2CQ@AG2[-=/951-&YJ:$KK//YG4BOCX"LM_<?OQLYN**@N
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M+;ANCK:)BP(_U]9K*B+GYMOK:-31-Z:O_< NH9UGLE9RAPN G7O"8;*&SP#
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M7C@&8=9M\B1;9<^?\^D-SMFN/5IHE 1+ZS15-S^:7WQ%1TQ$_3(!A\1=]?F
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MQB?V_[ [R9]:JFY3'_.ZC:J 7VQ?VZDQ.(D44CUXHI;=>NJ-:?X)K8?T41/
M;!(NAG96V>P /E!PXVG;[<[P07XB;)CQ\D>JOO<9S99'JPQ7@D,AXYZ9J25D
M@+-I=Z91$[25[J5&#/0F.^P*X5HHOD>R_L'M-+4&E0\I_KN:MFP_V<DC9I,"
M=0DU)9GUL.]\5P)=H3L)!MIO^^3H8BD7)(-MM*?>#['971RUEVV>,Q:H#T J
M-4_>H,ZEJ2H:8PXKW_OUI9)^M!$5HAR-]K3,(Z/PA\=TNL+G"'5NZ]OHA:/:
MWMY'.<Q!\CG&&%3P.JO1865VTLNGD9NWA\F?/0DM1'"NB8LAO3TMV]!JC,K7
M?;L09/7T8>7'\Z%H/RY)MA\(2R+'-)X.^$8PH7;!*]>X&\.J^I13=ZFBJ6\L
M!3*L+BCH)=>].DKO=E93?I1L]U)&[Z'B-_PN?[^,'NQ?>7*C$@7/G&*=^:->
M,NQ[%F(_1F0PKMEW^_,>5V-A%'< EV367L0X0Y G^F@M?M$O\>@G4'QCG%\[
M9MASGX[OZ/7?Y>D/&!5 R&YOV9ZTX8$?06')N.L^ZP>NEL94ZDA;D0S;IPE^
MRPE& C"J#K9?97< Z_Z-57*-<K=3;#];>4G[KS29^:V?_<,."3:22.&>SCD=
M+"VHAQW]UL2A#_ZQ0VQ2M>#:U8+G;YMJB4DXO6JBYLCN.PV23SB+"95*\'$X
M!;2[PP(?">^?PTHY0>M@@\UM6FQEDE&3%^QTP24ZXK%M=X"GZ2^SD_V&_S6S
MV(>""EOSO7H;GIV9[9MH?RWE'6EJK6TP/,<U+DJ4W25V-92,B3L7M-Y4*7%F
M8\_[\8O*V<1N,T$N*-[)0QSON(LBX^K@1A?:+0^^ S@E1^H&"4Z'<*-GNS>5
MG1YT<"%7OL_D]!(QB4TR3J<U]P3UW0$@%_ 'M_'0M:05EMO8BX/.1[LPQ@ZA
M((..UL1O= 7B*-X%\!?AQ^KF=/HR7/83$7_NT>9R2[3.2HB(W3NH9(IMF@$!
M_/P'YOT6T^\AE17"GS0C0Z\2AT?RC#-U_VG\LZ02)PN=@(_.;/)BA]BA6JJ=
M6Z=L.6CKMBZAIU58Q[DH^T]'Z.?OMSE+GH)KA-AFM3M WRR+I#!C-?]M#)AM
M"29::6,7Y$O"0KO\A_JU>([3=)OS?K^$O*.Q+,ZQ#50\S^K]P*H)X+!(ZO)@
M6^XQSL!6@BUTE3\GZ*V:F%O"\=O5!R&1>&;!42<)=FG8)TP&1524ZQJT<S?'
M%$H(+H;*'CI?)=ODX0_[%($4D'_C6TK4__6^-NKM; !A(H"@.\#[4?J].P#[
MY6T@UKQVE?8?;9#6C>7@@QRWF+[:*Q!*?J(!>U@M>%L(#B4"VB(*!FEPSAUZ
M*F#(>*? H)^W&:"_5U<WL;.CB%/X:[@T^CW+!-KR%>5V^LTSL-,38SSR'^$T
M9'"V=G&+%"46WF2,AM]Z(AU8=6Q'JSZ5[WM:2%DC.8YHJ!K=6H?L3B<7[96Y
MRWWD] @=OOH(CJ'.9'LPZUHAR5WK5&<:;,X;QFAML].^B5+KI&Q]1K*6),9_
M,?MN\MS<9&[1Q=?0;Z:2\15]=5&*R/LSH=FUXZ[QJ84VW^'+$#2_3:GY?H!;
M]RK>XHKE\(ZYL^&U0IR9N5:4I90QK;0\6%?Z41?>'UW"ST'O;W\D]X+N3=(=
M$@)^^S9U@N?MA^KEO09/$3V32YD/Y+/I8D94T> ^']I3O\/5^Y5RS"J*0/YB
M.,O0KR?RXR7\3)[DEIH^IRZ*9S2-Z?S,N@,9Z.>*2+,L:>@DP^"[.2C$0;1>
MFLHW85KC5:NCUE+$F&V^/35D!)P?:11B!- >Z^71K<A[G B2_K8LRE,R=5YN
MZO1:G5>8Y7TSET+ '\*D(*^9K:8_YPYIO==]P]R'70OUGQ>,K=T^:XG([#1V
MSK0GKY>/\D9XJT%,ELD;A\F:Q+^L8-1UTP4+0MXF&%&B!NP:)[WA*]S\ES&
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MY',U42T4Z;:5)4IPPIP6U!D9X0U83NPO=K(.KE73_7\S:9! BZF=&\/L2DC
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M@3G6;%)]')C@#J>\#/Q_9KXH]QO!:Y+CHKZ^F-$OSF?5F&+-QBUT/=QXT;)
M".LR/_C5\&QVBXX7W/DM;"9$@",;<@]@TEVYZ :E&OU^,DV3F*8R]BE>/PR0
MLJ]9T:SZWW&.5\4]X'F9,J:I''S^7C?.UOX!-I].@@_Z=^X!BL* @&[$X9L
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MLB;D*R*\+Z51> BZ_K-WJ(^(,V6$==A!>C8W?SFK(+^B_+CP8')R]P<>]]'
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M,\HU4<M/=H9:9PB>L5# HD28]';L*$2P&&YMA?,RRK(N6C/M"F6#PQ5*NOD
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M&I$0X3&DRX_[QSIG;SJ]B)Z,ICYD6FR'M/[)$4V2H26ES@>KX/&O(-8 ]WL
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M59(5S2UI=?&>AZ2M7J ##P[\.*MHT-9BA0ID.OQZ;]E+.$\<A6:9RH^/T/>
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ME%B>QG*TR9DF53U=_S#OQA]"0S:>%]TS3OZ)NZPK;J"_%E$:'_@I%8NM5AT
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M:N?I-2<NN"D]& T/M?,RM@[>50FU&(3RU?I;ZXH/./+@?3DS25_-8NMB$LD
MDOID$+&?J_;6U?Y+'J=L^9;4 N1/8R9XP6%(GIWEL')T]!L:9P&+8H[#I=26
M7PT":.'U2X@>0JV+'4C6G6."V)I0$14QZ=G38!YCIOGQ%R\<'$RK%HSZ" \<
MJ7J]&T)?JP]CB544>1QQ:HX[;D GCLRA(<(?5-8592EE 0&_O;!/RYZ^QHY
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MD;+<Y2S-M>W6NRBF-]6S4L[,[S9BG7@6L+1RMTS?1]_\I)$H*5HL_?/])D2
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ML[.0\"W=0JP$.I5P$2 +(:G8!J*T3JC17Q1D7?.MA-_&EZ%Z*UX_KG^I[R'
M:3VV^Z-38-U$+IH7^3O(7_.TF XV;SGNG+V4O/RYC,WGLM"#L+*:L A EC0:
M2W9SJ.M5^7\ER8]!Y^^U\(;O <108]./,\[OC3)Z/,-^M&^5>L73B."1]DAU
MAOA8^+9W!_+\>%+7P\<?FG1]59$N0V<$)XGD'5M6Y#("A# 7;.\&M!DR@$F$
M+^@8<K(U9 ]B,6(;I[_Q_M_%:\_B->6TKI&;K\VZ?KG^%[8.)B<[(E5>*C/>
M^(,-[%?L'B#PCD7\5EV<@:KE2L!9\U566OH2OQI';"7 +_OQT_U.CO:(RB'=
M[.TY7'@6"]N2SQ':R+M8ZUNRSM@2+J-;'KD[Q+$U?6]!96([Q@E96W3:/V3G
ME!V(,=ZG_%?E1-ZM'??A\,\(]:OS,47CE9U3X3[LHFYN864:[M;%U7O 15%R
M]6L<VW@?^,$=^,XS0\\+[8>3W_\KNU)WSL&I8J2E-RTZ7)P6Q8E"8L CXW__
M_,T*>1:G4J1T)+/W.X\+[WVT053D^_I> CA/&T#RZE%5D;ARJA*/AL:":GXM
MNJBE)=L:;#IS3?[H2:\X4\Z/TQQVB\[@4;*40UR_C#-PI%[+\TS%1AA"J3EG
M[V8O_"/48:#$,49<GIFKU/#KII4E1 .*FD(2?'SPF!P4;P^50=Q.K P#;PA0
MKX:<+WG**KE'K3 UV(X,;XB,94M<?-66\IQ65S%RB*=HIG.BJ.;U<$Z<?565
M5[Z&KKO?$9.--4>\A%O?0%G._/@2=87_[-U4;1,U5YN"E+]_?Z;<#<.O>X"&
MM/VR<F$%$8I]_1Y CLKLK(4@TE9V]3)RYEF,:E/8OPQ\(S3<9J%E2SHR661Y
M O(BD;K "6J5,]&0)#'%,O'@?.^:)?(]UV:KP>!5;NO:=8/.]PVJH_*CV_)[
MP)I1_W+ "K,!>W'G'Q9OUR2(TV.)?QI[DL)!<9\J/BZ.(B Q2>\N9W",(M=/
M$19FE)J]$BUNXCOYP$?C0F.>6#1RM[O554HIU1>]-"<W-[K@'G)("VT,. WP
M..]!.Y5HMXVD7T\7M!VMS,(6FD8N*@,?@MC8C6] $#C"S\P_]7_CDAY9'K^2
M&C-'-4,R'MN!SO_K@1 W#.\,:(UIS D*>OF*3^D$.IGH5>[O/M_R$?$J/1!)
MWX5 P;3&?Z>\S=YRHJ.615!XX3UFM7"-G[W:YUR083O0)5\861NH$V;FR9VU
M#ED1V1C4OOI+7-JLX2+ J;P&"CM$"ZXU&G(JG[&HY&)]&W\KIIV0(:^*WL6>
M*#LJ.V+6=S2/?_(=4-GU1UMV]U$\[F/-_]OM3+21F@^[%]Y"OGMZP/0"-GF\
MH8@K:<RQY.1TS&I!)686E24ZP$):6$__(_H:J/R?6$33-2--?JX!27W>K_,&
M.WO&_!^LO5547$&[+=J$!(*'X X!@KL[@>!!@P0:2X#@-$X#C05W"Y"@P9T.
M[F[!71MM+'@WVOC)O\]^V.<\W'''N/?A>ZVQ:JT:4ZI6?3/9ML@$/*)8.W4$
M_?KRA'1-:99FAS-B_%DNLVZFBRR=-3B\ZU:ZT2>MTHNK(9>R\_N4.#X^%OG
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MGX).1\EEN4/8*[A67?#H(KD69JH':B\'K;AZJA]#K;G+\^9..U8]E9;U)8V
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M$;;9S9>K?V&[<.R!#/EE5$(.VA(=66A5]IULQ516'2JVJE:@B.8CL]K&L"?
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M=+B-__OR]7GUE?(38-Z;_*Y\9OBF\[3*S]?@EW+%8:AGS-XIM\#M-XX):7*
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M[1W'$)R 6()K>M^6);RR($K+ZR'S"WAJ_)WQMI/T$G01NDQW)9YV%3%UJ19
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M%]MO)+DE)E_>KAX[;CM.8 M8BS%FWLY)&9*XQRH\B^W\TDSE:S$,.C^5I6.
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MM>'9$T80\=TP1/(VZ>ZEO>%.[U\IRV,Z?X8Z04@N0R&:MROE6G:/DYPM<+I
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M@OX]_F)&=<<&"^G5G4FR1]22R3"QLZ^9128ZT/PBS,EL*.YJJ#"V3=B^T>L
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MY?$#43Q&K]V9=GW'H"Y#GB9/^R(,R^,4ZHY$MR'R)@)O8$)PC&7..?PCIJ4
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MIVCJ116LKQZBRX=XEYJC6N+:'?TO^.X!EH@_Q^^GUJK1#3_*_.51[X&<IO>
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M4(TLAKN:29B!GH.LT!1EO>ZO#K5+!]O$63FYT]K+\\;NOF3CN;[B\N1:8!V
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M(-/4!T$0-M6%5Y?<V9GUIV2YM,N*<@C?Q1&3RJJ<RTE[YFR; (G5>T#DZ=O
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MPS0?%!2\6W"#O-QIK2='3NG1Y(T79XCM#)U,\[PC=S\Q;?J=CQX_2Y4:)BS
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M]Q)WM"JMM_]'TGEZQ7S?1])11UM@/4DR%=\4G)([JN^;.6M/.[Y#>&. T72
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M?FM[1ZX@?)0"S5\:JRE.5ARL8=9@.0@(_D).('R.&?[O*[16"Z3<,>'.CQ>
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M5V@O:.T)5A<RBGVW]]5E>/3^BT]UK2QHDR8^YW\SF\0W0Q^[*!O(?5[WH_B
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M;/11L3*-3550D8V==.@>1?FH>#!)1:3$U/LIQ)51_ D6%.-7-&L!>J-YC1)
M?DE"=G,(R)-=%PR!["XMQ=>GGP^YP6DR58M8^_!.S<F\Q73,WD)N]T_^*JZ[
M!Y.$TNW%(H4 6VO&&AD^J$8M\(AR-PM9T!(%C!80' V%S,EBD3WV@.:Z/QMP
M118&LK-Q.YJB-.FJX&/O>G!@<8S*8F/M1M#Q%IL_C&18/U3>="<I']20:8G+
MABU$^BC?;3[R6YUD81*RAVEUJ ]6[$K@CS%M&+O=RI-<=-<VMD@.%Y0&R?@2
M^>./^V[#(+QLY75.:[S!N+]I6JNA.]X06+)@%KTSM5A]U[CZW4O6]]Z8 OP'
M6^^AP,,>>$K!%2K+2H#U=DJHD_-7G%6O$!HES_,!6WR_-M6A!#:T\//IF_(;
M\NJ 0/JC$332'<E)<6IH:2:SG_,V 1H+=<FUR6BH)[_\$>C>.WN#*-1@QMKR
M/AVW#GP=N6;CFHD5<S)<?)HVT#F3NH>*@KXL2 2SM:EH"E/\&W/0"Y(]&/%O
M@3;/Z]&35L^ -Z4:.7GB*P:X= ;>Q@BEFOMG_9A0;,RL0)OO,%;IJY26?#.:
M\IN<\=^J;SY6G/,BBV5M($EZ[AQX%L0M-\2MB;VP>V< D[0N67IR@?$-F3R(
M].]J;<VR(FR75:8(8W:X)T#C:BB8 ,:A#W+(RP3)$=KP7_<LN\%7W)0P+.Q]
M,%*\_E[?CDDVTRK1!A]4^QO\^CKD2^Q@7IMCJ/;;$XUP]*3][=;QT%M$W$'#
MS];7F0Q^>N&J+BT!T==Q/HR>E2G1#LH6@(_.#9QNKZ-\7_9M=J][O<,3C5@X
M0W4:_W@AW4(^-$P6->RVB1*,F08AD(4"9C?-5^=YNZU1&;\*=K[[""W=%K3+
M%S&D*NJ(2_ ZLK;0ESZRJ=UOZ$M[:I&EM*:Y^%5ITQV?4<)V_-:JP)RB1$)N
M5A"=#:$<X7]!US4!0#JUGJ3O9 O0]=R_(NEO*TTJ,P=N2.I4O:UO-HE>9C\$
M=Y\!$H$L"$F7I^M4.I(ZSW#.#I?FE.N50=XG\:6/< H&'5<BF<>Z+U,6_R#G
M\J 7-;E7T&Y('J@K/-E>GBC$6NI;D BZ#E,$,=GTM^:+I3$-<KTTO6[G\. (
MUW1Y0UWXQ)**@M+4N8,OA=X:I=@1DA1E6#*4N\'1]N(DBX^>>L\_-U3,#]W>
MZ0[ZRT0YHKT2>#M+&Y%OIS!SN+^E*U7\Y0]_^D2?YAKN>')Y52$KZYK'C,(E
M);Z[%=LOTU0O-XT(1,)ATQ#.SPPOZ$5O7?).CSR!6E-^D7M/_$/UB4[(&/6'
M\RQ3C7WAHD3["C>9??X L]H_=59U@>JK@O[MZ&W?WN9&<;[7#]*E((WT7$OM
MRYU(WO ;X9/XRTM06HH.S[.T*4/W*MN5K&CL;O=QI=B+/Y76 ==3E?+\^'XV
M8^5(^73"+98[6W@*L,W?-"%+JD6R5YBAT6G\T&N1:G\&""-H<# 1/"F&\^VR
MS%KZBA5L"/N_<H,^EF]6D_*@@K]#+<GX>=![@<L3;<[P@9!REV.=7.]RVZ&2
M6)FRM-G9&Y*?3?BDTM@N?KNIE@Q8!\>= >KI.PNFRN92NB&6]C])1B-]^#A_
M"\R-'PUP 20AMW6E44ESZ%469XVMWOJ["F[_5P#Z^%WXA]U U$)!M&\!LU4@
M]" R&KLO/9_6;38::C2?Q_LX[A-]P6;.9%KF6UVWYC?Q"T-8=F:;FV#^H@JT
M(5*V%DW9+H?HB\UR8 Q-W6U@GIM016C'J=1I&FBN!%R+V4P@0*^3W\[#\+$*
M,)MN<2&,=^#6;Q=&4-:]^X,OG /#T;=<:2\:]12^IDT&&7HL!GUC'M<2NV50
MWQKSH$Q]ZV)4_C1F[OT9@/@H)09_?9]?M ^+1\$3J/RD)^ER?WR;*)(PK6)8
MTH)@G_9VAN>0;Z2JG4%TB@RM<_SIR]-<*KT;'A!Z5_1]/4NLO03Y8[+T)-Z<
M9#2=%>!?;4,/EM*_!8+^YB4E9O"9?<H-"-;@M!\(%U(9]DE?K*WQW-1]A&P[
M S UCAZ_CA<K=F1GVPGR5MN08?.\Z=?Q+[^HD%W:HM4RT,KDRH<F"2X1K;E(
M8ZZ;7ZC/<EI<-_9X9NRFP"'VL\YI-A0(V716O)GX'B&!WF@S\H@]Y G;@+F8
M"P>QWJFU]8C8&?O9I??<(?];$S %66\<@0!8/\>3BPPG]L-N'^ V(3]<TE=K
MK&VZVQ>DMC7^:7=MO!:YML#%]R5B'MD W*"?&\&6=1MRXCS5Z0@A["V9N!X!
M=KT-Q?7R8H:7^O5":O$]:T,";ZZU\NVX[SH?F/_WWT3X.)BQS9( OT3Q(RXG
M(%U&WB^8RY%-$**A#\;]<+S\UV%SEV;Q!JUW]:\V-2G?X7K3[.R/&GK:7,3V
M2:FF?GQ\L%'Q#$#KQ/4GHQU6F9:BYGE0L\G./J6\Z+^O$46 4MA&>NWED]<M
M3K,W*A59/C04HJH"*3V-RL=7>YAJ+71J0[*%,HTTYT438RM++5R2AQ:X]_%3
M"^88A)(+#[2'"^F%Y%S+T?@MCQ\L[G6?LV.63N30;>3(&8F6JE?@?RI)>!PP
MH@@+. -<+"(_A"Q(@_H*KOHEV<SYQV]"H!6A<D16[&KXY?962"VXJJ@4UW.K
M53D]FX=$OG&WU;NE';M+95P^D7:W)I 3S,B0^68_L+R3/[HNP=U07WBN-L@E
ML<E_^+[G,L)M8:3%8&UXQ![7"MU$?"^[K&Q;562X\,5AZ.)$0V*]^R0X"IU!
MMCF!4D>H,N0(V<XDR1ZJ#$DV06&UM#[]Z1^%UR=2N]@8"VC]7VN46V<VXS12
M?&Y'<IN!HN_*]D:Q.YHS\$3*^Z%\$",W3:/,A)HNZ?KHB64V^>&<:%=!S%9,
M9_X%(OZ]YRVZ5W_V8/?Z)E>'E0CZ#G&.+V^J^$TS7= U W\!$4V@6-&#03(+
M1Y)L%YXN$&I*UA(^[B6Q$&YW"F'/ %%[P-NOJ6BT[Z#[/@+1=&*-LSFR^-F6
M*^S?-ZI73)CY5S^%R]1@STP] ZB==@7W71[/R/6WC'0W5( YU2!E&BQ;ID_C
M(C?M!16J%7\XJ'[I:[9US.=:X.]<0CB1YT_ _XU+OP"9@\;B66\3*>EW8^?'
M]];/=9A=6J[6+D0A1.,!07&@*S/VPMO$N04B?2>0C2I''?4?=\?7TO>FI. Y
MU1T\5KTJGI/S1WH%V,G>I?7#CXA&I>L-!ZDS!I41D$4C+1,'5DHEKR#.ZQQ?
M"T <OMO,#TFMO?><DSW#-=>-A/.;OP6JH8YUH_<^^PYJ6U46O\-KETO:#F@,
MC4(:K^A,_(K/\-^S#JC%C+F< 6@,KJ4<%H_7O:)REAZ:>CU)R3AR"2\FOSU8
M)FLMG $NK=M+DKT)"7@V&U>YP=LWYE.NN9KJ.<0.Q*4_1U?JJZ"F 2'+BD3,
MNS. .Q"G=O"SC71U>6.?X!5E?QF]!W$V'YNO)JVM^6>-(]*#%!-:'[)@^=NF
M;CK3R7')H;A1 SS@#B .]/R//;J3"CPM4NAWSO*LR9<C(TO<['EW&9Z&#[D+
M9)3I>KLNLO]"W4V:?3'S-ZSDOXOY&$U* RNT$RS)>0LC7(%,?9:,RR/?*:(3
M+XCMF^WHT#Y]SZR3A\/M5P*,?2X?H;??%/F+[UFTAGGF4*S_9'=G90S_6G_>
MG5%?7]7<&'SPY\2R W\]7(4B0H3!#C>M%N!1J;:];(;0L'DKQ1=)2A=:==G'
MA3X[]W,G^JV"3<B\A$L?2*+:"3V(RQ,;?NW,5CQL[8VL/Q3Z?PP7WHN>N[>0
MO#"+O.UTF@-Z!8XX+O@;KAP^87^37!3P4F0P[\:"98_TW=[@XK2N-X-^KTG=
M=_6X?<X S?3^/I*K!2Q4#+2F,9(BSQD#<EY&JVN5K?X^Y+0'$NF*^QL,Z\TV
M[]I,X8SK'E>GMA5>7=Q7*2V>R$WTW0_8M_BC@>O.*-U#*CQS:+18A+6NU,^>
M4.."=L4O0XH=AJT,()0[6J>2DB99-LE.(?[H;]5'AKF9?I^O."$\CFS]!U"P
MT%2B[L$_\BU2UQG G(B,";4K=9V5'JU"UNY#;CQK<O&[JKG7R]?%&RMC.FM$
MM:UND+O#%8Q)")_ U\KV0.."$ZD*?T"N9P!.B@;QLC9;XSW.*!G/O4#A^GAV
MUE<+FVD/KE27OX8*?\J4CE21UK<_B+>8*E<\]-HYNBR+'WL8QE:U $4%3![8
M;81_Z@U4SVH^><2*1?$:[.@,BO^-MXJ5RS3K$(U*DY]% )K.4_8GZD!:Z*/T
M^>@44L!#8[Z2,\!?D7'%JYP]/Y6Q%V?->OG1JZNO':<O?]TUR$2IP+M9HL[A
MD),BGH+]@>_"&F_>(@GV@"]#%"=J>5ZW$EKA7$&3KBHI'CE/\JL'Y/RXY*6X
M/1;X,'^Q2,H-C.UI2:A=)1G9/2M,-/X V4\-\BX)S-^>5RJ[!'?PE@N2]GK1
MFF51GR'S-:RF5Z1C\'9T7V#Q)V5(?7OE]E)ZQF;#UF+SR?".OM5;"6MQ2,G$
M9*8U=H9E]E2P1[_<]=K:P7C](JQ'4BI [!HNXP6#D[FF)SH5I[YKG=GRH?>T
M+N7UP;:$'/#>XUAZC8> 'F*PHS<X%_\3M6%X#HG&;1A>@O*F(0&8PO.DW.6@
M)3P);N5V;6HE.U_59.-5ZX2LJ70<=RP=[3^/M_%'(P?D4QC2G>6=@,KXO_;:
M42J0.L0J/&TO2/X*F4^RL<?XGAKZ@J8.)D==[T7:TN7C-VLR.89IN[([YRJH
MX<B@-,M@&Z.PI;3&7 @T=R5\3'JKC!>)9=-=3!I_O*A=J)6O-?*9H7,F?V(7
MWPO&Z1X$DB5EIS1OD@]FA_>?JD\>/\G]X5[S,$UGRF%L4]9>9$&-3]*!GB^1
MRD4.(3CW@; \79A>8#6JKR !Q"GC9S44$R=$BG(/9HG\]H[.@2/WV[J@<1IW
M1!KXGG'#8^Z+@BZXD>K 6BKC @G4;<^#1MP,##$D1_F10#T-,6;D%,B\+(]K
ML! (1_/O?4G.M,WL7>BWAUZ10@7IJ,<FOMBQ[Z=E%>[CZA6[HQ,/6&?=[K@J
M OU09;@G@Q29'1NU>OBJT1F P@:<TRDBEMF0*\[3SE.,NGOQRL_9 6%86?1^
MGN:!137+4O$;M\E,H0;RE*70I;FH*# S1>FT"NH%/"\V!C&]R-HHZ@CB M'_
M^Z,6_P*2"CD2CWIJ_1O?;),KK>G>:N+[W3+X1\U6/VW\D6$WD ;I(>WFJJXZ
M=P:(+JA3RBL:4&\XQ,*3$?(KM2Z#XOZ&V39:6;KHURT-N\HU$K\?I3JX[Z8?
M>$4@Y]*MM8<R$+4$9 *8C<)$NCHA7&!)!L-$HV\UMK_@T6E\%G\XR'#T-W2R
MCX9MJVK/5;$$';P*,;4(64>72TAFFBX9VIMS6S66;.5A9C-C6FRI:"@KU)E!
M(>"T7E."PDT<RBP+<BJQL@MD1?<T8C YI44*_CF^+&P-E@QQ;X,4Y%NYT&[5
MJD^OABW.(;FZ%^Q$!NW&_%3\['BHBCG#!\/BM^_VK'%;I:T*OM"[N> BJ'A4
MXG?"3NV'UL)ZX8EG )>"^'QY<B-_7H\R!P=2P.\$Q&6C^4W([,4!QXTI7:F6
M2#NN_-Y;,^+-SRGUKSO@_O6G353:%8O)? $BYSNJG.TC0)2>T8TY<(_\_-*<
M5+A%V:5(W[VHK0C1W%I/!I6E#P%EU MI:YLA[;.Y+@/C^D(%BB<B^3-I;I-(
MK.9._B9!DO71YBW:)0\(/; WF=I$**]?G'X45U*3PF^8J8TRR_2@V5E.C\BA
MU) _G 'H.,D)Q/2^AGNZR6< 9R";-9GG#+"1942B*VYM&-\[O4<R=2QXFKA:
MDV!ULS'5FL"]E*QG92=T^9=V& M)TH3\\,0R%)AS!KA//@%]4.?^L5H*)C]6
MOT%0"[L="-FZ/3VN75Y;Y];/12%W"(XGNT"VU;R<6\?LQ'64;&;/ - P<Y4N
MDX,DX<&0<O'2O8;4E((N;+C+\2]C+I=O6AZ*V\S=/C8O]/?S5*V^?*%[3IU8
MXA#]8->L<0\SB*S#;R*)N0>/B?]F1<G%Q^U]!1Q*\.B]P20+*_V+$5P1_,:7
MGP0$^]P%QR/KH[^>*%/XB<O1>_CHZ^M(#HJ55^7*&T/XRK%%^8(QZW ?%:OJ
MB1C[BC.Z]5G<]7$)E^"%?]?D-+RZD P4RQ.3%1Z!@G^40.)!]C^4= ]"E#HV
M[@%YM?,G?/G)9%UND$CWG>_QRC)LRQ]+2V8E;<#?VO'&*<8!T+QLM_=.KB>&
M9=(O"O_ _/RX2O%AT+M[C0<&IZV:+%2LM441 ?Q!N?&>7W2*@A)&*5_L_2K/
M;_C;I:#7V%^N[/^T=VQ^WU(1IED'OQWP$AHK3-YY7CU,?N_QW*'L=V737@?E
M&#.?U6U,OFW<C;],,1FGWH%OTI,F,3WW('6INM]<K8]7!02\O15N#!S U*W#
M3\=@8R8]\1=J$QV_A(^1);O' W7UHQY";$PG>VN^<V)A?YO;WE17OE#M\(SE
M2M,DB7PRJ]]$'" )&9B11Q(5N=D/C/HX;&N#=Z;<OJ2-'QYZA3?<*^>&%?(V
M#IN$N]K*&-L_EU$]OMR38)FS[6MB$U:TY+@K>#KM/BS7I6.IIM<I(>?=ZWG#
M^Y9DW:/V.^&0;LQWU.BIJV#-!^:EI]M?ME[<+?#RV*/60UR=O8SC#QN?82W6
M8.&)@S.) :>+VP+Z&DH!_BU((Y[="8&W!)9X*@U1R!,A16*/3GYQ4<]IMZU.
M(F@P0S#Q[8C)<X0*>; DT*&S,5P5[;%,8HYZZ7B<-S1<$%*">]7'\!MM4&;:
M6F^)8ZW=O%B]4IAN!12 OD;&@.HXW^^#+I-_C1,8_'@-$_P1XXE*Q^\A]^18
M4>JIAG'LN3Y?WK@3L[J Q,=@K/-<6:]26T$OE!WDFA(5D#7T.IPK<)V@^-Z>
M^^>XK) <AQ)/E/Y%XE]<O],UJ9O]MQF:I+NF7-T/:AN?X#\6;JO\LM]=PEK4
M[ONXAFT<[_8BB>8I3(';G?D:!7-^O:4%\$"EGFDW90'1J,T$%]8EM=<N<^,B
M+9G^NWPR?Q=\M/I7C-X :QI[H/'@>EAR$<&8G3K5<@;H;MZH*D[6 '7F0#\H
MV-RO?M=Q)Q#?#?>9\<YX??%5.\[T7&T\H5R8W$]A)&]WWE/$;YP0KDJL@->.
MZ;M3-C;5]#!6A:E 8Q*;?P-.T<;XCI;\@[4KHZB;(!G)5=4SP,N4")[%DO:R
M)"H_V;C7M/-R]\&1KXV+I]!E>83#+K>0IZ' OS]5.^<2\(H# MO:+@WW,AHB
ME!O<T=>1KIOXEYN,T?\UEH;4V0YPS%'O-CZM1S!11#$+9%!YZ$M23!\RUJ*V
M]/-OWR$9R(/C'>7KK%Z^89K=CV0EDZWO5/-1RO@UCXB'\;#Z4V;^%UA[5](0
M0U8_0OODT<LL;^:;,LWV[\75,1_)3 =/3PL07*?Y8%J*./%)7)C[S\[O#PNG
M$OIGU=F\WU3'*5^@5QVAA84Q7A&_J,6A\DELE>?B$WHG6H"WN2?F:'T=LW^.
M5E&?@EH&1')<Q93V6K$6[?"UM\'VL+(UUL<>6[AK3B6,5U;DF)E#][BY0=TC
M\Y9;BKS--$9*N-].W,HWYB%_Q)8#?@,U=B/EOV"6.#</S\5-(UE6(+LR%$@L
M^(";]^5L)D<M7-5]4F"*'%4PE@#OX0S=-1Y,$O2-_C8DN.EL<#SPGW,,?VD3
M/H90(N_RNH-K=5';\<AK"$6KIKJ"CFC9:V2;^='H=<E0S\U]$_ZZ6BV)!YF;
M!_M=ZDT6 S=#-K+2+"B,7TK$E27Q1MLXXVZS8QKRUQ-+RG4RT)TW]!EI*:MH
MYA>8HP72?E#M^U4ITG[P<?36IJK'A3&Q5PS\5]_,\IVV( !D7'<.,I9"3Y!V
M[I5WE>_?=@5&UP]I!ED)XA>[%"69%%_IR%F]&UC/H7PECE!N9!'ZX$7*J)$X
M+'TB[B!R,FIJW1KXO@U2XIHIO^IO(/HSAWO+S%2G*=.]XF>GDQ"$V\3>\MQ3
M]D]L[=P;C\$1F@+4"?]=WA2)I4-S\FGA*I6K_M./Q73#W.[)ON._XA9^D>M7
M=V6(+JV6];"IBGUC3)DA.[>6I$ICP+:F8UV+VV#&U"H,AYC4G2*&8X'U9X!-
MZ2!8]XG4N8ZGH_(]7VW)HZ9? 0G\F]A4/,FN6X^3*FYN:!SUW'KE(O/ZPV+#
M;.YO68']BQ\U2\A@PAD .S+OG^I:0<7D@\@L=!]:M$5@07/+F-MV"5&J[]SD
M4,FT'K,:=\&"%,GSF+):UQ0=13:<UW[CV/!;X^I^<D&;^P4TTZBOZSQ/GN<^
MWU(4U"QL#)BL/G+5(#!,$AQ=,ZZI/#U':6H_OH:E<^<0*G &<-N.!W' I+C:
MES\@9$+UJTE*!6]NJJ;-KNN%:*?I_16W$E01<@SCS4RRDESWX_<=GQD/:?6G
M<Q5IGQ 5=G)$[KS^\ZKUV!_TNDUY098YL-4XX1EQJXRY[.4]QMO-[^231JOF
M?ND!(MOB,9 ']#-\=V3SQAY6T(T@@<OKX'Q[_E/X>?T',Y,U]N#OT"Y4.;1O
M GVF$6VG&-X-O2%]2]9;PL;ZH5I*C4U1__V$FSKWV=M/E*E8(!U"==VZ(>Z;
M^^&Q<VRE2<(J0M:F0M3*PEPG>5)#!]L_=%.(4LVA]O!ZAT@FS/5P:G6]6LG0
M[W?+U.9N+=AOI*GTCZPT:GL^6E$TH5PX6=*<C[@I%#^EH:-V.6-?9:$F<W]K
M(U_2+T@TD_'16+';';V=J8&;_LM'ELO_'>_)/<HC<MYWW8KU@CIF^-SV!Z+-
MC'[0M\ GX\=HTZ8FQTO8Y_M<V_\^L(IEOM"J"=TV:X(LDRKF0;W@"Y0KIZ44
M)^*AX>D/J@BYR"!,U/A:H&5/\&3)@@GDK?3PUQO]H1IEQ0%RNLJ9%5F)C*'M
MA7G1Y:%PK(5)PZ#%9..*BJCH5D7=MK.[C1'.O>+/Z3 IB\)F?*!'I(\E$ /B
MJ5*NQY9Q5;+SXX4_L_0GOV@6>=_#/63,E.1(O)0WILQY^6Z:]U"8TSR8%4<N
M,VC$^ X.\AL:M']PKLD?_'U50L7"0E)FO+""N9 OAQJN"/\K^ORTLDV_<IUI
M <BT<A"<8S?M>F]_N5,#:C3AN_X-KIAWBBB"EFLE5 2QB\1-/ SZWAH$+P$Y
M%/Q5.X@]35.\ZA;F?E!*:D09VJP[-XPK\(?B5X,U4[*+4JUG)\\ )LT6SQ[)
M2WG77(-A+B38;:6O-&?D^$\>-N0IGC+]<]4/27'V@RCBLNLR\Q01,\93HDUY
M$1<FY_4TGG6G@3C4P^E+'@:5V[AFWK4'3_<Z\XGM*&2EZ?+\*+R8'DE#.Q8$
M7\8<C)S6(]W D<!K>S F@G\ZE'@X9_1'.:&<8D),3J]<X\E(+N+M:%!"DB1R
MEA[;]AS>X;A^_;.NAF1GZ(W*< R^KOWP +-Q!B"P<%+LR'?#'>J]6 .W%IZB
MOW*R9+9'SZ(LFZJSKYBHJW^Z%26VS*YA4;'=WF[::K%KN7.KSTV^I<[IA[\Q
M5"'7&-;8:)0R!6>#=NJ< 5X;Q\R*_0F]NP"*R[Q '?:^8;UBST?2J97B-E>3
M$4+7#7Y_]&4YIF^<!69/0FYBB*1PCC7\=4V.W!&.3@=7[[=,,ZX\T=FTGP6=
M;\W_64!O7>(V2*V[D7PO"IQ1< WZTC@6S*"P">H5N$AT[I.]05[H]3]/+)I*
M#60(B5.76-*06YX5>$4N;@]F5'(;*V;[,Z.VB7FBDRQY7L+JU2%PK-74*HB]
M;CN&TZ?L8#*+%(":%!!/?=@@6[23)LW_.D9$.Y')YTK(?>G#A+%>A?PD\&SR
MCU-V.%GCLDDDN:YF<CL$.UU=YU@ OV-G_ /!3/FOKRZ5BL::PWMD/PB(G'Y1
M5YR'/()--,90GF(/#]K\:^0<XY]O(/ZH3R2^ZW3\7ZA[SZBFHN];- B*2$=Z
ME8[2!.DM(-)%BM*;TD.+]$X$!*0W >DH()U(";WW*ATD]-"D)R 02 B7WQW_
M,=YX]]XW7OOPQONP/IUSQMC[G+7FFG/OL]:6VWW0J=(&Q"CUKS,)OM!&HS:A
M]WH1@=&NAR6)/5/[J=W<Y[T"?,E<R6(Q4%F^^UU=TKR A9%K"):JL(NV(=K[
M!_8=N@S9:G Z?_>J(SX@'K:)?'"6F)RX"'0\.I9KFJK[Y1\%(/.K#EA:WSU4
MP0CL.R/ 7SKIQ$^B63GK,[Q\<.)SZZB&"O>0\09*UGR0_8*'I?_A3^Y7HO[=
M'XD*M;U"3*OD+6!8HIAP<&;3+8 _8,FR(:$S]'K[YQHHZSRWH:QD]");8U8+
M+!JE.-++'O;K[9#\X(:^_&RT1U+D9W9#6<T1J_ _FVX*)>)7&#N,)YK.<-JA
M!FV#G-GDJ:M2HF!EGK;:4$MH Q;LI]P#?#E8:&$$I?_R-\NU2]$16"=',)S>
M AY"NK5^PM"9#LBZS?R>0&AXRWP5R=F>$?QGK7"E?6.8\0>?O",!FX:&#$G*
MYS&@N:'?#Z@GYW+K]\J73DZ)/'E'ML?2YS/$##"FMP#W:YAWL(,-6W:@KS.(
M]<6.^01-"S-)CMA8^'DEOQ6]G].UB>#A^<TC_TW72"GO7%%?TD\?;2+W5G0X
MPYKW!L61)4?\2.@&W2"0^,]!AS#ZO!KMW(.,=KC+A)_! _.FAOFE0_K2//4@
M9BWFI@?BMH1/I(9HT,,H'1.TS8;P8T=+)C3GN@X]:+!753:PD]%/J_?Z)$9<
MF'%B)[.S7A@6_&CHY=E7K\;5_E])T _*AD>GOMAHIY4.;>#H]55^E16,#4O#
M=.%^DZK  P\21W>[;DIYQW;;HIQE'H0&EOV=4@MF?JMX:KY4%/M9X]W0RR1I
MEHI]J]#.^HR>1#B_,NM3M!XB%DQA\NK75;1?'>BR)KC@A>K/^2W%PQ!5$L,7
M"5N,V&KP(J_134.EF#"%WTS?+8!.@=XQ">1#:V1J6'-_/&UERU!BRK2]1Z'$
M#G\IMCAV_%T*KV/O)ZWWC/_(0]>0:I![6")T9Q'6#!V(4<+:S0K^PVA40>48
M2M'I_/'WKDU^-F;:9ZVNTG.2LBTN/OYH3:L&.%5Z"00=9=E_84CBO,9/CB-_
M?0M02+,N7Q1(7E*F+A^94DT.^LV2;1VQ/";%79-Z7O'N_^Y?>'@D'6 \SOC9
MQ.Q FL%)5VG$#S-U24*#/\M4'!X5K9W$G_Q_^^U4-ND7 5=.X!6F@RZA';]]
M2<=TQLP(\@(PDP\D2A#Y1*#*R0-6]DD7"PVC6-TY ==,]7T&WLR'G$V<<8%O
M[SQ&XO#I3'7]S4O:+M7I$]<347+E+RR1@*VS+N@9QQW735(0PAI/_6?9^TL+
M62HBD1K$2!W"/<^A5[+?$A_?]K%X>9U&8H'R$XW:3\ %S?7)+>#!+2!DP8H8
MRQJDT$D+ 0&)0<B?&3),5O3HGM5E@?B2US45PZ56LK2K1@P,*PG_\&ZZ,VP8
M[,PE1/&QA2BY]< %R3)G!=8&)O%V7\WI/_EI]@N"A]^N4=Q]O#-QE.-!_?X8
M?US_ &&LWDT)[N%2__,N,-I8AEYPV?,B26UCHAB2IX-E3L2H@7 "-]_;Z(!=
M^0DROE_:!'><(&X973CYUKPG1YXE5WB1&3Z<5QEC_.F'[JN?@#,9FIW30D?=
MTS!9;57 &^Z&SDCTX]#!;.9:LF^;XE56(X-8)G_H/N/"X531>/E^R^^*(&_E
MCMVWL\+@S*@_1Y#MXMG3&@8!]7-YV85SG?_CEOG_/[*'8]2TUO<2-.3OBW,G
M*+YVJR;4)U,L.5^/BZGRDH!;N.)!IG;D2#RW&^5T']@75Z$#A@CFQ-N%=?85
M6^<$78:QW'FB*CR9%>B *Y9_\3JO9^\QRQI;FEFD].:\4.;*= O,N@7(0=#2
MPH.KXE,=?'_,''&"\_]*WXV],K7L+/N3<U,\.,Y2U<<?1R:OZGQ.C",-1T7%
MMFD@X8=^B1:S,.]$/>_H<Q;-,]T,\&)5 K&%%OM!SMG@IB+;'R[&M/JM4M<X
M^NJ%*XTGFZ'7.'';>@R2,W%T8G75U^9FI>G&23LVY\C\^H@!]V[_OQ?]_V]6
MF%8,H$\SOESM5V3[)/V?7UZM,[DV/1CHHM[)-N17$SHA0CB#E"=Q]'Z6MX#^
M#@ZSGS-B?^WRW$'TZ:[)[#[PN!&BKLWD<8!OVAODDK^=$+?QW,#8"XJJUCA*
MK.(NO1R;YA5^;WXCY/ < <1+9.M'M ;+OI88V#V4*9Z+_UD*8#@=KS#?TEAR
M"T!9$@??R1,!Y.]*;QHDM N:V#+W,Q?LZ95U'A7F>MPF+^!34]_ADA7C1+IM
M2OWRY".G+.?H^B8U:,["9^9\LBE(:W5K 3%G=JQSZC#=2=-I<[*(V90H=J@.
M4D/[%_IE&\QLG=7?:)JI:+C:$CS_*F;GX5'>E7\<<]%)Z.>K@[1,M?N^N/^Q
M(?.GF8I#R9+V1W9:'\-]CL:&5[Z<MI3/5)OWZ1K%T5/EMX#N=VU&F\%L?89Y
M1&A71"Z_WHQU,F?[5-5 R[P'WT<F_?"1.-.T9T0,012]L)!@](M-0BPU_L6G
M6A0P^NA?J<)3$]-]>)M$Q<\UIRS#*A 8Y"NGNZA18@S29H.[ZHM'S(YX<C W
M@/IY45II(#MG6*-6Z5*%[S^QN/GI5 LFM[<[5YXJPECB[:5K^INZ3J?%3CO@
MYZR)OG')KI:,/J,9%R&W&8TI6QN!G]0>!6*4;P*J0_8F-+%S:+W-B3MBTYBM
M@HKZ#'2#X&/IIDZ$JL3YH5%/-]B(_&+[*/Y45,U>&RQ<1-<V16?1!(+L,"@W
M4;SDF!O2F^CZ6P"C,Y"@/M J-H^P8U+<O[[5$5I_1]DUY(9.'@E,R5CU,'%R
M!8VFSK>I(8RP5, +753CE^,VLP=196A/BUDADD9?&?OVBL5!X6R>O>0G]2V-
M,2(\)JJ3$L?KUJEKVIW5"]@Q*[NI]H#.9M@>N.VJXF()'5SNU,A*,.,-AC?J
MS,E9/2B*)?RTVQ:N.HEC7Q7,V:@_>OMZ!LS;F'(/?\5?U&1YL(-&P?(=Y6^L
M/#J6MSM8P%%!X8[E!3CG<<]!K95_'N0_[*#96^6<$I;[-2+L+?AZ[]JFJ/HX
M(3/&>I^+NZG[A@HM? L@V+G)QCVRZJ[V\^V59,R#N4B:63F;%N-*4>KNF1PR
M<0NJ$IR<'JY24K_)^(_-+&3H#;E/:2G=PO@,I8D,XL@>/"],6-;E1-8IH^]C
M5' +(1SM=X2O9%V8'"U[X1U#/QB.8T,7]OI<T\6(L9@:>@:'7"2!DG]1*5W0
M;P)=I/V8CL\5TM;9T-PG?591+2NHV(LN= ;A)^X6*L<U,J]FF.N+UY,N$AP-
MN1_<7:N_4];'<F7/4[,72S$;'4[MQ1UM JY#O#/94W@5?+.]F:.>43UY93/C
M _G-A[^5RW2A<),C%B]"'HUC,<-JSE&)7.1J(3A&-X,-CS^*G@X*?['M3!?S
MX1V)MEVB.GK54PJU1NI$M+%M\/NY_&?%N!=',<W^\-<?4$!P1YJ 2/6]'\9F
M9D4:C7%/7$B\3RRC(8)Y\6[7GQ><02!Z474NO%^$@NDVIYAK&R14.G$SL=NP
M21;'[J=)JJ0CD<&X\M67??"^Z8.,,0+*H:6\6;P5'8=@;XZ.[+*&=(.T'&E)
M[L*W&<K4)4YNYF6#*_O2-(%OZVOGQ)K_C1M.CUK5Y(FPG!?/ZHW3C/D3DCOM
M3S4MX\&[0A.=KEX, AL@O6N/,I?4%H(($?FU*9>&63HQWS/T$^Z#UYH:U!\*
M,_N[%G=Q439Y0^,[."#=!FV"_L$.&Y!(!:;I_#ZCLVSPD0Z=7T00L A477IH
MGXY8A6-K[21(I]:/SQ'1$AEBN>E9G2E66;_:B\#^&@J&J?,K^IHW*T?%\,/@
M.(@#=-%9#1T+VM0B)W3,(T$M4YISMQ_5)SNBY#PT2%(S:A,<77=XU!'LN<3"
M2I<)(:'9_1W,,Q?]9"7?M?R^$/AF2+8$US/H?1[K,1H ,)^E6HVK'66@F/JM
MZ.0HO&X!,3*=O>#[L16EQX(=_'Z/$:J%U0TIK<P0!^V2.PFW1]M?W4A$#?OS
M_OV3I\-W4%4S<=BYSA87PEB']D9 R/U2$8,1T+7#$Y3]4C^.8T:/UE_GI+\X
MYTSIB\D%9'"=M XJ=F774=7J?!F4<;[S%DK<5&T&MJ_&_<X9?RJ?'IT_N9N(
MX_ ;?8,$QYQ;D8)\ P:^__S+6'44VQ=[ :R'+XZ+"9+,'T@U]9;RQ67;=I$\
M_P.,8'N@(!>D>5.LP(G.Z 6R=3JNF*TS[;U]'23^,WJM!UINP;6J#W\Y7[?'
M@_S&J/%2^F-0^Y^1G4[M6X!=_J+#10(:;]-$$)88 W>(#2%[F2%Q;11^7)BT
M:F9:KZ]LG[(ZL:LE'6$B241_E>U_8/4!JW:3K4"*-0]]/*A -'V2\_RKEC.S
MCV?1-TZ/Y:5^YH*-Q"?A$QNJZ4LPV#X,\C.;AJ%?*TO$U$SM1.@6 )*_!>"?
M@B^RP)\Z&-#$I5A)5.*@#FV0V0+,&2-;)?L&>3.#[NP[_<+>E/B[<;)DOD:^
M,5/.&M2&JO]JSO('RG23[ 5<RMA@^UR((N_6P4?K#.83@4^V+/A[V*B.$GLA
M](OF/RJTW'VRW,*AYN*P/E&S2K=+%TDU'KKFFV0DX:$O1@XK,O_V'3+_$P%C
MPC35Z:D_3%C S? 9U,?V:;KNQQ)"?.1UR-KKFH9;0&*@5ZA/^>?X5XX >GH5
M/*5!YD?:HU=9\ L-R_F_]8(&FCB$NQNV;5S-MB'QV5Y[YSI.&SVQX8NE)KS(
MLN!NLT%,1$'JZ#[WO20UZNF@F-U&I_%^<?6M4U\8KW0,($FG&JI&?OMQ!E!D
MEAQ3_!>,CR-RQHCN)9NLF$)ZNJ:\0>R1$ I@*(X+/=$=(-1>*1,U>RZ;2ZPT
M=^2U':QY..HI%O+V*<B,.Q0Z+75XM.GCK9/Y^\UFDT,)X!_KG"U !J 03BV6
M=V A;FCFSWT=5L5=J]5HO+CTQL@[F+9\8B<(M4&^:+3.&_8^3)!_XR(^T-V%
M@J<0JG;37EXW&%^K4>IDC]@WT6!P\"=^X:$AMU!K;&*V&.X =G.M_*'/V1"V
M*%CPJ!#/:/0)!:"+?D#6W:S3(1:267]RO@Q)=]>62$HG4;9EOME\(^&[X_//
M'+[7?@6!-IF/[&$TL[A.1@.UM);6YL#5V2[V@UQ\IK+.7G4^]%3JL4RL@0"R
MLS6"1&C 3*-&LDZN9([.DT.BT+W0MP2Z #B9#!4>,%<F8_5&W>U&_*1JK;KJ
MCEDJL?]7GZ=[-"3/NRC_JH@;<-(;O-/["[@731*J$6V0_\O^&?GL^D)?!_M-
M91OA!C1&WP]_P#2OKH >"I]V'CT@#H20\0S^&8.W-8HDWTO22!I0T&NE-H-B
M@5>)9N#BBT[+BXZ.!H79W"0^0:+L/(#N,BK\'V'9D?E$3!#+1B>+H]$J&\HG
MVJ;\;TO<2_Y6V:%YQYU$CX8%DG910D^K9UCSFW:@0WYXBUQ %)9+;=!C!*GL
M7.1'%DCJ:="2Y:O^(XP8W/#2-GEE]EGD,&_,U0NSNZS:[!= :J0Y7:7P($@%
M.0;O[PK73D1$%""#KGN_K2K1QC[*/FE<IK%ZKEKL2=6ZNUT\_Y^M[RTCF6V]
M[:6*K_G+4+O+%\=6!+B1NXC#41]H0]'D+^>Q+P0BXBY,V;Z<QPH^\K4G[]A5
M"SL2NRK2?Q[/Q9ULT?7DA5&'$[PZI45E>R-R23]5&^8_W9WWM)IMU)):+3UX
M/ Z_D2LL<.$,A%JX.+VIPMJA,A21@[V>B$0"Q^N$_."/.-IVY)_\U[.*@08Q
M2E57JGX71 S4 EQ27VLX'2=@N$$%OILR&_1NE1,;#0[?+Q;#N#^J91P$MBES
M-LH*WCL3RC+&];J7F"T.V)#4BIB8<9@SNQ),[\^F^$X%#B\-ERZ=.!8?PG=:
MP^.KV +T4Z>/][A9VWWW7+7!,59(/?+H#BET&D(G/._A@A=T,2SX =:Q(>0I
M:J4];M+I&*7&-UL_*F@XJ>3^4/(>Q0_%*BX!46FH![+Q$Q"42( 5Z5@($;LC
MGR_KK=CV6G+H9"H#.E*1F.X.6E>%@7_RL[3SIWLR,; >4[.A9.Y>43F$""=@
M3/%Z<_,6<!B-Q+\HG3[*1CB$9IWHF2F#73W!'3W70^#DC-\8]DCE)PZ"Z<%_
M!AY"$^7NWS$@FYL<++O<P.4[E%#SS[M(1NT9!<S7/XE<-3%]!5OD*7OF[\Y.
MF9C*I*8T_3EU_LW$SG(^VBL&,\C[1B\^.S;^N%EH">0\[AT,#K'/^IMY%?X#
MRX>*[^S7Z!"%1K0)8XRQ(ED79D,[-<H(*Q8GB6E9U^1Z#3',J*=<=G@M!"3%
M !0YL')Q M*V62$L9!:T;M(A']:8L&0HER57[QOP !OA/R@Y:"&]GX;C]!@!
M:P.E2)[].8X/,7J+56.KSR>Y@W\YM.S&@0XQ&K_WXEHHV8[ !ZE8H#G*K$FC
MEC7:ED1HOM/.XLIN\KK[S07@<=,F_E(QYV-DY"B."(1B0Y2;8%^BU/KB@>LG
M?:3OB-OM#S9.HJRGA:O!!C%5 T77SHY'WN[;14Z6=O9\I<U=-!?@7K8_K+<
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M#U!*]UXI+Q0_X1_>Y8:=5=N(0A'YKB8]ZV>V[Q.GT.3"FX9.VYLWO\_TK1*
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M;3J"WITM)6H"IIJ1VPG%SD*Y54H\=22H-M'1H/3CRMJGAMS4][<>8VG0&:A
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M+^B/(&54ZP8DPL5Z%C9!N]=@Z+D[DIG3Y'+?YK3 GOGY/A_^7"GT6_%-S2W
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MKUW(YZ[@"@257[^'U43O-*<^),_<[F>J>;<\2*^K 4THO(/RO)"1RU6QJ*X
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M$B#]R_ZT?_XHK^C-& '<&X7P7X6\TC:UB#0>&-R+E5$AOE;"HF+@8P\)_9>
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M(MV2;7R8F5;H 5P7=!=I'<O%'3\Z]AQ+%PA^^$#";]%J#+=^O+1D9J<RE\B
M/+M5X[!RQ)[D@G5!$FVE ?]&6/8%?P-6>&:N2JIJUY?QCO3U&36I1.%".KE?
M9_#=#=!&*>4*,!3D>0E N_?FTB.;PKJON!52IPQ-_9%VN@Q[.&=LN!Z2+2^:
MQV,DMXB6EX*X^.IZTPURLK2+9W5<5'9XVEX"J =]2MR389H=A]:_8?XKWXWY
M%IGD[OVDRWS+4BD#UQVEZ/CBBN3]AJ+6YRN">/0("GB5N W$R-TC?OU%%A(7
M++ME-D^0?I9C*C.HE1GTSC)+^M^PEM5L!QI<G3R*R&0A.V4_IX#/=?"VWR$<
MPYAQMBLG_4;IX5(I7NRCV#-:Y<Y,4QHF1L6,>N;>EZ'Z9F/*LS-0\4[1#H@
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M&B"9ECCXX99GP7,Z.O/[893Y6Y.:[A2C/7F<DKJ]7D0!"3I#YRQID>5C#NC
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M$L9Q@2NCD6M3-XBY[--(AH8 #=E:_XB%CPN%]Q3/.[8!Y(VO-Q66YI3QNU>
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MD.,2NK9O42S,",=7NR)-#7TB^HJZ<':N@OA5V53:V]C^X^><1OA.&0_=)<"
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MEF?V')7[C%HOC.QQ7HDP%O2'<H7/8KTV)^'\&;-%(H^=Q].BIKYPS';CK[C
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M16,28T^8;6UL)2/R*.(+M?+<\-SO&&R*_C'9VU%G$<-UO&_+1A?2=)DK40Z
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M/N4Y%ED)_0.&]PWZIFDT?!>7@+L 8AQV@\@TLF2 <R;=#5LUC?Z78Y%P/=(
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MEAYCW/9W(;SNO<TO*@7OMKY?9BC!R 3C"F:99*O$]#1+%%L',]$'N]1I<Y
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M!>)@"4QA'@PY,<Y:=$$8A!T)NSGZVW8X+#)G>^FN--3-LU?I?HT$T7=PX+M
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MO,S$MOYD:6>5%H"'Y,OD*N2\.#K2K-0=,BXN;\,J-\!0RX3_:-VO#5*_C!N
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M,?Y&O'O1Y?2#Z<_E?TS0=BDZ37,%7*G.H\G3?*![Z$%KDB>_F5CL"5/T5$@
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MKT_>-)N^OVPE.%]I;;&JZ[DK< G!EV%A5-:6*JV./O5FUNPP)?)S%KUNN5:
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M>KS..?B"_I+FQ?"/H^*H(X*$<WX"0Q<[#Z]$N4&-R0K@[V@U8$P^,;+J"(Z
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MZYF@'H(&LXDCK*TV8/&3>Y)R!0BE!S,-G]@.4[0"&RE5342V)Z+8L[G.?FK
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M2I]?;B0&SHD%TOS\<_KF=#G=921#D(5CC405P*0&#DPUY;T75@8P  !D %*
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M:89?"3EC3_8ZU[)6[X&UX'% .G3O .,%=*.<WB[BS:QJ,<1H2<5%5'7ZU[0
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MYA/%8NO"IU 7<DV#T@%-,HM3WYI9J'YDT*C1G%K0EV3K6X#1GS6"XU.J+J@
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M/;%N'F<\7<_5MW?#R)YX#8ZL9(J?5(I=@.HOL1F;WF)S>^7[55D*3] //M[
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MG6-2EY""XL.<*H_EN-GBN^O7IZ7*WB1DZ)*)9W(QWPG^U[S:P4?7H%\=TOA
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MYV62]=%FY<^86P"* T'4$M:J$GGST!GMIISV+8=A]OQ5<1%1!9_0Z/MGBKD
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M,WOAN5R@%2KI+?G)T4^.C_OO+4 983/E."/9C$;;#B;G)3Q=Z4Q\.L"=N5W
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M9*8EQ/I+/=630<?R/+JIV6^5256JE2'" R1R1B_W7$\1[^4.).Q::_)_0 _
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M141SJO$*[?K)05!:4647M8?5$S Q?UGTB\EEA5<1Q;LO)$49F\Q_(W$WUQ[
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M<7O[T%3X.^[=:0NR'?=B?^2CU<BDBG.$X=4!;D$+_@9Q7$#!.)$%3D#5HL#
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MZ!+= 62"^6]&PRBQY_Q"KNA=5=%2]H-D/?F)6^&0\BM:#J%"@2VU2TVEE7O
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MN?W9$7O:3R*QE^&28^<^-EJ2O8./$R@UE\C!>[Z?1MIT<W_Y\?E*GQF6BWE
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M.^$<CH9:-HZ^HT'A:YV9&S'[EE@IE.34N_SWO$'R#WD-W,@>8*]&^H';%(7
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M["_7%>:)M-,+JQ=/*G*"@#[<*BWN]P IZI-^*6"%S-N+5?)H$?E$[<83D\Q
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MN<*IJ:_7OHGWD>KQRU7@EM')$JAN:HQXZWT?7!IVY[(B>^9\7<\*N)JC_&N
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M/LC*$%1/.4LDS@'?_ZLA>E*R_8,4)[/F&U\W@]4UXP1= R6QG:2Q+6IR[G_
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M"D17*5"@#+8:LKY)AEY8YB4S^M+MQ91.+;?(U2&#_OF*N1FZ-412*/3JSO?
M8#L,)\CCH^EZ,UXZQ^G#3V]A-[<"P=;3T'"[*WX=A!$\-%;Y&ABE&4,V\%SB
MB4Z=7>AQ*MVPO89_&%?4(Z2Q#9'T'1L4OJ2(=1= A2WNSH?;9:M4=1?C%J:$
ME,P)O43[94A\@._7E"TTLQ2WBAD^*6*W %T?V%-5/7[$),W&^;6DR;6#^-L'
M,3[MF%&LOQ LN?L*5/?PR. '(G6N%!24AG88WA![>9:A?,>%(75367$*(?QY
MKLQ[&]CU.1@C 9'\^ NP3KN[UM!YEJW(R6!KO(7"N(>AP539_PZFR9YV*?+#
M6'W%!X%+I2I$ 9Z=M1!^.UNPO&EB8;$=R+>9?KPZX?K:_E7O0*(&#.R80&"4
MVQ5EOG=/;)7&NN)2BTOSW>V[3Z84'_QT0=\X5'"E[S0WJQ@H =UXG"E<SB$E
MQI9;OM'&E=;;BDGQW2 CJ\;'#]#YA7H]9;:QVUDRYGNP]&9?&P-I@]G M@T@
M16"!W^]?RJC4KOW[;Y\U_&F;M,X!%Y-SQA\$ ^,U1YYQS[SBLN?TM-T2O8LQ
MXG]NPNQ]PUI(K-__BA3->@6W7QO\/G$:#VZ%7@L2"<3 N< <D:D_4<^$QP9^
M@HZ16=$6DY7,G+)%W^J$0FON>R8^GLOJG\:BR2//^IE7C1$HU)BYS^9O-\),
MATH5-,R566M7"GUCF*%WI%K"AMWD?:PYIT:@N$J4RZXR!YD=%]5^(KH;I+"^
MV_0\5:I[N-[&KH2ZEAN\"$PB/BJD?$;9S&>TVG%L*3--0$1$8(TV?L<C;LCZ
M3#[=8D2V-@M5!;G]4^)'=UL@R2EDIEEX[ )/?G&+ZXF2<$;BYVI/M7R_E/Z3
M'0&?&"30A@FQ.7"_W/-XPNTE)B(X"U&-A)@7-1>DS<6_^KDTZ("J-';UE(13
M;.IY$&\F0P7[6[T%GU$LRVSLM$8:G[%8@.6]<XNO3UVAG_/.%9:Q2YN R[+#
MUR$$A0M<-?LUF.$SR()Y*#Y59%)G?=2>5PNKGU#[Z3[12I8W^5XF9->$I#^B
M)V3 HM9\RH?@OV?A -_;^T2VHXVOGI&RD>I:R'A:\+# ^>6;S#2; F<+]ELE
M;[Z='N@);0[X8!U^P@++:T!DV)84*\>W<F,S1"'W.,C+'!*2$/#-XBQ'F1;E
M\A1\,X@?]]3%@#<3CAG!WE[I!5 MJ'Z/"RI(3@U-TMF08HK(8V@$OA<)TEW,
MH]M^HGD'J24FV5OT(NS!S9X;EH9OC "&M'>X/&VS.3L$_4'2&%F5)PM,)+42
M)9Q_B?'05>WDOHR4ERE_%#P"G*A#NQ[K"=D*BH'596;?PY%F*5:9??--K+M'
MDW:#18<!=H/-Z[E^YHM1[3S4>JP]GY2YB+H=J:W](X.%SH2:%(V!A,*[D@Q7
M6WND6C!BM!L+@DD[J+3(3@8NG8JVE-ZV+^N7JY(7FJ%G/Z'./#SDZ[CR8LPP
M(YEGDO)P#C1BX"%<+?)"Y!]>M:S'X0EJ7K<NS0.0D%TC=/"F9?&WW=46D)+H
M.: M[^K1A<0&0'N"E8<PF/&E\M E""MG"[;T:I;7N#?W<R5I6>:)?^HK-H.\
M+VZR.3H8:@U.:/=)O>.4'C?V<9MVM]VW>\A?CM2=UCU5@F_;'RT;$B&+W/3Z
MM<V3:XFH(932F,V"[BUMMSJ ]/$]D_*G6ES3/;:R9Y7G@+<&$0&9N..89B$]
M<(F$?Z#D('VG/(J/V>3*NO8XG/?E#<_Z9WMVB?5Y6"G2>R**9$QT)UF2>::4
M[\QLQT_=I9YXW5!_X5@=\<"_,8J617.2>1MPYY1^,PQFQ'^ 9^C.9642+K#+
MCEV9:C;[\3G GNDRV7%$+";7X&:0TGC9X73L8S\1SV)Y<(;)T&^9/^8:[Q<?
M*9IXFJ\F-8F6ODHY2,LRZ)O=,>>'W9[\4N-KABUOWCMK<I52<5#F=,FC"1%W
M3J\_!X1*Q<$\N@F/UI 3#N-[.\7)[PQ[5R&P_&3+<.I(0XU CL,NHOL2,)TD
MV.;->>\< &P5 *T+/]%W/S%?B^IHB477H)/(IB (;IO@-J[,%"156QNM!B-F
M.:?ME-E$\D,9V;VR]^8U/-ZB8/NY.;1;/5&+T]>3:>[>GRC;D^I,"!D73;M9
M&:G]G$RZYU_.3O4>Y_#>B692P!>L'5 *64?V54^_B@$5N\K4)$@=%TTV[MGW
M-^J1%/R<.DV >F>E93/9(,76] QE*^W]M#G>8:$A=ZR-XX7@J8])UDFVU&RQ
MW>@U3$]_._B%AOK;*4<=AB?Z[BW<N\9I6PF\1MP2IU]4GWLY6-H'E[K1;AZ'
MY'7PA5]J/*MJ<512,18*Q(^W&VMS>7QV132\&SLNOQH+#.5KY?>,4'6X'/KV
MBI"VNDCAX$+?QN'8UN;>O[KG4ZLIZ?U]2IRS-K8J">2D#S5$A:52<%3M ;QH
M ;!?]%D1'*8MR,3[[93 ZF878<N3%B=Y_%WSGY$H*^V/4T\R:7H%W3E,%.1)
MDE*YNT#D7+3KB%-HXFB_6F07J\Q+TIL.EY+.TC;9007/ #D?[XI,W>,?[8 *
M1>3>;WM&LTMT(NSB"X<C%+7M\5#+FA%$NK:)SD2C$([4^6?S0SA3G^"VT;\%
MR_X?S[4S'YK>Z7YF[")O5XB%/O5_X/7-H1Q;=4*AW>S:"V^D+NC6@)=;6J3Q
M;".4C/M'EZW=(^NRE+YKZKND9R\.1Z&Z9ZN36% N92NWLO6FRB#A3D53B-HO
MTH&OOV517@?)+<.8NEIN> ?;+9\E==FAZ-N9B6$4DS*BZ1'DAM_S'EV9RFJS
M@,C,=V_*%F>ML,CZT-VW[YQSI2UZ42KJ#F=%%)J@)SBR1$BG2I5MZ;(8,[#G
MSIBB6*&?FA7..SXU_]+5(-+9XS?1M^D/)#XR/4R<)T';6J 9F3I<0Z.NI?"
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M,4^?Z :L55%$@D#$8)R)!G*"[!Y8(FEN(&BE_J[(#BSS=.".=8%Z<9MB\GI
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MF<J%?*[QLS_\/0).I*A0PYF[[,\O4:+5,Z.G8^H(*(_7]$^%D,T*$16PRHA
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M!UYRYH$SG5=LEX/:UWWM_J2B\(7,?Z(VZ2Y15Q&*C"][(B/'(P_PG2,S0I1
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M/:0+8B9<XW.&>_';VC!2C\^KE\YOS-S<QS3G(.Y5OT.ZS_PC1]#3L!#K:=)
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MF,YC58I23@'1]NFLP5\[M!(973+W6<^7'J6^#GVC,;:S^F']QF#!1^<T+DZ
M5<VX9&V_RDC "NE0:4WE6+:]-^Q$[FYDG\2'_^O=68RJ7>N]SOO2B;I^\?7?
M?VR'=E0AZ6H;;2('>!;\'(U_4JU?UT:@;LQ.*8%X!I58*Q,7V\O@>=VF=(#4
M,/ G)J;HA363K='Y#D87GKD(-0;: <SP+(-CZ*/5<]RQAWA.EU\P8Z9NZ]>G
M@ 1B^9]+HC\@TI]UCO-$W*Z--.V]2W[!(:3:+X^Q,Y%V?4;.ER9;MQ(J+A63
M-(D,Q_?LJ4W0KOY%B["EW6X0U53=(X5]!N>Y/XO=Z+\HD_="Y4?T X:\SK:"
M5J\ERRXXS]V,K0@VTEJQ6D#1AL)"IH=:HKSW)6D.,E_CLPO,>@9Z7@5H$BJF
M/$L _:ONNR!.PB!EF&GOVTW=EFL#?>+."0 ZM$7AK,<<4I?(9]5,-*5P&2_T
MC"KGD+#)70VU7+Z0^VH9?F%+<*R\Q LWPLT)OO]AO@<M>,TKS=G6Y1'J95\5
M[#\_LRG1I,>WZXYW@6=C3#^:  ;CZ\ ^I'^>MK O>4@]2!8,DCVK&:ZVMH='
MZ6)=K<&E#^O6#]VV22X\_$X?+J*>_WP[\YK;\[/:#\S8-$?]MAG %:M  !Z,
MBZ6.Z[J^T<5W@+B#=F/SV4C344$^EMUVE=D%LR=9"\>/6X1$DR<BO/HQ?YW8
MXHL&",$]1P;"R\TE8W7M9,%Q-4KX%P0"'&-KWM[OT5+Y](_T8>4[0 $3@.$7
MPYL;1?4WAZYG8U\2A%EU2S\&_91C L45L//T\-_EO4Z(-V5P-C8&&A0P'%G]
M._(0V9EP'? YP:OTU8T A@-IX&# ]?-#F"M#A#Q-DQ8,2>"==DDM!Q_8YT78
MC8JZFL^"9C^SKP"T .%T5!*/8_QT&^F)'Q9N3HT,)^WV.=94QI(H"W+QY=ZP
M)P2EN-?ZR874J-_*,5,_AUX)H)-E)J_.^OG0,Y1&5)Z;C[6%I4^YXU<;G;EI
M>R_F_#=:TO'K H0V7I#KV;+#A:SG8'>H84NG 'XQ<%D8SF:B_%,..*S9_%&8
M5YQ]6EU EYJ'M&^12DT4ES$@0IEF<?(5Y)%W>_A:,U4T@I>:\<B/6KA"6JF%
M&=62+3:8WH&P^B*R/B4FE&7SGJ&)&/E>J>'UQXX:J"X@3J[O\!1 JHFX!1-L
MI")13\NZG$EX^PE035V>B5P5DKCWS#-PR(^_?HOE3OSR HR0$M-6',Z^I/F&
MIN?GY85R?_FOO)5"4DB .;3>0'&48OC2<7M%Z2='V,N6(/5I1W?2_$PN_]Z4
M;I0@-&M3'7 1D/*L=*M/_ 'SG@@!'@.40(/X["Q(ZY17$_H2AH'RUM,1Y]"C
MOC#3I2'9\VFOQ#CM?MX*FFS,E:\)#76YV#W487>R>G(V05Q&J(9TT8VFAA0T
M7(1::$.VX@RMI*KV3O_RU!?_M?+/<PU1DPR]IEPQ5?%_'*\-PA? 4BZ^[2<L
M8S0]YY+NBT:^(\TRGQO,^$@INI?UJ0<'%6*)&A]0F3KM9339=MUC'@-QS3?Z
MO+1;5"<_?[]%X 5W"=X$2NC.SM*O[2O5*9#<1M&P;'NG)TRKV?-SAZ[JOP\F
MF9Y8I9L!>,.0=J_^]Z7L5YD+:%_</[_A<"L=6?H_9]4SXI^*O)Z?H8<-">:G
M@-2@M#C(-6&YNB2)H\J$ZIV@X\9*:_?=1[<Z&+M]G /@BV[Y\+L :B(EFG1(
M%%CLF8!YD>1L$[O_9I;F[(RTYT2FZ^D_%O;@G6QP-)28 BC-7WIMLVK3 Z3*
M:A)5"3\J,")42+L*%-0[$.CCMMP\+UOE6RGOS>MBX1I^0\<Z.7E%HS.X;E9^
M4(85+4Z"%VYL3SWHT?V^\MPPK;OR/E1KY%F*\H9#N ?):^E%2<G?.3AWBT33
M7+F#O36(>V,4;T9,WYEF9_[7ME\F9:?D#>BC7G 70;'BU2=4%R@.B0:EJH<[
M/,=(C=-L"JF=>(OQB=XQK3%UG69V+_"]^^?DH]<<Y6L(>9,;6"$:'SNAH2=W
M"RY*'5CFH$R]-%H%+Z;&85WH-_))\P+.ND(#7V9-/7_=X+].TKKZ1(LAE)Z@
M<!"N,NY>5QLUH63<8,AVHE%R0:_)WXY;]$<SU^*MXW(K\@Z7^WER,P5VYBM#
MF 851&BN2N2A&5&34="JAV SWQ;5(B]!2@13M'R^+2_$0L1G-4ND.'2%3ZOY
MY8_JZ^<]%/Z>%&XH;VC;5R+6^D,NU44XY@;&2W]P^=C_/D;W4  ERC+MF26E
M=?1O-6W80O^-RO2=T2Q'K:!D!=?A7?6@8T/%G>:6#L'M=4R@G<NYFP92)2S"
M9QNC@!$+:@)=L7BOVRW;F"$E8A2E'X,T!CRXX>WD:JF]D@64TUBCW02A*OPE
M=*9@;BAH,.$!*3B2J_JK$?^>(C+@=[ZS24%O@GT&0DO\-=N!9XI9UH/S0L):
M1R)I=$]C !Q$US_[X"_TR386_<OS5/ R?#O7IQ :0#DZ"&?NSD'&$^ODV(^W
M^B/ZBJMRP_AN;P7Z2]^X:*89@V7YH6[3AT2G$F69DBL;",!W#0LLK5-Q<&;-
M*.G&Z;KC+9219-]7A]^G /<H84[,X;XK]/&@E5B- 0@-%("[[;Y#BOG(>V.N
M077ND^TQ>2$>X2Y-40B-PV"^OD /79_#+#.W!"V>R!\OF-%!=HZ=2 8/[?#*
M3.;8\AVU8^FG1(57 +_E!BL&JSL-^L_O73]_@UD\Z*R$/Z0!CYUHCN3DAFZD
M&)2O&\E/TT,9ZBK3%%LF5FM("P4-%F+%1 +>7/WK,T@1I[C[;Z#W;E*@@Q\!
M#X %G4%,B1#UQ;'F @PTJ:1;YF/9\1X:O-^-E4!RK9VC#U-Z;\FGK_WCPO4D
M^TV*"K0'_LQ:5#"YN'T*ZXMP=O9=$8R9PMYR_H<!\,$8D,;::QJX!19,+($,
M'UI3K$ESMQB*S2:4S]\:!@RK&@ 1\&K+[3B, ,F4<@KH#D,*+WCERW.'55$=
MNVNDFR[DR3YD0(\'91/C:]'*)L*=+O"\^=I]_T.WKI$H/ ==C#V.+D8%=TD(
MUS<U?6]J2;48_507NE-Y-;2R)/CMP&/I<9UFY<>-_V8,O=Z=67D_B_H>R@>Z
M<7V&__4EU-K??,^^-!XVPWI>TP4V;GV4WOW0PUT#5O6F(9'40!.67N=.PD9'
M']7?G*E<@SK3IGDXL@!ZO!DVOF3^$)#EJ-Y<_ZOQL/T4H+?I";C-L,GP-^&F
M]J+;!OA_^G6+_^J_^J_^7PI^.ON_ %!+ P04    "  OBH1:52A/$X41! !J
MH"4 #0   'IK,C4S,CDP,BYH=&WLO6EWVTB6(/J=OR+:/=7EG$?2!#>1=J;G
MT!+E9*6V)N6JRM=O3IT@$!21!@$F%LFL7__NO1&!A01E2I9$2$)WG;2()1#+
MW=>?_\^WA<.NA1_8GOO+7XUZXZ],N*9GV>[5+W\=3 Y'H[_^GX^5G_^C5AN=
M70X_C_[)IBLV_'?MGY_&)[4:W)F',  ,X@:_O)F'X?+]NW<W-S?UFU;=\Z_>
M&?U^_]TW?.:-?.B]8[M?,T]^F_H./=ML-%KO\/:4!T(_CG<M.WXA_7#WG;P9
M/[HQ=&82>%<_:HFU(0-AUJ^\ZW=P X9NMN,Q SMO1/BZ\>Z?IR<3<RX6O&:[
M0<A=,S-I^Y9%KC]O!UZ[:1S<]H9\(K,K8>ZN=.2NA/K1*/2WCMM_!W?C27P+
M:[ -F8?UMM@N[)[ ,W\7^MP-9IZ_X"& #(QB=&J-7JUEI,;)_^!M@S2;M4:S
M9G3U(*87N:&_RC\D=3-S4(&??'7&@RE]$2YF'K*_;=L*HY6:7@PEH5\+5TL1
MY+\%M]_A;37]5FH/HF#MQ7A*^DYF7N*;.<]?*M[)/.IRVPSRGZ5;V4VQS?Q'
MX4;VP7#I;WD2[F0>A05<<;[,71G>R'NX)J;;7\";F9?,Q6*:V7% E;G-7:]N
M>@MZTF@F6RU,:\O6F=8ZA&P[E/A6=AZ1[P,MW :$ZF[V(-UHT<Q#RV8#CC(4
M;F!/'5'#QX1/L!_4FO5&_,655>.S6A!-MWPSOI^=*%V^[97UQ[<^*Q_\^/-<
M<.OCSPL1<H9/UL2?D7W]RYM#SX5%A+5+V*PWS)2_?GD3PMK>(9'_P,PY]P,1
M_O+E\KC6>_/NX\^A'3KBXR'026_!I^QR#@M?BB@$6&4GH55G-69T6NUFNP=_
MP=<[/[^3K_S\3DYBZEDK%H0K1_SR9@9?K 7VO\5[H[$,/]#/&5_8SNK]I;T0
M 3L3-VP,'W*KC"Y462!\>_8!EF39UYO#,!IG?W<K3/U?^C'+#I8.7[UW/5>D
M'[&_O<<M$?Y'^M.V+.'2GS//"UTO%,R&DST^PUULM)K=IM'IMCKM=H]._KW#
M@:>_$6[MR^3-Q\NY'3"@+DYDP;:9?&F'W&&.%P3PTYLQOESZWC<;"+1P5NQ_
M&>UJL]EFX=R+ NY: 0/BS6[FMCF':P(@8;'D[HK=V([#3%_ 6XRS602_KKD3
M$:0S[CC>#;*]^L_O4I,&&6+K$CI&&R"CTS):.4LX$4$ 7^<N,^*)[31RFT;N
M=@#LNJUVSLAGT6(J?-R& , 9-F3. S85PF6^"'V/FZ%]C=O"K3^B(!06"SVX
M,W.$&=)VT%MP!>4J^+5T[)")V0QNP[.P$Z?<AXTSNE4$>(.]A7?A<S#(&<[3
M^.D.^]-O&,"]#"-G%08; )6Q3=B@(['T CAA?\4F-+>W@Z/)3S##):P.4#B
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MW>N_^0C_*OF3YI!\]>/621QY)EQSPV,[ !"^(.@XAFO!O2?2;[SY>/S[SA,
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M*7S=4R)^T*R0_>2B/*:%$M0.WPYM>,XG$['PA86VK]!C4Y&Z5F7+R \B]%G
M+7B-C&0R+0&.#,-\!F;!',4AFOF9*1QGR2T40WYY [0 ?\.\3/T[9^-2@2'Q
M/G]0+L1&XR_I!%C,D]7)MC(I>2.;E;&-"S@Y?_,Y></*.BT[G?J!\9</U\(/
M;:!=ZKLR.W@M5[@9)P3[5].WC2K#__UTE^W,G=+]B- 3\3$[=&0P S?GS,3"
M6;L#H5K<N]#:\2P:]8/FMJ-XV%W>S)&^!=+OO ZC7>_V2IC:!E,^)Z5ELEK
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MQ0E8>EYUP?XW)BS,T!DC*>@'YKG."M-$3(Q%DBZ8&SN<D_O%3U6O0EO3NKG
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M%GR-0ZU"79^9GDELN@#_FGG$4TJJNLI26K+2P3P9D>S)F$(&MP$70I'_X:2
MGVRL9U.\B1NHDB?4"RGY_$Y2<8E0)4(]P@R)"VB.DJJ4D\$P]#VL9.K>1N=(
MT#5L+#KGVU13B# HXV+)0XZ4VS$)W:*.KS-^[<GP<\ >K.83%ZY?.E3>;#9[
M&_Q$21SN2B$GQ9OL&R1*M'E-:"-3%'2V@XXPTFXUY;%3+C7T)L@:)22-47ZS
M31E#A$MH,_2BA =1:H85D=?.\LR(&!DE.%,EQ2J;"?1;KF(&)QV7JK*(K(F
M9?\"64CO"J,>J'@JIGW(B7&5(%B-PW\W9KQFCYQB&HD5F3(O4*" Z9+)AR+
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MU0&]>]G&1YKLI,/]8-FP-X&M;$U$"K%Q JR/J@#)RW]XL!4,]S7R9>)9HB$
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MV[C,76J-N3LH@ZR!O9N.P)U#L)A[#@;OAG90>7LQ.?R)O:4D[!D):,1O?I(
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M!2;BDM@\+B0+0ZCMT< S<O?S,J23E6,63J(S2G[)_ OC9HJL],M=-W!7_DG
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MUYO>_YH+,@U:%(^<(EQ*(0,!+T@YBB>0W[?GKN)H#F''T'B9!EPITD6G^-J
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MEWYD[H)$!6-?VN=K.H61:)/8*03];^V:,(Q KI>\42#2Z=EUC\22[(3-G+I
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MUJ:I_7:ML&@VIBFLWE@B!G/4'OA ];G]L,<1RYJK_HM2D.M:POSA#BNW J.
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M=Y_-F@4I_FII60Y/[1C(L.24WR0!=!5;W @X:OH((<%X=%=TQ]ASI0[4@(R
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M5YPQ8Z!GG(G[?>S<$$CX7=M[CV>Q_>![4EY!?>M@?<OG_*.D:5%*%S"E*=<
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M/LK_:<'^B\917(0=S*QE6GC49$K\OUAQ^B^?EJ\:^3GX79T]_JF*A\6Y4D1
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M!R4"@NR@:IYL([:*M(^#,QF\A&D*)^<3$ZKB0&H128&W.BD&-((4;KOQL5J
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MH*NTYB**X0H4])6M.?@P<O-76)\WTN.%W:IA,4HC?A3-Q:E*B<@SJ@^L^UF
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M"IC "C=(3J("P_I0=6H$AA=H4\@_&%KE75C^&:%-2LY[C#=U^HWI$*KYHG"
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MH#O6< '0=BYP+9.U+EGE0^ ]5![,U*X5UHF@W[/#S7M;D%UH%Q]03&)'B<>
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M;Y=!?PF[Y,(C4B,2 T<DYKHGP!YF'<C93^&<) L#1?9I7BXYJMT+>H^.I B
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M<;:[>S@^?I)E3_:&>T>#)[OCI\/!\<G7A(?I,^V:AE>#3U3:5&4Q<N,XVNW
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MAR]9GDN?,UJD33K/E\C!& 0D6+RALCG568C]]I9XU;A17 L]/5H5W3\LXQ!
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MZRJR#+)J<'RK>D6\2,/+N<-:8BH-P7;W/3:MN@<9XX5O^E(2<X8(@2 N\!%
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MB(:7U:28^%]AHS+8L:;XPR*Z#-QS@-IF>#.CWF;:A)X@COP=.KL<=)V2 8?
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M@>3O58G5/C1%144!G71J)T,IA*#DZWRQDLC.Q!#1'X/L"1+\@SB/Y&L,')8
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M-L>J!)(=N]'24J(<3U1R%Z07Q,"@&AT-2NB$Z+F8RR 9CGD'3X#<.M0+J@-
MIM _CK60I94$UX%=@(M!6K_W<MK]Z W<'>UO0@\+,DV3-#@[S.D1*SO^6NXV
MNM#.*?6=T1WQ1@UHMP]#!;(_44^=!BH!HQ36DGX1GWG/SP-_/5"QZ%ZHTD4*
M_UBWR^@2N5?:_21^567[\<U^_#.\D:9))869Q(<G\<O]$Q#-PZ.G3^.]PT/X
MYT71[&/%_/!1(B*\:HBS7/CEW'&U$&*4'S?X9U&W15 'BC9)?EV5:U97 T#
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MX7Q($<1O(K?^Z*'V[E11^N\(W<G^6^;\CKY9CYM8HO5R>2%XCY0UGLH'6PN
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M;"Z)-]8W3+K(]1*T[+*=\#4+ L6"K+Q*I@>GK+I-W1&#.3,_H/^Z:N4T9)Q
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M1(5CXSW(+!NRBD2?@35D-0O17I<-SV.PMS&+SO\4?H']PJX^JGFLI@ZJ=<W
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M^ES38602AUE<K52#FZ".*FNKH5 OGJ4%E8%BHY0O:"1X5#Z'@%85Y?@,H'Q
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M3XC_R6]Q.UZ%CME\UW[/U7ML^>_K[A1TAE<;EDWC+]IHN$CT=BB/N5J17M)
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M<-L4\H?J0WO,XZ/9PD2J,^E@6&6%;'M[\A-OTA.?9[4_O52Y8XTVC8=6-O<
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M99;S_F^"T*TK;*D=<W&9R\MK4<YC2ET%NPD(4-+V#%"(^B<N.:D$,:W,)F=
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MFP-6-,_U>*L5^+,BZSSK^(E"#26/MV^E>_,&GHO9?[[O]Y!E7+NOIG<)J*@
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MKC=I"4/6=DE?"K-C6$YJG9PF@"0V5Q3<9?T<4EN5T>\ZZPOT&$!5&$ILENG
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M&(M2<AS0(P[;Q#-N+D0#:8(7!/N %X2[P N^L5CM]*!CM>_S\(U<E%LXO<$
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M2>/C>[#X.F_#73IM2,='# @$Y2MO<YT!ND)7C9D)[PBG:Q"2*"-N>+IFPW[
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M<+\E/GSCE /BO'Z3O;>ZD>L%-9$]5-ZZLU]ZLW=#O2,H=WI"&Z76CMHR&JN
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M4+ARC.6QE;[@^PB:D)PQ=F*X+(HD7 JT"W,3H5A0)R<=>&\@5^*3GJ1L:4O
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M \K/]W:7X*(B!)!/5N1P79:4^$28L,:P06X*43YI*8K2<Y#SHDL,,XV[P,<
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MP"XIJ+.5@ZU/_D,2[ =>?[)5;5T<B_1 7):2H3M15&B;%T[?W[&&D*VLLD#
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M0!^*W%)BO1PHH:5K[AK7=2=2EHI%FE%.))E,\!16%\/ ;S^\;RLAQD)@Y]5
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ML2A0B4C==]/<C#PX[X?^R &-3'!2D!8<%Z7Z03#64BD16SN6A"[1,N4Z@WN
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MP*;=HA_.MJ3(&6>K)O-"('$VE%V:$6$EZ;]615HF*67X!+"H%?E6Y/="Y(5
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M%) +:IHBU#/,E0?8J5C!_"TJE0GWUYPTY"E=8]I<A&*U:QV*C1[ MB@\DU5
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M>Y,#8Y)@LSKUSQV7!$2?G83[NI=ZNS<L,#;\Z^\'*([OZ 4D'C223._\'1*
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M@C6%"\9;91,;C(D/"CI0;2=X9,E4ZU-?E62!"N,*=CN"Y51?@OKL SM[X<_
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M2_'!0=>"?W& JF)((T0L,C*YQBS-WJSV:7CAI >\?:#1E'8X!.B(]R[$;1,
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M&XZFH\GL/#Y')MYX/)F>M>=C;\]'J46WG$4Q@B=J<S*?27B6,*RX7(C]IPR
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M>'+X$3VU@SV+;R_>O0]?OZ;T+40 X1>O7W_WTY_^X^3D(HNUS79R\E-3:O6
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MWV.QR($O.OP%&&[!RU:'NG,7<.4S#5F*_I0VYK0#IC BP+3>@38Z;J,BS5=
M%2J3OS*3]_D_+=TG\7Z#7OM;=*<--<5V%U$(+X$^#VT8;57KJ1!WL*$H[#1Q
MCG8"X29568EV6X46%<,5_"CV)P^9<! V(1)*<WW_ZV\#!7IZ"QM ].=,5MX)
M[F&:#H?=D;,WSJ4#-.7A!?+)-KX!I$&L2VL"(WNG=K_7Y%RS" 6-\K$H(FU[
M@I6:9MH6C!)Q.6*M!2,]P#D;.X:UE@AA.P[=.YB;>B!)6L9SL.<I1N!)'DLM
M>#J6VDXX9>&#V@T&DU3$W?WR%Y.2-GC_:<'[LS]T\/Z15(QLY X[!JO$*PZ!
MJH8!?+XZ*X! /L^(KW>K5M,7 KM$K-\"U#*%*A?Z>A#B1'/*?]BX:H\9M7O"
MO3E*CTFW?-I__WN5%ZN; #S(RVNM(Z^UY:,7^5>E0.V6I^%OUPKX*9T+HOFB
MK^KG*/P='RVZE.)O"_T/A2R16K<+EWD!WHW6YQ_7':#)I2'@P[1FUZ>E7(:#
M0=A[-OA>;H<EU+610"2HQ_/5L@1W&/3Z;8XWQB*_ _Y=2H.4,+<2GJ<B?3E<
MJ4P5^@DW-$T, =G9EYU@L2K*%5#3LCQ=0%9XC@&_#-DS[76WT:J!7_EK0.RD
MT7VOISN54T*!NPS+N]S_)*WGLGDUX;<04BD2W"*3(/+&J:_+')><.$7E@=65
M#[R5WVVY._JLQFJQA#@6D+4*&?3]\X_ 'M V"'JWF&L"IJ#L5G\O\?8F@H.?
MSU=H\ E!.?O*&\BMD;F5(Y%+?9KP[0VC0EOW]Y4^P+,UAG<K>BGP]5*'U1$\
M%TQ->F:LO7*2!!0!(-$6F7 W&>7Z#NFS;W(PKW?>X^">[>N/*H=FQY-RA#S@
M]$79)JV:H^1?^D.9D>2YON> UYCFY,D\,KJB$6^^(P]BF[$C;@2:C&SPD<A0
MI!8$)D/3HBHBQZ=-1L >F? /U.$/5^*!JZXC3N4@07N2(]>OY6FGRY U<WBY
MS/6>_1H5']22U;9G,;OK;!X,PH?F$3P/+4%X?@X[%&#V+,*L;H<I?;5-KH^C
MA'5SB%/CB4JSVWQ^*Y3"I3:Z.WA\B."XT)*HQ[Q,6;?C;_DPD\Y:HY066GBC
M8FU$%:F#Q6D)4$]H=0UY !QCCC9#$:<EY@9 +BN/. 8?0+]4?[C?_=Z<0CXW
M[HG!S^M3O4CQ+,W\L17NUT5C^H?,>=94@2:AL+C,%@:'<7I<0?C3E;Y]EW0
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M_%\_NL) JJD^O3+]M_JAMWWNE0=W\.=.J8WIF7S+:KF_\*]$#?[E%/14"K;
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M;N600OO_]5U7V^%J/E^ ?Y%=F9_UF&/YN6&]+J"*Y<>*Z^JD )P)S=5LR7D
M@5.JFL=U(YIXH.N_KA"KC[__L4)ES4S6#R^T^\0-^=*RQZ)%N_OWO'9N-^9
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M,]OT#VBGK![13WFM;0_TZ[D\OWX]$N@REQ9)PA)C,IU-(8=3G+Z)\72*6Y=
M#!'Q;[Y))X2!)O/6,:WO7A3R3F)=%&=IJ$I#M4XY2J8@J$V/F^CC)KZ#!TW:
MS<:.N86-YT2Q(>8C+;/GC;#2D8U$!_H:.9AW2M'-2]5X8;YD+XDRD_EL.%O[
M;+[IMDM<=M<65;S4J6YD:RXE G:<G24"UB"\6H* ,L9RZB;N0,!T9K!$0(F
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MG]+S^%>3DLK\0U%4LK"_F/"-@S!W_UFGYH\H-3VCLK^'L^TR>]B9S@_S.4@
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M!%F&Y)^.$DZ094C^$=E9U62C):NE>CSINQ+VX:55>>Y6I4@^HES/I8;CJ?I
M4R?]M2ZE#/=4AEL4V5SSI89#K,9@HO=89 5P" FFRG[*S(UI6I'MNL$D[4GI
MCVA]&9)_.DHX098A^4=D?U;=9W[^ FL*1[Q;5 OP9,Y6%_Q>,F=+VO+2EA?0
M'S?.=2O9DO;1T% \39GVU]*7 MU3@6Y1?G,]38Z1WPH+>0_O;-(=^:U1)^^/
M\RX_^ED G5P0LU&XE1VDV_=P$]LXN@79QE*GJ*C<6??B^Z_WYUK@9()Z4M>7
MH")!I2.@TB*&Y)H'E<60L[$WNA,GZ(9Q\<Y;+NUP2;@JH V'@+/(ELL)%)6!
MH) ._'$'.H&)1V01^:CP8'FZ]QTX%H:*K@W5R7"J#R?3X1_[==8,'%R[LW<Q
M&%@$ \IJKD^!_<JUG;]>A'Z$R?KRAXEDK3-@K9PJ<QAK%2HT76"MFER:1@]=
MFBV[,4_<TAKMS_97=M! ]!YN8AO3F079QG)SDD5ES]I7WW]'9JY?8\8)47,E
MD:&-174^2#B1<-(9.&D1/7+=)'>C1X4C8 ;J\.#.KOU"CYI=E]TP<T6TI.4,
M%DDO2:]SH)>L/=U4&^X6IH\7Y.K8#WY!^%^1'3[+PE,!5-NN=C6?B,T]LJ"Q
MLWPMQ/9(_I'\(W)!;.BM*LQRJ6?N@$]L;]-_1E3W"-#.0*:N:(JJCG1E2#8V
MY_N$J*7GWH6>]?V3]\7T_\=T(ES"C_'[W<T?7[#_!UU!XM%0LAX-9<VA<1E@
M"YP:/SQ_%F!W3_155U1R1TT9*6-#*XSBEUGTINOV]$6[7H$'9N,-M#)]] A+
M0I?H.@H7GD\(/GNUCTSTB555-89&KH%.YHD9S=/KEGAN_KSI4]Y^^K"WA<YH
MJ P4A?X__XB02E4B?#Y556TZ.?5Q-GGOB,?9^3"). 5,G,P >7-T@RV\O,<^
MTE4"1V13!_#4#&AR'^H#1'ZYPN2*C]AYYM]Z\>>7,K.LQ\:P>)LIZ27IU1]Z
M5:+!==8/<!L$,#H>CEHO"H.0_,-V'_:H$0:<N\K4F.KCL9*;T, .V\_IU>I1
M'O;IHT334=2)KDSU7#.!G&; =J&>=9(]&JBZ-B"*YGZU;K!'Z0DR:H\R5";3
M<4[M*;/]%2@[910SNL+)"=M?P3JUB3$@K#H8%RAEN3<8/FRJ:D5Z&J537B=K
M3!OKNH$M_0_2?]7Z,GKHUR]E_@^UR43+Y9AD8+FLKZ-THLG<?L*SRW]CW[MX
M<]G7R:3=% )!EG&VLJ@/M9V^J[+.4BF+(A:@UL)8U[.9#<0R';0R[=FE[2++
M7-FAZ4A/8(\]%>)MIHCT$BQSIU3"[R0WHS85\2]$PF_==TR^:QY..QH0>K5S
M)$C1$$@T6I2$G#NQO"14EP:O*L/!:'SPJ&81)*'CW0#KT9<L*UI&CAGB&>&"
MN6W9H6SY)];*9,L_V9TK7ICLSG44< I7*?NBW(F?F[WW%8<F6?#LO>F[A&6#
M#'S?,/2N4PU& =E_\C70 K3!2--%+8>K'F^ZS&S[PFZ=H(H$UHX#:YLXFG,B
M'X6CE1E1*8Y.)L28$GI48A=@5$S4E-72@OIZI-M:TDO2ZQSHU7&/7Y/-\H),
M&?7_^=-$4\>OFRRF%M=4$&YETA\H_8'2;.V7/["4&3O-I8O3+"@.VN\I6-<;
M!=<'0UW8#GH25"2H= 146L00]2@,J3!_8#283L\<0Z1G2%JNTM,@Z27IU1J]
M:O(,]7R, BWM%,M3)% K:N%6)J<LR+;H\<)D6_3S\A7M&A=[[<Z:]AP1JV]T
MYMW315BL!)G.@TR+F+)K?&Q93*G.DZ1I W6HGC>F9,V8G_@;)N%A>"]YSIU'
MUM+T'VSW,O16KPC_Q"_Y0U".BN];XFJ<D9M/ _SS2Z2BZR5Y99&?W^"5%]AA
MTJ$3O;B^N7N)?+SR<4!'T6H*VFCB>;65;W8_S<;NE!3T7RF5$(,@VO72PH[#
M62AY#?2/7Q=LR2\;>_++ +%=071;7J_O[6O&@G]BLASSK:+\G$&?-2'P-\0F
M-8K9;X?*U?JO4^S:?(^_6P/E_]CQ7Q%%ZQAQO+#Q'+U_PE8$G8[0Y_G<MK!/
M;>4;V\=6Z/F,2[)_KB]N<P^+4&L=I XD2"-;OQ=ZZUL,(\('(M&N99M.3(02
MA\$&]J_YA7Y*WHQ!=8TV!R%#(8!FM)-_1D%HSY]?-P*8-V:(H7F7N5KYWB/9
M+_+O<('1/-G ("1?H=-47Z'KE6\[R*#MO89;MO2PO1!@"[Z1QS4MRUN2'S\3
ME$6N%X*'BQP7Y&HV45L>?-I%P@_CW2'*#(TNTFK)HJW:=H@<_+P[]LMRL.F#
MGK#(GMUJ_O!FFY-CU,S]+;)F[->C4.9^Q<UB%U0ZAY]-\#%_Y^+-!W2)],T-
MW'48K\P'?'GO8_/[I3DG#_+*='Z8ST%ZR"[\^*M<UV<XJ1#5++>+U " 3]*#
M\34G"00%UP_/G&(7?U! @;]LP ;_QW:N8&9*GB?>+?"2;/0](IQ+%$),3ALK
M0!_#V14]:FRBU@31?6#/;-.G(V]/E<PCM+L"#\B[K-#<):(",O5Y11X$E/8
MS1G#@-TQ2[_DS=.O %,Q=O!\*HW/A(((NS,\*PG)!8O+<\KA-,\)5,P%#IZ'
MK\PH].(W*&79.XPAP7#!^0MLXYE]Y+EUT>]W-V1SO"@@+!&@%_C)PJN0N>PI
MEY#MC%\MR;.$P<OZ^(3IN/4KMIG]@RW?K^@>'O>!EK;U^2B.O[*V[<HM++@N
M1UBSN[/5:9,7\V)\V<K#F?.Q (FR;52K]5!(8DEB26*)1ZP3NJL79*W5!_:5
MWFPGXZQ[Y/D!SA,Z=]RV&C][S5SXB5B7M3NCRY*J+D"1K%(%JT#D5;**9)5R
MK*)+5I&L4HY5M.ZQRFEYFBVE8G*GE?N \-,*NT'&&5?)+M>;4;%;0EI-YA N
M2:<E2C1R=TD,28S.$>,<,.JT,U&ZL7OC;&N'HG*#^K-!(LM7%25:0ZVI(3E?
M<8!-WUK0*.L,/V+'6T$,6[0Q,7(P4G4TGXI&7#F/J_]L5U1D5"I[W\@W0660
M=>W.;E+ >L]<%D7E0(JJJ*%7\6"5@:X5M8.0@B4%J_%!=Z7D*#<=\E YTA,Y
MJK"MRF2@3XJ*8:0<23D20HXV)J0/I[HRU',CC0Z5)2V1):W28M5QC\ZDJ@RI
M!N2FT[?H<#L4\393TDO22])+TJL=>E5U9+8V*O!OV,50O@;>2'.VM%T[""$G
MX3&?A"A>(\6>=UYMJH'W >RB*AU@"]FC-UV8[-%[%)_O2+^KS,^:&UC-L9B8
MM-=K2-RLIU4?D&OM-VJKS@B42""1H.-(4%;P<\ZLPP6_#M?P>* 4CIB3@B\%
M7PI^)9[LX7B4&]5[N/#7XLM6!\/AZ-RD7WJ\I8='>N0DO22])+TDO7J7;5O@
MFF&C"KR:"^\$R>\09!FUI)D(L3TR3:FS_%-_'FW.TDO*?;EI%S25.VL,QOJT
M/WE*W>1B098A9,Y?3G:FQ\A.'4Y1;3@PAE)VI.P(*SLY+Z.A3-3<!(8R\E.'
M7U&;#(:ZWA_YD1Y#:2%+CX:DEZ27I)>DUWGDR/)I(>X#LEW+6^(!<G%=]?KB
MYA4(M[*FTF-%W429XU);FHC,<2GC!GVQTQ[5%557-4TG_S#&.7OTD^<F09A;
MBJK-9KF.IT531GN3[-(8#[SLYJ9)..HX')5'GS'!GU/0IY8N# .R;1)_#B>Z
MA!L)-R+"3>I\'VFG*3MU..'U80D/?"<$272PD>$!Z0Z3[DM)+TDO22])KW-(
M*/[H!0&ZQT3_PB@TGV0F<><2<(38'IG U5G^J3R3./5A:<J86H'*9*S_L9$D
MJ2K:IIW);$M I ^^MWQ'[F:[$3&]TN'8;RE0L>]] [1Z_Q3Z)C');=?TGV]#
MO R(L0I&J>\Y#C570^SC(&S&+8\"LK'D:Q=O5'TP-8;]R1OKIKP(L@RA\R[W
M26G.&]2LE-;@ODZE5#,&FB:["4LI%5Y*$P?M4"="V:Y(UN#BS8CD9*!.E/Z(
MI/2H2@^"]/A(>DEZ27I)>IU'PC51L- ]=O'<EFG6K:],Q"[$:@?80J9GUY;C
M(Q.4*O ML_S(D3XE+XKM80+#/$_I+0/C>IS <_L)SR[_C7WOXLUEG_.4I/!+
MX:]%^,MUU5"W^;W*R'D%;F0IYU+.I9S7GH6L,EG/=QDO+^RU.JB'NJR\DLG(
MTE4DA*M(O,V4])+TDO22].J5Z]QHR#5:X 7ZA$/D0(XRT<Y0N,#H&9M^,\K5
MB4]=HQG5_LI*>]7;7VHMF]BTX2S0-J[;GF1A:.9%]P[NHN5<P^K%\(\/B2D]
M4A5-U55CF#.E":BF*6.BID8W94-+') XT!D<*.LJS]?P[Q%Y(?*LI<A+D9<B
M?T1F.'6:CXS\3-Y]8E]O+O=X,#($&LK7C-AG;?"?^!LF83/V'E Z^5GRT+_2
M;R +.PY?\U\OE OZ&FX8O^9/377!N;FTG>=7OWRSESA G_ /]-5;FNXO T3?
M&:  ^_:<Z8V!_6_\2E56858Z'#P/7[,]^!,[-N*-4Y2?+]:>@"VQ8\Z$BS=O
MS<"VD.G.T,QVHA#/F"=AA7WTF5<^H+N%Z>,.L%_/CYBF_ F'9.GI'6 +J8Q(
M941D/P3+TU-U71EJ>:/DO>F[A+F"+]BG.'S#8/H@C\3O=S=_D-__02^0U5-N
M/WW8TU>LG"F5Z[ZXN6IZS#2U9N5**9R%=5XZE@B+E6C6>30K"U[DCU'.M"H/
M7MM]*[6#U_!8\*IES<J5JA2U<I3@)<%+@E>%X!6L>894=:COU6*VP]=V'U'5
M\)7S:<'*CX:P6M9-(*S0DWU>$%9CGLGI,O0/^@+/D$FN93Y@1(AXCWWDS3?<
M/@'RHC (31?6,$#WP$>#-7_1BS_G\U9K(UL[?A]!?#K=\M<(HP (<[B+>W +
M[A_15$,%_\!$5Y7-DRY&LFL&9)\HCGV>\Z.:8=CG%,(.\D'49G+D#*4M3Y%;
M_N%^E".>01].!XHQ&8P*!UB(=(I+C)$8<Y+70IL.M4GUD++=,U ;I.02V$Z%
ME$J?0=.-P70Z&4P*!ZU+2)&0TFE(V? E3(BZ4CVH;+?5Z_,MD"?)^19.!99*
MGT/3QH/A9#K0)OW6579ES"3/4(+7=W\EGW2S6R!@5]8R;I(LFJ(/>3K.1C;.
M@.7BT%2<BS<O_OP2J>AZ25Y9Y.<W>.4%=IBX(]"+ZYN[E\C'*\)KV T#I"F;
M'HNK7_\"MWZ3_!7O3KEMVMB#QG?@VP(CT[*\)?GQ,TPD=KV0?!L>GES-)L+T
MX)L.6IE^".X:J/<A(D9KVTWPQ\S9*&/R%2*((5["+FW=DF-WPG*PZ0,/+UXO
M3?_!=B]#;\72I_AKSOEL)W*\E$%^"T,;U:+=XB:B"_+O\"PM^)B_<_'F [I$
MQN8SK=]H11#J\M['YO=+<T[N\\IT?IC/08+\OR[\^*O\S&$RK!")S3TD/8C@
MDS0)[#7?,:@R7T\4RWD8XP\*-N@O?.$;K/K3UDUCQV7.LL[0(D^*+3R9)KX=
M\^LM'+V>8+?_PN\6>$E^>(\(]Q,,Q!&!R@!]#&=7U-=H$T$/HOO GMFF;\,
MCKWLO'>S#I3TO7"8<VMTF!I9/+E+4 3@YMW"=!_(Q6T7O?]79(?/;!&@/K#7
MR0E98OT;5-PEQR6<2'F)/EPV<[@4KQLR05^94>C%;U"F8N\PX !- ^<OL$VV
M6SA9;EWT^]T-.3&\*"!2%: 7^,G"JQ %]&@UEV1#PN!E)6>%H,FZ,8^LAV:V
MQ6(([Q9U$SG (-K4'GWO1SE-LL+;C@ZX[;K=Q;>1-\[9L8:LOKSKE,^?6 6^
MX.H9_U?&R?3/6%G< CZ;&'2P$2GZ\_.H'HW:';(#ZV\TS.7ES:1#K+5J9>P
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M(*L\X"CM,\'E4(A%2#"8ZIH^/2C[H'XPZ&GD4Z* H(OH-0J4-&Y45=>,!F!
M&B8]-TRJB#.OS!G,N+]D'[S25D^B2]DG'"+'"P+@6Q0N,'K&IM\P'Y;?M0IA
MV_-GV,_<$@6>8\\0B( R0/"_5G#[A&659JG,%SL4< 9>:XWU:M9DI 1("9 2
M("7@'"6@E+6O#Z&7Q:::3Y276]?REO@CT6!ZG&HA!5\*_KD*OC$U\ITCZA-\
M,2OW) !( #A; !@:NM8< (@;T),@($&@?R!0SLVO&$0+R(7^ZT.!ZB)YVV,
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MK0>E('=F*><DR+E GZ9/-?5$8:XW?W@Z&"DMMXSHIF>MIHS96ICU2^1;"S/
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MYY>-_?EE@-@.(;I%K]?W.8MX#IZ'KYF+X$_L@(_94U%^OBCD([;4P^U\82L
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MO "H)AOQ;S,^/6A*)@,[^)2\"%DG/O@PSL*$PX@<*_ %%BPAEXW\@/HR[J.
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MRCC*C7F+!40)05-9"&7WW)^&@\V5'0(_,3WGY$4M["#T?%JCL;:FTBZ4GO%
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M3HUTOY*AS'!H0&7QG(]+2-_?"D(PN10SS E@QA@ T=?L>5)P$WJQV)L1.Q+
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M]B1Q I3I9/+.:(WD>JDQS3##8!T^F/XL]NJ1I^3-1X.L"+'*S+6+QT,;(:3
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M1[R#^'AR*?Z[.+.5#?-),C+8I]D.,:%/(X;DAK1Y33Q"+^F50)NZ4MV/)S!
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M%8(X%!5L/65:Z$*\%_:^1BK<AY#\+S&]NR>W5;-'40\'Q_,M4/5#X4L2>)H
M4]Z!<MS+NG8(@GT"W#F"EPH_*D5?[P0OC$^\#/CB&YI*\@G.0?6;]++4S1*S
M%6VP4FH2'X,^-<&J6SXNO64XB*Z#/EHI%GT7HG]TP])(X^8 73Y<PV2'E._,
MS.(9 'C>(KB&_SL7/=G+$/O]2N@97X?KG!><E]V!.^3G']4O%;$+V8^54K+*
MT+K=PU)]D"@]. 0>O)).*[%:ZTT8L!Q.>N:U[R"C4W[@0P,6:OOEJNW5ZA'.
MZNGL?S@+RY]C+ Y9_/)]#I?>T,B<=D.DBK$F ]@1FM7;SXDS]P?\G[!ZPH!A
M!/Z:#^'9$UK'RX;)W6;(_T9W 9M8M3VL$/W!2Y3G +:I]@R7'W(79$L E>3'
M]5$3*%_P7M4GLEZH+/7>7:^M@-F_H/_8KA]Z)P<.[:H+5!)DU7]U/IK'-Y&N
MI!0I:. >%JD!EL+MYO/N7>7,(X!K)-'>Q%&.;&['_3SPCE\PE]&W'@DLR9PX
ML.'?; L8K<!0MAR:8G\5)[IAW&_ATBBM[4 YZ4M8TD^II"U55I2=1:1*Z$V+
M*2%]?R,+&M#\#70STYNO1M(G9^F9&+4[1T_S2/I_B6G#Q;?$>X3'^-+'T%G$
M&7MWQ+["ZDS2K1O"37]9R?/>TR%(+Z.EQ)NP:-$F]/S0=&BR9E*Z"(.F'VB1
MET52Y8DDS&)'@X<[YK KF!;F8#W"XVF2YDNX=T&6EK/-QBS,]E64L(F:YL8,
M$"1&TE^P@:S<)XH6&\]=P'09=- LQ3BAU ?]9OO^8&5Y<+7IT9#7Y,)D]-GY
MX</@_G^3>9 >/,:ULS?9%F!65%PIM.UG"3-5=TVB$(9\09R>\#6M\X(46<39
MN33I/Z1EB##XV"-+^(/E&L"'-!Z9ANK3CU*KR6HU81X *&58+<-\8)6+;%NZ
M"0+/NJ<>O$_.W%T3RF5^"-Q*TU4/\QM=^A4^:QEZ<(V7':OG/H-,(0\M/7<M
M^:#7^=+:7!#I_CDU2'+<FG.YA-^2*5M.CN2_ ]<S$KA>##-IPA\D]ZA,S%+E
MX)C$16G@#/=PL^F2ND?7"-IK%5UX-9\#%3Q$-1]1S:=L$Q'5?$0UG[.IYI-C
MN/WR%7BN\\!K39[,@QN_O*:GX$ MH-P_$5W1H7/<TJ0\0J5^J#9K ;5OI<:J
M6%3#-TK#IA5\,><W4N@6TE=FAF64ODA7>Y4R;O<8 ?@+2R9$6R]K$(SRUD"4
MO5\XG.]8#62#J9B%=T*V70J6\C"4P:^4AIGFYKPG-750Q9[,DB1WN6-++Z^X
M[S7;$,\\(,T'1TY5N>+(WQ19HG"$P7:;ECU]^VLT*X:JJKH\EHM5*#X#BF&-
M[Z^A-P<A(UNH_$#\N6?1<LV'W<I_ACX^;O?3WCV_A]W\P?6>ORP_P;8>7[&X
M^6[YT=WOS0V(J7T308?_&]WM7[S].S!PJDI%N'$=5-O6EN]'J?HF)=('+WR0
M;C98S8!Y6&)/U.\?;F(7XDAZ9P'G/U"'56)6EMSS[G-R#]JHY/]"ZQ$,5H?5
M%2L'L4B%^<.QT(] ]1=?^NBZ"[KKL.$M,(P3=H_LVSZF1UAEOKX%'&)Z6+TJ
M&?K>@:%_+3,'P"@'</D!&S["L@"\$F?^C!;W+R'6,V:ULQPBK0!,/0K+\8@6
M +>FU\/(;GS+O):B ,#8.6 ^P,;P@)48F/L%RUO<$VD-#\)JPH[T=RU#SPUH
MD/EQC.*"& M:@'@[X'^'GN4OK#G;RZ*@V^A%^!)TX+B._0P_YNB[R1X'U6R]
MD0>B[%E6HA=DSJ_$7M+Q7G(O]A+54&93N=",FX^]!*OQY7>2+PY)-A.U"*Z(
M(M2=CP@&4)P#_ A_0-?[B]#0%5HR$+[,@N5/<!<"U&ZTJPU=3!K^/CYG_#KY
MY,)R%C"GGDR='97CT/#8%L*DM<(HJ6,G1UA25>^"#G=2!F+20R$FUH)BQ3U6
M7L1JM:-##4@H($T4C9;-S 7?H"69CIBH T,OWB;8X,Y9[=4Y*UIET=.=E]8K
M">,O$!"HXK.AASC8O(=XT8?T9@\V9>QB $+GL5(ZL5G[!H'FI04/,N$STV%G
M([39CFM+=X!(OAE);F(),]'-'8/-37^5"#<@%QZ N%1YBXY=I)?*CZ_B$0%4
MS,&2]B7/M!!#[I^WC[><J.07+ X\)3>G$0Y8^3%^$)#0!\R)=%D/A,!ZS#T/
MKJ=>5IS[RK7A8C^I")8FWM[I2R^IYQY8 [$NUC2C0GP;TUJ@@]"V +$740L(
MC\" Z8)%[)490&H)L/27.:=QQ-&L+(^>-?M!#-3QI2/)@K<ZSZ"AWX?T&]I-
M!H^E*7#G4!O4SI&< N[CP?7\Y']7O4T\)8F9*ZI5S42/65#1B2P%UWDBUJQF
ML-\FGEZJCBV7ZMC=QWR].["XQ^K<O2C8"?30H!(3@T"6]-"#L!,I+PK+H2R_
M 'RQW4W$YQOBP*X9>DGQ-8!R4%SQI'N#M;T]AKXH/I]\SR2V],EQ0%.EH'@3
M A1AL;'$Z_#IT];'$1?K]L/-QO4H&,;'ZCL'A.C\R'SGL!4@-K,C>_;NZ@+9
MI_;(&S1^<J*V;LF*1*M$"UQ2EIE;&S.G%5A^!(C!UD.^C3@Q66U/7-,*O8TQ
MC-F8;OODT?+F7Y/PC2]+%M>1Y&%^<6[!3OJRC$R1?IV%C=2,+/90I2I/%+#"
MMJ=(#D@222:]!%[YBY'_C^O;Z\A+AEW[-OA9-<IKQLS(-D3[S?R.:=_I!4@H
MOTQ";+HJIPF#+"<.W;+7L1Y%K6E_JQ*^Q#U-VMBAGR1((E=^_O3NR[=7M&/?
M]L HXGDPF)XQJ]+U28)$B#)6TJDA0 T1]#PI(/.5@U[=9]0WTPCEAG0X=0'I
M_& E08J%M:#::K0T5(>-5HL&IL74CSP4M._BCIKYK).E%E=-52^9OK<6&AL)
ME=,5B5T/-E2V!<<])DLHF=R:R,S!2MP,,0QE-LXBQOMPC:YS> A+B02<^)6N
M\+?HT3?.XEO2X*#=2B<C%0L8[2XYGN:Y410>C+'!Z08,&+'II4V__1J23UJU
M!7CGQ)T>J=1A^B)K044&:UYO$,&2 P^6+%2-S?XC@B5%L&29BB"")46PI B6
M%,&2YQ$L*7RW_?INWW?IN]VMA';AN/OOT"&8EFGL3LN,<]',;%HF;*PH3V@@
MN=L,2H3XV_0WVQ@QYOYE]E+ALB2S$EZ9#"3VH40C\./>F=B\'O;S (\HH]3&
MR)V3&=1(P@Z)'NPU#!8PEU+"9,K(44!],-;_A81]C4^.'P.6Z8AZ,S>AA^X<
M?Z\-ESZ<^R\_\:Z]_^U*D17:&?X)9!?_I2V%/-S^K/_$]C70VEU>2Q^C%+QH
MG\RUD<P2"V;DQN$3F)+GA$L3\V#Q;-*/,V"Q'Q"NY)J ^A.PX#CJ_@8"KDRP
M@.=47Z(Q(0\8;\PZ%-W,Y_3\]V';]=ZFW3>SK\F-+_OE]M26$@)=O:8'*[:@
MWJW(W9^=DL4.-;T%[?!).2RFZ7_A60&8Y\LH-B]*@ 6N1DOJ.C(%/U*S'#ZD
MX[;6Z;Y0<<)L]I4K$TAQ3P@($4@=G=0V&R^9'VL*FOHF1P=X-)Z%V.R,VO<E
MK&J0IP ^8@ZCI>0&1KN6_J#2D%OIM'.<KG'4Z#4;0YZ=Q=9G'C>CBAT0V?Q%
M9YN_&'>QBO(WXU'6/?V([-T2.SCS?;'>1;UZ#:W#8-1NL\0]F/5QH>:X2!PV
MB5S$ DL/?U-L$P=,;?LP'FY4IRFJ,0$<+4:J12<8O["WU_*='^\+TY7IODYU
M%>>C*?*T4"_SX'S:Z!FJCZ;:W@ZSA]L)LIK-NB*KAC8IU#HY."LUF97:V*R,
MD5I2Y6UON\B$B6F<5\+;;(MNT%=9JOG&'YUV=EH).41D!'_:]8<+T:X/=>AE
MBM.]Z?P5G1DN4/("SXH.#4 A8M\N"'QK!=D-I<9^H@-:%?J%?(M>11:?DM"Q
MTB/9QF!J4JQ-G,*H.'0@4KCIX369LYTYUZ2=H92)YRI++,*0Z[O.9Q"'0)U^
M4>>7"T&=3W$L)]-?MW%5EG1G?D]'5+WX='?SXA6>K(-EQ7)8DV;R-"(?( ?/
MW5A@+6JZ)A@;8#(Z1/J?FSO)#+&W[!RTWJ1;?0!O8,?OH.=,DK-C>M).]0YX
M91S"ZX-BX6&/6MNTUCYF P!,>#!7S*,R(PMTQ903O))5(41<P)?GE._?B/<
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MZWV*@D0K'QCCBOT.STU.=.^>W+O(->9_M,!J)PY>TT@<Q72DZ]I('I?7JL.
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M4D9U=%-?;.+9L2*\K^5T<>E-?&&AEB]E/O)];H>+U'O3XC"WB>GAE%=Q?=_
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M_VTZH>D]2[Q4C#N?@HA#J"%Y-"OW7H+I^[UG8R:=+FNJH:C*U-"FX_&?^01
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M" *4=C_%XTS]K)A:5%.).TI"2W>)4^4[R] U']SXY<B1TA3V&ZJ]2>_-C14
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M>S5,HW6G_/67'R @8;B0T#T":+(J*_!_535FT]F?1Q1\* >%HSW] A0Z'9(
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MN*:U5*W E_SPWK<6ENE9I."KV_?/=E4.H%&OZX"<N7\9C Z6H7AAQI?UNQO
M2P*7;BD?+0?V"@NVV=L MA,L#N9+)OP72!_(G*SOB2=IRDC"?:_.>A66;8L0
M">2B4$:J/ELHN2HTI-8UC0D'5J,( I1V/\7C3/TL;AQE'Y>I40=V61X\C\@
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MW\,K+2<$9>7+)FJTZ+^C;)Y$U1#_E^^!9X*6:CFF]_PI(&O_=]?!4!K/M8$
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ME9$R$<="G'HDA@T5G U'(-<.Y-);0ZY6?:G*:#P;"^3B$[FZ]*6>@;U\%V6
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MC\0)25?A-B-]//"&X#OELL^VCP(HA@44G+@Z:F-"&YY/?:3--($)W0Q(8(+
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M8FET7S$M,2YH=&U02P$"% ,4    "  OBH1:O%"T6* P   ]8P$ $
M        @ $KK $ 97AH:6)I=%\Q,2TQ+FAT;5!+ 0(4 Q0    ( "^*A%JH
M"]?\# @   (>   0              "  ?G< 0!E>&AI8FET7S$R+3$N:'1M
M4$L! A0#%     @ +XJ$6H6(_@TX"   V!X  !               ( !,^4!
M &5X:&EB:71?,3(M,BYH=&U02P$"% ,4    "  OBH1:F)=32*D$  !<$0
M$               @ &9[0$ 97AH:6)I=%\Q,RTQ+FAT;5!+ 0(4 Q0    (
M "^*A%H7,\,]J@0  &81   0              "  7#R 0!E>&AI8FET7S$S
M+3(N:'1M4$L! A0#%     @ +XJ$6B^S% >; P  =0P  !
M ( !2/<! &5X:&EB:71?,34M,2YH=&U02P$"% ,4    "  OBH1:16*)B/%7
M @#ZOP( "@              @ $1^P$ :6UA9V4P+FIP9U!+ 0(4 Q0    (
M "^*A%HK28(M]PD  *P*   .              "  2I3! !I;6%G93 P,# Q
M+FIP9U!+ 0(4 Q0    ( "^*A%H)XQ!;^I@  'ZW   .              "
M 4U=! !I;6%G93 P,#$Y+FIP9U!+ 0(4 Q0    ( "^*A%K:_]8EGFP  -!\
M   .              "  7/V! !I;6%G93 P,#(P+FIP9U!+ 0(4 Q0    (
M "^*A%K/IF/J@Z,  +VM   .              "  3UC!0!I;6%G93 P,#(Q
M+FIP9U!+ 0(4 Q0    ( "^*A%IJ35NN7H,  ,.,   .              "
M >P&!@!I;6%G93 P,#(R+FIP9U!+ 0(4 Q0    ( "^*A%K_<:87V)D  *F<
M   .              "  7:*!@!I;6%G93 P,#(S+FIP9U!+ 0(4 Q0    (
M "^*A%H6\&C!;G$  "9Y   .              "  7HD!P!I;6%G93 P,#(T
M+FIP9U!+ 0(4 Q0    ( "^*A%H'7KKN67L  #"#   .              "
M 126!P!I;6%G93 P,#(W+FIP9U!+ 0(4 Q0    ( "^*A%IM+6BVS3L  -5#
M   .              "  9D1" !I;6%G93 P,#(X+FIP9U!+ 0(4 Q0    (
M "^*A%HBGIIV-Y8  ,6:   .              "  9)-" !I;6%G93 P,#(Y
M+FIP9U!+ 0(4 Q0    ( "^*A%I2$.^2/48  -51   .              "
M ?7C" !I;6%G93 P,#,P+FIP9U!+ 0(4 Q0    ( "^*A%I^ S>D VH  (5S
M   .              "  5XJ"0!I;6%G93 P,#,Q+FIP9U!+ 0(4 Q0    (
M "^*A%H4V=/]LUT  $%>   .              "  8V4"0!I;6%G93 P,#,R
M+FIP9U!+ 0(4 Q0    ( "^*A%H+I][%?'<  ,=Y   .              "
M 6SR"0!I;6%G93 P,#,S+FIP9U!+ 0(4 Q0    ( "^*A%K#Z3M0@*L  %FL
M   .              "  11J"@!I;6%G93 P,#,T+FIP9U!+ 0(4 Q0    (
M "^*A%KV=\/Y$&H  )5V   .              "  < 5"P!I;6%G93 P,#,U
M+FIP9U!+ 0(4 Q0    ( "^*A%J<^]=6D.<  *K\   .              "
M ?Q_"P!I;6%G93 P,#,V+FIP9U!+ 0(4 Q0    ( "^*A%H2K%],WZ(  +J]
M   .              "  ;AG# !I;6%G93 P,#,W+FIP9U!+ 0(4 Q0    (
M "^*A%JGQ_F^%+L' )SR!P *              "  <,*#0!I;6%G934N:G!G
M4$L! A0#%     @ +XJ$6E4H3Q.%$00 :J E  T              ( !_\44
D 'IK,C4S,CDP,BYH=&U02P4&     "$ (0#?!P  K]<8

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>zk2532902_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cmmb="http://www.anchiano.com/20241231"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:currency="http://xbrl.sec.gov/currency/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cmmb-20241231.xsd" xlink:type="simple"/>
    <context id="C_20240101to20241231_srtStatementGeographicalAxis_countryIL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_srtStatementGeographicalAxis_countryUS_usgaapIncomeTaxAuthorityAxis_usgaapDomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20241231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_srtStatementGeographicalAxis_countryIL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtStatementGeographicalAxis_countryIL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_srtStatementGeographicalAxis_countryIL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_srtCurrencyAxis_currencyUSD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtCurrencyAxis_currencyUSD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_srtCurrencyAxis_currencyILS">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtCurrencyAxis_currencyILS">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_srtCurrencyAxis_currencyXXX">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:XXX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtCurrencyAxis_currencyXXX">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:XXX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cmmb:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20200510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2020-05-10</instant>
        </period>
    </context>
    <context id="C_20200501to20200510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-10</endDate>
        </period>
    </context>
    <context id="C_20211001to20211024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-24</endDate>
        </period>
    </context>
    <context id="C_20231212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2023-12-12</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cmmb:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapSoftwareDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapSoftwareDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_usgaapCapitalAdditionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:CapitalAdditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_cmmbCapitalAdditionsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">cmmb:CapitalAdditionsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20241229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="C_20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapStatementClassOfStockAxis_cmmbAmericanDepositarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmmb:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapStatementClassOfStockAxis_cmmbOrdinarySharesNoParValuePerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmmb:OrdinarySharesNoParValuePerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmmb:TwoThousandsFifteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmmb:TwoThousandsSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20220901to20220919_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:RepurchaseArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-19</endDate>
        </period>
    </context>
    <context id="C_20220930_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:RepurchaseArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_20221101to20221116_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:RepurchaseArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-16</endDate>
        </period>
    </context>
    <context id="C_20220401to20220425_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:AtmAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-25</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:AtmAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:AtmAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="C_20210301to20210322_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-22</endDate>
        </period>
    </context>
    <context id="C_20210301to20210315_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-15</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:AtmAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20231101to20231117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-17</endDate>
        </period>
    </context>
    <context id="C_20231001to20231031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="C_20231001to20231031_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRothCapitalPartnersLlcMember_usgaapSubsidiarySaleOfStockAxis_cmmbMarketOfferingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cmmb:RothCapitalPartnersLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:MarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRothCapitalPartnersLlcMember_usgaapSubsidiarySaleOfStockAxis_cmmbMarketOfferingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cmmb:RothCapitalPartnersLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:MarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240701to20240725_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-25</endDate>
        </period>
    </context>
    <context id="C_20240701to20240730_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-30</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember_usgaapStatementClassOfStockAxis_cmmbRestrictedOrdinarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmmb:TwoThousandsFifteenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmmb:RestrictedOrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="ILS_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="USD_Per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="C_20240101to20241231" id="FFact_0000000000489">0001534248</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus contextRef="C_20240101to20241231" id="FFact_0000000000490">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="C_20240101to20241231" id="FFact_0000000000491">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_20240101to20241231"
      id="Fxbrl_20230213103251859">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325124822695">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325124850731">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325125020590">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325125039815">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325125103526">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325125127518">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325125149159">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325125212477">001-40490</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_20240101to20241231"
      id="Fxbrl_20230213104107012">Chemomab Therapeutics Ltd.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325171717506">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325130645061">Kiryat Atidim, Building 7</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325130702398">Tel Aviv</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="Fxbrl_20240327173314698">6158002</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressPostalZipCode
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325125444047">6158002</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325125500854">IL</dei:EntityAddressCountry>
    <dei:ContactPersonnelName
      contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="Fxbrl_20240325125533965">Sigal Fattal</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="Fxbrl_20240325130613231">Kiryat Atidim Building 7</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="Fxbrl_20240325130913214">Tel Aviv</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="Fxbrl_20240325130944047">IL</dei:EntityAddressCountry>
    <dei:CityAreaCode
      contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="Fxbrl_20240325130506462">855</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_20240101to20241231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="Fxbrl_20240325130536510">492-5563</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_20240101to20241231_usgaapStatementClassOfStockAxis_cmmbAmericanDepositarySharesMember"
      id="Fxbrl_20230213103433506">American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_20240101to20241231_usgaapStatementClassOfStockAxis_cmmbAmericanDepositarySharesMember"
      id="Fxbrl_20230213103437662">CMMB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_20240101to20241231_usgaapStatementClassOfStockAxis_cmmbAmericanDepositarySharesMember"
      id="Fxbrl_20230213103445669">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="C_20240101to20241231_usgaapStatementClassOfStockAxis_cmmbOrdinarySharesNoParValuePerShareMember"
      id="Fxbrl_20230213103508728">Ordinary shares, no par-value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_20240101to20241231_usgaapStatementClassOfStockAxis_cmmbOrdinarySharesNoParValuePerShareMember"
      id="Fxbrl_20230213103458685">NA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_20240101to20241231_usgaapStatementClassOfStockAxis_cmmbOrdinarySharesNoParValuePerShareMember"
      id="Fxbrl_20230213103452851">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_20241231"
      decimals="INF"
      id="Fxbrl_20240325131407326"
      unitRef="Share">377132220</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325131448134">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325131518183">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325131547950">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325131614371">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325131641177">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325172008738">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240327182011473">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325173248259">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentAccountingStandard
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325172525187">U.S. GAAP</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325132317597">false</dei:EntityShellCompany>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240327183652256">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250402151124810">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250402151200330">
            &lt;div style="font-size:10pt;font-family:Times New Roman"&gt;
              &lt;div&gt;
                &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman';font-style:italic;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Risk management and strategy&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div style="line-height:1.25;font-family:'Times New Roman'"&gt;&#160;&lt;/div&gt;
                &lt;div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman'"&gt;
                  &lt;span style="font-size:10pt;font-family:Times New Roman"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;We maintain a cyber risk management program designed to identify, assess, manage, mitigate, and respond to material risks from cybersecurity threats&#160;to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic, or competitive in nature, and our clinical trial and related data (&#x201c;Information Systems and Data&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="line-height:1.25;font-family:'Times New Roman'"&gt;&#160;&lt;/div&gt;
                &lt;div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman'"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The underlying processes and controls of our cyber risk management program incorporate various practices and standards for cybersecurity and information technology. We conduct an annual assessment performed by a third-party service provider of our cyber risk management program. The annual risk assessment identifies, quantifies, and categorizes material cyber risks to our Company. In addition,&#160;we, in conjunction with the third-party cyber risk assessment vendor, develop a risk mitigation plan designed to address such risks, and where necessary, remediate potential vulnerabilities identified through the annual assessment process.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div style="line-height:1.25;font-family:'Times New Roman'"&gt;&#160;&lt;/div&gt;
                &lt;div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman'"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;In addition, we maintain various policies to help identify, address, and mitigate risks from cybersecurity threats, including, for example in areas such as information security, access on/offboarding, and access and account management. We monitor threat intelligence as well as other information obtained from governmental, public, or private sources, including external consultants engaged by us. We also partner with IT and cybersecurity providers, such as cybersecurity consultants. We leverage these third-party providers and solutions to support our cybersecurity risk management strategy and processes, which include, for example, maintenance of an IT assets inventory, periodic vulnerability scanning, identity access management controls, endpoint protection, endpoint detection and response, remote monitoring management on certain devices, encryption of certain data, critical data backups, infrastructure maintenance, incident detection and response, cybersecurity strategy, and cyber risk advisory, assessment and remediation.&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div style="line-height:1.25;font-family:'Times New Roman'"&gt;&#160;&lt;/div&gt;
                &lt;div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman'"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Our assessment and management of material risks from cybersecurity threats are integrated into the Company&#x2019;s overall risk management processes. For example, (1) cybersecurity risk is addressed as a component of the Company&#x2019;s enterprise risk management program and identified in the Company&#x2019;s risk register; (2) the security department/security management works with management to prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business; or (3) our senior management evaluates material risks from cybersecurity threats against our overall business objectives and reports to the audit committee of the board of directors, which evaluates our overall enterprise risk.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div style="line-height:1.25;font-family:'Times New Roman'"&gt;&#160;&lt;/div&gt;
                &lt;div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman'"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;We have implemented third-party risk management processes to manage material risks from cybersecurity threats associated with reliance on vendors, critical service providers, and other third parties we engage, such as software-as-a-service providers, data hosting companies, and contract research organizations. These processes include, for example, conducting risk assessment for certain vendors, reviewing vendor security assessments and questionnaires, and conducting annual reviews of vendor audits and reports.&#160;Depending on the nature of the services provided, the sensitivity of the Information Systems and Data at issue, and the identity of the provider, our third-party risk management process may involve different levels of assessment designed to help identify cybersecurity risks associated with a provider.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div style="line-height:1.25;font-family:'Times New Roman'"&gt;&#160;&lt;/div&gt;
                &lt;div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman'"&gt;
                  &lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 3. Section D Risk Factors in this Annual Report on Form 20-F, including &#x201c;Cyber-attacks, security breaches or other disruptions to our information technology systems, or those of third parties upon which we rely, or our data could irreparably damage our reputation and our business, expose us to liability and materially and adversely affect our results of operations.&#x201d;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          </cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250402151451097">&lt;span style="font-size:10pt;font-family:Times New Roman"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;We maintain a cyber risk management program designed to identify, assess, manage, mitigate, and respond to material risks from cybersecurity threats&#160;to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic, or competitive in nature, and our clinical trial and related data (&#x201c;Information Systems and Data&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250402151419652">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250402151639776">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250402151527434">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250402151855635">&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 3. Section D Risk Factors in this Annual Report on Form 20-F, including &#x201c;Cyber-attacks, security breaches or other disruptions to our information technology systems, or those of third parties upon which we rely, or our data could irreparably damage our reputation and our business, expose us to liability and materially and adversely affect our results of operations.&#x201d;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250402151839085">true</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250402155112636">
            &lt;div style="font-size:10pt;font-family:Times New Roman"&gt;
              &lt;div&gt;
                &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman';font-style:italic;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Governance&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman'"&gt;&#160;&lt;/div&gt;

                    &lt;div style="font-size:10pt;font-family:Times New Roman"&gt;
                      &lt;div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman'"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The audit committee of the board of directors oversees our cybersecurity risk exposures and the steps taken by management to monitor and mitigate cybersecurity risks. The cybersecurity stakeholders, including member(s) of management assigned with cybersecurity oversight responsibility and/or third-party consultants providing cyber risk services brief the audit committee of the board of directors on cyber vulnerabilities identified through the risk management process, the effectiveness of our cyber risk management program, and the emerging threat landscape and new cyber risks on at least an annual basis. In addition, cybersecurity risks are reviewed by our board of directors at least annually, as part of our corporate risk oversight processes.&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;

                  &lt;p style="margin:0pt;text-align:center"&gt;&#160;&lt;/p&gt;
                &lt;/div&gt;
                &lt;div&gt;&lt;/div&gt;&#160;&lt;div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:Times New Roman;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman"&gt;Our Chief Information Security Officer (&#x201c;CISO&#x201d;) is responsible for oversight and administration of our cyber risk management program, and for informing senior management and other relevant stakeholders regarding the prevention, detection, mitigation, and remediation of cybersecurity incidents.&lt;/span&gt;&#160;&lt;span style="font-size:10pt;font-family:Times New Roman"&gt;Our CISO is a Certified Information Systems Security Professional and has prior experience selecting, deploying, and overseeing cybersecurity technologies, initiatives, and processes directly or via selection of strategic third-party partners.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:Times New Roman;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                &lt;div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:Times New Roman;margin-top:0pt;margin-bottom:0pt"&gt;
                  &lt;span style="font-size:10pt;font-family:Times New Roman"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;We have developed an incident response plan&#160;that is designed to escalate certain cybersecurity incidents to members of management, including the CISO, depending on the circumstances. Such members of management work with the Company&#x2019;s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified. In addition, the Company&#x2019;s incident response plan includes reporting to the audit committee of the board of directors for certain cybersecurity incidents.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          </cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250402155410834">
                    &lt;div style="font-size:10pt;font-family:Times New Roman"&gt;
                      &lt;div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman'"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The audit committee of the board of directors oversees our cybersecurity risk exposures and the steps taken by management to monitor and mitigate cybersecurity risks. The cybersecurity stakeholders, including member(s) of management assigned with cybersecurity oversight responsibility and/or third-party consultants providing cyber risk services brief the audit committee of the board of directors on cyber vulnerabilities identified through the risk management process, the effectiveness of our cyber risk management program, and the emerging threat landscape and new cyber risks on at least an annual basis. In addition, cybersecurity risks are reviewed by our board of directors at least annually, as part of our corporate risk oversight processes.&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  </cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250402155336668">&lt;span style="font-size:10pt;font-family:Times New Roman"&gt;Our Chief Information Security Officer (&#x201c;CISO&#x201d;) is responsible for oversight and administration of our cyber risk management program, and for informing senior management and other relevant stakeholders regarding the prevention, detection, mitigation, and remediation of cybersecurity incidents.&lt;/span&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250402155628902">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250402160221706">&lt;span style="font-size:10pt;font-family:Times New Roman"&gt;Our CISO is a Certified Information Systems Security Professional and has prior experience selecting, deploying, and overseeing cybersecurity technologies, initiatives, and processes directly or via selection of strategic third-party partners.&lt;/span&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250402160109615">&lt;span style="font-size:10pt;font-family:Times New Roman"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;We have developed an incident response plan&#160;that is designed to escalate certain cybersecurity incidents to members of management, including the CISO, depending on the circumstances. Such members of management work with the Company&#x2019;s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified. In addition, the Company&#x2019;s incident response plan includes reporting to the audit committee of the board of directors for certain cybersecurity incidents.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250402160027285">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <dei:AuditorFirmId
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325185550517">1057</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325173623987">Somekh Chaikin</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325173629952">Tel Aviv, Israel</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000038"
      unitRef="usd">6071000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000039"
      unitRef="usd">9292000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DepositsAssetsCurrent
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000040"
      unitRef="usd">8195000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000041"
      unitRef="usd">10492000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20230213102216110_Fact_0000000000040"
      unitRef="usd">76000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20230213102216110_Fact_0000000000041"
      unitRef="usd">76000</us-gaap:RestrictedCashCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000042"
      unitRef="usd">1698000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000043"
      unitRef="usd">1037000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000044"
      unitRef="usd">16040000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000045"
      unitRef="usd">20897000</us-gaap:AssetsCurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000048"
      unitRef="usd">385000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20230131220311598"
      unitRef="usd">559000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000052"
      unitRef="usd">250000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000053"
      unitRef="usd">303000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000054"
      unitRef="usd">289000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000055"
      unitRef="usd">392000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AssetsNoncurrent
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000056"
      unitRef="usd">924000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000057"
      unitRef="usd">1254000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000058"
      unitRef="usd">16964000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000059"
      unitRef="usd">22151000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000060"
      unitRef="usd">666000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000061"
      unitRef="usd">516000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000062"
      unitRef="usd">1563000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000063"
      unitRef="usd">3423000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000064"
      unitRef="usd">874000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000065"
      unitRef="usd">823000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000066"
      unitRef="usd">115000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000067"
      unitRef="usd">76000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000068"
      unitRef="usd">3218000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000069"
      unitRef="usd">4838000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000070"
      unitRef="usd">209000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000071"
      unitRef="usd">316000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000072"
      unitRef="usd">209000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000073"
      unitRef="usd">316000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20241231"
      id="Fxbrl_20250325185935895_Fact_0000000000072"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20231231"
      id="Fxbrl_20250325185935895_Fact_0000000000073"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Liabilities
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000074"
      unitRef="usd">3427000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000075"
      unitRef="usd">5154000</us-gaap:Liabilities>
    <us-gaap:CommonStockNoParValue
      contextRef="C_20231231"
      decimals="0"
      id="Fxbrl_20230201163052384"
      unitRef="USD_Per_Share">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="C_20241231"
      decimals="0"
      id="Fxbrl_20230131220607422"
      unitRef="USD_Per_Share">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20241231"
      decimals="INF"
      id="Fxbrl_20230131221114549"
      unitRef="Share">4650000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20231231"
      decimals="INF"
      id="Fxbrl_20250325191129849"
      unitRef="Share">650000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:SharesOutstanding
      contextRef="C_20241231"
      decimals="INF"
      id="Fxbrl_20240325094937707"
      unitRef="Share">377132220</us-gaap:SharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20241231"
      decimals="INF"
      id="Fxbrl_20230213101830930"
      unitRef="Share">377132220</us-gaap:CommonStockSharesIssued>
    <us-gaap:SharesOutstanding
      contextRef="C_20231231"
      decimals="INF"
      id="Fxbrl_s_20250325190508979"
      unitRef="Share">284094700</us-gaap:SharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20231231"
      decimals="INF"
      id="Fxbrl_20250325190508980"
      unitRef="Share">284094700</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20230131221528825"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20230131221535249"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000086"
      unitRef="usd">116160000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000087"
      unitRef="usd">105675000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000088"
      unitRef="usd">-102623000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000089"
      unitRef="usd">-88678000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000090"
      unitRef="usd">13537000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000091"
      unitRef="usd">16997000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000092"
      unitRef="usd">16964000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000093"
      unitRef="usd">22151000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000094"
      unitRef="usd">11327000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000095"
      unitRef="usd">18381000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325095930537"
      unitRef="usd">16977000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000096"
      unitRef="usd">3412000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000097"
      unitRef="usd">7078000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325095935768"
      unitRef="usd">11556000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000098"
      unitRef="usd">14739000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000099"
      unitRef="usd">25459000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325095940813"
      unitRef="usd">28533000</us-gaap:OperatingExpenses>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20230131223230473"
      unitRef="usd">794000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230131223237304"
      unitRef="usd">1238000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325095946273"
      unitRef="usd">353000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20230207212310873_Fact_0000000000102"
      unitRef="usd">-13945000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230207212310873_Fact_0000000000103"
      unitRef="usd">-24221000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325095953001"
      unitRef="usd">-28180000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20230131223639023"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000101"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325100001097"
      unitRef="usd">-534000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20250326102131457"
      unitRef="usd">-13945000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000103"
      unitRef="usd">-24221000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325100006496"
      unitRef="usd">-27646000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20240101to20241231"
      decimals="INF"
      id="Fxbrl_20230131213305203"
      unitRef="USD_Per_Share">0.039</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20240101to20241231"
      decimals="INF"
      id="FFact_0000000000104"
      unitRef="USD_Per_Share">0.039</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="Fxbrl_20230131213312166"
      unitRef="USD_Per_Share">0.103</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="FFact_0000000000105"
      unitRef="USD_Per_Share">0.103</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_s_20240325100011534"
      unitRef="USD_Per_Share">0.121</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20240325100011535"
      unitRef="USD_Per_Share">0.121</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20240101to20241231"
      decimals="INF"
      id="Fxbrl_20230214141238310"
      unitRef="Share">359048638</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20240101to20241231"
      decimals="INF"
      id="FFact_0000000000106"
      unitRef="Share">359048638</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="Fxbrl_20230131213329528"
      unitRef="Share">234998859</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="FFact_0000000000107"
      unitRef="Share">234998859</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_s_20240325100018414"
      unitRef="Share">227589288</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20240325100018415"
      unitRef="Share">227589288</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207232832534"
      unitRef="Share">228090300</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004148281"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="INF"
      id="Fxbrl_20230208004108785"
      unitRef="Share">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20230208004208753"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207232638785_Fact_0000000000128"
      unitRef="usd">97639000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230207232638785_Fact_0000000000129"
      unitRef="usd">-36173000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20230207232638785_Fact_0000000000130"
      unitRef="usd">61466000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004236209"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20230208004232608"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207232932528"
      unitRef="usd">3211000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230208004229458"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230207232938175"
      unitRef="usd">3211000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20240325100655099_xbrl_20230207233201211"
      unitRef="Share">2576400</cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240325100655099_xbrl_20230208004904248"
      unitRef="usd">0</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="INF"
      id="Fxbrl_20240325100655099_xbrl_20230208004910523"
      unitRef="Share">0</cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20240325100655099_xbrl_20230208004901083"
      unitRef="usd">0</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20240325100655099_xbrl_20230207233210018"
      unitRef="usd">267000</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20240325100655099_xbrl_20230208004950211"
      unitRef="usd">0</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325100655099_xbrl_20230207233216009"
      unitRef="usd">267000</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207233039147"
      unitRef="Share">1970000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004521301"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="INF"
      id="Fxbrl_20230208004621028"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20230208004724885"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207233033563"
      unitRef="usd">143000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230208004807831"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230207233028090"
      unitRef="usd">143000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004938057"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="INF"
      id="Fxbrl_20230207233301376"
      unitRef="Share">-11640460</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20230207233406606"
      unitRef="usd">-1218000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230208004934609"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230208004932393"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230207233411324"
      unitRef="usd">-1218000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004352160"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20230208004349447"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230208004345432"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230207233044479"
      unitRef="usd">-27646000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230207233049858"
      unitRef="usd">-27646000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207234506438"
      unitRef="Share">232636700</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004359870"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="INF"
      id="Fxbrl_20230208004449318"
      unitRef="Share">-11640460</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20230208004357072"
      unitRef="usd">-1218000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207233106443"
      unitRef="usd">101260000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230207234203847"
      unitRef="usd">-63819000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230207233116634"
      unitRef="usd">36223000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207234515566"
      unitRef="Share">232636700</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004830175"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="INF"
      id="Fxbrl_20230208004835440"
      unitRef="Share">-11640460</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20230208004846448"
      unitRef="usd">-1218000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207233129314"
      unitRef="usd">101260000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230207233133644"
      unitRef="usd">-63819000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230207233141194"
      unitRef="usd">36223000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004855201"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20230208004852649"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207233154315"
      unitRef="usd">1491000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230208004943313"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230207233147476"
      unitRef="usd">1491000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207233201211"
      unitRef="Share">51458000</cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004904248"
      unitRef="usd">0</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="INF"
      id="Fxbrl_20230208004910523"
      unitRef="Share">0</cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20230208004901083"
      unitRef="usd">0</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207233210018"
      unitRef="usd">2924000</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230208004950211"
      unitRef="usd">0</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230207233216009"
      unitRef="usd">2924000</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240325100724019_xbrl_20230208004938057"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="INF"
      id="Fxbrl_20240325100724019_xbrl_20230207233301376"
      unitRef="Share">11640460</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20240325100724019_xbrl_20230207233406606"
      unitRef="usd">1218000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20240325100724019_xbrl_20230208004934609"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20240325100724019_xbrl_20230208004932393"
      unitRef="usd">-638000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325100724019_xbrl_20230207233411324"
      unitRef="usd">580000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208005011611"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20230208005008418"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230208005005802"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230207233416622"
      unitRef="usd">-24221000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230207233422744"
      unitRef="usd">-24221000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207233430996"
      unitRef="Share">284094700</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208005022333"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="INF"
      id="Fxbrl_20230207233657770"
      unitRef="Share">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20230207233728393"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207233439472"
      unitRef="usd">105675000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230207233445148"
      unitRef="usd">-88678000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20230207233450251"
      unitRef="usd">16997000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20240325100756924_xbrl_20230207234515566"
      unitRef="Share">284094700</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240325100756924_xbrl_20230208004830175"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="INF"
      id="Fxbrl_20240325100756924_xbrl_20230208004835440"
      unitRef="Share">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20240325100756924_xbrl_20230208004846448"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20240325100756924_xbrl_20230207233129314"
      unitRef="usd">105675000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20240325100756924_xbrl_20230207233133644"
      unitRef="usd">-88678000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240325100756924_xbrl_20230207233141194"
      unitRef="usd">16997000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240325100645650_xbrl_20230208004855201"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20240325100645650_xbrl_20230208004852649"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20240325100645650_xbrl_20230207233154315"
      unitRef="usd">617000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20240325100645650_xbrl_20230208004943313"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240325100645650_xbrl_20230207233147476"
      unitRef="usd">617000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207233006128"
      unitRef="Share">93037520</cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004339738"
      unitRef="usd">0</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="INF"
      id="Fxbrl_20230208004626295"
      unitRef="Share">0</cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20230208004335122"
      unitRef="usd">0</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207233012248"
      unitRef="usd">9868000</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230208004332317"
      unitRef="usd">0</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20230207233018475"
      unitRef="usd">9868000</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240325100739987_xbrl_20230208005011611"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20240325100739987_xbrl_20230208005008418"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20240325100739987_xbrl_20230208005005802"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20240101to20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20240325100739987_xbrl_20230207233416622"
      unitRef="usd">-13945000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240325100739987_xbrl_20230207233422744"
      unitRef="usd">-13945000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20240325100745487_xbrl_20230207233430996"
      unitRef="Share">377132220</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240325100745487_xbrl_20230208005022333"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="INF"
      id="Fxbrl_20240325100745487_xbrl_20230207233657770"
      unitRef="Share">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20240325100745487_xbrl_20230207233728393"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20240325100745487_xbrl_20230207233439472"
      unitRef="usd">116160000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20240325100745487_xbrl_20230207233445148"
      unitRef="usd">-102623000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20240325100745487_xbrl_20230207233450251"
      unitRef="usd">13537000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000149"
      unitRef="usd">-13945000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000150"
      unitRef="usd">-24221000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325104742349"
      unitRef="usd">-27646000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000151"
      unitRef="usd">53000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000152"
      unitRef="usd">67000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325104746496"
      unitRef="usd">58000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000153"
      unitRef="usd">617000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000154"
      unitRef="usd">1491000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325104750812"
      unitRef="usd">3211000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000155"
      unitRef="usd">487000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000156"
      unitRef="usd">-903000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325104755091"
      unitRef="usd">64000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000157"
      unitRef="usd">150000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000158"
      unitRef="usd">-1172000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325104759425"
      unitRef="usd">352000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000159"
      unitRef="usd">-1860000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230201002431792"
      unitRef="usd">45000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325104804410"
      unitRef="usd">2823000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000161"
      unitRef="usd">51000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000162"
      unitRef="usd">-737000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325104808746"
      unitRef="usd">907000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000163"
      unitRef="usd">35000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230201002424683"
      unitRef="usd">13000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325104815058"
      unitRef="usd">-11000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000165"
      unitRef="usd">-15386000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000166"
      unitRef="usd">-23611000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325104819434"
      unitRef="usd">-20370000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <cmmb:PaymentsForInvestmentInDeposits
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000167"
      unitRef="usd">-2297000</cmmb:PaymentsForInvestmentInDeposits>
    <cmmb:PaymentsForInvestmentInDeposits
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000168"
      unitRef="usd">-15882000</cmmb:PaymentsForInvestmentInDeposits>
    <cmmb:PaymentsForInvestmentInDeposits
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325104823921"
      unitRef="usd">-19601000</cmmb:PaymentsForInvestmentInDeposits>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000173"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000174"
      unitRef="usd">3000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325104839642"
      unitRef="usd">68000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000175"
      unitRef="usd">2297000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000176"
      unitRef="usd">15879000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325104844087"
      unitRef="usd">19533000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000179"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230131235658097"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325104931102"
      unitRef="usd">143000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20230201000241409"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000182"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325104937430"
      unitRef="usd">1218000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromSaleOfTreasuryStock
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240325104521419"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfTreasuryStock>
    <us-gaap:ProceedsFromSaleOfTreasuryStock
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325104453631_xbrl_20230201000241409"
      unitRef="usd">580000</us-gaap:ProceedsFromSaleOfTreasuryStock>
    <us-gaap:ProceedsFromSaleOfTreasuryStock
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325104453631_Fact_0000000000182"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfTreasuryStock>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000183"
      unitRef="usd">9868000</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000184"
      unitRef="usd">2924000</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325104942102"
      unitRef="usd">267000</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20230201002754453"
      unitRef="usd">9868000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000186"
      unitRef="usd">3504000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325104946388"
      unitRef="usd">-808000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20230201002721687"
      unitRef="usd">-3221000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000188"
      unitRef="usd">-4228000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325105003435"
      unitRef="usd">-1645000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000189"
      unitRef="usd">9368000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000190"
      unitRef="usd">13596000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20240325105007045"
      unitRef="usd">15241000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000191"
      unitRef="usd">6147000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000192"
      unitRef="usd">9368000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20240325105011131"
      unitRef="usd">13596000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <cmmb:IncomeTaxesReceived
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20230214142748754"
      unitRef="usd">0</cmmb:IncomeTaxesReceived>
    <cmmb:IncomeTaxesReceived
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230214143241770"
      unitRef="usd">187000</cmmb:IncomeTaxesReceived>
    <cmmb:IncomeTaxesReceived
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325105045604"
      unitRef="usd">351000</cmmb:IncomeTaxesReceived>
    <cmmb:InterestReceived
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20230207233819452"
      unitRef="usd">814000</cmmb:InterestReceived>
    <cmmb:InterestReceived
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230207233829491"
      unitRef="usd">1463000</cmmb:InterestReceived>
    <cmmb:InterestReceived
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325105050333"
      unitRef="usd">972000</cmmb:InterestReceived>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000193"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000194"
      unitRef="usd">392000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325105059739"
      unitRef="usd">17000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:NatureOfOperations
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325232417636">
    &lt;div&gt;
      &lt;div style="text-align:justify;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Note 1 - General&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:30pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;A.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Chemomab Therapeutics Ltd. (hereinafter - "the Company") is an Israeli-based company incorporated under the laws of the State of Israel in September 2011. The Company&#x2019;s registered office is located in Kiryat Atidim, Tel Aviv, Israel.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:65pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;i.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The Company is a clinical-stage biotech company discovering and developing innovative therapeutics for conditions with high-unmet medical need that involve inflammation and fibrosis.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:65pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;ii.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The wholly owned subsidiaries of the Company are: Chemomab Ltd. ("Chemomab"), Chemomab Therapeutics Inc. and Chemomab Therapeutics (Israel) Ltd.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:30pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;B.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The Company relies on one supplier for the production of the CM-101 used in its product development. If this supplier fails to deliver or experiences production delays, the Company will be required to seek an alternative solution. Switching suppliers may cause manufacturing delays and higher costs, potentially delaying the product's development and impacting the Company&#x2019;s operational results and financial position.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:30pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;C.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Going concern uncertainty&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. However, the Company has incurred recurring losses from operations as of December 31, 2024 of approximately $103 million and negative cash flows from operating activities in 2024 of $15.4 million with currently no products approved for sale.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;As of December 31, 2024, the Company had cash, cash equivalents, and short-term deposits of $14.3 million. The Company&#x2019;s current cash resources are sufficient to meet its planned expenditures through the end of March 2026. These indicators raising substantial doubt about its ability to continue as a going concern. The Company will be required to raise additional funds to support its operations and continue as a going concern. While management believes that the Company can raise additional funds, there can be no assurance that these efforts will be successful or sufficient.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:NatureOfOperations>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20240101to20241231"
      decimals="-6"
      id="Fxbrl_20250325233240211"
      unitRef="usd">-103000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20240101to20241231"
      decimals="-5"
      id="Fxbrl_20250325233246707"
      unitRef="usd">-15400000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_20241231"
      decimals="-5"
      id="Fxbrl_20250325233301811"
      unitRef="usd">14300000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325165827031">
    &lt;div&gt;
      &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Note 2 &#x2013; Summary of Significant Accounting Policies&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

            &lt;div&gt;
              &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;A.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-weight:bold"&gt;Basis of Preparation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;

        &lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;B.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;Use of estimates&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;

        &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
      &lt;/div&gt;
      &lt;div&gt;&lt;/div&gt;

        &lt;div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;C.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;Foreign currency&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The currency of the primary economic environment in which the operations of the Company are conducted is the U.S. dollar (&#x201c;dollar&#x201d; or &#x201c;$&#x201d;), thus; the dollar is the functional currency of the Company.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The transactions and balances of the Company denominated in U.S. dollars are presented at their original amounts as the U.S. dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Monetary assets and liabilities denominated in a non-U.S. dollar currency are translated using the current exchange rate and nonmonetary assets and liabilities and capital accounts denominated in a non-U.S. dollar currency are translated using historical exchange rates.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Statements of operations accounts denominated in a non-U.S. dollar currency are translated using the exchange rates in effect on the transaction dates, except for depreciation, which is translated using historical exchange rate.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;

      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

        &lt;div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;D.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Cash equivalents are short-term liquid bank deposits that are readily convertible to cash with original maturities of three months or less at the date acquired.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;

      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

        &lt;div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;E.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;Short-term bank deposits&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Bank deposits with original maturities exceeding three months but less than one year are classified as part of short-term investments. These deposits are recorded at cost, which approximates their market value, including accrued interest. Interest earned on these deposits is recognized as financial income. As of December 31, 2024, the range of interest rates paid on these deposits was between 4.24% and 5.75% (2023: between 4.22% and 6.65%).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;

      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

        &lt;div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;F.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; &lt;span style="font-weight:bold"&gt;Restricted cash&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Restricted cash is primarily invested in highly liquid deposits. These deposits were used to secure office lease payments.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;

      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

        &lt;div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;G.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-weight:bold"&gt;Property and equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Property and equipment are stated at cost less accumulated depreciation. Maintenance and repair expenses are charged to operation as incurred. Depreciation is calculated based on the straight-line method and&#160; the estimated useful lives of the assets and commences once the assets are ready for their intended use.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Annual rates at depreciation are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="margin-left:36pt"&gt;

              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td colspan="1" rowspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" rowspan="1" style="vertical-align:top;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Computers&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Laboratory equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Furniture and equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="4" style="vertical-align:top;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Leasehold improvement - over the shorter of the lease term or the estimated useful life of the improvement&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;

          &lt;/div&gt;
        &lt;/div&gt;

      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div&gt;&lt;/div&gt;

        &lt;div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;H.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-weight:bold"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The Company&#x2019;s property and equipment are reviewed for impairment in accordance with ASC 360, &#x201c;Property and Equipment&#x201d;, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less selling costs. During the periods ended December 31, 2024, 2023 and 2022, no impairment losses have been recorded.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;

      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

        &lt;div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;I.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; &lt;span style="font-weight:bold"&gt;Research and Development&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Research and development costs are charged to operations as incurred. Most of the research and development expenses are for subcontractors and salaries.&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;

      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

        &lt;div&gt;
          &lt;div style="text-indent:36pt;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;J.&#160; &#160; &#160; &#160;&#160; &#160; Income taxes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income,&#160;tax-planning&#160;strategies, and results of recent operations.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the income taxes expense.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50 percent likely of being realized.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;

      &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
      &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;/div&gt;

        &lt;div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;K.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-weight:bold"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;ASC 820, Fair Value Measurements and Disclosures, relating to fair value measurements, defines fair value and established a framework for measuring fair value. The ASC 820 fair value hierarchy distinguishes between market participant assumptions developed based on market data obtained from sources independent of the reporting entity and the reporting entity&#x2019;s own assumptions about market participant assumptions developed based on the best information available in the circumstances. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;In addition, the fair value of assets and liabilities should include consideration of non-performance risk, which for the liabilities described below includes the Company&#x2019;s own credit risk.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Level&#160;1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The carrying amounts of cash and cash equivalents, short-term deposits, trade payables, other receivables, and prepaid expenses approximate their fair value due to the short-term maturity of such instruments. None of the Company&#x2019;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;

      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

        &lt;div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;L.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-weight:bold"&gt;Share-based compensation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The Company accounts for share-based compensation as an expense in the financial statements based on ASC 718. All awards are equity classified and therefore such costs are measured at the grant date fair value of the award and graded vesting attribution approach to recognize compensation cost over the vesting period. The Company recognizes compensation cost for an award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant-date value of such award that is vested at that date.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The fair value for the Company&#x2019;s stock options granted to employees, consultants and directors was estimated using Black-Scholes option-pricing model at the grant date, using the inputs detailed in Note 8(C).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The Company has historically not paid dividends and has no foreseeable plans to pay dividends.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;

      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

        &lt;div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;M.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-weight:bold"&gt;Government-sponsored research and development&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Chemomab records grants received from the office of the Israel Innovation Authority (the &#x201c;IIA&#x201d;) as a liability, if it is probable that the Chemomab will have to repay the grants received. If it is not probable that the grants will be repaid, Chemomab records the grants as a reduction to research and development expenses.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;

      &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
      &lt;div&gt;&lt;/div&gt;
      &lt;div&gt;

          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;N.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-weight:bold"&gt;Severance pay&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Pursuant to Section 14 of the Severance Compensation Law, 1963 ("Section 14"), all employees of the Company are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made on their behalf with insurance companies. Upon release of the policy to the employee, no additional liability exists between the parties regarding the matter of severance pay and no additional payments shall be made by the Company to the employee. This plan has been accounted for as a defined contribution plan. Severance costs amounted to approximately $50&#160;thousands, $86 thousands, and $142 thousands for the year ended December 31, 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;

      &lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

        &lt;div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;O.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-weight:bold"&gt;Concentrations of credit risk:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Cash and cash equivalents and short- term deposits are invested in banks. Management believes that the financial institutions that hold the Company&#x2019;s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The Company have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;

      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

        &lt;div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;P.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-weight:bold"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Under Topic 842, the Company determines if an arrangement is a lease at inception. Right-of-use (ROU) assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company's incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be 9% in 2024 and 2023 and 5% in 2022, The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;When determining the probability of exercising such options, the Company considers contract-based, asset-based, entity-based, and market-based factors. For lease agreements, the Company has elected the practical expedient to account for the lease and non-lease maintenance components as a single lease component. Therefore, for those leases, the lease payments used to measure the lease liability include all the fixed considerations in the contract. The Company's lease agreements generally do not contain any residual value guarantees or restrictive covenants.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;ROU assets for operating leases are periodically reduced by impairment losses. The Company uses the long-lived assets impairment guidance in ASC Subtopic 360-10, Property, Plant, and Equipment to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;

      &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
      &lt;div&gt;&lt;/div&gt;

        &lt;div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;Q.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-weight:bold"&gt;Segments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The Company has one reportable segment, focused on the research and development of therapeutics for conditions with high unmet medical needs involving inflammation and fibrosis. The Company&#x2019;s chief operating decision maker ("CODM") is its chief executive officer of the company. The segment is managed on a consolidated basis, and the CODM uses total operating expenses and consolidated net loss to assess performance, forecast future financial results, and allocate resources.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;In evaluating the Company's financial performance and making strategic decisions, the CODM regularly reviews operating expenses by function. Furthermore, the CODM is provided only with the consolidated expenses, as presented in the income statement disclosures (see Notes 9 and 10&#160;with respect to salaries, professional services, consultants and subcontractors). This includes a review of budget versus actual expenses and direct program spending, which encompasses clinical costs, consultant fees, manufacturing expenses, and other direct external costs.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;

      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

        &lt;div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;R.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-weight:bold"&gt;Principles of consolidation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The consolidated financial statements include the accounts of the Company and its Subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;

      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

        &lt;div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;S.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-weight:bold"&gt;Loss per ordinary share&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Basic Loss per ordinary share are calculated using only weighted average ordinary shares outstanding. Diluted loss per share, if relevant, gives an effect to dilutive potential ordinary shares outstanding during the year.&#160; Such dilutive shares consist of incremental shares, using the treasury stock method, from the assumed exercise of share options.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;

    &lt;/div&gt;
  </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325170749806">
            &lt;div&gt;
              &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;A.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-weight:bold"&gt;Basis of Preparation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;
          </us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325170755069">
          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;B.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;Use of estimates&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325170802129">
        &lt;div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;C.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;Foreign currency&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The currency of the primary economic environment in which the operations of the Company are conducted is the U.S. dollar (&#x201c;dollar&#x201d; or &#x201c;$&#x201d;), thus; the dollar is the functional currency of the Company.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The transactions and balances of the Company denominated in U.S. dollars are presented at their original amounts as the U.S. dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Monetary assets and liabilities denominated in a non-U.S. dollar currency are translated using the current exchange rate and nonmonetary assets and liabilities and capital accounts denominated in a non-U.S. dollar currency are translated using historical exchange rates.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Statements of operations accounts denominated in a non-U.S. dollar currency are translated using the exchange rates in effect on the transaction dates, except for depreciation, which is translated using historical exchange rate.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;
      </us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325170807416">
        &lt;div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;D.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Cash equivalents are short-term liquid bank deposits that are readily convertible to cash with original maturities of three months or less at the date acquired.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;
      </us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <cmmb:ShortTermBankDepositsPolicyTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325170815861">
        &lt;div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;E.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;Short-term bank deposits&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Bank deposits with original maturities exceeding three months but less than one year are classified as part of short-term investments. These deposits are recorded at cost, which approximates their market value, including accrued interest. Interest earned on these deposits is recognized as financial income. As of December 31, 2024, the range of interest rates paid on these deposits was between 4.24% and 5.75% (2023: between 4.22% and 6.65%).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;
      </cmmb:ShortTermBankDepositsPolicyTextBlock>
    <cmmb:PercentageOfShortTermDeposits
      contextRef="C_20240101to20241231_srtRangeAxis_srtMinimumMember"
      decimals="4"
      id="Fxbrl_20250325184652403"
      unitRef="Pure">0.0424</cmmb:PercentageOfShortTermDeposits>
    <cmmb:PercentageOfShortTermDeposits
      contextRef="C_20240101to20241231_srtRangeAxis_srtMaximumMember"
      decimals="4"
      id="Fxbrl_20250325184700941"
      unitRef="Pure">0.0575</cmmb:PercentageOfShortTermDeposits>
    <cmmb:PercentageOfShortTermDeposits
      contextRef="C_20230101to20231231_srtRangeAxis_srtMinimumMember"
      decimals="4"
      id="Fxbrl_20250325184705304"
      unitRef="Pure">0.0422</cmmb:PercentageOfShortTermDeposits>
    <cmmb:PercentageOfShortTermDeposits
      contextRef="C_20230101to20231231_srtRangeAxis_srtMaximumMember"
      decimals="4"
      id="Fxbrl_20250325184709274"
      unitRef="Pure">0.0665</cmmb:PercentageOfShortTermDeposits>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325170822565">
        &lt;div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;F.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; &lt;span style="font-weight:bold"&gt;Restricted cash&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Restricted cash is primarily invested in highly liquid deposits. These deposits were used to secure office lease payments.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;
      </us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325170829453">
        &lt;div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;G.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-weight:bold"&gt;Property and equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Property and equipment are stated at cost less accumulated depreciation. Maintenance and repair expenses are charged to operation as incurred. Depreciation is calculated based on the straight-line method and&#160; the estimated useful lives of the assets and commences once the assets are ready for their intended use.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Annual rates at depreciation are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="margin-left:36pt"&gt;

              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td colspan="1" rowspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" rowspan="1" style="vertical-align:top;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Computers&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Laboratory equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Furniture and equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="4" style="vertical-align:top;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Leasehold improvement - over the shorter of the lease term or the estimated useful life of the improvement&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;

          &lt;/div&gt;
        &lt;/div&gt;
      </us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <cmmb:ScheduleOfAnnualRateOfDeprecationTableTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325170224477">
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td colspan="1" rowspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" rowspan="1" style="vertical-align:top;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Computers&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Laboratory equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Furniture and equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="4" style="vertical-align:top;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Leasehold improvement - over the shorter of the lease term or the estimated useful life of the improvement&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            </cmmb:ScheduleOfAnnualRateOfDeprecationTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage
      contextRef="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"
      decimals="2"
      id="FFact_0000000000214"
      unitRef="Pure">0.33</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage
      contextRef="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember"
      decimals="2"
      id="FFact_0000000000215"
      unitRef="Pure">0.10</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage
      contextRef="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember"
      decimals="2"
      id="FFact_0000000000216"
      unitRef="Pure">0.07</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <cmmb:AnnualRatesOfDepreciation
      contextRef="C_20240101to20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"
      id="FFact_0000000000217">over the shorter of the lease term or the estimated useful life of the improvement</cmmb:AnnualRatesOfDepreciation>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325170838965">
        &lt;div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;H.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-weight:bold"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The Company&#x2019;s property and equipment are reviewed for impairment in accordance with ASC 360, &#x201c;Property and Equipment&#x201d;, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less selling costs. During the periods ended December 31, 2024, 2023 and 2022, no impairment losses have been recorded.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;
      </us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325170845711">
        &lt;div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;I.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; &lt;span style="font-weight:bold"&gt;Research and Development&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Research and development costs are charged to operations as incurred. Most of the research and development expenses are for subcontractors and salaries.&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;
      </us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325170853037">
        &lt;div&gt;
          &lt;div style="text-indent:36pt;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;J.&#160; &#160; &#160; &#160;&#160; &#160; Income taxes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income,&#160;tax-planning&#160;strategies, and results of recent operations.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the income taxes expense.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50 percent likely of being realized.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;
      </us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325170901014">
        &lt;div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;K.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-weight:bold"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;ASC 820, Fair Value Measurements and Disclosures, relating to fair value measurements, defines fair value and established a framework for measuring fair value. The ASC 820 fair value hierarchy distinguishes between market participant assumptions developed based on market data obtained from sources independent of the reporting entity and the reporting entity&#x2019;s own assumptions about market participant assumptions developed based on the best information available in the circumstances. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;In addition, the fair value of assets and liabilities should include consideration of non-performance risk, which for the liabilities described below includes the Company&#x2019;s own credit risk.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Level&#160;1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The carrying amounts of cash and cash equivalents, short-term deposits, trade payables, other receivables, and prepaid expenses approximate their fair value due to the short-term maturity of such instruments. None of the Company&#x2019;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;
      </us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325170907896">
        &lt;div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;L.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-weight:bold"&gt;Share-based compensation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The Company accounts for share-based compensation as an expense in the financial statements based on ASC 718. All awards are equity classified and therefore such costs are measured at the grant date fair value of the award and graded vesting attribution approach to recognize compensation cost over the vesting period. The Company recognizes compensation cost for an award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant-date value of such award that is vested at that date.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The fair value for the Company&#x2019;s stock options granted to employees, consultants and directors was estimated using Black-Scholes option-pricing model at the grant date, using the inputs detailed in Note 8(C).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The Company has historically not paid dividends and has no foreseeable plans to pay dividends.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;
      </us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <cmmb:GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325170915750">
        &lt;div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;M.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-weight:bold"&gt;Government-sponsored research and development&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Chemomab records grants received from the office of the Israel Innovation Authority (the &#x201c;IIA&#x201d;) as a liability, if it is probable that the Chemomab will have to repay the grants received. If it is not probable that the grants will be repaid, Chemomab records the grants as a reduction to research and development expenses.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;
      </cmmb:GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock>
    <cmmb:SeverancePayPolicyTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325171008896">
          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;N.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-weight:bold"&gt;Severance pay&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Pursuant to Section 14 of the Severance Compensation Law, 1963 ("Section 14"), all employees of the Company are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made on their behalf with insurance companies. Upon release of the policy to the employee, no additional liability exists between the parties regarding the matter of severance pay and no additional payments shall be made by the Company to the employee. This plan has been accounted for as a defined contribution plan. Severance costs amounted to approximately $50&#160;thousands, $86 thousands, and $142 thousands for the year ended December 31, 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        </cmmb:SeverancePayPolicyTextBlock>
    <cmmb:PercentageOfMonthlyDepositsRate
      contextRef="C_20240101to20241231"
      decimals="4"
      id="Fxbrl_20230215220314714"
      unitRef="Pure">0.0833</cmmb:PercentageOfMonthlyDepositsRate>
    <us-gaap:SeveranceCosts1
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20230215220321806"
      unitRef="usd">50000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230215220329094"
      unitRef="usd">86000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325101644612"
      unitRef="usd">142000</us-gaap:SeveranceCosts1>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325171015865">
        &lt;div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;O.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-weight:bold"&gt;Concentrations of credit risk:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Cash and cash equivalents and short- term deposits are invested in banks. Management believes that the financial institutions that hold the Company&#x2019;s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The Company have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;
      </us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325171023616">
        &lt;div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;P.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-weight:bold"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Under Topic 842, the Company determines if an arrangement is a lease at inception. Right-of-use (ROU) assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company's incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be 9% in 2024 and 2023 and 5% in 2022, The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;When determining the probability of exercising such options, the Company considers contract-based, asset-based, entity-based, and market-based factors. For lease agreements, the Company has elected the practical expedient to account for the lease and non-lease maintenance components as a single lease component. Therefore, for those leases, the lease payments used to measure the lease liability include all the fixed considerations in the contract. The Company's lease agreements generally do not contain any residual value guarantees or restrictive covenants.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;ROU assets for operating leases are periodically reduced by impairment losses. The Company uses the long-lived assets impairment guidance in ASC Subtopic 360-10, Property, Plant, and Equipment to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;
      </us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325171031922">
        &lt;div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;Q.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-weight:bold"&gt;Segments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The Company has one reportable segment, focused on the research and development of therapeutics for conditions with high unmet medical needs involving inflammation and fibrosis. The Company&#x2019;s chief operating decision maker ("CODM") is its chief executive officer of the company. The segment is managed on a consolidated basis, and the CODM uses total operating expenses and consolidated net loss to assess performance, forecast future financial results, and allocate resources.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;In evaluating the Company's financial performance and making strategic decisions, the CODM regularly reviews operating expenses by function. Furthermore, the CODM is provided only with the consolidated expenses, as presented in the income statement disclosures (see Notes 9 and 10&#160;with respect to salaries, professional services, consultants and subcontractors). This includes a review of budget versus actual expenses and direct program spending, which encompasses clinical costs, consultant fees, manufacturing expenses, and other direct external costs.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;
      </us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325171038815">
        &lt;div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;R.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-weight:bold"&gt;Principles of consolidation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The consolidated financial statements include the accounts of the Company and its Subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;
      </us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325171048100">
        &lt;div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;S.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-weight:bold"&gt;Loss per ordinary share&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Basic Loss per ordinary share are calculated using only weighted average ordinary shares outstanding. Diluted loss per share, if relevant, gives an effect to dilutive potential ordinary shares outstanding during the year.&#160; Such dilutive shares consist of incremental shares, using the treasury stock method, from the assumed exercise of share options.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;
      </us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="C_20240101to20241231" id="FFact_0000000000244">
    &lt;div&gt;
      &lt;div&gt;
        &lt;div style="text-align:justify;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Note 3 - Cash and Cash Equivalents&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="line-height:1.25;margin-left:36pt"&gt;

              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In USD&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,545&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,718&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In NIS&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;525&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,574&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In other currencies&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;*-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,071&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9,292&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;

          &lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;line-height:1.25;margin-left:36pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;* Less than 1 thousand&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325103135178">
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In USD&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,545&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,718&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In NIS&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;525&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,574&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In other currencies&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;*-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,071&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9,292&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            </us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20241231_srtCurrencyAxis_currencyUSD"
      decimals="-3"
      id="FFact_0000000000235"
      unitRef="usd">5545000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20231231_srtCurrencyAxis_currencyUSD"
      decimals="-3"
      id="FFact_0000000000236"
      unitRef="usd">6718000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20241231_srtCurrencyAxis_currencyILS"
      decimals="-3"
      id="FFact_0000000000237"
      unitRef="usd">525000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20231231_srtCurrencyAxis_currencyILS"
      decimals="-3"
      id="FFact_0000000000238"
      unitRef="usd">2574000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20241231_srtCurrencyAxis_currencyXXX"
      decimals="-3"
      id="Fxbrl_20240325103200378"
      unitRef="usd">1000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20231231_srtCurrencyAxis_currencyXXX"
      decimals="-3"
      id="Fxbrl_20250325144319085"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000241"
      unitRef="usd">6071000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000242"
      unitRef="usd">9292000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock contextRef="C_20240101to20241231" id="FFact_0000000000252">
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Note 4 - Other Receivables and Prepaid Expenses&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;

      &lt;div&gt;
        &lt;div&gt;
          &lt;div style="line-height:1.25;margin-left:36pt"&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Government institutions&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;263&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;289&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Prepaid expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,435&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;748&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,698&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,037&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;

  </cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock>
    <cmmb:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325144838679">
      &lt;div&gt;
        &lt;div&gt;
          &lt;div style="line-height:1.25;margin-left:36pt"&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Government institutions&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;263&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;289&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Prepaid expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,435&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;748&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,698&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,037&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    </cmmb:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock>
    <cmmb:ReceivablesFromGovernmentInstitutions
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000245"
      unitRef="usd">263000</cmmb:ReceivablesFromGovernmentInstitutions>
    <cmmb:ReceivablesFromGovernmentInstitutions
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000246"
      unitRef="usd">289000</cmmb:ReceivablesFromGovernmentInstitutions>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000247"
      unitRef="usd">1435000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000248"
      unitRef="usd">748000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000249"
      unitRef="usd">1698000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000250"
      unitRef="usd">1037000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325145701936">
    &lt;div&gt;
      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Note 5 - Property and Equipment, Net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="line-height:1.25;margin-left:36pt"&gt;

          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Cost:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Computers&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;68&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;68&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Furniture and equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Laboratory equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;400&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;400&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Website development&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Leasehold improvements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;529&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;529&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Less - accumulated depreciation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(279&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(226&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;250&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;303&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;

      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325145709940">
          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Cost:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Computers&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;68&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;68&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Furniture and equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Laboratory equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;400&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;400&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Website development&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Leasehold improvements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;529&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;529&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Less - accumulated depreciation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(279&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(226&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;250&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;303&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"
      decimals="-3"
      id="FFact_0000000000253"
      unitRef="usd">68000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"
      decimals="-3"
      id="FFact_0000000000254"
      unitRef="usd">68000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember"
      decimals="-3"
      id="FFact_0000000000255"
      unitRef="usd">33000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember"
      decimals="-3"
      id="FFact_0000000000256"
      unitRef="usd">33000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember"
      decimals="-3"
      id="FFact_0000000000257"
      unitRef="usd">400000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember"
      decimals="-3"
      id="FFact_0000000000258"
      unitRef="usd">400000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapSoftwareDevelopmentMember"
      decimals="-3"
      id="FFact_0000000000259"
      unitRef="usd">14000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapSoftwareDevelopmentMember"
      decimals="-3"
      id="FFact_0000000000260"
      unitRef="usd">14000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20241231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"
      decimals="-3"
      id="FFact_0000000000261"
      unitRef="usd">14000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"
      decimals="-3"
      id="FFact_0000000000262"
      unitRef="usd">14000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20230201032006902"
      unitRef="usd">529000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000264"
      unitRef="usd">529000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20250325145509779"
      unitRef="usd">279000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000266"
      unitRef="usd">226000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20230201033845372"
      unitRef="usd">250000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000268"
      unitRef="usd">303000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="C_20240101to20241231" id="FFact_0000000000294">
    &lt;div&gt;
      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Note 6 - Leases&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On May 10, 2020, Chemomab entered into an office and lab space lease agreement (the "Agreement") for a three-year term in Atidim Park, Tel Aviv, with an option to extend for an additional three years. On October 24, 2021, the Company signed an amendment (the "Amendment"), under which it returned the previous space on December 12, 2021, and leased a larger space in the same location for three years through October 2024. In September 2024, the Company extended the agreement through October 2027. The annual lease and management fees are approximately $112 thousands, and a bank guarantee of approximately $76 thousands was issued to the property owner in 2023.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On September 30, 2024, the Company signed an addendum to the rent agreement stating that, as of January 1, 2025, the Company has an early termination period of 120 days for the lease agreement.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div&gt;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;The above operating leases are included in &#x201c;Operating lease right-of-use assets&#x201d; on the Company&#x2019;s Consolidated Balance sheets as of December 31, 2024 and 2023 represent the Company&#x2019;s right to use the underlying asset for the lease term. The Company&#x2019;s obligations to pay lease payments are included in the current liabilities as &#x201c;Operating lease liabilities&#x201d; and in the non-current liabilities as &#x201c;non-current operating lease liabilities&#x201d; in the Company&#x2019;s Consolidated Balance sheets as of December 31, 2024 and 2023. Based on the present value of the lease payments for the remaining lease term of the Company&#x2019;s existing lease agreement, the Company recognized operating right-of-use assets and operating lease liabilities of approximately $392 thousands on December 12, 2023.&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;During the year ended December 31, 2023, the Company recognized an increase in right of use assets of $392 thousand.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2024 and 2023 amounts of operating right-of-use assets were $289 thousands and $392 thousand, respectively. The operating lease liabilities amounts were $324 thousands and $392 thousand, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As most of Chemomab&#x2019;s leases do not provide an implicit rate, Chemomab uses its incremental borrowing rate based on the information available at the commencement date of each lease in determining the present value of lease payments. Chemomab&#x2019;s incremental borrowing rate is a hypothetical rate based on its estimation of its theoretical credit rating. The rate was 9% in 2024 and 2023.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Maturities of lease liabilities under non-cancellable leases as of December 31, 2024, are as follows: (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="margin-left:36pt"&gt;

          &lt;div&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;120&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:88%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;120&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;106&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:88%;padding-bottom:4px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;346&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Less imputed interest:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:88%;padding-bottom:4px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;324&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;

      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="C_20200510" id="Fxbrl_20230131233210356">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_20200501to20200510"
      id="Fxbrl_20230131233301410">three years</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_20211001to20211024"
      id="Fxbrl_20230201000916081">three years</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <cmmb:AnnualRentAndManagementFees
      contextRef="C_20211001to20211024"
      decimals="-3"
      id="Fxbrl_20230131234005244"
      unitRef="usd">112000</cmmb:AnnualRentAndManagementFees>
    <cmmb:BankGuaranteesToPropertyOwner
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240325135011021"
      unitRef="usd">76000</cmmb:BankGuaranteesToPropertyOwner>
    <cmmb:OperatingRightOfUseAssetsAndOperatingLeaseLiabilities
      contextRef="C_20231212"
      decimals="-3"
      id="Fxbrl_20250326210718797"
      unitRef="usd">392000</cmmb:OperatingRightOfUseAssetsAndOperatingLeaseLiabilities>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230131234513790"
      unitRef="usd">392000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20230214143811730"
      unitRef="usd">289000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20230214143818906"
      unitRef="usd">392000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20230214143827206"
      unitRef="usd">324000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20230214143833566"
      unitRef="usd">392000</us-gaap:OperatingLeaseLiability>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="C_20230101to20231231"
      decimals="2"
      id="Fxbrl_20250325212645077"
      unitRef="Pure">0.09</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="C_20240101to20241231"
      decimals="2"
      id="Fxbrl_20230131234937485"
      unitRef="Pure">0.09</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325105733072">
          &lt;div&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;120&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:88%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;120&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;106&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:88%;padding-bottom:4px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;346&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Less imputed interest:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:88%;padding-bottom:4px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;324&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
        </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20240325112906183"
      unitRef="usd">120000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20240325112921124"
      unitRef="usd">120000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20240325112940611"
      unitRef="usd">106000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000290"
      unitRef="usd">346000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000291"
      unitRef="usd">22000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000292"
      unitRef="usd">324000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsDisclosureTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325145247048">
    &lt;div&gt;
      &lt;div style="text-align:justify;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Note 7 - Commitments and Contingent Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;A.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-weight:bold"&gt;Exclusive License Agreement (hereinafter- &#x201c;the License Agreement&#x201d;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;In December 2011, Chemomab entered into a License Agreement with the Medical Research, Infrastructure, Health Services Fund of the Tel-Aviv Souraski Medical Center (&#x201c;Fund"), pursuant to which it was granted with an exclusive license to certain inventions (as defined in the License Agreement) including patents, knowhow and products and the right to sublicense to third parties the rights granted, pursuant to and subject to certain terms and limitation fully set in the License Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Chemomab has agreed to pay the Fund a non-refundable and non-creditable sublicense fees as a percentage of all Attributed Income (as such term defined in the License Agreement) and shall further pay the Fund royalties from sales made by sublicensee.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Royalties in percentage of Net sales or Service Income (as defined in the License Agreement), subject to certain additional terms set forth therein.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div&gt;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;In addition, with respect to each Licensed Product (as defined therein), Chemomab has agreed to pay the Fund the following non-refundable, non-creditable amounts:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:36pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(a)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
              &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$100 thousands upon submission of a New Drug Application (&#x201c;NDA&#x201d;), Biological License Application (&#x201c;BLA&#x201d;) or equivalent for each Licensed Product to the United States Food and Drug Administration (&#x201c;FDA&#x201d;), $100 thousands upon submission of a similar application for each Licensed Product to an equivalent foreign regulatory agency in Europe and one hundred thousands dollars upon submission of a similar application for each Licensed Product to an equivalent foreign regulatory agency in Asia. Payment in the aggregate shall not be more than $300 thousands per Licensed Product, provided that for each jurisdiction, payment shall be made only once.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:36pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(b)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
              &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$200 thousands upon the grant of FDA or equivalent agency marketing approval in Europe and/or Asia for each Licensed Product. Payment in the aggregate shall not be more than&#160;$600 thousands per Licensed Product, provided that for each jurisdiction, payment shall be made only once.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-indent:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;As of December 31, 2024, no payments were made to the Fund.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;In addition to the payments described above, upon the occurrence of either (i) closing of a public offering of the ordinary shares of Chemomab; or (ii) a Change of Control Transaction, Chemomab shall pay the Fund a cash payment equal to one percent (1%) of the proceeds raised by Chemomab in its initial public offering, or 1% of the consideration received by Chemomab or its shareholders at the closing of a Change of Control Transaction (after deduction of amounts paid as liquidation preference to the shareholders of Chemomab on account of their investment in Chemomab, if any), but in any event not more than&#160; $3,000 thousand.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;As of December 31, 2024 none of the above occurred and as such, no commitment exists.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:30pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;B.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Chemomab partially financed its research and development expenditures under programs sponsored by the Israel Innovation Authority (&#x201c;IIA&#x201d;) for the support of certain research and development activities conducted in Israel.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;In return for the IIA&#x2019;s participation, Chemomab is committed to pay royalties at rate of 3% of sales of the developed product (linked to U.S. dollar), up to 100% of the amount of grants received (100% plus interest at LIBOR). In addition, the IIA may impose certain conditions to transfer technology or development out of Israel.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Chemomab did not receive any grants from the IIA in the years ended December 31, 2024, 2023 and 2022.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Since Chemomab &#x2019;s incorporation through December 31, 2024, Chemomab received $1,227 thousands from the IIA, which was recognized as a reduction of research and development expenses.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;As of December 31, 2024, Chemomab had no commitment&#160; to pay royalties.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div&gt;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:30pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;C.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;In June 2015, Chemomab entered into a license agreement with subcontractor (&#x201c;the Subcontractor&#x201d;), under which the Subcontractor granted to Chemomab certain licenses to use proprietary rights of the subcontractor, materials and know how in the techniques and use of the same, for purposes of research and development of Chemomab 's product CM-101, as well as commercialization thereof. Further to the agreement, the Subcontractor also provides manufacturing services of intermediate and active pharmaceutical ingredients. According to the related manufacturing agreement, the manufacturing of the product is carried out by the Subcontractor in accordance with Chemomab's specifications and timeline.&#160; From time to time, Chemomab and the Subcontractor have been signing additional agreements for additional manufacturing and final process lock of the product for clinical use. Under the agreement, Chemomab is also obligated to pay the Subcontractor royalties determined as a percentage of net sales of each licensee product.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div&gt;&#160;&lt;/div&gt;
              &lt;div&gt;
                &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;During 2024, 2023 and 2022, Chemomab recorded expenses related to the above agreements in the amounts of $418 thousand, $4,832 thousands and $5,222 thousand, respectively. The expenses were recorded under research and development expenses.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="text-align:justify;line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:30pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;D.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;As of December 31, 2024 and 2023, the bank imposed restriction on a bank deposit in the amount of $76 thousand, for the purpose of securing lease payments under an office lease agreement.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:30pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;E.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;In&#160; 2022, the Israeli Tax Authority ("ITA") notified the Company that it had initiated a routine VAT audit covering the tax years 2017 through 2022. The ITA raised several claims, primarily regarding the recoverability of VAT related to the Merger Agreement expenses and the classification of the Company as a holding company. The Company accrued a provision for expenses&#160;of $638&#160;thousands in the year ended December 31, 2022. On December 29, 2024, the Company and the ITA reached a settlement agreement stipulating that the Company would pay $538 thousand. The amount was paid in January 2025.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
    &lt;/div&gt;
  </us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:LongTermPurchaseCommitmentDescription
      contextRef="C_20240101to20241231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_usgaapCapitalAdditionsMember"
      id="Fxbrl_20230215222406006">$100 thousands upon submission of a New Drug Application (&#x201c;NDA&#x201d;), Biological License Application (&#x201c;BLA&#x201d;) or equivalent for each Licensed Product to the United States Food and Drug Administration (&#x201c;FDA&#x201d;), $100 thousands upon submission of a similar application for each Licensed Product to an equivalent foreign regulatory agency in Europe and one hundred thousands dollars upon submission of a similar application for each Licensed Product to an equivalent foreign regulatory agency in Asia. Payment in the aggregate shall not be more than $300 thousands per Licensed Product, provided that for each jurisdiction, payment shall be made only once.</us-gaap:LongTermPurchaseCommitmentDescription>
    <us-gaap:LongTermPurchaseCommitmentDescription
      contextRef="C_20240101to20241231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_cmmbCapitalAdditionsOneMember"
      id="Fxbrl_20230215222519809">$200 thousands upon the grant of FDA or equivalent agency marketing approval in Europe and/or Asia for each Licensed Product. Payment in the aggregate shall not be more than&#160;$600 thousands per Licensed Product, provided that for each jurisdiction, payment shall be made only once.</us-gaap:LongTermPurchaseCommitmentDescription>
    <us-gaap:OtherCommitmentsDescription
      contextRef="C_20240101to20241231"
      id="Fxbrl_20230215222713212">upon the occurrence of either (i) closing of a public offering of the ordinary shares of Chemomab; or (ii) a Change of Control Transaction, Chemomab shall pay the Fund a cash payment equal to one percent (1%) of the proceeds raised by Chemomab in its initial public offering, or 1% of the consideration received by Chemomab or its shareholders at the closing of a Change of Control Transaction (after deduction of amounts paid as liquidation preference to the shareholders of Chemomab on account of their investment in Chemomab, if any), but in any event not more than&#160; $3,000 thousand.</us-gaap:OtherCommitmentsDescription>
    <cmmb:PercentageOfRoyaltyPaymentsOnSaleOfProduct
      contextRef="C_20240101to20241231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_usgaapCapitalAdditionsMember"
      decimals="2"
      id="Fxbrl_20230201002925810"
      unitRef="Pure">0.03</cmmb:PercentageOfRoyaltyPaymentsOnSaleOfProduct>
    <cmmb:MaximumPercentageOfPaymentsOfRoyalties
      contextRef="C_20240101to20241231"
      decimals="2"
      id="Fxbrl_20230201002935951"
      unitRef="Pure">1</cmmb:MaximumPercentageOfPaymentsOfRoyalties>
    <cmmb:CumulativeAmountsOfGrantsReceivedAndRecognized
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20230201002951961"
      unitRef="usd">1227000</cmmb:CumulativeAmountsOfGrantsReceivedAndRecognized>
    <us-gaap:RoyaltyExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20230213125722009"
      unitRef="usd">418000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230213125731080"
      unitRef="usd">4832000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325141025378"
      unitRef="usd">5222000</us-gaap:RoyaltyExpense>
    <us-gaap:RestrictedInvestments
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20230213125744104"
      unitRef="usd">76000</us-gaap:RestrictedInvestments>
    <us-gaap:AccretionExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20250325180625658"
      unitRef="usd">638000</us-gaap:AccretionExpense>
    <us-gaap:AccruedIncomeTaxes
      contextRef="C_20241229"
      decimals="-3"
      id="Fxbrl_20250325173724868"
      unitRef="usd">538000</us-gaap:AccruedIncomeTaxes>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="C_20240101to20241231" id="FFact_0000000000385">
    &lt;div&gt;
      &lt;div style="text-align:justify;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Note 8 - Share Capital&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="vertical-align:top;font-weight:bold;width:36pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;A.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="vertical-align:top;width:auto"&gt;
              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Right attached to shares&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold;margin-left:72pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Ordinary shares&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;All of the issued and outstanding ordinary shares of the Company are duly authorized, validly issued, fully paid and non-assessable. The ordinary shares are not redeemable, and each ordinary share is entitled to one vote. The holders of the ordinary shares have the right to vote and participate in shareholders' meetings, the right to receive profits, and the right to participate in the accumulated earnings when the Company is dissolved.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;1.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-weight:bold"&gt;Voting&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The holders of ordinary shares are entitled to vote on all matters submitted to shareholders for a vote.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div&gt;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;2.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-weight:bold"&gt;Dividends&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The holders of the ordinary shares are entitled to receive dividends, when and as declared by the Board of Directors, and out of funds legally available.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Since its inception, the Company has not declared any dividends.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;

            &lt;tr&gt;
              &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:top;font-weight:bold;width:36pt"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;B.&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:top;width:auto"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold"&gt;Financing rounds&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
      &lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:72pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="vertical-align:top;width:18pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="vertical-align:top;width:auto"&gt;
              &lt;div style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;On March 15, 2021, the Company entered into Securities Purchase Agreements with certain purchasers, pursuant to which the Company agreed to sell approximately $45.5 million of its American Depositary Shares (ADSs)&#160;in a private placement transaction, (or "The Private Placement"). The Private Placement closed on March 22, 2021, at which time the Company sold to the purchasers 2,619,270 ADSs together with warrants to purchase up to 261,929 ADSs at an exercise price of $17.35 per ADS. The warrants will expire five years from the date of issuance, and if exercised in full, will provide to the Company proceeds of approximately $4.5 million. 20 Ordinary Shares are equal to 1 American Depositary Share (ADS).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:72pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="vertical-align:top;width:18pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="vertical-align:top;width:auto"&gt;
              &lt;div style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;On April 30, 2021, the Company entered into an At the Market Offering Agreement (the "ATM Agreement") with Cantor Fitzgerald &amp;amp; Co., ("Cantor"). According to the ATM Agreement, the Company may offer and sell, from time to time, its ADSs having an aggregate offering price of up to $75 million through Cantor or the ATM Agreement. From April 30, 2021, through December 31, 2022, the Company issued 699,806 ADSs at an average price of $22.75 per ADS under the ATM Agreement, resulting in gross proceeds of $15,917 thousand.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:72pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="vertical-align:top;width:18pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;3.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="vertical-align:top;width:auto"&gt;
              &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;On April 25, 2022, the Company filed a prospectus supplement with the SEC for the issuance and sale of up to $18,125,000 of its ADSs in connection with the reactivation of the ATM Facility and pursuant to General Instruction I.B.6 of Form S-3, which, subject to certain exceptions, limits the amount of securities the Company is able to offer and sell under such registration statement to one-third of our unaffiliated public float. During the year ended December 31, 2022, the Company issued 130,505 ADSs at an average price of $2.11 per ADS under the ATM Agreement, resulting in gross proceeds of $275 thousand. During the year ended December 31, 2023, the Company issued 772,900 ADSs at an average price of $1.83 per ADS under the ATM Agreement, resulting in net proceeds of $1,371 thousand.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
      &lt;div&gt;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:72pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="vertical-align:top;width:18pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;4.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="vertical-align:top;width:auto"&gt;
              &lt;div style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;On September 19, 2022, the Company entered&#160; into a share purchase agreement (the &#x201c;Repurchase Arrangement&#x201d;) with Dr. Adi Mor, co-founder of Chemomab Ltd., then Chief Scientific Officer and a director of the Company and Professor Kobi George, co-founder of Chemomab Ltd. (together with Dr. Adi Mor, the &#x201c;Co-Founders&#x201d;), whereby the Company agreed, subject to the requisite court approval required under Section 303(a) of the Israeli Companies Law, 5759-1999 (the &#x201c;Companies Law&#x201d;), which the Company received on November 14, 2022, to repurchase up to 582,023 of the Company's ADSs owned by the Co-Founders, for consideration not to exceed an aggregate amount of $2,500,000, depending on the market price of the ADSs at the time of any repurchase. Accordingly, on November 16, 2022, the Company repurchased 582,023 ADSs (the "Treasury Shares") from the Co-Founders at an average price of $2.0848 and for total consideration of approximately $1,218 thousand.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div&gt;&#160;&lt;/div&gt;
              &lt;div&gt;
                &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;On November 17, 2023, the Company sold the Treasury Shares for an aggregate consideration of approximately $580 thousand.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:72pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="vertical-align:top;width:18pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="vertical-align:top;width:auto"&gt;
              &lt;div style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;In October 2023, the Company filed a prospectus supplement with the SEC for the issuance and sale of up to $2,863,664 of its ADSs in connection with the reactivation of the ATM Facility and pursuant to Rule 415(a)(6) under the Securities Act of 1933 Form F-3, which, subject to certain exceptions, limits the number of securities the Company may offer and sell under such registration statement to one-third of our unaffiliated public float.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:72pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="vertical-align:top;width:18pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;6.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="vertical-align:top;width:auto"&gt;
              &lt;div style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;In October 2023, the Company entered into an At the Market Offering Agreement (the "Roth ATM Agreement") with Roth Capital Partners, LLC, (&#x201c;Roth&#x201d;). According to the Roth ATM Agreement, the Company may offer and sell, from time to time, its ADSs having an aggregate offering price of up to $2,863,664 through Roth or the Roth ATM Agreement. From October 30, 2023, through December 31, 2024, the Company sold 2,303,009 ADSs at an average price of&#160; $1.11 per ADS under the Roth ATM Agreement, resulting in net proceeds of $2,348 thousand.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:72pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="vertical-align:top;width:18pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;7.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="vertical-align:top;width:auto"&gt;
              &lt;div style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;On July 25, 2024, the Company entered into Securities Purchase Agreements with existing and new investors of the Company (the "Purchasers"), pursuant to which the Company agreed to sell $10.0 million of its ADSs in a private placement transaction, (or "The Private Placement"). The Private Placement closed on July 30, 2024, at which time the Company sold to the Purchasers 4,148,867 ADSs together with pre-funded warrants to purchase up to 3,948,300 ADSs at an exercise price of $0.0001 per ADS, resulting in net proceeds of $9,071 thousand. The Pre-Funded Warrants were classified as equity, since the warrants are not considered as an ASC 480 liability, are indexed to the Company&#x2019;s own Ordinary share, and meet all the equity classification conditions pursuant to ASC 815-40. The Private Placement did not include any warrant coverage or other dilutive terms.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
      &lt;div&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;

            &lt;tr&gt;
              &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:top;font-weight:bold;width:36pt"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;C.&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:top;width:auto"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold"&gt;Share-based compensation&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      &lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;

            &lt;tr&gt;
              &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:top;font-weight:normal;width:36pt"&gt;(1)&lt;/td&gt;
              &lt;td style="vertical-align:top;width:auto"&gt;
                &lt;div style="font-weight:normal"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Share-based compensation plan:&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      &lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The Company maintains (i) the 2011 Share Option Plan (the &#x201c;2011 Plan&#x201d;), (ii) the 2017 Equity-Based Incentive Plan (the &#x201c;2017 Plan&#x201d;) and (iii) the Chemomab 2015 Share Incentive Plan (the &#x201c;2015 Plan&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;As of December 31, 2024, a total of&#160;28,443,060 of our Ordinary Shares (equal to 1,422,153 ADSs) were reserved for issuance under the 2015 Plan, of which 3,445,520 Ordinary Shares (equal to 172,276 ADSs) were issued pursuant to previous options exercise, and 9,134,900 Ordinary Shares (equal to 456,745 ADSs) were issuable under outstanding options and restricted shares ("RSAs"). Of such outstanding options and RSAs, options to purchase 6,677,380 Ordinary Shares (equal to 333,869 ADSs) had vested and became exercisable as of that date, with a weighted average exercise price of $0.31 per Ordinary Share (or $6.17 per ADS). During the year ended December 31, 2024, options to purchase 200,000 Ordinary Shares (equal to 10,000 ADSs) were canceled.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;During 2024, the Company issued 6,443,900 restricted Ordinary Shares (equal to 322,195 restricted ADSs) under the 2015 Plan.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;As of December 31, 2024, a total of 23,061,380 of our Ordinary Shares (equal to 1,153,069 of our ADSs) were reserved for issuance under the 2017 Plan, of which 22,915,400 Ordinary Shares (equal to 1,145,770 ADSs) were issuable under outstanding options. Of such outstanding options, options to purchase 11,460,260 Ordinary Shares (equal to 573,013 ADSs) had vested and became exercisable as of that date, with a weighted average exercise price of $0.13 per Ordinary Share (or $2.63 per ADS). During the year ended December 31, 2024, options to purchase 131,260 Ordinary Shares (equal to 6,563 ADSs) were canceled.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:36pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(2)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
              &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The expenses that were recognized in the consolidated statements of operations for services received from employees and service providers are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="line-height:1.25;margin-left:72pt"&gt;

          &lt;div&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Research and development&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;401&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;407&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;448&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;General and administrative&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;216&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,084&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,763&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Total share-based compensation expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;617&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,491&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;3,211&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;

        &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
      &lt;/div&gt;
      &lt;div&gt;&lt;/div&gt;
      &lt;div style="text-align:justify;line-height:1.25"&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;

            &lt;tr&gt;
              &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:36pt;vertical-align:top"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;(3)&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;The number and weighted average exercise price of options are as follows:&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
      &lt;/div&gt;

        &lt;div&gt;
          &lt;div style="line-height:1.25"&gt;
            &lt;div style="margin-left:72pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Weighted average&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;exercise price&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Number&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;of options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;average&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;remaining contractual life (in years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;average&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;exercise price&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Number&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;of options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;average&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;remaining contractual life&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(in years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Outstanding at January 1&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.33&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;35,191,540&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;7.42&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.38&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;27,003,260&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;8.12&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:28%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Exercised&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.07&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(1,970,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Forfeited&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.39&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(20,373,620&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.32&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(1,240,120&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:28%;padding-bottom:2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.07&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;15,055,180&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5.86&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.16&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;11,398,400&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:28%;padding-bottom:4px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Outstanding at December 31&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.16&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;29,873,100&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5.99&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.33&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;35,191,540&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;7.42&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:72pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Weighted average&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;exercise price&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Number&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;of options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;average&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;remaining contractual life (in years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;average&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;exercise price&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Number&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;of options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;average&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;remaining contractual life&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(in years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Outstanding at January 1&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.16&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;29,873,100&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5.99&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.33&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;35,191,540&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;7.42&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:28%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Exercised&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Forfeited&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.19&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(667,820&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.39&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(20,373,620&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:28%;padding-bottom:2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.03&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,845,020&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;8.56&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.07&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;15,055,180&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5.86&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:28%;padding-bottom:4px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Outstanding at December 31&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.15&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;32,050,300&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;7.34&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.16&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;29,873,100&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5.99&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;

      &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;

            &lt;tr&gt;
              &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:36pt;vertical-align:top"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;(3)&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;The number of&#160;RSAs is as follows:&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
      &lt;/div&gt;
      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;margin-left:72pt"&gt;

          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Number of RSAs&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;
                  &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;RSA&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Unvested at beginning of the year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td colspan="1" style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;6,443,900&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Vested&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td colspan="1" style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Forfeited&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td colspan="1" style="vertical-align:top;width:88%;padding-bottom:4px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;6,443,900&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;

        &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
      &lt;/div&gt;
      &lt;div&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;

            &lt;tr&gt;
              &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:36pt;vertical-align:top"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:36pt;vertical-align:top"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;4)&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Fair value measurement:&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
      &lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The fair value of the options is measured at the grant date using the Black-Scholes Option pricing model and the assumptions used to calculate the fair value of the options are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&#160;&lt;/div&gt;

        &lt;div&gt;
          &lt;div style="margin-left:72pt"&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;font-weight:bold;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024 grants of Options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Weighted average share price (in U.S. dollar)&lt;sup style="vertical-align:text-top;line-height:1;font-size:smaller"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.04&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:88%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Exercise price (in U.S. dollar)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.03-0.05&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Expected life of options (in years)&lt;sup style="vertical-align:text-top;line-height:1;font-size:smaller"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5.5-6.1&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:88%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Expected volatility&lt;sup style="vertical-align:text-top;line-height:1;font-size:smaller"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;89.29%-92.98&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Risk-free interest rate&lt;sup style="vertical-align:text-top;line-height:1;font-size:smaller"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;4.1%-4.5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:88%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
        &lt;/div&gt;

      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:72pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:36pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(a)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
              &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The weighted average share price is based on the Company's Ordinary Share closing price on the stock exchange as at the grant date&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:72pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:36pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(b)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
              &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Expected life for the periods presented was determined according to the simplified method since, at the date of grant, the Company did not have enough history to make an estimate. This method effectively assumes that exercise occurs over the period from vesting until expiration, and therefore the expected term is the midpoint between the service period and the contractual term of the award. The simplified method is applicable to service conditions.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:72pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:36pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(c)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
              &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Expected volatility is based on historical volatility over the most recent period commensurate with the expected term of the option. As the Company has a short trading history for its ordinary shares, when the Company's trading period is shorter than the expected term, the expected volatility is derived from the average historical share volatilities of several unrelated public companies within the Company&#x2019;s industry that the Company considers to be comparable to its own business over a period equivalent to the option&#x2019;s expected term.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:72pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:36pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(d)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
              &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The risk-free rate for the expected term of the options is based on the Black-Scholes option-pricing model on the yields of U.S. Treasury securities with maturities appropriate for the expected term of employee share option awards.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
    &lt;/div&gt;
  </us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <cmmb:ProceedsFromSaleOfAdss
      contextRef="C_20210301to20210315_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="-5"
      id="Fxbrl_20230213133908909"
      unitRef="usd">45500000</cmmb:ProceedsFromSaleOfAdss>
    <cmmb:NumberOfWarrantsPurchaseUpAdss
      contextRef="C_20210301to20210322_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="INF"
      id="Fxbrl_20230213133843633"
      unitRef="Share">2619270</cmmb:NumberOfWarrantsPurchaseUpAdss>
    <cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues
      contextRef="C_20210301to20210322_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="INF"
      id="Fxbrl_20230213133849363"
      unitRef="Share">261929</cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues>
    <cmmb:SaleOfStocksPricePerShare
      contextRef="C_20210301to20210322_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="2"
      id="Fxbrl_20230213133830904"
      unitRef="USD_Per_Share">17.35</cmmb:SaleOfStocksPricePerShare>
    <cmmb:ProceedsFromSaleOfAdss
      contextRef="C_20210301to20210322_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="-5"
      id="Fxbrl_20230213133820824"
      unitRef="usd">4500000</cmmb:ProceedsFromSaleOfAdss>
    <cmmb:AggregateOfferingPriceOfAtMarketOfferingAgreement
      contextRef="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="-6"
      id="Fxbrl_20230213133808746"
      unitRef="usd">75000000</cmmb:AggregateOfferingPriceOfAtMarketOfferingAgreement>
    <cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues
      contextRef="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="INF"
      id="Fxbrl_20230213133801744"
      unitRef="Share">699806</cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues>
    <cmmb:SaleOfStocksPricePerShare
      contextRef="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="2"
      id="Fxbrl_20230213133754484"
      unitRef="USD_Per_Share">22.75</cmmb:SaleOfStocksPricePerShare>
    <cmmb:ProceedsFromSaleOfAdss
      contextRef="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="-3"
      id="Fxbrl_20230213133747440"
      unitRef="usd">15917000</cmmb:ProceedsFromSaleOfAdss>
    <cmmb:ProceedsFromSaleOfAdss
      contextRef="C_20220401to20220425_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="0"
      id="Fxbrl_20230213133711976"
      unitRef="usd">18125000</cmmb:ProceedsFromSaleOfAdss>
    <cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues
      contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="INF"
      id="Fxbrl_20230213133726969"
      unitRef="Share">130505</cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues>
    <cmmb:SaleOfStocksPricePerShare
      contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="2"
      id="Fxbrl_20230213133719951"
      unitRef="USD_Per_Share">2.11</cmmb:SaleOfStocksPricePerShare>
    <cmmb:ProceedsFromSaleOfAdss
      contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="-3"
      id="Fxbrl_20230213133734136"
      unitRef="usd">275000</cmmb:ProceedsFromSaleOfAdss>
    <cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues
      contextRef="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="INF"
      id="Fxbrl_20240325123733602"
      unitRef="Share">772900</cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues>
    <cmmb:SaleOfStocksPricePerShare
      contextRef="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="2"
      id="Fxbrl_20240325123743170"
      unitRef="USD_Per_Share">1.83</cmmb:SaleOfStocksPricePerShare>
    <cmmb:ProceedsFromSaleOfAdss
      contextRef="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="-3"
      id="Fxbrl_20240325164632464"
      unitRef="usd">1371000</cmmb:ProceedsFromSaleOfAdss>
    <cmmb:RepurchaseOfAmericanDepositaryReceiptsShares
      contextRef="C_20220901to20220919_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember"
      decimals="INF"
      id="Fxbrl_20230213133614438"
      unitRef="Share">582023</cmmb:RepurchaseOfAmericanDepositaryReceiptsShares>
    <cmmb:RepurchaseOfAmericanDepositaryReceipts
      contextRef="C_20220930_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember"
      decimals="0"
      id="Fxbrl_20230213133621142"
      unitRef="usd">2500000</cmmb:RepurchaseOfAmericanDepositaryReceipts>
    <cmmb:RepurchaseOfAmericanDepositaryReceiptsShares
      contextRef="C_20221101to20221116_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember"
      decimals="INF"
      id="Fxbrl_20230213133633159"
      unitRef="Share">582023</cmmb:RepurchaseOfAmericanDepositaryReceiptsShares>
    <cmmb:WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts
      contextRef="C_20221101to20221116_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember"
      decimals="4"
      id="Fxbrl_20230213133700406"
      unitRef="USD_Per_Share">2.0848</cmmb:WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts>
    <cmmb:TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts
      contextRef="C_20221101to20221116_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember"
      decimals="-3"
      id="Fxbrl_20230213133643190"
      unitRef="usd">1218000</cmmb:TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts>
    <us-gaap:ProceedsFromSaleOfTreasuryStock
      contextRef="C_20231101to20231117"
      decimals="-3"
      id="Fxbrl_20240325170937255"
      unitRef="usd">580000</us-gaap:ProceedsFromSaleOfTreasuryStock>
    <cmmb:ProceedsFromSaleOfAdss
      contextRef="C_20231001to20231031"
      decimals="0"
      id="Fxbrl_20240325171010296"
      unitRef="usd">2863664</cmmb:ProceedsFromSaleOfAdss>
    <cmmb:ProceedsFromSaleOfAdss
      contextRef="C_20231001to20231031_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRothCapitalPartnersLlcMember_usgaapSubsidiarySaleOfStockAxis_cmmbMarketOfferingAgreementMember"
      decimals="0"
      id="Fxbrl_20240325171044931"
      unitRef="usd">2863664</cmmb:ProceedsFromSaleOfAdss>
    <cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues
      contextRef="C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRothCapitalPartnersLlcMember_usgaapSubsidiarySaleOfStockAxis_cmmbMarketOfferingAgreementMember"
      decimals="INF"
      id="Fxbrl_20240325171233284"
      unitRef="Share">2303009</cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues>
    <cmmb:WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts
      contextRef="C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRothCapitalPartnersLlcMember_usgaapSubsidiarySaleOfStockAxis_cmmbMarketOfferingAgreementMember"
      decimals="2"
      id="Fxbrl_20240325171244020"
      unitRef="USD_Per_Share">1.11</cmmb:WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts>
    <cmmb:TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts
      contextRef="C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRothCapitalPartnersLlcMember_usgaapSubsidiarySaleOfStockAxis_cmmbMarketOfferingAgreementMember"
      decimals="-3"
      id="Fxbrl_20240325171253164"
      unitRef="usd">2348000</cmmb:TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts>
    <cmmb:ProceedsFromSaleOfAdss
      contextRef="C_20240701to20240725_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="-5"
      id="Fxbrl_20250325215406745"
      unitRef="usd">10000000</cmmb:ProceedsFromSaleOfAdss>
    <cmmb:NumberOfWarrantsPurchaseUpAdss
      contextRef="C_20240701to20240730_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="INF"
      id="Fxbrl_20250325215437317"
      unitRef="Share">4148867</cmmb:NumberOfWarrantsPurchaseUpAdss>
    <cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues
      contextRef="C_20240701to20240730_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="INF"
      id="Fxbrl_20250325215503211"
      unitRef="Share">3948300</cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues>
    <cmmb:SaleOfStocksPricePerShare
      contextRef="C_20240701to20240730_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="4"
      id="Fxbrl_20250325215530459"
      unitRef="ILS_per_Share">0.0001</cmmb:SaleOfStocksPricePerShare>
    <cmmb:ProceedsFromSaleOfAdss
      contextRef="C_20240701to20240730_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="-3"
      id="Fxbrl_20250325215545276"
      unitRef="usd">9071000</cmmb:ProceedsFromSaleOfAdss>
    <cmmb:NumberOfStockReservedForIssuance
      contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207224906305"
      unitRef="Share">28443060</cmmb:NumberOfStockReservedForIssuance>
    <cmmb:NumberOfStockAdssResveredForIssuance
      contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207223247056"
      unitRef="Share">1422153</cmmb:NumberOfStockAdssResveredForIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225529762"
      unitRef="Share">3445520</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues
      contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207223254041"
      unitRef="Share">172276</cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues>
    <cmmb:NumberOfOptionsIssuableOutstanding
      contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225556251"
      unitRef="Share">9134900</cmmb:NumberOfOptionsIssuableOutstanding>
    <cmmb:NumberOfAdssOptionsIssuableOutstanding
      contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207223300376"
      unitRef="Share">456745</cmmb:NumberOfAdssOptionsIssuableOutstanding>
    <cmmb:NumberOfOptionsVestedAndExercisable
      contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225618055"
      unitRef="Share">6677380</cmmb:NumberOfOptionsVestedAndExercisable>
    <cmmb:NumberOfAdssVestedAndExercisable
      contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207223309640"
      unitRef="Share">333869</cmmb:NumberOfAdssVestedAndExercisable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207224602275"
      unitRef="USD_Per_Share">0.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="2"
      id="Fxbrl_20230207223316544"
      unitRef="USD_Per_Share">6.17</cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207224845387"
      unitRef="Share">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod
      contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207223324626"
      unitRef="Share">10000</cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember_usgaapStatementClassOfStockAxis_cmmbRestrictedOrdinarySharesMember"
      decimals="INF"
      id="Fxbrl_20250325215807778"
      unitRef="Share">6443900</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues
      contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember_usgaapStatementClassOfStockAxis_cmmbRestrictedOrdinarySharesMember"
      decimals="INF"
      id="Fxbrl_20250325215819491"
      unitRef="Share">322195</cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues>
    <cmmb:NumberOfStockReservedForIssuance
      contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225827725"
      unitRef="Share">23061380</cmmb:NumberOfStockReservedForIssuance>
    <cmmb:NumberOfStockAdssResveredForIssuance
      contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225729518"
      unitRef="Share">1153069</cmmb:NumberOfStockAdssResveredForIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225858382"
      unitRef="Share">22915400</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues
      contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225738550"
      unitRef="Share">1145770</cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues>
    <cmmb:NumberOfOptionsVestedAndExercisable
      contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225916606"
      unitRef="Share">11460260</cmmb:NumberOfOptionsVestedAndExercisable>
    <cmmb:NumberOfAdssVestedAndExercisable
      contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225743877"
      unitRef="Share">573013</cmmb:NumberOfAdssVestedAndExercisable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="2"
      id="Fxbrl_20230207225929980"
      unitRef="USD_Per_Share">0.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="2"
      id="Fxbrl_20230207225750293"
      unitRef="USD_Per_Share">2.63</cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="INF"
      id="Fxbrl_20250325215036218"
      unitRef="Share">131260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod
      contextRef="C_20240101to20241231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="INF"
      id="Fxbrl_20250325215042778"
      unitRef="Share">6563</cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325123602369">
          &lt;div&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Research and development&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;401&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;407&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;448&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;General and administrative&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;216&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,084&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,763&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Total share-based compensation expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;617&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,491&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;3,211&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
        </us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20240101to20241231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="FFact_0000000000338"
      unitRef="usd">401000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="FFact_0000000000339"
      unitRef="usd">407000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fxbrl_20240325160020593_Fact_0000000000339"
      unitRef="usd">448000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20240101to20241231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="FFact_0000000000340"
      unitRef="usd">216000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="FFact_0000000000341"
      unitRef="usd">1084000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fxbrl_20240325160020594_Fact_0000000000341"
      unitRef="usd">2763000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="FFact_0000000000342"
      unitRef="usd">617000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000343"
      unitRef="usd">1491000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325160020595_Fact_0000000000343"
      unitRef="usd">3211000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325123629767">
        &lt;div&gt;
          &lt;div style="line-height:1.25"&gt;
            &lt;div style="margin-left:72pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Weighted average&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;exercise price&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Number&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;of options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;average&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;remaining contractual life (in years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;average&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;exercise price&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Number&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;of options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;average&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;remaining contractual life&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(in years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Outstanding at January 1&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.33&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;35,191,540&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;7.42&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.38&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;27,003,260&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;8.12&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:28%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Exercised&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.07&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(1,970,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Forfeited&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.39&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(20,373,620&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.32&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(1,240,120&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:28%;padding-bottom:2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.07&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;15,055,180&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5.86&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.16&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;11,398,400&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:28%;padding-bottom:4px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Outstanding at December 31&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.16&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;29,873,100&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5.99&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.33&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;35,191,540&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;7.42&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:72pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Weighted average&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;exercise price&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Number&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;of options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;average&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;remaining contractual life (in years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;average&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;exercise price&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Number&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;of options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;average&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;remaining contractual life&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(in years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Outstanding at January 1&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.16&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;29,873,100&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5.99&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.33&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;35,191,540&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;7.42&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:28%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Exercised&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Forfeited&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.19&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(667,820&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.39&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(20,373,620&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:28%;padding-bottom:2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.03&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,845,020&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;8.56&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.07&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;15,055,180&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5.86&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:28%;padding-bottom:4px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Outstanding at December 31&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.15&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;32,050,300&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;7.34&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.16&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;29,873,100&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5.99&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      </us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20221231"
      decimals="INF"
      id="FFact_0000000000345"
      unitRef="USD_Per_Share">0.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20221231"
      decimals="INF"
      id="FFact_0000000000346"
      unitRef="Share">35191540</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_20220101to20221231" id="FFact_0000000000347">P7Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20211231"
      decimals="INF"
      id="FFact_0000000000348"
      unitRef="USD_Per_Share">0.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20211231"
      decimals="INF"
      id="FFact_0000000000349"
      unitRef="Share">27003260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_20210101to20211231" id="FFact_0000000000350">P8Y1M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="Fxbrl_20250325222230065"
      unitRef="USD_Per_Share">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="Fxbrl_20250325222216181"
      unitRef="Share">0</cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20250325222250292"
      unitRef="USD_Per_Share">0.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20250325222305533"
      unitRef="Share">1970000</cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="Fxbrl_20250325222118860_xbrl_20250325221717788"
      unitRef="USD_Per_Share">0.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="Fxbrl_20250325222118860_xbrl_20250325221737036"
      unitRef="Share">20373620</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20250325222118860_xbrl_20250325221754569"
      unitRef="USD_Per_Share">0.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20250325222118860_xbrl_20250325221806508"
      unitRef="Share">1240120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="FFact_0000000000360"
      unitRef="USD_Per_Share">0.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="FFact_0000000000361"
      unitRef="Share">15055180</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm contextRef="C_20230101to20231231" id="FFact_0000000000362">P5Y10M9D</cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000363"
      unitRef="USD_Per_Share">0.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000364"
      unitRef="Share">11398400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm contextRef="C_20220101to20221231" id="FFact_0000000000365">P7Y9M18D</cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20231231"
      decimals="INF"
      id="FFact_0000000000366"
      unitRef="USD_Per_Share">0.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20231231"
      decimals="INF"
      id="FFact_0000000000367"
      unitRef="Share">29873100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_20230101to20231231" id="FFact_0000000000368">P5Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20221231"
      decimals="INF"
      id="FFact_0000000000369"
      unitRef="USD_Per_Share">0.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20221231"
      decimals="INF"
      id="FFact_0000000000370"
      unitRef="Share">35191540</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_20220101to20221231" id="FFact_0000000000371">P7Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20231231"
      decimals="INF"
      id="Fxbrl_20240325121853866_Fact_0000000000345"
      unitRef="USD_Per_Share">0.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20231231"
      decimals="INF"
      id="Fxbrl_20240325121853866_Fact_0000000000346"
      unitRef="Share">29873100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325121853866_Fact_0000000000347">P5Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20240325121853866_Fact_0000000000348"
      unitRef="USD_Per_Share">0.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20240325121853866_Fact_0000000000349"
      unitRef="Share">35191540</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20220101to20221231"
      id="Fxbrl_20240325121853866_Fact_0000000000350">P7Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_20240101to20241231"
      decimals="INF"
      id="Fxbrl_20250325221902891"
      unitRef="USD_Per_Share">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1
      contextRef="C_20240101to20241231"
      decimals="INF"
      id="Fxbrl_20250325222019555"
      unitRef="Share">0</cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="Fxbrl_20250325221840311"
      unitRef="USD_Per_Share">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="Fxbrl_20250325221924813"
      unitRef="Share">0</cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_20240101to20241231"
      decimals="INF"
      id="Fxbrl_20250325221717788"
      unitRef="USD_Per_Share">0.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_20240101to20241231"
      decimals="INF"
      id="Fxbrl_20250325221737036"
      unitRef="Share">667820</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="Fxbrl_20250325221754569"
      unitRef="USD_Per_Share">0.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="Fxbrl_20250325221806508"
      unitRef="Share">20373620</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20240101to20241231"
      decimals="INF"
      id="Fxbrl_20240325121853884_Fact_0000000000360"
      unitRef="USD_Per_Share">0.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20240101to20241231"
      decimals="INF"
      id="Fxbrl_20240325121853884_Fact_0000000000361"
      unitRef="Share">2845020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325121853884_Fact_0000000000362">P8Y6M21D</cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="Fxbrl_20240325121853884_Fact_0000000000363"
      unitRef="USD_Per_Share">0.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="Fxbrl_20240325121853884_Fact_0000000000364"
      unitRef="Share">15055180</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325121853884_Fact_0000000000365">P5Y10M9D</cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20241231"
      decimals="INF"
      id="Fxbrl_20240325121853889_Fact_0000000000366"
      unitRef="USD_Per_Share">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20241231"
      decimals="INF"
      id="Fxbrl_20240325121853889_Fact_0000000000367"
      unitRef="Share">32050300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325121853889_Fact_0000000000368">P7Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20231231"
      decimals="INF"
      id="Fxbrl_20240325121853889_Fact_0000000000369"
      unitRef="USD_Per_Share">0.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20231231"
      decimals="INF"
      id="Fxbrl_20240325121853889_Fact_0000000000370"
      unitRef="Share">29873100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325121853889_Fact_0000000000371">P5Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325221214720">
          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Number of RSAs&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;
                  &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;RSA&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Unvested at beginning of the year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td colspan="1" style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;6,443,900&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Vested&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td colspan="1" style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Forfeited&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td colspan="1" style="vertical-align:top;width:88%;padding-bottom:4px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;6,443,900&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        </us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_20231231"
      decimals="INF"
      id="Fxbrl_20250325221306195"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_20240101to20241231"
      decimals="INF"
      id="Fxbrl_20250325221342084"
      unitRef="Share">6443900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_20240101to20241231"
      decimals="INF"
      id="Fxbrl_20250325221358846"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_20240101to20241231"
      decimals="INF"
      id="Fxbrl_20250325221420994"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_20241231"
      decimals="INF"
      id="Fxbrl_20250325221313724"
      unitRef="Share">6443900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325123652785">
        &lt;div&gt;
          &lt;div style="margin-left:72pt"&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;font-weight:bold;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024 grants of Options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Weighted average share price (in U.S. dollar)&lt;sup style="vertical-align:text-top;line-height:1;font-size:smaller"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.04&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:88%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Exercise price (in U.S. dollar)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.03-0.05&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Expected life of options (in years)&lt;sup style="vertical-align:text-top;line-height:1;font-size:smaller"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5.5-6.1&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:88%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Expected volatility&lt;sup style="vertical-align:text-top;line-height:1;font-size:smaller"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;89.29%-92.98&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Risk-free interest rate&lt;sup style="vertical-align:text-top;line-height:1;font-size:smaller"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;4.1%-4.5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:88%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharePrice
      contextRef="C_20241231"
      decimals="INF"
      id="FFact_0000000000373"
      unitRef="USD_Per_Share">0.04</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_20241231_srtRangeAxis_srtMinimumMember"
      decimals="INF"
      id="FFact_0000000000375"
      unitRef="USD_Per_Share">0.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_20241231_srtRangeAxis_srtMaximumMember"
      decimals="INF"
      id="FFact_0000000000376"
      unitRef="USD_Per_Share">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20240101to20241231_srtRangeAxis_srtMinimumMember"
      id="FFact_0000000000377">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20240101to20241231_srtRangeAxis_srtMaximumMember"
      id="FFact_0000000000378">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_20240101to20241231"
      decimals="4"
      id="FFact_0000000000379"
      unitRef="Pure">0.8929</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_20240101to20241231"
      decimals="4"
      id="FFact_0000000000380"
      unitRef="Pure">0.9298</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_20240101to20241231"
      decimals="3"
      id="FFact_0000000000381"
      unitRef="Pure">0.041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_20240101to20241231"
      decimals="3"
      id="FFact_0000000000382"
      unitRef="Pure">0.045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20240101to20241231"
      decimals="INF"
      id="FFact_0000000000383"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325142201448">
    &lt;div&gt;
      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Note 9 - Research and Development&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="line-height:1.25;margin-left:36pt"&gt;

          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Consultants and subcontractors&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;7,994&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;14,014&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;13,052&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Salaries and related expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,715&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;3,362&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,867&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Lease and maintenance&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;101&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;137&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;245&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Share-based compensation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;401&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;407&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;448&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Other expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;116&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;461&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;365&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;11,327&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;18,381&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;16,977&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;

      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <cmmb:ScheduleOfResearchAndDevelopmentTableTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325142211689">
          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Consultants and subcontractors&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;7,994&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;14,014&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;13,052&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Salaries and related expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,715&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;3,362&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,867&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Lease and maintenance&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;101&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;137&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;245&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Share-based compensation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;401&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;407&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;448&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Other expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;116&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;461&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;365&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;11,327&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;18,381&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;16,977&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        </cmmb:ScheduleOfResearchAndDevelopmentTableTextBlock>
    <cmmb:ConsultantsAndSubcontractorsExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240325111304537"
      unitRef="usd">7994000</cmmb:ConsultantsAndSubcontractorsExpense>
    <cmmb:ConsultantsAndSubcontractorsExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000386"
      unitRef="usd">14014000</cmmb:ConsultantsAndSubcontractorsExpense>
    <cmmb:ConsultantsAndSubcontractorsExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000387"
      unitRef="usd">13052000</cmmb:ConsultantsAndSubcontractorsExpense>
    <us-gaap:OfficersCompensation
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240325111310016"
      unitRef="usd">2715000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000388"
      unitRef="usd">3362000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000389"
      unitRef="usd">2867000</us-gaap:OfficersCompensation>
    <cmmb:RentAndMaintenanceResearchAndDevelopmentExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240325111315367"
      unitRef="usd">101000</cmmb:RentAndMaintenanceResearchAndDevelopmentExpense>
    <cmmb:RentAndMaintenanceResearchAndDevelopmentExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000390"
      unitRef="usd">137000</cmmb:RentAndMaintenanceResearchAndDevelopmentExpense>
    <cmmb:RentAndMaintenanceResearchAndDevelopmentExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000391"
      unitRef="usd">245000</cmmb:RentAndMaintenanceResearchAndDevelopmentExpense>
    <cmmb:ShareBasedCompensationResearchAndDevelopmentExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240325111320717"
      unitRef="usd">401000</cmmb:ShareBasedCompensationResearchAndDevelopmentExpense>
    <cmmb:ShareBasedCompensationResearchAndDevelopmentExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000392"
      unitRef="usd">407000</cmmb:ShareBasedCompensationResearchAndDevelopmentExpense>
    <cmmb:ShareBasedCompensationResearchAndDevelopmentExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000393"
      unitRef="usd">448000</cmmb:ShareBasedCompensationResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240325111247489"
      unitRef="usd">116000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000394"
      unitRef="usd">461000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325111250767"
      unitRef="usd">365000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240325111258130"
      unitRef="usd">11327000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000396"
      unitRef="usd">18381000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000397"
      unitRef="usd">16977000</us-gaap:ResearchAndDevelopmentExpense>
    <cmmb:GeneralAndAdministrativeDisclosureTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325141555128">
    &lt;div&gt;
      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Note 10 - General and Administrative&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="line-height:1.25;margin-left:36pt"&gt;

          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Salaries, fees and related expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,085&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,545&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;3,435&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Professional services&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,115&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,139&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,596&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Share-based compensation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;216&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,084&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,763&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Fees to directors&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;284&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;258&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;231&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Directors' and Officers' Insurance&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;538&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;648&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,084&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Lease and maintenance&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;81&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;24&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Other expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;124&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;323&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,423&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;3,412&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;7,078&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;11,556&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;

      &lt;/div&gt;
    &lt;/div&gt;
  </cmmb:GeneralAndAdministrativeDisclosureTextBlock>
    <cmmb:ScheduleOfGeneralAndAdministrativeTableTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325141625498">
          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Salaries, fees and related expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,085&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,545&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;3,435&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Professional services&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,115&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,139&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,596&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Share-based compensation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;216&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,084&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,763&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Fees to directors&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;284&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;258&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;231&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Directors' and Officers' Insurance&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;538&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;648&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,084&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Lease and maintenance&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;81&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;24&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Other expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;124&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;323&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,423&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;3,412&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;7,078&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;11,556&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        </cmmb:ScheduleOfGeneralAndAdministrativeTableTextBlock>
    <us-gaap:SalariesAndWages
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240325110603691"
      unitRef="usd">1085000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000400"
      unitRef="usd">2545000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000401"
      unitRef="usd">3435000</us-gaap:SalariesAndWages>
    <us-gaap:ProfessionalFees
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240325110618011"
      unitRef="usd">1115000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000402"
      unitRef="usd">2139000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000403"
      unitRef="usd">2596000</us-gaap:ProfessionalFees>
    <cmmb:ShareBasedCompensationGeneralAndAdministrativeExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240325110622931"
      unitRef="usd">216000</cmmb:ShareBasedCompensationGeneralAndAdministrativeExpense>
    <cmmb:ShareBasedCompensationGeneralAndAdministrativeExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000404"
      unitRef="usd">1084000</cmmb:ShareBasedCompensationGeneralAndAdministrativeExpense>
    <cmmb:ShareBasedCompensationGeneralAndAdministrativeExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000405"
      unitRef="usd">2763000</cmmb:ShareBasedCompensationGeneralAndAdministrativeExpense>
    <us-gaap:NoninterestExpenseDirectorsFees
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240325110632753"
      unitRef="usd">284000</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:NoninterestExpenseDirectorsFees
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000406"
      unitRef="usd">258000</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:NoninterestExpenseDirectorsFees
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230201004651041"
      unitRef="usd">231000</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:GeneralInsuranceExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240325110648131"
      unitRef="usd">538000</us-gaap:GeneralInsuranceExpense>
    <us-gaap:GeneralInsuranceExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000408"
      unitRef="usd">648000</us-gaap:GeneralInsuranceExpense>
    <us-gaap:GeneralInsuranceExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000409"
      unitRef="usd">1084000</us-gaap:GeneralInsuranceExpense>
    <cmmb:RentAndMaintenanceGeneralAndAdministrativeExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240325110658345"
      unitRef="usd">50000</cmmb:RentAndMaintenanceGeneralAndAdministrativeExpense>
    <cmmb:RentAndMaintenanceGeneralAndAdministrativeExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000410"
      unitRef="usd">81000</cmmb:RentAndMaintenanceGeneralAndAdministrativeExpense>
    <cmmb:RentAndMaintenanceGeneralAndAdministrativeExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000411"
      unitRef="usd">24000</cmmb:RentAndMaintenanceGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240325110704195"
      unitRef="usd">124000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000412"
      unitRef="usd">323000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000413"
      unitRef="usd">1423000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20250325141611203"
      unitRef="usd">3412000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000414"
      unitRef="usd">7078000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000415"
      unitRef="usd">11556000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325204325897">
    &lt;div&gt;
      &lt;div&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Note 11 - Income Taxes&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:top;width:34pt;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;A.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Tax rates&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25;margin-left:70pt"&gt;
          &lt;div style="text-align:justify;line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Ordinary taxable income in Israel is subject to a corporate tax rate of 23%.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="text-align:justify;line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Capital gain is subject to capital gain tax according to the corporate tax rate in the year the assets are sold.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&#x2019;s US subsidiary, Chemomab Therapeutics Inc. ("Chemomab Inc.) is taxed separately under the U.S. tax laws.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="text-align:justify;line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Chemomab Inc. is subject to a federal flat tax rate of 21% and state tax as applicable.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:top;width:34pt;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;B.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Tax assessments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:70pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2024, the Company&#x2019;s tax reports through December 31, 2019 are considered closed to audit inspections by the Israeli Tax Authority (&#x201c;ITA&#x201d;) due to statute of limitation rules effective in Israel.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;text-indent:36pt;line-height:1.25"&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;

              &lt;tr&gt;
                &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:top;width:34pt;font-weight:bold"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;C.&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top"&gt;
                  &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold"&gt;Losses for tax purposes carried forward to future years&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
        &lt;div style="line-height:1.25;margin-left:70pt"&gt;
          &lt;div style="text-align:justify;line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2024, 2023, and 2022, the Company and its subsidiaries had approximately $176 million, $165 million, and $159 million, respectively, in net operating loss carryforwards, which are available to reduce future taxable income with no limitation on the period of use.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="text-align:justify;line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On March 27, 2020 and December 27, 2020, the President of the United States signed and enacted into law the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) and the Consolidated Appropriations Act, 2021 (CAA). Among other provisions, the CARES Act and the CAA provide relief to U.S. federal corporate taxpayers through temporary adjustments to net operating loss rules, changes to limitations on interest expense deductibility, and the acceleration of available refunds for minimum tax credit carryforwards. The CARES Act also includes provisions for a carryback of any net operating loss (NOL) arising in a taxable year beginning after December 31, 2017, and before January 1, 2021, to each of the five taxable years preceding the taxable year in which the loss arises (carryback period).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Chemomab Therapeutics Inc., a wholly owned subsidiary of the Company, filed an application with the US Internal Revenue Service to carryback net operating losses. Chemomab Therapeutics Inc received $351 thousands in December 2022 on account of 2016 and 2017 and received the remainder $183 thousands in 2023. Accordingly, a tax benefit in the total amount of $534 thousands was recorded in the Company&#x2019;s statement of operations during 2022.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-indent:36pt;line-height:1.25"&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;

              &lt;tr&gt;
                &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:top;font-weight:bold;width:34pt"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;D.&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:top;width:auto"&gt;
                  &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold"&gt;Deferred taxes&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;text-indent:-1.1pt;margin-left:70pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In respect of:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;text-indent:-1.1pt;margin-left:72pt;line-height:1.25"&gt;&#160;&lt;/div&gt;

          &lt;div&gt;
            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;margin-left:72pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net operating loss carry-forward*&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;40,755&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;38,258&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;36,550&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom"&gt;
                      &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share-based compensation expense&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,163&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,774&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development costs&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,103&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,041&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,858&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;44,219&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;43,471&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;41,195&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Less - Valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(44,219&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(43,471&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(41,195&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:-1.1pt;margin-left:72pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="line-height:1.25;margin-left:72pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;* This excludes capital losses of approximately $14,224 thousands for which the company will create a full valuation allowance.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;

        &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:70pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. A valuation allowance is provided when it is more likely than not that the deferred tax assets will not be realized.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:70pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company has established a valuation allowance to offset deferred tax assets on December 31, 2024, 2023 and 2022 due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. The net change in the total valuation allowance for the year ended at December 31, 2024 was an increase of approximately $0.8 million.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;text-indent:36pt;line-height:1.25"&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;

              &lt;tr&gt;
                &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:top;width:34pt;font-weight:bold"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;E.&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top"&gt;
                  &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold"&gt;Roll forward of valuation allowance&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
      &lt;/div&gt;
      &lt;div&gt;&#160;&lt;div style="margin-left:72pt"&gt;

            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td rowspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:right;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;background-color:rgb(204, 238, 255);width:88%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;36,030&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Currency translation Income&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,316&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;background-color:rgb(204, 238, 255);width:88%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Income tax expense&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,481&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;41,195&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;background-color:rgb(204, 238, 255);width:88%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Currency translation Income&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(3,295&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Income tax expense&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,571&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;background-color:rgb(204, 238, 255);width:88%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;43,471&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Currency translation Income&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(2,459&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;background-color:rgb(204, 238, 255);width:88%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Income tax expense&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,207&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;44,219&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;

        &lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;

              &lt;tr&gt;
                &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:top;width:34pt;font-weight:bold"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;F.&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top"&gt;
                  &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold"&gt;Reconciliation of theoretical income tax expense to actual income tax expense&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:70pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;A reconciliation of the Company&#x2019;s theoretical income tax expense to actual income tax expense is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="line-height:1.25;margin-left:72pt"&gt;

            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Loss before income taxes&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(13,945&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(24,221&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(28,180&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Statutory tax rate&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Theoretical tax benefit&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(3,207&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(5,571&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(6,481&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Change in temporary differences for which deferred taxes were not recognized&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;858&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,177&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,696&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Tax rate differential&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Non-deductible expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;148&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;346&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,192&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,392&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,879&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Actual income tax expense (Benefit)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;border-bottom:2pt solid black"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;border-bottom:2pt solid black"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;border-bottom:2pt solid black"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;border-bottom:2pt solid black"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;border-bottom:2pt solid black"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;border-bottom:2pt solid black"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(534&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;

        &lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;

              &lt;tr&gt;
                &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:top;width:34pt;font-weight:bold"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;G.&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top"&gt;
                  &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold"&gt;Accounting for uncertainty in income taxes&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:70pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For the year ended December 31, 2024, the Company did not have any unrecognized tax benefits and does not expect that the amount of unrecognized tax benefits will change significantly within the next 12 months. The Company&#x2019;s accounting policy is to accrue interest and penalties related to unrecognized tax benefits as a component of income tax expense.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_20240101to20241231_srtStatementGeographicalAxis_countryIL"
      decimals="2"
      id="FFact_0000000000418"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_20240101to20241231_srtStatementGeographicalAxis_countryUS_usgaapIncomeTaxAuthorityAxis_usgaapDomesticCountryMember"
      decimals="2"
      id="FFact_0000000000419"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_20241231_srtStatementGeographicalAxis_countryIL"
      decimals="-6"
      id="Fxbrl_20230213140532094"
      unitRef="usd">176000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_20231231_srtStatementGeographicalAxis_countryIL"
      decimals="-6"
      id="Fxbrl_20230213140537759"
      unitRef="usd">165000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_20221231_srtStatementGeographicalAxis_countryIL"
      decimals="-6"
      id="Fxbrl_20240325142108415"
      unitRef="usd">159000000</us-gaap:TaxCreditCarryforwardAmount>
    <cmmb:ReceivedAmountOfChemomabTherapeuticsInc
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20230213140710654"
      unitRef="usd">351000</cmmb:ReceivedAmountOfChemomabTherapeuticsInc>
    <cmmb:ExpectsToReceiveAmountOfChemomabTherapeuticsInc
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230213140716671"
      unitRef="usd">183000</cmmb:ExpectsToReceiveAmountOfChemomabTherapeuticsInc>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230213140722797"
      unitRef="usd">-534000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325204425105">
          &lt;div&gt;
            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;margin-left:72pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net operating loss carry-forward*&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;40,755&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;38,258&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;36,550&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom"&gt;
                      &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share-based compensation expense&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,163&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,774&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development costs&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,103&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,041&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,858&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;44,219&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;43,471&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;41,195&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Less - Valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(44,219&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(43,471&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(41,195&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:-1.1pt;margin-left:72pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="line-height:1.25;margin-left:72pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;* This excludes capital losses of approximately $14,224 thousands for which the company will create a full valuation allowance.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20240325113127688"
      unitRef="usd">40755000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000422"
      unitRef="usd">38258000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000423"
      unitRef="usd">36550000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20240325113134551"
      unitRef="usd">351000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000424"
      unitRef="usd">1163000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000425"
      unitRef="usd">1774000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20240325113142383"
      unitRef="usd">3103000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000426"
      unitRef="usd">4041000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000427"
      unitRef="usd">2858000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20240325113151187"
      unitRef="usd">10000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000428"
      unitRef="usd">9000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000429"
      unitRef="usd">13000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20240325113158306"
      unitRef="usd">44219000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000430"
      unitRef="usd">43471000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000431"
      unitRef="usd">41195000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20240325113204191"
      unitRef="usd">44219000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000432"
      unitRef="usd">43471000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000433"
      unitRef="usd">41195000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20240325113212847"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20230201010225989_Fact_0000000000426"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230201010225989_Fact_0000000000427"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20250402185453246"
      unitRef="usd">14224000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_20240101to20241231"
      decimals="-5"
      id="Fxbrl_20230201010356964"
      unitRef="usd">800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325113717888">
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td rowspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:right;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;background-color:rgb(204, 238, 255);width:88%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;36,030&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Currency translation Income&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,316&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;background-color:rgb(204, 238, 255);width:88%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Income tax expense&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,481&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;41,195&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;background-color:rgb(204, 238, 255);width:88%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Currency translation Income&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(3,295&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Income tax expense&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,571&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;background-color:rgb(204, 238, 255);width:88%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;43,471&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Currency translation Income&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(2,459&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;background-color:rgb(204, 238, 255);width:88%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Income tax expense&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,207&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;44,219&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          </us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000438"
      unitRef="usd">36030000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <cmmb:CurrencyTransactionLossValuationAllowance
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000439"
      unitRef="usd">-1316000</cmmb:CurrencyTransactionLossValuationAllowance>
    <cmmb:IncomeTaxExpenseValuationAllowance
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000440"
      unitRef="usd">6481000</cmmb:IncomeTaxExpenseValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000441"
      unitRef="usd">41195000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <cmmb:CurrencyTransactionLossValuationAllowance
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230201010936607"
      unitRef="usd">-3295000</cmmb:CurrencyTransactionLossValuationAllowance>
    <cmmb:IncomeTaxExpenseValuationAllowance
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000444"
      unitRef="usd">5571000</cmmb:IncomeTaxExpenseValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240325112211572_Fact_0000000000441"
      unitRef="usd">43471000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <cmmb:CurrencyTransactionLossValuationAllowance
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240325112219753_xbrl_20230201010936607"
      unitRef="usd">-2459000</cmmb:CurrencyTransactionLossValuationAllowance>
    <cmmb:IncomeTaxExpenseValuationAllowance
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240325112200162_Fact_0000000000444"
      unitRef="usd">3207000</cmmb:IncomeTaxExpenseValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_0000000000445"
      unitRef="usd">44219000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20240325113734351">
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:88%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Loss before income taxes&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(13,945&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(24,221&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(28,180&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Statutory tax rate&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Theoretical tax benefit&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(3,207&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(5,571&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(6,481&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Change in temporary differences for which deferred taxes were not recognized&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;858&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,177&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,696&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Tax rate differential&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Non-deductible expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;148&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;346&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,192&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,392&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,879&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Actual income tax expense (Benefit)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;border-bottom:2pt solid black"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;border-bottom:2pt solid black"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;border-bottom:2pt solid black"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;border-bottom:2pt solid black"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;border-bottom:2pt solid black"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;border-bottom:2pt solid black"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(534&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240325113300491"
      unitRef="usd">-13945000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000447"
      unitRef="usd">-24221000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000448"
      unitRef="usd">-28180000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_20240101to20241231"
      decimals="2"
      id="Fxbrl_20240325113309002"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_20230101to20231231"
      decimals="2"
      id="FFact_0000000000449"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_20220101to20221231"
      decimals="2"
      id="FFact_0000000000450"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240325113316316"
      unitRef="usd">-3207000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000451"
      unitRef="usd">-5571000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000452"
      unitRef="usd">-6481000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <cmmb:ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240325113329731"
      unitRef="usd">858000</cmmb:ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized>
    <cmmb:ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230213113429979_Fact_0000000000453"
      unitRef="usd">-1177000</cmmb:ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized>
    <cmmb:ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230213113429979_Fact_0000000000454"
      unitRef="usd">-1696000</cmmb:ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240325113338019"
      unitRef="usd">9000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230213113425908_Fact_0000000000453"
      unitRef="usd">10000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230213113425908_Fact_0000000000454"
      unitRef="usd">-20000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240325113354492"
      unitRef="usd">148000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230213113423827_Fact_0000000000453"
      unitRef="usd">346000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230213113423827_Fact_0000000000454"
      unitRef="usd">744000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <cmmb:LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240325113401417"
      unitRef="usd">2192000</cmmb:LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded>
    <cmmb:LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230213113421604_Fact_0000000000453"
      unitRef="usd">6392000</cmmb:LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded>
    <cmmb:LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325114521690"
      unitRef="usd">6879000</cmmb:LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240325115329121"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325115408857"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325115419350"
      unitRef="usd">-534000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325140934102">
      &lt;div&gt;
        &lt;div style="text-align:justify;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Note 12 - Related Parties Balances and Transactions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:18pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;A.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Balances with Related Parties:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The following Related Party payables are included in the consolidated Balance Sheets:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;margin-left:36pt"&gt;

            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Employees, consultants and related expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;531&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;490&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Accrued expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;75&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;74&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;606&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;564&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;

        &lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:18pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;B.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Transactions with Related Parties:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The following transactions with related parties are included in the consolidated Statements of Operations:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="line-height:1.25;margin-left:36pt"&gt;

            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Salaries and related expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,718&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,795&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,409&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Share-based payments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;427&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,304&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,466&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Professional Services&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;284&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;258&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;231&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Research and development&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,465&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;4,393&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5,142&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;

        &lt;/div&gt;
      &lt;/div&gt;
    </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <cmmb:ScheduleOfRelatedPartyPayablesTableTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325140945214">
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Employees, consultants and related expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;531&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;490&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Accrued expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;75&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;74&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;606&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;564&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          </cmmb:ScheduleOfRelatedPartyPayablesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember"
      decimals="-3"
      id="FFact_0000000000459"
      unitRef="usd">531000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember"
      decimals="-3"
      id="FFact_0000000000460"
      unitRef="usd">490000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember"
      decimals="-3"
      id="FFact_0000000000461"
      unitRef="usd">75000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember"
      decimals="-3"
      id="FFact_0000000000462"
      unitRef="usd">74000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember"
      decimals="-3"
      id="FFact_0000000000463"
      unitRef="usd">606000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember"
      decimals="-3"
      id="FFact_0000000000464"
      unitRef="usd">564000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325140954486">
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Salaries and related expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,718&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,795&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,409&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Share-based payments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;427&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,304&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,466&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Professional Services&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;284&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;258&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;231&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Research and development&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,465&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;4,393&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5,142&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          </us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240325105700969"
      unitRef="usd">1718000</cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000466"
      unitRef="usd">2795000</cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000467"
      unitRef="usd">2409000</cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240325105708763"
      unitRef="usd">427000</cmmb:RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000468"
      unitRef="usd">1304000</cmmb:RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000469"
      unitRef="usd">2466000</cmmb:RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240325105715263"
      unitRef="usd">284000</cmmb:RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000470"
      unitRef="usd">258000</cmmb:RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000471"
      unitRef="usd">231000</cmmb:RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240325105723270"
      unitRef="usd">36000</cmmb:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000472"
      unitRef="usd">36000</cmmb:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000473"
      unitRef="usd">36000</cmmb:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty>
    <us-gaap:CostOfRevenue
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240325105729174"
      unitRef="usd">2465000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000474"
      unitRef="usd">4393000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000475"
      unitRef="usd">5142000</us-gaap:CostOfRevenue>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325135500617">
    &lt;div&gt;
      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Note 13 - Net Loss Per Share Attributable to Ordinary Shareholders&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Basic net loss per share is computed by dividing the net loss available to common stockholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares of were dilutive. Diluted net loss per share is the same as basic net loss per share of ordinary share, as the effect of potentially dilutive securities is antidilutive.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The following table sets forth the computation of basic and diluted net loss per share attributable to ordinary shareholders for the periods presented:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="margin-left:36pt"&gt;

          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;In USD thousands, except share and per share data&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-align:justify;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Numerator:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;
                  &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Net loss&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;13,945&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;24,221&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;27,646&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="text-align:justify;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Denominator:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;359,048,638&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;234,998,859&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;227,589,288&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                &lt;td style="width:64%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                  &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Net loss per share attributable to ordinary shareholders, basic&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;and diluted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.039&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.103&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.121&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;

      &lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;text-indent:0.55pt;margin-left:35.45pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The potential number of ordinary shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented since including them would have been anti-dilutive are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="margin-left:36pt"&gt;

          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Number of shares&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Outstanding options to purchase ordinary shares and RSAs&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;38,494,200&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;29,873,100&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;35,191,540&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;

      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325135622835">
          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;In USD thousands, except share and per share data&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-align:justify;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Numerator:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;
                  &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Net loss&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;13,945&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;24,221&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;27,646&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="text-align:justify;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Denominator:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;359,048,638&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;234,998,859&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;227,589,288&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                &lt;td style="width:64%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                  &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Net loss per share attributable to ordinary shareholders, basic&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;and diluted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.039&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.103&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.121&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240325110200438"
      unitRef="usd">-13945000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000478"
      unitRef="usd">-24221000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000479"
      unitRef="usd">-27646000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20240101to20241231"
      decimals="INF"
      id="Fxbrl_s_20240325110207874"
      unitRef="Share">359048638</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20240101to20241231"
      decimals="INF"
      id="Fxbrl_20240325110207874"
      unitRef="Share">359048638</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="Fxbrl_s_20230215224008037"
      unitRef="Share">234998859</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="Fxbrl_20230215224008037"
      unitRef="Share">234998859</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_s_20250325234313474"
      unitRef="Share">227589288</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20250325234313474"
      unitRef="Share">227589288</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="C_20240101to20241231"
      decimals="INF"
      id="Fxbrl_s_20240325110215226"
      unitRef="USD_Per_Share">0.039</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="C_20240101to20241231"
      decimals="INF"
      id="Fxbrl_20240325110215226"
      unitRef="USD_Per_Share">0.039</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="Fxbrl_20230131213444247"
      unitRef="USD_Per_Share">0.103</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="FFact_0000000000482"
      unitRef="USD_Per_Share">0.103</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20230131213458553"
      unitRef="USD_Per_Share">0.121</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000483"
      unitRef="USD_Per_Share">0.121</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250325135633684">
          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Number of shares&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Outstanding options to purchase ordinary shares and RSAs&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;38,494,200&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;29,873,100&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;35,191,540&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        </us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20240101to20241231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember"
      decimals="INF"
      id="Fxbrl_20250325234340730"
      unitRef="Share">38494200</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20230101to20231231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember"
      decimals="INF"
      id="Fxbrl_20250325234328859"
      unitRef="Share">29873100</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20220101to20221231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember"
      decimals="INF"
      id="FFact_0000000000486"
      unitRef="Share">35191540</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#FFact_0000000000422"
          xlink:label="FFact_0000000000422"
          xlink:type="locator"/>
        <link:footnote id="FN20250326215635448" xlink:label="FN20250326215635448" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">This excludes capital losses of approximately $14,224 thousands for which the company will create a full valuation allowance.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000422"
          xlink:to="FN20250326215635448"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_0000000000423"
          xlink:label="FFact_0000000000423"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000423"
          xlink:to="FN20250326215635448"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20240325113127688"
          xlink:label="Fxbrl_20240325113127688"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20240325113127688"
          xlink:to="FN20250326215635448"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20250325144319085"
          xlink:label="Fxbrl_20250325144319085"
          xlink:type="locator"/>
        <link:footnote id="FN20250325144245313" xlink:label="FN20250325144245313" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Less than 1 thousand</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20250325144319085"
          xlink:to="FN20250325144245313"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_0000000000106"
          xlink:label="FFact_0000000000106"
          xlink:type="locator"/>
        <link:footnote id="FN20240325165534634" xlink:label="FN20240325165534634" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Number of shares has been retroactively adjusted to reflect the share reverse split effected on March 16, 2021 (refer to Note 1)</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000106"
          xlink:to="FN20240325165534634"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230214141238310"
          xlink:label="Fxbrl_20230214141238310"
          xlink:type="locator"/>
        <link:footnote id="FN20250325190120111" xlink:label="FN20250325190120111" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">1 American Depositary Share (ADS) represents 20 Ordinary Shares.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230214141238310"
          xlink:to="FN20250325190120111"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_0000000000107"
          xlink:label="FFact_0000000000107"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000107"
          xlink:to="FN20240325165534634"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230131213329528"
          xlink:label="Fxbrl_20230131213329528"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230131213329528"
          xlink:to="FN20250325190120111"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20240325100018415"
          xlink:label="Fxbrl_20240325100018415"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20240325100018415"
          xlink:to="FN20240325165534634"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_s_20240325100018414"
          xlink:label="Fxbrl_s_20240325100018414"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_s_20240325100018414"
          xlink:to="FN20250325190120111"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230131221528825"
          xlink:label="Fxbrl_20230131221528825"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230131221528825"
          xlink:to="FN20250325190120111"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230131221535249"
          xlink:label="Fxbrl_20230131221535249"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230131221535249"
          xlink:to="FN20250325190120111"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230207232832534"
          xlink:label="Fxbrl_20230207232832534"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230207232832534"
          xlink:to="FN20250325190120111"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230207233006128"
          xlink:label="Fxbrl_20230207233006128"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230207233006128"
          xlink:to="FN20250325190120111"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230207233039147"
          xlink:label="Fxbrl_20230207233039147"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230207233039147"
          xlink:to="FN20250325190120111"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230207233201211"
          xlink:label="Fxbrl_20230207233201211"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230207233201211"
          xlink:to="FN20250325190120111"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230207233430996"
          xlink:label="Fxbrl_20230207233430996"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230207233430996"
          xlink:to="FN20250325190120111"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230207234506438"
          xlink:label="Fxbrl_20230207234506438"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230207234506438"
          xlink:to="FN20250325190120111"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230207234515566"
          xlink:label="Fxbrl_20230207234515566"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230207234515566"
          xlink:to="FN20250325190120111"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20240325100655099_xbrl_20230207233201211"
          xlink:label="Fxbrl_20240325100655099_xbrl_20230207233201211"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20240325100655099_xbrl_20230207233201211"
          xlink:to="FN20250325190120111"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20240325100745487_xbrl_20230207233430996"
          xlink:label="Fxbrl_20240325100745487_xbrl_20230207233430996"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20240325100745487_xbrl_20230207233430996"
          xlink:to="FN20250325190120111"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20240325100756924_xbrl_20230207234515566"
          xlink:label="Fxbrl_20240325100756924_xbrl_20230207234515566"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20240325100756924_xbrl_20230207234515566"
          xlink:to="FN20250325190120111"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_0000000000373"
          xlink:label="FFact_0000000000373"
          xlink:type="locator"/>
        <link:footnote id="FN20250326103158154" xlink:label="FN20250326103158154" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The weighted average share price is based on the Company's Ordinary Share closing price on the stock exchange as at the grant date</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000373"
          xlink:to="FN20250326103158154"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_0000000000377"
          xlink:label="FFact_0000000000377"
          xlink:type="locator"/>
        <link:footnote id="FN20250326103217779" xlink:label="FN20250326103217779" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Expected life for the periods presented was determined according to the simplified method since, at the date of grant, the Company did not have enough history to make an estimate. This method effectively assumes that exercise occurs over the period from vesting until expiration, and therefore the expected term is the midpoint between the service period and the contractual term of the award. The simplified method is applicable to service conditions.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000377"
          xlink:to="FN20250326103217779"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_0000000000378"
          xlink:label="FFact_0000000000378"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000378"
          xlink:to="FN20250326103217779"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_0000000000379"
          xlink:label="FFact_0000000000379"
          xlink:type="locator"/>
        <link:footnote id="FN20230201025249960" xlink:label="FN20230201025249960" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Expected volatility is based on historical volatility over the most recent period commensurate with the expected term of the option. As the Company has a short trading history for its ordinary shares, when the Company's trading period is shorter than the expected term, the expected volatility is derived from the average historical share volatilities of several unrelated public companies within the Company&#x2019;s industry that the Company considers to be comparable to its own business over a period equivalent to the option&#x2019;s expected term.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000379"
          xlink:to="FN20230201025249960"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_0000000000380"
          xlink:label="FFact_0000000000380"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000380"
          xlink:to="FN20230201025249960"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_0000000000381"
          xlink:label="FFact_0000000000381"
          xlink:type="locator"/>
        <link:footnote id="FN20230201025314607" xlink:label="FN20230201025314607" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The risk-free rate for the expected term of the options is based on the Black-Scholes option-pricing model on the yields of U.S. Treasury securities with maturities appropriate for the expected term of employee share option awards.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000381"
          xlink:to="FN20230201025314607"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_0000000000382"
          xlink:label="FFact_0000000000382"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000382"
          xlink:to="FN20230201025314607"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
